﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yamazaki, T
   Koizumi, H
   Yamagishi, T
   Kinoshita, S
AF Yamazaki, Taizo
   Koizumi, Hideki
   Yamagishi, Tetsuya
   Kinoshita, Shigeru
TI Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular
   Age-related Macular Degeneration: 12-Month Results
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; OPTICAL COHERENCE TOMOGRAPHY;
   ANTI-VEGF TREATMENT; INTRAVITREAL RANIBIZUMAB; PHOTODYNAMIC THERAPY;
   VASCULOPATHY; VERTEPORFIN; INJECTION; FRAGMENT
AB Purpose: To investigate the changes in subfoveal choroidal thickness after intravitreal injections of ranibizumab (IVRs) for neovascular age-related macular degeneration (AMD).
   Design: Prospective, consecutive, interventional case series.
   Participants: Eighty eyes (40 affected eyes with neovascular AMD and 40 unaffected fellow eyes) of 40 patients.
   Methods: Forty eyes with neovascular AMD were treated with 0.5-mg IVRs monthly for 3 months and received additional IVRs as needed over the following 9-month period. Subfoveal choroidal thickness in all 80 eyes was measured by use of enhanced depth imaging optical coherence tomography images before and after starting the IVRs.
   Main Outcome Measures: Changes in subfoveal choroidal thickness after treatment by IVRs over a 12-month period.
   Results: Twenty-three eyes (57.5%) were diagnosed with typical neovascular AMD, 16 eyes (40%) were diagnosed with polypoidal choroidal vasculopathy, and 1 eye (2.5%) was diagnosed with retinal angiomatous proliferation. Fifteen eyes (38%) had received some previous treatments for the neovascular lesion before undergoing the IVRs. The mean best-corrected visual acuity of the affected eyes was improved from 0.54 logarithm of the minimum angle of resolution units at baseline to 0.42 at 12 months (P = 0.020). The mean subfoveal choroidal thickness in the affected eyes decreased from 244 +/- 62 mu m at baseline to 234 +/- 66 mu m at 1 month (P = 0.013), 226 +/- 68 mu m at 3 months (P<0.001), 229 +/- 67 mu m at 6 months (P = 0.002), and 226 +/- 66 mu m at 12 months (P = 0.002; the change ratio, 93%), whereas that in the unaffected eyes changed from 237 +/- 80 mu m at baseline to 238 +/- 83 mu m at 12 months (P = 0.78). In the affected eyes, the change ratio of subfoveal choroidal thickness at 12 months was not correlated with the number of IVRs (mean, 5.8 +/- 2.9). Subfoveal choroidal thickness demonstrated a similar trend toward decreasing during the following period independent of the subtypes of neovascular AMD or the treatment histories.
   Conclusions: Subfoveal choroidal thickness decreased after IVRs in eyes with neovascular AMD. Intravitreal injections of ranibizumab may provide a pharmacologic effect not only on the neovascular lesion but also on the underlying choroid.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1621-1627 (C) 2012 by the American Academy of Ophthalmology.
C1 [Koizumi, Hideki] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan.
C3 Kyoto Prefectural University of Medicine
RP Koizumi, H (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM hidekoiz@koto.kpu-m.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology-Japan
   [21890226]
FX This study was supported in part by grant no. 21890226 from the Ministry
   of Education, Culture, Sports, Science and Technology-Japan (Dr.
   Koizumi).
CR Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Imamura Y, 2011, AM J OPHTHALMOL, V151, P297, DOI 10.1016/j.ajo.2010.08.014
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai TYY, 2007, GRAEF ARCH CLIN EXP, V245, P1877, DOI 10.1007/s00417-007-0679-1
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lim SJ, 2010, RETINA-J RET VIT DIS, V30, P100, DOI 10.1097/IAE.0b013e3181bcf0b4
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lutty G, 1999, MOL VIS, V5
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P3430, DOI 10.1167/iovs.10-6600
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reibaldi M, 2011, AM J OPHTHALMOL, V151, P112, DOI 10.1016/j.ajo.2010.07.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Torres VLL, 2011, AM J OPHTHALMOL, V151, P586, DOI 10.1016/j.ajo.2010.09.028
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 45
TC 135
Z9 142
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1621
EP 1627
DI 10.1016/j.ophtha.2012.02.022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100020
PM 22551738
DA 2022-11-30
ER

PT J
AU Huang, GH
   Klein, R
   Klein, BEK
   Tomany, SC
AF Huang, GH
   Klein, R
   Klein, BEK
   Tomany, SC
TI Birth cohort effect on prevalence of age-related maculopathy in the
   Beaver Dam Eye Study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE cohort effect; cohort studies; generalized estimating equation; macular
   degeneration; risk adjustment
ID VISUAL-ACUITY; PERIOD; MODELS; POPULATION; SMOKING; RATES
AB The number of people in the United States with age-related maculopathy is increasing in recent years because of increasing longevity. However, it is possible that a birth cohort effect, due to different levels of exposure to risk factors, may explain changes in the prevalence of age-related maculopathy by age. In this report, the authors utilize data from the population-based Beaver Dam Eye Study (1988-2000) to examine this possibility. They propose a strategy to handle issues of longitudinal measurements and risk factor adjustment for analyzing the birth cohort effect. Results from the analysis (after adjusting for known risk factors) showed an apparent independent birth cohort effect on age-related maculopathy. The authors also found a strong positive association between age-related maculopathy and age, when comparing participants from the same birth cohort. The birth cohort effect was the same across different age groups, except for early age-related maculopathy, where older age increased the association. Our findings demonstrate that the birth cohort effect is likely attributable to unmeasured risk factors for age-related maculopathy and limitations of risk factor measurements. Further study of possible unmeasured risk factors that cause the cohort effect may help us understand the etiology of the disease.
C1 Univ Wisconsin, Dept Populat Hlth Sci, Sch Med, Madison, WI 53726 USA.
   Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI USA.
   Univ Wisconsin, Sch Med, Dept Ophthalmol & Vis Sci, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Huang, GH (通讯作者)，Univ Wisconsin, Dept Populat Hlth Sci, Sch Med, 610 Walnut St, Madison, WI 53726 USA.
EM guanhuahuang@facstaff.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline
CR ALLAIN CC, 1974, CLIN CHEM, V20, P470
   [Anonymous], [No title captured]
   BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7
   CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405
   Heagerty PJ, 1996, J AM STAT ASSOC, V91, P1024, DOI 10.2307/2291722
   HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233
   Huang GH, 2002, J R STAT SOC C-APPL, V51, P37, DOI 10.1111/1467-9876.04739
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, IN PRESS OPHTHALMOLO
   Klein R, 1995, BEAVER DAM EYE STUDY
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   McCullagh P, 1989, GEN LINEAR MODELS, DOI [DOI 10.1007/978-1-4899-3242-6, 10.1007/978-1-4899-3242-6]
   1976, PREV MED, V5, P207
NR 26
TC 17
Z9 17
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD APR 15
PY 2003
VL 157
IS 8
BP 721
EP 729
DI 10.1093/aje/kwg011
PG 9
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 667XU
UT WOS:000182260800007
PM 12697576
OA Bronze
DA 2022-11-30
ER

PT J
AU Luo, L
   Harmon, J
   Yang, X
   Chen, HY
   Patel, S
   Mineau, G
   Yang, ZL
   Constantine, R
   Buehler, J
   Kammoh, Y
   Ma, X
   Wong, TY
   Zhang, MN
   Zhang, K
AF Luo, Ling
   Harmon, Jennifer
   Yang, Xian
   Chen, Haoyu
   Patel, Shrena
   Mineau, Geraldine
   Yang, Zhenglin
   Constantine, Ryan
   Buehler, Jeanette
   Kammoh, Yuuki
   Ma, Xiang
   Wong, Tien Y.
   Zhang, Maonian
   Zhang, Kang
TI Familial aggregation of age-related macular degeneration in the Utah
   population
SO VISION RESEARCH
LA English
DT Article
DE age-related macular degeneration; genetic epidemiology; genetics
ID BEAVER DAM EYE; CANCER SUSCEPTIBILITY GENE; COMPLEMENT FACTOR-H;
   ENDOTHELIAL GROWTH-FACTOR; RISK-FACTORS; MACULOPATHY; VARIANT; TWIN;
   PREVALENCE; CANDIDATE
AB We examined familial aggregation and risk of age-related macular degeneration in the Utah population using a population-based case-control study. Over one million unique patient records were searched within the University of Utah Health Sciences Center and the Utah Population Database (UPDB), identifying 4764 patients with AMD. Specialized kinship analysis software was used to test for familial aggregation of disease, estimate the magnitude of familial risks, and identify families at high risk for disease. The population-attributable risk (PAR) for AMD was calculated to be 0.34. Recurrence risks in relatives indicate increased relative risks in siblings (2.95), first cousins (1.29), second cousins (1.13), and parents (5.66) of affected cases. There were 16 extended large families with AMD identified for potential use in genetic studies. Each family had five or more living affected members. The familial aggregation of AMD shown in this study exemplifies the merit of the UPDB and supports recent research demonstrating significant genetic contribution to disease development and progression. (c) 2008 Published by Elsevier Ltd.
C1 [Luo, Ling; Zhang, Maonian] Hosp 301, Chinese Mol Post Grad Med Sch, Dept Ophthalmol, Beijing 100853, Peoples R China.
   [Luo, Ling; Harmon, Jennifer; Yang, Xian; Chen, Haoyu; Patel, Shrena; Yang, Zhenglin; Constantine, Ryan; Buehler, Jeanette; Kammoh, Yuuki; Ma, Xiang; Zhang, Kang] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Luo, Ling; Harmon, Jennifer; Yang, Xian; Chen, Haoyu; Patel, Shrena; Yang, Zhenglin; Constantine, Ryan; Buehler, Jeanette; Kammoh, Yuuki; Ma, Xiang; Zhang, Kang] Univ Utah, Sch Med, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA.
   [Mineau, Geraldine] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
   [Luo, Ling; Zhang, Maonian] Univ Utah, Sch Med, Dept Pediat, Primary Childrens Med Ctr Fdn Scholar,Div Neonato, Salt Lake City, UT 84112 USA.
   [Yang, Zhenglin] Sichuan Med Sci Acad, Chengdu 610071, Sichuan, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu 610071, Sichuan, Peoples R China.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Parkville, Vic 3052, Australia.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Huntsman Cancer Institute; Utah
   System of Higher Education; University of Utah; Utah System of Higher
   Education; University of Utah; Sichuan Provincial People's Hospital;
   Centre for Eye Research Australia; University of Melbourne
RP Zhang, MN (通讯作者)，Hosp 301, Chinese Mol Post Grad Med Sch, Dept Ophthalmol, Beijing 100853, Peoples R China.
EM zhangmaonian@medmail.com.cn; kang.zhang@hsc.utah.edu
RI Zhang, Kang/Y-2740-2019; Ma, Xiang/E-4173-2013; Wong, Tien
   Yin/AAC-9724-2020; Chen, Haoyu/A-7432-2013; Chu, Kai On/E-2325-2016
OI Zhang, Kang/0000-0002-4549-1697; Ma, Xiang/0000-0001-9427-8385; Wong,
   Tien Yin/0000-0002-8448-1264; Chen, Haoyu/0000-0003-0676-4610; 
CR [Anonymous], 1990, FERTILITY CHANGE AM
   Bai Y, 2000, AM J EPIDEMIOL, V151, P927
   Berthelemy-Okazaki N, 2005, STROKE, V36, P1283, DOI 10.1161/01.STR.0000166198.05439.f8
   Boucher K M, 2001, J Epidemiol Biostat, V6, P377
   BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   JORDE LB, 1989, ANN HUM GENET, V53, P339, DOI 10.1111/j.1469-1809.1989.tb01803.x
   Kamb A, 1994, Nat Genet, V8, P23
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   KERBER RA, 1995, GENET EPIDEMIOL, V12, P291, DOI 10.1002/gepi.1370120306
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R.J., 2005, SCIENCE
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   MCLELLAN T, 1984, AM J HUM GENET, V36, P836
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Okamoto N, 1997, AM J PATHOL, V151, P281
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SKOLNICK M, 1979, SOCIOL SOC RES, V63, P506
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808
   Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Wylie JE, 2003, TRENDS BIOTECHNOL, V21, P113, DOI 10.1016/S0167-7799(02)00039-2
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 46
TC 18
Z9 20
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
J9 VISION RES
JI Vision Res.
PD FEB
PY 2008
VL 48
IS 3
BP 494
EP 500
DI 10.1016/j.visres.2007.11.013
PG 7
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 272BG
UT WOS:000253832000021
PM 18252239
OA Bronze
DA 2022-11-30
ER

PT J
AU Riusala, A
   Sarna, S
   Immonen, I
AF Riusala, A
   Sarna, S
   Immonen, I
TI Visual acuity and structural findings in old age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE retina; age-related macular degeneration; visual acuity
ID SCANNING LASER OPHTHALMOSCOPE; CHOROIDAL NEOVASCULARIZATION;
   NATURAL-HISTORY; CENTRAL SCOTOMA; SUBFOVEAL
AB Background: Although exudative age-related macular degeneration (AMD) leads to a substantial visual loss in most patients there is still significant variation in the end- stage visual acuity level. We analysed lesions in eyes with long-standing AMD in order to find contributing factors for this variation. Methods: Sixty-one out of 121 patients examined for exudative AMD and still alive 4.8-9.2 (mean 6.8) years after the acute phase were re-examined. The lesion size, area of subretinal fibrosis, geographic atrophy, presence of a persistent exudative process, and shortest distance to normal looking retina were measured from digital fundus photographs taken at the re-examination and correlated with visual acuity. Results: Lesion size, the presence of a continuing exudative process, or subretinal fibrosis were independent predictors for poor vision. Better vision in the other eye was connected with poor vision in the affected study eye. Conclusions: In addition to lesion size, the presence of a continuing exudative process and subretinal fibrosis also have deleterious effects on long-term visual acuity after exudative AMD.
C1 Helsinki Univ Hosp, Dept Ophthalmol, FIN-00029 Helsinki, Finland.
   Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki
RP Immonen, I (通讯作者)，Helsinki Univ Hosp, Dept Ophthalmol, Haartmaninkatu 4 C,JP 220, FIN-00029 Helsinki, Finland.
EM ilkka.immonen@hus.fi
OI Sarna, Seppo/0000-0003-3458-1627
CR Cohen SY, 2003, GRAEF ARCH CLIN EXP, V241, P785, DOI 10.1007/s00417-003-0744-3
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Riusala A, 2003, AM J OPHTHALMOL, V135, P206, DOI 10.1016/S0002-9394(02)01832-9
   Riusala AM, 2004, AM J OPHTHALMOL, V138, P245, DOI 10.1016/j.ajo.2004.03.007
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
NR 10
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2005
VL 243
IS 9
BP 947
EP 950
DI 10.1007/s00417-005-1161-6
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 964CR
UT WOS:000231856800016
PM 15834599
DA 2022-11-30
ER

PT J
AU Chalam, KV
   Khetpal, V
   Rusovici, R
   Balaiya, S
AF Chalam, K. V.
   Khetpal, Vijay
   Rusovici, Raluca
   Balaiya, Sankarathi
TI A Review: Role of Ultraviolet Radiation in Age-Related Macular
   Degeneration
SO EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE
LA English
DT Review
DE Age-related macular degeneration; Retinal pigment epithelium;
   Ultraviolet; Photochemical damage; Lipofuscin
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; INDUCED APOPTOSIS;
   5-YEAR INCIDENCE; INTERLEUKIN-6 AND-8; VISUAL IMPAIRMENT; OXIDATIVE
   STRESS; LIGHT; LIPOFUSCIN; CELLS
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the western world. The retina is highly susceptible to photochemical damage from continuous exposure of light and oxygen. The cornea and the lens block a major portion of the ultraviolet (UV) radiation from reaching the retina (<295 nm). The relationship between UV light exposure and AMD is unclear, although short wavelength radiation and the blue light induce significant oxidative stress to the retinal pigment epithelium. Epidemiologic evidence indicates a trend toward association between severity of light exposure and AMD. In this review, we discuss type 1 and type 2 photochemical damage that occurs in response to UV exposure. We examine the impact of different doses of exposure to UV radiation and the subsequent production of oxidative stress in AMD. Local and systemic protective mechanisms of the retina including antioxidant enzymes and macular pigments are reviewed. This article provides a review of possible cellular and molecular effects of UV radiation exposure in AMD and potential therapies that may prevent blindness resulting from this disease.
C1 [Chalam, K. V.; Khetpal, Vijay; Rusovici, Raluca; Balaiya, Sankarathi] Univ Florida, Dept Ophthalmol, Coll Med, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Dept Ophthalmol, Coll Med, 580 W 8th St,Tower 2,3rd Floor, Jacksonville, FL 32209 USA.
EM kchalam@jax.ufl.edu
RI Chalam, kakarla/K-7507-2019
OI Chalam, K V/0000-0002-0004-9416; Chalam, kakarla/0000-0001-9325-8665
CR Balaiya S, 2010, CLIN OPHTHALMOL, V4, P33
   Bantseev V, 2006, ANN NY ACAD SCI, V1091, P17, DOI 10.1196/annals.1378.051
   Bastianon C, 2005, INT J BIOCHEM CELL B, V37, P901, DOI 10.1016/j.biocel.2004.11.016
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   Boulton ME, 2008, VISUAL TRANSDUCTION, P403
   BOULTON ME, 2000, HUNTERS OCCUPATIONAL, P419
   Cai S, 2008, EXP EYE RES, V86, P178, DOI 10.1016/j.exer.2007.10.008
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Di Girolamo N, 2003, INVEST OPHTH VIS SCI, V44, P4705, DOI 10.1167/iovs.03-0356
   Di Girolamo N, 2002, INVEST OPHTH VIS SCI, V43, P3430
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eldred GE, 1995, GERONTOLOGY, V41, P15
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEY L, 1976, INVEST OPHTH VISUAL, V15, P789
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Foote C.S., 1981, OXYGEN OXY RADICALS, P425
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hui S, 2009, PHOTOCHEM PHOTOBIOL, V85, P966, DOI 10.1111/j.1751-1097.2008.00506.x
   IRVINE AR, 1984, ARCH OPHTHALMOL-CHIC, V102, P1358, DOI 10.1001/archopht.1984.01040031100034
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   JUNQUEIRA LC, 2002, BASIC HISTOLOGY, P428
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Lawwill T, 1982, Trans Am Ophthalmol Soc, V80, P517
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   MARSHALL J, 1985, OPHTHAL PHYSL OPT, V5, P241, DOI 10.1111/j.1475-1313.1985.tb00666.x
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Naumann GOH, 1997, SPEZIELLE PATHOLOGIE
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Pauloin T, 2009, MOL VIS, V15, P577
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rapp L, 1985, RETINAL DEGENERATION, P421
   Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367
   Reme C, 1996, GRAEF ARCH CLIN EXP, V234, P2, DOI 10.1007/BF00186512
   Roanowska M., 2008, OPHTHALMOLOGY RES VI, P405
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Rozanowska M., 2009, PHOTOBIOLOGY RETINA
   Sahm M, 2001, GRAEF ARCH CLIN EXP, V239, P302, DOI 10.1007/s004170100271
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Saliba AJ, 2008, RURAL REMOTE HEALTH, V8
   Sarna T, 1995, MELANOMA RES, V5, P10
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Smith Bradley T., 2005, International Ophthalmology Clinics, V45, P107
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SPALTON VDJ, 1984, ATLAS OPHTHALMOLOGY, P245
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289
   Tratsk KS, 2003, GRAEF ARCH CLIN EXP, V241, P852, DOI 10.1007/s00417-003-0747-0
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Winkler BS, 1999, MOL VIS, V5
   Youn HY., 2010, OPEN TOXICOL J, V4, P13, DOI DOI 10.2174/1874340401004010013
   YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhu D, 2010, INVEST OPHTHALMOL
NR 86
TC 66
Z9 67
U1 1
U2 44
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1542-2321
EI 1542-233X
J9 EYE CONTACT LENS
JI Eye Contact Lens-Sci. Clin. Pra.
PD JUL
PY 2011
VL 37
IS 4
BP 225
EP 232
DI 10.1097/ICL.0b013e31821fbd3e
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784BJ
UT WOS:000292128300009
PM 21646979
DA 2022-11-30
ER

PT J
AU Jones, AA
AF Jones, Amanda A.
TI Age related macular degeneration - Should your patients be taking
   additional supplements?
SO AUSTRALIAN FAMILY PHYSICIAN
LA English
DT Article
ID DIETARY-FAT; BETA-CAROTENE; LUTEIN; ZEAXANTHIN; SERUM; RISK
AB BACKGROUND
   The use of over-the-counter complementary medicines and supplements is growing. Patients with age related macular degeneration (AMD) are likely to have heard of, or are possibly already taking, additional supplements that may increase their chances of retaining useful eyesight.
   OBJECTIVE
   This article looks specifically at evidence regarding the effects of over-the-counter oral supplements such as antioxidants and omega-3 fatty acids on AMD.
   DISCUSSION
   Diet manipulation and supplementation has a role to play in modifying the risk of disease progression in AMD patients. A combination of vitamins C and E, beta carotene, zinc oxide and cupric oxide has been shown to reduce the rate of visual loss in dry AMD. However, commercially available preparations do not always recommend the correct intake that would match levels found in clinical trials. Other carotenoids such as lutein and zeaxanthin may also be beneficial, intake of these can be increased by altering diet alone. Other useful dietary changes include reducing both animal and vegetable fats and increasing the consumption of fish and nuts.
EM draajones@hotmail.com
CR Alaimo K, 1994, Adv Data, P1
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   RICHER S, 2004, OPTOMETRY, P216
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Tyssandier V, 2002, AM J CLIN NUTR, V75, P526, DOI 10.1093/ajcn/75.3.526
   WENG T, 2006, CLIN EXPT OPHTHALMOL, V34, P9
NR 17
TC 4
Z9 6
U1 0
U2 7
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 0300-8495
J9 AUST FAM PHYSICIAN
JI Aust. Fam. Physician
PD DEC
PY 2007
VL 36
IS 12
BP 1026
EP 1028
PG 3
WC Primary Health Care; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 278LR
UT WOS:000254287800016
PM 18075628
DA 2022-11-30
ER

PT J
AU Baum, L
   Chan, WM
   Li, WY
   Lam, DSC
   Wang, PB
   Pang, CP
AF Baum, L
   Chan, WM
   Li, WY
   Lam, DSC
   Wang, PB
   Pang, CP
TI ABCA4 sequence variants in Chinese patients with age-related macular
   degeneration or Stargardt's disease
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; ATP-binding cassette transporter gene;
   ABCA4; mutation
ID CILIARY NEUROTROPHIC FACTOR; MEDIATED GENE-TRANSFER; APOLIPOPROTEIN-E
   GENE; RETINAL DEGENERATION; TRANSPORTER GENE; PHOTORECEPTOR
   DEGENERATION; ALLELIC VARIATION; EPSILON-4 ALLELE; RD MOUSE; MUTATIONS
AB ABCA4 gene sequence alterations cause Stargardt's disease (STGD) and may cause some age-related macular degeneration (AMD). We sought to shed light on these associations among Hong Kong Chinese by genotyping 140 AMD, 18 STGD and 95 normal control subjects for 15 ABCA4 exons which were reported to often contain AMD- or STGD-associated mutations. Sequence alterations R212H, T1428M, V14331, T1572M, 12166M, lVS65T>G and IVS33+1G>T were found in AMD patients. T1428M and R2040X occurred in STGD patients. Control subjects displayed all the above missense alterations but no splicing or nonsense changes. Therefore, ABCA4 splicing mutations may be associated with a small proportion of AMD cases.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   Shantou Univ, Coll Med, Shantou, Peoples R China.
C3 Chinese University of Hong Kong; Shantou University
RP Pang, CP (通讯作者)，Hong Kong Eye Hosp 3F, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk
RI Lam, Dennis/AAL-1211-2020; Pang, Chi P/I-5388-2014; Baum,
   Lawrence/B-1005-2013
OI Baum, Lawrence/0000-0002-5345-9355
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Akimoto M, 1999, INVEST OPHTH VIS SCI, V40, P273
   Allikmets R, 1998, GENE, V215, P111, DOI 10.1016/S0378-1119(98)00269-8
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Azarian SM, 1998, HUM GENET, V102, P699, DOI 10.1007/s004390050765
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Gerber S, 1998, GENOMICS, V48, P139, DOI 10.1006/geno.1997.5164
   Hauswirth WW, 2000, INVEST OPHTH VIS SCI, V41, P2821
   Inoue N, 2001, MOL THER, V3, P526, DOI 10.1006/mthe.2001.0283
   *J HOPK U, 2001, 601691 MIM J HOPK U
   *J HOPK U, 1999, 248200 MIM J HOPK U
   *J HOPK U, 2000, 153800 MIM J HOPK U
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622
   Leung YF, 2000, BIOTECHNIQUES, V29, P544, DOI 10.2144/00293bf01
   Leung YF, 2001, BIOTECHNIQUES, V30, P334, DOI 10.2144/01302tt02
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Masuda I, 1996, INVEST OPHTH VIS SCI, V37, P1914
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Papaioannou M, 2000, INVEST OPHTH VIS SCI, V41, P16
   Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schmidt S, 2000, MOL VIS, V6, P287
   Simonelli F, 2000, INVEST OPHTH VIS SCI, V41, P892
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   Zhang K, 1999, GENOMICS, V60, P234, DOI 10.1006/geno.1999.5896
NR 38
TC 19
Z9 21
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAR-APR
PY 2003
VL 217
IS 2
BP 111
EP 114
DI 10.1159/000068553
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 653VT
UT WOS:000181458300005
PM 12592048
DA 2022-11-30
ER

PT J
AU Vallee, A
   Lecarpentier, Y
   Guillevin, R
   Vallee, JN
AF Vallee, Alexandre
   Lecarpentier, Yves
   Guillevin, Remy
   Vallee, Jean-Noel
TI PPAR gamma agonists: Potential treatments for exudative age-related
   macular degeneration
SO LIFE SCIENCES
LA English
DT Review
DE Exudative AMD; Canonical WNT/beta-catenin pathway; PPAR gamma;
   Inflammation; PI3K/Akt pathway
ID ACTIVATED-RECEPTOR-GAMMA; ENDOTHELIAL GROWTH-FACTOR; II TYPE-1 RECEPTOR;
   INDUCIBLE FACTOR-I; WNT/BETA-CATENIN PATHWAY; HEMATOPOIETIC STEM-CELLS;
   GLYCOGEN-SYNTHASE KINASE; LACTATE-DEHYDROGENASE; SIGNALING PATHWAY; VEGF
   EXPRESSION
AB Choroidal neovascularization (CNV) characterizes the progression of exudative age-related macular degeneration (AMD) with the deterioration in the central vision. Vascular inflammation, and overproduction of inflammatory cytokines, growth factors and aberrant endothelial cell migration, initiate defective blood vessel proliferation in exudative AMD. CNV formation is initiated by the interplay between inflammation, the hallmark of exudative AMD, and the activation of WNT/beta-catenin pathway. Upregulation of WNT/beta-catenin pathway involves activation of PI3IC/Akt pathway and then the Warburg effect to produce lactate. Lactate production generates VEGF expression and then participates to the initiation of CNV in exudative AMD. WNT/beta-catenin pathway and PPAR gamma act in an opposite manner in several diseases. We focus this review on the interplay between PPAR gamma and canonical WNT/beta-catenin pathway and the anti-inflammatory role of PPAR gamma in exudative AMD. In exudative AMD, PPAR gamma agonists downregulate inflammation and the WNT/beta-catenin pathway. PPAR gamma agonists can appear as promising treatment against the initiation and the progression of CNV in exudative AMD.
C1 [Vallee, Alexandre] Univ Poitiers, INSERM U1084, Expt & Clin Neurosci Lab, Poitiers, France.
   [Vallee, Alexandre; Vallee, Jean-Noel] Univ Poitiers, UMR CNRS 7348, Lab Math & Applicat LMA, Poitiers, France.
   [Lecarpentier, Yves] GHEF, Ctr Rech Clin, Meaux, France.
   [Guillevin, Remy] Univ Poitiers, Futuroscope, France.
   [Guillevin, Remy] CHU Poitiers, UMR CNRS SP2MI 7348, DACTIM, Lab Math & Applicat, Futuroscope, France.
   [Vallee, Jean-Noel] UPJV, CHU Amiens Picardie, Amiens, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Poitiers; Universite de Poitiers; Universite de Poitiers;
   CHU Poitiers; Universite de Poitiers; Picardie Universites; Universite
   de Picardie Jules Verne (UPJV); CHU Amiens
RP Vallee, A (通讯作者)，Univ Poitiers, LMA UMR CNRS 7348, 11 Blvd Marie & Pierre Curie, Poitiers, France.
EM alexandre.g.vallee@gmail.com
CR Abdelrahman M, 2005, CARDIOVASC RES, V65, P772, DOI 10.1016/j.cardiores.2004.12.008
   Ajuwon KM, 2005, AM J PHYSIOL-REG I, V288, pR1220, DOI 10.1152/ajpregu.00397.2004
   Akinyeke TO, 2011, CANCER BIOL THER, V11, P1046, DOI 10.4161/cbt.11.12.15709
   Aljada A, 2008, ANGIOGENESIS, V11, P361, DOI 10.1007/s10456-008-9118-0
   Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bishop-Bailey D, 2011, BIOCHEM SOC T, V39, P1601, DOI 10.1042/BST20110643
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9
   Cariou B, 2012, TRENDS ENDOCRIN MET, V23, P205, DOI 10.1016/j.tem.2012.03.001
   Castrillo A, 2004, ANNU REV CELL DEV BI, V20, P455, DOI 10.1146/annurev.cellbio.20.012103.134432
   Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2
   Chen JL, 2014, INT J DEV NEUROSCI, V35, P35, DOI 10.1016/j.ijdevneu.2014.03.006
   Chen YJ, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/41/415501
   Chinetti G, 2003, INT J OBESITY, V27, pS41, DOI 10.1038/sj.ijo.0802499
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Coffe V, 2006, NEUROCHEM RES, V31, P103, DOI 10.1007/s11064-005-9236-7
   Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394
   Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902
   Di Gregorio J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171093
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donati G, 2007, OPHTHALMOLOGICA, V221, P366, DOI 10.1159/000107495
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7
   Drygiannakis I, 2013, J CROHNS COLITIS, V7, P286, DOI 10.1016/j.crohns.2012.04.008
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Easwaran V, 2003, CANCER RES, V63, P3145
   Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779
   Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907
   Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2
   Farshbaf MJ, 2014, MED HYPOTHESES, V82, P291, DOI 10.1016/j.mehy.2013.12.012
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021
   Garcia-Gras E, 2006, J CLIN INVEST, V116, P2012, DOI 10.1172/JCI27751
   Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345
   Giatromanolaki A, 2006, GYNECOL ONCOL, V103, P912, DOI 10.1016/j.ygyno.2006.05.043
   Goetze S, 2002, BIOCHEM BIOPH RES CO, V293, P1431, DOI 10.1016/S0006-291X(02)00385-6
   Gralinski MR, 1998, J CARDIOVASC PHARM, V31, P909, DOI 10.1097/00005344-199806000-00015
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Gustafson B, 2010, DIABETOLOGIA, V53, P536, DOI 10.1007/s00125-009-1615-1
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Huang J, 2012, NAT MED, V18, P1778, DOI 10.1038/nm.2984
   Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089
   Imayama I, 2006, CARDIOVASC RES, V72, P184, DOI 10.1016/j.cardiores.2006.07.014
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jeon KI, 2014, AM J PATHOL, V184, P1429, DOI 10.1016/j.ajpath.2014.01.026
   Jester JV, 2012, OCUL SURF, V10, P224, DOI 10.1016/j.jtos.2012.07.001
   Jin J, 2013, MOL CELL BIOCHEM, V381, P267, DOI 10.1007/s11010-013-1710-y
   Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje
   Katoh Y, 2006, INT J ONCOL, V28, P1585
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Kim KY, 2011, MOL CELL BIOCHEM, V358, P375, DOI 10.1007/s11010-011-0989-9
   Kim SP, 2010, BIOCHEM BIOPH RES CO, V399, P55, DOI 10.1016/j.bbrc.2010.07.038
   Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5
   Kostadinova R, 2005, CURR MED CHEM, V12, P2995, DOI 10.2174/092986705774462905
   Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205
   Koukourakis MI, 2011, CLIN CANCER RES, V17, P4892, DOI 10.1158/1078-0432.CCR-10-2918
   Kumar V, 2014, PHARM RES-DORDR, V31, P1158, DOI 10.1007/s11095-013-1239-5
   Kurihara T, 2006, INVEST OPHTH VIS SCI, V47, P5545, DOI 10.1167/iovs.06-0478
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Lecarpentier Y, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0144-7
   Lecarpentier Y, 2017, PPAR RES, V2017, DOI 10.1155/2017/5879090
   Lecarpentier Y, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00100
   Lecarpentier Y, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00429
   Lee YH, 2013, CELL MOL LIFE SCI, V70, P3959, DOI 10.1007/s00018-013-1363-8
   Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335
   Leveillard T., 2016, CELL MOL LIFE SCI CM
   Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967
   Libro R, 2016, LIFE SCI, V158, P78, DOI 10.1016/j.lfs.2016.06.024
   Lin CH, 2013, BRIT J PHARMACOL, V168, P920, DOI 10.1111/j.1476-5381.2012.02227.x
   Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441-06
   Liu JQ, 2004, J BIOL CHEM, V279, P24493, DOI 10.1074/jbc.M407050200
   Liu XX, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-356
   Lu DS, 2010, EUR J PHARMACOL, V636, P198, DOI 10.1016/j.ejphar.2010.03.010
   Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Menon G, 2009, EYE, V23, pS1, DOI 10.1038/eye.2009.13
   Michalik L, 2006, J CLIN INVEST, V116, P598, DOI 10.1172/JCI27958
   Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426
   Muranaka K, 2006, INVEST OPHTH VIS SCI, V47, P4547, DOI 10.1167/iovs.05-1432
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4
   Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128
   Park HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105809
   Park KS, 2004, EXP CELL RES, V297, P424, DOI 10.1016/j.yexcr.2004.03.034
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Pershadsingh, 1999, Expert Opin Investig Drugs, V8, P1859
   Phipps JA, 2007, INVEST OPHTH VIS SCI, V48, P927, DOI 10.1167/iovs.06-0892
   Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016
   Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200
   Qian JJ, 2012, PHARMACOL RES, V66, P219, DOI 10.1016/j.phrs.2012.06.003
   Qiu FF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01119-2
   Rigamonti E, 2008, ARTERIOSCL THROM VAS, V28, P1050, DOI 10.1161/ATVBAHA.107.158998
   Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross SE, 1999, MOL CELL BIOL, V19, P8433
   Sabatino L, 2014, WORLD J GASTROENTERO, V20, P7137, DOI 10.3748/wjg.v20.i23.7137
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   San-Millan I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127
   Sarayba MA, 2005, EXP EYE RES, V80, P435, DOI 10.1016/j.exer.2004.10.009
   Sarlos S, 2005, INVEST OPHTH VIS SCI, V46, P1069, DOI 10.1167/iovs.04-0885
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schupp M, 2004, CIRCULATION, V109, P2054, DOI 10.1161/01.CIR.0000127955.36250.65
   Schupp M, 2005, DIABETES, V54, P3442, DOI 10.2337/diabetes.54.12.3442
   Segel MJ, 2003, AM J PHYSIOL-LUNG C, V285, pL1255, DOI 10.1152/ajplung.00303.2002
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   Senanayake PD, 2007, INVEST OPHTH VIS SCI, V48, P3301, DOI 10.1167/iovs.06-1024
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Sharma C, 2004, J BIOL CHEM, V279, P35583, DOI 10.1074/jbc.M403143200
   Shim CY, 2014, J DIABETES INVEST, V5, P362, DOI 10.1111/jdi.12153
   Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658
   Shu QM, 2014, J MOL NEUROSCI, V54, P243, DOI 10.1007/s12031-014-0281-z
   Simon MF, 2005, J BIOL CHEM, V280, P14656, DOI 10.1074/jbc.M412585200
   Song MK, 2012, BRIT J PHARMACOL, V165, P4, DOI 10.1111/j.1476-5381.2011.01411.x
   Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010
   Sugiyama T, 2007, EXP EYE RES, V85, P406, DOI 10.1016/j.exer.2007.06.008
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takata S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09898
   Tan JTM, 2008, AM J PHYSIOL-CELL PH, V295, pC740, DOI 10.1152/ajpcell.00333.2007
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Thompson CB, 2014, EMBO J, V33, P1420, DOI 10.15252/embj.201488785
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Vallee A., 2017, ACTA BIOCH BIOPH SIN, P1, DOI DOI 10.1093/ABBS/GMX073
   Vallee A, 2017, J MOL NEUROSCI, V62, P368, DOI 10.1007/s12031-017-0947-4
   Vallee A, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00352
   Vallee A, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00459
   van Neerven S, 2008, PROG NEUROBIOL, V85, P433, DOI 10.1016/j.pneurobio.2008.04.006
   Vanden Heuvel JP, 2012, PROG MOL BIOL TRANSL, V108, P75, DOI 10.1016/B978-0-12-398397-8.00004-6
   Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200
   Wang HB, 2016, MOL VIS, V22, P189
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wilkinson-Berka JL, 2007, AM J HYPERTENS, V20, P423, DOI 10.1016/j.amjhyper.2006.09.018
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116
   Xu CY, 2016, CURR STEM CELL RES T, V11, P247, DOI 10.2174/1574888X10666150723145707
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Xu Y, 2014, J MOL NEUROSCI, V52, P331, DOI 10.1007/s12031-013-0153-y
   Yamasaki S, 2004, RHEUMATOLOGY, V43, P448, DOI 10.1093/rheumatology/keh092
   Yokosako K, 2014, OPEN OPHTHALMOL J, V8, P39, DOI 10.2174/1874364101408010039
   Yue XA, 2010, BRAIN RES, V1366, P27, DOI 10.1016/j.brainres.2010.10.032
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang HH, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006189, 10.1371/journal.pone.0007826]
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang P, 2009, GRAEF ARCH CLIN EXP, V247, P633, DOI 10.1007/s00417-008-1031-0
   Zhang S, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/275435
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zhang-Gandhi CX, 2007, J NEUROIMMUNOL, V183, P50, DOI 10.1016/j.jneuroim.2006.11.007
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 177
TC 16
Z9 16
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 1
PY 2017
VL 188
BP 123
EP 130
DI 10.1016/j.lfs.2017.09.008
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FI8LH
UT WOS:000412253600016
PM 28887057
DA 2022-11-30
ER

PT J
AU Jimenez, JR
   Ortiz, C
   Perez-Ocon, F
   Castro, JJ
AF Jimenez, Jose R.
   Ortiz, Carolina
   Perez-Ocon, Francisco
   Castro, Jose J.
TI Objective and subjective optical-quality measurements in subjects with
   keratitis and age-related macular degeneration
SO JOURNAL OF MODERN OPTICS
LA English
DT Article
DE aberrations; ocular scattering; contrast-sensitivity; keratitis;
   age-related macular degeneration
ID IMAGE QUALITY; CONTRAST SENSITIVITY; VISUAL PERFORMANCE; ABERRATIONS;
   INSTRUMENT
AB The use of commercial devices that objectively measure retinal image quality has increased in recent years although limited mostly to the analysis of surgical emmetropization techniques. In this work, we propose the use of optical-quality devices (an aberrometer and a double-pass device) to be extended to other highly prevalent ocular pathologies such as keratitis and age-related macular degeneration. For this, we determined whether the objective data correlate with visual performance. Data, including the contrast-sensitivity function, were taken for 26 patients. The results show a clear correspondence between objective and psychophysical measurements, revealing that optical-quality devices can be useful for additional visual clinical applications.
C1 [Jimenez, Jose R.; Ortiz, Carolina; Perez-Ocon, Francisco; Castro, Jose J.] Univ Granada, Dept Opt, Granada, Spain.
C3 University of Granada
RP Jimenez, JR (通讯作者)，Univ Granada, Dept Opt, Granada, Spain.
EM jrjimene@ugr.es
RI Jimenez, Jose R/C-9362-2017; Ortiz, Carolina/ABE-8963-2020;
   Castro-Torres, José J./D-3828-2013; ORTIZ, CAROLINA/B-1280-2016
OI Jimenez, Jose R/0000-0002-0333-6883; Ortiz,
   Carolina/0000-0003-0248-1699; Castro-Torres, José
   J./0000-0003-0461-925X; ORTIZ, CAROLINA/0000-0003-0248-1699; Perez-Ocon,
   Francisco/0000-0001-9532-3328
FU ONCE Foundation (Spain); Ministerio de Ciencia y Tecnologia (Spain) [FIS
   2006- 01369]; Junta de Andalucia (Spain) [P06-FQM-01359]
FX The authors wish to thank David Nesbitt for translating the text into
   English. This research was supported by the ONCE Foundation (Spain),
   Ministerio de Ciencia y Tecnologia (Spain) Grant FIS 2006- 01369 and
   Junta de Andalucia (Spain) Grant P06-FQM-01359.
CR CAMPBELL FW, 1967, J PHYSIOL-LONDON, V192, P345, DOI 10.1113/jphysiol.1967.sp008304
   Diaz-Douton F, 2006, INVEST OPHTH VIS SCI, V47, P1710, DOI 10.1167/iovs.05-1049
   Fosse P, 2001, VISUAL IMPAIRMENT RE, V3, P111
   Guell JL, 2004, J CATARACT REFR SURG, V30, P1598, DOI 10.1016/j.jcrs.2004.04.031
   Jimenez JR, 2008, J MOD OPTIC, V55, P783, DOI 10.1080/09500340701467637
   Jimenez JR, 1999, COLOR RES APPL, V24, P207, DOI 10.1002/(SICI)1520-6378(199906)24:3<207::AID-COL7>3.0.CO;2-V
   Jimenez JR, 2002, PERCEPT PSYCHOPHYS, V64, P140, DOI 10.3758/BF03194563
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   LAKSHMINARAYANAN V, 1995, OPTOMETRY VISION SCI, V72, P511, DOI 10.1097/00006324-199507000-00012
   McLellan JS, 2006, VISION RES, V46, P3009, DOI 10.1016/j.visres.2006.03.005
   PIERREYVES R, 2006, GRAEFES ARCH CLIN EX, V244, P210
   Rimbergas S, 2005, J MOD OPTIC, V52, P1255, DOI 10.1080/09500340512331330837
   Rocha KM, 2006, AM J OPHTHALMOL, V142, P750, DOI 10.1016/j.ajo.2006.06.031
   Yoon GY, 2002, J OPT SOC AM A, V19, P266, DOI 10.1364/JOSAA.19.000266
NR 14
TC 6
Z9 6
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0950-0340
EI 1362-3044
J9 J MOD OPTIC
JI J. Mod. Opt.
PY 2008
VL 55
IS 15
BP 2371
EP 2380
DI 10.1080/09500340802130688
PG 10
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 339PQ
UT WOS:000258589900004
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
AF Rovner, Barry W.
   Casten, Robin J.
TI Preventing late-life depression in age-related macular degeneration
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE problem-solving treatment; vision loss; age-related macular
   degeneration; depression
ID OLDER-ADULTS; POPULATION; DIAGNOSIS; SYMPTOMS
AB Objective: To determine whether problem-solving treatment (PST) can prevent depressive disorders in patients with age-related macular degeneration (AMD). Design: Two hundred six patients with AMD were randomly assigned to PST (n = 105) or usual care (n = 101). PST therapists delivered six PST sessions over 8 weeks in subjects' homes. Measurements: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Diagnoses of Depressive Disorders, Hamilton Depression Rating Scale scores, and rates of relinquishing valued activities were assessed at 2 months for short-term effects and 6 months for maintenance effects. Results: The 2-month incidence rate of depressive disorders in PST-treated subjects was significantly lower than controls (11.6% versus 23.2%, respectively; OR = 0.43; 95% CI [0.20, 0.95]). PST also reduced the odds of relinquishing a valued activity (OR = 0.48; 95% CI [0.25, 0.96]); this effect mediated the relationship between treatment group and depression. By 6 months most earlier observed benefits had diminished. Secondary analyses showed that a minimal level of depressive symptoms were disabling and predicted incident depressive disorders. Conclusion: PST prevented depressive disorders and loss of valued activities as a short-term treatment but these benefits were not maintained over time. To sustain PST's effect, an intervention that uses a problem-solving framework to enhance rehabilitative skills may be necessary.
C1 [Rovner, Barry W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Neurol, Philadelphia, PA 19107 USA.
   [Casten, Robin J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University
RP Rovner, BW (通讯作者)，Jefferson Hosp Neurosci, 900 Walnut St,4th Floor, Philadelphia, PA 19107 USA.
EM barry.rovner@jefferson.edu
FU NATIONAL EYE INSTITUTE [U01EY015839] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH
   RePORTER; NEI NIH HHS [U01 EY015839, U01 EY 015839] Funding Source:
   Medline; NIMH NIH HHS [R0 1 MH61331, R01 MH061331] Funding Source:
   Medline
CR Bilsbury CD, 2002, ACTA PSYCHIAT SCAND, V106, P5, DOI 10.1046/j.0001-690x.2002.00052.x
   Bruce ML, 1999, AM J GERIAT PSYCHIAT, V7, P8
   Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081
   Charney DS, 2003, ARCH GEN PSYCHIAT, V60, P664, DOI 10.1001/archpsyc.60.7.664
   Ciechanowski P, 2004, JAMA-J AM MED ASSOC, V291, P1569, DOI 10.1001/jama.291.13.1569
   Crystal S, 2003, J AM GERIATR SOC, V51, P1718, DOI 10.1046/j.1532-5415.2003.51555.x
   Cuijpers P, 2006, INT J GERIATR PSYCH, V21, P811, DOI 10.1002/gps.1565
   DZURILLA PJ, 1986, PROBLEM SOLVING THER
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hegel MT, 2004, FAM MED, V36, P204
   Hegel MT, 2003, PROBLEM SOLVING TREA
   Kennedy G J, 1990, J Community Health, V15, P93, DOI 10.1007/BF01321314
   Lyness JM, 2007, AM J GERIAT PSYCHIAT, V15, P214, DOI 10.1097/01.JGP.0000235763.50230.83
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Mrazek P., 1994, REDUCING RISK MENTAL
   Mulsant BH, 1997, INT J GERIATR PSYCH, V12, P537, DOI 10.1002/(SICI)1099-1166(199705)12:5<537::AID-GPS542>3.0.CO;2-Z
   Norton MC, 2006, AM J GERIAT PSYCHIAT, V14, P237, DOI 10.1097/01.JGP.0000196626.34881.42
   PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15
   Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2006, OPHTHALMOLOGY, V113, P1743, DOI 10.1016/j.ophtha.2006.05.033
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
NR 24
TC 53
Z9 54
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2008
VL 16
IS 6
BP 454
EP 459
DI 10.1097/JGP.0b013e31816b7342
PG 6
WC Geriatrics & Gerontology; Gerontology; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Psychiatry
GA 307GJ
UT WOS:000256307100004
PM 18515689
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sivaprasad, S
   Banister, K
   Azuro-Blanco, A
   Goulao, B
   Cook, JA
   Hogg, R
   Scotland, G
   Heimann, H
   Lotery, A
   Ghanchi, F
   Gale, R
   Menon, G
   Downey, L
   Hopkins, N
   Scanlon, P
   Burton, B
   Ramsay, C
   Chakravarthy, U
AF Sivaprasad, Sobha
   Banister, Katie
   Azuro-Blanco, Augusto
   Goulao, Beatriz
   Cook, Jonathan A.
   Hogg, Ruth
   Scotland, Graham
   Heimann, Heinrich
   Lotery, Andrew
   Ghanchi, Faruque
   Gale, Richard
   Menon, Geeta
   Downey, Louise
   Hopkins, Nicola
   Scanlon, Peter
   Burton, Ben
   Ramsay, Craig
   Chakravarthy, Usha
TI Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with
   Unilateral Neovascular Age-Related Macular Degeneration Early Detection
   of Neovascular Age-Related Macular Degeneration Study
SO OPHTHALMOLOGY
LA English
DT Article
DE Amsler; Diagnostic accuracy; Fluorescein angiography; Neovascular
   agerelated; macular degeneration; OCT; Sensitivity and specificity;
   Visual acuity
ID EVALUATING FLUORESCEIN ANGIOGRAMS; OPTICAL COHERENCE TOMOGRAPHY;
   PROPORTIONS; THERAPY; SYSTEM; AREDS; RISK
AB Purpose: To evaluate the diagnostic accuracy of routinely used tests of visual function and retinal morphology compared with fundus fluorescein angiography (FFA) to detect onset of active macular neovascularization in unaffected fellow eyes of patients with unilateral neovascular age-related macular degeneration (nAMD).
   Design: Prospective diagnostic accuracy cohort study conducted in 24 eye clinics in the United Kingdom over 3 years.
   Participants: Older adults (>50 years) with recently diagnosed unilateral nAMD with a fellow (study) eye free of nAMD.
   Methods: Self-reported vision, Amsler, clinic-measured visual acuity (VA), fundus assessment, and spectral domain OCT. The reference standard is FFA.
   Main Outcome Measures: Sensitivity and specificity of the 5 index tests.
   Results: Of 552 participants monitored for up to 3 years, 145 (26.3%) developed active nAMD in the study eye, of whom 120 had an FFA at detection and constituted the primary analysis cohort. Index test positives at nAMD detection in those confirmed by FFA were self-reported vision much worse (5), distortion on Amsler (33), 10-letter decrease in acuity from baseline (36), fundus examination (64), and OCT (110). Percentage index test sensitivities were: self-reported vision 4.2 (95% confidence interval [CI], 1.6-9.8); Amsler 33.7 (95% CI, 25.1-43.5); VA 30.0 (95% CI, 22.5-38.7); fundus examination 53.8 (95% CI, 44.8-62.5); and OCT 91.7 (95% CI, 85.2-95.6). All 5 index test specificities were high at 97.0 (95% CI, 94.6-98.5), 81.4 (95% CI, 76.4-85.5), 66.3 (95% CI, 61.0-71.1), 97.6 (95% CI, 95.3-98.9), and 87.8 (95% CI, 83.8-90.9), respectively. The combination of OCT with one other index test that was a secondary outcome measure increased sensitivity marginally and decreased specificity for all combinations except fundus examination.
   Conclusions: Tests of self-reported change in vision, unmasking of new distortion, measurements of acuity, and fundus checks to diagnose active nAMD performed poorly in contrast to OCT. Our findings support a change to guidelines in clinical practice to monitor for onset of nAMD. Crown Copyright (C) 2021 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology.
C1 [Sivaprasad, Sobha] Moorfields Natl Inst Hlth Res Biomed Res Ctr, London, England.
   [Banister, Katie; Goulao, Beatriz; Ramsay, Craig] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland.
   [Azuro-Blanco, Augusto; Hogg, Ruth; Chakravarthy, Usha] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Cook, Jonathan A.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
   [Scotland, Graham] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.
   [Heimann, Heinrich] Royal Liverpool Univ Hosp Fdn Trust, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Lotery, Andrew] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Ghanchi, Faruque] Bradford Teaching Hosp NHS Fdn Trust, Bradford, W Yorkshire, England.
   [Gale, Richard] York Teaching Hosp NHS Fdn Trust, York, N Yorkshire, England.
   [Menon, Geeta] Frimley Hlth NHS Fdn Trust, Surrey, England.
   [Downey, Louise] Hull & East Yorkshire NHS Trust, Kingston Upon Hull, N Humberside, England.
   [Hopkins, Nicola] Essex Cty Hosp, Colchester, Essex, England.
   [Scanlon, Peter] Gloucestershire Hosp NHSFT, Cheltenham, Glos, England.
   [Burton, Ben] James Paget Univ Hosp, Gorleston, England.
C3 University of Aberdeen; Queens University Belfast; University of Oxford;
   University of Aberdeen; University of Southampton
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Inst Clin Sci A, Ctr Publ Hlth, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravathy@qub.ac.uk
RI Ramsay, Craig/AAD-8249-2021; Cook, Jonathan/D-3648-2015
OI Ramsay, Craig/0000-0003-4043-7349; Cook, Jonathan/0000-0002-4156-6989;
   Sivaprasad, Sobha/0000-0001-8952-0659; Burton, Ben/0000-0001-9579-9078;
   Hogg, Ruth/0000-0001-9413-2669; Goulao, Beatriz/0000-0003-1490-7183
FU National Institute for Health Research Health Technology Assessment
   Programme [12/142/07]; Chief Scientist Office of the Scottish Government
   Health and Social Care Directorate
FX The project was funded by the National Institute for Health Research
   Health Technology Assessment Programme (Project Number: 12/142/07) and
   will be published in full in Health Technology Assessment. The Health
   Services Research Unit and the Health Economics Research Unit are core
   funded by the Chief Scientist Office of the Scottish Government Health
   and Social Care Directorate.
CR Banister K, 2016, OPHTHALMOLOGY, V123, P930, DOI 10.1016/j.ophtha.2016.01.041
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brown GC, 2020, AM J OPHTHALMOL, V218, P225, DOI 10.1016/j.ajo.2020.05.029
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Faes L, 2019, EYE, V33, P1327, DOI 10.1038/s41433-019-0421-3
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Karnon J, 2008, Health Technol Assess, V12, piii
   Lee AY, 2016, OPHTHALMOLOGY, V123, P1252, DOI 10.1016/j.ophtha.2016.02.014
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   Mendonca LSM, OPHTHALMOLOGY, V128, P1109
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Mowatt G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18690
   Nahen K, 2020, KLIN MONATSBL AUGENH, V237, P1410, DOI 10.1055/a-1271-6834
   Newcombe RG, 1998, STAT MED, V17, P2635, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.3.CO;2-3
   Obuchowski NA, 1998, STAT MED, V17, P1495, DOI 10.1002/(SICI)1097-0258(19980715)17:13<1495::AID-SIM863>3.0.CO;2-I
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Yu HJ, 2021, OPHTHALMOL RETINA, V5, P348, DOI 10.1016/j.oret.2020.08.003
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zayit-Soudry S, 2007, RETINA-J RET VIT DIS, V27, P798, DOI 10.1097/IAE.0b013e31802c50a3
   Zhou XH., 2002, STAT METHODS DIAGNOS, DOI 10.1002/9780470317082
NR 31
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2021
VL 128
IS 12
BP 1736
EP 1747
DI 10.1016/j.ophtha.2021.07.025
EA NOV 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA9BB
UT WOS:000720933000014
PM 34329651
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jiang, H
   Qu, Y
   Dang, GF
   Mang, X
   Yin, NN
   Mang, Y
   Bi, HS
   Pan, XM
   Xu, XY
   Zhou, F
   Dai, H
AF Jiang, Hua
   Qu, Yi
   Dang, Guangfu
   Mang, Xiao
   Yin, Ningning
   Mang, Ying
   Bi, Hongsheng
   Pan, Xuemei
   Xu, Xiaoyi
   Zhou, Fang
   Dai, Hong
TI ANALYSES OF SINGLE NUCLEOTIDE POLYMORPHISMS AND HAPLOTYPE LINKAGE OF
   LOC387715 AND THE HTRA1 GENE IN EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION IN A CHINESE COHORT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy susceptibility
   2 (ARMS2); allele; case-control study; Chinese; genotype; haplotype;
   high-temperature requirement A-1 (HTRA1); LOC387715; single nucleotide
   polymorphism
ID COMPLEMENT FACTOR-H; JAPANESE POPULATION; PROMOTER POLYMORPHISM; STRONG
   ASSOCIATION; VISUAL IMPAIRMENT; VARIANT INCREASES; ADULT-POPULATION;
   RISK-FACTORS; BEIJING EYE; PREVALENCE
AB Purpose: To investigate the effect of single nucleotide polymorphisms (SNPs) and haplotypes in the genes encoding age-related maculopathy susceptibility 2 (LOC387715/ARMS2) and high-temperature requirement A-1 (HTRA1) in a case-control study in a Chinese cohort of individuals with exudative age-related macular degeneration (AMD).
   Methods: We genotyped 2 SNPs, namely, LOC387715 rs10490924 and HTRA1 rs11200638, in 159 exudative AMD patients and 140 age- and sex-matched control subjects. All the four possible haplotypes of these two SNPs were detected. Comparisons of the risk genotypes and risk or protective haplotypes across multiple populations were performed.
   Results: Allelic or genotype association tests yielded significant results at P < 0.001. We observed that homozygous risk genotypes (TT in rs10490924 and AA in rs11200638) were more strongly associated with AMD than the heterozygous genotypes (GT in rs10490924 and geographic atrophy in rs11200638) for both SNPs. Comparisons of the odds ratios for genotypes revealed that there is ethnic disparity in AMD prevalence, even within the Chinese population. The haplotype TA, comprising both the SNPs, was identified as an at-risk factor and was significantly associated with AMD, whereas the protective haplotype GG was significantly overrepresented in the controls (P < 0.001). The frequency of the TA haplotype was relatively higher in the Chinese population than in the white population in both groups, whereas the frequency of the GG haplotype was relatively lower in the Chinese controls than in the white and Japanese controls.
   Conclusion: Both SNPs are significantly associated with exudative AMD in the Chinese cohort and seem to contribute equally to the disease status. A higher frequency of homozygous risk genotypes and risk haplotype and a lower frequency of protective haplotype in the Chinese may be the cause of higher prevalence of exudative AMD in the Chinese than in the whites.
C1 [Jiang, Hua; Qu, Yi; Mang, Xiao; Mang, Ying; Xu, Xiaoyi; Zhou, Fang] Shandong Univ, Dept Ophthalmol, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
   [Dang, Guangfu] Qianfoshan Hosp, Jinan, Peoples R China.
   [Yin, Ningning; Dai, Hong] Beijing Hosp, Jinan, Peoples R China.
   [Bi, Hongsheng; Pan, Xuemei] Shierming Eye Hosp, Jinan, Peoples R China.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Beijing Hospital
RP Qu, Y (通讯作者)，Shandong Univ, Dept Ophthalmol, Qilu Hosp, 107 Wenhuaxi Rd, Jinan 250100, Shandong, Peoples R China.
EM drquyi@gmail.com
FU Department of Science and Technology of Shandong Province [Y2008C89,
   2007GG30002026]
FX Supported in part by Grants Y2008C89 and 2007GG30002026 from the
   Department of Science and Technology of Shandong Province.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 40
TC 24
Z9 27
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2009
VL 29
IS 7
BP 974
EP 979
DI 10.1097/IAE.0b013e3181a3b90e
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 470DT
UT WOS:000267955400011
PM 19491722
DA 2022-11-30
ER

PT J
AU Pai, ASI
   Mitchell, P
   Rochtchina, E
   Iyengar, S
   Wang, JJ
AF Pai, Amy Shih-I
   Mitchell, Paul
   Rochtchina, Elena
   Iyengar, Sudha
   Wang, Jie Jin
TI Complement Factor H and the Bilaterality of Age-Related Macular
   Degeneration The Blue Mountains Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY LESIONS; STRONG ASSOCIATION; GRADING SYSTEM; POLYMORPHISM;
   SUSCEPTIBILITY; RISK; POPULATION; VARIANT; GENE; PROGRESSION
AB Objective: To determine whether complement factor H (CFH Y402H) genotype influences bilateral involvement of age-related macular degeneration (AMD) lesions.
   Methods: The Blue Mountains Eye Study (BMES) followed up 3654 participants 49 years and older (BMES 1, 1992-1994), including 2335 (75.3% of survivors) at the 5-year (BMES 2, 1997-1999) and 1952 (76.5%) at the 1.0-year (BMES 3, 2002-2004) examinations. Age-related macular degeneration retinal photographic grading used the Wisconsin system. Early and late AMD included prevalent and incident cases from all visits. CFH genotyping used TaqMan assays.
   Results: Of 767 AMD cases, 53.3% of early and 53.1% of late AMD cases were bilateral. After adjusting for age and other covariants, the CFH CC (Y402H polymorphism) genotype was associated with an increased likelihood of bilateral compared with unilateral involvement by any soft drusen (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.4-4.5), distinct soft drusen (OR, 2.8; 95% CI, 1.0-8.1.), and pigmentary abnormalities (OR, 1.7; 95% CI, 1.0-2.8). We could not establish significant associations between this genotype and the bilaterality of late AMD (OR, 1.8; 95% CI, 0.4-7.7), either geographic atrophy (OR, 0.6; 95% CI, 0.07-4.6) or neovascular AMD (OR, 3.4; 95% CI; 0.3-41.4).
   Conclusions: Persons with the CFH CC genotype at any given age have an increased likelihood of bilateral compared with unilateral involvement of some early AMD lesions.
C1 [Pai, Amy Shih-I; Mitchell, Paul; Rochtchina, Elena; Wang, Jie Jin] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Pai, Amy Shih-I; Mitchell, Paul; Rochtchina, Elena; Wang, Jie Jin] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
   [Wang, Jie Jin] Univ Melbourne, Retinal Vasc Imaging Ctr, Ctr Eye Res Australia, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Iyengar, Sudha] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; Centre for Eye Research Australia; University of
   Melbourne; Case Western Reserve University
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Wang, Jie Jin/P-1499-2014; wang, jie/GRS-0942-2022; Mitchell,
   Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
FU National Health and Medical Research Council (Australia) [974159,
   991407, 211069]
FX This study was supported by National Health and Medical Research Council
   (Australia) grants 974159, 991407, and 211069.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KINOSHITA T, 1995, CANCER, V76, P2504, DOI 10.1002/1097-0142(19951215)76:12<2504::AID-CNCR2820761215>3.0.CO;2-I
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509
   ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153
   Souied EH, 2005, MOL VIS, V11, P1135
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Wachtlin J, 2002, ARCH OPHTHALMOL-CHIC, V120, P860
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 32
TC 14
Z9 15
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2009
VL 127
IS 10
BP 1339
EP 1344
DI 10.1001/archophthalmol.2009.239
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 505GK
UT WOS:000270679900014
PM 19822851
OA Bronze
DA 2022-11-30
ER

PT J
AU Kadonosono, K
   Arakawa, A
   Yamane, S
   Inoue, M
   Yamakawa, T
   Uchio, E
   Yanagi, Y
AF Kadonosono, Kazuaki
   Arakawa, Akira
   Yamane, Shin
   Inoue, Maiko
   Yamakawa, Tadashi
   Uchio, Eiichi
   Yanagi, Yasuo
TI Displacement of Submacular Hemorrhages in Age-Related Macular
   Degeneration with Subretinal Tissue Plasminogen Activator and Air
SO OPHTHALMOLOGY
LA English
DT Article
ID PNEUMATIC DISPLACEMENT; INJECTION; MANAGEMENT; SURGERY; SECONDARY;
   REMOVAL
AB Objective: To study the anatomic and visual outcomes of a surgical procedure in which tissue plasminogen activator and air are injected subretinally to displace massive submacular hemorrhages secondary to age-related macular degeneration.
   Design: Prospective, consecutive, interventional case series.
   Participants: Thirteen consecutive patients (13 eyes) with massive submacular hemorrhages secondary to age-related macular degeneration.
   Intervention: The surgical procedure consisted of a 25-gauge vitrectomy and submacular injection of tissue plasminogen activator (25 mu g) and 0.4 ml air with a microneedle having an outer diameter of 50 mu m. The procedure was followed by having the patient remain in the prone position overnight.
   Main Outcome Measures: Mean visual acuity change from baseline, mean central lesion thickness change from baseline, fluorescein angiography findings, and surgical complications.
   Results: Total subfoveal blood displacement was achieved in all 13 eyes (100%). Central lesion thickness decreased from a mean baseline value of 867 mm to a mean value of 379 mu m at 1 month after surgery. There was visual improvement in 11 eyes, no visual improvement in 1 eye, and poorer vision in 1 eye. The mean change in Early Treatment Diabetic Retinopathy Study letter score from baseline was 19.4 letters at 1 month (P = 0.006) and 23.3 letters at 3 months (P = 0.001). There was intraoperative macular hole formation.
   Conclusions: Submacular air injection with a microneedle facilitates displacement of clots dissolved with tissue plasminogen activator with fewcomplications and results in earlier visual improvement. (C) 2015 by the American Academy of Ophthalmology.
C1 [Kadonosono, Kazuaki; Arakawa, Akira; Yamane, Shin; Inoue, Maiko; Yamakawa, Tadashi] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa 2320024, Japan.
   [Uchio, Eiichi] Fukuoka Univ, Dept Ophthalmol, Fukuoka 81401, Japan.
   [Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo 113, Japan.
C3 Yokohama City University; Fukuoka University; University of Tokyo
RP Kadonosono, K (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, 4-57 Urafune Cho Minami Ku, Yokohama, Kanagawa 2320024, Japan.
EM kado@med.yokohama-cu.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Yanagi, Yasuo/AAF-2670-2020
OI Yanagi, Yasuo/0000-0002-0362-7285
FU Grants-in-Aid for Scientific Research [15K10911] Funding Source: KAKEN
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Berger JW, 1998, RETINA-J RET VIT DIS, V18, P84
   Berger JW, 1998, RETINA, V18, P86
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hillenkamp J, 2012, OPHTHALMOLOGE, V109, P648, DOI 10.1007/s00347-012-2564-5
   Kadonosono K, 2013, JAMA OPHTHALMOL, V131, P783, DOI 10.1001/jamaophthalmol.2013.2585
   Kadonosono K, 2011, INVEST OPHTH VIS SCI, V52, P5790, DOI 10.1167/iovs.11-7327
   Kamei M, 1996, AM J OPHTHALMOL, V121, P267, DOI 10.1016/S0002-9394(14)70274-0
   Martel JN, 2013, JAMA OPHTHALMOL, V131, P1632, DOI 10.1001/jamaophthalmol.2013.5464
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   TOTH CA, 1992, AM J OPHTHALMOL, V113, P175, DOI 10.1016/S0002-9394(14)71530-2
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 21
TC 37
Z9 38
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2015
VL 122
IS 1
BP 123
EP 128
DI 10.1016/j.ophtha.2014.07.027
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1XK
UT WOS:000346737000028
PM 25200400
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Spandau, UH
   Harder, B
   Vossmerbaeumer, U
   Kamppeter, BA
AF Jonas, JB
   Spandau, UH
   Harder, B
   Vossmerbaeumer, U
   Kamppeter, BA
TI Intereye difference in exudative age-related macular degeneration with
   minimally classic or occult subfoveal neovascularization after
   unilateral intravitreal injection of triamcinolone acetonide
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NONINFECTIOUS ENDOPHTHALMITIS; CHOROIDAL NEOVASCULARIZATION; CRYSTALLINE
   CORTISONE; PHOTODYNAMIC THERAPY; ADJUNCTIVE TREATMENT; VERTEPORFIN;
   MACULOPATHY; INHIBITION; PREVALENCE; RECURRENCE
AB PURPOSE: To report on visual outcome after intravitreal injection of triamcinolone acetonide for exudative age-related macular degeneration.
   DESIGN: Interventional comparative non-randomized clinical trial.
   METHODS: SETTING: Institutional. PATIENTS: Twenty consecutive patients with bilateral exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularisation. INTERVENTIONS: Unilateral intravitreal injection of about 20 mg triamcinolone ace. tonide into the eye (study group) more severely affected or showing more pronounced progression of the disease. Mean follow,up was 13.5 +/- 4.1 months. MAIN OUTCOME MEASURES: Visual acuity.
   RESULTS: In the study group, visual acuity increased significantly (P < 0.001) from 0.96 +/- 0.32 logMar to a mean maximum of 0.76 +/- 0.30 logMar during follow,up. An increase in best visual acuity during follow-up was found in 18 (90%) eyes. In 11 (55%) eyes and 7 (35%) eyes, respectively, best visual acuity increased by at least two Snellen lines and three Snellen lines, respectively. In the control group, visual acuity at baseline and the highest visual acuity measurements during follow-up did not vary significantly (P = 0.90). Comparing study group and control group, visual acuity gain was significantly (P = 0.003) higher in the study group. Correspondingly, the number of eyes with an increase in visual acuity (P = 0.002) and with an increase in visual acuity higher >= 3 lines compared to a loss of >= 3 lines was significantly (P 0.027) higher in the study group.
   CONCLUSIONS: Intravitreal triamcinolone acetonide may temporarily increase visual acuity in eyes with exudative age-related macular degeneration. (c) 2005 by Elsevier Inc. All rights reserved.
C1 Fac Clin Med, Dept Ophthalmol, Mannheim, Germany.
   Heidelberg Univ, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Benz MS, 2003, ARCH OPHTHALMOL-CHIC, V121, P271
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   JONAS JB, 2004, IN PRESS EYE    0625
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Parke DW, 2003, AM J OPHTHALMOL, V136, P918, DOI 10.1016/j.ajo.2003.08.051
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spandau UHM, 2005, AM J OPHTHALMOL, V139, P712, DOI 10.1016/j.ajo.2004.09.059
   SPANDAU UHM, 2005, IN PRESS BR J OPHTHA
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
NR 42
TC 27
Z9 30
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2005
VL 139
IS 6
BP 1073
EP 1079
DI 10.1016/j.ajo.2005.01.032
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 939BC
UT WOS:000230046100016
PM 15953439
DA 2022-11-30
ER

PT J
AU Taylor, HR
   Tikellis, G
   Robman, LD
   McCarty, CA
   McNeil, JJ
AF Taylor, HR
   Tikellis, G
   Robman, LD
   McCarty, CA
   McNeil, JJ
TI Vitamin E supplementation and macular degeneration: randomised
   controlled trial
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID AGE-RELATED MACULOPATHY; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE;
   RISK-FACTORS; PROGRESSION
AB Objective To determine whether vitamin E supplementation influences the incidence or rate of progression of age related maculopathy (AMD).
   Design Prospective randomised placebo controlled clinical trial.
   Setting An urban study centre in a residential area supervised by university research staff.
   Participants 1193 healthy volunteers aged between 55 and 80 years; 73% completed the trial on full protocol.
   Interventions Vitamin E 500 IU or placebo daily for four years.
   Main outcome measures Primary outcome: development of early age related macular degeneration in retinal photographs. Other pleasures included alternative definitions of age related macular degeneration, progression, changes in component features, Visual acuity, and visual function
   Results The incidence of early age related macular degeneration (early AMD 3) was 8.6% in those receiving vitamin E versus 8.1% in those on placebo (relative risk 1.05, 95% confidence interval 0.69 to 1.61). For late disease the incidence was 0.8% versus 0.6% (1.36, 0.67 to 2.77). Further analysis showed no consistent differences in secondary outcomes.
   Conclusion Daily supplement with vitamin E supplement does not prevent the development or progression of early or later stages of age related macular degeneration.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 8002, Australia.
   Monash Univ, Dept Epidemiol & Prevent Med, Alfred Hosp, Caulfield, Vic 3145, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Florey
   Institute of Neuroscience & Mental Health; Monash University
RP Taylor, HR (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 8002, Australia.
EM h.taylor@unimelb.edu.au
RI McNeil, John/L-6440-2019
OI McNeil, John/0000-0002-1049-5129; McCarty,
   Catherine/0000-0003-1089-0142; Taylor, Hugh/0000-0002-9437-784X
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Garrett SKM, 2000, J CLIN EPIDEMIOL, V53, P541, DOI 10.1016/S0895-4356(99)00153-5
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST S, 1995, ARCH OPHTHALMOL-CHIC, V113, P1377, DOI 10.1001/archopht.1995.01100110037022
   Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302
NR 25
TC 110
Z9 117
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD JUL 6
PY 2002
VL 325
IS 7354
BP 11
EP 14
DI 10.1136/bmj.325.7354.11
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 573BC
UT WOS:000176808600014
PM 12098721
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ng, EWM
   Adamis, AP
AF Ng, EWM
   Adamis, AP
TI Targeting angiogenesis, the underlying disorder in neovascular
   age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
DE age factor; anecortave; antiangiogenesis; macular degeneration;
   pegaptanib; ranibizumab; triamcinolone acetonide; vascular endothelial
   growth factor
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   EPITHELIUM-DERIVED FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   RETINAL-PIGMENT EPITHELIUM; VASCULAR-PERMEABILITY FACTOR; FACTOR VEGF;
   IRIS NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; INCREASED EXPRESSION
AB Angiogenesis has a causal role in many diseases, including neovascular age-related macular degeneration (AMD). Identification of key regulators of angiogenesis, including vascular endothelial growth factor (VEGF), fibroblast growth factor 2, pigment epithelium-derived growth factor, angiopoietins and extracellular matrix molecules, has facilitated the development of novel therapeutic agents that target the underlying pathological angiogenic process. Among these,VEGF serves as a "master switch" for many ocular neovascular conditions through its promotion of endothelial cell proliferation and survival, vascular permeability and ocular inflammation. Two anti-VEGF agents are now clinically available: bevacizumab, an antibody for metastatic colorectal cancer, and pegaptanib sodium, an aptamer for neovascular AMD. Unlike bevacizumab, which binds all VEGF isoforms, pegaptanib targets only VEGF(165) the isoform responsible for pathological ocular neovascularization and thus an ideal target for treatment of AMD. Although other therapies targeting angiogenesis in AMD are in clinical development, to date, pegaptanib is the only therapy approved by the Food and Drug Administration of the United States for the treatment of all neovascular AMD and represents a valuable addition to the hitherto limited options available for patients.
C1 Eyetech Pharmaceut Inc, New York, NY 10036 USA.
RP Adamis, AP (通讯作者)，Eyetech Pharmaceut Inc, 3 Times Sq,12th Floor, New York, NY 10036 USA.
EM Tony.Adamis@eyetech.com
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   *ALN PHARM, SCI TECHN
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   *ANG FDN, UND ANG
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P482, DOI 10.1001/archopht.1963.00960050484010
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BLEI F, 1993, J CELL PHYSIOL, V155, P568, DOI 10.1002/jcp.1041550315
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chang T. S., 2004, INVEST OPHTHALMOL VI, V45
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Ciulla Thomas A, 2004, Curr Opin Ophthalmol, V15, P211, DOI 10.1097/01.icu.0000120711.35941.76
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   DAMICO LA, 2004, INVEST OPHTHALMOL VI, V45
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DONSHIK PC, 1981, ANN OPHTHALMOL, V13, P29
   Duh EJ, 2004, AM J OPHTHALMOL, V137, P668, DOI 10.1016/j.ajo.2003.11.015
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   GARCIA CA, 2004, INVEST OPHTHALMOL VI, V45
   Gass J.D., 1967, AM J OPHTHALMOL, V63, pS1
   GAUDREAULT J, 2004, INVEST OPHTHALMOL VI, V45
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968
   Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785
   HEIER JS, 2003, INVEST OPHTHALMOL VI, V44
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Kamizuru H, 2001, INVEST OPHTH VIS SCI, V42, P2664
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lowe J, 2003, INVEST OPHTHALMOL VI, V44
   Luna J, 1996, LAB INVEST, V75, P563
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   McColm J, 2004, MOL VIS, V10, P512
   Miller JW, 2003, OPHTHALMOLOGY, V110, P2384, DOI 10.1016/j.ophtha.2003.09.001
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Moromizato Y, 2000, AM J PATHOL, V157, P1277, DOI 10.1016/S0002-9440(10)64643-3
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Ogata N, 2002, AM J OPHTHALMOL, V134, P348, DOI 10.1016/S0002-9394(02)01568-4
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   *OX INC OPHTH, PIP
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   *REG PHARM INC, DIS IND VASC EYE CAU
   Renno RZ, 2004, ARCH OPHTHALMOL-CHIC, V122, P1002, DOI 10.1001/archopht.122.7.1002
   Roberts WG, 1997, CANCER RES, V57, P765
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHIMA DT, 2004, INVEST OPHTHALMOL VI, V45
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   SOUBRANE G, 1994, CURR EYE RES, V13, P183, DOI 10.3109/02713689408995776
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325
   Yeung CK, 2004, JPN J OPHTHALMOL, V48, P236, DOI 10.1007/s10384-003-0053-8
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   YU SY, 2004, INVEST OPHTHALMOL VI, V45
NR 129
TC 194
Z9 242
U1 1
U2 28
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 352
EP 368
DI 10.1016/S0008-4182(05)80078-X
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400011
PM 15947805
DA 2022-11-30
ER

PT J
AU Scharioth, GB
AF Scharioth, Gabor B.
TI New add-on intraocular lens for patients with age-related macular
   degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
AB We present a new option for visual rehabilitation of patients with advanced macular degeneration and evaluate the outcomes in the first 8 patients who had implantation of the ciliary sulcus-fixated macular add-on intraocular lens (IOL) (Scharioth Macula Lens) at our institute. The surgical technique for implantation of the add-on IOL is described. Near vision improved in 7 eyes and was stable in 1 eye. The corrected near visual acuity improved by 4.4 lines with the macular add-on IOL at 15 cm versus with glasses at 40 cm; it improved by 2.1 lines with the macular add-on IOL at 15 cm versus with glasses at 15 cm. Distance vision was stable in all eyes. No intraoperative or postoperative complication occurred. The macular add-on IOL has the potential of improving near vision and reading ability in patients with advanced age-related macular degeneration. (C) 2015 ASCRS and ESCRS
C1 [Scharioth, Gabor B.] Aurelios Augenzentrum, D-45657 Recklinghausen, Germany.
   [Scharioth, Gabor B.] Univ Szeged, Dept Ophthalmol, Szeged, Hungary.
C3 Szeged University
RP Scharioth, GB (通讯作者)，Aurelios Augenzentrum, Erlbruch 34-36, D-45657 Recklinghausen, Germany.
EM gabor.scharioth@augenzentrum.org
CR Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sauder G, 2012, OPHTHALMO CHIRURGIE, V24, P1
NR 9
TC 24
Z9 26
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD AUG
PY 2015
VL 41
IS 8
BP 1559
EP 1563
DI 10.1016/j.jcrs.2015.07.018
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CT7MM
UT WOS:000362998800002
PM 26432110
DA 2022-11-30
ER

PT J
AU Costagliola, C
   Romano, M
   Della Corte, M
   Perrotta, R
   Menzione, M
   Rinaldi, M
   Semeraro, F
   Parmeggiani, F
AF Costagliola, Ciro
   Romano, Mary
   Della Corte, Michele
   Perrotta, Raffaele
   Menzione, Massimo
   Rinaldi, Michele
   Semeraro, Francesco
   Parmeggiani, Francesco
TI INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NAIVE PATIENTS WITH SUBFOVEAL
   OCCULT CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR
   DEGENERATION A 12-Month Follow-Up Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; subfoveal occult choroidal
   neovascularization; intravitreal bevacizumab
ID PHOTODYNAMIC THERAPY; OCULAR NEOVASCULARIZATION; AVASTIN; RANIBIZUMAB;
   INJECTION; VERTEPORFIN; MACULOPATHY; MANAGEMENT; INHIBITORS; SAFETY
AB Purpose: The aim of this study was to assess the 12-month efficacy of intravitreal bevacizumab (IVB) injection for occult choroidal neovascularization secondary to age-related macular degeneration.
   Methods: In this retrospective, interventional case series, 68 treatment-naive patients with age-related macular degeneration, affected by subfoveal occult choroidal neovascularization showing recent disease progression, were monitored during the IVB protocol. The patients received 1 initial IVB injection (1.25 mg/0.05 mL), and they underwent further retreatment on a monthly basis only when necessary, according to a standardized as-required regimen, until no significant signs of choroidal neovascularization activity were present. Main outcome measures were the modifications in best-corrected visual acuity and in central retinal thickness measured by optical coherence tomography.
   Results: With respect to baseline, at the 12-month check, mean best-corrected visual acuity increased from 0.82 to 0.45 logMAR (P < 0.01) and mean central retinal thickness decreased from 517.0 mu m to 306.5 mu m (P < 0.01). To achieve these benefits, the required mean IVB number was lowered from 3.87 in the first 6 months to 1.085 in the second 6 months. A better final best-corrected visual acuity was correlated with greater best-corrected visual acuity (P < 0.005) and lesser central retinal thickness (P < 0.05) at baseline.
   Conclusion: In patients with age-related macular degeneration complicated by progressive occult choroidal neovascularization, first-line IVB administration represents a useful therapeutic option, especially considering its lower cost in comparison with other antiangiogenic drugs. RETINA 29:1227-1234, 2009
C1 [Costagliola, Ciro] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
   [Romano, Mary; Della Corte, Michele; Perrotta, Raffaele; Menzione, Massimo; Rinaldi, Michele] Univ Naples Federico II, Dept Ophthalmol, Naples, Italy.
   [Semeraro, Francesco] Univ Brescia, Dept Ophthalmol, Brescia, Italy.
   [Parmeggiani, Francesco] Univ Ferrara, Dept Ophthalmol, I-44100 Ferrara, Italy.
C3 University of Molise; University of Naples Federico II; University of
   Brescia; University of Ferrara
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Dipartimento Discipline Medicochirurg Comunicaz &, Sez Clin Oculist, Corso Giovecca 203, I-44100 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Semeraro, Francesco fs/K-8667-2016; Costagliola, Ciro/G-5707-2012
OI Semeraro, Francesco fs/0000-0002-2275-4917; Costagliola,
   Ciro/0000-0001-8477-6188; DELLA CORTE, MICHELE/0000-0003-1320-1883
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Ehrlich R, 2008, RETINA-J RET VIT DIS, V28, P1302, DOI 10.1097/IAE.0b013e3181803c2a
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 33
TC 13
Z9 13
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2009
VL 29
IS 9
BP 1227
EP 1234
DI 10.1097/IAE.0b013e3181b773e1
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506EF
UT WOS:000270755800003
PM 19934817
DA 2022-11-30
ER

PT J
AU Handa, JT
   Cano, M
   Wang, L
   Datta, S
   Liu, TY
AF Handa, James T.
   Cano, Marisol
   Wang, Lei
   Datta, Sayantan
   Liu, Tongyun
TI Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related
   Macular Degeneration
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Review
DE Age-related Macular Degeneration; Bruch's membrane; Basal deposits;
   Drusen; Very low-density lipoprotein (LDL); Oxidation-specific epitopes;
   Retinal pigmented epithelium (RPE)
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; SUBRETINAL DRUSENOID
   DEPOSITS; GENOME-WIDE ASSOCIATION; LOW-DENSITY-LIPOPROTEIN; LONG-TERM
   INCIDENCE; NF-KAPPA-B; RETICULAR PSEUDODRUSEN; 5-YEAR INCIDENCE;
   RISK-FACTORS
AB Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly in western societies. While antioxidant micronutrient treatment is available for intermediate non-neovascular disease, and effective anti-vascular endothelial growth factor treatment is available for neovascular disease, treatment for early AMD is lacking due to an incomplete understanding of the early molecular events. The role of lipids, which accumulate in the macula, and their oxidation, has emerged as an important factor in disease development. These oxidized lipids can either directly contribute to tissue injury or react with amine on proteins to form oxidation-specific epitopes, which can induce an innate immune response. If inadequately neutralized, the inflammatory response from these epitopes can incite tissue injury during disease development. This review explores how the accumulation of lipids, their oxidation, and the ensuing inflammatory response might contribute to the pathogenesis of AMD. This article is part of a Special Issue entitled: Lipid modification and lipid peroxidation products in innate immunity and inflammation edited by Christoph J. Binder. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Handa, James T.; Cano, Marisol; Wang, Lei; Datta, Sayantan; Liu, Tongyun] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Handa, JT (通讯作者)，400 North Broadway,Smith Bldg Room 3015, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu; mcano1@jhmi.edu; leiwang.011@gmail.com;
   saydatt@gmail.com; tliu5@jhmi.edu
RI Wang, Lei/C-1902-2015
OI Wang, Lei/0000-0002-7957-1003
FU National Eye Institute [EY019044, EY14005]; RPE Senior Scientist Award
   (JTH); Wilmer Core Grant [EY001765]; Research to Prevent Blindness to
   the Wilmer Eye Institute
FX National Eye Institute EY019044 (JTH) EY14005 (JTH), RPE Senior
   Scientist Award (JTH), Wilmer Core Grant EY001765, unrestricted grant
   from Research to Prevent Blindness to the Wilmer Eye Institute, Gifts
   from the Merlau family and Aleda Wright. Dr. Handa is the Robert Bond
   Welch Professor of Ophthalmology.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6
   Amarilyo G, 2010, EUR J IMMUNOL, V40, P699, DOI 10.1002/eji.200838951
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmark C, 2008, J LIPID RES, V49, P2230, DOI 10.1194/jlr.M800174-JLR200
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bienert GP, 2007, J BIOL CHEM, V282, P1183, DOI 10.1074/jbc.M603761200
   Biswas S.K., 2008, MOL ASP MED
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Centre for Eye Research Australia, 2006, CENTR FOC IMP AG REL
   Chang MK, 2004, J EXP MED, V200, P1359, DOI 10.1084/jem.20031763
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CROSS CE, 1993, ANN NY ACAD SCI, V686, P72, DOI 10.1111/j.1749-6632.1993.tb39157.x
   Cross CE, 1993, ANN NY ACAD SCI, V686, P89
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c
   Dube JB, 2012, CURR OPIN LIPIDOL, V23, P133, DOI 10.1097/MOL.0b013e32835111d8
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebrahimi K.B., 2012, J PATHOL
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eibinger G, 2013, EXP CELL RES, V319, P1828, DOI 10.1016/j.yexcr.2013.03.025
   Elner VM, 2003, EXP EYE RES, V76, P321, DOI 10.1016/S0014-4835(02)00310-X
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Farboud B, 1999, MOL VIS, V5, pU1
   Farese RV, 1996, P NATL ACAD SCI USA, V93, P6393, DOI 10.1073/pnas.93.13.6393
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman P, 2002, J BIOL CHEM, V277, P7010, DOI 10.1074/jbc.M108860200
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Garcia-Cruset S, 2001, FREE RADICAL RES, V35, P31, DOI 10.1080/10715760100300571
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines J.L, 2005, SCIENCE
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Handa JT, 2015, T AM OPHTHALMOL SOC, V113, pT51
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hoover-Plow J, 2013, METABOLISM, V62, P479, DOI 10.1016/j.metabol.2012.07.024
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R.J., 2005, SCIENCE
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Kronenberg F, 2013, J INTERN MED, V273, P6, DOI 10.1111/j.1365-2796.2012.02592.x
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Lykkesfeldt J, 2000, AM J CLIN NUTR, V71, P530
   Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC
   MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ohtsuka M, 2006, J ATHEROSCLER THROMB, V13, P256, DOI 10.5551/jat.13.256
   ONEILL CA, 1994, J LAB CLIN MED, V124, P359
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   ORTH DH, 1977, T AM ACAD OPHTHALMOL, V83, P506
   Osburn WO, 2008, TOXICOL SCI, V104, P218, DOI 10.1093/toxsci/kfn079
   Picard E., 2010, AGING ALBANY NY
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Raccosta L, 2013, J EXP MED, V210, P1711, DOI 10.1084/jem.20130440
   Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4
   Rahman I, 2005, ANTIOXID REDOX SIGN, V7, P42, DOI 10.1089/ars.2005.7.42
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun M., 2005, J BIOL CHEM
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thimmulappa RK, 2002, CANCER RES, V62, P5196
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Reyk DM, 2006, REDOX REP, V11, P255, DOI 10.1179/135100006X155003
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   WALSH AC, 1995, TOXICOL APPL PHARM, V133, P249, DOI 10.1006/taap.1995.1149
   Wang L., 2014, FREE RADIC BIOL MED
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weismann D, 2012, BBA-BIOMEMBRANES, V1818, P2465, DOI 10.1016/j.bbamem.2012.01.018
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Will O, 1999, CARCINOGENESIS, V20, P333, DOI 10.1093/carcin/20.2.333
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Winkler B S, 1999, Mol Vis, V5, P32
   Wu TH, 2010, LAB INVEST, V90, P963, DOI 10.1038/labinvest.2010.87
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 167
TC 60
Z9 61
U1 1
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 1879-2618
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD APR
PY 2017
VL 1862
IS 4
SI SI
BP 430
EP 440
DI 10.1016/j.bbalip.2016.07.013
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA EM3MC
UT WOS:000395218300008
PM 27480216
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Linton, KL
AF Klein, Ronald
   Klein, Barbara E. K.
   Linton, Kathryn L.
TI Prevalence of Age-related Maculopathy The Beaver Dam Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; DRUSEN; PROGNOSIS
AB Purpose: The relationships of retinal drusen, retinal pigmentary abnormalities, and macular degeneration to age and sex were studied in 4926 people between the ages of 43 and 86 years who participated in the Beaver Dam Eye Study.
   Methods: The presence and severity of various characteristics of drusen and other lesions typical of age-related maculopathy were determined by grading stereoscopic color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
   Results: One or more drusen were present in the macular area of at least 1 eye in 95.5% of the population. People 75 years of age or older had significantly higher frequencies (P < 0.01) of the following characteristics than people 43 to 54 years of age: larger sized drusen (>= 125 mu m, 24.0% versus 1.9%), soft indistinct drusen (23.0% versus 2.1%), retinal pigment abnormalities (26.6% versus 7.3%), exudative macular degeneration (5.2% versus 0.1%), and geographic atrophy (2.0% versus 0%).
   Conclusion: These data indicate signs of age-related maculopathy are common in people 75 years of age or older and may pose a substantial public health problem.
C1 [Klein, Ronald; Klein, Barbara E. K.; Linton, Kathryn L.] Univ Wisconsin, Dept Ophthalmol, 600 Highland Ave,E5-353 CSC, Madison, WI 53792 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol, 600 Highland Ave,E5-353 CSC, Madison, WI 53792 USA.
FU National Eye Institute/NIH, Bethesda, Maryland [EY06594]
FX Supported by National Eye Institute/NIH grant EY06594 (R. Klein and B.
   E. K. Klein), Bethesda, Maryland.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LESKE MC, 1989, BRIT J OPHTHALMOL, V73, P365, DOI 10.1136/bjo.73.5.365
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SAS Institute, 1990, SAS US GUID STAT VER
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
NR 31
TC 16
Z9 16
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2020
VL 127
IS 4
SU S
BP S122
EP S132
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW0TH
UT WOS:000520885600017
PM 32200811
DA 2022-11-30
ER

PT J
AU Kanadani, TCM
   Veloso, CE
   Nehemy, MB
AF Moreira Kanadani, Tereza Cristina
   Veloso, Carlos Eduardo
   Nehemy, Marcio B.
TI Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related
   Macular Degeneration Treated with Anti-Vascular Endothelial Growth
   Factor Agents
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; anti-VEGF treatment; Subfoveal
   choroidal thickness
ID INTRAVITREAL RANIBIZUMAB INJECTIONS; VERTEPORFIN PHOTODYNAMIC THERAPY;
   AFLIBERCEPT THERAPY; PATHOGENESIS
AB Purpose: We aimed to assess the subfoveal choroidal thickness (SFChT) and the effect of treatment with anti-vascular endothelial growth factor (anti-VEGF) agents on the SFChT in age-related macular degeneration (AMD) subtypes. Methods: We enrolled 128 eyes of 107 patients with neovascular AMD (60 women; 47 men; mean age, 73.6 +/- 8.9 years), and prospectively evaluated the best-corrected visual acuity (BCVA) and SFChT at baseline and at 3, 6, and 12 months after treatment with anti-VEGF agents. Patients were assigned to the typical AMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP) subgroups. Results: In total, 85 (66.4%), 31 (24.2%), and 12 (9.4%) eyes were assigned to the typical AMD, PCV, and RAP subgroups, respectively. The baseline mean BCVA was 0.75 +/- 0.26, 0.72 +/- 0.21, and 0.77 +/- 0.24 logMAR in the typical AMD, PCV, and RAP subgroups, respectively (p = 0.774). The mean baseline SFChT was 203.20 +/- 35.80, 271.80 +/- 24.50, and 182.93 +/- 31.31 mu m, respectively (p < 0.001). Mean SFChT significantly decreased from baseline to 3, 6, and 12 months after treatment. The RAP subtype presented a significantly higher decrease in SFChT compared to the other subtypes (p = 0.01). The percentage reduction in SFChT was not significantly correlated with the number of injections (r = -0.02; p = 0.823). No association was observed between baseline SFChT and final visual acuity at 12 months (r = 0.0; p = 0.586). Conclusions: SFChT was greatest in eyes with PCV and least in eyes with RAP. The reduction in SFChT after treatment was greater in the RAP cases. The decrease in SFChT after 12 months of anti-VEGF treatment was not associated with the number of injections and there was no correlation between the baseline SFChT and visual acuity in all AMD subtypes.
C1 [Moreira Kanadani, Tereza Cristina; Veloso, Carlos Eduardo; Nehemy, Marcio B.] Fed Univ Minas, Dept Ophthalmol, 1007 Maranhao St, BR-30150331 Belo Horizonte, MG, Brazil.
RP Kanadani, TCM (通讯作者)，Fed Univ Minas, Dept Ophthalmol, 1007 Maranhao St, BR-30150331 Belo Horizonte, MG, Brazil.
EM moreirakanadani@hotmail.com
RI Nehemy, Marcio/ABD-5089-2021
OI Nehemy, Marcio/0000-0002-4104-0346
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Boyer DS, 2015, OPHTHALMOLOGY, V122, P2504, DOI 10.1016/j.ophtha.2015.08.006
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gharbiya M, 2015, J OCUL PHARMACOL TH, V31, P357, DOI 10.1089/jop.2014.0160
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kano M, 2015, CLIN OPHTHALMOL, V9, P2049, DOI 10.2147/OPTH.S90932
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogasawara Masashi, 2012, Nippon Ganka Gakkai Zasshi, V116, P643
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 39
TC 3
Z9 3
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 240
IS 4
BP 200
EP 207
DI 10.1159/000488254
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HC3UH
UT WOS:000451727700003
PM 29768266
DA 2022-11-30
ER

PT J
AU Ilhan, N
   Daglioglu, MC
   Ilhan, O
   Coskun, M
   Tuzcu, EA
   Kahraman, H
   Keskin, U
AF Ilhan, Nilufer
   Daglioglu, Mutlu Cihan
   Ilhan, Ozgur
   Coskun, Mesut
   Tuzcu, Esra Ayhan
   Kahraman, Hilal
   Keskin, Ugurcan
TI Assessment of Neutrophil/Lymphocyte Ratio in Patients with Age-related
   Macular Degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; blindness; inflammation;
   neutrophil/lymphocyte ratio; retinal drusen
ID TO-LYMPHOCYTE RATIO; C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE;
   DIABETIC-RETINOPATHY; NEUTROPHIL; INFLAMMATION; DRUSEN; SEVERITY;
   MARKER; PATHOGENESIS
AB Purpose: To investigate the neutrophil/lymphocyte ratio (NLR) as an indicator of inflammation in patients with age-related macular degeneration (AMD).
   Methods: Patients were evaluated by a review of records. The study included 81 patients with dry AMD (group 1), 84 patients with wet AMD (group 2), and 80 healthy age-and sex-matched controls (group 3). The NLR of the patients was obtained from the hospital laboratory archive and was measured by dividing the neutrophil count by the lymphocyte count.
   Results: A significant difference was found in NLR values between groups 1 and 2 (p = 0.017), groups 2 and 3 (p<0.001), and groups 1 and 3 (p<0.001). In correlation analyses, NLR was correlated positively with age (r = 0.22, p<0.001) and disease severity (r = 0.40, p<0.001).
   Conclusions: Patients with AMD have higher NLR compared with controls, and NLR correlates with disease severity. NLR may be used as a biomarker of inflammation in AMD.
C1 [Ilhan, Nilufer; Daglioglu, Mutlu Cihan; Ilhan, Ozgur; Coskun, Mesut; Tuzcu, Esra Ayhan; Kahraman, Hilal; Keskin, Ugurcan] Mustafa Kemal Univ, Dept Ophthalmol, Fac Med, Antakya, Hatay, Turkey.
C3 Mustafa Kemal University
RP Ilhan, N (通讯作者)，Mustafa Kemal Univ, Dept Ophthalmol, Fac Med, Antakya, Hatay, Turkey.
EM niluferilhan@gmail.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arbel Y, 2012, ATHEROSCLEROSIS, V225, P456, DOI 10.1016/j.atherosclerosis.2012.09.009
   Azab B, 2012, RENAL FAILURE, V34, P571, DOI 10.3109/0886022X.2012.668741
   Buyukkaya E, 2014, CLIN APPL THROMB-HEM, V20, P159, DOI 10.1177/1076029612459675
   Chiang SF, 2012, INT J COLORECTAL DIS, V27, P1347, DOI 10.1007/s00384-012-1459-x
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Imtiaz F, 2012, INT ARCH MED, V5, P1
   Jin HL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-112
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mano Y, 2013, ANN SURG, V258, P301, DOI 10.1097/SLA.0b013e318297ad6b
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Papa A, 2008, CLIN CHIM ACTA, V395, P27, DOI 10.1016/j.cca.2008.04.019
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seretis C, 2013, AM J SURG, V205, P691, DOI 10.1016/j.amjsurg.2012.08.006
   Suppiah A, 2013, J GASTROINTEST SURG, V17, P675, DOI 10.1007/s11605-012-2121-1
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Torun S, 2012, CLIN RES HEPATOL GAS, V36, P491, DOI 10.1016/j.clinre.2012.06.004
   Turkmen K, 2012, RENAL FAILURE, V34, P155, DOI 10.3109/0886022X.2011.641514
   Ulu SM, 2013, DIABETES TECHNOL THE, V15, P942, DOI 10.1089/dia.2013.0097
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Woo SJ, 2011, INVEST OPHTH VIS SCI, V52, P7697, DOI 10.1167/iovs.11-7784
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zahorec R, 2001, Bratisl Lek Listy, V102, P5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 39
TC 36
Z9 36
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PY 2015
VL 23
IS 4
BP 287
EP 290
DI 10.3109/09273948.2014.921715
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR4TV
UT WOS:000361333100005
PM 24987927
DA 2022-11-30
ER

PT J
AU Jin, EZ
   Bai, YJ
   Luo, L
   Huang, LZ
   Zhu, XM
   Ding, X
   Qi, HJ
   Zhao, MW
AF Jin, Enzhong
   Bai, Yujing
   Luo, Ling
   Huang, Lvzhen
   Zhu, Xuemei
   Ding, Xue
   Qi, Huijun
   Zhao, Mingwei
TI SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER
   INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE vascular endothelial growth factor; conbercept; ranibizumab; age-related
   macular degeneration; polypoidal choroidal vasculopathy; systemic
   effects
ID VEGF-TRAP; PHARMACOKINETICS; AFLIBERCEPT; BEVACIZUMAB; SUPPRESSION;
   RETINOPATHY
AB Objective: To investigate the serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of conbercept or ranibizumab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients.
   Methods: This study is a prospective, interventional case series and involved 28 patients, 18 treated with 0.5 mg of conbercept and 10 treated with 0.5 mg of ranibizumab. Serum concentrations of VEGF were determined by enzyme-linked immunosorbent assay before the injection and at 1 day, 1 week, and 1 month after anti-VEGF treatments.
   Results: The baseline serum VEGF level of the ranibizumab group was 367.11 +/- 311.87 pg/mL, whereas that of the conbercept group was 315.06 +/- 170.88 pg/mL (P = 0.653). In the conbercept group, VEGF level significantly decreased to 36.32 +/- 72.11 pg/mL at 1 day (P = 0.03) and returned to 136.55 +/- 144.62 pg/mL at 1 week (P = 0.03). At 1 month, the concentration increased to 334.48 +/- 197.41 pg/mL and showed no significant difference compared with the baseline. In the ranibizumab group, the serum VEGF levels were 292.42 +/- 239.80 pg/mL, 282.60 +/- 201.36 pg/mL, and 308.83 +/- 266.89 pg/mL at 1 day, 1 week, and 1 month after intravitreal injection, respectively. There was no significant difference in the ranibizumab group at each detection time point (P = 0.45).
   Conclusion: Conbercept significantly decreased serum VEGF level 1 day and 1 week after injection, but this effect was not sustained for 1 month. In contrast, ranibizumab had no significant effect on serum VEGF concentration changes. The reduction in serum VEGF by conbercept may affect its systemic safety profile.
C1 [Jin, Enzhong; Bai, Yujing; Huang, Lvzhen; Zhu, Xuemei; Ding, Xue; Qi, Huijun; Zhao, Mingwei] Peking Univ, Beijing Key Lab Diag & Therapy Retinal & Choroid, Key Lab Vis Loss & Restorat, Peoples Hosp,Dept Ophthalmol,Minist Educ, Beijing, Peoples R China.
   [Luo, Ling] 306th Hosp PLA, Dept Ophthalmol, Beijing, Peoples R China.
C3 Peking University
RP Zhao, MW (通讯作者)，Peking Univ, Peoples Hosp, Key Lab Vis Loss & Restorat, Dept Ophthalmol,Minist Educ, South St 11, Beijing 100044, Peoples R China.
EM zhaomingwei64@163.com
OI Jin, Enzhong/0000-0003-1450-5846
FU National Natural Science Foundation of China [81470651, 81271016]
FX Supported by the National Natural Science Foundation of China (grant
   number 81470651) and the National Natural Science Foundation of China
   (grant number 81271016).
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Grierson R, 2013, J OCUL PHARMACOL TH, V29, P530, DOI 10.1089/jop.2012.0013
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu JF, 2008, CANCER CHEMOTH PHARM, V62, P779, DOI 10.1007/s00280-007-0664-8
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhao M, 2015, CHINESE MED J-PEKING, V128, P2505, DOI 10.4103/0366-6999.164937
NR 29
TC 17
Z9 21
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2017
VL 37
IS 5
BP 971
EP 977
DI 10.1097/IAE.0000000000001274
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0IO
UT WOS:000402173400039
PM 27617537
DA 2022-11-30
ER

PT J
AU Dang, KR
   Wu, T
   Hui, YN
   Du, HJ
AF Dang, Kuan-Rong
   Wu, Tong
   Hui, Yan-Nian
   Du, Hong-Jun
TI Newly-found functions of metformin for the prevention and treatment of
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE metformin; age-related macular degeneration; liver X receptor
ID PROTEIN-KINASE ACTIVATION; OXIDATIVE STRESS; MATRIX METALLOPROTEINASES;
   CELL-DEATH; LIVER; ANGIOGENESIS; RECEPTOR; PROLIFERATION; INFLAMMASOME;
   ACCUMULATION
AB Metformin (MET), a first-line oral agent used to treat diabetes, exerts its function mainly by activating adenosine monophosphate-activated protein. The accumulation of oxidized phospholipids in the outer layer of the retina plays a key role in retinal pigment epithelium (RPE) cells death and the formation of choroidal neovascularization (CNV), which mean the development of age-related macular degeneration (AMD). Recent studies have shown that MET can regulate lipid metabolism, inhibit inflammation, and prohibit retinal cell death and CNV formation due to various pathological factors. Here, newly discovered functions of MET that may be used for the prevention and treatment of AMD were reviewed.
C1 [Dang, Kuan-Rong; Wu, Tong; Hui, Yan-Nian; Du, Hong-Jun] Fourth Mil Med Univ, Xijing Hosp, Eye Inst Chinese PLA, Dept Ophthalmol, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Military Medical University
RP Du, HJ (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Eye Inst Chinese PLA, Dept Ophthalmol, Xian 710032, Shaanxi, Peoples R China.
EM dhj2020@126.com
FU Natural Science Foundation of Shaanxi Province [2019SF-047]
FX Supported by the Natural Science Foundation of Shaanxi Province
   (No.2019SF-047).
CR Abdul NS, 2021, TOXICON, V190, P58, DOI 10.1016/j.toxicon.2020.12.011
   Alomar SY, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107193
   Argaw AT, 2006, J IMMUNOL, V177, P5574, DOI 10.4049/jimmunol.177.8.5574
   Athanasiou D, 2017, HUM MOL GENET, V26, P305, DOI 10.1093/hmg/ddw387
   Bai B, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.622262
   Bharath LP, 2021, AM J PHYSIOL-CELL PH, V320, pC873, DOI 10.1152/ajpcell.00604.2020
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Buldak L, 2016, N-S ARCH PHARMACOL, V389, P1103, DOI 10.1007/s00210-016-1277-8
   Cahova M, 2015, AM J PHYSIOL-GASTR L, V309, pG100, DOI 10.1152/ajpgi.00329.2014
   Chen B, 2016, VASC PHARMACOL, V85, P1, DOI 10.1016/j.vph.2015.08.012
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chung EJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17744-w
   Dandapat A, 2007, ARTERIOSCL THROM VAS, V27, P2435, DOI 10.1161/ATVBAHA.107.152272
   Detaille D, 2005, DIABETES, V54, P2179, DOI 10.2337/diabetes.54.7.2179
   Ersoy C, 2008, DIABETES RES CLIN PR, V81, P56, DOI 10.1016/j.diabres.2008.02.006
   Esfahanian N, 2012, MOL MED REP, V5, P1068, DOI 10.3892/mmr.2012.753
   Fan YP, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/9161039
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Han J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193031
   Harun-Or-Rashid M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1346-7
   Hattori Y, 2006, HYPERTENSION, V47, P1183, DOI 10.1161/01.HYP.0000221429.94591.72
   He X, 2019, LIFE SCI, V216, P67, DOI 10.1016/j.lfs.2018.09.024
   Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Jansen T, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060525
   Jemni-Damer N, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.588014
   Jing YY, 2018, MOL CELL ENDOCRINOL, V461, P256, DOI 10.1016/j.mce.2017.09.025
   Joe SG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119708
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kalariya NM, 2012, INVEST OPHTH VIS SCI, V53, P3431, DOI 10.1167/iovs.12-9432
   Kamoshita M, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0268-5
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kawashima H, 2020, FASEB J, V34, P5016, DOI 10.1096/fj.201902387RR
   Kelly B, 2015, J BIOL CHEM, V290, P20348, DOI 10.1074/jbc.M115.662114
   Khallaghi B, 2016, LIFE SCI, V148, P286, DOI 10.1016/j.lfs.2016.02.024
   Kim GY, 2010, J IMMUNOL, V184, P3946, DOI 10.4049/jimmunol.0901735
   Kim SH, 2019, FREE RADICAL RES, V53, P865, DOI 10.1080/10715762.2019.1637862
   Kumar A, 2016, CELL MICROBIOL, V18, P1815, DOI 10.1111/cmi.12625
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Li S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061736
   Li WD, 2017, INT J MOL MED, V39, P1262, DOI 10.3892/ijmm.2017.2929
   Li XF, 2018, BIOCHEM BIOPH RES CO, V501, P293, DOI 10.1016/j.bbrc.2018.05.003
   Li XR, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01038
   Liu D, 2019, DRUG DELIV, V26, P522, DOI 10.1080/10717544.2019.1609623
   Luodan A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00102
   Martin-Rodriguez S, 2020, TRENDS ENDOCRIN MET, V31, P269, DOI 10.1016/j.tem.2020.02.003
   Mohr T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179065
   Ning HF, 2018, EXP THER MED, V15, P2485, DOI 10.3892/etm.2018.5704
   Noghero A, 2012, ARTERIOSCL THROM VAS, V32, P2280, DOI 10.1161/ATVBAHA.112.250621
   Pan K, 2019, PROGR MODERN BIOMEDI, V19, P1793
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Rotermund C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00400
   Saenz J, 2018, J NUTR BIOCHEM, V54, P48, DOI 10.1016/j.jnutbio.2017.11.006
   Schulman IG, 2017, FEBS LETT, V591, P2978, DOI 10.1002/1873-3468.12702
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Shu CW, 2020, GRAEF ARCH CLIN EXP, V258, P557, DOI 10.1007/s00417-019-04548-z
   Skrha J, 2007, EUR J CLIN PHARMACOL, V63, P1107, DOI 10.1007/s00228-007-0378-1
   Stein BD, 2019, CELL REP, V29, P3331, DOI 10.1016/j.celrep.2019.10.117
   Stewart JM, 2020, OPHTHALMOL RETINA, V4, P1118, DOI 10.1016/j.oret.2020.06.003
   Ursini F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01236
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Wang DD, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.114022
   Wang L, 2020, IUBMB LIFE, V72, P749, DOI 10.1002/iub.2174
   Wang X, 2017, GUOJI YANKE ZAZHI, V17, P673
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu T, 2020, CELL SIGNAL, V70, DOI 10.1016/j.cellsig.2020.109571
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yi QY, 2016, AM J TRANSL RES, V8, P3947
   Ying Y, 2017, ONCOTARGET, V8, P32794, DOI 10.18632/oncotarget.15825
   Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974
   Zhang L, 2019, EUR J PHARMACOL, V852, P99, DOI 10.1016/j.ejphar.2019.03.006
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhao QS, 2021, CURR RES TRANSL MED, V69, DOI 10.1016/j.retram.2020.103270
   Zhou J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102863
   Zhu X, 2018, ARCH PHARM RES, V41, P1009, DOI 10.1007/s12272-018-1059-6
NR 81
TC 1
Z9 1
U1 3
U2 7
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD AUG 18
PY 2021
VL 14
IS 8
BP 1274
EP 1280
DI 10.18240/ijo.2021.08.20
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TY4LS
UT WOS:000683756800020
PM 34414094
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Rodriguez, IR
   Larrayoz, IM
AF Rodriguez, Ignacio R.
   Larrayoz, Ignacio M.
TI Cholesterol oxidation in the retina: implications of 7KCh formation in
   chronic inflammation and age-related macular degeneration
SO JOURNAL OF LIPID RESEARCH
LA English
DT Review
DE 7-ketocholesterol; cytokines; oxysterols
ID LOW-DENSITY-LIPOPROTEIN; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   EPITHELIAL-CELLS; LIVER-X-RECEPTORS; OXIDIZED LDL; STEROL
   27-HYDROXYLASE; INDUCED APOPTOSIS; OXYSTEROL FORMATION;
   LIPID-METABOLISM; BASAL DEPOSITS
AB This review will discuss the formation and potential implications of 7-ketocholesterol (7KCh) in the retina. 7KCh is a proinflammatory oxysterol known to be present in high amounts in oxidized LDL deposits associated with atheromatous plaques. 7KCh is generated in situ in these lipoprotein deposits where it can accumulate and reach very high concentrations. In normal primate retina, 7KCh has been found associated with lipoprotein deposits in the choriocapillaris, Bruch's membrane, and the retinal pigment epithelium (RPE). In photodamaged rats, 7KCh has been found in the neural retina in areas of high mitochondrial content, ganglion cells, photoreceptor inner segments and synapses, and the RPE. Intermediates found by LCMS indicate 7KCh is formed via a free radical-mediated mechanism catalyzed by iron. 7KCh seems to activate several kinase signaling pathways that work via nuclear factor kappa B and cause the induction of vascular endothelial growth factor, interleukin (IL)-6, and IL-8. There seems to be little evidence of 7KCh metabolism in the retina, although some form of efflux mechanism may be active. The chronic mode of formation and the potent inflammatory properties of 7KCh indicate it may be an "age-related" risk factor in aging diseases such as atherosclerosis, Alzheimer's, and age-related macular degeneration.-Rodriguez, I. R., and I. M. Larrayoz. Cholesterol oxidation in the retina: implications of 7-KCh formation in chronic inflammation and age-related macular degeneration. J. Lipid Res. 2010. 51:2847-2862.
C1 [Rodriguez, Ignacio R.; Larrayoz, Ignacio M.] NEI, Mech Retinal Dis Sect, Lab Retinal Cell & Mol Biol, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Rodriguez, IR (通讯作者)，NEI, Mech Retinal Dis Sect, Lab Retinal Cell & Mol Biol, Bethesda, MD 20892 USA.
EM rodriguezi@nei.nih.gov
RI Larrayoz, Ignacio M/I-5613-2012
OI Larrayoz, Ignacio M/0000-0003-1629-152X
CR Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002
   Akiba S, 2004, BBA-MOL CELL BIOL L, V1686, P77, DOI 10.1016/j.bbalip.2004.08.016
   Akiba S, 2003, J LIPID RES, V44, P1676, DOI 10.1194/jlr.M300012-JLR200
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baranowski M, 2008, J PHYSIOL PHARMACOL, V59, P31
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   BERGER JW, 1999, AGE RELATED MACULAR
   Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x
   BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592
   Bjorkhem I, 2009, MOL ASPECTS MED, V30, P171, DOI 10.1016/j.mam.2009.02.001
   Boullier A, 2005, J LIPID RES, V46, P969, DOI 10.1194/jlr.M400496-JLR200
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Brown AJ, 1996, J LIPID RES, V37, P320
   Brown AJ, 2000, J BIOL CHEM, V275, P27627
   Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005
   Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje
   CALI JJ, 1991, J BIOL CHEM, V266, P7779
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chang JY, 1998, CURR EYE RES, V17, P95, DOI 10.1076/ceyr.17.1.95.5252
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng YW, 2005, FOOD CHEM TOXICOL, V43, P617, DOI 10.1016/j.fct.2005.01.007
   Choi GS, 2009, CLIN EXP ALLERGY, V39, P655, DOI 10.1111/j.1365-2222.2009.03216.x
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dotti MT, 2001, J INHERIT METAB DIS, V24, P696, DOI 10.1023/A:1012981019336
   Dulakk J, 2001, ATHEROSCLEROSIS, V159, P325, DOI 10.1016/S0021-9150(01)00520-2
   Dzeletovic S, 1995, CHEM PHYS LIPIDS, V78, P119, DOI 10.1016/0009-3084(95)02489-6
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Erridge C, 2007, ATHEROSCLEROSIS, V193, P77, DOI 10.1016/j.atherosclerosis.2006.08.032
   Erridge C, 2007, FREE RADICAL RES, V41, P260, DOI 10.1080/10715760601070091
   Fairn GD, 2008, CELL MOL LIFE SCI, V65, P228, DOI 10.1007/s00018-007-7325-2
   Falany CN, 2006, J STEROID BIOCHEM, V102, P214, DOI 10.1016/j.jsbmb.2006.09.011
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   Freeman NE, 2005, J LIPID RES, V46, P1933, DOI 10.1194/jlr.M500101-JLR200
   Fuda H, 2007, J LIPID RES, V48, P1343, DOI 10.1194/jlr.M700018-JLR200
   Ghelli A, 2002, ARCH BIOCHEM BIOPHYS, V402, P208, DOI 10.1016/S0003-9861(02)00085-1
   Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GORDON WC, 1997, CELLULAR ORG BIOCH R
   Hahn P, 2004, MOL VIS, V10, P598
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Hakamata H, 1998, J Atheroscler Thromb, V5, P66
   Handa James T., 2007, International Ophthalmology Clinics, V47, P15, DOI 10.1097/IIO.0b013e31802bd546
   Harper WS, 2001, PHOTOCHEM PHOTOBIOL, V73, P71, DOI 10.1562/0031-8655(2001)073<0071:SOATRA>2.0.CO;2
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Ikeda H, 2003, LAB INVEST, V83, P349, DOI 10.1097/01.LAB.0000059933.35157.40
   Ingueneau C, 2009, J CELL MOL MED, V13, P1620, DOI 10.1111/j.1582-4934.2008.00593.x
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishizuka T, 2008, J PHARMACOL EXP THER, V324, P103, DOI 10.1124/jpet.107.130336
   Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266
   Jaworski CJ, 2001, GENOMICS, V78, P185, DOI 10.1006/geno.2001.6663
   Jessup W, 2005, REJUV RES, V8, P9, DOI 10.1089/rej.2005.8.9
   Jessup W, 2002, VASC PHARMACOL, V38, P239, DOI 10.1016/S1537-1891(02)00174-X
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   KORYTOWSKI W, 1992, PHOTOCHEM PHOTOBIOL, V56, P1, DOI 10.1111/j.1751-1097.1992.tb09594.x
   Krishnamurthy P, 2009, CIRC RES, V104, pE9, DOI 10.1161/CIRCRESAHA.108.188243
   Kritharides L, 1996, J BIOL CHEM, V271, P27450, DOI 10.1074/jbc.271.44.27450
   LARRAYOZ IM, 2010, INVEST OPHTHALM 0616
   Lee CS, 2006, NEUROREPORT, V17, P183, DOI 10.1097/01.wnr.0000198436.52259.40
   Lee HS, 2005, BIOCHEM BIOPH RES CO, V333, P1093, DOI 10.1016/j.bbrc.2005.05.196
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200
   Liu Y, 1997, ARTERIOSCL THROM VAS, V17, P317, DOI 10.1161/01.ATV.17.2.317
   Lordan S, 2009, J NUTR BIOCHEM, V20, P321, DOI 10.1016/j.jnutbio.2009.01.001
   Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316
   Luoma PV, 2008, EUR J CLIN PHARMACOL, V64, P841, DOI 10.1007/s00228-008-0515-5
   Luthra S, 2008, MICROVASC RES, V75, P343, DOI 10.1016/j.mvr.2007.10.003
   Lyons MA, 1999, INT J BIOCHEM CELL B, V31, P369, DOI 10.1016/S1357-2725(98)00123-X
   Lyons MA, 2001, LIPIDS, V36, P701, DOI 10.1007/s11745-001-0775-8
   Lyons MA, 2001, BBA-MOL CELL BIOL L, V1530, P209, DOI 10.1016/S1388-1981(01)00083-X
   Lyons MA, 1999, J LIPID RES, V40, P1846
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malvitte L, 2008, CURR EYE RES, V33, P769, DOI 10.1080/02713680802337397
   Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab
   McCourt MP, 1997, J LIPID RES, V38, P1014
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Moreira EF, 2001, J BIOL CHEM, V276, P18570, DOI 10.1074/jbc.M011259200
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Naito Y, 2006, EUR J PHARMACOL, V546, P11, DOI 10.1016/j.ejphar.2006.07.030
   Napolitano M, 2005, EUR J CLIN INVEST, V35, P482, DOI 10.1111/j.1365-2362.2005.01523.x
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Norlin M, 2007, CURR MOL MED, V7, P199, DOI 10.2174/156652407780059168
   Noske UM, 1998, OPHTHALMOLOGE, V95, P814, DOI 10.1007/s003470050358
   Ogura S, 2009, CIRC J, V73, P1993, DOI 10.1253/circj.CJ-09-0587
   Ohishi K, 2005, FREE RADICAL RES, V39, P875, DOI 10.1080/10715760500177807
   Ohishi K, 2006, FREE RADICAL RES, V40, P799, DOI 10.1080/10715760600555027
   Olkkonen VM, 2009, MOL ASPECTS MED, V30, P123, DOI 10.1016/j.mam.2009.02.004
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   OYSTER WC, 1999, HUMAN EYE STRUCTURE, P595
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Palozza P, 2007, FREE RADICAL BIO MED, V42, P1579, DOI 10.1016/j.freeradbiomed.2007.02.023
   Panini SR, 2001, J LIPID RES, V42, P1678
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Phillips JE, 2001, ATHEROSCLEROSIS, V159, P125, DOI 10.1016/S0021-9150(01)00504-4
   Pikuleva IA, 2008, EXPERT OPIN DRUG MET, V4, P1403, DOI [10.1517/17425255.4.11.1403, 10.1517/17425255.4.11.1403 ]
   Poli G, 2009, MOL ASPECTS MED, V30, P180, DOI 10.1016/j.mam.2009.02.003
   Prunet C, 2005, J BIOCHEM MOL TOXIC, V19, P311, DOI 10.1002/jbt.20096
   Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605
   Ramos MA, 1998, ARTERIOSCL THROM VAS, V18, P1188, DOI 10.1161/01.ATV.18.7.1188
   Rhainds D, 2004, INT J BIOCHEM CELL B, V36, P39, DOI 10.1016/S1357-2725(03)00173-0
   Riazy M, 2009, ATHEROSCLEROSIS, V204, P47, DOI 10.1016/j.atherosclerosis.2008.08.004
   Rodriguez IR, 2009, PHOTOCHEM PHOTOBIOL, V85, P1116, DOI 10.1111/j.1751-1097.2009.00568.x
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Russell DW, 2009, ANNU REV BIOCHEM, V78, P1017, DOI 10.1146/annurev.biochem.78.072407.103859
   SanGiovanni John Paul, 2009, V99, P105, DOI 10.1159/000193002
   Scheidt HA, 2003, J BIOL CHEM, V278, P45563, DOI 10.1074/jbc.M303567200
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Seimon T, 2009, J LIPID RES, V50, pS382, DOI 10.1194/jlr.R800032-JLR200
   Sima AV, 2009, CELL TISSUE RES, V335, P191, DOI 10.1007/s00441-008-0678-5
   Sleer LS, 2001, ATHEROSCLEROSIS, V159, P49, DOI 10.1016/S0021-9150(01)00486-5
   SMITH LL, 1990, NATO ADV SCI I A-LIF, V189, P115
   SMITH LL, 1973, J ORG CHEM, V38, P1763, DOI 10.1021/jo00949a041
   Smith LL, 1996, LIPIDS, V31, P453, DOI 10.1007/BF02522641
   Song C, 2001, STEROIDS, V66, P473, DOI 10.1016/S0039-128X(00)00239-7
   Sung SC, 2009, J VASC RES, V46, P36, DOI 10.1159/000135663
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tall AR, 2008, J INTERN MED, V263, P256, DOI 10.1111/j.1365-2796.2007.01898.x
   Tall AR, 2008, CELL METAB, V7, P365, DOI 10.1016/j.cmet.2008.03.001
   Taylor CT, 2008, BIOCHEM J, V409, P19, DOI 10.1042/BJ20071249
   TAYLOR FR, 1985, CHEM PHYS LIPIDS, V38, P187, DOI 10.1016/0009-3084(85)90066-0
   Terasaka N, 2007, P NATL ACAD SCI USA, V104, P15093, DOI 10.1073/pnas.0704602104
   TERKELTAUB R, 1994, ARTERIOSCLER THROMB, V14, P47, DOI 10.1161/01.ATV.14.1.47
   THOMAS JP, 1987, CANCER LETT, V35, P295, DOI 10.1016/0304-3835(87)90131-5
   Torocsik D, 2009, MOL ASPECTS MED, V30, P134, DOI 10.1016/j.mam.2009.02.002
   Torrini M, 2007, GENET TEST, V11, P421, DOI 10.1089/gte.2007.0021
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   VAN REYK DM, 2006, REDOX REP, V11, P255
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   Wang C, 2002, BIOCHEM J, V361, P461, DOI 10.1042/0264-6021:3610461
   WANG N, 1993, EXP EYE RES, V57, P225, DOI 10.1006/exer.1993.1118
   Wielkoszynski T, 2006, BIOESSAYS, V28, P387, DOI 10.1002/bies.20383
   Wu ZL, 1999, J LIPID RES, V40, P2195
   Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Yurkova R, 2009, CHEM PHYS LIPIDS, V158, P16, DOI 10.1016/j.chemphyslip.2008.09.005
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
NR 147
TC 103
Z9 104
U1 0
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD OCT
PY 2010
VL 51
IS 10
BP 2847
EP 2862
DI 10.1194/jlr.R004820
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 649GS
UT WOS:000281756800001
PM 20567027
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Tan, HD
   Lv, M
   Tan, X
   Su, GN
   Chang, R
   Yang, PZ
AF Tan, Handan
   Lv, Meng
   Tan, Xiao
   Su, Guannan
   Chang, Rui
   Yang, Peizeng
TI Sharing of Genetic Association Signals by Age-Related Macular
   Degeneration and Alzheimer's Disease at Multiple Levels
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Alzheimer's disease; Genome-wide
   association studies; Gene expression profile; Weighted gene
   co-expression network analysis; Functional mapping and annotation
ID ARCHITECTURES; ACTIVATION; DIVERSITY; MODULES; FAMILY
AB Age-related macular degeneration and Alzheimer's disease are closely related complex diseases that may share overlapping pathogenesis in gene networks. This study was conducted to investigate the genetic factors shared by both diseases. We analyzed genome-wide association studies' summary statistics from both diseases using a new platform known as functional mapping and annotation (FUMA) and a co-localization analysis. We obtained disease-related gene expression profile data from the Gene Expression Omnibus and analyzed these data using weighted gene co-expression network analysis. FUMA analysis and Bayesian co-localization analysis showed that ten genes on chromosome 7, one pathway (complement and coagulation cascade), and forty-two biological processes were common for both diseases. Among these ten genes, two protein-coding genes, two pseudogenes, and two RNA genes were, for the first time, identified to be associated with both diseases. Weighted gene co-expression network analysis identified 19 age-related macular degeneration hub genes and 19 Alzheimer's disease hub genes and revealed that these two diseases shared nine pathways and 63 biological processes. Using FUMA, co-localization analysis, and weighted gene co-expression network analysis, 10 genes on chromosome 7, 10 pathways, and 105 biological processes were found to be associated with the two degenerative diseases. This suggests that these10 genes and the hub genes of these modules associated with the shared pathways are potential diagnostic markers for both diseases.
C1 [Tan, Handan; Lv, Meng; Tan, Xiao; Su, Guannan; Chang, Rui; Yang, Peizeng] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Youyi Rd 1, Chongqing 400016, Peoples R China.
   [Tan, Handan; Lv, Meng; Tan, Xiao; Su, Guannan; Chang, Rui; Yang, Peizeng] Chongqing Eye Inst, Youyi Rd 1, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University
RP Yang, PZ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol, Youyi Rd 1, Chongqing 400016, Peoples R China.; Yang, PZ (通讯作者)，Chongqing Eye Inst, Youyi Rd 1, Chongqing 400016, Peoples R China.
EM peizengycmu@126.com
RI Chang, Rui/ABC-2118-2021
OI Chang, Rui/0000-0001-5763-5371
FU Natural Science Foundation Major International (Regional) Joint Research
   Project [81720108009]; National Natural Science Foundation Key Program
   [81930023]; Chongqing Outstanding Scientists Project (2019); Chongqing
   Chief Medical Scientist Project (2018); Chongqing Key Laboratory of
   Ophthalmology (CSTC) [2008CA5003]; Chongqing Science & Technology
   Platform and Base Construction Program [cstc2014pt-sy10002]
FX This study was supported by Natural Science Foundation Major
   International (Regional) Joint Research Project (81720108009), National
   Natural Science Foundation Key Program (81930023), Chongqing Outstanding
   Scientists Project (2019), the Chongqing Chief Medical Scientist Project
   (2018), Chongqing Key Laboratory of Ophthalmology (CSTC, 2008CA5003),
   and Chongqing Science & Technology Platform and Base Construction
   Program (cstc2014pt-sy10002).
CR Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Bao XJ, 2015, NEUROBIOL AGING, V36, DOI 10.1016/j.neurobiolaging.2015.06.006
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   de Grey ADNJ, 2005, AGEING RES REV, V4, P315, DOI 10.1016/j.arr.2005.03.008
   Deng LT, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00024
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Ghanbari M, 2017, HUM MUTAT, V38, P827, DOI 10.1002/humu.23226
   Giambartolomei C, 2018, BIOINFORMATICS, V34, P2538, DOI 10.1093/bioinformatics/bty147
   HAN L, 2014, NAT COMMUN, V5, DOI DOI 10.1038/NCOMMS49634339277
   Hendrickx JO, 2020, PHARMACOL REV, V72, P191, DOI 10.1124/pr.119.017921
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018
   Kester HA, 1999, J BIOL CHEM, V274, P27439, DOI 10.1074/jbc.274.39.27439
   Kutmon M, 2016, NUCLEIC ACIDS RES, V44, pD488, DOI 10.1093/nar/gkv1024
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Langfelder P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061505
   Larsson SC, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j5375
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Loh PR, 2015, NAT GENET, V47, P1385, DOI 10.1038/ng.3431
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Miao L, 2018, CELL PHYSIOL BIOCHEM, V48, P1151, DOI 10.1159/000491982
   Miller JA, 2010, P NATL ACAD SCI USA, V107, P12698, DOI 10.1073/pnas.0914257107
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Patel T, 2018, NEUROPATH APPL NEURO, V44, P506, DOI 10.1111/nan.12452
   Pfaffenseller B, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.78
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Romano GL, 2015, PROG BRAIN RES, V220, P217, DOI 10.1016/bs.pbr.2015.04.013
   Ryan KJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7635
   Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
   Scheckel C, 2016, ELIFE, V5, DOI 10.7554/eLife.10421
   Shang DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104934
   Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003
   Solovieff N, 2013, NAT REV GENET, V14, P483, DOI 10.1038/nrg3461
   Sullivan PF, 2012, NAT REV GENET, V13, P537, DOI 10.1038/nrg3240
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Vemuri P, 2017, ANN NEUROL, V82, P706, DOI 10.1002/ana.25071
   Wan Q, 2018, EXP EYE RES, V166, P13, DOI 10.1016/j.exer.2017.10.007
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756
   Xue ZG, 2013, NATURE, V500, P593, DOI 10.1038/nature12364
   Yin XM, 2018, J ALZHEIMERS DIS, V61, P561, DOI 10.3233/JAD-170418
   Yokoyama K, 2011, EMBO J, V30, P4739, DOI 10.1038/emboj.2011.348
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
NR 53
TC 2
Z9 2
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD NOV
PY 2020
VL 57
IS 11
BP 4488
EP 4499
DI 10.1007/s12035-020-02024-y
EA AUG 2020
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NS9CD
UT WOS:000555379000001
PM 32748369
DA 2022-11-30
ER

PT J
AU Kadasi, LM
   Adhi, M
   Liang, MC
   Duker, JS
AF Kadasi, Laith M.
   Adhi, Mehreen
   Liang, Michelle C.
   Duker, Jay S.
TI Retinal Pigment Epithelial Detachment With Disgorgement in Age-Related
   Macular Degeneration Observed With OCT
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
AB This report describes a rare appearance of retinal pigment epithelial changes in a 71-year-old woman with known long-standing, non-exudative age-related macular degeneration. She presented with visual distortion in her right eye and was found to have a retinal pigment epithelial detachment (RPED) on optical coherence tomography (OCT). Over the following 8 years, sequential OCT imaging revealed an appearance and progression of a break in the existing RPED, disgorgement of material from within the RPED, and appearance of hyper-reflective spots within the inner retinal layers, suggesting pigment epithelial cell migration. Visual acuity remained stable over this period. The RPED resolved spontaneously without treatment. The patient later developed new intraretinal hemorrhage, which was treated with intravitreal bevacizumab.
C1 [Kadasi, Laith M.; Duker, Jay S.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Kadasi, Laith M.; Adhi, Mehreen; Liang, Michelle C.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
C3 Tufts University; Tufts Medical Center
RP Duker, JS (通讯作者)，New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
EM Jduker@tuftsmedicalcenter.org
RI Adhi, Mehreen/AAS-9733-2021
OI Kadasi, Laith/0000-0002-0716-4353
FU Research to Prevent Blindness Unrestricted grant; Tufts University
   School of Medicine; Massachusetts Lions Club; Carl Zeiss Meditec;
   Optovue
FX Supported in part by a Research to Prevent Blindness Unrestricted grant
   to the New England Eye Center/Department of Ophthalmology, Tufts
   University School of Medicine and the Massachusetts Lions Club.; Dr.
   Duker receives research support from Carl Zeiss Meditec and Optovue. The
   remaining authors have no financial or proprietary interest in the
   materials presented herein.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   HITCHCOCK PF, 1992, TRENDS NEUROSCI, V15, P103, DOI 10.1016/0166-2236(92)90020-9
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Schneider S, 1998, DOC OPHTH P, V62, P69
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
NR 6
TC 0
Z9 0
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD NOV-DEC
PY 2013
VL 44
IS 6
SU S
BP S30
EP S32
DI 10.3928/23258160-20131101-05
PG 3
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA V37XT
UT WOS:000209309200005
PM 24170230
DA 2022-11-30
ER

PT J
AU Framme, C
   Bunse, A
   Sofroni, R
   Thalhammer, T
   Walter, A
   Sachs, HG
   Gabel, VP
AF Framme, Carsten
   Bunse, Arnd
   Sofroni, Renata
   Thalhammer, Thomas
   Walter, Andreas
   Sachs, Helmut G.
   Gabel, Veit-Peter
TI Fundus autofluorescence before and after photodynamic therapy for
   choroidal neovascularization secondary to age-related macular
   degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; LASER-SCANNING OPHTHALMOSCOPE; GEOGRAPHIC
   ATROPHY; LIPOFUSCIN; FLUORESCENCE; RPE
AB BACKGROUND AND OBJECTIVE: To describe fundus autofluorescence patterns in choroidal neovascularization secondary to age-related macular degeneration before and after photodynamic therapy (PDT).
   PATIENTS AND METHODS: Sixty-eight consecutive eyes were indicated for PDT after standard fluorescein angiography, which showed completely classic choroidal neovascularization (CMV) (n = 52), occult with no classic CNV (n = 7), and predominantly classic CNV (n = 9). Standardized PDT was performed and patients were examined 2 to 3 months later. Angiography and autofluorescence measurements were performed again and compared with preoperative values.
   RESULTS: At baseline, autofluorescence was mainly decreased in areas of completely classic CNV (79%), but showed a regular or mottled pattern in occult CNV. A slightly increased (50%) or normal (50%) autofluorescence was seen at the rim of the classic lesions within the junctional zone. Membrane demarcation was improved (90%) in classic membranes 2 to 3 months after PDT After PDT for occult membranes, a transformation into classic membranes with residual leakage and need for further PDT was observed (6 of 7 eyes), showing the described autofluorescence patterns. For the mixed type of CNV, both described patterns of autofluorescence distribution were found.
   CONCLUSION: Especially classic CNVs reveal distinct characteristics of significantly decreased autofluorescence, presumably due to their localization above the retinal pigment epithelium level, leading to blockage of autofluorescence. Autofluorescence patterns after PDT included enhanced demarcation of the membrane, suggesting reactive retinal pigment epithelial changes. Autofluorescence might be an interesting tool to distinguish noninvasively between classic and occult CNV in age-related macular degeneration and to monitor changes after PDT.
C1 Univ Eye Hosp Regensburg, D-93042 Regensburg, Germany.
   Univ Eye Hosp Kiel, Kiel, Germany.
C3 University of Regensburg; University of Kiel; Schleswig Holstein
   University Hospital
RP Framme, C (通讯作者)，Univ Eye Hosp Regensburg, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.
CR [Anonymous], 1993, AM NAT STAND SAF US
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   BINDEWALD A, 2003, OPHTHALMOLOGE S1, V100, P130
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Framme C, 2002, BRIT J OPHTHALMOL, V86, P1099, DOI 10.1136/bjo.86.10.1099
   Framme C, 2001, OPHTHALMIC SURG LAS, V32, P383
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   von Ruckmann A, 1998, BRIT J OPHTHALMOL, V82, P346, DOI 10.1136/bjo.82.4.346
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 22
TC 8
Z9 8
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2006
VL 37
IS 5
BP 406
EP 414
DI 10.3928/15428877-20060901-08
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 087BE
UT WOS:000240716400008
PM 17017200
DA 2022-11-30
ER

PT J
AU Hosseini, H
   Lotfi, M
   Esfahani, MH
   Nassiri, N
   Khalili, MR
   Razeghinejad, MR
   Nouri-Mahdavi, K
AF Hosseini, Hamid
   Lotfi, Mehrzad
   Esfahani, Mina Heidari
   Nassiri, Nariman
   Khalili, Mohammad Reza
   Razeghinejad, Mohammad Reza
   Nouri-Mahdavi, Kouros
TI EFFECT OF INTRAVITREAL BEVACIZUMAB ON RETROBULBAR BLOOD FLOW IN INJECTED
   AND UNINJECTED FELLOW EYES OF PATIENTS WITH NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ISCHEMIC OPTIC NEUROPATHY; FACTOR THERAPY;
   CAPILLARIES; AVASTIN(R); SAFETY; ORBIT
AB Background: To determine the effect of intravitreal administration of bevacizumab (1.25 mg/0.05 mL) on retrobulbar circulation of the injected and the fellow (uninjected) eyes in patients with neovascular age-related macular degeneration.
   Methods: In this prospective study, the retrobulbar hemodynamics of 43 patients with neovascular age-related macular degeneration was examined by color Doppler ultrasonography. Peak systolic velocity, end-diastolic velocity, and resistive index values in the central retinal artery and short posterior ciliary artery in both injected and uninjected fellow eyes were measured at baseline and 7 days after a single intravitreal injection of bevacizumab.
   Results: At baseline, the peak systolic velocity, end-diastolic velocity, and the resistive index in the central retinal artery and short posterior ciliary artery of the injected eye were not significantly different compared with the fellow uninjected eye (P > 0.05 for all). However, intravitreal bevacizumab induced a significant reduction in the peak systolic velocity and end-diastolic velocity and a significant rise in the resistive index of the central retinal artery and short posterior ciliary artery of the injected eye (P <= 0.006 for all). Peak systolic velocity and end-diastolic velocity decreased in the central retinal artery (P = 0.023 and P = 0.030) and the short posterior ciliary artery (P = 0.001 and P < 0.000) in the uninjected eye while the resistive index did not significantly change in central retinal artery (P = 0.114) and short posterior ciliary artery (P = 0.082) of the fellow eyes.
   Conclusion: Intravitreal injection of bevacizumab significantly affects ocular hemodynamic parameters of both the injected and the uninjected fellow eyes with neovascular age-related macular degeneration. RETINA 32:967-971, 2012
C1 [Nassiri, Nariman] Vanak Eye Surg Ctr, Tehran 1517973813, Iran.
   [Hosseini, Hamid; Khalili, Mohammad Reza; Razeghinejad, Mohammad Reza] Shiraz Univ Med Sci, Poostchi Ophthalmol Res Ctr, Shiraz, Iran.
   [Lotfi, Mehrzad; Esfahani, Mina Heidari] Shiraz Univ Med Sci, Dept Radiol, Shiraz, Iran.
   [Nouri-Mahdavi, Kouros] Univ Calif Los Angeles, Jules Stein Eye Inst, Div Glaucoma, Los Angeles, CA 90024 USA.
C3 Shiraz University of Medical Science; Shiraz University of Medical
   Science; University of California System; University of California Los
   Angeles
RP Nassiri, N (通讯作者)，Vanak Eye Surg Ctr, 41 Haghani Highway, Tehran 1517973813, Iran.
EM drnassirin@sbmu.ac.ir
RI Lotfi, Mehrzad/V-3194-2017; Esfahani, Mina Heidari/N-1722-2018;
   Nouri-Mahdavi, Kouros/H-8922-2013; Khalili, Mohammmad Reza/K-1628-2013
OI Lotfi, Mehrzad/0000-0001-5192-4930; Esfahani, Mina
   Heidari/0000-0001-7569-6776; Nouri-Mahdavi, Kouros/0000-0001-9403-8904;
   Khalili, Mohammmad Reza/0000-0002-2664-8927; , reza/0000-0001-7961-8425
CR Al-Dhibi H, 2009, J AAPOS, V13, P400, DOI 10.1016/j.jaapos.2009.03.006
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   BAXTER GM, 1995, J ULTRAS MED, V14, P91, DOI 10.7863/jum.1995.14.2.91
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   DONATI G, 1995, INVEST OPHTH VIS SCI, V36, P2228
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Furino Claudio, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-57
   Ganssauge M, 2009, GRAEF ARCH CLIN EXP, V247, P1707, DOI 10.1007/s00417-009-1184-5
   Good TJ, 2010, BR J OPHTHALMOL
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P1055, DOI 10.1136/bjo.80.12.1055
   Hosseini H, 2009, J NEURO-OPHTHALMOL, V29, P160, DOI 10.1097/WNO.0b013e3181a58fd1
   Huang ZL, 2010, OPHTHALMOLOGICA, V224, P86, DOI 10.1159/000235726
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kim KS, 2008, ACTA OPHTHALMOL, V86, DOI 10.1111/j.1755-3768.2008.01175.x
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   LIEB WE, 1992, ACTA OPHTHALMOL, V70, P50
   Liu MH, 2002, ANN THORAC SURG, V73, P819, DOI 10.1016/S0003-4975(01)03404-X
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Mansour AM, 2010, ACTA OPHTHALMOL, V88, P730, DOI 10.1111/j.1755-3768.2009.01535.x
   Mendrinos E, 2009, INVEST OPHTHALMOL VI
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Sato E, 2006, GRAEF ARCH CLIN EXP, V244, P963, DOI 10.1007/s00417-005-0201-6
   Soliman W, 2008, ACTA OPHTHALMOL, V86, P365, DOI 10.1111/j.1600-0420.2007.01057.x
   Wei W, 2007, VASC PHARMACOL, V46, P253, DOI 10.1016/j.vph.2006.10.009
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   Yokoyama K, 2008, ACTA OPHTHALMOL, V86, P927, DOI 10.1111/j.1755-3768.2008.01187.x
NR 34
TC 28
Z9 30
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2012
VL 32
IS 5
BP 967
EP 971
DI 10.1097/IAE.0b013e31822c28d6
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 935EQ
UT WOS:000303502200013
PM 22146127
DA 2022-11-30
ER

PT J
AU El-Emam, S
   Chhablani, J
   Barteselli, G
   Wang, HY
   Lee, SN
   Kozak, I
   Cheng, LY
   Freeman, WR
AF El-Emam, Sharif
   Chhablani, Jay
   Barteselli, Giulio
   Wang, Haiyan
   Lee, Su Na
   Kozak, Igor
   Cheng, Lingyun
   Freeman, William R.
TI CORRELATION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
   CHARACTERISTICS WITH VISUAL ACUITY IN EYES WITH SUBFOVEAL SCARRING AFTER
   TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE wet age-related macular degeneration; subretinal scarring; visual
   acuity; spectral domain optic coherence tomography; inner segment/outer
   segment junction; external limiting membrane
ID CENTRAL SEROUS CHORIORETINOPATHY; INTRAVITREAL BEVACIZUMAB INJECTION;
   FOVEAL PHOTORECEPTOR LAYER; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; STRUCTURAL FINDINGS; RANIBIZUMAB; ASSOCIATION; SEGMENT;
   PREDICTORS
AB Purpose: Correlating spectral domain optical coherence tomography characteristics with final best-corrected visual acuity (BCVA) in eyes with subfoveal scarring after treatment for wet age-related macular degeneration.
   Methods: Seventy-nine eyes from 64 subjects, who developed subfoveal scarring after treatment of wet age-related macular degeneration, were retrospectively studied. Spectral domain optical coherence tomography characteristics were analyzed, including percentage disruption of inner segment/outer segment junction and external limiting membrane, central macular thickness, subfoveal scar thickness, subretinal scar area, and proximity of retina with intact outer structures to the fovea. A multivariate stepwise regression analysis was performed with the final BCVA logarithm of minimum angle of resolution as a response and the above-identified spectral domain optical coherence tomography variables as predictors.
   Results: There was no correlation between the final BCVA and any of the demographic data, treatment modality received, and central macular thickness. The final BCVA was significantly correlated with the percentage of inner segment/outer segment disruption (P = 0.011), external limiting membrane disruption (P = 0.005), and scar area on spectral domain optical coherence tomography (P = 0.018). Multivariate analysis showed that the baseline BCVA and distance between the fovea and nearest retina with intact outer structures are the most predictive of the final BCVA (R-2 = 0.52).
   Conclusion: Baseline BCVA and integrity of outer retinal structures are good predictors of the final BCVA of wet age-related macular degeneration patients developing scarring after treatment.
C1 [El-Emam, Sharif; Chhablani, Jay; Barteselli, Giulio; Wang, Haiyan; Lee, Su Na; Kozak, Igor; Cheng, Lingyun; Freeman, William R.] Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, Dept Ophthalmol, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
RI Emam, Sharif El/AAA-6627-2020; Kozak, Igor/AAC-4645-2019; Chhablani,
   Jay/F-6241-2012
OI Emam, Sharif El/0000-0001-6357-0471; Barteselli,
   Giulio/0000-0003-0533-1135; Chhablani, Jay/0000-0003-1772-3558
FU National Institutes of Health [R01EY007366, R01EY018589, R01EY020617];
   Jacobs Retina Center; NATIONAL EYE INSTITUTE [R01EY020617, R01EY007366,
   R01EY018589] Funding Source: NIH RePORTER
FX This study was supported by National Institutes of Health grants
   R01EY007366 and R01EY018589 (W.R.F.), and R01EY020617 (L.C.), "RPB
   incorporated and unrestricted funds from Jacobs Retina Center." The
   funding organizations had no role in the design or conduct of this
   research.
CR Aizawa S, 2009, EYE, V23, P304, DOI 10.1038/sj.eye.6703076
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baba T, 2008, RETINA-J RET VIT DIS, V28, P453, DOI 10.1097/IAE.0b013e3181571398
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Byun YJ, 2010, JPN J OPHTHALMOL, V54, P571, DOI 10.1007/s10384-010-0866-1
   Calvo-Gonzalez C, 2011, AM J OPHTHALMOL, V151, P529, DOI 10.1016/j.ajo.2010.09.021
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Duke-Elder WS, 1947, TXB OPHTHALMOLOGY, V3, P2116
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Hangai Masanori, 2007, Nippon Ganka Gakkai Zasshi, V111, P509
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Iida T, 2003, RETINA, V23, P137, DOI DOI 10.1097/00006982-200302000-00001
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Jonas JB, 2011, J OCUL PHARMACOL TH, V27, P401, DOI 10.1089/jop.2011.0080
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kuo JZC, 2011, RETINA-J RET VIT DIS, V31, P1835, DOI 10.1097/IAE.0b013e31821ba2dc
   Li D, 2007, ARCH OPHTHALMOL-CHIC, V125, P1194, DOI 10.1001/archopht.125.9.1194
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Maruko I, 2009, AM J OPHTHALMOL, V147, P489, DOI 10.1016/j.ajo.2008.09.030
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Oster SF, 2010, RETINA-J RET VIT DIS, V30, P713, DOI 10.1097/IAE.0b013e3181c596e3
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Riusala A, 2005, GRAEF ARCH CLIN EXP, V243, P947, DOI 10.1007/s00417-005-1161-6
   Riusala AM, 2004, AM J OPHTHALMOL, V138, P245, DOI 10.1016/j.ajo.2004.03.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 44
TC 9
Z9 9
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2013
VL 33
IS 6
BP 1249
EP 1257
DI 10.1097/IAE.0b013e31827b6439
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 151IU
UT WOS:000319454700023
PM 23446655
DA 2022-11-30
ER

PT J
AU Donoso, LA
   Kim, D
   Frost, A
   Callahan, A
   Hageman, G
AF Donoso, LA
   Kim, D
   Frost, A
   Callahan, A
   Hageman, G
TI The role of inflammation in the pathogenesis of age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; atherosclerosis; complement; drusen;
   Factor H gene; genetics; glomerulonephritis; inflammation; single
   nucleotide polymorphism
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; GLOMERULONEPHRITIS TYPE-II;
   STREPTOCOCCAL M PROTEINS; APOLIPOPROTEIN-E GENE; REGULATOR FACTOR-H;
   BEAVER DAM EYE; RISK-FACTORS; RETINITIS-PIGMENTOSA; 2 PARTS
AB Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, is a complex disease to study because of the potential role of demographic, environmental, and other systemic risk factors, such as age, sex, race, light exposure, diet, smoking, and underlying cardiovascular disease which may contribute to the pathogenesis of this disease. Recently, single nucleotide polymorphisms, DNA sequence variations found within the complement Factor H gene, have been found to be strongly associated with the development of AMD in Caucasians. One single nucleotide polymorphism, Tyr402His, was associated with approximately 50% of AMD cases. We review recent developments in the molecular biology of AMD, iucluding Single nucleotide polymorphisms within the Factor H gene, which may predispose individuals to the susceptibility of AMD as well as single nucleotide polymorphisms that may confer a protective effect. Taken together these findings help to provide new insights into the central issues surrounding the pathogenesis of AMD.
C1 Wills Eye Hosp & Res Inst, Eye Res Inst, Henry & Corinne Bower Lab, Philadelphia, PA USA.
   Int Retinal Res Fdn, Birmingham, AL USA.
   Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 Jefferson University; University of Iowa
RP Donoso, LA (通讯作者)，Bower Res Lab, POB 53429, Philadelphia, PA 19105 USA.
FU NEI NIH HHS [R01 EY011515] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY011515] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson JL, 2005, NEW ENGL J MED, V352, P1706, DOI 10.1056/NEJMe058019
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090
   Botto M, 2001, ARTHRITIS RES, V3, P207, DOI 10.1186/ar301
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Daiger Stephen P, 2004, Novartis Found Symp, V255, P17
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Davies JC, 2005, PEDIATR PULM, V39, P383, DOI 10.1002/ppul.20198
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107
   Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207
   Donoso LA, 2003, SURV OPHTHALMOL, V48, P191, DOI 10.1016/S0039-6257(02)00460-5
   Donoso LA, 2003, CAN J OPHTHALMOL, V38, P33, DOI 10.1016/S0008-4182(03)80006-6
   Donoso LA, 2001, SURV OPHTHALMOL, V46, P149, DOI 10.1016/S0039-6257(01)00251-X
   Dryja TP, 1997, P NATL ACAD SCI USA, V94, P12117, DOI 10.1073/pnas.94.22.12117
   DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903
   Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972
   Duthy TG, 2002, INFECT IMMUN, V70, P5604, DOI 10.1128/IAI.70.10.5604-5611.2002
   EDWARDS AO, 2005, COMPLEMENT FACTOR H, V10, P10
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Ewing B, 2000, NAT GENET, V25, P232, DOI 10.1038/76115
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4
   Forrester J V, 1999, Chem Immunol, V73, P159
   Framme C, 1998, KLIN MONATSBL AUGENH, V213, P252, DOI 10.1055/s-2008-1034983
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916
   Garrod AE, 1902, LANCET, V2, P1616
   Gass J.D., 1967, AM J OPHTHALMOL, V63, P1
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Giannakis E, 2002, J IMMUNOL, V168, P4585, DOI 10.4049/jimmunol.168.9.4585
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726
   GOODRICH DW, 1990, CANCER SURV, V9, P529
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Haab O, 1885, CENTRALBLAT AUGENHEI, V9, P384
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Heckenlively JR, 1999, AM J OPHTHALMOL, V127, P565, DOI 10.1016/S0002-9394(98)00446-2
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Helisalmi S, 2004, J NEUROL NEUROSUR PS, V75, P1746, DOI 10.1136/jnnp.2004.036574
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Hutchison J, 1875, R LOND OPHTHALMOL HO, V8, P231
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jozsi M, 2004, HISTOL HISTOPATHOL, V19, P251, DOI 10.14670/HH-19.251
   KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715
   Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khoubian FJ, 2005, RETINA-J RET VIT DIS, V25, P999, DOI 10.1097/00006982-200512000-00008
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KORNZWEIG AL, 1965, AM J OPHTHALMOL, V60, P835, DOI 10.1016/0002-9394(65)92002-7
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Lai E, 2001, GENOME RES, V11, P927, DOI 10.1101/gr.192301
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889
   Lerner MP, 1995, AUTOIMMUNITY, V22, P95, DOI 10.3109/08916939508995305
   Levinson W., 2002, MED MICROBIOLOGY IMM
   MACDONALD IM, 1994, CLIN INVEST MED, V17, P474
   MacDonald IM, 2004, SURV OPHTHALMOL, V49, P159, DOI 10.1016/j.survophthal.2003.12.003
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   MOLD C, 1984, J IMMUNOL, V133, P882
   MORELL AG, 1971, J BIOL CHEM, V246, P1461
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NATHANS J, 1993, AM J HUM GENET, V53, P987
   NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922
   Nettleship E, 1884, T OPHTHAL SOC UK, V4, P165
   NICHOLS BE, 1993, NAT GENET, V3, P202, DOI 10.1038/ng0393-202
   NICHOLS BE, 1993, HUM MOL GENET, V2, P601, DOI 10.1093/hmg/2.5.601
   Niculescu F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073
   Pager CK, 2001, AM J OPHTHALMOL, V131, P517, DOI 10.1016/S0002-9394(00)00821-7
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Ramanathan Y, 2002, GENOME RES, V12, P1175, DOI 10.1101/gr.156002
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   RIPOCHE J, 1988, BIOCHEM J, V253, P475, DOI 10.1042/bj2530475
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   ROYERPOKORA B, 1986, COLD SPRING HARB SYM, V51, P177, DOI 10.1101/SQB.1986.051.01.021
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   shwell G., 1974, BIOCHEM SOC S, V40, P117
   Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Singh K, 2001, AM J EPIDEMIOL, V154, P236, DOI 10.1093/aje/154.3.236
   SMALL KW, 1992, GENOMICS, V13, P681, DOI 10.1016/0888-7543(92)90141-E
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tantri A, 2004, SURV OPHTHALMOL, V49, P214, DOI 10.1016/j.survophthal.2003.12.007
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANLENTEN L, 1971, J BIOL CHEM, V246, P1889
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033
   WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213
   Wildner G, 2004, AUTOIMMUN REV, V3, P383, DOI 10.1016/j.autrev.2004.01.002
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zack DJ, 1999, MOL VIS, V5, pU37
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang C, 2001, J POROUS MEDIA, V4, P89
   ZIMMERMAN LE, 1979, AM J OPHTHALMOL, V88, P524, DOI 10.1016/0002-9394(79)90658-5
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
NR 164
TC 378
Z9 420
U1 1
U2 39
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAR-APR
PY 2006
VL 51
IS 2
BP 137
EP 152
DI 10.1016/j.survophthal.2005.12.001
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 019YJ
UT WOS:000235874300004
PM 16500214
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Keilhauer, CN
   Fritsche, LG
   Weber, BHF
AF Keilhauer, Claudia N.
   Fritsche, Lars G.
   Weber, Bernhard H. F.
TI Age-related macular degeneration with discordant late stage phenotypes
   in monozygotic twins
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; monozygotic twins; genetic risk
   factors
ID COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY; RISK-FACTORS; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; CARDIOVASCULAR-DISEASE;
   SUSCEPTIBILITY GENES; GROWTH-FACTORS; PROGRESSION; MACULOPATHY
AB Purpose: Age-related macular degeneration (AMD) is a complex disease caused by genetic and environmental factors. Monozygotic twins with late stage AMD provide an opportunity to evaluate the role of environmental factors on a genetically uniform background.
   Methods: Monozygosity was determined in four twin pairs by genotyping 15 highly polymorphic tetranucleotide repeat markers. Clinically, the monozygotic twin pairs were evaluated by ophthalmologic examination, fundus autofluorescence (FAF) imaging, and, upon suspicion of choroidal neovascular membranes, by fluorescein angiography. Twin pairs were followed over a period of 4-8 years.
   Results: Genetically confirmed monozygotic twins with early stages of AMD reveal striking symmetry of early macular pathology. Upon progression to late stage AMD each twin pair developed a discordant phenotype with respect to disease onset and specific phenotype as choroidal neovascularization (CNV) and geographic atrophy (GA).
   Conclusions: Genetic risk variants are known to predispose to the development of AMD. Course and visual outcome of the disease, however, appear to be influenced by environmental factors rather than genetic determinants.
C1 [Keilhauer, Claudia N.] Univ Wurzburg, Dept Ophthalmol, D-97080 Wurzburg, Germany.
   [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
C3 University of Wurzburg; University of Regensburg
RP Keilhauer, CN (通讯作者)，Univ Wurzburg, Dept Ophthalmol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.
EM ckeilhauer@yahoo.com; bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Weber, Bernhard
   H.F./0000-0002-8808-7723
FU German Research Foundation [We 1259/14-3, We 1259/18-1]; Alcon Research
   Institute; Ruth and Milton Steinbach Foundation New York
FX This work was supported in part by grants of the German Research
   Foundation (We 1259/14-3 and We 1259/18-1), the Alcon Research Institute
   and the Ruth and Milton Steinbach Foundation New York.
CR BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Frank RN, 2000, T AM OPHTHAL SOC, V98, P109
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goncalves LM, 2000, CARDIOVASC RES, V45, P294, DOI 10.1016/S0008-6363(99)00358-2
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Nyholt DR, 2006, TWIN RES HUM GENET, V9, P194, DOI 10.1375/183242706776382383
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sieberts SK, 2002, AM J HUM GENET, V70, P170, DOI 10.1086/338444
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SORENSEN TIA, 1995, METABOLISM, V44, P4, DOI 10.1016/0026-0495(95)90310-0
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   WWW INTERFACE ZYGPRO
NR 42
TC 6
Z9 6
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD NOV
PY 2011
VL 32
IS 4
BP 237
EP 244
DI 10.3109/13816810.2011.592177
PG 8
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 835DW
UT WOS:000296015800008
PM 21740222
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Kauppinen, A
   Blasiak, J
   Salminen, A
AF Kaarniranta, Kai
   Kauppinen, Anu
   Blasiak, Janusz
   Salminen, Antero
TI Autophagy regulating kinases as potential therapeutic targets for
   age-related macular degeneration
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; AMPK ACTIVATION; ENERGY
   SENSOR; CELL-DEATH; BECLIN 1; RAPAMYCIN; SIRT1; MTOR; DEGRADATION
AB Age-related macular degeneration (AMD) is the leading cause of central vision loss in the elderly in the developed countries. The number of AMD patients will double during the next decades due to increasing number of aged people. Chronic oxidative stress, inflammation and accumulation of protein-rich deposits both in the retinal pigment epithelium lysosomes and under the retinal pigment epithelium herald the onset of AMD. The disease can be divided into dry and wet AMD forms. The dry form of the disease is more prevalent accounting for up to 90% of all cases. Continued intraocular injections are the current treatment strategy to prevent progression of wet AMD. It is a major challenge to develop new drugs that could prevent or at least ease the symptoms of the increasing population of AMD patients. Since AMD pathology is clearly associated with accumulated protein deposits, the autophagy clearance system might represent a potential future therapeutic target for AMD as is thoroughly discussed here.
C1 [Kaarniranta, Kai; Kauppinen, Anu] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90131 Lodz, Poland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Lodz; University of Eastern Finland;
   Kuopio University Hospital; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
EM kai.kaarniranta@uef.fi
OI Blasiak, Janusz/0000-0001-9539-9584; Kaarniranta,
   Kai/0000-0003-2600-8679
FU Academy of Finland; EVO [5503726]; Finnish Cultural Foundation; Finnish
   Eye Foundation; Finnish Funding Agency for Technology and Innovation;
   Paivikki and Sakari Sohlberg Foundation
FX This work was supported by the Academy of Finland, the EVO grant
   5503726, the Finnish Cultural Foundation and its North Savo Fund, the
   Finnish Eye Foundation, Finnish Funding Agency for Technology and
   Innovation, and the Paivikki and Sakari Sohlberg Foundation. The authors
   have no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Beauloye C, 2011, CARDIOVASC RES, V90, P224, DOI 10.1093/cvr/cvr034
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Blander G, 2009, J INVEST DERMATOL, V129, P41, DOI 10.1038/jid.2008.179
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dejneka NS, 2004, MOL VIS, V10, P964
   Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giralt A, 2011, J BIOL CHEM, V286, P16958, DOI 10.1074/jbc.M110.202390
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Guarente L., 2009, NEW ENGL J MED, V364, P2235
   Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Harris H, 2012, NAT REV NEUROL, V8, P108, DOI 10.1038/nrneurol.2011.200
   HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hoff KG, 2005, NAT STRUCT MOL BIOL, V12, P560, DOI 10.1038/nsmb0705-560
   Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kinnunen PKJ, 2012, BBA-BIOMEMBRANES, V1818, P2446, DOI 10.1016/j.bbamem.2012.04.008
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Kong XX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011707
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200
   LAPLANTE M, 2009, CELL SCI 20, V122, P3589, DOI DOI 10.1242/JCS.051011
   Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665
   Law IKM, 2009, PROTEOMICS, V9, P2444, DOI 10.1002/pmic.200800738
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Lynch CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013502
   Mari M, 2010, J CELL BIOL, V190, P1005, DOI 10.1083/jcb.200912089
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McBride A, 2009, CELL METAB, V9, P23, DOI 10.1016/j.cmet.2008.11.008
   Mercer CA, 2009, AUTOPHAGY, V5, P649, DOI 10.4161/auto.5.5.8249
   Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200
   Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026
   Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200
   Oakhill JS, 2010, P NATL ACAD SCI USA, V107, P19237, DOI 10.1073/pnas.1009705107
   Palacios OM, 2009, AGING-US, V1, P771, DOI 10.18632/aging.100075
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Peng C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012658
   Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Qin SF, 2010, EXP EYE RES, V91, P818, DOI 10.1016/j.exer.2010.10.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2009, CELL SIGNAL, V21, P1356, DOI 10.1016/j.cellsig.2009.02.014
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200
   Shi T, 2010, J DIGEST DIS, V11, P55, DOI 10.1111/j.1751-2980.2009.00416.x
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162
   Suzuki M, 2007, MOL VIS, V13, P772
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   True O, 2012, IMMUNOL CELL BIOL, V90, P78, DOI 10.1038/icb.2011.103
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Viiri J, 2010, MOL VIS, V16, P1399
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang Y, 2011, FEBS LETT, V585, P986, DOI 10.1016/j.febslet.2010.11.047
   Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275
   Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x
   YAMAMOTO H, 2007, ENDOCRINOLOGY, V21, P1745, DOI DOI 10.1210/ME.2007-0079
   Yang DS, 2011, AUTOPHAGY, V7, P788, DOI 10.4161/auto.7.7.15596
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 111
TC 17
Z9 18
U1 0
U2 14
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD NOV
PY 2012
VL 4
IS 17
BP 2153
EP 2161
DI 10.4155/FMC.12.169
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 059AG
UT WOS:000312676200014
PM 23190104
DA 2022-11-30
ER

PT J
AU Yang, ZL
   Tong, ZZ
   Chen, YH
   Zeng, JX
   Lu, F
   Sun, XF
   Zhao, C
   Wang, K
   Davey, L
   Chen, HY
   London, N
   Muramatsu, D
   Salasar, F
   Carmona, R
   Kasuga, D
   Wang, XL
   Bedell, M
   Dixie, M
   Zhao, PQ
   Yang, RF
   Gibbs, D
   Liu, XQ
   Li, Y
   Li, C
   Li, YF
   Campochiaro, B
   Constantine, R
   Zack, DJ
   Campochiaro, P
   Fu, YB
   Li, DY
   Katsanis, N
   Zhang, K
AF Yang, Zhenglin
   Tong, Zongzhong
   Chen, Yuhong
   Zeng, Jiexi
   Lu, Fang
   Sun, Xufang
   Zhao, Chao
   Wang, Kevin
   Davey, Lisa
   Chen, Haoyu
   London, Nyall
   Muramatsu, Daisuke
   Salasar, Francesca
   Carmona, Ruben
   Kasuga, Daniel
   Wang, Xiaolei
   Bedell, Matthew
   Dixie, Manjuxia
   Zhao, Peiquan
   Yang, Ruifu
   Gibbs, Daniel
   Liu, Xiaoqi
   Li, Yan
   Li, Cai
   Li, Yuanfeng
   Campochiaro, Betsy
   Constantine, Ryan
   Zack, Donald J.
   Campochiaro, Peter
   Fu, Yinbin
   Li, Dean Y.
   Katsanis, Nicholas
   Zhang, Kang
TI Genetic and Functional Dissection of HTRA1 and LOC387715 in Age-Related
   Macular Degeneration
SO PLOS GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; STRONG ASSOCIATION; SUSCEPTIBILITY GENES; VARIANT;
   RISK; POLYMORPHISM; HAPLOTYPE; CFH; MACULOPATHY; INCREASES
AB A common haplotype on 10q26 influences the risk of age-related macular degeneration (AMD) and encompasses two genes, LOC387715 and HTRA1. Recent data have suggested that loss of LOC387715, mediated by an insertion/deletion (in/del) that destabilizes its message, is causally related with the disorder. Here we show that loss of LOC387715 is insufficient to explain AMD susceptibility, since a nonsense mutation (R38X) in this gene that leads to loss of its message resides in a protective haplotype. At the same time, the common disease haplotype tagged by the in/del and rs11200638 has an effect on the transcriptional upregulation of the adjacent gene, HTRA1. These data implicate increased HTRA1 expression in the pathogenesis of AMD and highlight the importance of exploring multiple functional consequences of alleles in haplotypes that confer susceptibility to complex traits.
C1 [Yang, Zhenglin; Lu, Fang; Liu, Xiaoqi; Li, Yan; Li, Cai; Li, Yuanfeng] Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin; Lu, Fang; Liu, Xiaoqi; Li, Yan; Li, Cai; Li, Yuanfeng] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin; Chen, Yuhong; Zeng, Jiexi; Sun, Xufang; Zhao, Chao; Wang, Kevin; Salasar, Francesca; Carmona, Ruben; Kasuga, Daniel; Wang, Xiaolei; Bedell, Matthew; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, San Diego, CA 92103 USA.
   [Yang, Zhenglin; Chen, Yuhong; Zeng, Jiexi; Sun, Xufang; Zhao, Chao; Wang, Kevin; Carmona, Ruben; Kasuga, Daniel; Wang, Xiaolei; Bedell, Matthew; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92103 USA.
   [Yang, Zhenglin; Tong, Zongzhong; Chen, Yuhong; Zeng, Jiexi; Sun, Xufang; Zhao, Chao; Chen, Haoyu; Dixie, Manjuxia; Gibbs, Daniel; Constantine, Ryan; Fu, Yinbin; Zhang, Kang] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT USA.
   [Davey, Lisa; Katsanis, Nicholas] Johns Hopkins Univ, Inst Med Genet, Baltimore, MD USA.
   [London, Nyall; Li, Dean Y.] Univ Utah, Sch Med, Eccles Inst Human Genet, Program Human Mol Biol & Genet, Salt Lake City, UT USA.
   [Muramatsu, Daisuke; Campochiaro, Betsy; Zack, Donald J.; Campochiaro, Peter; Katsanis, Nicholas] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Zhao, Peiquan] Shanghai Jiao Tong Univ, Xin Hua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
   [Yang, Ruifu] Inst Microbiol & Epidemiol, Lab Analyt Microbiol, Beijing, Peoples R China.
   [Katsanis, Nicholas] Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD USA.
   [Zhang, Kang] Vet Adm, San Diego, CA USA.
C3 Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; University of California System; University of California San
   Diego; University of California System; University of California San
   Diego; Utah System of Higher Education; University of Utah; Johns
   Hopkins University; Utah System of Higher Education; University of Utah;
   Johns Hopkins University; Johns Hopkins Medicine; Shanghai Jiao Tong
   University; Johns Hopkins University
RP Yang, ZL (通讯作者)，Sichuan Acad Med Sci, Ctr Human Mol Biol & Genet, Chengdu, Sichuan, Peoples R China.
EM zliny@yahoo.com; nkatsan1@jhmi.edu; kangzhang@ucsd.edu
RI Zhang, Kang/Y-2740-2019; Katsanis, Nicholas/E-1837-2012; Chen,
   Haoyu/A-7432-2013
OI Zhang, Kang/0000-0002-4549-1697; Chen, Haoyu/0000-0003-0676-4610; Zack,
   Don/0000-0002-7966-1973; Katsanis, Nicholas/0000-0002-2480-0171
FU NIH; VA Merit; Foundation Fighting Blindness; Macula Vision Research
   Foundation; Ruth and Milton Steinbach Fund; Research to Prevent
   Blindness; BWF Clinical Scientist Award in Translational Research;
   American Health Assistance Foundation; National Natural Science
   Foundation of China; Department of Science and Technology of Sichuan
   Provincial Government of China; NATIONAL EYE INSTITUTE [R01EY009769]
   Funding Source: NIH RePORTER; Veterans Affairs [I01BX001898] Funding
   Source: NIH RePORTER
FX Supported by grants from NIH (KZ, NK, YL, DJZ, PC), VA Merit Award (KZ),
   Foundation Fighting Blindness (KZ, NK, PC, DJZ), the Macula Vision
   Research Foundation (KZ, NK, DJZ), Ruth and Milton Steinbach Fund (KZ,
   PC, DJZ), Research to Prevent Blindness ( KZ), BWF Clinical Scientist
   Award in Translational Research (KZ, YL), American Health Assistance
   Foundation (KZ, RY), National Natural Science Foundation of China (RY),
   Department of Science and Technology of Sichuan Provincial Government of
   China (RY). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR ABRAMSON JH, 2001, PEPI VER 4 0 COMPUTE
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Singh KK, 2009, EXP EYE RES, V88, P479, DOI 10.1016/j.exer.2008.10.019
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 33
TC 81
Z9 87
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD FEB
PY 2010
VL 6
IS 2
AR e1000836
DI 10.1371/journal.pgen.1000836
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 565BG
UT WOS:000275262700031
PM 20140183
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Noel, A
   Jost, M
   Lambert, V
   Lecomte, J
   Rakic, JM
AF Noeel, Agnes
   Jost, Maud
   Lambert, Vincent
   Lecomte, Julie
   Rakic, Jean-Marie
TI Anti-angiogenic therapy of exudative age-related macular degeneration:
   current progress and emerging concepts
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; ACTIVATOR INHIBITOR TYPE-1; RETINAL-PIGMENT
   EPITHELIUM; CHOROIDAL NEOVASCULARIZATION; OCULAR NEOVASCULARIZATION;
   INCREASED EXPRESSION; STEM-CELLS; PHOTODYNAMIC THERAPY; ANECORTAVE
   ACETATE; TUMOR ANGIOGENESIS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in elderly patients. The more aggressive exudative form is characterized by abnormal blood-vessel development that occurs beneath the retina as a result of choroidal neovascularization (CNV). Vascular endothelial growth factor [VEGF) has emerged as the key mediator of CNV formation; this has led to intensive research on VEGF and the recent approval of anti-VEGF compounds by the US Food and Drug Administration. Despite this successful introduction of anti-angiogenic therapies into the clinical setting, there is still a lack of treatments that definitively reverse damaged vision. Here, we consider the importance of putative molecular targets other than VEGF that might have been underestimated. Emerging cellular mechanisms offer additional opportunities for innovative therapeutic approaches.
C1 Univ Liege, Ctr Biomed Integrat Genoproteom, Ctr Expt Canc Res, Lab Tumor & Dev Biol, B-4000 Cointe Ougree, Belgium.
   CHU, Dept Ophthalmol, B-4000 Liege, Belgium.
C3 University of Liege; University of Liege
RP Noel, A (通讯作者)，Univ Liege, Ctr Biomed Integrat Genoproteom, Ctr Expt Canc Res, Lab Tumor & Dev Biol, B-4000 Cointe Ougree, Belgium.
EM agnes.noel@ulg.ac.be
OI Noel, Agnes/0000-0002-7670-6179
CR Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bix G, 2005, TRENDS CELL BIOL, V15, P52, DOI 10.1016/j.tcb.2004.11.008
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Connolly Brian, 2006, Ophthalmol Clin North Am, V19, P381
   DEWAN A, IN PRESS CURR OPIN G
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Fariss RN, 1997, AM J PATHOL, V150, P323
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   He SK, 2005, INVEST OPHTH VIS SCI, V46, P4772, DOI 10.1167/iovs.05-0502
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Luttun A, 2004, BBA-REV CANCER, V1654, P79, DOI 10.1016/j.bbcan.2003.09.002
   Luttun A., 2002, NAT MED, V1, P1
   MAKINEN T, IN PRESS CELL MOL LI
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   NISHIJIMA K, IN PRESS AM J PATHOL
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Overall CM, 2006, CANCER METAST REV, V25, P69, DOI 10.1007/s10555-006-7890-0
   Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Zhou JH, 2005, MOL VIS, V11, P414
NR 81
TC 36
Z9 41
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD AUG
PY 2007
VL 13
IS 8
BP 345
EP 352
DI 10.1016/j.molmed.2007.06.005
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 203UK
UT WOS:000248999300004
PM 17644433
DA 2022-11-30
ER

PT J
AU Tan, LX
   Germer, CJ
   La Cunza, N
   Lakkaraju, A
AF Tan, Li Xuan
   Germer, Colin J.
   La Cunza, Nilsa
   Lakkaraju, Aparna
TI Complement activation, lipid metabolism, and mitochondrial injury:
   Converging pathways in age-related macular degeneration
SO REDOX BIOLOGY
LA English
DT Review
DE Retinal pigment epithelium; Complement; Mitochondria; Cholesterol;
   Ceramide; Autophagy
ID RETINAL-PIGMENT EPITHELIUM; APOLIPOPROTEIN-E; OXIDATIVE STRESS; MOUSE
   MODEL; PHOTORECEPTOR DEGENERATION; CERAMIDE BIOSYNTHESIS; MEDICATION
   USE; AUTOPHAGY; A2E; RPE
AB The retinal pigment epithelium (RPE) is the primary site of injury in non-neovascular age-related macular degeneration or dry AMD. Polymorphisms in genes that regulate complement activation and cholesterol metabolism are strongly associated with AMD, but the biology underlying disease-associated variants is not well understood. Here, we highlight recent studies that have used molecular, biochemical, and live-cell imaging methods to elucidate mechanisms by which aging-associated insults conspire with AMD genetic risk variants to tip the balance towards disease. We discuss how critical functions including lipid metabolism, autophagy, complement regulation, and mitochondrial dynamics are compromised in the RPE, and how a deeper understanding of these mechanisms has helped identify promising therapeutic targets to preserve RPE homeostasis in AMD.
C1 [Tan, Li Xuan; Germer, Colin J.; La Cunza, Nilsa; Lakkaraju, Aparna] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Germer, Colin J.; La Cunza, Nilsa; Lakkaraju, Aparna] Univ Calif San Francisco, Pharmaceut Sci & Pharmacogen Grad Program, San Francisco, CA 94143 USA.
   [Lakkaraju, Aparna] Univ Calif San Francisco, Dept Anat, Sch Med, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   University of California System; University of California San Francisco
RP Lakkaraju, A (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way,Room 233, San Francisco, CA 94143 USA.
EM Aparna.Lakkaraju@ucsf.edu
FU NIH/NEI [R01EY023299, R01EY030668]; Research to Prevent Blindness;
   BrightFocus Foundation [M2015350]; Macular Society UK
FX Supported by NIH/NEI grants R01EY023299 and R01EY030668, the Research to
   Prevent Blindness Catalyst Award for Innovative Approaches to AMD, the
   BrightFocus Foundation Award for AMD research M2015350 and Macular
   Society UK.
CR Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Anderson DMG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17402-1
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], 2014, INVEST OPHTH VIS SCI
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Berry KAZ, 2014, J LIPID RES, V55, P504, DOI 10.1194/jlr.M044990
   Caceres PS, 2020, CURR OPIN CELL BIOL, V62, P37, DOI 10.1016/j.ceb.2019.08.001
   Chen H, 2013, J LIPID RES, V54, P1616, DOI 10.1194/jlr.M035048
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Cox BE, 2007, J LIPID RES, V48, P1012, DOI 10.1194/jlr.M600390-JLR200
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dhingra A, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00351
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Fan J, 2016, INVEST OPHTH VIS SCI, V57, P4476, DOI 10.1167/iovs.16-19717
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fessler MB, 2018, PHARMACOL THERAPEUT, V181, P1, DOI 10.1016/j.pharmthera.2017.07.010
   Filippov V, 2012, J ALZHEIMERS DIS, V29, P537, DOI 10.3233/JAD-2011-111202
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Frost L.S., 2014, MOL NEUROBIOL
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Germer C.J., 2020, CERAMIDE DRIVES APIC
   Go YM, 2020, FASEB J, V34, P12502, DOI 10.1096/fj.202000612R
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gomez NM, 2018, FASEB J, V32, P782, DOI 10.1096/fj.201700220RR
   Guziewicz KE, 2017, PROG RETIN EYE RES, V58, P70, DOI 10.1016/j.preteyeres.2017.01.005
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
   Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008
   Heckmann BL, 2019, J CELL SCI, V132, DOI 10.1242/jcs.222984
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim H.J., 2020, J LIPID RES
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Kornhuber J, 2014, TRENDS PHARMACOL SCI, V35, P293, DOI 10.1016/j.tips.2014.04.003
   Kornhuber J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023852
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   La Cunza N., 2020, BIORXIV, DOI [10.1101/2020.07.15.201723, DOI 10.1101/2020.07.15.201723]
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Leduc Valerie, 2011, Int J Alzheimers Dis, V2011, P974361, DOI 10.4061/2011/974361
   Lenis TL, 2017, P NATL ACAD SCI USA, V114, P3987, DOI 10.1073/pnas.1620299114
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Lin G, 2019, TRENDS ENDOCRIN MET, V30, P106, DOI 10.1016/j.tem.2018.11.003
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y
   Lu W, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00242
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Molliex A, 2015, CELL, V163, P123, DOI 10.1016/j.cell.2015.09.015
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Opreanu M, 2011, DIABETES, V60, P2370, DOI 10.2337/db10-0550
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park MH, 2018, NEURON, V100, P762, DOI 10.1016/j.neuron.2018.10.038
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Perusek L, 2015, J BIOL CHEM, V290, P29035, DOI 10.1074/jbc.M115.682310
   Pujol-Lereis LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200739
   Racz B, 2018, J BIOL CHEM, V293, P11574, DOI 10.1074/jbc.RA118.002062
   Radu Roxana A, 2004, Novartis Found Symp, V255, P51
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014
   Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Shen DB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1735
   Simon MV, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000972
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P8325, DOI 10.1167/iovs.13-13214
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Strettoi E, 2010, P NATL ACAD SCI USA, V107, P18706, DOI 10.1073/pnas.1007644107
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697
   Simon MV, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00246
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang WY, 2015, P NATL ACAD SCI USA, V112, pE1373, DOI 10.1073/pnas.1419669112
   Wheeler RJ, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0193
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Yakovleva MA, 2020, PHOTOCH PHOTOBIO SCI, V19, P920, DOI 10.1039/c9pp00406h
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
   Yamazaki Y, 2019, NAT REV NEUROL, V15, P501, DOI 10.1038/s41582-019-0228-7
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang Y, 2017, MOL VIS, V23, P228
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2015, J BIOL CHEM, V290, P27215, DOI 10.1074/jbc.M115.680363
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 118
TC 5
Z9 5
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2020
VL 37
AR 101781
DI 10.1016/j.redox.2020.101781
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PO2BH
UT WOS:000604974200006
PM 33162377
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, ZL
   Qiao, BD
   Li, GX
   Li, SQ
   Wang, LY
   Dong, YL
AF Wang, Zhi Li
   Qiao, Bao Di
   Li, Guo Xing
   Li, Shi Qing
   Wang, Li Ya
   Dong, Ying Li
TI Bevacizumab cured age-related macular degeneration (AMD) via
   down-regulate TLR2 pathway
SO CENTRAL EUROPEAN JOURNAL OF BIOLOGY
LA English
DT Article
DE Bevacizumab; AMD; TLR2; RPE
ID RANIBIZUMAB; MACULOPATHY; EXPRESSION
AB AMD is the main cause of visual impairment in people over 50 years of age and the most common cause of blindness. In recent years, the use of bevacizumab to treat neovascular AMD has become a preferred treatment in the United States. However, whether bevacozumab is available for RPE or AMD patients is unknown. We firstly indicate that Pam3CSK4 (P3C) activates TLR2 pathway during ARPE-19 apoptosis as determined by western blotting. And then, the expression of MyD88, NF-kappa B, p-IKK in primary RPE cells from AMD patients is significantly down-regulated after treatment with 50 A mu g L-1 Bevacizumab. Therefore, our data shows that MyD88 is involved in the TLR2 pathway in ARPE-19 cell apoptosis resulting from Pam3CSK4 (P3C). And more importantly, our findings suggested that Bevacizumab cured age-related macular degeneration (AMD) via down-regulate Toll-like receptor 2 (TLR2) pathway in RPE from AMD patients.
C1 [Wang, Zhi Li; Li, Shi Qing; Wang, Li Ya; Dong, Ying Li] Henan Eye Hosp, Henan Eye Inst, Zhengzhou 450003, Peoples R China.
   [Qiao, Bao Di] Second Peoples Hosp Zhengzhou, Zhengzhou 450006, Peoples R China.
   [Li, Guo Xing] Wenzhou Med Univ, Hosp Eye, Wenzhou, Peoples R China.
C3 Wenzhou Medical University
RP Wang, ZL (通讯作者)，Henan Eye Hosp, Henan Eye Inst, Zhengzhou 450003, Peoples R China.
EM yinglidong2013@126.com
CR Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2002, P NATL ACAD SCI USA, V99, P14619, DOI 10.1073/pnas.242607899
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Hageman G.S., 1999, MOL VIS, V3, P25
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kook D, 2008, RETINA-J RET VIT DIS, V28, P1053, DOI 10.1097/IAE.0b013e318176de48
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin PM, 2009, MOL VIS, V15, P362
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Uh A, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-74
   Uh A, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.091
   Waintraub S.E., 2008, J CLIN ONCOL S, V26, P120
   Yu FSX, 2006, INVEST OPHTH VIS SCI, V47, P1255, DOI 10.1167/iovs.05-0956
   Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611
NR 22
TC 2
Z9 2
U1 1
U2 10
PU SCIENDO
PI WARSAW
PA DE GRUYTER POLAND SP Z O O, BOGUMILA ZUGA 32A STR, 01-811 WARSAW, POLAND
SN 1895-104X
EI 1644-3632
J9 CENT EUR J BIOL
JI Cent. Eur. J. Biol.
PD MAY
PY 2014
VL 9
IS 5
BP 469
EP 475
DI 10.2478/s11535-014-0290-5
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA AB2TB
UT WOS:000331643900002
DA 2022-11-30
ER

PT J
AU Diago, T
   Pulido, JS
   Molina, JR
   Collet, LC
   Link, TP
   Ryan, EH
AF Diago, Teresa
   Pulido, Jose S.
   Molina, Julian R.
   Collet, Lucienne C.
   Link, Thomas P.
   Ryan, Edwin H., Jr.
TI Ranibizumab combined with low-dose sorafenib for exudative age-related
   macular degeneration
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; REFRACTORY SOLID TUMORS
AB Angiogenesis is a common factor in the pathogenesis of cancer and in exudative age-related macular degeneration (AMD). Therefore, angiogenesis inhibition has been developed as a therapeutic strategy. We report 2 cases of recurrent exudative AMD in which oral sorafenib, a tyrosine kinase inhibitor approved for cancer, was added to intravitreal ranibizumab, an antibody to vascular endothelial growth factor. These 2 patients were followed up by determination of visual acuity, fluorescein angiography, fundoscopy, and optical coherence tomography. The visual acuity of 1 patient improved from 20/70 to 20/60 while he was receiving sorafenib therapy; that of the other did not. Marked improvement was noted in both patients on optical coherence tomography. Additionally, both patients appeared to receive some benefit when low-dose oral sorafenib was used as monotherapy after its initial addition to ranibizumab therapy. Randomized trials of adding sorafenib to standard therapy for patients with neovascular AMD should be considered.
C1 [Diago, Teresa; Pulido, Jose S.; Collet, Lucienne C.; Link, Thomas P.; Ryan, Edwin H., Jr.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Molina, Julian R.] Mayo Clin, Dept Oncol, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic
RP Pulido, JS (通讯作者)，Mayo Clin, Dept Ophthalmol, 200,First St SW, Rochester, MN 55905 USA.
EM pulido.jose@mayo.edu
FU NCI NIH HHS [K12 CA090628-08, K12 CA090628] Funding Source: Medline;
   NATIONAL CANCER INSTITUTE [K12CA090628] Funding Source: NIH RePORTER
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 2006, RETINA, P1075
   Cabebe Elwyn, 2007, Curr Treat Options Oncol, V8, P15, DOI 10.1007/s11864-007-0022-4
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   KERNT M, 2007, ACTA OPHTHALMOL SCAN
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Stein MN, 2007, CLIN CANCER RES, V13, P3765, DOI 10.1158/1078-0432.CCR-06-2844
   Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124
   Strumberg D, 2007, ONCOLOGIST, V12, P426, DOI 10.1634/theoncologist.12-4-426
NR 9
TC 28
Z9 31
U1 0
U2 2
PU MAYO CLINIC PROCEEDINGS
PI ROCHESTER
PA 660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD FEB
PY 2008
VL 83
IS 2
BP 231
EP 234
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 257PU
UT WOS:000252811800016
PM 18241635
DA 2022-11-30
ER

PT J
AU Scott, WK
   Schmidt, S
   Hauser, MA
   Gallins, P
   Schnetz-Boutaud, N
   Spencer, KL
   Gilbert, JR
   Agarwal, A
   Postel, EA
   Haines, JL
   Pericak-Vance, MA
AF Scott, William K.
   Schmidt, Silke
   Hauser, Michael A.
   Gallins, Paul
   Schnetz-Boutaud, Nathalie
   Spencer, Kylee L.
   Gilbert, John R.
   Agarwal, Anita
   Postel, Eric A.
   Haines, Jonathan L.
   Pericak-Vance, Margaret A.
TI Independent effects of complement factor HY402H polymorphism and
   cigarette smoking on risk of age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; BLUE-MOUNTAINS EYE; CHOROIDAL NEOVASCULARIZATION;
   ALTERNATIVE PATHWAY; GRADING SYSTEM; MACULOPATHY; GENE; ASSOCIATION;
   VARIANT; INCREASES
AB Objective: To examine the potential gene-environment interaction between cigarette smoking and the complement factor H (CFH) T1277C polymorphism, 2 strong risk factors for age-related macular degeneration (AMD).
   Design: Retrospective case-control study.
   Participants: A university clinic-based sample of 599 people with AMD and 242 controls.
   Methods: Standard criteria were used to rate disease severity (grades 1-5) from fundus photographs. Individuals were classified as "ever smokers" or "never smokers" based on self-reported lifetime smoking of at least 100 cigarettes. Intensity of smoking was evaluated by calculating pack-years of smoking, which was analyzed as a continuous variable, and by categorizing individuals as smoking more or less than the median 30 pack-years. T1277C genotypes were determined by sequencing the polymorphic site. Generalized estimating equations were used to analyze the effects of smoking and genotype, controlling for age and gender and adjusting for correlations among related subjects.
   Main Outcome Measure: Age-related macular degeneration affection status.
   Results: Interaction terms between T1277C genotype and smoking variables were not statistically significant, indicating a multiplicative relationship between risk factors. Effects of both T1277C genotype and cigarette smoking were stronger when comparing neovascular (grade 5) AMD with grade 1 controls than when comparing all cases (grades 3-5) with grades 1 to 2 controls.
   Conclusion: These results suggest that cigarette smoking and T1277C are independent risk factors for AMD and that both risk factors are associated more strongly with neovascular AMD than all forms of AMD combined.
C1 Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
C3 Duke University; Vanderbilt University
RP Scott, WK (通讯作者)，Duke Ctr Human Genet, DUMC Box 3445, Durham, NC 27710 USA.
EM bill.scott@duke.edu
RI Scott, William/A-7593-2009; Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU NATIONAL EYE INSTITUTE [R03EY015216, R01EY012118, P30EY005722,
   U10EY012118] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY005722,
   EY15216, EY12118, P30 EY005722-21] Funding Source: Medline
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   *CDC, 2005, MMWR-MORBID MORTAL W, V54, P509
   *CDC, 2004, MMWR-MORBID MORTAL W, V53, P1069
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MOLD C, 1984, J IMMUNOL, V133, P882
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Witte JS, 1999, AM J EPIDEMIOL, V149, P693
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 34
TC 31
Z9 32
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2007
VL 114
IS 6
BP 1151
EP 1156
DI 10.1016/j.ophtha.2006.08.054
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174AC
UT WOS:000246912600019
PM 17241667
DA 2022-11-30
ER

PT J
AU Nguyen, HV
   Li, AS
   Silva, AR
   Leng, T
AF Nguyen, Huy, V
   Li, Angela S.
   Silva, Amila R.
   Leng, Theodore
TI Ocular adverse events following intravitreal brolucizumab for
   neovascular age-related macular degeneration at a single tertiary care
   center
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; medical therapies; choroidal;
   retinal inflammation; anterior uveitis; arterial occlusive disease
ID AFLIBERCEPT INJECTION
AB Purpose To determine the incidence of ocular adverse effects (AEs) following brolucizumab injection for neovascular age-related macular degeneration at a tertiary academic institution. Design Retrospective, single center cohort study. Participants All patients who received an intravitreal injection of brolucizumab 6 mg for neovascular age-related macular degeneration between October 7, 2019 and July 31, 2020. Methods Medical records of all patients who received brolucizumab 6 mg during the aforementioned time period were carefully reviewed and all ocular adverse effects after injection were charted. Main Outcome Measures Incidence of post-injection ocular AEs, including intraocular inflammation (IOI), and time to development of AEs after injection. Results A total of 77 patients received brolucizumab 6 mg for a total of 115 administrations during the study period. There were 4 AEs (3.5%), including three cases of IOI (2.6%), one central retinal artery occlusion, and one retinal detachment. Two men and two women were affected. Conclusion Ocular AEs, including those leading to severe vision loss, may develop after intravitreal brolucizumab 6 mg. A careful discussion of benefits and risks to brolucizumab should be conducted with all patients. Precis In this first case series of ocular adverse effects after brolucizumab 6 mg injection at a single tertiary care center, the incidence of ocular adverse effects was 3.5%, including a 2.6% incidence of intraocular inflammation.
C1 [Nguyen, Huy, V; Li, Angela S.; Silva, Amila R.; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
C3 Stanford University
RP Leng, T (通讯作者)，Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu
RI Nguyen, Huy/GWQ-6433-2022
OI Leng, Theodore/0000-0002-8461-3562; Li, Angela/0000-0002-0397-2193
FU National Institutes of Health [P30-EY026877]; Research to Prevent
   Blindness
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported in part by the National Institutes of Health [P30-EY026877]
   and Research to Prevent Blindness.
CR [Anonymous], 2021, NOVARTIS REPORTS ONE
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Cox JT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10050981
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Hikichi T, 2021, JPN J OPHTHALMOL, V65, P208, DOI 10.1007/s10384-021-00819-7
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Iyer Prashanth G, 2020, Am J Ophthalmol Case Rep, V20, P100989, DOI 10.1016/j.ajoc.2020.100989
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Kataoka K, 2021, JPN J OPHTHALMOL, V65, P199, DOI 10.1007/s10384-021-00818-8
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Kondapalli SSA, 2020, JAMA OPHTHALMOL, V138, P1103, DOI 10.1001/jamaophthalmol.2020.2810
   Leclaire MD, 2022, OPHTHALMOLOGE, V119, P296, DOI 10.1007/s00347-021-01341-4
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Singer M, 2022, OPHTHALMOL RETINA, V6, P97, DOI 10.1016/j.oret.2021.05.003
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
NR 21
TC 2
Z9 2
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2022
VL 32
IS 5
BP 2747
EP 2751
AR 11206721211059332
DI 10.1177/11206721211059332
EA NOV 2021
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3S5GW
UT WOS:000718337700001
PM 34761684
DA 2022-11-30
ER

PT J
AU Klettner, A
   Kauppinen, A
   Blasiak, J
   Roider, J
   Salminen, A
   Kaarniranta, K
AF Klettner, Alexa
   Kauppinen, Anu
   Blasiak, Janusz
   Roider, Johan
   Salminen, Antero
   Kaarniranta, Kai
TI Cellular and molecular mechanisms of age-related macular degeneration:
   From impaired autophagy to neovascularization
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Review
DE Aging; Autophagy; Inflammasome; Lipofuscin; Retina; Neovascularization
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; GLYCATION
   END-PRODUCTS; PHOTORECEPTOR OUTER SEGMENTS; LIPID-PEROXIDATION PRODUCTS;
   AMYLOID-BETA PRODUCTION; LINKS OXIDATIVE STRESS; NECROSIS-FACTOR-ALPHA;
   TOLL-LIKE RECEPTORS; HUMAN RPE CELLS
AB Age-related macular degeneration (AMD) is a complex, degenerative and progressive disease involving multiple genetic and environmental factors. It can result in severe visual loss e.g. AMD is the leading cause of blindness in the elderly in the western countries. Although age, genetics, diet, smoking, and many cardiovascular factors are known to be linked with this disease there is increasing evidence that long-term oxidative stress, impaired autophagy clearance and inflammasome mediated inflammation are involved in the pathogenesis. Under certain conditions these may trigger detrimental processes e.g. release of vascular endothelial growth factor (VEGF), causing choroidal neovascularization e.g. in wet AMD. This review ties together these crucial pathological threads in AMD. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Klettner, Alexa; Roider, Johan] Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, Kiel, Germany.
   [Kauppinen, Anu; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Blasiak, Janusz] Univ Lod, Dept Mol Genet, Lodz, Poland.
   [Salminen, Antero] Univ Eastern Finland, Dept Neurol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Eastern Finland; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland.
EM kai.kaarniranta@uef.fi
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059; Blasiak,
   Janusz/0000-0001-9539-9584; Kaarniranta, Kai/0000-0003-2600-8679
FU Kuopio University Hospital [5503726]; Finnish Cultural Foundation and
   its North Savo Fund; Finnish Eye Foundation; Finnish Funding Agency for
   Technology and Innovation; Paivikki and Sakari Sohlberg Foundation;
   Health Research Council of the Academy of Finland [139567]
FX This work was supported by the EVO grants (5503726) of Kuopio University
   Hospital, the Finnish Cultural Foundation and its North Savo Fund, the
   Finnish Eye Foundation, the Finnish Funding Agency for Technology and
   Innovation, Health Research Council of the Academy of Finland (139567),
   and the Paivikki and Sakari Sohlberg Foundation.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Alizadeh P, 2006, EXP EYE RES, V83, P679, DOI 10.1016/j.exer.2006.03.009
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Arnold C, 2013, JAMA OPHTHALMOLOGY, P1, DOI [10.1001/jamaophthalmol.2013.2851, DOI 10.1001/JAMA0PHTHALM0L.2013.2851]
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Bansode RR, 2011, INT J BIOL SCI, V7, P629, DOI 10.7150/ijbs.7.629
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bergmann M, 2011, GRAEF ARCH CLIN EXP, V249, P1477, DOI 10.1007/s00417-011-1682-0
   Bhatnagar S, 2012, J CELL PHYSIOL, V227, P1042, DOI 10.1002/jcp.22821
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1291, DOI 10.2741/3789
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Comb WC, 2011, ONCOGENE, V30, P1727, DOI 10.1038/onc.2010.553
   Comb WC, 2012, MOL CELL, V45, P719, DOI 10.1016/j.molcel.2012.01.010
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   ELHIFNAWI E, 1995, ANN ANAT, V177, P11, DOI 10.1016/S0940-9602(11)80123-8
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Finnemann SC, 2006, ADV EXP MED BIOL, V572, P499
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Grimm S, 2012, FREE RADICAL BIO MED, V52, P1011, DOI 10.1016/j.freeradbiomed.2011.12.021
   Grimm S, 2010, FREE RADICAL RES, V44, P1013, DOI 10.3109/10715762.2010.495127
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hammer M, 2006, MOL VIS, V12, P1348
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Im E, 2007, EXP EYE RES, V84, P383, DOI 10.1016/j.exer.2006.05.017
   Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200
   Inomata M, 2012, CELL MOL LIFE SCI, V69, P963, DOI 10.1007/s00018-011-0819-y
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2010, ACTA OPHTHALMOL, V88, P387, DOI 10.1111/j.1755-3768.2009.01840.x
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kannan R, 2006, MOL VIS, V12, P1649
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kersse K, 2011, CYTOKINE GROWTH F R, V22, P257, DOI 10.1016/j.cytogfr.2011.09.003
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner A, 2012, ARVO M, V53, P3698
   Klettner A, OXIDATIVE STRESS APP, V2012277-305
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lee JJ, 2012, MOL VIS, V18, P838
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   Li LN, 2006, METABOLISM, V55, P1516, DOI 10.1016/j.metabol.2006.06.022
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Lueck K, 2012, INVEST OPHTH VIS SCI, V53, P1406, DOI 10.1167/iovs.11-8889
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Mallavarapu M, 2010, ADV EXP MED BIOL, V664, P123, DOI 10.1007/978-1-4419-1399-9_15
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Mayor A, 2007, NAT IMMUNOL, V8, P497, DOI 10.1038/ni1459
   McDonald C, 2005, J BIOL CHEM, V280, P20177, DOI 10.1074/jbc.R500001200
   McGuire KA, 2011, J VIROL, V85, P10806, DOI 10.1128/JVI.00675-11
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Miao EA, 2010, P NATL ACAD SCI USA, V107, P3076, DOI 10.1073/pnas.0913087107
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mole DR, 2001, IUBMB LIFE, V52, P43
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nakada-Tsukui K, 1999, J LEUKOCYTE BIOL, V66, P968, DOI 10.1002/jlb.66.6.968
   Nakahara H, 2003, ARTHRITIS RHEUM-US, V48, P1521, DOI 10.1002/art.11143
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Nivon M, 2009, AUTOPHAGY, V5, P766, DOI 10.4161/auto.8788
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Ogawa T, 2005, MOL VIS, V11, P380
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Ozawa K, 2001, CANCER RES, V61, P4206
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Paraoan L, 2010, VISION RES, V50, P737, DOI 10.1016/j.visres.2009.10.022
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Patschan S, 2008, AUTOPHAGY, V4, P521, DOI 10.4161/auto.5904
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824
   Pyo CW, 2008, BIOCHEM BIOPH RES CO, V377, P1001, DOI 10.1016/j.bbrc.2008.10.103
   Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Reggiori Fulvio, 2012, Int J Cell Biol, V2012, P219625, DOI 10.1155/2012/219625
   Reynolds R, 2013, OPHTHALMOLOGY
   Rodriguez-Muela N, 2013, AGING CELL
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Salminen A., 2012, INT J CELL BIOL, V2012
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schutt F, 2012, INVEST OPHTH VIS SCI, V53, P5354, DOI 10.1167/iovs.12-9845
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seglen P O, 1990, Semin Cell Biol, V1, P441
   Shang F, 2012, MOL ASPECTS MED, V33, P446, DOI 10.1016/j.mam.2012.04.001
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shi CS, 2008, J BIOL CHEM, V283, P33175, DOI 10.1074/jbc.M804478200
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sutinen EM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-199
   Tafani M, 2008, AUTOPHAGY, V4, P1042, DOI 10.4161/auto.7070
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Turk B, 2009, J BIOL CHEM, V284, P21783, DOI 10.1074/jbc.R109.023820
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   Vatsyayan R, 2012, BIOCHEM BIOPH RES CO, V417, P346, DOI 10.1016/j.bbrc.2011.11.113
   Viiri J, 2010, MOL VIS, V16, P1399
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Watanabe K, 2009, GRAEF ARCH CLIN EXP, V247, P207, DOI 10.1007/s00417-008-0990-5
   Watanabe N, 1998, EUR J BIOCHEM, V253, P576, DOI 10.1046/j.1432-1327.1998.2530576.x
   Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002
   Winkler BS, 1999, MOL VIS, V5
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu WC, 2010, MOL VIS, V16, P1864
   Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 184
TC 62
Z9 64
U1 0
U2 68
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUL
PY 2013
VL 45
IS 7
BP 1457
EP 1467
DI 10.1016/j.biocel.2013.04.013
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 175KH
UT WOS:000321229100033
PM 23603148
DA 2022-11-30
ER

PT J
AU Evans, JR
   Lawrenson, JG
AF Evans, J. R.
   Lawrenson, J. G.
TI Antioxidant vitamin and mineral supplements for preventing age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE *Dietary Supplements; Antioxidants [*administration & dosage]; Macular
   Degeneration [*prevention & control]; Minerals [*administration &
   dosage]; Randomized Controlled Trials as Topic; Vitamins
   [*administration & dosage]; alpha-Tocopherol [administration & dosage];
   beta Carotene [administration & dosage]; Humans
ID BETA-CAROTENE SUPPLEMENTATION; RANDOMIZED CONTROLLED-TRIAL; BASE-LINE
   CHARACTERISTICS; LONG-TERM SUPPLEMENTATION; CONTROLLED CLINICAL-TRIAL;
   KILLER-CELL ACTIVITY; LOW-DOSE ASPIRIN; ALPHA-TOCOPHEROL; CANCER
   PREVENTION; HIGH-RISK
AB Background
   There is inconclusive evidence from observational studies to suggest that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).
   Objectives
   To examine the evidence as to whether or not taking antioxidant vitamin or mineral supplements prevents the development of AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 12), MEDLINE (January 1950 to January 2012), EMBASE (January 1980 to January 2012), Open Grey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 January 2012.
   Selection criteria
   We included all randomised controlled trials (RCTs) comparing an antioxidant vitamin and/or mineral supplement (alone or in combination) to control.
   Data collection and analysis
   Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into RevMan 5 and the other author checked the data entry. We pooled data using a fixed-effect model.
   Main results
   We included four RCTs in this review; 62,520 people were included in the analyses. The trials were conducted in Australia, Finland and the USA and investigated vitamin E and beta-carotene supplements. Overall the quality of the evidence was high. People who took these supplements were not at decreased (or increased) risk of developing AMD. The pooled risk ratio for any antioxidant supplement in the prevention of any AMD was 0.98 (95% confidence interval 0.89 to 1.08) and for advanced AMD was 1.05 (95% CI 0.80 to 1.39). Similar results were seen when the analyses were restricted to beta-carotene and alpha-tocopherol alone.
   Authors' conclusions
   There is accumulating evidence that taking vitamin E or beta-carotene supplements will not prevent or delay the onset of AMD. There is no evidence with respect to other antioxidant supplements, such as vitamin C, lutein and zeaxanthin, or any of the commonly marketed multivitamin combinations. Although generally regarded as safe, vitamin supplements may have harmful effects and clear evidence of benefit is needed before they can be recommended. People with AMD should see the related Cochrane review 'Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration' written by the same review team.
C1 [Evans, J. R.] Univ London London Sch Hyg & Trop Med, Cochrane Eyes & Vis Grp, ICEH, London WC1E 7HT, England.
   [Lawrenson, J. G.] City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
C3 University of London; London School of Hygiene & Tropical Medicine; City
   University London
RP Evans, JR (通讯作者)，Univ London London Sch Hyg & Trop Med, Cochrane Eyes & Vis Grp, ICEH, Keppel St, London WC1E 7HT, England.
EM jennifer.evans@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030; Lawrenson, John/0000-0002-2031-6390
FU NIHR/Department of Health, UK; NIHR; Department of Health through
   National Institute for Health Research; UCL Institute of Ophthalmology
   for a Specialist Biomedical Research Centre for Ophthalmology
FX Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial
   support for his CEVG research sessions from the Department of Health
   through the award made by the National Institute for Health Research to
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology. The views expressed in this publication are those of the
   authors and not necessarily those of the Department of Health.; Internal
   sources; NIHR/Department of Health, UK.; JE was funded by NIHR during
   the updating of this review (Issue 6, 2012)
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Albanes D, 1997, AM J CLIN NUTR, V66, P366, DOI 10.1093/ajcn/66.2.366
   Albanes D, 1986, J NUTR GROWTH CANCER, V3, P207
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Ambler J S, 1995, Ophthalmic Epidemiol, V2, P137, DOI 10.3109/09286589509057095
   ANDREWS J, 1969, BRIT MED J, V2, P416, DOI 10.1136/bmj.2.5654.416
   [Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1
   [Anonymous], 1996, RICERCA E, V12, P175
   BENNER SE, 1994, SEMIN HEMATOL, V31, P26
   BENTON D, 1995, PSYCHOPHARMACOLOGY, V117, P298, DOI 10.1007/BF02246104
   Berger K, 1996, STROKE, V27, P238, DOI 10.1161/01.STR.27.2.238
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Blok WL, 1997, EUR J CLIN INVEST, V27, P1003, DOI 10.1046/j.1365-2362.1997.2240775.x
   BLUMBERG J, 1994, NUTR REV, V52, P242, DOI 10.1111/j.1753-4887.1994.tb01430.x
   BOGDEN JD, 1990, J AM COLL NUTR, V9, P214
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Brewer GJ, 1997, J LAB CLIN MED, V129, P649, DOI 10.1016/S0022-2143(97)90200-6
   Brown BG, 1998, CAN J CARDIOL, V14, p6A
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Buring J E, 1994, Ann Epidemiol, V4, P75
   BURING JE, 1995, ARCH NEUROL-CHICAGO, V52, P129, DOI 10.1001/archneur.1995.00540260031012
   BURING JE, 1990, STAT MED, V9, P29, DOI 10.1002/sim.4780090109
   Buring Julie E., 1994, Annals of Epidemiology, V4, P111
   BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F
   Cairns J, 1991, Ann Epidemiol, V1, P395
   Caligiuri MP, 1997, PSYCHOPHARMACOLOGY, V132, P61, DOI 10.1007/s002130050320
   Camargo CA, 1997, CIRCULATION, V95, P577, DOI 10.1161/01.CIR.95.3.577
   CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen W G, 1998, Ophthalmic Epidemiol, V5, P133, DOI 10.1076/opep.5.3.133.8368
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   Chylack L T Jr, 1995, Ophthalmic Epidemiol, V2, P59, DOI 10.3109/09286589509057085
   Cianfriglia F, 1994, Minerva Stomatol, V43, P255
   Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957
   CLAUSEN J, 1989, BIOL TRACE ELEM RES, V20, P135, DOI 10.1007/BF02919106
   Constans J, 1996, CLIN INFECT DIS, V23, P654, DOI 10.1093/clinids/23.3.654
   COSTANTINO JP, 1988, AM J CLIN NUTR, V48, P1277, DOI 10.1093/ajcn/48.5.1277
   Cucinotta D, 1994, J NEUROL, V241, pS129
   de Klerk NH, 1998, INT J CANCER, V75, P362, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;362::AID-IJC6&gt;3.0.CO;2-0
   DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290
   DOBSON HM, 1984, SCOT MED J, V29, P176, DOI 10.1177/003693308402900308
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 1994, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253
   Fairley CK, 1996, INT J GYNECOL CANCER, V6, P225, DOI 10.1046/j.1525-1438.1996.06030225.x
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   FONTHAM ETH, 1995, CANCER EPIDEM BIOMAR, V4, P801
   Fotouhi N, 1996, AM J CLIN NUTR, V63, P553, DOI 10.1093/ajcn/63.4.553
   Gail MH, 1998, CONTROL CLIN TRIALS, V19, P352, DOI 10.1016/S0197-2456(98)00016-6
   Galan P, 1997, INT J VITAM NUTR RES, V67, P450
   GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220
   Garewal H, 1995, P AN M AM SOC CLIN, V14, pA1623
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Gerstein HC, 1996, DIABETES CARE, V19, P1225, DOI 10.2337/diacare.19.11.1225
   Girodon F, 1997, J AM COLL NUTR, V16, P357, DOI 10.1080/07315724.1997.10718698
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297
   GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204
   GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153
   GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301
   GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6
   Hartman TJ, 1998, CANCER EPIDEM BIOMAR, V7, P335
   HEBERT PR, 1993, CIRCULATION, V88, P1437, DOI 10.1161/01.CIR.88.4.1437
   Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440
   HENNEKENS CH, 1985, PREV MED, V14, P165, DOI 10.1016/0091-7435(85)90031-3
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Hercberg S, 1998, INT J VITAM NUTR RES, V68, P3
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Huang HY, 2006, ANN INTERN MED, V145, P372, DOI 10.7326/0003-4819-145-5-200609050-00135
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   Johnson MA, 1997, NUTR REV, V55, P400, DOI 10.1111/j.1753-4887.1997.tb01582.x
   Jyothirmayi R, 1996, ORAL ONCOL, V32B, P373, DOI 10.1016/S0964-1955(96)00010-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KUKLINSKI B, 1994, MOL ASPECTS MED, V15, P143, DOI 10.1016/0098-2997(94)90023-X
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010
   Laurila AL, 1997, INT J CANCER, V74, P31, DOI 10.1002/(SICI)1097-0215(19970220)74:1&lt;31::AID-IJC6&gt;3.0.CO;2-1
   Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1
   Leng G C, 1997, Vasc Med, V2, P279
   Levine N, 1997, CANCER EPIDEM BIOMAR, V6, P957
   Li Jun-Yao, 1993, Zhonghua Zhongliu Zazhi, V15, P165
   Li W G, 1992, Zhonghua Yu Fang Yi Xue Za Zhi, V26, P268
   Liede K, 1998, Oral Dis, V4, P78
   Liede KE, 1998, ANN MED, V30, P542, DOI 10.3109/07853899709002602
   Liede KE, 1998, EUR J CLIN NUTR, V52, P872, DOI 10.1038/sj.ejcn.1600646
   Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864
   Lonn EM, 1996, AM J CARDIOL, V78, P914, DOI 10.1016/S0002-9149(96)00467-5
   Ma J, 1997, CANCER RES, V57, P1098
   MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0
   MANSON JE, 1994, AM J PREV MED, V10, P156, DOI 10.1016/S0749-3797(18)30612-3
   Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7
   Marchioli R, 1993, G Ital Cardiol, V23, P933
   Mayne ST, 1998, AM J CLIN NUTR, V68, P642, DOI 10.1093/ajcn/68.3.642
   MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701
   MEYSKENS FL, 1994, J CLIN ONCOL, V12, P2060, DOI 10.1200/JCO.1994.12.10.2060
   MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615
   MUNOZ N, 1985, LANCET, V2, P111
   Munoz N, 1996, IARC SCI PUBL, P125
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   NORTON EWD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1460, DOI 10.1001/archopht.1993.01090110018003
   ODonnell CJ, 1997, CIRCULATION, V95, P1132
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   PASTORINO U, 1988, ACTA ONCOL, V27, P773, DOI 10.3109/02841868809094356
   Pemp B, 2010, INVEST OPHTH VIS SCI, V51, P2, DOI 10.1167/iovs.09-3888
   PENG YM, 1993, CANCER EPIDEM BIOMAR, V2, P145
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720
   PRASAD MPR, 1995, ORAL ONCOL, V31B, P155, DOI 10.1016/0964-1955(95)00013-8
   Rapola JM, 1998, HEART, V79, P454, DOI 10.1136/hrt.79.5.454
   Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8
   Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693
   RECCHIA F, 1995, J INTERF CYTOK RES, V15, P605, DOI 10.1089/jir.1995.15.605
   Reed P. I., 1995, Acta Endoscopica, V25, P45, DOI 10.1007/BF02965773
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835
   Ridker PM, 1998, CIRCULATION, V97, P425
   Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6
   ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502
   SALVINI S, 1992, J CLIN ENDOCR METAB, V74, P139, DOI 10.1210/jc.74.1.139
   Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704
   Santos MS, 1997, AM J CLIN NUTR, V66, P917, DOI 10.1093/ajcn/66.4.917
   Santos MS, 1998, AM J CLIN NUTR, V68, P164, DOI 10.1093/ajcn/68.1.164
   Santos MS, 1996, AM J CLIN NUTR, V64, P772, DOI 10.1093/ajcn/64.5.772
   SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8
   Schaumberg D. A., 1996, American Journal of Epidemiology, V143, pS9
   SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788
   Sharma Y R, 1989, Indian J Ophthalmol, V37, P134
   SHOULSON I, 1989, ARCH NEUROL-CHICAGO, V46, P1052, DOI 10.1001/archneur.1989.00520460028009
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202
   STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S
   Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1
   TAKAMATSU S, 1995, J INT MED RES, V23, P342, DOI 10.1177/030006059502300504
   TAYLOR H, 2002, BMJ-BRIT MED J, V325, P325
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   Teikari JM, 1998, J EPIDEMIOL COMMUN H, V52, P468, DOI 10.1136/jech.52.7.468
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P68, DOI 10.1034/j.1600-0420.1998.760112.x
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 1
   TOMEO AC, 1995, LIPIDS, V30, P1179, DOI 10.1007/BF02536621
   Tornwall ME, 1997, ARTERIOSCL THROM VAS, V17, P3475, DOI 10.1161/01.ATV.17.12.3475
   Tsubono Y, 1997, JPN J CANCER RES, V88, P344, DOI 10.1111/j.1349-7006.1997.tb00387.x
   Varis K, 1998, SCAND J GASTROENTERO, V33, P294, DOI 10.1080/00365529850170892
   VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924
   Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668
   WAHLQVIST ML, 1994, AM J CLIN NUTR, V60, P936, DOI 10.1093/ajcn/60.6.936
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   WRIGHT JP, 1985, GASTROENTEROLOGY, V88, P512, DOI 10.1016/0016-5085(85)90514-1
   YU SY, 1991, BIOL TRACE ELEM RES, V29, P289, DOI 10.1007/BF03032685
   YU SY, 1990, BIOL TRACE ELEM RES, V24, P105, DOI 10.1007/BF02917199
   Zaridze D, 1993, Ann Epidemiol, V3, P225
   Zee RYL, 1999, CIRCULATION, V99, P340, DOI 10.1161/01.CIR.99.3.340
NR 171
TC 20
Z9 20
U1 0
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2012
IS 6
AR CD000253
DI 10.1002/14651858.CD000253.pub3
PG 50
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 957VC
UT WOS:000305192400005
PM 22696317
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cheung, CMG
   Lai, TYY
   Ruamviboonsuk, P
   Chen, SJ
   Chen, YX
   Freund, KB
   Gomi, F
   Koh, AH
   Lee, WK
   Wong, TY
AF Cheung, Chui Ming Gemmy
   Lai, Timothy Y. Y.
   Ruamviboonsuk, Paisan
   Chen, Shih-Jen
   Chen, Youxin
   Freund, K. Bailey
   Gomi, Fomi
   Koh, Adrian H.
   Lee, Won-Ki
   Wong, Tien Yin
TI Polypoidal Choroidal Vasculopathy Definition, Pathogenesis, Diagnosis,
   and Management
SO OPHTHALMOLOGY
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; CENTRAL SEROUS
   CHORIORETINOPATHY; INDOCYANINE GREEN ANGIOGRAPHY; VERTEPORFIN
   PHOTODYNAMIC THERAPY; PIGMENT EPITHELIAL DETACHMENTS; MACULAR
   DEGENERATION; VASCULAR HYPERPERMEABILITY; INTRAVITREAL AFLIBERCEPT;
   CLINICAL CHARACTERISTICS
AB Polypoidal choroidal vasculopathy (PCV) is an age-related macular degeneration (AMD) subtype and is seen particularly in Asians. Previous studies have suggested disparity in response to intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents between PCV and typical AMD, and thus, the preferred treatment for PCV has remained unclear. Recent research has provided novel insights into the pathogenesis of PCV, and imaging studies based on OCT suggest that PCV belongs to a spectrum of conditions characterized by pachychoroid, in which disturbance in the choroidal circulation seems to be central to its pathogenesis. Advances in imaging, including enhanced depth imaging, swept-source OCT, en face OCT, and OCT angiography, have facilitated the diagnosis of PCV. Importantly, 2 large, multicenter randomized clinical trials evaluating the safety and efficacy of anti-VEGF monotherapy and combination with photodynamic therapy (PDT) recently reported initial first-year outcomes, providing level I evidence to guide clinicians in choosing the most appropriate therapy for PCV. In this review, we summarize the latest updates in the epidemiologic features, pathogenesis, and advances in imaging and treatment trials, with a focus on the most recent key clinical trials. Finally, we propose current management guidelines and recommendations to help clinicians manage patients with PCV. Remaining gaps in current understanding of PCV, such as significance of polyp closure, high recurrence rate, and heterogeneity within PCV, are highlighted where further research is needed. (C) 2018 by the American Academy of Ophthalmology
C1 [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Cheung, Chui Ming Gemmy; Wong, Tien Yin] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Chen, Youxin] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Chen, Youxin] Chinese Acad Med Sci, Beijing, Peoples R China.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   [Gomi, Fomi] Hyogo Coll Med, Dept Ophthalmol, Nishinomiya, Hyogo, Japan.
   [Koh, Adrian H.] Camden Med Ctr, Eye & Retina Surg, Singapore, Singapore.
   [Lee, Won-Ki] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Chinese University of Hong Kong;
   Rajavithi Hospital; National Yang Ming Chiao Tung University; Taipei
   Veterans General Hospital; National Yang Ming Chiao Tung University;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Vitreous Retina Macula Consultants of New York; New York University;
   Hyogo College of Medicine; Catholic University of Korea; Seoul St.
   Mary's Hospital
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI Lai, Timothy Y Y/AAC-2120-2020; Wong, Tien Yin/AAC-9724-2020; Freund, K.
   Bailey/V-7488-2018
OI Lai, Timothy Y Y/0000-0002-7832-6428; Wong, Tien
   Yin/0000-0002-8448-1264; Gomi, Fumi/0000-0003-0807-8817; Cheung, Chui
   Ming Gemmy/0000-0003-3358-3516; Freund, K. Bailey/0000-0002-7888-9773
FU National Medical Research Council Singapore, Republic of Singapore
FX Supported by the National Medical Research Council Singapore, Republic
   of Singapore. The sponsor or funding organization had no role in the
   design or conduct of this research.
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2013, RETINA-J RET VIT DIS, V33, P1949, DOI 10.1097/IAE.0b013e31828bcafa
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jeon S, 2013, RETINA-J RET VIT DIS, V33, P1193, DOI 10.1097/IAE.0b013e318276e096
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim SW, 2009, OPHTHAL SURG LAS IM, V40, P300, DOI 10.3928/15428877-20090430-14
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Lee JH, 2014, AM J OPHTHALMOL, V157, P710, DOI 10.1016/j.ajo.2013.12.011
   Lee MY, 2013, AM J OPHTHALMOL, V156, P343, DOI 10.1016/j.ajo.2013.04.001
   Lee W. K., 2016, RETINA, V36, P73
   Lee WKIT, 2017, JAMA OPHTHALMOL
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Recchia FM, 2006, RETINA-J RET VIT DIS, V26, P1042, DOI 10.1097/01.iae.0000254894.94013.d8
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki S, 2012, INVEST OPHTH VIS SCI, V53, P3424, DOI 10.1167/iovs.11-7913
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Sayanagi K, 2015, BRIT J OPHTHALMOL, V99, P29, DOI 10.1136/bjophthalmol-2013-304658
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tan CSH, 2014, BRIT J OPHTHALMOL, V98, P1528, DOI 10.1136/bjophthalmol-2014-305059
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yamashita A, 2013, AM J OPHTHALMOL, V155, P96, DOI 10.1016/j.ajo.2012.06.027
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Yuzawa M, 2015, INVEST OPHTH VIS SCI, V56, P3998, DOI 10.1167/iovs.15-17207
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 140
TC 188
Z9 192
U1 5
U2 38
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2018
VL 125
IS 5
BP 708
EP 724
DI 10.1016/j.ophtha.2017.11.019
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD5PL
UT WOS:000430558800021
PM 29331556
OA Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Ahmed, D
   Stattin, M
   Graf, A
   Forster, J
   Glittenberg, C
   Krebs, I
   Ansari-Shahrezaei, S
AF Ahmed, Daniel
   Stattin, Martin
   Graf, Alexandra
   Forster, Julia
   Glittenberg, Carl
   Krebs, Ilse
   Ansari-Shahrezaei, Siamak
TI DETECTION OF TREATMENT-NAIVE CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED
   MACULAR DEGENERATION BY SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY
   ANGIOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; fluorescein angiography; indocyanine green
   angiography; neovascular age-related macular degeneration; swept source
   optical coherence tomography angiography
ID SOURCE OCT ANGIOGRAPHY; SPECTRAL-DOMAIN; ULTRAHIGH-SPEED
AB Purpose: To compare the detection rate of choroidal neovascularization (CNV) in treatment-naive neovascular age-related macular degeneration by swept source optical coherence tomography angiography (SS-OCTA, Topcon's DRI Triton) working at 1,050 nm wavelength versus fluorescence angiography.
   Methods: Cross-sectional analysis of 156 eyes (107 neovascular age-related macular degeneration and 49 dry AMD) in 98 patients, previously diagnosed by multimodal imaging using fluorescein (FA) and indocyanine green angiography (Heidelberg's Spectralis) in a tertiary retina center, evaluated by SS-OCTA 4.5 mm x 4.5 mm and 6 mm x 6 mm macular cubes. Main outcome measures were sensitivity and specificity of SS-OCTA in AMD. Potential factors influencing CNV detection rate were analyzed.
   Results: Swept source optical coherence tomography angiography detected CNV in 81 of 107 eyes, resulting in a sensitivity of 75.7%. In 49 eyes with dry AMD, no CNV could be identified (specificity 100%). A statistical significance was calculated for nondetection of treatment-naive CNV by SS-OCTA in pigment epithelial detachment over 400 mu m (P = 0.0238).
   Conclusion: Topcon's SS-OCTA was not able to detect all CNV lesions. Large pigment epithelial detachments were associated with signal loss. Fluorescence angiography still remains the gold standard, but the tested SS-OCTA device can be considered as a feasible additional diagnostic tool in AMD.
C1 [Ahmed, Daniel; Stattin, Martin; Forster, Julia; Glittenberg, Carl; Krebs, Ilse; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
   [Ahmed, Daniel; Stattin, Martin; Krebs, Ilse; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
   [Graf, Alexandra] Med Univ Vienna, Inst Med Stat, Vienna, Austria.
   [Glittenberg, Carl] Topcon Europe Med BV, Capelle Aan Den Ijssel, Netherlands.
   [Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
C3 Medical University of Vienna; Medical University of Graz
RP Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM siamak.ansari-shahrezaei@wienkav.at
OI Graf, Alexandra/0000-0003-0035-2658
CR An L, 2013, BIOMED OPT EXPRESS, V4, P245, DOI 10.1364/BOE.4.000245
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Cole ED, 2017, OPHTHALMOL RETINA
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   Shaimov T B, 2015, Vestn Oftalmol, V131, P4, DOI 10.17116/oftalma201513154-12
   Srinivasan VJ, 2007, OPT LETT, V32, P361, DOI 10.1364/OL.32.000361
   Stanga PE, 2016, DEV OPHTHALMOL, V56, P13, DOI 10.1159/000442771
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 28
TC 18
Z9 18
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2018
VL 38
IS 11
BP 2143
EP 2149
DI 10.1097/IAE.0000000000001832
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VZ
UT WOS:000454007400005
PM 28902095
DA 2022-11-30
ER

PT J
AU Gonzalez, EG
   Tarita-Nistor, L
   Mandelcorn, ED
   Mandelcorn, M
   Steinbach, MJ
AF Gonzalez, Esther G.
   Tarita-Nistor, Luminita
   Mandelcorn, Efrem D.
   Mandelcorn, Mark
   Steinbach, Martin J.
TI Fixation Control before and after Treatment for Neovascular Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC
   ATROPHY; CENTRAL SCOTOMAS; VISUAL-ACUITY; EYE POSITION; FELLOW EYE;
   RANIBIZUMAB; AMD; DISEASE
AB PURPOSE. We studied changes in visual acuity (VA), fixation stability, and location of the preferred retinal locus (PRL) after treatment for unilateral neovascular age-related macular degeneration (AMD) for previously untreated eyes. Concomitant changes in fixation stability, PRL, and VA in the untreated fellow eye were also analyzed.
   METHODS. Pre- and posttreatment tests of visual acuity, fixation stability, and PRL location in both the treated and the untreated eyes were performed on 13 patients undergoing three monthly intravitreal injections of ranibizumab in one eye.
   RESULTS. For the treated eyes there were improvements in VA and fixation stability but no changes in the location of the PRL. No significant changes in any of the three variables were found in the untreated eye.
   CONCLUSIONS. For previously untreated eyes, the improvement in visual acuity after intravitreal ranibizumab injections was accompanied by improvement in fixation stability. (Invest Ophthalmol Vis Sci. 2011;52:4208-4213) DOI:10.1167/iovs.107026
C1 [Gonzalez, Esther G.] Toronto Western Hosp, Vis Sci Res Program, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada.
   [Gonzalez, Esther G.; Tarita-Nistor, Luminita; Steinbach, Martin J.] York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   [Gonzalez, Esther G.; Mandelcorn, Efrem D.; Mandelcorn, Mark; Steinbach, Martin J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; University of Toronto
RP Gonzalez, EG (通讯作者)，Toronto Western Hosp, Vis Sci Res Program, Toronto Western Res Inst, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
EM gonzalez@yorku.ca
FU Natural Sciences and Engineering Research Council [A7664]; Sir Jules
   Thorn Charitable Trust; Krembil Family Foundation; Vision Science
   Research Program, Toronto Western Hospital
FX Supported by Natural Sciences and Engineering Research Council Grant
   A7664, the Sir Jules Thorn Charitable Trust, the Krembil Family
   Foundation, Vision Science Research Program, Toronto Western Hospital,
   and by an anonymous donor.
CR Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   BARTLETT MS, 1949, BIOMETRICS, V5, P207, DOI 10.2307/3001936
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Eldaly MA, 2009, RETINA-J RET VIT DIS, V29, P325, DOI 10.1097/IAE.0b013e31819a6154
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Haegerstrom-Portnoy G, 2005, OPTOMETRY VISION SCI, V82, P87, DOI 10.1097/01.OPX.0000153162.05903.4C
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   SKAVENSKI AA, 1972, VISION RES, V12, P221, DOI 10.1016/0042-6989(72)90113-7
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STEINBACH MJ, 1987, VISION RES, V27, P1737, DOI 10.1016/0042-6989(87)90103-9
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   TABACHNICK BG, 2007, USING MULTIVARIATE S, P73
   Tarita-Nistor L, 2009, INVEST OPHTH VIS SCI, V50, P84, DOI 10.1167/iovs.08-2342
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   TIMBERLAKE GT, 1972, VISION RES, V12, P1059, DOI 10.1016/0042-6989(72)90027-2
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
NR 44
TC 25
Z9 26
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 4208
EP 4213
DI 10.1167/iovs.10-7026
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500038
PM 21398288
DA 2022-11-30
ER

PT J
AU Ferrara, D
   Newton, EM
   Lee, AY
AF Ferrara, Daniela
   Newton, Elizabeth M.
   Lee, Aaron Y.
TI Artificial intelligence-based predictions in neovascular age-related
   macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; deep learning; machine learning; neovascular
   age-related macular degeneration; treatment prediction
ID GROWTH-FACTOR THERAPY; 2.0 MG RANIBIZUMAB; FLUID VOLUMES;
   QUANTIFICATION; BIOMARKERS; EFFICACY; OUTCOMES; NETWORK; SAFETY; ACUITY
AB Purpose of review Predicting treatment response and optimizing treatment regimen in patients with neovascular age-related macular degeneration (nAMD) remains challenging. Artificial intelligence-based tools have the potential to increase confidence in clinical development of new therapeutics, facilitate individual prognostic predictions, and ultimately inform treatment decisions in clinical practice. Recent findings To date, most advances in applying artificial intelligence to nAMD have focused on facilitating image analysis, particularly for automated segmentation, extraction, and quantification of imaging-based features from optical coherence tomography (OCT) images. No studies in our literature search evaluated whether artificial intelligence could predict the treatment regimen required for an optimal visual response for an individual patient. Challenges identified for developing artificial intelligence-based models for nAMD include the limited number of large datasets with high-quality OCT data, limiting the patient populations included in model development; lack of counterfactual data to inform how individual patients may have fared with an alternative treatment strategy; and absence of OCT data standards, impairing the development of models usable across devices. Artificial intelligence has the potential to enable powerful prognostic tools for a complex nAMD treatment landscape; however, additional work remains before these tools are applicable to informing treatment decisions for nAMD in clinical practice.
C1 [Ferrara, Daniela; Newton, Elizabeth M.] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
   [Lee, Aaron Y.] Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98195 USA.
C3 Roche Holding; Genentech; University of Washington; University of
   Washington Seattle
RP Ferrara, D (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM ferrara.daniela@gene.com
OI Lee, Aaron/0000-0002-7452-1648
FU Genentech, Inc.
FX Funding was provided by Genentech, Inc., a member of the Roche Group,
   for the study and third-party writing assistance, which was provided by
   Kathryn H. Condon, PhD, CMPP, of Envision Pharma Group.
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ehlers JP, 2021, OPHTHALMOL RETINA, V5, P1204, DOI 10.1016/j.oret.2021.02.012
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Feng DH, 2020, IEEE ENG MED BIO, P5428, DOI 10.1109/EMBC44109.2020.9176743
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Flaxel CJ, 2020, OPHTHALMOLOGY, V127, P1, DOI DOI 10.1016/J.0PHTHA.2019.09.0242
   Fu DJ, 2021, OPHTHALMOL RETINA, V5, P1074, DOI 10.1016/j.oret.2021.01.009
   Gill CR, 2020, OPHTHALMOL THER, V9, P725, DOI 10.1007/s40123-020-00288-0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2020, RETINA-J RET VIT DIS, V40, P1673, DOI 10.1097/IAE.0000000000002670
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hosoda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75451-5
   Kawczynski MG, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.51
   Keenan TDL, 2021, AM J OPHTHALMOL, V224, P267, DOI 10.1016/j.ajo.2020.12.012
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Lee AY, 2021, OPHTHALMOLOGY, V128, P969, DOI 10.1016/j.ophtha.2021.03.003
   Lee CS, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.9
   Lee CS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42042-y
   Lee H, 2021, RETINA-J RET VIT DIS, V41, P572, DOI 10.1097/IAE.0000000000002898
   Lee H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56420-z
   Liefers B, 2021, AM J OPHTHALMOL, V226, P1, DOI 10.1016/j.ajo.2020.12.034
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michl M, 2022, BRIT J OPHTHALMOL, V106, P113, DOI 10.1136/bjophthalmol-2020-317416
   Moraes G, 2021, OPHTHALMOLOGY, V128, P693, DOI 10.1016/j.ophtha.2020.09.025
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Reiter GS, 2021, RETINA-J RET VIT DIS, V41, P1318, DOI 10.1097/IAE.0000000000003023
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Romo-Bucheli D., 2020, IEEE J BIOMED HEALTH, V24, P3456, DOI DOI 10.1109/JBHI.2020.3000136
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schwartz Roy, 2021, Ophthalmol Retina, V5, pe11, DOI 10.1016/j.oret.2021.04.001
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P1153, DOI 10.1097/IAE.0000000000003116
   Thomas DS, 2021, CTS-CLIN TRANSL SCI, V14, P1166, DOI 10.1111/cts.12974
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Zhang XY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9640131
NR 47
TC 2
Z9 2
U1 5
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD SEP
PY 2021
VL 32
IS 5
BP 389
EP 396
DI 10.1097/ICU.0000000000000782
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TT8AN
UT WOS:000680565900002
PM 34265783
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Burgmuller, M
   Cakmak, N
   Weingessel, B
   Vecsei, C
   Vecsei-Marlovits, P
AF Burgmueller, Michael
   Cakmak, Nesrin
   Weingessel, Birgit
   Vecsei, Christina
   Vecsei-Marlovits, Pia Veronika
TI Patient knowledge concerning age-related macular degeneration: an AMD
   questionnaire
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE Age-related macular degeneration; AMD; Patient knowledge; Questionnaire;
   Interview
ID HEALTH-BEHAVIOR; PREVALENCE; EDUCATION; COHORT
AB Age-related macular degeneration (AMD) is a disease with rising prevalence. This study evaluates patients' knowledge and the need for more patient information.
   271 patients with AMD were asked to complete a questionnaire concerning their knowledge about AMD. 150 patients were interviewed by a physician and 121 patients completed the questionnaire on their own.
   79.4 % of patients had previous knowledge about AMD. Most patients, 97.3 %, got their information from physicians. 58 % of patients find their knowledge concerning AMD adequate. Only 23.9 % knew about aid organizations for patients with visual impairments.
   Though the majority of patients had good knowledge concerning AMD, there was a large percentage of patients who seemed to lack information. Physicians should actively ask their patients if they have any questions related to their disease. Medial focus on AMD and information about aid organizations could help patients to cope with their disease.
   A large number of patients seemed to need additional information. We suggest that ophthalmologists provide general information concerning AMD to their patients every 3 to 5 years. Information about aid organizations specializing in visual impairment could also be provided. Well-informed patients would be better able to follow their physician's instructions and would have a better understanding of their disease, particularly for the sake of therapy.
C1 [Burgmueller, Michael; Weingessel, Birgit; Vecsei, Christina; Vecsei-Marlovits, Pia Veronika] Wiener Krankenanstaltenverbund, Augenabteilung Krankenhaus Hietzing, Wolkersbergenstr 1,Pavillon 2a & 2b, A-1130 Vienna, Austria.
   [Burgmueller, Michael; Cakmak, Nesrin; Weingessel, Birgit; Vecsei, Christina; Vecsei-Marlovits, Pia Veronika] Karl Landsteiner Gesellschaft, Inst Prozessoptimierung & Qual Management Katarak, St Polten, Austria.
C3 Hietzing Hospital
RP Burgmuller, M (通讯作者)，Wiener Krankenanstaltenverbund, Augenabteilung Krankenhaus Hietzing, Wolkersbergenstr 1,Pavillon 2a & 2b, A-1130 Vienna, Austria.
EM michael.burgmueller@wienkav.at
RI Weingessel, Birgit/AAM-6617-2021; Weingessel, Birgit/ABD-5201-2021
OI Weingessel, Birgit/0000-0002-1110-0432
CR Altenhoner T, 2014, GESUNDHEITSWESEN, V76, P19, DOI 10.1055/s-0033-1333729
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Brannlund A, 2013, SCAND J PUBLIC HEALT, V41, P284, DOI 10.1177/1403494813475531
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hu YH, 2015, PATIENT EDUC COUNS, V98, P1651, DOI 10.1016/j.pec.2015.06.015
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mocan N, 2014, EUR J HEALTH ECON, V15, P265, DOI 10.1007/s10198-013-0473-4
   Peng JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079181
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schmidt-Erfurth U, 2007, AUGENHEILKUNDE, P339
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Stocke V, 2004, Z SOZIOL, V33, P303
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 20
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD MAY
PY 2017
VL 129
IS 9-10
BP 345
EP 350
DI 10.1007/s00508-016-1044-3
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EU9FJ
UT WOS:000401343300006
PM 27457875
DA 2022-11-30
ER

PT J
AU Ito, M
   Okubo, A
   Sonoda, Y
   Yamakiri, K
   Sakamoto, T
AF Ito, M
   Okubo, A
   Sonoda, Y
   Yamakiri, K
   Sakamoto, T
TI Intravitreal triamcinolone acetonide for exudative age-related macular
   degeneration among Japanese patients
SO OPHTHALMOLOGICA
LA English
DT Article
DE triamcinolone acetonide; age-related macular degeneration; choroidal
   neovascularization; intraocular pressure; endophthalmitis
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   PHOTODYNAMIC THERAPY; ACUTE ENDOPHTHALMITIS; INJECTION; VERTEPORFIN;
   MACULOPATHY; PREVALENCE; EYE
AB Aim: To study the results of intravitreal triamcinolone acetonide (TA) for exudative age-related macular degeneration (AMD) among Japanese patients. Methods: 13 eyes of 12 Japanese patients (9 males and 3 females) with subfoveal choroidal neovascularization (CNV) of exudative AMD received intravitreal TA (8 mg). Visual acuity, size of CNV and serous retinal detachment, and complications related to treatment were evaluated for 6 months or longer. Results: Postoperative maximum visual acuity significantly improved (p < 0.05). Postoperative eyes had a greater probability of a reduced size of CNV and/or retinal detachment compared to preoperative eyes. Seven eyes showed increased intraocular pressure (21 mm Hg or over), which was controlled well by medication. Cataract development and advancement were observed in 90% of phakic eyes. No other serious complications were found. Conclusions: Intravitreal TA might be an effective treatment for subfoveal CNV of exudative AMD among Japanese as well as Caucasian patients for a comparatively short period. Copyright (c) 2006 S. Karger AG, Basel.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Fac Med, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Sakamoto, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Fac Med, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM tsakamot@m3.kufm.kagoshima-u.ac.jp
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Parke DW, 2003, AM J OPHTHALMOL, V136, P918, DOI 10.1016/j.ajo.2003.08.051
   Pauleikhoff D, 1995, Curr Opin Ophthalmol, V6, P51
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Sakamoto T, 2004, AM J OPHTHALMOL, V138, P137, DOI 10.1016/j.ajo.2004.02.072
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 20
TC 7
Z9 10
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2006
VL 220
IS 2
BP 118
EP 124
DI 10.1159/000090577
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 014RW
UT WOS:000235498600008
PM 16491035
DA 2022-11-30
ER

PT J
AU Gemenetzi, M
   Lotery, AJ
   Patel, PJ
AF Gemenetzi, M.
   Lotery, A. J.
   Patel, P. J.
TI Risk of geographic atrophy in age-related macular degeneration patients
   treated with intravitreal anti-VEGF agents
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL ATROPHY; CHOROIDAL
   NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN; 7-YEAR OUTCOMES;
   RANIBIZUMAB; EYES; DRUSEN; RPE; CHORIOCAPILLARIS
AB Anti-vascular endothelial growth factor (VEGF) intravitreal agents are the only successful treatment for wet age-related macular degeneration (AMD). However, there are emerging signals that anti-VEGF treatment can potentially increase development of geographic atrophy (GA). Histopathologic, animal, and clinical studies support this hypothesis although direct proof of a relationship between GA and use of anti-VEGF agents in neovascular AMD is not yet established. This review presents current evidence supporting an association between anti-VEGF therapy and progression of geographic atrophy. The need of exploring alternative methods of treating AMD is indirectly but clearly emphasized.
C1 [Gemenetzi, M.; Patel, P. J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Lotery, A. J.] Univ Southampton, Div Neurosci, Fac Med, Southampton, Hants, England.
   [Lotery, A. J.] Southampton Univ Hosp NHS Fdn Trust, Eye Unit, Southampton, Hants, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Southampton
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
EM praveen.patel@moorfields.nhs.uk
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grob S, 2012, EYE, V26, P1106, DOI 10.1038/eye.2012.107
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2016, ARVO
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HARRIS MJ, 1985, OPHTHALMOLOGY, V92, P1550
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Kent D, 2003, MOL VIS, V9, P747
   Kent DL, 2014, MOL VIS, V20, P46
   Kim YG, 2011, ACTA OPHTHALMOL, V89, pE52, DOI 10.1111/j.1755-3768.2010.01958.x
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Macular Photocoagulation Study Group, 1996, ARCH OPHTHALMOL-CHIC, V114, P1023
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marsiglia M, 2015, RETINA-J RET VIT DIS, V35, P966, DOI 10.1097/IAE.0000000000000460
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda S, 2014, AAO ANN M RET SUBSP
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 57
TC 68
Z9 74
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2017
VL 31
IS 1
BP 1
EP 9
DI 10.1038/eye.2016.208
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AU
UT WOS:000394353700001
PM 27716750
OA Green Accepted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Forster, TM
   Steinmetz, P
   Schlichtenbrede, FC
   Harder, BC
AF Jonas, Jost B.
   Forster, Tessa M.
   Steinmetz, Philippe
   Schlichtenbrede, Frank C.
   Harder, Bjoern C.
TI CHOROIDAL THICKNESS IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal thickness; age-related macular degeneration; enhanced depth
   imaging; optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   BLOOD-FLOW; HEALTHY-SUBJECTS; DRUSEN EXTENT; EYES; VASCULOPATHY;
   NEOVASCULARIZATION; GLAUCOMA; THERAPY
AB Purpose: To examine choroidal thickness in age-related macular degeneration (AMD).
   Methods: The hospital-based case series study included patients with nonexudative or exudative AMD as study group, and the control group consisted of subjects with a normal fundus. Choroidal thickness was measured by enhanced depth imaging of spectral domain optical coherence tomography.
   Results: The study group (126 patients; 204 eyes) included a nonexudative subgroup (n = 50 eyes) and an exudative subgroup (n = 154 eyes), differentiated into eyes with mostly retinal pigment epithelium detachment (n = 35), mostly retinal edema (n = 36), and a subretinal fibrotic scar (n = 83). For 29 patients with unilateral AMD, contralateral normal eyes were compared with affected eyes. The control group consisted of 189 patients (228 eyes). Comparing choroidal thickness between the affected eyes and contralateral unaffected eyes in patients with unilateral AMD revealed no statistically significant differences (all P > 0.20). After adjusting for age and refractive error, subfoveal choroidal thickness was not significantly (all P > 0.10) related with AMD neither as a whole nor with the nonexudative or exudative AMD subgroup nor with the single exudative AMD subtypes (except for the subretinal fibrotic scar subgroup; P = 0.03). Correspondingly, choroidal thickness at a horizontal distance of 1000 mu m from the fovea was not significantly (all P >= 0.30) associated with any subgroup of AMD. In binary regression analysis, the presence of AMD or of its subtypes (except for subretinal fibrotic scar type) was not significantly (all P >= 0.20) associated with subfoveal or parafoveal choroidal thickness after adjustment for age and refractive error. After matching for age, refractive error, and axial length, study group and control group did not differ significantly (all P > 0.25) in foveal or parafoveal choroidal thickness measurements.
   Conclusion: After adjusting for age and refractive error, AMD, neither in its nonexudative form nor exudative form, was significantly associated with a marked thinning or thickening of the choroid in the foveal and parafoveal region.
C1 [Jonas, Jost B.; Forster, Tessa M.; Steinmetz, Philippe; Schlichtenbrede, Frank C.; Harder, Bjoern C.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM jost.jonas@medma.uni-heidelberg.de
CR Arora KS, 2012, INVEST OPHTH VIS SCI, V53, P7813, DOI 10.1167/iovs.12-10483
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mwanza JC, 2012, INVEST OPHTH VIS SCI, V53, P6695, DOI 10.1167/iovs.12-10388
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Shao L, 2013, INVEST OPHTH VIS SCI, V54, P230, DOI 10.1167/iovs.12-10351
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 31
TC 63
Z9 65
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2014
VL 34
IS 6
BP 1149
EP 1155
DI 10.1097/IAE.0000000000000035
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI8GP
UT WOS:000337149000016
PM 24220257
DA 2022-11-30
ER

PT J
AU Ke, KM
   Chakravarthy, U
   O'Neill, C
AF Ke, Kathleen M.
   Chakravarthy, Usha
   O'Neill, Ciaran
TI Economic cost of age-related macular degeneration - A review of recent
   research
SO DRUGS & AGING
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; VISUAL
   IMPAIRMENT; UTILITY; SUPPLEMENTATION; MACULOPATHY; DEPRESSION;
   AUSTRALIA; BLINDNESS; ZINC
AB As the population of most developed countries ages so the prevalence of diseases such as age-related macular degeneration (AMD) are likely to increase. To facilitate planning and informed debate regarding making provisions for this disease it is important that we have a clear understanding of the economic impact of visual impairment associated with AMD. In this paper we assess the state of current knowledge based on a review of published evidence in scientific journals. Based on our assessment of the evidence we argue that the paucity of research studies on the subject and wide variation in estimates produced from the few studies available make it difficult to assess with confidence the likely average direct cost-of-illness associated with AMD. We further argue that significant gaps in our understanding of the costs of AMD (particularly in respect of indirect costs) also exist. Current research should be augmented by more comprehensive studies.
C1 Univ Ulster, Sch Econ & Polit, Jordanstown BT37 0QB, Newtownabbey, North Ireland.
   Queens Univ Belfast, Ctr Ophthalmol & Vis Sci, Inst Clin Sci, Royal Grp Hosp Trust, Belfast, Antrim, North Ireland.
C3 Ulster University; Queens University Belfast
RP O'Neill, C (通讯作者)，Univ Ulster, Sch Econ & Polit, Jordanstown BT37 0QB, Newtownabbey, North Ireland.
EM C.ONeill2@ulster.ac.uk
OI Ke, Kathleen Melissa/0000-0002-2670-2188; Chakravarthy,
   Usha/0000-0002-2606-3734
CR Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Curtis L, 2004, UNIT COSTS HLTH SOCI
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Drummond MF, 2005, METHODS EC EVALUATIO
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Hopley C, 2003, CLIN EXP OPHTHALMOL, V31, P522, DOI 10.1046/j.1442-9071.2003.00715.x
   HUSEREAU DR, 2002, PHOTODYNAMIC THERAPY, V31, P40
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   *NAT I CLIN EXC, FIN APPR DET PHOT TH
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Ovretveit J, 1998, EVALUATING HLTH INTE
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
NR 35
TC 5
Z9 6
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2006
VL 23
IS 3
BP 217
EP 225
DI 10.2165/00002512-200623030-00004
PG 9
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 045OZ
UT WOS:000237752700004
PM 16608377
DA 2022-11-30
ER

PT J
AU Mantel, I
   Gillies, MC
   Souied, EH
AF Mantel, Irmela
   Gillies, Mark C.
   Souied, Eric H.
TI Switching between ranibizumab and aflibercept for the treatment of
   neovascular age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; vascular endothelial growth factor;
   ranibizumab; lucentis; aflibercept; eylea; switch; refractory
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL DETACHMENT; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF THERAPY;
   INTRAVITREAL AFLIBERCEPT; ANATOMIC OUTCOMES; CLINICAL BURDEN; LEGAL
   BLINDNESS; DOSING REGIMEN
AB The introduction of antivascular endothelial growth factor agents such as ranibizumab and aflibercept has revolutionized the management of neovascular age -related macular degeneration. A number of randomized clinical trials have shown that ranibizumab and aflibercept produce similar efficacy and safety outcomes. Most of the switching studies published to date show that efficacy benefits are uncontrolled, retrospective trials with limitations in terms of their selection, monitoring, numbers, and assessment criteria. Based on the published literature to date, we propose arguments for and against switching antivascular endothelial growth factor agents, provide our own perspective on this topic, and suggest a focus for future research. (C) 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
C1 [Mantel, Irmela] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight & Eye Hlth Inst, Sydney, NSW, Australia.
   [Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
C3 University of Lausanne; University of Sydney; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Av France Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
OI Gillies, mark/0000-0001-8580-0274
FU Novartis
FX Rebecca Franklin and Spela Ferjancic of Fishawack Communications Ltd,
   provided medical writing support, which was funded by Novartis but did
   not contribute to analysis or interpretation of data.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Batioglu F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0025-z
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   European Medicines Agency, LUC EPAR SCI DISC
   European Medicines Agency, EYL AFL SUMM PROD CH
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferris FL, 2017, JAMA OPHTHALMOL, V135, P145, DOI 10.1001/jamaophthalmol.2016.4820
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   He LM, 2015, OSLI RETINA, V46, P542, DOI 10.3928/23258160-20150521-05
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Johnston RL, 2016, OPHTHALMOLOGY, V123, P2386, DOI 10.1016/j.ophtha.2016.07.037
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P431, DOI 10.1016/j.jcjo.2014.07.012
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Narayan DS, 2015, INDIAN J OPHTHALMOL, V63, P832, DOI 10.4103/0301-4738.171964
   Nomura Y, 2015, JPN J OPHTHALMOL, V59, P261, DOI 10.1007/s10384-015-0387-z
   Nudleman E, 2016, CLIN OPHTHALMOL, V10, P1053, DOI 10.2147/OPTH.S109894
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Ricci F, 2016, EYE, V30, P1077, DOI 10.1038/eye.2016.95
   Roche Pharma AG, AV SUMM PROD CHAR
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Slean Geraldine R, 2016, Int J Retina Vitreous, V2, P2, DOI 10.1186/s40942-016-0028-9
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   US Food and Drug Administration, EYL AFL US PRESCR IN
   Van Lancker L, 2017, EUR J OPHTHALMOL, V27, P342, DOI 10.5301/ejo.5000861
   Warwick AN, 2016, INT J OPHTHALMOL-CHI, V9, P1156, DOI 10.18240/ijo.2016.08.12
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Zehetner C, 2015, INVEST OPHTH VIS SCI, V56, P3279, DOI 10.1167/iovs.15-16686
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 70
TC 32
Z9 32
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2018
VL 63
IS 5
BP 638
EP 645
DI 10.1016/j.survophthal.2018.02.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR1TS
UT WOS:000442335200004
PM 29476754
OA hybrid
DA 2022-11-30
ER

PT J
AU Byrne, S
   Beatty, S
AF Byrne, S
   Beatty, S
TI Current concepts and recent advances in the management of age-related
   macular degeneration
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; SURGICAL
   REMOVAL; MACULOPATHY; PREVALENCE; TRANSLOCATION; THALIDOMIDE; SECONDARY;
   DISEASE; MODEL
AB Background Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the Western World in those aged 65 and older. At present, several treatment modalities are utilised and several more are undergoing investigation in an attempt to retard the occurrence and progression of this devastating condition.
   Aims To provide the non-ophthalmologist with an understanding of the current treatment options available to patients suffering from all variants of AMD.
   Methods Medline and Embase search.
   Results Several treatment modalities have been investigated and utilised in the treatment of all variants of this condition. While promising results have been reported, no treatment is ideal.
   Conclusion While no curative treatment for this condition currently exists, early recognition and treatment, if indicated, have been shown to reduce the risk of severe vision loss in patients with this condition.
C1 Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
C3 Newcastle University - UK
RP Byrne, S (通讯作者)，162 Warkworth Woods,Brunton Lane,Great Pk, Newcastle Upon Tyne, Tyne & Wear, England.
EM sineadambyrne@eircom.net
CR ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1998, Ophthalmology, V105, P11
   ARCHER D B, 1991, Eye (London), V5, P239
   ARLETT CF, 1980, CANCER RES, V40, P926
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Chakravarthy U, 2000, EYE, V14, P151, DOI 10.1038/eye.2000.45
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   COSCAS G, 1991, DEGENERESCENCES MACU, P447
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FERRIS FL, ARCH OPHTHALMOL, V102, P1640
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   GERSTER H, 1991, AGE AGEING, V20, P60, DOI 10.1093/ageing/20.1.60
   GREEN WR, 1977, T AM OPHTHAL SOC, V75, P80
   GREY RHB, 1979, BRIT J OPHTHALMOL, V63, P85, DOI 10.1136/bjo.63.2.85
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   HUSSAIN D, 1997, SEM OPHTHALMOL, V12, P14
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kychenthal A, 1999, INVEST OPHTH VIS SCI, V40, pS207
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LOWENSTEIN A, 2000, RETINAL PIGMENT EPIT
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MANYAK MJ, 1988, J CLIN ONCOL, V6, P380, DOI 10.1200/JCO.1988.6.2.380
   MARCUS DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P275
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   PAGENSTECHER H, ATLAS PATHOLOGISCHEN
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   REINHOLD HS, 1973, BRIT J RADIOL, V46, P54, DOI 10.1259/0007-1285-46-541-54
   *ROY COLL OPHTH, 2001, PHOT THER SUBF CHOR
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schmidt-Erfurth U, 1998, LASER PHYS, V8, P191
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   SHERR DL, 1997, SEM OPHTHALMOL, V12, P26
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   VINGERLING JR, 1987, OPHTHALMOLOGY, V94, P1191
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wright AF, 1997, BRIT J OPHTHALMOL, V81, P620, DOI 10.1136/bjo.81.8.620
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 60
TC 2
Z9 3
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
EI 1863-4362
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD OCT-DEC
PY 2003
VL 172
IS 4
BP 185
EP 190
DI 10.1007/BF02915287
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 805PS
UT WOS:000220378800006
PM 15029987
DA 2022-11-30
ER

PT J
AU Topouzis, F
   Coleman, AL
   Harris, A
   Anastasopoulos, E
   Yu, F
   Koskosas, A
   Pappas, T
   Mavroudis, L
   Wilson, MR
AF Topouzis, Fotis
   Coleman, Anne L.
   Harris, Alon
   Anastasopoulos, Eleftherios
   Yu, Fei
   Koskosas, Archimidis
   Pappas, Theofanis
   Mavroudis, Leonidas
   Wilson, M. Roy
TI Prevalence of age-related macular degeneration in Greece: The
   Thessaloniki Eye Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY
AB PURPOSE: To estimate the age, and gender-specific prevalence of age-related macular degeneration (AMD) in a population-based sample of subjects 60 years of age or older in Thessaloniki, Greece.
   DESIGN: Cross-sectional population based study.
   METHODs: A total of 2554 subjects randomly identified from municipality registers in Thessaloniki underwent a complete ophthalmologic examination.
   RESULTS: Of the 3617 eligible subjects, 2554 (71%) participants completed a clinical examination. The prevalence was 2.5% for AMD, 1.4% for neovascular (NV) AMD, and 1.3% for geographic atrophy (GA). Bilateral AMD was present in 40% of AMD cases. The prevalence of AMD, NV, GA, and bilateral AMD increased with increasing age (P <.0001). No gender-specific statistically significant differences were noted. Of all participants with AMD, 67% were unaware of the diagnosis.
   CONCLUSIONS: The prevalence of AMD in Greece is comparable to that in other Caucasian populations. A dramatic increase in prevalence in people older than 80 years of age was observed.
C1 Aristotle Univ Thessaloniki, Gen Hosp Papageorgiou, Dept Ophthalmol 2, Thessaloniki 56403, Greece.
   Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Ctr Eye Epidemiol, Los Angeles, CA 90024 USA.
   Indiana Univ, Dept Ophthalmol, Indianapolis, IN 46204 USA.
   Univ Colorado, Denver, CO 80202 USA.
   Hlth Sci Ctr, Denver, CO USA.
C3 Aristotle University of Thessaloniki; Papageorgiou Hospital; University
   of California System; University of California Los Angeles; University
   of California Los Angeles Medical Center; David Geffen School of
   Medicine at UCLA; Indiana University System; Indiana University-Purdue
   University Indianapolis; University of Colorado System; University of
   Colorado Denver
RP Topouzis, F (通讯作者)，Aristotle Univ Thessaloniki, Gen Hosp Papageorgiou, Dept Ophthalmol 2, Thessaloniki 56403, Greece.
EM ftopouzis@otenet.gr
OI Topouzis, Fotis/0000-0002-8966-537X
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P993
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P60, DOI 10.1016/j.ajo.2006.02.055
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 7
TC 21
Z9 22
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 1076
EP 1079
DI 10.1016/j.ajo.2006.07.042
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100033
PM 17157601
DA 2022-11-30
ER

PT J
AU Takahashi, H
   Ohkubo, Y
   Sato, A
   Takezawa, M
   Fujino, Y
   Yanagi, Y
   Kawashima, H
AF Takahashi, Hidenori
   Ohkubo, Yuko
   Sato, Aya
   Takezawa, Mikiko
   Fujino, Yujiro
   Yanagi, Yasuo
   Kawashima, Hidetoshi
TI RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL
   INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; intravitreal injection; pro re nata;
   ranibizumab; visual prognosis
ID VEGF TRAP; PHARMACOKINETICS; ENDOPHTHALMITIS; THERAPY; SAFETY
AB Background:In age-related macular degeneration, various factors in clinical practice cause delays to arise between the time exudative change is observed and the time anti-vascular endothelial growth factor drugs are actually injected. We investigated the influence of injection delay on prognosis.Methods:Subjects were 50 eyes (50 patients from 2 hospitals) that were administered ranibizumab monotherapy for age-related macular degeneration for 1 year since exudative change was first observed. We investigated the mean number of delay days for each injection.Results:Mean injection delay was between 0 and 104 days. Significant prognostic factors for visual acuity were initial best-corrected visual acuity (P < 0.01) and mean injection delay (P = 0.03). We estimated that for an initial best-corrected visual acuity of 0.40 logMAR unit (20/50 Snellen equivalent), the respective best-corrected visual acuity values after 1 year for mean injection delays of 0, 7, 14, 28, and 56 days would be 0.22 (20/33), 0.24 (20/35), 0.26 (20/37), 0.31 (20/40), and 0.39 (20/49). For an initial best-corrected visual acuity of 0.097 (20/25), the respective values would be 0.054 (20/23), 0.075 (20/24), 0.10 (20/25), 0.14 (20/28), and 0.22 (20/33).Conclusion:Long-term visual acuity prognosis worsened when scheduling problems delayed intravitreal injection of anti-vascular endothelial growth factor drugs.
C1 [Takahashi, Hidenori; Ohkubo, Yuko; Sato, Aya; Takezawa, Mikiko; Kawashima, Hidetoshi] Jichi Med Univ, Shimotsuke, Tochigi 3290431, Japan.
   [Takahashi, Hidenori; Fujino, Yujiro] Japan Community Hlth Care Org Tokyo Shinjuku Med, Dept Ophthalmol, Tokyo, Japan.
   [Takahashi, Hidenori; Yanagi, Yasuo] Univ Tokyo, Dept Ophthalmol, Tokyo 113, Japan.
C3 Jichi Medical University; University of Tokyo
RP Takahashi, H (通讯作者)，Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290431, Japan.
EM takahah-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Takahashi, Hidenori/H-2945-2019; Yanagi,
   Yasuo/AAF-2670-2020
OI Takahashi, Hidenori/0000-0001-5331-4730; Yanagi,
   Yasuo/0000-0002-0362-7285
FU Jichi Medical University; Novartis Pharmaceuticals; Santen
   Pharmaceutical; Bayer Healthcare
FX Supported by the research funds of Jichi Medical University.; H.
   Takahashi and H. Kawashima received lecturer's fees from Novartis
   Pharmaceuticals and Santen Pharmaceutical. Y. Yanagi received lecturer's
   fees from Novartis Pharmaceuticals, Bayer Healthcare, and Santen
   Pharmaceutical. He is also an advisory board member for Novartis
   Pharmaceuticals and Bayer Healthcare. The remaining authors have no
   conflicting interests to disclose.
CR Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Iida T, 2014, JHEOR, V2, P41, DOI DOI 10.36469/9887
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park Y, 2013, J OCUL PHARMACOL TH, V29, P900, DOI 10.1089/jop.2013.0052
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 19
TC 16
Z9 16
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1331
EP 1338
DI 10.1097/IAE.0000000000000513
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600006
PM 25719984
DA 2022-11-30
ER

PT J
AU White, CE
   Olabisi, RM
AF White, Corina E.
   Olabisi, Ronke M.
TI Scaffolds for retinal pigment epithelial cell transplantation in
   age-related macular degeneration
SO JOURNAL OF TISSUE ENGINEERING
LA English
DT Review
DE Scaffolds; retina; retinal pigment epithelium; age-related macular
   degeneration
ID HUMAN BRUCHS MEMBRANE; SYNTHETIC BIODEGRADABLE POLYMERS; ANTERIOR LENS
   CAPSULE; EMBRYONIC STEM-CELLS; MORI SILK FIBROIN; SUBRETINAL SPACE; RCS
   RATS; AMNIOTIC MEMBRANE; VISUAL IMPAIRMENT; THIN-FILMS
AB In several retinal degenerative diseases, including age-related macular degeneration, the retinal pigment epithelium, a highly functionalized cell monolayer, becomes dysfunctional. These retinal diseases are marked by early retinal pigment epithelium dysfunction reducing its ability to maintain a healthy retina, hence making the retinal pigment epithelium an attractive target for treatment. Cell therapies, including bolus cell injections, have been investigated with mixed results. Since bolus cell injection does not promote the proper monolayer architecture, scaffolds seeded with retinal pigment epithelium cells and then implanted have been increasingly investigated. Such cell-seeded scaffolds address both the dysfunction of the retinal pigment epithelium cells and age-related retinal changes that inhibit the efficacy of cell-only therapies. Currently, several groups are investigating retinal therapies using seeded cells from a number of cell sources on a variety of scaffolds, such as degradable, non-degradable, natural, and artificial substrates. This review describes the variety of scaffolds that have been developed for the implantation of retinal pigment epithelium cells.
C1 [White, Corina E.; Olabisi, Ronke M.] Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08855 USA.
C3 Rutgers State University New Brunswick
RP Olabisi, RM (通讯作者)，Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08855 USA.
EM ronke.olabisi@rutgers.edu
RI Olabisi, Ronke M/A-6599-2011
OI Olabisi, Ronke M/0000-0003-3738-5250
FU National Institutes of Health under Ruth L. Kirschstein National
   Research Service Award from the NIGMS [T32 GM8339]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: C.E.W. was
   supported by the National Institutes of Health under Ruth L. Kirschstein
   National Research Service Award T32 GM8339 from the NIGMS.
CR Abe T, 2000, CURR EYE RES, V20, P268
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Beutel J, 2007, GRAEF ARCH CLIN EXP, V245, P1469, DOI 10.1007/s00417-007-0566-9
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Cao SJ, 2013, MOL VIS, V19, P718
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Chirila TV, 2008, TISSUE ENG PT A, V14, P1203, DOI [10.1089/ten.tea.2007.0224, 10.1089/tea.2007.0224]
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Elner SG, 2006, EXP EYE RES, V83, P374, DOI 10.1016/j.exer.2006.01.013
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   Farrokh-Siar L, 1999, CURR EYE RES, V19, P89, DOI 10.1076/ceyr.19.2.89.5331
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Goncalves S, 2016, COLLOID SURFACE B, V139, P1, DOI 10.1016/j.colsurfb.2015.11.051
   GOURAS P, 1984, AN ACAD BRAS CIENC, V56, P431
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Harkin DG, 2011, BIOMATERIALS, V32, P2445, DOI 10.1016/j.biomaterials.2010.12.041
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z
   JAFFE GJ, 1992, EXP EYE RES, V54, P595, DOI 10.1016/0014-4835(92)90138-I
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   Krishna Y, 2011, BRIT J OPHTHALMOL, V95, P569, DOI 10.1136/bjo.2009.169953
   LAVAIL MM, 1992, EXP EYE RES, V55, P555, DOI 10.1016/S0014-4835(05)80168-X
   Lee CJ, 2006, BIOMATERIALS, V27, P1670, DOI 10.1016/j.biomaterials.2005.09.008
   LI LX, 1988, EXP EYE RES, V47, P771, DOI 10.1016/0014-4835(88)90044-9
   Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082061
   LIVERSIDGE J, 1992, CURR EYE RES, V11, P49, DOI 10.3109/02713689208999511
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   Ohno-Matsui K, 2006, MOL VIS, V12, P1022
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sauve Y, 1998, EXP NEUROL, V152, P243, DOI 10.1006/exnr.1998.6849
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shadforth AMA, 2012, BIOMATERIALS, V33, P4110, DOI 10.1016/j.biomaterials.2012.02.040
   Shahmoradi S, 2017, MAT SCI ENG C-MATER, V73, P300, DOI 10.1016/j.msec.2016.11.076
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Singhal Shweta, 2005, Indian Journal of Ophthalmology, V53, P109
   Sorkio A, 2017, J TISSUE ENG REGEN M, V11, P3134, DOI 10.1002/term.2221
   Spencer C, 2017, J CELL MOL MED, V21, P2542, DOI 10.1111/jcmm.13175
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 90
TC 20
Z9 21
U1 2
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2041-7314
J9 J TISSUE ENG
JI J. Tissue Eng.
PD JUL 21
PY 2017
VL 8
AR 2041731417720841
DI 10.1177/2041731417720841
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FB4KS
UT WOS:000406111100001
PM 28794849
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gupta, B
   Elagouz, M
   Sivaprasad, S
AF Gupta, B.
   Elagouz, M.
   Sivaprasad, S.
TI Intravitreal bevacizumab for choroidal neovascularisation secondary to
   causes other than age-related macular degeneration
SO EYE
LA English
DT Review
DE bevacizumab; non-AMD; choroidal neovascularisation
ID PUNCTATE INNER CHOROIDOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   ENDOTHELIAL GROWTH-FACTOR; PATHOLOGICAL MYOPIA; VISUAL PROGNOSIS;
   ANGIOID STREAKS; SUBFOVEAL; AVASTIN; RANIBIZUMAB; INJECTION
AB Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies. Eye (2010) 24, 203-213; doi: 10.1038/eye.2009.201; published online 7 August 2009
C1 [Gupta, B.; Elagouz, M.; Sivaprasad, S.] Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM Senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Gupta, Bhaskar/0000-0002-2122-3559
CR Adan A, 2007, RETINA-J RET VIT DIS, V27, P1180, DOI 10.1097/IAE.0b013e31815e9834
   Ahmadieh H, 2007, GRAEF ARCH CLIN EXP, V245, P1731, DOI 10.1007/s00417-007-0636-z
   [Anonymous], 1987, ARCH OPHTHALMOL-CHIC, V105, P1499
   Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x
   Apte RS, 2008, EYE, V22, P734, DOI 10.1038/sj.eye.6702941
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1035, DOI 10.1136/bjo.2007.130260
   Arias L, 2006, GRAEF ARCH CLIN EXP, V244, P753, DOI 10.1007/s00417-005-0131-3
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bennett MD, 2007, GRAEF ARCH CLIN EXP, V245, P903, DOI 10.1007/s00417-006-0472-6
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P897, DOI 10.1097/IAE.0b013e31809ff5df
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown J, 1996, OPHTHALMOLOGY, V103, P1100, DOI 10.1016/S0161-6420(96)30561-7
   Browning AC, 2005, OPHTHALMOLOGY, V112, P1227, DOI 10.1016/j.ophtha.2005.02.011
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P71, DOI 10.1097/IAE.0b013e31815e9339
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Chan WM, 2007, AM J OPHTHALMOL, V143, P977, DOI 10.1016/j.ajo.2007.02.039
   Chan WM, 2007, BRIT J OPHTHALMOL, V91, P174, DOI 10.1136/bjo.2006.103606
   Chan WM, 2003, OPHTHALMOLOGY, V110, P2395, DOI 10.1016/S0161-6420(03)00788-7
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Derriman L, 2008, RETINA-J RET VIT DIS, V28, P910, DOI 10.1097/IAE.0b013e31816d81d0
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   Finger RP, 2008, BRIT J OPHTHALMOL, V92, P483, DOI 10.1136/bjo.2007.129916
   Flaxel CJ, 2007, BRIT J OPHTHALMOL, V91, P564, DOI 10.1136/bjo.2006.111450
   Fujisato Kaori, 2008, Nippon Ganka Gakkai Zasshi, V112, P777
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Fung AE, 2009, OPHTHALMOLOGY, V116, P286, DOI 10.1016/j.ophtha.2008.09.014
   Gharbiya M, 2009, AM J OPHTHALMOL, V147, P84, DOI 10.1016/j.ajo.2008.07.022
   Glacet-Bernard A, 2001, AM J OPHTHALMOL, V131, P78, DOI 10.1016/S0002-9394(00)00733-9
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   GUTHOFF R, 2008, ACTA OPHTHALMOL
   HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
   HAWKINS BS, 1989, ARCH OPHTHALMOL-CHIC, V107, P344, DOI 10.1001/archopht.1989.01070010354023
   Heimann H, 2005, GRAEF ARCH CLIN EXP, V243, P1115, DOI 10.1007/s00417-005-1193-y
   Hernandez-Rojas ML, 2007, RETINA-J RET VIT DIS, V27, P707
   HO AC, 1995, OPHTHALMOLOGY, V102, P782, DOI 10.1016/S0161-6420(95)30968-2
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   Hubbard GB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1597, DOI 10.1001/archopht.122.11.1597
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   JAMERSON SC, 2008, INT OPHTHALMOL
   Japiassu RM, 2008, ARQ BRAS OFTALMOL, V71, P427, DOI 10.1590/S0004-27492008000300024
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P311, DOI 10.1007/s00417-008-0995-0
   Kumar A, 2004, ACTA OPHTHALMOL SCAN, V82, P205, DOI 10.1046/j.1600-0420.2004.00217.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Leslie T, 2005, BRIT J OPHTHALMOL, V89, P147, DOI 10.1136/bjo.2004.046623
   Leu J, 2007, GRAEF ARCH CLIN EXP, V245, P1723, DOI 10.1007/s00417-007-0604-7
   LIM JI, 1993, AM J OPHTHALMOL, V116, P414, DOI 10.1016/S0002-9394(14)71398-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mandal S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1487, DOI 10.1001/archopht.125.11.1487
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   McCarty CA, 1997, J REFRACT SURG, V13, P229
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   MOLINA GI, 2008, ACTA OPHTHALMOL
   Mones JM, 2009, EYE, V23, P1276, DOI 10.1038/eye.2009.88
   Montero JA, 2007, EUR J OPHTHALMOL, V17, P983, DOI 10.1177/112067210701700620
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Neri P, 2009, BRIT J OPHTHALMOL, V93, P155, DOI 10.1136/bjo.2008.145896
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ohno-Matsui K, 2006, GRAEF ARCH CLIN EXP, V244, P1363, DOI 10.1007/s00417-006-0303-9
   OLK RJ, 1984, OPHTHALMOLOGY, V91, P1592
   Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016/j.ajo.2004.03.029
   Rensch F, 2008, OPHTHAL SURG LAS IM, V39, P182, DOI 10.3928/15428877-20080501-14
   Rheaume MA, 2008, CAN J OPHTHALMOL, V43, P576, DOI 10.3129/i08-104
   Rinaldi M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1422, DOI 10.1001/archopht.125.10.1422
   Rogers AH, 2003, OPHTHALMOLOGY, V110, P1315, DOI 10.1016/S0161-6420(03)00466-4
   ROSEN E, 2008, EYE
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2009, EYE, V23, P334, DOI 10.1038/sj.eye.6703052
   Ruiz-Moreno JM, 2001, BRIT J OPHTHALMOL, V85, P1041, DOI 10.1136/bjo.85.9.1041
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Schadlu R, 2008, AM J OPHTHALMOL, V145, P875, DOI 10.1016/j.ajo.2007.12.030
   Secretan M, 1997, Eur J Ophthalmol, V7, P307
   Shaikh S, 2003, AM J OPHTHALMOL, V135, P1, DOI 10.1016/S0002-9394(02)01835-4
   Silva RM, 2008, RETINA-J RET VIT DIS, V28, P1117, DOI 10.1097/IAE.0b013e31817eda41
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Teixeira A, 2006, ACTA OPHTHALMOL SCAN, V84, P835, DOI 10.1111/j.1600-0420.2006.00762.x
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
   Tran T, 2008, GRAEF ARCH CLIN EXP, V246, P1685, DOI 10.1007/s00417-008-0906-4
   Wiegand TW, 2009, BRIT J OPHTHALMOL, V93, P47, DOI 10.1136/bjo.2008.143461
   Wilkinson CP, 1996, ARCH OPHTHALMOL-CHIC, V114, P677
   WU PC, 2009, EYE, P1476
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
NR 86
TC 20
Z9 20
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2010
VL 24
IS 2
BP 203
EP 213
DI 10.1038/eye.2009.201
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 553WQ
UT WOS:000274397900001
PM 19662081
OA Bronze
DA 2022-11-30
ER

PT J
AU Mammadzada, P
   Corredoira, PM
   Andre, H
AF Mammadzada, Parviz
   Corredoira, Pablo M.
   Andre, Helder
TI The role of hypoxia-inducible factors in neovascular age-related macular
   degeneration: a gene therapy perspective
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Age-related macular degeneration; Angiogenesis; Hypoxia-inducible
   factors; Gene therapy
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; INDUCED CHOROIDAL
   NEOVASCULARIZATION; FACTOR 1-ALPHA; TRANSCRIPTIONAL REGULATION;
   FACTOR-I; PROTEIN-KINASE; FACTOR-B; COMPLEMENT ACTIVATION; NUCLEAR
   TRANSLOCATION
AB Understanding the mechanisms that underlie age-related macular degeneration (AMD) has led to the identification of key molecules. Hypoxia-inducible transcription factors (HIFs) have been associated with choroidal neovascularization and the progression of AMD into the neovascular clinical phenotype (nAMD). HIFs regulate the expression of multiple growth factors and cytokines involved in angiogenesis and inflammation, hallmarks of nAMD. This knowledge has propelled the development of a new group of therapeutic strategies focused on gene therapy. The present review provides an update on current gene therapies in ocular angiogenesis, particularly nAMD, from both basic and clinical perspectives.
C1 [Mammadzada, Parviz; Corredoira, Pablo M.; Andre, Helder] Karolinska Inst, St Erik Eye Hosp, Dept Clin Neurosci, Div Eye & Vis, Stockholm, Sweden.
C3 Karolinska Institutet
RP Andre, H (通讯作者)，Karolinska Inst, St Erik Eye Hosp, Dept Clin Neurosci, Div Eye & Vis, Stockholm, Sweden.
EM helder.andre@ki.se
OI Andre, Helder/0000-0002-2926-2376; Mammadzada,
   Parviz/0000-0003-4171-5291
CR Adler L, 2015, PHOTOCH PHOTOBIO SCI, V14, P1983, DOI 10.1039/c5pp00156k
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Auricchio A, 2003, VISION RES, V43, P913, DOI 10.1016/S0042-6989(02)00676-4
   Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bainbridge JWB, 2003, GENE THER, V10, P1336, DOI 10.1038/sj.gt.3301990
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Baltaziak M, 2013, FOLIA HISTOCHEM CYTO, V51, P320, DOI 10.5603/FHC.2013.0043
   Barben M, 2018, CELL DEATH DIFFER, V25, P2071, DOI 10.1038/s41418-018-0094-7
   Barchitta M, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/8486406
   Berghoff AS, 2014, CLIN EXP METASTAS, V31, P841, DOI 10.1007/s10585-014-9675-0
   Bertozzi D, 2014, MOL CANCER THER, V13, P239, DOI 10.1158/1535-7163.MCT-13-0729
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biagi C, 2014, EUR J CLIN PHARMACOL, V70, P1505, DOI 10.1007/s00228-014-1755-1
   Biswal MR, 2018, J MOL MED, V96, P1107, DOI 10.1007/s00109-018-1683-0
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boye SL, 2016, J VIROL, V90, P4215, DOI 10.1128/JVI.00200-16
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Buhler K, 2009, BIOCHEM J, V424, P119, DOI 10.1042/BJ20090311
   Cammalleri M, 2019, J CELL MOL MED, V23, P5176, DOI 10.1111/jcmm.14391
   Cammalleri M, 2016, INVEST OPHTH VIS SCI, V57, P2600, DOI 10.1167/iovs.15-18758
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Carriero MV, 2014, MOL CANCER THER, V13, P1092, DOI 10.1158/1535-7163.MCT-13-0949
   Cascio S, 2010, J CELL PHYSIOL, V224, P242, DOI 10.1002/jcp.22126
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chowdhury R, 2009, STRUCTURE, V17, P981, DOI 10.1016/j.str.2009.06.002
   Coco RM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-138
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Collins M, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3003
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254
   Corydon TJ, 2015, HUM GENE THER, V26, P525, DOI 10.1089/hum.2015.064
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   D'souza YB, 2010, CAN J OPHTHALMOL, V45, P297, DOI 10.3129/i09-232
   Dal Monte M, 2015, INVEST OPHTH VIS SCI, V56, P2392, DOI 10.1167/iovs.14-16323
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Darrow JJ, 2019, DRUG DISCOV TODAY, V24, P949, DOI 10.1016/j.drudis.2019.01.019
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Depping R, 2008, BBA-MOL CELL RES, V1783, P394, DOI 10.1016/j.bbamcr.2007.12.006
   Ding K, 2017, MABS-AUSTIN, V9, P269, DOI 10.1080/19420862.2016.1268305
   Dougherty CJ, 2008, MOL VIS, V14, P471
   Duan CM, 2016, AM J PHYSIOL-CELL PH, V310, pC260, DOI 10.1152/ajpcell.00315.2015
   Eadie JA, 2014, OSLI RETINA, V45, P394, DOI 10.3928/23258160-20140909-03
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gorlach A, 2003, THROMB HAEMOSTASIS, V89, P926
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gu YZ, 1998, GENE EXPRESSION, V7, P205
   Guan GF, 2015, CANCER LETT, V357, P254, DOI 10.1016/j.canlet.2014.11.034
   Guha S, 2014, ADV EXP MED BIOL, V801, P105, DOI 10.1007/978-1-4614-3209-8_14
   Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010
   Hagiwara H, 2006, LIFE SCI, V78, P2249, DOI 10.1016/j.lfs.2005.09.036
   Han ZB, 2008, CARCINOGENESIS, V29, P1853, DOI 10.1093/carcin/bgn066
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Hutt DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106224
   Ichiyama Y, 2017, RETINA-J RET VIT DIS, V37, P724, DOI 10.1097/IAE.0000000000001576
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jazwa A, 2013, GENE, V525, P229, DOI 10.1016/j.gene.2013.03.093
   Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253
   Jo DH, 2014, J MOL MED, V92, P1083, DOI 10.1007/s00109-014-1168-8
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones DT, 2012, EXPERT OPIN THER TAR, V16, P463, DOI 10.1517/14728222.2012.674516
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P161, DOI 10.1016/j.pdpdt.2015.03.007
   KHALIQ A, 1995, EXP EYE RES, V60, P415, DOI 10.1016/S0014-4835(05)80098-3
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Khandrika L, 2009, ONCOGENE, V28, P1248, DOI 10.1038/onc.2008.476
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kimoto K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/852183
   Kimura D, 2002, TOHOKU J EXP MED, V196, P259, DOI 10.1620/tjem.196.259
   Kishi S, 2011, J BIOL CHEM, V286, P32162, DOI 10.1074/jbc.M111.244541
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Ko A, 2013, RETINA-J RET VIT DIS, V33, P1005, DOI 10.1097/IAE.0b013e31827d266e
   Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656
   Kurihara T, 2014, ADV EXP MED BIOL, V801, P275, DOI 10.1007/978-1-4614-3209-8_35
   Kuschel A, 2012, J CELL PHYSIOL, V227, P514, DOI 10.1002/jcp.22798
   Kvanta A, 2008, ACTA OPHTHALMOL, V86, P468, DOI 10.1111/j.1755-3768.2008.01283.x
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Kymalainen H, 2014, HUM GENE THER, V25, P428, DOI 10.1089/hum.2013.172
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e
   Lanner MC, 2005, AM J RESP CELL MOL, V33, P412, DOI 10.1165/rcmb.2005-0004OC
   Lazzeri S, 2012, SCI WORLD J, DOI 10.1100/2012/420190
   Le Meur G, 2005, ARCH OPHTHALMOL-CHIC, V123, P500, DOI 10.1001/archopht.123.4.500
   Lei Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007629
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262
   Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200
   Li QH, 2008, MOL VIS, V14, P1760
   Li R, 2016, CURR EYE RES, V41, P1566, DOI 10.3109/02713683.2016.1145234
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009
   Li Y, 2010, CURR CANCER DRUG TAR, V10, P782, DOI 10.2174/156800910793605857
   Li Y, 2009, CANCER BIOL THER, V8, P322, DOI 10.4161/cbt.8.4.7332
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Liu Wei, 2012, Int J Biochem Mol Biol, V3, P165
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054
   Ma J, 2016, INVEST OPHTH VIS SCI, V57, P3138, DOI 10.1167/iovs.15-18795
   Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085
   Mammadzada P, 2016, ACTA OPHTHALMOL, V94, P805, DOI [10.1111/aos.13119, 10.1111/j.1755-3768.2016.0399]
   Mantel I, 2014, OPHTHALMIC GENET, V35, P12, DOI 10.3109/13816810.2013.766217
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martin KRG, 2002, METHODS, V28, P267, DOI 10.1016/S1046-2023(02)00232-3
   Martin SK, 2010, HAEMATOL-HEMATOL J, V95, P776, DOI 10.3324/haematol.2009.015628
   Mattapallil MJ, 2017, IMMUNITY, V46, P167, DOI 10.1016/j.immuni.2017.02.008
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McDonough MA, 2006, P NATL ACAD SCI USA, V103, P9814, DOI 10.1073/pnas.0601283103
   Metzger CS, 2015, CYTOKINE, V76, P519, DOI 10.1016/j.cyto.2015.07.015
   Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200
   MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mole DR, 2002, ADV ENZYME REGUL, V42, P333, DOI 10.1016/S0065-2571(01)00037-1
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   MURPHY RP, 1986, OPHTHALMOLOGY, V93, P969
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Narumi K, 2012, INT J PHARMACEUT, V428, P25, DOI 10.1016/j.ijpharm.2012.02.021
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nikitenko LL, 2003, FASEB J, V17, P1499, DOI 10.1096/fj.02-0993fje
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nomura M, 1998, J NEURO-ONCOL, V40, P123, DOI 10.1023/A:1006198422718
   Nys K, 2010, J INVEST DERMATOL, V130, P2269, DOI 10.1038/jid.2010.93
   O'Rourke JF, 1997, ONCOL RES, V9, P327
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Osinsky SP, 2005, EXP ONCOL, V27, P202
   Peet DJ, 2017, EXP CELL RES, V356, P136, DOI 10.1016/j.yexcr.2017.03.030
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Ren BF, 2008, JOINT BONE SPINE, V75, P176, DOI 10.1016/j.jbspin.2007.05.012
   Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631
   Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Ruas JL, 2005, SEMIN CELL DEV BIOL, V16, P514, DOI 10.1016/j.semcdb.2005.04.001
   Ruas JL, 2002, J BIOL CHEM, V277, P38723, DOI 10.1074/jbc.M205051200
   Rush RB, 2014, RETINA-J RET VIT DIS, V34, P846, DOI 10.1097/IAE.0000000000000033
   Russo A, 2013, BRIT J OPHTHALMOL, V97, P1273, DOI 10.1136/bjophthalmol-2013-303417
   Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Selim A, 2014, TURK J MED SCI, V44, P889, DOI 10.3906/sag-1104-54
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Sharma V, 2012, INFLAMMATION, V35, P516, DOI 10.1007/s10753-011-9340-6
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Song SJ, 2008, OPHTHALMIC RES, V40, P35, DOI 10.1159/000111157
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stout JT, 2011, HUM GENE THER, V22, P531, DOI 10.1089/hum.2011.060
   Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Sunness JS, 1999, MOL VIS, V5
   Takei A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42546
   Tanaka T, 2017, J CELL PHYSIOL, V232, P192, DOI 10.1002/jcp.25411
   Tang NN, 2014, WORLD J GASTROENTERO, V20, P17894, DOI 10.3748/wjg.v20.i47.17894
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   Thamotharan S, 2013, AM J PHYSIOL-ENDOC M, V304, pE583, DOI 10.1152/ajpendo.00513.2012
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72
   Toh YM, 2011, CLIN CANCER RES, V17, P5026, DOI 10.1158/1078-0432.CCR-11-0235
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Trapani I, 2014, PROG RETIN EYE RES, V43, P108, DOI 10.1016/j.preteyeres.2014.08.001
   Vadlapatla RK, 2013, CURR DRUG TARGETS, V14, P919, DOI 10.2174/13894501113149990015
   Vavilala DT, 2013, BIOCHEM BIOPH RES CO, V438, P697, DOI 10.1016/j.bbrc.2013.07.118
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Vichi A, 2005, P NATL ACAD SCI USA, V102, P1945, DOI 10.1073/pnas.0409800102
   Wan X, 2016, SCI REP-UK, V6, DOI 10.1038/srep21587
   Wang B, 2014, ONCOL LETT, V8, P539, DOI 10.3892/ol.2014.2189
   Wang R, 2011, CURR MED CHEM, V18, P3168, DOI 10.2174/092986711796391606
   Wang XO, 2012, BIOCHEM BIOPH RES CO, V417, P1227, DOI 10.1016/j.bbrc.2011.12.115
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Welsh SJ, 2003, MOL CANCER THER, V2, P235
   Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje
   Willam C, 2000, CIRC RES, V87, P370
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JB, 2015, MOL MED REP, V11, P2677, DOI 10.3892/mmr.2014.3093
   Xia MH, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-117
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
   Yang H, 2015, ONCOL REP, V34, P334, DOI 10.3892/or.2015.3975
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yang SL, 2015, MOL MED REP, V12, P2411, DOI 10.3892/mmr.2015.3689
   Yeo EJ, 2004, BIOCHEM PHARMACOL, V68, P1061, DOI 10.1016/j.bcp.2004.02.040
   Yoshida D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhou CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13834
NR 240
TC 23
Z9 25
U1 3
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2020
VL 77
IS 5
BP 819
EP 833
DI 10.1007/s00018-019-03422-9
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KS7QS
UT WOS:000518501800005
PM 31893312
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Carnevali, A
   Mastropasqua, R
   Gatti, V
   Vaccaro, S
   Mancini, A
   D'Aloisio, R
   Lupidi, M
   Cerquaglia, A
   Sacconi, R
   Borrelli, E
   Iovino, C
   Vitiello, L
   Toro, MD
   Vagge, A
   Bernabei, F
   Pellegrini, M
   Di Zazzo, A
   Forlini, M
   Giannaccare, G
AF Carnevali, Adriano
   Mastropasqua, Rodolfo
   Gatti, Valentina
   Vaccaro, Sabrina
   Mancini, Alessandra
   D'Aloisio, Rossella
   Lupidi, Marco
   Cerquaglia, Alessio
   Sacconi, Riccardo
   Borrelli, Enrico
   Iovino, Claudio
   Vitiello, Livio
   Toro, Mario Damiano
   Vagge, Aldo
   Bernabei, Federico
   Pellegrini, Marco
   Di Zazzo, Antonio
   Forlini, Matteo
   Giannaccare, Giuseppe
TI Optical Coherence Tomography Angiography in Intermediate and Late
   Age-Related Macular Degeneration: Review of Current Technical Aspects
   and Applications
SO APPLIED SCIENCES-BASEL
LA English
DT Review
DE age-related macular degeneration; macular neovascularization; optical
   coherence tomography angiography (OCTA); retinal disease; posterior
   segment
ID GROWTH-FACTOR THERAPY; CHOROIDAL NEOVASCULARIZATION; GEOGRAPHIC ATROPHY;
   SPECTRAL-DOMAIN; OCT ANGIOGRAPHY; SWEPT-SOURCE; TYPE-2
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; QUANTITATIVE-ANALYSIS;
   PIGMENT-EPITHELIUM
AB Optical coherence tomography angiography (OCTA) is a non-invasive diagnostic instrument that has become indispensable for the management of age-related macular degeneration (AMD). OCTA allows quickly visualizing retinal and choroidal microvasculature, and in the last years, its use has increased in clinical practice as well as for research into the pathophysiology of AMD. This review provides a discussion of new technology and application of OCTA in intermediate and late AMD.
C1 [Carnevali, Adriano; Gatti, Valentina; Vaccaro, Sabrina; Mancini, Alessandra; Giannaccare, Giuseppe] Magna Graecia Univ Catanzaro, Dept Ophthalmol, I-88100 Catanzaro, Italy.
   [Mastropasqua, Rodolfo] Univ Modena & Reggio Emilia, Azienda Osped Univ Modena, Ophthalmol Clin, I-41125 Modena, Italy.
   [D'Aloisio, Rossella] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, I-66100 Chieti, Italy.
   [Lupidi, Marco; Cerquaglia, Alessio] Univ Perugia, S Maria Misericordia Hosp, Sect Ophthalmol, Dept Surg & Biomed Sci, I-06156 Perugia, Italy.
   [Lupidi, Marco] Univ Eye Clin, DiNOGMi, Fdn Macula Onlus, Viale Benedetto XV 5, I-16132 Genoa, Italy.
   [Lupidi, Marco] Ctr Odeon, 113 Blvd St Germain, F-75006 Paris, France.
   [Sacconi, Riccardo; Borrelli, Enrico] Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
   [Iovino, Claudio] Univ Campania Luigi Vanvitelli, Multidisciplinary Dept Med Surg & Dent Sci, Eye Clin, I-80131 Naples, Italy.
   [Vitiello, Livio] Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Eye Clin, I-84081 Salerno, Italy.
   [Toro, Mario Damiano] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, CH-9081 Zurich, Switzerland.
   [Toro, Mario Damiano] Cardinal Stefan Wyszynski Univ, Coll Med, Fac Med, PL-01815 Warsaw, Poland.
   [Vagge, Aldo] DiNOGMI Univ Genova IRCCS Osped, Eye Clin Genoa, Policlin San Martino, I-16132 Genoa, Italy.
   [Bernabei, Federico; Pellegrini, Marco] Alma Mater Studiorum Univ Bologna, S Orsola Malpighi Teaching Hosp, Dept Expt Diagnost & Specialty Med DIMES, Ophthalmol Unit, I-40138 Bologna, Italy.
   [Di Zazzo, Antonio] Univ Campus Biomed Rome, Dept Ophthalmol, I-00128 Rome, Italy.
   [Forlini, Matteo] San Marino State Hosp, Ist Sicurezza Sociale, Dept Ophthalmol, San Marino 47890, San Marino.
C3 Magna Graecia University of Catanzaro; Universita di Modena e Reggio
   Emilia; Universita di Modena e Reggio Emilia Hospital; G d'Annunzio
   University of Chieti-Pescara; University of Perugia; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; Universita della
   Campania Vanvitelli; University of Salerno; University of Zurich;
   University Zurich Hospital; Cardinal Stefan Wyszynski University in
   Warsaw; University of Genoa; IRCCS AOU San Martino IST; IRCCS Azienda
   Ospedaliero-Universitaria di Bologna; University of Bologna; University
   Campus Bio-Medico - Rome Italy
RP Carnevali, A (通讯作者)，Magna Graecia Univ Catanzaro, Dept Ophthalmol, I-88100 Catanzaro, Italy.
EM adrianocarnevali@unicz.it; rodolfo.mastropasqua@unimore.it;
   valentina.gatti91@gmail.com; sabrina_vaccaro@libero.it;
   alessandra.mancini@studenti.unicz.it; rossella.daloisio@unich.it;
   marco.lupidi@ospedale.perugia.it; alessio.cerquaglia@studenti.unipg.it;
   sacconi.riccardo@hsr.it; enrico.borrelli@hsr.it;
   claudio.iovino1@unicampania.it; lvitiello@unisa.it; toro.mario@email.it;
   aldo.vagge@unige.it; federico.bernabei2@studio.unibo.it;
   marco.pellegrini9@studio.unibo.it; a.dizazzo@unicampus.it;
   matteo.forlini@iss.sm; giuseppe.giannaccare@unicz.it
RI Toro, Mario/AAA-1371-2021; Vitiello, Livio/GPC-7452-2022; DAloisio,
   Rossella/L-2251-2019; Iovino, Claudio/O-7680-2019; Toro, Mario
   D/N-8051-2018; Mastropasqua, Rodolfo/AAC-6453-2022
OI Vitiello, Livio/0000-0001-7867-3342; Iovino,
   Claudio/0000-0003-1984-0555; Vaccaro, Sabrina/0000-0002-0881-1276;
   Mancini, Alessandra/0000-0001-7719-5772; Giannaccare,
   Giuseppe/0000-0003-2617-0289; Di Zazzo, Antonio/0000-0002-5264-5973;
   Borrelli, Enrico/0000-0003-2815-5031; Sacconi,
   Riccardo/0000-0003-2891-2012
CR Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Bacci T, 2020, OPHTHALMOLOGY, V127, P887, DOI 10.1016/j.ophtha.2020.03.036
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaskas K, 2019, CLIN EXP OPHTHALMOL, V47, P233, DOI 10.1111/ceo.13367
   Bansal R, 2018, INT OPHTHALMOL, V38, P2149, DOI 10.1007/s10792-017-0664-6
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Bhavsar Kavita V, 2017, Am J Ophthalmol Case Rep, V8, P53, DOI 10.1016/j.ajoc.2017.10.001
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonfiglio V, 2020, ACTA OPHTHALMOL, V98, pE563, DOI 10.1111/aos.14315
   Borrelli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53307-x
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali Adriano, 2018, Retin Cases Brief Rep, V12 Suppl 1, pS41, DOI 10.1097/ICB.0000000000000648
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Corbelli E, 2018, RETINA-J RET VIT DIS, V38, P2128, DOI 10.1097/IAE.0000000000001859
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   de Jong JH, 2019, OPHTHALMOLOGICA, V241, P143, DOI 10.1159/000491798
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Endersid C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210505
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hormel TT, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100878
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kataoka K, 2020, RETINA-J RET VIT DIS, V40, P109, DOI 10.1097/IAE.0000000000002357
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Markan A, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420950513
   Martins A, 2018, OPHTHALMIC RES, V59, P88, DOI 10.1159/000481262
   Maruyama-Inoue M, 2018, GRAEF ARCH CLIN EXP, V256, P2089, DOI 10.1007/s00417-018-4121-7
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nassisi M, 2021, AM J OPHTHALMOL, V222, P302, DOI 10.1016/j.ajo.2020.04.018
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Rabiolo A, 2016, EXPERT REV OPHTHALMO, V11, P243, DOI 10.1080/17469899.2016.1209409
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Roberts KF, 2012, ARCH OPHTHALMOL-CHIC, V130, P980, DOI 10.1001/archophthalmol.2012.371
   Roisman Luiz, 2017, Curr Ophthalmol Rep, V5, P136, DOI 10.1007/s40135-017-0131-6
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Smid LM, 2021, ACTA OPHTHALMOL, V99, P207, DOI 10.1111/aos.14525
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   THULLIEZ M, 2019, IMAGING OPHTHALMOL R, V3, P478, DOI DOI 10.1016/j.oret.2019.01.024
   Tilton RG, 1999, INVEST OPHTH VIS SCI, V40, P689
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Yeo JH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091272
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhao Z, 2019, OPHTHALMOLOGICA, V242, P178, DOI 10.1159/000497491
NR 122
TC 10
Z9 10
U1 3
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD DEC
PY 2020
VL 10
IS 24
AR 8865
DI 10.3390/app10248865
PG 20
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA PL1BH
UT WOS:000602865800001
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Stanton, CM
   Yates, JRW
   den Hollander, AI
   Seddon, JM
   Swaroop, A
   Stambolian, D
   Fauser, S
   Hoyng, C
   Yu, Y
   Atsuhiro, K
   Branham, K
   Othman, M
   Chen, W
   Kortvely, E
   Chalmers, K
   Hayward, C
   Moore, AT
   Dhillon, B
   Ueffing, M
   Wright, AF
AF Stanton, Chloe M.
   Yates, John R. W.
   den Hollander, Anneke I.
   Seddon, Johanna M.
   Swaroop, Anand
   Stambolian, Dwight
   Fauser, Sascha
   Hoyng, Carel
   Yu, Yi
   Atsuhiro, Kanda
   Branham, Kari
   Othman, Mohammad
   Chen, Wei
   Kortvely, Elod
   Chalmers, Kevin
   Hayward, Caroline
   Moore, Anthony T.
   Dhillon, Baljean
   Ueffing, Marius
   Wright, Alan F.
TI Complement Factor D in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ALTERNATIVE PATHWAY; SERINE-PROTEASE; ADIPOSE-TISSUE; BIOSYNTHESIS;
   ACTIVATION; COMPONENTS; PROTEINS; SUSCEPTIBILITY; ASSOCIATION;
   ADIPOCYTES
AB PURPOSE. To examine the role of complement factor D (CFD) in age-related macular degeneration (AMD) by analysis of genetic association, copy number variation, and plasma CFD concentrations.
   METHODS. Single nucleotide polymorphisms (SNPs) in the CFD gene were genotyped and the results analyzed by binary logistic regression. CFD gene copy number was analyzed by gene copy number assay. Plasma CFD was measured by an enzyme-linked immunosorbent assay.
   RESULTS. Genetic association was found between CFD gene SNP rs3826945 and AMD (odds ratio 1.44; P = 0.028) in a small discovery case-control series (462 cases and 325 controls) and replicated in a combined cohorts meta-analysis of 4765 cases and 2693 controls, with an odds ratio of 1.11 (P = 0.032), with the association almost confined to females. Copy number variation in the CFD gene was identified in 13 out of 640 samples examined but there was no difference in frequency between AMD cases (1.3%) and controls (2.7%). Plasma CFD concentration was measured in 751 AMD cases and 474 controls and found to be elevated in AMD cases (P = 0.00025). The odds ratio for those in the highest versus lowest quartile for plasma CFD was 1.81. The difference in plasma CFD was again almost confined to females.
   CONCLUSIONS. CFD regulates activation of the alternative complement pathway, which is implicated in AMD pathogenesis. The authors found evidence for genetic association between a CFD gene SNP and AMD and a significant increase in plasma CFD concentration in AMD cases compared with controls, consistent with a role for CFD in AMD pathogenesis. (Invest Ophthalmol Vis Sci. 2011;52:8828-8834) DOI:10.1167/iovs.11-7933
C1 [Stanton, Chloe M.; Chalmers, Kevin; Hayward, Caroline; Wright, Alan F.] Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Yates, John R. W.; Moore, Anthony T.] UCL, Inst Ophthalmol, London, England.
   [den Hollander, Anneke I.; Hoyng, Carel] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
   [Seddon, Johanna M.; Yu, Yi] Tufts Med Ctr, Dept Ophthalmol, New England Eye Ctr, Boston, MA USA.
   [Swaroop, Anand; Atsuhiro, Kanda] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Fauser, Sascha] Univ Eye Clin Cologne, Cologne, Germany.
   [Branham, Kari; Othman, Mohammad] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Chen, Wei] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Kortvely, Elod; Ueffing, Marius] Inst Ophthalm Res, Ctr Ophthalmol, Tubingen, Germany.
   [Dhillon, Baljean] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh; University of London; University College
   London; Radboud University Nijmegen; Tufts Medical Center; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   University of Pennsylvania; Pennsylvania Medicine; University of
   Cologne; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; University
   of Edinburgh
RP Wright, AF (通讯作者)，Inst Genet & Mol Med, MRC Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.
EM alan.wright@hgu.mrc.ac.uk
RI Branham, Kari/AAA-8336-2022; Hoyng, C.B./H-8050-2014; Chen,
   Wei/AAX-5994-2020; Hollander, Anneke den/N-4911-2014; Hayward,
   Caroline/M-8818-2016
OI Chen, Wei/0000-0001-7196-8703; Hayward, Caroline/0000-0002-9405-9550;
   Swaroop, Anand/0000-0002-1975-1141; Branham, Kari/0000-0002-2492-254X
FU Medical Research Council (UK); Macula Vision Research Foundation, Fight
   for Sight; National Eye Institute (NEI) [RO1-EY11309]; Netherlands
   Organisation for Scientific Research [016.096.309, AIdH]; Massachusetts
   Lions Eye Research Fund, Inc.; Ophthalmic Epidemiology and Genetics
   Service, Tufts University School of Medicine, Boston, MA, USA; Medical
   Research Council [G0000067, G0700704B, MC_U127584475, MC_PC_U127584475]
   Funding Source: researchfish; NATIONAL EYE INSTITUTE [ZIAEY000475,
   R01EY011309] Funding Source: NIH RePORTER; MRC [G0000067, MC_U127584475]
   Funding Source: UKRI
FX Supported by the Medical Research Council (UK); Macula Vision Research
   Foundation, Fight for Sight (AFW),; the National Eye Institute (NEI)
   intramural program (AS); the Netherlands Organisation for Scientific
   Research (Grant 016.096.309; AIdH); NEI Grant RO1-EY11309 (JMS);
   Massachusetts Lions Eye Research Fund, Inc.; Macular Degeneration
   Research Fund of the Ophthalmic Epidemiology and Genetics Service, Tufts
   University School of Medicine, Boston, MA, USA.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BARNUM SR, 1984, J IMMUNOL METHODS, V67, P303, DOI 10.1016/0022-1759(84)90470-8
   BARNUM SR, 1985, J IMMUNOL, V134, P1799
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   CHOY LN, 1992, J BIOL CHEM, V267, P12736
   COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   FEARON DT, 1974, J EXP MED, V139, P355, DOI 10.1084/jem.139.2.355
   Gabrielsson BG, 2003, OBES RES, V11, P699, DOI 10.1038/oby.2003.100
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Miner JL, 2004, J ANIM SCI, V82, P935
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   PASCUAL M, 1988, KIDNEY INT, V34, P529, DOI 10.1038/ki.1988.214
   Peake PW, 1997, EUR J CLIN INVEST, V27, P922, DOI 10.1046/j.1365-2362.1997.2090759.x
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SCHREIBER RD, 1978, J EXP MED, V148, P1722, DOI 10.1084/jem.148.6.1722
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726
   WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501
   WHITE RT, 1992, J BIOL CHEM, V267, P9210
   Xu YY, 2001, IMMUNOL REV, V180, P123, DOI 10.1034/j.1600-065X.2001.1800111.x
   YAMAUCHI Y, 1994, J IMMUNOL, V152, P3645
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 32
TC 68
Z9 80
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2011
VL 52
IS 12
BP 8828
EP 8834
DI 10.1167/iovs.11-7933
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 856IB
UT WOS:000297631400012
PM 22003108
OA Green Published
DA 2022-11-30
ER

PT J
AU Rowan, S
   Taylor, A
AF Rowan, Sheldon
   Taylor, Allen
TI Gut microbiota modify risk for dietary glycemia-induced age-related
   macular degeneration
SO GUT MICROBES
LA English
DT Article
DE Age-related macular degeneration; glycemic index; gut microbiome;
   microbial cometabolite; biomarker
ID NATURAL-HISTORY; INDEX; METABOLISM; OBESITY; HEALTH
AB Age-related macular degeneration (AMD) is a leading cause of blindness world-wide. Although the etiology of AMD is multifactorial, diet and nutrition have strong epidemiologic associations with disease onset and progression. Recent studies indicate a role for gut microbiota in development of AMD in mouse models and in some forms of human AMD. We previously found that consuming lower glycemia diets is associated with protection against AMD in humans and switching from higher to lower glycemia diets arrests AMD phenotypes in mice. Gut microbiota populations and circulating microbial cometabolites were altered in response to dietary carbohydrates, indicating a gut-retina axis. Here we explore additional gut microbiota-AMD interactions that point toward pathogenic roles for some gut microbiota families, including Ruminococcaceae and Lachnospiraceae, and individual members of Turicibacteraceae, Clostridiaceae, and Mogibacteriaceae. We also speculate on potential mechanisms by which gut microbiota influence AMD, with the objective of devising new AMD diagnoses and treatments.
C1 [Rowan, Sheldon; Taylor, Allen] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Rowan, S (通讯作者)，711 Washington St, Boston, MA 02111 USA.
EM Sheldon.rowan@tufts.edu
RI Rowan, Sheldon/AAA-3271-2019
OI Rowan, Sheldon/0000-0002-1123-6743
FU HHS \ NIH \ National Eye Institute (NEI) [EY13250, EY021212, EY026979];
   U.S. Department of Agriculture (USDA) [58-1950-0-014, 58-1950-4-003];
   USDA \ National Institute of Food and Agriculture (NIFA) [2015-05470];
   NATIONAL EYE INSTITUTE [R01EY026979] Funding Source: NIH RePORTER
FX This work was supported by the HHS broken vertical bar NIH broken
   vertical bar National Eye Institute (NEI) (EY13250) U.S. Department of
   Agriculture (USDA) (58-1950-0-014) U.S. Department of Agriculture (USDA)
   (58-1950-4-003) USDA broken vertical bar National Institute of Food and
   Agriculture (NIFA) (2015-05470) HHS broken vertical bar NIH broken
   vertical bar National Eye Institute (NEI) (EY021212) HHS broken vertical
   bar NIH broken vertical bar National Eye Institute (NEI) (EY026979).
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   ALWAIZ M, 1992, METABOLISM, V41, P135, DOI 10.1016/0026-0495(92)90140-6
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Atkinson FS, 2008, DIABETES CARE, V31, P2281, DOI 10.2337/dc08-1239
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035
   Diaz E, 2001, MICROBIOL MOL BIOL R, V65, P523, DOI 10.1128/MMBR.65.4.523-569.2001
   Donohoe DR, 2011, CELL METAB, V13, P517, DOI 10.1016/j.cmet.2011.02.018
   Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145
   Lees HJ, 2013, J PROTEOME RES, V12, P1527, DOI 10.1021/pr300900b
   Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889
   Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Schroeder B, 2016, NAT MED, V22, P1079, DOI 10.1038/nm.4185
   Shreiner AB, 2015, CURR OPIN GASTROEN, V31, P69, DOI 10.1097/MOG.0000000000000139
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106
   Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047
   Yap IKS, 2008, J PROTEOME RES, V7, P3718, DOI 10.1021/pr700864x
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 25
TC 18
Z9 22
U1 4
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1949-0976
EI 1949-0984
J9 GUT MICROBES
JI Gut Microbes
PY 2018
VL 9
IS 5
BP 452
EP 457
DI 10.1080/19490976.2018.1435247
PG 6
WC Gastroenterology & Hepatology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Microbiology
GA HJ1BI
UT WOS:000456896500005
PM 29431583
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Varadaraj, V
   Mihailovic, A
   Ehrenkranz, R
   Lesche, S
   Ramulu, PY
   Swenor, BK
AF Varadaraj, Varshini
   Mihailovic, Aleksandra
   Ehrenkranz, Rebecca
   Lesche, Stephen
   Ramulu, Pradeep Y.
   Swenor, Bonnielin K.
TI Gait Characteristics of Age-Related Macular Degeneration Patients
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; gait; walking; mobility performance
ID OLDER-ADULTS; VISUAL IMPAIRMENT; WATERLOO VISION; INJURIOUS FALLS;
   RISK-FACTORS; MOBILITY; MACULOPATHY; PEOPLE; INDIVIDUALS; ADAPTATION
AB Purpose: To identify potential differences between age-related macular degeneration (AMD) patients and controls in fall-relevant gait characteristics.
   Methods: Spatiotemporal gait characteristics using the GAITRite walkway were collected from 29 AMD patients and 20 controls, aged 60 to 90 years, at the Wilmer Eye Institute. Multiple linear regressions, controlling for age, sex, body mass index (BMI), and comorbidities were used to assess associations between gait characteristics and AMD.
   Results: Study participants were predominantly white (86%) and female (55%). Mean age of the full study population was 73.51 (SD: 8.14) years, and mean BMI was 27.80 (SD: 5.44) kg/m(2). Median better-eye acuity (logMAR) was 0.23 (interquartile range [IQR] = 0.18, 0.36) and - 0.02 (IQR = - 0.08, 0.02), while median binocular log contrast sensitivity was 1.44 (IQR = 1.32, 1.56) and 1.76 (IQR = 1.76, 1.80) for the AMD and control groups, respectively. In multivariable regression models, AMD patients had significantly slower walking speeds (beta = - 0.118 m/sec [95% confidence interval (CI): - 0.229, - 0.007], P = 0.038) and stride velocities (beta = - 0.119 m/sec [95% CI: - 0.232, - 0.007], P = 0.038), and greater double support time (beta = 3.381% of the walk cycle, 95% CI = 1.006, 5.757, P = 0.006) than controls. There were no group differences in base of support, step length, stride length, or gait variability measures.
   Conclusion: AMD patients exhibited many fall-relevant gait characteristics.
   Translational Relevance: The finding of fall-relevant gait characteristics suggests that AMD patients may be at a greater risk of falls during ambulation than those without AMD.
C1 [Varadaraj, Varshini; Mihailovic, Aleksandra; Ehrenkranz, Rebecca; Lesche, Stephen; Ramulu, Pradeep Y.; Swenor, Bonnielin K.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Swenor, BK (通讯作者)，600 N Wolfe St, Baltimore, MD 21287 USA.
EM bswenor@jhmi.edu
RI Ehrenkranz, Rebecca/GLR-9423-2022; Swenor, Bonnie/ABH-1542-2021
OI Swenor, Bonnie/0000-0002-6044-0951; Ehrenkranz,
   Rebecca/0000-0003-2810-6045
FU Foundation Fighting Blindness
FX Supported by grants from Foundation Fighting Blindness.
CR Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893
   Hill K, 1999, AUST NZ J PUBL HEAL, V23, P41, DOI 10.1111/j.1467-842X.1999.tb01203.x
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jorgensen T, 2001, ANN PHARMACOTHER, V35, P1004, DOI 10.1345/aph.10351
   KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Linjakumpu T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0
   Lord SR, 1996, AGE AGEING, V25, P292, DOI 10.1093/ageing/25.4.292
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Lord SR, 2010, CLIN GERIATR MED, V26, P569, DOI 10.1016/j.cger.2010.06.002
   Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x
   Morrison A, 2013, CLINICOECONOMIC OUTC, V5, P9, DOI 10.2147/CEOR.S38721
   National Eye Institute (NEI), 2010, US AG SPCE PREV RAT
   Patino CM, 2010, OPHTHALMOLOGY, V117, P199, DOI 10.1016/j.ophtha.2009.06.063
   Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, P1159, DOI 10.1016/j.ophtha.2012.01.013
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881
   Wilcox D T, 1989, J Am Optom Assoc, V60, P504
   WOLFSON L, 1990, J GERONTOL, V45, pM12, DOI 10.1093/geronj/45.1.M12
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Woollacott MH, 1997, PHYS THER, V77, P646, DOI 10.1093/ptj/77.6.646
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2017
VL 6
IS 4
AR 13
DI 10.1167/tvst.6.4.13
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FH2HH
UT WOS:000410959300013
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Varadaraj, V
   Mihailovic, A
   Ehrenkranz, R
   Lesche, S
   Ramulu, PY
   Swenor, BK
AF Varadaraj, Varshini
   Mihailovic, Aleksandra
   Ehrenkranz, Rebecca
   Lesche, Stephen
   Ramulu, Pradeep Y.
   Swenor, Bonnielin K.
TI Gait Characteristics of Age-Related Macular Degeneration Patients
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; gait; walking mobility performance
ID OLDER-ADULTS; VISUAL IMPAIRMENT; WATERLOO VISION; INJURIOUS FALLS;
   MOBILITY; RISK; MACULOPATHY; INDIVIDUALS; ADAPTATION; PEOPLE
AB Purpose: To identify potential differences between age-related macular degeneration (AMD) patients and controls in fall-relevant gait characteristics.
   Methods: Spatiotemporal gait characteristics using the GAITRite walkway were collected from 29 AMD patients and 20 controls, aged 60 to 90 years, at the Wilmer Eye Institute. Multiple linear regressions, controlling for age, sex, body mass index (BMI), and comorbidities were used to assess associations between gait characteristics and AMD.
   Results: Study participants were predominantly white (86%) and female (55%). Mean age of the full study population was 73.51 (SD: 8.14) years, and mean BMI was 27.80 (SD: 5.44) kg/m(2). Median better-eye acuity (logMAR) was 0.23 (interquartile range [IQR] = 0.18, 0.36) and -0.02 (IQR = -0.08, 0.02), while median binocular log contrast sensitivity was 1.44 (IQR = 1.32, 1.56) and 1.76 (IQR = 1.76, 1.80) for the AMD and control groups, respectively. In multivariable regression models, AMD patients had significantly slower walking speeds (beta = -0.118 m/sec [95% confidence interval (CI): -0.229, -0.007], P = 0.038) and stride velocities (beta = -0.119 m/sec [95% CI: -0.232, -0.007], P = 0.038), and greater double support time (beta = 3.381% of the walk cycle, 95% CI = 1.006, 5.757, P = 0.006) than controls. There were no group differences in base of support, step length, stride length, or gait variability measures.
   Conclusion: AMD patients exhibited many fall-relevant gait characteristics.
   Translational Relevance: The finding of fall-relevant gait characteristics suggests that AMD patients may be at a greater risk of falls during ambulation than those without AMD.
C1 [Varadaraj, Varshini; Mihailovic, Aleksandra; Ehrenkranz, Rebecca; Lesche, Stephen; Ramulu, Pradeep Y.; Swenor, Bonnielin K.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Swenor, BK (通讯作者)，600 N Wolfe St, Baltimore, MD 21287 USA.
EM bswenor@jhmi.edu
RI Swenor, Bonnie/ABH-1542-2021
OI Swenor, Bonnie/0000-0002-6044-0951
FU Foundation Fighting Blindness
FX Supported by grants from Foundation Fighting Blindness.
CR Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P733
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893
   Hill K, 1999, AUST NZ J PUBL HEAL, V23, P41, DOI 10.1111/j.1467-842X.1999.tb01203.x
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jorgensen T, 2001, ANN PHARMACOTHER, V35, P1004, DOI 10.1345/aph.10351
   KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x
   Kuyk T, 1999, J REHABIL RES DEV, V36, P303
   Linjakumpu T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0
   Lord SR, 1996, AGE AGEING, V25, P292, DOI 10.1093/ageing/25.4.292
   Lord SR, 2010, CLIN GERIATR MED, V26, P569, DOI 10.1016/j.cger.2010.06.002
   Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x
   Morrison A, 2013, CLINICOECONOMIC OUTC, V5, P9, DOI 10.2147/CEOR.S38721
   National Eye Institute (NEI), 2010 US AG SPEC PREV
   Patino CM, 2010, OPHTHALMOLOGY, V117, P199, DOI 10.1016/j.ophtha.2009.06.063
   Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, P1159, DOI 10.1016/j.ophtha.2012.01.013
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SPAULDING SJ, 1995, GAIT POSTURE, V3, P227
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881
   Wilcox D T, 1989, J Am Optom Assoc, V60, P504
   WOLFSON L, 1990, J GERONTOL, V45, pM12, DOI 10.1093/geronj/45.1.M12
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Woollacott MH, 1997, PHYS THER, V77, P646, DOI 10.1093/ptj/77.6.646
NR 35
TC 4
Z9 4
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2017
VL 6
IS 4
AR 14
DI 10.1167/tvst.6.4.14
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA FH2HH
UT WOS:000410959300014
PM 28781927
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hatz, K
   Prunte, C
AF Hatz, Katja
   Prunte, Christian
TI INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
   WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aflibercept; ranibizumab; treat-and-extend; anti-VEGF; neovascular
   age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-VEGF AGENTS; ANATOMICAL OUTCOMES; DOSING
   REGIMEN; EYES; BEVACIZUMAB; INJECTION; TRAP; THERAPY
AB Purpose: To evaluate aflibercept treat-and-extend regimen for treatment of neovascular age-related macular degeneration in patients with limited response to ranibizumab.
   Methods: This prospective single-arm trial included 33 patients with neovascular age-related macular degeneration pretreated with treat-and-extend regimen ranibizumab for >= 6 months who failed to be extended to a 6-week interval at least twice. All patients received aflibercept (2 mg/0.05 mL) at baseline, and were subsequently treated according to treat-and-extend regimen, starting with a 4-week interval and extending in 2-week steps. Evaluations included mean maximum recurrence-free treatment interval; best-corrected visual acuity; central retinal thickness; and pigment epithelium detachment height and horizontal diameter.
   Results: At Week 24, the maximum recurrence-free treatment interval increased to >= 6 weeks in similar to 35% of patients, whereas the mean interval was 4.9 +/- 1.3 weeks. Best-corrected visual acuity score remained stable, but significant reductions in central retinal thickness (P < 0.001) and pigment epithelium detachment height (P = 0.001) were observed compared with baseline, as was a small decrease in horizontal pigment epithelium detachment diameter (P = 0.035).
   Conclusion: After switching patients with limited ranibizumab response to aflibercept, signs of choroidal neovascularization activity regressed, and an increased duration of treatment effects was seen in approximately one-third of lesions, but visual acuity was unchanged.
C1 [Hatz, Katja; Prunte, Christian] Vista Klin, Dept Ophthalmol, Binningen, Switzerland.
   [Hatz, Katja; Prunte, Christian] Univ Basel, Basel, Switzerland.
   [Hatz, Katja; Prunte, Christian] Eye Clin, Dept Ophthalmol, Kantonsspital Baselland, Liestal, Switzerland.
C3 University of Basel; Kantonsspital Baselland
RP Prunte, C (通讯作者)，Kantonsspital Baselland, Dept Ophthalmol, Rheinstr 26, CH-4410 Liestal, Switzerland.
EM office@pruente.ch
FU Bayer Switzerland
FX This study was in part supported by Bayer Switzerland. Medical writing
   support was provided by Samuel Cooper, PhD, of Inspired Science, London,
   United Kingdom.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Augustin AJ., 2012, CLIN PRACT, V9, P149
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Batioglu F, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0025-z
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   He LM, 2016, RETINA-J RET VIT DIS, V36, P492, DOI 10.1097/IAE.0000000000000749
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rezaei KA, 2015, 2015 GLOBAL TRENDS R
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
NR 45
TC 9
Z9 10
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2017
VL 37
IS 6
BP 1185
EP 1192
DI 10.1097/IAE.0000000000001318
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0KL
UT WOS:000402179100038
PM 27652915
DA 2022-11-30
ER

PT J
AU Sasahara, M
   Tsujikawa, A
   Musashi, K
   Gotoh, N
   Otani, A
   Mandai, M
   Yoshimura, N
AF Sasahara, Manabu
   Tsujikawa, Akitaka
   Musashi, Kunihiro
   Gotoh, Norimoto
   Otani, Atsushi
   Mandai, Michiko
   Yoshimura, Nagahisa
TI Polypoidal choroidal vasculopathy with choroidal vascular
   hyperpermeability
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   ANGIOGRAPHY
AB PURPOSE: To describe the incidence and clinical characteristics of polypoidal choroidal vasculopathy (PCV) associated with choroidal vascular hyperpermeability.
   DESIGN: Retrospective observational case series.
   METHODS: We reviewed the medical records of 122 consecutive eyes with PCV and 106 consecutive eyes with exudative age,related macular degeneration (AMD). Fluorescein angiography and indocyanine green (ICG) angiography were performed using a confocal scanning laser system. In the midphase of ICG angiography, we evaluated choroidal vascular hyperpermeability, which is recognized as one of the characteristic findings in central serous chorioretinopathy (CSC). Choroidal vascular hyperpermeability appeared as multifocal patchy areas of hyperfluorescence with blurred margins within the choroid that increased in intensity with time after injection of the dye.
   RESULTS: Of 122 eyes with PCV, 12 (9.8%) eyes of 10 patients exhibited multifocal choroidal hyperfluorescence in the midphase of ICG angiography, whereas two (1.9%) of 106 eyes with exudative AMD showed a similar appearance (P = .013). Of the 12 eyes in 10 patients with PCV that demonstrated multifocal choroidal hyperfluorescence, we also noted that the early phase of ICG angiography showed choroidal filling delay in seven eyes (58%) and venous dilation in 12 eyes (100%). Four of these 12 eyes (33%) had a medical history of CSC, and nine (90%) of the 10 patients revealed multifocal choroidal hyperfluorescence bilaterally.
   CONCLUSIONS: Multifocal choroidal hyperfluorescence seen by ICG angiography occurs more frequently in eyes with PCV than in those with AMD. Choroidal vascular hyperpermeability, reportedly a characteristic finding in CSC, might be one of the risk factors of PCV.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068386, Japan.
C3 Kyoto University
RP Sasahara, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, 54 Shogoin Kawahara Cho, Kyoto 6068386, Japan.
EM sasahara@kuhp.kyoto-u.ac.jp
RI Mandai, Michiko/E-7986-2011
OI Tsujikawa, Akitaka/0000-0003-0779-7799
CR GASS JDM, 1991, ARCH OPHTHALMOL-CHIC, V109, P677, DOI 10.1001/archopht.1991.01080050091036
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   HAYASHI K, 1986, INT OPHTHALMOL, V9, P37
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Iida Tomohiro, 1994, Japanese Journal of Clinical Ophthalmology, V48, P1583
   Karadimas P, 2004, GRAEF ARCH CLIN EXP, V242, P800, DOI 10.1007/s00417-004-0885-z
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Michael JC, 2003, AM J OPHTHALMOL, V136, P182, DOI 10.1016/S0002-9394(03)00076-X
   Okushiba Utako, 1997, Nippon Ganka Gakkai Zasshi, V101, P74
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   PRUNTE C, 1995, INT OPHTHALMOL, V19, P77, DOI 10.1007/BF00133176
   SCHEIDER A, 1993, AM J OPHTHALMOL, V115, P50, DOI 10.1016/S0002-9394(14)73524-X
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   SPAIDE RF, 2004, MED RETINA, P77
   Steinle JJ, 2000, AM J PHYSIOL-REG I, V279, pR202, DOI 10.1152/ajpregu.2000.279.1.R202
   Sun Jinghua, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P313
   Tamakoshi A., 1992, CASE CONTROL STUDY S, P134
   Tittl MK, 1999, AM J OPHTHALMOL, V128, P63, DOI 10.1016/S0002-9394(99)00075-6
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi L A, 1986, Trans Am Ophthalmol Soc, V84, P799
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   YOSHIOKA H, 1991, Nippon Ganka Gakkai Zasshi, V95, P1181
NR 30
TC 144
Z9 157
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2006
VL 142
IS 4
BP 601
EP 607
DI 10.1016/j.ajo.2006.05.051
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 092LS
UT WOS:000241098900011
PM 17011852
DA 2022-11-30
ER

PT J
AU Kim, J
   Park, JR
   Choi, J
   Park, I
   Hwang, Y
   Bae, H
   Kim, Y
   Choi, W
   Yan, JM
   Han, S
   Chung, TY
   Kim, P
   Kubota, Y
   Augustin, HG
   Oh, WY
   Koh, GY
AF Kim, Jaeryung
   Park, Jang Ryul
   Choi, Jeongwoon
   Park, Intae
   Hwang, Yoonha
   Bae, Hosung
   Kim, Yongjoo
   Choi, WooJhon
   Yan, Jee Myung
   Han, Sangyeul
   Chung, Tae-Young
   Kim, Pilhan
   Kubota, Yoshiaki
   Augustin, Hellmut G.
   Oh, Wang-Yuhl
   Koh, Gou Young
TI Tie2 activation promotes choriocapillary regeneration for alleviating
   neovascular age-related macular degeneration
SO SCIENCE ADVANCES
LA English
DT Article
ID SUPPRESSES CHOROIDAL NEOVASCULARIZATION; INTRAOCULAR-PRESSURE;
   BLOOD-FLOW; ANGIOGENESIS; GROWTH; MODEL; VEGF; MICE; ANGIOPOIETIN-1;
   BREAKDOWN
AB Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. In this study, Tie2 activation by angiopoietin-2-binding and Tie2-activating antibody (ABTAA) presents a therapeutic strategy for NV-AMD. Conditional Tie2 deletion impeded choriocapillary maintenance, rendering eyes susceptible to NV-AMD development. Moreover, in a NV-AMD mouse model, ABTAA not only suppressed choroidal neovascularization (CNV) and vascular leakage but also regenerated the choriocapillaris and relieved hypoxia. Conversely, VEGF blockade degenerated the choriocapillaris and exacerbated hypoxia, although it suppressed CNV and vascular leakage. Together, we establish that angiopoietin-Tie2 signaling is critical for choriocapillary maintenance and that ABTAA represents an alternative, combinative therapeutic strategy for NV-AMD by alleviating anti-VEGF adverse effects.
C1 [Kim, Jaeryung; Choi, Jeongwoon; Park, Intae; Bae, Hosung; Han, Sangyeul; Koh, Gou Young] Inst for Basic Sci Korea, Ctr Vasc Res, Daejeon 34141, South Korea.
   [Kim, Jaeryung; Choi, Jeongwoon; Park, Intae; Bae, Hosung; Yan, Jee Myung; Koh, Gou Young] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon 34141, South Korea.
   [Kim, Jaeryung; Chung, Tae-Young] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul 06351, South Korea.
   [Park, Jang Ryul; Kim, Yongjoo; Oh, Wang-Yuhl] Korea Adv Inst Sci & Technol, Dept Mech Engn, Daejeon 34141, South Korea.
   [Park, Jang Ryul; Hwang, Yoonha; Kim, Yongjoo; Choi, WooJhon; Kim, Pilhan; Oh, Wang-Yuhl] Korea Adv Inst Sci & Technol, KIHST, Daejeon 34141, South Korea.
   [Hwang, Yoonha; Kim, Pilhan] Korea Adv Inst Sci & Technol, Grad Sch Nanosci & Technol, Daejeon 34141, South Korea.
   [Kubota, Yoshiaki] Keio Univ, Sch Med, Lab Vasc Biol, Tokyo 1608582, Japan.
   [Augustin, Hellmut G.] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, D-68167 Mannheim, Germany.
   [Augustin, Hellmut G.] DKFZ ZMBH Alliance, German Canc Res Ctr, Div Vasc Oncol & Metastasis, D-69121 Heidelberg, Germany.
C3 Institute for Basic Science - Korea (IBS); Korea Advanced Institute of
   Science & Technology (KAIST); Sungkyunkwan University (SKKU); Samsung
   Medical Center; Korea Advanced Institute of Science & Technology
   (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Korea
   Advanced Institute of Science & Technology (KAIST); Keio University;
   Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ)
RP Koh, GY (通讯作者)，Inst for Basic Sci Korea, Ctr Vasc Res, Daejeon 34141, South Korea.; Koh, GY (通讯作者)，Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon 34141, South Korea.; Oh, WY (通讯作者)，Korea Adv Inst Sci & Technol, Dept Mech Engn, Daejeon 34141, South Korea.; Oh, WY (通讯作者)，Korea Adv Inst Sci & Technol, KIHST, Daejeon 34141, South Korea.
EM woh1@kaist.ac.kr; gykoh@kaist.ac.kr
RI Kim, Jaeryung/AAB-6693-2022; Augustin, Hellmut/AAA-5246-2020
OI Augustin, Hellmut/0000-0002-7173-4242; Bae, Hosung/0000-0001-5848-7972;
   Yang, Jee Myung/0000-0001-5729-2233; Hwang, Yoonha/0000-0002-0574-1372;
   Han, Sangyeul/0000-0002-2762-6340; Kim, Jaeryung/0000-0002-8003-5849
FU Institute for Basic Science - Ministry of Science and ICT, Republic of
   Korea [IBS-R025-D1-2015]; National Research Foundation of Korea
   [2016M3C7A1913844]; Ministry of Health and Welfare of Republic of Korea
   [HI15C0001]
FX This study was supported by grants from the Institute for Basic Science
   (IBS-R025-D1-2015 to G.Y.K) funded by the Ministry of Science and ICT,
   Republic of Korea, from the National Research Foundation of Korea
   (2016M3C7A1913844 to W.-Y.O), and from the Ministry of Health and
   Welfare of Republic of Korea (HI15C0001 to W.-Y.O.).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arita Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5552
   Augustin HG, 2017, SCIENCE, V357, DOI 10.1126/science.aal2379
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blazek JD, 2010, DEV DYNAM, V239, P1645, DOI 10.1002/dvdy.22295
   Cavallotti C, 2005, J ANAT, V206, P243, DOI 10.1111/j.1469-7580.2005.00389.x
   Chan-Ling T, 2011, INVEST OPHTH VIS SCI, V52, P399, DOI 10.1167/iovs.10-5403
   Cone FE, 2012, EXP EYE RES, V99, P27, DOI 10.1016/j.exer.2012.04.006
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guizar-Sicairos M, 2008, OPT LETT, V33, P156, DOI 10.1364/OL.33.000156
   Han S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9260
   Hayashi M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2683
   Higgins SJ, 2018, J CLIN INVEST, V128, P1471, DOI 10.1172/JCI97488
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kenig-Kozlovsky Y, 2018, J AM SOC NEPHROL, V29, P1097, DOI 10.1681/ASN.2017090962
   Khawaja AP, 2018, NAT GENET, V50, P778, DOI 10.1038/s41588-018-0126-8
   Kim J, 2017, J CLIN INVEST, V127, P3447, DOI 10.1172/JCI93825
   Koh G. Y., TRENDS MOL MED
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee JY, 2016, INVEST OPHTH VIS SCI, V57, P3390, DOI 10.1167/iovs.15-18862
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Long D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120231
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mazzieri R, 2011, CANCER CELL, V19, P512, DOI 10.1016/j.ccr.2011.02.005
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Morgan JE, 2015, EXP EYE RES, V141, P9, DOI 10.1016/j.exer.2015.06.020
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Park JR, 2016, INVEST OPHTH VIS SCI, V57, pOCT331, DOI 10.1167/iovs.15-18946
   Park JS, 2016, CANCER CELL, V30, P953, DOI 10.1016/j.ccell.2016.10.018
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   Ratner M, 2014, NAT BIOTECHNOL, V32, P701, DOI 10.1038/nbt0814-701
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Savant S, 2015, CELL REP, V12, P1761, DOI 10.1016/j.celrep.2015.08.024
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thomson BR, 2017, J CLIN INVEST, V127, P4421, DOI 10.1172/JCI95545
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zhi ZW, 2012, BIOMED OPT EXPRESS, V3, P2220, DOI 10.1364/BOE.3.002220
   Zhou BO, 2015, ELIFE, V4, DOI 10.7554/eLife.05521
NR 54
TC 28
Z9 29
U1 0
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD FEB
PY 2019
VL 5
IS 2
AR eaau6732
DI 10.1126/sciadv.aau6732
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HN4HT
UT WOS:000460145700030
PM 30788433
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, L
   Packer, TL
   Tang, SH
   Girdler, S
AF Lee, Lily
   Packer, Tanya L.
   Tang, Seok Hun
   Girdler, Sonya
TI Self-management education programs for age-related macular degeneration:
   A systematic review
SO AUSTRALASIAN JOURNAL ON AGEING
LA English
DT Review
DE health education; macular degeneration; older adults; self-management;
   systematic review
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; VISUAL IMPAIRMENT; ELDERLY
   PERSONS; INTERVENTION
AB Objective: To review the effectiveness of education programs to improve emotional status, daily living and self-efficacy in adults older than 60 years with age-related macular degeneration (AMD).
   Method: Electronic searches of three databases and manual searches of references lists located randomised controlled trials (RCTs) and quasi-experimental studies. Health education programs aimed at increasing knowledge of AMD, skills training or behavioural change were included. Data extraction and quality assessment were undertaken by two reviewers. A narrative analysis was possible.
   Results: Three protocols were reported in four studies (n = 532) with three follow-up studies - all contained elements of self-management programs. Effect sizes for the three outcomes ranged from small to very large (0.14-1.21).
   Conclusions: Self-management programs appear effective for older adults with AMD. Small sample size, use of non-traditional statistics and methodological quality meant only a narrative analysis was possible. Future studies with more robust methodology including intent-to-treat analysis are still required.
C1 [Lee, Lily; Packer, Tanya L.; Girdler, Sonya] Curtin Univ Technol, Sch Occupat Therapy, Ctr Res Disabil & Soc, Perth, WA, Australia.
   [Lee, Lily; Tang, Seok Hun] Royal Perth Hosp, Perth, WA, Australia.
   [Packer, Tanya L.] Assoc Blind Western Australia, Perth, WA, Australia.
C3 Curtin University; Royal Perth Hospital; University of Western Australia
RP Packer, TL (通讯作者)，Curtin Univ Technol, Sch Occupat Therapy, Ctr Res Disabil & Soc, Perth, WA, Australia.
EM T.Packer@exchange.curtin.edu.au
RI Lee, Lily/GWZ-7968-2022; Girdler, Sonya/ABC-9629-2021
OI Girdler, Sonya/0000-0001-7992-0800; Packer, Tanya/0000-0003-4831-7691
CR Access Economics, 2004, ACC EC CLEAR INS EC
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Crews J. E., 2000, LIGHTHOUSE HDB VISIO, P1287
   Dahlin-Ivanoff S, 2001, DISABIL REHABIL, V23, P69
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   DAHLINIVANOFF S, 2000, SCANDINAVIAN J OCCUP, V7, P148, DOI DOI 10.1080/110381200300008689
   DAHLINIVANOFF S, 1996, DISABILITY REHABILIT, V18, P515
   Eklund K, 2005, DISABIL REHABIL, V27, P1203, DOI 10.1080/09638280500052716
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   Ferraro JG, 2006, OPHTHAL EPIDEMIOL, V13, P127, DOI 10.1080/09286580500545717
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Higgins JPT, 2005, COCHRANE LIB
   Horowitz A, 2004, TOP GERIATR REHABIL, V20, P185
   Ivanoff SD, 2002, AM J OCCUP THER, V56, P322, DOI 10.5014/ajot.56.3.322
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Kmet L.M., STANDARD QUALITY ASS
   National Health and Medical Research Council (NHMRC), 1999, GUID DEV IMPL EV CLI
   *NORD COCHR CTR CO, 2003, COCHR LIB REV MAN RE
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Russell W, 2001, OPHTHAL PHYSL OPT, V21, P36, DOI 10.1046/j.1475-1313.2001.00569.x
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Stone TW, 2001, SOUTHERN MED J, V94, P22
   Thalheimer W, 2002, CALCULATE EFFECT SIZ
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 30
TC 84
Z9 84
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1440-6381
EI 1741-6612
J9 AUSTRALAS J AGEING
JI Australas. Ageing
PD DEC
PY 2008
VL 27
IS 4
BP 170
EP 176
DI 10.1111/j.1741-6612.2008.00298.x
PG 7
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 365ZX
UT WOS:000260450000001
PM 19032617
DA 2022-11-30
ER

PT J
AU Joachim, N
   Mitchell, P
   Burlutsky, G
   Kifley, A
   Wang, JJ
AF Joachim, Nichole
   Mitchell, Paul
   Burlutsky, George
   Kifley, Annette
   Wang, Jie Jin
TI The Incidence and Progression of Age-Related Macular Degeneration over
   15 Years The Blue Mountains Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM-EYE; 5-YEAR INCIDENCE; CHOROIDAL NEOVASCULARIZATION;
   INFLAMMATORY MARKERS; VISUAL IMPAIRMENT; 10-YEAR INCIDENCE; GRADING
   SYSTEM; RISK-FACTORS; MACULOPATHY; POPULATION
AB Purpose: To assess the 15-year incidence and progression of age-related macular degeneration (AMD) in an older Australian population.
   Design: Population-based cohort study.
   Participants: Blue Mountains Eye Study (BMES) participants (n = 3654) aged 49+ years were examined during 1992-1994. Of these, 2334 (75.8% of survivors) were reexamined after 5 years (1997-1999), 1952 (76.7% of survivors) after 10 years (2002-2004), and 1149 (56.1% of survivors) after 15 years (2007-2010).
   Methods: Color retinal photographs were taken, and comprehensive questionnaires were administered at each visit and DNA was genotyped. Retinal photographic grading was performed by the same graders following the Wisconsin AMD grading protocol. Side-by-side comparisons were used to confirm newly developed AMD lesions. Incidence was estimated using KaplaneMeier estimates. Associations of AMD incidence with age, sex, smoking status, presence of the complement factor H (CFH)-rs1061170 and age-related maculopathy susceptibility 2 (ARMS2)-rs10490924 polymorphisms, and fish consumption were analyzed using discrete logistic regression models. Generalized estimation equation models were used to assess the risk of incident late AMD associated with baseline AMD lesion characteristics.
   Main Outcome Measures: The 15-year incidence and progression of AMD, and associated factors.
   Results: The 15-year incidence was 22.7% for early AMD and 6.8% for late AMD. After adjusting for competing risks, early and late AMD incidence were 15.1% and 4.1%, respectively. Age was strongly associated with early and lateAMD incidence (both P<0.0001). After age standardization to the Beaver Dam Eye Study (BDES) population, early and late AMD incidence in the BMES were 13.1% and 3.3%, respectively. Female sex and the presence of both risk alleles of CFH-rs1061170 or ARMS2-rs10490924 were independently associated with early AMD incidence, whereas current smoking and presence of >= 1 risk allele of CFH-rs1061170 or ARMS2-rs10490924 were associated with late AMD incidence. Fish consumption was inversely associated with late but not early AMD incidence. Severity of early AMD lesion characteristics was a strong predictor of progression to late AMD.
   Conclusions: We documented the 15-year incidence of early and late AMD in an older Australian population that were comparable to BDES observations. Risk of progression to late AMD was strongly associated with severity of early AMD lesions. (C) 2015 by the American Academy of Ophthalmology.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2006, Australia.
   Univ Sydney, Westmead Millennium Inst Med Res, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney
RP Wang, JJ (通讯作者)，Univ Sydney, Ctr Vis Res, Westmead Millennium Inst Med Res, Westmead, NSW 2145, Australia.
EM jiejin.wang@sydney.edu.au
RI Mitchell, Paul/P-1498-2014; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022
OI Wang, Jie Jin/0000-0001-9491-4898; 
FU National Health and Medical Research Council, Australia [974159, 211069,
   457349, 512423]
FX Supported by the National Health and Medical Research Council, Australia
   (Grants 974159, 211069, 457349, 512423), which had no role in the design
   or conduct of this research.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hong T, 2013, OPHTHALMOLOGY, V120, P2091, DOI 10.1016/j.ophtha.2013.03.032
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   The GENMOD Procedure, 2004, GENMOD PROC
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 32
TC 104
Z9 105
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2015
VL 122
IS 12
BP 2482
EP 2489
DI 10.1016/j.ophtha.2015.08.002
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4EZ
UT WOS:000367057500027
PM 26383995
DA 2022-11-30
ER

PT J
AU Yang, M
   So, KF
   Lam, WC
   Lo, ACY
AF Yang, Ming
   So, Kwok-Fai
   Lam, Wai Ching
   Lo, Amy Cheuk Yin
TI Novel Programmed Cell Death as Therapeutic Targets in Age-Related
   Macular Degeneration?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retina; vision; ocular stress; cell damage; homeostasis
ID PIGMENT EPITHELIAL-CELLS; NLRP3 INFLAMMASOME ACTIVATION; ENDOTHELIAL
   GROWTH-FACTOR; OXIDATIVE STRESS; AMYLOID-BETA; ABDOMINAL OBESITY; EYE
   DISEASE; RPE CELL; NECROPTOSIS; PYROPTOSIS
AB Age-related macular degeneration (AMD) is a leading cause of severe visual loss among the elderly. AMD patients are tormented by progressive central blurring/loss of vision and have limited therapeutic options to date. Drusen accumulation causing retinal pigment epithelial (RPE) cell damage is the hallmark of AMD pathogenesis, in which oxidative stress and inflammation are the well-known molecular mechanisms. However, the underlying mechanisms of how RPE responds when exposed to drusen are still poorly understood. Programmed cell death (PCD) plays an important role in cellular responses to stress and the regulation of homeostasis and diseases. Apart from the classical apoptosis, recent studies also discovered novel PCD pathways such as pyroptosis, necroptosis, and ferroptosis, which may contribute to RPE cell death in AMD. This evidence may yield new treatment targets for AMD. In this review, we summarized and analyzed recent advances on the association between novel PCD and AMD, proposing PCD's role as a therapeutic new target for future AMD treatment.
C1 [Yang, Ming; So, Kwok-Fai; Lam, Wai Ching; Lo, Amy Cheuk Yin] Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China.
   [So, Kwok-Fai] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Lam, WC; Lo, ACY (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China.
EM hrmeym@hku.hk; hrmaskf@hku.hk; waichlam@hku.hk; amylo@hku.hk
RI Lo, Amy C. Y./C-1195-2009
OI Lo, Amy C. Y./0000-0003-4239-6851; Lam, Wai-Ching/0000-0003-2057-9374;
   So, Kwok-Fai/0000-0003-4039-4246
FU Albert Bing-Ching Young Professorship Endowment in Ophthalmology; Health
   and Medical Research Fund, the Food and Health Bureau, The Government of
   the Hong Kong Special Administrative Region [06171516]; General Research
   Fund, Research Grants Council, The Government of the Hong Kong Special
   Administrative Region [17112919]
FX This study is supported by Albert Bing-Ching Young Professorship
   Endowment in Ophthalmology to WC Lam; Health and Medical Research Fund,
   the Food and Health Bureau, The Government of the Hong Kong Special
   Administrative Region (06171516) and General Research Fund, Research
   Grants Council, The Government of the Hong Kong Special Administrative
   Region (17112919) to ACY Lo.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonilha VL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.15
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cabral T., 2017, INT J RETINA VITREOU, V3, P31, DOI [10.1186/s40942-017-0084-9, DOI 10.1186/S40942-017-0084-9]
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chakravarthy U, 2013, OPHTHALMOLOGY, V120, P342, DOI 10.1016/j.ophtha.2012.08.004
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen X, 2020, FEBS J, V287, P4747, DOI 10.1111/febs.15266
   Chen X, 2016, CELL RES, V26, P1007, DOI 10.1038/cr.2016.100
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Chung HY, 2019, AGING DIS, V10, P367, DOI 10.14336/AD.2018.0324
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Cramer AO, 2013, CURR GENE THER, V13, P139
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dhuriya YK, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1235-0
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Fang PH, 2018, DIABETES RES CLIN PR, V139, P262, DOI 10.1016/j.diabres.2018.03.007
   Feng L, 2019, DISCOV MED, V27, P153
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1610
   Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hadian K, 2020, CELL, V181, P1188, DOI 10.1016/j.cell.2020.04.039
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hao YM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071515
   Haymes SA, 2006, OPHTHAL PHYSL OPT, V26, P169, DOI 10.1111/j.1475-1313.2006.00367.x
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Hu X, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0276-0
   Huang PR, 2020, CELL BIOL INT, V44, P2213, DOI 10.1002/cbin.11429
   Hudson N, 2020, NEURAL REGEN RES, V15, P1656, DOI 10.4103/1673-5374.276332
   Hwang N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236028
   Im E, 2010, MOL CELL BIOL, V30, P2401, DOI 10.1128/MCB.01275-09
   Ito Y, 2016, SCIENCE, V353, P603, DOI 10.1126/science.aaf6803
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jager Martine J, 2014, J Ophthalmic Vis Res, V9, P1
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim SH, 2019, FREE RADICAL RES, V53, P865, DOI 10.1080/10715762.2019.1637862
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kokkinopoulos I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018921
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627
   Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2298-2
   Li S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061736
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin YC, 2018, J OCUL PHARMACOL TH, V34, P500, DOI 10.1089/jop.2017.0073
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Markowitz SN, 2020, RETINA-J RET VIT DIS, V40, P1471, DOI 10.1097/IAE.0000000000002632
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Masse A, 2017, ACTUAL PHARMACEUT, V56, P18, DOI 10.1016/j.actpha.2017.02.005
   Masuda N, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1076-3
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Mullins RF, 2006, MOL VIS, V12, P224
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Nahavandipour A, 2020, ACTA OPHTHALMOL, V98, P434, DOI 10.1111/aos.14402
   Parmeggiani F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38919-7
   Pedrosa AC, 2016, CLIN OPHTHALMOL, V10, P541, DOI 10.2147/OPTH.S90913
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Rashid A, 2016, ADV EXP MED BIOL, V854, P757, DOI 10.1007/978-3-319-17121-0_101
   Rohrer B, 2019, MOL VIS, V25, P79
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schroeder M, 2020, ACTA OPHTHALMOL, V98, P274, DOI 10.1111/aos.14239
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shao LF, 2017, NEUROCHEM RES, V42, P2117, DOI 10.1007/s11064-017-2249-1
   Shi J, 2016, TRENDS BIOCHEM SCI, DOI [10.1016/j.tibs.2016.10.004, 10.1038/s41568-019-0123-y, DOI 10.1038/s41568-019-0123-y, DOI 10.1016/J.TIBS.2016.10.004]
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Sun HJ, 2020, PHARMACOLOGY, V105, P28, DOI 10.1159/000502614
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Tower J, 2015, AGEING RES REV, V23, P90, DOI 10.1016/j.arr.2015.04.002
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Turbert D., ANTI VEGF TREATMENTS
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Vazquez-Alfageme C, 2019, RETINA-J RET VIT DIS, V39, P664, DOI 10.1097/IAE.0000000000002029
   Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477
   Wang K, 2017, EXP CELL RES, V357, P335, DOI 10.1016/j.yexcr.2017.05.030
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang S, 2019, INT IMMUNOPHARMACOL, V67, P458, DOI 10.1016/j.intimp.2018.12.019
   Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149
   Wooff Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58849-z
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yazama F, 2002, J ELECTRON MICROSC, V51, P127, DOI 10.1093/jmicro/51.2.127
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37279
   Zhao S, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014645
NR 125
TC 13
Z9 14
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2020
VL 21
IS 19
AR 7279
DI 10.3390/ijms21197279
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ON4AR
UT WOS:000586646400001
PM 33019767
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Floriano, AG
   Marquez, CY
   Nieto, OC
AF Floriano, A. G.
   Marquez, C. Y.
   Nieto, O. C.
TI Detection of Age-Related Macular Degeneration in Fundus Images by an
   Associative Classifier
SO IEEE LATIN AMERICA TRANSACTIONS
LA English
DT Article
DE Age-Related Macular Degeneration; Fundus images; Homomorphic filtering;
   Mathematical Morphology; Zernike Moments; Heaviside's Classifier
ID MOMENT INVARIANTS; SEGMENTATION; CONTOUR; DRUSEN; RECOGNITION;
   REGRESSION; TRANSFORM; VESSELS; RISK
AB In this paper we propose the application of a novel associative classifier, the Heaviside's Classifier, for the early detection of Age-Related Macular Degeneration un retinal fundus images. Retinal fundus images are, first, processed by a simple method based on the Homomorphic filtering and some basic mathematical morphology operations; in the second phase we extract relevant features of the images using the Zernike moments, we also apply a feature selection method to select the best features from the original features set. The dataset created from the images with the best features are used to train and test a new classification model whose learning and classification phases are based on the Heaviside's Function. Experimental results show that our method is capable to achieve an accuracy value about the 94.12% with a dataset created from images belonging to famous image repositories.
C1 [Floriano, A. G.] Univ Mexiquense Bicentenario, Ocoyoacac, Mexico.
   [Marquez, C. Y.] IPN, Ctr Invest Comp, Mexico City, DF, Mexico.
   [Nieto, O. C.] IPN, Ctr Innovac & Desarrollo Tecnol, Mexico City, DF, Mexico.
C3 Instituto Politecnico Nacional - Mexico; Instituto Politecnico Nacional
   - Mexico
RP Floriano, AG (通讯作者)，Univ Mexiquense Bicentenario, Ocoyoacac, Mexico.
EM andres.garcia@umb.mx; cyanez@cic.ipn.mx; oscarc@cic.ipn.mx
RI Yáñez-Márquez, Cornelio/A-1411-2008; Floriano, Andrés
   García/G-7761-2018; Camacho-Nieto, Oscar/A-8820-2012
OI Yáñez-Márquez, Cornelio/0000-0002-6250-4728; Floriano, Andrés
   García/0000-0002-9948-5954; Camacho-Nieto, Oscar/0000-0003-1142-5277
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Abramowitz M., 1965, HDB MATH FUNCTIONS F, V55
   AHA DW, 1991, MACH LEARN, V6, P37, DOI 10.1023/A:1022689900470
   Ali S, 2013, COMPUT MED IMAG GRAP, V37, P358, DOI 10.1016/j.compmedimag.2013.06.006
   BELKASIM SO, 1991, PATTERN RECOGN, V24, P1117, DOI 10.1016/0031-3203(91)90140-Z
   Boughrara H, 2014, IET COMPUT VIS, V8, P729, DOI 10.1049/iet-cvi.2013.0294
   Burger W, 2008, TEXTS COMPUT SCI, P37
   Cohen S, RETINA GALLERY FULL
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Duda R.O., 2006, PATTERN CLASSIFICATI
   Eaton J. W., 2015, GNU OCTAVE
   Floriano A. Garcia, 2011, THESIS
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Franklin SW, 2014, APPL SOFT COMPUT, V22, P94, DOI 10.1016/j.asoc.2014.04.024
   Freund Y., 1996, Machine Learning. Proceedings of the Thirteenth International Conference (ICML '96), P148
   García-Floriano Andrés, 2015, Nova scientia, V7, P365
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Gorgel P, 2010, J MED SYST, V34, P993, DOI 10.1007/s10916-009-9316-3
   Guerroudji MA, 2016, OPTIK, V127, P1251, DOI 10.1016/j.ijleo.2015.10.192
   Hall M., 2009, SIGKDD EXPLORATIONS, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Hall MA, 1999, CORRELATION BASED FE
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Kedzierski M, 2016, MEASUREMENT, V92, P70, DOI 10.1016/j.measurement.2016.06.003
   Kovacs G, 2016, MED IMAGE ANAL, V29, P24, DOI 10.1016/j.media.2015.12.003
   Li N, 2015, IEEE T INSTRUM MEAS, V64, P2409, DOI 10.1109/TIM.2015.2411999
   Liang ZY, 2010, IEEE ENG MED BIO, P4100, DOI 10.1109/IEMBS.2010.5627289
   Lichman M., 2013, UCI MACHINE LEARNING
   Marin D, 2015, COMPUT METH PROG BIO, V118, P173, DOI 10.1016/j.cmpb.2014.11.003
   Mary MCVS, 2015, BIOMED SIGNAL PROCES, V18, P19, DOI 10.1016/j.bspc.2014.11.003
   Mathworks Inc, 2015, MATLAB R2015A
   Mittal D, 2015, COMPUT ELECTR ENG, V47, P82, DOI 10.1016/j.compeleceng.2015.08.014
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pearl J, 1985, CSD850021
   Quinlan JR, 1996, J ARTIF INTELL RES, V4, P77, DOI 10.1613/jair.279
   Raza G, 2013, P 2013 IEEE JORD C A, P1
   Skiena S. S., 2012, ALGORITHM DESIGN MAN, P230
   Soille P., 2004, MORPHOLOGICAL IMAGE, P63, DOI DOI 10.1007/978-3-662-05088-0_3
   Soille P., 2004, MORPHOLOGICAL IMAGE, P105, DOI [10.1007/978-3-662-05088-0_4, DOI 10.1007/978-3-662-05088-0_4]
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Wolf C., 2009, ZERNIKE MOMENTS
   Wong TT, 2015, PATTERN RECOGN, V48, P2839, DOI 10.1016/j.patcog.2015.03.009
NR 41
TC 3
Z9 4
U1 0
U2 3
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1548-0992
J9 IEEE LAT AM T
JI IEEE Latin Am. Trans.
PD MAR
PY 2018
VL 16
IS 3
BP 933
EP 939
PG 7
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA GF8HK
UT WOS:000432210400034
DA 2022-11-30
ER

PT J
AU Abedi, F
   Wickremasinghe, S
   Islam, AFM
   Inglis, KM
   Guymer, RH
AF Abedi, Farshad
   Wickremasinghe, Sanjeewa
   Islam, Amirul F. M.
   Inglis, Kellie M.
   Guymer, Robyn H.
TI ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A
   Treat-and-Extend Protocol Over 2 Years
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; neovascular; ranibizumab;
   treat and extend
ID SUBGROUP ANALYSIS; DOSING REGIMEN; RANIBIZUMAB; VERTEPORFIN;
   BEVACIZUMAB; ANCHOR
AB Purpose: To evaluate 2-year visual acuity outcome of a treat-and-extend protocol of anti-vascular endothelial growth factor treatment in age-related macular degeneration.
   Methods: In this prospective cohort study, 120 age-related macular degeneration patients with choroidal neovascularization received 3 initial monthly ranibizumab or bevacizumab injections; monthly injections were continued until there was no choroidal neovascularization activity (subretinal/intraretinal fluid, loss of >5 letters, or persistent/recurrent retinal hemorrhage). When there was no choroidal neovascularization activity, the interval to the next visit/injection was extended by 2 weeks to a maximum of 12 weeks. In the presence of choroidal neovascularization activity, this interval was shortened by 2 weeks. Main outcome measures included the percentage losing <15 letters and the mean visual acuity change after 12 months and 24 months.
   Results: Mean baseline visual acuity was 51.2 +/- 12.1 Early Treatment Diabetic Retinopathy Study scores. Mean visual acuity change from baseline was +9.5 +/- 10.9 and +8.0 +/- 12.9 letters after 12 months and 24 months, respectively, with, on average, 8.6 +/- 1.1 visits/injections in the first year and 5.6 +/- 2.0 in the second year. After 12 months and 24 months, 97.5% and 95.0% of patients, respectively, lost <15 letters.
   Conclusion: The "inject-and-extend" protocol-with fewer injections and visits-delivered outcomes comparable to those of the pivotal clinical trials of monthly ranibizumab.
C1 [Abedi, Farshad; Wickremasinghe, Sanjeewa; Islam, Amirul F. M.; Inglis, Kellie M.; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Abedi, F (通讯作者)，3-5-13 Huchinson St, Surry Hills 2010, Australia.
EM abedifarshad@yahoo.com
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Guymer,
   Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) [590205, 1008979];
   NHMRC Clinical Research Excellence [529923]; NHMRC practitioner
   fellowship; NHMRC Fight Retinal Blindness [632663]
FX Supported by the National Health and Medical Research Council (NHMRC)
   project grants 590205 and 1008979, an NHMRC Clinical Research Excellence
   grant 529923, NHMRC practitioner fellowship (RHG), and NHMRC Fight
   Retinal Blindness (FRB) grant 632663. The Centre for Eye Research
   Australia (CERA) receives Operational Infrastructure Support from the
   Victorian Government. The sponsor or funding organizations had no role
   in the design or conduct of this research.
CR Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
NR 17
TC 105
Z9 109
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2014
VL 34
IS 8
BP 1531
EP 1538
DI 10.1097/IAE.0000000000000134
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM7ZE
UT WOS:000340086600012
PM 24637667
DA 2022-11-30
ER

PT J
AU Storey, PP
   Ho, V
   Yeh, S
   Reddy, S
   Fang-Yen, NH
   Pequignot, E
   Leiby, BE
   Fineman, M
   Garg, S
   Hubbard, GB
   Hsu, J
AF Storey, Philip P.
   Ho, Vincent
   Yeh, Steven
   Reddy, Sahitya
   Fang-Yen, Natalie Hsiao
   Pequignot, Edward
   Leiby, Benjamin E.
   Fineman, Mitchell
   Garg, Sunir
   Hubbard, G. Baker, III
   Hsu, Jason
TI INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS
   FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE ocular hypertension; glaucoma; intravitreal injection; bevacizumab;
   age-related macular degeneration; choroidal neovascularization; vascular
   endothelial growth factor
ID INTRAOCULAR-PRESSURE ELEVATION; GROWTH-FACTOR THERAPY; REPACKAGED
   BEVACIZUMAB; MONOCLONAL-ANTIBODY; AQUEOUS-SOLUTION; SILICONE OIL;
   RANIBIZUMAB; INJECTIONS; AGGREGATION; SAFETY
AB Purpose:To compare the incidence of sustained ocular hypertension (OHT) after intravitreal injections of prepackaged versus freshly prepared bevacizumab monotherapy for the treatment of neovascular age-related macular degeneration.Methods:Charts of 1,216 patients with neovascular age-related macular degeneration receiving intravitreal bevacizumab monotherapy at 2 retina practices using different preparations of bevacizumab between January 1, 2009, and December 31, 2011, were reviewed. Primary outcome was incidence of sustained OHT, defined as intraocular pressure >25 mmHg with an increase 6 from baseline on 2 consecutive visits or requiring treatment.Results:A total of 6,479 injections in 740 eyes of 634 patients were included and 14 eyes (0.81% incidence per eye-year) developed sustained OHT. For eyes receiving prepackaged bevacizumab, 10 of 339 eyes (1.39% incidence per eye-year) developed sustained OHT compared with 4 of 401 eyes (0.39% incidence per eye-year) receiving freshly prepared bevacizumab, giving an incidence rate ratio of 3.55 (95% confidence interval, 0.93-13.49; P = 0.063). All eyes that developed sustained OHT achieved intraocular pressure control with observation or topical therapy alone.Conclusion:Incidence of sustained OHT after intravitreal bevacizumab is low. We found a trend toward higher rates of sustained OHT with prepackaged bevacizumab although this difference was not statistically or clinically significant.
C1 [Storey, Philip P.; Reddy, Sahitya; Fang-Yen, Natalie Hsiao; Fineman, Mitchell; Garg, Sunir; Hsu, Jason] Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
   [Ho, Vincent; Yeh, Steven; Hubbard, G. Baker, III] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA.
   [Pequignot, Edward; Leiby, Benjamin E.] Thomas Jefferson Univ, Jefferson Med Coll, Div Biostat, Philadelphia, PA 19107 USA.
   [Storey, Philip P.] Univ So Calif, USC Eye Inst, Los Angeles, CA USA.
C3 Jefferson University; Emory University; Jefferson University; University
   of Southern California
RP Hsu, J (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
FU J. Arch McNamara Memorial Fund for Retina Research Grant
FX Supported by J. Arch McNamara Memorial Fund for Retina Research Grant.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bee JS, 2009, J PHARM SCI-US, V98, P3218, DOI 10.1002/jps.21768
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Hoang QV, 2012, OPHTHALMOLOGY, V119, P321, DOI 10.1016/j.ophtha.2011.08.011
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kempen JH, 2011, AM J OPHTHALMOL, V151, P7, DOI 10.1016/j.ajo.2010.08.047
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Mahler HC, 2009, J PHARM SCI-US, V98, P2909, DOI 10.1002/jps.21566
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mueller R, 2009, J PHARM SCI-US, V98, P3548, DOI 10.1002/jps.21672
   Orr P, 1999, OPHTHALMOLOGY, V106, P904, DOI 10.1016/S0161-6420(99)00508-4
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Thirumangalathu R, 2009, J PHARM SCI-US, V98, P3167, DOI 10.1002/jps.21719
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
NR 25
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2015
VL 35
IS 10
BP 1992
EP 2000
DI 10.1097/IAE.0000000000000620
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS6US
UT WOS:000362219000010
PM 26035396
DA 2022-11-30
ER

PT J
AU Grzybowski, A
   Wang, J
   Mao, FF
   Wang, DB
   Wang, NL
AF Grzybowski, Andrzej
   Wang, Jin
   Mao, Feifei
   Wang, Dabo
   Wang, Ningli
TI Intraocular vision-improving devices in age-related macular degeneration
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Intraocular devices; implantable miniature telescope (IMT); EyeMax Mono;
   IOL-VIP system; Scharioth macula lens (SML)
ID IMPLANTABLE MINIATURE TELESCOPE; CATARACT-SURGERY; VISUAL-ACUITY;
   RISK-FACTORS; LENS; SAFETY; SYSTEM
AB Age-related macular degeneration (AMD) is a leading cause of blindness, especially in western countries, and will substantially burden society and the world's health care system. Patients with late AMD often accompany a progressive loss of central vision, which will heavily influence the quality of life and associated with increased risk of functional disability. The principal visual rehabilitation methods with low-vision magnifiers, such as hand or stand magnifiers, spectacles, and closed-circuit television, were cumbersome to use and cosmetically burdensome. Therefore, the development of intraocular vision improving devices has become an attractive alternative to extraocular visual aids, and better life quality improvement has been reached among AMD patients. To evaluate each device's safety and efficacy based on current research, we searched the Cochrane Library, PubMed using pre-reported search terms and keywords combined with both Mesh term and text words. We explored randomized clinical controlled trials, cohort studies, and case serial reports and summarizes three aspects: visual outcomes, safety outcome, and quality of life outcomes. There are four types of devices recommended for AMD patients illustrating in this article: an implantable miniature telescope (IMT), IOL-VIP System, EyeMax Mono, and Scharioth macula lens (SML). There is no doubt that these technological advancements would bring new hope for AMD patients. However, the lack of randomized controls, limited follow-up duration, and various visual acuity (VA) measurements in different studies would be difficult than IOL devices.
C1 [Grzybowski, Andrzej] Univ Warmia & Mazury, Dept Ophthalmol, Olsztyn, Poland.
   [Grzybowski, Andrzej] Fdn Ophthalmol Dev, Inst Res Ophthalmol, Poznan, Poland.
   [Wang, Jin; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Mao, Feifei] Capital Med Univ, Beijing DiTan Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Wang, Dabo] Qingdao Univ, Affiliated Hosp, Dept Ophthalmol, Qingdao, Peoples R China.
   [Wang, Ningli] Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Wang, Ningli] Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Wang, Ningli] Beijing Key Lab Ophthalmol & Visual Sci, Beijing, Peoples R China.
C3 University of Warmia & Mazury; Capital Medical University; Capital
   Medical University; Qingdao University
RP Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dong Jiao Min Xiang St, Beijing, Peoples R China.
EM wningli@vip.163.com
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391
CR Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Badala F, 2019, 37 ESCRS C PAR
   Bereczki Arpad, 2019, Rom J Ophthalmol, V63, P128
   Borkenstein AF, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016583
   Borkenstein AF, 2019, CLIN CASE REP, V7, P74, DOI 10.1002/ccr3.1912
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   Dag MY, 2019, EUR J OPHTHALMOL, V29, P615, DOI 10.1177/1120672118803831
   Dunbar HMP, 2018, OPHTHALMOL THER, V7, P33, DOI 10.1007/s40123-018-0129-7
   Grzybowski A, 2017, GRAEF ARCH CLIN EXP, V255, P1687, DOI 10.1007/s00417-017-3740-8
   Hau VS, 2016, OPHTHALMOL THER, V5, P21, DOI 10.1007/s40123-016-0047-5
   Hengerer FH, 2015, CATARACT REFRACT SUR, V2, P40
   Hengerer FH, 2018, OPHTHALMOL RETINA, V2, P900, DOI 10.1016/j.oret.2018.02.003
   Hengerer FH, 2015, J REFRACT SURG, V31, P158, DOI 10.3928/1081597X-20150220-03
   Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kaskaloglu M, 2001, J CATARACT REFR SURG, V27, P1751, DOI 10.1016/S0886-3350(01)00976-2
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   Lazarou John, IMPLANTABLE TELESCOP
   Lipuma Lauren, 2015, IOL CAN SAVE SIGHT
   Mao FF, 2019, INVEST OPHTH VIS SCI, V60, P4966, DOI 10.1167/iovs.19-27325
   MIRROR, 2017, WELL DOES ORILENS HU, DOI 10.1186/ISRCTN47403123
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nielsen JP, 2018, ST HIST ANC NE EAST, P22
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Qureshi MA, 2018, EUR J OPHTHALMOL, V28, P198, DOI 10.5301/ejo.5001052
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Robbie SJ, 2018, J REFRACT SURG, V34, P718, DOI 10.3928/1081597X-20180831-01
   Savaresi G, 2004, INVEST OPHTHALMOL VI, V45, P2010
   Scharioth GB, 2015, J CATARACT REFR SURG, V41, P1559, DOI 10.1016/j.jcrs.2015.07.018
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Srinivasan S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000322
   Tabernero J, 2015, BIOMED OPT EXPRESS, V6, P1010, DOI 10.1364/BOE.6.001010
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   United Nations Population Division, WORLD POP PROSP 2010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 40
TC 6
Z9 6
U1 2
U2 4
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD NOV
PY 2020
VL 8
IS 22
AR 1549
DI 10.21037/atm-20-5851
PG 14
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PE4UL
UT WOS:000598361800021
PM 33313294
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Parisi, V
   Perillo, L
   Tedeschi, M
   Scassa, C
   Gallinaro, G
   Capaldo, N
   Varano, M
AF Parisi, Vincenzo
   Perillo, Loredana
   Tedeschi, Massimiliano
   Scassa, Cecilia
   Gallinaro, Geltrude
   Capaldo, Nicoletta
   Varano, Monica
TI Macular function in eyes with early age-related macular degeneration
   with or without contralateral late age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; mfERG; microperimetry
ID FELLOW EYES; MULTIFOCAL ELECTRORETINOGRAM; FUNDUS AUTOFLUORESCENCE;
   CONTRAST SENSITIVITY; GEOGRAPHIC ATROPHY; PIGMENT EPITHELIUM; FOLLOW-UP;
   MACULOPATHY; DRUSEN; RISK
AB Purpose: To evaluate psychophysical and electrophysiologic responses in eyes with early age-related macular degeneration (AMD) without a decrease in visual acuity and with or without late AMD in the fellow eye.
   Methods: Fifteen patients (mean age: 67.9 +/- 7.20 years) with early AMD in both eyes (AMD1 group, 15 eyes) and 15 patients (mean age: 71.40 +/- 7.06 years) with early AMD in one eye and late AMD in the fellow eye (AMD2 group, 15 eyes) were enrolled. They were compared to 15 age-similar normal control subjects. LogMAR visual acuity (VA), macular sensitivity by MP-1 microperimetry, and multifocal electroretinog rams (mfERG) were assessed in control, AMD1, and AMD2 eyes. mfERG response amplitude density (RAD, nWdeg2) of the N1-P1 component of first order binary kernels was measured.
   Results: When compared to controls, AMD1 and AIVID2 eyes showed a significant (analysis of variance, P < 0.01) decrease in MP-1 microperimetry assessed in the 0 +/- 2.5 and 2.5 +/- 5 degrees of the macula, significantly correlated (Pearson test, P < 0.01) to the corresponding significant decrease (P < 0.01) in mfERG N1-P1 RADs assessed in the 0 +/- 2.5 and 2.5 +/- 5 degrees. In AMD1 and AMD2 eyes, VA and mfERG N1 -P1 RADs assessed in the 5 +/- 20 degrees were similar (P > 0.01) to controls. VA, MP-1, and mfERG values were not significantly different in AMID1 and AMD2 eyes.
   Conclusion: In eyes with early AMD there is a dysfunction of preganglionic elements in the central 0-5 retinal degrees detectable by mfERG or MP-1 microperimetry. This impairment is not further influenced by the presence of late AMD in the fellow eye.
C1 GB Bietti IRCCS, Fdn Oftalmol, I-00199 Rome, Italy.
RP Parisi, V (通讯作者)，GB Bietti IRCCS, Fdn Oftalmol, Via Livenza 3, I-00199 Rome, Italy.
EM vparisi@tin.it
RI Varano, Monica/K-8573-2016; Parisi, Vincenzo/J-6137-2018
OI Varano, Monica/0000-0002-6530-1563
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   FRISEN L, 1979, A VONGRAEFES ARCH KL, V2, P69
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Iarossi G, 2003, INVEST OPHTH VIS SCI, V44, P866, DOI 10.1167/iovs.01-1256
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parisi V, 1998, Semin Ophthalmol, V13, P178, DOI 10.3109/08820539809056051
   Parisi V, 2002, INVEST OPHTH VIS SCI, V43, P2741
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Scullica Luigi, 2001, Documenta Ophthalmologica, V102, P237, DOI 10.1023/A:1017562532731
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Varano M, 2005, INVEST OPHTH VIS SCI, V46, P1453, DOI 10.1167/iovs.04-0903
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 56
TC 60
Z9 60
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 879
EP 890
DI 10.1097/IAE.0b013e318042d6aa
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600012
PM 17891012
DA 2022-11-30
ER

PT J
AU Geirsdottir, A
   Hardarson, SH
   Olafsdottir, OB
   Stefansson, E
AF Geirsdottir, Asbjorg
   Hardarson, Sveinn Hakon
   Olafsdottir, Olof Birna
   Stefansson, Einar
TI Retinal oxygen metabolism in exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; oximetry; oxygen; retina; retinal
   image; retinal vessels; spectrophotometry
ID CHOROIDAL BLOOD-FLOW; POSTERIOR VITREOMACULAR ADHESION; NEOVASCULAR
   MEMBRANES; DIABETIC-PATIENTS; SATURATION; EXPRESSION; MACULOPATHY;
   RETINOPATHY; OXIMETRY; DRUSEN
AB PurposeTo determine whether retinal vessel oxygen saturation in patients with exudative age-related macular degeneration (AMD) is different from that of a healthy population.
   MethodsOxygen saturation was measured in retinal arterioles and venules in 46 eyes of 46 treatment-naive exudative AMD patients and 120 eyes of 120 healthy controls. Simple and multiple linear regression analyses were used to compare the two study groups.
   ResultsOxygen saturation in retinal venules increases with age in patients with exudative AMD (0.450.19% per year; p=0.026), while it decreases with age in healthy individuals (-0.13 +/- 0.03% per year; p=0.0002). The slopes are statistically different (ANCOVA; p=0.0003). The reverse is true for the arteriovenous difference in oxygen saturation, which decreases with age in AMD patients (-0.29 +/- 0.16% per year; p=0.065) and increases in healthy individuals (0.12 +/- 0.03% per year; p<0.0001). At age 80years, AMD patients have 2.7 percentage points higher venous oxygen saturation than healthy persons and 4.2 percentage points less arteriovenous difference.
   ConclusionsThe data suggest that retinal oxygen metabolism may be altered in exudative AMD. The arteriovenous difference is smaller in exudative AMD than in a healthy cohort, consistent with reduced oxygen extraction by retinal vessels in AMD patients. Further studies are needed to fully understand the role of retinal oxygen metabolism in the pathophysiology of exudative AMD.
C1 [Geirsdottir, Asbjorg; Hardarson, Sveinn Hakon; Olafsdottir, Olof Birna; Stefansson, Einar] Univ Iceland, IS-101 Reykjavik, Iceland.
   [Geirsdottir, Asbjorg; Hardarson, Sveinn Hakon; Stefansson, Einar] Landspitali, Dept Ophthalmol, Reykjavik, Iceland.
   [Geirsdottir, Asbjorg] St Erik Eye Hosp, Stockholm, Sweden.
C3 University of Iceland
RP Stefansson, E (通讯作者)，Univ Iceland, Landspitali, Eiriksgata 37, IS-101 Reykjavik, Iceland.
EM einarste@landspitali.is
OI Hardarson, Sveinn Hakon/0000-0001-5865-6756
FU Prevention of Blindness Fund; Landspitali-University Hospital Research
   Fund; Rasmussen Foundation; University of Iceland Research Fund;
   Icelandic Centre for Research (Rannis)
FX The paper was presented in part at ARVO 2012. The authors like to
   acknowledge Prevention of Blindness Fund, Landspitali-University
   Hospital Research Fund, The Rasmussen Foundation, University of Iceland
   Research Fund and Icelandic Centre for Research (Rannis) for their
   support. The authors would also like to acknowledge Friobert Jonasson
   for his assistance regarding clinical diagnosis of AMD patients and
   Sigrun Helga Lund for her statistical consultation.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Blondal R, 2011, GRAEF ARCH CLIN EXP, V249, P1311, DOI 10.1007/s00417-011-1680-2
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Geirsdottir A, 2012, INVEST OPHTH VIS SCI, V53, P5433, DOI 10.1167/iovs.12-9912
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hammer M, 2009, GRAEF ARCH CLIN EXP, V247, P1025, DOI 10.1007/s00417-009-1078-6
   Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032
   Hardarson SH, 2012, BRIT J OPHTHALMOL, V96, P560, DOI 10.1136/bjophthalmol-2011-300640
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Holekamp NM, 2006, AM J OPHTHALMOL, V141, P1027, DOI 10.1016/j.ajo.2006.01.016
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Nowak Izabela, 2007, Klin Oczna, V109, P135
   Palsson O, 2012, INVEST OPHTH VIS SCI, V53, P1729, DOI 10.1167/iovs.11-8621
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Sato E, 2006, EYE, V20, P697, DOI 10.1038/sj.eye.6701951
   Schweitzer D, 2005, KLIN MONATSBL AUGENH, V222, P396, DOI 10.1055/s-2005-858088
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
NR 28
TC 52
Z9 53
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2014
VL 92
IS 1
BP 27
EP 33
DI 10.1111/aos.12294
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292TJ
UT WOS:000329925000007
PM 24447786
OA Bronze
DA 2022-11-30
ER

PT J
AU Piermarocchi, S
   Sartore, M
   Lo Giudice, G
   Maritan, V
   Midena, E
   Segato, T
AF Piermarocchi, Stefano
   Sartore, Mauro
   Lo Giudice, Giuseppe
   Maritan, Veronica
   Midena, Edoardo
   Segato, Tatiana
TI Combination of photodynamic therapy and intraocular triamcinolone for
   exudative age-related macular degeneration and long-term chorioretinal
   macular atrophy
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; DOSE INTRAVITREAL TRIAMCINOLONE; BRUCHS
   MEMBRANE; VERTEPORFIN; ACETONIDE; EXPRESSION; CHORIOCAPILLARIS;
   INJECTION
AB Objective: To evaluate the long-term effect of intravitreal triamcinolone acetonide (IVT) treatment combined with photodynamic therapy (PDT) vs PDT alone for neovascular age related macular degeneration.
   Methods: Prospective randomized study. Eighty-four patients were enrolled to receive PDT (n=41) or IVT treatment followed by PDT (n =43) within approximately a 7- to 15-day interval. All patients were naive to treatment. At baseline and each follow-up visit at 3,6,12, and 24 months, measurement of best-corrected visual acuity (VA), fluorescein angiography, indocyanine green angiography, and optical coherence tomography were performed. Mean changes in VA and retreatment rate were considered as primary outcome indicators. Analysis of vascular choroidal changes documented by indocyanine green angiography and fundus antofluoresence measurements were also performed.
   Results: Mean VA increased at 1 month of follow-up but decreased progressively by the 24-month point in both groups (P=.74). The retreatment rate was significantly lower (P<.001) in the combined therapy group. Choroidal hypoperfusion/nonperfusion (P<.00.1) and areas with decreascd/absent fundus autofluorescence within the PDT spot area were significantly greater with combined therapy (P<.001).
   Conclusions: Combination IVT treatment with PDT seemed to be more effective for managing neovascular age-related macular degeneration, but long-term analysis failed to demonstrate functional benefits.
C1 [Piermarocchi, Stefano; Sartore, Mauro; Midena, Edoardo; Segato, Tatiana] Univ Padua, Dept Ophthalmol, I-35128 Padua, Italy.
   [Lo Giudice, Giuseppe] S Antonio Hosp, Padua, Italy.
   [Maritan, Veronica] Conegliano Hosp, Conegliano, TV, Italy.
C3 University of Padua; ULSS 6 Euganea; Ospedale Sant'antonio Padova; ULSS
   2 Marca TV; Ospedale Conegliano
RP Piermarocchi, S (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM stefano.piermarocchi@unipd.it
RI Midena, Edoardo/AAB-6010-2020; LO GIUDICE, GIUSEPPE/GQB-0418-2022
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fleiss J.L., 1981, STAT METHODS RATES P
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hussain Nazimul, 2006, Indian Journal of Ophthalmology, V54, P247
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P872, DOI 10.1007/s00417-002-0547-y
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   KORTE GE, 1986, ACTA ANAT, V127, P171
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Landa Gennady, 2009, International Ophthalmology, V29, P1, DOI 10.1007/s10792-007-9176-0
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Michels S, 2002, OPHTHALMOLOGE, V99, P96, DOI 10.1007/s003470100532
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   SAS Institute Inc, 2007, SAS STAT US GUID VER
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Winer BJ., 1970, STAT PRINCIPLES EXPT, V2nd
NR 42
TC 16
Z9 17
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2008
VL 126
IS 10
BP 1367
EP 1374
DI 10.1001/archopht.126.10.1367
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 358EU
UT WOS:000259900700005
PM 18852414
OA Bronze
DA 2022-11-30
ER

PT J
AU Querques, G
   Massamba, N
   Coscas, F
   Forte, R
   Souied, EH
AF Querques, Giuseppe
   Massamba, Nathalie
   Coscas, Florence
   Forte, Raimondo
   Souied, Eric H.
TI Choroidal neovascularisation complicating geographic atrophy in
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; VEGF
AB Objective To investigate the morphological and functional outcomes after intravitreal ranibizumab injections for choroidal neovascularisation (CNV) complicating geographic atrophy (GA).
   Design Retrospective, interventional, consecutive case series.
   Methods We reviewed the charts of all consecutive patients with GA due to age-related macular degeneration (AMD), who received intravitreal ranibizumab injections for the development of CNV at least 24 months earlier.
   Results 21 treatment-naive eyes of 21 consecutive patients (4 men, 17 women, mean age 86.9 +/- 1.6 years) were included. In 95.2% of eyes a type 2 CNV was present, extrafoveal in 42.8% of cases. After a mean of 5.0 +/- 0.87 (range 1-20) intravitreal ranibizumab injections, best-corrected visual acuity (BCVA) significantly worsened at the 24-month follow-up visit (0.73 +/- 0.05 vs 0.88 +/- 0.08 logMAR, respectively; p=0.01). A significant reduction of intraretinal cystic lesions, subretinal fluid and pigment epithelium detachment (p<0.001) and a significant increase of GA area (p=0.003) were present at last visit.
   Conclusions Ranibizumab treatment of GA-associated CNVs provides no BCVA improvement at 24 months follow-up despite an anatomic response of CNV. Low effectiveness of ranibizumab in these cases is likely due to GA progression.
C1 [Querques, Giuseppe; Massamba, Nathalie; Coscas, Florence; Forte, Raimondo; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Siegel S., 1988, NONPARAMETRIC STAT B, P284
NR 13
TC 14
Z9 14
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2012
VL 96
IS 12
BP 1479
EP 1483
DI 10.1136/bjophthalmol-2012-302191
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 041SX
UT WOS:000311422600008
PM 23077229
DA 2022-11-30
ER

PT J
AU Thornton, J
   Edwards, R
   Mitchell, P
   Harrison, RA
   Buchan, I
   Kelly, SP
AF Thornton, J
   Edwards, R
   Mitchell, P
   Harrison, RA
   Buchan, I
   Kelly, SP
TI Smoking and age-related macular degeneration: a review of association
SO EYE
LA English
DT Review
DE age-related macular degeneration; age-related maculopathy; tobacco
   smoking; blindness; visual impairment; smoking cessation
ID BEAVER DAM EYE; BLUE-MOUNTAINS EYE; RISK-FACTORS; CIGARETTE-SMOKING;
   CHOROIDAL NEOVASCULARIZATION; SUSCEPTIBILITY LOCI; POOLED FINDINGS; 3
   CONTINENTS; MACULOPATHY; DISEASE
AB Purpose Age-related macular degeneration (AMD) is the leading cause of severe and irreversible vision loss in the Western world. As there is no effective treatment for all types of AMD, identifying modifiable risk factors is of great importance. This review evaluates the epidemiological evidence associating smoking with AMD.
   Methods Systematic review of published epidemiological studies evaluated against established criteria for evidence of a causal relationship.
   Results In total, 17 studies (cross-sectional studies, prospective cohort studies, and case-control studies) were included in the review. A total of 13 studies found a statistically significant association between smoking and AMD with increased risk of AMD of two- to three-fold in current-smokers compared with never-smokers. Five studies found no association between smoking and AMD. There was also evidence of dose-response, a temporal relationship and reversibility of effect.
   Conclusion The literature review confirmed a strong association between current smoking and AMD, which fulfilled established causality criteria. Cigarette smoking is likely to have toxic effects on the retina. In spite of the strength of this evidence, there appears to be a lack of awareness about the risks of developing eye disease from smoking among both healthcare professionals and the general public.
C1 Bolton Hosp, NHS Trust, Bolton Eye Unit, Bolton BL4 0JR, England.
   Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead Hosp, Westmead, NSW 2145, Australia.
   Bolton Primary Care Trust, Bolton, England.
C3 Royal Bolton Hospital; University of Sydney
RP Kelly, SP (通讯作者)，Bolton Hosp, NHS Trust, Bolton Eye Unit, Minerva Rd, Bolton BL4 0JR, England.
EM Simon.Kelly@boltonh-tr.nwest.nhs.uk
RI Mitchell, Paul/P-1498-2014; Buchan, Iain E/H-5767-2013; Edwards,
   Richard/O-4771-2017
OI Buchan, Iain E/0000-0003-3392-1650; Edwards, Richard/0000-0003-2264-9823
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Carroll T, 2003, TOB CONTROL, V12, P40
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   *DEP HLTH, 1999, SURV ENGL 1998 CARD
   Enstrom JE, 2003, BMJ-BRIT MED J, V326, P1057, DOI 10.1136/bmj.326.7398.1057
   Evans J., 1996, HEALTH TRENDS, V28, P5
   EVANS J, 2003, ANTIOXIDANT VITAMIN
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KELLY SP, 2004, BRIT MED J, V328, P357
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Lutty G, 1999, Mol Vis, V5, P35
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 1999, MED J AUSTRALIA, V171, P173, DOI 10.5694/j.1326-5377.1999.tb123591.x
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Pauleikhoff D, 1992, Ger J Ophthalmol, V1, P12
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SHIRAGA F, 1987, FOLIA OPHTHALMOL JPN, V38, P525
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Starzycka M, 1997, Klin Oczna, V99, P249
   Stead LF, 2006, REP SCI COMM TOB HLT, DOI 10.1002/14651858.CD002850.pub2
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   SUSSER M, 1991, AM J EPIDEMIOL, V133, P635, DOI 10.1093/oxfordjournals.aje.a115939
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wilson N, 2002, NEW ZEAL MED J, V115, P199
   WILSON N, 2004, BR MED J
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 55
TC 364
Z9 374
U1 2
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2005
VL 19
IS 9
BP 935
EP 944
DI 10.1038/sj.eye.6701978
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 961WB
UT WOS:000231691400001
PM 16151432
OA Bronze
DA 2022-11-30
ER

PT J
AU Mete, A
   Saygili, O
   Mete, A
   Bayram, M
   Bekir, N
AF Mete, Ahmet
   Saygili, Oguzhan
   Mete, Alper
   Bayram, Metin
   Bekir, Necdet
TI Effects of Intravitreal Bevacizumab (Avastin (R)) Therapy on Retrobulbar
   Blood Flow Parameters in Patients With Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF CLINICAL ULTRASOUND
LA English
DT Article
DE color Doppler imaging; retrobulbar blood flow; neovascular age-related
   macular degeneration; intravitreal bevacizumab injection
ID ENDOTHELIAL GROWTH-FACTOR; DOPPLER ULTRASONOGRAPHY; HEMODYNAMICS; ORBIT;
   EYE; MACULOPATHY; SAFETY; EDEMA
AB Background. To investigate the effects of intravitreal bevacizumab on retrobulbar circulation in patients with neovascular age-related macular degeneration (AMD).
   Method. Thirty patients with neovascular age-related macular degeneration were assessed prospectively by both color Doppler imaging and fundus fluorescein angiography. Spectral Doppler analysis allowed the measurement of the maximum velocity (Vmax) and minimum velocity (Vmin) of the central retinal vein (CRV), and peak systolic (PSV), end-diastolic (EDV) velocities of blood flows, and pulsatility index (PI) and resistance index (RI) values in the central retinal artery (CRA), nasal and temporal posterior ciliary arteries (NPCA, TPCA), and ophthalmic artery (OA). The t test for paired samples was used to compare retrobulbar blood flow values before and after intravitreal bevacizumab injection.
   Result. PSV and EDV of the NPCA and PSV of the TPCA were significantly decreased after intravitreal bevacizumab injection (p < 0.05). There was no statistically significant difference in the other parameters.
   Conclusion. Our results suggest that intravitreal bevacizumab therapy has a measurable effect on retrobulbar blood flow. (C) 2009 Wiley Periodicals, Inc. J Clin Ultrasound 38:66-70, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jcu.20650
C1 [Mete, Ahmet; Bayram, Metin] Gaziantep Univ, Sch Med, Dept Radiol, Sahinbey, Gaziantep, Turkey.
   [Saygili, Oguzhan; Mete, Alper; Bekir, Necdet] Gaziantep Univ, Sch Med, Dept Ophtalmol, Sahinbey, Gaziantep, Turkey.
C3 Gaziantep University; Gaziantep University
RP Mete, A (通讯作者)，Gaziantep Univ, Sch Med, Dept Radiol, Sahinbey, Gaziantep, Turkey.
RI Mete, Alper/AAH-7332-2020; Bekir, Necdet/AAH-5385-2020
OI Mete, Alper/0000-0002-1712-5163; Bekir, Necdet/0000-0002-6755-2550
CR Akyuz Unsal AI, 2007, J AAPOS, V11, P277, DOI 10.1016/j.jaapos.2006.12.059
   Augustin Albert J, 2006, Expert Opin Emerg Drugs, V11, P725, DOI 10.1517/14728214.11.4.725
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Cekic Osman, 2007, International Ophthalmology, V27, P313, DOI 10.1007/s10792-007-9080-7
   Chen E, 2009, OPHTHAL SURG LAS IM, V40, P68, DOI 10.3928/15428877-20090101-04
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   GOBEL W, 1995, INVEST OPHTH VIS SCI, V36, P864
   Grunwald JE, 1996, BRIT J OPHTHALMOL, V80, P327, DOI 10.1136/bjo.80.4.327
   GUTHOFF RF, 1991, ARCH OPHTHALMOL-CHIC, V109, P532, DOI 10.1001/archopht.1991.01080040100037
   GUVEN D, 1996, OPHTHALMOLOGY, V103, P1243
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koz OG, 2007, ACTA OPHTHALMOL SCAN, V85, P838, DOI 10.1111/j.1600-0420.2007.00960.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Lieb WE, 1998, RADIOL CLIN N AM, V36, P1059, DOI 10.1016/S0033-8389(05)70231-1
   RIMMER T, 1989, BRIT J OPHTHALMOL, V73, P1, DOI 10.1136/bjo.73.1.1
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   TAYLOR GA, 1990, RADIOLOGY, V176, P231, DOI 10.1148/radiology.176.1.2112768
   Tosun O, 2007, ACTA RADIOL, V48, P763, DOI 10.1080/02841850701348713
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 25
TC 24
Z9 27
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0091-2751
J9 J CLIN ULTRASOUND
JI J. Clin. Ultrasound
PD FEB
PY 2010
VL 38
IS 2
BP 66
EP 70
DI 10.1002/jcu.20650
PG 5
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 548FP
UT WOS:000273945400002
PM 19953626
DA 2022-11-30
ER

PT J
AU Arikan, S
   Ersan, I
   Kara, S
   Gencer, B
   Korkmaz, S
   Vural, AS
AF Arikan, Sedat
   Ersan, Ismail
   Kara, Selcuk
   Gencer, Baran
   Korkmaz, Safak
   Vural, Azer Sara
TI Corneal thickness of eyes with unilateral age-related macular
   degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Central corneal thickness; Corneal
   volume; Peripheral corneal thickness
ID OPTICAL COHERENCE TOMOGRAPHY; OCULAR RESPONSE ANALYZER; BIOMECHANICAL
   PROPERTIES; SCLERAL RIGIDITY; BLOOD-FLOW; MACULOPATHY; VOLUME; RISK;
   GLAUCOMA; LASIK
AB Purpose: To compare the central corneal thicknesses (CCT), peripheral corneal thicknesses, and corneal volumes (CV) of the 2 eyes of patients with unilateral age-related macular degeneration (AMD).
   Methods: Twenty patients who were diagnosed with unilateral AMD were included in this prospective study for the purpose of making comparison between the diseased and healthy eyes. Optical coherence tomography and fundus fluorescein angiography imaging were applied to all patients in order to confirm and reveal the presence of unilateral AMD. Then, the measurements of CCT, peripheral corneal thickness measured 4 mm distant from the center of the cornea (4 mm CT), and CV of each eye of these patients were obtained through the rotating Scheimpflug corneal topographer.
   Results: Wilcoxon signed-rank test did not demonstrate a statistically significant difference between the 2 eyes of patients with unilateral AMD when we compared the CCT and CV of diseased and healthy eyes (p>0.05). However, 4 mm CT of the diseased eyes of these patients were statistically significantly thicker than the healthy eyes (p<0.05).
   Conclusions: The significant difference in terms of 4 mm CT between the diseased and healthy eyes of patients with unilateral AMD may demonstrate the possible effect of peripheral corneal thickness on the development of AMD.
C1 [Arikan, Sedat; Ersan, Ismail; Kara, Selcuk; Gencer, Baran; Vural, Azer Sara] Canakkale Onsekiz Mart Univ, Sch Med, Dept Ophthalmol, Canakkale, Turkey.
   [Korkmaz, Safak] Duzce State Hosp, Dept Ophthalmol, Duzce, Turkey.
C3 Canakkale Onsekiz Mart University; Duzce Ataturk State Hospital
RP Arikan, S (通讯作者)，Canakkale Onsekiz Mart Univ, Tip Fak, Sch Med, Dept Ophthalmol, Canakkale, Turkey.
EM drsarikan@gmail.com
RI Kara, Selcuk/C-8315-2015
OI Kara, Selcuk/0000-0002-8017-2173
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Detorakis ET, 2013, CLIN EXP OPHTHALMOL, V41, P73, DOI 10.1111/j.1442-9071.2012.02809.x
   Ebneter A, 2009, EYE, V23, P606, DOI 10.1038/eye.2008.47
   Ethier CR, 2006, CAN J OPHTHALMOL, V41, P9, DOI 10.1016/S0008-4182(06)80060-8
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Fukuda R, 2013, CURR EYE RES, V38, P531, DOI 10.3109/02713683.2012.745878
   Ishii Kotaro, 2012, International Ophthalmology, V32, P553, DOI 10.1007/s10792-012-9608-3
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Knez N, 2009, J INT MED RES, V37, P1552, DOI 10.1177/147323000903700533
   Kymionis GD, 2007, CORNEA, V26, P182, DOI 10.1097/ICO.0b013e31802c9def
   Lau W, 2011, INVEST OPHTH VIS SCI, V52, P3207, DOI 10.1167/iovs.10-6754
   Li Y, 2008, OPHTHALMOLOGY, V115, P2159, DOI 10.1016/j.ophtha.2008.08.004
   Liu Rui, 2008, Zhonghua Yan Ke Za Zhi, V44, P715
   Luce DA, 2005, J CATARACT REFR SURG, V31, P156, DOI 10.1016/j.jcrs.2004.10.044
   Mangouritsas G, 2011, CLIN OPHTHALMOL, V5, P1071, DOI 10.2147/OPTH.S23086
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Muller A, 2004, BRIT J OPHTHALMOL, V88, P325, DOI 10.1136/bjo.2003.019315
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pepose JS, 2007, AM J OPHTHALMOL, V143, P39, DOI 10.1016/j.ajo.2006.09.036
   Pulido J, 2006, AM J OPHTHALMOL, V141, P731, DOI 10.1016/j.ajo.2005.12.021
   Rosa N, SEMIN OPHTHALMOL
   Sedaghat MR, 2012, J RES MED SCI, V17, P32
   Shah Sunil, 2006, Cont Lens Anterior Eye, V29, P257, DOI 10.1016/j.clae.2006.09.006
   Shah S, 2007, INVEST OPHTH VIS SCI, V48, P3026, DOI 10.1167/iovs.04-0694
   Sharma N, 2005, J REFRACT SURG, V21, P496
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Suzuki H, 2006, AM J OPHTHALMOL, V142, P525, DOI 10.1016/j.ajo.2006.04.024
NR 31
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY-JUN
PY 2015
VL 25
IS 3
BP 214
EP 217
DI 10.5301/ejo.5000544
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR2IN
UT WOS:000361151700095
PM 25449636
DA 2022-11-30
ER

PT J
AU Tunon, J
   Ruiz-Moreno, JM
   Martin-Ventura, JL
   Blanco-Colio, LM
   Lorenzo, O
   Egido, J
AF Tunon, Jose
   Maria Ruiz-Moreno, Jose
   Luis Martin-Ventura, Jose
   Blanco-Colio, Luis M.
   Lorenzo, Oscar
   Egido, Jesus
TI Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular
   Degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; angiogenesis; antiangiogenic drugs;
   atherosclerosis; atherothrombosis; cardiovascular risk; myocardial
   infarction; stroke
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN
   ATHEROSCLEROTIC PLAQUES; METASTATIC COLORECTAL-CANCER; ACUTE CORONARY
   SYNDROMES; BLOOD-RETINAL BARRIER; NITRIC-OXIDE SYNTHASE; SMOOTH-MUSCLE
   CELLS; RABBIT MODEL; CHOROIDAL NEOVASCULARIZATION
AB The neovascular form of the age-related macular degeneration (AMD) causes most cases of severe blindness. Because vascular endothelial growth factor (VEGF) plays a leading role in this disorder, several inhibitors of this molecule are being used in its treatment. However,VEGF has important functions in vascular pathophysiology. It enhances the development of collateral vessels that may supply blood to areas whose arteries are severely affected by atherosclerotic lesions. Additionally, it promote restoration of the damaged endothelium, a vessel layer that protects against the development and it has hypotensive effects. In contrast, VEGF may stimulate the formation of microvessels inside the atherosclerotic plaque. These vessels may become disrupted and cause intraplaque hemorrhage, stimulating disease progression. VEGF also has a role in thrombus formation, The effects of anti-VEGF therapy may therefore compromise patient safety. When administered systemically to cancer patients, the main cardiovascular adverse effects of these compounds have been thrombosis, hemorrhage and hypertension. As patients with AMD constitute a high-risk population for cardiovascular events, the safety of new anti-VEGF therapies must be assessed. In this review we analyze the effects of VEGF on atherosclerosis and the cardiovascular safety of anti-VEGF therapies in AMD. (Surv Ophthalmol 54:339-348, 2009. (c) 2009 Elsevier Inc. All rights reserved.)
C1 [Tunon, Jose; Luis Martin-Ventura, Jose; Blanco-Colio, Luis M.; Lorenzo, Oscar; Egido, Jesus] Fdn Jimenez Diaz, Dept Cardiol, E-28040 Madrid, Spain.
   [Tunon, Jose; Luis Martin-Ventura, Jose; Blanco-Colio, Luis M.; Lorenzo, Oscar; Egido, Jesus] Fdn Jimenez Diaz, Vasc Res Lab, E-28040 Madrid, Spain.
   [Tunon, Jose; Luis Martin-Ventura, Jose; Blanco-Colio, Luis M.; Lorenzo, Oscar; Egido, Jesus] Univ Autonoma Madrid, Madrid, Spain.
   [Maria Ruiz-Moreno, Jose] Univ Castilla La Mancha, Dept Ophthalmol, Albacete, Spain.
C3 Autonomous University of Madrid; Universidad de Castilla-La Mancha
RP Tunon, J (通讯作者)，Fdn Jimenez Diaz, Dept Cardiol, Ave Reyes Catolicos 2, E-28040 Madrid, Spain.
EM j.tunon@wanadoo.es
RI Tuñón, José L/R-3037-2016; Blanco-Colio, Luis M./Z-2390-2019; Lorenzo,
   Oscar/L-2526-2013; Tunon, Jose/ABA-8847-2020; Ruiz-Moreno, José
   M/E-4644-2016; MARTIN-VENTURA, JOSE LUIS/Z-2386-2019
OI Tuñón, José L/0000-0003-2220-180X; Lorenzo, Oscar/0000-0001-5515-6078;
   MARTIN-VENTURA, JOSE LUIS/0000-0003-2090-8641; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788; Blanco-Colio, Luis Miguel/0000-0002-1560-6609;
   Tunon, Jose/0000-0002-1373-0999
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bauriedel G, 1999, CARDIOVASC RES, V41, P480, DOI 10.1016/S0008-6363(98)00318-6
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   Blanco-Colio LM, 2003, KIDNEY INT, V63, P12, DOI 10.1046/j.1523-1755.2003.00744.x
   Breitbart AS, 2001, ANN PLAS SURG, V46, P555, DOI 10.1097/00000637-200105000-00016
   Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2
   Cho HJ, 2003, CIRCULATION, V108, P2918, DOI 10.1161/01.CIR.0000097001.79750.78
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013
   de Lemos JA, 2003, CIRCULATION, V107, P690, DOI 10.1161/01.CIR.0000049742.68848.99
   Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Falk E, 1996, ATHEROSCLEROSIS CORO, V1, P491
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fliser D, 2004, CIRCULATION, V110, P1103, DOI 10.1161/01.CIR.0000140265.21608.8E
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406
   FUSTER V, 1996, SYNDROMES ATHEROSCLE, P1
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gowdak LHW, 2000, CIRCULATION, V102, P565
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141
   Guba M, 2005, BLOOD, V105, P4463, DOI 10.1182/blood-2004-09-3540
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0
   HernandezPresa M, 1997, CIRCULATION, V95, P1532
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hutter R, 2004, CIRCULATION, V110, P2430, DOI 10.1161/01.CIR.0000145120.37891.8A
   Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092
   JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613
   Juan-Babot JO, 2003, REV ESP CARDIOL, V56, P978, DOI 10.1157/13052386
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kolodgie FD, 2007, J AM COLL CARDIOL, V49, P2093, DOI 10.1016/j.jacc.2006.10.083
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348
   Martin-Ventura JL, 2005, STROKE, V36, P1796, DOI 10.1161/01.STR.0000174289.34110.b0
   Martin-Ventura JL, 2004, CIRCULATION, V110, P2216, DOI 10.1161/01.CIR.0000136814.87170.B1
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   NICOSIA RF, 1994, AM J PATHOL, V145, P1023
   Oemar BS, 1998, CIRCULATION, V97, P2494, DOI 10.1161/01.CIR.97.25.2494
   Rajagopalan S, 1996, CIRCULATION, V94, P240, DOI 10.1161/01.CIR.94.3.240
   RENKIN EM, 1977, CIRC RES, V41, P735, DOI 10.1161/01.RES.41.6.735
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   SCHWARTZ CJ, 1996, SYNDROMES ATHEROSCLE, P17
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SCOTTBURDEN T, 1993, CIRCULATION, V87, P51
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121
   Shiojima I, 2004, CIRCULATION, V110, P2283, DOI 10.1161/01.CIR.0000146723.23523.47
   Simons M, 2005, CIRCULATION, V111, P1556, DOI 10.1161/01.CIR.0000159345.00591.8F
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STEIN Y, 1977, BIOCHEM, V7, P313
   Suga SI, 2001, KIDNEY INT, V60, P1297, DOI 10.1046/j.1523-1755.2001.00935.x
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594
   Tziakas DN, 2007, J AM COLL CARDIOL, V49, P2081, DOI 10.1016/j.jacc.2006.08.069
   VANHOUTTE PM, 1988, NEW ENGL J MED, V319, P512, DOI 10.1056/NEJM198808253190809
   Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070
   *VISION CLIN TRIAL, 1996, OPHTHALMOLOGY, V113, P992
   Weltermann A, 1999, ARTERIOSCL THROM VAS, V19, P1757, DOI 10.1161/01.ATV.19.7.1757
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011
NR 87
TC 42
Z9 45
U1 2
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2009
VL 54
IS 3
BP 339
EP 348
DI 10.1016/j.survophthal.2009.02.003
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446VX
UT WOS:000266150700003
PM 19422962
DA 2022-11-30
ER

PT J
AU Axer-Siegel, R
   Bourla, D
   Ehrlich, R
   Dotan, G
   Benjamini, Y
   Gavendo, S
   Weinberger, D
   Sela, BA
AF Axer-Siegel, R
   Bourla, D
   Ehrlich, R
   Dotan, G
   Benjamini, Y
   Gavendo, S
   Weinberger, D
   Sela, BA
TI Association of neovascular age-related macular degeneration and
   hyperhomocysteinemia
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; TOTAL HOMOCYSTEINE LEVELS; RISK-FACTORS;
   CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN; VASCULAR-DISEASE;
   NATIONAL-HEALTH; MACULOPATHY; PLASMA; SERUM
AB PURPOSE: To assess the relationship between plasma homocysteine levels and exudative neovascular age-related macular degeneration (AMD).
   DESIGN: Cross-sectional study.
   METHODS: A prospective comparative cross,sectional study was conducted in outpatient ophthalmology clinics in a university affiliated medical institution. The cohort consisted of 59 patients (25 male, 34 female) with a mean age of 78 years (standard deviation [SD] = 8.4) with neovascular AMD who were candidates for photodynamic treatment. Patients were compared for plasma homocysteine levels with 58 patients who had dry AMD (24 male, 34 female) with a mean age of 76.3 years (SD = 8.4) and with a control group of 56 age,matched subjects (27 male, 29 female), with a mean age of 77.3 years (SD = 8.2). A 3,ml venous blood sample was obtained from each participant after an 8-hour fast. Levels of plasma homocysteine were measured by high performance liquid chromatography. The main outcome measure was hyperhomocysteinemia, defined as a plasma homocysteine level above 15 mumol/l.
   RESULTS: Homocysteine levels were higher by 27.9% in the neovascular AMD than in the dry AMD group, and by 21.9% than in the control group (P <.02). Hyperhomocysteinemia was found in 44. 1 % of the study group, in 22.4% of the dry AMD group, and in 21.4% of the control group (P = .0 11).
   CONCLUSIONS: This study suggests an association between an elevated plasma level of homocysteine and exudative neovascular AMD but not dry AMD.
C1 Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   Chaim Sheba Med Ctr, Inst Chem Pathol, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   Tel Aviv Univ, Sackler Fac Exact Sci, Dept Stat, IL-69978 Tel Aviv, Israel.
C3 Rabin Medical Center; Chaim Sheba Medical Center; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv University
RP Axer-Siegel, R (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
RI Benjamini, Yoav/C-4219-2008
CR ARCHER DB, 1981, AM J OPHTHALMOL, V91, P433, DOI 10.1016/0002-9394(81)90230-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bostom AG, 1999, ANN INTERN MED, V131, P352, DOI 10.7326/0003-4819-131-5-199909070-00006
   CHEN J C, 1989, Investigative Ophthalmology and Visual Science, V30, P153
   Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449
   CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701
   DUVIGNEAUD V, 1952, TRIAL RES SULFUR CHE, P213
   Eikelboom JW, 2000, STROKE, V31, P1069, DOI 10.1161/01.STR.31.5.1069
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JACOBSEN DW, 1989, ANAL BIOCHEM, V178, P208, DOI 10.1016/0003-2697(89)90381-3
   Jakubowski H, 1997, J BIOL CHEM, V272, P1935
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P183
   Kluijtmans LAJ, 2003, BLOOD, V101, P2483, DOI 10.1182/blood.V101.7.2483
   MCCULLY KS, 1969, AM J PATHOL, V56, P111
   *NAT ADV EYE COUNC, 1993, US DEP HLTH HUM SERV
   PECKLIN L, 2001, OPHTHALMOLOGY, V108, P705
   Pianka P, 2000, OPHTHALMOLOGY, V107, P1588, DOI 10.1016/S0161-6420(00)00181-0
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1
   STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187
   UELAND PM, 1993, CLIN CHEM, V39, P1764
   Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoneya S, 1998, INVEST OPHTH VIS SCI, V39, P1286
   Yoneya S, 1998, RETINA-J RET VIT DIS, V18, P30
NR 36
TC 58
Z9 64
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2004
VL 137
IS 1
BP 84
EP 89
DI 10.1016/S0002-9394(03)00864-X
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 757JJ
UT WOS:000187559000011
PM 14700648
DA 2022-11-30
ER

PT J
AU Scholl, HPN
   Issa, PC
   Walier, M
   Janzer, S
   Pollok-Kopp, B
   Borncke, F
   Fritsche, LG
   Chong, NV
   Fimmers, R
   Wienker, T
   Holz, FG
   Weber, BHF
   Oppermann, M
AF Scholl, Hendrik P. N.
   Issa, Peter Charbel
   Walier, Maja
   Janzer, Stefanie
   Pollok-Kopp, Beatrix
   Boerncke, Florian
   Fritsche, Lars G.
   Chong, Ngaihang V.
   Fimmers, Rolf
   Wienker, Thomas
   Holz, Frank G.
   Weber, Bernhard H. F.
   Oppermann, Martin
TI Systemic Complement Activation in Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
AB Dysregulation of the alternative pathway (AP) of complement cascade has been implicated in the pathogenesis of age-related macular degeneration (AMD), the leading cause of blindness in the elderly. To further test the hypothesis that defective control of complement activation underlies AMD, parameters of complement activation in blood plasma were determined together with disease-associated genetic markers in AMD patients. Plasma concentrations of activation products C3d, Ba, C3a, C5a, SC5b-9, substrate proteins C3, C4, factor B and regulators factor H and factor D were quantified in patients (n = 112) and controls (n = 67). Subjects were analyzed for single nucleotide polymorphisms in factor H (CFH), factor B-C2 (BF-C2) and complement C3 (C3) genes which were previously found to be associated with AMD. All activation products, especially markers of chronic complement activation Ba and C3d (p<0.001), were significantly elevated in AMD patients compared to controls. Similar alterations were observed in factor D, but not in C3, C4 or factor H. Logistic regression analysis revealed better discriminative accuracy of a model that is based only on complement activation markers Ba, C3d and factor D compared to a model based on genetic markers of the complement system within our study population. In both the controls' and AMD patients' group, the protein markers of complement activation were correlated with CFH haplotypes. This study is the first to show systemic complement activation in AMD patients. This suggests that AMD is a systemic disease with local disease manifestation at the ageing macula. Furthermore, the data provide evidence for an association of systemic activation of the alternative complement pathway with genetic variants of CFH that were previously linked to AMD susceptibility.
C1 [Scholl, Hendrik P. N.; Issa, Peter Charbel; Janzer, Stefanie; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Walier, Maja; Fimmers, Rolf; Wienker, Thomas] Univ Bonn, Inst Med Biomet, Informat & Epidemiol, Bonn, Germany.
   [Pollok-Kopp, Beatrix; Boerncke, Florian; Oppermann, Martin] Univ Gottingen, Dept Cellular & Mol Immunol, Gottingen, Germany.
   [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Chong, Ngaihang V.] Univ Oxford, Oxford Eye Hosp, Oxford, England.
C3 University of Bonn; University of Bonn; University of Gottingen;
   University of Regensburg; University of Oxford
RP Scholl, HPN (通讯作者)，Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
EM mopperm@gwdg.de
RI Issa, Peter Charbel/O-2580-2019; Issa, Peter Charbel/E-8935-2018;
   Fritsche, Lars G/AAF-9387-2019; Chong, Ngaihang V/A-5141-2009; Chong,
   Victor/Q-6565-2018; Issa, Peter Charbel/F-9603-2011; Mohammed,
   Imran/J-8271-2012
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Fritsche, Lars G/0000-0002-2110-1690;
   Chong, Victor/0000-0002-7693-522X; Mohammed, Imran/0000-0002-8412-0768;
   Weber, Bernhard H.F./0000-0002-8808-7723
FU European Commission (EU FP6), Integrated Project "EVIGENORET"
   [LSHG-CT-2005-512036]; German Research Foundation (DFG) Heisenberg
   Fellowship [SCHO 734/2-1, HO 1926/1-3]
FX Pro Retina Foundation Pro-Re/Seed/Issa.1; European Commission (EU FP6),
   Integrated Project "EVIGENORET" (LSHG-CT-2005-512036); German Research
   Foundation (DFG) Heisenberg Fellowship SCHO 734/2-1, HO 1926/1-3. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Becker T, 2005, ANN HUM GENET, V69, P747, DOI 10.1111/j.1529-8817.2005.00198.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BOURKE BE, 1982, CLIN EXP IMMUNOL, V48, P726
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Comitato A, 2007, HUM MOL GENET, V16, P1699, DOI 10.1093/hmg/ddm118
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   DERODRIGUEZ CS, 2004, MOL IMMUNOL, V41, P355
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MOLLNES TE, 1986, ARTHRITIS RHEUM, V29, P715, DOI 10.1002/art.1780290603
   MOLLNES TE, 1988, CLIN EXP IMMUNOL, V73, P484
   Mollnes TE, 2007, MOL IMMUNOL, V44, P3838, DOI 10.1016/j.molimm.2007.06.150
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OPPERMANN M, 1991, KIDNEY INT, V40, P939, DOI 10.1038/ki.1991.298
   OPPERMANN M, 1990, J IMMUNOL METHODS, V133, P181, DOI 10.1016/0022-1759(90)90358-3
   OPPERMANN M, 1992, IMMUNOPHARMACOLOGY, V24, P119, DOI 10.1016/0162-3109(92)90018-8
   OPPERMANN M, 1991, COMPLEMENT INFLAMMAT, V8, P13, DOI 10.1159/000463173
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   WURZNER R, 1991, COMPLEMENT INFLAMMAT, V8, P328
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 41
TC 297
Z9 317
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2008
VL 3
IS 7
AR e2593
DI 10.1371/journal.pone.0002593
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 406IM
UT WOS:000263288200052
PM 18596911
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Sahinoglu-Keskek, N
   Sermet, F
AF Sahinoglu-Keskek, Nedime
   Sermet, Figen
TI Impact of ocular and systemic risk factors on progression of geographic
   atrophy in age-related macular degeneration
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age related macular degeneration; Geographic atrophy; Fundus
   autofluorescence; Reticular pseudodrusen
AB Background: Geographic atrophy (GA) corresponds to an end-stage form of age-related macular degeneration and the leading cause of irreversible vision loss. The aim of this study was to investigate the role of fundus autofluorescence (FAF) patterns surrounding GA, baseline GA size, the presence of reticular pseudodrusen (RPD), the condition of the fellow eye and the presence of systemic vascular diseases (diabetes, atherosclerosis, systemic hypertension) on the progression of GA due to age-related macular degeneration.
   Methods: Seventy-five eyes of 52 patients with GA were included into this retrospective study. Digital FAF images were achieved using scanning laser ophthalmoscopy. Areas of GA were measured with the Region Finder software program on an Heidelberg Retinal Angiograph 2. FAF patterns around GA were classified and the presence of RPD and systemic diseases were noted. The median follow-up of the patients was 2.6 years (interquartile range, 1-9.2).
   Results: The median progression rate of the banded pattern (median 0.97 mm(2)/year) was significantly higher than the other patterns (median 0.85 mm(2)/year) (p = 0.03). Eyes with RPD had a significantly higher progression rate (median 1.21 mm(2)/year) than those without RPD (median 0.79 mm(2)/year) (p = 0.007). The presence of systemic diseases was not related with lesion progression rates.
   Conclusions: The results demonstrate that the banded pattern and the presence of RPD accelerate the progression of GA and function as predictive factors.
C1 [Sahinoglu-Keskek, Nedime] Baskent Univ, Adana Res & Training Ctr, Dept Ophthalmol, Fac Med, Adana, Turkey.
   [Sermet, Figen] Ankara Univ, Dept Ophthalmol, Fac Med, Ankara, Turkey.
C3 Baskent University; Ankara University
RP Sahinoglu-Keskek, N (通讯作者)，Baskent Univ, Adana Res & Training Ctr, Fac Med, 39 Sok,6, TR-01250 Adana, Turkey.
EM nedime_sahin@yahoo.com
RI SAHINOGLU-KESKEK, NEDIME/T-4258-2017
OI SAHINOGLU-KESKEK, NEDIME/0000-0001-8544-103X
CR Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   Bagheri Saghar, 2019, J Vitreoretin Dis, V3, P278, DOI 10.1177/2474126419859454
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Grassmann F, 2019, JAMA OPHTHALMOL, V137, P867, DOI 10.1001/jamaophthalmol.2019.1318
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kiziltunc PB, 2018, TURK OFTALMOL DERG, V48, P304, DOI 10.4274/tjo.69260
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Ludtke L, 2019, MED SCI MONITOR, V25, P6383, DOI 10.12659/MSM.915493
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Olcay K, 2015, TURK OFTALMOL DERG, V45, P235, DOI 10.4274/tjo.93276
   Sastre-Ibanez M, 2018, Arch Soc Esp Oftalmol (Engl Ed), V93, P22, DOI 10.1016/j.oftal.2017.07.004
   Shen LBL, 2019, RETINA-J RET VIT DIS, V39, P1829, DOI 10.1097/IAE.0000000000002480
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Vaclavik V, 2008, OPHTHALMOLOGY, V115, P342, DOI 10.1016/j.ophtha.2007.04.023
NR 28
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2021
VL 33
AR 102171
DI 10.1016/j.pdpdt.2020.102171
EA JAN 2021
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RC2HD
UT WOS:000632624000005
PM 33401025
DA 2022-11-30
ER

PT J
AU Mullins, RF
   Grassi, MA
   Skeie, JM
AF Mullins, RF
   Grassi, MA
   Skeie, JM
TI Glycoconjugates of choroidal neovascular membranes in age-related
   macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; ENDOTHELIAL GROWTH-FACTOR; SORSBYS FUNDUS
   DYSTROPHY; LASER PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; ADHESION
   MOLECULES; TISSUE INHIBITOR; LECTIN-BINDING; MACULOPATHY; EXPRESSION
AB Purpose: Choroidal neovascularization (CNV) is a complication of multiple eye diseases, including age-related macular degeneration, that usually results in irreversible vision loss. It is characterized by proliferation and growth of choroidal blood vessels through Bruch's membrane into the subpigment epithelial and/or subretinal space. The purpose of this study was to characterize the carbohydrate groups associated with CNV by lectin histochemistry.
   Methods: Frozen sections from three human eyes with CNV (two fixed eyes and one unfixed eye) were prepared. Sections containing choroidal neovascular membranes were incubated with a battery of biotinylated lectins directed against a number of distinct oligosaccharide moieties. Lectin labeling of the vessels in CNV was visualized with avidin-Texas red.
   Results: Several carbohydrate groups were preferentially associated with the vascular elements in CNV. Glycoconjugates that react with lectins derived from wheat germ, soybean, and hairy vetch seed (sWGA, SBA, and VVA, respectively) all showed reactivity with CNV vessels that was higher than the labeling of the surrounding matrix. SBA and sWGA also reacted with CNV vessels at low concentrations at which normal retinal and choroidal vessels were largely unlabeled.
   Conclusions: Choroidal neovascular membranes possess a distinct set of carbohydrate moieties. These data may be valuable in understanding endothelial cell biology in CNV.
C1 Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, Iowa City, IA USA.
C3 University of Iowa
RP Mullins, RF (通讯作者)，4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891
FU NEI NIH HHS [R03 EY14563, F32 EY022280] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R03EY014563, F32EY022280] Funding Source: NIH
   RePORTER
CR ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   AUGUSTINVOSS HG, 1992, J CELL BIOL, V119, P483, DOI 10.1083/jcb.119.2.483
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Danguy A, 1998, ACTA ANAT, V161, P206
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2004, NEW ENGL J MED, V351, P2863, DOI 10.1056/NEJMe048316
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grisanti S, 2004, EXP EYE RES, V78, P207, DOI 10.1016/j.exer.2003.11.008
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HAWKINS BS, 1992, ARCH OPHTHALMOL-CHIC, V110, P761
   HENRY CBS, 1995, MICROVASC RES, V49, P201, DOI 10.1006/mvre.1995.1016
   Jimenez D, 2005, J BIOL CHEM, V280, P5854, DOI 10.1074/jbc.M412104200
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLIFFEN M, 1994, INVEST OPHTH VIS SCI, V35, P2901
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pinart E, 2001, TERATOLOGY, V63, P42, DOI 10.1002/1096-9926(200101)63:1&lt;42::AID-TERA1007&gt;3.0.CO;2-K
   Rayborn ME, 1997, DEGENERATIVE RETINAL DISEASES, P17
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sgambati E, 2003, BIOL NEONATE, V84, P119, DOI 10.1159/000071946
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   VORBRODT AW, 1986, ACTA NEUROPATHOL, V70, P103, DOI 10.1007/BF00691427
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong SC, 2003, BRIT J OPHTHALMOL, V87, P796, DOI 10.1136/bjo.87.6.796
   Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200
   Yasukawa T, 2000, CURR EYE RES, V21, P952, DOI 10.1076/ceyr.21.6.952.6992
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
NR 44
TC 17
Z9 18
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 14
PY 2005
VL 11
IS 58-60
BP 509
EP 517
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 950GP
UT WOS:000230845900002
PM 16052166
DA 2022-11-30
ER

PT J
AU Spandau, UHM
   Jonas, JB
AF Spandau, Ulrich H. M.
   Jonas, Jost B.
TI Retinal pigment epithelium tear after intravitreal bevacizumab for
   exudative age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY
AB PURPOSE: To report on the development of retinal pigment epithelium tears after intravitreal injections of bevacizumab as treatment of exudative age-related macular degeneration (AMD).
   DESIGN: Interventional case series.
   METHODS: The study included 63 patients who received an intravitreal injection of 1.5 mg bevacizumab as treatment of a detachment of the retinal pigment epithelium attributable to AMD and who had a follow,up of at least two months.
   RESULTS: Four patients (6%) developed a tear of the retinal pigment epithelium in the parafoveal region. Compared with the baseline value, visual acuity at the end of follow,up remained stable in three patients and declined in the fourth patient.
   CONCLUSIONS: Intravitreal injections of bevacizumab may be followed by a tear of the retinal pigment epithelium in eyes with exudative AMD and a retinal pigment epithelium detachment.
C1 Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Spandau, UHM (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Ulrich.Spandau@augen.ma.uni-heidelberg.de
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   JONAS JB, 2006, IN PRESS INDIAN J OP
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
NR 6
TC 51
Z9 57
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 1068
EP 1070
DI 10.1016/j.ajo.2006.06.048
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100029
PM 17157597
DA 2022-11-30
ER

PT J
AU Biesemeier, A
   Taubitz, T
   Julien, S
   Yoeruek, E
   Schraermeyer, U
AF Biesemeier, Antje
   Taubitz, Tatjana
   Julien, Sylvie
   Yoeruek, Efdal
   Schraermeyer, Ulrich
TI Choriocapillaris breakdown precedes retinal degeneration in age-related
   macular degeneration
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Age related macular degeneration; Choriocapillaris; Retinal pigment
   epithelium; Transition between healthy and atrophied areas;
   Whole-section panorama images
ID BASAL LINEAR DEPOSIT; BRUCHS-MEMBRANE; CHOROIDAL NEOVASCULARIZATION;
   MORPHOMETRIC-ANALYSIS; PIGMENT EPITHELIUM; HUMAN EYES; DRUSEN;
   PATHOGENESIS; ASSOCIATION; IMPAIRMENT
AB This work presents a combined light and electron microscopical approach to investigate the initial breakdown of the retinal pigment epithelium (RPE) and choriocapillaris (CC) in age-related macular degeneration (AMD). Perimacular sections of 12 dry and wet AMD eyes (82 +/- 15 years) and 7 age-matched controls (75 +/- 10 years) without retinal pathology were investigated. Disease progression was classified into 5 stages of retinal degeneration to investigate the concurrent CC breakdown. Special emphasis was laid on transitions where intact CC-RPE-retina complexes went over into highly atrophied areas. AMD sections showed elevated loss of photoreceptors, RPE and CC (p < 0.01), and thickened Bruch's membrane with increased basal laminar and linear deposits compared with controls. Up to 27% of the CC was lost in controls although RPE and retina were still intact. This primary loss of CC further increased with AMD (up to 100%). The data implicate that CC breakdown already occurs during normal aging and precedes degeneration of the RPE and retina with AMD, defining AMD as a vascular disease. Particular attention should be given to the investigation of early AMD stages and transitional stages to the late stage that reveal a possible sequence of degenerative steps with aging and AMD. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Biesemeier, Antje; Taubitz, Tatjana; Julien, Sylvie; Schraermeyer, Ulrich] Univ Tubingen, Ctr Ophthalmol, Sect Expt Vitreoretinal Surg, D-72076 Tubingen, Germany.
   [Yoeruek, Efdal] Univ Tubingen, Ctr Ophthalmol, Cornea Bank, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP Biesemeier, A (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Sect Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM antje.biesemeier@med.uni-tuebingen.de
RI Taubitz, Tatjana/AAA-2941-2021
OI Taubitz, Tatjana/0000-0002-6747-4484; Biesemeier,
   Antje/0000-0002-3462-8803; Julien-Schraermeyer,
   Sylvie/0000-0002-2322-511X
FU Deutsche Forschungsgemeinschaft [BI 1551/2-1, fortuene 1957-0-0,
   fortuene 2062-0-0]
FX The authors thank Prof Dr Joe Hollyfield and Dr Vera Bonilha (Retinal
   Degeneration Histopathology Laboratory, Cole Eye Institute - The
   Cleveland Clinic Foundation) for their kind help in providing them with
   AMD donor eyes. They also thank the collegues of Dr Yoeruek, namely, Dr
   MaxWarga, Johanna Hofmann, and Dr Barbara Wallenfels-Thilo of the Cornea
   Bank Tuebingen, and Dr Bernhard Hirt of the Department of Anatomy
   Tuebingen for providing them with the control eyes. They are indebted to
   the donors and their families for allowing the use of their eyes in
   reseach. They thank Sigrid Schultheiss for excellent technical
   assistance and Judith Birch for proof reading. This work was supported
   by the following grants: Deutsche Forschungsgemeinschaft BI 1551/2-1,
   fortuene 1957-0-0, and fortuene 2062-0-0.
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown NH, 2009, GRAEF ARCH CLIN EXP, V247, P1069, DOI 10.1007/s00417-009-1044-3
   Brown WR, 2011, NEUROPATH APPL NEURO, V37, P56, DOI 10.1111/j.1365-2990.2010.01139.x
   Curcio C.A., 2012, RETINA, V33, P265
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Duke-Elder S., 1966, SYSTEM OPHTHALMOLOGY, P610
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Herrmann P, 2013, OPHTHALMOLOGE, V110, P377, DOI 10.1007/s00347-012-2779-5
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hogan M J, 1967, Trans Ophthalmol Soc U K, V87, P113
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lutty G, 1999, MOL VIS, V5
   Machalinska Anna, 2011, Klin Oczna, V113, P228
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sierra C, 2012, PANMINERVA MED, V54, P179
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Whitmore SS, 2013, MOL VIS, V19, P2274
NR 48
TC 184
Z9 188
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD NOV
PY 2014
VL 35
IS 11
BP 2562
EP 2573
DI 10.1016/j.neurobiolaging.2014.05.003
PG 12
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA AR2LX
UT WOS:000343419800017
PM 24925811
OA hybrid
DA 2022-11-30
ER

PT J
AU Markowitz, SN
   Aleykina, N
AF Markowitz, Samuel N.
   Aleykina, Natalya
TI The relationship between scotoma displacement and preferred retinal loci
   in low-vision patients with age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE scotoma displacement; PRL; macular perimetry; age-related macular
   degeneration
ID VISUAL-ACUITY; FIXATION
AB Objective: Adaptive strategies in low-vision patients with age-related macular degeneration use preferred retinal loci (PRLs) for the purpose of achieving better visual function. In the process of redirecting the eye toward the PRL, central scotomata are displaced eccentrically. The consequential effect of the first on the second may offer an indirect method for PRL identification. The purpose of this study was to clarify the relationship between scotoma displacement and PRL location.
   Design: Prospective, nonrandomized, observational case series.
   Participants: Forty-one adults with a confirmed diagnosis of age-related macular degeneration.
   Methods: Scotoma characteristics were obtained with automated perimetry. PRL topography was obtained with the Nidek MP-1 instrument. Outcome measures selected for this study were scotoma displacement and PRL eccentricities estimates.
   Results: We tested 16 males and 25 females aged 70-98 years (mean 82.5 [SD 6.71] years) with best-corrected visual acuity of 0.81 (SD 0.24) logMar units (20/128). PRL location logically matched scotoma displacement in 30 study subjects (73.17%, p < 0.00432). In this subgroup (n = 30), PRL eccentricity (5.55 [SD 3.35]degrees) was almost identical to scotoma displacement eccentricity (5.22 [SD 1.98]degrees) (p < 0.65).
   Conclusions: Scotoma displacement recorded with macular perimetry methods offers reasonable indirect estimates of PRL location.
C1 [Markowitz, Samuel N.; Aleykina, Natalya] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
CR Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Jarc-Vidmar M, 2006, EYE, V20, P688, DOI 10.1038/sj.eye.6701949
   LEE KK, CAN J OPHTH IN PRESS
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Markowitz SN, 2004, CAN J OPHTHALMOL, V39, P56, DOI 10.1016/S0008-4182(04)80053-X
   MARKOWITZ SN, P 9 INT C LOW VIS VI
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   WARREN M, 1996, PREREADING WRITING E
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 13
TC 11
Z9 11
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2010
VL 45
IS 1
BP 58
EP 61
DI 10.3129/i09-244
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 558YD
UT WOS:000274783900011
PM 20130712
DA 2022-11-30
ER

PT J
AU Xu, XR
   Zhong, L
   Huang, BL
   Wei, YH
   Zhou, X
   Wang, L
   Wang, FQ
AF Xu, Xin-Rong
   Zhong, Lu
   Huang, Bing-Lin
   Wei, Yuan-Hua
   Zhou, Xin
   Wang, Ling
   Wang, Fu-Qiang
TI Comparative proteomic analysis of plasma proteins in patients with
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; clinical patients; comparative
   proteomics; plasma proteins; two-dimensional electrophoresis
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; PROGRESSIVE
   STAGES; OXIDATIVE STRESS; BINDING-PROTEIN; EXPRESSION; POPULATIONS;
   INHIBITORS; RECEPTOR; COMPLEX
AB AIM: To find the significant altered proteins in age - related macular degeneration (AMD) patients as potential biomarkers of AMD.
   METHODS: A comparative analysis of the protein pattern of AMD patients versus healthy controls was performed by means of proteomic analysis using two dimensional gel electrophoresis followed by protein identification with MALDI TOF/TOF mass spectrometry.
   RESULTS: We identified 28 proteins that were significantly altered with clinical relevance in AMD patients. These proteins were involved in a wide range of biological functions including immune responses, growth cytokines, cell fate determination, wound healing, metabolism, and anti-oxidance.
   CONCLUSION: These results demonstrate the capacity of proteomic analysis of AMD patient plasma. In addition to the utility of this approach for biomarker discovery, identification of alterations in endogenous proteins in the plasma of AMD patient could improve our understanding of the disease pathogenesis.
C1 [Xu, Xin-Rong; Zhong, Lu; Huang, Bing-Lin; Zhou, Xin] Jiangsu Prov Hosp Tradit Chinese Med, Dept Ophthalmol, Nanjing 210029, Jiangsu, Peoples R China.
   [Wei, Yuan-Hua] Jiangsu Prov Hosp Tradit Chinese Med, Dept Clin Lab, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Ling; Wang, Fu-Qiang] Nanjing Med Univ, Analyt Instrumentat Ctr, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine
RP Xu, XR (通讯作者)，Jiangsu Prov Hosp Tradit Chinese Med, Dept Ophthalmol, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM xinrong_xu@aliyun.com
RI Xu, Xinrong/AAX-3118-2021
OI Wang, Fuqiang/0000-0002-7777-3541
FU Jiangsu Provincial Program of Leading Talents in Traditional Chinese
   Medicine [LJ200911]; Jiangsu Provincial Administration of Traditional
   Chinese Medicine [LZ11041]
FX Foundations: Supported by the Jiangsu Provincial Program of Leading
   Talents in Traditional Chinese Medicine (No. LJ200911) and the
   Scientific Project Funded by Jiangsu Provincial Administration of
   Traditional Chinese Medicine (No.LZ11041)
CR Abe R, 2010, J DERMATOL SCI, V57, P183, DOI 10.1016/j.jdermsci.2009.12.010
   Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x
   Barelli S, 2007, EXPERT REV PROTEOMIC, V4, P363, DOI 10.1586/14789450.4.3.363
   Bukrinsky M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-85
   Colman RW, 2010, THROMB HAEMOSTASIS, V104, P875, DOI 10.1160/TH10-01-0017
   Ganan A, 2004, HUM BIOL, V76, P253, DOI 10.1353/hub.2004.0031
   Gordon SM, 2012, CURR OPIN ENDOCRINOL, V19, P109, DOI 10.1097/MED.0b013e32835056d4
   Gross JD, 2001, COLD SPRING HARB SYM, V66, P397, DOI 10.1101/sqb.2001.66.397
   Gupta N, 2007, J PROTEOME RES, V6, P3669, DOI 10.1021/pr070223p
   Heron-Milhavet L, 2011, HISTOL HISTOPATHOL, V26, P651, DOI 10.14670/HH-26.651
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Ifuku K, 2011, PLANT CELL PHYSIOL, V52, P1560, DOI 10.1093/pcp/pcr098
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kalsheker N, 2002, BIOCHEM SOC T, V30, P93, DOI 10.1042/BST0300093
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kocak Nilufer, 2010, Ann Ophthalmol (Skokie), V42 Spec No, P10
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luc G, 2000, ATHEROSCLEROSIS, V152, P399, DOI 10.1016/S0021-9150(99)00484-0
   Miravitlles M, 2012, CURR OPIN PHARMACOL, V12, P309, DOI 10.1016/j.coph.2012.02.004
   Morrow G, 2012, INT J BIOCHEM CELL B, V44, P1613, DOI 10.1016/j.biocel.2012.03.009
   National fundus disease study group, 1986, REC ADV OPHTHALMOL, V6, P14
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Rabilloud Thierry, 2012, Methods Mol Biol, V893, P61, DOI 10.1007/978-1-61779-885-6_5
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sniderman AD, 2006, CLIN LAB MED, V26, P733, DOI 10.1016/j.cll.2006.07.007
   Speeckaert M, 2006, CLIN CHIM ACTA, V372, P33, DOI 10.1016/j.cca.2006.03.011
   Strzalka W, 2011, ANN BOT-LONDON, V107, P1127, DOI 10.1093/aob/mcq243
   Wolf G, 2007, NUTR REV, V65, P251, DOI 10.1111/j.1753-4887.2007.tb00302.x
   Yan Q, 2001, IN VITRO CELL DEV-AN, V37, P45
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang H, 2010, MOL BIOL REP, V37, P1585, DOI 10.1007/s11033-009-9564-9
NR 34
TC 6
Z9 8
U1 0
U2 5
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2014
VL 7
IS 2
BP 256
EP 263
DI 10.3980/j.issn.2222-3959.2014.02.12
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF4BI
UT WOS:000334656000012
PM 24790867
DA 2022-11-30
ER

PT J
AU Bromfield, S
   Keenan, J
   Jolly, P
   McGwin, G
AF Bromfield, Samantha
   Keenan, John
   Jolly, Pauline
   McGwin, Gerald, Jr.
TI A Suggested Association Between Hypothyroidism and Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE AMD; hypothyroidism; epidemiology; National Health Interview Survey; eye
   research
ID BEAVER DAM EYE; RISK-FACTORS; THYROID-DISEASE; UNITED-STATES;
   EPIDEMIOLOGY; MACULOPATHY; VALIDITY
AB Objective: To explore the relationship between age-related macular degeneration (AMD) and hypothyroidism in a population-based sample of adults 50 years and older in the United States.
   Study Population: Participants aged 50 years and older (N = 9,677). Of this total, 356 participants reported having AMD and 9321 reported not having AMD.
   Methods: Information pertaining to self-reported thyroid disease (specifically hypothyroidism) and AMD was obtained from the 2008 National Health Interview Survey. The association between self-reported data on hypothyroidism and AMD was estimated using logistic regression adjusting for the potentially confounding influence of demographic, behavioral, and health-related characteristics.
   Results: Of the 356 people with AMD, 20.9% reported hypothyroidism compared to 11.2% of those 9,321 without AMD (odds ratio [OR] 2.33; 95% confidence interval [CI] 1.69-3.21). After adjusting for the confounding influence of age, sex, smoking, and race, the association between AMD and hypothyroidism remained significant (OR 1.59; 95% CI 1.10-2.30).
   Conclusions: The results of this study add to the small body of literature indicating a possible relationship between AMD and hypothyroidism. As many of the risk factors for AMD are also risk factors for hypothyroidism, future studies are warranted to ascertain the relationship between the two diseases.
C1 [Bromfield, Samantha; Keenan, John; Jolly, Pauline; McGwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP McGwin, G (通讯作者)，Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, 1720 Univ Blvd,Suite 609, Birmingham, AL 35294 USA.
EM mcgwin@uab.edu
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Brix TH, 2001, THYROID, V11, P769, DOI 10.1089/10507250152484619
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Devdhar M, 2007, ENDOCRIN METAB CLIN, V36, pv
   Devdhar M, 2007, ENDOCRIN METAB CLIN, V36, P595, DOI 10.1016/j.ecl.2007.04.008
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Duntas LH, 2002, THYROID, V12, P287, DOI 10.1089/10507250252949405
   Fink A, 2002, J AM GERIATR SOC, V50, P1717, DOI 10.1046/j.1532-5415.2002.50467.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goulding MR, 2003, JAMA-J AM MED ASSOC, V289, P1371
   Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   LIBERTO JG, 1992, HOSP COMMUNITY PSYCH, V43, P975
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   *NAT EYE I, 2010, FACTS AG REL MAC DEG
   NCfH, 2009, 2008 NAT HLTH INT SU
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   RAO JNK, 1987, ANN STAT, V15, P385, DOI 10.1214/aos/1176350273
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   WHO, 2010, PRIOR EYE DIS AG REL
NR 24
TC 10
Z9 11
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUN
PY 2012
VL 37
IS 6
BP 549
EP 552
DI 10.3109/02713683.2011.647223
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 942RH
UT WOS:000304064200014
PM 22577773
DA 2022-11-30
ER

PT J
AU Kovacevic, D
   Caljkusic-Mance, T
   Misljenovic, T
   Mikulicic, M
   Alpeza-Dunato, Z
AF Kovacevic, Damir
   Caljkusic-Mance, Tea
   Misljenovic, Tamara
   Mikulicic, Masa
   Alpeza-Dunato, Zvjezdana
TI Intravitreal Bevacizumab for the Management of Age-Related Macular
   Degeneration
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE bevacizumab; choroidal neovascularization; age-related macular
   degeneration
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; AVASTIN
AB The aim of this study is to report short-term effect of the treatment of "wet" ARMD (age-related macular degeneration) with intravitreal bevacizumab (Avastin). Prospective study included 36 patients (36 eyes) with "wet" form of ARMD. All patients were over 60 year old (22 female, 14 male). Changes of macula included minimally classic CW (choroidal neovascularisation) (24), occult subfoveal CNV (10) and first stage of cicatrial CNV (2). Bevacizumab 1.25 mg was administered intravitreally through pars plana using a 27-gauge needle. Patients had no previous eye treatment. Ophthalmic exam before and after the treatment included: Snellen VA (visual acuity) and examination including measurement of IOP (intraocular pressure), FA (fluorescein angiography) and interview with patients. After 4-6 weeks 28 (78%)patients had significant improvement of VA. Median VA improved from 0.083 to 0.200 (p < 0.01). Eightpatients (22%) had no significant improvement in VA but three of them reported to see more light. FA showed complete resolution of macular edema in 6 patients (17%), partially resolved in 23 patients (64%) and no change in 7 patients (19%). No systemic side-effect was found. Short-term results suggest that intravitreally administered bevacizumab is well tolerated treatment for ARMD with very high number of patients showing improvement in VA.
C1 [Kovacevic, Damir; Caljkusic-Mance, Tea; Alpeza-Dunato, Zvjezdana] Univ Hosp Rijeka, Dept Ophthalmol, Rijeka 51000, Croatia.
   [Misljenovic, Tamara; Mikulicic, Masa] Eye Polyclin Dr L Pavicevic, Rijeka, Croatia.
C3 University of Rijeka
RP Kovacevic, D (通讯作者)，Univ Hosp Rijeka, Dept Ophthalmol, Kresimirova 42, Rijeka 51000, Croatia.
EM damir.kovacevic@ri.t-com.hr
RI Vuceric, Tamara Misljenovic/AAF-4128-2020
CR Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FRAUNFELDER F, 2005, DRUG TODAY BARC, V41, P3
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P71
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Njiric S, 2007, COLLEGIUM ANTROPOL, V31, P107
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Polito A, 2006, ANN ACAD MED SINGAP, V35, P145
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   SPAIDE R, 2006, OPHTALMOL, V113, P22
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 12
TC 6
Z9 7
U1 0
U2 2
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD OCT
PY 2008
VL 32
SU 2
BP 5
EP 7
PG 3
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 380WK
UT WOS:000261496600003
PM 19137998
DA 2022-11-30
ER

PT J
AU Yu, E
   Song, Y
   Gu, SM
   Jo, YH
   Yeon, SW
   Han, KJ
   Lee, MK
   Min, JK
   Yun, J
AF Yu, Eunhye
   Song, Yunjeong
   Gu, Sun Mi
   Jo, Yang Hee
   Yeon, Sang Won
   Han, Kyu Jin
   Lee, Mi Kyeong
   Min, Jung Kee
   Yun, Jaesuk
TI Alpinumisoflavone ameliorates choroidal neovascularisation and fibrosis
   in age-related macular degeneration in in vitro and in vivo models
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS;
   MESENCHYMAL TRANSITION; RISK-FACTORS; RANIBIZUMAB; VEGF; MODULATION;
   LINE
AB Age-related macular degeneration (AMD) is a major cause of vision loss in the elderly population. Anti-vascular endothelial growth factor (VEGF) antibody therapy is applicable to neovascularisation of AMD; however, the prevention of fibrosis after anti-VEGF monotherapy is an unmet medical need. Subretinal fibrosis causes vision loss in neovascular age-related macular degeneration (nAMD) even with anti-VEGF therapy. We report the anti-fibrotic and anti-neovascularisation effects of alpinumisoflavone (AIF), an isoflavonoid derived from unripe Maclura tricuspidata fruit, in in vitro and in vivo models. For in vitro study, we treated H2O2 or THP-1 conditioned media (TCM) following activation with phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS) in a human retinal pigment epithelial cell line (ARPE-19). Choroidal neovascularisation (CNV) was induced by laser photocoagulation in mice, immediately followed by intravitreal administration of 25 mu g AIF. CNV area and fibrosis were measured 7 days after laser photocoagulation. AIF showed anti-fibrosis and anti-neovascularisation effects in both the models. The laser induced CNV area was reduced upon AIF administration in nAMD mouse model. Additionally, AIF decreased the levels of the cleaved form of crystallin alpha B (CRYAB), a chaperone associated with VEGF stabilisation and fibrosis. Our results demonstrate a novel therapeutic application of AIF against neovascularisation and fibrosis in nAMD.
C1 [Yu, Eunhye; Song, Yunjeong; Gu, Sun Mi; Min, Jung Kee; Yun, Jaesuk] Chungbuk Natl Univ, Coll Pharm, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungcheongbuk, South Korea.
   [Jo, Yang Hee; Yeon, Sang Won; Lee, Mi Kyeong] Chungbuk Natl Univ, Coll Pharm, 194-21 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungcheongbuk, South Korea.
   [Han, Kyu Jin; Min, Jung Kee] Univ Ulsan, Dept Ophthalmol, Ulsan Univ Hosp, Coll Med, 877,Bangeojinsunhwando Ro, Ulsan 44033, South Korea.
C3 Chungbuk National University; Chungbuk National University; University
   of Ulsan; Ulsan University Hospital
RP Min, JK; Yun, J (通讯作者)，Chungbuk Natl Univ, Coll Pharm, 194-31 Osongsaengmyeong 1 Ro, Cheongju 28160, Chungcheongbuk, South Korea.; Min, JK (通讯作者)，Univ Ulsan, Dept Ophthalmol, Ulsan Univ Hosp, Coll Med, 877,Bangeojinsunhwando Ro, Ulsan 44033, South Korea.
EM jkmin@uuh.ulsan.kr; jyun@chungbuk.ac.kr
OI Min, Jung Kee/0000-0002-8006-8560
FU Regional Innovation Strategy (RIS)" through the National Research
   Foundation of Korea (NRF) - Ministry of Education (MOE) [2021RIS-001];
   National Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2017R1A5A2015541]; Ministry of Food and Drug Safety [22214MFDS252];
   Ulsan University Hospital Research Grant [UUH-2020-07]
FX This research was supported by "Regional Innovation Strategy (RIS)"
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (MOE) (2021RIS-001), the National Research
   Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
   (No. MRC, 2017R1A5A2015541), and the Ministry of Food and Drug Safety
   (22214MFDS252). This research was also supported by Ulsan University
   Hospital Research Grant (UUH-2020-07).
CR Alos H.C., 2019, CURR ENZYM INHIB, V15, P159, DOI [10.2174/1573408016666200123160509, DOI 10.2174/1573408016666200123160509]
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002
   Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dinc E, 2017, CURR EYE RES, V42, P1659, DOI 10.1080/02713683.2017.1368085
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gao M, 2017, AM J TRANSL RES, V9, P986
   Han XH, 2005, ARCH PHARM RES, V28, P1324, DOI 10.1007/BF02977895
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hu Q, 2009, NEPHROL DIAL TRANSPL, V24, P3033, DOI 10.1093/ndt/gfp245
   Huang XY, 2013, HEPATOLOGY, V57, P2235, DOI 10.1002/hep.26255
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jo MJ, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080366
   Jo YH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172069
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kingsford-Adaboh R, 2006, ACTA CRYSTALLOGR B, V62, P843, DOI 10.1107/S0108768106019616
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Leger H, 2019, JOVE-J VIS EXP, DOI 10.3791/59683
   Li PY, 2018, RSC ADV, V8, P31515, DOI 10.1039/c8ra04098b
   Liu Y, 2009, J BIOL CHEM, V284, P5859, DOI 10.1074/jbc.M806744200
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Namkoong S, 2011, BIOL PHARM BULL, V34, P203, DOI 10.1248/bpb.34.203
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shaik-Dasthagirisaheb YB, 2013, INT J IMMUNOPATH PH, V26, P327, DOI 10.1177/039463201302600206
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang TT, 2017, AM J CANCER RES, V7, P999
   Weinberger D, 2017, CURR EYE RES, V42, P1545, DOI 10.1080/02713683.2017.1349154
   Winter K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10245804
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zhang YF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1333-7
NR 42
TC 0
Z9 0
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 22
PY 2022
VL 12
IS 1
AR 14316
DI 10.1038/s41598-022-18531-y
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 3Z0XT
UT WOS:000844144900042
PM 35995845
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kang, SW
   Lee, H
   Bae, K
   Shin, JY
   Kim, SJ
   Kim, JM
AF Kang, Se Woong
   Lee, Hoyoung
   Bae, Kunho
   Shin, Joo Young
   Kim, Sang Jin
   Kim, Jong Min
CA Korean Age-related Maculopathy
TI Investigation of precursor lesions of polypoidal choroidal vasculopathy
   using contralateral eye findings
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusen-like deposit; Pigmentary
   change; Polypoidal choroidal vasculopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; JAPANESE PATIENTS; CLINICAL CHARACTERISTICS; RETICULAR
   PSEUDODRUSEN; FELLOW-EYES; DRUSEN; RISK; HYPERFLUORESCENCE
AB The purpose was to investigate precursor lesions of polypoidal choroidal vasculopathy (PCV).
   This cross-sectional study involved 276 unaffected contralateral eyes from unilateral PCV patients (Group 1), unilateral typical exudative age-related macular degeneration (AMD) patients (Group 2), and unilateral epiretinal membrane patients (Group 3) as age-matched controls. Grayish-yellow sub-retinal or sub-retinal-pigment-epithelial deposits larger than 63 mu m in size with irregular but discrete margins were defined as drusen-like deposits (DLDs). The frequencies of DLDs, drusen, and pigmentary changes in each group were compared.
   DLDs larger than 125 mu m in size were found more frequently in Group 1 (19.5 %) than in Groups 2 (3.4 %) and 3 (3.2 %) (p < 0.001). Soft drusen were discovered more frequently in Group 2 eyes than in Groups 1 and 3 (p < 0.001). Pigmentary changes were found more frequently in Groups 1 and 2 compared to Group 3. Compared with the other groups, Group 1 manifested a higher frequency of choroidal vascular hyperpermeability (p < 0.005) and thicker choroid (p < 0.001).
   The precursor lesions of PCV are different from those of exudative AMD. DLDs larger than 125 mu m and pigmentary changes may be early preclinical markers of PCV. Long-term longitudinal studies are warranted for validation.
C1 [Kang, Se Woong; Lee, Hoyoung; Bae, Kunho; Kim, Sang Jin; Kim, Jong Min] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 81 Irwon Ro, Seoul 06351, South Korea.
   [Shin, Joo Young] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp Healthcare Syst, Dept Ophthalmol,Gangnam Ctr, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National
   University (SNU); Seoul National University Hospital
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 81 Irwon Ro, Seoul 06351, South Korea.
EM swkang@skku.edu
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Shin, Joo Young/0000-0001-5062-6392
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   [Anonymous], 2005, NIPPON GANKA GAKKAI, V109, P417
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P759, DOI 10.1097/IAE.0b013e3181fbce8e
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sasaki M, 2014, OPTOMETRY VISION SCI, V91, P849, DOI 10.1097/OPX.0000000000000317
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wang M, 2005, ACTA OPHTHALMOL SCAN, V83, P691, DOI 10.1111/j.1600-0420.2005.00582.x
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 34
TC 23
Z9 23
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2017
VL 255
IS 2
BP 281
EP 291
DI 10.1007/s00417-016-3452-5
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK8ET
UT WOS:000394157400008
PM 27596850
OA Green Published
DA 2022-11-30
ER

PT J
AU Larochelle, RD
   Patnaik, JL
   Lynch, AM
   Mandava, N
   Hanson, K
AF Larochelle, Ryan D.
   Patnaik, Jennifer L.
   Lynch, Anne M.
   Mandava, Naresh
   Hanson, Kara
CA Univ Colorado Retina Res Grp
TI Low Vision Referral Patterns in Intermediate Age-Related Macular
   Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; low vision rehabilitation; low vision
ID REHABILITATION; INTERVENTION; BARRIERS
AB Purpose Sparse data exist regarding low vision (LV) services referral patterns. We retrospectively examined our institution's intermediate age-related macular degeneration (iAMD) patients to determine factors influencing referral. Methods We compared visual acuity (VA) and Visual Function Questionnaire (VFQ-25) composite and subscale scores for referred and non-referred iAMD patients. VA was collected at time of referral or most recent visit, and VFQ-25 was taken upon enrollment into the registry. Results Thirty-six (15.5%) of the 232 iAMD patients were referred to LV. Referred patients were more likely to have older age, worse VA in both eyes, and lower VFQ-25 scores. Univariate analysis of VFQ-25 subscales demonstrated worse scores in general vision, near, distance, mental health, role limitations, dependency, and driving. Multivariable analysis revealed lower scores in general health, general vision, and driving. Forty-eight percent of non-referred patients had VA or VFQ-25 composite scores at least as poor as the median for referred patients. Two-thirds of patients who were not referred had no discernable obstacle to referral. Conclusions Our institution refers patients with worse objective and functioning vision, but more patients may benefit from referral. Future studies should identify metrics to prompt referral and evaluate this approach.
C1 [Larochelle, Ryan D.; Patnaik, Jennifer L.; Lynch, Anne M.; Mandava, Naresh; Hanson, Kara] Univ Colorado Denver, Dept Ophthalmol, Sch Med, Aurora, CO USA.
C3 Children's Hospital Colorado; University of Colorado System; University
   of Colorado Anschutz Medical Campus
RP Larochelle, RD (通讯作者)，Univ Colorado, Rocky Mt Lions Eye Inst, Dept Ophthalmol, 1675 Aurora Ct, Aurora, CO 80045 USA.
EM ryandlarochelle@gmail.com
OI , Ryan/0000-0002-2218-984X
FU National Eye Institute of the National Institutes of Health
   [R01EY032456]; Research to Prevent Blindness; Frederic C. Hamilton
   Macular Degeneration Center; Sue Anschutz-Rodgers Eye Center Research
   Fund; NIH/NCATS Colorado CTSA [UL1 TR002535]
FX This research was funded by the National Eye Institute of the National
   Institutes of Health under award number R01EY032456 (AML); a Research to
   Prevent Blindness grant to the Department of Ophthalmology, University
   of Colorado; the Frederic C. Hamilton Macular Degeneration Center, Sue
   Anschutz-Rodgers Eye Center Research Fund; and by NIH/NCATS Colorado
   CTSA under Grant Number UL1 TR002535. No commercial relationship existed
   in the form of financial support or personal financial interest.
CR AAO, 2022, AC IN VIS REH
   Coker MA, 2018, JAMA OPHTHALMOL, V136, P400, DOI 10.1001/jamaophthalmol.2018.0241
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Goldstein JE, 2020, OPHTHAL EPIDEMIOL, V27, P252, DOI 10.1080/09286586.2020.1717546
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Gopalakrishnan S, 2020, INDIAN J OPHTHALMOL, V68, P886, DOI 10.4103/ijo.IJO_1093_19
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Malkin AG, 2020, OPTOMETRY VISION SCI, V97, P45, DOI 10.1097/OPX.0000000000001468
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   O'Connor PM, 2008, BRIT J OPHTHALMOL, V92, P252, DOI 10.1136/bjo.2007.125955
   O'Connor PM, 2008, CLIN EXP OPHTHALMOL, V36, P547, DOI 10.1111/j.1442-9071.2008.01830.x
   Overbury O, 2011, INVEST OPHTH VIS SCI, V52, P8933, DOI 10.1167/iovs.11-8116
   Owsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681, DOI 10.1001/archophthalmol.2009.55
   Patnaik JL, 2021, ACTA OPHTHALMOL, V99, P750, DOI 10.1111/aos.14731
   Pyatova Y, 2022, EUR J OPHTHALMOL, V32, P296, DOI 10.1177/1120672120973621
   Shah P, 2018, THER ADV OPHTHALMOL, V10, DOI 10.1177/2515841418776264
   Sunness JS, 2009, RETINA-J RET VIT DIS, V29, P1036, DOI 10.1097/IAE.0b013e3181a91da8
   Wagner BD, 2022, OPHTHAL EPIDEMIOL, V29, P139, DOI 10.1080/09286586.2021.1910314
   WHO, 1996, ASS LOW VIS DEV COUN
   World Health Organization, 1994, INT CLASS DIS
NR 23
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD DEC 2
PY 2022
VL 47
IS 12
BP 1641
EP 1645
DI 10.1080/02713683.2022.2135104
EA OCT 2022
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5X8LZ
UT WOS:000870157100001
PM 36259507
DA 2022-11-30
ER

PT J
AU Brilliant, MH
   Vaziri, K
   Connor, TB
   Schwartz, SG
   Carroll, JJ
   McCarty, CA
   Schrodi, SJ
   Hebbring, SJ
   Kishor, KS
   Flynn, HW
   Moshfeghi, AA
   Moshfeghi, DM
   Fini, ME
   McKay, BS
AF Brilliant, Murray H.
   Vaziri, Kamyar
   Connor, Thomas B., Jr.
   Schwartz, Stephen G.
   Carroll, Joseph J.
   McCarty, Catherine A.
   Schrodi, Steven J.
   Hebbring, Scott J.
   Kishor, Krishna S.
   Flynn, Harry W., Jr.
   Moshfeghi, Andrew A.
   Moshfeghi, Darius M.
   Fini, M. Elizabeth
   McKay, Brian S.
TI Mining Retrospective Data for Virtual Prospective Drug Repurposing:
   L-DOPA and Age-related Macular Degeneration
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Age-related macular degeneration (AMD); GPR143; L-DOPA; Movement
   disorder; Parkinson's disease Retrospective study; Retinal pigment
   epithelium (RPE)
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; VISUAL IMPAIRMENT;
   CIGARETTE-SMOKING; FACTOR PEDF; PREVALENCE; VEGF; PATHOGENESIS;
   EXPRESSION; THERAPY
AB BACKGROUND: Age-related macular degeneration (AMD) is a leading cause of visual loss among the elderly. A key cell type involved in AMD, the retinal pigment epithelium, expresses a G proteine-coupled receptor that, in response to its ligand, L-DOPA, up-regulates pigment epitheliae-derived factor, while down-regulating vascular endothelial growth factor. In this study we investigated the potential relationship between L-DOPA and AMD.
   METHODS: We used retrospective analysis to compare the incidence of AMD between patients taking vs not taking L-DOPA. We analyzed 2 separate cohorts of patients with extensive medical records from the Marshfield Clinic (approximately 17,000 and approximately 20,000) and the Truven MarketScan outpatient and databases (approximately 87 million) patients. We used International Classification of Diseases, 9th Revision codes to identify AMD diagnoses and L-DOPA prescriptions to determine the relative risk of developing AMD and age of onset with or without an L-DOPA prescription.
   RESULTS: In the retrospective analysis of patients without an L-DOPA prescription, AMD age of onset was 71.2, 71.3, and 71.3 in 3 independent retrospective cohorts. Age-related macular degeneration occurred significantly later in patients with an L-DOPA prescription, 79.4 in all cohorts. The odds ratio of developing AMD was also significantly negatively correlated by L-DOPA (odds ratio 0.78; confidence interval, 0.76-0.80; P < .001). Similar results were observed for neovascular AMD (P < .001).
   CONCLUSIONS: Exogenous L-DOPA was protective against AMD. L-DOPA is normally produced in pigmented tissues, such as the retinal pigment epithelium, as a byproduct of melanin synthesis by tyrosinase. GPR143 is the only known L-DOP Areceptor; it is therefore plausible that GPR143 may be a fruitful target to combat this devastating disease. (C) 2016 The Authors. Published by Elsevier Inc.
C1 [Brilliant, Murray H.; Schrodi, Steven J.; Hebbring, Scott J.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA.
   [Vaziri, Kamyar; Schwartz, Stephen G.; Kishor, Krishna S.; Flynn, Harry W., Jr.] Univ Miami, Dept Ophthalmol, Bascom Palmer Eye Inst, Miller Sch Med, Palm Beach Gardens, FL USA.
   [Connor, Thomas B., Jr.; Carroll, Joseph J.] Med Coll Wisconsin, Dept Ophthalmol, Milwaukee, WI 53226 USA.
   [Carroll, Joseph J.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.
   [McCarty, Catherine A.] Essentia Inst Rural Hlth, Duluth, MN USA.
   [Moshfeghi, Andrew A.] Univ So Calif, Keck Sch Med, Inst Eye, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Fini, M. Elizabeth] Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA.
   [Fini, M. Elizabeth] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90033 USA.
   [Fini, M. Elizabeth] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [McKay, Brian S.] Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ 85711 USA.
   [McKay, Brian S.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85711 USA.
C3 Bascom Palmer Eye Institute; Medical College of Wisconsin; Medical
   College of Wisconsin; University of Southern California; Stanford
   University; University of Southern California; University of Southern
   California; University of Southern California; University of Arizona;
   University of Arizona
RP McKay, BS (通讯作者)，Univ Arizona, Dept Ophthalmol & Vis Sci, 655 N Alvernon,Ste 108, Tucson, AZ 85711 USA.
EM bsmckay@eyes.arizona.edu
RI Schrodi, Steven J./O-4288-2019
OI Schrodi, Steven J./0000-0003-2304-8528; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; McCarty, Catherine/0000-0003-1089-0142;
   McKay, Brian/0000-0002-2893-3959
FU National Institutes of Health (NIH) [UL1TR000427, 1U01HG006389-01];
   Wisconsin Genome Initiative; Marshfield Clinic (Marshfield Clinic);
   Edward N. & Della L. Thome Memorial Foundation, (Medical College of
   Wisconsin) [P30EY001931, UL1TR000055]; NIH Center Core (Bascom Palmer
   Eye Institute) [P30EY014801]; BrightFocus Foundation; Research to
   Prevent Blindness; Bascom Palmer Eye Institute; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR000055, UL1TR000427] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001931, P30EY014801]
   Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE
   [U01HG006389] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE
   [K22LM011938] Funding Source: NIH RePORTER
FX This project was partially supported by National Institutes of Health
   (NIH) grants UL1TR000427 and 1U01HG006389-01, The Wisconsin Genome
   Initiative and the Marshfield Clinic (Marshfield Clinic); P30EY001931,
   UL1TR000055, The Edward N. & Della L. Thome Memorial Foundation,
   (Medical College of Wisconsin); NIH Center Core Grant P30EY014801
   (Bascom Palmer Eye Institute); BrightFocus Foundation and unrestricted
   grants from Research to Prevent Blindness to the University of Arizona
   and Bascom Palmer Eye Institute.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Falk T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/278932
   Frick KD, 2010, INVEST OPHTH VIS SCI, V51, P1801, DOI 10.1167/iovs.09-4469
   Greenlee Robert T, 2003, Clin Med Res, V1, P273
   Handa James T., 2007, International Ophthalmology Clinics, V47, P15, DOI 10.1097/IIO.0b013e31802bd546
   Haurigot V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041511
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Levinson DR, 2012, MICR RAD REM SENS EN, P1
   Li YY, 2012, GENOME MED, V4, DOI 10.1186/gm326
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Lopez VM, 2008, PLOS BIOL, V6, P1861, DOI 10.1371/journal.pbio.0060236
   Machalinska Anna, 2012, Klin Oczna, V114, P115
   Maguire Maureen G, 2012, LDI Issue Brief, V17, P1
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   McCarty Catherine A, 2005, Per Med, V2, P49, DOI 10.1517/17410541.2.1.49
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Ngondi J, 2006, PLOS MED, V3, P2416, DOI 10.1371/journal.pmed.0030477
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Rein DB, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12818
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Roden DM, 2012, CLIN PHARMACOL THER, V91, P1083, DOI 10.1038/clpt.2012.42
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Thacker EL, 2007, NEUROLOGY, V68, P764, DOI 10.1212/01.wnl.0000256374.50227.4b
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   van der Mark M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095297
   Wagner LD, 2013, OPHTHALMOLOGY, V120, P1497, DOI 10.1016/j.ophtha.2012.12.030
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
NR 46
TC 43
Z9 44
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD MAR
PY 2016
VL 129
IS 3
BP 292
EP 298
DI 10.1016/j.amjmed.2015.10.015
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DD5FE
UT WOS:000369947300023
PM 26524704
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Lylyk, I
   Bleise, C
   Lylyk, PN
   Perez, N
   Lundquist, J
   Scrivano, E
   Francone, AA
   Charles, M
   Zompa, T
   Lylyk, P
AF Lylyk, Ivan
   Bleise, Carlos
   Lylyk, Pedro N.
   Perez, Nicolas
   Lundquist, Javier
   Scrivano, Esteban
   Francone, Anibal A.
   Charles, Martin
   Zompa, Tamara
   Lylyk, Pedro
TI Ophthalmic artery angioplasty for age-related macular degeneration
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE angioplasty; orbit; plaque; stenosis; atherosclerosis
ID VITAMIN-D; ATHEROSCLEROSIS
AB Background There is considerable overlap of contributors to cardiovascular disease and the development of age-related macular degeneration (AMD). Compromised ocular microcirculation due to aging and vascular disease contribute to retinal dysfunction and vision loss. Decreased choroidal perfusion is evident in eyes with dry AMD and is thought to play a role in retinal pigment epithelial dysfunction, the rate of development of geographic atrophy, and the development of neovascularization. The aim of the study was to demonstrate that AMD is correlated with a compromised blood flow in the ocular pathway and show OA angioplasty as a potential treatment of late-stage AMD. Methods Based on the potential for the ophthalmic artery (OA) to be an anatomical target for the treatment of AMD as outlined above, five patients were found to be eligible for compassionate use treatment, presenting clinically significant late-stage AMD with profound vision loss in one or both eyes, and are included in this retrospective study. Results OA narrowing, or significant calcium burden at the ophthalmic segment of the internal carotid artery compromising the origin of the OA was confirmed in all cases. Subsequent OA cannulation was achieved in all patients with some difficulty. Subjective patient reports indicated that all patients perceived a benefit following the procedure; however, improved postoperative visual acuity did not confirm that perceived benefit for one of the patients. Conclusions Feasibility and safety of the OA angioplasty were demonstrated, and a benefit perceived in five patients with profound vision loss and a desire to achieve improved quality of life. A clinical trial with controlled schedule, imaging, and methodologies is needed to confirm these results.
C1 [Lylyk, Ivan; Bleise, Carlos; Lylyk, Pedro N.; Lundquist, Javier; Scrivano, Esteban; Lylyk, Pedro] Inst Med ENERI, Dept Intervent Neuroradiol, RA-1426 Buenos Aires, DF, Argentina.
   [Perez, Nicolas] Inst Med ENERI, Dept Neuroradiol, Buenos Aires, DF, Argentina.
   [Francone, Anibal A.; Charles, Martin; Zompa, Tamara] Ctr Oftalmol Dr Daniel Charles SA, Dept Ophthalmol, Buenos Aires, DF, Argentina.
RP Lylyk, I (通讯作者)，Inst Med ENERI, Dept Intervent Neuroradiol, RA-1426 Buenos Aires, DF, Argentina.
EM ivan@lylyk.com.ar
OI Bleise, Carlos/0000-0003-2292-3263; Lylyk, Ivan/0000-0002-6048-4225
CR Aadland TD, 2010, AM J NEURORADIOL, V31, P476, DOI 10.3174/ajnr.A1840
   ANMAT, 2005, REG ADM NAT MED FOOD
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Coleman DJ, 2018, OPHTHALMOLOGICA, V240, P45, DOI 10.1159/000486105
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Dighe S, 2020, BRIT J OPHTHALMOL, V104, P1070, DOI 10.1136/bjophthalmol-2019-314813
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gounis MJ, 2019, STROKE, V50, P218, DOI 10.1161/STROKEAHA.118.022315
   Hayreh SS, 2017, OPHTHALMOL RETINA, V1, P12, DOI 10.1016/j.oret.2016.08.003
   Hibert ML, 2021, AM J NEURORADIOL, V42, P1653, DOI 10.3174/ajnr.A7187
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Hwang GJ, 2010, J NEURO-OPHTHALMOL, V30, P228, DOI 10.1097/WNO.0b013e3181dc2078
   Ishii M, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2530914
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
NR 30
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD OCT
PY 2022
VL 14
IS 10
BP 968
EP +
DI 10.1136/neurintsurg-2021-018222
EA JAN 2022
PG 6
WC Neuroimaging; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Surgery
GA 4Q1PR
UT WOS:000739870400001
PM 34987072
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Klein, R
   Knudtson, MD
   Cruickshanks, KJ
   Klein, BEK
AF Klein, Ronald
   Knudtson, Michael D.
   Cruickshanks, Karen J.
   Klein, Barbara E. K.
TI Further observations on the association between smoking and the
   long-term incidence and progression of age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; CIGARETTE-SMOKING; RISK-FACTORS; VISUAL-ACUITY; POOLED
   FINDINGS; 3 CONTINENTS; MACULOPATHY; POPULATION; EXPOSURE; PERIOD
AB Objective: To examine the association between smoking and the 15-year cumulative incidence of age-related macular degeneration (AMD).
   Methods: Population-based longitudinal cohort study of people in Beaver Darn, Wisconsin, who were aged 43 to 84 years (N=4926) in 1987-1988. Participants were examined in 1988-1990 and were reexamined at 5-year intervals during a 15-year period. Age-related macular degeneration status was determined by grading stereoscopic color fundus photographs.
   Results: Controlling for age, sex, and baseline AMD severity, people who were current smokers at baseline, compared with those who never smoked, were at increased risk of incident early AMD (odds ratio, 1.47; 95% confidence interval, 1.08-1.99; P=.01) and for progression of AMD (odds ratio, 1.43; 95% confidence interval, 1.05-1.94; P=.02) during a 15-year follow-up. There were few associations of specific characteristics of smoking (eg, intensity, pack-years smoked, duration, and age at initiation and quitting) with AMD outcomes.
   Conclusions: Smoking appears to be related to the long-term incidence and progression of AMD. This has important health care implications because early AMD increases the risk of developing late AMD and smoking behavior is modifiable.
C1 [Klein, Ronald; Knudtson, Michael D.; Cruickshanks, Karen J.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Cruickshanks, Karen J.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY06594] Funding Source: Medline; NIA NIH HHS [AG11900]
   Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BETTMAN JW, 1958, ARCH OPHTHALMOL-CHIC, V59, P481
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hosmer DW., 1989, APPL LOGISTIC REGRES
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUD, V2, DOI UNSP B95-B273827
   Klein R, 1991, WISCONSIN AGE RELATE
   KLEIN R, 1991, BEAVER DAM EYE STUD, DOI UNSP B91-B149823
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Leffondre K, 2002, AM J EPIDEMIOL, V156, P813, DOI 10.1093/aje/kwf122
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Nondahl DM, 2005, ENVIRON RES, V97, P76, DOI 10.1016/j.envres.2004.02.005
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009
   SAS Institute, 2004, SAS STAT US GUID VER
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 39
TC 92
Z9 100
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2008
VL 126
IS 1
BP 115
EP 121
DI 10.1001/archopht.126.1.115
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 250PP
UT WOS:000252312800017
PM 18195228
OA Bronze
DA 2022-11-30
ER

PT J
AU Zor, KR
   Sari, I
   Bicer, GY
   Gunturk, I
   Kucuk, E
   Ersan, S
   Seydel, GS
AF Zor, Kursad Ramazan
   Sari, Ismail
   Bicer, Gamze Yildirim
   Gunturk, Inayet
   Kucuk, Erkut
   Ersan, Serpil
   Seydel, Gonul Seyda
TI EVALUATION OF OXIDATIVE STRESS, 3-NITROTYROSINE, AND HMGB-1 LEVELS IN
   PATIENTS WITH WET TYPE AGE-RELATED MACULAR DEGENERATION
SO JOURNAL OF MEDICAL BIOCHEMISTRY
LA English
DT Article
DE HMGB-1; 3-Nitrotyrosine; TAS; TOS; OSI; wet type AMD
ID MOBILITY GROUP BOX; INFLAMMATION; PROTEIN
AB Background: This study aims to compare serum HMGB-1, 3-nitrotyrosine (3-NT), TAS, TOS, and OSI levels in Wettype Age-Related Macular Degeneration (wAMD) patients and healthy controls to determine the correlation of these parameters with each other.
   Methods: Thirty patients with Wet-type Age-Related Macular Degeneration (wAMD) and 27 healthy adults, as controls were enrolled in the study. We determined the TAS and TOS levels in serum samples of both groups using commercial kits on a microplate reader. Serum HMGB-1 and 3-NT levels were measured with the enzyme-linked immunosorbent assay method.
   Results: HMGB-1 levels were significantly higher in the patient group (137.51 pg/mL, p=0.001), while there was no difference between the two groups in serum 3-NT levels (p = 0.428). A statistically significant difference found in the levels of TOS and OSI (p = 0.001 and p = 0.045, respectively) between the patients and controls, however, no significant difference was observed between the groups in terms of TAS levels (p = 0.228).
   Conclusions: Oxidative stress and HMGB-1 levels were increased in wAMD patients and enhanced oxidative stress may be associated with increased tissue necrosis and inflammation. Thus administration of antioxidant treatment in addition to routine therapy should be considered in wAMD.
C1 [Zor, Kursad Ramazan; Bicer, Gamze Yildirim; Kucuk, Erkut] Nigde Omer Halisdemir Univ, Sch Med, Dept Ophthalmol, Bor Yolu, Nigde, Turkey.
   [Sari, Ismail; Ersan, Serpil] Nigde Omer Halisdemir Univ, Sch Med, Dept Biochem, Bor Yolu, Nigde, Turkey.
   [Gunturk, Inayet] Nigde Omer Halisdemir Univ, Healthcare Serv, Zubeyde Hanim Hlth Serv Vocat High Sch, Bor Yolu, Nigde, Turkey.
   [Seydel, Gonul Seyda] Nigde Omer Halisdemir Univ, Sch Med, Dept Med Biochem, Bor Yolu, Nigde, Turkey.
C3 Nigde Omer Halisdemir University; Nigde Omer Halisdemir University;
   Nigde Omer Halisdemir University; Nigde Omer Halisdemir University
RP Zor, KR (通讯作者)，Nigde Omer Halisdemir Univ, Sch Med, Dept Ophthalmol, Bor Yolu, Nigde, Turkey.; Zor, KR (通讯作者)，Nigde Omer Halisdemir Univ, Sch Med, Dept Ophthalmol, Bor Yolu Nigde, Turkey.
EM kursadzor@hotmail.com
OI Gunturk, Inayet/0000-0002-8299-1359; SEYDEL, GONUL
   SEYDA/0000-0001-9317-0719
CR Altinisik M, 2018, SEMIN OPHTHALMOL, V33, P675, DOI 10.1080/08820538.2017.1416412
   Bandookwala M, 2020, INT J NEUROSCI, V130, P1047, DOI 10.1080/00207454.2020.1713776
   Chang YC, 2017, CELL SIGNAL, V40, P248, DOI 10.1016/j.cellsig.2017.09.019
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Elbay A, 2017, INT OPHTHALMOL, V37, P1095, DOI 10.1007/s10792-016-0367-4
   Erdogan HK, 2017, J COSMET DERMATOL-US, V16, P527, DOI 10.1111/jocd.12300
   Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300
   Gnanasekar M, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/157103
   GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Icel E, 2019, CUTAN OCUL TOXICOL, V38, P88, DOI 10.1080/15569527.2018.1530258
   Jafri AJA, 2018, MOL VIS, V24, P495
   Kanan Y, 2019, J NEUROCHEM, V148, P307, DOI 10.1111/jnc.14613
   Kauppinen A, 2020, CELL MOL LIFE SCI, V77, P779, DOI 10.1007/s00018-019-03418-5
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khan F, 2006, SCAND J IMMUNOL, V64, P507, DOI 10.1111/j.1365-3083.2006.01794.x
   Kikuchi H, 2014, J SURG RES, V190, P134, DOI 10.1016/j.jss.2014.02.047
   Liu QP, 2013, ANTIOXID REDOX SIGN, V18, P1141, DOI 10.1089/ars.2012.4583
   Lymperaki E, 2015, HIPPOKRATIA, V19, P293
   Malarkey CS, 2012, TRENDS BIOCHEM SCI, V37, P553, DOI 10.1016/j.tibs.2012.09.003
   Murakami Y, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.58
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Oruc Y, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/7459496
   Qian J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079962
   Qin S, 2008, J INFLAMM RES, V1, P49
   Radi R, 2013, ACCOUNTS CHEM RES, V46, P550, DOI 10.1021/ar300234c
   Sakamoto K, 2015, EXP EYE RES, V137, P63, DOI 10.1016/j.exer.2015.06.003
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Shen X, 2015, WORLD J GASTROENTERO, V21, P1424, DOI 10.3748/wjg.v21.i5.1424
   Shukla V, 2020, J MED BIOCHEM, V39, P165, DOI 10.2478/jomb-2019-0033
   Sun S, 2019, AGING-US, V11, P4323, DOI 10.18632/aging.102039
   Thomson L, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/708282
   Tsung A, 2014, J INTERN MED, V276, P425, DOI 10.1111/joim.12276
   van Beijnum JR, 2013, ONCOGENE, V32, P363, DOI 10.1038/onc.2012.49
   Wang Boshi, 2009, Wei Sheng Yan Jiu, V38, P433
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Watanabe T, 2009, INVEST OPHTH VIS SCI, V50, P2283, DOI 10.1167/iovs.08-2709
   Yang S, 2014, J LEUKOCYTE BIOL, V95, P563, DOI 10.1189/jlb.0713412
NR 43
TC 0
Z9 0
U1 3
U2 3
PU SOC MEDICAL BIOCHEMISTS SERBIA
PI BELGRADE
PA VOJISLAVA ILICA 94B, I SPRAT, STAN 7, BELGRADE, VOZDOVAC, SERBIA
SN 1452-8258
EI 1452-8266
J9 J MED BIOCHEM
JI J. Med. Biochem.
PY 2022
VL 41
IS 3
BP 275
EP 281
DI 10.5937/jomb0-32189
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 3N7OR
UT WOS:000836336400002
PM 36042902
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Boyer, DS
   Schmidt-Erfurth, U
   Campagne, MV
   Henry, EC
   Brittain, C
AF Boyer, David S.
   Schmidt-Erfurth, Ursula
   Campagne, Menno van Lookeren
   Henry, Erin C.
   Brittain, Christopher
TI THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED
   MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; atrophy; complement; eculizumab;
   geographic atrophy; lampalizumab
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FACTOR-H
   POLYMORPHISM; NLRP3 INFLAMMASOME ACTIVATION; HEMOLYTIC-UREMIC SYNDROME;
   MEDIATED DARK-ADAPTATION; MEMBRANE ATTACK COMPLEX; FUNDUS
   AUTOFLUORESCENCE; HIGH-RISK; VISUAL-ACUITY
AB Purpose: Geographic atrophy (GA) is an advanced, vision-threatening form of age-related macular degeneration (AMD) affecting approximately five million individuals worldwide. To date, there are no approved therapeutics for GA treatment; however, several are in clinical trials. This review focuses on the pathophysiology of GA, particularly the role of complement cascade dysregulation and emerging therapies targeting the complement cascade.
   Methods: Primary literature search on PubMed for GA, complement cascade in age-related macular degeneration. ClinicalTrials. gov was searched for natural history studies in GA and clinical trials of drugs targeting the complement cascade for GA.
   Results: Cumulative damage to the retina by aging, environmental stress, and other factors triggers inflammation via multiple pathways, including the complement cascade. When regulatory components in these pathways are compromised, as with several GA-linked genetic risk factors in the complement cascade, chronic inflammation can ultimately lead to the retinal cell death characteristic of GA. Complement inhibition has been identified as a key candidate for therapeutic intervention, and drugs targeting the complement pathway are currently in clinical trials.
   Conclusion: The complement cascade is a strategic target for GA therapy. Further research, including on natural history and genetics, is crucial to expand the understanding of GA pathophysiology and identify effective therapeutic targets.
C1 [Boyer, David S.] Retina Vitreous Associates, Los Angeles, CA 90017 USA.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Campagne, Menno van Lookeren; Henry, Erin C.] Genentech Inc, San Francisco, CA USA.
   [Brittain, Christopher] F Hoffmann La Roche Ltd, Basel, Switzerland.
C3 Retina Vitreous Associates Medical Group; Medical University of Vienna;
   Roche Holding; Genentech; Roche Holding
RP Boyer, DS (通讯作者)，Retina Vitreous Associates, Med Grp, 1127 Wilshire Blvd,Suite 1620, Los Angeles, CA 90017 USA.
EM vitdoc@aol.com
RI Mitchell, Paul/P-1498-2014
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
FU Genentech, Inc.
FX Third-party writing assistance was provided by Kathryn H. Condon, PhD,
   CMPP, of Envision Scientific Solutions and funded by Genentech, Inc.
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   [Anonymous], 2013, CERT VIS IMP EXPL NO
   [Anonymous], 2014, APELLIS PHARM ACQUIR
   [Anonymous], 2014, SOLIRIS ECULIZUMAB P
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Atkinson JP, 2007, J EXP MED, V204, P1245, DOI 10.1084/jem.20070664
   Barbu A, 2015, MOL IMMUNOL, V67, P101, DOI 10.1016/j.molimm.2015.02.027
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Boyd SR, 2014, ARVO M ABSTR, V55, P1241
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding JD, 2014, ADV EXP MED BIOL, V801, P213, DOI 10.1007/978-1-4614-3209-8_28
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Doyle SL, 2014, NAT MED, V20, P1376, DOI 10.1038/nm.3741
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   Harboe M, 2009, MOL IMMUNOL, V47, P373, DOI 10.1016/j.molimm.2009.09.005
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Janeway Jr C.A., 2001, IMMUNOBIOLOGY IMMUNE, V5th
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kvanta A, 2014, ACTA OPHTHALMOL, V92, P21, DOI 10.1111/aos.12185
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Law SKA, 1997, PROTEIN SCI, V6, P263
   Le KN, 2015, CPT-PHARMACOMET SYST, V4, P595, DOI 10.1002/psp4.12031
   Le KN, 2015, J PHARMACOL EXP THER, V355, P288, DOI 10.1124/jpet.115.227223
   LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Ralston P, 2010, ARVO M ABSTR, V51, P913
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Samstad EO, 2014, J IMMUNOL, V192, P2837, DOI 10.4049/jimmunol.1302484
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schlanitz FG, 2015, AM J OPHTHALMOL, V1602
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schoengraf P, 2013, IMMUNOBIOLOGY, V218, P1, DOI 10.1016/j.imbio.2012.01.020
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Silva AS, 2012, MOL VIS, V18, P2288
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P8325, DOI 10.1167/iovs.13-13214
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stephan AH, 2012, ANNU REV NEUROSCI, V35, P369, DOI 10.1146/annurev-neuro-061010-113810
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sweigard JH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1482
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Wagner E, 2010, NAT REV DRUG DISCOV, V9, P43, DOI 10.1038/nrd3011
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Wright AF, 2011, NAT GENET, V43, P1176, DOI 10.1038/ng.1012
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 150
TC 85
Z9 86
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2017
VL 37
IS 5
BP 819
EP 835
DI 10.1097/IAE.0000000000001392
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0IO
UT WOS:000402173400020
PM 27902638
OA Green Published
DA 2022-11-30
ER

PT J
AU Caldani, S
   Chatard, H
   Wiener-Vacher, S
   Bucci, MP
AF Caldani, Simona
   Chatard, Hortense
   Wiener-Vacher, Sylvette
   Bucci, Maria Pia
TI Visual searching capabilities in Age-Related Macular Degeneration (AMD)
   subjects
SO APPLIED NEUROPSYCHOLOGY-ADULT
LA English
DT Article
DE AMD subjects; elderly; visual searching
ID FUNCTIONAL NEUROANATOMY; EYE-MOVEMENTS; PERFORMANCE; RECOGNITION;
   PREVALENCE; ATTENTION; OBJECTS; DISEASE; SCENES
AB A decrease in visual perception with age was observed due to a decline in neurocognitive and visual functions. Previous studies showed that aging affects visual processes and contextual perceptual phenomena. The aim of our study was to explore the effect of age as well as the effect of Age-Related Macular Degeneration (AMD) on the visual searching task. Three groups of twenty-one subjects were recruited: AMD subjects (mean age 72.29???4.83 years); healthy elderly (72.55???4.95); and young healthy volunteers (28.38???2.77). Visual perception functions were evaluated with a modified barrage test developed by Metrisquare. Our results showed that AMD patients and elderly do not differ in terms of time, omissions and errors. However both were slower to perform the visual perception tests when compared with young adults. Regarding the number of errors and omissions, we only found significant differences between the young and the AMD subjects, the later making more omissions and errors respect to young healthy volunteers. Despite AMD patients made more errors likely because to their poor fixation capability, we could conclude that AMD patients, as well as healthy elderly subjects, could compensate their altered visual strategies by taking more time to perform the visual searching tasks, probably due to cortical plasticity.
C1 [Caldani, Simona; Chatard, Hortense; Wiener-Vacher, Sylvette; Bucci, Maria Pia] Univ Paris, Robert Debre Hosp, INSERM, UMR 1141, 48 Blvd Serurier, F-75019 Paris, France.
   [Caldani, Simona; Chatard, Hortense; Wiener-Vacher, Sylvette; Bucci, Maria Pia] Robert Debre Hosp, ENT Dept, EFEE Ctr Funct Explorat Balance Children, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Robert-Debre - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite Paris
   Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Robert-Debre - APHP; UDICE-French Research Universities; Universite
   Paris Cite
RP Caldani, S (通讯作者)，Univ Paris, Robert Debre Hosp, INSERM, UMR 1141, 48 Blvd Serurier, F-75019 Paris, France.
EM simona.caldani@gmail.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Aspinall PA, 2014, BRIT J OPHTHALMOL, V98, P1393, DOI 10.1136/bjophthalmol-2014-305032
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19
   Ball KK, 2006, J AM GERIATR SOC, V54, P77, DOI 10.1111/j.1532-5415.2005.00568.x
   Boucart M, 2008, VISUAL NEUROSCI, V25, P603, DOI 10.1017/S0952523808080656
   Cabeza R, 1997, J NEUROSCI, V17, P391
   Chatard H., 2019, J SURG, V13, P1239, DOI [10.29011/2575-9760.001239, DOI 10.29011/2575-9760.001239]
   Chatard H, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00158
   Crabb DP, 2017, BEHAV BRAIN SCI, V40, P23, DOI 10.1017/S0140525X16000054
   Cross JM, 2009, BRIT J OPHTHALMOL, V93, P400, DOI 10.1136/bjo.2008.144584
   Crossland MD, 2006, VISION RES, V46, P590, DOI 10.1016/j.visres.2005.05.015
   Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259
   Ellis RD, 1996, J GERONTOL B-PSYCHOL, V51, pP155, DOI 10.1093/geronb/51B.3.P155
   Faubert J, 2002, CAN J EXP PSYCHOL, V56, P164, DOI 10.1037/h0087394
   Haute Autorite de Sante, 2012, DEG MAC LIEE LAG PRI
   Hommel B, 2004, DEV PSYCHOL, V40, P545, DOI 10.1037/0012-1649.40.4.545
   Irving EL, 2006, INVEST OPHTH VIS SCI, V47, P2478, DOI 10.1167/iovs.05-1311
   Lacroix E., 2017, 6 INT C AUD CORT BAN
   Leveziel N, 2009, J FR OPHTALMOL, V32, P440, DOI 10.1016/j.jfo.2009.04.009
   Madden DJ, 2002, BRAIN COGNITION, V49, P297, DOI 10.1006/brcg.2001.1502
   Madden DJ, 1999, HUM BRAIN MAPP, V7, P115, DOI 10.1002/(SICI)1097-0193(1999)7:2<115::AID-HBM5>3.0.CO;2-N
   Malavita MS, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20632
   Martinez-Roda JA, 2016, CLIN EXP OPTOM, V99, P518, DOI 10.1111/cxo.12369
   Michely J, 2018, NEUROIMAGE-CLIN, V18, P443, DOI 10.1016/j.nicl.2018.02.001
   Munoz DP, 1998, EXP BRAIN RES, V121, P391, DOI 10.1007/s002210050473
   MURPHY KS, 1989, OPHTHAL PHYSL OPT, V9, P317, DOI 10.1111/j.1475-1313.1989.tb00915.x
   Owsley C, 2011, VISION RES, V51, P1610, DOI 10.1016/j.visres.2010.10.020
   Ramanoel S, 2018, VISUAL NEUROSCI, V35, DOI 10.1017/S0952523817000372
   Ricci R, 2016, NEUROPSYCHOLOGIA, V92, P158, DOI 10.1016/j.neuropsychologia.2016.05.004
   RUSH MC, 1987, J GENET PSYCHOL, V148, P225, DOI 10.1080/00221325.1987.9914552
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Senger C, 2019, GRAEF ARCH CLIN EXP, V257, P153, DOI 10.1007/s00417-018-4164-9
   Smith ND, 2011, OPHTHAL PHYSL OPT, V31, P225, DOI 10.1111/j.1475-1313.2011.00836.x
   Taylor DJ, 2017, INVEST OPHTH VIS SCI, V58, P1887, DOI 10.1167/iovs.16-21122
   Thibaut M, 2016, J FR OPHTALMOL, V39, P82, DOI 10.1016/j.jfo.2015.08.010
   Vaes N, 2015, BEHAV RES METHODS, V47, P27, DOI 10.3758/s13428-014-0448-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4
NR 40
TC 3
Z9 3
U1 2
U2 2
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 2327-9095
EI 2327-9109
J9 APPL NEUROPSYCH-ADUL
JI Appl. Neuropsychol.-Adult
PD SEP 3
PY 2021
VL 28
IS 5
BP 619
EP 626
DI 10.1080/23279095.2019.1678158
EA OCT 2019
PG 8
WC Clinical Neurology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology; Psychology
GA TZ3RO
UT WOS:000491380900001
PM 31625771
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   McKay, GJ
   de Jong, PTVM
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Vingerling, JR
   Vioque, J
   Young, IS
   Sofat, R
   Hingorani, AD
   Fletcher, AE
AF Chakravarthy, Usha
   McKay, Gareth J.
   de Jong, Paulus T. V. M.
   Rahu, Mati
   Seland, Johan
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Vingerling, Johannes R.
   Vioque, Jesus
   Young, Ian S.
   Sofat, Reecha
   Hingorani, Aroon D.
   Fletcher, Astrid E.
TI ARMS2 Increases the Risk of Early and Late Age-related Macular
   Degeneration in the European Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; CIGARETTE-SMOKING; POLYMORPHISM; MACULOPATHY;
   LOC387715; CFH; GENE; AMD; SUSCEPTIBILITY; ASSOCIATION
AB Objective: To study associations between severity stages of early and late age-related macular degeneration (AMD) and genetic variations in age-related maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) and to investigate potential interactions between smoking and ARMS2.
   Design: Population-based, cross-sectional European Eye Study in 7 countries in Europe.
   Participants: Four thousand seven hundred fifty participants, 65 years of age and older, recruited through random sampling.
   Methods: Participants were classified on the basis of the more severely affected eye into 5 mutually exclusive AMD severity stages ranging from no AMD, 3 categories of early AMD, and late AMD. History of cigarette smoking was available and allowed classification into never, former, and current smokers, with the latter 2 groups combined into a single category of ever smokers for analysis. Genotyping was performed for single nucleotide polymorphisms rs10490924 and rs4146894 in ARMS2 and rs1061170 in CFH. Associations were analyzed by logistic regression.
   Main Outcome Measures: Odds ratios (ORs) for stage of AMD associated with genetic variations in ARMS2 and CFH and interactions between ARMS2 and smoking status.
   Results: Early AMD was present in 36.4% and late AMD was present in 3.3% of participants. Data on both genotype and AMD were available for 4276 people. The ORs for associations between AMD stage and ARMS2 increased monotonically with more severe stages of early AMD and were altered little by adjustment for potential confounders. Compared with persons with no AMD, carriers of the TT genotype for rs10490924 in ARMS2 had a 10-fold increase in risk of late AMD (P<3x10(-20)). The ORs for associations with CFH were similar for stage 3 early AMD and late AMD. Interactions between rs10490924 in ARMS2 and smoking status were significant in both unadjusted and adjusted models (P = 0.001). The highest risk was observed in those doubly homozygous for rs10490924 and rs1061170 in CFH (OR, 62.3; 95% confidence interval, 16-242), with P values for trend ranging from 0.03 (early AMD, stage 1) to 1 x 10(-26) (late AMD).
   Conclusions: A strong association was demonstrated between all stages of AMD and genetic variation in ARMS2, and a significant gene-environment interaction with cigarette smoking was confirmed.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:342-348 (C) 2013 by the American Academy of Ophthalmology.
C1 [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [McKay, Gareth J.; Young, Ian S.] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT12 6BA, Antrim, North Ireland.
   [de Jong, Paulus T. V. M.] Netherlands Inst Neurosci, Amsterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, Johan] Univ Bergen, Stavanger Univ Hosp, Eye Dept, Bergen, Norway.
   [Soubrane, Gisele] Univ Paris Descartes 1, Dept Ophthalmol, Hotel Dieu Paris, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Clin Oculist, I-37100 Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Dept Ophthalmol, Sch Med, GR-54006 Thessaloniki, Greece.
   [Vingerling, Johannes R.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   [Vingerling, Johannes R.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Vioque, Jesus] Univ Miguel Hernandez, Dept Salud Publ, Alicante, Spain.
   [Vioque, Jesus] CIBERESP, Alicante, Spain.
   [Sofat, Reecha] UCL, Div Med, Ctr Clin Pharmacol, London, England.
   [Hingorani, Aroon D.] UCL, Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, London, England.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London WC1, England.
C3 Queens University Belfast; Queens University Belfast; Royal Netherlands
   Academy of Arts & Sciences; Netherlands Institute for Neuroscience
   (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam;
   National Institute for Health Development - Estonia; Stavanger
   University Hospital; University of Bergen; Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French
   Research Universities; Universite Paris Cite; University of Verona;
   Aristotle University of Thessaloniki; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Universidad Miguel
   Hernandez de Elche; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERESP; University of London; University College London; University of
   London; University College London; University of London; London School
   of Hygiene & Tropical Medicine
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Ctr Vis & Vasc Sci, Inst Clin Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Vioque, Jesus/A-1066-2008; Rahu, Mati/A-9981-2008; McKay,
   Gareth/AAZ-2601-2020
OI Vioque, Jesus/0000-0002-2284-148X; McKay, Gareth/0000-0001-8197-6280;
   Topouzis, Fotis/0000-0002-8966-537X; Young, Ian/0000-0003-3890-3152;
   Hingorani, Aroon/0000-0001-8365-0081; Chakravarthy,
   Usha/0000-0002-2606-3734; Sofat, Reecha/0000-0002-0242-6115
FU European Commission [QLK6-CT-1999-02094]; MRC [G0601354]; Macular
   Disease Society UK; Estonian Ministry of Education and Science
   [01921112s02, SF0940026s07]; Spanish Ministry of Health [FIS 01/1692E];
   CIBER en Epidemiologia y Salud Publica CIBERESP; Generalitat Valenciana
   [CTGCA/2002/06, G03/136]; British Heart Foundation [RG/10/12/28456]
   Funding Source: researchfish; Medical Research Council [MC_CF023241,
   G0601354] Funding Source: researchfish
FX Supported by the European Commission Vth Framework (QLK6-CT-1999-02094)
   with follow-up funding for DNA extraction and genotyping from MRC
   Biomarkers Award G0601354. Additional funding for cameras was provided
   by the Macular Disease Society UK. M. Rahu was financed by the Estonian
   Ministry of Education and Science (target funding 01921112s02 and
   SF0940026s07). Additional funding in Alicante was received from the
   Spanish Ministry of Health (grants FIS 01/1692E and CIBER en
   Epidemiologia y Salud Publica CIBERESP) and the Generalitat Valenciana
   (grants CTGCA/2002/06 and G03/136). The sponsors or funding
   organizations had no role in study design, data collection, data
   analysis, data interpretation, writing of the article, or decision to
   submit the article for publication.
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   BIRD AC, 1995, INT ARM EPIDEMIOLOGI, V5, P367
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2011, CLIN OPHTHALMOL, V5, P1127, DOI 10.2147/OPTH.S11627
   Hadley D, 2010, INVEST OPHTH VIS SCI, V51, P2191, DOI 10.1167/iovs.09-3798
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1605, DOI 10.1001/archophthalmol.2011.372
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Recalde S, 2008, OPHTHALMOLOGY, V115, P916, DOI 10.1016/j.ophtha.2007.12.012
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
NR 30
TC 31
Z9 32
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 342
EP 348
DI 10.1016/j.ophtha.2012.08.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100019
PM 23098369
DA 2022-11-30
ER

PT J
AU Winiarczyk, M
   Kaarniranta, K
   Winiarczyk, S
   Adaszek, L
   Winiarczyk, D
   Mackiewicz, J
AF Winiarczyk, Mateusz
   Kaarniranta, Kai
   Winiarczyk, Stanislaw
   Adaszek, Lukasz
   Winiarczyk, Dagmara
   Mackiewicz, Jerzy
TI Tear film proteome in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Biomarker; Proteomics; Tear film
ID RETINAL-PIGMENT EPITHELIUM; AQUEOUS-HUMOR; DRY EYE; ALZHEIMERS-DISEASE;
   OXIDATIVE STRESS; AUTOPHAGY; PROTEINS; CELLS; HSP90; CANCER
AB Purpose Age-related macular degeneration (AMD) is the main reason for blindness in elderly people in the developed countries. Current screening protocols have limitations in detecting the early signs of retinal degeneration. Therefore, it would be desirable to find novel biomarkers for early detection of AMD. Development of novel biomarkers would help in the prevention, diagnostics, and treatment of AMD. Proteomic analysis of tear film has shown promise in this research area. If an optimal set of biomarkers could be obtained from accessible body fluids, it would represent a reliable way to monitor disease progression and response to novel therapies.
   Methods Tear films were collected on Schirmer strips from a total of 22 patients (8 with wet AMD, 6 with dry AMD, and 8 control individuals). 2D electrophoresis was used to separate tear film proteins prior to their identification with matrix-assisted laser desorption/ionization time of flight spectrometer (MALDI-TOF/TOF) and matching with functional databases.
   Results A total of 342 proteins were identified. Most of them were previously described in various proteomic studies concerning AMD. Shootin-1, histatin-3, fidgetin-like protein 1, SRC kinase signaling inhibitor, Graves disease carrier protein, actin cytoplasmic 1, prolactin-inducible protein 1, and protein S100-A7A were upregulated in the tear film samples isolated from AMD patients and were not previously linked with this disease in any proteomic analysis.
   Conclusion The upregulated proteins supplement our current knowledge of AMD pathogenesis, providing evidence that certain specific proteins are expressed into the tear film in AMD. As far we are aware, this is the first study to have undertaken a comprehensive in-depth analysis of the human tear film proteome in AMD patients.
C1 [Winiarczyk, Mateusz; Mackiewicz, Jerzy] Med Univ Lublin, Dept Vitreoretinal Surg, Lublin, Poland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Kuopio, Finland.
   [Winiarczyk, Stanislaw; Adaszek, Lukasz; Winiarczyk, Dagmara] Univ Life Sci Lublin, Dept Epizootiol, Lublin, Poland.
C3 Medical University of Lublin; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland; University of Life
   Sciences in Lublin
RP Mackiewicz, J (通讯作者)，Med Univ Lublin, Dept Vitreoretinal Surg, Lublin, Poland.
EM jerzymackiewicz@umlub.pl
RI Winiarczyk, Mateusz/S-9712-2019
OI Winiarczyk, Dagmara/0000-0002-1257-869X; Adaszek,
   Lukasz/0000-0003-0261-2695; Winiarczyk, Mateusz/0000-0001-9704-3848;
   Mackiewicz, Jerzy/0000-0003-0984-8908; Winiarczyk,
   Stanislaw/0000-0002-8468-2154
FU National Science Centre, Poland (NCN) [2017/25/N/NZ5/01875]; Kuopio
   University Hospital VTR grant [KK5503743]; Academy of Finland [KK296840]
FX The study was partially funded by National Science Centre, Poland (NCN),
   grant number 2017/25/N/NZ5/01875. The Kuopio University Hospital VTR
   grant (KK5503743) and the Academy of Finland (KK296840) provided
   financial support in the form of KK and MW funding. The sponsor had no
   role in the design or conduct of this research.
CR Ablamowicz AF, 2017, MOL VIS, V23, P529
   Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Aguila M, 2014, HUM MOL GENET, V23, P2164, DOI 10.1093/hmg/ddt613
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Boehm N, 2013, INVEST OPHTH VIS SCI, V54, P2385, DOI 10.1167/iovs.11-8751
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ecker SM, 2012, MOL VIS, V18, P1658
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Gonzalez N, 2012, MOL VIS, V18, P1572
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Green-Church KB, 2008, MOL VIS, V14, P456
   Hagan S, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0065-3
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Iannaccone A, 2012, ADV EXP MED BIOL, V723, P11, DOI 10.1007/978-1-4614-0631-0_2
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32548
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kim HJ, 2012, CLIN BIOCHEM, V45, P60, DOI 10.1016/j.clinbiochem.2011.10.006
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li B, 2014, INVEST OPHTH VIS SCI, V55, P177, DOI 10.1167/iovs.13-12080
   LI BL, 2014, SCI REP UK, V4
   Li KJ, 2010, GRAEF ARCH CLIN EXP, V248, P853, DOI 10.1007/s00417-009-1275-3
   Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Patel Amit K, 2013, JAKSTAT, V2, pe25434, DOI 10.4161/jkst.25434
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Posa A, 2013, ANN ANAT, V195, P137, DOI 10.1016/j.aanat.2012.10.001
   Rentka A, 2017, ANN CLIN BIOCHEM, V54, P521, DOI 10.1177/0004563217695843
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Salminen A, 2011, PROG NEUROBIOL, V93, P99, DOI 10.1016/j.pneurobio.2010.10.006
   Samarasinghe B, 2014, BIOCHEM PHARMACOL, V87, P445, DOI 10.1016/j.bcp.2013.11.014
   Saraygord-Afshari N, 2015, BIOMED CHROMATOGR, V29, P1056, DOI 10.1002/bmc.3392
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Sung HJ, 2012, MOL VIS, V18, P234
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Tripathi S, 2015, BMC SYST BIOL, V9, DOI 10.1186/s12918-015-0181-z
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wang BL, 2016, TUMOR BIOL, V37, P1, DOI 10.1007/s13277-015-4142-3
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Xiong R, 2015, MOL PHARMACOL, V88, P1045, DOI 10.1124/mol.115.101451
   Xu XR, 2014, INT J OPHTHALMOL-CHI, V7, P256, DOI 10.3980/j.issn.2222-3959.2014.02.12
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zamora DO, 2007, MOL VIS, V13, P2058
   Zhang LY, 2016, INT J GYNECOL CANCER, V26, P810, DOI 10.1097/IGC.0000000000000694
   Zhou L, 2013, PROTEOMICS, V13, P2469, DOI 10.1002/pmic.201200230
NR 72
TC 19
Z9 21
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2018
VL 256
IS 6
BP 1127
EP 1139
DI 10.1007/s00417-018-3984-y
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG1AY
UT WOS:000432412900011
PM 29696386
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Yoshida, T
   Dewan, A
   Zhang, H
   Sakamoto, R
   Okamoto, H
   Minami, M
   Obazawa, M
   Mizota, A
   Tanaka, M
   Saito, Y
   Takagi, I
   Hoh, J
   Iwata, T
AF Yoshida, Tsunehiko
   DeWan, Andrew
   Zhang, Hong
   Sakamoto, Ryosuke
   Okamoto, Haru
   Minami, Masayoshi
   Obazawa, Minoru
   Mizota, Atsushi
   Tanaka, Minoru
   Saito, Yoshihiro
   Takagi, Ikue
   Hoh, Josephine
   Iwata, Takeshi
TI HTRA1 promoter polymorphism predisposes Japanese to age-related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY; ASSOCIATION; GENE; LOC387715
AB Purpose: To study the effect of candidate single nucleotide polymorphisms (SNPs) on chromosome 10q26, recently shown to be associated with wet age-related macular degeneration (AMD) in Chinese and Caucasian cohorts, in a Japanese cohort.
   Methods: Using genomic DNA isolated from peripheral blood of wet AMD cases and age-matched controls, we genotyped two SNPs, rs10490924, and rs11200638, on chromosome 10q26, 6.6 kb and 512 bp upstream of the HTRA1 gene, respectively, using temperature gradient capillary electrophoresis (TGCE) and direct sequencing. Association tests were performed for individual SNPs and jointly with SNP complement factor H (CFH) Y402H.
   Results: The two SNPs, rs10490924 and rs11200638, are in complete linkage disequilibrium (D'=1). Previous sequence comparisons among seventeen species revealed that the genomic region containing rs11200638 was highly conserved while the region surrounding rs10490924 was not. The allelic association test for rs11200638 yielded a p-value < 10(-11). SNP rs11200638 conferred disease risk in an autosomal recessive fashion: Odds ratio was 10.1 (95% CI 4.36, 23.06), adjusted for SNP CFH 402, for those carrying two copies of the risk allele, whereas indistinguishable from unity if carrying only one risk allele.
   Conclusions: The HTRA1 promoter polymorphism, rs11200638, is a strong candidate with a functional consequence that predisposes Japanese to develop neovascular AMD.
C1 Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo, Japan.
   Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba, Japan.
   Natl Hosp Org, Osaka Med Ctr, Div Ophthalmol, Osaka, Japan.
   Natl Hosp Org, Kyushu Med Ctr, Div Ophthalmol, Fukuoka, Japan.
C3 Yale University; Juntendo University; Osaka Medical Center for Cancer &
   Cardiovascular Diseases
RP Hoh, J (通讯作者)，Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,Room 416, New Haven, CT 06520 USA.
EM josephine.hoh@yale.edu
OI DeWan, Andrew/0000-0002-7679-8704
CR Armitage P, 1971, STAT METHODS MED RES
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Scheffe H., 1964, ANAL VARIANCE
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 12
TC 80
Z9 84
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 4
PY 2007
VL 13
IS 57-61
BP 545
EP 548
PG 4
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 157KT
UT WOS:000245719300002
PM 17438519
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Figueroa, MS
   Arias, L
   Araiz, J
   Ruiz-Moreno, JM
   Garcia-Arumi, J
   Gomez-Ulla, F
   Lopez-Galvez, MI
   Cabrera-Lopez, F
   Garcia-Campos, JM
   Mones, J
   Cervera, E
   Armada, F
   Gallego-Pinazo, R
AF Garcia-Layana, Alfredo
   Figueroa, Marta S.
   Arias, Luis
   Araiz, Javier
   Maria Ruiz-Moreno, Jose
   Garcia-Arumi, Jose
   Gomez-Ulla, Francisco
   Isabel Lopez-Galvez, Mara
   Cabrera-Lopez, Francisco
   Manuel Garcia-Campos, Jose
   Mones, Jordi
   Cervera, Enrique
   Armada, Felix
   Gallego-Pinazo, Roberto
TI Individualized Therapy with Ranibizumab in Wet Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID INTRAVITREAL RANIBIZUMAB; BEVACIZUMAB; REGIMEN; AFLIBERCEPT; EFFICACY;
   TRIAL
AB Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that "treat and extend" and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services.
C1 [Garcia-Layana, Alfredo] Univ Navarra Clin, Pamplona 31008, Spain.
   [Garcia-Layana, Alfredo; Figueroa, Marta S.; Arias, Luis; Araiz, Javier; Maria Ruiz-Moreno, Jose; Garcia-Arumi, Jose; Gomez-Ulla, Francisco; Isabel Lopez-Galvez, Mara; Cabrera-Lopez, Francisco; Manuel Garcia-Campos, Jose; Mones, Jordi; Cervera, Enrique; Armada, Felix; Gallego-Pinazo, Roberto] SERV, Santiago De Compostela 15705, Spain.
   [Garcia-Layana, Alfredo; Figueroa, Marta S.; Arias, Luis; Araiz, Javier; Maria Ruiz-Moreno, Jose; Garcia-Arumi, Jose; Gomez-Ulla, Francisco; Isabel Lopez-Galvez, Mara] Inst Hlth Carlos III, RETICS OFTARED Prevent Early Detect & Treatment P, Madrid 28029, Spain.
   [Figueroa, Marta S.] Hosp Univ Ramon y Cajal, Madrid 28034, Spain.
   [Figueroa, Marta S.] Vissum Madrid, Madrid 28002, Spain.
   [Arias, Luis] Bellvitge Hosp, Barcelona 08907, Spain.
   [Araiz, Javier] Hosp San Eloy, Baracaldo 48902, Spain.
   [Maria Ruiz-Moreno, Jose] Hosp Univ Albacete, Albacete 02006, Spain.
   [Garcia-Arumi, Jose] Hosp Valle De Hebron, Barcelona 08035, Spain.
   [Gomez-Ulla, Francisco] Inst Oftalmol Gomez Ulla, Santiago De Compostela 15706, Spain.
   [Isabel Lopez-Galvez, Mara] Hosp Clin Univ Valladolid, IOBA, Valladolid 47011, Spain.
   [Cabrera-Lopez, Francisco] Complejo Hosp Univ Insular Materno Infantil Gran, Las Palmas Gran Canaria 35016, Spain.
   [Manuel Garcia-Campos, Jose] Hosp Univ Virgen de la Victoria, Malaga 29010, Spain.
   [Mones, Jordi] Inst Macula & Retina, Barcelona 08022, Spain.
   [Cervera, Enrique] Hosp Gen Valencia, Valencia 46014, Spain.
   [Armada, Felix] Hosp La Paz, Madrid 28046, Spain.
   [Gallego-Pinazo, Roberto] Hosp La Fe, Valencia 46026, Spain.
C3 University of Navarra; Hospital Universitario Ramon y Cajal; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University
   Hospital; University of Barcelona; Hospital Universitari Vall d'Hebron;
   Universidad de Malaga; Hospital Universitario La Paz; Hospital
   Universitari i Politecnic La Fe
RP Garcia-Layana, A (通讯作者)，Univ Navarra Clin, Ave Pio 12 36, Pamplona 31008, Spain.
EM aglayana@unav.es
RI CABRERA LOPEZ, FRANCISCO/ABE-2892-2021; Ruiz-Moreno, José M/E-4644-2016;
   mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Garcia-Arumi,
   Jose/0000-0001-8827-1160; CABRERA LOPEZ, FRANCISCO/0000-0002-5074-5102;
   Ruiz-Moreno, Jose M/0000-0001-9636-0788
FU PN I+D+i; ISCIII; Subdireccion General de Redes y Centros de
   Investigacion Cooperativa; European Program FEDER
FX This work has been developed by members of the Spanish Vitreoretinal
   Society (SERV), the RETICs (RD07-0062) "Age Related Ocular Diseases,
   Quality of Life and Vision," and RETICS OFTARED (RD12/0034) "
   Prevention, Early Detection and Treatment of the Prevalent Degenerative
   and Chronic Ocular Pathology" from the Instituto de Salud Carlos III
   from the Ministerio de Economia y Competitividad, Spain. This work has
   been partly funded by the PN I+D+i 2008-2011, ISCIII, Subdireccion
   General de Redes y Centros de Investigacion Cooperativa, and the
   European Program FEDER.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Amoaku WMK, 2008, EYE, V22, P864, DOI 10.1038/eye.2008.1
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bidot ML, 2011, J FR OPHTALMOL, V34, P376, DOI 10.1016/j.jfo.2011.03.004
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo P., 2014, BRIT J OPHTHALMOLOGY
   Casaroli-Marano R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/346360
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cruess AF, 2012, CAN J OPHTHALMOL, V47, P227, DOI 10.1016/j.jcjo.2012.03.007
   de Geus SJR, 2013, ACTA OPHTHALMOL, V91, pE411, DOI 10.1111/aos.12090
   Garcia-Layana A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/595132
   Gaudric A, 2010, AM J OPHTHALMOL, V149, P4, DOI 10.1016/j.ajo.2009.08.039
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hoyng C. B., 2013, P WORLD C CONTR OPHT
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lopez J. D., 2013, ACT 17 C SOC ESP RET
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P227
   Mitchel P., 2012, P WOC M
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mones J., 2005, DEGENERACION MACULAR
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   Sainz-Gomez C, 2010, EUR J OPHTHALMOL, V20, P442, DOI 10.1177/112067211002000228
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Seidel G, 2013, ACTA OPHTHALMOL, V91, pe482, DOI 10.1111/aos.12111
   Shin HJ, 2013, RETINA-J RET VIT DIS, V33, P964, DOI 10.1097/IAE.0b013e3182835f70
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Trichonas G, 2013, OPHTHALMOL THER, V2, P89, DOI 10.1007/s40123-013-0015-2
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 46
TC 13
Z9 13
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 412903
DI 10.1155/2015/412903
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT4BM
UT WOS:000362750900001
PM 26491550
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Hong, T
   Zhu, MD
   Li, HT
   Schlub, TE
   Wijeyakumar, W
   Chang, AA
AF Broadhead, Geoffrey K.
   Hong, Thomas
   Zhu, Meidong
   Li, Haitao
   Schlub, Timothy E.
   Wijeyakumar, Wijeyanthy
   Chang, Andrew A.
TI RESPONSE OF PIGMENT EPITHELIAL DETACHMENTS TO INTRAVITREAL AFLIBERCEPT
   AMONG PATIENTS WITH TREATMENT-RESISTANT NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; pigment epithelial
   detachment; aflibercept
ID OCCULT CHOROIDAL NEOVASCULARIZATION; VEGF TRAP; RANIBIZUMAB;
   BEVACIZUMAB; OUTCOMES; THERAPY; TEARS
AB Purpose: To assess the effect of intravitreal aflibercept on pigment epithelial detachment (PED) in patients with treatment-resistant neovascular age-related macular degeneration.
   Methods: Forty-six patients with vascularized PEDs participating in a wider, prospective clinical trial of treatment-resistant neovascular age-related macular degeneration received 2-mg aflibercept as 3 loading doses 1 month apart, followed by further 2-monthly doses over a total 12-month period. Change in PED dimensions and reflective properties were assessed by optical coherence tomography. Reflectivity was subclassified as solid (hyperreflective), hollow (hyporeflective), or mixed (elements of both).
   Results: Aflibercept reduced PED height, width, and length at 48 weeks compared with baseline values (P <= 0.01 for all). Reductions in PED height were correlated with reductions in central macular thickness at 48 weeks (R-2 = 0.36, P < 0.001). There was no significant correlation between PED height decrease and visual acuity changes at 48 weeks. Solid PEDs were less likely to experience reductions in all three dimensions than either hollow or mixed PEDs.
   Conclusion: Aflibercept is effective in reducing PED dimensions in treatment-resistant patients and is most effective in PEDs demonstrating some hyporeflective optical coherence tomography characteristics. Reduction in PED dimensions correlated with central macular thickness, but not with visual acuity changes. The role of PEDs as markers of disease requires further investigation; however, lesions should be monitored for retinal fluid recurrence.
C1 [Broadhead, Geoffrey K.; Hong, Thomas; Zhu, Meidong; Li, Haitao; Wijeyakumar, Wijeyanthy; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Zhu, Meidong; Wijeyakumar, Wijeyanthy; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Sydney
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
OI Schlub, Timothy/0000-0001-7746-9649
FU Bayer Corporation Global
FX Supported by Bayer Corporation Global.
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Keane PA, 2012, INVEST OPHTH VIS SCI, V53, P1152, DOI 10.1167/iovs.11-8130
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parodi MB, 2013, AM J OPHTHALMOL, V155, P103, DOI 10.1016/j.ajo.2012.07.001
   Patel KH, 2013, EYE, V27, P668
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 19
TC 35
Z9 36
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2015
VL 35
IS 5
BP 975
EP 981
DI 10.1097/IAE.0000000000000409
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG6KI
UT WOS:000353408900019
PM 25627086
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Kiel, C
   den Hollander, AI
   Weeks, DE
   Lotery, A
   Cipriani, V
   Weber, BHF
AF Grassmann, Felix
   Kiel, Christina
   den Hollander, Anneke I.
   Weeks, Daniel E.
   Lotery, Andrew
   Cipriani, Valentina
   Weber, Bernhard H. F.
CA Int Age-Related Macular Degenera
TI Y chromosome mosaicism is associated with age-related macular
   degeneration
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DISEASE; CANCER; BLOOD; IMMUNOSENESCENCE; GENETICS; RISK
AB Age-related macular degeneration (AMD) is the leading cause of blindness in industrialised countries, and thereby a major individual but also a socio-economic burden. Y chromosome loss in nucleated blood cells has been implicated in age-related diseases such as Alzheimer disease and was shown to be caused by increasing age, smoking and genetic factors. Mosaic loss of Y chromosome (mLOY) in peripheral blood was estimated from normalised dosages of genotyping chip data covering the male-specific region of the Y chromosome. After quality control, we assessed the association of mLOY on AMD risk in 5772 male cases and 6732 male controls. In controls the prevalence of mLOY increased significantly with age, which is consistent with previous reports. Importantly, mLOY was associated with late-stage AMD with genome-wide significance (OR: 1.332 [95% CI: 1.206; 1.472], P = 1.60e-08), independent of age, the AMD genetic risk score and the first two principle components of ancestry. Additionally conditioning on smoking behaviour had no influence on the observed association strength. mLOY was strongest associated in individuals aged between 65 and 75 years. Taken together, mLOY is significantly associated with risk for AMD, independent of known and potential confounding factors.
C1 [Grassmann, Felix; Kiel, Christina; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Grassmann, Felix] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Weeks, Daniel E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Lotery, Andrew] Univ Southampton, Clin & Expt Sci, Fac Med, Southampton, Hants, England.
   [Cipriani, Valentina] UCL, Inst Ophthalmol, London, England.
C3 University of Regensburg; Karolinska Institutet; Radboud University
   Nijmegen; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; University of Southampton;
   University of London; University College London
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Hollander, Anneke den/N-4911-2014; Weeks, Daniel E/B-2995-2012
OI Weeks, Daniel E/0000-0001-9410-7228; Grassmann,
   Felix/0000-0003-1390-7528; Lotery, Andrew/0000-0001-5541-4305; Kiel,
   Christina/0000-0003-3154-4847
FU German Research Foundation [GR 5065/1-1]; Institute of Human Genetics,
   University of Regensburg [TG77]; CIDR [HHSN268201200008I];  [EY022310];
   NATIONAL EYE INSTITUTE [R01EY022310] Funding Source: NIH RePORTER
FX The work was funded, in parts by a grant from the German Research
   Foundation (GR 5065/1-1 to FG) and institutional funds of the Institute
   of Human Genetics, University of Regensburg (TG77 to BHFW). Genotyping
   was conducted as part of the IAMDGC exomechip project supported by CIDR
   (contract number HHSN268201200008I) and funded by EY022310 (to Jonathan
   L. Haines, Case Western Reserve University, Cleveland) and 1 x
   01HG006934-01 (to Goncalo R. Abecasis, University of Michigan,
   Department of Biostatistics). The funding bodies had no role in the
   design of the study and collection, analysis, and interpretation of data
   and in writing the manuscript.
CR [Anonymous], 2011, R LANG ENV STAT COMP
   Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756
   Dumanski JP, 2016, AM J HUM GENET, V98, P1208, DOI 10.1016/j.ajhg.2016.05.014
   Dumanski JP, 2015, SCIENCE, V347, P81, DOI 10.1126/science.1262092
   ERSHLER WB, 1993, J GERONTOL, V48, pB3, DOI 10.1093/geronj/48.1.B3
   Forsberg LA, 2017, HUM GENET, V136, P657, DOI 10.1007/s00439-017-1799-2
   Forsberg LA, 2017, NAT REV GENET, V18, P128, DOI 10.1038/nrg.2016.145
   Forsberg LA, 2014, NAT GENET, V46, P624, DOI 10.1038/ng.2966
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F., 2018, OPHTHALMOLOGY
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Haitjema S, 2017, CIRC-CARDIOVASC GENE, V10, DOI 10.1161/CIRCGENETICS.116.001544
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Noveski P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146264
   Tsoukas C, 2014, CURR OPIN HIV AIDS, V9, P398, DOI 10.1097/COH.0000000000000077
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Williams G.C., 2001, SCI AGING KNOWL ENV, V2001, pcp13
   Winkler TW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194321
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright DJ, 2017, NAT GENET, V49, P674, DOI 10.1038/ng.3821
   Zhou WY, 2016, NAT GENET, V48, P563, DOI 10.1038/ng.3545
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 30
TC 24
Z9 24
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD JAN
PY 2019
VL 27
IS 1
BP 36
EP 41
DI 10.1038/s41431-018-0238-8
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA HF3BW
UT WOS:000454111500006
PM 30158665
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Loewenstein, A
AF Loewenstein, Anat
TI The significance of early detection of age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization
   (CNV); early detection; progressive; subfoveal
ID PREFERENTIAL HYPERACUITY PERIMETER; OPTICAL COHERENCE TOMOGRAPHY;
   QUALITY-OF-LIFE; CHOROIDAL NEOVASCULARIZATION; VISION LOSS; SUBRETINAL
   NEOVASCULARIZATION; CLINICAL-TRIAL; RANIBIZUMAB; VERTEPORFIN; MEMBRANES
AB Background: The main cause for visual loss in age-related macular degeneration (AMD) is the development of choroidal neovascularization (CNV), which has been shown to occur in 18% of patients over 5 years. Even though satisfactory treatments for CNV are available, in the majority of cases no improvement in visual acuity occurs and in those it does it is mostly limited. Early detection has the potential of significantly improving the final visual outcome of patients who develop subfoveal CNIV.
   Methods: This review is a summary of the importance of early detection in the management of AMD, in view of the current available treatment methods. It is a review of the results of early detection of AMD using the Preferential Hyperacuity Perimeter (PHP).
   Results: Awareness for symptoms, use of the Amsler grid and monitoring by an ophthalmologist are not satisfactory means for early detection of AMD. The PHP has good sensitivity and specificity in detecting CNV patient early and differentiate them from intermediate AMD.
   Conclusion: In an era of excellent treatments available for CNV treatment, early detection of CNV by novel technology modalities such as the PHP at a frequency that allows early detection (similar to 4 times a year) is crucial in the armamentarium of AMD patient management.
C1 Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Fac Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center
RP Loewenstein, A (通讯作者)，Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Fac Med, Dept Ophthalmol, 6 Weitzman St, IL-64239 Tel Aviv, Israel.
EM anatlow@tasmc.health.gov.il
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Coscas G, 2004, J FR OPHTALMOL, V27, P81, DOI 10.1016/S0181-5512(04)96099-8
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Haddad WM, 2002, GRAEF ARCH CLIN EXP, V240, P31, DOI 10.1007/s00417-001-0404-4
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Martinez A, 2006, J TELEMED TELECARE, V12, P234, DOI 10.1258/135763306777889109
   MICHELS S, 2005, RETINA, V25, P815
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROY MS, 1985, OPHTHALMOLOGICA, V191, P215, DOI 10.1159/000309590
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stone EM, 2006, NEW ENGL J MED, V355, P1493, DOI 10.1056/NEJMe068191
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
NR 32
TC 39
Z9 39
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 873
EP 878
DI 10.1097/IAE.0b013e318050d2ec
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600011
PM 17891011
DA 2022-11-30
ER

PT J
AU Du, JD
   Fong, WK
   Caliph, S
   Boyd, BJ
AF Du, Joanne D.
   Fong, Wye-Khay
   Caliph, Suzanne
   Boyd, Ben J.
TI Lipid-based drug delivery systems in the treatment of wet age-related
   macular degeneration
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Lipids; Liposomes; Intravitreal;
   Stimuli responsive
ID TARGETED PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULARIZATION; POSTERIOR
   SEGMENT; SUSTAINED-RELEASE; IN-VITRO; INTRAVITREAL INJECTION;
   LIQUID-CRYSTALS; CUBIC PHASE; LIPOSOMES; LIGHT
AB Recent advances in drug delivery technology have amplified potential opportunities to treat the debilitating diseases that affect the posterior segment of the eye in a less invasive and more efficient manner. Current methods for effective drug delivery to the back of the eye are hindered by many barriers and limitations. As a consequence, considerable efforts have been directed towards developing new materials to selectively deliver drug directly to the target site. This review focuses on lipid-based delivery systems which show promise in improving treatment for the most common disease of the posterior segment of the eye in the developed world, age-related macular degeneration, with an emphasis upon on-demand delivery systems as they have greater potential to overcome the current limitations.
C1 [Du, Joanne D.; Fong, Wye-Khay; Caliph, Suzanne; Boyd, Ben J.] Monash Univ Parkville Campus, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, 381 Royal Parade, Parkville, Vic 3052, Australia.
   [Fong, Wye-Khay] Swiss Fed Inst Technol, Dept Hlth Sci & Technol, CH-8092 Zurich, Switzerland.
   [Boyd, Ben J.] Monash Univ Parkville Campus, Monash Inst Pharmaceut Sci, ARC Ctr Excellence Convergent Bionano Sci & Techn, 381 Royal Parade, Parkville, Vic 3052, Australia.
C3 Monash University; Swiss Federal Institutes of Technology Domain; ETH
   Zurich; Monash University
RP Boyd, BJ (通讯作者)，Monash Univ Parkville Campus, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, 381 Royal Parade, Parkville, Vic 3052, Australia.; Boyd, BJ (通讯作者)，Monash Univ Parkville Campus, Monash Inst Pharmaceut Sci, ARC Ctr Excellence Convergent Bionano Sci & Techn, 381 Royal Parade, Parkville, Vic 3052, Australia.
EM ben.boyd@monash.edu
RI ; Du, Joanne/E-3467-2015
OI Boyd, Ben/0000-0001-5434-590X; , Khay/0000-0002-0437-9332; Du,
   Joanne/0000-0003-1186-7024
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Araujo J, 2012, NANOMED-NANOTECHNOL, V8, P1034, DOI 10.1016/j.nano.2011.10.015
   Araujo J, 2011, COLLOID SURFACE B, V88, P150, DOI 10.1016/j.colsurfb.2011.06.025
   Arruebo M, 2007, NANO TODAY, V2, P22, DOI 10.1016/S1748-0132(07)70084-1
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Barun V. V., 2007, Journal of Applied Spectroscopy, V74, P430, DOI 10.1007/s10812-007-0071-2
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Bonilha VL, 2006, ADV EXP MED BIOL, V572, P519
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Cao J, 2013, BIOMATERIALS, V34, P6272, DOI 10.1016/j.biomaterials.2013.05.008
   Chen CW, 2013, INT J NANOMED, V8, P2613, DOI 10.2147/IJN.S39622
   Chen CW, 2011, INT J NANOMED, V6, P2567, DOI 10.2147/IJN.S24447
   Cho YW, 2014, INT J OPHTHALMOL-CHI, V7, P952, DOI 10.3980/j.issn.2222-3959.2014.06.07
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Clogston J, 2005, J CONTROL RELEASE, V107, P97, DOI 10.1016/j.jconrel.2005.05.015
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Dong YD, 2008, LANGMUIR, V24, P6998, DOI 10.1021/la8005579
   Du JD, 2015, PHYS CHEM CHEM PHYS, V17, P14021, DOI 10.1039/c5cp01229e
   Du JD, 2014, INT J PHARMACEUT, V471, P358, DOI 10.1016/j.ijpharm.2014.05.044
   Fong WK, 2014, PHYS CHEM CHEM PHYS, V16, P24936, DOI 10.1039/c4cp03635b
   Fong WK, 2012, LANGMUIR, V28, P14450, DOI 10.1021/la302901q
   Fong WK, 2010, LANGMUIR, V26, P6136, DOI 10.1021/la100644s
   Fong WK, 2009, J CONTROL RELEASE, V135, P218, DOI 10.1016/j.jconrel.2009.01.009
   Fujisawa T, 2012, INT J PHARMACEUT, V436, P564, DOI 10.1016/j.ijpharm.2012.07.024
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gross N, 2013, MOL VIS, V19, P54
   Habib FS, 2010, ACTA OPHTHALMOL, V88, P901, DOI 10.1111/j.1755-3768.2009.01584.x
   Hironaka K, 2011, EUR J PHARM BIOPHARM, V79, P119, DOI 10.1016/j.ejpb.2011.01.019
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   Honda M, 2011, ARCH OPHTHALMOL-CHIC, V129, P317, DOI 10.1001/archophthalmol.2011.12
   Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2
   ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P161, DOI 10.1016/j.pdpdt.2015.03.007
   Kimura H, 2001, ADV DRUG DELIVER REV, V52, P79, DOI 10.1016/S0169-409X(01)00190-9
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lee KWY, 2009, INT J PHARMACEUT, V365, P190, DOI 10.1016/j.ijpharm.2008.08.022
   Leung SJ, 2012, THERANOSTICS, V2, P1020, DOI 10.7150/thno.4847
   Li PY, 2008, SENSOR ACTUAT A-PHYS, V143, P41, DOI 10.1016/j.sna.2007.06.034
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Macular Disease Foundation Australia, 2004, SCHEM RET
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   Malmsten M, 2006, SOFT MATTER, V2, P760, DOI 10.1039/b608348j
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Maurice D. M., 1984, HANDB EXP PHARM, P19
   Mishra GP, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/863734
   Muir BW, 2012, J PHYS CHEM B, V116, P3551, DOI 10.1021/jp300239g
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/nmat3776, 10.1038/NMAT3776]
   Natarajan JV, 2012, INT J NANOMED, V7, DOI 10.2147/IJN.S25468
   Negrini R, 2015, CHEM COMMUN, V51, P6671, DOI 10.1039/c4cc10274f
   Ninawe PR, 2010, CHEM ENG SCI, V65, P5170, DOI 10.1016/j.ces.2010.06.014
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Peng K, 2011, SOFT MATTER, V7, P4881, DOI 10.1039/c1sm05291h
   Phan S, 2011, INT J PHARMACEUT, V421, P176, DOI 10.1016/j.ijpharm.2011.09.022
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pirmoradi FN, 2011, LAB CHIP, V11, P2744, DOI 10.1039/c1lc20134d
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Nguyen TH, 2011, J CONTROL RELEASE, V153, P180, DOI 10.1016/j.jconrel.2011.03.033
   Wang JL, 2012, INVEST OPHTH VIS SCI, V53, P7348, DOI 10.1167/iovs.12-9955
   Wang JL, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/780634
   Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YAMAUCHI H, 1995, INT J PHARM, V113, P141, DOI 10.1016/0378-5173(94)00188-B
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yavlovich A, 2010, MOL MEMBR BIOL, V27, P364, DOI 10.3109/09687688.2010.507788
   Yavlovich A, 2009, J THERM ANAL CALORIM, V98, P97, DOI 10.1007/s10973-009-0228-8
NR 84
TC 13
Z9 13
U1 0
U2 25
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD DEC
PY 2016
VL 6
IS 6
BP 781
EP 792
DI 10.1007/s13346-016-0299-6
PG 12
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA ED2MD
UT WOS:000388679000013
PM 27194165
DA 2022-11-30
ER

PT J
AU Kumar, JB
   Stinnett, S
   Han, JIL
   Jaffe, GJ
AF Kumar, Jaya B.
   Stinnett, Sandra
   Han, Jung I. L.
   Jaffe, Glenn J.
TI CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL
   ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE subretinal hyperreflective material; morphology; age-related macular
   degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; EYES
AB Purpose: To evaluate the association of subretinal hyperreflective material (SHRM) morphological features with visual acuity in eyes with neovascular age-related macular degeneration. Methods: Retrospective analysis of treatment-naive patients with neovascular age-related macular degeneration enrolled in randomized anti-vascular endothelial growth factor (VEGF) and anti-platelet-derived growth factor clinical trials. Standardized spectral domain optical coherence tomography images were graded at baseline, 12-week, and 24-week follow-up visits. Masked readers evaluated the morphology of SHRM (reflectivity, shape, anterior, and posterior boundaries) and measured SHRM height, width, and area at the fovea, within the center 1 mm(2), and outside the center 1 mm(2). Results: Baseline SHRM characteristics that correlated with worse visual acuity at 12 and 24 weeks included layered appearance (P = 0.006, 0.001), hyperreflective spots in SHRM (P = 0.001, 0.011), and separation between SHRM and outer retina (P = 0.03, 0.019). The disappearance of SHRM correlated with better visual acuity at Weeks 12 and 24 (P < 0.001). Layered appearance of SHRM at baseline was significantly associated with increased reflectivity at Weeks 12 and 24 (P = 0.009, 0.003). Decreasing reflectivity of SHRM lesion at Weeks 12 and 24 correlated with better visual acuity (P < 0.01, 0.01). Increased width and area of baseline SHRM at the foveal center correlated with worse visual acuity at 12 (P < 0.001, <0.001) and 24 weeks (<0.001, <0.001). Conclusion: Several attributes of SHRM including, layered appearance, increased reflectivity, larger size, and hyperreflective spots correlated with worse visual acuity at 12- and 24-week follow-ups. Baseline SHRM characteristics can help practitioners predict visual and morphological prognosis and guide therapy.
C1 [Kumar, Jaya B.; Stinnett, Sandra; Han, Jung I. L.; Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Kumar, Jaya B.] Florida Retina Inst, Orlando, FL USA.
   [Han, Jung I. L.] Koyang Univ Hosp, Dept Ophthalmol, Gaigeturi, South Korea.
C3 Duke University
RP Jaffe, GJ (通讯作者)，Duke Univ, Dept Ophthalmol, Duke Eye Ctr, Box 3802, Durham, NC 28810 USA.
EM jaffe001@mc.duke.edu
OI Stinnett, Sandra/0000-0001-7192-0195
CR BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Pokroy R, 2017, PROGNOSTIC VALUE SUB
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Saito M, 2013, RETINA-J RET VIT DIS, V33, P559, DOI 10.1097/IAE.0b013e31826710ea
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 19
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2020
VL 40
IS 5
BP 845
EP 856
DI 10.1097/IAE.0000000000002552
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2HK
UT WOS:000531376000008
PM 31305505
DA 2022-11-30
ER

PT J
AU Wang, LP
   Zhang, CW
   Hua, R
AF Wang, Luping
   Zhang, Canwei
   Hua, Rui
TI Clinical effectiveness of ranibizumab and conbercept for neovascular
   age-related macular degeneration: a meta-analysis
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE age-related macular degeneration; best-corrected visual acuity; central
   macular thickness; choroidal neovascularization; vision loss
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; VISUAL-ACUITY;
   INTRAVITREAL AFLIBERCEPT; EFFICACY; SAFETY; PREVALENCE; SECONDARY
AB Introduction: To assess the ocular efficacy of intravitreal ranibizumab and conbercept injection in patients with neovascular age-related macular degeneration.
   Materials and methods: We searched PubMed, Wed of Science, Cochrane Library, EMBASE, Google Scholar, Medline, China National Knowledge Infrastructure, and WANFANG DATA databases, up to June 20, 2018. We also searched abstracts and clinical study presentations at meetings as well as trial registries; we contacted authors of included studies if questions arose. Eligibility criteria for selection of studies were randomized controlled trials and retrospective trials that compared ranibizumab with conbercept for treatment of neovascular age-related macular degeneration.
   Results: Eight randomized controlled trials and four retrospective studies were included with a total of 853 patients. Best-corrected visual acuity after loading dosage was improved in the conbercept group, compared with the ranibizumab group (weighted mean difference: -0.04; 95% CI: -0.07 to 0.00; P=0.04). There was a significant difference between conbercept and ranibizumab therapy with respect to unchanged or recurrent leakage of choroidal neovascularization (OR: 0.46; 95% CI: 0.24-0.88; P=0.02). No significant differences were observed in central macular thickness (weighted mean difference: -2.92; 95% CI: -9.00 to 3.17; P=0.35), complete and partial closure of leakage of choroidal neovascularization (complete closure, P=0.70; partial closure, P=0.35), or number of injections (weighted mean difference: 0.42; 95% CI: -0.46 to 1.29; P=0.35) between the conbercept and ranibizumab groups at the end of the follow-up periods.
   Conclusion: Pooled evidence confirmed that conbercept was superior to ranibizumab with respect to visual gain after treatment. Additional studies with long-term follow-up are needed to support our conclusion.
C1 [Wang, Luping] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Zhang, Canwei] Weifang Eye Hosp, Dept Ophthalmol, Weifang, Peoples R China.
   [Hua, Rui] China Med Univ, Dept Ophthalmol, Hosp 1, 155 Nanjingbei St, Shenyang, Liaoning, Peoples R China.
C3 University of Bonn; China Medical University
RP Hua, R (通讯作者)，China Med Univ, Dept Ophthalmol, Hosp 1, 155 Nanjingbei St, Shenyang, Liaoning, Peoples R China.
EM woodshua@126.com
RI Zhang, Canwei/AAG-8602-2021
FU Natural Science Foundation of Liaoning Province [20170541041]; Fund for
   Scientific Research of The First Hospital of China Medical University
   [FSFH201712]
FX This study was supported by the Natural Science Foundation of Liaoning
   Province (No 20170541041) and the Fund for Scientific Research of The
   First Hospital of China Medical University (No FSFH201712).
CR Beazley-Long N, 2013, AM J PATHOL, V183, P918, DOI 10.1016/j.ajpath.2013.05.031
   Bringmann A, 2004, OPHTHALMIC RES, V36, P241, DOI 10.1159/000081203
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Cai XA., 2016, INT EYE SCI, V16, P1501
   Chen YT, 2018, J OCUL PHARMACOL TH, V34, P235, DOI 10.1089/jop.2017.0097
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Clarke M, 2001, LANCET, V357, P1728, DOI 10.1016/S0140-6736(00)04934-5
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Helmy YM, 2013, CLIN OPHTHALMOL, V7, P1731, DOI 10.2147/OPTH.S47987
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hua R, 2015, PHOTODIAGN PHOTODYN, V12, P310, DOI 10.1016/j.pdpdt.2015.03.005
   Huang Z, 2018, RETINA, P1
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Li L, 2018, CHINESE COMMUNITY DO, V34, P14
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Lv P., 2016, J COMMUNITY MED, V14, P30
   Mantelli F, 2014, EUR J OPHTHALMOL, V24, P247, DOI 10.5301/ejo.5000359
   Niu JY., 2016, GUANGXI MED, V38, P641
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Peng YT, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0481-8
   Phillips Bob, 2011, Arch Dis Child, V96, P1199, DOI 10.1136/archdischild-2011-300860
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schoenberger SD, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/281981
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu D, 2013, IMMUNOTHERAPY-UK, V5, P121, DOI [10.2217/IMT.12.158, 10.2217/imt.12.158]
   Yang JH., 2018, J N SICHUAN MED COLL, V33, P108
   Zhang HX, 2016, CHIN J BIOCH PHARM, V36, P134
   Zhang LL., 2017, J CHANGZHI MED COLL, V3, P209
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang ZQ, 2017, INT EYE SCI, V17, P1123
   Zhao YZ, 2015, WORLD LATEST MED INF, V64, P97
   Zheng M, 2017, J MATH MED, V2, P228
NR 44
TC 12
Z9 13
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2018
VL 12
BP 3625
EP 3633
DI 10.2147/DDDT.S176021
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GY5IQ
UT WOS:000448608200001
PM 30464394
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Cacho, I
   Dickinson, CM
   Smith, HJ
   Harper, RA
AF Cacho, Isabel
   Dickinson, Christine Margaret
   Smith, Heather Jane
   Harper, Robert Anthony
TI Clinical Impairment Measures and Reading Performance in a Large
   Age-Related Macular Degeneration Group
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE low vision; AMD; reading speed; central scotoma; contrast sensitivity;
   visual acuity
ID PREFERRED RETINAL LOCI; LOW-VISION; CENTRAL SCOTOMAS; SPEED; DISEASE;
   PSYCHOPHYSICS; FIXATION; CONTRAST
AB Purpose. To investigate the relationship between clinical impairment measures and reading performance in a large population with age-related macular degeneration.
   Methods. The following clinical measures were evaluated on 243 patients with age-related macular degeneration: better eye distance visual acuity (ETDRS chart); threshold near word reading acuity (Bailey-Lovie Word Reading chart); maximum reading speed and critical print size (MNREAD chart); letter contrast sensitivity (Pelli-Robson); and kinetic perimetry (Bjerrum screen) to determine the nearest non-scotomatous point to fovea (NNPF; in degrees) and the central scotoma area (mm(2)).
   Results. Distance acuity correlated well to threshold near word acuity (r = 0.71), but word acuity was usually poorer. Critical print size was strongly related (p < 0.001) to near visual acuity (r(2) = 0.31 and beta = 0.47) and was poorer than threshold near word visual acuity by a mean difference of -0.41 (range, -1.10 to 0.34), which represents a mean acuity reserve of 2.5:1. On single regression, distance (p < 0.0001, r(2) = 0.35, and beta = -102.37) and near acuities (p < 0.0001, r(2) = 0.52, beta = -126.53), critical print size (p = 0.0001, r(2) = 19, and beta = 0.002), contrast sensitivity (p < 0.0001, r(2) = 19, and beta = 79.47), scotoma size (p = 0.006, r(2) = 12, and beta = -0.04), and NNPF (p = 0.001, r(2) = 12, and beta = -4.39) were all highly significantly related to reading speed although these predicted only a low percentage of variance. Best prediction of reading speed was obtained on multiple regression, where NNPF and near word acuity explained 60% of the variance (p < 0.0001).
   Conclusions. Optimal prediction of reading speed with clinical parameters appears to be based on the combination of near word acuity and scotoma area, explaining 60% of the variance. Other factors not measured in this study are likely to account for the rest of the prediction. (Optom Vis Sci 2010; 87: 344-349)
C1 [Cacho, Isabel; Dickinson, Christine Margaret; Smith, Heather Jane; Harper, Robert Anthony] Univ Manchester, Fac Life Sci, Manchester M60 1QD, Lancs, England.
C3 University of Manchester
RP Cacho, I (通讯作者)，Plaza Pere Garau,20 3B, Palma de Mallorca 07007, Baleares, Spain.
EM isabelcacho@hotmail.com; chris.dickinson@manchester.ac.uk
OI Harper, Robert/0000-0001-5437-2553
FU Health Foundation
FX This research was supported by funding from The Health Foundation.
CR BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499
   BULLIMORE MA, 1995, OPTOMETRY VISION SCI, V72, P125, DOI 10.1097/00006324-199502000-00011
   Cheong AMY, 2007, VISION RES, V47, P2943, DOI 10.1016/j.visres.2007.07.010
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   David W, 2000, APPL LOGISTIC REGRES, P26, DOI 10.1002/0471722146
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Friedman SM, 1999, INVEST OPHTH VIS SCI, V40, P858
   Kabanarou SA, 2006, OPTOMETRY VISION SCI, V83, P789, DOI 10.1097/01.opx.0000238642.65218.64
   LEAT SJ, 1993, OPHTHAL PHYSL OPT, V13, P9, DOI 10.1111/j.1475-1313.1993.tb00420.x
   Legge GE, 1997, VISION RES, V37, P1999, DOI 10.1016/S0042-6989(97)00017-5
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Messias A, 2007, INVEST OPHTH VIS SCI, V48, P5815, DOI 10.1167/iovs.06-0367
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Pelli DG, 2007, J VIS, V7
   Pesudovs K, 2002, CLIN EXP OPHTHALMOL, V30, P183, DOI 10.1046/j.1442-9071.2002.00522.x
   RUBIN GS, 1989, VISION RES, V29, P79, DOI 10.1016/0042-6989(89)90175-2
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   WENSVEEN JM, 1995, OPTOMETRY VISION SCI, V72, P100, DOI 10.1097/00006324-199502000-00009
   Whatham AR, 2006, OPHTHAL PHYSL OPT, V26, P156, DOI 10.1111/j.1475-1313.2006.00345.x
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 28
TC 25
Z9 25
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2010
VL 87
IS 5
BP 344
EP 349
DI 10.1097/OPX.0b013e3181d9515c
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 593IS
UT WOS:000277447900007
PM 20386356
DA 2022-11-30
ER

PT J
AU Boretsky, A
   Khan, F
   Burnett, G
   Hammer, DX
   Ferguson, RD
   van Kuijk, F
   Motamedi, M
AF Boretsky, Adam
   Khan, Faraz
   Burnett, Garrett
   Hammer, Daniel X.
   Ferguson, R. Daniel
   van Kuijk, Frederik
   Motamedi, Massoud
TI In vivo imaging of photoreceptor disruption associated with age-related
   macular degeneration: A pilot study
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article
DE adaptive optics; AMD; drusen; fundus reflectance; retina; retinal
   pigment epithelium; SLO
ID SCANNING LASER OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY;
   ADAPTIVE-OPTICS; GEOGRAPHIC ATROPHY; PACKING DENSITY; MACULOPATHY; EYE;
   PREVALENCE; TOPOGRAPHY; OCT
AB Background and Objective Age-related macular degeneration is one of the leading causes of vision loss in the developed world. As the disease progresses, the central part of the retina, called the macula, is compromised leading to a disruption of both structure and visual function. In this study, we investigate the disruption of macular photoreceptor cells in vivo as a function of disease stage in patients with the dry form of age-related macular degeneration AMD. Materials and Methods An investigational confocal Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO) was used to obtain high resolution images of the macular photoreceptor mosaic in patients previously diagnosed with AMD. Four patients were selected as representative cases, comprising each of the four clinical stages of AMD progression. Results AOSLO imaging revealed slight disruption in the photoreceptor mosaic in early stage AMD due to focal drusen formation and identified several small drusen deposits that were not observed with standard clinical imaging techniques. An increase in photoreceptor disruption was visualized within the macula in direct correlation with the stage of AMD progression leading to a decrease in visual acuity. Large coalescent drusen and areas of geographic atrophy in advanced stage dry AMD exhibited a significant decrease in visible photoreceptor density. Significant decrease in photoreceptor counts (similar to 3550%) were observed when comparing earlier stages of AMD progression (Categories I and II) to later stages of the disease (Categories III and IV). Conclusions This study demonstrates the capabilities of adaptive optics retinal imaging to monitor disruption of individual photoreceptor cells as a function of disease progression yielding valuable diagnostic findings in early stage AMD beyond what can be learned about the health of photoreceptors using conventional retinal imaging techniques. Lasers Surg. Med. 44: 603610, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Boretsky, Adam; Khan, Faraz; Motamedi, Massoud] Univ Texas Med Branch, Ctr Biomed Engn, Galveston, TX 77555 USA.
   [Burnett, Garrett] Univ Texas Med Branch, Sch Med, Galveston, TX 77555 USA.
   [Hammer, Daniel X.; Ferguson, R. Daniel] Phys Sci Inc, Andover, MA 01810 USA.
   [van Kuijk, Frederik] Univ Minnesota, Dept Ophthalmol, Minneapolis, MN 55455 USA.
   [Motamedi, Massoud] Univ Texas Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston; Physical Sciences Inc.; University of Minnesota
   System; University of Minnesota Twin Cities; University of Texas System;
   University of Texas Medical Branch Galveston
RP Motamedi, M (通讯作者)，Univ Texas Med Branch, Ctr Biomed Engn, 301 Univ Blvd, Galveston, TX 77555 USA.
EM mmotamed@utmb.edu
RI Boretsky, Adam/B-8591-2013; Burnett, Garrett/AAM-7615-2020
OI Burnett, Garrett/0000-0003-0565-9499
FU American Society for Laser Medicine & Surgery (ASLMS) Student Research;
   Wagner AMD Fund; Seymour Fisher; Institute for Translational Sciences at
   the University of Texas Medical Branch; Research to Prevent Blindness
   (RPB); CTSA NIH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCES [UL1RR029876] Funding Source: NIH RePORTER; Directorate For
   Engineering [1053978] Funding Source: National Science Foundation
FX Contract grant sponsor: American Society for Laser Medicine & Surgery
   (ASLMS) Student Research; Contract grant sponsor: Wagner AMD Fund;
   Contract grant sponsor: Seymour Fisher; Contract grant sponsor:
   Institute for Translational Sciences at the University of Texas Medical
   Branch; Contract grant sponsor: Research to Prevent Blindness (RPB);
   Contract grant sponsor: CTSA NIH.
CR Burns SA, 2007, J OPT SOC AM A, V24, P1313, DOI 10.1364/JOSAA.24.001313
   Byun JY, 2006, MOL VIS, V12, P949
   Chui TYP, 2008, INVEST OPHTH VIS SCI, V49, P4679, DOI 10.1167/iovs.08-2135
   Chui TYP, 2008, J OPT SOC AM A, V25, P3021, DOI 10.1364/JOSAA.25.003021
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Doble N, 2011, OPT LETT, V36, P31, DOI 10.1364/OL.36.000031
   Dubra A, 2011, BIOMED OPT EXPRESS, V2, P1864, DOI 10.1364/BOE.2.001864
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Li KY, 2010, INVEST OPHTH VIS SCI, V51, P6858, DOI 10.1167/iovs.10-5499
   Liang JZ, 1997, J OPT SOC AM A, V14, P2884, DOI 10.1364/JOSAA.14.002884
   Miller DT, 2011, EYE, V25, P321, DOI 10.1038/eye.2011.1
   Mujat M, 2010, OPT EXPRESS, V18, P11607, DOI 10.1364/OE.18.011607
   Porter J., 2006, ADAPTIVE OPTICS VISI
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roorda A, 2002, OPT EXPRESS, V10, P405, DOI 10.1364/OE.10.000405
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Song HX, 2011, INVEST OPHTH VIS SCI, V52, P7376, DOI 10.1167/iovs.11-7199
   Zawadzki RJ, 2007, J OPT SOC AM A, V24, P1373, DOI 10.1364/JOSAA.24.001373
   Zhang Y, 2006, OPT EXPRESS, V14, P4380, DOI 10.1364/OE.14.004380
   Zhang YH, 2006, OPT LETT, V31, P1268, DOI 10.1364/OL.31.001268
NR 27
TC 39
Z9 40
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
J9 LASER SURG MED
JI Lasers Surg. Med.
PD OCT
PY 2012
VL 44
IS 8
BP 603
EP 610
DI 10.1002/lsm.22070
PG 8
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology; Surgery
GA 007JQ
UT WOS:000308885000001
PM 22930575
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ren, JB
   Ren, AL
   Deng, XZ
   Huang, ZR
   Jiang, ZY
   Li, Z
   Gong, Y
AF Ren, Jiangbo
   Ren, Anli
   Deng, Xizhi
   Huang, Zhengrong
   Jiang, Ziyu
   Li, Zhi
   Gong, Yan
TI Long-Chain Polyunsaturated Fatty Acids and Their Metabolites Regulate
   Inflammation in Age-Related Macular Degeneration
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Review
DE inflammation; long-chain polyunsaturated fatty acids; age-related
   macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; NF-KAPPA-B; OXIDATIVE STRESS;
   DOCOSAHEXAENOIC ACID; NLRP3 INFLAMMASOME; CHOROIDAL NEOVASCULARIZATION;
   PPAR-ALPHA; CELL-DEATH; EICOSAPENTAENOIC ACID; NUCLEAR RECEPTORS
AB Age-related macular degeneration (AMD) is a blinding eye disease, whose incidence strongly increases with ages. The etiology of AMD is complex, including aging, abnormal lipid metabolism, chronic inflammation and oxidative stress. Long-chain polyunsaturated fatty acids (LCPUFA) are essential for ocular structures and functions. This review summarizes the regulatory effects of LCPUFA on inflammation in AMD. LCPUFA are related to aging, autophagy and chronic inflammation. They are metabolized to pro- and anti-inflammatory metabolites by various enzymes. These metabolites stimulate inflammation in response to oxidative stress, causing innate and acquired immune responses. This review also discusses the possible clinical applications, which provided novel targets for the prevention and treatment of AMD and other age-related diseases.
C1 [Ren, Jiangbo; Ren, Anli; Huang, Zhengrong; Jiang, Ziyu; Gong, Yan] Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Ren, Jiangbo; Ren, Anli; Deng, Xizhi; Li, Zhi] Wuhan Univ, Dept Ophthalmol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Gong, Yan] Wuhan Univ, Human Genet Resource Preservat Ctr, Wuhan, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University
RP Gong, Y (通讯作者)，Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.; Li, Z (通讯作者)，Wuhan Univ, Dept Ophthalmol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
EM 1103945483@qq.com; yan.gong@whu.edu.cn
OI Gong, Yan/0000-0002-4805-0459
FU National Natural Science Foundation of China [81800429]; Nature Science
   Foundation of Hubei Province [2020CFB612]; Young and Middle-Aged Medical
   Backbone Talents of Wuhan [WHQG201902]; Application Foundation Frontier
   Project of Wuhan [2020020601012221]; Zhongnan Hospital of Wuhan
   University Science, Technology and Innovation Seed Fund [znpy2019001];
   Translational Medicine and Interdisciplinary Research Joint Fund of
   Zhongnan Hospital of Wuhan University [ZNJC202007]
FX This study was supported by National Natural Science Foundation of China
   (81800429) , Nature Science Foundation of Hubei Province (2020CFB612) ,
   Young and Middle-Aged Medical Backbone Talents of Wuhan (WHQG201902) ,
   Application Foundation Frontier Project of Wuhan (2020020601012221) ,
   Zhongnan Hospital of Wuhan University Science, Technology and Innovation
   Seed Fund (znpy2019001) , and Translational Medicine and
   Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan
   University (ZNJC202007) .
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Acar N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.404
   Acar N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035102
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Allingham MJ, 2021, ADV EXP MED BIOL, V1256, P143, DOI 10.1007/978-3-030-66014-7_6
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Ardeljan D, 2011, DRUG FUTURE, V36, P713, DOI 10.1358/dof.2011.36.9.1678338
   Arnold C, 2010, PHARMACOL REP, V62, P536, DOI 10.1016/S1734-1140(10)70311-X
   Arslan S, 2019, J AM COLL NUTR, V38, P424, DOI 10.1080/07315724.2018.1538830
   Barth T, 2021, OPHTHALMOLOGE, V118, P1255, DOI 10.1007/s00347-020-01297-x
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Bazan NG, 2018, MOL ASPECTS MED, V64, P18, DOI 10.1016/j.mam.2018.09.003
   Bhattacharjee S, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700735
   Bilgic A, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7462098
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144994
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Bonilha VL, 2018, ADV EXP MED BIOL, V1074, P3, DOI 10.1007/978-3-319-75402-4_1
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Caceres PS, 2020, CURR OPIN CELL BIOL, V62, P37, DOI 10.1016/j.ceb.2019.08.001
   Calder PC, 2020, P NUTR SOC, V79, P404, DOI 10.1017/S0029665120007077
   Capozzi ME, 2016, SCI REP-UK, V6, DOI 10.1038/srep39211
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chataigner M, 2021, BRAIN BEHAV IMMUN, V91, P716, DOI 10.1016/j.bbi.2020.09.022
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen L, 2020, DEV GROWTH DIFFER, V62, P139, DOI 10.1111/dgd.12650
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chen X, 2018, BIOMED PHARMACOTHER, V101, P87, DOI 10.1016/j.biopha.2018.02.054
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Cheng YS, 2019, EXP EYE RES, V181, P325, DOI 10.1016/j.exer.2018.09.012
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Choudhary M, 2016, ADV EXP MED BIOL, V854, P45, DOI 10.1007/978-3-319-17121-0_7
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Clare AJ, 2022, EYE, V36, P266, DOI 10.1038/s41433-021-01725-5
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Daftarian N, 2020, FASEB J, V34, P8001, DOI 10.1096/fj.201901902RR
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR246, DOI 10.1093/hmg/ddx343
   Delmas D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031295
   Devassy JG, 2016, ADV NUTR, V7, P905, DOI 10.3945/an.116.012187
   Di Cara F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163877
   Do KV, 2019, P NATL ACAD SCI USA, V116, P24317, DOI 10.1073/pnas.1912959116
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Echeverria F, 2016, PROSTAG LEUKOTR ESS, V114, P28, DOI 10.1016/j.plefa.2016.10.001
   Elmasry K, 2019, BRIT J PHARMACOL, V176, P93, DOI 10.1111/bph.14507
   Erhardt R, 2021, J NUTR HEALTH AGING, V25, P454, DOI 10.1007/s12603-020-1553-7
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fang YX, 2020, RETINA-J RET VIT DIS, V40, P456, DOI 10.1097/IAE.0000000000002404
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Fernandez-Albarral JA, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030189
   Fernandez-Vega B, 2020, ACTA OPHTHALMOL, V98, pE282, DOI 10.1111/aos.14280
   Fleming I, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00739
   Fontaine V, 2021, AGING-US, V13, P22040, DOI 10.18632/aging.203558
   Fu ZJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041503
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Gallo G, 2020, J PHYSIOL PHARMACOL, V71, P15, DOI 10.26402/jpp.2020.1.07
   Garweg JG, 2021, GRAEF ARCH CLIN EXP, V259, P2181, DOI 10.1007/s00417-020-05048-1
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Gong Y, 2016, ARTERIOSCL THROM VAS, V36, P1919, DOI 10.1161/ATVBAHA.116.307558
   Gorusupudi A, 2016, J LIPID RES, V57, P499, DOI 10.1194/jlr.P065540
   Granstam E, 2021, GRAEF ARCH CLIN EXP, V259, P2085, DOI 10.1007/s00417-020-05059-y
   Green CJ, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2019-000871
   Gubitosi-Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07-1217
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Hadley KB, 2017, PROSTAG LEUKOTR ESS, V118, P10, DOI 10.1016/j.plefa.2017.01.011
   Harauma A, 2017, PROSTAG LEUKOTR ESS, V116, P9, DOI 10.1016/j.plefa.2016.11.002
   Hasegawa E, 2017, P NATL ACAD SCI USA, V114, pE7545, DOI 10.1073/pnas.1620898114
   Heitmar R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030649
   Hellstrom A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28771
   Hellstrom A, 2021, JAMA PEDIATR, V175, P359, DOI 10.1001/jamapediatrics.2020.5653
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jacob J, 2021, OPHTHALMOL THER, V10, P299, DOI 10.1007/s40123-021-00335-4
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Jhingan M, 2021, GRAEF ARCH CLIN EXP, V259, P2687, DOI 10.1007/s00417-021-05147-7
   Jiang PF, 2020, J CONTROL RELEASE, V320, P442, DOI 10.1016/j.jconrel.2020.01.036
   Joffre C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01022
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaarniranta K, 2017, ACTA OPHTHALMOL, V95, P335, DOI 10.1111/aos.13344
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karahan Mine, 2021, Ther Adv Ophthalmol, V13, p25158414211010550, DOI 10.1177/25158414211010550
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim Se Young, 2020, Korean J Ophthalmol, V34, P11, DOI 10.3341/kjo.2019.0081
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Koscielniak A, 2017, CELL BIOCHEM BIOPHYS, V75, P443, DOI 10.1007/s12013-017-0832-3
   Krezel W, 2019, MOL CELL ENDOCRINOL, V491, DOI 10.1016/j.mce.2019.04.016
   Kuhn H, 2015, BBA-MOL CELL BIOL L, V1851, P308, DOI 10.1016/j.bbalip.2014.10.002
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee Ji Min, 2017, Korean J Ophthalmol, V31, P360, DOI 10.3341/kjo.2017.0054
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Leung HH, 2019, FREE RADICAL BIO MED, V145, P349, DOI 10.1016/j.freeradbiomed.2019.10.007
   Leuti A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8107265
   Li W, 2020, APPL MICROBIOL BIOT, V104, P6129, DOI 10.1007/s00253-020-10614-y
   Lin CH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071799
   Lister Tracy, 2019, Integr Med (Encinitas), V18, P30
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Mau T, 2018, EXP GERONTOL, V105, P27, DOI 10.1016/j.exger.2017.10.014
   McGrattan AM, 2019, CURR NUTR REP, V8, P53, DOI 10.1007/s13668-019-0271-4
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   Meagher KA, 2014, JAMA OPHTHALMOL, V132, P230, DOI 10.1001/jamaophthalmol.2013.6667
   Meri S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611830
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moran E, 2014, INVEST OPHTH VIS SCI, V55, P4568, DOI 10.1167/iovs.13-13127
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Mukhtar S, 2019, INT OPHTHALMOL, V39, P2975, DOI 10.1007/s10792-019-01140-6
   Munoz-Ramon P V, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P75, DOI 10.1016/j.oftal.2019.09.011
   Nakamura M, 2017, BIOL PHARM BULL, V40, P1219, DOI 10.1248/bpb.b16-01008
   Narimatsu T, 2014, FREE RADICAL BIO MED, V71, P176, DOI 10.1016/j.freeradbiomed.2014.03.020
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nelson AJ, 2020, J LIPID RES, V61, P143, DOI 10.1194/jlr.RA119000281
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Ontko CD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89000-1
   Opreanu M, 2010, INVEST OPHTH VIS SCI, V51, P3253, DOI 10.1167/iovs.09-4731
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Pearsall EA, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0451-x
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Pujol-Lereis LM, 2016, ADV EXP MED BIOL, V854, P87, DOI 10.1007/978-3-319-17121-0_13
   Qiu FF, 2017, INVEST OPHTH VIS SCI, V58, P5065, DOI 10.1167/iovs.17-22091
   Ramchani-Ben Othman K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128395
   Ravi R, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117397
   Remmerie A, 2018, CELL IMMUNOL, V330, P27, DOI 10.1016/j.cellimm.2018.01.020
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Roh M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.20
   Romero-Vazquez S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070763
   Roubeix C, 2020, M S-MED SCI, V36, P886, DOI 10.1051/medsci/2020159
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Sasaki H, 2019, PROSTAG LEUKOTR ESS, V148, P1, DOI 10.1016/j.plefa.2019.07.003
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schnabolk G, 2019, ADV EXP MED BIOL, V1185, P27, DOI 10.1007/978-3-030-27378-1_5
   Schnebelen C, 2009, OPHTHALMIC RES, V41, P216, DOI 10.1159/000217726
   Shao Z, 2014, ARTERIOSCL THROM VAS, V34, P581, DOI 10.1161/ATVBAHA.113.302927
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Shen HH, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060489
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Skowronska-Krawczyk D, 2019, ADV EXP MED BIOL, V1185, P39, DOI 10.1007/978-3-030-27378-1_7
   Song Y, 2019, ARTIF CELL NANOMED B, V47, P1995, DOI 10.1080/21691401.2019.1608220
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Su LJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5080843
   Suarez-Barrio C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031021
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Sulaiman RS, 2018, ACS CHEM BIOL, V13, P45, DOI 10.1021/acschembio.7b00854
   Sulaiman RS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25509
   Sun Q, 2020, FREE RADICAL BIO MED, V147, P271, DOI 10.1016/j.freeradbiomed.2019.12.029
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thalgott V, 2016, OPHTHALMOLOGE, V113, P668, DOI 10.1007/s00347-016-0228-6
   Tokuda H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69560-4
   Toth CA, 2019, OPHTHALMOL RETINA, V3, P316, DOI 10.1016/j.oret.2018.11.011
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsujinaka H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14340-x
   Ueta T, 2019, P NATL ACAD SCI USA, V116, P23705, DOI 10.1073/pnas.1908355116
   Vallee A, 2017, LIFE SCI, V188, P123, DOI 10.1016/j.lfs.2017.09.008
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   Vatsyayan R, 2011, EXP EYE RES, V92, P147, DOI 10.1016/j.exer.2010.11.010
   Vogl WD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85110-y
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wang HB, 2016, MOL VIS, V22, P116
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wang K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51151-7
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang TM, 2011, J NUTR BIOCHEM, V22, P187, DOI 10.1016/j.jnutbio.2010.01.007
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Xie HK, 2020, FOOD FUNCT, V11, P2349, DOI 10.1039/d0fo00051e
   Xu JW, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109606
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Xu Y, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12660
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   Yang X, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5763658
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241
   Yuan JS, 2019, EXP THER MED, V17, P4249, DOI 10.3892/etm.2019.7427
   Yumnamcha T, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01065
   Zapadka TE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103547
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang M, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032698
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
   Zhao Y, 2004, J AM COLL NUTR, V23, P71, DOI 10.1080/07315724.2004.10719345
   Zhong YY, 2021, EUR J NUTR, V60, P3013, DOI 10.1007/s00394-020-02445-4
   Zhou YD, 2017, MOL MED REP, V15, P3949, DOI 10.3892/mmr.2017.6491
NR 220
TC 2
Z9 2
U1 4
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2022
VL 15
BP 865
EP 880
DI 10.2147/JIR.S347231
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA YX7DR
UT WOS:000754259600003
PM 35173457
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hassell, JB
   Lamoureux, EL
   Keeffe, JE
AF Hassell, JB
   Lamoureux, EL
   Keeffe, JE
TI Impact of age related macular degeneration on quality of life
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; VISUAL IMPAIRMENT; VISION
   REHABILITATION; SELF-MANAGEMENT; DEPRESSION; FALLS; EYE
AB Aims: To describe the impact of age related macular degeneration (AMD) on quality of life and explore the association with vision, health, and demographic variables.
   Methods: Adult participants diagnosed with AMD and with impaired vision (visual acuity <6/12) were assessed with the Impact of Vision Impairment (IVI) questionnaire. Participants rated the extent that vision restricted participation in activities affecting quality of life and completed the Short Form General Health Survey (SF-12) and a sociodemographic questionnaire.
   Results: The mean age of the 106 participants (66% female) was 83.6 years (range 64-98). One quarter had mild vision impairment, (VA <6/12-6/18) and 75% had moderate or severely impaired vision. Participants reported from at least "a little" concern on 23 of the 32 IVI items including reading, emotional health, mobility, and participation in relevant activities. Those with mild and moderate vision impairment were similarly affected but significantly different from those with severe vision loss (p < 0.05). Distance vision was associated with IVI scores but not age, sex, or duration of vision loss.
   Conclusion: AMD affects many quality of life related activities and not just those related to reading. Referral to low vision care services should be considered for people with mild vision loss and worse.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne
RP Hassell, JB (通讯作者)，Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 8002, Australia.
EM hassell@unimelb.edu.au
RI Lamoureux, Ecosse/Z-5482-2019
CR Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Bylsma Guy W, 2005, Clin Exp Optom, V88, P322
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Culham LE, 2002, BRIT J OPHTHALMOL, V86, P743, DOI 10.1136/bjo.86.7.743
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Lovie-Kitchin JE., 1996, CLIN EXP OPTOM, V79, P227
   O'Donnell C, 2005, J VISUAL IMPAIR BLIN, V99, P197
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Ware JE., 1993, SCORING SF 36 SF 36
   Ware JE, 1998, SF 12 SCORE SF 12 PH
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
NR 19
TC 147
Z9 151
U1 0
U2 26
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2006
VL 90
IS 5
BP 593
EP 596
DI 10.1136/bjo.2005.086595
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 033ZG
UT WOS:000236892900021
PM 16622089
OA Green Published
DA 2022-11-30
ER

PT J
AU Parmar, T
   Ortega, JT
   Jastrzebska, B
AF Parmar, Tanu
   Ortega, Joseph T.
   Jastrzebska, Beata
TI Retinoid analogs and polyphenols as potential therapeutics for
   age-related macular degeneration
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Degeneration; flavonoids; macula; polyphenols; retina; retinoids
ID PIGMENT EPITHELIUM; OXIDATIVE-STRESS; SUNLIGHT EXPOSURE; GLOBAL
   PREVALENCE; A2E ACCUMULATE; RISK-FACTORS; MOUSE MODEL; LIPOFUSCIN;
   PROGRESSION; HESPERETIN
AB Progressive retinal degeneration manifesting as age-related macular degeneration (AMD) in the elderly affects millions of individuals worldwide. Among various blinding diseases, AMD is the leading cause of central vision impairment in developed countries. Poor understanding of AMD etiology hampers the development of therapeutics against this devastating ocular disease. Currently, daily intravitreal injections of anti-angiogenic drugs, preventing abnormal vessel growth are the only treatment option for wet AMD. However, for dry AMD associated with retinal atrophy, at present there is no cure available. Recent clinical research has demonstrated beneficial effects of plant-derived compounds for various eye disorders. Thus, the ongoing efforts toward discovering efficient treatments preventing or delaying AMD progression focus on implementing a healthy diet rich in vitamins, including vitamin A, E, and C, minerals and carotenoids, in particular lutein and zeaxanthin, to reduce the disease burden. In addition, studies in cell culture and animal models indicated therapeutic potential of dietary polyphenolic compounds present in fruits and vegetables. These natural compounds protect visual function and retinal morphology likely due to their anti-oxidant and anti-inflammatory properties. Although understanding of the exact mechanism of these compounds' positive effects requires further investigation, they provide non-invasive alternative to battle AMD-like condition. Additionally, studies carried in animal models mimicking AMD-like pathology, examining the pharmacological potential of particular retinoid analogs, demonstrated promising results for their use, and thus they should be considered as an option in developing therapies for AMD. In here, we summarize the most current knowledge regarding developments of therapeutic options to maintain ocular health and prevent vision loss associated with aging.
   Impact statement
   Age-related macular degeneration (AMD) is a devastating retinal degenerative disease. Epidemiological reports showed an expected increasing prevalence of AMD in the near future. The only one existing FDA-approved pharmacological treatment involves an anti-vascular endothelial growth factor (VEGF) therapy with serious disadvantages. This limitation emphasizes an alarming need to develop new therapeutic approaches to prevent and treat AMD. In this review, we summarize scientific data unraveling the therapeutic potential of the specific retinoid and natural compounds. The experimental results reported by us and other research groups demonstrated that retinoid analogs and compounds with natural product scaffolds could serve as lead compounds for the development of new therapeutic agents with potential to prevent or slow down the pathogenesis of AMD.
C1 [Jastrzebska, Beata] Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Cleveland Ctr Membrane & Struct Biol, Sch Med, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Jastrzebska, B (通讯作者)，Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA.
EM bxj27@case.edu
RI Ortega, Joseph/AFN-8883-2022
OI Jastrzebska, Beata/0000-0001-5209-8685
FU National Institutes of Health [EY025214]
FX This work was supported by funding from the National Institutes of
   Health EY025214 (BJ).
CR Abdal DA, 2016, NUTRIENTS, V8, P581, DOI DOI 10.3390/nu8090581
   Abotaleb M, 2019, CANCERS, V11, DOI 10.3390/cancers11010028
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Anand David Alexander Victor, 2016, Pharmacogn Rev, V10, P84, DOI 10.4103/0973-7847.194044
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Arumugam B, 2019, MOL VIS, V25, P47
   Baksheeva VE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8010003
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Bohm MRR, 2019, KLIN MONATSBL AUGENH, V236, P682, DOI 10.1055/s-0043-105266
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Boyer NP, 2012, PHOTOCHEM PHOTOBIOL, V88, P1373, DOI 10.1111/j.1751-1097.2012.01127.x
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chen R, 2014, MOL VIS, V20, P242
   Christakis PG, 2019, OPHTHALMOLOGY, VS0161-6420, P32297
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Connolly E, 2018, BRIT J OPHTHALMOL, V102, P1691, DOI 10.1136/bjophthalmol-2017-311673
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   de Jong PTVM, 2016, OPHTHALMOL EYE DIS, V8, P5, DOI 10.4137/OED.S40523
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Fan J, 2005, J PHYSIOL-LONDON, V568, P83, DOI 10.1113/jphysiol.2005.091942
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Gao SQ, 2018, MOL PHARMACOL, V94, P1132, DOI 10.1124/mol.118.112581
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ginwala R, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8020035
   GROSS EG, 1992, DERMATOL CLIN, V10, P521
   Herrera-Hernandez MG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11391-x
   Guan ZQ, 2020, MOLECULES, V25, DOI 10.3390/molecules25061413
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hussain Tarique, 2016, Oxid Med Cell Longev, V2016, P7432797
   Hytti M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17645
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jastrzebska B, 2010, BIOCHEM J, V428, P1, DOI 10.1042/BJ20100270
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katibeh Marzieh, 2015, J Ophthalmic Vis Res, V10, P279, DOI 10.4103/2008-322X.170362
   Kaufman Y, 2011, J BIOL CHEM, V286, P7958, DOI 10.1074/jbc.M110.178640
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Klein BEK, 2014, INVEST OPHTH VIS SCI, V55, P5855, DOI 10.1167/iovs.14-14602
   Kubota R, 2020, DRUG DISCOV TODAY, V25, P292, DOI 10.1016/j.drudis.2019.11.013
   Kubota R, 2019, INVEST OPHTH VIS SCI, V60, P4924, DOI 10.1167/iovs.19-28194
   Kumar B, 2013, MICROVASC RES, V87, P65, DOI 10.1016/j.mvr.2013.01.002
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lei L, 2013, EXP EYE RES, V112, P57, DOI 10.1016/j.exer.2013.04.006
   Li AN, 2014, NUTRIENTS, V6, P6020, DOI 10.3390/nu6126020
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513
   Liu LB, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22052
   Liu SXL, 1996, J OCUL PHARMACOL TH, V12, P377, DOI 10.1089/jop.1996.12.377
   Ma L, 2011, J BIOL CHEM, V286, P7966, DOI 10.1074/jbc.M110.178657
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   Majumdar S, 2010, J PHARM PHARMACOL, V62, P951, DOI 10.1211/jpp.62.08.0001
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Monge ZA, 2016, NEUROSCI BIOBEHAV R, V69, P166, DOI 10.1016/j.neubiorev.2016.07.031
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Nakaishi H, 2000, Altern Med Rev, V5, P553
   Nakamura N, 2003, EXP EYE RES, V77, P195, DOI 10.1016/S0014-4835(03)00116-7
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nomi Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24183311
   Oddone E, 2019, MED LAV, V110, P241, DOI 10.23749/mdl.v110i3.8125
   Ortega JT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246218
   Ortega JT, 2019, J BIOL CHEM, V294, P8101, DOI 10.1074/jbc.RA119.007808
   Ortega JT, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0183-6
   Palczewski K, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15502
   Palczewski K, 2012, J BIOL CHEM, V287, P1612, DOI 10.1074/jbc.R111.301150
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Pallitto P, 2015, PHOTOCH PHOTOBIO SCI, V14, P1888, DOI 10.1039/c5pp00170f
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Parhiz H, 2015, PHYTOTHER RES, V29, P323, DOI 10.1002/ptr.5256
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Puntel A, 2015, BIOMATERIALS, V44, P103, DOI 10.1016/j.biomaterials.2014.12.019
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Rizzo M, 2009, J CLIN EXP NEUROPSYC, V31, P245, DOI 10.1080/13803390802279668
   Rodrigo-Diaz E, 2019, INVEST OPHTH VIS SCI, V60, P5070, DOI 10.1167/iovs.19-27971
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Tai MC, 2005, CNS DRUG REV, V11, P141
   Ortega JT, 2019, EXCLI J, V18, P1037, DOI 10.17179/excli2019-1837
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.16
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Weng SS, 2017, MOL MED REP, V16, P3461, DOI 10.3892/mmr.2017.6964
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Xu DP, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010096
   Yahfoufi N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111618
   Yan TQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0154-3
   Yanamala N, 2009, PHOTOCHEM PHOTOBIOL, V85, P454, DOI 10.1111/j.1751-1097.2008.00517.x
   Zhang JY, 2015, J CLIN INVEST, V125, P2781, DOI 10.1172/JCI80950
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
NR 118
TC 3
Z9 3
U1 0
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD NOV
PY 2020
VL 245
IS 17
SI SI
BP 1615
EP 1625
AR 1535370220926938
DI 10.1177/1535370220926938
EA MAY 2020
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA OK2BY
UT WOS:000534943500001
PM 32438835
OA Green Published
DA 2022-11-30
ER

PT J
AU Sharma, NK
   Prabhakar, S
   Gupta, A
   Singh, R
   Gupta, PK
   Gupta, PK
   Anand, A
AF Sharma, Neel Kamal
   Prabhakar, Sudesh
   Gupta, Amod
   Singh, Ramandeep
   Gupta, Pawan Kumar
   Gupta, Pramod Kumar
   Anand, Akshay
TI New Biomarker for Neovascular Age-Related Macular Degeneration:
   Eotaxin-2
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID ACUTE INTRAOCULAR INFLAMMATION; CHEMOKINE RECEPTOR CCR3; HUMAN
   EOSINOPHIL; INTRAVITREAL INJECTION; MOLECULAR-CLONING; EXPRESSION;
   BEVACIZUMAB; RISK; CHEMOATTRACTANT; RECRUITMENT
AB Recently, eotaxin-CCR3 was reported to play an important role in choroidal neovascularization (CNV) development and was documented to be superior than vascular endothelial growth factor-A treatment when tested in CNV animals. As eotaxin studies are lacking in the human age-related macular degeneration (AMD) patients, we sought to determine whether eotaxin-2 (CCL24) has any association with inflammatory processes that occur in CNV. CCL24 levels were determined by enzyme linked immunosorbant assay (ELISA) after normalization to total serum protein and levels of ELISA were correlated to various risk factors in about 133 AMD patients and 80 healthy controls. The CCL24 levels were significantly higher in wet AMD patients as compared with dry AMD and normal controls. There was a significant difference when compared among wet AMD patients (i.e., minimally classic, predominantly classic, and occult). We also report significant difference in the CCL24 levels of Avastin-treated and untreated AMD patients. This study shows that CCL24 levels were found to be significantly increased in AMD patients despite Avastin treatment as compared with normal controls and those without Avastin, indicating that CCL24 may have an association with CNV and may be an important target to validate future therapeutic approaches in AMD in tandem with Avastin treatment.
C1 [Sharma, Neel Kamal; Prabhakar, Sudesh; Gupta, Pawan Kumar; Anand, Akshay] Postgrad Inst Med Educ & Res PGIMER, Dept Neurol, Chandigarh, India.
   [Gupta, Amod; Singh, Ramandeep] Postgrad Inst Med Educ & Res PGIMER, Dept Ophthalmol, Chandigarh, India.
   [Gupta, Pramod Kumar] Postgrad Inst Med Educ & Res PGIMER, Dept Biostat, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh
RP Anand, A (通讯作者)，Postgrad Inst Med Educ & Res, Dept Neurol, Chandigarh 160012, India.
EM akshay1anand@rediffmail.com
RI Gupta, Amod/V-7633-2017; Gupta, Pramod K./D-8251-2019
OI Gupta, Amod/0000-0001-8427-5738; Gupta, Pramod K./0000-0002-6767-3520
FU Department of Science and Technology, India [SR/SO/HS-109/205]
FX The study was carried out at Department of Neurology, PGIMER,
   Chandigarh, India. The authors acknowledge Department of Science and
   Technology, India, for providing funds (F. No. SR/SO/HS-109/205 dated
   1-05-2007). We are grateful to the volunteers involved in the study,
   laboratory staff, and all those who contributed in terms of time and
   effort.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349
   Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   Jahnz-Rozyk K, 2005, ALLERGY, V60, P685, DOI 10.1111/j.1398-9995.2005.00774.x
   Johnson D, 2010, CAN J OPHTHALMOL, V45, P239, DOI 10.3129/i10-013
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kagami S, 2003, CLIN EXP IMMUNOL, V134, P309, DOI 10.1046/j.1365-2249.2003.02273.x
   Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975
   Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manousou P, 2010, CLIN EXP IMMUNOL, V162, P337, DOI 10.1111/j.1365-2249.2010.04248.x
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Petkovic V, 2004, J BIOL CHEM, V279, P23357, DOI 10.1074/jbc.M309283200
   Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456
   Pope SM, 2005, J IMMUNOL, V175, P5341, DOI 10.4049/jimmunol.175.8.5341
   Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Shahabuddin S, 2000, J IMMUNOL, V164, P3847, DOI 10.4049/jimmunol.164.7.3847
   Sharma NK, 2009, ANN NEUROSCI, V16, P62, DOI 10.5214/ans.0972.7531.2009.160208
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690
   Tin LL, 2002, J HUM HYPERTENS, V16, P147, DOI 10.1038/sj.jhh.1001373
   Vinish M, 2010, J NEUROL NEUROSUR PS, V81, P166, DOI 10.1136/jnnp.2008.157255
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x
   Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839
NR 39
TC 40
Z9 41
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD NOV
PY 2012
VL 31
IS 11
BP 1618
EP 1627
DI 10.1089/dna.2012.1786
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 029WL
UT WOS:000310527700008
PM 23025269
DA 2022-11-30
ER

PT J
AU Rozing, MP
   Durhuus, JA
   Nielsen, MK
   Subhi, Y
   Kirkwood, TBL
   Westendorp, RGJ
   Sorensen, TL
AF Rozing, Maarten P.
   Durhuus, Jon A.
   Nielsen, Marie Krogh
   Subhi, Yousif
   Kirkwood, Thomas B. L.
   Westendorp, Rudi G. J.
   Sorensen, Torben Lykke
TI Age-related macular degeneration: A two-level model hypothesis
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Ageing; Inflammation; Immune response;
   Two-level model
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; LOW-GRADE INFLAMMATION;
   C-REACTIVE PROTEIN; DELTA-T-CELLS; MEMBRANE ATTACK COMPLEX; RARE
   GENETIC-VARIANTS; OXIDATIVE STRESS; BRUCHS MEMBRANE; NADPH OXIDASE
AB Age-related diseases, including age-related macular degeneration (AMD), are of growing importance in a world where population ageing has become a dominant global trend. Although a wide variety of risk factors for AMD have been identified, age itself remains by far the most important risk factor, making it an urgent priority to understand the connections between underlying ageing mechanisms and pathophysiology of AMD. Ageing is both multicausal and variable, so that differences between individuals in biological ageing processes are the focus of a growing number of pathophysiological studies seeking to explain how ageing contributes to chronic, age-related conditions. The aim of this review is to integrate the available knowledge on the pathophysiology of AMD within the framework of the biology of ageing. One highly significant feature of biological ageing is systemic inflammation, which arises as a second-level response to a first level of molecular damage involving oxidative stress, mutations etc. Combining these insights, the various co-existing pathophysiological explanations in AMD arrange themselves according to a two-level hypothesis. Accordingly, we describe how AMD can be considered the consequence of age-related random accumulation of molecular damage at the ocular level and the subsequent systemic inflammatory host response thereof. We summarize evidence and provide original data to enlighten where evidence is lacking. Finally, we discuss how this two-level hypothesis provides a foundation for thoughts and future studies in prevention, prognosis, and intervention.
C1 [Rozing, Maarten P.] Univ Copenhagen, Dept Publ Hlth, Res Unit Gen Practice, Copenhagen, Denmark.
   [Rozing, Maarten P.] Univ Copenhagen, Dept Publ Hlth, Sect Gen Practice, Copenhagen, Denmark.
   [Rozing, Maarten P.; Durhuus, Jon A.; Kirkwood, Thomas B. L.; Westendorp, Rudi G. J.] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Hlth Aging, Copenhagen, Denmark.
   [Nielsen, Marie Krogh; Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ, Dept Ophthalmol, Clin Eye Res Div, Roskilde, Denmark.
   [Nielsen, Marie Krogh; Subhi, Yousif; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Westendorp, Rudi G. J.] Univ Copenhagen, Sect Epidemiol, Dept Publ Hlth, Copenhagen, Denmark.
   [Durhuus, Jon A.; Kirkwood, Thomas B. L.] Univ Copenhagen, Dept Cellular & Mol Med, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; University of Copenhagen; University of Copenhagen;
   University of Copenhagen
RP Sorensen, TL (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM tlso@regionsjaelland.dk
RI Durhuus, Jon/AAZ-8283-2021; Rozing, Maarten/AHC-7454-2022; Subhi,
   Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
CR Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Adams AA, 2008, MECH AGEING DEV, V129, P656, DOI 10.1016/j.mad.2008.09.004
   Adler L, 2015, PHOTOCH PHOTOBIO SCI, V14, P1983, DOI 10.1039/c5pp00156k
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3231, DOI 10.1167/iovs.08-1754
   Alpert A, 2019, NAT MED, V25, P487, DOI 10.1038/s41591-019-0381-y
   Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Andersen M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183620
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Bailey JNC, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030031
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Barrientos RM, 2015, NEUROSCIENCE, V309, P84, DOI 10.1016/j.neuroscience.2015.03.007
   Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Besser M, 2012, DEV BIOL, V369, P163, DOI 10.1016/j.ydbio.2012.05.020
   Betteridge DJ, 2000, METABOLISM, V49, P3, DOI 10.1016/S0026-0495(00)80077-3
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5
   Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bohr V, 1998, TOXICOL LETT, V103, P47
   BOK D, 1993, J CELL SCI, P189
   Boren E, 2004, AUTOIMMUN REV, V3, P401, DOI 10.1016/j.autrev.2004.03.004
   Borrego F, 1999, EXP GERONTOL, V34, P253, DOI 10.1016/S0531-5565(98)00076-X
   Brockmann C, 2018, ACTA OPHTHALMOL, V96, pE789, DOI 10.1111/aos.13716
   Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009
   Brynskov T, 2020, ACTA OPHTHALMOL, V98, P132, DOI 10.1111/aos.14183
   Camino A, 2019, NEUROPHOTONICS, V6, DOI 10.1117/1.NPh.6.4.041108
   Campochiaro PA, 2018, OPHTHALMOL RETINA, V2, P320, DOI 10.1016/j.oret.2017.07.013
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Caretto D, 2010, J IMMUNOL, V184, P30, DOI 10.4049/jimmunol.0903412
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Chandra D, 2011, BBA-BIOENERGETICS, V1807, P620, DOI 10.1016/j.bbabio.2010.10.023
   Chapman CML, 2004, STROKE, V35, P1619, DOI 10.1161/01.STR.0000130857.19423.ad
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Coder B, 2017, ONCOTARGET, V8, P7116, DOI 10.18632/oncotarget.12572
   Coder BD, 2015, J IMMUNOL, V194, P5825, DOI 10.4049/jimmunol.1500082
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Correia SC, 2012, ADV EXP MED BIOL, V724, P205, DOI 10.1007/978-1-4614-0653-2_16
   Costa RA, 2006, PROG RETIN EYE RES, V25, P325, DOI 10.1016/j.preteyeres.2006.03.001
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664
   DAVIES KA, 1994, SPRINGER SEMIN IMMUN, V15, P397, DOI 10.1007/BF01837367
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Craen AJM, 2005, GENES IMMUN, V6, P167, DOI 10.1038/sj.gene.6364162
   De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Devireddy LR, 2010, CELL, V141, P1006, DOI 10.1016/j.cell.2010.04.040
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ding QX, 2006, FASEB J, V20, P1055, DOI 10.1096/fj.05-5495com
   Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P163, DOI 10.1089/ars.2006.8.163
   Dorn GW, 2019, ANNU REV PHYSIOL, V81, P1, DOI 10.1146/annurev-physiol-020518-114358
   Dow CT, 2016, CLIN OPHTHALMOL, V10, P243, DOI 10.2147/OPTH.S100042
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Drenos F, 2006, BIOGERONTOLOGY, V7, P287, DOI 10.1007/s10522-006-9027-9
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702
   Durhuus JA, 2015, MITOCHONDRION, V20, P7, DOI 10.1016/j.mito.2014.10.004
   Dutta D, 2013, AUTOPHAGY, V9, P328, DOI 10.4161/auto.22971
   Dyer Douglas P, 2017, Sci Rep, V7, P42681, DOI 10.1038/srep42681
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Espinosa-Heidmann D.G., 2003, INVESTIG OPHTHALMOL, V44, P3586
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fasler-Kan E, 2013, XENOTRANSPLANTATION, V20, P469, DOI 10.1111/xen.12070
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Finsterer J, 2012, SEIZURE-EUR J EPILEP, V21, P316, DOI 10.1016/j.seizure.2012.03.003
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Giunta Sergio, 2006, Immun Ageing, V3, P12, DOI 10.1186/1742-4933-3-12
   Goldberg EL, 2015, IMMUNOL REV, V265, P63, DOI 10.1111/imr.12295
   Gordon SM, 2010, J PROTEOME RES, V9, P5239, DOI 10.1021/pr100520x
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Harris J, 2017, PATHOBIOL AGING AGE, V7, DOI 10.1080/20010001.2017.1398016
   Hartnett M Elizabeth, 2010, Doc Ophthalmol, V120, P25, DOI 10.1007/s10633-009-9181-x
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Haynes L, 2009, CURR OPIN IMMUNOL, V21, P414, DOI 10.1016/j.coi.2009.05.009
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632
   Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Huang J, 2015, AGEING RES REV, V24, P3, DOI 10.1016/j.arr.2014.10.004
   Ichiishi E, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3458276
   Immonen I, 2013, ACTA OPHTHALMOL, V91, P453, DOI 10.1111/j.1755-3768.2012.02427.x
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kanneganti T.-D., 2006, NAT IMMUNOL, V11, P401, DOI [10.1038/nrm3013, DOI 10.1038/NRM3013]
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kim YW, 2014, BLOOD, V123, P625, DOI 10.1182/blood-2013-09-512749
   Kirkwood TBL, 2008, J INTERN MED, V263, P117, DOI 10.1111/j.1365-2796.2007.01901.x
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Kirkwood TBL, 2017, EXP PHYSIOL, V102, P1067, DOI 10.1113/EP086205
   Klein R, 2019, OPHTHALMOLOGY, V126, P752, DOI 10.1016/j.ophtha.2018.12.026
   Klettner A, 2015, MOL VIS, V21, P736
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Kuningas M, 2009, PLOS ONE, V4, pA174, DOI 10.1371/journal.pone.0007795
   Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757
   Labbadia J, 2015, ANNU REV BIOCHEM, V84, P435, DOI 10.1146/annurev-biochem-060614-033955
   Lahoute C, 2011, NAT REV CARDIOL, V8, P348, DOI 10.1038/nrcardio.2011.62
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Lazzarini R, 2018, AGING-US, V10, P3173, DOI 10.18632/aging.101624
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee IC, 2013, J CHILD NEUROL, V28, P404, DOI 10.1177/0883073812469722
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Lennon L., 2015, LOW GRADE INFLAMMATI, DOI [10.1136/bmj.321.7255.199, DOI 10.1136/BMJ.321.7255.199]
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li LN, 2006, METABOLISM, V55, P1516, DOI 10.1016/j.metabol.2006.06.022
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Li YJ, 2015, CELL PHYSIOL BIOCHEM, V35, P1663, DOI 10.1159/000373980
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin TH, 2014, 2014 IEEE-EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS (BHI), P9, DOI 10.1109/BHI.2014.6864291
   Lio D, 2003, J MED GENET, V40, P296, DOI 10.1136/jmg.40.4.296
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Loftsson T, 2017, INT J PHARMACEUT, V531, P413, DOI 10.1016/j.ijpharm.2017.04.010
   Loos B, 2014, AUTOPHAGY, V10, P2087, DOI 10.4161/15548627.2014.973338
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   MacPherson M, 2011, J BIOL CHEM, V286, P17303, DOI 10.1074/jbc.M110.182998
   Madelung CF, 2015, CLIN OPHTHALMOL, V9, DOI 10.2147/OPTH.S82116
   Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006
   MARGULIS L, 1971, AM SCI, V59, P230
   Marsik C, 2004, J CLIN IMMUNOL, V24, P62, DOI 10.1023/B:JOCI.0000018064.13793.83
   Martinez GJ, 2008, ANN NY ACAD SCI, V1143, P188, DOI 10.1196/annals.1443.021
   Matsuda N, 2015, AUTOPHAGY, V11, P1700, DOI 10.1080/15548627.2015.1071760
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Michaelides M, 2008, ARCH OPHTHALMOL-CHIC, V126, P320, DOI 10.1001/archopht.126.3.320
   Milush JM, 2009, BLOOD, V114, P4823, DOI 10.1182/blood-2009-04-216374
   Minihane AM, 2015, BRIT J NUTR, V114, P999, DOI 10.1017/S0007114515002093
   Mitchell GF, 2008, J APPL PHYSIOL, V105, P1652, DOI 10.1152/japplphysiol.90549.2008
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Mold C, 1999, IMMUNOPHARMACOLOGY, V42, P23, DOI 10.1016/S0162-3109(99)00007-7
   Morgan J, 2005, EXP EYE RES, V80, P297, DOI 10.1016/j.exer.2004.12.010
   Morimoto RI, 2014, J GERONTOL A-BIOL, V69, pS33, DOI 10.1093/gerona/glu049
   Mujal AM, 2019, SCIENCE, V364, P28, DOI 10.1126/science.aau8694
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nesargikar PN, 2012, EUR J MICROBIOL IMMU, V2, P103, DOI 10.1556/EuJMI.2.2012.2.2
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Nikas JB, 2013, SCI REP-UK, V3, DOI 10.1038/srep03254
   Norris GT, 2018, J EXP MED, V215, P1789, DOI 10.1084/jem.20172244
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park C, 2013, CELL BIOCHEM BIOPHYS, V67, P3, DOI 10.1007/s12013-013-9623-7
   Park CB, 2011, J CELL BIOL, V193, P809, DOI 10.1083/jcb.201010024
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Piermarocchi S, 2016, OPHTHALMIC RES, V55, P111, DOI 10.1159/000441795
   Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x
   Rambold AS, 2018, TRENDS IMMUNOL, V39, P6, DOI 10.1016/j.it.2017.08.006
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reinhard J, 2017, FRONT INTEGR NEUROSC, V11, DOI 10.3389/fnint.2017.00030
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rinsky B, 2017, MOL VIS, V23, P889
   Roginska D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5306790
   Roizenblatt M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113688
   Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355
   Rozing MP, 2019, PSYCHONEUROENDOCRINO, V99, P20, DOI 10.1016/j.psyneuen.2018.08.029
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   SAGAN L, 1967, J THEOR BIOL, V14, P225, DOI 10.1016/0022-5193(67)90079-3
   Saito T, 2015, CIRC RES, V116, P1477, DOI 10.1161/CIRCRESAHA.116.303790
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002
   Samardzija M, 2006, FASEB J, V20, P2411, DOI 10.1096/fj.06-5895fje
   Saxena N, 2016, OPHTHAL EPIDEMIOL, V23, P232, DOI 10.1080/09286586.2016.1193617
   Schaefer L, 2014, J BIOL CHEM, V289, P35237, DOI 10.1074/jbc.R114.619304
   SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488
   Schittenhelm L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01866
   Schmidt T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132703
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schrier SA, 2011, CURR OPIN OPHTHALMOL, V22, P325, DOI 10.1097/ICU.0b013e328349419d
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   See DM, 1996, IMMUNOL INVEST, V25, P153, DOI 10.3109/08820139609059298
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Silvestri G, 2012, EYE, V26, P1357, DOI 10.1038/eye.2012.165
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stehouwer CDA, 2002, DIABETES, V51, P1157, DOI 10.2337/diabetes.51.4.1157
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Tawfik A, 2009, INVEST OPHTH VIS SCI, V50, P878, DOI 10.1167/iovs.08-2005
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Thallas-Bonke V, 2008, DIABETES, V57, P460, DOI 10.2337/db07-1119
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Urban CF, 2006, CELL MICROBIOL, V8, P1687, DOI 10.1111/j.1462-5822.2006.00792.x
   Van Bodegom D, 2007, ANN NY ACAD SCI, V1100, P84, DOI 10.1196/annals.1395.007
   van den Biggelaar AHJ, 2004, FASEB J, V18, P1022, DOI 10.1096/fj.03-1162fje
   van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072
   van der Linden MW, 1998, J IMMUNOL METHODS, V218, P63, DOI 10.1016/S0022-1759(98)00108-2
   van Exel E, 2009, ARCH GEN PSYCHIAT, V66, P1263, DOI 10.1001/archgenpsychiatry.2009.146
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vanhorebeek I, 2011, J CLIN ENDOCR METAB, V96, pE633, DOI 10.1210/jc.2010-2563
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Veilleux CC, 2014, BRAIN BEHAV EVOLUT, V83, P43, DOI 10.1159/000357830
   Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659
   Vogelzangs N, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.92
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang LL, 2015, CELL PHYSIOL BIOCHEM, V37, P2012, DOI 10.1159/000438561
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788
   Westendorp RGJ, 1997, LANCET, V349, P1912, DOI 10.1016/S0140-6736(05)63910-4
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Wong E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a006734
   Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355
   Wu Y, 2019, CLIN INTERV AGING, V14, P1277, DOI 10.2147/CIA.S200637
   Wu YT, 2017, NAT REV NEUROL, V13, P327, DOI 10.1038/nrneurol.2017.63
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1
   YASAKA T, 1981, J IMMUNOL, V127, P1515
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   YOUNG RW, 1968, J CELL BIOL, V39, P169, DOI 10.1083/jcb.39.1.169
   Yu Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01852
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang T, 2019, BRIT J PHARMACOL, V176, P2063, DOI 10.1111/bph.14650
   Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184
   Zhao ZY, 2017, FASEB J, V31, P4903, DOI 10.1096/fj.201700533R
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zheng C, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0054-4
   Zhou JH, 2005, MOL VIS, V11, P414
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 346
TC 66
Z9 67
U1 7
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2020
VL 76
AR 100825
DI 10.1016/j.preteyeres.2019.100825
PG 27
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LZ3TM
UT WOS:000541151000007
PM 31899290
DA 2022-11-30
ER

PT J
AU Rosa, R
   Corazza, P
   Musolino, M
   Mochi, C
   Maiello, G
   Traverso, CE
   Nicolo, M
AF Rosa, Raffaella
   Corazza, Paolo
   Musolino, Maria
   Mochi, Chiara
   Maiello, Guido
   Traverso, Carlo Enrico
   Nicolo, Massimo
TI Choroidal changes in intermediate age-related macular degeneration
   patients with drusen or pseudodrusen
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; techniques of retinal
   examination; choroidal ischemia; uvea; anatomy; biochemistry; physiology
ID OPTICAL COHERENCE TOMOGRAPHY; SWEPT-SOURCE OCT; RETICULAR PSEUDODRUSEN;
   SPECTRAL-DOMAIN; THICKNESS; CHORIOCAPILLARIS; EYES; DEPOSITS; DENSITY;
   VOLUME
AB Reticular pseudodrusen are associated with a thinner choroid. The aim of our study was to determine the differences in central choroidal thickness and choriocapillaris vascular flow area between eyes with and without reticular pseudodrusen using swept-source optical coherence tomography and swept-source optical coherence tomography angiography. We conducted a retrospective case control study which included 27 eyes from 27 consecutive patients with intermediate age-related macular degeneration and 17 eyes from 17 healthy participants. Complete ophthalmic examinations were carried out including axial length measurements; fundus color retinography; fundus autofluorescence; swept-source optical coherence tomography and swept-source optical coherence tomography angiography; central choroidal thickness and choriocapillaris vascular flow area. Patients were classified as no reticular pseudodrusen, mild reticular pseudodrusen, and severe reticular pseudodrusen. Mean central choroidal thickness in patients exhibiting severe reticular pseudodrusen (110 +/- 56 mu m) was significantly smaller than in patients with no reticular pseudodrusen (201 +/- 76 mu m, p < 0.01). Mean choriocapillaris vascular flow area in severe reticular pseudodrusen patients (45.2% +/- 3.0%) was also significantly less than in patients with no (47.9% +/- 1.6%, p < 0.001) and mild reticular pseudodrusen (47.7% +/- 1.0%, p < 0.05). Stepwise multiple regression models confirmed the association of reticular pseudodrusen with central choroidal thickness (p < 0.001) and choriocapillaris vascular flow area (p < 0.01) even after accounting for age, axial length, and refractive error. Soft drusen were not associated with changes in either central choroidal thickness (p = 0.13) nor choriocapillaris vascular flow area (p = 0.29). A significant, positive relationship was found between central choroidal thickness and choriocapillaris vascular flow area (r = 0.44, p = 0.01). Therefore, both central choroidal thickness and choriocapillaris vascular flow area are decreased in eyes with reticular pseudodrusen, as compared to healthy eyes and intermediate age-related macular degeneration eyes not exhibiting reticular pseudodrusen. In addition, central choroidal thickness and choriocapillaris vascular flow area are related, and the reduction of either is directly associated to the severity of reticular pseudodrusen. Further studies are needed to assess the clinical significance of these findings.
C1 [Rosa, Raffaella; Corazza, Paolo; Musolino, Maria; Mochi, Chiara; Traverso, Carlo Enrico; Nicolo, Massimo] Univ Genoa, Clin Oculist, DINOGMI, Osped Policlin San Martino, Viale Benedetto XV 5, I-16126 Genoa, Italy.
   [Maiello, Guido] Justus Liebig Univ Giessen, Dept Expt Psychol, Giessen, Germany.
   [Nicolo, Massimo] Fdn Macula Onlus, Genoa, Italy.
C3 University of Genoa; Justus Liebig University Giessen
RP Rosa, R (通讯作者)，Univ Genoa, Clin Oculist, DINOGMI, Osped Policlin San Martino, Viale Benedetto XV 5, I-16126 Genoa, Italy.
EM dr.raffaellarosa@gmail.com
RI Maiello, Guido/U-9105-2019
OI Maiello, Guido/0000-0001-6625-2583; Rosa, Raffaella/0000-0003-3304-7625;
   Mochi, Chiara/0000-0001-5539-6215
FU Marie Sklodowska-Curie Actions Individual Fellowship [793660]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Guido
   Maiello was supported by a Marie Sklodowska-Curie Actions Individual
   Fellowship (H2020-MSCA-IF-2017: "VisualGrasping" Project ID: 793660).
CR Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Benavente-Perez A, 2010, OPTOMETRY VISION SCI, V87, P867, DOI 10.1097/OPX.0b013e3181f3eced
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Caramoy A, 2017, CLIN OPHTHALMOL, V11, P1835, DOI 10.2147/OPTH.S145932
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Copete S, 2014, BRIT J OPHTHALMOL, V98, P334, DOI 10.1136/bjophthalmol-2013-303904
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Esmaeelpour M, 2010, INVEST OPHTH VIS SCI, V51, P5260, DOI 10.1167/iovs.10-5196
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Huber R, 2007, OPT LETT, V32, P2049, DOI 10.1364/OL.32.002049
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Nicolo M, 2017, INVEST OPHTH VIS SCI, V58, P2002, DOI 10.1167/iovs.17-21417
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Yasuno Y, 2009, J BIOPHOTONICS, V2, P435, DOI 10.1002/jbio.200910017
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
   Zweifel SA, 2010, OPHTHALMOLOGY, V117
NR 49
TC 4
Z9 4
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2021
VL 31
IS 2
BP 505
EP 513
AR 1120672120914530
DI 10.1177/1120672120914530
EA APR 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SB1ZQ
UT WOS:000534609700001
PM 32338527
OA Green Published
DA 2022-11-30
ER

PT J
AU Blitzer, AL
   Ham, SA
   Colby, KA
   Skondra, D
AF Blitzer, Andrea L.
   Ham, Sandra A.
   Colby, Kathryn A.
   Skondra, Dimitra
TI Association of Metformin Use With Age-Related Macular Degeneration A
   Case-Control Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID POPULATION; RISK; INFLAMMATION; RETINOPATHY; GLUCOSE; CANCER; HEALTH
AB This case-control study uses a national database to assess whether metformin use is associated with reduced odds of developing age-related macular degeneration.
   Question Is there an association between metformin use and the development of age-related macular degeneration (AMD)? Findings In this large case-control study using a national database of patients, we found that metformin use was associated with decreased odds of developing AMD in a dose-dependent manner, with the greatest benefit at low to moderate dosages. Meaning The use of metformin may protect against the development of AMD and lead to a novel therapeutic strategy for the prevention of this disease.
   Importance Age-related macular degeneration (AMD), the leading cause of irreversible blindness in older adults, appears to have no effective preventive measures. The common antidiabetic drug metformin has been shown to have protective outcomes in multiple age-associated diseases and may have the potential to protect against the development of AMD. Objective To determine whether metformin use is associated with reduced odds of developing AMD. Design, Setting, and Participants This case-control study of patients from a nationwide health insurance claims database included a population-based sample of patients. Those aged 55 years and older with newly diagnosed AMD from January 2008 to December 2017 were defined as cases and matched with control participants. Data analyses were completed from June 2019 to February 2020. Exposures Dosage of metformin and exposure to other prescribed medications, as identified from outpatient drug claims. Main Outcomes and Measures Risk of developing AMD. Results A total of 312 404 affected individuals were included (181 817 women [58.2%]). After matching, 312 376 control participants were included (172 459 women [55.2%]; age range, 55 to 107 years). The case group had a slightly higher percentage of participants with diabetes (81 262 participants [26.0%]) compared with the control group (79 497 participants [25.5%]). Metformin use was associated with reduced odds of developing AMD (odds ratio [OR], 0.94 [95% CI, 0.92-0.96]). This association was dose dependent, with low to moderate doses of metformin showing the greatest potential benefit (dosages over 2 years: 1-270 g, OR, 0.91 [95% CI, 0.88-0.94]; 271-600 g, OR, 0.90 [95% CI, 0.87-0.93]; 601-1080 g, OR, 0.95 [95% CI, 0.92-0.98]). Doses of more than 1080 g of metformin over 2 years did not have reduced odds of developing AMD. Both the reduction in odds ratio and the dose-dependent response were preserved in a cohort consisting only of patients with diabetes. Metformin use was associated with a decreased OR of AMD in patients with diabetes without coexisting diabetic retinopathy (OR, 0.93 [95% CI, 0.91-0.95]) but was a risk factor in patients with diabetic retinopathy (OR, 1.07 [95% CI, 1.01-1.15]). Conclusion and Relevance In this study, metformin use was associated with reduced odds of developing AMD. This association was dose dependent, with the greatest benefit at low to moderate doses. When looking only at patients with diabetes, we saw a preservation of the dose-dependent decrease in the odds of patients developing AMD. Metformin does not appear to be protective in patients with diabetes and coexisting diabetic retinopathy. This study suggests that metformin may be useful as a preventive therapy for AMD and provides the basis for potential prospective clinical trials.
C1 [Blitzer, Andrea L.; Skondra, Dimitra] Univ Chicago, Med Ctr, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Ham, Sandra A.] Univ Chicago, Ctr Hlth & Social Sci, Chicago, IL 60637 USA.
   [Colby, Kathryn A.] New York Univ, Dept Ophthalmol, New York, NY USA.
C3 University of Chicago; University of Chicago Medical Center; University
   of Chicago; New York University
RP Skondra, D (通讯作者)，Univ Chicago, Med Ctr, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM dskondra@bsd.uchicago.edu
FU University of Chicago Institute for Translational Medicine
FX This work was supported by a grant from The University of Chicago
   Institute for Translational Medicine (Dr Skondra).
CR Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791
   Borrone R, 2008, EUR J OPHTHALMOL, V18, P949, DOI 10.1177/112067210801800615
   Bosco JLF, 2011, CANCER EPIDEM BIOMAR, V20, P101, DOI 10.1158/1055-9965.EPI-10-0817
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Campbell JM, 2017, AGEING RES REV, V40, P31, DOI 10.1016/j.arr.2017.08.003
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Howell JJ, 2017, CELL METAB, V25, P463, DOI 10.1016/j.cmet.2016.12.009
   Kooy A, 2009, ARCH INTERN MED, V169, P616, DOI 10.1001/archinternmed.2009.20
   Lin HC, 2015, JAMA OPHTHALMOL, V133, P915, DOI 10.1001/jamaophthalmol.2015.1440
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Mazzone PJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-410
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Ng TP, 2014, J ALZHEIMERS DIS, V41, P61, DOI 10.3233/JAD-131901
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Prattichizzo F, 2018, AGEING RES REV, V48, P87, DOI 10.1016/j.arr.2018.10.003
   Rena G, 2013, DIABETOLOGIA, V56, P1898, DOI 10.1007/s00125-013-2991-0
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Saisho Y, 2015, ENDOCR METAB IMMUNE, V15, P196, DOI 10.2174/1871530315666150316124019
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Tseng CH, 2019, AGING DIS, V10, P37, DOI 10.14336/AD.2017.1202
   Tseng CH, 2012, EUR J ENDOCRINOL, V167, P409, DOI 10.1530/EJE-12-0369
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vinolo MAR, 2011, NUTRIENTS, V3, P858, DOI 10.3390/nu3100858
   Wang LW, 2016, CANCER INFORM, V15, P237, DOI 10.4137/CIN.S40604
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Zheng Z, 2012, DIABETES, V61, P217, DOI 10.2337/db11-0416
NR 32
TC 30
Z9 30
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2021
VL 139
IS 3
BP 302
EP 309
DI 10.1001/jamaophthalmol.2020.6331
EA JAN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QZ2CP
UT WOS:000612969400007
PM 33475696
OA Green Published
DA 2022-11-30
ER

PT J
AU Hu, XF
   Waldstein, SM
   Klimscha, S
   Sadeghipour, A
   Bogunovic, H
   Gerendas, BS
   Osborne, A
   Schmidt-Erfurth, U
AF Hu, Xiaofeng
   Waldstein, Sebastian M.
   Klimscha, Sophie
   Sadeghipour, Amir
   Bogunovic, Hrvoje
   Gerendas, Bianca S.
   Osborne, Aaron
   Schmidt-Erfurth, Ursula
TI MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTICS AT THE ONSET OF EXUDATIVE
   CONVERSION IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE exudative age-related macular degeneration; onset of choroidal
   neovascularization; optical coherence tomography; pigment epithelial
   detachment
ID CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; RANIBIZUMAB; FLUID
AB Purpose: To characterize retinal morphology differences among different types of choroidal neovascularization and visual function changes at the onset of exudative age-related macular degeneration. Methods: In a post hoc analysis of a prospective clinical study, 1,097 fellow eyes from subjects with choroidal neovascularization in the study eye enrolled in the HARBOR trial were evaluated. The onset of exudation was diagnosed on monthly optical coherence tomography by two masked graders. At conversion as well as 1 month earlier, pigment epithelial detachment, intraretinal cystoid fluid, subretinal fluid, subretinal hyperreflective material, as well as ellipsoid zone and external limiting membrane loss were quantitatively analyzed. Hyperreflective foci, retinal pigment epithelial defects, haze and vitreoretinal interface status were evaluated qualitatively. Main outcome measures included visual acuity and rates of morphologic features at conversion and 1 month earlier. Results: New-onset exudation was detected in 92 eyes. One month before conversion, hyperreflective foci, pigment epithelial detachment, retinal pigment epithelial defects, and haze were present in the majority of eyes. At the onset of exudation, the volumes of intraretinal cystoid fluid, subretinal fluid, subretinal hyperreflective material and pigment epithelial detachment, and the areas of external limiting membrane and ellipsoid zone loss significantly increased. The mean vision loss was -2.2 letters. Pathognomonic patterns of the different choroidal neovascularization types were already apparent 1 month before conversion. Conclusion: Characteristic choroidal neovascularization-associated morphological changes are preceding disease conversion, while vision loss at the onset of exudation is minimal. Individual lesion types are related to specific changes in optical coherence tomography morphology already before the time of conversion. Our findings may help to elucidate the pathophysiology of neovascular age-related macular degeneration and support the diagnosis of imminent disease conversion.
C1 [Hu, Xiaofeng; Waldstein, Sebastian M.; Klimscha, Sophie; Sadeghipour, Amir; Bogunovic, Hrvoje; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Hu, Xiaofeng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Osborne, Aaron] Genentech Inc, San Francisco, CA 94080 USA.
C3 Medical University of Vienna; Capital Medical University; Roche Holding;
   Genentech
RP Waldstein, SM (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM sebastian.waldstein@meduniwien.ac.at
OI Riedl, Sophie/0000-0003-0003-0886; Gerendas, Bianca
   S./0000-0001-8940-8130
FU Austrian Federal Ministry of Science, Research and Economy; Austrian
   National Foundation for Research, Technology and Development; Genentech,
   Inc, South San Francisco, CA
FX Supported by the Austrian Federal Ministry of Science, Research and
   Economy, the Austrian National Foundation for Research, Technology and
   Development, and Genentech, Inc, South San Francisco, CA. Genentech
   participated in review and approval of the manuscript.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Fragiotta S, 2018, RETINA-J RET VIT DIS, V38, P245, DOI 10.1097/IAE.0000000000001540
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kim JH, 2016, RETINA-J RET VIT DIS, V36, P1506, DOI 10.1097/IAE.0000000000000932
   Liang F, 2009, GRAEF ARCH CLIN EXP, V247, P1285, DOI 10.1007/s00417-009-1098-2
   Michalewski J, 2014, CAN J OPHTHALMOL, V49, P339, DOI 10.1016/j.jcjo.2014.04.018
   Naysan J, 2016, RETINA-J RET VIT DIS, V36, P449, DOI 10.1097/IAE.0000000000000758
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
NR 24
TC 8
Z9 8
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2020
VL 40
IS 6
BP 1070
EP 1078
DI 10.1097/IAE.0000000000002531
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LW6LN
UT WOS:000539255800013
PM 30932998
DA 2022-11-30
ER

PT J
AU Parravano, M
   Oddone, F
   Tedeschi, M
   Lomoriello, DS
   Chiaravalloti, A
   Ripandelli, G
   Varano, M
AF Parravano, Mariacristina
   Oddone, Francesco
   Tedeschi, Massimiliano
   Lomoriello, Domenico Schiano
   Chiaravalloti, Adele
   Ripandelli, Guido
   Varano, Monica
TI RETINAL FUNCTIONAL CHANGES MEASURED BY MICROPERIMETRY IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION PATIENTS TREATED WITH RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE anti-VEGF drugs; choroidal neovascular membrane; CNV; neovascular
   age-related macular degeneration; microperimetry; ranibizumab; retinal
   sensitivity; vascular endothelial growth factor; VEGF wet AMD
ID SCANNING LASER MICROPERIMETRY; ANTI-VEGF ANTIBODY; VISUAL-ACUITY;
   OPHTHALMOSCOPE; BEVACIZUMAB; SELECTION; DISEASES; EDEMA
AB Purpose: To assess functional and structural retinal changes in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab 0.5 mg.
   Methods: Eighteen patients with neovascular age-related macular degeneration have been evaluated in this retrospective, 24-week follow-up study. All patients were treated with three injections of ranibizumab 0.5 mg, 1 month apart and retreated according to predefined criteria. At baseline, all patients were subjected to visual acuity measurement, fluorescein angiography, microperimetry, and optical coherence tomography stratus. Visual acuity, microperimetry, and optical coherence tomography evaluations were repeated 28 +/- 2 days after each injection.
   Results: Mean retinal sensitivity significantly improved from 3.89 +/- 3.0 dB at baseline to 6.61 +/- 3.4 dB at 24 weeks (P = 0.044). Mean visual acuity significantly improved from 48.67 +/- 8.58 to 60.72 +/- 16.09 (P = 0.026); visual acuity improved in 44.4% of patients; >= 15 letters (24.5 +/- 8.0 letters), and in 38.9% of patients improved < 15 letters (6.14 +/- 3.7 letters); 16.7% of patients lost < 15 letters (7.3 +/- 2.1 letters). An improvement of fixation stability from baseline was observed in 33.3% of patients. Central macular thickness significantly decreased from 310.5 +/- 85.7 mu m to 217.3 +/- 46.8 mu m at 24 weeks (P < 0.001).
   Conclusions: Although visual acuity and retinal thickness changes seemed to be almost maximum at 4 weeks after intravitreal ranibizumab 0.5 mg, retinal sensitivity as measured by microperimetry showed a trend of progressive improvement till 24 weeks suggesting that microperimetry may give additional information about macular function not given by visual acuity alone.
C1 [Parravano, Mariacristina; Oddone, Francesco; Tedeschi, Massimiliano; Lomoriello, Domenico Schiano; Chiaravalloti, Adele; Ripandelli, Guido; Varano, Monica] Fdn GB Bietti IRCCS, I-00198 Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia
RP Parravano, M (通讯作者)，Fdn GB Bietti IRCCS, Via Livenza 3, I-00198 Rome, Italy.
EM criparra@tin.it
RI Oddone, Francesco/K-8876-2016; Varano, Monica/K-8573-2016
OI Oddone, Francesco/0000-0002-2504-0004; Varano,
   Monica/0000-0002-6530-1563; Schiano Lomoriello,
   Domenico/0000-0001-6035-225X
CR Andersen IVN, 1996, ACTA OPHTHALMOL SCAN, V74, P135
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   LALWANI GA, 2007, ANN M ASS RES VIS OP
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MIDENA E, 2007, PERIMETRY FUNDUS INT, P229
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   NUSSENBLATT RB, 1987, OPHTHALMOLOGY, V94, P1134
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SCHNEIDER U, 1993, KLIN MONATSBL AUGENH, V203, P212, DOI 10.1055/s-2008-1045670
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
NR 33
TC 27
Z9 28
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2009
VL 29
IS 3
BP 329
EP 334
DI 10.1097/IAE.0b013e31819093e6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 420RK
UT WOS:000264306700008
PM 19092732
DA 2022-11-30
ER

PT J
AU Kolomeyer, AM
   Smith, E
   Daniel, E
   Ying, GS
   Pan, W
   Pistilli, M
   Grunwald, J
   Maguire, MG
   Kim, BJ
AF Kolomeyer, Anton M.
   Smith, Eli
   Daniel, Ebenezer
   Ying, Gui-Shuang
   Pan, Wei
   Pistilli, Max
   Grunwald, Juan
   Maguire, Maureen G.
   Kim, Benjamin J.
CA CATT Res Grp
TI BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF
   AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; beta-peripapillary
   atrophy; CATT
AB Purpose: To determine associations between beta-peripapillary atrophy (B-PPA) and incidence and growth of geographic atrophy (GA) in eyes treated with anti-vascular endothelial growth factor agents in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Methods: We included 245 cases with incident GA and 245 controls matched by baseline demographics and characteristics associated with development of GA in the CATT. Baseline color images were graded for the type of B-PPA, defined as presence of hypopigmentation with visible choroidal vessels and sclera that is adjacent to the optic disk. Beta-peripapillary atrophy was further classified as scleral ring, sclera, sclera/choroidal blood vessels, or combination. Areas of each type of B-PPA and the circumferential extent of B-PPA were measured. Results: Beta-peripapillary atrophy was present in 58% of eyes developing GA and in 52% without GA (P = 0.17). The greater circumferential extent of sclera/choroidal blood vessels B-PPA in relation to the optic disk was associated with incident GA (P = 0.02) and the GA size at first observation (P = 0.047). Beta-peripapillary atrophy was not associated with GA growth rates (P>0.05). Patients without B-PPA had a higher number of GA-associated risk alleles of ARMS2 (P = 0.0003) and HTRA1 (P = 0.001). Conclusion: The extent of sclera/choroidal blood vessel B-PPA was associated with the GA incidence and size but not with the growth rate in eyes treated for neovascular age-related macular degeneration. Beta-peripapillary atrophy and GA may share some common pathophysiologic pathways unrelated to the GA-associated risk alleles evaluated.
C1 [Kolomeyer, Anton M.; Smith, Eli; Daniel, Ebenezer; Ying, Gui-Shuang; Pan, Wei; Pistilli, Max; Grunwald, Juan; Maguire, Maureen G.; Kim, Benjamin J.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Kim, BJ (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM Benjamin.Kim@uphs.upenn.edu
OI Russell, Stephen/0000-0003-3776-1367; Folk, James/0000-0002-6271-2906
FU National Eye Institute, National Institutes of Health [U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828]; Department of Health and Human
   Services; Heed Ophthalmic Foundation
FX Supported by cooperative agreements U10 EY017823, U10 EY017825, U10
   EY017826, and U10 EY017828 from the National Eye Institute, National
   Institutes of Health, and Department of Health and Human Services.
   Supported by the Heed Ophthalmic Foundation. ClinicalTrials.gov number,
   NCT00593450.
CR Banitt MR, 2009, J GLAUCOMA, V18, P412, DOI 10.1097/IJG.0b013e31818624bd
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Chang P, 2016, INVEST OPHTH VIS SCI, V57, P2277, DOI 10.1167/iovs.15-18629
   Dai Y, 2013, INVEST OPHTH VIS SCI, V54, P2013, DOI 10.1167/iovs.12-11255
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Fazio MA, 2014, BIOMECH MODEL MECHAN, V13, P551, DOI 10.1007/s10237-013-0517-9
   Garg A, 2017, INVEST OPHTH VIS SCI, V58, P2810, DOI 10.1167/iovs.16-20343
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Hayashi K, 2012, INVEST OPHTH VIS SCI, V53, P1499, DOI 10.1167/iovs.11-8572
   Healey PR, 2007, INVEST OPHTH VIS SCI, V48, P2529, DOI 10.1167/iovs.06-0714
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237
   Lee KYC, 2010, INVEST OPHTH VIS SCI, V51, P666, DOI 10.1167/iovs.09-3663
   Lim CW, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0976-y
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Manjunath V, 2011, OPHTHALMOLOGY, V118, P531, DOI 10.1016/j.ophtha.2010.07.013
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mataki N, 2018, ACTA OPHTHALMOL, V96, pE701, DOI 10.1111/aos.13702
   Rojas-Fernandez CH, 2017, ANN PHARMACOTHER, V51, P264, DOI 10.1177/1060028016680643
   Savatovsky E, 2015, OPHTHALMOLOGY, V122, P79, DOI 10.1016/j.ophtha.2014.07.033
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   See JLS, 2009, OPHTHALMOLOGY, V116, P840, DOI 10.1016/j.ophtha.2008.12.005
   Song MK, 2018, BRIT J OPHTHALMOL, V102, P1527, DOI 10.1136/bjophthalmol-2017-311152
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Uchida H, 1998, OPHTHALMOLOGY, V105, P1541, DOI 10.1016/S0161-6420(98)98044-7
   Wang Y, 2008, EYE, V22, P261, DOI 10.1038/sj.eye.6702601
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 37
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2021
VL 41
IS 1
BP 125
EP 134
DI 10.1097/IAE.0000000000002825
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PR6YJ
UT WOS:000607379100018
PM 32383840
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Heussen, FM
   Shao, Q
   Ouyang, YL
   Joussen, AM
   Muller, B
AF Heussen, Florian M.
   Shao, Qing
   Ouyang, Yanling
   Joussen, Antonia M.
   Mueller, Bert
TI Clinical outcomes after switching treatment from intravitreal
   ranibizumab to aflibercept in neovascular age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF treatment; Ranibizumab;
   Aflibercept; Tachyphylaxis
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; VEGF-TRAP; TACHYPHYLAXIS;
   MACROPHAGE; BEVACIZUMAB
AB Purpose To describe the treatment response to aflibercept in patients with exudative age-related macular degeneration that showed insufficient or diminishing treatment effects under ranibizumab.
   Methods From December 2012 till June 2013 all patients receiving intravitreal injections of aflibercept after previous treatment with ranibizumab were collected in a database and retrospectively reviewed. Clinical data such as visual acuity or central subfield retinal thickness on optical coherence tomography (OCT) scans were analyzed for the time frame before, during, and shortly after the aflibercept injections. Of particular interest was the comparison of clinical features under ongoing ranibizumab treatment to the time during aflibercept treatment.
   Results Seventy-one eyes of 65 patients were included in the study. All eyes had previous ranibizumab injections in their medical history, the average number of which was nine (range 3-43). For the total group the mean visual acuity (VA) before the first ranibizumab injection was 0.54 logMAR, and after the last ranibizumab injection was 0.57 logMAR. Mean VA changed from 0.47 logMAR before the first aflibercept injection to 0.25 logMAR after the last aflibercept injection. Central subfield retinal thickness (CSRT) on OCT changed from a mean of 417.28 mu m to 349.52 mu m under ranibizumab treatment and from 338.76 mu m to 272.00 mu m under aflibercept treatment. Interestingly, 33 % of cases that did not show a functional improvement under ranibizumab therapy gained visual acuity after aflibercept treatment.
   Conclusion Aflibercept appears to be an effective choice for patients with neovascular age-related macular degeneration who were resistant to previous therapy of ranibizumab. The longevity of this effect still remains questionable.
C1 [Heussen, Florian M.; Shao, Qing; Ouyang, Yanling; Joussen, Antonia M.; Mueller, Bert] Charite, Dept Ophthalmol, D-13353 Berlin, Germany.
   [Shao, Qing] Shanghai First Peoples Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Heussen, FM (通讯作者)，Charite, Dept Ophthalmol, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM florian.heussen@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
OI Heussen, Florian Moritz/0000-0003-0536-9870
FU Novartis; Heidelberg Engineering; Novartis Inc.; Allergan Inc.; Bayer
   Inc.
FX Dr. Florian Heussen receives research support from Novartis and
   Heidelberg Engineering. He also serves as a consultant for Allergan Inc.
   Dr. Antonia Joussen receives financial compensation for lectures from
   Novartis Inc., Allergan Inc., and Bayer Inc.
CR Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
NR 20
TC 39
Z9 40
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2014
VL 252
IS 6
BP 909
EP 915
DI 10.1007/s00417-013-2553-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK5UN
UT WOS:000338492000006
PM 24362854
DA 2022-11-30
ER

PT J
AU Kashani, AH
AF Kashani, Amir H.
TI Stem Cell Therapy in Nonneovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE nonneovascular; macular; degeneration
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; 360-DEGREES
   PERIPHERAL RETINECTOMY; MEDIATED MULTIFOCAL ELECTRORETINOGRAM;
   GEOGRAPHIC ATROPHY; VISUAL FUNCTION; AUTOLOGOUS TRANSLOCATION; FUNDUS
   AUTOFLUORESCENCE; RETINITIS-PIGMENTOSA; BRUCHS MEMBRANE
AB Age-related macular degeneration (ARMD) is the leading cause of blindness in subjects older than 50 years of age in the developed world. There are two types of ARMD, neovascular (NV) and nonneovascular (NN). While anti-VEGF-based therapies have significantly decreased the visual morbidity associated with NV-ARMD, there are no effective treatments for NN-ARMD. A detailed discussion of NV-ARMD and related therapies is the topic of another section of this special supplement. This review will focus mainly on NN-ARMD. Vision loss in nonneovascular ARMD is highly correlated with the loss of RPE cells and areas of geographic atrophy (GA). Pilot studies using subretinal transplantation of autologous or allogeneic RPE during the past 20 to 30 years have demonstrated that stem cell-derived RPE have the potential to rescue photoreceptor function and restore vision. New methods of differentiating RPE from human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC) have created a potentially unlimited supply of RPE cells to meet the demands of future commercially viable stem cell products. Thanks to fundamental advances in stem cell biology, vitreoretinal surgery, and noninvasive retinal imaging, stem cell-based therapies for NN-ARMD are emerging and several clinical trials are in progress. However, there are major regulatory, safety, and technical challenges that remain. This review will focus on summarizing the most promising aspects of stem cell-based therapy for NN-ARMD and highlighting areas that require further research.
C1 [Kashani, Amir H.] Univ So Calif, Keck Sch Med, Inst Eye, 1450 San Pablo St,Ste 4701, Los Angeles, CA 90033 USA.
C3 University of Southern California
RP Kashani, AH (通讯作者)，Univ So Calif, Keck Sch Med, Inst Eye, 1450 San Pablo St,Ste 4701, Los Angeles, CA 90033 USA.
EM ahkashan@usc.edu
FU California Institute for Regenerative Medicine (San Francisco, CA, USA);
   Research to Prevent Blindness (New York, NY, USA)
FX Supported by grants from the California Institute for Regenerative
   Medicine (San Francisco, CA, USA) and Research to Prevent Blindness (New
   York, NY, USA).
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ARAMANT RB, 1995, EXP NEUROL, V133, P244, DOI 10.1006/exnr.1995.1027
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Benner JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P586, DOI 10.1001/archopht.120.5.586
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christiansen AT, 2012, STEM CELLS INT, V2012
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Duncan JL, 2003, ADV EXP MED BIOL, V533, P165
   Durlu YK, 1997, CELL TRANSPLANT, V6, P149, DOI 10.1016/S0963-6897(96)00142-X
   Eandi CM, 2015, AM J OPHTHALMOL, V159, P652, DOI 10.1016/j.ajo.2014.12.023
   Fawzi AA, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3640813
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feng W, 2003, GRAEF ARCH CLIN EXP, V241, P232, DOI 10.1007/s00417-002-0617-1
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   Gouras P, 1989, Prog Clin Biol Res, V314, P659
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Hu QR, 2010, STEM CELLS, V28, P1981, DOI 10.1002/stem.531
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Kamao H, 2014, INVEST OPHTH VIS SCI, V55, P8309, DOI 10.1167/iovs.14-14694
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012
   Kashani AH, 2014, RETINA, V35, P149
   Kashani AH, 2014, RETINA-J RET VIT DIS, V34, P1854, DOI 10.1097/IAE.0000000000000146
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Oyagi T, 2004, RETINA-J RET VIT DIS, V24, P548, DOI 10.1097/00006982-200408000-00007
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Radtke ND, 1999, AM J OPHTHALMOL, V128, P384, DOI 10.1016/S0002-9394(99)00250-0
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Ritter M, 2013, INVEST OPHTH VIS SCI, V54, P6416, DOI 10.1167/iovs.12-11550
   Rowland TJ, 2013, J TISSUE ENG REGEN M, V7, P642, DOI 10.1002/term.1458
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Subrizi A, 2012, BIOMATERIALS, V33, P8047, DOI 10.1016/j.biomaterials.2012.07.033
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Zuber AA, 2014, J MATER SCI-MATER M, V25, P1367, DOI 10.1007/s10856-014-5163-y
NR 113
TC 14
Z9 15
U1 0
U2 19
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 5
SI SI
DI 10.1167/iovs.15-17681
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DO8NC
UT WOS:000378039300012
PM 27116669
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Nusinowitz, S
   Wang, Y
   Kim, P
   Habib, S
   Baron, R
   Conley, Y
   Gorin, M
AF Nusinowitz, S.
   Wang, Y.
   Kim, P.
   Habib, S.
   Baron, R.
   Conley, Y.
   Gorin, M.
TI Retinal Structure in Pre-Clinical Age-Related Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; AMD; OCT; retina; structure
ID MEDIATED DARK-ADAPTATION; VISUAL FUNCTION; ASSOCIATION; MACULOPATHY;
   MICROPERIMETRY; AMD
AB Purpose: To determine, if there are identifiable retinal structural changes associated with genetic risk for age-related macular degeneration (AMD).
   Materials and Methods: Seventy-three subjects (range 51.5 to 68.9 years) participated in this prospective study. Subjects were recruited based on the presence of a family history of AMD in one or both parents. All participants underwent a complete ophthalmic exam and imagery for staging of disease severity and genetic testing to assess genetic risk for AMD development. Optical coherence tomography (OCT) imaging was performed on all participants. Semi-automated retinal layer segmentation was performed to assess retinal structural changes.
   Results: Of 73 subjects, 47 subjects had normal appearing retina with no evidence of drusen or other changes consistent with AMD, 16 subjects were classified as early AMD, and 13 were designated as intermediate AMD. Retinal volume measures of total retina, outer retina, outer nuclear layer and the retinal pigment epithelium, were not related to AMD classification, genetic risk scores, or age. The thickness of the outer retina showed statistically significant thickening in the foveal region in only the intermediate AMD group and a statistically significant thickening of the RPE in early and intermediate AMD groups in the central retina.
   Conclusion: No consistent changes were observed in retinal structure at multiple locations that are associated with pre-clinical AMD, based on AMD genetic risk or with aging within the age range of our cohort.
C1 [Nusinowitz, S.; Wang, Y.; Kim, P.; Habib, S.; Gorin, M.] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Baron, R.; Conley, Y.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
   [Conley, Y.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot, Pittsburgh, PA 15261 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Nusinowitz, S (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza,3-115, Los Angeles, CA 90095 USA.
EM Nusinowitz@jsei.ucla.edu
RI wang, yiyi/GWZ-5830-2022; Wang, Charlotte Yiyi/AAA-6825-2021
OI Wang, Charlotte Yiyi/0000-0001-6896-6432; Conley,
   Yvette/0000-0002-1784-6067
FU NIH [EY09859]; Research to Prevent Blindness; Harold and Pauline Price
   Foundation; Beckman Initiative for Macular Research; NATIONAL EYE
   INSTITUTE [R01EY009859] Funding Source: NIH RePORTER
FX This work was supported by NIH EY09859, an unrestricted grant from
   Research to Prevent Blindness to the Department of Ophthalmology, the
   Harold and Pauline Price Foundation, and the Beckman Initiative for
   Macular Research.
CR Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Chen Changzheng, 2003, Yan Ke Xue Bao, V19, P15
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2014, J CLIN MED, V3, P1335, DOI 10.3390/jcm3041335
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Jackson GR, 2006, OPHTHAL PHYSL OPT, V26, P431, DOI 10.1111/j.1475-1313.2006.00390.x
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Mukhopadhyay N, 2005, BIOINFORMATICS, V21, P2556, DOI 10.1093/bioinformatics/bti364
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2016, INVEST OPHTH VIS SCI, V57, P1782, DOI 10.1167/iovs.15-18962
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Renteria Miguel E, 2013, Methods Mol Biol, V1019, P193, DOI 10.1007/978-1-62703-447-0_8
   Richer S, 2012, NUTRIENTS, V4, P1812, DOI 10.3390/nu4121812
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
NR 24
TC 8
Z9 8
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2018
VL 43
IS 3
BP 376
EP 382
DI 10.1080/02713683.2017.1401646
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FV2SX
UT WOS:000424419400015
PM 29135322
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jang, JW
   Kim, JM
   Kang, SW
   Kim, SJ
   Bae, K
   Kim, KT
AF Jang, Jun Won
   Kim, Jong Min
   Kang, Se Woong
   Kim, Sang Jin
   Bae, Kunho
   Kim, Kyung Tae
TI TYPICAL POLYPOIDAL CHOROIDAL VASCULOPATHY AND POLYPOIDAL CHOROIDAL
   NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE polypoidal choroidal vasculopathy; classification; choroidal
   neovascularization; prognosis
ID MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; CLASSIFICATION;
   ANGIOGRAPHY; SUBTYPES; DISEASE; EYES
AB Purpose: To compare typical polypoidal choroidal vasculopathy (T-PCV) and polypoidal choroidal neovascularization (P-CNV), which can be defined as two subtypes of PCV, and to elucidate the significance of the classification.
   Methods: Seventy-seven patients diagnosed with PCV and followed up for more than 12 months were reviewed. The PCV cases were divided into a T-PCV group (n = 36) and a P-CNV group (n = 41) according to the presence of features of pachychoroid or age-related macular degeneration. Angiographic and tomographic characteristics and changes in vision during the follow-up period were compared between the two groups.
   Results: Logarithm of the minimum angle of resolution visual acuity of T-PCV and P-CNV was 0.27 +/- 0.31 and 0.62 +/- 0.47 at baseline (P < 0.001) and 0.28 +/- 0.41 and 0.54 +/- 0.52 at the final visit (P = 0.006), respectively. A marginally higher rate of complete response to anti-vascular endothelial growth factor treatment was noted in the T-PCV group (47.2%) compared with the P-CNV group (26.8%) (P = 0.05). At the final visit, subfoveal fibrosis was noted in 11.1% of the T-PCV group and 39.0% of the P-CNV group (P = 0.009).
   Conclusion: The two subtypes of PCV, P-CNV and T-PCV, behave differently in terms of angiographic and tomographic manifestations and visual outcomes. Classifying PCVs would be helpful not only for pathogenic implications, but also for prognostic significance.
C1 [Jang, Jun Won; Kim, Jong Min; Kang, Se Woong; Kim, Sang Jin; Bae, Kunho; Kim, Kyung Tae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 81 Irwon Ro, Seoul 06351, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 81 Irwon Ro, Seoul 06351, South Korea.
EM swkang@skku.edu
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bartlett HM, 2001, RETINA-J RET VIT DIS, V21, P396
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Goldman DR, 2013, RETINA-J RET VIT DIS, V33, P48, DOI 10.1097/IAE.0b013e31825df12a
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jeong SY, 2017, BRIT J OPHTHALMOL, V101, P758, DOI 10.1136/bjophthalmol-2016-309144
   Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kim JH, 2015, INVEST OPHTH VIS SCI, V56, P1909, DOI 10.1167/iovs.14-16000
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147139
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mashayekhi Arman, 2013, J Ophthalmic Vis Res, V8, P264
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Peiretti Enrico, 2009, Retin Cases Brief Rep, V3, P12, DOI 10.1097/ICB.0b013e318166bd70
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Tsai DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066858
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200
NR 39
TC 6
Z9 6
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1995
EP 2003
DI 10.1097/IAE.0000000000002259
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300020
PM 30024574
DA 2022-11-30
ER

PT J
AU Nobl, M
   Reich, M
   Dacheva, I
   Siwy, J
   Mullen, W
   Schanstra, JP
   Choi, CY
   Kopitz, J
   Kretz, FTA
   Auffarth, GU
   Koch, F
   Koss, MJ
AF Nobl, Matthias
   Reich, Michael
   Dacheva, Ivanka
   Siwy, Justyna
   Mullen, William
   Schanstra, Joost P.
   Choi, Chul Young
   Kopitz, Jurgen
   Kretz, Florian T. A.
   Auffarth, Gerd U.
   Koch, Frank
   Koss, Michael J.
TI Proteomics of vitreous in neovascular age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Neovascular age-related macular degeneration; Vitreous humor;
   Proteomics; Biomarker; Clusterin; Opticin; Pigment epithelium-derived
   factor; Prostaglandin-H2 D-isomerase
ID EPITHELIUM-DERIVED FACTOR; MASS-SPECTROMETRY; AQUEOUS-HUMOR; BIOMARKER
   DISCOVERY; BLADDER-CANCER; HUMAN EYE; PROTEINS; ANGIOGENESIS; OPTICIN;
   LOCALIZATION
AB Neovascular age-related macular degeneration (nAMD) has been described as a predominantly inflammatory and proangiogenic retino-choroidal disease. Vitreous humor (VH) is the adjacent and accessible compartment which, due to the vicinity to the retina, might best represent changes of protein-based mediators of nAMD. The aim of this clinical-experimental study was to analyze the nAMD associated VH proteome of previously untreated patients whilst taking different groups of nAMD into account, based on their clinical presentation (clinical diagnosis groups). Electrophoresis coupled online to mass spectrometry (CE-MS) as well as liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were used to analyze VH of 108 nAMD patients and 24 controls with idiopathic floaters. A total of 101 different proteins with at least two unique peptides could be identified. Using a stringent statistical analysis with implementation of the closed test principle, we were able to identify four proteins that may be involved in the pathophysiology of nAMD: Clusterin, opticin, pigment epithelium-derived factor and prostaglandin-H2 D-isomerase. Using independent samples, ROC-Area under the curve was determined proving the validity of the results: Clusterin 0.747, opticin 0.656, pigment epithelium-derived factor 0.514, prostaglandin-H2 D-isomerase 0.712. In addition, validation through ELISA measurements was performed. The identified proteins may serve as potential biomarkers or even targets of therapy for nAMD. (c) 2016 Elsevier Ltd. All rights reserved.
C1 [Nobl, Matthias; Reich, Michael; Dacheva, Ivanka; Kretz, Florian T. A.; Auffarth, Gerd U.; Koss, Michael J.] Heidelberg Univ, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
   [Reich, Michael] Univ Freiburg, Dept Ophthalmol, Freiburg, Germany.
   [Siwy, Justyna] Mosa Diagnost GmbH, Hannover, Germany.
   [Mullen, William] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
   [Schanstra, Joost P.] INSERM, Inst Cardiovasc & Metab Dis, U1048, Toulouse, France.
   [Schanstra, Joost P.] Univ Toulouse III Paul Sabatier, Toulouse, France.
   [Choi, Chul Young] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Choi, Chul Young; Auffarth, Gerd U.; Koss, Michael J.] David J Apple Int Lab Ocular Pathol, Heidelberg, Germany.
   [Choi, Chul Young; Auffarth, Gerd U.; Koss, Michael J.] IVCRC, Heidelberg, Germany.
   [Kopitz, Jurgen] Heidelberg Univ, Dept Pathol, Bergheimer Str 58, D-69115 Heidelberg, Germany.
   [Koch, Frank] Goethe Univ, Dept Ophthalmol, Frankfurt, Germany.
   [Koss, Michael J.] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90089 USA.
C3 Ruprecht Karls University Heidelberg; University of Freiburg; Modular
   Open Systems Approach (MOSA) Solutions; University of Glasgow; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Toulouse; Universite Toulouse III - Paul Sabatier; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Ruprecht Karls University
   Heidelberg; Goethe University Frankfurt; University of Southern
   California
RP Koss, MJ (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM Michael.koss@med.uni-heidelberg.de
RI Schanstra, Joost P/X-7724-2018; Auffarth, Gerd/AAE-6805-2021; Mullen,
   William/GWC-8078-2022
OI Schanstra, Joost P/0000-0002-7471-372X; Siwy,
   Justyna/0000-0003-1407-2534; Kretz, Florian/0000-0002-8771-2187; Nobl,
   Matthias/0000-0001-8772-3583; Auffarth, Gerd/0000-0002-6927-5251; Reich,
   Michael/0000-0002-9813-8483
FU Adolf Messer Stiftung, Konigstein, Hessen (Germany); Klaus Tschira
   Stiftung, Heidelberg, Baden Wurttemberg (Germany); PRO RETINA-Stiftung
   zur Verhutung von Blindheit; Dr. Gabriele Lederle-Stiftung;
   Studienstiftung des deutschen Volkes
FX The research group was supported by the Adolf Messer Stiftung,
   Konigstein, Hessen and the Klaus Tschira Stiftung, Heidelberg, Baden
   Wurttemberg (both Germany). Matthias Nobl is a recipient of scholarships
   from the PRO RETINA-Stiftung zur Verhutung von Blindheit and the Dr.
   Gabriele Lederle-Stiftung. Michael Reich is a recipient of scholarships
   from the Studienstiftung des deutschen Volkes and the Dr. Gabriele
   Lederle-Stiftung. The funding organizations had no role in the design or
   conduct of the research.
CR BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Beuckmann CT, 1996, J NEUROSCI, V16, P6119
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ecker SM, 2012, MOL VIS, V18, P1658
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P816, DOI 10.1097/OPX.0000000000000337
   Friedman JS, 2002, HUM MOL GENET, V11, P1333, DOI 10.1093/hmg/11.11.1333
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Ischia J, 2013, NAT REV UROL, V10, P386, DOI 10.1038/nrurol.2013.108
   Jackson John K., 2005, Angiogenesis, V8, P229, DOI 10.1007/s10456-005-9018-5
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kim SJ, 2006, CURR EYE RES, V31, P231, DOI 10.1080/02713680600557030
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Koch FH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1599, DOI 10.1001/archophthalmol.2011.341
   Koss MJ, 2010, OPHTHALMOLOGICA, V224, P72, DOI 10.1159/000235724
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Latosinska A, 2013, PROTEOM CLIN APPL, V7, P779, DOI 10.1002/prca.201300038
   Le Goff MM, 2012, INVEST OPHTH VIS SCI, V53, P228, DOI 10.1167/iovs.11-8514
   Mathurin K, 2011, J BIOL CHEM, V286, P2696, DOI 10.1074/jbc.M110.178277
   McDonald JF, 1997, BIOCHEMISTRY-US, V36, P7464, DOI 10.1021/bi962895r
   Mckay RR, 2013, DRUGS, V73, P1417, DOI 10.1007/s40265-013-0107-2
   Metzger J, 2013, GUT, V62, P122, DOI 10.1136/gutjnl-2012-302047
   Mischak H, 2013, CLIN BIOCHEM, V46, P432, DOI 10.1016/j.clinbiochem.2012.09.025
   Neuhoff NV, 2004, RAPID COMMUN MASS SP, V18, P149, DOI 10.1002/rcm.1294
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto H, 2010, EXP ANIM TOKYO, V59, P171, DOI 10.1538/expanim.59.171
   Park S, 2014, REV ENDOCR METAB DIS, V15, P45, DOI 10.1007/s11154-013-9275-3
   Ramesh S, 2004, BRIT J OPHTHALMOL, V88, P697, DOI 10.1136/bjo.2003.031989
   Shen YF, 2005, PROTEOMICS, V5, P4034, DOI 10.1002/pmic.200401246
   Sonnemann E., 2008, EDV MED BIOL, V13, P641
   Stalmach A, 2015, METHODS MOL BIOL, V1243, P187, DOI 10.1007/978-1-4939-1872-0_11
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78
   Theodorescu D, 2006, LANCET ONCOL, V7, P230, DOI 10.1016/S1470-2045(06)70584-8
   Tombran-Tink J, 2003, TRENDS MOL MED, V9, P244, DOI 10.1016/S1471-4914(03)00074-1
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Yorulmaz S., 2015, BIOMACROMOLECULES
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhang P., 2014, PROTEOMICS
   Zhou YY, 2010, FASEB J, V24, P4668, DOI 10.1096/fj.10-164863
   Zurbig P, 2006, ELECTROPHORESIS, V27, P2111, DOI 10.1002/elps.200500827
NR 53
TC 27
Z9 30
U1 0
U2 13
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2016
VL 146
BP 107
EP 117
DI 10.1016/j.exer.2016.01.001
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM4QS
UT WOS:000376332400014
PM 26769219
DA 2022-11-30
ER

PT J
AU Li, X
   Li, HY
   Cheng, JD
   Wang, MT
   Zhong, YM
   Shi, GL
   Yu, AY
AF Li, Xi
   Li, Hanyu
   Cheng, Jingdan
   Wang, Mengting
   Zhong, Yiming
   Shi, Guilian
   Yu, A-Yong
TI Causal Associations of Thyroid Function and Age-Related Macular
   Degeneration: A Two-Sample Mendelian Randomization Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLOBAL PREVALENCE; INSTRUMENTS; DISEASE; POWER; RISK; BIAS
AB PURPOSE: To determine whether causal association lies between thyroid function and age-related macular degeneration (AMD) risk in human beings. DESIGN: Two-sample Mendelian randomization (MR) study. METHODS: The single-nucleotide polymorphisms associated with free thyroxine (FT4) and thyroid-stimulating hormone (TSH) were selected from a genome-wide association study (GWAS) of 72,167 individuals of European descent. Summary-level data for AMD were obtained from a GWAS published by the International Age-related Macular Degeneration Genomics Consortium of 33,526 individuals (16,144 cases and 17,832 controls). An inverse-variance -weighted (IVW) method was the main MR analysis. Maximum likelihood, weighted median, MR-Egger, MR-pleiotropy residual sum outlier methods were used for the sensitivity analysis. RESULTS: An increase of 1 SD in genetically predicted FT4 levels was found to be significantly associated with an 18.9 % increase in the overall AMD risk ( P = .005). In the multivariable MR analysis controlling for TSH level, the causal effect of FT4 level on the risk of AMD remained (odds ratio [OR] = 1.207, P = .004). A 1-SD increase in TSH levels was nominally associated with a 10.0% decrease in the overall AMD risk ( P = .032). After adjusting for FT4 level by multivariable MR analysis, no direct causal relationship was found between TSH level and AMD risk (95% CI = 0.810, 1.125, P = .582). CONCLUSIONS: Genetic variants predisposing to higher FT4 levels within the normal range were associated with higher AMD risk. Further studies are required to understand the mechanism underlying this putative causal relationship. ((C) 2022 Elsevier Inc. All rights reserved.)
C1 [Li, Xi; Wang, Mengting; Zhong, Yiming; Shi, Guilian; Yu, A-Yong] Wenzhou Med Univ, Eye Hosp, Wenzhou, Zhejiang, Peoples R China.
   [Li, Xi; Wang, Mengting; Zhong, Yiming; Shi, Guilian; Yu, A-Yong] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Wenzhou, Zhejiang, Peoples R China.
   [Li, Xi; Wang, Mengting; Zhong, Yiming; Shi, Guilian; Yu, A-Yong] Natl Clin Res Ctr Ocular Dis, Wenzhou, Zhejiang, Peoples R China.
   [Li, Hanyu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Ggeriatr Mmed, Hangzhou, Zhejiang, Peoples R China.
   [Cheng, Jingdan] Shanxi Cardiovasc Hosp, Dept Neurol, Taiyuan 030000, Shanxi, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Zhejiang
   University
RP Yu, AY (通讯作者)，Wenzhou Med Univ, Eye Hosp, Wenzhou, Zhejiang, Peoples R China.
EM yaybetter@hotmail.com
OI Yu, A-Yong/0000-0001-6787-4018
FU National Natural Science Foundation of China [80215088]; Zhejiang
   Provincial Medical and health Science and Technology Project [2020RC057]
FX Funding/Support: This work was supported by grants from the National
   Natural Science Foundation of China (80215088) and Zhejiang Provincial
   Medical and health Science and Technology Project (2020RC057) . The
   sponsor or funding organization had no role in the design or conduct of
   this research.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bowden J, 2019, INT J EPIDEMIOL, V48, P728, DOI 10.1093/ije/dyy258
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2017, EUR J EPIDEMIOL, V32, P377, DOI 10.1007/s10654-017-0255-x
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Burgess S, 2011, INT J EPIDEMIOL, V40, P755, DOI 10.1093/ije/dyr036
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328
   Eldred KC, 2018, SCIENCE, V362, P200, DOI 10.1126/science.aau6348
   Ellervik C, 2020, THYROID, V30, P365, DOI 10.1089/thy.2019.0167
   Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Jones SR, 2003, EMERG MED J, V20, P453, DOI 10.1136/emj.20.5.453
   Kjaergaard AD, 2021, EUR J EPIDEMIOL, V36, P335, DOI 10.1007/s10654-021-00721-z
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Kus A, 2021, THYROID, V31, P1171, DOI 10.1089/thy.2020.0884
   Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034
   Levine M, 2001, PHARMACOTHERAPY, V21, P405, DOI 10.1592/phco.21.5.405.34503
   Ma HW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2216-7
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   Roberts JD, 2019, JAMA CARDIOL, V4, P97, DOI 10.1001/jamacardio.2018.4614
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Teumer A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06356-1
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 36
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2022
VL 239
BP 108
EP 114
DI 10.1016/j.ajo.2022.01.026
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V7CL
UT WOS:000806243000011
PM 35176254
DA 2022-11-30
ER

PT J
AU Lindner, M
   Boker, A
   Mauschitz, MM
   Gobel, AP
   Fimmers, R
   Brinkmann, CK
   Schmitz-Valckenberg, S
   Schmid, M
   Holz, FG
   Fleckenstein, M
AF Lindner, Moritz
   Boeker, Alexander
   Mauschitz, Matthias M.
   Goebel, Arno P.
   Fimmers, Rolf
   Brinkmann, Christian K.
   Schmitz-Valckenberg, Steffen
   Schmid, Matthias
   Holz, Frank G.
   Fleckenstein, Monika
CA Fundus Autofluorescence Age-Relate
TI Directional Kinetics of Geographic Atrophy Progression in Age-Related
   Macular Degeneration with Foveal Sparing
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; SCANNING LASER
   OPHTHALMOSCOPE; BEAVER DAM EYE; FUNDUS AUTOFLUORESCENCE; DISEASE
   PROGRESSION; VISUAL IMPAIRMENT; NATURAL-HISTORY; MACULOPATHY;
   ENLARGEMENT
AB Purpose: To describe the directional kinetics of the spread of geographic atrophy (GA) spread in eyes with age-related macular degeneration and foveal sparing.
   Design: Prospective, noninterventional natural history study: Fundus Autofluorescence Imaging in Age-Related Macular Degeneration (FAM; clinicaltrials. gov identifier, NCT00393692).
   Subjects: Participants of the FAM study exhibiting foveal sparing of GA.
   Methods: Eyes were examined longitudinally with fundus autofluorescence (FAF; excitation wavelength, 488 nm; emission wavelength, >500 nm) and near infrared (NIR) reflectance imaging (Spectralis HRA_OCT or HRA2; Heidelberg Engineering, Heidelberg, Germany). Areas of foveal sparing and GA were measured by 2 independent readers using a semiautomated software tool that allows for combined NIR reflectance and FAF image grading (RegionFinder; Heidelberg Engineering). A linear mixed effect model was used to model GA kinetics over time.
   Main Outcome Measure: Change of GA lesion size over time (central vs. peripheral progression).
   Results: Atotal of 47 eyes of 36 patients (mean age, 73.8 +/- 7.5 years) met the inclusion criteria. Mean follow-up time was 25.2 +/- 16.9 months (range, 5.9-74.6 months). Interreader agreement for measurements of GA and foveal-sparing size were 0.995 and 0.946, respectively. Mean area progression of GA toward the periphery was 2.27 +/- 0.22 mm(2)/year and 0.25 +/- 0.03mm(2)/year toward the center. Analysis of square rootetransformeddata revealeda 2.8-fold faster atrophy progression toward the periphery than toward the fovea. Faster atrophy progression toward the fovea correlated with faster progression toward the periphery in presence of marked interindividual differences.
   Conclusions: The results demonstrate a significantly faster centrifugal than centripetal GA spread in eyes with GA and foveal sparing. Although the underlying pathomechanisms for differential GA progression remain unknown, local factors may be operative that protect the foveal retinaeretinal pigment epithelial complex. Quantification of directional spread characteristics and modeling may be useful in the design of interventional clinical trials aiming to prolong foveal survival in eyes with GA. (C) 2015 by the American Academy of Ophthalmology.
C1 [Lindner, Moritz; Boeker, Alexander; Mauschitz, Matthias M.; Goebel, Arno P.; Brinkmann, Christian K.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Fimmers, Rolf; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukb.uni-bonn.de
RI Lindner, Moritz/AAC-8639-2021; Mitchell, Paul/P-1498-2014
OI Lindner, Moritz/0000-0002-4416-3421; Fleckenstein,
   Monika/0000-0001-8321-8037; Schmid, Matthias/0000-0002-0788-0317
FU Genentech, Inc (San Francisco, CA); Genentech, Inc; Novartis; Bayer
   Healthcare (Leverkusen, Germany); Acucela (Seattle, Washington); Alcon
   (Huenenberg, Switzerland); Allergan (Parsippany, NJ); Optos; Heidelberg
   Engineering; Bayer Healthcare; Acucela; Alcon; Allergan; Boehringer
   Ingelheim (Ingelheim, Germany); Bayer; Formycon (Martinsried, Germany);
   Roche (Basel, Switzerland); Alimera; German Research Foundation (DFG,
   Bonn, Germany) [Ho1926/3-1, FL 658/4-1]
FX The author(s) have made the following disclosure(s): M.L.: Financial
   support - Genentech, Inc (San Francisco, CA; Grant provided during
   conduct of this study); Nonfinancial support - Heidelberg Engineering
   (Heidelberg, Germany); Carl Zeiss Meditec (Jena, Germany); Optos
   (Dunfermline, Scotland, UK); Alimera Sciences (Alpharetta, GA; Financed
   meeting participation); Novartis (Basel, Switzerland; Financed meeting
   participation).; A.B.: Financial support - Genentech, Inc (Grant
   provided during conduct of this study); Nonfinancial support -
   Heidelberg Engineering; Carl Zeiss Meditec; Optos.; S.S.-V.: Financial
   support - Genentech, Inc (Grant provided during conduct of this study);
   Novartis (Grants and personal fees outside this study); Bayer Healthcare
   (Leverkusen, Germany; Grants and personal fees outside this study);
   Acucela (Seattle, Washington; Grants outside this study); Alcon
   (Huenenberg, Switzerland; Grants outside this study); Allergan
   (Parsippany, NJ; Grants outside this study); Optos (Grants and personal
   fees outside this study); Heidelberg Engineering (Grants and personal
   fees outside this study).; F.G.H.: Financial support - Genentech, Inc
   (Grant provided during conduct of this study); Novartis (Grants and
   personal fees outside this study); Bayer Healthcare (Grants and personal
   fees outside this study); Acucela (Grants and personal fees outside this
   study); Alcon (Grants and personal fees outside this study); Allergan
   (Grants and personal fees outside this study); Optos (Grants and
   personal fees outside this study); Boehringer Ingelheim (Ingelheim,
   Germany; Personal fees outside this study); Heidelberg Engineering
   (Grants and personal fees outside this study).; M.F.: Financial support
   - Novartis (Grants or personal fees outside this study); Allergan
   (Grants or personal fees outside this study); Bayer (Grants or personal
   fees outside this study); Formycon (Martinsried, Germany; Grants or
   personal fees outside this study); Genentech, Inc (Grant provided during
   conduct of this study); Heidelberg Engineering (Grants or personal fees
   outside this study); Optos (Grants or personal fees outside this study);
   Roche (Basel, Switzerland; Grants or personal fees outside this study);
   Alimera (Grants or personal fees outside this study); Nonfinancial
   support-Carl Zeiss Meditec; Patent - US20140303013 A1 pending.;
   Supported in part by the German Research Foundation (DFG, Bonn, Germany;
   grant nos.: Ho1926/3-1 and FL 658/4-1); and Genentech, Inc. The sponsor
   or funding organization had no role in the design or conduct of this
   research.
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHUANG EL, 1987, EYE, V1, P120, DOI 10.1038/eye.1987.18
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Danis R, 2013, ARVO M, V54, P6311
   de Laat P, 2013, OPHTHALMOLOGY, V120, P2684, DOI 10.1016/j.ophtha.2013.05.013
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Holz FG, 2010, ARVO M, V51, P94
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7467, DOI 10.1167/iovs.13-13825
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 59
TC 78
Z9 79
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2015
VL 122
IS 7
BP 1356
EP 1365
DI 10.1016/j.ophtha.2015.03.027
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL0HI
UT WOS:000356621700018
PM 25972258
DA 2022-11-30
ER

PT J
AU Forooghian, F
   Cukras, C
   Meyerle, CB
   Chew, EY
   Wong, WT
AF Forooghian, Farzin
   Cukras, Catherine
   Meyerle, Catherine B.
   Chew, Emily Y.
   Wong, Wai T.
TI TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED
   MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-angiogenic treatment;
   bevacizumab; intravitreal injection; neovascularization; optical
   coherence tomography; tachyphylaxis; vascular endothelial growth factor
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   PHOTODYNAMIC THERAPY; INFLAMMATION; RANIBIZUMAB; MACROPHAGE; ANTIBODIES;
   EXPRESSION; AVASTIN; DISEASE
AB Purpose: To describe tachyphylaxis to intravitreal bevacizumab (IVB) in patients with exudative age-related macular degeneration (AMD).
   Methods: We retrospectively reviewed the records of 59 consecutive patients treated with IVB at the National Eye Institute over a 14-month period and identified cases demonstrating loss of treatment efficacy as revealed by spectral domain optical coherence tomography. We defined tachyphylaxis as a loss of therapeutic response to IVB 28 7 days after administration in an eye that had previously demonstrated a therapeutic response in the same time interval.
   Results: Five patients (six eyes) were identified as developing tachyphylaxis after repeated treatment with IVB. High-dose IVB (2.50 mg) did not restore therapeutic response in these patients. Bilateral tachyphylaxis to IVB was seen after an episode of unilateral postinjection anterior uveitis. After the first treatment of IVB, the median time taken to develop tachyphylaxis was 100 weeks (range: 31-128 weeks), and the median number of IVB treatments to the development of tachyphylaxis was 8 treatments (range: 5-10 treatments).
   Conclusion: Tachyphylaxis can occur after long-term intravitreal use of bevacizumab in patients with AMD. The precise mechanism of tachyphylaxis is unclear, but both local and/or systemic factors may be involved. RETINA 29:723-731, 2009
C1 [Wong, Wai T.] NEI, Off Sci Director, NIH, Bethesda, MD 20892 USA.
   [Forooghian, Farzin; Cukras, Catherine; Meyerle, Catherine B.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Off Sci Director, NIH, 7 Mem Dr,Bldg 7,Room 217, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
FU National Eye Institute Intramural Research Program; NATIONAL EYE
   INSTITUTE [ZIAEY000497, ZIEEY000487, ZIAEY000494] Funding Source: NIH
   RePORTER
FX Supported by the National Eye Institute Intramural Research Program.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Calabresi PA, 2007, NEUROLOGY, V69, P1391, DOI 10.1212/01.wnl.0000277457.17420.b5
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fox EJ, 2007, NEUROLOGIST, V13, P355, DOI 10.1097/NRL.0b013e318148c08e
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Svenson M, 2007, RHEUMATOLOGY, V46, P1828, DOI 10.1093/rheumatology/kem261
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
NR 18
TC 137
Z9 141
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2009
VL 29
IS 6
BP 723
EP 731
DI 10.1097/IAE.0b013e3181a2c1c3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 464HS
UT WOS:000267496600001
PM 19516114
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Roufail, E
   Polkinghorne, PJ
AF Roufail, Edward
   Polkinghorne, Philip J.
TI Combined cataract surgery and vitrectomy for vitreous haemorrhage
   secondary to age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cataract; vitreous haemorrhage
AB Purpose: To report on the functional outcome of surgery on patients with concurrent cataract and breakthrough vitreous haemorrhage from age-related macular degeneration (ARMD).
   Methods: Retrospective case series.
   Results: Five eyes were included in the study. The post operative follow-up interval ranged from 9 to 12 months. Preoperative visual acuity ranged from hand motion to perception of light. Two surgeries were complicated by iatrogenic breaks, and a further surgery was required to re-attach the retina in one of these eyes. Only one of the five eyes experienced an improvement in visual functioning.
   Conclusion: In this series, the outcome of surgery for combined cataract and breakthrough vitreous haemorrhage, secondary to ARMD was poor. The functional outcome of surgery for combined cataract and vitreous haemorrhage secondary to ARMD in this series was poor.
C1 [Roufail, Edward; Polkinghorne, Philip J.] Univ Auckland, Dept Ophthalmol, Fac Med & Hlth Sci, Auckland 1, New Zealand.
C3 University of Auckland
RP Polkinghorne, PJ (通讯作者)，Univ Auckland, Dept Ophthalmol, Fac Med & Hlth Sci, Pvt Bag 92019, Auckland 1, New Zealand.
EM philip@pjpolk.co.nz
CR Bindewald A, 2004, OPHTHALMOLOGE, V101, P886, DOI 10.1007/s00347-004-1077-2
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Chaudhry NA, 2002, OPHTHALMIC SURG LAS, V33, P16
   Chong NHV, 1998, BRIT J OPHTHALMOL, V82, P1441, DOI 10.1136/bjo.82.12.1441
   DECLERCQ SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1051, DOI 10.1001/archopht.1977.04450060138014
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   GOOGE JM, 1987, SURV OPHTHALMOL, V32, P123, DOI 10.1016/0039-6257(87)90104-4
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KREIGER AE, 1983, RETINA-J RET VIT DIS, V3, P318, DOI 10.1097/00006982-198300340-00017
   ORTH DH, 1982, RETINA-J RET VIT DIS, V2, P89, DOI 10.1097/00006982-198200220-00006
   TANI PM, 1980, AM J OPHTHALMOL, V90, P525, DOI 10.1016/S0002-9394(14)75023-8
   Tilanus MAD, 2000, GRAEF ARCH CLIN EXP, V238, P482, DOI 10.1007/PL00007887
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P186, DOI 10.1136/bjo.2003.019273
NR 18
TC 7
Z9 8
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2008
VL 36
IS 1
BP 36
EP 38
DI 10.1111/j.1442-9071.2007.01651.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263YD
UT WOS:000253251500010
PM 18290952
DA 2022-11-30
ER

PT J
AU Li, XH
   He, SK
   Zhao, MW
AF Li, Xiaohua
   He, Shikun
   Zhao, Mingwei
TI An Updated Review of the Epigenetic Mechanism Underlying the
   Pathogenesis of Age-related Macular Degeneration
SO AGING AND DISEASE
LA English
DT Review
DE age-related macular degeneration; epigenetics; single nucleotide
   polymorphisms
ID HISTONE DEACETYLASE INHIBITORS; POLYPOIDAL CHOROIDAL VASCULOPATHY; DNA
   METHYLATION; POTENTIAL BIOMARKERS; INDUCED EXPRESSION; GENETIC-VARIANTS;
   SIRT1; RESVERATROL; HYPOXIA; TRANSCRIPTION
AB Epigenetics has been recognized to play an important role in physiological and pathological processes of the human body. Accumulating evidence has indicated that epigenetic mechanisms contribute to the pathogenesis of age-related macular degeneration (AMD). Although the susceptibility related to genetic variants has been revealed by genome-wide association studies, those genetic variants may predict AMD risk only in certain human populations. Other mechanisms, particularly those involving epigenetic factors, may play an important role in the pathogenesis of AMD. Therefore, we briefly summarize the most recent reports related to such epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNA, and the interplay of genetic and epigenetic factors in the pathogenesis of AMD.
C1 [Li, Xiaohua; He, Shikun] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China.
   [Li, Xiaohua; He, Shikun] Henan Eye Hosp, Henan Eye Inst, Henan Key Lab Ophthalmol & Visual Sci, Zhengzhou, Peoples R China.
   [Li, Xiaohua; He, Shikun] Zhengzhou Univ, Peoples Hosp, Zhengzhou, Peoples R China.
   [Li, Xiaohua; He, Shikun] Henan Univ, Peoples Hosp, Zhengzhou, Peoples R China.
   [He, Shikun] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90007 USA.
   [He, Shikun] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90007 USA.
   [He, Shikun; Zhao, Mingwei] Peking Univ Peoples Hosp, Ophthalmol Optometry Ctr, Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; Henan University; University
   of Southern California; University of Southern California
RP He, SK (通讯作者)，Henan Prov Peoples Hosp, Zhengzhou, Peoples R China.; Zhao, MW (通讯作者)，Peking Univ Peoples Hosp, Beijing, Peoples R China.
EM shikunhe@tned.usc.edu; dr_zhaomingwei@163.com
FU National Nature Science Foundation of China [81873681, 81770952]; Nature
   Science Foundation of Henan Province [162300410296]; "23456" project of
   Henan Provincial People's Hospital
FX This study was supported by grants from the National Nature Science
   Foundation of China (81873681, 81770952), the Nature Science Foundation
   of Henan Province (162300410296) and the "23456" project of Henan
   Provincial People's Hospital.
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Atilano SR, 2015, HUM MOL GENET, V24, P4491, DOI 10.1093/hmg/ddv173
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4
   Bode KA, 2007, IMMUNOLOGY, V122, P596, DOI 10.1111/j.1365-2567.2007.02678.x
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Chan N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120587
   Chang CJ, 2019, CHIN LIT CULT WORLD, P35, DOI 10.1007/978-3-030-18634-0_2
   Chen XY, 2017, MICROMACHINES-BASEL, V8, DOI 10.3390/mi8030064
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066
   Clyde D, 2019, NAT REV GENET, V20, P254, DOI 10.1038/s41576-019-0115-5
   Crosson CE, 2010, INVEST OPHTH VIS SCI, V51, P3639, DOI 10.1167/iovs.09-4538
   Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108
   Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956
   Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835
   Feinberg AP, 2010, NAT BIOTECHNOL, V28, P1049, DOI 10.1038/nbt1010-1049
   Fisher VA, 2018, BMC GENET, V19, DOI 10.1186/s12863-018-0635-6
   Fox CR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050431
   Frank-Bertoncelj M, 2017, EPIGENOMICS-UK, V9, P493, DOI 10.2217/epi-2016-0142
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gnana-Prakasam JP, 2013, INVEST OPHTH VIS SCI, V54, P63, DOI 10.1167/iovs.12-10312
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guo HY, 2016, NAT GENET, V48, P1142, DOI 10.1038/ng.3637
   Hajjari M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00113
   He S, 2015, INVEST OPHTH VIS SCI, V56, P5579, DOI 10.1167/iovs.14-16258
   Hrgovic I, 2017, EXP DERMATOL, V26, P194, DOI 10.1111/exd.13159
   Hsing CH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/163140
   Huang HL, 2019, NATURE, V567, P414, DOI 10.1038/s41586-019-1016-7
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Ishida T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183775
   Ji YY, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-140
   Jones PA, 2019, NAT REV CANCER, V19, P151, DOI 10.1038/s41568-019-0109-9
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Koks G, 2015, AM J PATHOL, V185, P2898, DOI 10.1016/j.ajpath.2015.07.006
   Kwa FAA, 2014, DRUG DISCOV TODAY, V19, P1387, DOI 10.1016/j.drudis.2014.03.026
   Lasser C, 2012, EXPERT OPIN BIOL TH, V12, pS189, DOI 10.1517/14712598.2012.680018
   Lee SM, 2016, EPIGENOMICS-UK, V8, P993, DOI 10.2217/epi-2016-0027
   Li LG, 2015, MOL MED REP, V12, P2231, DOI 10.3892/mmr.2015.3570
   Li YA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13316
   Liang XY, 2014, EYE, V28, P1502, DOI 10.1038/eye.2014.226
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Lim DA, 2014, TRENDS NEUROSCI, V37, P563, DOI 10.1016/j.tins.2014.08.006
   Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Maloney SC, 2013, RETINA-J RET VIT DIS, V33, P862, DOI 10.1097/IAE.0b013e31826af556
   Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118
   Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Millen AE, 2015, JAMA OPHTHALMOL, V133, P1171, DOI 10.1001/jamaophthalmol.2015.2715
   Min KW, 2018, AGING CELL, V17, DOI 10.1111/acel.12753
   Miyake M, 2015, INVEST OPHTH VIS SCI, V56, P5353, DOI 10.1167/iovs.14-16020
   Moufarrij S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0602-0
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nakamura K, 2017, J HEPATOL, V67, P1232, DOI 10.1016/j.jhep.2017.08.010
   Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078-0432.CCR-06-2903
   Nishida N, 2011, CURR GENOMICS, V12, P130, DOI 10.2174/138920211795564359
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Patnaik S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00588
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Ponnaluri VKC, 2011, BIOCHEM BIOPH RES CO, V415, P373, DOI 10.1016/j.bbrc.2011.10.075
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Poulose N, 2015, BBA-MOL BASIS DIS, V1852, P2442, DOI 10.1016/j.bbadis.2015.08.017
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   SanGiovanni JP, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017228
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seo JS, 2012, NEUROBIOL AGING, V33, P1110, DOI 10.1016/j.neurobiolaging.2010.09.019
   Shen F, 2015, J CLIN ENDOCR METAB, V100, pE148, DOI 10.1210/jc.2014-1893
   Sivagurunathan S., 2018, BIORXIV
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tai DJC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10552
   Tan L, 2008, MED HYPOTHESES, V71, P664, DOI 10.1016/j.mehy.2008.06.031
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   To M, 2012, CHEST, V141, P1233, DOI 10.1378/chest.11-1536
   Tucci P, 2012, AGING-US, V4, P525, DOI 10.18632/aging.100481
   Turner RS, 2015, NEUROLOGY, V85, P1383, DOI 10.1212/WNL.0000000000002035
   Uchida H, 2005, EXP EYE RES, V80, P23, DOI 10.1016/j.exer.2004.08.004
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Ventham NT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13507
   Vladan Bajic, 2013, Med Hypothesis Discov Innov Ophthalmol, V2, P74
   Vu LP, 2019, CANCER DISCOV, V9, P25, DOI 10.1158/2159-8290.CD-18-0959
   Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Wang Y, 2015, ANAL CHIM ACTA, V891, P32, DOI 10.1016/j.aca.2015.06.049
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   WeiW Zhang Y, 2014, MATH PROBL ENG, V2014, P1, DOI DOI 10.1155/2014/750634
   Xing YY, 2015, ONCOL REP, V33, P163, DOI 10.3892/or.2014.3592
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8
   Yasuma TR, 2010, MOL VIS, V16, P2923
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Yong RL, 2015, SEMIN PEDIATR NEUROL, V22, P14, DOI 10.1016/j.spen.2014.12.004
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
   Zhang HM, 2015, CYTOKINE, V76, P549, DOI 10.1016/j.cyto.2015.06.019
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
   Zhang XZ, 2013, EXP EYE RES, V108, P16, DOI 10.1016/j.exer.2012.12.005
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 120
TC 6
Z9 7
U1 1
U2 5
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD OCT
PY 2020
VL 11
IS 5
BP 1219
EP 1234
DI 10.14336/AD.2019.1126
PG 16
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA NV6KQ
UT WOS:000574428300016
PM 33014534
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gibbs, D
   Yang, ZL
   Constantine, R
   Ma, X
   Camp, NJ
   Yang, X
   Chen, HY
   Jorgenson, A
   Hau, V
   Dewan, A
   Zeng, JX
   Harmon, J
   Buehler, J
   Brand, JM
   Hoh, J
   Cameron, DJ
   Dixit, M
   Tong, ZZ
   Zhang, K
AF Gibbs, Daniel
   Yang, Zhenglin
   Constantine, Ryan
   Ma, Xiang
   Camp, Nicola J.
   Yang, Xian
   Chen, Hayou
   Jorgenson, Adam
   Hau, Vincent
   DeWan, Andrew
   Zeng, Jiexi
   Harmon, Jennifer
   Buehler, Jeanette
   Brand, John M.
   Hoh, Josephine
   Cameron, D. Joshua
   Dixit, Manjusha
   Tong, Zongzhong
   Zhang, Kang
TI Further mapping of 10q26 supports strong association of HTRA1
   polymorphisms with age-related macular degeneration
SO VISION RESEARCH
LA English
DT Article
DE age-related macular degeneration; HTRA1; genetics; single nucleotide
   polymorphisms
ID COMPLEMENT FACTOR-H; PROMOTER POLYMORPHISM; VARIANT; SUSCEPTIBILITY;
   RISK; GENE; CFH; MACULOPATHY; POPULATION; LOC387715
AB Age-related macular degeneration (AMD) is a complex disorder with genetic and environmental influences. The genetic influences affecting AMD are not well understood and few genes have been consistently implicated and replicated for this disease. A polymorphism (rs11200638) in a transcription factor binding site of the HTRA1 gene has been described, in previous reports, as being most significantly associated with AMD. In this paper, we investigate haplotype association and individual polymorphic association by genotyping additional variants in the AMD risk-associated region of chromosome 10q26. We demonstrate that rs11200638 in the promoter region and rs2293870 in exon 1 of HTRA1, are among the most significantly associated variants for advanced forms of AMD. (C) 2008 Published by Elsevier Ltd.
C1 [Gibbs, Daniel; Yang, Zhenglin; Constantine, Ryan; Ma, Xiang; Yang, Xian; Chen, Hayou; Jorgenson, Adam; Hau, Vincent; Zeng, Jiexi; Harmon, Jennifer; Buehler, Jeanette; Cameron, D. Joshua; Dixit, Manjusha; Tong, Zongzhong; Zhang, Kang] Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Gibbs, Daniel; Yang, Zhenglin; Constantine, Ryan; Ma, Xiang; Yang, Xian; Chen, Hayou; Jorgenson, Adam; Zeng, Jiexi; Harmon, Jennifer; Buehler, Jeanette; Cameron, D. Joshua; Tong, Zongzhong; Zhang, Kang] Univ Utah, Sch Med, Program Human Mol Biol & Genet, Salt Lake City, UT 84132 USA.
   [Yang, Zhenglin] Sichuan Med Sci Acad, Chengdu 610071, Sichuan, Peoples R China.
   [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu 610071, Sichuan, Peoples R China.
   [DeWan, Andrew; Hoh, Josephine] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.
   [Brand, John M.] Dept Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA.
   [Camp, Nicola J.] Univ Utah, Sch Med, Div Genet Epidemiol, Dept Biomed Informat, Salt Lake City, UT 84108 USA.
C3 Utah System of Higher Education; University of Utah; Sichuan Provincial
   People's Hospital; Yale University; US Department of Veterans Affairs;
   Utah System of Higher Education; University of Utah
RP Yang, ZL (通讯作者)，Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Bldg 533,Room 3160A,15 N 2030 E, Salt Lake City, UT 84132 USA.
EM zhenglin.yang@hsc.utah.edu; kang.zhang@hsc.utah.edu
RI Chu, Kai On/E-2325-2016; Ma, Xiang/E-4173-2013; Chen, Haoyu/A-7432-2013;
   Zhang, Kang/Y-2740-2019; Dixit, Manjusha/Y-9892-2019
OI Ma, Xiang/0000-0001-9427-8385; Chen, Haoyu/0000-0003-0676-4610; Zhang,
   Kang/0000-0002-4549-1697; Dixit, Manjusha/0000-0002-6997-1054; DeWan,
   Andrew/0000-0002-7679-8704
FU NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NEI NIH HHS
   [P30EY014800, R01EY14448, R01EY14428] Funding Source: Medline; NATIONAL
   CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY014800, R01EY014448, R01EY014428]
   Funding Source: NIH RePORTER
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines J.L, 2005, SCIENCE
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein R.J., 2005, SCIENCE
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 19
TC 37
Z9 44
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
J9 VISION RES
JI Vision Res.
PD FEB
PY 2008
VL 48
IS 5
BP 685
EP 689
DI 10.1016/j.visres.2007.10.022
PG 5
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 276AC
UT WOS:000254112500004
PM 18207215
OA Bronze
DA 2022-11-30
ER

PT J
AU Lindsley, K
   Li, TJ
   Ssemanda, E
   Virgili, G
   Dickersin, K
AF Lindsley, Kristina
   Li, Tianjing
   Ssemanda, Elizabeth
   Virgili, Gianni
   Dickersin, Kay
TI Interventions for Age-Related Macular Degeneration Are Practice
   Guidelines Based on Systematic Reviews?
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; VERTEPORFIN PHOTODYNAMIC THERAPY;
   METHODOLOGICAL QUALITY; RANIBIZUMAB LUCENTIS; SETTING PRIORITIES;
   METAANALYSES; OUTCOMES; PREVENTION; COCHRANE; SAFETY
AB Purpose: Are existing systematic reviews of interventions for age-related macular degeneration incorporated into clinical practice guidelines?
   Design: High-quality systematic reviews should be used to underpin evidence-based clinical practice guidelines and clinical care. We examined the reliability of systematic reviews of interventions for age-related macular degeneration (AMD) and described the main findings of reliable reviews in relation to clinical practice guidelines.
   Methods: Eligible publications were systematic reviews of the effectiveness of treatment interventions for AMD. We searched a database of systematic reviews in eyes and vision without language or date restrictions; the database was up to date as of May 6, 2014. Two authors independently screened records for eligibility and abstracted and assessed the characteristics and methods of each review. We classified reviews as reliable when they reported eligibility criteria, comprehensive searches, methodologic quality of included studies, appropriate statistical methods for meta-analysis, and conclusions based on results. We mapped treatment recommendations from the American Academy of Ophthalmology (AAO) Preferred Practice Patterns (PPPs) for AMD to systematic reviews and citations of reliable systematic reviews to support each treatment recommendation.
   Results: Of 1570 systematic reviews in our database, 47 met inclusion criteria; most targeted neovascular AMD and investigated anti-vascular endothelial growth factor (VEGF) interventions, dietary supplements, or photodynamic therapy. We classified 33 (70%) reviews as reliable. The quality of reporting varied, with criteria for reliable reporting met more often by Cochrane reviews and reviews whose authors disclosed conflicts of interest. Anti-VEGF agents and photodynamic therapy were the only interventions identified as effective by reliable reviews. Of 35 treatment recommendations extracted from the PPPs, 15 could have been supported with reliable systematic reviews; however, only 1 recommendation cited a reliable intervention systematic review. No reliable systematic review was identified for 20 treatment recommendations, highlighting areas of evidence gaps.
   Conclusions: For AMD, reliable systematic reviews exist for many treatment recommendations in the AAO PPPs and should be cited to support these recommendations. We also identified areas where no high-level evidence exists. Mapping clinical practice guidelines to existing systematic reviews is one way to highlight areas where evidence generation or evidence synthesis is either available or needed. (C) 2016 by the American Academy of Ophthalmology.
C1 [Lindsley, Kristina; Li, Tianjing; Ssemanda, Elizabeth; Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Virgili, Gianni] Univ Florence, Eye Clin, Dept Translat Surg & Med, Florence, Italy.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; University of Florence
RP Lindsley, K (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, 615 N Wolfe St,Room E6009, Baltimore, MD 21205 USA.
EM klindsley@jhu.edu
RI Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989; Lindsley,
   Kristina/0000-0003-4536-9920
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [1 U01 EY020522]; NATIONAL EYE INSTITUTE [U01EY020522] Funding
   Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (grant no.: 1 U01 EY020522). The sponsor had no role
   in the design or conduct of this research.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Aziz T, 2013, J ORAL REHABIL, V40, P263, DOI 10.1111/joor.12028
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bolland MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115934
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown A, 2008, 110 CAN AG DRUGS TEC
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041325
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Cochrane Methodological Expectations of Cochrane Intervention Reviews (MECIR), 2012, STAND REP NEW COCHR
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Cornelius VR, 2009, PHARMACOEPIDEM DR S, V18, P1223, DOI 10.1002/pds.1844
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Critical Appraisal Skills Programme UK, CRIT APPR SKILLS PRO
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Delaney A, 2007, CRIT CARE MED, V35, P589, DOI 10.1097/01.CCM.0000253394.15628.FD
   Eandi CM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006928.pub2
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Evans JR, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001775.pub2
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Fleming PS, 2013, EUR J ORTHODONT, V35, P244, DOI 10.1093/ejo/cjs016
   Gehlbach P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub3
   Geltzer A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005022.pub3
   Giansanti F, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006931.pub2
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Haute Autorite de sante/French National Authority for Health, 2001, TREATM AG REL MAC DE
   Haynes RB, 2005, CLIN EPIDEMIOLOGY DO
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Husereau DR, 2002, PHOTODYNAMIC THERAPY, P40
   Institute of Medicine, 2011, CLIN PRACTICE GUIDEL
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Ip S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-15
   Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Lawrenson JG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub2
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee L, 2008, AUSTRALAS J AGEING, V27, P170, DOI 10.1111/j.1741-6612.2008.00298.x
   Li T, 2010, CMAJ, V182, P13
   Li TJ, 2014, OPHTHALMOLOGY, V121, P438, DOI 10.1016/j.ophtha.2013.10.003
   Li TJ, 2013, OPHTHALMOLOGY, V120, P1113, DOI 10.1016/j.ophtha.2012.11.038
   Li TJ, 2012, ANN INTERN MED, V156, P367, DOI 10.7326/0003-4819-156-5-201203060-00009
   Li TJ, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-79
   Li TJ, 2010, OPHTHALMOLOGY, V117, P1937, DOI 10.1016/j.ophtha.2010.07.004
   Lucenteforte E, 2015, J CLIN EPIDEMIOL, V68, P246, DOI 10.1016/j.jclinepi.2014.11.004
   Lundh A, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000033.pub2, 10.1002/14651858.MR000033.pub3]
   Lundh A, 2009, CANCER TREAT REV, V35, P645, DOI 10.1016/j.ctrv.2009.08.010
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   MacDonald SL, 2010, J UROLOGY, V184, P648, DOI 10.1016/j.juro.2010.03.127
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Melchiors Ana Carolina, 2012, Int J Clin Pharm, V34, P32, DOI 10.1007/s11096-011-9592-0
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Moher D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5040
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moja LP, 2005, BMJ-BRIT MED J, V330, P1053, DOI 10.1136/bmj.38414.515938.8F
   Mulrow CD, 1997, ANN INTERN MED, V126, P389, DOI 10.7326/0003-4819-126-5-199703010-00008
   Oliva G, 2002, PHOTODYNAMIC THERAPY
   Oliva G, 2009, AGE RELATED MACULAR
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Reddy U, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005138.pub2
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saokaew Surasak, 2012, J Pain Palliat Care Pharmacother, V26, P341, DOI 10.3109/15360288.2012.734904
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2011, BRIT J OPHTHALMOL, V95, P308, DOI 10.1136/bjo.2009.178574
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Seo HJ, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-129
   Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Siontis KC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4501
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Vanner EA, 2015, AM J OPHTHALMOL, V160, P849, DOI 10.1016/j.ajo.2015.08.020
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Weir CR, 2012, INT J MED INFORM, V81, P219, DOI 10.1016/j.ijmedinf.2012.01.009
   Wild C, 2009, OPHTHALMOLOGE, V106, P127, DOI 10.1007/s00347-008-1768-1
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Windsor B, 2012, HUM REPROD, V27, P3460, DOI 10.1093/humrep/des342
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wu T, 2009, COCHRANE DB SYST REV, P51
   Yu T, 2015, J GLAUCOMA, V24, P348, DOI 10.1097/IJG.0b013e31829e5616
   Zhang FD, 2010, CHINESE J CLIN NUTR, V18, P126
   [周佳 Zhou Jia], 2012, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University .Medical Science], V32, P1621
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 107
TC 15
Z9 15
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2016
VL 123
IS 4
BP 884
EP 897
DI 10.1016/j.ophtha.2015.12.004
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH3WU
UT WOS:000372718300033
PM 26804762
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gong, D
   Kras, A
   Miller, JB
AF Gong, Dan
   Kras, Ashley
   Miller, John B.
TI Application of Deep Learning for Diagnosing, Classifying, and Treating
   Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Review
DE Artificial intelligence; deep learning; age-related macular degeneration
AB Age-related macular degeneration (AMD) affects nearly 200 million people and is the third leading cause of irreversible vision loss worldwide. Deep learning, a branch of artificial intelligence that can learn image recognition based on pre-existing datasets, creates an opportunity for more accurate and efficient diagnosis, classification, and treatment of AMD on both individual and population levels. Current algorithms based on fundus photography and optical coherence tomography imaging have already achieved diagnostic accuracy levels comparable to human graders. This accuracy can be further increased when deep learning algorithms are simultaneously applied to multiple diagnostic imaging modalities. Combined with advances in telemedicine and imaging technology, deep learning can enable large populations of patients to be screened than would otherwise be possible and allow ophthalmologists to focus on seeing those patients who are in need of treatment, thus reducing the number of patients with significant visual impairment from AMD.
C1 [Gong, Dan; Miller, John B.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02115 USA.
   [Kras, Ashley; Miller, John B.] Massachusetts Eye & Ear Infirm, Harvard Retinal Imaging Lab, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Massachusetts Eye & Ear Infirmary
RP Miller, JB (通讯作者)，Massachusetts Eye & Ear Infirm, Harvard Retinal Imaging Lab, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Baba T, 2010, INVEST OPHTH VIS SCI, V51
   BIRD A, SURV OPHTHALMOL, V39
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   BURLINA P, 2017, JAMA OPHTHALMOL, V135
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   CHEW E, 2014, JAMA OPHTHALMOL, V132
   Consejo A, 2019, SEMIN OPHTHALMOL, V34, P19, DOI 10.1080/08820538.2018.1551496
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Fang L., 2017, BIOMED OPT EXPRESS, V8
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gianfrancesco MA, 2018, JAMA INTERN MED, V178, P1544, DOI 10.1001/jamainternmed.2018.3763
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   GULSHAN V, 2016, JAMA-J AM MED ASSOC, V316
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hwang D, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040158
   Kanagasingam Y, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2665
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Keel S, 2019, CLIN EXP OPHTHALMOL, V47, P1009, DOI 10.1111/ceo.13575
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Krizhevsky A., IMAGENET CLASSIFICAT
   LEE C, 2017, OPHTHALMOL RETIN, V1
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Long EP, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-016-0024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mori Y, 2018, ANN INTERN MED, V169, P357, DOI 10.7326/M18-0249
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   NAM J, 2019, RADIOLOGY, V290
   Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RUSSAKOFF D, 2019, INVEST OPHTH VIS SCI, V60
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   SAHA S, 2019, SCI REP-UK, V9
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schroff F, 2015, PROC CVPR IEEE, P815, DOI 10.1109/CVPR.2015.7298682
   Seebock P, 2019, IEEE T MED IMAGING, V38, P1037, DOI 10.1109/TMI.2018.2877080
   Shah A, 2018, BIOMED OPT EXPRESS, V9, P4509, DOI 10.1364/BOE.9.004509
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   STEIN J, 2013, AM J OPHTHALMOL, V155
   Ting DS, 2020, BRIT J OPHTHALMOL, V104, P299, DOI 10.1136/bjophthalmol-2019-315066
   Told R, 2020, RETINA-J RET VIT DIS, V40, P2010, DOI 10.1097/IAE.0000000000002695
   TOPOL E, 2019, NAT MED, V25
   TREDER M, 2018, GRAEF ARCH CLIN EXP, V256
   Wang P, 2018, NAT BIOMED ENG, V2, P741, DOI 10.1038/s41551-018-0301-3
   WONG T, 2019, OPHTHALMOLOGICA, V243
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   XIE Y, 2020, LANCET DIGIT HEAL, V2
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   2019, BRIT J OPHTHALMOL, V103
   2017, JAMA-J AM MED ASSOC, V318
NR 60
TC 2
Z9 2
U1 1
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY 19
PY 2021
VL 36
IS 4
SI SI
BP 198
EP 204
DI 10.1080/08820538.2021.1889617
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SB4FX
UT WOS:000620512400001
PM 33617390
DA 2022-11-30
ER

PT J
AU Koolen, L
   Gagliardi, G
   ten Brink, SCA
   de Breuk, A
   Heesterbeek, T
   Hoyng, CB
   Albert, S
   Den Hollander, AI
AF Koolen, Louet
   Gagliardi, Giuliana
   ten Brink, Sofie C. A.
   de Breuk, Anita
   Heesterbeek, Thomas
   Hoyng, Carel B.
   Albert, Silvia
   Den Hollander, Anneke I.
TI Generation and characterization of human induced pluripotent stem cells
   (iPSCs) from three individuals without age-related macular degeneration
SO STEM CELL RESEARCH
LA English
DT Article
AB Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. AMD is multifactorial eye disease with a strong genetic contribution. Here, we report the generation and characterization of induced pluripotent stem cells (iPSCs) derived from peripheral blood mononuclear cells of three individuals above 70 years of age without AMD. These cell lines were generated to serve as control lines for cellular studies investigating the disease mechanisms and developing therapeutic interventions for AMD.
C1 [Koolen, Louet; Gagliardi, Giuliana; ten Brink, Sofie C. A.; de Breuk, Anita; Heesterbeek, Thomas; Hoyng, Carel B.; Den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Albert, Silvia; Den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Koolen, L (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
EM louet.koolen@radboudumc.nl
RI Brink, Sofie ten/AAZ-4663-2020
OI Brink, Sofie ten/0000-0001-7127-025X
FU Stichting Toegepast Wetenschappelijk Instituut voor Neuromodulatie
   (TWIN) under the project 'Inflammation and Edema in an Organ-on-a-Chip
   Model of Wet Age-Related Macular Degeneration"
FX The authors acknowledge the funding received from Stichting Toegepast
   Wetenschappelijk Instituut voor Neuromodulatie (TWIN) under the project
   'Inflammation and Edema in an Organ-on-a-Chip Model of Wet Age-Related
   Macular Degeneration'" "The authors wish to thank the Radboudumc Stem
   Cell Technology Center
   (https://www.radboudumc.nl/en/research/radboud-technology-centers/stem-c
   ells) for reprogramming and characterizing the patient/control cell
   lines."
CR de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD APR
PY 2022
VL 60
AR 102670
DI 10.1016/j.scr.2022.102670
PG 4
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA 0Z7DV
UT WOS:000791235400002
PM 35078129
OA gold
DA 2022-11-30
ER

PT J
AU Ellabban, AA
   Hangai, M
   Yamashiro, K
   Nakagawa, S
   Tsujikawa, A
   Yoshimura, N
AF Ellabban, A. A.
   Hangai, M.
   Yamashiro, K.
   Nakagawa, S.
   Tsujikawa, A.
   Yoshimura, N.
TI Tomographic fundus features in pseudoxanthoma elasticum: comparison with
   neovascular age-related macular degeneration in Japanese patients
SO EYE
LA English
DT Article
DE pseudoxanthoma elasticum; angioid streaks; age-related macular
   degeneration; spectral-domain optical coherence tomography
ID OPTICAL-COHERENCE-TOMOGRAPHY; ANGIOID STREAKS; CHOROIDAL
   NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; INTRAVITREAL
   BEVACIZUMAB; PHOTODYNAMIC THERAPY; LASER TREATMENT; PHOTORECEPTORS;
   SECONDARY; MOUSE
AB Purpose To determine the retinal and subretinal features characteristic to pseudoxanthoma elasticum (PXE) compared with age-related macular degeneration by using spectral-domain optical coherence tomography (SD-OCT) in Japanese patients.
   Methods We reviewed colour fundus photographs, fluorescein angiograms, and SD-OCT images of 52 eyes (27 Japanese patients) with angioid streaks (AS) due to PXE. Then we compared the incidence of tomographic features between 24 eyes (24 patient) with choroidal neovascularization (CNV) secondary to AS and 44 eyes (44 patients) with CNV secondary to age-related macular degeneration (AMD).
   Results Secondary CNV was found in 44 eyes (84.6%) of 52 patients with PXE during follow-up. We found characteristic round or ovoid tubular structures with highly reflective annular lines (termed 'outer retinal tubulation' (ORT)) in 31 (70.5%) of 44 eyes with CNV, but none were found in eyes without CNV. We also found characteristic undulations of Bruch's membrane in 38 (73.1%) eyes with AS. The incidence of ORT was significantly greater in eyes with CNV secondary to AS (70.8%; P = 0.005) compared with eyes with CNV secondary to AMD (34.1%). The incidence of Bruch's membrane undulation was significantly greater in eyes with CNV secondary to AS (70.8%; P<0.0001) than in eyes with CNV secondary to AMD (11.4%).
   Conclusion SD-OCT imaging clearly revealed a greater incidence of unique lesions, including ORT and Bruch's membrane undulation, in eyes in PXE patients with CNV secondary to AS than in eyes with CNV secondary to AMD. Eye (2012) 26, 1086-1094; doi:10.1038/eye.2012.101; published online 1 June 2012
C1 [Hangai, M.] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.
   [Ellabban, A. A.] Suez Canal Univ, Dept Ophthalmol, Ismailia, Egypt.
C3 Kyoto University; Egyptian Knowledge Bank (EKB); Suez Canal University
RP Hangai, M (通讯作者)，Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM hangai@kuhp.kyoto-u.ac.jp
OI Yamashiro, Kenji/0000-0001-9354-8558; Ellabban,
   Abdallah/0000-0002-6033-2969; Tsujikawa, Akitaka/0000-0003-0779-7799
FU Topcon; Heidelberg Engineering; Santen; Nidek; Canon
FX Masanori Hangai is a paid advisory board member for NIDEK, and received
   consulting fees from Topcon, lecture fees from Heidelberg Engineering
   and Santen. Yoshimura Nagahisa is a paid advisory board member for
   NIDEK, lecture fees from Nidek, Topcon, and Canon, and research funding
   from Topcon, Nidek, and Canon. The other authors declare no conflict of
   interest.
CR Aras C, 2004, RETINA-J RET VIT DIS, V24, P801, DOI 10.1097/00006982-200410000-00020
   Bhatnagar P, 2007, RETINA-J RET VIT DIS, V27, P897, DOI 10.1097/IAE.0b013e31809ff5df
   BRANCATO R, 1987, OPHTHALMOLOGICA, V195, P84, DOI 10.1159/000309793
   CLARKSON JG, 1982, SURV OPHTHALMOL, V26, P235, DOI 10.1016/0039-6257(82)90158-8
   CONNOR PJ, 1961, AM J MED, V30, P537, DOI 10.1016/0002-9343(61)90078-X
   DABBS TR, 1990, BRIT J OPHTHALMOL, V74, P579, DOI 10.1136/bjo.74.10.579
   Daniele LL, 2005, INVEST OPHTH VIS SCI, V46, P2156, DOI 10.1167/iovs.04-1427
   Dreyer R, 1978, Trans Pa Acad Ophthalmol Otolaryngol, V31, P158
   Finger RP, 2009, SURV OPHTHALMOL, V54, P272, DOI 10.1016/j.survophthal.2008.12.006
   Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507
   Green WR., 1996, OPHTHALMIC PATHOLOGY
   Hagedoorn A, 1939, ARCH OPHTHALMOL-CHIC, V21, P746
   Hangai M, 2009, OPT EXPRESS, V17, P4221, DOI 10.1364/OE.17.004221
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Karacorlu M, 2002, AM J OPHTHALMOL, V134, P360, DOI 10.1016/S0002-9394(02)01626-4
   Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102
   LIM JI, 1993, AM J OPHTHALMOL, V116, P414, DOI 10.1016/S0002-9394(14)71398-4
   MANSOUR AM, 1988, OPHTHALMOLOGICA, V197, P36, DOI 10.1159/000309915
   Menchini U, 2004, RETINA-J RET VIT DIS, V24, P763, DOI 10.1097/00006982-200410000-00013
   Mimoun G, 2010, AM J OPHTHALMOL, V150, P692, DOI 10.1016/j.ajo.2010.06.004
   Nikonov SS, 2005, J GEN PHYSIOL, V125, P287, DOI 10.1085/jgp.200409208
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Ozdek S, 2007, CAN J OPHTHALMOL, V42, P95, DOI 10.3129/can.j.ophthalmol.06-089
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Sawa M, 2009, AM J OPHTHALMOL, V148, P584, DOI 10.1016/j.ajo.2009.04.026
   SHIELDS JA, 1975, BRIT J OPHTHALMOL, V59, P257, DOI 10.1136/bjo.59.5.257
   Wenzel A, 2007, INVEST OPHTH VIS SCI, V48, P534, DOI 10.1167/iovs.06-0652
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 30
TC 18
Z9 21
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD AUG
PY 2012
VL 26
IS 8
BP 1086
EP 1094
DI 10.1038/eye.2012.101
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991TW
UT WOS:000307726000012
PM 22653517
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Gibson, J
   Hakobyan, S
   Cree, AJ
   Collins, A
   Harris, CL
   Ennis, S
   Morgan, BP
   Lotery, AJ
AF Gibson, J.
   Hakobyan, S.
   Cree, A. J.
   Collins, A.
   Harris, C. L.
   Ennis, S.
   Morgan, B. P.
   Lotery, A. J.
TI Variation in complement component C1 inhibitor in age-related macular
   degeneration
SO IMMUNOBIOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complement pathways; Complement
   component C1 inhibitor; SERPING1
ID SERPING1 GENE; FACTOR-H; PLASMA-CONCENTRATIONS; ASSOCIATION; VARIANT;
   HTRA1; LOC387715/ARMS2; SUSCEPTIBILITY; POLYMORPHISMS; C1-INHIBITOR
AB This study assessed variation in plasma levels of the complement regulatorC1 inhibitor (C1inh) in patients with age related macular degeneration (AMD) and controls. Plasma from 391 AMD cases and 370 controls was assayed by rate nephelometry to determine C1inh protein levels. Protein levels were analysed for relationships with age, gender, smoking. AMD disease status and genetic variation in the SERPING1 gene, which encodes C1inh, using a multivariate analysis. t-Tests show a significant difference in C1inh levels in AMD cases compared with controls (p = 2.340E-6), smokers compared to non-smokers (p = 1.022E-4) and females compared to males (p = 1.661E-7). Multivariate analysis shows that after accounting for gender and smoking AMD status remained significant. Age was included in the model but was not significant. Including genetic variation in the model shows that one significant SNP (rs2649663) 5' of the SERPING1 gene is associated with C1inh levels though this SNP is not associated with AMD. This suggests that genetic variation in the promoter region of the SERPING1 gene may influence expression of the gene. (C) 2011 Elsevier GmbH. All rights reserved.
C1 [Hakobyan, S.; Harris, C. L.; Morgan, B. P.] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales.
   [Gibson, J.; Collins, A.; Ennis, S.] Univ Southampton, Southampton Gen Hosp, Sch Med, Genet Epidemiol & Bioinforrnat Grp,Human Genet Di, Southampton SO16 6YD, Hants, England.
   [Cree, A. J.; Lotery, A. J.] Univ Southampton, Southampton Gen Hosp, Sch Med, Clin Neurosci Div, Southampton SO16 6YD, Hants, England.
   [Lotery, A. J.] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO9 4XY, Hants, England.
C3 Cardiff University; University of Southampton; University of
   Southampton; University of Southampton
RP Morgan, BP (通讯作者)，Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales.
EM MorganBP@Cardiff.ac.uk; A.J.Lotery@soton.ac.uk
RI Collins, Andrew/A-6595-2010; Collins, Andrew/S-2196-2019; Gibson,
   Jane/I-1630-2012
OI Collins, Andrew/0000-0001-7108-0771; Collins,
   Andrew/0000-0001-7108-0771; Gibson, Jane/0000-0002-0973-8285; Morgan,
   Paul/0000-0003-4075-7676; Lotery, Andrew/0000-0001-5541-4305; Cree,
   Angela/0000-0002-1987-8900
FU Macular Disease Society; T.F.C. Frost Charitable Trust; British Council
   for the Prevention of Blindness; MS Society [Ref 884/08]; National
   Institute for Health Research [NF-SI-0507-10094] Funding Source:
   researchfish; Alzheimer&quot;s Society [104] Funding Source:
   researchfish
FX The authors wish to acknowledge grant funding from Macular Disease
   Society, T.F.C. Frost Charitable Trust and The British Council for the
   Prevention of Blindness to AJL and MS Society Project Grant Ref 884/08
   to BPM. The authors also wish to thank Helen Griffiths and Victoria
   Bryant for their help in this study and manuscript preparation.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   BRIDGES RB, 1985, LIFE SCI, V36, P955, DOI 10.1016/0024-3205(85)90391-1
   Cai SH, 2005, J IMMUNOL, V174, P6462, DOI 10.4049/jimmunol.174.10.6462
   Carter JG, 2011, ACTA OPHTHALMOL, V89, pE212, DOI 10.1111/j.1755-3768.2009.01788.x
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, MOL VIS, V14, P1395
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GORDON EM, 1980, J LAB CLIN MED, V96, P762
   Hecker L.A., 2009, HUM MOL GENET
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lu F, 2010, MOL VIS, V16, P1
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   OHKOHCHI K, 1989, DERMATOLOGICA, V179, P30, DOI 10.1159/000248445
   Park KH, 2009, MOL VIS, V15, P200
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ramsden C., 2009, 59 ANN M AM SOC HUM
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   WYATT RJ, 1981, J CLIN LAB IMMUNOL, V6, P131
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 31
TC 14
Z9 14
U1 0
U2 11
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD FEB
PY 2012
VL 217
IS 2
SI SI
BP 251
EP 255
DI 10.1016/j.imbio.2011.07.015
PG 5
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 902GI
UT WOS:000301026200015
PM 21852020
DA 2022-11-30
ER

PT J
AU Swiech, A
   Dolar-Szczasny, J
   Wrobel-Dudzinska, D
   Kosior-Jarecka, E
   Mackiewicz, J
AF Swiech, Anna
   Dolar-Szczasny, Joanna
   Wrobel-Dudzinska, Dominika
   Kosior-Jarecka, Ewa
   Mackiewicz, Jerzy
TI Quality of life among patients from urban and rural areas with advanced
   age-related macular degeneration assessed using the NEI-VFQ-25
SO ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
DE AMD; rural areas; urban areas; quality of life
AB Objective. The aim of the study was to explore the influence of exudative age-related macular degeneration on the quality of life of patients from urban and rural areas.
   Materials and method. The retrospective study included 144 Polish Caucasians with exudative age-related macular degeneration, treated with anti-VEGF, recruited from Department of Medical Retina in Lublin between March and June 2017. Clinical assessment included age, gender, visual acuity, complete ophthalmic examination, fundus fluorescein angiography and optical coherence tomography, medical history and the NEI VFQ-25 questionnaire.
   Results. The mean age of the study group was 76.73 +/- 12.3 years, average time of AMD was 4.24 +/- 4.1 years. 21.5% of patients reported comorbidities such as hypertension, cardiovascular disease, diabetes mellitus. 99 (68.75%) lived in a city, while 45(31.25%) in a village. There was a tendency of females to complain more than males about moderate and severe discomfort and pain (p=0.09). Most of the patients did not drive a car before the onset of the disease (female vs.male: 81% vs 62.9%; p=0.01). 62.8% males and 25.8% females gave up driving (p=0.003), whereas significantly more males gave up driving' and 25% of villagers gave up driving (p =0.07). The parameter because of the eyesight - female vs. male: 50% vs. 20.8%; p = 0.03. There was a tendency of village respondents to complain more often about extreme difficulty in reading newspapers, street signs or the names of stores than (p=0.08). 44.2% city residents. Rural patients felt to achieve much less because of their eyesight, which was not observed in patients from the city (p = 0.06).
   Conclusions. The place of residence and gender influenced perception of the disease in exudative form of age-related macular degeneration.
C1 [Swiech, Anna; Dolar-Szczasny, Joanna; Mackiewicz, Jerzy] Medical Univ, Dept Vitreoretinal Surg, Lublin, Poland.
   [Wrobel-Dudzinska, Dominika; Kosior-Jarecka, Ewa] Medical Univ, Dept Diagnost & Microsurg Glaucoma, Lublin, Poland.
RP Swiech, A (通讯作者)，Medical Univ, Dept Vitreoretinal Surg, Lublin, Poland.
EM anna.zub@umlub.pl
OI Swiech-Zubilewicz, Anna/0000-0002-2238-6966; Mackiewicz,
   Jerzy/0000-0003-0984-8908; Wrobel-Dudzinska,
   Dominika/0000-0002-1325-6692; Dolar-Szczasny, Joanna/0000-0003-4206-4371
CR Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Cwirlej-Sozanska AB, 2018, ANN AGR ENV MED, V25, P539, DOI 10.26444/aaem/93847
   Inan S, 2019, SAO PAULO MED J, V137, P25, DOI 10.1590/1516-3180.2018.0195071218
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Lane J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209218
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Riva I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43203-9
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Ryu So Jung, 2017, Korean J Ophthalmol, V31, P412, DOI 10.3341/kjo.2016.0086
   Xu KY, 2018, CAN J OPHTHALMOL, V53, P168, DOI 10.1016/j.jcjo.2017.08.006
   Yang L, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1176-0
NR 13
TC 0
Z9 0
U1 0
U2 5
PU INST AGRICULTURAL MEDICINE
PI LUBLIN
PA JACZEWSKIEGO 2, PO BOX 185, 20-950 LUBLIN, POLAND
SN 1232-1966
EI 1898-2263
J9 ANN AGR ENV MED
JI Ann. Agr. Env. Med.
PY 2021
VL 28
IS 2
BP 243
EP 249
DI 10.26444/aaem/130436
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA SW4IH
UT WOS:000664478800008
PM 34184505
OA gold
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Rosenfeld, PJ
AF Ciulla, Thomas A.
   Rosenfeld, Philip J.
TI Antivascular endothelial growth factor therapy for neovascular
   age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Article
DE bevacizumab; macular degeneration; neovascularization; pegaptanib
   sodium; ranibizumab
ID INTRAVITREAL BEVACIZUMAB AVASTIN; OCCULT CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; VASCULAR-PERMEABILITY FACTOR;
   DIABETIC-RETINOPATHY; FACTOR VEGF; RANIBIZUMAB; TRIAMCINOLONE;
   EXPRESSION; EFFICACY
AB Purpose of review The most important recent advance in the treatment of neovascular age-related macular degeneration (AMD) is the development of antivascular endothelial growth factor (anti-VEGF) therapeutic agents that preserve and improve visual acuity by arresting choroidal neovascular growth and reducing vascular permeability. This review describes the current literature on the use of this therapeutic approach in the management of neovascular AMD.
   Recent findings Two anti-VEGF agents, pegaptanib sodium and ranibizumab, are currently approved by the United States Food and Drug Administration for the treatment of neovascular AMD. In addition, off-label use of a third anti-VEGF agent, bevacizumab, as a treatment option for neovascular AMD has become common worldwide. Other anti-VEGF agent strategies that have shown efficacy include small interfering RNA agents to silence the VEGF gene and receptor and the fusion protein VEGF trap.
   Summary The accumulation of preclinical and clinical evidence implicating VEGF-A in the pathogenesis of neovascular AMD has provided a strong rationale for the development of anti-VEGF agents for this disease. Anti-VEGF therapies have been used successfully in the clinic, encouraging their use in the treatment of other neovascular eye diseases.
C1 [Ciulla, Thomas A.] Midwest Eye Inst, Vitreoretinal Serv, Indianapolis, IN 46280 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Ciulla, TA (通讯作者)，Midwest Eye Inst, Vitreoretinal Serv, 201 Penn Pkwy, Indianapolis, IN 46280 USA.
EM thomasciulla@yahoo.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
FU Genentech USA, Inc
FX The support for third-party medical writing assistance was provided by
   Genentech USA, Inc.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Azad RV, 2008, JPN J OPHTHALMOL, V52, P52, DOI 10.1007/s10384-007-0496-4
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Ergun E, 2006, AM J OPHTHALMOL, V142, P10, DOI 10.1016/j.ajo.2006.02.048
   Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRONE PJ, 2008, 26 ANN M AM SOC RET
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Gerhardt H, 2004, DEV DYNAM, V231, P503, DOI 10.1002/dvdy.20148
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Jonas JB, 2007, ACTA OPHTHALMOL SCAN, V85, P563, DOI 10.1111/j.1600-0420.2007.00891.x
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kawasaki T, 1999, DEVELOPMENT, V126, P4895
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KOKAME G, 2008, 26 ANN M AM SOC RET
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Michels M, 2008, 26 ANN M AM SOC RET
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Monsky WL, 1999, CANCER RES, V59, P4129
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Noma H, 2006, GRAEF ARCH CLIN EXP, V244, P309, DOI 10.1007/s00417-004-1087-4
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2
   Pedersen R, 2007, ACTA OPHTHALMOL SCAN, V85, P526, DOI 10.1111/j.1600-0420.2007.00895.x
   PEER J, 1995, LAB INVEST, V72, P638
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reich S, 2003, MOL VIS, V9, P210
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Roberts WG, 1997, CANCER RES, V57, P765
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Schmidt-Erfurth U, 2006, ARCH OPHTHALMOL-CHIC, V124, P561, DOI 10.1001/archopht.124.4.561
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Zhang HT, 2000, BRIT J CANCER, V83, P63
NR 93
TC 98
Z9 107
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2009
VL 20
IS 3
BP 158
EP 165
DI 10.1097/ICU.0b013e32832d25b3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446TN
UT WOS:000266144200003
PM 19417570
DA 2022-11-30
ER

PT J
AU Schmier, JK
   Hulme-Lowe, CK
AF Schmier, Jordana K.
   Hulme-Lowe, Carolyn K.
TI Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues
   and Challenges
SO PHARMACOECONOMICS
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; QUALITY-OF-LIFE; TIME TRADE-OFF;
   PHOTODYNAMIC THERAPY; CONTRAST SENSITIVITY; LASER PHOTOCOAGULATION;
   VISUAL IMPAIRMENT; PEGAPTANIB SODIUM; UTILITY ANALYSIS; STANDARD GAMBLE
AB Age-related macular degeneration (AMD) is a common ophthalmic condition that can have few symptoms in its early stage but can progress to major visual impairment. While there are no treatments for early-stage AMD, there are multiple modalities of treatment for advanced disease. Given the increasing prevalence of the disease, there are dozens of analyses of cost effectiveness of AMD treatments, but methods and approaches vary broadly. The goal of this review was to identify, characterize, and critique published models in AMD and provide guidance for their interpretation. After a literature review was performed to identify studies, and exclusion criteria applied to limit the review to studies comparing treatments for AMD, we compared methods across the 36 studies meeting the review criteria. To some extent, variation was related to targeting different audiences or acknowledging the most appropriate population for a given treatment. However, the review identified potential areas of uncertainty and difficulty in interpretation, particularly regarding duration of observation periods and the importance of visual acuity as an endpoint or a proxy for patient-reported utilities. We urge thoughtful consideration of these study characteristics when comparing results.
C1 [Schmier, Jordana K.; Hulme-Lowe, Carolyn K.] Exponent Inc, 1800 Diagonal Rd,Suite 500, Alexandria, VA 22314 USA.
C3 Exponent
RP Schmier, JK (通讯作者)，Exponent Inc, 1800 Diagonal Rd,Suite 500, Alexandria, VA 22314 USA.
EM jschmier@exponent.com
RI Schmier, Jordana/I-2994-2019
OI Schmier, Jordana/0000-0002-4662-8800
CR American Academy of Ophthalmology, 2015, PREF PRACT PATT AG R
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Bojke L, 2009, VALUE HEALTH, V12, P739, DOI 10.1111/j.1524-4733.2008.00502.x
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Brown M M, 1999, Curr Opin Ophthalmol, V10, P221, DOI 10.1097/00055735-199906000-00012
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2008, OPHTHALMOLOGY, V115, pe5
   Busbee BG, 2003, RETINA-J RET VIT DIS, V23, P279, DOI 10.1097/00006982-200306000-00001
   Busbee BG, 2003, RETINA, V23, P443
   Butt T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006535
   Butt T, 2014, APPL HEALTH ECON HEA, V12, P289, DOI 10.1007/s40258-014-0090-0
   Caro JJ, 2012, MED DECIS MAKING, V32, P667, DOI 10.1177/0272989X12454577
   Caro JJ, 2012, VALUE HEALTH, V15, P796, DOI 10.1016/j.jval.2012.06.012
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Eong KGA, 2012, EYE, V26, P379, DOI 10.1038/eye.2011.218
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Evans K, 2009, CLIN OPHTHALMOL, V3, P433
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Foster WJ, 2010, BRIT J OPHTHALMOL, V94, P1118, DOI 10.1136/bjo.2009.170282
   Gensler G, 2002, J NUTR, V132, P697
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Hodge W, 2010, CAN J OPHTHALMOL, V45, P223, DOI 10.3129/i10-047
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Hernandez-Pastor LJ, 2010, GRAEF ARCH CLIN EXP, V248, P467, DOI 10.1007/s00417-009-1156-9
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Kymes SM, 2008, OPHTHAL EPIDEMIOL, V15, P76, DOI 10.1080/09286580801939346
   Mauskopf J, 2014, PHARMACOECONOMICS, V32, P521, DOI 10.1007/s40273-014-0157-7
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Muslera E., 2006, Arch Soc Esp Oftalmol, V81, P199
   Neubauer AS, 2010, INT J OPHTHALMOL-CHI, V3, P228, DOI 10.3980/j.issn.2222-3959.2010.03.11
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Patel PJ, 2011, INVEST OPHTH VIS SCI, V52, P3089, DOI 10.1167/iovs.10-6208
   Pearson Isobel, 2013, J Med Econ, V16, P1307, DOI 10.3111/13696998.2013.839946
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Reddy P, 2006, CURR MED RES OPIN, V22, P1311, DOI 10.1185/030079906X115586
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Sharma S, 2005, CAN J OPHTHALMOL, V40, P369, DOI 10.1016/S0008-4182(05)80079-1
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Siegel JE, 1997, PHARMACOECONOMICS, V11, P159, DOI 10.2165/00019053-199711020-00005
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Studnicka J, 2013, OPHTHALMOLOGICA, V230, P34, DOI 10.1159/000350802
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
NR 74
TC 9
Z9 10
U1 0
U2 9
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-7690
EI 1179-2027
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PD MAR
PY 2016
VL 34
IS 3
BP 259
EP 272
DI 10.1007/s40273-015-0347-y
PG 14
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA DF2HW
UT WOS:000371164200006
PM 26563248
DA 2022-11-30
ER

PT J
AU Field, MG
   Comer, GM
   Kawaji, T
   Petty, HR
   Elner, VM
AF Field, Matthew G.
   Comer, Grant M.
   Kawaji, Takahiro
   Petty, Howard R.
   Elner, Victor M.
TI Noninvasive Imaging of Mitochondrial Dysfunction in Dry Age-Related
   Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; PROGRESSIVE STAGES;
   METABOLIC STRESS; DNA DAMAGE; AUTOFLUORESCENCE; APOPTOSIS; CELLS;
   EXPRESSION; PROTEOMICS
AB BACKGROUND AND OBJECTIVE: Oxidative stress and mitochondrial dysfunction are implicated in the pathogenesis of age-related macular degeneration (AMD). Because increased flavoprotein fluorescence (FPF) is indicative of mitochondrial dysfunction, the authors attempted to detect mitochondrial dysfunction in eyes with AMD using FPF.
   PATIENTS AND METHODS: Six nonexudative eyes with AMD, including three with geographic atrophy (GA), and age-matched control eyes were imaged with a FPF device. Qualitative and quantitative analyses were conducted on the FPF images.
   RESULTS: Five eyes with AMD, including all three eyes with GA, showed qualitative and/or quantitative FPF heterogeneity that was not present in control eyes. Mean FPF average intensities of eyes with AMD with (P = .044) and without (P = .00060) GA were significantly greater than those of control eyes. The standard deviations of FPF images were greater in eyes with AMD (P = .020).
   CONCLUSION: In this small cluster of patients with AMD, retinal FPF is increased, suggesting elevated mitochondrial dysfunction. FPF heterogeneity indicates that an increased variability in mitochondrial dysfunction seems to be present in eyes with advanced disease. [Ophthalmic Surg Lasers Imaging 2012;43:358-365.]
C1 [Elner, Victor M.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
   [Field, Matthew G.; Comer, Grant M.; Kawaji, Takahiro; Petty, Howard R.; Elner, Victor M.] Univ Michigan, Dept Visual Sci, Ann Arbor, MI 48105 USA.
   [Petty, Howard R.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48105 USA.
   [Elner, Victor M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Elner, VM (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM velner@umich.edu
RI Kawaji, Takahiro/AAH-2481-2020
OI Elner, Victor/0000-0001-7708-1898; , Howard/0000-0001-8516-3666
FU Michigan Universities Commercialization Initiative; OcuSciences, Inc.
FX Supported by a grant from the Michigan Universities Commercialization
   Initiative and research funding from OcuSciences, Inc.
CR [Anonymous], 2007, SAF LAS PROD 1
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   BENSON RC, 1979, J HISTOCHEM CYTOCHEM, V27, P44, DOI 10.1177/27.1.438504
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   CHANCE B, 1979, J BIOL CHEM, V254, P4764
   Choudhry N, 2010, SEMIN OPHTHALMOL, V25, P206, DOI 10.3109/08820538.2010.518121
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Elner Susan G, 2008, Trans Am Ophthalmol Soc, V106, P215
   Elner VM, 2008, ARCH OPHTHALMOL-CHIC, V126, P259, DOI 10.1001/archophthalmol.2007.44
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Field MG, 2008, ARCH OPHTHALMOL-CHIC, V126, P934, DOI 10.1001/archopht.126.7.934
   Field MG, 2011, EXP EYE RES, V93, P548, DOI 10.1016/j.exer.2011.06.023
   Field MG, 2009, RETINA-J RET VIT DIS, V29, P1162, DOI 10.1097/IAE.0b013e3181a3b923
   Field MG, 2009, ARCH OPHTHALMOL-CHIC, V127, P943, DOI 10.1001/archophthalmol.2009.157
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Kim SY, 2002, RETINA, V22, P664
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Long XL, 2004, J MOL CELL CARDIOL, V37, P63, DOI 10.1016/j.yjmcc.2004.04.001
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Perona P., 1987, Proceedings of the IEEE Computer Society Workshop on Computer Vision (Cat. No.87TH0210-5), P16
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Udan N, 2009, INVEST OPHTH VIS SCI, V50, P2966
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Zarbin M, 2009, SURV OPHTHALMOL, V54, P96
NR 36
TC 9
Z9 10
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2012
VL 43
IS 5
BP 358
EP 365
DI 10.3928/15428877-20120712-02
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 054TP
UT WOS:000312367000001
PM 22822904
DA 2022-11-30
ER

PT J
AU Iqbal, K
   Baig, J
   Jamil, AZ
   Jamil, H
   Mirza, K
   Khan, T
AF Iqbal, Kashif
   Baig, Jamil
   Jamil, Ahmad Zeeshan
   Jamil, Hannan
   Mirza, Khurram
   Khan, Tariq
TI Visual Results Following Intravitreal Bevacizumab in Neovascular
   Age-Related Macular Degeneration
SO JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
LA English
DT Article
DE Age-related macular degeneration; Bevacizumab; Choroidal
   neovascularization; Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULOPATHY;
   ANTIBODY; AVASTIN
AB Objective: To determine the visual and anatomic outcome of intravitreal Bevacizumab injection in the treatment of neovascular age-related macular degeneration (AMD).
   Study Design: Quasi-experimental study.
   Place and Duration of Study: Layton Rahmatulla Benevolent Trust Eye Hospital (LRBT), Lahore, from January to July 2010.
   Methodology: Patients who received, one or more intravitreal Bevacizumab injections (1.25 mg per 0.05 ml) for exudative AMD were included in the study. Outcome measures included standardized visual acuity, optical coherence tomography (OCT), macular thickness, intraocular pressure, and blood pressure at 24 or more weeks follow-up. Descriptive statistics were obtained.
   Results: Fifty eyes with exudative AMD were observed for six months. The mean VA improved from 0.21 +/- 0.11 before injections to 0.43 +/- 0.11 after injections at six months. Overall, mean OCT macular thickness decreased by 99 micron at last follow-up. At last follow-up, all eyes received an average of 3.28 +/- 0.85 injections. There was no incidence of severe vision loss or adverse effects like endophthalmitis or retinal detachment.
   Conclusion: Intravitreal Bevacizumab has the potential for improvement of vision in exudative AMD for at least 6 months.
C1 [Iqbal, Kashif; Baig, Jamil; Jamil, Ahmad Zeeshan; Jamil, Hannan; Mirza, Khurram; Khan, Tariq] Layton Rahmatulla Benevolent Trust Eye Hosp LRBT, Dept Ophthalmol, Lahore, Pakistan.
RP Iqbal, K (通讯作者)，40A-195 Allaudin Rd, Lahore Cantt, Pakistan.
EM kashifind@hotmail.com
CR AVERY RL, 2006, OPHTHALMOLOGY, V113
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   Kanski JJ., 2006, CLIN OPHTHALMOLOGY S
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 2005, RANDOMIZED CONTROLLE
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosiak Jean, 2005, Clin J Oncol Nurs, V9, P407
   ULLAH N, 2003, PAK J OPHTHALMOL, V19, P9
   Wong D, 2008, BRIT J OPHTHALMOL, V92, P1011, DOI 10.1136/bjo.2007.135681
NR 15
TC 1
Z9 1
U1 0
U2 0
PU COLL PHYSICIANS & SURGEONS PAKISTAN
PI KARACHI
PA SEVENTH CENTRAL ST, DEFENCE HOUSING AUTHORITY, KARACHI, 75500, PAKISTAN
SN 1022-386X
J9 JCPSP-J COLL PHYSICI
JI JCPSP-J. Coll. Physicians Surg.
PD SEP
PY 2011
VL 21
IS 9
BP 535
EP 538
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 823CT
UT WOS:000295100500006
PM 21914409
DA 2022-11-30
ER

PT J
AU Curtis, LH
   Hammill, BG
   Schulman, KA
   Cousins, SW
AF Curtis, Lesley H.
   Hammill, Bradley G.
   Schulman, Kevin A.
   Cousins, Scott W.
TI Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke
   Associated With Therapies for Age-Related Macular Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; CHOROIDAL NEOVASCULARIZATION;
   CLINICAL-TRIALS; RANIBIZUMAB; VERTEPORFIN; SAFETY; ICD-9-CM; EDEMA
AB Objective: To examine associations between therapies for age-related macular degeneration and risks of all-cause mortality, incident myocardial infarction, bleeding, and incident stroke.
   Methods: We conducted a retrospective cohort study of 146 942 Medicare beneficiaries 65 years or older with a claim for age-related macular degeneration between January 1, 2005, and December 31, 2006. On the basis of claims for the initial treatment, we assigned beneficiaries to 1 of 4 groups. The active control group included patients who received photodynamic therapy. The other groups included patients who received intravitreous pegaptanib octasodium, bevacizumab, or ranibizumab. We censored data from patients when they received a therapy different from the initial therapy. The main outcome measures were associations between photodynamic, pegaptanib, bevacizumab, and ranibizumab therapies and the risks of all-cause mortality, incident myocardial infarction, bleeding, and incident stroke.
   Results: After adjustment for baseline characteristics and comorbid conditions, we found significant differences in the rates of mortality and myocardial infarction by treatment group. Specifically, the hazard of mortality was significantly lower with ranibizumab therapy than with photodynamic therapy (hazard ratio, 0.85; 99% confidence interval, 0.75-0.95) or pegaptanib use (0.84; 0.74-0.95), and the hazard of myocardial infarction was significantly lower with ranibizumab use than with photodynamic therapy (0.73; 0.58-0.92). There were no significant differences in the hazard of mortality or myocardial infarction between bevacizumab use and the other therapies. We found no statistically significant relationship between treatment group and bleeding events or stroke.
   Conclusion: Bevacizumab and ranibizumab use was not associated with increased risks of mortality, myocardial infarction, bleeding, or stroke compared with photodynamic therapy or pegaptanib use.
C1 [Curtis, Lesley H.; Hammill, Bradley G.; Schulman, Kevin A.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27715 USA.
   [Curtis, Lesley H.; Schulman, Kevin A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27715 USA.
   [Cousins, Scott W.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27715 USA.
C3 Duke University; Duke University; Duke University
RP Curtis, LH (通讯作者)，Duke Univ, Sch Med, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.
EM lesley.curtis@duke.edu
FU OSI Eyetech; Duke University
FX This study was supported by a research agreement between OSI Eyetech and
   Duke University.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   *CLIN GOV, COMP AG REL MAC DEG
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
   Gutthann SP, 1997, EPIDEMIOLOGY, V8, P18, DOI 10.1097/00001648-199701000-00003
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2006, BRIT J OPHTHALMOL, V90, P1333, DOI 10.1136/bjo.2006.102293
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   PETRI H, 1991, STAT MED, V10, P577, DOI 10.1002/sim.4780100409
   PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231
   Reed SD, 2008, HEALTH AFFAIR, V27, pW360, DOI 10.1377/hlthaff.27.5.w360
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rournie CL, 2008, PHARMACOEPIDEM DR S, V17, P20, DOI 10.1002/pds.1518
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   *US FDA, 2005, MEDWATCH SAF AV BEV
   White RH, 1999, AM J MED, V107, P414, DOI 10.1016/S0002-9343(99)00267-3
NR 34
TC 166
Z9 175
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD OCT
PY 2010
VL 128
IS 10
BP 1273
EP 1279
DI 10.1001/archophthalmol.2010.223
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 662WC
UT WOS:000282844000005
PM 20937996
OA Bronze
DA 2022-11-30
ER

PT J
AU Barresi, C
   Borrelli, E
   Fantaguzzi, F
   Grosso, D
   Sacconi, R
   Bandello, F
   Querques, G
AF Barresi, Costanza
   Borrelli, Enrico
   Fantaguzzi, Federico
   Grosso, Domenico
   Sacconi, Riccardo
   Bandello, Francesco
   Querques, Giuseppe
TI Complications Associated with Worse Visual Outcomes in Patients with
   Exudative Neovascular Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Neovascular age-related macular
   degeneration; Complications
ID RETINAL-PIGMENT EPITHELIUM; TREAT-AND-EXTEND; TISSUE-PLASMINOGEN
   ACTIVATOR; SUBMACULAR HEMORRHAGE; LASER PHOTOCOAGULATION; SUBRETINAL
   HEMORRHAGE; CLINICAL-TRIAL; RISK-FACTORS; RANIBIZUMAB; TEARS
AB Background: Neovascular age-related macular degeneration (AMD) represents a leading cause of vision loss in older subjects. The introduction of anti-vascular endothelial growth factor therapy has enormously improved the visual prognosis in these patients. Summary: However, severe complications may still occur in this disease and their development may significantly affect short- and long-term visual outcomes. Key Messages: In this article, we provided a review of these complications, highlighting their distinctive signs or symptoms and focusing on the current evidence of treatment. To place the complications related to neovascular AMD in a proper context, this review deals with core components essential for proper comprehension of neovascular AMD that includes pathogenesis, clinical signs, and basic principles of treatment.
C1 [Barresi, Costanza; Borrelli, Enrico; Fantaguzzi, Federico; Grosso, Domenico; Sacconi, Riccardo; Bandello, Francesco; Querques, Giuseppe] Vita Salute San Raffaele Univ Milan, Milan, Italy.
   [Barresi, Costanza; Borrelli, Enrico; Fantaguzzi, Federico; Grosso, Domenico; Sacconi, Riccardo; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Vita Salute San Raffaele Univ Milan, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Milan, Italy.
EM giuseppe.querques@hotmail.it
OI Borrelli, Enrico/0000-0003-2815-5031; Querques,
   Giuseppe/0000-0002-3292-9581; bandello, francesco/0000-0003-3238-9682;
   Sacconi, Riccardo/0000-0003-2891-2012
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2018, AM J OPHTHALMOL, V192, P84, DOI 10.1016/j.ajo.2018.05.008
   Akyol E, 2020, BIOL-TARGETS THER, V14, P83, DOI 10.2147/BTT.S252581
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Azzolini C, 1991, Eur J Ophthalmol, V1, P142
   Baumal CR, 2020, AM J MANAG CARE, V26, pS103, DOI 10.37765/ajmc.2020.43435
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Casalino G, 2018, OPHTHALMOL RETINA, V2, P451, DOI 10.1016/j.oret.2017.08.019
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Daniel E., 2015, NIH PUBLIC ACCESS
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hasegawa T, 2010, AM J OPHTHALMOL, V149, P322, DOI 10.1016/j.ajo.2009.09.012
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jung JH, 2010, RETINA-J RET VIT DIS, V30, P865, DOI 10.1097/IAE.0b013e3181c969e9
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57297-8
   Kim Tae Young, 2020, Korean J Ophthalmol, V34, P281, DOI 10.3341/kjo.2020.0014
   Lim LL., 2007, GARNER KLINTWORTHS P, P371
   Maberley D, 2005, Issues Emerg Health Technol, P1
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mertz L, 2019, IEEE PULSE, V10, P8, DOI 10.1109/MPULS.2019.2899702
   Moreira CA, 2013, RETINA-J RET VIT DIS, V33, P277, DOI 10.1097/IAE.0b013e318263d139
   Mouallem A, 2016, RETINA-J RET VIT DIS, V36, P2197, DOI 10.1097/IAE.0000000000001062
   Mukai R., 2014, ACTA OPHTHALMOL, V92, P2013
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Querques G, 2016, RETINA-J RET VIT DIS, V36, pS65, DOI 10.1097/IAE.0000000000001231
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Roberts SP., 1992, CLIN EYE VIS CARE, V4, P33
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Sastre-Ibanez M, 2019, J FR OPHTALMOL, V42, P63, DOI 10.1016/j.jfo.2018.04.017
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Toth CA., 2020, HHS PUBLIC ACCESS
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   YANNUZZI LA, 1982, OPHTHALMOLOGY, V89, P157
   Ying GS, 2016, OPHTHALMOLOGY, V123, P352, DOI 10.1016/j.ophtha.2015.09.046
   Yiu G, 2014, DEV OPHTHALMOL, V54, P213, DOI 10.1159/000360469
NR 82
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2021
VL 244
IS 6
BP 512
EP 522
DI 10.1159/000519518
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1U6VT
UT WOS:000805548500005
PM 34517374
OA Bronze
DA 2022-11-30
ER

PT J
AU Corvi, F
   Corradetti, G
   Tiosano, L
   McLaughlin, JA
   Lee, TK
   Sadda, SR
AF Corvi, Federico
   Corradetti, Giulia
   Tiosano, Liran
   McLaughlin, John Adam
   Lee, Thomas K.
   Sadda, Srinivas R.
TI Topography of choriocapillaris flow deficit predicts development of
   neovascularization or atrophy in age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choriocapillaris; Complete retinal
   pigment epithelial and outer retinal atrophy; Macular
   neovascularization; Optical coherence tomography angiography
AB Purpose To evaluate the relationship between choriocapillaris (CC), flow deficits (FD), and structural optical coherence tomography (OCT) biomarkers, and the progression of intermediate age-related macular degeneration (iAMD) to complete retinal pigment epithelial and outer retinal atrophy (cRORA) or macular neovascularization (MNV). Methods Consecutive patients with iAMD were sequentially reviewed to define three equal sized groups: progressed to MNV, progressed to cRORA, or remained stable over 12 months of follow-up. Odds ratios for progression to cRORA and MNV were estimated by logistic regression for intraretinal hyperreflective foci (IHRF), hyporeflective drusen cores (hDC), subretinal drusenoid deposits (SDDs), high central drusen volume, fellow eye with late AMD, and peripheral and central CC FD. Results Thirty iAMD eyes from 30 patients were enrolled into each group. The CC FD was greater in the peripheral sectors of the macula of eyes which progressed to cRORA compared to the other two groups (P < 0.0001). The central CC FD was also significantly impaired in eyes that progressed to cRORA or MNV compared to eyes that did not progress (P = 0.001 and P = 0.02, respectively). CC FD in the peripheral macula was significantly and independently associated with the development of cRORA, while CC FD in the center was significantly and independently associated with the development of MNV. Conclusions While the CC is diffusely impaired throughout the macula in iAMD eyes that progress to cRORA, it is relatively spared in the more peripheral macula among eyes which progress to MNV. These differential findings may have implications for the pathophysiology of the different late-stage manifestations of AMD.
C1 [Corvi, Federico; Corradetti, Giulia; Tiosano, Liran; Sadda, Srinivas R.] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA 90095 USA.
   [Corvi, Federico; Corradetti, Giulia; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Corvi, Federico] Univ Milan, Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Tiosano, Liran] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [McLaughlin, John Adam; Lee, Thomas K.] Univ Ottawa, Dept Ophthalmol, Retina Ctr Ottawa, Ottawa, ON, Canada.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of Milan;
   Luigi Sacco Hospital; Hebrew University of Jerusalem; University of
   Ottawa
RP Sadda, SR (通讯作者)，Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA 90095 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
OI Corvi, Federico/0000-0002-2661-5500
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Alagorie AR, 2020, RETINA-J RET VIT DIS, V40, P2106, DOI 10.1097/IAE.0000000000002878
   Alagorie AR, 2020, GRAEF ARCH CLIN EXP, V258, P995, DOI 10.1007/s00417-020-04615-w
   Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Byon I, 2020, AM J OPHTHALMOL, V219, P21, DOI 10.1016/j.ajo.2020.05.027
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Corradetti G, 2021, BRIT J OPHTHALMOL, V105, P1584, DOI 10.1136/bjophthalmol-2020-316893
   Corvi F, 2021, EYE, V35, P110, DOI 10.1038/s41433-020-01217-y
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Corvi F, 2021, GRAEF ARCH CLIN EXP, V259, P291, DOI 10.1007/s00417-020-04821-6
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lane M, 2016, INVEST OPHTH VIS SCI, V57
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Moult EM, 2020, AM J OPHTHALMOL, V214, P172, DOI 10.1016/j.ajo.2019.12.006
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nattagh Khashayar, 2020, Transl Vis Sci Technol, V9, P6, DOI 10.1167/tvst.9.7.6
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
NR 41
TC 10
Z9 10
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2021
VL 259
IS 10
BP 2887
EP 2895
DI 10.1007/s00417-021-05167-3
EA APR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UX9SZ
UT WOS:000644280200001
PM 33900443
DA 2022-11-30
ER

PT J
AU Feng, LL
   Ju, MH
   Lee, KYV
   Mackey, A
   Evangelista, M
   Iwata, D
   Adamson, P
   Lashkari, K
   Foxton, R
   Shima, D
   Ng, YS
AF Feng, Lili
   Ju, Meihua
   Lee, Kei Ying V.
   Mackey, Ashley
   Evangelista, Mariasilvia
   Iwata, Daiju
   Adamson, Peter
   Lashkari, Kameran
   Foxton, Richard
   Shima, David
   Ng, Yin Shan
TI A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal
   Pigment Epithelium as a Novel Target for Reducing Choroidal
   Neovascularization in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; CHLAMYDIA-PNEUMONIAE;
   INCREASED EXPRESSION; OXIDATIVE STRESS; TRANSGENIC MICE; INNATE
   IMMUNITY; VEGF-A; RANIBIZUMAB; ANGIOGENESIS
AB Current treatments for choroidal neovascularization, a major cause of blindness for patients with age related macular degeneration, treat symptoms but not the underlying causes of the disease. Inflammation has been strongly implicated in the pathogenesis of choroidal neovascularization. We examined the inflammatory role of Toll-Like receptor 2 (TLR2) in age-related macular degeneration. TLR2 was robustly expressed by the retinal pigment epithelium in mouse and human eyes, both normal and with macular degeneration/choroidal neovascularization. Nuclear Localization of NF-kappa B, a major downstream target of TLR2 signaling, was detected in the retinal pigment epithelium of human eyes, particularly in eyes with advanced stages of age-related macular degeneration. TLR2 antagonism effectively suppressed initiation and growth of spontaneous choroidal neovascularization in a mouse model, and the combination of anti-TLR2 and antivascular endothelial growth factor receptor 2 yielded an additive therapeutic effect on both area and number of spontaneous choroidal neovascularization lesions. Finally, in primary human fetal retinal pigment epithelium cells, Ligand binding to TLR2 induced robust expression of proinflammatory cytokines, and end products of lipid oxidation had a synergistic effect on TLR2 activation. Our data illustrate a functional role for TLR2 in the pathogenesis of choroidal neovascularization, likely by promoting inflammation of the retinal pigment epithelium, and validate TLR2 as a novel therapeutic target for reducing choroidal neovascularization.
C1 [Feng, Lili; Mackey, Ashley; Evangelista, Mariasilvia; Lashkari, Kameran; Ng, Yin Shan] Harvard Med Sch, Dept Ophthalmol, Schepens Eye Res Inst Massachusetts Eye & Ear, 20 Staniford St, Boston, MA 02114 USA.
   [Ju, Meihua; Lee, Kei Ying V.; Iwata, Daiju; Foxton, Richard; Shima, David] Dept Ocular Biol & Therapeut, London, England.
   [Ju, Meihua; Lee, Kei Ying V.; Iwata, Daiju; Adamson, Peter; Foxton, Richard; Shima, David] UCL, Inst Ophthalmol, London, England.
C3 Harvard University; Harvard Medical School; University of London;
   University College London
RP Ng, YS (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Schepens Eye Res Inst Massachusetts Eye & Ear, 20 Staniford St, Boston, MA 02114 USA.
EM eric_ng@meei.harvard.edu
OI Ng, Yin Shan/0000-0002-4982-1999; Lashkari, Kameran/0000-0003-3855-0246
FU BrightFocus Foundation Macular Degeneration Research (MDR) grant
   [M2015214]; Grimshaw-Gudewicz Charitable Foundation; MB National Eye
   Institute Core grant [P30EY003790]; NIHR Biomedical Research Centre for
   Ophthalmology (UK); NATIONAL EYE INSTITUTE [P30EY003790] Funding Source:
   NIH RePORTER
FX Supported by the BrightFocus Foundation Macular Degeneration Research
   (MDR) grant M2015214 (Y.S.N.), a grant from the Grimshaw-Gudewicz
   Charitable Foundation (Y.S.N.), and the MB National Eye Institute Core
   grant P30EY003790 for Schepens Eye Research Institute. UCL Institute of
   Ophthalmology is supported by the NIHR Biomedical Research Centre for
   Ophthalmology (UK).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955
   Cousins SW, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002671
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Doyle SL, 2015, INVEST OPHTH VIS SCI, V56, P5424, DOI 10.1167/iovs.15-17264
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erridge C, 2010, J LEUKOCYTE BIOL, V87, P989, DOI 10.1189/jlb.1209775
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gay NJ, 2007, ANNU REV BIOCHEM, V76, P141, DOI 10.1146/annurev.biochem.76.060305.151318
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grote K, 2011, THESCIENTIFICWORLDJO, V11, P981, DOI 10.1100/tsw.2011.92
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maminishkis Arvydas, 2010, J Vis Exp, DOI 10.3791/2032
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Nagai N, 2015, AM J PATHOL, V185, P2534, DOI 10.1016/j.ajpath.2015.04.029
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saeed AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106421
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Wooten RM, 2002, J IMMUNOL, V168, P348, DOI 10.4049/jimmunol.168.1.348
   Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 52
TC 18
Z9 18
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2017
VL 187
IS 10
BP 2208
EP 2221
DI 10.1016/j.ajpath.2017.06.015
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FI0ZQ
UT WOS:000411658900009
PM 28739342
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Matsumoto, H
   Hoshino, J
   Mukai, R
   Nakamura, K
   Akiyama, H
AF Matsumoto, Hidetaka
   Hoshino, Junki
   Mukai, Ryo
   Nakamura, Kosuke
   Akiyama, Hideo
TI Short-term outcomes of intravitreal brolucizumab for treatment-naive
   neovascular age-related macular degeneration with type 1 choroidal
   neovascularization including polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
AB We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naive nAMD associated with type 1 CNV. Three monthly injections of brolucizumab were completed in 36 eyes (85.7%). In those cases, best-corrected visual acuity (BCVA) was 0.24 +/- 0.27 at baseline and improved significantly to 0.12 +/- 0.23 after 3 months (P<0.001). Central macular thickness was 301<plus/minus>110 mu m at baseline and decreased significantly to 160 +/- 49 mu m after 3 months (P<0.001). Dry macula was achieved in 34 eyes (94.4%) after the loading phase. Central choroidal thickness was 264<plus/minus>89 mu m at baseline and decreased significantly to 223 +/- 81 mu m after 3 months (P<0.001). Indocyanine green angiography after the loading phase revealed complete regression of polypoidal lesions in 15 of the 19 eyes (78.9%) with polypoidal lesions. Non-infectious intraocular inflammation (IOI) was observed in 8 of 42 eyes (19.0%) during the loading phase, while showing amelioration in response to combination therapy with topical and subtenon injection of steroids. In these eyes, BCVA after 3 months had not deteriorated as compared to that at baseline. These results indicate that loading phase treatment with intravitreal brolucizumab might be effective for improving visual acuity and reducing exudative changes in eyes with nAMD associated with type 1 CNV. Moreover, polypoidal lesions appear to frequently regress after this treatment. However, we must monitor patients carefully for brolucizumab-related IOI, and administer steroid therapy promptly.
C1 [Matsumoto, Hidetaka; Hoshino, Junki; Mukai, Ryo; Nakamura, Kosuke; Akiyama, Hideo] Gunma Univ, Grad Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Grad Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Cho SC, 2021, ACTA OPHTHALMOL, V99, pE706, DOI 10.1111/aos.14676
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Kataoka K, 2021, JPN J OPHTHALMOL, V65, P199, DOI 10.1007/s10384-021-00818-8
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Sato T, 2013, AM J OPHTHALMOL, V156, P95, DOI 10.1016/j.ajo.2013.02.006
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yanai H., 2015, STATCEL USEFUL ADD I
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoshihara N, 2017, RETINA-J RET VIT DIS, V37, P179, DOI 10.1097/IAE.0000000000001117
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 30
TC 25
Z9 25
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 24
PY 2021
VL 11
IS 1
AR 6759
DI 10.1038/s41598-021-86014-7
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RF6SN
UT WOS:000634972100009
PM 33762600
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Brand, C
   Arnoldussen, M
AF Brand, Christopher
   Arnoldussen, Mark
TI IRay therapy as an adjuvant therapy in newly diagnosed patients with
   neovascular age-related macular degeneration
SO EYE
LA English
DT Article
ID VISUAL-ACUITY OUTCOMES; STEREOTACTIC RADIOTHERAPY; RANIBIZUMAB;
   AFLIBERCEPT
AB Objectives To determine the safety and efficacy at 12 months of follow-up after stereotactic radiotherapy in combination therapy with intravitreal ranibizumab injections in treatment naive patients with neovascular age-related macular degeneration.
   Methods Retrospective data analysis in patients who received stereotactic radiotherapy (IRay Therapy) during the induction phase of intravitreal ranibizumab injections and a monotherapy control group.
   Results The baseline VA in the IRay and control group was 59.87 and 59.12 letters respectively. The real world visual acuity outcomes for the IRay group showed a mean gain of +3.0 letters at 12 months. The historical control group had a mean change of -0.3 letters. The average number of injections for the IRay group and control group over 12 months was 4.45 and 5.64, respectively with three loading injections. Excluding the loading phase, the difference over 12 months was a 45.2% reduction in injections (P < 0.001). The number of subjects in the IRay group that didn't require farther injections following the loading phase was 45.5 vs. 24.0% control group (P = 0.005). The difference in mean change in central macular thickness from baseline is significant at 6 (P = 0.010) and 12 months (P < 0.01). There were no safety concerns with the IRay therapy group.
   Conclusions Stereotactic radiotherapy in the induction phase of intravitreal injections of ranibizumab for treatment naive patients with neovascular age-related macular degeneration, resulted in improved visual outcome, statistically fewer injections and statistically drier macular at 12 months, compared to historical controls treated with monotherapy intravitreal ranibizumab injections.
C1 [Brand, Christopher] Sheffield Hosp NHS Fdn Trust, Eye Dept, Sheffield, S Yorkshire, England.
   [Arnoldussen, Mark] Carl Zeiss Meditec Inc, Dublin, CA USA.
C3 Carl Zeiss AG
RP Brand, C (通讯作者)，Sheffield Hosp NHS Fdn Trust, Eye Dept, Sheffield, S Yorkshire, England.
EM Christopher.brand@sth.nhs.uk
FU Bayer; Novartis; Oraya Therapeutics
FX CB has received travel bursaries and attended advisory board meetings
   for Bayer, Novartis and Oraya Therapeutics. MA is an employee of Carl
   Zeiss, and was involved in the writing of this paper and statistical
   analysis.
CR [Anonymous], 2008, RANIBIZUMAB PEGAPTAN
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Ranjbar M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005729
   Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 16
TC 5
Z9 5
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2018
VL 32
IS 8
BP 1345
EP 1352
DI 10.1038/s41433-018-0080-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP8GQ
UT WOS:000441148700009
PM 29662155
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Willoughby, AS
   Ying, GS
   Toth, CA
   Maguire, MG
   Burns, RE
   Grunwald, JE
   Daniel, E
   Jaffe, GJ
AF Willoughby, Alex S.
   Ying, Gui-shuang
   Toth, Cynthia A.
   Maguire, Maureen G.
   Burns, Russell E.
   Grunwald, Juan E.
   Daniel, Ebenezer
   Jaffe, Glenn J.
CA Comparison Age-Related Macular
TI Subretinal Hyperreflective Material in the Comparison of Age-Related
   Macular Degeneration Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY LOSS; PHOTORECEPTOR LAYER; RANIBIZUMAB; RISK
AB Purpose: To evaluate the association of subretinal hyperreflective material (SHRM) with visual acuity (VA), geographic atrophy (GA), and scar in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
   Design: Prospective cohort study within a randomized clinical trial.
   Participants: The 1185 CATT participants.
   Methods: Masked readers graded scar and GA on fundus photography and fluorescein angiography and graded SHRM on time-domain and spectral-domain (SD) optical coherence tomography (OCT) throughout 104 weeks. Measurements of SHRM height and width in the fovea, within the center 1 mm(2), or outside the center 1mm(2) were obtained on SD OCT images at 56 (n = 76) and 104 (n = 66) weeks.
   Main Outcome Measures: Presence of SHRM, as well as location and size, and associations with VA, scar, and GA.
   Results: Among CATT participants, the percentage with SHRM at enrollment was 77%, decreasing to 68% at 4 weeks after treatment and to 54% at 104 weeks. At 104 weeks, scar was present more often in eyes with persistent SHRM than in eyes with SHRM that resolved (64% vs. 31%; P < 0.0001). Among eyes with detailed evaluation of SHRM at weeks 56 (n = 76) and 104 (n = 66), mean VA letter score was 73.5 (standard error [SE], 2.8), 73.1 (SE, 3.4), 65.3 (SE, 3.5), and 63.9 (SE, 3.7) when SHRM was absent, present outside the central 1mm(2), present within the central 1mm(2) but not the foveal center, or present at the foveal center (P = 0.02), respectively. When SHRM was present, the median maximum height under the fovea, within the central 1mm(2) including the fovea and anywhere within the scan, was 86 mm, 120 mm, and 122 mm, respectively. Visual acuity was decreased with greater SHRM height and width (P < 0.05).
   Conclusions: In eyes with neovascular age-related macular degeneration (AMD), SHRM is common and often persists after antievascular endothelial growth factor treatment. At 2 years, eyes with scar were more likely to have SHRM than other eyes. Greater SHRM dimensions were associated with worse VA. In eyes with neovascular AMD, SHRM is an important morphologic biomarker. (C) 2015 by the American Academy of Ophthalmology.
C1 [Willoughby, Alex S.; Toth, Cynthia A.; Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Ying, Gui-shuang; Maguire, Maureen G.; Grunwald, Juan E.; Daniel, Ebenezer] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Burns, Russell E.] Duke Reading Ctr, Durham, NC USA.
C3 Duke University; University of Pennsylvania; Pennsylvania Medicine
RP Jaffe, GJ (通讯作者)，Duke Eye Ctr, Box 3802, Durham, NC 27710 USA.
EM glenn.jaffe@dm.duke.edu
RI Toth, Cynthia/L-5534-2019; Ciulla, Thomas/AAA-1299-2020; Hwang, Thomas
   S./AAW-6618-2020
OI Toth, Cynthia/0000-0002-2324-0854; Ciulla, Thomas/0000-0001-5557-6777;
   Hwang, Thomas S./0000-0002-0535-4823; Vavvas,
   Demetrios/0000-0002-8622-6478; Ho, Allen/0000-0003-3921-608X; Elman,
   Michael/0000-0001-7726-9508; Stinnett, Sandra/0000-0001-7192-0195;
   Ferris, Frederick/0000-0002-4933-0639; Russell,
   Stephen/0000-0003-3776-1367; Johnson, Mark W/0000-0001-9720-8761; Folk,
   James/0000-0002-6271-2906; mruthyunjaya, prithvi/0000-0003-1087-9736;
   Losordo, Douglas/0000-0002-6857-7506; Bailey,
   Steven/0000-0003-4949-1464; Morse, Lawrence/0000-0002-1758-2348
FU Bioptigen (Morrisville, NC); Genentech (San Francisco, CA); Physical
   Sciences Inc (Andover, MA); Patent - Alcon Laboratories (Fort Worth,
   TX); National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; NATIONAL EYE INSTITUTE [U10EY017828, R21EY023689,
   U10EY017825] Funding Source: NIH RePORTER
FX C.A.T.: Financial Support - Bioptigen (Morrisville, NC), Genentech (San
   Francisco, CA), Physical Sciences Inc (Andover, MA).; Patent - Alcon
   Laboratories (Fort Worth, TX); Supported by the National Eye Institute,
   National Institutes of Health, Bethesda, Maryland (cooperative agreement
   nos.: U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828, and
   R21EY023689). The sponsor or funding organization had no role in the
   design or conduct of this research.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saxena S, 2014, CLIN OPHTHALMOL, V8, P2507, DOI 10.2147/OPTH.S72132
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Theodossiadis PG, 2011, OPHTHALMOLOGICA, V225, P176, DOI 10.1159/000323322
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 16
TC 108
Z9 111
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2015
VL 122
IS 9
BP 1846
EP +
DI 10.1016/j.ophtha.2015.05.042
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP8BU
UT WOS:000360116900025
PM 26143666
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sniatecki, JJ
   Ho-Yen, G
   Clarke, B
   Barbara, R
   Lash, S
   Papathomas, T
   Antonakis, S
   Gupta, B
AF Sniatecki, Jan Janusz
   Ho-Yen, Gregory
   Clarke, Benjamin
   Barbara, Ramez
   Lash, Stephen
   Papathomas, Thomas
   Antonakis, Serafeim
   Gupta, Bhaskar
TI Treatment of submacular hemorrhage with tissue plasminogen activator and
   pneumatic displacement in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Wet age-related macular degeneration; submacular hemorrhage; tissue
   plasminogen activator; pneumatic displacement; subretinal tissue
   plasminogen activator; intravitreal tissue plasminogen activator
ID SUBRETINAL HEMORRHAGE; MANAGEMENT; VITRECTOMY; AMD
AB Purpose: To evaluate visual and anatomic outcomes following pars plana vitrectomy and intravitreal or subretinal tissue plasminogen activator for submacular hemorrhage in patients with age-related macular degeneration. Methods: This was a retrospective study on patients with a minimum follow-up of 12 months undertaken at a tertiary referral center. Data collected include demographic details, visual and optical coherence tomography changes, surgical details, and complications. Surgical results were compared with patients who were age and lesion size matched and treated with anti-vascular endothelial growth factor injections alone. Results: There were 36 patients in surgical and 18 patients in control group. Patients in surgical arm had pars plana vitrectomy, intravitreal tissue plasminogen activator with air 24 (67%), 6 (16%) with C3F8 gas, 1 (3%) with SF6 gas, 4 (11%) subretinal tissue plasminogen activator with air, and 1 (3%) with C2F6 as post-operative tamponade. Mean LogMAR in tissue plasminogen activator group at baseline was 1.56, and it was improved at all time points 1.06 at 1 month (p < 0.05), 0.91 at 6 months (p < 0.05), and 1.07 at 1 year (p < 0.05). Mean best corrected visual acuity in control group at baseline was 1.22LogMAR with no significant improvement at any time points: 1 month (1.27), 6 months (1.35), and 12 months (1.36). Complications included retinal detachment 5%, vitreous hemorrhage 7.5%, and cataract 19%. Conclusion: Pars plana vitrectomy with intravitreal (or subretinal) tissue plasminogen activator and pneumatic displacement can offer better outcome in comparison to anti-vascular endothelial growth factor alone in patients with submacular hemorrhage secondary to age-related macular degeneration.
C1 [Sniatecki, Jan Janusz; Ho-Yen, Gregory; Clarke, Benjamin; Barbara, Ramez; Lash, Stephen; Papathomas, Thomas; Antonakis, Serafeim; Gupta, Bhaskar] Univ Hosp Southampton NHS Fdn Trust, Tremona Rd, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University Hospital Southampton NHS
   Foundation Trust
RP Sniatecki, JJ (通讯作者)，Univ Hosp Southampton NHS Fdn Trust, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM jan.sniatecki@gmail.com
RI Sniatecki, Jan J/C-4826-2017
OI Sniatecki, Jan J/0000-0001-8945-2094
CR Al-Hity A, 2019, EYE, V33, P486, DOI 10.1038/s41433-018-0239-4
   Bardak H, 2018, EUR J OPHTHALMOL, V28, P306, DOI 10.5301/ejo.5001074
   Bell JE, 2016, OPHTHAL SURG LAS IM, V48, P26
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   de Silva SR, 2016, EYE, V30, P952, DOI 10.1038/eye.2016.67
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gok M, 2017, INDIAN J OPHTHALMOL, V65, P482, DOI 10.4103/ijo.IJO_129_16
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Lange C, GRAEFES ARCH CLIN EX, V247, P137
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Tognetto D, 2011, CLIN OPHTHALMOL, V5, P459, DOI 10.2147/OPTH.S15864
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2017, GRAEF ARCH CLIN EXP, V255, P1115, DOI 10.1007/s00417-017-3620-2
NR 15
TC 5
Z9 5
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2021
VL 31
IS 2
BP 643
EP 648
AR 1120672119891625
DI 10.1177/1120672119891625
EA DEC 2019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SB1ZQ
UT WOS:000501955100001
PM 31813290
DA 2022-11-30
ER

PT J
AU Hanout, M
   Ferraz, D
   Ansari, M
   Maqsood, N
   Kherani, S
   Sepah, YJ
   Rajagopalan, N
   Ibrahim, M
   Do, DV
   Nguyen, DQ
AF Hanout, Mostafa
   Ferraz, Daniel
   Ansari, Mehreen
   Maqsood, Natasha
   Kherani, Saleema
   Sepah, Yasir J.
   Rajagopalan, Nithya
   Ibrahim, Mohamed
   Do, Diana V.
   Quan Dong Nguyen
TI Therapies for Neovascular Age-Related Macular Degeneration: Current
   Approaches and Pharmacologic Agents in Development
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; DOUBLE-STRANDED-RNA; FACTOR
   TRAP-EYE; EPIMACULAR BRACHYTHERAPY; LASER PHOTOCOAGULATION; PHOTODYNAMIC
   THERAPY; SR-90 BRACHYTHERAPY; EMERGING THERAPIES; INDUCED MIGRATION;
   VERTEPORFIN PDT
AB As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.
C1 [Hanout, Mostafa; Ferraz, Daniel; Ansari, Mehreen; Maqsood, Natasha; Kherani, Saleema; Sepah, Yasir J.; Ibrahim, Mohamed] Johns Hopkins Univ, Wilmer Eye Inst, Retinal Imaging Res & Reading Ctr, Sch Med, Baltimore, MD 21218 USA.
   [Hanout, Mostafa; Sepah, Yasir J.; Rajagopalan, Nithya; Ibrahim, Mohamed; Do, Diana V.; Quan Dong Nguyen] Univ Nebraska Med Ctr, Ocular Imaging Res & Reading Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA.
   [Ferraz, Daniel] Univ Sao Paulo, Sch Med, Dept Ophthalmol, Retina Serv, BR-05403000 Sao Paulo, Brazil.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Nebraska
   System; University of Nebraska Medical Center; Universidade de Sao Paulo
RP Nguyen, DQ (通讯作者)，Univ Nebraska Med Ctr, Ocular Imaging Res & Reading Ctr, Stanley M Truhlsen Eye Inst, 3902 Leavenworth St, Omaha, NE USA.
EM quan.nguyen@unmc.edu
RI Ibrahim, Mohamed Fahmy/AAP-7467-2021; Hanout, Mostafa/Q-6840-2017;
   Kherani, Saleema/AAD-8723-2019
OI Hanout, Mostafa/0000-0001-7829-9776; 
CR Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Barik S, 2004, ANN MED, V36, P540, DOI 10.1080/07853890410018817
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen X, 2013, DIABETES OBES METAB, V15, P224, DOI 10.1111/dom.12008
   Cross WG, 2001, MED PHYS, V28, P1385, DOI 10.1118/1.1376442
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Eric H., 2011, ARVO
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521
   GlaxoSmithKline, SAF STUD EX PAZ EYE
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jackson TL, 2012, EYE, V26, P557, DOI 10.1038/eye.2011.351
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lpath Inc, EFF SAF STUD ISONEP
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Molecular Partners AG, 2010, PHAS 1 2 OP LAB NONC
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   National Eye Institute (NEI), PAL 529 PAT NEOV AG
   Novartis N.C.I., SAF EFF OR PTK787 PA
   Ohr Pharmaceutical Inc, EFF SAF SQUAL LACT E
   Ophthotech Corporation, 2012, SAF EFF STUD E10030
   Ophthotech Corporation, 2012, PHAS 1 SAF TOL PHARM
   Oraya Therapeutics Inc., DOUBL MASK SHAM CONT
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Roundtable V., 2002, RETINA, V22, P6
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   van Ginderdeuren R, 2005, BRIT J OPHTHALMOL, V89, P1306, DOI 10.1136/bjo.2005.068460
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
NR 62
TC 32
Z9 32
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
VL 2013
AR 830837
DI 10.1155/2013/830837
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 257AR
UT WOS:000327355800001
PM 24319688
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Baas, DC
   Despriet, DD
   Gorgels, TGMF
   Bergeron-Sawitzke, J
   Uitterlinden, AG
   Hofman, A
   van Duijn, CM
   Merriam, JE
   Smith, RT
   Barile, GR
   ten Brink, JB
   Vingerling, JR
   Klaver, CCW
   Allikmets, R
   Dean, M
   Bergen, AAB
AF Baas, Dominique C.
   Despriet, Dominiek D.
   Gorgels, Theo G. M. F.
   Bergeron-Sawitzke, Julie
   Uitterlinden, Andre G.
   Hofman, Albert
   van Duijn, Cornelia M.
   Merriam, Joanna E.
   Smith, R. Theodore
   Barile, Gaetano R.
   ten Brink, Jacoline B.
   Vingerling, Johannes R.
   Klaver, Caroline C. W.
   Allikmets, Rando
   Dean, Michael
   Bergen, Arthur A. B.
TI The ERCC6 Gene and Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; COCKAYNE-SYNDROME; OXIDATIVE STRESS; RISK; REPAIR;
   POLYMORPHISM; MACULOPATHY; ROTTERDAM; VARIANT; DAMAGE
AB Background: Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the developed countries and is caused by both environmental and genetic factors. A recent study (Tuo et al., PNAS) reported an association between AMD and a single nucleotide polymorphism (SNP) (rs3793784) in the ERCC6 (NM_000124) gene. The risk allele also increased ERCC6 expression. ERCC6 is involved in DNA repair and mutations in ERCC6 cause Cockayne syndrome (CS). Amongst others, photosensitivity and pigmentary retinopathy are hallmarks of CS.
   Methodology/Principal Findings: Separate and combined data from three large AMD case-control studies and a prospective population-based study (The Rotterdam Study) were used to analyse the genetic association between ERCC6 and AMD (2682 AMD cases and 3152 controls). We also measured ERCC6 mRNA levels in retinal pigment epithelium (RPE) cells of healthy and early AMD affected human donor eyes. Rs3793784 conferred a small increase in risk for late AMD in the Dutch population (The Rotterdam and AMRO-NL study), but this was not replicated in two non-European studies (AREDS, Columbia University). In addition, the AMRO-NL study revealed no significant association for 9 other variants spanning ERCC6. Finally, we determined that ERCC6 expression in the human RPE did not depend on rs3793784 genotype, but, interestingly, on AMD status: Early AMD-affected donor eyes had a 50% lower ERCC6 expression than healthy donor eyes (P = 0.018).
   Conclusions/Significance: Our meta-analysis of four Caucasian cohorts does not replicate the reported association between SNPs in ERCC6 and AMD. Nevertheless, our findings on ERCC6 expression in the RPE suggest that ERCC6 may be functionally involved in AMD. Combining our data with those of the literature, we hypothesize that the AMD-related reduced transcriptional activity of ERCC6 may be caused by diverse, small and heterogeneous genetic and/or environmental determinants.
C1 [Baas, Dominique C.; Gorgels, Theo G. M. F.; ten Brink, Jacoline B.; Bergen, Arthur A. B.] Royal Netherlands Acad Arts & Sci KNAW, Dept Clin & Mol Ophthalmogenet, Netherlands Inst Neurosci NIN, Amsterdam, Netherlands.
   [Despriet, Dominiek D.; Uitterlinden, Andre G.; Hofman, Albert; van Duijn, Cornelia M.; Vingerling, Johannes R.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Bergeron-Sawitzke, Julie] SAIC Frederick, Basic Sci Program, Human Genet Sect, Frederick, MD USA.
   [Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   [Merriam, Joanna E.; Smith, R. Theodore; Barile, Gaetano R.; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Merriam, Joanna E.; Smith, R. Theodore; Barile, Gaetano R.; Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10027 USA.
   [Dean, Michael] NCI, Expt Immunol Lab, Canc & Inflammat Program, Frederick, MD 21701 USA.
   [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Bergen, Arthur A. B.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Science Applications International Corporation (SAIC); SAIC-Frederick;
   Erasmus University Rotterdam; Erasmus MC; Columbia University; Columbia
   University; National Institutes of Health (NIH) - USA; NIH National
   Cancer Institute (NCI); University of Amsterdam; Academic Medical Center
   Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam;
   Vrije Universiteit Amsterdam
RP Baas, DC (通讯作者)，Royal Netherlands Acad Arts & Sci KNAW, Dept Clin & Mol Ophthalmogenet, Netherlands Inst Neurosci NIN, Amsterdam, Netherlands.
EM a.bergen@nin.knaw.nl
RI Bergen, Arthur/J-3637-2013; Allikmets, Rando/ABD-4533-2021; Dean,
   Michael C/G-8172-2012; Dean, Michael/R-7501-2019; Klaver, Caroline
   C.W./A-2013-2016
OI Dean, Michael C/0000-0003-2234-0631; smith,
   theodore/0000-0002-1693-943X; Van Duijn, Cornelia/0000-0002-2374-9204;
   Bergen, Arthur/0000-0002-6333-9576; Sawitzke, Julie/0000-0002-1715-4626;
   Klaver, Caroline/0000-0002-2355-5258; Baas, Dominique
   C./0000-0003-0989-9828
FU Merck & Co, Inc., NJ, USA; Nederlandse Vereniging ter Voorkoming van
   Blindheid; Dutch Macula Foundation; LSBS; Oogfonds Nederland; de
   Rotterdamse Vereniging Blindenbelangen; Netherlands Organization of
   Scientific Research NWO Investments [175.010.2005.011, 911-03-012];
   Research Institute for Diseases in the Elderly [014-93-015, RIDE2];
   Netherlands Genomics Initiative (NGI)/Netherlands Organization for
   Scientific Research (NWO) [050-060-810]; Erasmus Medical Center; Erasmus
   University, Rotterdam; Netherlands Organization for the Health Research
   and Development (ZonMw); Research Institute for Diseases in the Elderly
   (RIDE),; Ministry for Health, Welfare and Sports; European Commission;
   Municipality of Rotterdam; National Eye Institute [EY13435, EY017404];
   Macula Vision Research Foundation; Kaplen Foundation; Wigdeon Point
   Charitable Foundation; Research to Prevent Blindness, Inc.; Merck Co;
   Ministry of Education, Culture and Science; NATIONAL CANCER INSTITUTE
   [ZIABC011301] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY013435, R24EY017404] Funding Source: NIH RePORTER
FX This work was in part supported by an unrestricted research grant from
   Merck & Co, Inc., NJ, USA and the Nederlandse Vereniging ter Voorkoming
   van Blindheid, The Dutch Macula Foundation, the LSBS, the Oogfonds
   Nederland, de Rotterdamse Vereniging Blindenbelangen (to A. A. B.). The
   generation and management of GWAS genotype data for the Rotterdam Study
   is supported by the Netherlands Organization of Scientific Research NWO
   Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by
   the Research Institute for Diseases in the Elderly (014-93-015; RIDE2),
   the Netherlands Genomics Initiative (NGI)/Netherlands Organization for
   Scientific Research (NWO) project nr. 050-060-810, and funding from the
   Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands
   Organization for the Health Research and Development (ZonMw), the
   Research Institute for Diseases in the Elderly (RIDE), the Ministry of
   Education, Culture and Science, the Ministry for Health, Welfare and
   Sports, the European Commission (DG XII), and the Municipality of
   Rotterdam. The Columbia University study population is supported in part
   by the grants from the National Eye Institute EY13435 and EY017404; the
   Macula Vision Research Foundation; Kaplen Foundation; Wigdeon Point
   Charitable Foundation and an unrestricted grant to the Department of
   Ophthalmology, Columbia University, from Research to Prevent Blindness,
   Inc. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; The
   funding of Merck & Co was an unrestricted grant to A. A. B. and did not,
   in any way, interfere with the conception and/or design and/or outcome
   and/or publication of this study. This does not alter the authors'
   adherence to all the PLoS ONE policies on sharing data and materials.
CR Age related eye disease study research group, 2001, ARCH OPHTHALMOL, V119, P1439
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Assink JJM, 1997, AM J HUM GENET, V61, P934, DOI 10.1086/514884
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   de Waard H, 2003, DNA REPAIR, V2, P13, DOI 10.1016/S1568-7864(02)00188-X
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorgels TGMF, 2007, MOL CELL BIOL, V27, P1433, DOI 10.1128/MCB.01037-06
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Hofman A, 2007, EUR J EPIDEMIOL, V22, P819, DOI 10.1007/s10654-007-9199-x
   HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012
   Hu XF, 2004, GENET TEST, V8, P292, DOI 10.1089/gte.2004.8.292
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686
   NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Spivak G, 2006, DNA REPAIR, V5, P13, DOI 10.1016/j.dnarep.2005.06.017
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com
   van der Pluijm I, 2007, PLOS BIOL, V5, P23, DOI 10.1371/journal.pbio.0050002
   van Soest SS, 2007, MOL VIS, V13, P1608
   vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 50
TC 20
Z9 21
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 1
PY 2010
VL 5
IS 11
AR e13786
DI 10.1371/journal.pone.0013786
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 673FY
UT WOS:000283645700009
PM 21072178
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Moschos, MM
   Nitoda, E
   Chatziralli, IP
   Demopoulos, CA
AF Moschos, Marilita M.
   Nitoda, Eirini
   Chatziralli, Irini P.
   Demopoulos, Constantinos A.
TI Age-Related Macular Degeneration: Pathogenesis, Genetic Background, and
   the Role of Nutritional Supplements
SO JOURNAL OF CHEMISTRY
LA English
DT Review
ID PLATELET-ACTIVATING-FACTOR; COMPLEMENT-FACTOR-H; NECROSIS-FACTOR-ALPHA;
   RISK-FACTORS; FACTOR B; CIGARETTE-SMOKING; DOCOSAHEXAENOIC ACID;
   POLYMORPHISMS; MACULOPATHY; EYE
AB Age-related macular degeneration (ARMD) is the leading cause of severe vision loss and blindness worldwide, mainly affecting people over 65 years old. Dry and wet ARDM are the main types of the disease, which seem to have a multifactorial background. The aim of this review is to summarize the mechanisms of ARMD pathogenesis and exhibit the role of diet and nutritional supplements in the onset and progression of the disease. Environmental factors, such as smoking, alcohol, and, diet appear to interact with mutations in nuclear and mitochondrial DNA, contributing to the pathogenesis of ARMD. Inflammatory mediators and oxidative stress, induced by the daily exposure of retina to high pressure of oxygen and light radiation, have been also associated with ARMD lesions. Other than medical and surgical therapies, nutritional supplements hold a significant role in the prevention and treatment of ARMD, eliminating the progression of macular degeneration.
C1 [Moschos, Marilita M.; Nitoda, Eirini; Chatziralli, Irini P.] Natl & Kapodistrian Univ Athens, Sch Med, Dept Ophthalmol 1, Athens 11527, Greece.
   [Demopoulos, Constantinos A.] Natl & Kapodistrian Univ Athens, Fac Chem, Biochem Lab, Athens 11527, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   National & Kapodistrian University of Athens
RP Moschos, MM (通讯作者)，Natl & Kapodistrian Univ Athens, Sch Med, Dept Ophthalmol 1, 154 Mesog St, Athens 11527, Greece.
EM moschosmarilita@yahoo.fr
RI Demopoulos, Constantinos/AAC-6148-2020; Chatziralli, Irini/AAG-4779-2020
OI Demopoulos, Constantinos/0000-0003-2038-4411; Chatziralli,
   Irini/0000-0001-8523-1024; Nitoda, Eirini/0000-0003-3246-0709
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Alberg AJ, 2002, TOXICOLOGY, V180, P121, DOI 10.1016/S0300-483X(02)00386-4
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   [Anonymous], 1994, NEW ENGL J MED, V330, P1029
   Arai H, 2002, PROSTAG OTH LIPID M, V68-9, P83, DOI 10.1016/S0090-6980(02)00023-0
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bazan NG, 2005, MOL NEUROBIOL, V32, P89, DOI 10.1385/MN:32:1:089
   Bessho H, 2011, MOL VIS, V17, P977
   Bhatia M, 2005, SCAND J SURG, V94, P97, DOI 10.1177/145749690509400203
   Bhattacherjee P, 1989, Prog Clin Biol Res, V312, P211
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Cao SJ, 2013, MOL VIS, V19, P718
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Cheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053665
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Cousins S. W., 2005, AGE RELATED MACULAR, P167
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Davey MP, 2000, AM J OPHTHALMOL, V129, P235, DOI 10.1016/S0002-9394(99)00433-X
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355
   Derewenda ZS, 1998, CELL MOL LIFE SCI, V54, P446, DOI 10.1007/s000180050172
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DHARMA S, 1991, CURR EYE RES, V10, P1031, DOI 10.3109/02713689109020341
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Ecker SM, 2012, MOL VIS, V18, P1658
   Ethen CM, 2007, FEBS LETT, V581, P885, DOI 10.1016/j.febslet.2007.01.061
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   He JC, 2006, INVEST OPHTH VIS SCI, V47, P883, DOI 10.1167/iovs.05-0581
   He JC, 2010, CURR EYE RES, V35, P1063, DOI 10.3109/02713683.2010.513797
   He YG, 2009, CURR EYE RES, V34, P957, DOI 10.3109/02713680903231135
   Heier JS, 2013, OPHTHALMOLOGY, V120, P209
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Hughes AE, 2011, MOL VIS, V17, P983
   Irani AMA, 2008, IMMUNOL ALLERGY CLIN, V28, P25, DOI 10.1016/j.iac.2007.12.006
   Jia LH, 2011, BIOMED ENVIRON SCI, V24, P506, DOI 10.3967/0895-3988.2011.05.008
   Johnson T. M., 2002, CLIN RETINA
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Jonisch J, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P23, DOI 10.1007/978-1-4614-0125-4_3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Leonardi A, 2008, CLIN EXP IMMUNOL, V153, P17, DOI 10.1111/j.1365-2249.2008.03716.x
   Lim JI, 2008, AGE RELATED MACULAR
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Luo WT, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/925267
   Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128
   Ma X, 2000, INVEST OPHTH VIS SCI, V41, P1696
   Malesinski Roman, 2007, Klin Oczna, V109, P345
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   McManus LM, 2000, CRIT REV ORAL BIOL M, V11, P240, DOI 10.1177/10454411000110020701
   Menerath JM, 1997, J OCUL PHARMACOL TH, V13, P81, DOI 10.1089/jop.1997.13.81
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moschos M. M., 2013, CUTANEOUS OCULAR TOX
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Okumura N, 2006, J OCUL PHARMACOL TH, V22, P347, DOI 10.1089/jop.2006.22.347
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Parisi V., 2008, OPHTHALMOLOGY, V115
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   RABY O, 1987, J FR OPHTALMOL, V10, P683
   Ramana KV, 2010, INT J BIOCHEM CELL B, V42, P1076, DOI 10.1016/j.biocel.2010.03.011
   Sharif NA, 2009, MOL VIS, V15, P1153
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Silva AS, 2012, MOL VIS, V18, P2288
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Skeie JM, 2011, MOL VIS, V17, P576
   SMITH D, 1994, EXP EYE RES, V59, P425, DOI 10.1006/exer.1994.1127
   Snell R. S., 1997, CLIN ANATOMY EYE, P189
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Taheri F, 2007, INVEST OPHTH VIS SCI, V48, P1931, DOI 10.1167/iovs.06-1008
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thumann G, 2012, CURR GENOMICS, V13, P350, DOI 10.2174/138920212801619214
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tong Y, 2010, MOL VIS, V16, P1958
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   WAKEFIELD D, 1992, CYTOKINE, V4, P1, DOI 10.1016/1043-4666(92)90028-P
   Wallace GR, 2004, PROG RETIN EYE RES, V23, P435, DOI 10.1016/j.preteyeres.2004.04.004
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yadav UCS, 2010, CURR MOL MED, V10, P540
   Zinchuk O, 2005, MOL VIS, V11, P114
NR 124
TC 12
Z9 12
U1 0
U2 20
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-9063
EI 2090-9071
J9 J CHEM-NY
JI J. Chem.
PY 2014
VL 2014
AR 317536
DI 10.1155/2014/317536
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA AL1DV
UT WOS:000338866900001
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Qin, SQ
   Dong, N
   Yang, M
   Wang, JL
   Feng, X
   Wang, YL
AF Qin, Shuqi
   Dong, Ning
   Yang, Ming
   Wang, Jialin
   Feng, Xue
   Wang, Yanling
TI Complement Inhibitors in Age-Related Macular Degeneration: A Potential
   Therapeutic Option
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Review
ID MEMBRANE ATTACK COMPLEX; FACTOR-H POLYMORPHISM; GEOGRAPHIC ATROPHY
   SECONDARY; RETINAL-PIGMENT EPITHELIUM; RARE GENETIC-VARIANTS; STRUCTURAL
   INSIGHTS; ALTERNATIVE PATHWAY; Y402H POLYMORPHISM; BINDING-AFFINITY;
   OXIDATIVE STRESS
AB Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD.
C1 [Qin, Shuqi; Dong, Ning; Yang, Ming; Wang, Jialin; Feng, Xue; Wang, Yanling] Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Feng, Xue] Beijing Moslem Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
C3 Capital Medical University
RP Feng, X; Wang, YL (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China.; Feng, X (通讯作者)，Beijing Moslem Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
EM qsqbest@126.com; eye_dongning@163.com; ym8901@sina.com;
   wangjialin@bjmu.edu.cn; fengxue200220@126.com; doctorwyl2020@sina.com
OI Feng, Xue/0000-0002-5060-7324; Wang, Yanling/0000-0002-7191-6660; ,
   Ming/0000-0003-4932-3225
FU Capital's Funds for Health Improvement and Research [2018-1-2021]
FX This work was supported by Capital's Funds for Health Improvement and
   Research (grant numbers 2018-1-2021).
CR Akyol E, 2020, BIOL-TARGETS THER, V14, P83, DOI 10.2147/BTT.S252581
   Altay L, 2019, EYE, V33, P1859, DOI 10.1038/s41433-019-0501-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Bordet T, 2019, DRUG DISCOV TODAY, V24, P1685, DOI 10.1016/j.drudis.2019.05.038
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fanelli G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15212-z
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Finger RP, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01554-2
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Forneris F, 2016, EMBO J, V35, P1133, DOI 10.15252/embj.201593673
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x
   HARRIMAN GR, 1981, J IMMUNOL, V127, P2386
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108324
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim BJ, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100936
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krilis M, 2018, FREE RADICAL BIO MED, V129, P237, DOI 10.1016/j.freeradbiomed.2018.09.034
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Kuraya M, 2005, IMMUNOBIOLOGY, V209, P689, DOI 10.1016/j.imbio.2004.11.001
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6
   Mastellos DC, 2016, IMMUNOBIOLOGY, V221, P1046, DOI 10.1016/j.imbio.2016.06.013
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Morgan BP, 2016, IMMUNOBIOLOGY, V221, P747, DOI 10.1016/j.imbio.2015.04.006
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Morgan BP, 2016, IMMUNOL REV, V274, P141, DOI 10.1111/imr.12461
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   PODACK ER, 1982, J EXP MED, V156, P268, DOI 10.1084/jem.156.1.268
   Puliafito CA, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0174-y
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156
   Ricklin D, 2016, SEMIN IMMUNOL, V28, P205, DOI 10.1016/j.smim.2016.07.001
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   ROLLINS SA, 1990, J IMMUNOL, V144, P3478
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P648, DOI 10.1016/j.ophtha.2019.11.010
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   The L., 2018, LANCET, V392
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Tzoumas N, 2021, SURV OPHTHALMOL, V66, P378, DOI 10.1016/j.survophthal.2020.10.008
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Volanakis JE, 1996, PROTEIN SCI, V5, P553
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhang YL, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101222
NR 131
TC 4
Z9 4
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD JUL 30
PY 2021
VL 2021
AR 9945725
DI 10.1155/2021/9945725
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA TZ2WG
UT WOS:000684336100001
PM 34368372
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hijazi, MHA
   Coenen, F
   Zheng, YL
AF Hijazi, Mohd Hanafi Ahmad
   Coenen, Frans
   Zheng, Yalin
TI Data mining techniques for the screening of age-related macular
   degeneration
SO KNOWLEDGE-BASED SYSTEMS
LA English
DT Article
DE Image classification; Spatial-histograms; Image decomposition; Case
   based reasoning; Weighted frequent sub-graph mining
ID SEGMENTATION; HISTOGRAMS; QUADTREE
AB Age related macular degeneration (AMD) is the primary cause of adult blindness. Currently AMD cannot be cured, however early detection does allow the progress of the condition to be inhibited. One of the first symptoms of AMD is the presence of fatty deposits, called drusen, on the retina. The presence of drusen may be identified through the manual inspection/screening of retinal images. This task, however, requires recourse to domain experts and is therefore resource intensive. This paper proposes and compares two data mining techniques to support the automated screening for AMD. The first uses spatial-histograms, that maintain both image colour and spatial information, for the image representation; to which a case based reasoning (CBR) classification technique is applied. The second is founded on a hierarchical decomposition of the image set so that a tree representation is generated. A weighted frequent sub-graph mining technique is then applied to this representation to identify sub-trees that frequently occur across the data set. The identified sub-trees are then encoded in the form of feature vectors to which standard classification techniques can be applied. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Hijazi, Mohd Hanafi Ahmad; Coenen, Frans] Univ Liverpool, Dept Comp Sci, Liverpool L69 3BX, Merseyside, England.
   [Zheng, Yalin] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3GA, Merseyside, England.
   [Hijazi, Mohd Hanafi Ahmad] Univ Malaysia Sabah, Sch Engn & Informat Technol, Kota Kinabalu 88999, Sabah, Malaysia.
C3 University of Liverpool; University of Liverpool; Universiti Malaysia
   Sabah
RP Hijazi, MHA (通讯作者)，Univ Liverpool, Dept Comp Sci, Ashton Bldg,Ashton St, Liverpool L69 3BX, Merseyside, England.
EM m.ahmad-hijazi@liverpool.ac.uk; coenen@liverpool.ac.uk;
   yalin.zheng@liverpool.ac.uk
RI Hijazi, Mohd Hanafi Ahmad/I-5702-2015; Zheng, Yalin/N-6432-2017
OI Hijazi, Mohd Hanafi Ahmad/0000-0003-0431-8967; Zheng,
   Yalin/0000-0002-7873-0922
CR Ben Sbeh Z, 2001, IEEE T MED IMAGING, V20, P1321, DOI 10.1109/42.974927
   Birchfield ST, 2007, ETRI J, V29, P697, DOI 10.4218/etrij.07.0207.0017
   Brandon L, 2003, LECT NOTES COMPUT SC, V2878, P618
   Brunelli R, 2001, PATTERN RECOGN, V34, P1625, DOI 10.1016/S0031-3203(00)00054-6
   Cantu-Paz E, 2004, LECT NOTES COMPUT SC, V3102, P959
   Cantu-Paz E., 2004, P 10 ACM SIGKDD INT, P788
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Chang Y-W, 2008, CAUSATION PREDICTION, P53
   Clifford J, 1994, P KDD WORKSH SEATTL, P359, DOI DOI 10.5555/3000850.3000887
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Elsayed A, 2010, KNOWL-BASED SYST, V23, P330, DOI 10.1016/j.knosys.2009.11.008
   Elsayed A., 2010, IEEE INT JOINT C NEU, P3465
   Fan RE, 2008, J MACH LEARN RES, V9, P1871
   Fayyad U. M., 1995, Journal of Intelligent Information Systems: Integrating Artificial Intelligence and Database Technologies, V4, P7, DOI 10.1007/BF00962819
   FLOYD RW, 1976, P SOC INFORM DISPLAY, V17, P75
   Foracchia M, 2005, MED IMAGE ANAL, V9, P179, DOI 10.1016/j.media.2004.07.001
   Forman G., 2003, Journal of Machine Learning Research, V3, P1289, DOI 10.1162/153244303322753670
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Golchin F, 2003, DIGIT SIGNAL PROCESS, V13, P656, DOI 10.1016/S1051-2004(03)00020-4
   Gonzalez RC, 2008, DIGITAL IMAGE PROCES
   Hijazi M.H.A., 2009, MED IMAGE UNDERSTAND, P154
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Holt A, 2005, KNOWL ENG REV, V20, P289, DOI 10.1017/S0269888906000622
   Hsieh C.J., 2008, P 25 INT C MACHINE L, P408, DOI DOI 10.1145/1390156.1390208
   Hsu W., 1995, P ACM MULT, P305
   Hsu WM, 2002, J INTELL INF SYST, V19, P7, DOI 10.1023/A:1015508302797
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang C., 2008, P AI 2008, P63
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kolodner J., 1993, CASE BASED REASONING
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Leake David B, 1996, CASE BASED REASONING
   MYERS CS, 1981, AT&T TECH J, V60, P1389, DOI 10.1002/j.1538-7305.1981.tb00272.x
   Ooi BC, 1998, VLDB J, V7, P115, DOI 10.1007/s007780050057
   OSAREH A, 2004, THESIS U BRISTOL UK
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Perner P, 2008, STUD COMPUT INTELL, V73, P1
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   SAMET H, 1984, COMPUT SURV, V16, P187, DOI 10.1145/356924.356930
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   SPANN M, 1985, PATTERN RECOGN, V18, P257, DOI 10.1016/0031-3203(85)90051-2
   SWAIN MJ, 1991, INT J COMPUT VISION, V7, P11, DOI 10.1007/BF00130487
   Wu HC, 2007, FUND INFORM, V76, P481
   Wu X., 1994, GRAPHIC GEMS, P126
   Yan XF, 2002, 2002 IEEE INTERNATIONAL CONFERENCE ON DATA MINING, PROCEEDINGS, P721, DOI 10.1109/ICDM.2002.1184038
   Zhang HM, 2006, IMAGE VISION COMPUT, V24, P327, DOI 10.1016/j.imavis.2005.11.010
   Zuiderveld K., 1994, ACAD PRESS GRAPHICS
NR 48
TC 29
Z9 30
U1 1
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0950-7051
EI 1872-7409
J9 KNOWL-BASED SYST
JI Knowledge-Based Syst.
PD MAY
PY 2012
VL 29
SI SI
BP 83
EP 92
DI 10.1016/j.knosys.2011.07.002
PG 10
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA 926HB
UT WOS:000302820800010
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Amaro, MH
   Roller, AB
AF Amaro, Miguel Hage
   Roller, Aaron Brock
TI Intravitreal ranibizumab and bevacizumab therapy for choroidal
   neovascularization in age-related macular degeneration with extensive
   pre-existing geographic atrophy
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Macular degeneration; Geographic atrophy; Retinal pigment epithelium,
   Choroidal neovascularization; Antibodies, monoclonal/therapeutic use;
   Retina; Antibodies, monoclonal, humanized; Tomography, optical coherence
AB Purpose: To report the response of choroidal neovascularization to intravitreal ranibizumab or bevacizumab treatment in the setting of age-related macular degeneration with extensive pre-existing geographic atrophy of the retinal pigment epithelium.
   Methods: This is a retrospective case series of 11 eyes in ten consecutive patients retrieved from a photographic database. The patients were treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration with pre-existing geographic atrophy. Patients were included if they had geographic atrophy at or adjacent to the foveal center of at least 1 disc area in size that was present before the development of choroidal neovascularization. The best corrected visual acuity and optical coherence tomography analysis of the central macular thickness were recorded for each visit. Serial injections of ranibizumab or bevacizumab were administered until there was complete resolution of subretinal fluid on optical coherence tomography. Data over the entire follow-up period were analyzed for overall visual and optical coherence tomography changes.
   Results: The patients received an average of 7 +/- 3 intravitreal injections over the treatment period. Seven of 11 eyes had reduced retinal thickening on optical coherence tomography. On average, the central macular thickness was reduced by 72 +/- 115 mu m. Six of these 7 eyes had improvement of one or more lines of vision and one had no change. The average acuity change for all patients was -0.04 +/- 0.46 logMAR units, which corresponded to a gain of 0.2 +/- 4.4 lines of Snellen acuity. The treatment resulted in a good anatomic response with resolution of the subretinal fluid and overall stable visual acuity.
   Conclusions: The results of this case series suggest that the use of an intravitreal anti-vascular endothelial growth factor (VEGF) agent (ranibizumab or bevacizumab) for choroidal neovascularization in age-related macular degeneration with pre-existing geographic atrophy is effective. Our results are not as striking as published results from large-scale trials of anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization, presumably due to the limitation in the baseline visual acuity caused by the underlying geographic atrophy. The favorable anatomic response with the resolution of subretinal fluid and stable acuity were consistent with other ranibizumab and bevacizumab studies.
C1 [Amaro, Miguel Hage] Inst Olhos & Laser Belem, Belem, PA, Brazil.
   [Roller, Aaron Brock] Univ Iowa Hosp & Clin, Dept Ophthalmol, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Roller, AB (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM aaron-roller@uiowa.edu
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2006, NEW ENGL J MED, V355, P1493
   Brown DM, 2006, NEW ENGL J MED, V355, P1409
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN DS, 2004, JAMA-J AM MED ASSOC, V291, P1900
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Macular Photocoagulation Study Group, 1991, ARCH OPHTHALMOL-CHIC, V109, P614
   Martin DF, 2011, NEW ENGL J MED, V365, P2237
   Martin DF, 2011, CLIN EXP OPHTHALMOL, V39, P718, DOI 10.1111/j.1442-9071.2011.02703.x
   Martin DF, 1919, NEW ENGL J MED, V364, P1897
   Martin DF, 2011, NEW ENGL J MED, V364, P1966
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2007, NEW ENGL J MED, V356, P749
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROSENFELD PJ, 2005, OPHTHAL SURG LAS IM, V36, P270
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   1994, ARCH OPHTHALMOL, V112, P874
NR 32
TC 5
Z9 5
U1 1
U2 4
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD JUL-AUG
PY 2012
VL 75
IS 4
BP 273
EP 276
DI 10.1590/S0004-27492012000400011
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 058XV
UT WOS:000312669300011
PM 23258660
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Carneiro, A
   Andrade, JP
AF Carneiro, Angela
   Andrade, Jose Paulo
TI Nutritional and Lifestyle Interventions for Age-Related Macular
   Degeneration: A Review
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID POLYUNSATURATED FATTY-ACIDS; PIGMENT OPTICAL-DENSITY; LONG-TERM
   INCIDENCE; MEDITERRANEAN DIET; EYE DISEASE; GENETIC SUSCEPTIBILITY;
   CIGARETTE-SMOKING; 10-YEAR INCIDENCE; BETA-CAROTENE; RISK-FACTORS
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. In this narrative review, we will summarize the nutritional interventions evaluated in numerous observational studies and a few randomized clinical trials. The AREDS and AREDS2 studies demonstrated that supplements including vitamins C and E, beta-carotene, and zinc may reduce the progression to advanced AMD, in some patients, by 25% in five years. This is one of the few nutritional supplements known to have beneficial effects in any eye disease. Lutein/zeaxanthin supplementation may have beneficial effects in some individuals whereas omega-3 fatty acids supplementation needs to be further investigated and supported by more evidence. Genetic factors may explain the different patterns of response and explain differences found among individuals. More importantly, a combination of lifestyle behaviors such as the avoidance of smoking, physical activity, and the adoption of a healthy dietary pattern like theMediterranean diet was associated with a lower prevalence of AMD. The adoption of these lifestyles may reduce the prevalence of the early stages of AMD and decrease the number of individuals who develop advanced AMD and consequently the onerous and climbing costs associated with the treatment of this disease.
C1 [Carneiro, Angela] Univ Porto, Ophthalmol Unit, Fac Med, Dept Surg & Physiol, Oporto, Portugal.
   [Carneiro, Angela] Hosp Sao Joao, Serv Ophthalmol, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
   [Andrade, Jose Paulo] Univ Porto, Fac Med, Anat Unit, Dept Biomed, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
   [Andrade, Jose Paulo] Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Rua Dr Placido da Costa, P-4200450 Oporto, Portugal.
C3 Universidade do Porto; Sao Joao Hospital; Universidade do Porto;
   Universidade do Porto
RP Andrade, JP (通讯作者)，Univ Porto, Fac Med, Anat Unit, Dept Biomed, Al Prof Hernani Monteiro, P-4200319 Oporto, Portugal.; Andrade, JP (通讯作者)，Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Rua Dr Placido da Costa, P-4200450 Oporto, Portugal.
EM jandrade@med.up.pt
RI Andrade, José Paulo/L-8036-2013; Carneiro, Angela/N-9680-2013
OI Andrade, José Paulo/0000-0003-2585-200X; Carneiro,
   Angela/0000-0002-3370-7243
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arnold C, 2013, NUTRITION, V29, P1412, DOI 10.1016/j.nut.2013.05.012
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Aslam T, 2013, OPHTHALMOLOGICA, V229, P75, DOI 10.1159/000343708
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Bernstein M, 2012, J ACAD NUTR DIET, V112, P1255, DOI 10.1016/j.jand.2012.06.015
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Birlouez-Aragon I, 2001, INT J VITAM NUTR RES, V71, P53, DOI 10.1024/0300-9831.71.1.53
   Bouwens M, 2009, AM J CLIN NUTR, V90, P415, DOI 10.3945/ajcn.2009.27680
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Buhler AD, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0335-9
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Calder PC, 2009, BIOCHIMIE, V91, P791, DOI 10.1016/j.biochi.2009.01.008
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Carneiro A., 2015, ANTIAGEING NUTRIENTS, P277
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu C. - J., 2014, AM J OPHTHALMOL, V158
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Connor W E, 1988, Prog Clin Biol Res, V282, P275
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Lorgeril M, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0370-4
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Decsi T, 2011, AM J CLIN NUTR, V94, p1914S, DOI 10.3945/ajcn.110.000893
   Bibiloni MD, 2014, NUTR HOSP, V29, P880, DOI 10.3305/nh.2014.29.4.7078
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Gerster H, 1998, INT J VITAM NUTR RES, V68, P159
   Hammond BR, 2016, ADV NUTR, V7, P433, DOI 10.3945/an.115.011866
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q
   Iqbal R, 2008, CIRCULATION, V118, P1929, DOI 10.1161/CIRCULATIONAHA.107.738716
   Islam F. M. Amirul, 2014, OPHTHALMOLOGY, V121
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Lawrenson JG, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1186/1471-2415-7-3
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lien EL, 2011, PROG RETIN EYE RES, V30, P188, DOI 10.1016/j.preteyeres.2011.01.001
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   McCusker MM, 2016, CLIN DERMATOL, V34, P276, DOI 10.1016/j.clindermatol.2015.11.009
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Montgomery MP, 2010, OPHTHAL EPIDEMIOL, V17, P58, DOI 10.3109/09286580903450353
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   O'Donnell M, 2010, NEUROEPIDEMIOLOGY, V35, P36, DOI 10.1159/000306058
   Offord E, 2000, Free Radic Res, V33 Suppl, pS5
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Pallauf K, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/707421
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Philip LP, 2004, JAMA-J AM MED ASSOC, V292, P43, DOI 10.1001/jama.292.1.43-a
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Rees K, 2013, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD009825.PUB2
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673
   Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Subhi Y, 2014, CLIN OPHTHALMOL, V8, P15, DOI 10.2147/OPTH.S55080
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tomada I, 2015, ANTIAGEING NUTRIENTS, P335
   Ugarte M, 2014, METALLOMICS, V6, P189, DOI 10.1039/c3mt00291h
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Valls-Pedret C, 2013, EPIDEMIOLOGY, V24, P503, DOI 10.1097/EDE.0b013e318296bf8e
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhu L, 2010, J NUTR BIOCHEM, V21, P1089, DOI 10.1016/j.jnutbio.2009.09.006
NR 120
TC 37
Z9 37
U1 1
U2 35
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2017
VL 2017
AR 6469138
DI 10.1155/2017/6469138
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EI6EX
UT WOS:000392588900001
PM 28154734
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Wu, AM
   Wu, CM
   Young, BK
   Wu, DJ
   Margo, CE
   Greenberg, PB
AF Wu, Annie M.
   Wu, Conni M.
   Young, Benjamin K.
   Wu, Dominic J.
   Margo, Curtis E.
   Greenberg, Paul B.
TI Critical Appraisal of Clinical Practice Guidelines for Age-Related
   Macular Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGREE II; RECOMMENDATIONS; QUALITY
AB Purpose. To evaluate the methodological quality of age-related macular degeneration (AMD) clinical practice guidelines (CPGs). Methods. AMD CPGs published by the American Academy of Ophthalmology (AAO) and Royal College of Ophthalmologists (RCO) were appraised by independent reviewers using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument, which comprises six domains (Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity of Presentation, Applicability, and Editorial Independence), and an Overall Assessment score summarizing methodological quality across all domains. Results. Average domain scores ranged from 35% to 83% for the AAO CPG and from 17% to 83% for the RCO CPG. Intraclass correlation coefficients for the reliability of mean scores for the AAO and RCO CPGs were 0.74 and 0.88, respectively. The strongest domains were Scope and Purpose and Clarity of Presentation. The weakest were Stakeholder Involvement (AAO) and Editorial Independence (RCO). Conclusions. Future AMD CPGs can be improved by involving all relevant stakeholders in guideline development, ensuring transparency of guideline development and review methodology, improving guideline applicability with respect to economic considerations, and addressing potential conflict of interests within the development group.
C1 [Wu, Annie M.; Wu, Conni M.; Young, Benjamin K.; Wu, Dominic J.; Greenberg, Paul B.] Providence VA Med Ctr, Sect Ophthalmol, Providence, RI 02908 USA.
   [Wu, Annie M.; Wu, Conni M.; Young, Benjamin K.; Wu, Dominic J.; Greenberg, Paul B.] Brown Univ, Warren Alpert Med Sch, Div Ophthalmol, Providence, RI 02903 USA.
   [Wu, Annie M.; Wu, Conni M.; Young, Benjamin K.; Wu, Dominic J.; Greenberg, Paul B.] Rhode Isl Hosp, Div Ophthalmol, Providence, RI 02903 USA.
   [Margo, Curtis E.] Morsani Coll Med, Dept Ophthalmol, Dept Pathol, Tampa, FL 33612 USA.
   [Margo, Curtis E.] Morsani Coll Med, Dept Cell Biol, Tampa, FL 33612 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University; Lifespan Health Rhode
   Island; Rhode Island Hospital
RP Greenberg, PB (通讯作者)，Providence VA Med Ctr, Sect Ophthalmol, Providence, RI 02908 USA.
EM paul_greenberg@brown.edu
CR American Academy of Ophthalmology Glaucoma Panel, 2010, PREF PRACT PATT OPHT
   American Academy of Ophthalmology Retina/Vitreous Panel, 2008, PREF PRACT PATT AG R
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449
   Brouwers MC, 2010, CAN MED ASSOC J, V182, P1045, DOI 10.1503/cmaj.091714
   Cluzeau F, 2003, QUAL SAF HEALTH CARE, V12, P18
   Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715
   Institute of Medicine, 2011, CLIN PRACTICE GUIDEL
   Kung J, 2012, ARCH INTERN MED, V172, P1628, DOI 10.1001/2013.jamainternmed.56
   Laine C, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-11-201106070-00011
   Marciano N J, 2014, Int J Clin Pract, V68, P761, DOI 10.1111/ijcp.12393
   Novack GD, 2007, OPHTHALMOLOGY, V114, P1037, DOI 10.1016/j.ophtha.2007.02.027
   Ou Y, 2011, OPHTHALMOLOGY, V118, P1017, DOI 10.1016/j.ophtha.2011.03.038
   Poitras S, 2010, JOINT BONE SPINE, V77, P458, DOI 10.1016/j.jbspin.2010.08.001
   Ransohoff DF, 2013, J CLIN ONCOL, V31, P2530, DOI 10.1200/JCO.2013.50.0462
   Ransohoff DF, 2013, JAMA-J AM MED ASSOC, V309, P139, DOI 10.1001/jama.2012.156703
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Sabharwal S, 2014, CLIN ORTHOP RELAT R, V472, P1982, DOI 10.1007/s11999-014-3530-0
   Shaneyfelt TM, 2009, JAMA-J AM MED ASSOC, V301, P868, DOI 10.1001/jama.2009.225
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Vale L, 2007, EUR J HEALTH ECON, V8, P111, DOI 10.1007/s10198-007-0043-8
   Wu CM, 2015, BRIT J OPHTHALMOL, V99, P401, DOI 10.1136/bjophthalmol-2014-305567
   Zeng LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087711
NR 22
TC 4
Z9 5
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2015
VL 2015
AR 710324
DI 10.1155/2015/710324
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CL1HB
UT WOS:000356692300001
PM 26106484
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, YL
   Vuong, LN
   Liu, J
   Ho, J
   Srinivasan, VJ
   Gorczynska, I
   Witkin, AJ
   Duker, JS
   Schuman, J
   Fujimoto, JG
AF Chen, Yueli
   Vuong, Laurel N.
   Liu, Jonathan
   Ho, Joseph
   Srinivasan, Vivek J.
   Gorczynska, Iwona
   Witkin, Andre J.
   Duker, Jay S.
   Schuman, Joel
   Fujimoto, James G.
TI Three-dimensional ultrahigh resolution optical coherence tomography
   imaging of age-related macular degeneration
SO OPTICS EXPRESS
LA English
DT Article
ID HIGH-SPEED; RETINA; IDENTIFICATION; PATHOGENESIS; PATHOLOGY; IMAGES;
   EDEMA
AB Ultrahigh resolution optical coherence tomography (OCT) enhances the ability to visualize different intra retinal layers. In age-related macular degeneration (AMD), pathological changes in individual retinal layers, including photoreceptor inner and outer segments and retinal pigment epithelium, can be detected. OCT using spectral/Fourier domain detection enables high speed, volumetric imaging of the macula, which provides comprehensive three-dimensional tomographic and morphologic information. We present a case series of AMD patients, from mild drusen to more advanced geographic atrophy and exudative AMD. Patients were imaged with a research prototype, ultrahigh resolution spectral/Fourier domain OCT instrument with 3.5 mu m axial image resolution operating at 25,000 axial scans per second. These cases provide representative volumetric datasets of well-documented AMD pathologies which could be used for the development of visualization and imaging processing methods and algorithms. (C) 2009 Optical Society of America
C1 [Chen, Yueli; Liu, Jonathan; Srinivasan, Vivek J.; Gorczynska, Iwona; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Chen, Yueli; Liu, Jonathan; Srinivasan, Vivek J.; Gorczynska, Iwona; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Chen, Yueli; Vuong, Laurel N.; Ho, Joseph; Gorczynska, Iwona; Witkin, Andre J.; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02116 USA.
   [Schuman, Joel] Univ Pittsburgh, Sch Med, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15261 USA.
C3 Massachusetts Institute of Technology (MIT); Massachusetts Institute of
   Technology (MIT); Tufts Medical Center; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); University of Pittsburgh
RP Fujimoto, JG (通讯作者)，MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI Gorczynska, Iwona M./P-9367-2015; Schuman, Joel S/K-7304-2012; Schuman,
   Joel S/M-2389-2019
OI Gorczynska, Iwona M./0000-0002-6120-8791; Schuman, Joel
   S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766
FU National Institutes of Health [R01-EY11289-23, R01-EY13178-07,
   P30-EY008098]; National Science Foundation [BES-0522845]; Air Force
   Office of Scientific Research [FA9550-07-1-0014]; Medical Free Electron
   Laser Program [FA9550-07-1-0101]; Massachusetts Lions Eye Research Fund;
   NATIONAL EYE INSTITUTE [R01EY011289, P30EY008098, R01EY013178] Funding
   Source: NIH RePORTER
FX Dr. Iwona Gorczynska's present address is the Institute of Physics,
   Nicolaus Copernicus University, Torun, Poland. Dr. Srinivasan's present
   address it the Martinos Imaging Center of the Massachusetts General
   Hospital, Boston, MA. The authors would like to acknowledge the research
   support from the National Institutes of Health R01-EY11289-23,
   R01-EY13178-07, P30-EY008098; National Science Foundation BES-0522845;
   Air Force Office of Scientific Research, FA9550-07-1-0014 and Medical
   Free Electron Laser Program contract FA9550-07-1-0101; Massachusetts
   Lions Eye Research Fund; and Research to Prevent Blindness Unrestricted
   Grant.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Ergun E, 2005, INVEST OPHTH VIS SCI, V46, P310, DOI 10.1167/iovs.04-0212
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujimoto JG, 2003, NAT BIOTECHNOL, V21, P1361, DOI 10.1038/nbt892
   Fujimoto JG., 2004, OPTICAL COHERENCE TO, V2nd
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   GORCZYNSKA I, 2008, BR J OPHTHALMOL
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GROUP MPS, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   GROUP MPS, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, OPHTHALMOLOGY, V102, P748, DOI 10.1016/S0161-6420(95)30959-1
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jiao SL, 2006, OPT EXPRESS, V14, P3368, DOI 10.1364/OE.14.003368
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Ko TH, 2006, ARCH OPHTHALMOL-CHIC, V124, P827, DOI 10.1001/archopht.124.6.827
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Paunescu LA, 2006, OPHTHALMOLOGY, V113, P48, DOI 10.1016/j.ophtha.2005.08.016
   Potsaid B, 2008, OPT EXPRESS, V16, P15149, DOI 10.1364/OE.16.015149
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Scholda C, 2006, RETINA-J RET VIT DIS, V26, P1034, DOI 10.1097/01.iae.0000254898.80552.e7
   Schuman J S, 1995, Curr Opin Ophthalmol, V6, P89
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P5103, DOI 10.1167/iovs.08-2127
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Wirtitsch MG, 2005, AM J OPHTHALMOL, V140, P976, DOI 10.1016/j.ajo.2005.06.029
   Witkin AJ, 2006, AM J OPHTHALMOL, V142, P945, DOI 10.1016/j.ajo.2006.07.024
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2003, OPT LETT, V28, P1745, DOI 10.1364/OL.28.001745
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 52
TC 40
Z9 40
U1 0
U2 4
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1094-4087
J9 OPT EXPRESS
JI Opt. Express
PD MAR 2
PY 2009
VL 17
IS 5
BP 4046
EP 4060
DI 10.1364/OE.17.004046
PG 15
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 417QJ
UT WOS:000264090900108
PM 19259245
OA Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Chen, X
   Kang, XL
   Zhao, KX
   Zhao, C
AF Chen, Xue
   Kang, Xiaoli
   Zhao, Kanxing
   Zhao, Chen
TI C2 rs547154 polymorphism and polypoidal choroidal vasculopathy
   susceptibility: a meta-analysis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; GENE POLYMORPHISMS; FACTOR B; COMPLEMENT;
   ASSOCIATIONS; DEFICIENCY; ALLELE
AB Previous studies have indicated the association between C2 rs547154 polymorphism and polypoidal choroidal vasculopathy (PCV) risk, while the results are controversial and inconsistent. Herein, we perform a meta-analysis to gain a precise estimation of the association using 5 eligible studies involving 4076 subjects, of which 1220 were PCV cases, 1073 were age-related macular degeneration (AMD) cases and 1783 were controls. Allelic frequencies of C2 rs547154 polymorphism between PCV and AMD were also compared. Both crude and adjusted odds ratios (OR) with their 95% confidence interval (CI) were included to assess the strength of the association. The pooled OR in random-effect model for allele T versus G was 0.64 (95% CI, 0.52-0.80; p < 0.0001),for genotype TG versus GG was 0.65 (95% CI, 0.52-0.83; p, 0.0004), and for genotype TT+TG versus GG was 0.64 (95% CI, 0.51-0.80; p, 0.0002). No difference in allelic frequency was observed between PCV and AMD (OR, 0.86; 95% CI, 0.64-1.16; p, 0.32). Sensitivity analysis proved the robustness of our data. No significant ethnic divergence was suggested by subgroup analysis, and no publication bias was detected via Egger's test. In conclusion, our data indicate that C2 rs547154 polymorphism plays a protective role in the development of PCV.
C1 [Chen, Xue; Zhao, Chen] Nanjing Med Univ, State Key Lab Reprod Med, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
   [Kang, Xiaoli] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhao, Kanxing] Tianjin Med Univ, Tianjin Eye Hosp, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin, Peoples R China.
C3 Nanjing Medical University; Shanghai Jiao Tong University; Tianjin
   Medical University
RP Zhao, C (通讯作者)，Nanjing Med Univ, State Key Lab Reprod Med, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
EM dr_zhaochen@163.com
FU National Key Basic Research Program of China (973 Program)
   [2013CB967500]; National Natural Science Foundation of China [81222009,
   81170856]; Thousand Youth Talents Program of China; Jiangsu Outstanding
   Young Investigator Program [BK2012046]; Jiangsu Province's Key
   Provincial Talents Program [RC201149]; Fundamental Research Funds of the
   State Key Laboratory of Ophthalmology; Jiangsu Province's Scientific
   Research Innovation Program for Postgraduates [CXZZ13_0590]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD)
FX This work was supported by National Key Basic Research Program of China
   (973 Program, 2013CB967500); National Natural Science Foundation of
   China (81222009 and 81170856); Thousand Youth Talents Program of China
   (to C. Z.); Jiangsu Outstanding Young Investigator Program (BK2012046);
   Jiangsu Province's Key Provincial Talents Program (RC201149); the
   Fundamental Research Funds of the State Key Laboratory of Ophthalmology
   (to C. Z.); Jiangsu Province's Scientific Research Innovation Program
   for Postgraduates (CXZZ13_0590); and A Project Funded by the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BENTLEY DR, 1984, P NATL ACAD SCI-BIOL, V81, P1212, DOI 10.1073/pnas.81.4.1212
   BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen HY, 2012, MOL VIS, V18, P816
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kondo N, 2009, OPHTHALMOLOGY, V116, P1502, DOI 10.1016/j.ophtha.2009.03.004
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P794, DOI 10.1167/iovs.11-8468
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Sun C, 2012, CURR EYE RES, V37, P259, DOI 10.3109/02713683.2011.635401
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Wang ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088324
   Wetsel RA, 1996, J BIOL CHEM, V271, P5824, DOI 10.1074/jbc.271.10.5824
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Zhu ZB, 1998, J IMMUNOL, V161, P578
NR 31
TC 1
Z9 1
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 3
PY 2015
VL 5
AR 8709
DI 10.1038/srep08709
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC4UX
UT WOS:000350350700002
PM 25732348
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kaarniranta, K
   Salminen, A
AF Kaarniranta, K.
   Salminen, A.
TI Age-related macular degeneration: activation of innate immunity system
   via pattern recognition receptors
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review
DE AMD; CFH; Inflammation; Inflammasome; Innate immunity; Macular
   degeneration
ID PIGMENT EPITHELIAL-CELLS; COMPLEMENT FACTOR-H; PHOTORECEPTOR OUTER
   SEGMENTS; GLYCATION END-PRODUCTS; C-REACTIVE PROTEIN; BRUCHS MEMBRANE;
   OXIDATIVE STRESS; SCAVENGER RECEPTORS; CYTOKINE EXPRESSION; CULTURED RPE
AB Age-related macular degeneration (AMD) is the most common cause of irreversible loss of central vision. Histopathological studies have demonstrated that inflammation is the key player in the pathogenesis of AMD. Genetic studies have revealed that complement factor H is a strong risk factor for the development of AMD. However, innate immunity defence involves several other pattern recognition receptors (PRRs) which can trigger inflammatory responses. Retinal pigment epithelial (RPE) cells have the main role in the immune defence in macula. In this study, we examine in detail the endogenous danger signals which can activate different PRRs in RPE cells, such as Toll-like, NOD-like and scavenger receptors along with complement system. We also characterise the signalling pathways triggered by PRRs in evoking inflammatory responses. In addition, we will discuss whether AMD pathology could represent the outcome of chronic activation of the innate immunity defence in human macula.
C1 [Salminen, A.] Univ Kuopio, Dept Neurol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Kaarniranta, K.] Univ Kuopio, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland
RP Salminen, A (通讯作者)，Univ Kuopio, Dept Neurol, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland.
EM kai.kaarniranta@uku.fi; antero.salminen@uku.fi
OI Kaarniranta, Kai/0000-0003-2600-8679
FU Academy of Finland; Finnish Eye Foundation; University of Kuopio,
   Finland
FX This study was financially supported by grants from the Academy of
   Finland, The Finnish Eye Foundation and the University of Kuopio,
   Finland. The authors thank Dr. Ewen MacDonald for checking the language
   of the manuscript.
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Alizadeh P, 2006, EXP EYE RES, V83, P679, DOI 10.1016/j.exer.2006.03.009
   Arai J, 2006, JPN J OPHTHALMOL, V50, P417, DOI 10.1007/s10384-006-0352-y
   Barton GM, 2007, SEMIN IMMUNOL, V19, P33, DOI 10.1016/j.smim.2007.01.003
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7
   Blander JM, 2007, CELL MICROBIOL, V9, P290, DOI 10.1111/j.1462-5822.2006.00864.x
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Dutot M, 2008, MOL VIS, V14, P889
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Edwards AO, 2008, ADV EXP MED BIOL, V613, P211, DOI 10.1007/978-0-387-74904-4_24
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Elner VM, 2003, EXP EYE RES, V76, P321, DOI 10.1016/S0014-4835(02)00310-X
   Febbraio M, 2007, INT J BIOCHEM CELL B, V39, P2012, DOI 10.1016/j.biocel.2007.03.012
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Gay NJ, 2007, ANNU REV BIOCHEM, V76, P141, DOI 10.1146/annurev.biochem.76.060305.151318
   GONZALEZ B, 2008, MEDIAT INFLAMM
   Graf GA, 1999, TRENDS CARDIOVAS MED, V9, P221, DOI 10.1016/S1050-1738(00)00031-1
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hazen SL, 2008, J BIOL CHEM, V283, P15527, DOI 10.1074/jbc.R700054200
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollyfield JG, 1997, EXP EYE RES, V65, P603, DOI 10.1006/exer.1997.0369
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Houssier M, 2008, PLOS MED, V5, P323, DOI 10.1371/journal.pmed.0050039
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kohl J, 2006, ADV EXP MED BIOL, V586, P71
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   Mitchell CH, 2008, PURINERG SIGNAL, V4, P101, DOI 10.1007/s11302-007-9054-2
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Pancer Z, 2006, ANNU REV IMMUNOL, V24, P497, DOI 10.1146/annurev.immunol.24.021605.090542
   Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002
   Primo L, 2005, FASEB J, V19, P1713, DOI 10.1096/fj.05-3697fje
   Proell M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002119
   Rodriguez-Martinez S, 2005, BRIT J OPHTHALMOL, V89, P904, DOI 10.1136/bjo.2004.056218
   Rosenzweig HL, 2008, J LEUKOCYTE BIOL, V84, P529, DOI 10.1189/jlb.0108015
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Sola-Villa D, 2006, KIDNEY INT, V70, P1935, DOI 10.1038/sj.ki.5001948
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugano E, 2006, CURR EYE RES, V31, P607, DOI 10.1080/02713680600744851
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu W, 2008, J IMMUNOL, V180, P7613, DOI 10.4049/jimmunol.180.11.7613
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
NR 74
TC 66
Z9 82
U1 2
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD FEB
PY 2009
VL 87
IS 2
BP 117
EP 123
DI 10.1007/s00109-008-0418-z
PG 7
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 414DC
UT WOS:000263843100002
PM 19009282
DA 2022-11-30
ER

PT J
AU Cakmak, H
   Kocaturk, T
   Dundar, SO
   Dundar, M
   Karabulut, M
AF Cakmak, Harun
   Kocaturk, Tolga
   Dundar, Sema Oruc
   Dundar, Mehmet
   Karabulut, Mujdat
TI The Relationship between Neovascular Age-Related Macular Degeneration
   and Erectile Dysfunction
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; SEXUAL DYSFUNCTION; CARDIOVASCULAR-DISEASE;
   INTERNATIONAL INDEX; FUNCTION IIEF; DEPRESSION; PEOPLE; HYPERTENSION;
   PREVALENCE; ADHERENCE
AB Purpose. To evaluate association between erectile dysfunction (ED) and neovascular age-related macular degeneration (AMD). Methods. 195 men enrolled in this cross-sectional study. 90 of them had neovascular AMD and 105 of them were healthy volunteers. The International Index of Erectile Function (IIEF) questionnaire's erectile function (EF) domain was used to assess ED. The patients in the study and control groups were statistically compared according to visual acuity, EF score, and body mass index. Results. The mean ages were 62 (54.5-73) and 60 (54-68), in the neovascular AMD and control groups, respectively. The total EF scores were 9 (6-16) in neovascular AMD and 18 (9.5-27) in control group. The results of IIEF questionnaire on neovascular AMD patients revealed that 85 men (94.4%) had some degree of ED, whereas 68 men (64.8%) had some degree of ED on control group. Patients with neovascular AMD had a significantly higher incidence of ED than control patients (P < 0.01). There was a significant association between ED and neovascular AMD (P < 0.01). Conclusions. Our results suggested that neovascular AMD has a high association with ED.
C1 [Cakmak, Harun; Kocaturk, Tolga; Dundar, Sema Oruc; Karabulut, Mujdat] Adnan Menderes Univ, Fac Med, Dept Ophthalmol, TR-09100 Aytepe, Aydin, Turkey.
   [Dundar, Mehmet] Adnan Menderes Univ, Fac Med, Dept Urol, Aydin, Turkey.
C3 Adnan Menderes University; Adnan Menderes University
RP Cakmak, H (通讯作者)，Adnan Menderes Univ, Fac Med, Dept Ophthalmol, Merkez Kampus Kepez Mevkii, TR-09100 Aytepe, Aydin, Turkey.
EM dharuncakmak@gmail.com
RI kocaturk, tolga/AAB-5890-2021; , mujdat/AAH-2911-2021
OI kocaturk, tolga/0000-0001-5187-227X; , mujdat/0000-0002-7844-5638
CR Althof SE, 2002, UROLOGY, V59, P803, DOI 10.1016/S0090-4295(02)01606-0
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Baldwin DS, 2001, BRIT MED BULL, V57, P81, DOI 10.1093/bmb/57.1.81
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Burchardt M, 2000, J UROLOGY, V164, P1188, DOI 10.1016/S0022-5347(05)67138-8
   Chan SSC, 2010, AM J PREV MED, V39, P251, DOI 10.1016/j.amepre.2010.05.006
   Costa C, 2009, J SEX MED, V6, P2390, DOI 10.1111/j.1743-6109.2009.01356.x
   El-Sakka AI, 2007, J SEX MED, V4, P1691, DOI 10.1111/j.1743-6109.2006.00342.x
   Esposito K, 2011, CLIN PHARMACOL THER, V90, P169, DOI 10.1038/clpt.2011.91
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fillo J, 2012, INT UROL NEPHROL, V44, P1113, DOI 10.1007/s11255-012-0132-1
   Fischer Tamas, 2006, Orv Hetil, V147, P2465
   Horowitz A, 2005, AM J GERIAT PSYCHIAT, V13, P180, DOI 10.1176/appi.ajgp.13.3.180
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   JACK CIA, 1995, GERONTOLOGY, V41, P280
   Jackson G, 2008, INT J IMPOT RES, V20, pS9, DOI 10.1038/ijir.2008.47
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lucca Ilaria, 2012, Rev Med Suisse, V8, P2327
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McCabe MP, 1997, J SEX MARITAL THER, V23, P276, DOI 10.1080/00926239708403932
   Montorsi F, 2010, J SEX MED, V7, P3572, DOI 10.1111/j.1743-6109.2010.02062.x
   Moreira ED, 2005, INT J CLIN PRACT, V59, P6, DOI 10.1111/j.1742-1241.2005.00382.x
   O'Leary MP, 2003, INT J IMPOT RES, V15, P185, DOI 10.1038/sj.ijir.3900996
   Paick JS, 2007, INT J UROL, V14, P48, DOI 10.1111/j.1442-2042.2006.01661.x
   Rosen RC, 2009, BJU INT, V103, P42, DOI 10.1111/j.1464-410X.2009.08370.x
   Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0
   Rosen RC, 2002, INT J IMPOT RES, V14, P226, DOI 10.1038/sj.ijir.3900857
   Schaaf L, 2012, MMW Fortschr Med, V154, P65
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scranton RE, 2013, J SEX MED, V10, P551, DOI 10.1111/j.1743-6109.2012.02998.x
   Shamloul R, 2013, LANCET, V381, P153, DOI 10.1016/S0140-6736(12)60520-0
   Shin D, 2011, CARDIOL REV, V19, P5, DOI 10.1097/CRD.0b013e3181fb7eb8
   Smith AMA, 2012, INTERN MED J, V42, P641, DOI 10.1111/j.1445-5994.2011.02597.x
   Tan HM, 2012, J SEX MED, V9, P663, DOI 10.1111/j.1743-6109.2011.02582.x
   Tsai D. C., 2012, ACTA OPHTHALMOLOGICA
   Ucok A, 2007, EUR PSYCHIAT, V22, P328, DOI 10.1016/j.eurpsy.2007.01.001
NR 38
TC 0
Z9 0
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 589274
DI 10.1155/2013/589274
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 229VT
UT WOS:000325296400001
PM 24191192
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Mitchell, SL
   Ma, CY
   Scott, WK
   Agarwal, A
   Pericak-Vance, MA
   Haines, JL
   Jones, DP
   Uppal, K
   Brantley, MA
AF Mitchell, Sabrina L.
   Ma, Chunyu
   Scott, William K.
   Agarwal, Anita
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
   Jones, Dean P.
   Uppal, Karan
   Brantley Jr, Milam A.
TI Plasma Metabolomics of Intermediate and Neovascular Age-Related Macular
   Degeneration Patients
SO CELLS
LA English
DT Article
DE age-related macular degeneration; IAMD; NVAMD; metabolomics;
   acylcarnitines; carnitine shuttle; phospholipids
ID HIGH-RESOLUTION METABOLOMICS; MASS-SPECTROMETRY; N-ACYLETHANOLAMINE;
   WIDE ASSOCIATION; CHROMATOGRAPHY; MODEL
AB To characterize metabolites and metabolic pathways altered in intermediate and neovascular age-related macular degeneration (IAMD and NVAMD), high resolution untargeted metabolomics was performed via liquid chromatography-mass spectrometry on plasma samples obtained from 91 IAMD patients, 100 NVAMD patients, and 195 controls. Plasma metabolite levels were compared between: AMD patients and controls, IAMD patients and controls, and NVAMD and IAMD patients. Partial least-squares discriminant analysis and linear regression were used to identify discriminatory metabolites. Pathway analysis was performed to determine metabolic pathways altered in AMD. Among the comparisons, we identified 435 unique discriminatory metabolic features. Using computational methods and tandem mass spectrometry, we identified 11 metabolic features whose molecular identities had been previously verified and confirmed the molecular identities of three additional discriminatory features. Included among the discriminatory metabolites were acylcarnitines, phospholipids, amino acids, and steroid metabolites. Pathway analysis revealed that lipid, amino acid, and vitamin metabolism pathways were altered in NVAMD, IAMD, or AMD in general, including the carnitine shuttle pathway which was significantly altered in all comparisons. Finally, few discriminatory features were identified between IAMD patients and controls, suggesting that plasma metabolic profiles of IAMD patients are more similar to controls than to NVAMD patients.
C1 [Mitchell, Sabrina L.; Agarwal, Anita; Brantley Jr, Milam A.] Vanderbilt Univ, Vanderbilt Eye Inst, Med Ctr, Nashville, TN 37232 USA.
   [Ma, Chunyu; Jones, Dean P.; Uppal, Karan] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   [Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami Miller, John P Hussman Inst Human Genom, Sch Med, Miami, FL 33136 USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Inst Computat Biol, Dept Populat & Quantitat Hlth Sci, Cleveland Hts, OH 44106 USA.
C3 Vanderbilt University; Emory University; University of Miami; Case
   Western Reserve University
RP Brantley, MA (通讯作者)，Vanderbilt Univ, Vanderbilt Eye Inst, Med Ctr, Nashville, TN 37232 USA.
EM sabrina.l.mitchell@vumc.org; machunyu4402@hotmail.com;
   w.scott@med.miami.edu; anita.agarwal@vanderbilt.edu;
   mpericak@med.miami.edu; jonathan.haines@case.edu; dpjones@emory.edu;
   kuppal2@emory.edu; milam.brantley@vumc.org
OI Mitchell, Sabrina/0000-0001-7930-2447
FU National Institutes of Health [R01 EY22618, R01 EY012118]; Vanderbilt
   Department of Ophthalmology and Visual Sciences
FX This work was supported by National Institutes of Health grants R01
   EY22618 (MAB) and R01 EY012118 (MP-V, JLH, WKS, and AA) and an
   unrestricted award to the Vanderbilt Department of Ophthalmology and
   Visual Sciences from Research to Prevent Blindness. The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Accardi CJ, 2016, J OCCUP ENVIRON MED, V58, pS80, DOI 10.1097/JOM.0000000000000770
   Benton HP, 2010, BIOINFORMATICS, V26, P2488, DOI 10.1093/bioinformatics/btq441
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Burgess LG, 2015, INVEST OPHTH VIS SCI, V56, P5020, DOI 10.1167/iovs.15-16702
   Chen GB, 2017, ANAL CHEM, V89, P4897, DOI 10.1021/acs.analchem.6b05006
   de la Barca JMC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030631
   Duncan RS, 2011, CLIN OPHTHALMOL, V5, P543, DOI 10.2147/OPTH.S18309
   Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335
   Frediani JK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108854
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Garg P, 2010, NEUROSCIENCE, V166, P252, DOI 10.1016/j.neuroscience.2009.11.069
   Go YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142916
   Go YM, 2015, TOXICOL SCI, V148, P531, DOI 10.1093/toxsci/kfv198
   Han GG, 2020, J PROTEOME RES, V19, P2358, DOI 10.1021/acs.jproteome.0c00036
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Johnson JM, 2010, ANALYST, V135, P2864, DOI 10.1039/c0an00333f
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kalucka J, 2018, CELL METAB, V28, P881, DOI 10.1016/j.cmet.2018.07.016
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375
   Lains Ines, 2021, Ophthalmol Sci, V1, DOI 10.1016/j.xops.2021.100017
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lambert V, 2020, J MOL MED, V98, P1737, DOI 10.1007/s00109-020-01994-9
   Li SZ, 2017, CELL, V169, P862, DOI 10.1016/j.cell.2017.04.026
   Li SZ, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003123
   Liu XJ, 2017, TRENDS BIOCHEM SCI, V42, P274, DOI 10.1016/j.tibs.2017.01.004
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Matias I, 2006, PROSTAG LEUKOTR ESS, V75, P413, DOI 10.1016/j.plefa.2006.08.002
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Montgomery CL, 2016, LIPIDS, V51, P857, DOI 10.1007/s11745-016-4161-x
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Patel RM, 2015, TRANSFUSION, V55, P544, DOI 10.1111/trf.12884
   Payne Andrew J, 2013, Mo Med, V110, P429
   Roede JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077629
   Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752
   Ruttkies C, 2016, J CHEMINFORMATICS, V8, DOI 10.1186/s13321-016-0115-9
   Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Soltow QA, 2013, METABOLOMICS, V9, pS132, DOI 10.1007/s11306-011-0332-1
   Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Tautenhahn R, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-504
   Uppal K, 2017, ANAL CHEM, V89, P1063, DOI 10.1021/acs.analchem.6b01214
   Uppal K, 2016, CHEM RES TOXICOL, V29, P1956, DOI 10.1021/acs.chemrestox.6b00179
   Uppal K, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-15
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu TW, 2009, BIOINFORMATICS, V25, P1930, DOI 10.1093/bioinformatics/btp291
NR 55
TC 2
Z9 2
U1 2
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2021
VL 10
IS 11
AR 3141
DI 10.3390/cells10113141
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XL0KJ
UT WOS:000727842300001
PM 34831363
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Modi, YS
   Tanchon, C
   Ehlers, JP
AF Modi, Yasha S.
   Tanchon, Carley
   Ehlers, Justis P.
TI Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related
   Macular Degeneration
SO DRUG SAFETY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN THERAPY; INTRAVITREAL
   INJECTION; RANIBIZUMAB LUCENTIS; PLASMA-LEVELS; DOSING REGIMEN;
   ENDOPHTHALMITIS; AFLIBERCEPT; MACULOPATHY; PEGAPTANIB
AB Neovascular age-related macular degeneration (NVAMD) is one of the leading causes of blindness. Over the last decade, the treatment of NVAMD has been revolutionized by the development of intravitreal anti-vascular endothelial growth factor (VEGF) therapies. Several anti-VEGF medications are used for the treatment of NVAMD. The safety and tolerability of these medications deserve review given the high prevalence of NVAMD and the significant utilization of these medications. Numerous large randomized clinical trials have not shown any definitive differential safety relative to ocular or systemic safety of these medications. Intravitreal anti-VEGF therapy does appear to impact systemic VEGF levels, but the implications of these changes remain unclear. One unique safety concern relates drug compounding and the potential risks of contamination, specifically for bevacizumab. Continued surveillance for systemic safety concerns, particularly for rare events, is merited. Overall, these medications are well tolerated and effective in the treatment of NVAMD.
C1 [Modi, Yasha S.; Tanchon, Carley; Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Ehlers, JP (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,i32, Cleveland, OH 44195 USA.
EM ehlersj@ccf.org
FU National Institutes of Health/National Eye Institute [NIH/NEI
   K23-EY022947-01A1]; Ohio Department of Development Grant [TECH-13-059];
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [K23EY022947]
   Funding Source: NIH RePORTER
FX This work was funded by the National Institutes of Health/National Eye
   Institute Grant NIH/NEI K23-EY022947-01A1 (Justis P. Ehlers), Ohio
   Department of Development Grant TECH-13-059 (Justis P. Ehlers) and
   institutional Grant from Research to Prevent Blindness to Cole Eye
   Institute. The funders had no role in data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brouzas D, 2009, CLIN OPHTHALMOL, V3, P457
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 1997, EXS, V79, P209
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Mezad-Koursh D, 2010, RETINA-J RET VIT DIS, V30, P1051, DOI 10.1097/IAE.0b013e3181cd47ed
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Sheyman AT, 2013, JAMA OPHTHALMOL, V131, P864, DOI 10.1001/jamaophthalmol.2013.88
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Theoulakis PE, 2010, KLIN MONATSBL AUGENH, V227, P280, DOI 10.1055/s-0029-1245201
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Wang FH, 2013, OPHTHALMOLOGY, V120, P355, DOI 10.1016/j.ophtha.2012.07.083
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 71
TC 13
Z9 13
U1 1
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD MAR
PY 2015
VL 38
IS 3
BP 279
EP 293
DI 10.1007/s40264-015-0273-0
PG 15
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA CE3BF
UT WOS:000351698400006
PM 25700714
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaluzny, J
   Purta, P
   Poskin, Z
   Rogers, JD
   Fawzi, AA
AF Kaluzny, Joel
   Purta, Patryk
   Poskin, Zach
   Rogers, Jeremy D.
   Fawzi, Amani A.
TI Ex Vivo Confocal Spectroscopy of Autofluorescence in Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; QUANTITATIVE FUNDUS AUTOFLUORESCENCE; BRUCHS
   MEMBRANE; MORPHOMETRIC-ANALYSIS; HUMAN RPE; LIPOFUSCIN; FLUORESCENCE;
   DISEASE; DRUSEN; EYES
AB Purpose
   We investigated the autofluorescence (AF) signature of the microscopic features of retina with age-related macular degeneration (AMD) using 488 nm excitation.
   Methods
   The globes of four donors with AMD and four age-matched controls were embedded in paraffin and sectioned through the macula. Sections were excited using a 488 nm argon laser, and the AF emission was captured using a laser scanning confocal microscope (496-610 nm, 6 nm resolution). The data cubes were then analyzed to compare peak emission spectra between the AMD and the controls. Microscopic features, including individual lipofuscin and melanolipofuscin granules, Bruch's Membrane, as well macroscopic features, were considered.
   Results
   Overall, the AMD eyes showed a trend of blue-shifted emission peaks compared with the controls. These differences were statistically significant when considering the emission of the combined RPE/Bruch's Membrane across all the tissue cross-sections (p = 0.02).
   Conclusions
   The AF signatures of ex vivo AMD RPE/BrM show blue-shifted emission spectra (488 nm excitation) compared with the control tissue. The magnitude of these differences is small (similar to 4 nm) and highlights the potential challenges of detecting these subtle spectral differences in vivo.
C1 [Kaluzny, Joel; Purta, Patryk; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Poskin, Zach; Rogers, Jeremy D.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
C3 Northwestern University; Feinberg School of Medicine; University of
   Wisconsin System; University of Wisconsin Madison
RP Fawzi, AA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.; Rogers, JD (通讯作者)，Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
EM jdrogers5@wisc.edu; amani.fawzi@northwestern.edu
RI Rogers, Jeremy/A-4572-2008; fawzi, amani/AAA-9199-2021
OI Rogers, Jeremy/0000-0003-3049-2803; fawzi, amani/0000-0002-9568-3558
FU National Institutes of Health [NIH-EY021470]; Illinois Society for the
   Prevention of Blindness; Edwin and Dorothy Gamewell Professorship,
   Retina Research Foundation; National Cancer Institute (Northwestern
   University) [NCI-CCSG-P30-CA060553]; NCI CCSG [P30 CA060553]; NATIONAL
   CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [DP3DK108248]
   Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health
   (http://www.nih.gov/; NIH-EY021470; AAF), Illinois Society for the
   Prevention of Blindness (http://www.eyehealthillinois.org/; JK), and the
   Edwin and Dorothy Gamewell Professorship, Retina Research Foundation
   (http://retinaresearchfnd.org/; JDR), National Cancer Institute
   (http://www.cancer.gov/; NCI-CCSG-P30-CA060553; Northwestern
   University). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.;
   Confocal microscopy was performed at the Northwestern University Center
   for Advanced Microscopy generously supported by NCI CCSG P30 CA060553
   awarded to the Robert H Lurie Comprehensive Cancer Center.
CR Ach T, 2012, BRIT J OPHTHALMOL, V96, P1141, DOI 10.1136/bjophthalmol-2012-301547
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2011, EXP EYE RES, V93, P29, DOI 10.1016/j.exer.2011.04.004
   Bourg-Heckly G, 2008, IN VIVO ENDOSCOPIC A
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cucio CA, 2010, J LIPID RES, V51, P451, DOI [10.1194/jlr.R002238, DOI 10.1194/JLR.R002238]
   Cummings TJ., 2013, OPHTHALMIC PATHOLOGY
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feldman TB, 2015, ANAL BIOANAL CHEM, V407, P1075, DOI 10.1007/s00216-014-8353-z
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Greenberg JP, 2013, INVEST OPHTH VIS SCI, V54, P5684, DOI 10.1167/iovs.13-12445
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kim SR, 2010, VISION RES, V50, P729, DOI 10.1016/j.visres.2009.09.015
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rocha R, 2008, PHOTOMED LASER SURG, V26, P329, DOI 10.1089/pho.2007.2208
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schweitzer D, 2009, OPHTHALMOLOGE, V106, P714, DOI 10.1007/s00347-009-1975-4
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   SISKEN JE, 1989, METHOD CELL BIOL, V30, P113
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1480, DOI 10.1039/c0pp00207k
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Thiberville L, 2007, AM J RESP CRIT CARE, V175, P22, DOI 10.1164/rccm.200605-684OC
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Warburton S, 2005, MOL VIS, V11, P1122
   Warburton S, 2007, MOL VIS, V13, P318
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
NR 46
TC 2
Z9 3
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 15
PY 2016
VL 11
IS 9
AR e0162869
DI 10.1371/journal.pone.0162869
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DW5SJ
UT WOS:000383706900089
PM 27631087
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Snellen, ELM
   Verbeek, ALM
   van den Hoogen, GWP
   Cruysberg, JRM
   Hoyng, CB
AF Snellen, ELM
   Verbeek, ALM
   van den Hoogen, GWP
   Cruysberg, JRM
   Hoyng, CB
TI Neovascular age-related macular degeneration and its relationship to
   antioxidant intake
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE age-related macular degeneration; antioxidant intake; lutein and
   zeaxanthin; aetiology; prevention
ID DIETARY-FAT; MACULOPATHY; LIGHT; RISK
AB Purpose: Experimental and epidemiological studies suggest that low antioxidant intake may be associated with the occurrence of neovascular age-related macular degeneration (AMD).
   Methods: We investigated this hypothesis further with a case-control study involving 72 case and 66 control patients attending the Ophthalmology Department of the University Hospital in Nijmegen. Data were collected by interview on antioxidant intake (i.e. in fruit and vegetables), cigarette smoking, sunlight exposure and familial predisposition. Antioxidant intake was calculated according to the method described in the Framingham Eye Study. Logistic regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CI).
   Results: The prevalence rate of AMD in patients with low antioxidant intake and low lutein intake (dichotomized at the median value) was about twice as high as that in patients with high intake: OR = 1.7, 95% CI (0.8-3.7), and OR = 2.4, 95% CI (1.1-5.1). Further specification of intake data into quartiles of antioxidant intake and lutein/zeaxanthine intake showed a clear dose-response relationship.
   Conclusion: The effect of dietary antioxidants upon macular health warrants preventive studies.
C1 Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands.
   Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Verbeek, ALM (通讯作者)，Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat 252, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM A.Verbeek@mie.kun.nl
RI Hoyng, C.B./H-8050-2014; Cruysberg, Johannes R. M./D-4313-2009
OI Cruysberg, Johannes R. M./0000-0002-5330-0774
CR ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MICHELS M, 1992, AM J OPHTHALMOL, V114, P287, DOI 10.1016/S0002-9394(14)71792-1
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   ROTHMAN K, 1998, MODERN EPIDEMIOLOGY, pCH8
   SCHALCH W, 1999, CRC MOD NUT, P215
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VITALE S, 1993, EPIDEMIOLOGY, V4, P195, DOI 10.1097/00001648-199305000-00003
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 26
TC 92
Z9 105
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2002
VL 80
IS 4
BP 368
EP 371
DI 10.1034/j.1600-0420.2002.800404.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 586MU
UT WOS:000177588400003
PM 12190777
OA Bronze
DA 2022-11-30
ER

PT J
AU Wolf, A
   Ruping, J
   Neubauer, AS
   Mayer, W
   Ulbig, M
   Haritoglou, C
   Holz, FG
   Eter, N
   Kampik, A
AF Wolf, Armin
   Rueping, Johann
   Neubauer, Aljoscha S.
   Mayer, Wolfgang
   Ulbig, Michael
   Haritoglou, Christos
   Holz, Frank G.
   Eter, Nicole
   Kampik, Anselm
TI ALTERATIONS OF VASCULAR PIGMENT EPITHELIUM DETACHMENTS ASSOCIATED WITH
   AGE-RELATED MACULAR DEGENERATION DURING UPLOAD WITH INTRAVITREAL
   RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; pigment epithelium detachment; ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; DOSING REGIMEN; BEVACIZUMAB; INJECTION; TEARS;
   AMD; REPRODUCIBILITY; TRIAMCINOLONE
AB Purpose: To describe morphologic alterations of pigment epithelial detachments (PEDs) associated with neovascular age-related macular degeneration during anti-vascular endothelial growth factor upload therapy with ranibizumab.
   Methods: Prospective, single-arm interventional study. Primary outcome was the reduction of height of PED during monthly treatment using ranibizumab. Secondary outcomes were factors influencing the regression of PED. Inclusion criteria were presence of PED associated with naive neovascular age-related macular degeneration, visual acuity of >20/200, and height of PED> 150 mu m on optical coherence tomography. All eyes (n = 54) received 3 injections of ranibizumab in monthly intervals ("upload therapy"). Last review examination was performed 14 weeks after the initial treatment.
   Results: The mean PED height decreased from 515 mu m (SD, 268.3) to 294 mu m (SD, 201.9) at Week 14 with the highest degree of regression after the first treatment. A complete resolution of PED was noted in 8 eyes (15%). Using conventional regression model, none of the factors investigated, including height of PED, presence of intraretinal or subretinal fluid, intraretinal cysts, macular volume, retinal thickness, presence of foveal depression, presence of hemorrhage, and visual acuity, had a significant impact on the morphologic response. Using a modified binary logistic regression model ("bootstrapping"), presence of foveal depression (P > 0.033), and retinal thickness (P > 0.004) showed statistical significance.
   Conclusion: This study on the responses and potential predictive factors associated with vascularized PED during the uploading phase of intravitreal ranibizumab shows a complete resolution of the PED in 15% of the cases.
C1 [Wolf, Armin; Rueping, Johann; Neubauer, Aljoscha S.; Mayer, Wolfgang; Ulbig, Michael; Haritoglou, Christos; Kampik, Anselm] Univ Eye Hosp, Klinikum Univ Munchen, LMU, Dept Ophthalmol, Munich, Germany.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Eter, Nicole] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munich; University of Bonn; University of Munster
RP Wolf, A (通讯作者)，Klinikum Univ Munchen, Dept Ophthalmol, LMU Campus Innenstadt,Mathildenstr 8, D-80336 Munich, Germany.
EM armin.wolf@med.uni-muenchen.de
RI Mayer, Wolfgang/AAJ-1407-2020
OI Mayer, Wolfgang/0000-0001-8891-4875
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   [Anonymous], 1991, ARCH OPHTHALMOL, V109, P1242
   Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BIRD AC, 1991, EYE, V5, P1
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Boos DD, 2003, STAT SCI, V18, P168, DOI 10.1214/ss/1063994971
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chin EK, 2012, OPHTHAL SURG LAS IM, V43, P97, DOI 10.3928/15428877-20111222-02
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Frimpong-Boateng A, 2008, OPHTHALMOLOGE, V105, P661, DOI 10.1007/s00347-007-1655-1
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975
   Haefeli M, 2008, VALUE HEALTH, V11, P575, DOI 10.1111/j.1524-4733.2007.00282.x
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Loukianou E, 2010, CASE REP OPHTHALM, V1, P110, DOI 10.1159/000321730
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Reznicek L., 2011, ARV ABSTR
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Ruppenstein M, 2010, OPHTHALMOLOGE, V107, P827, DOI 10.1007/s00347-010-2166-z
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wasmuth S, 2010, OPHTHALMOLOGE, V107, P1109, DOI 10.1007/s00347-010-2142-7
   Yeh B, 2011, OPTOMETRY, V82, P152, DOI 10.1016/j.optm.2010.09.010
NR 40
TC 12
Z9 12
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2013
VL 33
IS 9
BP 1843
EP 1849
DI 10.1097/IAE.0b013e318287d9be
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297DL
UT WOS:000330235500012
PM 23598795
DA 2022-11-30
ER

PT J
AU Liu, AH
   Chang, J
   Lin, YH
   Shen, ZQ
   Bernstein, PS
AF Liu, Aihua
   Chang, James
   Lin, Yanhua
   Shen, Zhengqing
   Bernstein, Paul S.
TI Long-chain and very long-chain polyunsaturated fatty acids in ocular
   aging and age-related macular degeneration
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE retina; retinal pigment epithelium (RPE)/choroid; eye
ID RETINAL-PIGMENT EPITHELIUM; DOCOSAHEXAENOIC ACID; ELECTRICAL RESPONSE;
   DIETARY-FAT; ELOVL4; LIPIDS; BRAIN; DEFICIENCY; DISEASE; DIFFERENTIATION
AB Retinal long-chain PUFAs (LC-PUFAs, C-12-C-22) play important roles in normal human retinal function and visual development, and some epidemiological studies of LC-PUFA intake suggest a protective role against the incidence of advanced age-related macular degeneration (AMD). On the other hand, retinal very long-chain PUFAs (VLC-PUFAs, C-n>22) have received much less attention since their identification decades ago, due to their minor abundance and more difficult assays, but recent discoveries that defects in VLC-PUFA synthetic enzymes are associated with rare forms of inherited macular degenerations have refocused attention on their potential roles in retinal health and disease. We thus developed improved GC-MS methods to detect LC-PUFAs and VLC-PUFAs, and we then applied them to the study of their changes in ocular aging and AMD. With ocular aging, some VLC-PUFAs in retina and retinal pigment epithelium (RPE)/choroid peaked in middle age. Compared with age-matched normal donors, docosahexaenoic acid, adrenic acid, and some VLC-PUFAs in AMD retina and RPE/choroid were significantly decreased, whereas the ratio of n-6/n-3 PUFAs was significantly increased. All these findings suggest that deficiency of LC-PUFAs and VLC-PUFAs, and/or an imbalance of n-6/n-3 PUFAs, may be involved in AMD pathology.-Liu, A., J. Chang, Y. Lin, Z. Shen, and P. S. Bernstein. Long-chain and very long-chain polyunsaturated fatty acids in ocular aging and age-related macular degeneration. J. Lipid Res. 2010. 51: 3217-3229.
C1 [Liu, Aihua; Lin, Yanhua; Shen, Zhengqing; Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Chang, James] ThermoFisher Sci, Sci Instruments Div, San Jose, CA 95134 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU Steinbach Foundation; Macula Vision Research Foundation; Research to
   Prevent Blindness
FX This work was supported by grants from the Steinbach Foundation, the
   Macula Vision Research Foundation, and a departmental grant from
   Research to Prevent Blindness.
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   Alessandri JM, 2004, REPROD NUTR DEV, V44, P509, DOI 10.1051/rnd:2004063
   ANDERSON RE, 1978, BIOCHIM BIOPHYS ACTA, V510, P316, DOI 10.1016/0005-2736(78)90032-9
   ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   BENOLKEN RM, 1973, SCIENCE, V182, P1253, DOI 10.1126/science.182.4118.1253
   Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331
   Bok D., 1979, RETINAL PIGMENT EPIT, P148
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   CONNOR WE, 1992, NUTR REV, V50, P21
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Farooqui AA, 2007, J NEUROCHEM, V101, P577, DOI 10.1111/j.1471-4159.2006.04371.x
   FELLENBERG AJ, 1987, BIOMED ENVIRON MASS, V14, P127, DOI 10.1002/bms.1200140306
   FUTTERMAN S, 1964, INVEST OPHTH VISUAL, V3, P441
   GORDON WC, 1992, CURR EYE RES, V11, P73, DOI 10.3109/02713689209069169
   GORDON WC, 1993, INVEST OPHTH VIS SCI, V34, P2402
   Greiner RS, 1999, LIPIDS, V34, pS239, DOI 10.1007/BF02562305
   Gu JY, 2009, MOL CELL PROTEOMICS, V8, P1338, DOI 10.1074/mcp.M800453-MCP200
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715
   Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S
   HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5
   HARDY SJ, 1994, J IMMUNOL, V153, P1754
   Hibbeln JR, 2007, LANCET, V369, P578, DOI 10.1016/S0140-6736(07)60277-3
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hubbard AF, 2006, ARCH OPHTHALMOL-CHIC, V124, P257, DOI 10.1001/archopht.124.2.257
   Innis SM, 2008, AM J CLIN NUTR, V87, P548, DOI 10.1093/ajcn/87.3.548
   Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7
   Li F, 2009, MOL VIS, V15, P1185
   MARTINEZ M, 1988, J NEUROSCI RES, V20, P484, DOI 10.1002/jnr.490200412
   MCMAHON A, BR J OPHTHALMOL
   McMahon A, 2007, FEBS LETT, V581, P5459, DOI 10.1016/j.febslet.2007.10.050
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nourooz-Zadeh J, 1999, OPHTHALMIC RES, V31, P273, DOI 10.1159/000055547
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002
   POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036
   POULOS A, 1986, BIOCHEM J, V235, P607, DOI 10.1042/bj2350607
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Rotstein NP, 1998, INVEST OPHTH VIS SCI, V39, P2750
   RUSSELL Y, 1989, J LIPID RES, V30, P877
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Suh M, 2005, CURR EYE RES, V30, P959, DOI 10.1080/02713680500246957
   TINOCO J, 1971, J NUTR, V101, P937, DOI 10.1093/jn/101.7.937
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1
   Uauy R, 1996, LIPIDS, V31, pS167, DOI 10.1007/BF02637071
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Weisinger HS, 1996, LIPIDS, V31, P65, DOI 10.1007/BF02522413
   WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 67
TC 91
Z9 92
U1 2
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD NOV
PY 2010
VL 51
IS 11
BP 3217
EP 3229
DI 10.1194/jlr.M007518
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 662LG
UT WOS:000282808200014
PM 20688753
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ling, SK
   Yang, SQ
   Hu, XD
   Yin, D
   Dai, Y
   Qian, XQ
   Wang, DW
   Pan, XY
   Hong, JX
   Sun, XD
   Yang, H
   Paludan, SR
   Cai, YJ
AF Ling, Sikai
   Yang, Shiqi
   Hu, Xinde
   Yin, Di
   Dai, Yao
   Qian, Xiaoqing
   Wang, Dawei
   Pan, Xiaoyong
   Hong, Jiaxu
   Sun, Xiaodong
   Yang, Hui
   Paludan, Soren Riis
   Cai, Yujia
TI Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide
   RNA prevents wet age-related macular degeneration in mice
SO NATURE BIOMEDICAL ENGINEERING
LA English
DT Article
ID IN-VIVO DELIVERY; NANOPARTICLE DELIVERY; GENE-THERAPY; GENOME;
   CRISPR/CAS9; VECTORS; PROTEIN; CELLS; EXPRESSION
AB Therapeutic genome editing requires effective and targeted delivery methods. The delivery of Cas9 mRNA using adeno-associated viruses has led to potent in vivo therapeutic efficacy, but can cause sustained Cas9 expression, anti-Cas9 immune responses and off-target edits. Lentiviral vectors have been engineered to deliver nucleases that are expressed transiently, but in vivo evidence of their biomedical efficacy is lacking. Here, we show that the lentiviral codelivery of Streptococcus pyogenesCas9 mRNA and expression cassettes that encode a guide RNA that targets vascular endothelial growth factor A (Vegfa) is efficacious in a mouse model of wet age-related macular degeneration induced by Vegfa. A single subretinal injection of engineered lentiviruses knocked out 44% of Vegfa in retinal pigment epithelium and reduced the area of choroidal neovascularization by 63% without inducing off-target edits or anti-Cas9 immune responses. Engineered lentiviruses for the transient expression of nucleases may form the basis of new treatments for retinal neovascular diseases.
   Lentiviruses co-packaging expression cassettes that encode SpCas9 mRNA and a guide RNA targeting the Vegfa gene prevent mice from developing wet age-related macular degeneration induced by Vegfa.
C1 [Ling, Sikai; Yin, Di; Dai, Yao; Cai, Yujia] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai, Peoples R China.
   [Yang, Shiqi; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai Peoples Hosp 1,Sch Med, Shanghai, Peoples R China.
   [Hu, Xinde; Yang, Hui] Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, State Key Lab Neurosci,Key Lab Primate Neurobiol, Shanghai, Peoples R China.
   [Qian, Xiaoqing] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.
   [Wang, Dawei] Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med, Ruijin Hosp, Sch Med, Shanghai, Peoples R China.
   [Pan, Xiaoyong] Shanghai Jiao Tong Univ, Inst Image Proc & Pattern Recognit, Key Lab Syst Control & Informat Proc, Minist Educ, Shanghai, Peoples R China.
   [Hong, Jiaxu] Fudan Univ, Dept Ophthalmol & Vis Sci Shanghai, Shanghai Eye Ear Nose & Throat Hosp, Shanghai, Peoples R China.
   [Paludan, Soren Riis] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS;
   Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Fudan University; Aarhus University
RP Cai, YJ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai, Peoples R China.
EM yujia.cai@sjtu.edu.cn
RI Yang, Shiqi/CAI-7690-2022
OI Yang, Shiqi/0000-0003-1314-951X; Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China [31971364]; Pujiang Talent
   Project of Shanghai [18PJ1404500]; Shanghai Municipal Natural Science
   Foundation [18ZR1419300]; Shanghai Center for Systems Biomedicine,
   Shanghai Jiao Tong University [WF220441504]
FX We thank W. Yang at the Southern Medical University, China, for
   discussions and scientific input for the immunology part of the study.
   Y.C. is supported by the National Natural Science Foundation of China
   (no. 31971364), Pujiang Talent Project of Shanghai (no. 18PJ1404500),
   Shanghai Municipal Natural Science Foundation (no. 18ZR1419300), and
   startup funding from Shanghai Center for Systems Biomedicine, Shanghai
   Jiao Tong University (no. WF220441504).
CR Akcakaya P, 2018, NATURE, V561, P416, DOI 10.1038/s41586-018-0500-9
   Alkilany AM, 2010, J NANOPART RES, V12, P2313, DOI 10.1007/s11051-010-9911-8
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Beyret E, 2019, NAT MED, V25, P419, DOI 10.1038/s41591-019-0343-4
   Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936
   Cai Y., 2014, MOB GENET ELEMENTS, V4, DOI [10.4161/mge.29591, DOI 10.4161/MGE.29591]
   Cai YJ, 2016, CURR GENE THER, V16, P194, DOI 10.2174/1566523216666160527143702
   Cai YJ, 2014, ELIFE, V3, DOI 10.7554/eLife.01911
   Cai YJ, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gkt1163
   Campochiaro PA, 2019, J CLIN INVEST, V129, P3029, DOI 10.1172/JCI129861
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cheng Y, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1610-2
   Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993
   Choi JG, 2016, GENE THER, V23, P627, DOI 10.1038/gt.2016.27
   Dang Y, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0846-3
   Dever DP, 2016, NATURE, V539, P384, DOI 10.1038/nature20134
   Ellis J, 2005, HUM GENE THER, V16, P1241, DOI 10.1089/hum.2005.16.1241
   Gao X, 2018, NATURE, V553, P217, DOI 10.1038/nature25164
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Holmgaard A, 2017, MOL THER-NUCL ACIDS, V9, P89, DOI 10.1016/j.omtn.2017.08.016
   Hughes CP, 2019, MOL THER-METH CLIN D, V13, P86, DOI 10.1016/j.omtm.2018.11.005
   Ihry RJ, 2018, NAT MED, V24, P939, DOI 10.1038/s41591-018-0050-6
   Kim EH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14964
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim S, 2014, GENOME RES, V24, P1012, DOI 10.1101/gr.171322.113
   Kluesner MG, 2018, CRISPR J, V1, P239, DOI 10.1089/crispr.2018.0014
   Koblan LW, 2018, NAT BIOTECHNOL, V36, P843, DOI 10.1038/nbt.4172
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kuzembayeva M, 2014, VIROLOGY, V454, P362, DOI 10.1016/j.virol.2014.01.019
   Lee B, 2018, NAT BIOMED ENG, V2, P497, DOI 10.1038/s41551-018-0252-8
   Lee K, 2017, NAT BIOMED ENG, V1, P889, DOI 10.1038/s41551-017-0137-2
   Li A, 2019, MOL THER-METH CLIN D, V12, P111, DOI 10.1016/j.omtm.2018.11.009
   Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ling S, 2020, FIGHARE, DOI 10.6084/m9.figshare.12611819
   Lu BS, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz093
   Lyu P, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz605
   Maeder ML, 2019, NAT MED, V25, P229, DOI 10.1038/s41591-018-0327-9
   Mangeot PE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07845-z
   Mingozzi F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005795
   Montagna C, 2018, MOL THER-NUCL ACIDS, V12, P453, DOI 10.1016/j.omtn.2018.05.010
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Naldini L, 2016, SCIENCE, V353, P1101, DOI 10.1126/science.aah6192
   Nelson CE, 2019, NAT MED, V25, P427, DOI 10.1038/s41591-019-0344-3
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Ortinski PI, 2017, MOL THER-METH CLIN D, V5, P153, DOI 10.1016/j.omtm.2017.04.002
   Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0
   Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561
   Perry B Hackett NVS, 2014, ELIFE, V3, pe02904
   PICKETT GG, 1993, NUCLEIC ACIDS RES, V21, P4621, DOI 10.1093/nar/21.19.4621
   Prel A, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.39
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Santiago-Fernandez O, 2019, NAT MED, V25, P423, DOI 10.1038/s41591-018-0338-6
   Sedlazeck FJ, 2018, NAT METHODS, V15, P461, DOI 10.1038/s41592-018-0001-7
   Shahbazi R, 2019, NAT MATER, V18, P1124, DOI 10.1038/s41563-019-0385-5
   Skipper KA, 2018, MOL THER-NUCL ACIDS, V11, P253, DOI 10.1016/j.omtn.2018.02.006
   Staunstrup NH, 2009, MOL THER, V17, P1205, DOI 10.1038/mt.2009.10
   Stemmer M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124633
   Surun D, 2018, MOL THER-NUCL ACIDS, V10, P1, DOI 10.1016/j.omtn.2017.11.001
   Thuronyi BW, 2019, NAT BIOTECHNOL, V37, P1070, DOI 10.1038/s41587-019-0193-0
   Tsai SQ, 2015, NAT BIOTECHNOL, V33, P187, DOI 10.1038/nbt.3117
   Usui-Ouchi A, 2019, J CLIN INVEST, V129, P3032, DOI 10.1172/JCI129862
   van Diemen FR, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005701
   Voelkel C, 2010, P NATL ACAD SCI USA, V107, P7805, DOI 10.1073/pnas.0914517107
   Wagner DL, 2019, NAT MED, V25, P242, DOI 10.1038/s41591-018-0204-6
   Wang D, 2015, HUM GENE THER, V26, P432, DOI 10.1089/hum.2015.087
   Wignakumar T, 2019, CURR TRANSPLANT REP, V6, P127, DOI 10.1007/s40472-019-00237-2
   Zeka B, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0355-y
NR 76
TC 40
Z9 45
U1 33
U2 147
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2157-846X
J9 NAT BIOMED ENG
JI Nat. Biomed. Eng
PD FEB
PY 2021
VL 5
IS 2
DI 10.1038/s41551-020-00656-y
EA JAN 2021
PG 16
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA QG4HB
UT WOS:000604859600002
PM 33398131
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Mehryar, M
   Farvardin, M
   Hosseini, H
   Aslani, M
AF Mehryar, M
   Farvardin, M
   Hosseini, H
   Aslani, M
TI Potential role of uric acid in the molecular pathogenesis of age-related
   macular degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID LIPID-PEROXIDATION; OXIDATIVE STRESS; DIETARY-FAT; FISH INTAKE;
   MACULOPATHY; PROTECTION; DISEASE; RETINA; SYSTEM; EYE
AB Age-related macular degeneration (ARMD) is the foremost cause of blindness among the elderly population in industriatised countries. Currently, there is no effective treatment for the majority of patients. To develop new and effective modes of therapy, understanding of the molecular basis of the disease is mandatory. Many age-related pathologies have been attributed to cumulative oxidative damage caused by reactive oxygen intermediates. There is growing evidence that uric acid has antioxidant properties and it is a naturally occurring antioxidant. Based on antioxidant role in pathogenesis of ARMD and antioxidant properties of uric acid we conclude that altered uric acid metabolism could play a role in ARMD damage and pathogenesis. Future research needs to evaluate uric acid metabolism in ARMD patients. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Shiraz Univ Med Sci, Khalili Hosp, Dept Ophthalmol, Shiraz, Iran.
C3 Shiraz University of Medical Science
RP Hosseini, H (通讯作者)，Shiraz Univ Med Sci, Khalili Hosp, Dept Ophthalmol, Shiraz, Iran.
EM hosseinih@sums.ac.ir
RI farvardin, Mohsen/K-7466-2016
OI farvardin, Mohsen/0000-0001-5820-4581
CR ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonne C, 2000, J FR OPHTALMOL, V23, P835
   Chiou GCY, 2001, J OCUL PHARMACOL TH, V17, P189, DOI 10.1089/10807680151125555
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DETURCO EBR, 1991, J NEUROSCI, V11, P3667
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Kean RB, 2000, J IMMUNOL, V165, P6511, DOI 10.4049/jimmunol.165.11.6511
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Santos CXC, 1999, ARCH BIOCHEM BIOPHYS, V372, P285, DOI 10.1006/abbi.1999.1491
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Spitsin SV, 2002, FREE RADICAL BIO MED, V33, P1363, DOI 10.1016/S0891-5849(02)01048-1
   Stinefelt B, 2005, ANN CLIN LAB SCI, V35, P37
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Van LR, 2003, INVEST OPHTH VIS SCI, V44, P3771
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Wittenstein B, 2002, FREE RADICAL BIO MED, V33, P103, DOI 10.1016/S0891-5849(02)00863-8
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 31
TC 2
Z9 2
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2006
VL 66
IS 4
BP 793
EP 795
DI 10.1016/j.mehy.2005.10.014
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 024KS
UT WOS:000236194500016
PM 16326027
DA 2022-11-30
ER

PT J
AU Nath, M
   Halder, N
   Velpandian, T
AF Nath, Madhu
   Halder, Nabanita
   Velpandian, Thirumurthy
TI Circulating biomarkers in glaucoma, age-related macular degeneration,
   and diabetic retinopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; circulating biomarkers in glaucoma;
   diabetic retinopathy
ID ANGIOTENSIN-CONVERTING ENZYME; ENDOTHELIAL PROGENITOR CELLS; TOTAL
   ANTIOXIDANT CAPACITY; INCREASED PLASMA-LEVELS; OPEN-ANGLE GLAUCOMA;
   OXIDATIVE STRESS; MICROVASCULAR COMPLICATIONS; AQUEOUS-HUMOR;
   NATRIURETIC PEPTIDE; LIPID-PEROXIDATION
AB Biomarkers to predict the altering physiological conditions over the period leading toward the ocular disorders are of major importance in therapeutics. Isolation and validation of the biomarkers specific to ocular diseases are a challenging task. Glaucoma is a neurodegenerative disease of the eye where the correlation of biomarkers in circulating fluid may be made specific for the eye. However, conditions such as wet age-related macular degeneration (AMD) and proliferative diabetic retinopathy (DR), circulating biomarkers might be having some degree of overlap with other conditions like cancer where a common factor such as angiogenesis is involved. Diabetes, a systemic disorder affecting the target organs such as eye, kidney, heart, and nervous system can be predicted using common circulating biomarkers. However, these markers need to be validated along with various stages of disease progression to enable the possibility of targeted pharmacological interventions apart from good glycemic control alone. This review compiles the attempts made to correlate such circulating biomarkers in the ocular conditions such as glaucoma, AMD, and DR in the search for a surrogate marker for diagnostic and prognostic value. To make biomarkers for the common convenience, genetic markers are excluded from this review.
C1 [Nath, Madhu; Halder, Nabanita; Velpandian, Thirumurthy] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ocular Pharmacol & Pharm Div, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Velpandian, T (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Ocular Pharmacol & Pharm Div, New Delhi 110029, India.
EM tvelpandian@hotmail.com
RI Velpandian, Thirumurthy/ABE-7016-2021
CR Abhary S, 2009, DIABETES CARE, V32, P2084, DOI 10.2337/dc09-0816
   Abu El-Asrar AM, 2011, ACTA OPHTHALMOL, V89, P222, DOI 10.1111/j.1755-3768.2009.01700.x
   Abu-Amero K, 2015, INT J MOL SCI, V16, P28886, DOI 10.3390/ijms161226135
   Al-Mesallamy HO, 2011, J DIABETES COMPLICAT, V25, P168, DOI 10.1016/j.jdiacomp.2010.06.005
   ARNER P, 1989, DIABETOLOGIA, V32, P753, DOI 10.1007/BF00274537
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Baumane K, 2017, CURR EYE RES, V42, P233, DOI 10.1080/02713683.2016.1180397
   Bell K, 2013, PROG RETIN EYE RES, V36, P199, DOI 10.1016/j.preteyeres.2013.02.003
   Blaslov K, 2015, EUR J OPHTHALMOL, V25, P328, DOI 10.5301/ejo.5000547
   Brunner S, 2009, INVEST OPHTH VIS SCI, V50, P392, DOI 10.1167/iovs.08-1748
   Caliumi C, 2007, Minerva Endocrinol, V32, P73
   Cellini M, 1997, ACTA OPHTHALMOL SCAN, V75, P11
   Chang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027218
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   DUNTAS L, 1992, DIABETES RES CLIN PR, V16, P203, DOI 10.1016/0168-8227(92)90118-B
   Engin KN, 2010, MOL VIS, V16, P1260
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Fasching P, 1996, J CLIN ENDOCR METAB, V81, P4313, DOI 10.1210/jc.81.12.4313
   Fourgeux C, 2009, INVEST OPHTH VIS SCI, V50, P5712, DOI 10.1167/iovs.09-3655
   Fraenkl SA, 2011, J OCUL PHARMACOL TH, V27, P577, DOI 10.1089/jop.2011.0062
   Galassi F, 2004, BRIT J OPHTHALMOL, V88, P757, DOI 10.1136/bjo.2003.028357
   Ghaffariyeh A, 2011, OPTOMETRY VISION SCI, V88, P80, DOI 10.1097/OPX.0b013e3181fc329f
   Golubnitschaja O, 2002, AMINO ACIDS, V23, P293, DOI 10.1007/s00726-001-0141-3
   Golubnitschaja O, 2007, SURV OPHTHALMOL, V52, pS155, DOI 10.1016/j.survophthal.2007.08.011
   Goyal A, 2014, CURR EYE RES, V39, P823, DOI 10.3109/02713683.2011.556299
   Grus FH, 2006, INVEST OPHTH VIS SCI, V47, P968, DOI 10.1167/iovs.05-0685
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hamano K, 2014, VASC HEALTH RISK MAN, V10, P585, DOI 10.2147/VHRM.S67753
   Hulka B., 1990, BIOL MARKERS EPIDEMI, P3
   Jacqueminet S, 2006, CLIN CHIM ACTA, V367, P103, DOI 10.1016/j.cca.2005.11.029
   Javadiyan S, 2012, INVEST OPHTH VIS SCI, V53, P1923, DOI 10.1167/iovs.11-8420
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Kado S, 1999, DIABETES RES CLIN PR, V46, P143, DOI 10.1016/S0168-8227(99)00083-2
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Laurenti O, 1997, EXP CLIN ENDOCR DIAB, V105, P40, DOI 10.1055/s-0029-1211795
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lee IG, 2006, EYE, V20, P546, DOI 10.1038/sj.eye.6701920
   Liu YH, 2014, PPAR RES, V2014, DOI 10.1155/2014/374075
   Lopez-Riquelme N, 2015, INT OPHTHALMOL, V35, P527, DOI 10.1007/s10792-014-9979-8
   Machalinska Anna, 2014, Klin Oczna, V116, P16
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Malishevskaia T N, 2014, Vestn Oftalmol, V130, P67
   Mancino R, 2011, MOL VIS, V17, P1298
   Mokbel TH, 2010, CLIN EXP OPHTHALMOL, V38, P560, DOI 10.1111/j.1442-9071.2010.02318.x
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Ni JQ, 2009, MOL CELL PROTEOMICS, V8, P1921, DOI 10.1074/mcp.M900127-MCP200
   Nowak M, 1997, Klin Oczna, V99, P11
   Nucci C, 2013, MOL VIS, V19, P1841
   Pan HZ, 2008, BRIT J OPHTHALMOL, V92, P548, DOI 10.1136/bjo.2007.130542
   PETTY RG, 1991, DIABETES RES CLIN EX, V17, P115
   Pfeiffer A, 1996, DIABETES CARE, V19, P1113, DOI 10.2337/diacare.19.10.1113
   Qing S, 2014, CELL PHYSIOL BIOCHEM, V34, P1733, DOI 10.1159/000366374
   Salzmann J, 1998, BRIT J OPHTHALMOL, V82, P830, DOI 10.1136/bjo.82.7.830
   Schram MT, 2005, DIABETOLOGIA, V48, P370, DOI 10.1007/s00125-004-1628-8
   Seshasai S, 2015, INVEST OPHTH VIS SCI, V56, P1880, DOI 10.1167/iovs.14-15933
   Shalchi Z, 2008, ANN NY ACAD SCI, V1137, P253, DOI 10.1196/annals.1448.008
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Sharma S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/279393
   Shiba T, 2013, GRAEF ARCH CLIN EXP, V251, P2689, DOI 10.1007/s00417-013-2373-9
   Slepova O S, 2012, Vestn Oftalmol, V128, P27
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Takada T, 2013, ATHEROSCLEROSIS, V228, P270, DOI 10.1016/j.atherosclerosis.2013.02.035
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   Wang Q, 2014, INVEST OPHTH VIS SCI, V55, P3986, DOI 10.1167/iovs.13-13076
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Weinstein BI, 1996, EXP EYE RES, V62, P39, DOI 10.1006/exer.1996.0005
   Wunderlich K, 2002, MOL VIS, V8, P431
   Yang JJ, 2001, AM J OPHTHALMOL, V131, P421, DOI 10.1016/S0002-9394(00)00862-X
   Yildirim O, 2005, EYE, V19, P580, DOI 10.1038/sj.eye.6701565
NR 70
TC 13
Z9 13
U1 0
U2 8
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAR
PY 2017
VL 65
IS 3
BP 191
EP 197
DI 10.4103/ijo.IJO_866_16
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ET9GV
UT WOS:000400616400004
PM 28440247
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pinelli, R
   Bertelli, M
   Scaffidi, E
   Polzella, M
   Fulceri, F
   Biagioni, F
   Fornai, F
AF Pinelli, R.
   Bertelli, M.
   Scaffidi, E.
   Polzella, M.
   Fulceri, F.
   Biagioni, F.
   Fornai, F.
TI Nutraceuticals for dry age-related macular degeneration: a case report
   based on novel pathogenic and morphological insights
SO ARCHIVES ITALIENNES DE BIOLOGIE
LA English
DT Article
DE Age-related macular degeneration; Neurodegeneration; Autophagy; Lutein;
   Vaccinium Myrtillus; Resveratrol; Anthocyanins; Antioxidants;
   Carotenoids
ID VISUAL IMPAIRMENT; OXIDATIVE STRESS; SNELLEN CHART; MECHANISMS; EYE;
   INFLAMMATION; RESVERATROL; ANTIOXIDANT; UPDATE
AB Age-related macular degeneration represents the main retinal disorder leading to irreversible blindness in people over the age of 50 in the Western World. Here we describe a case report, which suggest that specific nutraceutical compounds may exert beneficial effects on the progression of dry age-related macular degeneration (AMD), an eye disease with no approved treatment or cure. Specific antioxidants, such as lutein, resveratrol and Vaccinium Myrtillus, which are known to reduce the risk of developing AMD, when co-administered alone, were supplemented to diet of an informed patient suffering from dry AMD. The case report indicates an improvement of visual acuity and a long lasting decrease in druse volume and number. The concomitant intake of lutein, resveratrol and Vaccinium Myrtillus when administered for six months produced a marked decrease in the drusen observed at OCT at the 6-month follow-up. At this time interval, the patient experienced a noticeable improvement in visual acuity, a decrease in eye strain, more color contrast, higher visual definition. The case report indicates the potential benefit for a non-invasive treatment with improved quality of vision in dry AMD. A larger population followed over a long-term period is warranted. The support of nutraceuticals could therefore offer a new non-invasive, adverse-effect-free which may restore the pathology affecting the cross talk between choroid and retinal cells. The results of this case report are discussed within the frame of molecular mechanisms synergizing site-specifically at the anatomical border between the outer retina and inner choroid.
C1 [Pinelli, R.; Bertelli, M.; Scaffidi, E.] Switzerland Eye Res Inst, Lugano, Switzerland.
   [Polzella, M.] Aliveda Labs, Fauglia, PI, Italy.
   [Fulceri, F.] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Biagioni, F.; Fornai, F.] IRCCS Neuromed, Pozzilli, IS, Italy.
   [Fornai, F.] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
C3 University of Pisa; IRCCS Neuromed; University of Pisa
RP Fornai, F (通讯作者)，IRCCS Neuromed, Pozzilli, IS, Italy.; Fornai, F (通讯作者)，Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
EM francesco.fornai@med.unipi.it
RI Polzella, Maico/ABF-8232-2020
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chen FK, 2014, ASIA-PAC J OPHTHALMO, V3, P277, DOI 10.1097/APO.0000000000000007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Forte R, 2011, J OCUL PHARMACOL TH, V27, P109, DOI 10.1089/jop.2010.0159
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Johnson AT, 1998, COMPUT METH PROG BIO, V57, P161, DOI 10.1016/S0169-2607(98)00036-4
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Khoo HE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8040085
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Munia I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030879
   Natoli R, 2010, MOL VIS, V16, P1801
   Neal SE, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.32
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Riva A, 2017, EUR REV MED PHARMACO, V21, P2518
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Schink A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203907
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Su D, 2016, OPHTHALMOLOGY, V123, P737, DOI 10.1016/j.ophtha.2015.12.003
   Tao Y, 2016, INT J OPHTHALMOL-CHI, V9, P153, DOI 10.18240/ijo.2016.01.25
   Untea AE, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10020191
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
NR 34
TC 8
Z9 8
U1 0
U2 4
PU PISA UNIV PRESS
PI PISA
PA LUNGARNO A PACINOTTI 43, 56100 PISA, ITALY
SN 0003-9829
J9 ARCH ITAL BIOL
JI Arch. Ital. Biol.
PD MAR
PY 2020
VL 158
IS 1
BP 24
EP 34
DI 10.12871/00039829202013
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA MC6XX
UT WOS:000543428300003
PM 32575145
DA 2022-11-30
ER

PT J
AU Wang, YM
   Shen, MX
   Cheng, JW
   Sun, XD
   Kaiser, PK
AF Wang, Yimin
   Shen, Mengxi
   Cheng, Jinwei
   Sun, Xiaodong
   Kaiser, Peter K.
TI The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A
   Systematic Review
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ONE-YEAR OUTCOMES; INTRAVITREAL
   AFLIBERCEPT; RANIBIZUMAB MONOTHERAPY; EXTEND REGIMEN; COMBINATION;
   MULTICENTER; INJECTION; SUBTYPES; EVEREST
AB Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients.Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (nAMD), has been well established in randomized clinical trials. This meta-analysis has evaluated the efficacy of a novel anti-VEGF agent, conbercept, in the management of PCV using ranibizumab and aflibercept as the reference agents. Methods. Thirty studies with 1308 eyes were identified and included in this study. The primary outcome measures were best-corrected visual acuity (BCVA), and secondary outcomes were optical coherence tomography characteristics and polyp regression rates. The pooled results were calculated by the random-effect or fixed-effect model according to the heterogeneity of the data. Results. Despite a large standard deviation in means (SMD) improvement for BCVA and central retinal thickness (CRT) in the conbercept group, there was no statistically significant difference in the other outcomes compared to ranibizumab and aflibercept. However, there was a greater polyp regression rate in the conbercept group at 12 months. Conclusions. This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months.
C1 [Wang, Yimin; Cheng, Jinwei; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Wang, Yimin; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Shen, Mengxi] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Sun, Xiaodong] Natl Clin Res Ctr Ophthalm Dis, Beijing, Peoples R China.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Shanghai Jiao Tong University; Bascom Palmer Eye Institute; University
   of Miami
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Natl Clin Res Ctr Ophthalm Dis, Beijing, Peoples R China.; Kaiser, PK (通讯作者)，Cole Eye Inst, Cleveland, OH 44106 USA.
EM wangwangwym@sjtu.edu.cn; ccjuly@gmail.com; jinwei_cheng@yeah.net;
   xdsun@sjtu.edu.cn; pkkaiser@gmail.com
RI Shen, Mengxi/ABC-6941-2021
OI Shen, Mengxi/0000-0002-1336-1695; Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China [81730026]; National Key RD
   Program [2017YFA0105301]; Frontier Project of Shanghai Hospital
   Development Center [SHDC12016105]; National Science and Technology Major
   Project [2019ZX09301113]
FX This study was supported by the National Natural Science Foundation of
   China (81730026), National Key R&D Program (2017YFA0105301), Frontier
   Project of Shanghai Hospital Development Center (SHDC12016105), and
   National Science and Technology Major Project (2019ZX09301113).
CR Arakawa A, 2017, CLIN OPHTHALMOL, V11, P797, DOI 10.2147/OPTH.S129164
   Bessho H, 2011, RETINA-J RET VIT DIS, V31, P1598, DOI 10.1097/IAE.0b013e31820d3f28
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Cheng Y, 2016, CHINESE MED J-PEKING, V129, P2610, DOI 10.4103/0366-6999.192779
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   de Oliveira Dias J. R., 2016, INT J RETINA VITREOU, V2, P1, DOI [10.1186/s40942-016-0026-y2-s2.0-85026815754, DOI 10.1186/S40942-016-0026-Y2-S2.0-85026815754]
   Farooq A, 2017, OSLI RETINA, V48, P34, DOI 10.3928/23258160-20161219-05
   Hara C, 2016, RETINA-J RET VIT DIS, V36, P37, DOI 10.1097/IAE.0000000000000767
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2016, RETINA-J RET VIT DIS, V36, P1527, DOI 10.1097/IAE.0000000000000933
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lai KB, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0801-7
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu H., 2018, OPHTHALMOLOGY, V38, P1144, DOI [10.13389/j.cnki.rao.2018.0270, DOI 10.13389/J.CNKI.RAO.2018.0270]
   Liu L, 2017, PHOTODIAGN PHOTODYN, V20, P215, DOI 10.1016/j.pdpdt.2017.09.008
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Marcus DM, 2015, EYE, V29, P1427, DOI 10.1038/eye.2015.150
   Maruyama-Inoue M, 2018, RETINA-J RET VIT DIS, V38, P2001, DOI 10.1097/IAE.0000000000001818
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   NAGAI N, 2019, SCI REPORTS, V9, DOI DOI 10.1038/S41598-019-47738-92-S2.0-85070324818
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Qi HJ, 2019, INT J OPHTHALMOL-CHI, V12, P51, DOI 10.18240/ijo.2019.01.08
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Reuter BK, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-19
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Sakai T, 2016, ACTA OPHTHALMOL, V94, pE765, DOI 10.1111/aos.13130
   Stewart MW, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010021
   Takahashi K, 2018, CLIN OPHTHALMOL, V12, P1789, DOI 10.2147/OPTH.S171015
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Tan CS, 2018, INVEST OPHTH VIS SCI, V59, P889, DOI 10.1167/iovs.17-22683
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Wang LP, 2018, DRUG DES DEV THER, V12, P3625, DOI 10.2147/DDDT.S176021
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yoneda A, 2020, EUR J OPHTHALMOL, V30, P1473, DOI 10.1177/1120672119871886
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
NR 55
TC 1
Z9 2
U1 1
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD AUG 13
PY 2020
VL 2020
AR 4924053
DI 10.1155/2020/4924053
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NI2XC
UT WOS:000565218600001
PM 32855818
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schiffelers, RM
   van der Vaart, TK
   Storm, G
AF Schiffelers, Raymond M.
   van der Vaart, Tjitske K.
   Storm, Gert
TI Neovascular Age-Related Macular Degeneration Opportunities for
   Development of First-in-Class Biopharmaceuticals
SO BIODRUGS
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PIGMENT EPITHELIAL-CELLS; INTERFERING
   RNA SIRNA; OCULAR DRUG-DELIVERY; ANTI-VEGF APTAMER; CIS-ELEMENT DECOY;
   SHORT-TERM SAFETY; LASER-INDUCED CNV
AB Age-related macular degeneration (AMD) is a condition that may cause blindness. The prevalence of the disease in the Western world is estimated at 1-2% of the population. Over the past decade, treatment of neovascular AMD has been shifting from destruction of newly formed blood vessels towards inhibitors that silence the vascular endothelial growth factor (VEGF) pathway. Such agents are often first-in-class biopharmaceuticals that benefit from the fact that they can be locally administered in an immune-privileged environment with slow clearance. These new VEGF pathway inhibitors have improved therapeutic effects over conventional treatment and have promoted the identification of novel targets for inhibition of AMD angiogenesis. This review describes the rationale behind the shift from conventional to current treatment options and discusses investigational, most notably biopharmaceutical, drugs that are in clinical trials. It also provides possible points for improvement of these treatments, specifically regarding their delivery.
C1 [Schiffelers, Raymond M.; van der Vaart, Tjitske K.; Storm, Gert] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmaceut, NL-3584 CA Utrecht, Netherlands.
C3 Utrecht University
RP Schiffelers, RM (通讯作者)，Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmaceut, Sorbonnelaan 16, NL-3584 CA Utrecht, Netherlands.
EM R.M.Schiffelers@uu.nl
RI Schiffelers, Raymond/E-8786-2011; Storm, Gerrit/O-8696-2016
OI Schiffelers, Raymond/0000-0002-1012-9815; 
CR Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391
   Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Aiello L P, 1997, Curr Opin Ophthalmol, V8, P19
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arland V, 2003, VISION RES, V43, P919, DOI 10.1016/S0042-6989(02)00389-9
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bennett J, 2003, GENE THER, V10, P977, DOI 10.1038/sj.gt.3302030
   Berdugo M, 2003, ANTISENSE NUCLEIC A, V13, P107, DOI 10.1089/108729003321629647
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bilodeau MT, 2002, EXPERT OPIN INV DRUG, V11, P737, DOI 10.1517/13543784.11.6.737
   BLICK SK, 2007, DRUGS, V67, P207
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   BOHLEN P, 2008, TUMOR ANGIOGENESIS B, P424
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning AC, 2008, BRIT J OPHTHALMOL, V92, P1003, DOI 10.1136/bjo.2007.127670
   Buch PK, 2008, GENE THER, V15, P849, DOI 10.1038/gt.2008.66
   Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6
   Camelo S, 2007, MOL VIS, V13, P2263
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   *CATT RES GROUP, N ENGL J MED
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang B, 2009, CELL CYCLE, V8, P780, DOI 10.4161/cc.8.5.7887
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dejneka NS, 2008, MOL VIS, V14, P997
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   dos Santos ALG, 2006, PHARM RES-DORDR, V23, P770, DOI 10.1007/s11095-006-9748-0
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Evans JR, 2010, COCHRANE DB SYST REV, V5
   Fattal E, 2006, ADV DRUG DELIVER REV, V58, P1203, DOI 10.1016/j.addr.2006.07.020
   Fens MHAM, 2010, EXPERT OPIN INV DRUG, V19, P1321, DOI 10.1517/13543784.2010.524204
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1019, DOI 10.1001/archopht.122.7.1019
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Geitzenauer W, 2008, RETINA-J RET VIT DIS, V28, P1375, DOI 10.1097/IAE.0b013e3181863f96
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   dos Santos ALG, 2006, J CONTROL RELEASE, V112, P369, DOI 10.1016/j.jconrel.2006.02.010
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hadj-Slimane R, 2007, BIOCHIMIE, V89, P1234, DOI 10.1016/j.biochi.2007.06.012
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Heller J, 2005, ADV DRUG DELIVER REV, V57, P2053, DOI 10.1016/j.addr.2005.09.007
   Hironaka K, 2009, J CONTROL RELEASE, V136, P247, DOI 10.1016/j.jconrel.2009.02.020
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Inokuchi Y, 2010, INVEST OPHTH VIS SCI, V51, P3162, DOI 10.1167/iovs.09-4697
   JIANG J, 2005, P 96 ANN M AM ASS CA
   Jonas JB, 2002, AM J OPHTHALMOL, V133, P857, DOI 10.1016/S0002-9394(02)01423-X
   Jost LM, 2006, DRUG METAB DISPOS, V34, P1817, DOI 10.1124/dmd.106.009944
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kreppel F, 2002, INVEST OPHTH VIS SCI, V43, P1965
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Li NJ, 2008, CIRC RES, V102, P1101, DOI 10.1161/CIRCRESAHA.107.169201
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   LIM LA, 2009, EYE, V24, P673
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V109, P1219
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Marcen R, 2009, DRUGS, V69, P2227, DOI 10.2165/11319260-000000000-00000
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Meyer CH, 2010, J OCUL PHARMACOL TH, V26, P491, DOI 10.1089/jop.2010.0045
   Miao HQ, 2006, BIOCHEM BIOPH RES CO, V345, P438, DOI 10.1016/j.bbrc.2006.04.119
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nilsson B, 1998, BLOOD, V92, P1661, DOI 10.1182/blood.V92.5.1661
   Nisato Riccardo E., 2003, Angiogenesis, V6, P105, DOI 10.1023/B:AGEN.0000011801.98187.f2
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Parker CJ, 2007, NAT REV DRUG DISCOV, V6, P515, DOI 10.1038/nrd2369
   Parkinson TM, 2003, J OCUL PHARMACOL TH, V19, P145, DOI 10.1089/108076803321637672
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Reich S, 2003, MOL VIS, V9, P210
   Reynolds AR, 2009, NAT MED, V15, P392, DOI 10.1038/nm.1941
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saemann MD, 2009, AM J TRANSPLANT, V9, P2655, DOI 10.1111/j.1600-6143.2009.02832.x
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Salesi N, 2005, ANTICANCER RES, V25, P3619
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schneider S, 1998, RETINA-J RET VIT DIS, V18, P242, DOI 10.1097/00006982-199803000-00009
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Spitzer MS, 2008, CLIN OPHTHALMOL, V2, P1
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stragies R, 2007, J MED CHEM, V50, P3786, DOI 10.1021/jm070002v
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Temming K, 2005, DRUG RESIST UPDATE, V8, P381, DOI 10.1016/j.drup.2005.10.002
   Thelen U, 2010, KLIN MONATSBL AUGENH, V227, P67, DOI 10.1055/s-0028-1109632
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tomita N, 2000, GENE THER, V7, P1326, DOI 10.1038/sj.gt.3301243
   Ton NC, 2007, CLIN CANCER RES, V13, P7113, DOI 10.1158/1078-0432.CCR-07-1550
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wojciak JM, 2009, P NATL ACAD SCI USA, V106, P17717, DOI 10.1073/pnas.0906153106
   Wood JM, 2000, CANCER RES, V60, P2178
   Wouters BG, 2005, SEMIN CELL DEV BIOL, V16, P487, DOI 10.1016/j.semcdb.2005.03.009
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058
   Yamasaki K, 2003, GENE THER, V10, P356, DOI 10.1038/sj.gt.3301875
   Yokoseki O, 2001, CIRC RES, V89, P899, DOI 10.1161/hh2201.099373
   Zahn G, 2010, INVEST OPHTH VIS SCI, V51, P1028, DOI 10.1167/iovs.09-3575
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhou XY, 2009, CHINESE MED J-PEKING, V122, P2711, DOI 10.3760/cma.j.issn.0366-6999.2009.22.007
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 161
TC 0
Z9 0
U1 0
U2 11
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PY 2011
VL 25
IS 3
BP 171
EP 189
DI 10.2165/11589330-000000000-00000
PG 19
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 790LA
UT WOS:000292588300004
PM 21627341
DA 2022-11-30
ER

PT J
AU Schaumberg, DA
   Hankinson, SE
   Guo, Q
   Rimm, E
   Hunter, DJ
AF Schaumberg, Debra A.
   Hankinson, Susan E.
   Guo, Qun
   Rimm, Eric
   Hunter, David J.
TI A prospective study of 2 major age-related macular degeneration
   susceptibility alleles and interactions with modifiable risk factors
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; ATTRIBUTABLE RISK; CIGARETTE-SMOKING; DIETARY-FAT;
   MACULOPATHY; VARIANT; POLYMORPHISM; ASSOCIATION; DISEASE; GENES
AB Objectives: To delineate the magnitude of susceptibility to age-related macular degeneration (AMD) due to common variants in the gene for complement factor H (CFH) and the predicted gene LOC387715 and to determine whether these variants interact with modifiable risk factors.
   Methods: We compared cases who developed AMD (n = 457) with 1071 age- and sex-matched control subjects in a prospective nested case-control study within the Nurses' Health Study and the Health Professionals Follow-up Study. We determined the incidence rate ratios and 95% confidence intervals (CIs) for AMD for each genotype and examined the interactions with modifiable risk factors.
   Results: Participants with 1 or 2 copies of the Y402H variant of CFH were, respectively, 1.98 (95% CI, 1.64-2.40) and 3.92 (95% CI, 2.69-5.76) times more likely to develop AMD, whereas the incident rate ratios (95% CIs) for 1 and 2 copies of LOC387715 A69S were 2.38 (1.92-2.96) and 5.66 (3.69-8.76), respectively. The fraction of AMD cases attributable to these 2 variants was 63% ( 95% CI, 58%-68%). Subjects homozygous for both risk alleles had a 50-fold increased risk of AMD (95% CI, 10.8-237), and cigarette smoking and obesity multiplied the risks associated with these variants.
   Conclusion: Age-related macular degeneration has emerged as a paradigmatic example of a common disease caused by the interplay of genetic predisposition and exposure to modifiable risk factors.
C1 Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.
   Brigham & Womens Hosp, Channing Lab, Boston, MA 02215 USA.
   Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Cambridge, MA 02138 USA.
   Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Cambridge, MA 02138 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA.
   Harvard Univ, Sch Publ Hlth, Dept Nutr, Cambridge, MA 02138 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Brigham & Women's
   Hospital; Harvard University; Harvard University; Harvard T.H. Chan
   School of Public Health; Harvard University; Harvard T.H. Chan School of
   Public Health; Harvard University; Harvard T.H. Chan School of Public
   Health
RP Schaumberg, DA (通讯作者)，Brigham & Womens Hosp, Div Prevent Med, 900 Commonwlth Ave E,3rd Floor, Boston, MA 02215 USA.
EM dschaumberg@rics.bwh.harvard.edu
FU NCI NIH HHS [CA87969, CA49449] Funding Source: Medline; NEI NIH HHS
   [EY013834, EY009611] Funding Source: Medline; NHLBI NIH HHS [HL35464]
   Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049449,
   U01CA049449, P01CA087969] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY013834, R01EY009611] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source:
   NIH RePORTER
CR Akaike H., 1973, P 2 INT S INF THEOR, P267, DOI 10.1007/978-1-4612-1694-0
   Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Garcia-Lorda P, 2006, INT J OBESITY, V30, P468, DOI 10.1038/sj.ijo.0803182
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LIMM, 2006, NAT GENET, V38, P1049
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P133
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Siddiqui MAA, 2005, DRUGS, V65, P1571, DOI 10.2165/00003495-200565110-00010
   Skrondal A, 2003, AM J EPIDEMIOL, V158, P251, DOI 10.1093/aje/kwg113
   SOULED EH, 2005, MOL VIS, V11, P1135
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vinores SA, 2005, IDRUGS, V8, P327
   WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 40
TC 144
Z9 150
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2007
VL 125
IS 1
BP 55
EP 62
DI 10.1001/archopht.125.1.55
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ZQ
UT WOS:000243336800007
PM 17210852
OA Bronze
DA 2022-11-30
ER

PT J
AU Barboni, MTS
   Recsan, Z
   Szepessy, Z
   Ecsedy, M
   Nagy, BV
   Ventura, DF
   Nagy, ZZ
   Nemeth, J
AF Barboni, Mirella T. S.
   Recsan, Zsuzsanna
   Szepessy, Zsuzsanna
   Ecsedy, Monika
   Nagy, Balazs Vince
   Ventura, Dora F.
   Nagy, Zoltan Zsolt
   Nemeth, Janos
TI Preliminary Findings on the Optimization of Visual Performance in
   Patients with Age-Related Macular Degeneration Using Biofeedback
   Training
SO APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK
LA English
DT Article
DE Biofeedback training; Psychophysiology; Visual system; Low vision;
   Macular degeneration
ID PREFERRED RETINAL LOCUS; VISION; FIXATION; LOCATION; ACUITY; IMPAIRMENT;
   PERCEPTION; STABILITY; CONTRAST; AMD
AB Biofeedback training has been used to improve fixation stability in subjects with central vision loss, but the psychophysiological mechanisms underlying the functional improvements resulted was not reported. The aim of this study was to investigate the effects of microperimetric biofeedback training on different visual functions and self-reported quality of vision in subjects with age-related macular degeneration. This case-control study included six subjects (72.0 +/- 6.1years of age) diagnosed with age-related macular degeneration (wet or dry) with low vision (best corrected visual acuity ranging from 0.5 to 0.1 in the study eye) and five healthy volunteers (64.2 +/- 3.7years of age). Ophthalmological and functional examinations were obtained from all subjects twice with an approximately 3-month interval. Subjects with central vision loss performed 12 sessions (10min each) of biofeedback training between the two examinations. Functional evaluation included: microperimetry, spatial luminance contrast sensitivities, color vision thresholds, visual acuity, and reading speed. Visual performance during daily activities was also assessed using a standardized questionnaire. The ratio (2nd/1st examination) of the spatial luminance contrast sensitivity at lower spatial frequencies were much higher for the training subjects compared with the controls. In addition, self-reported quality of vision improved after the training. The significant improvement of the visual function such as spatial luminance contrast sensitivity may explain the better self-reported quality of vision. Possible structural and physiological mechanisms underlying this neuromodulation are discussed.
C1 [Barboni, Mirella T. S.; Recsan, Zsuzsanna; Szepessy, Zsuzsanna; Ecsedy, Monika; Nagy, Zoltan Zsolt; Nemeth, Janos] Semmelweis Univ, Dept Ophthalmol, Maria U 39, H-1085 Budapest, Hungary.
   [Barboni, Mirella T. S.; Nagy, Balazs Vince; Ventura, Dora F.] Univ Sao Paulo, Dept Expt Psychol, Sao Paulo, Brazil.
   [Barboni, Mirella T. S.; Recsan, Zsuzsanna; Szepessy, Zsuzsanna; Nemeth, Janos] Bion Innovat Ctr, Budapest, Hungary.
   [Nagy, Balazs Vince] Budapest Univ Technol & Econ, Dept Mech Opt & Mech Engn Informat, Budapest, Hungary.
C3 Semmelweis University; Universidade de Sao Paulo; Budapest University of
   Technology & Economics
RP Nemeth, J (通讯作者)，Semmelweis Univ, Dept Ophthalmol, Maria U 39, H-1085 Budapest, Hungary.; Nemeth, J (通讯作者)，Bion Innovat Ctr, Budapest, Hungary.
EM nemeth.janos@med.semmelweis-univ.hu
RI Ventura, Dora F/B-9071-2012
OI Ventura, Dora F/0000-0002-7616-4031; , Mirella/0000-0002-0717-1852;
   Nemeth, Janos/0000-0001-8575-4888
FU Sao Paulo Research Foundation - FAPESP [2016/22007-5, 2016/04538-3];
   National Council for Scientific and Technological Development - CNPq
   [470785/2014-4, 404239/2016-1]; Janos Bolyai Scholarship of the
   Hungarian Academy of Sciences
FX We would like to thank very much Kornel Szekeres, Miklos Maczko, and
   agnes Urbin for their support to develop the software. We would also
   like to acknowledge financial support from the Sao Paulo Research
   Foundation - FAPESP (Grant Nos. 2016/22007-5 and 2016/04538-3), National
   Council for Scientific and Technological Development - CNPq (Grant Nos.
   470785/2014-4 and 404239/2016-1), and the Janos Bolyai Scholarship of
   the Hungarian Academy of Sciences. We also thank the patients and the
   healthy volunteers for their participation in this study.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amore FM, 2013, CAN J OPHTHALMOL, V48, P431, DOI 10.1016/j.jcjo.2013.07.013
   Bausz M, 2006, C SHIOL 2005 2006 PE, P53
   BROWN PK, 1964, SCIENCE, V144, P45, DOI 10.1126/science.144.3614.45
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CHUANG EL, 1987, EYE-T OPHTH SOC UK, V1, P311, DOI 10.1038/eye.1987.50
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HARRIS MJ, 1985, OPHTHALMOLOGY, V92, P1550
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Liu R, 2016, J VISION, V16, DOI 10.1167/16.6.10
   Mandelcorn MS, 2013, CAN J OPHTHALMOL, V48, P364, DOI 10.1016/j.jcjo.2013.05.006
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Mollon J. D., 1989, P PHYS SOC, V414
   NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   OWSLEY C, 1987, BRIT J OPHTHALMOL, V71, P791, DOI 10.1136/bjo.71.10.791
   Peyrin C, 2017, VISION RES, V130, P36, DOI 10.1016/j.visres.2016.11.004
   Polyak S, 1949, DOC OPHTHALMOL, V3
   Putnam NM, 2005, J VISION, V5, P632, DOI 10.1167/5.7.3
   Rodriguez-Carmona M., 2005, 10 C INT COL ASS, P979
   Rosa AM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568354
   Schotter ER, 2012, ATTEN PERCEPT PSYCHO, V74, P5, DOI 10.3758/s13414-011-0219-2
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   THOMSON LC, 1946, NATURE, V157, P805, DOI 10.1038/157805a0
   Ueda-Consolvo T, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/572942
   Vemala R, 2017, INVEST OPHTH VIS SCI, V58, P247, DOI 10.1167/iovs.17-21771
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2013, APPL PSYCHOPHYS BIOF, V38, P11, DOI 10.1007/s10484-012-9203-4
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   WESTHEIMER G, 1965, ANNU REV PSYCHOL, V16, P359, DOI 10.1146/annurev.ps.16.020165.002043
   WESTHEIMER G, 1984, ANNU REV PSYCHOL, V35, P201, DOI 10.1146/annurev.ps.35.020184.001221
   ZEFFREN BS, 1990, INVEST OPHTH VIS SCI, V31, P2099
NR 40
TC 5
Z9 6
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-0586
EI 1573-3270
J9 APPL PSYCHOPHYS BIOF
JI Appl. Psychophysiol. Biofeedback
PD MAR
PY 2019
VL 44
IS 1
BP 61
EP 70
DI 10.1007/s10484-018-9423-3
PG 10
WC Psychology, Clinical
WE Social Science Citation Index (SSCI)
SC Psychology
GA HL1TW
UT WOS:000458486200007
PM 30506266
DA 2022-11-30
ER

PT J
AU Dunbar, HMP
   Dhawahir-Scala, FE
AF Dunbar, Hannah M. P.
   Dhawahir-Scala, Felipe E.
TI A Discussion of Commercially Available Intra-ocular Telescopic Implants
   for Patients with Age-Related Macular Degeneration
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Age-related macular degeneration; Implant; Intra-ocular lens; Low
   vision; Rehabilitation; Telescope; Visual acuity; Visual impairment
ID VISUAL FUNCTION QUESTIONNAIRE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   LOW-VISION SERVICES; QUALITY-OF-LIFE; REPORT NO. 11; MINIATURE
   TELESCOPE; SAFETY OUTCOMES; EYE DISEASE; LENS; REHABILITATION
AB Age-related macular degeneration (AMD) is the leading cause of visual impairment in the western world, causing significant reduction in quality of life. Despite treatment advances, the burden of visual impairment caused by AMD continues to rise. In addition to traditional low vision rehabilitation and support, optical and electronic aids, and strategies to enhance the use of peripheral vision, implantable telescopic devices have been indicated as a surgical means of enhancing vision. Here we examine the literature on commercially available telescopic devices discussing their design, mode of action, surgical procedure and published outcomes on visual acuity, quality of life, surgical complication rates and cost effectiveness data where available.
C1 [Dunbar, Hannah M. P.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Dhawahir-Scala, Felipe E.] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Manchester Royal Eye Hospital
RP Dunbar, HMP (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London, England.
EM hannah.dunbar@moorfields.nhs.uk
FU VisionCare Inc.
FX Article processing charges were funded by VisionCare Inc.
CR Agarwal A, 2008, J CATARACT REFR SURG, V34, P87, DOI 10.1016/j.jcrs.2007.08.031
   Alio JL, 2004, J CATARACT REFR SURG, V30, P1177, DOI 10.1016/j.jcrs.2003.10.038
   Amselem L, 2008, J CATARACT REFR SURG, V34, P1571, DOI 10.1016/j.jcrs.2008.05.032
   Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown GC, 2011, OPHTHALMOLOGY, V118, P1834, DOI 10.1016/j.ophtha.2011.02.012
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Colby KA, 2007, ARCH OPHTHALMOL-CHIC, V125, P1118, DOI 10.1001/archopht.125.8.1118
   Colenbrander A, 2007, INVEST OPHTHALMOL VI, V48, P3563
   Colenbrander A, 2008, OPHTHALMOLOGY, V115, P1437, DOI 10.1016/j.ophtha.2008.04.021
   Culham LE, 2002, BRIT J OPHTHALMOL, V86, P743, DOI 10.1136/bjo.86.7.743
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Felipe A, 2007, J CATARACT REFR SURG, V33, P1781, DOI 10.1016/j.jcrs.2007.05.032
   Garfinkel RA, 2006, AM J OPHTHALMOL, V141, P766, DOI 10.1016/j.ajo.2005.11.005
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   Hau VS, 2016, OPHTHALMOL THER, V5, P21, DOI 10.1007/s40123-016-0047-5
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hudson HL, 2008, AM J OPHTHALMOL, V146, P664, DOI 10.1016/j.ajo.2008.07.003
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Joondeph Brian C, 2014, Retin Cases Brief Rep, V8, P342, DOI 10.1097/ICB.0000000000000065
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Margrain TH, 1999, BRIT MED J, V318, P1504, DOI 10.1136/bmj.318.7197.1504
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   National Institute for Health and Care Excellence (NICE), 2012, GUID MAN PROC METH P, V7
   National Institute for Health and Care Excellence (NICE), 2016, MIN LENS SYST IMPL A
   Nollett CL, 2016, OPHTHALMOLOGY, V123, P440, DOI 10.1016/j.ophtha.2015.07.009
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Primo SA, 2010, OPTOMETRY, V81, P86, DOI 10.1016/j.optm.2009.08.014
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   RYAN B, 1999, FRAGMENTED VISION SU
   Scharioth GB, 2015, J CATARACT REFR SURG, V41, P1559, DOI 10.1016/j.jcrs.2015.07.018
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tabernero J, 2015, BIOMED OPT EXPRESS, V6, P1010, DOI 10.1364/BOE.6.001010
   Teh BL, 2017, SURV OPHTHALMOL, V62, P346, DOI 10.1016/j.survophthal.2016.12.003
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 57
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD JUN
PY 2018
VL 7
IS 1
BP 33
EP 48
DI 10.1007/s40123-018-0129-7
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GJ2VS
UT WOS:000435132600003
PM 29700786
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Villegas, VM
   Aranguren, LA
   Kovach, JL
   Schwartz, SG
   Flynn, HW
AF Villegas, Victor M.
   Aranguren, Luis A.
   Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Flynn, Harry W., Jr.
TI Current advances in the treatment of neovascular age-related macular
   degeneration
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE Age-related macular degeneration; retina; and vascular endothelial
   growth factor
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL TRIAMCINOLONE ACETONIDE;
   CHOROIDAL NEOVASCULARIZATION; DRUG-DELIVERY; BEVACIZUMAB AVASTIN;
   EPIRETINAL BRACHYTHERAPY; EPIMACULAR BRACHYTHERAPY; RADIATION-THERAPY;
   MAMMALIAN PROTEIN; 12-MONTH SAFETY
AB Introduction: Age-related macular degeneration (AMD) is the most common cause of permanent central visual acuity loss in persons over 65years of age in industrialized nations. Today, intravitreal vascular endothelial growth factor (VEGF) inhibitors are the mainstay of treatment worldwide.
   Areas covered: The following review covers the current treatments and challenges of wet AMD management. It also covers emerging therapies including radiation, latest generation anti-VEGF agents, and combination therapies.
   Expert opinion: Current neovascular AMD therapy is aimed at decreasing the VEGF effect at the choroidal neovascularization (CNV) complex. The most important existing challenges in the treatment of neovascular AMD are improving visual outcomes, decreasing the treatment burden, and minimizing geographic atrophy. Clinicians are using many treatment strategies to minimize intravitreal injections without sacrificing visual outcomes. Combination of anti-VEGF therapy with other previously available treatments that target a different pathophysiological mechanism may be a reasonable clinical strategy to minimize intravitreal injections. Many exciting novel drugs that target newly discovered pathways associated with CNV development and progression hold clinical promise. The results of ongoing randomized clinical trials will answer the important concerns surrounding new drugs and delivery devices: safety and visual outcomes.
C1 [Villegas, Victor M.; Aranguren, Luis A.; Kovach, Jaclyn L.; Schwartz, Stephen G.; Flynn, Harry W., Jr.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Villegas, VM (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, 3880 Tamiami Trail North, Naples, FL 34103 USA.
EM v.villegas@med.miami.edu
FU NIH Center [P30EY014801]
FX Supported by NIH Center Core Grant P30EY014801, Research to Prevent
   Blindness Unrestricted Grant, Department of Defense.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Binley K, 2012, HUM GENE THER, V23, P980, DOI 10.1089/hum.2012.008
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Camardo J, 2003, TRANSPL P, V35, p18S, DOI 10.1016/S0041-1345(03)00356-7
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2015, AM J OPHTHALMOL, V159, P659, DOI 10.1016/j.ajo.2014.12.013
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Danis R, 2014, BRIT J OPHTHALMOL, V98, P172, DOI 10.1136/bjophthalmol-2013-303117
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dugel P, 2014, ANN M AM SOC RET SPE
   Dugel P, 2012, RET SUBSP DAY AM AC
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Garba AO, 2010, OPHTHALMOL EYE DIS, V2, P75, DOI 10.4137/OED.S4878
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gooch N, 2013, J FUNCT BIOMATER, V4, P14, DOI 10.3390/jfb4010014
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2015, OSLI RETINA, V46, P643, DOI 10.3928/23258160-20150610-08
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   Honda M, 2011, ARCH OPHTHALMOL-CHIC, V129, P317, DOI 10.1001/archophthalmol.2011.12
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2014, ANG EX DEG 2014 FEB
   Kang DJJ, 2008, T AM OPHTHAL SOC, V106, P206
   Kazokoglu H, 2010, OPHTHAL SURG LAS IM, DOI [10.3928/1542887-20100215-35, DOI 10.3928/1542887-20100215-35]
   Kernt M, 2012, RETINA-J RET VIT DIS, V32, P1652, DOI 10.1097/IAE.0b013e318240a558
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   KRISHNAN L, 1988, INT J RADIAT ONCOL, V15, P147, DOI 10.1016/0360-3016(88)90359-8
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Liu Q, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-181
   Loewenstein A, 2013, REFILLABLE DRUG DELI
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Medina C, 2007, BRIT J PHARMACOL, V150, P552, DOI 10.1038/sj.bjp.0707130
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mudumba S, 2012, J OCUL PHARMACOL TH, V28, P507, DOI 10.1089/jop.2011.0226
   Myers AL, 2010, J PEDIATR SURG, V45, P1080, DOI 10.1016/j.jpedsurg.2010.02.068
   Nieder C, 2006, CANCER TREAT REV, V32, P348, DOI 10.1016/j.ctrv.2006.03.006
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Petrarca Robert, 2014, Retina, V34, P874, DOI 10.1097/IAE.0000000000000026
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   Phillips BN, 2011, J OPHTHALMIC INFLAMM, V1, P29, DOI 10.1007/s12348-010-0015-5
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saati S., 2009, T AM OPHTHAL SOC, V107, P60
   SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3
   Sabbadini RA, 2011, BRIT J PHARMACOL, V162, P1225, DOI 10.1111/j.1476-5381.2010.01118.x
   Sahoo SK, 2007, NANOMED-NANOTECHNOL, V3, P20, DOI 10.1016/j.nano.2006.11.008
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sanchez A, 2006, NANOPARTICULATES DRU, P1
   Schwartz SG, 2009, EXPERT OPIN PHARMACO, V10, P2119, DOI 10.1517/14656560903081752
   Shanmuganathan VA, 2005, BRIT J OPHTHALMOL, V89, P666, DOI 10.1136/bjo.2004.048199
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Sherman S, 2012, INVEST OPHTH VIS SCI, V53, P7894
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Silva-Garcia R, 2014, CLIN OPHTHALMOL, V8, P2529, DOI 10.2147/OPTH.S68028
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V4
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stevenson CL, 2012, ADV DRUG DELIVER REV, V64, P1590, DOI 10.1016/j.addr.2012.02.005
   Thakur A, 2011, MICROVASC RES, V82, P346, DOI 10.1016/j.mvr.2011.09.001
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Willett CG, 2006, SEMIN ONCOL, V33, pS35, DOI 10.1053/j.seminoncol.2006.08.007
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zaman RT, 2012, LASER SURG MED, V44, P30, DOI 10.1002/lsm.21149
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
   Zhao C, 2011, AGING-US, V3, P346, DOI 10.18632/aging.100303
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 114
TC 54
Z9 56
U1 0
U2 26
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD FEB
PY 2017
VL 14
IS 2
BP 273
EP 282
DI 10.1080/17425247.2016.1213240
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EK2YG
UT WOS:000393792400012
PM 27434329
DA 2022-11-30
ER

PT J
AU Lotery, A
   Trump, D
AF Lotery, Andrew
   Trump, Dorothy
TI Progress in defining the molecular biology of age related macular
   degeneration
SO HUMAN GENETICS
LA English
DT Review
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; APOLIPOPROTEIN-E GENE;
   GLOMERULONEPHRITIS TYPE-II; STARGARDT-DISEASE GENE; HTRA1 PROMOTER
   POLYMORPHISM; SHORT CONSENSUS REPEAT; BODY-MASS INDEX;
   CIGARETTE-SMOKING; DIETARY-FAT
AB Age related macular degeneration (AMD) is an extremely prevalent complex genetic disorder. Its incidence rises exponentially in the elderly to a frequency of 1 in 2 in the general population by age 85. It affects approximately 25 million people and is the commonest cause of irreversible visual loss in the Western world. It is therefore a major public health problem. However, until recently its aetiology was unknown. Our understanding of both the molecular biology of AMD and the relevant clinical treatments has progressed dramatically in the last 2 years. Two genes of large effect have beeen identified which together contribute to over 70% of the population attributable risk of AMD. Treatments which inhibit expression of vascular endothelial growth factor have been developed which can rescue vision in the "wet" form of the disease. The association of complement factor H with AMD highlights the importance of the alternative complement pathway in the developemnt of AMD whilst the pathophysiology of the serine protease HTRA1 is now under intensive study. This review will give an insight into these developments and will summarise our current knowledge of the molecular biology of AMD.
C1 Univ Southampton, Southampton Gen Hosp, Clin Neurosci Div, Southampton SO16 6YD, Hants, England.
   Univ Manchester, St Marys Hosp, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England.
C3 University of Southampton; University of Manchester
RP Lotery, A (通讯作者)，Univ Southampton, Southampton Gen Hosp, Clin Neurosci Div, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305
FU Wellcome Trust [076169] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Alexander JJ, 2007, MOL IMMUNOL, V44, P123, DOI 10.1016/j.molimm.2006.07.287
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   CARRENO MP, 1989, EUR J IMMUNOL, V19, P2145, DOI 10.1002/eji.1830191126
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DERODRIGUEZ CS, 2004, MOL IMMUNOL, V41, P355
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Dryja T. P., 1998, SCIENCE, V279
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2007, BRIT J OPHTHALMOL, V91, P966, DOI 10.1136/bjo.2007.114090
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   HAAB O, 1885, ZENTRALBL AUGENHEILK, V9, P384
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200
   Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kolb H, 2003, AM SCI, V91, P28, DOI 10.1511/2003.11.841
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   McKay GJ, 2004, MOL VIS, V10, P682
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOSS MA, 2006, ARVO 2006
   Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   NETTLESHIP E, 1984, T AM OPHTHAL SOC, V6, P165
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   *ROYAL COLL OPHTH, 2002, NAT RES STRAT OPHTH
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V35, P2003
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seitsonen S, 2006, MOL VIS, V12, P796
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma AK, 1997, INFECT IMMUN, V65, P484, DOI 10.1128/IAI.65.2.484-487.1997
   SHIOSE Y, 1969, ACTA SOC OPHTHALMOL, V73, P1606
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith JD, 1998, INT J CLIN LAB RES, V28, P116, DOI 10.1007/s005990050030
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   *SST, 2004, AM J OPHTHALMOL, V138, P91
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Tikellis G, 2007, ARCH OPHTHALMOL-CHIC, V125, P68, DOI 10.1001/archopht.125.1.68
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
   Zipfel PF, 2001, SEMIN THROMB HEMOST, V27, P191, DOI 10.1055/s-2001-15248
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
   1997, MACULAR PHOTOCOAGULA, V115, P741
NR 207
TC 47
Z9 50
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD NOV
PY 2007
VL 122
IS 3-4
BP 219
EP 236
DI 10.1007/s00439-007-0406-3
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 221OI
UT WOS:000250236800001
PM 17659362
DA 2022-11-30
ER

PT J
AU Panthier, C
   Querques, G
   Puche, N
   Le Tien, V
   Garavito, RB
   Bechet, S
   Massamba, N
   Souied, EH
AF Panthier, Christophe
   Querques, Giuseppe
   Puche, Nathalie
   Le Tien, Valerie
   Garavito, Rocio B.
   Bechet, Stephane
   Massamba, Nathalie
   Souied, Eric H.
TI EVALUATION OF SEMIAUTOMATED MEASUREMENT OF GEOGRAPHIC ATROPHY IN
   AGE-RELATED MACULAR DEGENERATION BY FUNDUS AUTOFLUORESCENCE IN CLINICAL
   SETTING
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; geographic
   atrophy; Region Finder; scanning laser ophthalmoscope
ID PROGRESSION; EYE
AB Purpose: To assess intraobserver and interobserver agreement among physicians with different degrees of clinical experience, using a novel fundus autofluorescence semiautomated software for quantification of geographic atrophy in clinical setting.
   Methods: Fundus autofluorescence frames (excitation: 488 nm; emission: 500-700 nm) of 29 eyes (20 patients; mean age, 79.6 +/- 6.2 years) with geographic atrophy secondary to age-related macular degeneration, and no signs of choroidal neovascularization, were analyzed using Region Finder, a semiautomated software embedded in Spectralis (Heidelberg Engineering, Heidelberg, Germany). For each study eye, semiautomated atrophy identification and quantification were independently performed, twice (in a 2-week time frame), by 3 readers with different degrees of clinical experience (2 fellows, and 1 resident). Intraobserver and interobserver agreements were assessed.
   Results: Mean difference in intraobserver agreement (Bland-Altman statistics) ranged from -0.17 mm(2) to 0.13 mm(2). Intraobserver agreement was excellent until the geographic atrophy threshold value of 15.72 mm(2). Variability correlated with the size of atrophy. Mean difference in interobserver agreement (Bland-Altman statistics) ranged from -0.25 mm(2) to 0.27 mm(2), with no significant difference between senior and junior readers. Multifocal lesion or foveal involvement in atrophy was not the cause of disagreement.
   Conclusion: Region Finder is a reliable tool for the identification and quantification of geographic atrophy in patients with age-related macular degeneration, in a clinical setting even when performed by junior reader.
C1 [Panthier, Christophe; Querques, Giuseppe; Puche, Nathalie; Le Tien, Valerie; Garavito, Rocio B.; Massamba, Nathalie; Souied, Eric H.] Univ Paris 12, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Bechet, Stephane] CHI Creteil, Ctr Rech Clin, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM esouied@hotmail.com
OI Querques, Giuseppe/0000-0002-3292-9581
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 17
TC 22
Z9 22
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2014
VL 34
IS 3
BP 576
EP 582
DI 10.1097/01.iae.0000433986.32991.1e
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6DL
UT WOS:000336960100025
PM 24056526
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Sacconi, R
   Zuccaro, B
   Cavalleri, M
   Bordato, A
   Zucchiatti, I
   Querques, L
   Bandello, F
   Querques, G
AF Borrelli, Enrico
   Sacconi, Riccardo
   Zuccaro, Biancamaria
   Cavalleri, Michele
   Bordato, Alessandro
   Zucchiatti, Ilaria
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI Photoreceptor alteration in intermediate age-related macular
   degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
AB The aim of this study was to analyze photoreceptor alterations occurring in eyes with intermediate age-related macular degeneration (AMD) and to investigate their associations with choriocapillaris (CC) flow. In this retrospective case-control study, we collected data from 35 eyes with intermediate AMD from 35 patients who had swept source optical coherence tomography structural and angiography imaging obtained. A control group of 35 eyes from 35 healthy subjects was included for comparison. Our main outcome measure for comparison between groups was the normalized reflectivity of en face image segmented at the ellipsoid zone (EZ) level, which was calculated to quantify the photoreceptor damage. OCTA metrics to quantify CC flow signal were also computed. These metrics were measured in a circle centered on the fovea and with a diameter of 5 mm. In intermediate AMD eyes, the macular area occupied by drusen was identified. Therefore, the EZ reflectivity and CC flow signal were separately measured in regions without drusen ("drusen-free" region). Measurements were generated using previously published algorithms. Mean +/- SD age was 74.1 +/- 6.8 years in the intermediate AMD group and 72.1 +/- 6.0 years in the control group (p = 0.206). The normalized EZ reflectivity was 0.76 +/- 0.10 in the intermediate AMD group and 0.85 +/- 0.08 in the control group (p <.0001). In the "drusen-free" region, the normalized EZ reflectivity was 0.77 +/- 0.10 (p < .0001 vs. healthy controls) and was positively correlated with the CC flow signal density (rho = - 0.340 and p = 0.020). In conclusion, eyes with intermediate AMD exhibit a diffuse reduced EZ normalized reflectivity, and this reduction is correlated with CC flow signal in the regions without drusen. This study supports the concept of the damage of the unit comprised of photoreceptor, CC, and intervening tissues as an early event in AMD.
C1 [Borrelli, Enrico; Sacconi, Riccardo; Cavalleri, Michele; Bordato, Alessandro; Zucchiatti, Ilaria; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.
   [Borrelli, Enrico; Sacconi, Riccardo; Zuccaro, Biancamaria; Cavalleri, Michele; Bordato, Alessandro; Zucchiatti, Ilaria; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Milan, Italy.
EM giuseppe.querques@unisr.it
OI Querques, Giuseppe/0000-0002-3292-9581; Borrelli,
   Enrico/0000-0003-2815-5031; Sacconi, Riccardo/0000-0003-2891-2012;
   Cavalleri, Michele/0000-0001-5308-1201; bandello,
   francesco/0000-0003-3238-9682
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Borrelli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53307-x
   Borrelli E, 2020, RETINA-J RET VIT DIS, V40, P1062, DOI 10.1097/IAE.0000000000002538
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Braun PX, 2019, INVEST OPHTH VIS SCI, V60, P4985, DOI 10.1167/iovs.19-27861
   Brown B., 1986, OPTOM VIS SCI, DOI [10.1097/00006324-198606000-00009, DOI 10.1097/00006324-198606000-00009]
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P1644, DOI 10.1097/IAE.0000000000002893
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Hu ZH, 2013, OSLI RETINA, V44, pS5, DOI 10.3928/23258160-20131101-02
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Maruko I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34102-6
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Oh J, 2010, INVEST OPHTH VIS SCI, V51, P1651, DOI 10.1167/iovs.09-4420
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roberts KF, 2012, ARCH OPHTHALMOL-CHIC, V130, P980, DOI 10.1001/archophthalmol.2012.371
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Sallo FB, 2012, INVEST OPHTH VIS SCI, V53, P6145, DOI 10.1167/iovs.12-10580
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Villate N, 2005, AM J OPHTHALMOL, V139, P280, DOI 10.1016/j.ajo.2004.09.029
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 62
TC 3
Z9 3
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 3
PY 2020
VL 10
IS 1
AR 21036
DI 10.1038/s41598-020-78201-9
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QD2ZZ
UT WOS:000615394300036
PM 33273666
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shin, OR
   Kim, YH
AF Shin, Ok Ran
   Kim, Yeong Hoon
TI Age-Related Macular Degeneration (AMD): Current Concepts in Pathogenesis
   and Prospects for Treatment
SO TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Review
DE macular degeneration; pathogenesis; treatment; inflammation; stem cell
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIAL-CELLS; HEMATOPOIETIC STEM-CELLS;
   CHOROIDAL ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; RETINAL DEGENERATION;
   SUBSTANCE-P; ALZHEIMERS-DISEASE; DRUSEN FORMATION; LOC387715 GENE
AB Age-related macular degeneration (AMD) is a degenerative disease of the eye that has been a subject of numerous studies in pathogenesis as well as clinical research in treatment owing to its notoriety as the leading cause of irreversible blindness in the elderly. Genetic studies have elucidated various pathways related to inflammation that contribute to AMID development such as those of the complement system, coagulation system, and the immune system. The current standard of treatment in AMD is inhibition of neovascularization using anti-vascular endothelial growth factor antibodies, which is effective in wet AMD. Furthermore, the absence of screening methods or preventive measures for AMD poses yet another challenge. Stem cell therapy now holds great promise for various diseases, and AMD may well be one of the earliest diseases such treatment modality may be employed, considering the unique characteristics of the eye as a localized and immune-privileged organ.
C1 [Shin, Ok Ran] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Hosp Pathol, Seoul 480717, South Korea.
   [Kim, Yeong Hoon] Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Ophthalmol & Visual Sci, Seoul 130709, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Kim, YH (通讯作者)，Catholic Univ Korea, Coll Med, St Pauls Hosp, Dept Ophthalmol & Visual Sci, Seoul 130709, South Korea.
EM kiwise@catholic.ac.kr
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Truong A, 2011, J MOL MED, V89, P343, DOI 10.1007/s00109-010-0709-z
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Armstrong ME, 2001, GERONTOLOGY, V47, P180, DOI 10.1159/000052795
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Castanheira P, 2008, ARQ BRAS OFTALMOL, V71, P644, DOI 10.1590/S0004-27492008000500007
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Coin LJM, 2010, NAT METHODS, V7, P541, DOI [10.1038/NMETH.1466, 10.1038/nmeth.1466]
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   Datar P, 2004, CURR TOP MED CHEM, V4, P75, DOI 10.2174/1568026043451636
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dowling J, 2009, EYE, V23, P1999, DOI 10.1038/eye.2008.385
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   GABRIELIAN K, 1994, INVEST OPHTH VIS SCI, V35, P4253
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   Hong HS, 2012, ARCH PHARM RES, V35, P201, DOI 10.1007/s12272-012-0201-0
   Hong HS, 2009, NAT MED, V15, P425, DOI 10.1038/nm.1909
   Hong HS, 2011, ARCH PHARM RES, V34, P2003, DOI 10.1007/s12272-011-1221-x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joeres S, 2008, EYE, V22, P782, DOI 10.1038/sj.eye.6702761
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kinnunen Kati, 2012, Front Biosci (Elite Ed), V4, P2546
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4
   LATERVEER L, 1995, BLOOD, V85, P2269, DOI 10.1182/blood.V85.8.2269.bloodjournal8582269
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Link DC, 2000, SEMIN HEMATOL, V37, P25, DOI 10.1016/S0037-1963(00)90086-6
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003
   MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer KJ, 2011, HUM GENET, V129, P91, DOI 10.1007/s00439-010-0904-6
   Moore JH, 2002, ANN MED, V34, P88, DOI 10.1080/07853890252953473
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P1350, DOI 10.1167/iovs.08-2618
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OBRIEN C, 1993, BRIT J OPHTHALMOL, V77, P778, DOI 10.1136/bjo.77.12.778
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Rickles FR, 2006, PATHOPHYSIOL HAEMO T, V35, P103, DOI 10.1159/000093551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL, V124, P995
   Shastry BS, 2007, J HUM GENET, V52, P384, DOI 10.1007/s10038-007-0120-y
   Shen Y, 2003, PROG NEUROBIOL, V70, P463, DOI 10.1016/j.pneurobio.2003.08.001
   Sickel W, 1972, Adv Exp Med Biol, V24, P101
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith JD, 2000, ANN MED, V32, P118, DOI 10.3109/07853890009011761
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Streilein JW, 1999, SPRINGER SEMIN IMMUN, V21, P95
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tibbetts MD, 2012, CURR OPIN OPHTHALMOL, V23, P226, DOI 10.1097/ICU.0b013e328352407d
   To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233
   Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wiggs JL, 2006, ARCH OPHTHALMOL-CHIC, V124, P577, DOI 10.1001/archopht.124.4.577
   Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451
   Zhang YS, 2012, J ASSIST REPROD GENE
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 145
TC 3
Z9 3
U1 2
U2 48
PU KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
PI JONGRO-GU
PA 199-1, DONGSUNG-DONG,, JONGRO-GU, SEOUL 110-810, SOUTH KOREA
SN 1738-2696
EI 2212-5469
J9 TISSUE ENG REGEN MED
JI Tissue Eng. Regen. Med.
PD AUG
PY 2013
VL 10
IS 4
BP 164
EP 175
DI 10.1007/s13770-012-0374-0
PG 12
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering
GA 200PZ
UT WOS:000323082700003
DA 2022-11-30
ER

PT J
AU Hamdi, HK
   Reznik, J
   Castellon, R
   Atilano, SR
   Ong, JM
   Udar, N
   Tavis, JH
   Aoki, AM
   Nesburn, AB
   Boyer, DS
   Small, KW
   Brown, DJ
   Kenney, MC
AF Hamdi, HK
   Reznik, J
   Castellon, R
   Atilano, SR
   Ong, JM
   Udar, N
   Tavis, JH
   Aoki, AM
   Nesburn, AB
   Boyer, DS
   Small, KW
   Brown, DJ
   Kenney, MC
TI Alu DNA polymorphism in ACE gene is protective for age-related macular
   degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Alu sequences; polymorphism; ACE; TPA; AMD
ID INSERTION DELETION POLYMORPHISM; ANGIOTENSIN-II; REPEATED SEQUENCES;
   EVOLUTION; APOPTOSIS; RETROPOSONS; EXPRESSION; SILENCER; SYSTEM
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. We report an association between all Alu polymorphism in the angiotensin-converting enzyme (ACE) gene with the dry/atrophic form of AMD. Using the polymerase chain reaction (PCR) on genomic DNA isolated from patients with AMD (n = 173), and an age-matched control population (n = 189), we amplified a region polymorphic for an Alu element insertion in the ACE gene. The Alu(+/+) genotype occurred 4.5 times more frequently in the control population than the dry/atrophic AMD patient population. (p = 0.004). The predominance of the Alu(+/+) genotype within the unaffected control group represents a protective insertion with respect to the human Ocular disease, dry/atrophic AMD. This is the first demonstration of an Alu element insertion exerting protective effects against a known human disease. (C) 2002 Elsevier Science (USA). All rights reserved.
C1 Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med Affiliate, Dept Surg,Ophthalmol Res Labs,Burns & Allen Res I, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Retina Vitreous Associates Med Grp, Beverly Hills, CA 90211 USA.
C3 Cedars Sinai Medical Center; University of California System; University
   of California Los Angeles; University of California System; University
   of California Los Angeles; Retina Vitreous Associates Medical Group
RP Hamdi, HK (通讯作者)，Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med Affiliate, Dept Surg,Ophthalmol Res Labs,Burns & Allen Res I, Los Angeles, CA 90048 USA.
OI Udar, Nitin/0000-0001-8533-9190; Hamdi, Hamdi/0000-0001-6976-0874;
   Atilano, Shari/0000-0002-7729-7864
CR Batzer MA, 1997, J MOL EVOL, V45, P7, DOI 10.1007/PL00006198
   Batzer MA, 1996, J MOL EVOL, V42, P22, DOI 10.1007/BF00163207
   BERGER JW, 1999, AGE RELATED MACULAR
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770
   Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141
   Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22
   HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056
   Hamdi H, 1999, J MOL BIOL, V289, P861, DOI 10.1006/jmbi.1999.2797
   Hamdi HK, 2000, J MOL BIOL, V299, P931, DOI 10.1006/jmbi.2000.3795
   HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908
   Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610
   Jern C, 1999, ARTERIOSCL THROM VAS, V19, P454, DOI 10.1161/01.ATV.19.2.454
   JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775
   Kajstura J, 1997, J MOL CELL CARDIOL, V29, P859, DOI 10.1006/jmcc.1996.0333
   Kohler K, 1997, VISUAL NEUROSCI, V14, P63, DOI 10.1017/S0952523800008762
   Lehtonen JYA, 1999, MOL ENDOCRINOL, V13, P1051, DOI 10.1210/mend.13.7.0303
   PUCCI L, 2001, DIABETES
   RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   ROGERS J, 1983, NATURE, V301, P460, DOI 10.1038/301460e0
   SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29
   TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P
   Tomilin NV, 1999, INT REV CYTOL, V186, P1
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
NR 27
TC 43
Z9 46
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 19
PY 2002
VL 295
IS 3
BP 668
EP 672
AR PII S0006-291X(02)00728-3
DI 10.1016/S0006-291X(02)00728-3
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 574UM
UT WOS:000176908000016
PM 12099691
DA 2022-11-30
ER

PT J
AU Kumar, S
   Nakashizuka, H
   Jones, A
   Lambert, A
   Zhao, XC
   Shen, M
   Parker, M
   Wang, SX
   Berriochoa, Z
   Fnu, A
   VanBeuge, S
   Chevez-Barrios, P
   Tso, M
   Rainier, J
   Fu, YB
AF Kumar, Sandeep
   Nakashizuka, Hiroyuki
   Jones, Alex
   Lambert, Alyssia
   Zhao, Xuchen
   Shen, Megan
   Parker, Mackenzie
   Wang, Shixian
   Berriochoa, Zachary
   Fnu, Amrita
   VanBeuge, Stephanie
   Chevez-Barrios, Patricia
   Tso, Mark
   Rainier, Jon
   Fu, Yingbin
TI Proteolytic Degradation and Inflammation Play Critical Roles in
   Polypoidal Choroidal Vasculopathy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; HIGH-TEMPERATURE REQUIREMENT; HTRA1 PROMOTER
   POLYMORPHISM; RETINAL-PIGMENT EPITHELIUM; SERINE-PROTEASE HTRA1;
   MACULAR-DEGENERATION; PHOTODYNAMIC THERAPY; INTRAVITREAL AFLIBERCEPT;
   INCREASED EXPRESSION; MESSENGER-RNA
AB Polypoidal choroidal vasculopathy (PCV) is a common subtype of wet age-related macular degeneration in Asian populations, whereas choroidal neovascularization is the typical subtype in Western populations. The cause of PCV is unknown. By comparing the phenotype of a PCV mouse model expressing protease high temperature requirement factor A1 (HTRA1) in retinal pigment epithelium with trans genic mice expressing the inactive HTRA1(S328A), we showed that HTRA1-mediated degradation of elastin in choroidaL vessels is critical for the development of PCV, which exhibited destructive extracellular matrix remodeling and vascular smooth muscle cell loss. Compared with weak PCV, severe PCV exhibited prominent immune complex deposition, complement activation, and infiltration of inflammatory cells, suggesting inflammation plays a key role in PCV progression. More important, we validated these findings in human PCV specimens. Intravitreal delivery of an HTRA1 inhibitor (DPMFKLboroV) was effective (36% Lesion reduction; P = 0.009) in preventing PCV initiation but ineffective in treating existing Lesions. Anti-inflammatory glucocorticoid was effective in preventing PCV progression but ineffective in preventing PCV initiation. These results suggest that PCV pathogenesis occurs through two stages. The initiation stage is mediated by proteolytic degradation of extracellular matrix proteins attributable to increased HTRA1 activity, whereas the progression stage is driven by inflammatory cascades. This study provides a basis for understanding the differences between PCV and choroidal neovascularization, and helps guide the design of effective therapies for PCV.
C1 [Kumar, Sandeep; Shen, Megan; Parker, Mackenzie; Fnu, Amrita; Fu, Yingbin] Baylor Coll Med, Dept Ophthalmol, 6550 Fannin St,Neurosensory Bldg,NC 506, Houston, TX 77030 USA.
   [Nakashizuka, Hiroyuki] Nihon Univ, Sch Med, Dept Visual Sci, Tokyo, Japan.
   [Jones, Alex; Wang, Shixian; Berriochoa, Zachary; VanBeuge, Stephanie; Fu, Yingbin] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Lambert, Alyssia; Zhao, Xuchen; Rainier, Jon] Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA.
   [Chevez-Barrios, Patricia] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX USA.
   [Tso, Mark] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Baylor College of Medicine; Nihon University; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah; The Methodist Hospital System; The Methodist
   Hospital - Houston; Johns Hopkins University; Johns Hopkins Medicine
RP Fu, YB (通讯作者)，Baylor Coll Med, 6550 Fannin St,Neurosensory Bldg,NC 506, Houston, TX 77030 USA.
EM yingbin.fu@bcm.edu
OI Shen, Megan/0000-0003-4422-0198; kumar, sandeep/0000-0002-2918-8276;
   VanBeuge, Stephanie/0000-0002-8491-8606
FU NIH [5R01EY022901, 2P30EY002520, 5P30EY014800]; Sarah Campbell Blaffer
   Endowment in Ophthalmology; Research to Prevent Blindness Career
   Development Award; Research to Prevent Blindness; C.M. Reeves and M.A.
   Reeves Foundation; Moran Center for Translational Medicine; Department
   of Ophthalmology, Baylor College of Medicine; NATIONAL EYE INSTITUTE
   [P30EY014800, R01EY022901, P30EY002520] Funding Source: NIH RePORTER
FX Supported by NIH grants 5R01EY022901 (Y.F.), 2P30EY002520 (Baylor
   College of Medicine), and 5P30EY014800 (University of Utah); The Sarah
   Campbell Blaffer Endowment in Ophthalmology (Y.F.); the Research to
   Prevent Blindness Career Development Award (Y.F.) and Research to
   Prevent Blindness unrestricted grants to the Department of
   Ophthalmology, University of Utah and Department of Ophthalmology,
   Baylor College of Medicine; the C.M. Reeves and M.A. Reeves Foundation
   (Y.F.); and the Moran Center for Translational Medicine (Y.F.).
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Cheung CMG, 2017, SCI REP-UK, V7, DOI 10.1038/srep41386
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   DAMATO R, 1993, MICROVASC RES, V46, P135, DOI 10.1006/mvre.1993.1042
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duca L, 2016, CARDIOVASC RES, V110, P298, DOI 10.1093/cvr/cvw061
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Iejima D, 2015, J BIOL CHEM, V290, P2784, DOI 10.1074/jbc.M114.593384
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2010, MOL VIS, V16, P1317
   Kang HM, 2013, AM J OPHTHALMOL, V155, P438, DOI 10.1016/j.ajo.2012.09.020
   Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Kumar S, 2014, JOVE-J VIS EXP, DOI 10.3791/51061
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li H, 2006, EXP EYE RES, V83, P824, DOI 10.1016/j.exer.2006.04.014
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ojima Y, 2006, AM J OPHTHALMOL, V141, P958, DOI 10.1016/j.ajo.2005.12.002
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Truebestein L, 2011, NAT STRUCT MOL BIOL, V18, P386, DOI 10.1038/nsmb.2013
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zeng RP, 2013, MOL VIS, V19, P729
   Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867
NR 75
TC 19
Z9 20
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD DEC
PY 2017
VL 187
IS 12
BP 2841
EP 2857
DI 10.1016/j.ajpath.2017.08.025
PG 17
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA FO6WF
UT WOS:000417009100019
PM 28941979
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Koh, LHL
   Agrawal, R
   Khandelwal, N
   Charan, LS
   Chhablani, J
AF Koh, Lilian Hui Li
   Agrawal, Rupesh
   Khandelwal, Neha
   Charan, Labishetty Sai
   Chhablani, Jay
TI Choroidal vascular changes in age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal vascularity index; enhanced
   depth imaging OCT; image binarization; optical coherence tomography;
   subfoveal choroidal thickness
ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW; AUTOMATED SEGMENTATION;
   THICKNESS; EYES; DISEASE; NEOVASCULARIZATION; CHORIOCAPILLARIS; INDEX;
   RPE
AB Purpose: To assess the choroidal vascular changes using choroidal vascularity index (CVI) in patients with age-related macular degeneration (AMD) compared to controls.
   Methods: Enhanced depth imaging (EDI) optical coherence tomography (OCT) scans of 64 patients with unilateral or bilateral AMD were obtained. Images with a poorly demarcated choroidal-scleral interface (CSI) were excluded from the analysis. Foveal scans of 63 AMD eyes and 35 'normal fellow' eyes were analysed. Images of 30 eyes from 18 age-matched healthy subjects were included as controls. Choroidal vascularity index (CVI) was derived from binarization of EDI OCT images, using fiji software.
   Results: The mean age was 56.505.50years for AMD patients and 52.25 +/- 6.75years for controls. All patients were treatment naive. Subfoveal choroidal thickness (SFCT) in AMD, normal fellow' eyes and controls was 314.02 +/- 78.80m, 300.88 +/- 53.85m and 278.5 +/- 65.31m, respectively. Choroidal vascularity index (CVI) in AMD, normal fellow' eyes and controls was 64.04 +/- 2.43%, 64.66 +/- 2.25% and 66.07 +/- 1.72%, respectively. Choroidal vascularity index (CVI) of both AMD and normal fellow' eyes was significantly lower compared to controls (p<0.0001 and p=0.007). The SFCT of AMD eye was not found to be significantly different from normal fellow eyes' (p=0.45).
   Conclusion: There was no statistical difference in SFCT, but CVI was significantly lower in patients with AMD. Choroidal vascularity index (CVI) was also lower in normal fellow' AMD eyes as compared to controls. This suggests possible reduction in choroidal vascularity in eyes with AMD and also to a certain extent in the normal fellow' eyes without phenotypical manifestations and may suggest underlying choroidal morphological change leading to wet AMD.
C1 [Koh, Lilian Hui Li; Agrawal, Rupesh; Khandelwal, Neha; Charan, Labishetty Sai] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Chhablani, Jay] LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
C3 Tan Tock Seng Hospital; L. V. Prasad Eye Institute
RP Agrawal, R (通讯作者)，Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.; Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Retina Vitreous Ctr, Kallam Anji Reddy Campus,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.
EM rupesh_agrawal@ttsh.com.sg; jay.chhablani@gmail.com
RI CHARAN, LABISHETTY SAI/AAO-1354-2021
OI CHARAN, LABISHETTY SAI/0000-0001-7983-7169
CR Agrawal R, 2016, RETINA
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Agrawal R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146344
   Beaton L, 2015, BIOMED OPT EXPRESS, V6, P1694, DOI 10.1364/BOE.6.001694
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gupta P, 2015, AM J OPHTHALMOL, V159, P293, DOI 10.1016/j.ajo.2014.10.034
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Karampelas M, 2013, GRAEF ARCH CLIN EXP, V251, P2029, DOI 10.1007/s00417-013-2330-7
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mahajan NR, 2013, IEEE ENG MED BIO, P3355, DOI 10.1109/EMBC.2013.6610260
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P865, DOI 10.1097/IAE.0b013e318251a3a8
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shao L, 2013, INVEST OPHTH VIS SCI, V54, P230, DOI 10.1167/iovs.12-10351
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   StataCorp, 2013, STATA STAT SOFTW REL
   Tan KA, 2016, ACTA OPHTHALMOL, V94, pE612, DOI 10.1111/aos.13044
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Wei X, 2016, RETINA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zhang L, 2015, INVEST OPHTH VIS SCI, V56, P3202, DOI 10.1167/iovs.14-15669
NR 37
TC 87
Z9 89
U1 2
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2017
VL 95
IS 7
BP E597
EP E601
DI 10.1111/aos.13399
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM0JE
UT WOS:000414648500011
PM 28391615
OA hybrid
DA 2022-11-30
ER

PT J
AU Oczos, J
   Grimm, C
   Barthelmes, D
   Sutter, F
   Menghini, M
   Kloeckener-Gruissem, B
   Berger, W
AF Oczos, Jadwiga
   Grimm, Christian
   Barthelmes, Daniel
   Sutter, Florian
   Menghini, Moreno
   Kloeckener-Gruissem, Barbara
   Berger, Wolfgang
TI Regulatory regions of the paraoxonase 1 (PON1) gene are associated with
   neovascular age-related macular degeneration (AMD)
SO AGE
LA English
DT Article
DE Paraoxonase 1; Gene regulation; SNP association; Age-related macular
   degeneration (AMD)
ID COMPLEMENT FACTOR-H; LOW-DENSITY-LIPOPROTEIN; MANGANESE
   SUPEROXIDE-DISMUTASE; JAPANESE POPULATION; HAPLOTYPE RECONSTRUCTION;
   CARDIOVASCULAR-DISEASE; SERUM CONCENTRATIONS; OXIDATIVE STRESS;
   POLYMORPHISM; RISK
AB Physiological stress response and oxidative damage are factors for aging processes and, as such, are thought to contribute to neovascular age-related macular degeneration (AMD). Paraoxonase 1 (PON1) is an enzyme that plays an important role in oxidative stress and aging. We investigated association of DNA sequence variants (SNP) within the upstream regulatory region of the PON1 gene with neovascular AMD in 305 patients and 288 controls. Four of the seven tested SNPs (rs705379, rs705381, rs854573, and rs757158) were more frequently found in AMD patients compared to controls (P = 0.0099, 0.0295, 0.0121, and 0.0256, respectively), and all but one (SNP rs757158) are in linkage disequilibrium. Furthermore, haplotype TGGCCTC conferred protection (odds ratio (OR) = 0.76, (CI) = 0.60-0.97) as it was more frequently found in control individuals, while haplotype CGATGCT increased the risk (OR = 1.55, CI = 1.09-2.21) for AMD. These results were also reflected when haplotypes for the untranscribed and the 5'untranslated regions (5'UTR) were analyzed separately. To assess haplotype correlation with levels of gene expression, the three SNPs within the 5'UTR were tested in a luciferase reporter assay. In retinal pigment epithelium-derived ARPE19 cells, we were able to measure significant differences in reporter levels, while this was not observed in kidney-derived HEK293 cells. The presence of the risk allele A (SNP rs705381) caused an increase in luciferase activity of approximately twofold. Our data support the view that inflammatory reactions mediated through anti-oxidative activity may be relevant to neovascular age-related macular degeneration.
C1 [Oczos, Jadwiga; Kloeckener-Gruissem, Barbara; Berger, Wolfgang] Univ Zurich, Inst Med Mol Genet, CH-8603 Schwerzenbach, Switzerland.
   [Oczos, Jadwiga; Grimm, Christian] Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, Zurich, Switzerland.
   [Oczos, Jadwiga; Grimm, Christian; Berger, Wolfgang] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Grimm, Christian; Berger, Wolfgang] Zurich Ctr Neurosci ZNZ, Zurich, Switzerland.
   [Barthelmes, Daniel; Sutter, Florian; Menghini, Moreno] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Barthelmes, Daniel] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Kloeckener-Gruissem, Barbara] ETH, Dept Biol, Zurich, Switzerland.
C3 University of Zurich; University of Zurich; University of Zurich; Zurich
   Center Integrative Human Physiology (ZIHP); University of Zurich;
   University Zurich Hospital; University of Sydney; Swiss Federal
   Institutes of Technology Domain; ETH Zurich
RP Kloeckener-Gruissem, B (通讯作者)，Univ Zurich, Inst Med Mol Genet, CH-8603 Schwerzenbach, Switzerland.
EM kloeckener@medgen.uzh.ch; berger@medgen.uzh.ch
OI Grimm, Christian/0000-0001-9318-4352; Menghini,
   Moreno/0000-0002-1432-2524
FU Zurich Center for Integrative Human Physiology (ZIHP) of the University
   of Zurich, Zurich, Switzerland; Swiss National Foundation (SNF/SSMBS);
   Holcim Foundation; Walter and Gertrud Siegenthaler Foundation Zurich,
   Switzerland
FX We would like to thank Marijana Samardzija for help with Excel macros to
   ease data entry in PHASE. We appreciate the genomic DNA preparations by
   Esther Glaus. Financial support by a cooperative project grant by the
   Zurich Center for Integrative Human Physiology (ZIHP) of the University
   of Zurich, Zurich, Switzerland, is greatly acknowledged. DB was
   supported by a grant from the Swiss National Foundation (SNF/SSMBS), a
   grant from the Holcim Foundation, and the Walter and Gertrud
   Siegenthaler Foundation Zurich, Switzerland.
CR Androutsopoulos VP, 2011, TOXICOL APPL PHARM, V256, P418, DOI 10.1016/j.taap.2011.08.009
   Aviram M, 2004, FREE RADICAL BIO MED, V37, P1301, DOI 10.1016/j.freeradbiomed.2004.07.009
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Brophy VH, 2001, PHARMACOGENETICS, V11, P77, DOI 10.1097/00008571-200102000-00009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Deakin SP, 2004, CLIN SCI, V107, P435, DOI 10.1042/CS20040187
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134
   Gotoh N, 2008, AM J OPHTHALMOL, V146, P146, DOI 10.1016/j.ajo.2008.03.017
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Leviev I, 2000, ARTERIOSCL THROM VAS, V20, P516, DOI 10.1161/01.ATV.20.2.516
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Mackness B, 1998, ATHEROSCLEROSIS, V139, P341, DOI 10.1016/S0021-9150(98)00095-1
   Mackness B, 1998, FEBS LETT, V423, P57, DOI 10.1016/S0014-5793(98)00064-7
   Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maziere C, 2009, FREE RADICAL BIO MED, V46, P127, DOI 10.1016/j.freeradbiomed.2008.10.024
   Moskvina V, 2005, ANN HUM GENET, V69, P566, DOI 10.1111/j.1529-8817.2005.00175.x
   Mueller JC, 2004, BRIEF BIOINFORM, V5, P355, DOI 10.1093/bib/5.4.355
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Paragh G, 1998, NEPHRON, V80, P166, DOI 10.1159/000045161
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Senti M, 2003, J CLIN ENDOCR METAB, V88, P5422, DOI 10.1210/jc.2003-030648
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Weger M, 2007, MOL VIS, V13, P1274
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zuercher J, 2010, INVEST OPHTH VIS SCI, V51, P3354, DOI 10.1167/iovs.10-5193
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 61
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
J9 AGE
JI Age
PD OCT
PY 2013
VL 35
IS 5
BP 1651
EP 1662
DI 10.1007/s11357-012-9467-x
PG 12
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 219XO
UT WOS:000324545200010
PM 22956172
OA Green Accepted, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Keane, PA
   Tufail, A
   Patel, PJ
AF Keane, Pearse A.
   Tufail, Adnan
   Patel, Praveen J.
TI Management of Neovascular Age-Related Macular Degeneration in Clinical
   Practice: Initiation, Maintenance, and Discontinuation of Therapy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF
   AGENTS; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RETINA STUDY-GROUP;
   FACTOR TRAP-EYE; INTRAVITREAL BEVACIZUMAB; VISUAL-ACUITY; RANIBIZUMAB
   TREATMENT; PIGMENT EPITHELIUM
AB Neovascular age-related macular degeneration (AMD) is a leading cause of irreversible visual loss in elderly populations. In recent years, pharmacological inhibition of vascular endothelial growth factor (VEGF), via intravitreal injection of ranibizumab (Lucentis) or bevacizumab (Avastin), has offered the first opportunity to improve visual outcomes in patients diagnosed with this disorder. In this paper, we provide recommendations on how bevacizumab and ranibizumab may be best applied in current clinical practice, with an emphasis on their underlying pharmacology and efficacy. In addition, we review current guidelines for the initiation, maintenance, and discontinuation of anti-VEGF therapies, as well as emerging treatment strategies and future directions in the field.
C1 [Keane, Pearse A.; Tufail, Adnan; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Tufail, Adnan/0000-0001-6131-7640
FU Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; Novartis UK;
   National Institute for Health Research [CL-2010-18-004] Funding Source:
   researchfish
FX P. A. Keane, A. Tufail, and P. J. Patel have received a proportion of
   their funding from the Department of Health's NIHR Biomedical Research
   Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of
   Ophthalmology. The views expressed in the publication are those of the
   authors and not necessarily those of the Department of Health. P. A.
   Tufail has been on advisory boards for Novartis, Pfizer, GSK,
   Thrombogenics, Bayer, and Allergan. P. J. Patel has received travel
   grants from Novartis UK and is a member of the Allergan European Retina
   Panel.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Amoaku WMK, 2008, EYE, V22, P864, DOI 10.1038/eye.2008.1
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eghoj M. S., BRIT J OPHT IN PRESS
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2010, BRIT J OPHTHALMOL, V94, P143, DOI 10.1136/bjo.2009.159863
   Keane PA, 2010, EYE, V24, P422, DOI 10.1038/eye.2009.309
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2009, RETINA-J RET VIT DIS, V29, P592, DOI 10.1097/IAE.0b013e31819b17a5
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   MEYER CH, ACTA OPHTHA IN PRESS
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rodrigues EB, 2011, J OCUL PHARMACOL TH, V27, P197, DOI 10.1089/jop.2010.0082
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tennant Matthew T S, 2002, Ophthalmol Clin North Am, V15, P445, DOI 10.1016/S0896-1549(02)00049-4
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 78
TC 2
Z9 2
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2011
VL 2011
AR 752543
DI 10.1155/2011/752543
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979BO
UT WOS:000306790100034
PM 22174995
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Oishi, A
   Fang, PP
   Thiele, S
   Holz, FG
   Krohne, TU
AF Oishi, Akio
   Fang, Petra P.
   Thiele, Sarah
   Holz, Frank G.
   Krohne, Tim U.
TI LONGITUDINAL CHANGE OF OUTER NUCLEAR LAYER AFTER RETINAL PIGMENT
   EPITHELIAL TEAR SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE RPE tear; RPE rip; age-related macular degeneration; optical coherence
   tomography; outer nuclear layer; photoreceptor; pigment epithelial
   detachment
ID OPTICAL COHERENCE TOMOGRAPHY; GROWTH-FACTOR THERAPY; ANTI-VEGF THERAPY;
   INJECTION; RANIBIZUMAB; TRANSPLANTATION; DETACHMENT; PROGNOSIS;
   MECHANISM
AB Purpose: To investigate longitudinal changes of outer nuclear layer (ONL) thickness in patients with retinal pigment epithelium tears secondary to neovascular age-related macular degeneration.
   Methods: This is an institutional retrospective interventional case series. Twenty-six eyes of 22 patients with retinal pigment epithelium tears identified between April 2009 and March 2015. The patients underwent intravitreal injection of anti-vascular endothelial growth factor agents as needed. Volume scans of optical coherence tomography at first diagnosis of tear (baseline) and after 12 months were analyzed. Outer nuclear layer was segmented, and average ONL thickness inside the tear area, at the border of the tear, and in areas outside the tear was measured. Change of ONL thickness. We also explored several factors for their association with ONL thinning including tear area, number of treatments, and the duration with persistent subretinal fluid.
   Results: Thinning of ONL was found in all the investigated areas (P < 0.01, respectively). Among the investigated factors, larger tear area was associated with greater ONL thinning outside the tear area (standardized beta = -0.37, P = 0.030), and younger age was associated with greater ONL thinning inside the tear area (standardized beta = 0.37, P = 0.041).
   Conclusion: After an retinal pigment epithelium tear, thinning of ONL occurs in the area devoid of retinal pigment epithelium and also in adjacent areas. Few factors were predictive for the degree of ONL thinning. These results provide new insight in disease progression of this particular neovascular age-related macular degeneration subphenotype.
C1 [Oishi, Akio; Fang, Petra P.; Thiele, Sarah; Holz, Frank G.; Krohne, Tim U.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Krohne, TU (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM krohne@uni-bonn.de
RI Krohne, Tim/D-1497-2013; Oishi, Akio/AAE-9996-2020; Larsen,
   Petra/AAV-3114-2020; Krohne, Tim/AAG-4412-2020
OI Krohne, Tim/0000-0003-2280-925X; Oishi, Akio/0000-0002-0977-9458;
   Larsen, Petra/0000-0003-2486-632X; 
FU Alexander von Humboldt Foundation, Bonn, Germany; Alcon Japan, Tokyo,
   Japan; Novartis, Basel, Switzerland
FX The work of A. Oishi was supported by the Alexander von Humboldt
   Foundation, Bonn, Germany and Alcon Japan, Tokyo, Japan. The study was
   partly supported by Novartis, Basel, Switzerland.
CR Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Cho HJ, 2015, AM J OPHTHALMOL, V160, P1000, DOI 10.1016/j.ajo.2015.07.023
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Doguizi S, 2014, RETINA-J RET VIT DIS, V34, P1156, DOI 10.1097/IAE.0000000000000056
   Durkin SR, 2016, GRAEF ARCH CLIN EXP, V254, P1, DOI 10.1007/s00417-015-2978-2
   Hata M, 2016, RETINA
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Saito M, 2013, CLIN OPHTHALMOL, V7, P1287, DOI 10.2147/OPTH.S47735
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 22
TC 4
Z9 5
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2018
VL 38
IS 7
BP 1331
EP 1337
DI 10.1097/IAE.0000000000001688
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CX
UT WOS:000440630000015
PM 28492434
DA 2022-11-30
ER

PT J
AU Suri, R
   Neupane, YR
   Jain, GK
   Kohli, K
AF Suri, Reshal
   Neupane, Yub Raj
   Jain, Gaurav Kumar
   Kohli, Kanchan
TI Recent theranostic paradigms for the management of Age-related macular
   degeneration
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration; Molecular targeted therapy; Stem cell
   therapy; Nanotechnology; Exosomes; Artificial intelligence; 3D printing
ID RETINAL-PIGMENT EPITHELIUM; STEM-CELLS; DRUG-DELIVERY; GEOGRAPHIC
   ATROPHY; CHOROIDAL NEOVASCULARIZATION; PLGA NANOPARTICLES; POSTERIOR
   SEGMENT; OCULAR NEOVASCULARIZATION; EXTRACELLULAR VESICLES; PHOTODYNAMIC
   THERAPY
AB Degenerative diseases of eye like Age-related macular degeneration (AMD), that affects the central portion of the retina (macula), is one of the leading causes of blindness worldwide especially in the elderly population. It is classified mainly as wet and dry form. With expanding knowledge about the underlying pathophysiology of the disease, various treatment strategies are being employed to halt the course of the disease progression. Hitherto, there is no ideal therapy which can cure the disease completely, and targeting the posterior segment of the eye is yet another challenge. The purpose of this review is to summarize the recent advances in the management and treatment stratagems (therapies, delivery systems and diagnostic tools) pertaining to AMD viz. molecular targeting, stem cell therapy, nanotechnology and exosomes with special reference to newer technologies like artificial intelligence and 3D printing. Furthermore, the role of diet and nutritional supplements in the prevention and treatment of the disease has also been highlighted. The alarming increase in the said disorder around the globe demands exhaustive research and investigations in the treatment zone. This review thus additionally directs the attention towards the challenges and future perspectives of different treatment approaches for AMD.
C1 [Suri, Reshal; Jain, Gaurav Kumar; Kohli, Kanchan] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
   [Neupane, Yub Raj] Natl Univ Singapore, Dept Pharm, Singapore 117559, Singapore.
C3 Jamia Hamdard University; National University of Singapore
RP Kohli, K (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
EM dr.kanchankohli65@gmail.com
RI ; Neupane, Yub Raj/ABG-1685-2020
OI Suri, Reshal/0000-0002-1741-7449; Neupane, Yub Raj/0000-0002-4535-5396
FU Indian Council of Medical Research, New Delhi, India
   [ICMR-45/51/2018-NAN-BMS]; Jamia Hamdard, New Delhi
FX Authors are thankful to Indian Council of Medical Research
   (ICMR-45/51/2018-NAN-BMS), New Delhi, India for providing Senior
   Research Fellowship to R.S. The authors are also grateful to Jamia
   Hamdard, New Delhi for providing DST's PURSE (Promotion for University
   Research in Science and Engineering) fellowship to R.S. during her
   initial period of higher studies.
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Aharony I, 2017, NEURAL REGEN RES, V12, P173, DOI 10.4103/1673-5374.200793
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2019, GRAEFES ARCH CLIN EX, DOI DOI 10.1080/02699931.2019.1602028
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Barile L, 2017, PHARMACOL THERAPEUT, V174, P63, DOI 10.1016/j.pharmthera.2017.02.020
   Bastos-Amador P, 2012, J PROTEOMICS, V75, P3574, DOI 10.1016/j.jprot.2012.03.054
   Batrakova EV, 2015, J CONTROL RELEASE, V219, P396, DOI 10.1016/j.jconrel.2015.07.030
   Behroozi F, 2018, INT J PHARMACEUT, V548, P62, DOI 10.1016/j.ijpharm.2018.05.056
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, pBIO141, DOI 10.1167/iovs.17-21789
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Brandl C, 2015, J CLIN MED, V4, P282, DOI 10.3390/jcm4020282
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cameron DA, 2000, VISUAL NEUROSCI, V17, P789, DOI 10.1017/S0952523800175121
   Cao SJ, 2013, MOL VIS, V19, P718
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Chang Z, 2017, ASIA-PAC CONF COMMUN, P12
   Chatterji B.P., 2018, OPEN STEM CELL J, V5
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Choi SW, 2018, ACTA OPHTHALMOL, V96, pE399, DOI 10.1111/aos.13179
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133272
   Daraee H, 2016, ARTIF CELL NANOMED B, V44, P381, DOI 10.3109/21691401.2014.953633
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Dejneka NS, 2004, MOL VIS, V10, P964
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Dismuke WM, 2015, EXP EYE RES, V132, P73, DOI 10.1016/j.exer.2015.01.019
   Ebrahimi KB, 2014, ADV EXP MED BIOL, V801, P259, DOI 10.1007/978-1-4614-3209-8_33
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   El-Sayed MM, 2017, DRUG DEV IND PHARM, V43, P902, DOI 10.1080/03639045.2016.1272120
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Elshelmani H, 2017, METHODS MOL BIOL, V1509, P93, DOI 10.1007/978-1-4939-6524-3_10
   Esmaili D.D., 2015, RETINA TODAY
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Fletcher EC, 2008, EYE, V22, P742, DOI 10.1038/sj.eye.6703008
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Gokuladhas K, 2017, GENES DIS, V4, P88, DOI 10.1016/j.gendis.2017.01.002
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Gonzalez E, 2015, EXPERT REV MOL DIAGN, V15, P907, DOI 10.1586/14737159.2015.1043272
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gunda Sriram, 2008, P399, DOI 10.1007/978-1-59745-375-2_21
   Hafner A, 2014, INT J NANOMED, V9, P1005, DOI 10.2147/IJN.S55359
   Hageman GS, 1999, MOL VIS, V5
   Hajrasouliha AR, 2013, J BIOL CHEM, V288, P28058, DOI 10.1074/jbc.M113.470765
   Harrell CR, 2018, ADV EXP MED BIOL, V1089, P47, DOI 10.1007/5584_2018_219
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Huang WB, 2014, INVEST OPHTH VIS SCI, V55, P5380, DOI 10.1167/iovs.14-15231
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Ito A, 2005, TISSUE ENG, V11, P489, DOI 10.1089/ten.2005.11.489
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Ji WW, 2017, EUR J PHARM SCI, V109, P624, DOI 10.1016/j.ejps.2017.09.021
   Jiang J, 2018, EUR J PHARM SCI, V121, P251, DOI 10.1016/j.ejps.2018.04.043
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson TV, 2014, BRAIN, V137, P503, DOI 10.1093/brain/awt292
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Joseph RR, 2017, NANOMEDICINE-UK, V12, P683, DOI 10.2217/nnm-2016-0379
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Karl MO, 2008, P NATL ACAD SCI USA, V105, P19508, DOI 10.1073/pnas.0807453105
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kelly SJ, 2019, DRUG DEV IND PHARM, V45, P715, DOI 10.1080/03639045.2019.1569024
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Khalil M, 2020, INT J BIOL MACROMOL, V143, P483, DOI 10.1016/j.ijbiomac.2019.10.256
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim JH, 2022, ARCH PHYSIOL BIOCHEM, V128, P859, DOI 10.1080/13813455.2020.1733026
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Knickelbein JE, 2016, INVEST OPHTH VIS SCI, V57, P4101, DOI 10.1167/iovs.15-18353
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koo H, 2012, BIOMATERIALS, V33, P3485, DOI 10.1016/j.biomaterials.2012.01.030
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li N, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1372-0
   Li Q, 2014, EUR J PHARM SCI, V62, P115, DOI 10.1016/j.ejps.2014.05.020
   Li XM, 2010, INVEST OPHTH VIS SCI, V51, P516, DOI 10.1167/iovs.09-3822
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lorber B, 2016, CURR OPIN OPHTHALMOL, V27, P262, DOI 10.1097/ICU.0000000000000252
   Lu W, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5278196
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Maeda N, 2004, J CONTROL RELEASE, V100, P41, DOI 10.1016/j.jconrel.2004.07.033
   Maier AKB, 2007, CURR EYE RES, V32, P801, DOI 10.1080/02713680701553052
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maloca P.M., 2017, ACTA OPHTHALMOL, P1
   Maloca PM, 2019, ACTA OPHTHALMOL, V97, pE313, DOI 10.1111/aos.13637
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Mazzilli JL, 2017, STEM CELL RES, V18, P37, DOI 10.1016/j.scr.2016.12.005
   McKechnie NM, 2006, EXP EYE RES, V83, P304, DOI 10.1016/j.exer.2005.11.028
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16-0428
   Mead B, 2013, INVEST OPHTH VIS SCI, V54, P7544, DOI 10.1167/iovs.13-13045
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Mesentier-Louro LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110722
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Minnelli C, 2018, INT J PHARMACEUT, V552, P225, DOI 10.1016/j.ijpharm.2018.10.004
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moisseiev E, 2017, DEV OPHTHALMOL, V58, P87, DOI 10.1159/000455276
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Mousavinejad M, 2016, CELL J, V18
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munagala R, 2016, CANCER LETT, V371, P48, DOI 10.1016/j.canlet.2015.10.020
   Nakahara T, 2017, BIOL PHARM BULL, V40, P2045, DOI 10.1248/bpb.b17-00475
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Neupane YR, 2015, SCI ADV MATER, V7, P433, DOI 10.1166/sam.2015.2133
   Neupane YR, 2014, INT J PHARMACEUT, V477, P601, DOI 10.1016/j.ijpharm.2014.11.001
   Neupane YR, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/41/415102
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nobl M, 2016, EXP EYE RES, V146, P107, DOI 10.1016/j.exer.2016.01.001
   O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Olver Christine, 2007, V43, P99, DOI 10.1007/978-1-4020-5943-8_7
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Ouyang H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030415
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Quiroz-Mercado H., 2013, RETINA TODAY, P60
   Ricci-Junior E, 2006, INT J PHARMACEUT, V310, P187, DOI 10.1016/j.ijpharm.2005.10.048
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shah SS, 2010, EXPERT REV OPHTHALMO, V5, P75, DOI 10.1586/EOP.09.70
   Sharghi-Namini S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04031
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Sivan PP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8304879
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Sugitani S, 2013, EXP EYE RES, V116, P254, DOI 10.1016/j.exer.2013.09.013
   Suri R, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101389
   Suri R, 2020, MED HYPOTHESES, V136, DOI 10.1016/j.mehy.2019.109518
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   van Niel G, 2015, CELL REP, V13, P43, DOI 10.1016/j.celrep.2015.08.057
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Ventola C Lee, 2012, P T, V37, P512
   Wang A.L., 2009, PLOS ONE, V4
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright K., 2019, NAT COMMUN, V10, P1, DOI DOI 10.1038/S41467-018-07882-8
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yan RT, 2013, INVEST OPHTH VIS SCI, V54, P4766, DOI 10.1167/iovs.13-11936
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yen CH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/809234
   Yu B, 2016, SCI REP-UK, V6, DOI 10.1038/srep34562
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang XH, 2017, MOL THER, V25, P1606, DOI 10.1016/j.ymthe.2017.01.014
   Zhang Y, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0282-2
   Zhao YJ, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.6
   Zwart I, 2009, EXP NEUROL, V216, P439, DOI 10.1016/j.expneurol.2008.12.028
NR 183
TC 6
Z9 6
U1 2
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD OCT 1
PY 2020
VL 153
AR 105489
DI 10.1016/j.ejps.2020.105489
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NY8LF
UT WOS:000576633800018
PM 32717428
DA 2022-11-30
ER

PT J
AU Erke, MG
   Bertelsen, G
   Peto, T
   Sjolie, AK
   Lindekleiv, H
   Njolstad, I
AF Erke, Maja G.
   Bertelsen, Geir
   Peto, Tunde
   Sjolie, Anne K.
   Lindekleiv, Haakon
   Njolstad, Inger
TI Lactation, female hormones and age-related macular degeneration: the
   TromsO Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Epidemiology; Macula
ID RISK-FACTORS; PREVALENCE
AB Objective
   Some risk factors for age-related macular degeneration (AMD) have been shown to act differently in women and men. The present study aims to investigate this disparity by examining associations between female hormones, reproductive history and AMD.
   Methods
   Women aged 65-87years were invited to this cross-sectional, population-based study in Norway. Participants underwent physical examination, retinal photography, answered questionnaires and had blood samples taken.
   Results
   The sample included 1512 women, of whom 48 (3.2%) had late AMD and 378 (25%) had large drusen >125m phenotype. Length of breast feeding per child was significantly associated with late AMD (OR per month 0.80, 95% CI 0.68 to 0.94) in multivariable regression analysis. We observed no associations between late AMD or drusen >125m and contraceptives, oral hormonal replacement therapy, parity, age at first childbirth, age of menarche, age of menopause, number of menstruating years or the reason for menopause.
   Conclusions
   Longer duration of lactation was associated with lower frequency of maternal late AMD when controlled for confounders. Other reproductive factors and hormone replacement therapy were not significantly associated with AMD.
C1 [Erke, Maja G.; Bertelsen, Geir] Univ Hosp North Norway, Dept Ophthalmol & Neurosurg, N-9038 Tromso, Norway.
   [Erke, Maja G.; Bertelsen, Geir; Lindekleiv, Haakon; Njolstad, Inger] Univ Tromso, Dept Community Med, Tromso, Norway.
   [Peto, Tunde] NHS Fdn Trust, Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde] UCL Inst Ophthalmol, London, England.
   [Sjolie, Anne K.] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense, Denmark.
C3 UiT The Arctic University of Tromso; University Hospital of North
   Norway; UiT The Arctic University of Tromso; Oxford University Hospitals
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; University of Southern Denmark; Odense
   University Hospital
RP Erke, MG (通讯作者)，Univ Hosp North Norway, Dept Ophthalmol & Neurosurg, POB 100, N-9038 Tromso, Norway.
EM maja.g.erke@uit.no
RI Bertelsen, Geir/ABB-9865-2021; Peto, Tunde/G-8812-2018; Njolstad,
   Inger/X-3784-2019
OI Peto, Tunde/0000-0001-6265-0381; 
FU Northern Norway Regional Health Authority [SFP897-09]; NIHR Biomedical
   Research Centre for Ophthalmology, at Moorfields Eye Hospital NHS
   Foundation Trust; UCL Institute of Ophthalmology, London, UK
FX Maja Gran Erke was supported by a PhD grant from The Northern Norway
   Regional Health Authority, grant number SFP897-09. TP was supported by
   NIHR Biomedical Research Centre for Ophthalmology, at Moorfields Eye
   Hospital NHS Foundation Trust and UCL Institute of Ophthalmology,
   London, UK. The funding organisations had no role in the design or
   conduct of this research.
CR Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0
   Bertelsen G, 2013, ACTA OPHTHALMOL, V91, P635, DOI 10.1111/j.1755-3768.2012.02511.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Jacobsen BK, 2012, INT J EPIDEMIOL, V41, P961, DOI 10.1093/ije/dyr049
   Lee SY, 2005, PREV MED, V41, P433, DOI 10.1016/j.ypmed.2004.11.025
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schwarz EB, 2009, OBSTET GYNECOL, V113, P974, DOI 10.1097/01.AOG.0000346884.67796.ca
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 15
TC 9
Z9 9
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2013
VL 97
IS 8
BP 1036
EP 1039
DI 10.1136/bjophthalmol-2012-302461
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186JI
UT WOS:000322039400020
PM 23759439
DA 2022-11-30
ER

PT J
AU Lei, JQ
   Al-Sheikh, M
   Shi, Y
   Uji, A
   Fan, WY
   Balasubramanian, S
   Sadda, SR
AF Lei, Jianqin
   Al-Sheikh, Mayss
   Shi, Yue
   Uji, Akihito
   Fan, Wenying
   Balasubramanian, Siva
   Sadda, Srinivas R.
TI RELIABILITY OF CONFOCAL WHITE-LIGHT FUNDUS IMAGING FOR MEASUREMENT OF
   RETINA PIGMENT EPITHELIAL ATROPHY IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; atrophy; measurement; color fundus
   photograph; fundus autofluorescence
ID MEASURING GEOGRAPHIC ATROPHY; EYE DISEASE; AUTOFLUORESCENCE
AB Purpose: To assess the reproducibility of confocal white-light color fundus photography (C-CFP) for the measurement of retinal pigment epithelial atrophy in comparison with confocal blue-light fundus autofluorescence (FAF) imaging and flash color fundus photography (F-CFP).
   Methods: In this prospective study, eyes with age-related macular degeneration associated with evidence of retinal pigment epithelial atrophy were imaged by C-CFP, F-CFP, and FAF. Intergrader reproducibility of each modality was assessed by comparison of manual measurements by two expert graders.
   Results: The mean areas of atrophy measured by the 2 graders were 6.67 +/- 6.39, 6.35 +/- 6.13, and 6.07 +/- 5.48 mm(2) for FAF, C-CFP, and F-CFP, respectively. The mean differences between the 2 graders in measuring the atrophic areas were 0.52, 0.69, and 1.62 mm(2) for the three modalities. The intraclass correlation coefficient between the 2 graders for each modality was 0.998, 0.990, and 0.961, respectively.
   Conclusion: Measurements of atrophy from C-CFP were similar to those obtained by FAF and F-CFP. The grading reproducibility for C-CFP, however, was better than that for F-CFP and approached the level of FAF imaging. The use of C-CFP as a tool for quantitatively monitoring atrophic age-related macular degeneration lesions warrants further study, particularly in the context of clinical trials.
C1 [Lei, Jianqin; Al-Sheikh, Mayss; Shi, Yue; Uji, Akihito; Fan, Wenying; Balasubramanian, Siva; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St,DVRC211, Los Angeles, CA 90033 USA.
   [Lei, Jianqin; Al-Sheikh, Mayss; Shi, Yue; Uji, Akihito; Fan, Wenying; Balasubramanian, Siva; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian, Shaanxi, Peoples R China.
   [Al-Sheikh, Mayss] Univ Zurich, Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Fan, Wenying] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Xi'an Jiaotong
   University; University of Zurich; University Zurich Hospital; Capital
   Medical University
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St,DVRC211, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI fan, wenying/GSI-5125-2022
FU NATIONAL EYE INSTITUTE [P30EY019007] Funding Source: NIH RePORTER
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Cioffi CL, 2015, J MED CHEM, V58, P5863, DOI 10.1021/acs.jmedchem.5b00423
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Kuehlewein L, 2016, OSLI RETINA, V47, P224, DOI 10.3928/23258160-20160229-04
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Le KN, 2015, CPT-PHARMACOMET SYST, V4, P595, DOI 10.1002/psp4.12031
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
NR 20
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2018
VL 38
IS 10
BP 1930
EP 1936
DI 10.1097/IAE.0000000000001949
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VS
UT WOS:000454005600015
PM 29160788
DA 2022-11-30
ER

PT J
AU Pauleikhoff, D
AF Pauleikhoff, D
TI Neovascular age-related macular degeneration - Natural history and
   treatment outcomes
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   PIGMENT EPITHELIAL DETACHMENT; PHOTODYNAMIC THERAPY; VERTEPORFIN
   THERAPY; VISUAL IMPAIRMENT; EYES; DISABILITY; MEMBRANES; TRANSLOCATION
AB Background: This review summarizes the data reported in peer-reviewed literature and presents current knowledge on differentiation, natural history, and therapeutic outcomes of neovascular age-related macular degeneration (AMD).
   Methods: The MEDLINE database was searched to review natural history of neovascular AMD and therapeutic effects of available treatments.
   Results: The search produced >7,000 articles. Research suggests that fluorescein angiographic characterization of location, composition, and size of neovascular lesions may be important in prognosis and should be considered for evaluation of treatment benefits in conjunction with evidence of recent disease progression for lesions not composed of predominantly classic choroidal neovascularization (CNV). Laser photocoagulation, photodynamic therapy with verteporfin, and administration of pegaptanib sodium reduce the risk of vision loss in selected cases of neovascular AMD, while submacular surgery can reduce the risk of severe visual acuity loss in selected cases of predominantly hemorrhagic CNV; further approaches are under investigation.
   Conclusion: Visual prognosis of neovascular AMD is variable according to lesion location, composition, and size. Often, lesions have a poor prognosis, resulting in rapid and progressive loss of visual acuity and contrast sensitivity. Such losses have a profound effect on patients' quality of life and ability to perform everyday tasks. Reducing the risk of further loss of visual acuity and contrast sensitivity might enable patients with neovascular AMD to maintain better functional abilities.
C1 St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
C3 St. Franziskus-Hospital
RP Pauleikhoff, D (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM dapauleikhoff@muenster.de
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   *ALC INC, 2004, ALC PRES MOR RET CLI
   [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Heier J. S., 2004, INVEST OPHTHALMOL VI, V45
   Heier JS, 2005, INVEST OPHTH VIS SCI, V46
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Hossain P, 2005, BMJ-BRIT MED J, V330, P30, DOI 10.1136/bmj.330.7481.30
   *IRIDEX CORP, 2004, PRES PREL RES TTT4CN
   KAISER PK, 2003, INVEST OPHTHALMOL VI, V44
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KUPPERMANN BD, 2004, AM AC OPHTH EUR SOC
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   LEYS AM, 2004, INVEST OPHTHALMOL VI, V45
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   *QLT INC, 2003, NOV OPHTH AG NEW CLI
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   REGILLO CD, 2004, INVEST OPHTHALMOL VI, V45
   REICHEL E, 2004, TRANSPUPILLARY THERM
   Rogers AH, 2001, CURR OPIN OPHTHALMOL, V12, P212, DOI 10.1097/00055735-200106000-00012
   Rolling F, 2004, GENE THER, V11, pS26, DOI 10.1038/sj.gt.3302366
   ROSENFELD PJ, 2004, INVEST OPHTHALMOL VI, V45
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   RUBIN GS, 1994, OPTOMETRY VISION SCI, V71, P750, DOI 10.1097/00006324-199412000-00005
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   SLAKTER JS, 2004, AM AC OPHTH EUR SOC
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   *SST RES GROUP, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Staurenghi G, 2001, Semin Ophthalmol, V16, P233, DOI 10.1076/soph.16.4.233.10297
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sugino IK, 2003, MOL NEUROBIOL, V28, P177, DOI 10.1385/MN:28:2:177
   TAP and VIP Study Group, 2002, RETINA, V22, P6
   Tholen AM, 2003, OPHTHALMOLOGE, V100, P28, DOI 10.1007/s00347-002-0681-2
   THOMAS EL, 2004, AM AC OPHTH EUR SOC
   THOMAS EL, 2004, INVEST OPHTHALMOL VI, V45
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
   *US DEP HHS CMS, NAT COV AN NCA OC PH
   *VAM STUD WRIT COM, 2004, RETINA, V24, P512
   WALSH AW, 1989, ANN OPHTHALMOL, V21, P348
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
NR 100
TC 71
Z9 93
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2005
VL 25
IS 8
BP 1065
EP 1084
DI 10.1097/00006982-200512000-00016
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AQ
UT WOS:000235013000016
PM 16340538
DA 2022-11-30
ER

PT J
AU Chew, JK
   Zhu, MD
   Broadhead, GK
   Luo, KH
   Hong, T
   Chang, AA
AF Chew, Jamie K.
   Zhu, Meidong
   Broadhead, Geoffrey K.
   Luo, Kehui
   Hong, Thomas
   Chang, Andrew A.
TI Bilateral Neovascular Age-Related Macular Degeneration: Comparisons
   between First and Second Eyes
SO OPHTHALMOLOGICA
LA English
DT Article
DE Macular degeneration; Anti-vascular endothelial growth factor; Choroidal
   neovascularization; Neovascular eye disease
ID CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY; REPRODUCIBILITY;
   RANIBIZUMAB; MANAGEMENT; THERAPY; TESTS
AB Purpose: To compare 12-month outcomes and clinical presentations between first and second eyes of patients who developed neovascular age-related macular degeneration (nAMD) in both eyes and received ranibizumab intravitreal therapy (IVT). Methods: This is a retrospective case series of 45 patients undergoing IVT for unilateral nAMD who subsequently developed second-eye nAMD. At each visit, both eyes underwent visual acuity (VA) measurement and optical coherence tomography (OCT). Results: In second eyes, 53% were asymptomatic at baseline, with OCT retinal fluid as the only sign of nAMD among 33% of patients. In eyes with baseline VA >6/9, 82% of second treated eyes maintained this vision versus 12% of first eyes (p = 0.05). At 12 months, 70% of second eyes were fluid free versus 41% of first eyes (p = 0.02). Conclusions: A large proportion of patients are asymptomatic at diagnosis of second-eye nAMD. Early intervention following earlier detection of nAMD in the second eye may lead to improved clinical outcomes. (C) 2017 S. Karger AG, Basel
C1 [Chew, Jamie K.; Zhu, Meidong; Broadhead, Geoffrey K.; Hong, Thomas; Chang, Andrew A.] Univ Sydney, Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Chew, Jamie K.; Zhu, Meidong; Broadhead, Geoffrey K.; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Luo, Kehui] Macquarie Univ, Dept Stat, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Macquarie University
RP Chang, AA (通讯作者)，Sydney Inst Vis Sci, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Ariyasu RG, 1996, OPHTHALMOLOGY, V103, P1751, DOI 10.1016/S0161-6420(96)30431-4
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chaikitmongkol Voraporn, 2015, Retin Cases Brief Rep, V9, P33, DOI 10.1097/ICB.0000000000000085
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chevreaud O, 2016, EUR J OPHTHALMOL, V26, P44, DOI 10.5301/ejo.5000649
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Krebs I, 2012, BRIT J OPHTHALMOL, V96, P271, DOI 10.1136/bjo.2010.194662
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liu L, 2014, OPTOMETRY VISION SCI, V91, P956, DOI 10.1097/OPX.0000000000000324
   Lu CD, 2014, BIOMED OPT EXPRESS, V5, P293, DOI 10.1364/BOE.5.000293
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 29
TC 10
Z9 10
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 1-2
BP 23
EP 30
DI 10.1159/000469652
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FC1MB
UT WOS:000406600200004
PM 28395293
DA 2022-11-30
ER

PT J
AU Zampatti, S
   Ricci, F
   Cusumano, A
   Marsella, LT
   Novelli, G
   Giardina, E
AF Zampatti, Stefania
   Ricci, Federico
   Cusumano, Andrea
   Marsella, Luigi Tonino
   Novelli, Giuseppe
   Giardina, Emiliano
TI Review of nutrient actions on age-related macular degeneration
SO NUTRITION RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Disease susceptibility; Antioxidants;
   Nutrients; Nutrition surveys; Food habits
ID LONG-TERM SUPPLEMENTATION; 3RD NATIONAL-HEALTH; DIETARY-FAT; GLYCEMIC
   INDEX; VITAMIN-E; PRIMARY PREVENTION; ZINC SUPPLEMENTS; BETA-CAROTENE;
   EYE DISEASE; FISH INTAKE
AB The actions of nutrients and related compounds on age-related macular degeneration (AMD) are explained in this review. The findings from 80 studies published since 2003 on the association between diet and supplements in AMD were reviewed. Antioxidants and other nutrients with an effect on AMD susceptibility include carotenoids (lutein and zeaxanthin, beta-carotene), vitamins (vitamin A, E, C, D, B), mineral supplements (zinc, copper, selenium), dietary fatty acids [monounsaturated fatty acids, polyunsaturated fatty acids (PUPA both omega-3 PUFA and omega-6 PUPA), saturated fatty acids and cholesterol], and dietary carbohydrates. The literature revealed that many of these antioxidants and nutrients exert a protective role by functioning synergistically. Specifically, the use of dietary supplements with targeted actions can Provide minimal benefits on the onset or progression of AMD; however, this does not appear to be particularly beneficial in healthy people. Furthermore, some supplements or nutrients have demonstrated discordant effects on AMD in some studies. Since intake of dietary supplements, as well as exposure to damaging environmental factors, is largely dependent on population habits (including dietary practices) and geographical localization, an overall healthy diet appears to be the best strategy in reducing the risk of developing AMD. As of now, the precise mechanism of action of certain nutrients in AMD prevention remains unclear. Thus, future studies are required to examine the effects that nutrients have on AMD and to determine which factors are most strongly correlated with reducing the risk of AMD or preventing its progression. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Zampatti, Stefania; Marsella, Luigi Tonino; Novelli, Giuseppe; Giardina, Emiliano] Univ Roma Tor Vergata, Sch Med, Dept Biomed & Prevent, Rome, Italy.
   [Ricci, Federico; Cusumano, Andrea] UOSD Patol Retin Fdn PTV Policlin Tor Vergata, Rome, Italy.
   [Novelli, Giuseppe] S Pietro Fatebenefratelli Hosp, Rome, Italy.
   [Giardina, Emiliano] Fdn Santa Lucia, Lab Genet Mol UILDM, Rome, Italy.
C3 University of Rome Tor Vergata; IRCCS Santa Lucia
RP Giardina, E (通讯作者)，Univ Roma Tor Vergata, Sch Med, Dept Biomed & Prevent, Rome, Italy.
EM emiliano.giardina@uniroma2.it
RI ricci, federico/AAC-3836-2020; Novelli, Giuseppe/A-5195-2013; Zampatti,
   Stefania/AAC-4589-2022; Novelli, Giuseppe/GQB-3329-2022; Novelli,
   Giuseppe/T-8822-2019; Giardina, Emiliano/J-1965-2012
OI ricci, federico/0000-0002-4224-9280; Novelli,
   Giuseppe/0000-0002-7781-602X; Zampatti, Stefania/0000-0003-2502-7157;
   Novelli, Giuseppe/0000-0002-7781-602X; giardina,
   emiliano/0000-0002-2741-5009; Marsella, Luigi Tonino/0000-0002-7005-7526
FU Macula & Genoma Foundation-onlus
FX This work was supported by the "Macula & Genoma Foundation-onlus."
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2012, OPHTHALMOLOGY
   Berger CT, 2012, INFECT DIS CLIN N AM, V26, P863, DOI 10.1016/j.idc.2012.08.010
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boeing H, 2012, EUR J NUTR, V51, P637, DOI 10.1007/s00394-012-0380-y
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P1104, DOI 10.1016/j.ajo.2011.12.010
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Flohe L, 2005, DEV OPHTHALMOL, V38, P89, DOI 10.1159/000082770
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gensler G, 2002, J NUTR, V132, P697
   Giardina Emiliano, 2004, Current Drug Targets - Inflammation and Allergy, V3, P129, DOI 10.2174/1568010043343877
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   JACQUES PF, 1995, AM J CLIN NUTR, V62, P1228, DOI 10.1093/ajcn/62.6.1228
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jenkins DJA, 2008, JAMA-J AM MED ASSOC, V300, P2742, DOI 10.1001/jama.2008.808
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Kuzniarz M, 2002, OPHTHAL EPIDEMIOL, V9, P283, DOI 10.1076/opep.9.4.283.1511
   Lawrenson JG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub2
   Lepre T, 2011, AM J OPHTHALMOL, V152, P325, DOI 10.1016/j.ajo.2011.04.021
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Moriarty-Craige SE, 2007, AM J OPHTHALMOL, V143, P206, DOI 10.1016/j.ajo.2006.09.056
   Muir AJ, 2013, J CLIN GASTROENTEROL, V47, P222, DOI 10.1097/MCG.0b013e3182680221
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Ricci F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066978
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schreier P, 2005, DEV OPHTHALMOL, V38, P1, DOI 10.1159/000082765
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Seddon JM, 2010, MOL VIS, V16, P2412
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Stahl W, 2005, DEV OPHTHALMOL, V38, P70, DOI 10.1159/000082768
   Stocchi L, 2012, CURR GENOMICS, V13, P314, DOI 10.2174/138920212800793311
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Woodside JV, 2013, EUR J NUTR, V52, P1493, DOI 10.1007/s00394-012-0456-8
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 93
TC 60
Z9 64
U1 1
U2 69
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
EI 1879-0739
J9 NUTR RES
JI Nutr. Res.
PD FEB
PY 2014
VL 34
IS 2
BP 95
EP 105
DI 10.1016/j.nutres.2013.10.011
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA AA2KV
UT WOS:000330924400001
PM 24461310
DA 2022-11-30
ER

PT J
AU Bonyadi, M
   Bonyadi, MHJ
   Yaseri, M
   Soheilian, M
AF Bonyadi, Mortaza
   Bonyadi, Mohammad Hossein Jabbarpoor
   Yaseri, Mehdi
   Soheilian, Masoud
TI Interactions among different genetic loci in age-related macular
   degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration (AMD); ARMS2/LOC387715 (A69S); DNA
   repair SMUG1 rs3087404; CCL2-2518, C3 (R102G); CFH Y402H; complement
   factor B (L9H); complement factor I (CFI) (G119R); synergy index; single
   nucleotide polymorphism (SNP)
ID COMPLEMENT FACTOR-H; SUSCEPTIBILITY; POLYMORPHISMS; ASSOCIATION;
   MACULOPATHY; LOC387715; Y402H; RISK
AB Purpose: To evaluate the possible synergistic effect of at risk genotypes of ARMS2/LOC387715 (A69S), DNA repair SMUG1 rs3087404, CCL2-2518, C3 (R102G), CFH Y402H, complement factor B (L9H), and complement factor I (CFI) (G119R) in advanced age-related macular degeneration compared to those of healthy controls. Elucidation of synergistic effects between different genetic loci may clarify their pathogenetic pathways.
   Methods: We calculated relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S) to estimate the additive or supra-additive effects of the mentioned genotypes.
   Results: ARMS2-CFH [RERI = 4.78 (95% CI 2.17-10.61), AP = 0.65 (95% CI 0.33-0.83), S = 4.11 (95% CI 1.40-12.06)], and CFH-C3 combinations [RERI = 2.71 (95% CI 0.04-7.01) AP = 0.47 (95% CI -0.03-0.7) S = 2.30 (95% CI 0.97-5.45)] have the most significant levels of synergism and C3-CFI combination [RERI = -1.65 (95% CI -4.34-0.06), AP = -0.92(95% CI -3.09 - -0.09), S = 0.32 (95% CI 0.09 = 1.20)] has the most significant level of antagonism.
   Conclusion: Among different genotype combinations ARMS2-CFH and CFH-C3 combinations have the most significant levels of synergism and C3-CFI combination has the most significant level of antagonism in AMD patients.
C1 [Bonyadi, Mortaza] Univ Tabriz, Fac Nat Sci, Ctr Excellence Biodivers, Tabriz, Iran.
   [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Ocular Tissue Engn Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
C3 University of Tabriz; Shahid Beheshti University Medical Sciences;
   Tehran University of Medical Sciences
RP Bonyadi, MHJ (通讯作者)，Ophthalm Res Ctr, Pasdaran Ave,Boustan 9th St, Tehran, Iran.
EM mhbonyadi@yahoo.com
RI Hossein, Jabbarpoor Bonyadi Mohammad/A-1886-2014; Yaseri,
   Mehdi/I-1645-2018; Soheilian, Masoud/AAW-4743-2020
OI Yaseri, Mehdi/0000-0002-4066-873X; Soheilian, Masoud/0000-0001-7508-426X
CR Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x
   Bonyadi MHJ, 2016, CURR EYE RES, V41, P1519, DOI 10.3109/02713683.2016.1158274
   Bonyadi Mohammad Hossein Jabbarpoor, 2015, J Ophthalmic Vis Res, V10, P155, DOI 10.4103/2008-322X.163781
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P422, DOI 10.1080/13816810.2016.1251947
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P365, DOI 10.1080/13816810.2016.1242019
   Bonyadi M, 2017, OPHTHALMIC GENET, V38, P61, DOI 10.3109/13816810.2015.1126612
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Fremeaux-Bacchi V, 2015, KIDNEY INT, V88, P967, DOI 10.1038/ki.2015.253
   Jabbarpoor Bonyadi MH, 2017, OPHTHALMIC GENET, V17, P1
   Keir LS, 2012, DRUG DES DEV THER, V6, P195, DOI 10.2147/DDDT.S25757
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   Wang XF, 2010, HUM HERED, V70, P269, DOI 10.1159/000321967
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zou GY, 2008, AM J EPIDEMIOL, V168, P212, DOI 10.1093/aje/kwn104
NR 21
TC 3
Z9 3
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2018
VL 39
IS 2
BP 189
EP 193
DI 10.1080/13816810.2017.1393829
PG 5
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA FX5HO
UT WOS:000426109100007
PM 29087762
DA 2022-11-30
ER

PT J
AU Chong, EWT
   Robman, LD
   Simpson, JA
   Hodge, AM
   Aung, KZ
   Dolphin, TK
   English, DR
   Giles, GG
   Guymer, RH
AF Chong, Elaine W. -T.
   Robman, Luibov D.
   Simpson, Julie A.
   Hodge, Allison M.
   Aung, Khin Zaw
   Dolphin, Theresa K.
   English, Dallas R.
   Giles, Graham G.
   Guymer, Robyn H.
TI Fat Consumption and Its Association With Age-Related Macular
   Degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID DIETARY-FAT; MULTIPLE COMPARISONS; ACID-COMPOSITION; RISK-FACTORS; FISH
   INTAKE; INFLAMMATION; MACULOPATHY; PREVALENCE; ADJUSTMENT; SMOKING
AB Objective: To evaluate associations between past dietary fat intake and the prevalence of age-related macular degeneration (AMD).
   Methods: Six thousand seven hundred thirty-four participants aged 58 to 69 years in 1990-1994 took part in this cohort study. Participants' nutrient intakes were estimated from a food frequency questionnaire at baseline. At follow-up from 2003 to 2006, digital macula photographs of both eyes were evaluated for early and late AMD signs. Logistic regression was used to estimate odds ratios, with adjustment for age, smoking, and other potential confounders.
   Results: Higher trans-unsaturated fat intake was associated with an increased prevalence of late AMD; the odds ratio comparing the highest with the lowest quartile of trans fat was 1.76 (95% confidence interval, 0.92-3.37; P=.02). Higher omega-3 fatty acid intake (highest quartile vs lowest quartile) was inversely associated with early AMD (odds ratio, 0.85; 95% confidence interval, 0.71-1.02; P=.03). Olive oil intake (>= 100 mL/week vs <1 mL/week) was associated with decreased prevalence of late AMD (odds ratio, 0.48; 95% confidence interval, 0.22-1.04 P=.03). No significant associations with AMD were observed for intakes of fish, total fat, butter, or margarine.
   Conclusion: A diet low in trans-unsaturated fat and rich in w-3 fatty acids and olive oil may reduce the risk of AMD.
C1 [Chong, Elaine W. -T.; Robman, Luibov D.; Aung, Khin Zaw; Dolphin, Theresa K.; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Simpson, Julie A.; English, Dallas R.; Giles, Graham G.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [Hodge, Allison M.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
   [Simpson, Julie A.; English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia.
   [Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne; University of Melbourne; Cancer Council Victoria; Royal
   Victorian Eye & Ear Hospital
RP Chong, EWT (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM elaine.chong@eyeandear.org.au
RI Simpson, Julie A/P-7299-2014; Robman, Liubov/N-9075-2013; English,
   Dallas/AAH-5005-2019
OI English, Dallas/0000-0001-7828-8188; Hodge, Allison/0000-0001-5464-2197;
   Simpson, Julie/0000-0002-2660-2013; Giles, Graham/0000-0003-4946-9099;
   Guymer, Robyn/0000-0002-9441-4356
FU National Health & Medical Research Council Public Health Scholarship;
   National Health & Medical Research Council; Royal Victorian Eye and Ear
   Hospital Wagstaff fellowship; National Health and Medical Research
   Council [209057, 251533, 396414]; Ophthalmic Research Institute of
   Australia; John Reid Charitable Trust; Perpetual Trustees
FX This study was supported by the National Health & Medical Research
   Council Public Health Scholarship (Dr Chong); National Health & Medical
   Research Council Career Development award (Dr Guymer); Royal Victorian
   Eye and Ear Hospital Wagstaff fellowship (Dr Robman); and National
   Health and Medical Research Council Program Grant 209057, Capacity
   Building Grant 251533, and Enabling Grant 396414 from the National
   Health and Medical Research Council. The ophthalmic component was funded
   by the Ophthalmic Research Institute of Australia, John Reid Charitable
   Trust, and Perpetual Trustees.
CR *ACC EC PTY LTD, 2004, CLEAR INS EC IMP COS
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Baghurst KI., 2000, AUST J NUTR DIET, V57, pE36
   Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BROWN CC, 1994, AM J EPIDEMIOL, V139, P323, DOI 10.1093/oxfordjournals.aje.a117000
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2006, CLIN EXP OPHTHALMOL, V34, P464, DOI 10.1111/j.1442-9071.2006.01250.x
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giles G G, 2002, IARC Sci Publ, V156, P69
   GILES GG, 2004, ASIA PAC J CLIN NU S, V13, pS30
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hodge AM, 2007, NUTR METAB CARDIOVAS, V17, P415, DOI 10.1016/j.numecd.2006.04.005
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hunter D, 1998, NUTR EPIDEMIOLOGY, P174, DOI DOI 10.1093/ACPR0F:OSO/9780195122978.003.09
   HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302
   Ireland P, 1994, Asia Pac J Clin Nutr, V3, P19
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Klein Ronald, 2006, Trans Am Ophthalmol Soc, V104, P98
   KRISETHERTON PM, 2003, AM J MED S9B, V113, pS71
   Lewis J., 1995, NUTTAB95 NUTR DATA T
   Lopez-Garcia E, 2005, J NUTR, V135, P562, DOI 10.1093/jn/135.3.562
   MA J, 1995, AM J CLIN NUTR, V62, P564, DOI 10.1093/ajcn/62.3.564
   Perez-Jimenez F, 2007, MOL NUTR FOOD RES, V51, P1199, DOI [10.1002/mnfr.200600273, 10.1002/mnfr.200790023]
   *RMIT LIP RES GROU, 2001, FATT AC COMP DAT XYR
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Savitz DA, 1998, AM J EPIDEMIOL, V147, P813, DOI 10.1093/oxfordjournals.aje.a009532
   SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Willett W, 1998, NUTR EPIDEMIOLOGY, V40, P101, DOI DOI 10.1093/AJCN/69.5.1020
   Willett WC, 2006, ATHEROSCLEROSIS SUPP, V7, P5, DOI 10.1016/j.atherosclerosissup.2006.04.002
   [No title captured]
NR 50
TC 93
Z9 96
U1 0
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2009
VL 127
IS 5
BP 674
EP 680
DI 10.1001/archophthalmol.2009.60
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 442NK
UT WOS:000265847700013
PM 19433719
OA Bronze
DA 2022-11-30
ER

PT J
AU Figueroa, AG
   Boyd, BM
   Christensen, CA
   Javid, CG
   McKay, BS
   Fagan, TC
   Snyder, RW
AF Figueroa, Anna G.
   Boyd, Brennan M.
   Christensen, Cory A.
   Javid, Cameron G.
   McKay, Brian S.
   Fagan, Timothy C.
   Snyder, Robert W.
TI Levodopa Positively Affects Neovascular Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Age-related macular degeneration (AMD); Carbidopa-levodopa; GPR143;
   L-DOPA; nAMD; Neovascular AMD; Prospective study; Retinal pigment
   epithelium; Wet AMD
ID EPITHELIUM-DERIVED FACTOR; L-DOPA; RANIBIZUMAB; PREVALENCE; PROGRESSION;
   DISEASE
AB BACKGROUND: Age-related macular degeneration (AMD) is a common cause of blindness worldwide. Neovascular AMD (nAMD) is an advanced form of the disease, in which excess vascular endothelial growth factor (VEGF) induces growth of new blood vessels that leak fluid, accounting for 90% of vision loss in AMD. Dysfunction of the retinal pigment epithelium likely initiates AMD. Retinal pigment epithelial cells express a G protein-coupled receptor, GPR143, which downregulates VEGF in response to levodopa. Anti-VEGF therapy effectively treats nAMD, suggesting that excessive VEGF activity drives the pathology.
   METHODS: In an open-label pilot study, in patients with newly diagnosed nAMD and naive to anti-VEGF injections (Cohort-1), the effects of carbidopa-levodopa on vision and anatomic outcomes were evaluated for 4 weeks. Then patients were followed 5 months further with ascending levodopa doses. Patients previously treated with anti-VEGF injection therapy (Cohort-2) were also treated with ascending levodopa doses and evaluated for 6 months.
   RESULTS: Levodopa was safe, well tolerated, and delayed anti-VEGF injection therapy while improving visual outcomes. In the first month, retinal fluid decreased by 29% (P = .02, n = 12) without anti-VEGF treatment. Through 6 months the decrease in retinal fluid was sustained, with a mean frequency of 0.38 injections/month. At month 6, mean visual acuity improved by 4.7 letters in Cohort-1 (P = .004, n = 15) and by 4.8 letters in Cohort-2 (P = .02, n = 11). Additionally, there was a 52% reduction in the need for anti-VEGF injections in Cohort-2 (P = .002).
   CONCLUSIONS: Our findings suggest efficacy and support the pharmacological targeting of GPR143 with levodopa for the treatment of nAMD in future studies. (C) 2020 The Authors. Published by Elsevier Inc.
C1 [Figueroa, Anna G.; McKay, Brian S.] Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ 85704 USA.
   [Boyd, Brennan M.; Fagan, Timothy C.] Univ Arizona, Coll Med, 9510 Calle Buena Vista, Tucson, AZ 85704 USA.
   [Christensen, Cory A.] Univ Arizona, Coll Publ Hlth, Tucson, AZ 85704 USA.
   [Javid, Cameron G.] Retina Associates, Tucson, AZ USA.
   [Fagan, Timothy C.; Snyder, Robert W.] Snyder Biomed Corp, Tucson, AZ USA.
   [Snyder, Robert W.] Univ Arizona, Dept Biomed Engn, Tucson, AZ 85704 USA.
C3 University of Arizona; University of Arizona; University of Arizona;
   University of Arizona
RP Fagan, TC (通讯作者)，Univ Arizona, Coll Med, 9510 Calle Buena Vista, Tucson, AZ 85704 USA.
EM tcfagan@arizona.edu
OI Christensen, Cory/0000-0001-6872-4919; Figueroa, Anna
   G./0000-0002-5047-6942
FU Snyder Biomedical Corporation; NEI [RO1-EY026544]
FX Snyder Biomedical Corporation (RWS) financially supported the clinical
   trials. NEI RO1-EY026544 (BSM) supported other aspects of the study.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], 1974, Drug Ther Bull, V12, P83
   BARBEAU A, 1969, Canadian Medical Association Journal, V101, P59
   Bastide MF, 2015, PROG NEUROBIOL, V132, P96, DOI 10.1016/j.pneurobio.2015.07.002
   Boehm BO, 2003, DIABETOLOGIA, V46, P394, DOI 10.1007/s00125-003-1040-9
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Brunton L., 2011, GOODMAN GILMANS PHAR
   D'Mello SAN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071144
   Falk T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/278932
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gracies J-M, 2002, NEUROPSYCHOPHARMACOL, P1795
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lopez VM, 2008, PLOS BIOL, V6, P1861, DOI 10.1371/journal.pbio.0060236
   Maguire Maureen G, 2012, LDI Issue Brief, V17, P1
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 29
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD JAN
PY 2021
VL 134
IS 1
BP 122
EP +
DI 10.1016/j.amjmed.2020.05.038
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PI3BE
UT WOS:000600969100056
PM 32628915
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Lee, H
   Kim, S
   Kim, MA
   Chung, H
   Kim, HC
AF Lee, Hyungwoo
   Kim, Seungmin
   Kim, Myung Ae
   Chung, Hyewon
   Kim, Hyung Chan
TI POST-TREATMENT PREDICTION OF OPTICAL COHERENCE TOMOGRAPHY USING A
   CONDITIONAL GENERATIVE ADVERSARIAL NETWORK IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; deep learning; generative
   adversarial network; optical coherence tomography; prediction; prognosis
AB Purpose: To develop a deep learning model to generate posttreatment optical coherence tomography (OCT) images of neovascular age-related macular degeneration. Methods: Two hundred ninety-eight patients with neovascular age-related macular degeneration were included. The conditional generative adversarial network was trained using 15,183 augmented paired OCT B-scan images obtained from 723 scans of 241 patients at baseline and 1 month after 3 loading doses of an anti-vascular endothelial growth factor treatment. The network was also trained using baseline fluorescein angiography (FA) or indocyanine green angiography (ICGA) images together with baseline OCT images. A test set of 150 images of 50 eyes was used to evaluate its ability to predict the presence of intraretinal fluid, subretinal fluid, PED, and subretinal hyperreflective material. Posttreatment OCT images were compared with images generated from baseline OCT with or without FA and indocyanine green angiography images. Results: The predicted images inferred from baseline OCT images achieved an acceptable accuracy, specificity, and negative predictive value for four lesions (range: 77.0-91.9, 94.1-95.1, and 54.7-96.5%, respectively). The addition of both FA and indocyanine green angiography images improved the accuracy, specificity, and negative predictive value (range: 80.7-96.3, 97.3-99.0, and 59.0-98.3%, respectively). Conclusion: A conditional generative adversarial network is able to generate posttreatment OCT images from baseline OCT, FA, and indocyanine green angiography images.
C1 [Lee, Hyungwoo; Kim, Seungmin; Kim, Myung Ae; Chung, Hyewon; Kim, Hyung Chan] Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, 120-1 Neungdong Ro, Seoul 05030, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Med Ctr, Dept Ophthalmol, Sch Med, 120-1 Neungdong Ro, Seoul 05030, South Korea.
EM eyekim@kuh.ac.kr
RI 于, 于增臣/AAH-4657-2021
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2019R1F1A1051183]
FX Supported by the Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (No. NRF-2019R1F1A1051183).
CR Armanious K, 2020, COMPUT MED IMAG GRAP, V79, DOI 10.1016/j.compmedimag.2019.101684
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   Isola P, 2017, PROC CVPR IEEE, P5967, DOI 10.1109/CVPR.2017.632
   Kim T, 2019, NAT ASTRON, V3, P397, DOI 10.1038/s41550-019-0711-5
   Mirza M., 2014, CONDITIONAL GENERATI
   Nie D, 2018, IEEE T BIO-MED ENG, V65, P2720, DOI 10.1109/TBME.2018.2814538
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Yi X, 2018, J DIGIT IMAGING, V31, P655, DOI 10.1007/s10278-018-0056-0
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 12
TC 7
Z9 7
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2021
VL 41
IS 3
BP 572
EP 580
DI 10.1097/IAE.0000000000002898
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL1OK
UT WOS:000656688600024
PM 32568984
DA 2022-11-30
ER

PT J
AU Muftuoglu, IK
   Alam, M
   You, QS
   Gaber, R
   Ramkumar, HL
   Mendoza, N
   Meshi, A
   Freeman, WR
AF Muftuoglu, Ilkay Kilic
   Alam, Mostafa
   You, Qi Sheng
   Gaber, Raouf
   Ramkumar, Hema L.
   Mendoza, Nadia
   Meshi, Amit
   Freeman, William R.
TI LONG-TERM REMISSION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH
   AS-NEEDED ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; pro re nata; as needed; remission; long-term remission; optical
   coherence tomography
ID TREATMENTS TRIALS; VISUAL-ACUITY; RANIBIZUMAB; OUTCOMES;
   CHORIOCAPILLARIS; AFLIBERCEPT; CATT; VEGF; RPE
AB Purpose: To determine the presenting characteristics of patients with neovascular age-related macular degeneration with long-term remission (LTR), which was defined as the absence of intraretinal/subretinal fluid, or hemorrhage, and absence of leakage on fluorescein angiography for longer than 6 months while on as-needed antivascular endothelial growth factor treatment.
   Methods: The presenting characteristics of patients with LTR were compared with a control group including 32 eyes of 28 age-, gender-, and ethnicity-matched patients who did not achieve LTR.
   Results: Seventy-four percent of patients in the LTR group had Type 1 choroidal neovascular membrane and 18.5% had retinal angiomatous proliferation. In the control group, 28 eyes had Type 1 choroidal neovascular membrane (87.5%), and none of the patients had retinal angiomatous proliferation; overall, there was a significant difference in lesion types between the 2 groups (P = 0.036). Eyes with LTR at presentation had significantly thinner subfoveal choroidal thickness (147 vs. 178 mu m, P = 0.04). There was more intraretinal fluid and less subretinal fluid at the presentation in the remission group (59.3% intraretinal fluid and 11.1% subretinal fluid) compared with the control group (28.1% intraretinal fluid and 34.4% subretinal fluid, P = 0.03).
   Conclusion: The presence of retinal angiomatous proliferation, thinner choroidal thickness, more intraretinal fluid, and less subretinal fluid at presentation were associated with LTR in patients receiving as-needed treatment for age-related macular degeneration.
C1 [Muftuoglu, Ilkay Kilic; Alam, Mostafa; You, Qi Sheng; Gaber, Raouf; Ramkumar, Hema L.; Mendoza, Nadia; Meshi, Amit; Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Dept Ophthalmol, Jacobs Retina Ctr, San Diego, CA 92103 USA.
   [Alam, Mostafa] Tanta Univ, Dept Ophthalmol, Tanta, Egypt.
   [You, Qi Sheng] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
C3 University of California System; University of California San Diego;
   Egyptian Knowledge Bank (EKB); Tanta University; Capital Medical
   University
RP Freeman, WR (通讯作者)，9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM wrfreeman@ucsd.edu
RI Gaber, Raouf/GSN-8206-2022; You, Qisheng/AAG-7153-2020
OI You, Qisheng/0000-0003-0743-7320
FU UCSD Vision Research Center Core Grant [P30EY022589]; Research to
   Prevent Blindness, NY; ICO-Retina Research Foundation Helmerich
   Fellowship; Beijing Talents Fund [2015000021223ZK22]; National Natural
   Science Foundation of China [81400422]; NATIONAL EYE INSTITUTE
   [P30EY022589] Funding Source: NIH RePORTER
FX Supported in part by UCSD Vision Research Center Core Grant P30EY022589,
   an unrestricted grant from Research to Prevent Blindness, NY (W. R.
   Freeman), and ICO-Retina Research Foundation Helmerich Fellowship,
   Beijing Talents Fund (2015000021223ZK22), and National Natural Science
   Foundation of China (No. 81400422) (Q. S. You). The funding
   organizations had no role in the design or conduct of this research.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin Joo Young, 2013, Korean J Ophthalmol, V27, P425, DOI 10.3341/kjo.2013.27.6.425
   Stone TW, 2014, ASRS 2014 PREFERENCE
NR 23
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2018
VL 38
IS 3
BP 516
EP 522
DI 10.1097/IAE.0000000000001572
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2AB
UT WOS:000440619200013
PM 28221254
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Segal, O
   Ferencz, JR
   Mimouni, M
   Nesher, R
   Cohen, P
   Nemet, AY
AF Segal, Ori
   Ferencz, Joseph R.
   Mimouni, Michael
   Nesher, Ronit
   Cohen, Perri
   Nemet, Arie Y.
TI Lamellar Macular Holes Associated with End-Stage Exudative Age-Related
   Macular Degeneration
SO ISRAEL MEDICAL ASSOCIATION JOURNAL
LA English
DT Article
DE age-related macular degeneration (AMD); end-stage AMD; lamellar macular
   hole (LMH); optical coherence tomography (OCT)
ID OPTICAL COHERENCE TOMOGRAPHY; SURGICAL-TREATMENT; PSEUDOHOLES;
   VITRECTOMY; FEATURES
AB Background: Reports of lamellar macular holes (LMHs) with underlying age-related macular degeneration (AMD) are rare, and the specific definition, pathogenesis and surgical recommendations for this macular condition remain unclear. Objectives: To present a series of LMHs in eyes with underlying end-stage AMD, and describe optical coherence tomography (OCT) detection of associated morphologic abnormalities.
   Methods: We reviewed the files of consecutive patients diagnosed with LMH and underlying end-stage AMD between September 2007 and September 2011.
   Results: Sixteen eyes of 14 patients were included in this study. The average follow-up after the OCT-established diagnosis of LMH was 19.8 months (range 4-48). The average visual acuity (VA) at last follow-up visit was 20/400 (20/60-20/1200). The best-corrected VA was stable in 10 eyes (62.5%) and deteriorated in 6(37.5%). There was a statistically significant correlation between VA and minimal foveal thickness (r=-0.598, P=0.014).
   Conclusions: In this series of LMHs with underlying AMD the OCT findings were intraretinal fluid, cystic spaces and window defect.
C1 Meir Med Ctr, Dept Ophthalmol, IL-44281 Kefar Sava, Israel.
   [Segal, Ori; Ferencz, Joseph R.; Nesher, Ronit; Cohen, Perri; Nemet, Arie Y.] Tel Aviv Univ, Sackler Fac Med, Meir Med Ctr Kfar Saba, Dept Ophthalmol, IL-69978 Tel Aviv, Israel.
   [Mimouni, Michael] Rambam Hlth Care Campus, Dept Ophthalmol, Haifa, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Rambam Health Care Campus
RP Segal, O (通讯作者)，Meir Med Ctr, Dept Ophthalmol, IL-44281 Kefar Sava, Israel.
EM orisegal@gmail.com
RI Mimouni, Michael/S-2916-2018
OI Mimouni, Michael/0000-0002-4661-0993; Segal, Ori/0000-0001-5701-9544
CR Abu Asleh S, 2007, ISRAEL MED ASSOC J, V9, P656
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Casparis H, 2011, RETINA-J RET VIT DIS, V31, P1783, DOI 10.1097/IAE.0b013e31820a6818
   Chen JC, 2008, BRIT J OPHTHALMOL, V92, P1342, DOI 10.1136/bjo.2007.133041
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Garcia-Fernandez M, 2012, CAN J OPHTHALMOL, V47, P442, DOI 10.1016/j.jcjo.2012.06.007
   Garretson BR, 2008, OPHTHALMOLOGY, V115, P884, DOI 10.1016/j.ophtha.2007.06.029
   GASS JDM, 1976, ARCH OPHTHALMOL-CHIC, V94, P793, DOI 10.1001/archopht.1976.03910030391008
   GUYER DR, 1990, OPHTHALMOLOGY, V97, P1045
   Haouchine B, 2004, AM J OPHTHALMOL, V138, P732, DOI 10.1016/j.ajo.2004.06.088
   Haouchine B, 2001, OPHTHALMOLOGY, V108, P15, DOI 10.1016/S0161-6420(00)00519-4
   Michalewska Z, 2012, RETINA-J RET VIT DIS, V32, P922, DOI 10.1097/IAE.0b013e318227a9ef
   Michalewska Z, 2010, GRAEF ARCH CLIN EXP, V248, P1395, DOI 10.1007/s00417-010-1400-3
   Ophir A, 2009, EYE, V23, P1781, DOI 10.1038/eye.2008.369
   Takahashi H, 2000, AM J OPHTHALMOL, V130, P677, DOI 10.1016/S0002-9394(00)00626-7
   Theodossiadis P, 2010, EUR J OPHTHALMOL, V20, P1086, DOI 10.1177/112067211002000613
   Witkin AJ, 2006, OPHTHALMOLOGY, V113, P388, DOI 10.1016/j.ophtha.2005.10.047
NR 17
TC 6
Z9 6
U1 0
U2 1
PU ISRAEL MEDICAL ASSOC JOURNAL
PI RAMAT GAN
PA 2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136,
   ISRAEL
SN 1565-1088
J9 ISR MED ASSOC J
JI Isr. Med. Assoc. J.
PD DEC
PY 2015
VL 17
IS 12
BP 750
EP 754
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DB4GJ
UT WOS:000368471200005
PM 26897976
DA 2022-11-30
ER

PT J
AU Klein, R
   Chou, CF
   Klein, BEK
   Zhang, XZ
   Meuer, SM
   Saaddine, JB
AF Klein, Ronald
   Chou, Chiu-Fang
   Klein, Barbara E. K.
   Zhang, Xinzhi
   Meuer, Stacy M.
   Saaddine, Jinan B.
TI Prevalence of Age-Related Macular Degeneration in the US Population
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID NATIONAL-HEALTH; RACIAL-DIFFERENCES; MACULOPATHY; WISCONSIN; ADULTS
AB Objective: To examine the prevalence of age-related macular degeneration (AMD) in non-Hispanic white, non-Hispanic black, Mexican American, and other racial/ethnic groups.
   Design: A US nationally representative, population-based, cross-sectional study involving a total of 5553 persons aged 40 years and older from the 2005-2008 National Health and Nutrition Examination Survey. The main outcome measure was AMD determined by the grading of 45 degrees digital images from both eyes using a standardized protocol.
   Results: In the civilian, noninstitutionalized, US population aged 40 years and older, the estimated prevalence of any AMD was 6.5% (95% confidence interval, 5.5-7.6) and the estimated prevalence of late AMD was 0.8% (95% confidence interval, 0.5-1.3). Non-Hispanic black persons aged 60 years and older had a statistically significantly lower prevalence of any AMD than non-Hispanic white persons aged 60 years and older (odds ratio=0.37; 95% confidence interval, 0.21-0.67).
   Conclusions: Overall, the prevalence of any AMD in the 2005-2008 National Health and Nutrition Examination Survey was 6.5%, which is lower than the 9.4% prevalence reported in the 1988-1994 Third National Health and Nutrition Examination Survey. While this finding might be explained in part by possible methodological differences, these estimates are consistent with a decreasing incidence of AMD and suggest important public health care implications.
C1 [Klein, Ronald; Klein, Barbara E. K.; Meuer, Stacy M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
   [Chou, Chiu-Fang; Zhang, Xinzhi; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Div Diabet Translat, Vis Hlth Initiat, Atlanta, GA USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Centers
   for Disease Control & Prevention - USA
RP Klein, R (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,Room 417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
OI Klein, Ronald/0000-0002-4428-6237
FU National Health and Nutrition Examination Survey [200-2004-07459];
   Research to Prevent Blindness
FX This research was supported by National Health and Nutrition Examination
   Survey contract 200-2004-07459, which provided funding for the entire
   study including collection and analyses of data. Additional support was
   provided by Senior Scientific Investigator Awards from Research to
   Prevent Blindness (Drs R. Klein and B.E.K. Klein).
CR [Anonymous], [No title captured]
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   HOLT D, 1991, J R STAT SOC D-STAT, V40, P333
   Huang GH, 2003, AM J EPIDEMIOL, V157, P721, DOI 10.1093/aje/kwg011
   HURLEY SF, COST EFFECTIVENESS S
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2005, MACULAR DEGENERATION, P79
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   National Center for Health Statistics, NAT HLTH NUTR EX SUR
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   United States Department of Health and Human Services. National Center for Health Statistics, 2006, NAT HLTH NUTR EX SUR
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang CY, 2010, AM J EPIDEMIOL, V171, P426, DOI 10.1093/aje/kwp412
NR 32
TC 364
Z9 374
U1 0
U2 28
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2011
VL 129
IS 1
BP 75
EP 80
DI 10.1001/archophthalmol.2010.318
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 704MI
UT WOS:000286056700010
PM 21220632
OA Bronze
DA 2022-11-30
ER

PT J
AU Korb, C
   Zwiener, I
   Lorenz, K
   Mirshahi, A
   Pfeiffer, N
   Stoffelns, B
AF Korb, Christina
   Zwiener, Isabella
   Lorenz, Katrin
   Mirshahi, Alireza
   Pfeiffer, Norbert
   Stoffelns, Bernhard
TI Risk factors of a reduced response to ranibizumab treatment for
   neovascular age-related macular degeneration - evaluation in a clinical
   setting
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Ranibizumab; Lucentis; Age-related macular degeneration; Response to
   treatment
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   VERTEPORFIN THERAPY; VISUAL-ACUITY; LESIONS; TRIAL; NONRESPONDERS;
   DELAY; TAP
AB Background: To identify risk factors for being a "reduced responder" to ranibizumab treatment in a clinical setting in patients with neovascular age-related macular degeneration.
   Methods: This retrospective study included 165 eyes of 165 consecutive patients with choroidal neovascularisation secondary to neovascular, age-related macular degeneration. Eyes were treated with three intravitreal injections of ranibizumab, followed by PRN (pro re nata) dosing thereafter. All patients were reevaluated every four weeks and then followed for six months. Reduced responders were defined as patients with a loss in visual acuity of at least 1 visual acuity line at the last follow-up and/or persistent intraretinal or subretinal fluid or detectable choroidal neovascularisation at the last follow-up, compared to baseline.
   Results: Overall, 58 out of 165 eyes (35.2%) were considered to be reduced responders to treatment at the end of follow-up. The initial CNV size at baseline was correlated with the risk of being a reduced responder at the end of follow-up (p = 0.017).
   Conclusion: We identified the initial lesion size as a predictor for a reduced response to treatment in this study. Patients with a large initial lesion size should be thoroughly informed about the possible poorer response to the intravitreal treatment.
C1 [Korb, Christina; Lorenz, Katrin; Mirshahi, Alireza; Pfeiffer, Norbert; Stoffelns, Bernhard] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, D-55131 Mainz, Germany.
   [Zwiener, Isabella] Johannes Gutenberg Univ Mainz, IMBEI, D-55131 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz
RP Korb, C (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Langenbeckstr 1, D-55131 Mainz, Germany.
EM christina.korb@unimedizin-mainz.de
RI Pfeiffer, Norbert/AAO-7586-2020
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Reche-Frutos J, 2011, EUR J OPHTHALMOL, V21, P783, DOI 10.5301/EJO.2011.6526
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 18
TC 1
Z9 1
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 20
PY 2013
VL 13
AR 84
DI 10.1186/1471-2415-13-84
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 290LK
UT WOS:000329758600003
PM 24359591
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wolf, S
   Holz, FG
   Korobelnik, JF
   Lanzetta, P
   Mitchell, P
   Prunte, C
   Schmidt-Erfurth, U
   Weichselberger, A
   Hashad, Y
AF Wolf, Sebastian
   Holz, Frank G.
   Korobelnik, Jean-Francois
   Lanzetta, Paolo
   Mitchell, Paul
   Pruente, Christian
   Schmidt-Erfurth, Ursula
   Weichselberger, Andreas
   Hashad, Yehia
TI Outcomes following three-line vision loss during treatment of
   neovascular age-related macular degeneration: subgroup analyses from
   MARINA and ANCHOR
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; VERTEPORFIN
AB Aim This study aims to assess the impact of continued ranibizumab treatment for neovascular age-related macular degeneration on patients from the MARINA and ANCHOR randomised clinical studies who lost >= 3 lines of best-corrected visual acuity (BCVA) at any time during the first year of treatment.
   Methods Baseline characteristics, mean BCVA over time and ocular adverse events (AEs) were evaluated both for patients whose BCVA loss occurred at any post-baseline visit and for patients whose BCVA loss was acute. The visit when the >= 3-line BCVA loss was detected was defined as the new baseline.
   Results Continued monthly ranibizumab treatment led to an improvement in mean BCVA from the new baseline. On average, patients with acute BCVA loss gained 11.9 letters at 3 months after the new baseline, compared with 0.3 letters gained with sham. No strong signals were detected in patient demographics and baseline characteristics for prognostic markers of BCVA loss. Furthermore, there was no pattern in the AE profile of patients with acute BCVA loss to suggest that BCVA recovery could be attributed to spontaneously resolving AEs.
   Conclusion Continued ranibizumab treatment appears to be beneficial for patients with neovascular age-related macular degeneration who experience a >= 3-line BCVA loss during the first year of treatment.
C1 [Wolf, Sebastian] Univ Bern, Inselspital, Univ Klin Augenheilkunde, Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, Dept Ophthalmol, CHU Bordeaux, F-33076 Bordeaux, France.
   [Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Mitchell, Paul] Univ Sydney, Discipline Ophthalmol, Sydney, NSW 2006, Australia.
   [Pruente, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Weichselberger, Andreas; Hashad, Yehia] Novartis Pharma AG, Basel, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bonn; CHU
   Bordeaux; UDICE-French Research Universities; Universite de Bordeaux;
   University of Udine; University of Sydney; Medical University of Vienna;
   Novartis
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Univ Klin Augenheilkunde, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Mitchell, Paul/P-1498-2014; KOROBELNIK, Jean-Francois/A-5448-2016; Wolf,
   Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Novartis Pharma AG; Novartis Pharma AG (Basel, Switzerland); Heidelberg
   Engineering; Iridex Co.; Pfizer; Allergan; Abbott; Bayer; Alcon
FX The clinical studies were designed and performed by Genentech
   (California, USA). The authors would like to acknowledge Laura
   Saunderson of Chameleon Communications International, who provided
   medical writing services with funding from Novartis Pharma AG. The
   services encompassed preparing the first draft, editing, checking
   content and language, formatting, referencing, preparing tables and
   figures, and incorporating the authors' revisions, all under the
   direction of the authors. At all stages, the authors have had control
   over the content of this manuscript, for which they have given final
   approval and take full responsibility. Novartis Pharma AG enforces a
   'no-ghost-writing' policy.; Medical writing services were provided with
   funding from Novartis Pharma AG (Basel, Switzerland).; SW is a
   consultant and/or lecturer for Allergan, Bayer, Molecular Partners and
   Novartis Pharma AG. The University of Bern performs contract research as
   a clinical trial centre and as a central reading centre. FH received
   honoraria from Alcon, Bayer, GlaxoSmithKline, Heidelberg Engineering,
   Novartis Pharma AG, Ophthotec and Pfizer, and grants from Heidelberg
   Engineering. J-FK is a consultant for Alcon, Allergan, Bayer and
   Novartis Pharma AG. PL is a consultant and/or lecturer for Allergan,
   NeoVista, Novartis Pharma AG, Optimedica and QLT, and has received
   patents and royalties from Iridex Co. PM received consultancy and
   lecture fees from Novartis Pharma AG, Pfizer, Allergan, Solvay (now
   Abbott) and Bayer. He has also received travel reimbursements from these
   companies. CP received consultancy fees and honoraria from Alcon, Bayer
   and Novartis Pharma AG, and grants from Novartis Pharma AG. US-E is a
   consultant for Alcon, Bayer, Novartis Pharma AG and Pfizer. The
   University of Vienna performs contract research as a clinical trial
   centre and as a central reading centre. AW is an employee of Novartis
   Pharma AG. YH is a former employee of Novartis Pharma AG and is
   currently an employee of Allergan.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
NR 6
TC 11
Z9 12
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2011
VL 95
IS 12
BP 1713
EP 1718
DI 10.1136/bjophthalmol-2011-300471
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 851IM
UT WOS:000297261700020
PM 21951567
DA 2022-11-30
ER

PT J
AU Chaudhary, V
   Matonti, F
   Zarranz-Ventura, J
   Stewart, MW
AF Chaudhary, Varun
   Matonti, Frederic
   Zarranz-Ventura, Javier
   Stewart, Michael W.
TI IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH
   NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Systematic Literature
   Review
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE antivascular endothelial growth factor treatment; neovascular
   age-related macular degeneration; retinal fluid compartments; subretinal
   fluid; intraretinal fluid; systematic literature review
ID BASE-LINE PREDICTORS; ANTI-VEGF THERAPY; VISUAL-ACUITY; SUBRETINAL
   FLUID; IMAGING BIOMARKERS; RANIBIZUMAB; MORPHOLOGY; BEVACIZUMAB;
   RELEVANT
AB Purpose: Understanding the impact of fluid in different retinal compartments is critical to developing treatment paradigms that optimize visual acuity and reduce treatment burden in neovascular age-related macular degeneration. This systematic review aimed to determine the impact of persistent/new subretinal fluid, intraretinal fluid, and subretinal pigment epithelial fluid on visual acuity over 1 year of treatment. Methods: Publication eligibility and data extraction were conducted according to Cochrane methods: 27 of the 1,797 screened records were eligible. Results: Intraretinal fluid negatively affected visual acuity at baseline and throughout treatment, with foveal intraretinal fluid associated with lower visual acuity than extrafoveal intraretinal fluid. Some studies found that subretinal fluid (particularly subfoveal) was associated with higher visual acuity at Year 1 and longer term, and others suggested subretinal fluid did not affect visual acuity at Years 1 and 2. Data on the effects of subretinal pigment epithelial fluid were scarce, and consensus was not reached. Few studies reported numbers of injections associated with fluid status. Conclusion: To optimally manage neovascular age-related macular degeneration, clinicians should understand the impact of fluid compartments on visual acuity. After initial treatment, antivascular endothelial growth factor regimens that tolerate stable subretinal fluid (if visual acuity is stable/improved) but not intraretinal fluid may enable patients to achieve their best possible visual acuity. Confirmatory studies are required to validate these findings.
C1 [Chaudhary, Varun] McMaster Univ, Dept Hlth Res Methods, Dept Surg, St Josephs Healthcare Hamilton,Div Ophthalmol,Ham, Hamilton, ON, Canada.
   [Matonti, Frederic] Ctr Monticelli Paradis, 433 Bis Rue Paradis, Marseille, France.
   [Matonti, Frederic] Aix Marseille Univ, INT, CNRS, Marseille, France.
   [Matonti, Frederic] Grp Almaviva Sante, Clin Juge, Marseille, France.
   [Zarranz-Ventura, Javier] Hosp Clin Barcelona, Inst Clin Oftalmol, Barcelona, Spain.
   [Zarranz-Ventura, Javier] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain.
   [Stewart, Michael W.] Mayo Clin, Dept Ophthalmol, Jacksonville, FL 32224 USA.
C3 McMaster University; Centre National de la Recherche Scientifique
   (CNRS); UDICE-French Research Universities; Aix-Marseille Universite;
   University of Barcelona; Hospital Clinic de Barcelona; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Mayo Clinic
RP Chaudhary, V (通讯作者)，McMaster Univ, Dept Hlth Res Methods, Dept Surg, St Josephs Healthcare Hamilton,Div Ophthalmol,Ham, Hamilton, ON, Canada.; Chaudhary, V (通讯作者)，McMaster Univ, 1280 Main St West, Hamilton, ON L8S 4L8, Canada.
EM vchaudh@mcmaster.ca
RI Chaudhary, Varun/AAQ-2371-2021; Zarranz-Ventura, Javier/AAB-5390-2021
OI Chaudhary, Varun/0000-0002-9988-4146; Zarranz-Ventura,
   Javier/0000-0003-2338-8143
CR Bringmann A, 2012, OPHTHALMOLOGICA, V227, P1, DOI 10.1159/000328979
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2020, EYE, V34, P2249, DOI 10.1038/s41433-020-0799-y
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Curry B, 2017, ASIA-PAC J OPHTHALMO, V6, P481, DOI 10.22608/APO.2017364
   de Massougnes S, 2018, RETINA-J RET VIT DIS, V38, P717, DOI 10.1097/IAE.0000000000001613
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Ebneter A, 2015, OPHTHALMOLOGICA, V234, P61, DOI 10.1159/000430103
   Ersoy L, 2014, GRAEF ARCH CLIN EXP, V252, P889, DOI 10.1007/s00417-013-2519-9
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Inan Sibel, 2019, Rom J Ophthalmol, V63, P238
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Kim JH, 2017, RETINA-J RET VIT DIS, V37, P2254, DOI 10.1097/IAE.0000000000001494
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Lin TZ, 2020, BRIT J OPHTHALMOL, V104, P58, DOI 10.1136/bjophthalmol-2018-313447
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ogasawara M, 2018, JPN J OPHTHALMOL, V62, P584, DOI 10.1007/s10384-018-0605-6
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Riedl S, 2020, RETINA-J RET VIT DIS, V40, P2148, DOI 10.1097/IAE.0000000000002717
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin Joo Young, 2013, Korean J Ophthalmol, V27, P425, DOI 10.3341/kjo.2013.27.6.425
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Tarsilla M., 2010, COCHRANE HDB SYSTEMA, V6, P142, DOI [DOI 10.1002/9781119536604, 10.1002/9781119536604.ch23]
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 42
TC 6
Z9 6
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2022
VL 42
IS 4
BP 589
EP 606
DI 10.1097/IAE.0000000000003283
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0A8RN
UT WOS:000774215200003
PM 34393212
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Storey, PP
   Aziz, HA
   O'Keefe, GAD
   Borchert, M
   Lam, LA
   Puliafito, CA
   de Koo, LCO
AF Storey, Philip P.
   Aziz, Hassan A.
   O'Keefe, Ghazala A. Datoo
   Borchert, Mark
   Lam, Linda A.
   Puliafito, Carmen A.
   de Koo, Lisa C. Olmos
TI Decreased severity of age-related macular degeneration in amblyopic eyes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE macula; child health (paediatrics); degeneration; retina; visual
   (cerebral) cortex
ID NERVE-FIBER LAYER; LATERAL GENICULATE-NUCLEUS; THICKNESS; PATTERN;
   ELECTRORETINOGRAMS; POTENTIALS; VOLUME
AB Aim To evaluate whether people with age-related macular degeneration (AMD) and a history of amblyopia have equal severity of AMD in both eyes.
   Methods Billing records were used to locate all people with a history of amblyopia and AMD evaluated between 1 January 2003 and 1 June 2015 at a single ophthalmology institute. Two ophthalmic graders blinded to amblyopia status determined the severity of AMD in each eye using fundus photos and a validated grading scale.
   Results A total of 14 people were found to have AMD and a documented history of amblyopia. Average patient age was 77.0 years and average best corrected visual acuity was 20/160 in eyes with a history of amblyopia and 20/40 in fellow eyes without amblyopia. Eyes with a history of amblyopia were found to have a lower AMD severity score (mean lower score: -1.38; paired t-test P=0.019). Of the 11 people with asymmetric disease severity, 10 individuals had worse AMD in the non-amblyopic eye while one person had worse AMD in the amblyopic eye (P=0.0067).
   Conclusions Our pilot study suggests that eyes with a history of amblyopia may manifest decreased severity of AMD compared with non-ambylopic eyes in the same patient. Further research is warranted to investigate this clinical observation.
C1 [Storey, Philip P.] Wills Eye Hosp & Res Inst, Retina Serv, Philadelphia, PA USA.
   [Storey, Philip P.; Aziz, Hassan A.; Borchert, Mark; Lam, Linda A.; Puliafito, Carmen A.] Univ Southern Calif, USC Roski Eye Inst, Los Angeles, CA USA.
   [O'Keefe, Ghazala A. Datoo] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA.
   [Borchert, Mark] Childrens Hosp Los Angeles, Dept Ophthalmol, Los Angeles, CA 90027 USA.
   [de Koo, Lisa C. Olmos] Univ Washington, Inst Eye, Seattle, WA 98195 USA.
C3 Jefferson University; University of Southern California; Emory
   University; Children's Hospital Los Angeles; University of Washington;
   University of Washington Seattle
RP de Koo, LCO (通讯作者)，Univ Washington, Inst Eye, Seattle, WA 98195 USA.
EM lolmos@uw.udu
RI Aziz, Hassan/GNW-5884-2022
OI Aziz, Hassan/0000-0003-0406-1946; Borchert, Mark/0000-0003-4704-9795;
   Olmos de Koo, Lisa/0000-0002-8146-4653
CR Adams DL, 2013, J NEUROSCI, V33, P3752, DOI 10.1523/JNEUROSCI.3228-12.2013
   Al-Haddad CE, 2011, BRIT J OPHTHALMOL, V95, P1696, DOI 10.1136/bjo.2010.195081
   Altintas O, 2005, J PEDIAT OPHTH STRAB, V42, P216
   Andalib D, 2013, J PEDIAT OPHTH STRAB, V50, P218, DOI 10.3928/01913913-20130319-02
   ARDEN GB, 1980, T OPHTHAL SOC UK, V100, P453
   ARDEN GB, 1985, INVEST OPHTH VIS SCI, V26, P88
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Dickmann A, 2012, J AAPOS, V16, P86, DOI 10.1016/j.jaapos.2011.09.011
   El Mallah MK, 2000, BRIT J OPHTHALMOL, V84, P952, DOI 10.1136/bjo.84.9.952
   Firat PG, 2013, INT J OPHTHALMOL-CHI, V6, P90, DOI 10.3980/j.issn.2222-3959.2013.01.19
   GOTTLOB I, 1987, INVEST OPHTH VIS SCI, V28, P187
   HESS RF, 1984, VISION RES, V24, P1367, DOI 10.1016/0042-6989(84)90192-5
   Hess RF, 2009, EUR J NEUROSCI, V29, P1064, DOI 10.1111/j.1460-9568.2009.06650.x
   Huynh SC, 2009, OPHTHALMOLOGY, V116, P1604, DOI 10.1016/j.ophtha.2009.03.013
   Kee Se-Young, 2006, Korean J Ophthalmol, V20, P177
   Miki A, 2003, OPHTHALMOLOGICA, V217, P365, DOI 10.1159/000071353
   Pang Y, 2011, INVEST OPHTH VIS SCI, V52, P2444, DOI 10.1167/iovs.10-5550
   Repka MX, 2009, AM J OPHTHALMOL, V148, P143, DOI 10.1016/j.ajo.2009.01.015
   SOKOL S, 1979, INVEST OPHTH VIS SCI, V18, P848
   Walker RA, 2011, CAN J OPHTHALMOL, V46, P425, DOI 10.1016/j.jcjo.2011.07.013
   WANGER P, 1984, ACTA OPHTHALMOL, V62, P643
   WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978
   WILLIAMS C, 1995, BRIT J OPHTHALMOL, V79, P218, DOI 10.1136/bjo.79.3.218
   Yen MY, 2004, INVEST OPHTH VIS SCI, V45, P2224, DOI 10.1167/iovs.03-0297
   Yoon Sang Won, 2005, Korean J Ophthalmol, V19, P62
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 26
TC 2
Z9 2
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2018
VL 102
IS 11
BP 1575
EP 1578
DI 10.1136/bjophthalmol-2017-311671
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD3UI
UT WOS:000452446800019
PM 29437581
DA 2022-11-30
ER

PT J
AU Cumurcu, T
   Mendil, D
   Etikan, I
AF Cumurcu, T
   Mendil, D
   Etikan, I
TI Serum zinc and copper level in age-related macular degeneration
SO TRACE ELEMENTS AND ELECTROLYTES
LA English
DT Article
DE zinc; copper; age-related macular degeneration (AMD); atomic absorption
   spectrometry
ID ORAL ZINC; ANTIOXIDANT; MACULOPATHY; EYE
AB Objective: To evaluate the association between serum zinc and copper level in age-related macular degeneration (AMD). The purpose of this study was to measure zinc and copper levels in the serum with AMD and similar age control group. Material and methods: There were 30 late-form AMD patients and 30 normal subjects studied, who were similar for age and gender. Serum zinc and copper were analyzed using graphite furnace atomic absorption spectrometry after microwave digestion. Results: The zinc and copper concentration in samples with AMD group were found to be 12.95 +/- 2.55 mu mol/l and 12.25 +/- 4.93 mu mol/l, respectively, and 14.66 +/- 4.11 mu mol/l and 13.94 +/- 4.10 mu mol/l, respectively, with control group. The result demonstrated that the concentration of Zn in the serum of control group was found to be significantly higher than AMD group (p < 0.001), however, the concentration of Cu in serum of control group and AMD group were not detected to be of statistically significant difference (p = 0.155). In addition to copper/zinc ratios were no statistically significant differences between control and AMD group (p = 0.54). Conclusion: A deficit of zinc serum level seems to be associated with AMD, particularly in advanced form. It is also suggested that in AMD patients macular susceptibility to oxidative damage is related with age.
C1 Gaziosmanpasa Univ, Sch Med, Dept Ophthalmol, Tokat, Turkey.
   Gaziosmanpasa Univ, Fac Arts & Sci, Dept Chem, Tokat, Turkey.
   Gaziosmanpasa Univ, Sch Med, Dept Biostat, Tokat, Turkey.
C3 Gaziosmanpasa University; Gaziosmanpasa University; Gaziosmanpasa
   University
RP Cumurcu, T (通讯作者)，Gaziosmanpasa Univ, Sch Med, Dept Ophthalmol, Tokat, Turkey.
EM tcumurcu@gop.edu.tr
CR *AERDS REAARCH GRO, 2002, J NUTR, V132, P697
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Bartlett H, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-16
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLACK MR, 1988, AM J CLIN NUTR, V47, P970, DOI 10.1093/ajcn/47.6.970
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   FISCHER PWF, 1984, AM J CLIN NUTR, V40, P743, DOI 10.1093/ajcn/40.4.743
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Gottschall-Pass KT, 1998, J NUTR BIOCHEM, V9, P621, DOI 10.1016/S0955-2863(98)00063-1
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   HAYMAN L, 2002, CURR OPIN OPHTHALMOL, V13, P171
   Ishihara Nanae, 1997, Nippon Ganka Gakkai Zasshi, V101, P248
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   KARCIOGLU ZA, 1984, CURR EYE RES, V3, P1043, DOI 10.3109/02713688409011750
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klevay LM, 2000, J NUTR, V130, p489S, DOI 10.1093/jn/130.2.489S
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Mezzetti A, 1998, FREE RADICAL BIO MED, V25, P676, DOI 10.1016/S0891-5849(98)00109-9
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Paterson P G, 1999, Nutr Neurosci, V2, P175, DOI 10.1080/1028415X.1999.11747276
   PATTERSON WP, 1985, ANN INTERN MED, V103, P385, DOI 10.7326/0003-4819-103-3-385
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   SIGEL H, 1983, ZINC ITS ROLE BIOL N
   SILVERSTONE BZ, 1985, ANN OPHTHALMOL, V17, P419
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   SIMONELLI F, 1989, EXP EYE RES, V49, P181, DOI 10.1016/0014-4835(89)90088-2
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   SOLOMONS NW, 1980, AM J CLIN NUTR, V33, P2031, DOI 10.1093/ajcn/33.9.2031
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINTON NE, 1990, AM J CLIN NUTR, V52, P895, DOI 10.1093/ajcn/52.5.895
   Wu L, 1996, Yan Ke Xue Bao, V12, P58
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 40
TC 3
Z9 3
U1 0
U2 1
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-2104
J9 TRACE ELEM ELECTROLY
JI Trace Elem. Electrolytes
PY 2006
VL 23
IS 2
BP 103
EP 107
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 033TQ
UT WOS:000236872800005
DA 2022-11-30
ER

PT J
AU Querques, G
   Souied, EH
AF Querques, Giuseppe
   Souied, Eric H.
TI The role of omega-3 and micronutrients in age-related macular
   degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; omega-3; docosahexaenoic acid;
   polyunsaturated fatty acid; supplementation; nutrition
ID POLYUNSATURATED FATTY-ACIDS; C-REACTIVE PROTEIN; DIETARY-FAT; FISH
   INTAKE; DOCOSAHEXAENOIC ACID; ADJUNCTIVE THERAPY; GENETIC RISK; EYE
   DISEASE; US TWIN; MACULOPATHY
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the United States, Europe, and other developed countries. Although the pathogenesis of AMD remains unclear, current evidence suggests a multifactorial aetiology. Nutrition may play an important role in the development and progression of AMD. There have been several epidemiological studies suggesting that omega-3 fatty acids could have a protective role in AMD, but a beneficial effect remains to be demonstrated in randomized controlled trials. There also exists a substantial body of evidence suggesting that protection against AMD may be provided by specific micronutrients (vitamins and minerals and antioxidants). The identification of risk factors for the development and progression of AMD is of particular importance for understanding the origins of the disorder and for establishing strategies for its prevention. We examine the relationship between dietary omega-3 intake and the incidence and progression of AMD, as well as the role of omega-3 supplementation in the prevention of the disorder, and also explore the role of other micronutrients in AMD. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Querques, Giuseppe; Souied, Eric H.] Creteil Univ, Eye Clin, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Hop Intercommunal Creteil, Serv Ophtalmol, Praticien Hosp Mi Temps,Prof Associe Univ, 40 Verdun, F-94010 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
FU Bausch Lomb SpA
FX Medical writing assistance was provided by Andrea Bothwell and Mary
   Hines of inScience Communications, Springer Healthcare. This assistance
   was funded by Bausch & Lomb SpA.
CR Age-Related Eye Disease Study 2 Research Group, JAMA
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Ciulla Thomas A, 2004, Curr Opin Ophthalmol, V15, P211, DOI 10.1097/01.icu.0000120711.35941.76
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   James MJ, 2003, PROSTAG LEUKOTR ESS, V68, P399, DOI 10.1016/S0952-3278(03)00064-4
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MacDonald A, 2006, GASTROENTEROL NURS, V29, P295, DOI 10.1097/00001610-200607000-00005
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   Philip LP, 2004, JAMA-J AM MED ASSOC, V292, P43, DOI 10.1001/jama.292.1.43-a
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, ARCH OPHTHALMOL-CHIC, V122, P426
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 1995, JAMA IN PRESS, V273, P6221
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shaikh SR, 2012, MOL ASPECTS MED, V33, P46, DOI 10.1016/j.mam.2011.10.002
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Turner D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006320.pub2
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
NR 63
TC 17
Z9 18
U1 0
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2014
VL 59
IS 5
BP 532
EP 539
DI 10.1016/j.survophthal.2014.01.001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN6WO
UT WOS:000340739300005
PM 24657038
DA 2022-11-30
ER

PT J
AU Lechanteur, YTE
   van de Camp, PL
   Smailhodzic, D
   van de Ven, JPH
   Buitendijk, GHS
   Klaver, CCW
   Groenewoud, JM
   den Hollander, AI
   Hoyng, CB
   Klevering, BJ
AF Lechanteur, Yara T. E.
   van de Camp, Patrick L.
   Smailhodzic, Dzenita
   van de Ven, Johannes P. H.
   Buitendijk, Gabrielle H. S.
   Klaver, Caroline C. W.
   Groenewoud, JoannesM. M.
   den Hollander, Anneke I.
   Hoyng, Carel B.
   Klevering, B. Jeroen
TI Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age
   at Onset of Neovascular Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BLUE-MOUNTAINS-EYE; BODY-MASS INDEX; BEAVER DAM
   EYE; CHOROIDAL NEOVASCULARIZATION; ENVIRONMENTAL ASSOCIATIONS;
   CIGARETTE-SMOKING; 5-YEAR INCIDENCE; ADVANCED AMD; DIETARY-FAT
AB IMPORTANCE The age at which the first signs of age-related macular degeneration (AMD) manifest is variable. Better insight into factors that influence disease onset has direct implications for preventive measures and patient counseling.
   OBJECTIVE To identify risk factors for an earlier age at onset of neovascular AMD.
   DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study, including patient data from the European Genetic Database collected between April 2006 and July 2010. All patients had at least 1 documented visit to the outpatient AMD clinic of the Radboud University Medical Center, Nijmegen, the Netherlands, a tertiary referral center for retinal disorders. In total, 275 patients with a known age at onset of neovascular AMD and a genetic risk analysis were included.
   MAIN OUTCOMES AND MEASURES Effects of several genetic, sociodemographic, behavioral, and ocular factors on the age at onset of neovascular AMD. The mean differences in the age at onset were determined using general linear models with the age at onset as the dependent variable.
   RESULTS Past smokers and current smokers developed neovascular AMD on average 4.9 (95% CI, 3.0-6.8) and 7.7 (95% CI, 5.3-10.0) years earlier, respectively, than never smokers (P < .001 for both). Compared with the reference group, the age at onset was 5.2 (95% CI, 2.8-7.7) years earlier for homozygous carriers of the A69S risk allele in the age-related maculopathy susceptibility 2 (ARMS2) gene (P < .001). Homozygous carriers of the Y402H risk variant in the complement factor H (CFH) gene developed neovascular AMD 2.8 (95% CI, 0.5-5.0) years earlier (P = .02). Patients carrying 4 risk alleles in CFH and ARMS2 developed neovascular AMD 12.2 (95% CI, 6.2-18.3) years earlier than patients with zero risk alleles (P < .001).
   CONCLUSIONS AND RELEVANCE Genetic and environmental risk factors influence the age at onset of neovascular AMD. Individuals at risk could be identified at an early age if and when preventive or therapeutic options become available. Insight into individual risk profiles might influence patients' consideration of interventions to increase their chance of avoiding vision loss from AMD.
C1 [Lechanteur, Yara T. E.; Smailhodzic, Dzenita; van de Ven, Johannes P. H.; den Hollander, Anneke I.; Hoyng, Carel B.; Klevering, B. Jeroen] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
   [van de Camp, Patrick L.] Univ Eye Clin Maastricht, Maastricht, Netherlands.
   [Buitendijk, Gabrielle H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Buitendijk, Gabrielle H. S.; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Groenewoud, JoannesM. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, NL-6500 HB Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Maastricht University; Maastricht
   University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus
   MC; Erasmus University Rotterdam; Erasmus MC; Radboud University
   Nijmegen; Radboud University Nijmegen
RP Klevering, BJ (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM jeroen.klevering@radboudumc.nl
RI Lehtimäki, Terho/AAD-1094-2022; Klevering, B.J./L-4434-2015; Hollander,
   Anneke den/N-4911-2014; Klaver, Caroline C.W./A-2013-2016; Lechanteur,
   Yara/ABB-6875-2020; Hoyng, C.B./H-8050-2014; Groenewoud, Hans
   JMM/R-3588-2017
OI Lehtimäki, Terho/0000-0002-2555-4427; Lechanteur,
   Yara/0000-0003-0951-4625; Groenewoud, Hans JMM/0000-0002-4974-150X;
   Klaver, Caroline/0000-0002-2355-5258
FU MD Fonds; Oogfonds; Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid
FX This study was supported by MD Fonds, Oogfonds, and Algemene Nederlandse
   Vereniging ter Voorkoming van Blindheid.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bernhard D, 2007, EXP GERONTOL, V42, P160, DOI 10.1016/j.exger.2006.09.016
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chowers I, 2008, MOL VIS, V14, P1829
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chu YK, 2013, INVEST OPHTH VIS SCI, V54, P7329, DOI 10.1167/iovs.13-12149
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hofman A, 2013, EUR J EPIDEMIOL, V28, P889, DOI 10.1007/s10654-013-9866-z
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keilhauer CN, 2013, EUR J MED GENET, V56, P72, DOI 10.1016/j.ejmg.2012.10.005
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nicita-Mauro V, 2008, EXP GERONTOL, V43, P95, DOI 10.1016/j.exger.2007.06.011
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Othman H, 2012, MOL BIOL REP, V39, P3299, DOI 10.1007/s11033-011-1098-2
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schalnus R, 2010, OPHTHALMOLOGICA, V224, P176, DOI 10.1159/000239236
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HP, 2008, PLOS ONE, V3, DOI [10.1371/annotation/32b9bc31-ed6d-4d31-9ce0-480407017bad, DOI 10.1371/ANNOTATION/32B9BC31-ED6D-4D31-9CE0-480407017BAD]
   Scholl HP, 2008, PLOS ONE, V3, DOI [10.1371/annotation/511a1029-bc43-4510-a4ca-c1db31810acc, DOI 10.1371/ANNOTATION/511A1029-BC43-4510-A4CA-C1DB31810ACC]
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 74
TC 22
Z9 26
U1 0
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2015
VL 133
IS 5
BP 533
EP 541
DI 10.1001/jamaophthalmol.2015.18
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK2NF
UT WOS:000356046700006
PM 25695752
OA Bronze
DA 2022-11-30
ER

PT J
AU Gangwani, R
   Lai, WW
   Sum, R
   McGhee, SM
   Chan, CWS
   Hedley, AJ
   Wong, D
AF Gangwani, Rita
   Lai, Wico W.
   Sum, Rita
   McGhee, Sarah M.
   Chan, Catherine W. S.
   Hedley, Anthony J.
   Wong, David
TI The incidental findings of age-related macular degeneration during
   diabetic retinopathy screening
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Diabetic retinopathy; Screening
ID RISK-FACTORS; PREVALENCE; MACULOPATHY; PHOTOGRAPHY; DRUSEN
AB The purpose of this study was to determine the reliability of detecting age-related macular degeneration (AMD) during screening for diabetic retinopathy (DR).
   This prospective study included 2,003 subjects with diabetes mellitus who underwent photographic screening for DR. The reliability of detecting AMD lesions was tested by interobserver and intraobserver agreement, and the sensitivity and specificity of diagnosing AMD at different grades of severity were tested using the consensus grading of a group as the reference standard.
   DR affected 24.7 % of the subjects. The age-standardized prevalence of early AMD was 17.9 %, and late AMD was 0.1 %. The interobserver and intraobserver agreement for grading AMD was substantial (k = 0.72 and 0.71 respectively, p < 0.001). It was equally good in those with different severities of DR. There was also no difference in sensitivity and specificity of detecting AMD in those with different levels of DR (sensitivity 62-68 % and specificity 97-98 %).
   Intermediate- and high-risk AMD that warrant treatment with zinc and anti-oxidant supplements could be reliably detected during screening for diabetic retinopathy.
C1 [Gangwani, Rita; Lai, Wico W.; Chan, Catherine W. S.; Wong, David] Univ Hong Kong, Dept Ophthalmol, Cyberport, Hong Kong, Peoples R China.
   [McGhee, Sarah M.; Hedley, Anthony J.] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China.
   [Sum, Rita] Hong Kong Polytech Univ, Sch Optometry, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; Hong Kong Polytechnic
   University
RP Gangwani, R (通讯作者)，Univ Hong Kong, Dept Ophthalmol, Room 301,Block B,Cyberport 4,100 Cyberport Rd, Cyberport, Hong Kong, Peoples R China.
EM gangwani@hku.hk
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   ALDINGTON SJ, 1995, DIABETOLOGIA, V38, P437, DOI 10.1007/BF00410281
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Karnon J, 2008, Health Technol Assess, V12, piii
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kinshuck D, 2008, EXAMINING GRADING RE
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2003, ELLENBERG RIFKINS DI, P664
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ong HS, 2013, J GLAUCOMA, V22, P496, DOI 10.1097/IJG.0b013e3182447d58
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Scanlon PH, 2003, BRIT J OPHTHALMOL, V87, P1258, DOI 10.1136/bjo.87.10.1258
   Scanlon PH, 2003, DIABETIC MED, V20, P467, DOI 10.1046/j.1464-5491.2003.00954.x
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   WHO Vision, 2020, RIGHT SIGHT GLOB IN
   Williams MA, 2009, AGE AGEING, V38, P648, DOI 10.1093/ageing/afp136
   Wu L Z, 1987, Yan Ke Xue Bao, V3, P179
   Wu L Z, 1987, Yan Ke Xue Bao, V3, P175
   Wu Z Q, 1992, Zhonghua Yan Ke Za Zhi, V28, P246
NR 32
TC 9
Z9 10
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2014
VL 252
IS 5
BP 723
EP 729
DI 10.1007/s00417-013-2530-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG8HS
UT WOS:000335660000003
PM 24281784
DA 2022-11-30
ER

PT J
AU Dridi, S
   Hirano, Y
   Tarallo, V
   Kim, Y
   Fowler, BJ
   Ambati, BK
   Bogdanovich, S
   Chiodo, VA
   Hauswirth, WW
   Kugel, JF
   Goodrich, JA
   Ponicsan, SL
   Hinton, DR
   Kleinman, ME
   Baffi, JZ
   Gelfand, BD
   Ambati, J
AF Dridi, Sami
   Hirano, Yoshio
   Tarallo, Valeria
   Kim, Younghee
   Fowler, Benjamin J.
   Ambati, Balamurali K.
   Bogdanovich, Sasha
   Chiodo, Vince A.
   Hauswirth, William W.
   Kugel, Jennifer F.
   Goodrich, James A.
   Ponicsan, Steven L.
   Hinton, David R.
   Kleinman, Mark E.
   Baffi, Judit Z.
   Gelfand, Bradley D.
   Ambati, Jayakrishna
TI ERK1/2 activation is a therapeutic target in age-related macular
   degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cell death; mobile elements; retinal degeneration
ID MESSENGER-RNA TRANSCRIPTION; ALU REPEATS; HEAT-SHOCK; RECOMBINATION;
   DUPLICATION; SEQUENCES; KINASES; STRESS; EXONS; GENE
AB Deficient expression of the RNase III DICER1, which leads to the accumulation of cytotoxic Alu RNA, has been implicated in degeneration of the retinal pigmented epithelium (RPE) in geographic atrophy (GA), a late stage of age-related macular degeneration that causes blindness in millions of people worldwide. Here we show increased extracellular-signal-regulated kinase (ERK) 1/2 phosphorylation in the RPE of human eyes with GA and that RPE degeneration in mouse eyes and in human cell culture induced by DICER1 depletion or Alu RNA exposure is mediated via ERK1/2 signaling. Alu RNA overexpression or DICER1 knockdown increases ERK1/2 phosphorylation in the RPE in mice and in human cell culture. Alu RNA-induced RPE degeneration in mice is rescued by intravitreous administration of PD98059, an inhibitor of the ERK1/2-activating kinase MEK1, but not by inhibitors of other MAP kinases such as p38 or JNK. These findings reveal a previously unrecognized function of ERK1/2 in the pathogenesis of GA and provide a mechanistic basis for evaluation of ERK1/2 inhibition in treatment of this disease.
C1 [Dridi, Sami; Hirano, Yoshio; Tarallo, Valeria; Kim, Younghee; Fowler, Benjamin J.; Bogdanovich, Sasha; Kleinman, Mark E.; Baffi, Judit Z.; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
   [Fowler, Benjamin J.; Ambati, Jayakrishna] Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
   [Ambati, Balamurali K.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Ambati, Balamurali K.] Vet Affairs Salt Lake City Healthcare Syst, Dept Ophthalmol, Salt Lake City, UT 84148 USA.
   [Chiodo, Vince A.; Hauswirth, William W.] Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Kugel, Jennifer F.; Goodrich, James A.; Ponicsan, Steven L.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA.
   [Hinton, David R.] Univ So Calif, Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
C3 University of Kentucky; University of Kentucky; Utah System of Higher
   Education; University of Utah; US Department of Veterans Affairs; State
   University System of Florida; University of Florida; University of
   Colorado System; University of Colorado Boulder; Doheny Eye Institute;
   University of Southern California
RP Ambati, J (通讯作者)，Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40506 USA.
EM jamba2@email.uky.edu
RI Dridi, Sami/Q-8207-2019; Gelfand, Brad/L-3926-2019
OI Tarallo, Valeria/0000-0002-6920-4402; Hirano,
   Yoshio/0000-0002-9173-0839; Kleinman, Mark/0000-0001-8557-7949;
   hauswirth, william/0000-0002-3244-4947
FU National Eye Institute/National Institutes of Health (NIH) [R01EY018350,
   R01EY018836, R01EY020672, R01EY022238, R21EY019778, RC1EY020442]; Doris
   Duke Distinguished Clinical Scientist Award; Burroughs Wellcome Fund
   Clinical Scientist Award in Translational Research; Dr. E. Vernon Smith
   and Eloise C. Smith Macular Degeneration Endowed Chair; Senior Scientist
   Investigator Award (Research to Prevent Blindness); NIH [K08EY021521,
   K08EY021757, T32HL091812, UL1RR033173, P30EY021721, R01EY017182,
   R01EY017950, P30EY003040, R01EY001545, R01GM068414]; International
   Retinal Research Foundation; American Health Assistance Foundation;
   Alcon Japan Research Award; Macula Vision Research Foundation; Veterans
   Administration Merit Award; Department of Defense; Research to Prevent
   Blindness; University of Kentucky Physician Scientist Awards; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000117, TL1TR000115,
   UL1TR001998] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH
   RESOURCES [TL1RR033172, UL1RR033173] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [P30EY021721, R01EY017950, R21EY019778,
   R01EY018350, K08EY021521, RC1EY020442, R01EY018836, P30EY014800,
   K08EY021757, R01EY017182, R01EY001545, R01EY022238, R01EY020672,
   P30EY003040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [T32HL091812] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068414] Funding Source: NIH
   RePORTER
FX We thank A. Brunet, J. Garcia-Perez, T. Heidmann, and J. V. Moran for
   providing reagents; R. King, L. Xu, M. McConnell, C. Payne, D.
   Robertson, G. Botzet, G. R. Pattison, and C. Spee for technical
   assistance; and A. M. Rao, G. S. Rao, and K. Ambati for discussions. J.
   A. was supported by National Eye Institute/National Institutes of Health
   (NIH) Grants R01EY018350, R01EY018836, R01EY020672, R01EY022238,
   R21EY019778, and RC1EY020442; a Doris Duke Distinguished Clinical
   Scientist Award; a Burroughs Wellcome Fund Clinical Scientist Award in
   Translational Research; the Dr. E. Vernon Smith and Eloise C. Smith
   Macular Degeneration Endowed Chair; and a Senior Scientist Investigator
   Award (Research to Prevent Blindness). The authors also acknowledge the
   following support: NIH Grant K08EY021521, the International Retinal
   Research Foundation, and the American Health Assistance Foundation (all
   to J.Z.B.); NIH Grant K08EY021757 (to M.E.K.); NIH Grants T32HL091812
   and UL1RR033173 (to B.J.F., S.B., and M.E.K.); an Alcon Japan Research
   Award (to Y.H.); NIH Grant P30EY021721 and the Macula Vision Research
   Foundation (both W.W.H.); NIH Grants R01EY017182 and R01EY017950, a
   Veterans Administration Merit Award, and the Department of Defense (all
   to B.K.A.); NIH Grants P30EY003040 and R01EY001545 (to D.R.H.); NIH
   Grant R01GM068414 (to J.F.K. and J.A.G.); departmental unrestricted
   grants from Research to Prevent Blindness (to J.A. and W.W.H.); and
   University of Kentucky Physician Scientist Awards (to J.Z.B. and
   M.E.K.).
CR Alexander JJ, 2008, ADV EXP MED BIOL, V613, P121, DOI 10.1007/978-0-387-74904-4_13
   Allen TA, 2004, NAT STRUCT MOL BIOL, V11, P816, DOI 10.1038/nsmb813
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798
   Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864
   Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223
   Espinoza CA, 2004, NAT STRUCT MOL BIOL, V11, P822, DOI 10.1038/nsmb812
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Hebert SS, 2010, HUM MOL GENET, V19, P3959, DOI 10.1093/hmg/ddq311
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1
   Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Mariner PD, 2008, MOL CELL, V29, P499, DOI 10.1016/j.molcel.2007.12.013
   Mauillon JL, 1996, CANCER RES, V56, P5728
   Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245
   PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x
   Sawe N, 2008, J NEUROSCI RES, V86, P1659, DOI 10.1002/jnr.21604
   SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889
   Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390
   Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
NR 29
TC 73
Z9 79
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 21
PY 2012
VL 109
IS 34
BP 13781
EP 13786
DI 10.1073/pnas.1206494109
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 996KJ
UT WOS:000308085200067
PM 22869729
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Gigon, A
   Mosinska, A
   Montesel, A
   Derradji, Y
   Apostolopoulos, S
   Ciller, C
   De Zanet, S
   Mantel, I
AF Gigon, Anthony
   Mosinska, Agata
   Montesel, Andrea
   Derradji, Yasmine
   Apostolopoulos, Stefanos
   Ciller, Carlos
   De Zanet, Sandro
   Mantel, Irmela
TI Personalized Atrophy Risk Mapping in Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE atrophy; optical; coherence tomography; artificial; intelligence
ID GEOGRAPHIC ATROPHY; PROGRESSION; PREDICTION; ENHANCEMENT; SECONDARY
AB Purpose: To develop and validate an automatic retinal pigment epithelial and outer retinal atrophy (RORA) progression prediction model for nonexudative age-related macular degeneration (AMD) cases in optical coherence tomography (OCT) scans.
   Methods: Longitudinal OCT data from 129 eyes/119 patients with RORA was collected and separated into training and testing groups. RORA was automatically segmented in all scans and additionally manually annotated in the test scans. OCT-based features such as layers thicknesses, mean reflectivity, and a drusen height map served as an input to the deep neural network. Based on the baseline OCT scan or the previous visit OCT, en face RORA predictions were calculated for future patient visits. The performance was quantified over time with the means of Dice scores and square root area errors.
   Results: The average Dice score for segmentations at baseline was 0.85. When predicting progression from baseline OCTs, the Dice scores ranged from 0.73 to 0.80 for total RORA area and from 0.46 to 0.72 for RORA growth region. The square root area error ranged from 0.13 mm to 0.33 mm. By providing continuous time output, the model enabled creation of a patient-specific atrophy risk map.
   Conclusions: We developed a machine learning method for RORA progression prediction, which provides continuous-time output. It was used to compute atrophy risk maps, which indicate time-to-RORA-conversion, a novel and clinically relevant way of representing disease progression.
   Translational Relevance: Application of recent advances in artificial intelligence to predict patient-specific progression of atrophic AMD.
C1 [Gigon, Anthony; Montesel, Andrea; Derradji, Yasmine; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, Lausanne, Switzerland.
   [Mosinska, Agata; Apostolopoulos, Stefanos; Ciller, Carlos; De Zanet, Sandro] RetinAI Med AG, Bern, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Jules Gonin Eye Hosp, 15 Ave France,CP 5143, CH-1004 Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Apellis Pharmaceuticals Inc, PHAS 2 MULT RAND SIN
   Apostolopoulos S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64724-8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boski M, 2017, 2017 10TH INTERNATIONAL WORKSHOP ON MULTIDIMENSIONAL (ND) SYSTEMS (NDS)
   Cousins SW, 2019, INVEST OPHTH VIS SCI, V60
   Dabov K, 2006, PROC SPIE, V6064, DOI 10.1117/12.643267
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Derradji Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-01227-0
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Halupka KJ, 2018, BIOMED OPT EXPRESS, V9, P6205, DOI 10.1364/BOE.9.006205
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Immerkaer J, 1996, COMPUT VIS IMAGE UND, V64, P300, DOI 10.1006/cviu.1996.0060
   Jaffe GJ, 2021, OPHTHALMOL RETINA, V5, P855, DOI 10.1016/j.oret.2020.12.009
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Mantel I, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.4.17
   Moult EM, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.7.26
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Rogowska J, 2002, PHYS MED BIOL, V47, P641, DOI 10.1088/0031-9155/47/4/307
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Tan MX, 2019, PR MACH LEARN RES, V97
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wang JY, 2021, OPHTHALMIC RES, V64, P205, DOI 10.1159/000510507
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang YH, 2021, MED IMAGE ANAL, V68, DOI 10.1016/j.media.2020.101893
   Zhang YH, 2019, I S BIOMED IMAGING, P565, DOI 10.1109/ISBI.2019.8759253
NR 33
TC 2
Z9 2
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD NOV
PY 2021
VL 10
IS 13
AR 18
DI 10.1167/tvst.10.13.18
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XU5WJ
UT WOS:000734334400015
PM 34767623
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU He, LM
   Silva, RA
   Ayoub, N
   Moshfeghi, DM
   Leng, T
AF He, Lingmin
   Silva, Ruwan A.
   Ayoub, Noel
   Moshfeghi, Darius M.
   Leng, Theodore
TI Experience With Aflibercept for the Treatment of Neovascular Age-Related
   Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; OUTCOMES; BEVACIZUMAB; EYES
AB BACKGROUND AND OBJECTIVE: Describe visual and anatomic outcomes of eyes with exudative age-related macular degeneration (AMD) after treatment with aflibercept.
   PATIENTS AND METHODS: Eyes treated with intravitreal injections of aflibercept for exudative AMD were retrospectively reviewed to compare visual acuity and central subfield thickness (CST) on optical coherence tomography.
   RESULTS: A total of 142 eyes receiving aflibercept were previously treated with bevacizumab or ranibizumab intravitreal injections. Baseline vision was 20/73 +/- 5.18 lines when switched to aflibercept. It improved by 0.2 +/- 1.91 lines (P =. 14) after three injections but decreased by 0.45 +/- 2.9 lines (P =.06) after 1 year of follow-up. The reduction in CST was 9.9 +/- 46.5 mu m (P =.06) after three injections and grew to 19.3 +/- 50.6 mu m (P =.002), a statistically significant amount, after 1 year.
   CONCLUSION: Switching to aflibercept resulted in no clinically significant differences in visual acuity after 1 year. There was a significant reduction in CST, but this may not be clinically significant.
C1 [He, Lingmin; Silva, Ruwan A.; Ayoub, Noel; Moshfeghi, Darius M.; Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
C3 Stanford University
RP Leng, T (通讯作者)，Byers Eye Inst Stanford, 2452 Watson Court, Palo Alto, CA 94303 USA.
EM tedleng@stanford.edu
RI Leng, Theodore/AAQ-7459-2020
OI Leng, Theodore/0000-0002-8461-3562; Moshfeghi, Darius
   Mohammad/0000-0003-2254-292X; Ayoub, Noel/0000-0003-1867-994X
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Center for Drug Evaluation and Research. Eylea Label, 2013, 125387ORIGLS000 CTR
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.OPHTHA.2006.01.027
   Stone TW, 2013, ASRS 2013 PREFERENCE
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 21
TC 5
Z9 5
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2015
VL 46
IS 5
BP 542
EP 549
DI 10.3928/23258160-20150521-05
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UQ
UT WOS:000359292500005
PM 26057757
DA 2022-11-30
ER

PT J
AU Liva, F
   Cuffaro, D
   Nuti, E
   Nencetti, S
   Orlandini, E
   Vozzi, G
   Rossello, A
AF Liva, Francesca
   Cuffaro, Doretta
   Nuti, Elisa
   Nencetti, Susanna
   Orlandini, Elisabetta
   Vozzi, Giovanni
   Rossello, Armando
TI Age-related Macular Degeneration: Current Knowledge of Zinc
   Metalloproteinases Involvement
SO CURRENT DRUG TARGETS
LA English
DT Review
DE AMD; RPE; MMPs; ADAMs; ADAMTSs; MMP inhibitors
ID RETINAL-PIGMENT EPITHELIUM; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   DOXYCYCLINE-MEDIATED INHIBITION; MATRIX-METALLOPROTEINASE; BRUCHS
   MEMBRANE; RISK-FACTORS; CORNEAL NEOVASCULARIZATION; PROINFLAMMATORY
   CYTOKINES; INTERPHOTORECEPTOR MATRIX; TRIAMCINOLONE ACETONIDE
AB Background: Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly with limited therapeutic options. The disease is characterized by photoreceptor loss in the macula and reduced Retinal Pigment Epithelium (RPE) function, associated with matrix degradation, cell proliferation, neovascularization and inflammation. Matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) play a critical role in the physiology of extracellular matrix (ECM) turnover and, in turn, in ECM pathologies, such as AMD. A balance between the activities of MMPs and Tissue Inhibitors of Metalloproteinase (TIMPs) is crucial for the integrity of the ECM components; indeed, a dysregulation in the ratio of these factors produces profound changes in the ECM, including thickening and deposit formation, which eventually might lead to AMD development.
   Objective: This article reviews the relevance and impact of zinc metalloproteinases on the development of AMD and their roles as biomarkers and/or therapeutic targets. We illustrate some studies on several inhibitors of MMPs currently used to dissect physiological properties of MMPs. Moreover, all molecules or technologies used to control MMP and ADAM activity in AMD are analyzed.
   Conclusion: This study underlines the changes in the activity of MMPs expressed by RPE cells, highlights the functions of already used MMP inhibitors and consequently suggests their application as therapeutic agents for the treatment of AMD.
C1 [Liva, Francesca; Cuffaro, Doretta; Nuti, Elisa; Nencetti, Susanna; Rossello, Armando] Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy.
   [Cuffaro, Doretta; Orlandini, Elisabetta; Vozzi, Giovanni; Rossello, Armando] Univ Pisa, Res Ctr E Piaggio, I-56122 Pisa, Italy.
   [Orlandini, Elisabetta] Univ Pisa, Dept Earth Sci, Via Santa Maria 53, I-56126 Pisa, Italy.
C3 University of Pisa; University of Pisa; University of Pisa
RP Rossello, A (通讯作者)，Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy.
EM armando.rossello@farm.unipi.it
RI Vozzi, Giovanni/AAS-5320-2021; Nencetti, Susanna/AAF-3442-2021; Cuffaro,
   Doretta/AAH-1491-2021; Nuti, Elisa/B-2137-2018; Rossello,
   Armando/C-5803-2014
OI Cuffaro, Doretta/0000-0002-8842-542X; Nuti, Elisa/0000-0003-2669-5376;
   vozzi, giovanni/0000-0002-9414-9994; Rossello,
   Armando/0000-0002-6795-8091; Francesca, Liva/0000-0003-1881-2210;
   ORLANDINI, Elisabetta/0000-0003-3398-2787
FU M-era.Net 2016 European programme [4246]
FX The present study was supported by funding from M-era.Net 2016 European
   programme to project "Biomembrane" (reference number: project4246).
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alcazar O, 2009, EXP EYE RES, V89, P638, DOI 10.1016/j.exer.2009.06.014
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Antcliff RJ, 1999, INVEST OPHTH VIS SCI, V40, pS973
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bennett N, 2018, ADV THER, V35, P591, DOI 10.1007/s12325-018-0698-9
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bevitt DJ, 2003, BBA-GENE STRUCT EXPR, V1626, P83, DOI 10.1016/S0167-4781(03)00047-2
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Camodeca C, 2019, CURR MED CHEM, V26, P2661, DOI 10.2174/0929867325666180326164104
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374
   Cox CA, 2010, OPHTHALMOLOGY, V117, P1782, DOI 10.1016/j.ophtha.2010.01.037
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   El Bradey M, 2004, J OCUL PHARMACOL TH, V20, P217, DOI 10.1089/1080768041223657
   Elliot S, 2006, INVEST OPHTH VIS SCI, V47, P1696, DOI 10.1167/iovs.05-1258
   Nano ME, 2013, ARQ BRAS OFTALMOL, V76, P80, DOI 10.1590/S0004-27492013000200005
   Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garcia CR, 2002, CURR EYE RES, V24, P33, DOI 10.1076/ceyr.24.1.33.5429
   Garcia RA, 2005, MOL PHARMACOL, V67, P1128, DOI 10.1124/mol.104.006346
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Griffioen A W, 2000, IDrugs, V3, P336
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   HACKETT SF, 1993, INVEST OPHTH VIS SCI, V34, P2055
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Hollyfield JG, 1999, EXP EYE RES, V69, P311, DOI 10.1006/exer.1999.0707
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   HUNT RC, 1993, INVEST OPHTH VIS SCI, V34, P3179
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Inoue K, 2012, CLIN CANCER RES, V18, P3924, DOI 10.1158/1078-0432.CCR-11-2041
   Itoh Y, 2006, MOL BIOL CELL, V17, P5390, DOI 10.1091/mbc.e06-08-0740
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2012, RETINA-J RET VIT DIS, V32, P2150, DOI 10.1097/IAE.0b013e3182576d07
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelwick R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0676-3
   Kim D, 2017, EXP THER MED, V13, P1415, DOI 10.3892/etm.2017.4110
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Kutty RK, 2016, MOL VIS, V22, P1156
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Kwon JE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162051
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115
   Lim JM, 2002, J CATARACT REFR SURG, V28, P697, DOI 10.1016/S0886-3350(01)01236-6
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liutkeviciene R, 2014, BIOLOGIJA VILNIUS, V60, P107, DOI [10.6001/biologija.v60i2.2910, DOI 10.6001/BIOLOGIJA.V60I2.2910]
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Maretzky T, 2008, J INVEST DERMATOL, V128, P1737, DOI 10.1038/sj.jid.5701242
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Molins B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00808
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2012, AGE RELATED MACULAR, V3, P300
   Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459
   Murthy A, 2012, IMMUNITY, V36, P105, DOI 10.1016/j.immuni.2012.01.005
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Or C, 2014, INVEST OPHTH VIS SCI, V55
   Park GB, 2015, INVEST OPHTH VIS SCI, V56, P5162, DOI 10.1167/iovs.14-16058
   Parmet Sharon, 2002, JAMA, V288, P2358
   Parry DA, 2009, AM J HUM GENET, V84, P683, DOI 10.1016/j.ajhg.2009.04.005
   Pasquale TR, 2005, EXPERT OPIN PHARMACO, V6, P1681, DOI 10.1517/14656566.6.10.1681
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Rossello A, 2016, CURR DRUG TARGETS, V17, P1908, DOI 10.2174/1389450117666160727143618
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Saftig P, 2011, EUR J CELL BIOL, V90, P527, DOI 10.1016/j.ejcb.2010.11.005
   Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Singh M, 2017, INT J OPHTHALMOL-CHI, V10, P1308, DOI 10.18240/ijo.2017.08.20
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Su WR, 2013, INVEST OPHTH VIS SCI, V54, P783, DOI 10.1167/iovs.12-10323
   Su WR, 2011, INVEST OPHTH VIS SCI, V52, P9108, DOI 10.1167/iovs.11-7255
   Su WR, 2011, GRAEF ARCH CLIN EXP, V249, P421, DOI 10.1007/s00417-010-1539-y
   Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416
   Szeto HH, 2014, CLIN PHARMACOL THER, V96, P672, DOI 10.1038/clpt.2014.174
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Webb AH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3418-y
   Weber S, 2011, DEVELOPMENT, V138, P495, DOI 10.1242/dev.055210
   White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan X, 2011, DEV GROWTH DIFFER, V53, P726, DOI 10.1111/j.1440-169X.2011.01282.x
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zeng RP, 2013, MOL VIS, V19, P729
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
   Zhu WH, 2000, LAB INVEST, V80, P545, DOI 10.1038/labinvest.3780060
NR 119
TC 3
Z9 3
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2019
VL 20
IS 9
BP 903
EP 918
DI 10.2174/1389450120666190122114857
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IC4VN
UT WOS:000470965200002
PM 30666909
DA 2022-11-30
ER

PT J
AU Liu, K
   Lai, TYY
   Chiang, SWY
   Chan, VCK
   Young, AL
   Tam, POS
   Pang, CP
   Chen, LJ
AF Liu, Ke
   Lai, Timothy Y. Y.
   Chiang, Sylvia W. Y.
   Chan, Vesta C. K.
   Young, Alvin L.
   Tam, Pancy O. S.
   Pang, Chi Pui
   Chen, Li Jia
TI Gender specific association of a complement component 3 polymorphism
   with polypoidal choroidal vasculopathy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; C3 LEVELS; FACTOR-H; AGE; RISK; VARIANT;
   HAPLOTYPE; SERUM
AB Neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are leading causes of irreversible blindness in developed countries. In this study, we investigated the associations of haplotype-tagging single nucleotide polymorphisms (SNPs) in the complement component 3 (C3) gene with both neovascular AMD and PCV, and potential epistatic effects on C3. Eight tagging SNPs in C3 were genotyped in 708 unrelated study subjects: 200 neovascular AMD patients, 233 PCV patients and 275 controls. Among the eight C3 SNPs, rs17030 was associated with PCV after adjusted for gender and SNP-gender interaction (P=0.008, OR=2.94; 95% CI: 1.32-6.52). Moreover, an interaction between rs17030 and gender was identified in PCV (P=0.02). After stratification by gender, the rs17030 G allele was found to confer an increased risk for PCV in male (P=0.010, OR=1.56) but not in female. The haplotype AG defined by the major alleles of rs17030 and rs344555 was also associated with PCV in male (P=0.010, OR=0.64). In contrast to PCV, none of the eight SNPs was significantly associated with neovascular AMD. This study shows an association of C3 rs17030 with PCV in male, indicating that C3 may have an epistatic effect with gender in the pathogenesis of PCV.
C1 [Liu, Ke; Lai, Timothy Y. Y.; Chiang, Sylvia W. Y.; Tam, Pancy O. S.; Pang, Chi Pui; Chen, Li Jia] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chan, Vesta C. K.; Young, Alvin L.; Chen, Li Jia] Prince Wales Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Ke] Shenzhen Eye Hosp, Shenzhen, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital
RP Chen, LJ (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM lijia_chen@cuhk.edu.hk
RI Lai, Timothy Y Y/AAC-2120-2020; Chen, Li Jia/I-5078-2014
OI Lai, Timothy Y Y/0000-0002-7832-6428; Chen, Li Jia/0000-0003-3500-5840;
   Holloway, Courtney Jean/0000-0003-3661-1957
FU Endowment Fund for Lim Por-Yen Eye Genetics Research Centre; Research
   Grants Council, Hong Kong [473410]
FX The authors express their highest gratitude to all the participants in
   this study. This study was supported in part by an Endowment Fund for
   Lim Por-Yen Eye Genetics Research Centre and the General Research Fund
   from the Research Grants Council (grant number: 473410), Hong Kong.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Chen HY, 2012, MOL VIS, V18, P816
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu K, 2013, OPHTHALMOLOGY, V120, P837, DOI 10.1016/j.ophtha.2012.10.003
   Liu LY, 2012, HUM GENET, V131, P353, DOI 10.1007/s00439-011-1081-y
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Muscari A, 1998, ACTA CARDIOL, V53, P345
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Tian J., 2012, INVEST OPHTHALMOL VI
   Wiggs JL, 2011, HUM MOL GENET, V20, P4707, DOI 10.1093/hmg/ddr382
   Yanagisawa S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028847
   Yang MM, 2011, MOL VIS, V17, P2655
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YONEMASU K, 1978, IMMUNOLOGY, V35, P523
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 28
TC 23
Z9 24
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 12
PY 2014
VL 4
AR 7018
DI 10.1038/srep07018
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AT2JL
UT WOS:000344760700008
PM 25388911
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lains, I
   Mendez, KM
   Gil, JQ
   Miller, JB
   Kelly, RS
   Barreto, P
   Kim, IK
   Vavvas, DG
   Murta, JN
   Liang, LM
   Silva, R
   Miller, JW
   Lasky-Su, J
   Husain, D
AF Lains, Ines
   Mendez, Kevin M.
   Gil, Joao Q.
   Miller, John B.
   Kelly, Rachel S.
   Barreto, Patricia
   Kim, Ivana K.
   Vavvas, Demetrios G.
   Murta, Joaquim Neto
   Liang, Liming
   Silva, Rufino
   Miller, Joan W.
   Lasky-Su, Jessica
   Husain, Deeba
TI Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; metabolomics; urine
ID METABOLIC SIGNATURES; NMR-SPECTROSCOPY; DISEASE; CANCER; LIPIDS
AB We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feasible alternative to plasma biomarkers. However, no studies have applied urinary mass spectrometry (MS) metabolomics to AMD. This study aimed to assess urinary metabolomic profiles of patients with different stages of AMD and a control group. We included two prospectively designed, multicenter, cross-sectional study cohorts: Boston, US (n = 185) and Coimbra, Portugal (n = 299). We collected fasting urine samples, which were used for metabolomic profiling (Ultrahigh Performance Liquid chromatography-Mass Spectrometry). Multivariable logistic and ordinal logistic regression models were used for analysis, accounting for gender, age, body mass index and use of AREDS supplementation. Results from both cohorts were then meta-analyzed. No significant differences in urine metabolites were seen when comparing patients with AMD and controls. When disease severity was considered as an outcome, six urinary metabolites differed significantly (p < 0.01). In particular, two of the metabolites identified have been previously shown by our group to also differ in the plasma of patients of AMD compared to controls and across severity stages. While there are fewer urinary metabolites associated with AMD than plasma metabolites, this study identified some differences across stages of disease that support previous work performed with plasma, thus highlighting the potential of these metabolites as future biomarkers for AMD.
C1 [Lains, Ines; Miller, John B.; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Mendez, Kevin M.; Kelly, Rachel S.; Lasky-Su, Jessica] Brigham & Womens Hosp, Channing Div Network Med, Syst Genet & Genom Unit, 75 Francis St, Boston, MA 02115 USA.
   [Mendez, Kevin M.; Kelly, Rachel S.; Lasky-Su, Jessica] Harvard Med Sch, Boston, MA 02115 USA.
   [Gil, Joao Q.; Murta, Joaquim Neto; Silva, Rufino] Univ Coimbra, Fac Med, P-3000548 Coimbra, Portugal.
   [Barreto, Patricia; Murta, Joaquim Neto; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, P-3000548 Coimbra, Portugal.
   [Murta, Joaquim Neto; Silva, Rufino] Ctr Hosp & Univ Coimbra, Ophthalmol Dept, P-3004561 Coimbra, Portugal.
   [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School; Universidade de Coimbra;
   Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Harvard University; Harvard T.H. Chan
   School of Public Health
RP Husain, D (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA 02114 USA.
EM ines_lains@meei.harvard.edu; kevin_mendez@meei.harvard.edu;
   joaomqgil@gmail.com; john_miller@meei.harvard.edu;
   hprke@channing.harvard.edu; pbarreto@aibili.pt;
   ivana_kim@meei.harvard.edu; demetrios_vavvas@meei.harvard.edu;
   jmurta@netcabo.pt; llinag@hsph.harvard.edu;
   rufino.silva@oftalmologia.co.pt; joan_miller@meei.harvard.edu;
   jessica.su@channing.harvard.edu; deeba_husain@meei.harvard.edu
RI Miller, John J/GZG-5663-2022; Murta, Joaquim/V-5494-2017
OI Kelly, Rachel/0000-0003-3023-1822; Murta, Joaquim/0000-0001-8926-5176;
   Silva, Rufino/0000-0001-8676-0833; Lains, Ines/0000-0002-8136-4724;
   Quadrado Gil, Joao/0000-0001-9032-1008
FU Miller Retina Research Fund (Mass. Eye and Ear); Champalimaud Vision
   Award; National Institutes of Health (NIH) [R01EY030088]; Research to
   Prevent Blindness, Inc., New York; Portuguese Foundation for Science and
   Technology/Harvard Medical School Portugal Program [HMSP-ICJ/006/2013];
   Commonwealth Unrestricted Grant for Eye Research
FX This research was funded by the Miller Retina Research Fund (Mass. Eye
   and Ear), Champalimaud Vision Award, National Institutes of Health (NIH)
   R01EY030088, the unrestricted departmental Grant from Research to
   Prevent Blindness, Inc., New York, Portuguese Foundation for Science and
   Technology/Harvard Medical School Portugal Program (HMSP-ICJ/006/2013),
   and the Commonwealth Unrestricted Grant for Eye Research. The study was
   conducted in accordance with the Declaration of Helsinki and approved by
   the Institutional Review Board of the Massachusetts General Brigham.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Barnes S, 2016, J MASS SPECTROM, V51, P461, DOI 10.1002/jms.3782
   Chistyakov DV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030704
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Deng YH, 2021, AGING-US, V13, P13968, DOI 10.18632/aging.203006
   Duarte IF, 2012, PROG NUCL MAG RES SP, V62, P51, DOI 10.1016/j.pnmrs.2011.11.002
   Duarte IF, 2010, VIRCHOWS ARCH, V457, P715, DOI 10.1007/s00428-010-0993-6
   Emwas AH, 2016, J PROTEOME RES, V15, P360, DOI 10.1021/acs.jproteome.5b00885
   Fliesler SJ, 2010, J LIPID RES, V51, P1, DOI 10.1194/jlr.E003533-JLR200
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Kennedy AD, 2017, MOL GENET METAB, V121, P83, DOI 10.1016/j.ymgme.2017.04.005
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Lains Ines, 2021, Ophthalmol Sci, V1, DOI 10.1016/j.xops.2021.100017
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, J PROTEOME RES, V18, P1278, DOI 10.1021/acs.jproteome.8b00877
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P1145, DOI 10.1097/IAE.0000000000001659
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Parfitt A, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000276
   Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314
   Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957
   Rocha CM, 2011, J PROTEOME RES, V10, P4314, DOI 10.1021/pr200550p
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Senn T, 2012, PROG CARDIOVASC DIS, V55, P70, DOI 10.1016/j.pcad.2012.06.004
   Shen YC, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01392-2
   Shiwani HA, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112197
   Simon MV, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000972
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Suhre K, 2012, NAT REV GENET, V13, P759, DOI 10.1038/nrg3314
   Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 39
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2022
VL 11
IS 4
AR 940
DI 10.3390/jcm11040940
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0G6ZL
UT WOS:000778190600001
PM 35207212
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ehlken, C
   Wilke, T
   Bauer-Steinhusen, U
   Agostini, HT
   Hasanbasic, Z
   Muller, S
AF Ehlken, Christoph
   Wilke, Thomas
   Bauer-Steinhusen, Ulrike
   Agostini, Hansjuergen T.
   Hasanbasic, Zoran
   Mueller, Sabrina
TI TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH
   VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE
   Identification of Health Care Constraints in Germany-The PONS Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE adherence; AMD (age-related macular degeneration); intravitreal
   injection; persistence; Phase IV clinical trial; real life; VEGF;
   interview
ID RANIBIZUMAB TREATMENT; VISUAL-ACUITY; FOLLOW-UP; ADHERENCE; BEVACIZUMAB;
   REGIMENS; BARRIERS; OUTCOMES; THERAPY; EYE
AB Purpose: The PONS study was conceived to analyze the extent of nonpersistence (NP) and nonadherence (NA) in the treatment of patients with neovascular age-related macular degeneration in everyday clinical practice in Germany. Further objectives were to identify factors that can affect NP and NA and to analyze clinical outcomes under everyday conditions.
   Methods: Nonpersistence (no contact with doctor for at least 3 months) and NA (no treatment or follow-up for at least 6 weeks) as well as clinical data were analyzed up to 24 months retrospectively and 12 months prospectively in 480 patients with neovascular age-related macular degeneration in 23 treatment centers. Patients were interviewed for factors possibly affecting NP and NA.
   Results: One third of patients fulfilled criteria of NA in the first 3 months and two thirds after 6 months. The NP was 18.8% after 12 months. Treatment exclusively at one center, a higher number of patients with neovascular age-related macular degeneration at the treating center, and fixed appointments were associated with a lower risk for NP. An initial gain in visual acuity after upload was not preserved after 12 months (mean change -0.5 Early Treatment Diabetic Retinopathy Study letters). Whereas visual acuity declined by 7.5 Early Treatment Diabetic Retinopathy Study letters in patients with good baseline visual acuity >20/40, visual acuity improved by 8.5 letters in patients with baseline visual acuity of <20/200. Only 7.5% of patients underwent an optical coherence tomography scan after 3 upload injections, and only 2.0 optical coherence tomographies were performed in the first 12 months.
   Conclusion: The NP and NA were high in our study population and are likely to have contributed to a suboptimal clinical outcome compared with randomized clinical trials. Shortcomings in the management of patients with neovascular age-related macular degeneration, including restrictions in the timely and adequate follow-up (including optical coherence tomography) and retreatment, appear to be constraining factors in Germany.
C1 [Ehlken, Christoph; Agostini, Hansjuergen T.] Albert Ludwigs Univ, Dept Ophthalmol, Freiburg, Germany.
   [Ehlken, Christoph] Univ Kiel, Dept Ophthalmol, Fac Med, Kiel, Germany.
   [Wilke, Thomas; Mueller, Sabrina] Inst Pharmaokon & Arzneimittellogist IPAM, Wismar, Germany.
   [Bauer-Steinhusen, Ulrike; Hasanbasic, Zoran] Bayer Vital GmbH, Leverkusen, Germany.
C3 University of Freiburg; University of Kiel; Bayer AG
RP Ehlken, C (通讯作者)，Univ Klinikum Schleswig Holstein, Dept Ophthalmol, Campus Kiel,Arnold Heller Str 3, D-24105 Kiel, Germany.
EM christoph.ehlken@uksh.de
FU Bayer Vital GmbH, Leverkusen, Germany; Bayer Vital GmbH
FX Supported by Bayer Vital GmbH, Leverkusen, Germany. Language check was
   provided by Alistair Reeves, Ascribe Medical Writing and Translation
   (Wiesbaden, Germany) and was funded by Bayer Vital GmbH.
CR [Anonymous], 2014, STELLUNGNAHME DTSCH
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Horne R, 1999, J PSYCHOSOM RES, V47, P491, DOI 10.1016/S0022-3999(99)00058-6
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Newman-Casey PA, 2015, OPHTHALMOLOGY, V122, P1308, DOI 10.1016/j.ophtha.2015.03.026
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Thompson AC, 2015, INVEST OPHTH VIS SCI, V56, P4324, DOI 10.1167/iovs.15-16444
   Wilke T, 2011, VALUE HEALTH, V14, P1092, DOI 10.1016/j.jval.2011.06.002
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
   Ziemssen F, 2009, OPHTHALMOLOGE, V106, P465, DOI 10.1007/s00347-009-1964-7
NR 26
TC 13
Z9 13
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2018
VL 38
IS 6
BP 1134
EP 1144
DI 10.1097/IAE.0000000000001681
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GP2CC
UT WOS:000440627100012
PM 28489692
DA 2022-11-30
ER

PT J
AU Kauppinen, A
   Paterno, JJ
   Blasiak, J
   Salminen, A
   Kaarniranta, K
AF Kauppinen, Anu
   Paterno, Jussi J.
   Blasiak, Janusz
   Salminen, Antero
   Kaarniranta, Kai
TI Inflammation and its role in age-related macular degeneration
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Signaling; Aging; Immune system; NLRP3; Eye; Retina
ID COMPLEMENT-FACTOR-H; PIGMENT EPITHELIAL-CELLS; C-REACTIVE PROTEIN;
   NEUTROPHIL EXTRACELLULAR TRAPS; GLYCOSYLATION END-PRODUCTS;
   LIGAND-INDUCED APOPTOSIS; DOSE DATA INTERPRETATION; ANTI-RETINAL
   ANTIBODIES; NF-KAPPA-B; NLRP3 INFLAMMASOME
AB Inflammation is a cellular response to factors that challenge the homeostasis of cells and tissues. Cell-associated and soluble pattern-recognition receptors, e.g. Toll-like receptors, inflammasome receptors, and complement components initiate complex cellular cascades by recognizing or sensing different pathogen and damage-associated molecular patterns, respectively. Cytokines and chemokines represent alarm messages for leukocytes and once activated, these cells travel long distances to targeted inflamed tissues. Although it is a crucial survival mechanism, prolonged inflammation is detrimental and participates in numerous chronic age-related diseases. This article will review the onset of inflammation and link its functions to the pathogenesis of age-related macular degeneration (AMD), which is the leading cause of severe vision loss in aged individuals in the developed countries. In this progressive disease, degeneration of the retinal pigment epithelium (RPE) results in the death of photoreceptors, leading to a loss of central vision. The RPE is prone to oxidative stress, a factor that together with deteriorating functionality, e.g. decreased intracellular recycling and degradation due to attenuated heterophagy/autophagy, induces inflammation. In the early phases, accumulation of intracellular lipofuscin in the RPE and extracellular drusen between RPE cells and Bruch's membrane can be clinically detected. Subsequently, in dry (atrophic) AMD there is geographic atrophy with discrete areas of RPE loss whereas in the wet (exudative) form there is neovascularization penetrating from the choroid to retinal layers. Elevations in levels of local and systemic biomarkers indicate that chronic inflammation is involved in the pathogenesis of both disease forms.
C1 [Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, POB 1627, Kuopio 70211, Finland.
   [Kauppinen, Anu; Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
   [Paterno, Jussi J.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, PL-90131 Lodz, Poland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio 70211, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland; University of Lodz;
   University of Eastern Finland
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, POB 1627, Kuopio 70211, Finland.; Kauppinen, A (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
EM anu.kauppinen@uef.fi
RI Paterno, Jussi/AAY-5526-2020
OI Paterno, Jussi/0000-0002-5442-4314; Kaarniranta,
   Kai/0000-0003-2600-8679; Blasiak, Janusz/0000-0001-9539-9584
FU Finnish Cultural Foundation; Alfred Kordelin Foundation; Finnish Eye
   Foundation; Kuopio University Hospital
FX Dr. Ewen MacDonald is warmly acknowledged for the language revision.
   This work was financially supported by the Finnish Cultural Foundation,
   the Alfred Kordelin Foundation, the Finnish Eye Foundation, and the
   Kuopio University Hospital.
CR Agrawal A, 2009, ADV EXP MED BIOL, V653, P98
   Ahn JK, 2005, J IMMUNOL, V175, P6133, DOI 10.4049/jimmunol.175.9.6133
   Alexander P, 2014, MOL VIS, V20, P1253
   Allen IC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00169
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   An EY, 2008, MOL VIS, V14, P2292
   An LL, 2014, EUR J IMMUNOL, V44, P3669, DOI 10.1002/eji.201444560
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ansari MA, 2013, J VIROL, V87, P8606, DOI 10.1128/JVI.00805-13
   Aprahamian T, 2008, CLIN EXP IMMUNOL, V152, P448, DOI 10.1111/j.1365-2249.2008.03658.x
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Aspinall R, 2014, BIOCHEM SOC T, V42, P651, DOI 10.1042/BST20140021
   BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6
   Bergstrom I, 2012, ATHEROSCLEROSIS, V224, P515, DOI 10.1016/j.atherosclerosis.2012.07.033
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blann AD, 2000, BLOOD COAGUL FIBRIN, V11, P623, DOI 10.1097/00001721-200010000-00006
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen GY, 2014, EUR J IMMUNOL, V44, P321, DOI 10.1002/eji.201344135
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15029
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cui BB, 2012, AUTOIMMUNITY, V45, P593, DOI 10.3109/08916934.2012.719952
   Cumpelik A, 2016, ANN RHEUM DIS, V75, P1236, DOI 10.1136/annrheumdis-2015-207338
   DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Daoudi M, 2004, J BIOL CHEM, V279, P19649, DOI 10.1074/jbc.M313457200
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   De Falco S, 2014, KOREAN J INTERN MED, V29, P1, DOI 10.3904/kjim.2014.29.1.1
   Deban L, 2009, BIOFACTORS, V35, P138, DOI 10.1002/biof.21
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dhillon B, 2010, INVEST OPHTH VIS SCI, V51, P5858, DOI 10.1167/iovs.09-5124
   DiScipio RG, 2007, INT IMMUNOPHARMACOL, V7, P1909, DOI 10.1016/j.intimp.2007.07.006
   Doyle SL, 2014, INVEST OPHTH VIS SCI, V55, P8349, DOI 10.1167/iovs.14-15786
   Doyle SL, 2014, NAT MED, V20, P1376, DOI 10.1038/nm.3741
   Doyle SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007616
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249
   Elzey BD, 2001, J IMMUNOL, V167, P3049, DOI 10.4049/jimmunol.167.6.3049
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Ferguson TA, 2001, CELL DEATH DIFFER, V8, P771, DOI 10.1038/sj.cdd.4400891
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Fernandez-Velasco M, 2014, BIOCHEM J, V458, P187, DOI 10.1042/BJ20131501
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Frasca D, 2011, J CLIN IMMUNOL, V31, P430, DOI 10.1007/s10875-010-9501-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gonzalez I, 2013, IMMUNOBIOLOGY, V218, P790, DOI 10.1016/j.imbio.2012.09.005
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawlisch H, 2006, MOL IMMUNOL, V43, P13, DOI 10.1016/j.molimm.2005.06.028
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Ildefonso CJ, 2015, MOL THER, V23, P875, DOI 10.1038/mt.2015.30
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jiang SN, 2008, INVEST OPHTH VIS SCI, V49, P1345, DOI 10.1167/iovs.07-0308
   Jin B, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/836485
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2012, FUTURE MED CHEM, V4, P2153, DOI [10.4155/FMC.12.169, 10.4155/fmc.12.169]
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kaneko H, 2014, INVEST OPHTH VIS SCI, V55, P8350, DOI 10.1167/iovs.14-15878
   Katagiri N, 2012, MICROBES INFECT, V14, P1123, DOI 10.1016/j.micinf.2012.03.006
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kerur N, 2011, CELL HOST MICROBE, V9, P363, DOI 10.1016/j.chom.2011.04.008
   Khare S, 2012, IMMUNITY, V36, P464, DOI 10.1016/j.immuni.2012.02.001
   Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406
   Kim B, 2005, J IMMUNOL, V175, P509, DOI 10.4049/jimmunol.175.1.509
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kobayashi Y, 2008, FRONT BIOSCI-LANDMRK, V13, P2400, DOI 10.2741/2853
   Koreck A, 2002, CLIN EXP IMMUNOL, V127, P176, DOI 10.1046/j.1365-2249.2002.01721.x
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Lee IT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117911
   Lemster BH, 2008, J IMMUNOL, V180, P1979, DOI 10.4049/jimmunol.180.3.1979
   Lentsch AB, 2000, J PATHOL, V190, P343
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li WX, 2010, CLIN RHEUMATOL, V29, P315, DOI 10.1007/s10067-009-1322-9
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Liao JCC, 2011, STRUCTURE, V19, P418, DOI 10.1016/j.str.2010.12.015
   Lin L, 2006, CELL MOL IMMUNOL, V3, P351
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu BY, 2010, MOL VIS, V16, P184
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Lupfer C, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00285
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Martinon F, 2007, SEMIN IMMUNOPATHOL, V29, P213, DOI 10.1007/s00281-007-0079-y
   Masters SL, 2014, CURR OPIN IMMUNOL, V26, pV, DOI 10.1016/j.coi.2013.12.006
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michel JJ, 2007, ARTHRITIS RHEUM-US, V56, P43, DOI 10.1002/art.22310
   Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499
   MITCHINSON MJ, 1989, LANCET, V2, P1520
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Nilsson G, 1996, J IMMUNOL, V157, P1693
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Pawelec G, 2014, CURR OPIN IMMUNOL, V29, P23, DOI 10.1016/j.coi.2014.03.007
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Qiao H, 2007, J LEUKOCYTE BIOL, V81, P1012, DOI 10.1189/jlb.0506342
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   RATHER LJ, 1971, B NEW YORK ACAD MED, V47, P303
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sallo FB, 2009, CURR EYE RES, V34, P238, DOI 10.1080/02713680802714058
   Salvioli S, 2006, CURR PHARM DESIGN, V12, P3161, DOI 10.2174/138161206777947470
   Samstad EO, 2014, J IMMUNOL, V192, P2837, DOI 10.4049/jimmunol.1302484
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sharma NK, 2012, DNA CELL BIOL, V31, P1618, DOI 10.1089/dna.2012.1786
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Shen JK, 2014, J CELL PHYSIOL, V229, P974, DOI 10.1002/jcp.24575
   Shi GP, 2015, INVEST OPHTH VIS SCI, V56, P1658, DOI 10.1167/iovs.14-14557
   Shi Y, 2002, EUR J IMMUNOL, V32, P155, DOI 10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P
   Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590, DOI 10.1073/pnas.260497597
   Silva AS, 2012, MOL VIS, V18, P2288
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Sprague AH, 2009, BIOCHEM PHARMACOL, V78, P539, DOI 10.1016/j.bcp.2009.04.029
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Stefanini FR, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/632307
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swirski FK, 2013, CIRC RES, V112, P744, DOI 10.1161/CIRCRESAHA.113.300867
   Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013
   Tanaka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-83
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thomas CJ, 2013, TRENDS IMMUNOL, V34, P317, DOI 10.1016/j.it.2013.02.008
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Unterholzner L, 2010, NAT IMMUNOL, V11, P997, DOI 10.1038/ni.1932
   Vallejo AN, 2005, IMMUNOL REV, V205, P158, DOI 10.1111/j.0105-2896.2005.00256.x
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Vladimer GI, 2012, IMMUNITY, V37, P96, DOI 10.1016/j.immuni.2012.07.006
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
   Weber C, 2007, NAT REV IMMUNOL, V7, P467, DOI 10.1038/nri2096
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Winkler B S, 1999, Mol Vis, V5, P32
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhang SR, 2015, INFLAMMATION, V38, P658, DOI 10.1007/s10753-014-9973-3
   Zhao H, 2013, INVEST OPHTH VIS SCI, V54, P5321, DOI 10.1167/iovs.13-12122
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
NR 278
TC 341
Z9 353
U1 7
U2 113
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2016
VL 73
IS 9
BP 1765
EP 1786
DI 10.1007/s00018-016-2147-8
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DJ3NH
UT WOS:000374111800002
PM 26852158
OA hybrid, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Sabeti, F
   Maddess, T
   Essex, RW
   James, AC
AF Sabeti, Faran
   Maddess, Ted
   Essex, Rohan W.
   James, Andrew C.
TI Multifocal Pupillographic Assessment of Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE multifocal; objective perimetry; central visual field; pupils; exudative
   age-related macular degeneration
ID VISUAL-FIELD DEFECTS; DOUBLING TECHNOLOGY PERIMETRY; TEST-RETEST
   VARIABILITY; RETINAL GANGLION-CELLS; PUPIL PERIMETRY; 2ND EYE;
   RETINITIS-PIGMENTOSA; AUTOMATED PERIMETRY; EVOKED POTENTIALS; GLAUCOMA
AB Purpose. To investigate retinal function in subjects with unilateral exudative age-related macular degeneration (AMD) using multifocal pupillographic objective perimetry (mfPOP) and to assess the diagnostic accuracy of this technique.
   Methods. We tested each of 20 exudative AMD patients and 20 control subjects with 4 different mfPOP stimulus variants. Multifocal stimuli consisting of 24 or 44 independent stimulus regions per eye extending from fixation to 15 eccentricity were presented dichoptically. The aperiodic stimuli were presented at 1 or 4 s mean intervals. Video cameras recorded pupil responses under infrared illumination. Test duration consisted of 8 segments of 30 s. Stimuli were presented at a luminance of 250 cd/m(2) and a background of 10 cd/m(2). Peak regional contraction amplitudes, time to peaks, and a linear combination of these were used to produce receiver operator characteristic (ROC) curves to measure the diagnostic accuracy of this method.
   Results. Mean constriction amplitudes of exudative AMD subjects were decreased by 0.77 +/- 0.15 dB (p < 5 x 10(-7)). Stimulus ensembles with 44 regions and faster presentation rates produced the largest effect on response sizes (t = 3.63; p < 0.0002). When comparing the control eyes to exudative AMD eyes, the area under the curve of ROC plots was 0.96 +/- 0.03 (mean +/- SE). This was achieved for asymmetry analysis of the difference in response amplitudes obtained from the two eyes at each point in the visual field.
   Conclusions. The mean effect of exudative AMD on contraction amplitudes reflected the severity of disease, and ROC analysis from amplitude deviations improved the sensitivity of detection of exudative AMD. A longitudinal investigation into the mfPOP responses of patients with non-exudative AMD may detect and classify visual fields with poor prognosis. (Optom Vis Sci 2011; 88: 1477-1485)
C1 [Sabeti, Faran; Maddess, Ted; Essex, Rohan W.; James, Andrew C.] Australian Natl Univ, Ctr Visual Sci, Res Sch Biol, Canberra, ACT 0200, Australia.
   [Sabeti, Faran; Maddess, Ted; Essex, Rohan W.; James, Andrew C.] Australian Natl Univ, ARC Ctr Excellence Vis Sci, Res Sch Biol, Canberra, ACT 0200, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Canberra Hosp, Dept Ophthalmol, Canberra, ACT 0200, Australia.
C3 Australian National University; Australian National University;
   Australian National University; Canberra Hospital
RP Sabeti, F (通讯作者)，Australian Natl Univ, Ctr Visual Sci, Res Sch Biol, GPO Box 4, Canberra, ACT 0200, Australia.
EM faran.sabeti@anu.edu.au
RI Maddess, Teddy L/A-3200-2008; James, Andrew C/C-9307-2009; Sabeti,
   Faran/AAR-1767-2021
OI Maddess, Teddy L/0000-0003-4591-3658; James, Andrew
   C/0000-0002-2447-8549; SABETI, Faran/0000-0001-9187-7569; Essex,
   Rohan/0000-0001-5323-0334
FU Australian Research Council (ARC) through the ARC Centre of Excellence
   in Vision Science [CE0561903]; AusIndustry; Seeing Machines, Canberra
FX This work was supported by Australian Research Council (ARC) through the
   ARC Centre of Excellence in Vision Science (CE0561903), AusIndustry, and
   Seeing Machines, Canberra.
CR Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   Budenz DL, 2002, OPHTHALMOLOGY, V109, P1052, DOI 10.1016/S0161-6420(02)01047-3
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P604, DOI 10.1167/iovs.10-5737
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P2365, DOI 10.1167/iovs.10-6335
   Chauhan BC, 1999, INVEST OPHTH VIS SCI, V40, P648
   Chen YJ, 2008, OPTOMETRY VISION SCI, V85, P471, DOI 10.1097/OPX.0b013e318177ec02
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dacey DM, 2005, NATURE, V433, P749, DOI 10.1038/nature03387
   Delgado MF, 2002, OPHTHALMOLOGY, V109, P2362, DOI 10.1016/S0161-6420(02)01726-8
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Fletcher EL, 1996, J COMP NEUROL, V376, P343
   Fortune B, 2002, J OPT SOC AM A, V19, P173, DOI 10.1364/JOSAA.19.000173
   Gamlin PDR, 2007, VISION RES, V47, P946, DOI 10.1016/j.visres.2006.12.015
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Guler AD, 2008, NATURE, V453, P102, DOI 10.1038/nature06829
   Hawkins BS, 1999, MOL VIS, V5
   HEIJL A, 1989, AM J OPHTHALMOL, V108, P130, DOI 10.1016/0002-9394(89)90006-8
   Henson DB, 1996, INVEST OPHTH VIS SCI, V37, P444
   Hong S, 2001, INVEST OPHTH VIS SCI, V42, P957
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   James AC, 2005, VISUAL NEUROSCI, V22, P45, DOI 10.1017/S0952523805221053
   Joson PJ, 2002, OPHTHALMOLOGY, V109, P757, DOI 10.1016/S0161-6420(01)01002-8
   KARDON RH, 1991, OPHTHALMOLOGY, V98, P485, DOI 10.1016/s0161-6420(91)32267-x
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li RS, 2006, INVEST OPHTH VIS SCI, V47, P2951, DOI 10.1167/iovs.05-1295
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Maddess T, 2005, VISUAL NEUROSCI, V22, P153, DOI 10.1017/S0952523805222046
   Maddess T, 2011, J GLAUCOMA, V20, P336, DOI 10.1097/IJG.0b013e3181efb097
   Maddess T, 2009, CLIN EXP OPHTHALMOL, V37, P678, DOI 10.1111/j.1442-9071.2009.02107.x
   Maddess TL, 2006, Patents, Patent No. 7006863
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nitta K, 2006, RETINA-J RET VIT DIS, V26, P797, DOI 10.1097/01.iae.0000244263.98642.61
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Sabeti F, 2011, INVEST OPHTHALMOL VI, V52
   Sabeti F, 2011, VISION RES, V51, P303, DOI 10.1016/j.visres.2010.10.015
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Spry PGD, 2001, INVEST OPHTH VIS SCI, V42, P1404
   Spry PGD, 2003, BRIT J OPHTHALMOL, V87, P107, DOI 10.1136/bjo.87.1.107
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P375, DOI 10.1016/S0161-6420(89)32883-1
   Tan L, 2001, VISION RES, V41, P1073, DOI 10.1016/S0042-6989(01)00030-X
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Wilhelm H, 2000, INVEST OPHTH VIS SCI, V41, P1229
NR 53
TC 16
Z9 16
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD DEC
PY 2011
VL 88
IS 12
BP 1477
EP 1485
DI 10.1097/OPX.0b013e318235af61
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 861PI
UT WOS:000298031300013
PM 21983122
DA 2022-11-30
ER

PT J
AU Ntumba, K
   Akla, N
   Oh, SP
   Eichmann, A
   Larrivee, B
AF Ntumba, Kalonji
   Akla, Naoufal
   Oh, S. Paul
   Eichmann, Anne
   Larrivee, Bruno
TI BMP9/ALK1 inhibits neovascularization in mouse models of age-related
   macular degeneration
SO ONCOTARGET
LA English
DT Article
DE age-related macular degeneration; ocular pathologies; angiogenesis; BMP
   signaling
ID ENDOTHELIAL GROWTH-FACTOR; ADVERSE EVENTS; VEGF; NOTCH; ANGIOGENESIS;
   CELLS; ALK1; RETINOPATHY; RECEPTORS; BMP9
AB Age-related macular degeneration (AMD) is the leading cause of blindness in aging populations of industrialized countries. The drawbacks of inhibitors of vascular endothelial growth factor (VEGFs) currently used for the treatment of AMD, which include resistance and potential serious side-effects, require the identification of new therapeutic targets to modulate angiogenesis. BMP9 signaling through the endothelial Alk1 serine-threonine kinase receptor modulates the response of endothelial cells to VEGF and promotes vessel quiescence and maturation during development. Here, we show that BMP9/Alk1 signaling inhibits neovessel formation in mouse models of pathological ocular angiogenesis relevant to AMD. Activating Alk1 signaling in laser-induced choroidal neovascularization (CNV) and oxygen-induced retinopathy (OIR) inhibited neovascularization and reduced the volume of vascular lesions. Alk1 signaling was also found to interfere with VEGF signaling in endothelial cells whereas BMP9 potentiated the inhibitory effects of VEGFR2 signaling blockade, both in OIR and laser-induced CNV. Together, our data show that targeting BMP9/Alk1 efficiently prevents the growth of neovessels in AMD models and introduce a new approach to improve conventional anti-VEGF therapies.
C1 [Ntumba, Kalonji; Larrivee, Bruno] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Biomed Sci, Res Ctr, Montreal, PQ, Canada.
   [Akla, Naoufal] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Biochem, Res Ctr, Montreal, PQ, Canada.
   [Larrivee, Bruno] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Mol Biol, Res Ctr, Montreal, PQ, Canada.
   [Larrivee, Bruno] Univ Montreal, Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Montreal, PQ, Canada.
   [Oh, S. Paul] Univ Florida, Dept Physiol & Funct Genom, Gainesville, FL USA.
   [Eichmann, Anne] Yale Cardiovasc Res Ctr, New Haven, CT USA.
   [Eichmann, Anne] Paris Cardiovasc Res Ctr, Inserm U970, Paris, France.
   [Larrivee, Bruno] Univ Quebec Montreal, Dept Biol Sci, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal;
   Universite de Montreal; State University System of Florida; University
   of Florida; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite Paris Cite;
   University of Quebec; University of Quebec Montreal
RP Larrivee, B (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp, Dept Biomed Sci, Res Ctr, Montreal, PQ, Canada.; Larrivee, B (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp, Dept Mol Biol, Res Ctr, Montreal, PQ, Canada.; Larrivee, B (通讯作者)，Univ Montreal, Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Montreal, PQ, Canada.; Larrivee, B (通讯作者)，Univ Quebec Montreal, Dept Biol Sci, Montreal, PQ, Canada.
EM bruno.larrivee@umontreal.ca
OI Larrivee, Bruno/0000-0003-1388-3108
FU Foundation Fighting Blindness; Antoine-Turmel Foundation; FRQS Vision
   Health Research Network; Heart and Stroke Foundation of Canada; NIH [R01
   EY025979-01, R01HLI125811]; Hopital Maisonneuve-Rosemont Foundation;
   NATIONAL EYE INSTITUTE [R01EY025979] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL125811] Funding Source:
   NIH RePORTER
FX We would like to thank Elisabeth Andrienssen for help with the Laser-CNV
   model. The work described in this paper was supported by the Foundation
   Fighting Blindness, The Antoine-Turmel Foundation and the FRQS Vision
   Health Research Network and Hopital Maisonneuve-Rosemont Foundation.
   B.L. was supported by a New Investigator Award from the Heart and Stroke
   Foundation of Canada. A.E. was supported by NIH grants R01 EY025979-01
   and R01HLI125811.
CR Agosta E, 2012, PHARMACOGENOMICS, V13, P1037, DOI [10.2217/PGS.12.77, 10.2217/pgs.12.77]
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Aspalter IM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8264
   Bayrak-Toydemir P, 2006, AM J MED GENET A, V140A, P2155, DOI 10.1002/ajmg.a.31450
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MA, 2005, J BIOL CHEM, V280, P25111, DOI 10.1074/jbc.M503328200
   Chen J, 2011, CIRCULATION, V124, P1871, DOI 10.1161/CIRCULATIONAHA.111.040337
   Cole SG, 2005, J MED GENET, V42, P577, DOI 10.1136/jmg.2004.028712
   Cunha SI, 2015, CANCER RES, V75, P2445, DOI 10.1158/0008-5472.CAN-14-3706
   David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124
   Ehlken C, 2011, ACTA OPHTHALMOL, V89, P82, DOI 10.1111/j.1755-3768.2009.01609.x
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Hawinkels LJAC, 2016, CLIN CANCER RES, V22, P96, DOI 10.1158/1078-0432.CCR-15-0743
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hellstrom M, 2007, CELL ADHES MIGR, V1, P133, DOI 10.4161/cam.1.3.4978
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Jin Y, 2014, BIOCHEM SOC T, V42, P1576, DOI 10.1042/BST20140231
   Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189
   Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114
   Keating AM, 2011, OCUL SURF, V9, P227, DOI 10.1016/S1542-0124(11)70035-0
   Larrivee B, 2012, DEV CELL, V22, P489, DOI 10.1016/j.devcel.2012.02.005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Long L, 2015, NAT MED, V21, P777, DOI 10.1038/nm.3877
   MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345
   Moya IM, 2012, DEV CELL, V22, P501, DOI 10.1016/j.devcel.2012.01.007
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015
   Ricard N, 2012, BLOOD, V119, P6162, DOI 10.1182/blood-2012-01-407593
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Scott A, 2010, EYE, V24, P416, DOI 10.1038/eye.2009.306
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Shao ES, 2009, BLOOD, V114, P2197, DOI 10.1182/blood-2009-01-199166
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   Umeda N, 2004, AM J OPHTHALMOL, V138, P270, DOI 10.1016/j.ajo.2004.04.006
   Walker EJ, 2012, STROKE, V43, P1925, DOI 10.1161/STROKEAHA.111.647982
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 46
TC 19
Z9 21
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 30
PY 2016
VL 7
IS 35
BP 55957
EP 55969
DI 10.18632/oncotarget.11182
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EA8TL
UT WOS:000386911600003
PM 27517154
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Yeung, L
   Hsieh, YT
   Yang, CH
   Chen, LJ
   Chen, SJ
   Cheng, CK
   Sheu, SJ
   Tsai, CY
   Wu, TT
   Wu, WC
   Chen, SN
AF Yeung, Ling
   Hsieh, Yi-Ting
   Yang, Chang-Hao
   Chen, Lee-Jen
   Chen, Shih-Jen
   Cheng, Cheng-Kuo
   Sheu, Shwu-Jiuan
   Tsai, Ching-Yao
   Wu, Tsung-Tien
   Wu, Wei-Chi
   Chen, San-Ni
TI Management of neovascular age-related macular degeneration: Taiwan
   expert consensus
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE Neovascular age-related macular degeneration; Wet age-related macular
   degeneration; Vascular endothelial growth factors
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ELDERLY CHINESE POPULATION;
   RISK-FACTORS; RANIBIZUMAB TREATMENT; CIGARETTE-SMOKING; VISUAL OUTCOMES;
   DOSING REGIMEN; VISION LOSS; PREDICTORS; AFLIBERCEPT
AB Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss. The present consensus provides suggestions on diagnosis, evaluation, treatment, and follow-up strategies for nAMD from a panel of 11 practicing ophthalmologists. The experts suggest that the baseline visit for nAMD management should include a comprehensive ophthalmologic examination via a multimodal approach consisting of visual and anatomical evaluation. Patients diagnosed with nAMD should be subjected to treatment with the goal of maintaining visual function while diminishing anatomical disease activity and minimizing treatment burden. Currently, anti-VEGF therapy is the main treatment strategy for nAMD, and evaluation involving comprehensive ophthalmologic examination within 1 month of completion of the loading phase comprising three monthly injections is recommended to guide subsequent management. Either a treat-and-extend or pro re nata regimen can be considered for the maintenance phase of anti-VEGF therapy, and the regimen should be chosen and adjusted according to disease activity, reimbursement criteria, financial burden, and patient preferences. In the event of inactive nAMD or poor treatment outcomes, after thorough evaluation and patient education, anti-VEGF therapy may be stopped. The consensus provides practical nAMD management guidelines for ophthalmologists and fellow healthcare professionals. Copyright 2021, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Yeung, Ling] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung, Taiwan.
   [Yeung, Ling; Wu, Wei-Chi] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Hsieh, Yi-Ting; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Yang, Chang-Hao] Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen; Tsai, Ching-Yao; Wu, Tsung-Tien] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Cheng, Cheng-Kuo] Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan.
   [Sheu, Shwu-Jiuan] Kaohsiung Med Univ, Dept Ophthalmol, Chung Ho Mem Hosp, Kaohsiung, Taiwan.
   [Sheu, Shwu-Jiuan] Kaohsiung Med Univ, Sch Med, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Tsai, Ching-Yao] Taipei City Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Wu, Tsung-Tien] Kaohsiung Vet Gen Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Wu, Wei-Chi] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan, Taiwan.
   [Chen, San-Ni] Changhua Christian Hosp, Dept Ophthalmol, 135 Nanxiao St, Changhua 500, Changhua, Taiwan.
   [Chen, San-Ni] Chung Shan Med Univ, Coll Med, Taichung, Taiwan.
   [Chen, San-Ni] Da Yeh Univ, Coll Nursing & Hlth Sci, Dept Optometry, Changhua, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; Mackay Memorial Hospital; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; Shin Kong Wu Ho Su Memorial
   Hospital; Fu Jen Catholic University; Kaohsiung Medical University;
   Kaohsiung Medical University Hospital; Kaohsiung Medical University;
   Taipei City Hospital; Kaohsiung Veterans General Hospital; Chang Gung
   Memorial Hospital; Changhua Christian Hospital; Chung Shan Medical
   University; Da Yeh University
RP Chen, SN (通讯作者)，Changhua Christian Hosp, Dept Ophthalmol, 135 Nanxiao St, Changhua 500, Changhua, Taiwan.
EM 108562@cch.org.tw
OI YANG, CHANG-HAO/0000-0002-4328-8716; Chen, Shih-Jen/0000-0001-9798-1578
FU Full Universe Integrated Marketing Ltd., Taiwan - Novartis Taiwan
FX Editorial assistance in the preparation of this manuscript was provided
   by Full Universe Integrated Marketing Ltd., Taiwan. The content and
   final decision of all aspects of this article was completed and made
   independently by all authors. The related support of this assistance was
   funded by Novartis Taiwan.
CR Adrean SD, 2018, OPHTHALMOL RETINA, V2, P225, DOI 10.1016/j.oret.2017.07.009
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arendt P, 2019, RETINA-J RET VIT DIS, V39, P27, DOI 10.1097/IAE.0000000000001923
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chen LJ, 2020, J FORMOS MED ASSOC, V119, P569, DOI 10.1016/j.jfma.2019.04.012
   Chen N, 2012, JPN J OPHTHALMOL, V56, P624, DOI 10.1007/s10384-012-0178-8
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Chou YB, 2019, J CHIN MED ASSOC, V82, P659, DOI 10.1097/JCMA.0000000000000138
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Evans RN, 2019, INVEST OPHTH VIS SCI, V60
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Gelman SK, 2014, RETINA-J RET VIT DIS, V34, P2088, DOI 10.1097/IAE.0000000000000207
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hsia Y, 2020, GRAEF ARCH CLIN EXP, V258, P273, DOI 10.1007/s00417-019-04546-1
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jin GM, 2019, CLIN EXP OPHTHALMOL, V47, P1019, DOI 10.1111/ceo.13580
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lo KJ, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4538135
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   NICE Guidance, 2018, AGE RELATED MACULAR
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Panel AAoORV, 2019, PREF PRACT PATT GUID
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2020, EYE, V34, P1825, DOI 10.1038/s41433-019-0747-x
   Sasaki M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186955
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spooner K, 2017, CLIN OPHTHALMOL, V11, P161, DOI 10.2147/OPTH.S125676
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang BCL, 2019, TAIWAN J OPHTHALMOL, V9, P249, DOI 10.4103/tjo.tjo_34_19
   Yeung L, 2018, RETINA-J RET VIT DIS, V38, P263, DOI 10.1097/IAE.0000000000001556
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 68
TC 2
Z9 3
U1 2
U2 3
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD DEC
PY 2021
VL 120
IS 12
BP 2061
EP 2071
DI 10.1016/j.jfma.2021.06.012
EA NOV 2021
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XG6CV
UT WOS:000724839700003
PM 34274193
OA gold
DA 2022-11-30
ER

PT J
AU De Massougnes, S
   Dirani, A
   Ambresin, A
   Decugis, D
   Marchionno, L
   Mantel, I
AF De Massougnes, Sophie
   Dirani, Ali
   Ambresin, Aude
   Decugis, Doris
   Marchionno, Laetitia
   Mantel, Irmela
TI PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB Time Course
   and Drug Effects
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE angiogenesis; antiangiogenic drugs; intravitreal injection; retinal
   pigment epithelial detachment; vascular endothelial growth factor;
   visual impairment; neovascular age-related macular degeneration;
   ranibizumab; aflibercept; refractoriness
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT; CHOROIDAL
   NEOVASCULARIZATION; VEGF TRAP; ANATOMICAL OUTCOMES; EYES; BEVACIZUMAB;
   FLUID; RECEPTORS; RESISTANT
AB Purpose: To investigate the time course of pigment epithelium detachment (PED) height and its change after anti-vascular endothelial growth factor switch from ranibizumab to aflibercept in neovascular age-related macular degeneration.
   Methods: This retrospective study included 60 eyes of 50 consecutive patients with neovascular age-related macular degeneration who showed refractory intraretinal or subretinal fluid (>= 9 months) despite monthly ranibizumab treatment and an associated PED (height >= 150 mu m). The treatment was switched to aflibercept, and patients were followed-up for at least 9 months. Data on the height and type of PED, exudative fluid, and best-corrected visual acuity were collected at four different time points (two before and two after the drug switch).
   Results: The maximal PED height was significantly decreased over time, both under ranibizumab and aflibercept treatment. However, the reduction was significantly greater during the 3 months after the switch to aflibercept, due to two outliers. Visual acuity remained stable. Complete resolution of intraretinal or subretinal fluid was observed in 9 cases (15%) at 3 months after switch, allowing for treatment interval extension.
   Conclusion: Maximal PED height continuously decreased over time. Switching the intravitreal anti-vascular endothelial growth factor medication from ranibizumab to aflibercept had a significantly stronger short-term effect on PED height reduction, without changes in visual acuity.
C1 [De Massougnes, Sophie; Dirani, Ali; Ambresin, Aude; Decugis, Doris; Marchionno, Laetitia; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fondat Asile Aveugles Fdn Asylum Blind, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Jules Gonin Eye Hosp, 15 Ave France,Case Postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, P813
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Guber J, 2014, OPEN OPHTHALMOL J, V8, P3, DOI 10.2174/1874364101408010003
   Hariri A, 2015, OSLI RETINA, V46, P195, DOI 10.3928/23258160-20150213-18
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Hoerster R, 2014, RETINA-J RET VIT DIS, V34, P1767, DOI 10.1097/IAE.0000000000000188
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Ozaki NK, 2002, INVEST OPHTH VIS SCI, V43, P1546
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Wolf A, 2013, RETINA-J RET VIT DIS, V33, P1843, DOI 10.1097/IAE.0b013e318287d9be
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 41
TC 19
Z9 19
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 881
EP 888
DI 10.1097/IAE.0000000000000813
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL2RG
UT WOS:000375482100012
PM 27115852
DA 2022-11-30
ER

PT J
AU Li, W
   Dong, LJ
   Ma, MW
   Hu, BJ
   Lu, ZY
   Liu, X
   Liu, JP
   Li, XR
AF Li, Wenbo
   Dong, Lijie
   Ma, Minwang
   Hu, Bojie
   Lu, Zhenyu
   Liu, Xun
   Liu, Juping
   Li, Xiaorong
TI Preliminary in vitro and in vivo assessment of a new targeted inhibitor
   for choroidal neovascularization in age-related macular degeneration
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE choroidal neovascularization; macular degeneration; complement
   activation; vascular endothelial growth factor
ID ALTERNATIVE PATHWAY; COMPLEMENT ACTIVATION; OCULAR NEOVASCULARIZATION;
   GENE-TRANSFER; MOUSE MODEL; RECEPTOR; GROWTH; DRUSEN; VEGF; SFLT-1
AB Choroidal neovascularization (CNV) in age-related macular degeneration usually causes blindness. We established a novel targeted inhibitor for CNV in age-related macular degeneration. The inhibitor CR2-sFlt 1 comprises a CR2-targeting fragment and an anti-vascular endothelial growth factor (VEGF) domain (sFlt 1). The targeting of CR2-sFlt 1 was studied using the transwell assay in vitro and frozen sections in vivo using green fluorescent labeling. Trans-well assay results showed that CR2-sFlt 1 migrated to the interface of complement activation products and was present in the retinal tissue of the CR2-sFlt 1-treated CNV mice. Treatment effects were assessed by investigating the VEGF concentration in retinal pigmented epithelial cell medium and the thickness of the CNV complex in the mice treated with CR2-sFlt 1. CR2-sFlt 1 significantly reduced the VEGF secretion from retinal pigmented epithelial cells in vitro and retarded CNV progress in a mouse model. Expression analysis of VEGF and VEGFRs after CR2-sFlt 1 intervention indicated the existence of feedback mechanisms in exogenous CR2-sFlt 1, endogenous VEGF, and VEGFR interaction. In summary, we demonstrated for the first time that using CR2-sFlt 1 could inhibit CNV with clear targeting and high selectivity.
C1 [Li, Wenbo; Dong, Lijie; Hu, Bojie; Liu, Xun; Liu, Juping; Li, Xiaorong] Tianjin Med Univ, Hosp Eye, 251 Fu Kang Rd, Tianjin 300384, Peoples R China.
   [Ma, Minwang] Chinese Peoples Armed Police Forces CapF, Coll Med, Affiliated Hosp, Tianjin, Peoples R China.
   [Lu, Zhenyu] Tianjin Precis Cell Biotechnol Co Ltd, Tianjin, Peoples R China.
C3 Tianjin Medical University
RP Li, XR (通讯作者)，Tianjin Med Univ, Hosp Eye, 251 Fu Kang Rd, Tianjin 300384, Peoples R China.
EM lixr10@126.com
FU National Natural Science Foundation of China [81400425, 81570872];
   Tianjin Municipal Science and Technology Commission [15JCYBJC24900]
FX This research was supported by grants from the National Natural Science
   Foundation of China (Nos 81400425 and 81570872) and Tianjin Municipal
   Science and Technology Commission (15JCYBJC24900).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Banda NK, 2009, J IMMUNOL, V183, P5928, DOI 10.4049/jimmunol.0901826
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Fridkis-Hareli M, 2011, BLOOD, V118, P4705, DOI 10.1182/blood-2011-06-359646
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Hu XZ, 2012, NEUROSCI LETT, V531, P35, DOI 10.1016/j.neulet.2012.10.012
   Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Li WB, 2010, MED SCI MONITOR, V16, pBR17
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 27
TC 6
Z9 11
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2016
VL 10
BP 3415
EP 3423
DI 10.2147/DDDT.S115801
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DZ2II
UT WOS:000385665100001
PM 27799741
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Neri, P
   Mariotti, C
   Arapi, I
   Bambini, E
   Giovannini, A
AF Neri, Piergiorgio
   Mariotti, Cesare
   Arapi, Ilir
   Bambini, Elisa
   Giovannini, Alfonso
TI Anti vascular endothelial growth factor sequential therapy for
   neovascular age-related macular degeneration: is this the new deal?
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE Age-related macular degeneration; Anti-VEGF; maintenance therapy;
   Neovascularisation
ID PEGAPTANIB SODIUM; COST-EFFECTIVENESS; OCULAR NEOVASCULARIZATION;
   SYSTEMIC SAFETY; BEVACIZUMAB; VEGF; RANIBIZUMAB; MAINTENANCE
AB Objective:
   To review clinical data on the sequential use of the non-selective vascular endothelial growth factor (VEGF) inhibitors (ranibizumab and bevacizumab) and the selective VEGF inhibitor (pegaptanib) in the treatment of neovascular age related macular degeneration (n-AMD).
   Methods:
   This is a selective review of the literature based on a PubMed search using the terms 'age-related macular degeneration', 'selective anti-VEGF', 'non-selective anti-VEGF' and 'combination therapy' from 2000 to date in the English language. Studies on the management of n-AMD reporting adherence, patient-reported outcomes, costs, side effects, resource use and cost effectiveness were also included.
   Results:
   The trial data suggest that pan-VEGF inhibition provides improved treatment outcomes in patients with n-AMD with selective anti-VEGF agents offering better tolerability on long-term treatment. A pilot trial and a large-scale, multicentre study confirmed the long-term efficacy of a selective VEGF inhibitor when used as maintenance therapy. Importantly, there is evidence that selective VEGF inhibition also reduces the risks associated with pan-VEGF blockade in patients with n-AMD.
   Discussion:
   Anti-VEGF agents play a principal role in the management of n-AMD. The most potent are the pan-VEGF agents although there is some discussion regarding their long-term tolerability. The sequential use of nonselective VEGF inhibitors as booster therapy with a selective VEGF inhibitor as maintenance therapy seems to offer a promising safety/efficacy profile, as well as improved cost/effectiveness.
C1 [Neri, Piergiorgio] Polytech Univ Marche, Ocular Immunol Serv, Eye Clin, I-60020 Ancona, Italy.
   [Arapi, Ilir] Mother Teresa Univ Hosp Ctr, Ophthalmol Ear Nose & Throat Dept, Tirana, Albania.
C3 Marche Polytechnic University; University Hospital Center Mother Teresa
   (QSUT)
RP Neri, P (通讯作者)，Polytech Univ Marche, Ocular Immunol Serv, Eye Clin, Via Conca 71, I-60020 Ancona, Italy.
EM p.neri@univpm.it
RI Piergiorgio Neri, BMedSc/K-5600-2019; Neri, Piergiorgio/K-3173-2019
OI Piergiorgio Neri, BMedSc/0000-0002-7673-4276; 
FU Pfizer, Italy
FX This study was funded by Pfizer, Italy.
CR Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Brar VS, 2010, MOL VIS, V16, P1848
   Cleary C A, 2011, Ir Med J, V104, P146
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Foy JWD, 2007, J OCUL PHARMACOL TH, V23, P452, DOI 10.1089/jop.2006.0149
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hughes MS, 2006, OPHTHAL SURG LAS IM, V37, P446, DOI 10.3928/15428877-20061101-01
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Neri Piergiorgio, 2008, International Ophthalmology, V28, P425, DOI 10.1007/s10792-007-9152-8
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 27
TC 6
Z9 6
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD MAR
PY 2012
VL 28
IS 3
BP 395
EP 400
DI 10.1185/03007995.2012.662153
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 908ZH
UT WOS:000301531100010
PM 22283373
DA 2022-11-30
ER

PT J
AU Gnanaguru, G
   Wagschal, A
   Oh, J
   Saez-Torres, KL
   Li, T
   Temel, RE
   Kleinman, ME
   Naar, AM
   D'Amore, PA
AF Gnanaguru, Gopalan
   Wagschal, Alexandre
   Oh, Justin
   Saez-Torres, Kahira L.
   Li, Tong
   Temel, Ryan E.
   Kleinman, Mark E.
   Naar, Anders M.
   D'Amore, Patricia A.
TI Targeting of miR-33 ameliorates phenotypes linked to age-related macular
   degeneration
SO MOLECULAR THERAPY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; BRUCHS MEMBRANE;
   CHOLESTEROL; MACROPHAGES; MICRORNA-33; EFFLUX; ATHEROSCLEROSIS;
   ASSOCIATIONS; COACTIVATOR
AB Abnormal cholesterol/lipid homeostasis is linked to neurode-generative conditions such as age-related macular degeneration (AMD), which is a leading cause of blindness in the elderly. The most prevalent form, termed "dry" AMD, is characterized by pathological cholesterol accumulation beneath the retinal pigment epithelial (RPE) cell layer and inflammation-linked degeneration in the retina. We show here that the cholesterol-regulating microRNA miR-33 was elevated in the RPE of aging mice. Expression of the miR-33 target ATP-binding cassette transporter (ABCA1), a cholesterol efflux pump genetically linked to AMD, declined reciprocally in the RPE with age. In accord, miR-33 modulated ABCA1 expression and cholesterol efflux in human RPE cells. Subcutaneous delivery of miR-33 antisense oligonucleotides (ASO) to aging mice and non-human primates fed a Western-type high fat/cholesterol diet resulted in increased ABCA1 expression, decreased cholesterol accumulation, and reduced immune cell infiltration in the RPE cell layer, accompanied by decreased pathological changes to RPE morphology. These findings suggest that miR-33 targeting may decrease cholesterol deposition and ameliorate AMD initiation and progression.
C1 [Gnanaguru, Gopalan; Saez-Torres, Kahira L.; D'Amore, Patricia A.] Harvard Med Sch, Dept Ophthalmol, Schepens Eye Res Inst Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Wagschal, Alexandre; Oh, Justin; Naar, Anders M.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc Res, Dept Cell Biol, Charlestown, MA 02129 USA.
   [Li, Tong; Temel, Ryan E.] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA.
   [Li, Tong; Temel, Ryan E.] Univ Kentucky, Dept Pharmacol & Nutr Sci, Lexington, KY 40536 USA.
   [Kleinman, Mark E.] Univ Kentucky, Coll Med, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
   [D'Amore, Patricia A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02129 USA.
   [Gnanaguru, Gopalan] Harvard Med Sch, Angiogenesis Lab, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
   [Wagschal, Alexandre; Oh, Justin] Exon Inc, Watertown, MA 02472 USA.
   [Li, Tong] Qingdao Municipal Hosp, Dept Neurosurg, Qingdao, Shandong, Peoples R China.
   [Kleinman, Mark E.] East Tennessee State Univ, Dept Surg, Johnson City, TN 37614 USA.
   [Naar, Anders M.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
C3 Harvard University; Harvard Medical School; Harvard University;
   Massachusetts General Hospital; University of Kentucky; University of
   Kentucky; University of Kentucky; Harvard University; Harvard Medical
   School; Massachusetts General Hospital; Harvard University; Harvard
   Medical School; Massachusetts Eye & Ear Infirmary; Qingdao Municipal
   Hospital; East Tennessee State University; University of California
   System; University of California Berkeley
RP D'Amore, PA (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Schepens Eye Res Inst Massachusetts Eye & Ear, Boston, MA 02114 USA.; Naar, AM (通讯作者)，Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
EM naar@berkeley.edu; patricia_damore@meei.harvard.edu
RI Gnanaguru, Gopalan/AAJ-9336-2021
OI Li, Tong/0000-0002-2608-2855; Kleinman, Mark/0000-0001-8557-7949
FU NIH National Eye Institute core grant [P30EY003790]; Grimshaw-Gudewicz
   Charitable Foundation for AMD Research; NIH [R01 HL111932]; Stein
   Innovation Award from the Research to Prevent Blindness Foundation; MGH
   Research Scholar Award
FX Supported by the NIH National Eye Institute core grant P30EY003790
   (P.A.D.), the Grimshaw-Gudewicz Charitable Foundation for AMD Research
   (P.A.D.), NIH grant R01 HL111932 (R.E.T.), the Stein Innovation Award
   from the Research to Prevent Blindness Foundation (A.M.N.), and
   anMGHResearch Scholar Award (A.M.N.). We would like to thank Sierra
   Schlicht and Courtney Burkett and the Temel Lab, Saha Cardiovascular
   Research Center, Department of Pharmacology and Nutritional Sciences,
   University of Kentucky, Lexington, KY, USA, for technical assistance;
   Marcelo Cicconet, Department of Cell Biology, Harvard Medical School,
   Boston, MA, USA, for assistance with RPE image analysis; and Philip
   Seifert, morphology core, Schepens Eye Research Institute of Mass Eye
   and Ear, Boston, MA, USA.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Asare-Bediako B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020464
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Davalos A, 2011, P NATL ACAD SCI USA, V108, P9232, DOI 10.1073/pnas.1102281108
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Dighe S, 2020, BRIT J OPHTHALMOL, V104, P1070, DOI 10.1136/bjophthalmol-2019-314813
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Gerin I, 2010, J BIOL CHEM, V285, P33652, DOI 10.1074/jbc.M110.152090
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Horie T, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.003376
   Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789
   Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Picaud S, 2019, P NATL ACAD SCI USA, V116, P26280, DOI 10.1073/pnas.1902292116
   Rayner KJ, 2011, NATURE, V478, P404, DOI 10.1038/nature10486
   Rayner KJ, 2011, J CLIN INVEST, V121, P2921, DOI 10.1172/JCI57275
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Roddy GW, 2020, CURR EYE RES, V45, P726, DOI 10.1080/02713683.2019.1694156
   Rotllan N, 2013, ARTERIOSCL THROM VAS, V33, P1973, DOI 10.1161/ATVBAHA.113.301732
   Rottiers V, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006840
   Rottiers V, 2012, NAT REV MOL CELL BIO, V13, P239, DOI 10.1038/nrm3313
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wagschal A, 2015, NAT MED, V21, P1290, DOI 10.1038/nm.3980
   Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045
   Walker AK, 2010, GENE DEV, V24, P1403, DOI 10.1101/gad.1901210
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang LF, 2020, CELL, V183, P684, DOI 10.1016/j.cell.2020.09.017
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 65
TC 6
Z9 6
U1 1
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD JUL 7
PY 2021
VL 29
IS 7
BP 2281
EP 2293
DI 10.1016/j.ymthe.2021.03.014
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA TF2HH
UT WOS:000670532400009
PM 33744470
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Hartmann, KI
   Oster, SF
   Amini, P
   Bartsch, DU
   Cheng, LY
   Freeman, WR
AF Hartmann, Kathrin I.
   Oster, Stephen F.
   Amini, Payam
   Bartsch, Dirk-Uwe
   Cheng, Lingyun
   Freeman, William R.
TI SLO-Microperimetry in Wet Age-Related Macular Degeneration During
   Anti-VEGF Therapy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; VISUAL-ACUITY;
   INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; SD-OCT;
   RANIBIZUMAB; EDEMA; DISRUPTION; SECONDARY
AB BACKGROUND AND OBJECTIVE: To evaluate the morphological and functional outcome of wet age-related macular degeneration (AMD) during antivascular endothelial growth factor therapy with bevacizumab using SLO microperimetry (SLO-MP) with eye tracking.
   PATIENTS AND METHODS: First, reproducibility was tested over the choroidal neovascularization (CNV) in 21 eyes of 19 patients with wet AMD. Second, 21 eyes of 19 patients with active CNV were studied longitudinally during bevacizumab therapy. Best-corrected visual acuity, SLO-MP, spectral-domain optical coherence tomography and fluorescein angiography were performed.
   RESULTS: There was good reproducibility with a concordance correlation coefficient of 0.85. In the longitudinal study, eyes with anatomical response demonstrated a significant increase of retinal sensitivity. Non-responders showed no change in SLO-MP. Retinal sensitivity at baseline had a significant predictive value for the change in retinal sensitivity during therapy with bevacizumab (P = .032).
   CONCLUSION: SLO-MP is able to analyze retinal function overlying lesions in wet AMD and can be a useful tool to monitor therapy in patients with macular diseases.
C1 [Hartmann, Kathrin I.; Oster, Stephen F.; Amini, Payam; Bartsch, Dirk-Uwe; Cheng, Lingyun; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92037 USA.
   [Hartmann, Kathrin I.] Univ Munich, Dept Ophthalmol, Marchioninistr 15, D-81377 Munich, Germany.
C3 University of California System; University of California San Diego;
   University of Munich
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
RI Amini, Payam/K-5164-2019
OI Amini, Payam/0000-0001-8675-0045
FU NIH [NEI EY 07366, EY 016323]; RPB Inc.; Jacobs Retina Center; NATIONAL
   EYE INSTITUTE [R01EY007366, R01EY016323] Funding Source: NIH RePORTER
FX Supported in part by NIH grant NEI EY 07366 (WRF), EY 016323 (DUB), RPB
   Inc., and an unrestricted grant from the Jacobs Retina Center.
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Freeman WR, 2006, RETINA-J RET VIT DIS, V26, P853, DOI 10.1097/01.iae.0000244722.35073.7c
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kozak I, 2005, RETINA-J RET VIT DIS, V25, P994, DOI 10.1097/00006982-200512000-00007
   Kozak I, 2009, RETINA, V30, P431
   Kriechbaum K, 2009, OPHTHALMOLOGY, V116, P2415, DOI 10.1016/j.ophtha.2009.05.001
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Oster SF, 2010, RETINA-J RET VIT DIS, V30, P713, DOI 10.1097/IAE.0b013e3181c596e3
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   Rensch F, 2008, ACTA OPHTHALMOL, V86, P696, DOI 10.1111/j.1600-0420.2007.01131.x
   Rohrschneider K, PROG RETIN EYE RES, V827, P536
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Varano M, 2010, RETINA-J RET VIT DIS, V30, P413, DOI 10.1097/IAE.0b013e3181bd2d23
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
NR 35
TC 4
Z9 4
U1 0
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2015
VL 46
IS 8
BP 824
EP 830
DI 10.3928/23258160-20150909-06
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UD
UT WOS:000378842000007
PM 26431297
DA 2022-11-30
ER

PT J
AU Leveziel, N
   Pelat, T
   Watier, H
   Thullier, P
   Souied, EH
AF Leveziel, Nicolas
   Pelat, Thibaut
   Watier, Herve
   Thullier, Philippe
   Souied, Eric H.
TI Detection of Antiranibizumab Antibodies among Patients with Exudative
   Age-Related Macular Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor antibody; Immunization; Non-responder; Ranibizumab; Lucentis;
   Bevacizumab; Avastin; Tachyphylaxis; Resistance
ID RANIBIZUMAB; TACHYPHYLAXIS; BEVACIZUMAB
AB Purpose: The aim of this study was to detect immune responses induced by intravitreal injection (IVT) of ranibizumab in patients with exudative age-related macular degeneration (AMD) in real life conditions. Methods: An ELISA protocol from blood samples, following 2 different steps, was used to detect antibodies directed against the variable regions of ranibizumab. Results: Among 91 patients included, 46 received more than 10 IVTs, 36 had received 10 IVTs or fewer, and 9 were treatment naive. Specific antiranibizumab immunoglobulins G were detected in 14/82 treated patients (17.1%). No immunization was detected among naive patients. For patients with 10 or fewer previous IVTs, immunization against ranibizumab was detected in 4/36 patients (11.1%) whereas immunization was observed in 10/46 patients (21.7%) with more IVTs (p = 0.20). Conclusions: lmmunization against ranibizumab can be detected in 17% of treated patients. Further clinical studies are needed to investigate the relationship between specific immunization to anti-vascular endothelial growth factor antibodies and response or resistance to ranibizumab treatments. (C) 2014 S. Karger AG, Basel
C1 [Leveziel, Nicolas; Souied, Eric H.] Hosp Intercommunal Creteil, UPEC, Dept Ophthalmol, Creteil, France.
   [Leveziel, Nicolas] Univ Hosp Poitiers, Dept Ophthalmol, FR-86021 Poitiers, France.
   [Pelat, Thibaut; Thullier, Philippe] Ctr Rech Serv Sante Armees CRSSA IRBA, DBAT Biotechnol Anticorps, La Tronche, France.
   [Watier, Herve] Univ Tours, CHRU Tours, Pilot Ctr Therapeut Antibody Monitoring, CNRS UMR 7292, Tours, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; CHU
   Poitiers; Universite de Poitiers; Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU
   Tours; Universite de Tours
RP Leveziel, N (通讯作者)，Univ Hosp Poitiers, Dept Ophthalmol, FR-86021 Poitiers, France.
EM nicolas.leveziel@chu-poitiers.fr
OI Nicolas, Leveziel/0000-0001-8533-9457; Pelat,
   thibaut/0000-0003-4312-1032
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dery JP, 2004, AM J CARDIOL, V93, P979, DOI 10.1016/j.amjcard.2003.12.051
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Garces S, 2013, ANN RHEUM DIS, V72, P1947, DOI 10.1136/annrheumdis-2012-202220
   HALL JM, 1971, INVEST OPHTH VISUAL, V10, P775
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nelson AL, 2009, NAT BIOTECHNOL, V27, P331, DOI 10.1038/nbt0409-331
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 17
TC 8
Z9 11
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 232
IS 1
BP 53
EP 56
DI 10.1159/000360186
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ9AW
UT WOS:000338000200006
PM 24854579
DA 2022-11-30
ER

PT J
AU Hilely, A
   Au, A
   Freund, KB
   Loewenstein, A
   Souied, EH
   Zur, D
   Sacconi, R
   Borrelli, E
   Peiretti, E
   Iovino, C
   Sugiura, Y
   Ellabban, AA
   Mones, J
   Waheed, NK
   Ozdek, S
   Yalinbas, D
   Thiele, S
   Mendonca, LSD
   Lee, MY
   Lee, WK
   Turcotte, P
   Capuano, V
   Ansary, MF
   Chakravarthy, U
   Lommatzsch, A
   Gunnemann, F
   Pauleikhoff, D
   Ip, MS
   Querques, G
   Holz, FG
   Spaide, RF
   Sadda, S
   Sarraf, D
AF Hilely, Assaf
   Au, Adrian
   Freund, K. Bailey
   Loewenstein, Anat
   Souied, Eric H.
   Zur, Dinah
   Sacconi, Riccardo
   Borrelli, Enrico
   Peiretti, Enrico
   Iovino, Claudio
   Sugiura, Yoshimi
   Ellabban, Abdallah A.
   Mones, Jordi
   Waheed, Nadia K.
   Ozdek, Sengul
   Yalinbas, Duygu
   Thiele, Sarah
   de Moura Mendonca, Luisa Salles
   Lee, Mee Yon
   Lee, Won Ki
   Turcotte, Pierre
   Capuano, Vittorio
   Filali Ansary, Meryem
   Chakravarthy, Usha
   Lommatzsch, Albrecht
   Gunnemann, Frederic
   Pauleikhoff, Daniel
   Ip, Michael S.
   Querques, Giuseppe
   Holz, Frank G.
   Spaide, Richard F.
   Sadda, SriniVas
   Sarraf, David
TI Non-neovascular age-related macular degeneration with subretinal fluid
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; Angiogenesis; Choroid; Degeneration; Macula
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENT; ENDOTHELIAL
   GROWTH-FACTOR; HYPOTHESIS; OCT
AB Purpose To evaluate the various patterns of subretinal fluid (SRF) in eyes with age-related macular degeneration (AMD) in the absence of macular neovascularisation (MNV) and to assess the long-term outcomes in these eyes. Methods This retrospective study included only eyes with non-neovascular AMD and associated SRF. Eyes with evidence of MNV were excluded. Spectral-domain optical coherence tomography (SD-OCT) was obtained at baseline and at follow-up, and qualitative and quantitative SD-OCT analysis of macular drusen including drusenoid pigment epithelial detachment (PED) and associated SRF was performed to determine anatomic outcomes. Results Forty-five eyes (45 patients) were included in this analysis. Mean duration of follow-up was 49.7 +/- 36.7 months. SRF exhibited three different morphologies: crest of fluid over the apex of the drusenoid PED, pocket of fluid at the angle of a large druse or in the crypt of confluent drusen or drape of low-lying fluid over confluent drusen. Twenty-seven (60%) of the 45 eyes with fluid displayed collapse of the associated druse or drusenoid PED and 24 (53%) of the 45 eyes developed evidence of complete or incomplete retinal pigment epithelial and outer retinal atrophy. Conclusion Non-neovascular AMD with SRF is an important clinical entity to recognise to avoid unnecessary anti-vascular endothelial growth factor therapy. Clinicians should be aware that SRF can be associated with drusen or drusenoid PED in the absence of MNV and may be the result of retinal pigment epithelial (RPE) decompensation and RPE pump failure.
C1 [Hilely, Assaf; Loewenstein, Anat; Zur, Dinah] Tel Aviv Ichilov Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
   [Au, Adrian; Sarraf, David] Univ Calif Los Angeles, Retinal Disorders & Ophthalm Genet Div, Stein Eye Inst, Los Angeles, CA USA.
   [Freund, K. Bailey; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Souied, Eric H.; Capuano, Vittorio; Filali Ansary, Meryem] Ctr Hospitalier Intercommunal Creteil, Ophthalmol, Creteil, France.
   [Sacconi, Riccardo; Borrelli, Enrico; Querques, Giuseppe] Osped San Raffaele, Ophthalmol, Milan, Italy.
   [Peiretti, Enrico; Iovino, Claudio] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
   [Sugiura, Yoshimi] Univ Tsukuba, Dept Ophthalmol, Fac Med, Tsukuba, Ibaraki, Japan.
   [Ellabban, Abdallah A.] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
   [Ellabban, Abdallah A.] Suez Canal Univ, Fac Med, Ismailia, Egypt.
   [Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [Waheed, Nadia K.; de Moura Mendonca, Luisa Salles] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
   [Ozdek, Sengul; Yalinbas, Duygu; de Moura Mendonca, Luisa Salles] Gazi Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Thiele, Sarah] Univ Bonn, Ophthalmol, Bonn, Germany.
   [Lee, Mee Yon] Catholic Univ Korea, Coll Med, Seoul, South Korea.
   [Lee, Won Ki] Nune Eye Hosp, Seoul, South Korea.
   [Chakravarthy, Usha] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Lommatzsch, Albrecht; Gunnemann, Frederic; Pauleikhoff, Daniel] Sankt Franziskus Hosp Munster GmbH, Dept Ophthalmol, Munster, Germany.
   [Ip, Michael S.; Sadda, SriniVas] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA USA.
   [Sarraf, David] Greater Angeles Vet Affairs Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   Vitreous Retina Macula Consultants of New York; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; University of
   Cagliari; University of Tsukuba; Egyptian Knowledge Bank (EKB); Suez
   Canal University; Tufts University; Gazi University; University of Bonn;
   Catholic University of Korea; Queens University Belfast; Doheny Eye
   Institute
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI mones, jordi/CAJ-2963-2022; Özdek, Şengül/CAF-5314-2022; Freund, K.
   Bailey/V-7488-2018
OI mones, jordi/0000-0003-3685-2160; Özdek, Şengül/0000-0002-7494-4106;
   Freund, K. Bailey/0000-0002-7888-9773; Peiretti,
   Enrico/0000-0003-1088-0163; Sacconi, Riccardo/0000-0003-2891-2012;
   Borrelli, Enrico/0000-0003-2815-5031
FU Research to Prevent Blindness, New York, New York, USA; Macula
   Foundation, New York, New York, USA
FX This study was supported by the Research to Prevent Blindness (DS), New
   York, New York, USA and the Macula Foundation (DS, KBF), New York, New
   York, USA.
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Au A, 2019, INVEST OPHTH VIS SCI, V60, P3310, DOI 10.1167/iovs.18-26478
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khlifi, 2017, OPHTHALMOL POINT CAR, DOI [10.5301/oapoc.0000009, DOI 10.5301/OAPOC.0000009]
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Mones J, 2017, OPHTHALMOL RETINA, V1, P461, DOI 10.1016/j.oret.2017.02.006
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Negi A, 1983, INVESTIG OPHTHALMOL
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sikorski BL, 2011, OPHTHALMOLOGY, V118, P82, DOI 10.1016/j.ophtha.2010.04.017
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
NR 34
TC 17
Z9 17
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2021
VL 105
IS 10
BP 1415
EP 1420
DI 10.1136/bjophthalmol-2020-317326
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UZ8JS
UT WOS:000702446300019
PM 32920528
DA 2022-11-30
ER

PT J
AU Aslam, T
   Mahmood, S
   Balaskas, K
   Patton, N
   Tanawade, RG
   Tan, SZ
   Roberts, SA
   Parkes, J
   Bishop, PN
AF Aslam, Tariq
   Mahmood, Sajjad
   Balaskas, Konstantinos
   Patton, Niall
   Tanawade, Rajeev G.
   Tan, Shi Zhuan
   Roberts, Stephen A.
   Parkes, Jeremy
   Bishop, Paul N.
TI Repeatability of visual function measures in age-related macular
   degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; contrast sensitivity; distance visual
   acuity; reading performance; repeatability
ID ACUITY MEASUREMENTS; MACULOPATHY; EYES
AB Purpose To assess repeatability of visual function measures in patients with early, intermediate or late age-related macular degeneration (AMD) without active neovascular disease in the study eye, but active neovascular AMD in the fellow eye.
   One hundred subjects from an ongoing trial were screened for this study in which their LogMAR acuity, contrast sensitivity and reading performance were assessed using standardised protocols by trained optometrists. The same measures were repeated one month later and repeatability of the visual functions assessed.
   Data from 83 subjects satisfied inclusion criteria for analysis. Coefficient of repeatability was 14.9 letters for LogMAR visual acuity , 7.2 letters for Pelli Robson contrast sensitivity, 0.72 for LogMAR reading acuity, 110.4 words/ min for reading speed and 0.67 for LogMAR critical print size. Intraclass correlation coefficients allowed comparison between measures and were found to be 0.96 for LogMAR visual acuity, 0.93 for contrast sensitivity, 0.75 for LogMAR reading acuity, 0.79 for reading speed and 0.74 for LogMAR critical print size. Coefficients of variation were 9.4 %, 10.7 %, 48.4 %, 28.4 % and 31.8 % respectively.
   We found coefficients of repeatability that concurred with previous studies demonstrating variability of visual functions in patients with AMD. In addition, we found intraclass correlation coefficients to be better with visual acuity and contrast sensitivity than with measures of reading performance.
C1 [Aslam, Tariq; Mahmood, Sajjad; Balaskas, Konstantinos; Patton, Niall; Tanawade, Rajeev G.; Tan, Shi Zhuan; Parkes, Jeremy; Bishop, Paul N.] Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester M13 9WH, Lancs, England.
   [Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Ctr Adv Discovery & Expt Therapeut, Manchester, Lancs, England.
   [Aslam, Tariq; Bishop, Paul N.] Univ Manchester, Inst Human Dev, Ctr Ophthalmol & Vis Res, Manchester, Lancs, England.
   [Roberts, Stephen A.] Univ Manchester, Inst Populat Hlth, Ctr Biostat, Manchester, Lancs, England.
   [Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; University of Manchester; University of Manchester;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Balaskas, K (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, City Rd, London, England.
EM konstantinos.balaskas@gmail.com
RI Mahmood, Sajjad/AAK-7645-2021; Balaskas, Konstantinos/ABD-5979-2020;
   Aslam, Tariq/A-8532-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Tan, Shi
   Zhuan/0000-0001-7747-7219; Aslam, Tariq/0000-0002-9739-7280; Roberts,
   Steve/0000-0002-7477-7731; Bishop, Paul/0000-0001-7937-7932
FU Greater Manchester Primary Care Trusts; NIHR Manchester Biomedical
   Research Centre
FX We gratefully acknowledge financial support from Greater Manchester
   Primary Care Trusts and the NIHR Manchester Biomedical Research Centre.
CR ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
NR 9
TC 10
Z9 10
U1 2
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2014
VL 252
IS 2
BP 201
EP 206
DI 10.1007/s00417-013-2421-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA3LS
UT WOS:000330994600002
PM 23884391
DA 2022-11-30
ER

PT J
AU Knudtson, MD
   Klein, R
   Klein, BEK
AF Knudtson, Michael D.
   Klein, Ronald
   Klein, Barbara E. K.
TI Alcohol consumption and the 15-year cumulative incidence of age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; DIABETIC-RETINOPATHY; ABNORMALITIES; CALIBER
AB Purpose: To investigate alcohol consumption as a risk factor for the 15-year cumulative incidence and progression of age-related macular degeneration (AMD).
   Design: Prospective population,based study in Beaver Dam, WI with four examinations at five,year intervals initiated in 1988 (n = 3,509 contributed data for this analysis).
   Methods: History of alcohol consumption was obtained via questionnaire. Cumulative incidence of early AMD, exudative AMD, pure geographic atrophy, and progression of AMD were assessed from fundus photographs taken at each examination.
   Results: Heavy drinking (four or more drinks daily) at baseline was related to the 15-year cumulative incidence of pure geographic atrophy in men (odds ratio, 9.2; 95% confidence interval, 1.7 to 51.2). There were no consistent associations with the amount of beer, wine, or liquor consumption and the incidence or progression of AMD.
   Conclusions: Alcohol consumption is unlikely to strongly increase (or decrease) the risk of AMD.
C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Knudtson, MD (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM knudtson@epi.ophth.wisc.edu
FU NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY06594, U10 EY006594-20, U10 EY006594] Funding Source: Medline
CR Alibrahim E, 2006, OPHTHALMOLOGY, V113, P1499, DOI 10.1016/j.ophtha.2006.05.009
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Ciulla TA, 2002, ACTA OPHTHALMOL SCAN, V80, P468, DOI 10.1034/j.1600-0420.2002.800503.x
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P76, DOI 10.1001/archopht.122.1.76
   Klein R, 2003, OPHTHALMOLOGY, V110, P2118, DOI 10.1016/S0161-6420(03)00863-7
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1996, WISCONSIN AGE RELATE
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KOHNER EM, 1995, DIABETES, V44, P603, DOI 10.2337/diabetes.44.6.603
   Lorenzi M, 2001, DIABETOLOGIA, V44, P791, DOI 10.1007/s001250100544
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Sherry LM, 2002, CLIN EXP OPHTHALMOL, V30, P179, DOI 10.1046/j.1442-9071.2002.00520.x
NR 14
TC 26
Z9 26
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2007
VL 143
IS 6
BP 1026
EP 1029
DI 10.1016/j.ajo.2007.01.036
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 177QG
UT WOS:000247167000016
PM 17524768
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Navea, A
   Mataix, J
   Desco, C
   Garcia-Pous, M
   Palacios, E
AF Navea, Amparo
   Mataix, Jorge
   Desco, Carmen
   Garcia-Pous, Maria
   Palacios, Elena
TI ONE-YEAR FOLLOW-UP OF COMBINED CUSTOMIZED THERAPY. PHOTODYNAMIC THERAPY
   AND BEVACIZUMAB FOR ESUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE combined therapy; photodynamic therapy; bevacizumab; choroidal
   neovascularization; age-related macular degeneration
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; RANIBIZUMAB;
   VERTEPORFIN; PEGAPTANIB
AB Purpose: To evaluate whether combined, personalised photodynamic therapy (PDT) and Bevacizumab in choroidal neovascularization associated with age-related macular degeneration can improve vision, and whether it is possible to decrease the frequency and number of intravitreal antiangiogenics.
   Methods: A prospective, noncomparative, interventional study of a case series of 63 patients with exudative age-related macular degeneration, treated with an initial dose of PDT and intravitreal Bevacizumab 24 to 48 hours afterwards. Retreatments were carried out as required with monthly Bevacizumab and PDT every 3 months if there were relapses. Follow-up lasted 1 year in all cases.
   Results: After the first month of treatment, the mean best-corrected visual acuity increased by 4.85 letters, reaching 5.65 letters at the 12-month follow-up (P < 0.05). Compared with initial vision, 79.3% of the eyes had the same or better vision and 95.2% lost fewer than 15 letters. The total number of PDT treatments was 92 (a mean of 1.46 treatments per patient). The mean number of Bevacizumab injections was two per patient. In 29 cases (46%), only one initial treatment with PDT + Bevacizumab was necessary. In 15 cases (23.8%), more than two combined treatments per patient were necessary.
   Conclusions: Combined, customized PDT + Bevacizumab therapy makes it possible to obtain visual results similar to those obtained in monotherapy, but with fewer intravitreal injections. It appears to be an interesting option for this type of patients.
C1 [Navea, Amparo; Mataix, Jorge; Desco, Carmen; Garcia-Pous, Maria; Palacios, Elena] Fdn Oftalmol Mediterraneo, Valencia 46015, Spain.
RP Navea, A (通讯作者)，Fdn Oftalmol Mediterraneo, Bifurcacion Pio Baroja Gen Aviles S-N, Valencia 46015, Spain.
EM navea_amp@gva.es
RI Navea, Amparo/D-4577-2009; ESTEBAN, MARIA CARMEN DESCO/J-2281-2016
OI Navea, Amparo/0000-0002-9856-5370; ESTEBAN, MARIA CARMEN
   DESCO/0000-0002-9239-7847; Mataix Boronat, Jorge/0000-0002-7018-3506
CR Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P831, DOI 10.1111/j.1600-0420.2006.00764.x
   Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Calvo-Gonzalez C, 2008, BRIT J OPHTHALMOL, V92, P74, DOI 10.1136/bjo.2007.128942
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   MORENO JMR, 2006, RETINA, V26, P602
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rogers MS, 2004, FASEB J, V18, P1050, DOI 10.1096/fj.03-1241com
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 20
TC 12
Z9 14
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2009
VL 29
IS 1
BP 13
EP 19
DI 10.1097/IAE.0b013e31818a1fd3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 393YV
UT WOS:000262413300003
PM 18854782
DA 2022-11-30
ER

PT J
AU O'Neill, HC
   Limnios, IJ
   Barnett, NL
AF O'Neill, Helen C.
   Limnios, Ioannis J.
   Barnett, Nigel L.
TI Advancing a Stem Cell Therapy for Age-Related Macular Degeneration
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Pluripotent stem cells; retinal pigment epithelium; age-related macular
   degeneration; cell transplantation; stem cell therapy
ID RETINAL-PIGMENT EPITHELIUM; DIRECTED DIFFERENTIATION; IN-VITRO; RPE;
   TRANSPLANTATION; IMPLANTATION; POPULATION; SURVIVAL
AB The retinal pigment epithelium (RPE) is a multifunctional monolayer located at the back of the eye required for the survival and function of the light-sensing photoreceptors. In Age-related Macular Degeneration (AMD), the loss of RPE cells leads to photoreceptor death and permanent blindness. RPE cell transplantation aims to halt or reverse vision loss by preventing the death of photoreceptor cells and is considered one of the most viable applications of stem cell therapy in the field of regenerative medicine. Proof-of-concept of RPE cell transplantation for treating retinal degenerative disease, such as AMD, has long been established in animal models and humans using primary RPE cells, while recent research has focused on the transplantation of RPE cells derived from human pluripotent stem cells (hPSC). Early results from clinical trials indicate that transplantation of hPSC-derived RPE cells is safe and can improve vision in AMD patients. Current hPSC-RPE cell production protocols used in clinical trials are nevertheless inefficient. Treatment of large numbers of AMD patients using stem cell- derived products may be dependent on the ability to generate functional cells from multiple hPSC lines using robust and clinically-compliant methods. Transplantation outcomes may be improved by delivering RPE cells on a thin porous membrane for better integration into the retina, and by manipulation of the outcome through control of immune rejection and inflammatory responses.
C1 [O'Neill, Helen C.; Limnios, Ioannis J.; Barnett, Nigel L.] Bond Univ, Clem Jones Ctr Regenerat Med, Gold Coast, Qld 4229, Australia.
C3 Bond University
RP O'Neill, HC (通讯作者)，Bond Univ, Clem Jones Ctr Regenerat Med, Fac Hlth Sci & Med, Gold Coast, Qld 4229, Australia.
EM honeill@bond.edu.au
RI O'NEILL, Helen/AAW-8921-2021; Barnett, Nigel L/F-1226-2010
OI O'NEILL, Helen/0000-0002-9506-284X; Barnett, Nigel
   L/0000-0002-0704-2233; Limnios, Ioannis/0000-0002-2358-3355
FU Clem Jones Foundation (Brisbane, QLD, Australia); Cutmore Bequest
FX This study was supported by funding provided by the Clem Jones
   Foundation (Brisbane, QLD, Australia) and the Cutmore Bequest provided
   to Bond University, Gold Coast, Australia.
CR Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bobba S, 2018, EXP EYE RES, V177, P65, DOI 10.1016/j.exer.2018.07.019
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Foltz LP, 2017, JOVE-J VIS EXP, P21
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Karabekian Z, 2015, TISSUE ENG PT A, V21, P2559, DOI [10.1089/ten.tea.2015.0105, 10.1089/ten.TEA.2015.0105]
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Limnios IJ, 2017, International Patent Application, Patent No. [NoPCT/AU2016/000390, 2017091844]
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Maminishkis A, 2010, JOVE-J VIS EXP, V45, P3032
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Nakajima F, 2007, STEM CELLS, V25, P983, DOI 10.1634/stemcells.2006-0566
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pappas DJ, 2015, STEM CELL TRANSL MED, V4, P413, DOI 10.5966/sctm.2015-0052
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Surrao D, 2016, FRONT BIOENG BIOTECH, V4
   Surrao DC, 2017, ACTA BIOMATER, V64, P357, DOI 10.1016/j.actbio.2017.09.032
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Warnke PH, 2013, [US Patent, US Publication], Patent No. [9,095,524 B2, 2013/0095167 A1, 9095524B2]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021
NR 42
TC 10
Z9 10
U1 2
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-888X
EI 2212-3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2020
VL 15
IS 2
BP 89
EP 97
DI 10.2174/1574888X15666191218094020
PG 9
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KX8VD
UT WOS:000522151600001
PM 31854278
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ortiz, C
   Jimenez, JR
   Perez-Ocon, F
   Castro, JJ
   Anera, RG
AF Ortiz, Carolina
   Jimenez, Jose R.
   Perez-Ocon, Francisco
   Castro, Jose J.
   Anera, Rosario G.
TI Retinal-Image Quality and Contrast-Sensitivity Function in Age-Related
   Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Contrast-sensitivity function;
   Retinal-image quality; Scattering; Visual performance
ID OPTICAL-QUALITY; VISUAL-ACUITY; HUMAN EYE; ABERRATIONS; PERFORMANCE;
   INSTRUMENT; SENSOR
AB Purpose: In this article, retinal-image quality and contrast sensitivity were measured in 25 patients with age-related macular degeneration (ARMD) and 15 patients with normal retinal health.
   Materials and Method: Retinal-image quality was evaluated with an objective device based on the double-pass technique, and for visual performance we measured the contrast-sensitivity function.
   Results: The results from double-pass device revealed the Strehl ratio to be significantly (p < 0.0001) lower for the ARMD group with a 54.3% reduction for 3 mm pupil size and a 46.9% reduction for 4 mm. Contrast-sensitivity function for ARMD subjects was also significantly lower than for the control group (p < 0.05) with a 38.6% reduction.
   Conclusions: Patients affected with ARMD showed poorer retinal-image quality and visual performance than normal subjects. The use of objective devices based on the double-pass technique could be useful for the accurate description of the retinal-image quality of ARMD eyes, in which retinal scattering is significantly increased.
C1 [Ortiz, Carolina; Jimenez, Jose R.; Perez-Ocon, Francisco; Castro, Jose J.; Anera, Rosario G.] Univ Granada, Dept Opt, Lab Vis Sci & Applicat, E-18071 Granada, Spain.
C3 University of Granada
RP Ortiz, C (通讯作者)，Univ Granada, Dept Opt, Lab Vis Sci & Applicat, Edificio Mecenas,Fuentenueve S-N, E-18071 Granada, Spain.
EM ortizh@ugr.es
RI ORTIZ, CAROLINA/B-1280-2016; Jimenez, Jose R/C-9362-2017; Castro-Torres,
   José J./D-3828-2013; Anera, Rosario G./L-4692-2017; Ortiz,
   Carolina/ABE-8963-2020
OI ORTIZ, CAROLINA/0000-0003-0248-1699; Jimenez, Jose
   R/0000-0002-0333-6883; Castro-Torres, José J./0000-0003-0461-925X;
   Anera, Rosario G./0000-0003-3614-2142; Ortiz,
   Carolina/0000-0003-0248-1699; Perez-Ocon, Francisco/0000-0001-9532-3328
FU ONCE Foundation (Spain); Ministerio de Educacion y Ciencia (Spain) [FIS
   2006-01369]; Junta de Andalucia (Spain) [P06-FQM-01359]
FX The authors wish to thank David Nesbitt for translating the text into
   English. This research was supported by the ONCE Foundation (Spain),
   Ministerio de Educacion y Ciencia (Spain) grant FIS 2006-01369 and Junta
   de Andalucia (Spain) grant P06-FQM-01359.
CR Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Diaz-Douton F, 2006, INVEST OPHTH VIS SCI, V47, P1710, DOI 10.1167/iovs.05-1049
   Fosse P, 2001, VISUAL IMPAIRMENT RE, V3, P111
   Guell JL, 2004, J CATARACT REFR SURG, V30, P1598, DOI 10.1016/j.jcrs.2004.04.031
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jimenez JR, 2008, J MOD OPTIC, V55, P2371, DOI 10.1080/09500340802130688
   Jimenez JR, 1999, COLOR RES APPL, V24, P207, DOI 10.1002/(SICI)1520-6378(199906)24:3<207::AID-COL7>3.0.CO;2-V
   Jimenez JR, 2002, PERCEPT PSYCHOPHYS, V64, P140, DOI 10.3758/BF03194563
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Liang JZ, 1997, J OPT SOC AM A, V14, P2873, DOI 10.1364/JOSAA.14.002873
   Marsack JD, 2004, J VISION, V4, P322, DOI 10.1167/4.4.8
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   Prieto PM, 2000, J OPT SOC AM A, V17, P1388, DOI 10.1364/JOSAA.17.001388
   Shahidi M, 2004, OPTOMETRY VISION SCI, V81, P853, DOI 10.1097/01.OPX.0000145022.74296.45
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
NR 17
TC 11
Z9 12
U1 0
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG
PY 2010
VL 35
IS 8
BP 757
EP 761
DI 10.3109/02713683.2010.486521
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 663PO
UT WOS:000282900000012
PM 20673053
DA 2022-11-30
ER

PT J
AU Freeman, WR
   El-Bradey, M
   Plummer, DJ
AF Freeman, WR
   El-Bradey, M
   Plummer, DJ
TI Scanning laser entoptic perimetry for the detection of age-related
   macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; VISION; EYE
AB Objective: To determine the sensitivity and specificity of scanning laser entoptic perimetry for detecting visual function damage due to age-related macular degeneration (ARMD).
   Methods: We measured the presence or absence of visual field disturbances by entoptic perimetry and determined the severity of ARMD based on masked readings of fundus photographs. A prospective masked study comparing the findings of entoptic perimetry with fundus photographs was performed. We recruited 91 patients with ARMD and 24 patients without ARMD during ophthalmologic visits. An appropriate institutional review board approval was obtained for the project. The main outcome measure was the detection of visual scotomata.
   Results: Scanning laser entoptic perimetry had an overall sensitivity of 82% and a specificity of 100% for the detection of ARMD. The sensitivity for early stages of the disease is greater than 70%, and increases to above 90% for moderate to late stages. Conclusion: Scanning laser entoptic perimetry is a specific and sensitive test for detecting ARMD, even at the earliest stages when patients are typically asymptomatic.
C1 Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, Jacobs Retina Ctr, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Dept Ophthalmol, Jacobs Retina Ctr, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM freeman@eyecenter.ucsd.edu
FU NEI NIH HHS [R01 EY007366, EY11961] Funding Source: Medline; PHS HHS
   [E407366] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011961,
   R01EY007366] Funding Source: NIH RePORTER
CR AULHORN E, 1989, P 8 INT PER SOC M OC
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   Plummer DJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P1205
   Plummer DJ, 1999, ARCH OPHTHALMOL-CHIC, V117, P202
   Plummer DJ, 2000, OPHTHALMOLOGY, V107, P1693, DOI 10.1016/S0161-6420(00)00248-7
   RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0
   RAMACHANDRAN VS, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0592-86
   Schiefer Ulrich, 1996, Ophthalmologe, V93, P604, DOI 10.1007/s003470050047
   Sheu Shwu-Jiuan, 2002, Zhonghua Yi Xue Za Zhi (Taipei), V65, P435
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Troxler DIPV., 1804, OPHTHALMOLOGISCHE BI, V2, P1
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
NR 23
TC 10
Z9 10
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2004
VL 122
IS 11
BP 1647
EP 1651
DI 10.1001/archopht.122.11.1647
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 868SC
UT WOS:000224932300005
PM 15534125
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Zhu, MH
   Jiang, L
   Yuan, Y
   Chen, LL
   Liu, XJ
   Liang, J
   Zhu, QJ
   Ding, DM
   Song, E
AF Zhu, Manhui
   Jiang, Li
   Yuan, You
   Chen, Lili
   Liu, Xiaojuan
   Liang, Juan
   Zhu, Qiujian
   Ding, Dongmei
   Song, E.
TI Intravitreal Ets1 siRNA alleviates choroidal neovascularization in a
   mouse model of age-related macular degeneration
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Choroidal neovascularization; Ets1; Macrophages; Microglia; Activation
ID RETINAL-PIGMENT EPITHELIUM; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA;
   TRANSCRIPTION FACTOR ETS-1; E26 ONCOGEN HOMOLOG-1; GROWTH-FACTOR VEGF;
   MACROPHAGE POLARIZATION; PI3K/AKT/MTOR PATHWAY; EXPRESSION;
   ANGIOGENESIS; CELLS
AB Choroidal neovascularization (CNV) is the basic feature of neovascular age-related macular degeneration (AMD), the leading cause of blindness in elders. Macrophages and microglia promote CNV via producing pro-angiogenic factors and inflammatory cytokines. Transcription factor E26 transformation specific-1 (Ets1) plays a pro-angiogenic role via its pro-inflammatory function. In this study, Ets1 increased and localized in the macrophages and microglia of a mouse laser-induced CNV region. Ets1 siRNA intravitreal injection ameliorated the leakage and area of CNV, as well as inhibiting the dysfunction of retinal pigment epithelium (RPE) cells and the activation of macrophages/microglia. Taken together, we provide a new insight into the molecular mechanism of CNV progression, in which Ets1 can be a new therapeutic target.
C1 [Zhu, Manhui; Yuan, You; Chen, Lili; Liang, Juan; Zhu, Qiujian; Song, E.] Soochow Univ, Lixiang Eye Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.
   [Jiang, Li; Ding, Dongmei] Laizhou City Peoples Hosp, Dept Ophthalmol, Yantai, Shandong, Peoples R China.
   [Liu, Xiaojuan] Nantong Univ, Med Coll, Dept Pathogen Biol, Nantong, Jiangsu, Peoples R China.
C3 Soochow University - China; Nantong University
RP Song, E (通讯作者)，Soochow Univ, Lixiang Eye Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.; Ding, DM (通讯作者)，Laizhou City Peoples Hosp, Dept Ophthalmol, Yantai, Shandong, Peoples R China.
EM dingdm2005@aliyun.com; songe@suda.edu.cn
FU Suzhou Science and Technology Bureau [SYS2018005]; Suzhou Commission of
   Health and Family Planning [KJXW2018076]; Jiangsu Distinguished Medical
   Experts Program [2016]; Gusu Health Leading Talent Plan [025]; 14th Six
   Talents Peak Project of Jiangsu Province [SWYY-058]
FX The study was supported by the Suzhou Science and Technology Bureau (No.
   SYS2018005), Suzhou Commission of Health and Family Planning (No.
   KJXW2018076), Jiangsu Distinguished Medical Experts Program (No. 2016),
   Gusu Health Leading Talent Plan (Grant No. 025) and the 14th Six Talents
   Peak Project of Jiangsu Province (No. SWYY-058).
CR Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Ashcroft GS, 2012, WOUND REPAIR REGEN, V20, P38, DOI 10.1111/j.1524-475X.2011.00748.x
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhattacharya R, 2018, J CELL BIOCHEM, V119, P8174, DOI 10.1002/jcb.26820
   Bility MT, 2016, SCI REP-UK, V6, DOI 10.1038/srep39520
   Cai Y, 2014, EXP EYE RES, V123, P87, DOI 10.1016/j.exer.2014.04.012
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chan YC, 2012, J BIOL CHEM, V287, P41032, DOI 10.1074/jbc.M112.413294
   Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089548
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Feng WG, 2015, HYPERTENSION, V65, P813, DOI 10.1161/HYPERTENSIONAHA.114.04533
   Feng WG, 2012, HYPERTENSION, V60, P1226, DOI 10.1161/HYPERTENSIONAHA.112.197871
   Feng WG, 2010, HYPERTENSION, V55, P1381, DOI 10.1161/HYPERTENSIONAHA.110.150995
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Garcia-Maceira P, 2009, ONCOGENE, V28, P313, DOI 10.1038/onc.2008.398
   Ghosh S, 2012, J BIOL CHEM, V287, P15001, DOI 10.1074/jbc.M111.284034
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guha S, 2014, ADV EXP MED BIOL, V801, P105, DOI 10.1007/978-1-4614-3209-8_14
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hashiya N, 2004, CIRCULATION, V109, P3035, DOI 10.1161/01.CIR.0000130643.41587.DB
   He RG, 2017, MOL IMMUNOL, V90, P42, DOI 10.1016/j.molimm.2017.06.249
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Hui K, 2018, CELL SIGNAL, V48, P38, DOI 10.1016/j.cellsig.2018.04.006
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Katsumoto A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00978
   Kinoshita S, 2014, J NUTR BIOCHEM, V25, P1177, DOI 10.1016/j.jnutbio.2014.06.004
   Konno S, 2004, J GASTROENTEROL, V39, P931, DOI 10.1007/s00535-004-1423-9
   KRAMER B, 1995, J BIOL CHEM, V270, P6577
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Li Z, 2015, AM J PATHOL, V185, P2412, DOI 10.1016/j.ajpath.2015.05.017
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.0.CO;2-F
   Peet DJ, 2017, EXP CELL RES, V356, P136, DOI 10.1016/j.yexcr.2017.03.030
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sasore T, 2014, ADV EXP MED BIOL, V801, P805, DOI 10.1007/978-1-4614-3209-8_101
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Sheets KG, 2013, MOL VIS, V19, P1747
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823
   Wang HB, 2016, MOL VIS, V22, P116
   Wei G, 2009, BLOOD, V114, P1123, DOI 10.1182/blood-2009-03-211391
   Xu S, 2017, BIOMED PHARMACOTHER, V96, P634, DOI 10.1016/j.biopha.2017.10.037
   Zhang HL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038157
   Zhang XM, 2016, ANAT REC, V299, P1145, DOI 10.1002/ar.23371
   Zhao N, 2018, ENDOCRINE, V59, P120, DOI 10.1007/s12020-017-1465-4
   Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090
   Zhou YD, 2017, MOL MED REP, V15, P3949, DOI 10.3892/mmr.2017.6491
NR 63
TC 5
Z9 5
U1 2
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302-766X
EI 1432-0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD JUN
PY 2019
VL 376
IS 3
BP 341
EP 351
DI 10.1007/s00441-019-03001-1
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HZ6AP
UT WOS:000468934500003
PM 30834976
DA 2022-11-30
ER

PT J
AU Mulder, DJ
   Bieze, M
   Graaff, R
   Smit, AJ
   Hooymans, JMM
AF Mulder, D. J.
   Bieze, M.
   Graaff, R.
   Smit, A. J.
   Hooymans, J. M. M.
TI Skin autofluorescence is elevated in neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ADVANCED GLYCATION ENDPRODUCTS; RISK-FACTORS; END-PRODUCTS; DISEASE;
   ACCUMULATION; PROGRESSION; RECEPTOR; AREDS
AB Background/aims Skin autofluorescence (AF) is a non-invasive marker for advanced glycation endproducts (AGE) in tissues, making use of their characteristic AF pattern. The aim of this study was to investigate whether skin AF is increased in patients with neovascular age-related macular degeneration (AMD) compared with healthy controls.
   Methods Skin AF was assessed in 73 consecutive patients with active and documented neovascular AMD without evidence for diabetic or hypertensive retinopathy and in 31 healthy age-matched controls. Exclusion criteria were: known renal disease, current inflammatory or malignant disease, or skin type V or VI. Skin AF was measured on the forearm and was calculated as a ratio of mean intensities detected from the skin between 420-600 and 300-420 nm. Student t test and chi(2) test were used to compare differences between groups.
   Results Skin AF was increased in neovascular AMD compared with controls (2.57+/-0.68 vs 2.23+/-0.63 arbitrary units x 10(-2); p=0.018). In patients without vascular risk factors or cardiovascular disease, skin AF was not significantly higher than that of the controls. Skin AF correlated with age in both patients and controls.
   Conclusion Skin AF is increased in patients with neovascular AMD, suggesting that AMD is accompanied by enhanced systemic AGE accumulation, which may indicate a role in the pathophysiology of AMD.
C1 [Mulder, D. J.; Bieze, M.; Smit, A. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Med, NL-9700 RB Groningen, Netherlands.
   [Graaff, R.] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Engn, NL-9700 RB Groningen, Netherlands.
   [Hooymans, J. M. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Ophthalmol, NL-9700 RB Groningen, Netherlands.
C3 University of Groningen; University of Groningen; University of
   Groningen
RP Mulder, DJ (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Med, POB 30-001, NL-9700 RB Groningen, Netherlands.
EM udomulder@gmail.com
RI Graaff, Reindert/G-8941-2011
CR Cerami C, 1997, P NATL ACAD SCI USA, V94, P13915, DOI 10.1073/pnas.94.25.13915
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Hartog JWL, 2005, ANN NY ACAD SCI, V1043, P299, DOI 10.1196/annals.1333.037
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koschinsky T, 1997, P NATL ACAD SCI USA, V94, P6474, DOI 10.1073/pnas.94.12.6474
   Meerwaldt R, 2004, DIABETOLOGIA, V47, P1324, DOI 10.1007/s00125-004-1451-2
   MEERWALDT R, 2005, ANN NY ACAD SCI, V1043, P911
   Meerwaldt R, 2007, DIABETES CARE, V30, P107, DOI 10.2337/dc06-1391
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mulder DJ, 2008, ATHEROSCLEROSIS, V197, P217, DOI 10.1016/j.atherosclerosis.2007.03.027
   Mulder DJ, 2006, DIABETES TECHNOL THE, V8, P523, DOI 10.1089/dia.2006.8.523
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smit AJ, 2004, CURR MED CHEM, V11, P2767, DOI 10.2174/0929867043364342
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 24
TC 7
Z9 7
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2010
VL 94
IS 5
BP 622
EP 625
DI 10.1136/bjo.2009.162990
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 592JH
UT WOS:000277374500020
PM 19726430
DA 2022-11-30
ER

PT J
AU Latalska, M
   Matysik-Wozniak, A
   Bylina, J
   Latalski, M
   Rejdak, R
   Mackiewicz, J
   Jarosz, MJ
AF Latalska, Malgorzata
   Matysik-Wozniak, Anna
   Bylina, Jerzy
   Latalski, Michal
   Rejdak, Robert
   Mackiewicz, Jerzy
   Jarosz, Miroslaw J.
TI Wet age-related macular degeneration (wet AMD) in rural and urban
   inhabitants in south-eastern Poland
SO ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; AMD; rural area; urban area;
   anti-VEGF; VEGF-trap
ID POPULATION; PREVALENCE; MACULOPATHY
AB Objective: Evaluation of the demographic profile of patients from south-eastern Poland treated. due to wet age-related macular degeneration.
   Material and methods: Data concerning 201 patients were analyzed (133 F/ 68 M), aged from 50 -91, (mean age 76 +/- 8.6), with the wet form of age-related macular degeneration treated by intravitreal injections of vascular endothelial growth factor inhibiting drugs. The significance of the relationships between variables was investigated by means of chi-square test for independence.The differences between the empirical and theoretical sample distribution was examined by means of chi-square goodness-of-fit test. The significance level was set at p=0.05.
   Results: Analysis did not show any significant differences in the access to treatment with intravitreal injections of vascular endothelial growth factor inhibitors between the rural and urban patients. Urban males and females living in the rural areas received treatment statistically more often (p=0.05). No significant differences were observed with respect to either the waiting time for a visit in a specialist outpatient department, nor the duration of waiting for treatment. Patients from the rural and urban areas presented a similar degree of visual impairment, evidencing the advancement of the pathological process.
   Conclusions: Place of residence has no effect on obtaining treatment by patients. The lack of significant differences in treatment between the rural and urban inhabitants may indicate a sufficient level of ophthalmological care in the area of south-eastern Poland. An improvement in the awareness of hazards resulting from inadequate diet and life style could exert a positive effect on the state of health of rural and urban inhabitants. At the same time, knowledge of the disease and risk of blindness related with this disease would increase alertness among rural and urban inhabitants, and in consequence, accelerate an early diagnosis and implementation of an effective treatment.
C1 [Latalska, Malgorzata; Mackiewicz, Jerzy] Med Univ Lublin, Dept Vitreoretinal Surg, PL-20079 Lublin, Poland.
   [Matysik-Wozniak, Anna; Rejdak, Robert] Med Univ Lublin, Gen Ophthalmol Dept, PL-20079 Lublin, Poland.
   [Bylina, Jerzy; Jarosz, Miroslaw J.] Inst Rural Hlth, Dept Informat & Hlth Stat, Lublin, Poland.
   [Latalski, Michal] Med Univ Lublin, Clin Childrens Orthopaed, PL-20079 Lublin, Poland.
   [Jarosz, Miroslaw J.] Univ Econ & Innovat, Fac Pedag & Psychol, Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin; Institute of
   Rural Health in Lublin, Poland; Medical University of Lublin
RP Latalska, M (通讯作者)，Med Univ Lublin, Dept Vitreoretinal Surg, Chmielna 1, PL-20079 Lublin, Poland.
EM mlatalska@o2.pl
RI Jarosz, Mirosław/F-6592-2013
OI Jarosz, Mirosław/0000-0002-8163-3437; Latalska,
   Malgorzata/0000-0002-7607-7843; Latalski, Michal/0000-0002-7919-0294;
   Rejdak, Robert/0000-0003-3321-2723
CR Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Czapinski J., 2011, CONT EC, V5, P160, DOI DOI 10.5709/CE.18979254.57
   Czapinski J, 2011, CONTEMP ECON, V5, P13, DOI 10.5709/ce.18979254.53
   Dziechciaz M, 2012, ANN AGR ENV MED, V19, P746
   Edbom-Kolarz A, 2011, HYGEIA PUB HLTH, V46, P304
   Ergun E, 2004, WIEN KLIN WOCHENSCHR, V116, P737, DOI 10.1007/s00508-004-0262-2
   Golinowska S, 2008, QUALITY EQUALITY ACC
   Kaluzny BJ, 2002, OKULISTYKA, V2, P5
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Stankiewicz A, 2010, TERMEDICA WYDAWNICTW, V1, P7
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Zagozdzon P, 2011, ANN AGR ENV MED, V18, P429
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 16
TC 2
Z9 2
U1 0
U2 4
PU INST AGRICULTURAL MEDICINE
PI LUBLIN
PA JACZEWSKIEGO 2, PO BOX 185, 20-950 LUBLIN, POLAND
SN 1232-1966
EI 1898-2263
J9 ANN AGR ENV MED
JI Ann. Agr. Env. Med.
PY 2013
VL 20
IS 4
BP 726
EP 730
PG 5
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 281FJ
UT WOS:000329085100018
PM 24364443
DA 2022-11-30
ER

PT J
AU Chamberlain, M
   Baird, P
   Dirani, M
   Guymer, R
AF Chamberlain, Matt
   Baird, Paul
   Dirani, Mohamed
   Guymer, Robyn
TI Unraveling a complex genetic disease: Age-related macular degeneration
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; environment; genetic epidemiology;
   genetic techniques; genetic polymorphism; phenotype; variation
   (genetics)
ID CHLAMYDIA-PNEUMONIAE INFECTION; FACTOR-H POLYMORPHISM; APOLIPOPROTEIN-E;
   STARGARDT-DISEASE; SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; RISK-FACTORS;
   ENVIRONMENT INTERACTIONS; MALATTIA LEVENTINESE; SEQUENCE VARIATION
AB In most of the Western world, age-related macular degeneration (AMD) remains the largest single cause of severe visual impairment, and its prevalence continues to increase. It is considered to be a complex disease, in which multiple genes and environment play a role in pathogenesis. Several environmental insults are implicated with smoking, serum cholesterol, hypertension, sunlight exposure, and many other factors being variously associated with disease pathogenesis. Until recently, there have been relatively few breakthroughs to further our understanding of the genetics of AMD, despite remarkable progress in molecular genetic techniques over the last 20 years, and the fact that many rare inherited macular diseases have had their causative genes mapped. Development of new tools such as high-density single-nucleotide polymorphism chips and microarrays have changed the face of genetic research, but have yet to directly translate into improved clinical outcomes in ophthalmology. However with the recent finding of the Tyr402His polymorphism in the complement factor H gene being implicated in AMD, we are about to witness a new wave of research in this disease. Not only does the identification of a biologically plausible gene identify a new pathway, but it also identifies new biological mechanisms for disease, avenues to pursue treatment, and a better understanding of how the environment interacts with the genetic background to create disease. This article aims to review the process of gene discovery in complex disease, why the search for genes remains difficult, how to translate laboratory findings to a clinical setting, and how these findings will impact on disease treatment and public health issues.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Vis Cooperat Res Ctr, Sydney, NSW, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Visa Inc
RP Guymer, R (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
OI Guymer, Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Alpert JS, 2005, AM J MED, V118, P203, DOI 10.1016/j.amjmed.2005.01.020
   Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090
   Cardon LR, 2003, TRENDS GENET, V19, P135, DOI 10.1016/S0168-9525(03)00022-2
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Cooper RS, 2003, ANN INTERN MED, V139, P437, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00011
   Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards BJ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-18
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans JP, 2001, BMJ-BRIT MED J, V322, P1052, DOI 10.1136/bmj.322.7293.1052
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Goldstein AM, 1997, GENET EPIDEMIOL, V14, P1085, DOI 10.1002/(SICI)1098-2272(1997)14:6<1085::AID-GEPI87>3.0.CO;2-D
   Gregory CY, 1996, HUM MOL GENET, V5, P1055, DOI 10.1093/hmg/5.7.1055
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Hirschhorn JN, 2005, PEDIATR RES, V57, p74R, DOI 10.1203/01.PDR.0000159574.98964.87
   HOPPER JL, 1992, ACTA GENET MED GEMEL, V41, P261, DOI 10.1017/S0001566000002129
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kang SJ, 2004, GENET EPIDEMIOL, V26, P132, DOI 10.1002/gepi.10301
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khoury MJ, 2005, AM J EPIDEMIOL, V161, P799, DOI 10.1093/aje/kwi113
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2001, AM J EPIDEMIOL, V154, P207, DOI 10.1093/aje/154.3.207
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Mahlknecht U, 2005, CURR MED RES OPIN, V21, P1041, DOI 10.1185/030079905X50633
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   ORDOVAS JM, 1995, ATHEROSCLEROSIS, V113, P157, DOI 10.1016/0021-9150(94)05439-P
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Pritchard JK, 2001, AM J HUM GENET, V69, P124, DOI 10.1086/321272
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Risch N, 2005, AM J HUM GENET, V76, P221, DOI 10.1086/428067
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Rothman N, 1999, IARC Sci Publ, P89
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schork NJ, 1997, AM J RESP CRIT CARE, V156, pS103, DOI 10.1164/ajrccm.156.4.12-tac-5
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sing CF, 1996, CIBA F SYMP, V197, P211
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866
   Yang QH, 2005, INT J EPIDEMIOL, V34, P1129, DOI 10.1093/ije/dyi130
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 106
TC 29
Z9 31
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD NOV-DEC
PY 2006
VL 51
IS 6
BP 576
EP 586
DI 10.1016/j.survophthal.2006.08.003
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 104SS
UT WOS:000241980000004
PM 17134647
DA 2022-11-30
ER

PT J
AU Huang, LL
   Zhang, XZ
   Tam, POS
   Chen, HY
   Hao, F
   Pang, CP
   Wen, F
   Yang, ZL
AF Huang, Lulin
   Zhang, Xiongze
   Tam, Pancy O. S.
   Chen, Haoyu
   Hao, Fang
   Pang, Chi-Pui
   Wen, Fen
   Yang, Zhenglin
TI Association of coding and UTR variants in the known regions with wet
   age-related macular degeneration in Han Chinese population
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; GENE POLYMORPHISMS;
   COMMON VARIANTS; OVARIAN-CANCER; SUSCEPTIBILITY; RISK; HTRA1; LOCI;
   INCREASES
AB Age-related macular degeneration (AMD) is the leading cause worldwide of severe visual impairment among people older than 55 years of age. This study aimed to investigate the genetic association between coding and untranslated region (UTR) variants in previously reported loci and exudative age-related macular degeneration (wet AMD) in a Han Chinese population. Using our previously published whole exome sequencing dataset of 349 wet AMD patients and 1253 controls, we searched for associations between coding and UTR variants of the 72 genes located within the 47 reported wet AMD loci regions. From these, 25 variants in 18 of the 72 genes with P < 10 x 10(-3) were selected for the first replication of Sequenom mass-array genotyping in 885 wet AMD subjects and 562 controls. Next, four SNPs were selected for further validation by SNaPshot genotyping in a third Chinese cohort with 456 wet AMD subjects and 211 controls. As a result, we identified two new potential coding and UTR variant SNPs (rs189132250 in BBX located in 3q12.1 and rs144351944 in FILIP1L located in 3q12.1) that showed weak associations with wet AMD in the Han Chinese population. These findings provide new information regarding the coding and UTR variants of the known wet AMD loci in the studied Chinese cohort.
C1 [Huang, Lulin; Hao, Fang; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China.
   [Huang, Lulin; Hao, Fang; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Dept Lab Med, Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China.
   [Huang, Lulin; Hao, Fang; Yang, Zhenglin] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Zhang, Xiongze; Wen, Fen] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Tam, Pancy O. S.; Pang, Chi-Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Haoyu] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Chen, Haoyu] Chinese Univ Hong Kong, Shantou, Peoples R China.
   [Yang, Zhenglin] Chinese Acad Sci, Inst Chengdu Biol, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin] Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Sichuan, Peoples R China.
   [Yang, Zhenglin] Univ Elect Sci & Technol China, Ctr Informat Biomed, Chengdu, Sichuan, Peoples R China.
C3 University of Electronic Science & Technology of China; Sichuan
   Provincial People's Hospital; University of Electronic Science &
   Technology of China; Sichuan Provincial People's Hospital; University of
   Electronic Science & Technology of China; Sun Yat Sen University;
   Chinese University of Hong Kong; Shantou University; Chinese Academy of
   Sciences; Chinese Academy of Sciences; University of Electronic Science
   & Technology of China
RP Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China.; Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Dept Lab Med, Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China.; Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.; Wen, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.; Yang, ZL (通讯作者)，Chinese Acad Sci, Inst Chengdu Biol, Chengdu, Sichuan, Peoples R China.; Yang, ZL (通讯作者)，Chinese Acad Sci, Sichuan Translat Med Hosp, Chengdu, Sichuan, Peoples R China.; Yang, ZL (通讯作者)，Univ Elect Sci & Technol China, Ctr Informat Biomed, Chengdu, Sichuan, Peoples R China.
EM wenfeng208@foxmail.com; zliny@yahoo.com
RI Chen, Haoyu/A-7432-2013; Hao, Fang/GRJ-3165-2022
OI Chen, Haoyu/0000-0003-0676-4610; 
FU National key scientific research program [2016YFC0905200]; National
   Natural Science Foundation of China [81170883, 81430008, 81470647,
   81300802, 81670895]; Department of Science and Technology of Sichuan
   Province, China [2014SZ0169, 2015SZ0052, 2015JQO057, 2013JY0195,
   2016HH0072, 2017JQ0024]
FX We would like to thank all the AMD patients and their families for
   participating in this study. This research project was supported by:
   National key scientific research program (2016YFC0905200, ZY), the
   National Natural Science Foundation of China (81170883(ZY), 81430008
   (ZY), 81470647(FW), 81300802 and 81670895 (LH), the Department of
   Science and Technology of Sichuan Province, China (2014SZ0169 (ZY),
   2015SZ0052 (ZY), 2015JQO057 (LH), 2013JY0195 (LH), 2016HH0072(LH), and
   2017JQ0024(LH).
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Bernstein PS, 2009, ACTA HORTIC, V841, P103
   Caporaso N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004653
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Davila S, 2010, NAT GENET, V42, P772, DOI 10.1038/ng.640
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dieterich LC, 2012, J PATHOL, V228, P378, DOI 10.1002/path.4072
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kwon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082620
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Notaridou M, 2011, INT J CANCER, V128, P2063, DOI 10.1002/ijc.25554
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Xie C, 2011, HUM GENE THER, V22, P1413, DOI 10.1089/hum.2011.047
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Ye Z, 2015, EUR J HUM GENET, V23, P523, DOI 10.1038/ejhg.2014.123
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 34
TC 1
Z9 1
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD OCT
PY 2018
VL 63
IS 10
BP 1055
EP 1070
DI 10.1038/s10038-018-0490-3
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GU7UV
UT WOS:000445533500006
PM 30026504
DA 2022-11-30
ER

PT J
AU Noel, NCL
   Nadolski, NJ
   Hocking, JC
   MacDonald, IM
   Allison, WT
AF Noel, Nicole C. L.
   Nadolski, Nathan J.
   Hocking, Jennifer C.
   MacDonald, Ian M.
   Allison, W. Ted
TI Progressive Photoreceptor Dysfunction and Age-Related Macular
   Degeneration-Like Features in rp1l1 Mutant Zebrafish
SO CELLS
LA English
DT Article
DE rp1l1; axoneme; maculopathy; photoreceptor outer segment; occult macular
   dystrophy; retinitis pigmentosa; retinal dystrophy; age-related macular
   degeneration; subretinal drusenoid deposits; drusen
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY;
   RETINITIS-PIGMENTOSA; MUTATIONS; PROTEIN; MODEL; MICE; IDENTIFICATION;
   DYSTROPHY; DISEASES
AB Photoreceptor disease results in irreparable vision loss and blindness, which has a dramatic impact on quality of life. Pathogenic mutations in RP1L1 lead to photoreceptor degenerations such as occult macular dystrophy and retinitis pigmentosa. RP1L1 is a component of the photoreceptor axoneme, the backbone structure of the photoreceptor's light-sensing outer segment. We generated an rp1l1 zebrafish mutant using CRISPR/Cas9 genome editing. Mutant animals had progressive photoreceptor functional defects as determined by electrophysiological assessment. Optical coherence tomography showed gaps in the photoreceptor layer, disrupted photoreceptor mosaics, and thinner retinas. Mutant retinas had disorganized photoreceptor outer segments and lipid-rich subretinal drusenoid deposits between the photoreceptors and retinal pigment epithelium. Our mutant is a novel model of RP1L1-associated photoreceptor disease and the first zebrafish model of photoreceptor degeneration with reported subretinal drusenoid deposits, a feature of age-related macular degeneration.
C1 [Noel, Nicole C. L.; Nadolski, Nathan J.; Hocking, Jennifer C.; MacDonald, Ian M.; Allison, W. Ted] Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada.
   [Hocking, Jennifer C.] Univ Alberta, Div Anat, Dept Surg, Edmonton, AB T6G 2H7, Canada.
   [Hocking, Jennifer C.] Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.
   [Hocking, Jennifer C.] Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB T6G 1C9, Canada.
   [MacDonald, Ian M.] Univ Alberta, Dept Ophthalmol & Visual Sci, Edmonton, AB T6G 2R7, Canada.
   [Allison, W. Ted] Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.
   [Allison, W. Ted] Univ Alberta, Ctr Prions & Prot Folding Dis, Edmonton, AB T6G 2M8, Canada.
C3 University of Alberta; University of Alberta; University of Alberta;
   University of Alberta; University of Alberta; University of Alberta;
   University of Alberta
RP Noel, NCL (通讯作者)，Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada.
EM nnoel@ualberta.ca; nadolski@ualberta.ca; jhocking@ualberta.ca;
   macdonal@ualberta.ca; ted.allison@ualberta.ca
RI Allison, Ted/A-2612-2014
OI Allison, Ted/0000-0002-8461-4864; Noel, Nicole C. L./0000-0001-9094-6745
FU Canadian Institutes of Health Research through a Rare Disease Models and
   Mechanisms grant; Rare Disease Foundation microgrant; Natural Science
   and Engineering Research Council of Canada [RGPIN-2018-05756]; Stollery
   Children's Hospital Foundation through a Women and Children's Research
   Institute (WCHRI) Innovation Grant [WCHRIIG-2846]; University of
   Alberta; Alberta Innovates Doctoral Graduate Student Scholarship;
   Frederick Banting and Charles Best Canada Graduate Scholarship from the
   Canadian Institutes of Health Research; Queen Elizabeth II PhD
   Scholarship through the Government of Alberta; Natural Science and
   Engineering Research Council of Canada; Walter H. John Graduate
   Fellowship from the University of Alberta; Queen Elizabeth II and
   Alberta Graduate Excellence scholarships from the Government of Alberta
FX This research was funded by the Canadian Institutes of Health Research
   through a Rare Disease Models and Mechanisms grant to W.T.A. and I.M.M.,
   a Rare Disease Foundation microgrant to I.M.M. and N.C.L.N., and funding
   from the Natural Science and Engineering Research Council of Canada via
   a Discovery Grant (RGPIN-2018-05756) and Stollery Children's Hospital
   Foundation through a Women and Children's Research Institute (WCHRI)
   Innovation Grant (WCHRIIG-2846) to J.C.H. N.C.L.N was supported by a
   Doctoral Recruitment Scholarship from the University of Alberta, Alberta
   Innovates Doctoral Graduate Student Scholarship, Frederick Banting and
   Charles Best Canada Graduate Scholarship from the Canadian Institutes of
   Health Research, a President's Doctoral Prize of Distinction from the
   University of Alberta, and Queen Elizabeth II PhD Scholarship through
   the Government of Alberta. N.J.N. was supported by a Master's
   studentship from the Natural Science and Engineering Research Council of
   Canada, Walter H. John Graduate Fellowship from the University of
   Alberta, and Queen Elizabeth II and Alberta Graduate Excellence
   scholarships from the Government of Alberta.
CR Akahori M, 2010, AM J HUM GENET, V87, P424, DOI 10.1016/j.ajhg.2010.08.009
   Albarry MA, 2019, OPHTHALMIC GENET, V40, P507, DOI 10.1080/13816810.2019.1703014
   Aleman TS, 2011, INVEST OPHTH VIS SCI, V52, P6898, DOI 10.1167/iovs.11-7701
   Allison WT, 2010, J COMP NEUROL, V518, P4182, DOI 10.1002/cne.22447
   Bachmann-Gagescu R, 2019, CURR OPIN GENET DEV, V56, P22, DOI 10.1016/j.gde.2019.05.004
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Brockhurst RJ, 2007, AM J OPHTHALMOL, V143, P516, DOI 10.1016/j.ajo.2006.10.025
   Browne S, 2003, MOL VIS, V9, P129
   Bujakowska KM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028274
   CASTANOS MV, 2020, INVEST OPHTH VIS SCI, V0061
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Conte I, 2003, EUR J HUM GENET, V11, P155, DOI 10.1038/sj.ejhg.5200942
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Davidson AE, 2013, HUM MUTAT, V34, P506, DOI 10.1002/humu.22264
   Dias Marina Franca, 2018, Prog Retin Eye Res, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Dimopoulos IS, 2018, AM J OPHTHALMOL, V193, P130, DOI 10.1016/j.ajo.2018.06.011
   Do KV, 2019, P NATL ACAD SCI USA, V116, P24317, DOI 10.1073/pnas.1912959116
   Doerre G, 2002, MECH DEVELOP, V110, P125, DOI 10.1016/S0925-4773(01)00571-8
   Doerre G, 2001, J NEUROSCI, V21, P6745, DOI 10.1523/JNEUROSCI.21-17-06745.2001
   Fadool JM, 2003, DEV BIOL, V258, P277, DOI 10.1016/S0012-1606(03)00125-8
   Fernandez EJ, 2008, OPT EXPRESS, V16, P11083, DOI 10.1364/OE.16.011083
   Gagnon JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098186
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004
   Liu Q, 2003, INVEST OPHTH VIS SCI, V44, P4171, DOI 10.1167/iovs.03-0410
   Liu Q, 2002, INVEST OPHTH VIS SCI, V43, P22
   Liu YFP, 2017, OPHTHALMIC GENET, V38, P127, DOI 10.3109/13816810.2016.1151898
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Meeker ND, 2007, BIOTECHNIQUES, V43, P610, DOI 10.2144/000112619
   Miyake Y, 1996, AM J OPHTHALMOL, V122, P644, DOI 10.1016/S0002-9394(14)70482-9
   MIYAKE Y, 1989, AM J OPHTHALMOL, V108, P292, DOI 10.1016/0002-9394(89)90120-7
   Miyake Y, 2015, JPN J OPHTHALMOL, V59, P71, DOI 10.1007/s10384-015-0371-7
   Nadolski NJ, 2021, DOC OPHTHALMOL, V142, P99, DOI 10.1007/s10633-020-09783-y
   Narayan DS, 2016, ACTA OPHTHALMOL, V94, P748, DOI 10.1111/aos.13141
   National Eye Institute (National Institutes of Health), AMD DAT STAT
   Noel NCL, 2020, SURV OPHTHALMOL, V65, P725, DOI 10.1016/j.survophthal.2020.04.005
   Oishi M, 2014, INVEST OPHTH VIS SCI, V55, P7369, DOI 10.1167/iovs.14-15458
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Pierce EA, 1999, NAT GENET, V22, P248, DOI 10.1038/10305
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Verbakel SK, 2019, INVEST OPHTH VIS SCI, V60, P1192, DOI 10.1167/iovs.18-26084
   Vessey KA, 2012, INVEST OPHTH VIS SCI, V53, P7833, DOI 10.1167/iovs.12-10650
   Wilkinson RN, 2013, BIOTECHNIQUES, V55, P314, DOI 10.2144/000114116
   Yamashita T, 2009, J NEUROSCI, V29, P9748, DOI 10.1523/JNEUROSCI.5854-08.2009
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
NR 51
TC 5
Z9 5
U1 1
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD OCT
PY 2020
VL 9
IS 10
AR 2214
DI 10.3390/cells9102214
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OJ7PJ
UT WOS:000584148000001
PM 33007938
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, WQ
   Gawlik, K
   Lopez, J
   Wen, C
   Zhu, J
   Wu, F
   Shi, W
   Scheibler, S
   Cai, HM
   Vairavan, R
   Shi, A
   Haw, W
   Ferreyra, H
   Zhang, M
   Chang, S
   Zhang, K
AF Wang, Wenqiu
   Gawlik, Katarzyna
   Lopez, Joe
   Wen, Cindy
   Zhu, Jie
   Wu, Frances
   Shi, William
   Scheibler, Samuel
   Cai, Huimin
   Vairavan, Ram
   Shi, Alexander
   Haw, Weldon
   Ferreyra, Henry
   Zhang, Ming
   Chang, Sherman
   Zhang, Kang
TI Genetic and environmental factors strongly influence risk, severity and
   progression of age-related macular degeneration
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; GLOBAL PREVALENCE; SUSCEPTIBILITY; VARIANTS;
   SMOKING; VEGFA; CFH; C2
AB Age-related macular degeneration (AMD) is characterized by complex interactions between genetic and environmental factors. Here we genotyped the selected 25 single-nucleotide polymorphisms (SNPs) in 983 cases with advanced AMD and 271 cases with intermediate AMD and build an AMD life-risk score model for assessment of progression from intermediate to advanced AMD. We analyzed the performance of the prediction model for geographic atrophy progressors or choroidal neovascularization progressors versus non-progressors based on the 25 SNPs plus body mass index and smoking status. Our results suggest that a class prediction algorithm can be used for the risk assessment of progression from intermediate to late AMD stages. The algorithm could also be potentially applied for therapeutic response, and toward personalized care and precision medicine.
C1 [Wang, Wenqiu; Wen, Cindy; Zhu, Jie; Wu, Frances; Shi, William; Scheibler, Samuel; Shi, Alexander; Haw, Weldon; Ferreyra, Henry; Zhang, Kang] Shiley Eye Inst, San Diego, CA 92093 USA.
   [Wang, Wenqiu; Wen, Cindy; Zhu, Jie; Wu, Frances; Shi, William; Scheibler, Samuel; Shi, Alexander; Haw, Weldon; Ferreyra, Henry; Zhang, Kang] Inst Genom Med, San Diego, CA 92093 USA.
   [Gawlik, Katarzyna; Lopez, Joe; Vairavan, Ram; Chang, Sherman] AutoGen Inc, Vista, CA 92081 USA.
   [Cai, Huimin; Zhang, Ming; Zhang, Kang] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
   [Cai, Huimin; Zhang, Ming; Zhang, Kang] Sichuan Univ, West China Hosp, Mol Med Res Ctr, Chengdu, Sichuan, Peoples R China.
   [Cai, Huimin] Guangzhou KangRui Biol Pharmaceut Technol Co, Guangzhou, Guangdong, Peoples R China.
   [Haw, Weldon; Zhang, Kang] Vet Adm Healthcare Syst, San Diego, CA 92161 USA.
C3 Sichuan University; Sichuan University
RP Zhang, K (通讯作者)，Shiley Eye Inst, San Diego, CA 92093 USA.; Zhang, K (通讯作者)，Inst Genom Med, San Diego, CA 92093 USA.; Chang, S (通讯作者)，AutoGen Inc, Vista, CA 92081 USA.; Zhang, M; Zhang, K (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.; Zhang, M; Zhang, K (通讯作者)，Sichuan Univ, West China Hosp, Mol Med Res Ctr, Chengdu, Sichuan, Peoples R China.; Zhang, K (通讯作者)，Vet Adm Healthcare Syst, San Diego, CA 92161 USA.
EM zhangmingscu@126.com; schang@autogenomics.com; kang.zhang@gmail.com
RI Zhang, Kang/Y-2740-2019; Zhu, Jie/AAD-1330-2022
OI Zhang, Kang/0000-0002-4549-1697; Zhu, Jie/0000-0001-6862-9022; Shi,
   William/0000-0001-5452-2902
FU NSFC [81300778, 81271020]; 973 program [2012CB917304]; 863 Program
   [2014AA021604]; NIH [R01EY024134, R01HG008135, R01EY018660,
   R01EY021374]; VA Merit Award; NATIONAL EYE INSTITUTE [R01EY021374,
   R01EY024134, R01EY018660] Funding Source: NIH RePORTER; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTE [R01HG008135] Funding Source: NIH RePORTER
FX We thank the participants, their families and ophthalmologists who
   participated in this study. The study was partially supported by NSFC
   (81300778, 81271020), 973 program (2012CB917304), 863 Program
   (2014AA021604), NIH (R01EY024134, R01HG008135, R01EY018660, R01EY021374)
   and VA Merit Award.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 25
TC 10
Z9 10
U1 3
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PY 2016
VL 1
AR e16016
DI 10.1038/sigtrans.2016.16
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA VH7TQ
UT WOS:000454602900009
PM 29263899
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Meyer, KJ
   Davis, LK
   Schindler, EI
   Beck, JS
   Rudd, DS
   Grundstad, AJ
   Scheetz, TE
   Braun, TA
   Fingert, JH
   Alward, WL
   Kwon, YH
   Folk, JC
   Russell, SR
   Wassink, TH
   Stone, EM
   Sheffield, VC
AF Meyer, Kacie J.
   Davis, Lea K.
   Schindler, Emily I.
   Beck, John S.
   Rudd, Danielle S.
   Grundstad, A. Jason
   Scheetz, Todd E.
   Braun, Terry A.
   Fingert, John H.
   Alward, Wallace L.
   Kwon, Young H.
   Folk, James C.
   Russell, Stephen R.
   Wassink, Thomas H.
   Stone, Edwin M.
   Sheffield, Val C.
TI Genome-wide analysis of copy number variants in age-related macular
   degeneration
SO HUMAN GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; JUVENILE NEPHRONOPHTHISIS; GENE;
   DELETION; POLYMORPHISM; ASSOCIATION; CFH; SUSCEPTIBILITY; EXPRESSION
AB Age-related macular degeneration (AMD) is a complex genetic disease, with many loci demonstrating appreciable attributable disease risk. Despite significant progress toward understanding the genetic and environmental etiology of AMD, identification of additional risk factors is necessary to fully appreciate and treat AMD pathology. In this study, we investigated copy number variants (CNVs) as potential AMD risk variants in a cohort of 400 AMD patients and 500 AMD-free controls ascertained at the University of Iowa. We used three publicly available copy number programs to analyze signal intensity data from Affymetrix (R) GeneChip SNP Microarrays. CNVs were ranked based on prevalence in the disease cohort and absence from the control group; high interest CNVs were subsequently confirmed by qPCR. While we did not observe a single-locus "risk CNV" that could account for a major fraction of AMD, we identified several rare and overlapping CNVs containing or flanking compelling candidate genes such as NPHP1 and EFEMP1. These and other candidate genes highlighted by this study deserve further scrutiny as sources of genetic risk for AMD.
C1 [Wassink, Thomas H.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
   [Stone, Edwin M.; Sheffield, Val C.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
   [Scheetz, Todd E.; Braun, Terry A.; Fingert, John H.; Alward, Wallace L.; Kwon, Young H.; Folk, James C.; Russell, Stephen R.; Stone, Edwin M.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Grundstad, A. Jason; Scheetz, Todd E.; Braun, Terry A.] Univ Iowa, Ctr Bioinformat & Computat Biol, Iowa City, IA 52242 USA.
   [Beck, John S.; Sheffield, Val C.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Davis, Lea K.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA.
   [Meyer, Kacie J.; Schindler, Emily I.; Rudd, Danielle S.; Scheetz, Todd E.; Braun, Terry A.; Fingert, John H.; Wassink, Thomas H.; Stone, Edwin M.; Sheffield, Val C.] Univ Iowa, Interdisciplinary Genet Program, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa;
   University of Iowa; University of Iowa; University of Iowa; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital; University of Iowa
RP Wassink, TH (通讯作者)，Univ Iowa, Dept Psychiat, 500 Newton Rd,1-191 MEB, Iowa City, IA 52242 USA.
EM thomas-wassink@uiowa.edu
RI Fingert, John/F-8787-2012; Fingert, John/AAX-4750-2021; Alward,
   Wallace/AAY-4149-2020
OI Fingert, John/0000-0002-0377-0479; Fingert, John/0000-0002-0377-0479;
   Russell, Stephen/0000-0003-3776-1367; Sheffield,
   Val/0000-0002-6282-0835; Kwon, Young/0000-0002-1116-8250; Stone, Edwin
   M./0000-0003-3343-4414; Folk, James/0000-0002-6271-2906; Wassink,
   Thomas/0000-0002-0952-8333; Alward, Wallace/0000-0001-6368-9018;
   Scheetz, Todd/0000-0002-1965-5811
FU National Institutes of Health [T32GM008629, R01-EY-010564,
   R01-EY-016822]; Carver Endowment for Molecular Ophthalmology; Research
   to Prevent Blindness (Department of Ophthalmology, University of Iowa);
   Foundation Fighting Blindness; NATIONAL EYE INSTITUTE [R01EY016822,
   R01EY010564, R01EY011298] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008629, T32GM007337] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH080128]
   Funding Source: NIH RePORTER
FX We are grateful to the patients and their families for participating in
   this study. We thank Dr. Kai Wang for helpful discussion. Alcon
   Research, Ltd. (Ft. Worth, TX) provided funds for the purchase of the
   SNP genotyping chips used in this study. This work was supported by the
   following grants and organizations: National Institutes of Health
   Predoctoral Training Grant T32GM008629 (L. K. D.); National Institutes
   of Health grants R01-EY-010564 (V. C. S.) and R01-EY-016822 (E. M. S.);
   the Carver Endowment for Molecular Ophthalmology (E. M. S. and V. C.
   S.); and Research to Prevent Blindness (Department of Ophthalmology,
   University of Iowa, Career Development Awards to T. E. S. and J.H. F.,
   and the Lew Wasserman Award to W. L. M. A.); and Foundation Fighting
   Blindness. V. C. S. and E. M. S. are investigators of the Howard Hughes
   Medical Institute.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Caridi G, 1998, AM J KIDNEY DIS, V32, P1059, DOI 10.1016/S0272-6386(98)70083-6
   de Marco MD, 2001, J BIOL CHEM, V276, P23009
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fan BJ, 2006, CLIN BIOCHEM, V39, P231, DOI 10.1016/j.clinbiochem.2005.11.010
   Fan J, 2007, BIOCHEM BIOPH RES CO, V363, P757, DOI 10.1016/j.bbrc.2007.09.047
   Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GRIMBERG J, 1989, NUCLEIC ACIDS RES, V17, P8390, DOI 10.1093/nar/17.20.8390
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416
   Jiang ST, 2009, HUM MOL GENET, V18, P1566, DOI 10.1093/hmg/ddp068
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kirov G, 2008, HUM MOL GENET, V17, P458, DOI 10.1093/hmg/ddm323
   Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Konrad M, 1996, HUM MOL GENET, V5, P367, DOI 10.1093/hmg/5.3.367
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Matsumine H, 1997, AM J HUM GENET, V60, P588
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   ORKIN SH, 1979, J CLIN INVEST, V64, P866, DOI 10.1172/JCI109535
   Parisi MA, 2004, AM J HUM GENET, V75, P82, DOI 10.1086/421846
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Surace EM, 2006, MOL THER, V13, P573, DOI 10.1016/j.ymthe.2005.10.010
   Szatmari P, 2007, NAT GENET, V39, P319, DOI 10.1038/ng1985
   VANDENPLAS S, 1987, BRIT J HAEMATOL, V66, P539, DOI 10.1111/j.1365-2141.1987.tb01341.x
   Verpy E, 2001, NAT GENET, V29, P345, DOI 10.1038/ng726
   Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang F, 2009, ANNU REV GENOM HUM G, V10, P451, DOI 10.1146/annurev.genom.9.081307.164217
NR 53
TC 29
Z9 29
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD JAN
PY 2011
VL 129
IS 1
BP 91
EP 100
DI 10.1007/s00439-010-0904-6
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 708WY
UT WOS:000286396200010
PM 20981449
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Arora, S
   Musadiq, M
   Mukherji, S
   Yang, YC
AF Arora, S
   Musadiq, M
   Mukherji, S
   Yang, YC
TI Eye nutrient products for age-related macular degeneration: what do they
   contain?
SO EYE
LA English
DT Article
DE antioxidant; eye nutrient; zinc; age-related macular degeneration
ID VITAMIN-E SUPPLEMENTATION; ORAL ZINC; ANTIOXIDANTS; MACULOPATHY; TRIAL
AB Background and purpose Patients are increasingly well informed about the availability of antioxidant products and the claims made for their benefits in age-related macular degeneration (AMD). Consequently, their use is becoming widespread. The purpose of this study is to conduct a survey of the commonly encountered products, and to compare their ingredients with the current Age-Related Eye Disease Study (AREDS) recommendations.
   Methods A search was undertaken for products sold as 'eye nutrients' at local pharmacies and health food shops, and for products advertised via the Internet. Information about these products was collated and analysed.
   Results We identified 22 eye nutrient products. Analysis of their constituents showed that, although over 75% contained all the constituents used in AREDS, only two matched the dosage profiles recommended in the study.
   Conclusion The authors draw no conclusion on the efficacy of nutritional supplements in the prevention of AMD. In order to advise their patients, ophthalmologists should be familiar with these products. The compiled list in this paper should provide a useful reference for them.
C1 Wolverhampton & Midlands Counties Eye Infirm, Wolverhampton WV3 9QR, W Midlands, England.
RP Arora, S (通讯作者)，Wolverhampton & Midlands Counties Eye Infirm, Compton Rd, Wolverhampton WV3 9QR, W Midlands, England.
EM seema20@msn.com
CR Evans J. R., 2002, COCHRANE DB SYST REV, V2
   GARROW JS, 1998, HUMAN NUTR DIETETICS
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   *NAT AC SCI FOOD N, DIET REF INT TABL 20
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
NR 13
TC 8
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2004
VL 18
IS 5
BP 470
EP 473
DI 10.1038/sj.eye.6700700
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 818NU
UT WOS:000221252600005
PM 15131676
OA Bronze
DA 2022-11-30
ER

PT J
AU Kessel, L
   Theil, PK
   Sorensen, TL
   Munch, IC
AF Kessel, Line
   Theil, Pernille Koefoed
   Sorensen, Torben Lykke
   Munch, Inger Christine
TI Cataract surgery in patients with neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE cataract; neovascular AMD; phacoemulsification; ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; BLINDNESS; EYES;
   AMD
AB PurposeTo examine the outcome after cataract surgery in patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in routine clinical practice.
   MethodsWe extracted information about patients recorded in electronic databases managing anti-VEGF injections and cataract surgery. We compared Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity and frequency of anti-VEGF injections before and after cataract surgery.
   ResultsWe identified 89 eyes from 89 patients who had cataract surgery after being treated with a median of 10 (range 3-36) anti-VEGF injections for neovascular AMD. Visual acuity improved by a mean of 7.1 [95% confidence interval (CI) 4.6-9.6] ETDRS letters in the first 6months after cataract surgery. The need of anti-VEGF injections did not change after cataract surgery with an average of 1.5 in the 6months before surgery versus 1.7 in the 6months after surgery (p=0.25). Visual improvement was greater in patients when the time from latest injection to cataract surgery was lower.
   ConclusionsCataract surgery improves vision in patients undergoing treatment for neovascular AMD. Cataract surgery was not associated with an increased need for anti-VEGF treatment and patients who were in active anti-VEGF treatment had better visual outcomes than patients who had cataract surgery after long injection-free periods.
C1 [Kessel, Line; Theil, Pernille Koefoed; Sorensen, Torben Lykke; Munch, Inger Christine] Roskilde Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Roskilde, Denmark.
   [Kessel, Line] Rigshosp, Dept Ophthalmol, Glostrup, Denmark.
   [Kessel, Line; Sorensen, Torben Lykke; Munch, Inger Christine] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen
RP Kessel, L (通讯作者)，Roskilde Hosp, Dept Ophthalmol, Nordre Ringvej 57, DK-2600 Roskilde, Denmark.
EM line.kessel@dadlnet.dk
RI Munch, Inger Christine/E-9652-2010
OI Kessel, Line/0000-0002-9375-1510
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Howard KP, 2013, OPHTHALMOLOGY, V120, P1509, DOI 10.1016/j.ophtha.2013.03.025
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P599, DOI 10.1089/jop.2007.0050
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
NR 18
TC 13
Z9 13
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2016
VL 94
IS 8
BP 755
EP 760
DI 10.1111/aos.13120
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1AR
UT WOS:000388576400017
PM 27255691
DA 2022-11-30
ER

PT J
AU Wang, AL
   Lukas, TJ
   Yuan, M
   Du, N
   Tso, MO
   Neufeld, AH
AF Wang, Ai Ling
   Lukas, Thomas J.
   Yuan, Ming
   Du, Nga
   Tso, Mark O.
   Neufeld, Arthur H.
TI Autophagy, exosomes and drusen formation in age-related macular
   degeneration
SO AUTOPHAGY
LA English
DT Article
DE lysosome; retinal pigment epithelium; aging; mitochondria; DNA damage;
   exosome
AB Age-related macular degeneration (AMD) is the leading cause of loss of vision in developed countries. AMD is characterized by a progressive degeneration of the macula of the retina, usually bilateral, leading to a severe decrease in central vision. An early sign of AMD is the appearance of drusen, which are extracellular deposits that accumulate on Bruch's membrane below the retinal pigment epithelium (RPE). Drusen are a risk factor for developing AMD. Some of the protein components of drusen are known, yet we know little about the processes that lead to formation of drusen. We have previously reported increased mitochondrial DNA (mtDNA) damage and decreased DNA repair enzyme capabilities in the rodent RPE/choroid with age. In this study, we used in vitro modeling of increased mtDNA damage. Under conditions of increased mtDNA damage, autophagy markers and exosome markers were upregulated. In addition, we found autophagy markers and exosome markers in the region of Bruch's membrane in the retinas of old mice. Furthermore, we found that drusen in AMD donor eyes contain markers for autophagy and for exosomes. We speculate that increased autophagy and the release of intracellular proteins via exosomes by the aged RPE may contribute to the formation of drusen. Molecular and cellular changes in the old RPE may underlie susceptibility to genetic mutations that are found in AMD patients.
C1 [Wang, Ai Ling; Lukas, Thomas J.; Yuan, Ming; Du, Nga; Neufeld, Arthur H.] Northwestern Univ, Sch Med, Dept Ophthalmol, Forsythe Lab Invest Aging Retina, Chicago, IL 60611 USA.
   [Tso, Mark O.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Northwestern University; Johns Hopkins University; Johns Hopkins
   Medicine
RP Neufeld, AH (通讯作者)，Northwestern Univ, Sch Med, Dept Ophthalmol, Forsythe Lab Invest Aging Retina, 303 E Chicago Ave,13-753 Tarry, Chicago, IL 60611 USA.
EM a-neufeld@northwestern.edu
NR 0
TC 81
Z9 85
U1 0
U2 24
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD MAY 16
PY 2009
VL 5
IS 4
BP 563
EP 564
DI 10.4161/auto.5.4.8163
PG 2
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 446JW
UT WOS:000266118900023
PM 19270489
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhao, R
   Camino, A
   Wang, J
   Hagag, AM
   Lu, YS
   Bailey, ST
   Flaxel, CJ
   Hwang, TS
   Huang, D
   Li, DW
   Jia, YL
AF Zhao, Rui
   Camino, Acner
   Wang, Jie
   Hagag, Ahmed M.
   Lu, Yansha
   Bailey, Steven T.
   Flaxel, Christina J.
   Hwang, Thomas S.
   Huang, David
   Li, Dengwang
   Jia, Yali
TI Automated drusen detection in dry age-related macular degeneration by
   multiple-depth, en face optical coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID SD-OCT IMAGES; RETINAL FUNDUS IMAGES; RETICULAR PSEUDODRUSEN; MOTION
   CORRECTION; GEOGRAPHIC-ATROPHY; LAYER SEGMENTATION; FELLOW-EYES;
   RISK-FACTOR; ANGIOGRAPHY; PREVALENCE
AB We introduce a method to automatically detect drusen in dry age-related macular degeneration (AMD) from optical coherence tomography with minimum need for layer segmentation. The method is based on the en face detection of drusen areas in C-scans at certain distances above the Bruch's membrane, circumventing the difficult task of pathologic retinal pigment epithelium segmentation. All types of drusen can be detected, including the challenging subretinal drusenoid deposits (pseudodrusen). The high sensitivity and accuracy demonstrated here shows its potential for detection of drusen onset in early AMD. (C) 2017 Optical Society of America.
C1 [Zhao, Rui; Camino, Acner; Wang, Jie; Hagag, Ahmed M.; Lu, Yansha; Bailey, Steven T.; Flaxel, Christina J.; Hwang, Thomas S.; Huang, David; Jia, Yali] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 27239 USA.
   [Zhao, Rui; Lu, Yansha; Li, Dengwang] Shandong Normal Univ, Sch Phys & Elect, Shandong Prov Key Lab Med Phys & Image Proc Techn, Jinan 250014, Shandong, Peoples R China.
C3 Oregon Health & Science University; Shandong Normal University
RP Li, DW (通讯作者)，Shandong Normal Univ, Sch Phys & Elect, Shandong Prov Key Lab Med Phys & Image Proc Techn, Jinan 250014, Shandong, Peoples R China.
EM dengwang@sdnu.edu.en; jiaya@ohsu.edu
RI Hwang, Thomas S./AAW-6618-2020; Hagag, Ahmed M/F-3505-2016; Hwang,
   Thomas/AAV-5146-2020
OI Hwang, Thomas S./0000-0002-0535-4823; Hagag, Ahmed/0000-0002-3372-7885;
   Jia, Yali/0000-0002-2784-1905; Li, Dengwang/0000-0001-5126-3888; Bailey,
   Steven/0000-0003-4949-1464
FU National Institutes of Health (Bethesda, MD) [R01 EY024544, R01EY027833,
   DP3 DK104397, P30 EY010572]; National Natural Science Foundation of
   China [61471226]; Natural Science Foundation for Distinguished Young
   Scholars of Shandong Province [JQ201516]; China Scholarship Council,
   China [201608370107]; Taishan scholar project of Shandong Province;
   Research to Prevent Blindness (New York, NY)
FX This work was supported by grants R01 EY024544, R01EY027833, DP3
   DK104397, P30 EY010572 from the National Institutes of Health (Bethesda,
   MD), National Natural Science Foundation of China (NO. 61471226),
   Natural Science Foundation for Distinguished Young Scholars of Shandong
   Province (NO. JQ201516), China Scholarship Council, China (grant no.:
   201608370107) and an unrestricted departmental funding grant and William
   & Mary Greve Special Scholar Award from Research to Prevent Blindness
   (New York, NY). The authors also thank the supporting of Taishan scholar
   project of Shandong Province.
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bussel II, 2014, BRIT J OPHTHALMOL, V98, P15, DOI 10.1136/bjophthalmol-2013-304326
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   de Sisternes Luis, 2017, Transl Vis Sci Technol, V6, P12, DOI 10.1167/tvst.6.1.12
   Dong Z. M., 2016, INVEST OPHTH VIS SCI, V57
   Dongye CL, 2017, BIOMED OPT EXPRESS, V8, P1101, DOI 10.1364/BOE.8.001101
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Farsiu S, 2008, PROC SPIE, V6844, DOI 10.1117/12.768624
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Guerroudji MA, 2016, OPTIK, V127, P1251, DOI 10.1016/j.ijleo.2015.10.192
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Kraus MF, 2014, BIOMED OPT EXPRESS, V5, P2591, DOI 10.1364/BOE.5.002591
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Lee KM, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.14
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Mazzaferri J, 2017, SCI REP-UK, V7, DOI 10.1038/srep42112
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Mortensen E. N., 1995, Computer Graphics Proceedings. SIGGRAPH 95, P191
   Muller H., 1856, ARCH OPHTHALMOL-CHIC, V2, P1
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Rathke F., 2017, P MICCAI
   Schaal KB, 2017, OPHTHALMOLOGY, V124, P205, DOI 10.1016/j.ophtha.2016.10.009
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Stankiewicz A, 2016, METROL MEAS SYST, V23, P269, DOI 10.1515/mms-2016-0016
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Trichonas G, 2014, BRIT J OPHTHALMOL, V98, P24, DOI 10.1136/bjophthalmol-2014-305305
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 66
TC 18
Z9 20
U1 0
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD NOV 1
PY 2017
VL 8
IS 11
BP 5049
EP 5064
DI 10.1364/BOE.8.005049
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA FL4SE
UT WOS:000414220600021
PM 29188102
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Haas, P
   Aggermann, T
   Steindl, K
   Krugluger, W
   Puhringer, H
   Oberkanins, C
   Frantal, S
   Binder, S
AF Haas, Paulina
   Aggermann, Tina
   Steindl, Kerstin
   Krugluger, Walter
   Puehringer, Helene
   Oberkanins, Christian
   Frantal, Sophie
   Binder, Susanne
TI Genetic cardiovascular risk factors and age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cardiovascular risk factors; genetics
ID FACTOR-V GENE; MYOCARDIAL-INFARCTION; MUTATION; DISEASE; POLYMORPHISMS;
   PATHOGENESIS; VARIANTS; GENOTYPE
AB Purpose: To investigate the association between genetic cardiovascular risk factors and exudative age-related macular degeneration (AMD) in a White Austrian population.
   Methods: Seventy-five unrelated AMD patients and 75 unrelated healthy, sex-and age-matched control patients were genotyped for the following 19 single nucleotide polymorphisms (SNPs) in 14 different genes: blood coagulation factor V (FV) R506Q, factor II (prothrombin) G20210A and factor XIII (FXIII) V34L; 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T, A1298C; plasminogen activator inhibitor 1 (PAI-1) 4G/5G; endothelial protein C receptor (EPCR) 4600 A > G (A3 haplotype), 4678 G > C (A1 haplotype); apolipoprotein B (ApoB) R3500Q; apolipoprotein E (ApoE) E2/E3/E4; beta-fibrinogen -455 G > A; human platelet antigen 1 (HPA1) a/b; angiotensin-converting enzyme (ACE) I/D; endothelial nitric oxide synthase (eNOS) 786 T > C, 894 G > T; lymphotoxin alpha (LTA) 804 C > A and 9p21 rs10757278. Genotyping was carried out by polymerase chain reaction (PCR) followed by reverse hybridization (CVD StripAssays; ViennaLab Diagnostics, Vienna, Austria).
   Results: No statistically significant association could be observed between AMD and the investigated genetic risk factors for cardiovascular disease (CVD). All factors seem to be uniformly distributed in the two groups of AMD patients and healthy controls. Two variables - beta-fibrinogen: -455 G > A (p = 0.0786) and apolipoprotein E4 (p = 0.0636) - were not as far from association as the others.
   Conclusion: Our data show that the 19 tested CVD risk markers do not play a significant role in AMD. beta-Fibrinogen and apolipoprotein E4 should be examined in a larger cohort.
C1 [Haas, Paulina; Binder, Susanne] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krugluger, Walter] Social Medial Ctr E, Inst Lab Med, Vienna, Austria.
   [Puehringer, Helene; Oberkanins, Christian] ViennaLab Diagnost GmbH, Vienna, Austria.
   [Frantal, Sophie] Med Univ Vienna, Inst Med Stat, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Donauspital; Medical University of Vienna
RP Haas, P (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM paulina.haas@wienkav.at
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Braun A, 1996, HUM GENET, V97, P263, DOI 10.1007/BF02265279
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cooke GE, 2007, PHARMACOGENOMICS, V8, P1723, DOI 10.2217/14622416.8.12.1723
   Dedoussis GV, 2007, PHARMACOGENOMICS, V8, P1179, DOI 10.2217/14622416.8.9.1179
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gemmati D, 2007, MOL MED, V13, P112, DOI 10.2119/2006-00049.Gemmati
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Lijnen HR, 2005, J THROMB HAEMOST, V3, P35, DOI 10.1111/j.1538-7836.2004.00827.x
   LIP GYH, 1995, QJM-INT J MED, V88, P155
   Lunghi B, 1996, THROMB HAEMOSTASIS, V75, P45
   Medina P, 2005, THROMB HAEMOSTASIS, V94, P389, DOI 10.1160/TH05-02-0089
   Muthumala A, 2007, HYPERTENSION, V50, P348, DOI 10.1161/HYPERTENSIONAHA.107.086843
   Real JT, 2003, EUR J HUM GENET, V11, P959, DOI 10.1038/sj.ejhg.5201079
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Sofi F, 2005, J VASC SURG, V41, P255, DOI 10.1016/j.jvs.2004.11.015
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Topol EJ, 2006, HUM MOL GENET, V15, pR117, DOI 10.1093/hmg/ddl183
   Utheim OA, 2008, ACTA OPHTHALMOL, V86, P401, DOI 10.1111/j.1600-0420.2007.01070.x
   Varga EA, 2004, CIRCULATION, V110, pE15, DOI 10.1161/01.CIR.0000135582.53444.87
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
NR 25
TC 11
Z9 11
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2011
VL 89
IS 4
BP 335
EP 338
DI 10.1111/j.1755-3768.2009.01697.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 769ZQ
UT WOS:000291057200029
PM 19860767
OA Bronze
DA 2022-11-30
ER

PT J
AU Kopitz, J
   Holz, FG
   Kaemmerer, E
   Schutt, F
AF Kopitz, J
   Holz, FG
   Kaemmerer, E
   Schutt, F
TI Lipids and lipid peroxidation products in the pathogenesis of
   age-related macular degeneration
SO BIOCHIMIE
LA English
DT Article
DE age-related macular degeneration; lipofuscin; retinoid; A2-E; lipid
   peroxidation
ID RETINAL-PIGMENT EPITHELIUM; LYSOSOMAL DEGRADATIVE FUNCTIONS; HUMAN RPE
   CELLS; OCULAR LIPOFUSCIN; COMPONENT; A2E; PROTEINS; FLUOROPHORES;
   APOPTOSIS; MEMBRANES
AB In people over 50, age-related macular degeneration (ARMD) has become the most common cause for severe visual loss and legal blindness in all industrialized nations. Currently, there is no effective treatment for the majority of patients. To develop new and effective modes of therapy, understanding of the molecular basis of the disease in mandatory. However, the pathogenesis of ARMD is still poorly understood. Several lines of evidence suggest that aging changes of the retinal pigment epithelium (RPE), in particular the accumulation of autofluorescent lipofuscin granules in the lysosomal compartment of postmitotic RPE cells, play a key role in the pathogenesis of the disease. Recent studies indicate that lipidic compounds of lipofuscin, represented by the retinoid A2-E, and protein damage by lipid peroxidation products, in particular malondialdehyde and 4-hydroxynonenal, induce lysosomal dysfunction and lipofuscinogenesis in the RPE. The possible mechanisms underlying this lysosomal dysfunction and the resulting adverse effects on overall RPE function are discussed. (C) 2004 Elsevier SAS. All rights reserved.
C1 Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany.
   Univ Bonn, Hosp Eye, D-53127 Bonn, Germany.
   Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; University of Bonn; Ruprecht Karls
   University Heidelberg
RP Kopitz, J (通讯作者)，Heidelberg Univ, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.
EM juergen_kopitz@med.uni-heidelberg.de
CR Agha AM, 1995, PHARMACOL RES, V32, P279, DOI 10.1016/S1043-6618(05)80015-5
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arora S, 2004, EYE, V18, P470, DOI 10.1038/sj.eye.6700700
   Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bermann M, 2001, EXP EYE RES, V72, P191
   Bird A.C., 2004, AGE RELATED MACULAR
   BOK D, 1993, J CELL SCI, P189
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Burcham PC, 1997, ARCH BIOCHEM BIOPHYS, V340, P331, DOI 10.1006/abbi.1997.9903
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200
   Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, INVEST OPHTH VIS SCI, V45, pU122
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Hoppe G, 2004, BBA-MOL BASIS DIS, V1689, P33, DOI 10.1016/j.bbadis.2004.01.004
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lamb LE, 2001, ARCH BIOCHEM BIOPHYS, V393, P316, DOI 10.1006/abbi.2001.2492
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   MARTINEZ CM, 1990, CELL BIOL INT REP, V14, P255, DOI 10.1016/S0309-1651(05)80008-6
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   MYERS BM, 1991, J CLIN INVEST, V88, P1207, DOI 10.1172/JCI115423
   ONeil J, 1997, FREE RADICAL BIO MED, V23, P215, DOI 10.1016/S0891-5849(96)00612-0
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Schneider P, 1997, MICROSC RES TECHNIQ, V36, P253
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Taute A, 2002, BIOCHEM BIOPH RES CO, V298, P5, DOI 10.1016/S0006-291X(02)02387-2
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Tsai L, 1998, P NATL ACAD SCI USA, V95, P7975, DOI 10.1073/pnas.95.14.7975
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Wassell J, 1997, BRIT J OPHTHALMOL, V81, P911, DOI 10.1136/bjo.81.10.911
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 54
TC 107
Z9 116
U1 0
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD NOV
PY 2004
VL 86
IS 11
BP 825
EP 831
DI 10.1016/j.biochi.2004.09.029
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 882LC
UT WOS:000225939400011
PM 15589692
DA 2022-11-30
ER

PT J
AU Kodjikian, L
   Decullier, E
   Souied, EH
   Roux, A
   Aulagner, G
   Huot, L
AF Kodjikian, Laurent
   Decullier, Evelyne
   Souied, Eric H.
   Roux, Adeline
   Aulagner, Gilles
   Huot, Laure
CA GEFAL Study Grp
TI PREDICTORS OF ONE-YEAR VISUAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL
   GROWTH FACTOR TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; predictors; visual
   acuity
ID BASE-LINE PREDICTORS; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB;
   BEVACIZUMAB; HEMORRHAGE; SECONDARY; RELEVANT; TRIAL
AB Purpose: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular agerelated macular degeneration (GEFAL).
   Methods: Patients aged >= 50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen). The main outcome measures were BCVA and its change from baseline at 1 year. Variables with a P value,0.20 in the univariate model and/or which were clinically relevant were included in the multivariate analysis.
   Results: The following baseline factors were associated with a lower BCVA score at 1 year and with less improvement in BCVA (multivariate analysis): intraretinal fluid, thickness of central subfield macular <= 277 mu m, predominantly classic choroidal neovascularization, and total area of choroidal neovascularization (all P <= 0.01). Pigment epithelium detachment and high baseline BCVA were associated with less improvement in BCVA (P = 0.03, P = 0.05, respectively). Patients who met retreatment criteria but did not receive the corresponding injection had significantly poorer outcomes (only tested in the univariate analysis).
   Conclusion: This study confirms the predictors of BCVA score at 1 year posttreatment; the presence of intraretinal fluid was associated with a poor prognosis.
C1 [Kodjikian, Laurent] Hosp Civils Lyon, Hop Croix Rousse, Grp Hosp Nord, Serv Ophtalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
   [Kodjikian, Laurent; Decullier, Evelyne; Aulagner, Gilles; Huot, Laure] Univ Lyon, Lyon, France.
   [Kodjikian, Laurent] Mateis, CNRS, UMR 5510, Villeurbanne, France.
   [Decullier, Evelyne; Roux, Adeline; Huot, Laure] Hosp Civils Lyon, Pole Informat Med Evaluat Rech, Unite Rech Clin, Lyon, France.
   [Decullier, Evelyne; Huot, Laure] Univ Lyon 1, EAM 4128 P2S, Lyon, France.
   [Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Serv Ophtalmol, Creteil, France.
   [Souied, Eric H.] Univ Paris Est Creteil, CRC, Creteil, France.
   [Aulagner, Gilles] Hosp Civils Lyon, Grp Hosp Est, Serv Pharmaceut, Bron, France.
   [Aulagner, Gilles] Univ Lyon 1, Inst Sci Pharmaceut & Biol, Fac Pharm, Lyon, France.
C3 CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS -
   Institute for Engineering & Systems Sciences (INSIS); Institut National
   des Sciences Appliquees de Lyon - INSA Lyon; CHU Lyon; UDICE-French
   Research Universities; Universite Claude Bernard Lyon 1; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux
   Paris (APHP); CHU Lyon; UDICE-French Research Universities; Universite
   Claude Bernard Lyon 1; Universite de Franche-Comte
RP Kodjikian, L (通讯作者)，Hosp Civils Lyon, Hop Croix Rousse, Grp Hosp Nord, Serv Ophtalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
EM laurent.kodjikian@chu-lyon.fr
RI Huot, Laure/GLS-5988-2022; decullier, evelyne/AAL-5861-2021
OI Huot, Laure/0000-0002-7870-9912; 
FU French Ministry of Health ("Programme Hospitalier de Recherche Clinique
   National") [27-29]; French Health Insurance System
FX Supported by a grant from the French Ministry of Health ("Programme
   Hospitalier de Recherche Clinique National 2008 number 27-29"); the
   French Health Insurance System cofinanced the study and funded the
   drugs. The funding organizations had no role in designing or carrying
   out this research.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Iida T, 2003, RETINA-J RET VIT DIS, V23, P1, DOI 10.1097/00006982-200302000-00001
   Iida T, 2003, RETINA, V23, P137, DOI DOI 10.1097/00006982-200302000-00001
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 27
TC 15
Z9 15
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2018
VL 38
IS 8
BP 1492
EP 1499
DI 10.1097/IAE.0000000000001736
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VJ
UT WOS:000454002400017
PM 28654629
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Takahashi, K
   Obata, R
   Iida, T
   Yanagi, Y
   Koizumi, H
   Yamashita, H
   Shiraga, F
   Sakamoto, T
AF Tsujikawa, Akitaka
   Takahashi, Kanji
   Obata, Ryo
   Iida, Tomohiro
   Yanagi, Yasuo
   Koizumi, Hideki
   Yamashita, Hidetoshi
   Shiraga, Fumio
   Sakamoto, Taiji
TI Dry age-related macular degeneration in the Japanese population
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Drusen; Dry age-related macular degeneration; Geographic atrophy;
   Reticular pseudodrusen; Smoking
ID GEOGRAPHIC ATROPHY; PREVALENCE
AB Purpose To elucidate the clinical characteristics of eyes with dry age-related macular degeneration (AMD) in Japan. Study design Retrospective. Methods We performed a nationwide survey of dry AMD. A questionnaire on dry AMD was sent to 3,801 major hospitals and eye clinics nationwide. Whenever both eyes met the diagnostic criteria, only the eye with more advanced geographic atrophy was included. Results In the current survey, 81 patients (81 eyes) with dry AMD were included. Of the 81 patients, 56 (69.1%) were men, and the mean age of the patients was 76.6 +/- 8.4 (range, 54-94) years. Twenty-four patients (29.6%) had a history of smoking. The decimal best corrected-visual acuity (BCVA) was equal to or better than 0.7 in 25 eyes (30.9%), but worse than 0.1 in 17 eyes (21.0%). The mean BCVA was 0.62 +/- 0.59 in logarithm of the minimum angle of resolution. Lesion size (the greatest linear dimension of the largest geographic atrophy) was >= 2 disc diameter in 33 eyes (40.7%) and < 1 disc diameter in 21 eyes (25.9%). Soft drusen was observed in 27 eyes (33.3%), and reticular pseudodrusen was observed in 31 eyes (38.3%). Of the 81 patients, the other eye was diagnosed as dry AMD in 26 eyes (32.1%), neovascular AMD in 16 eyes (19.8%), and intermediate AMD in 18 eyes (22.2%). Conclusion Dry AMD in the Japanese population has characteristics of male predominance, older age, high prevalence of reticular pseudodrusen, and high bilaterality.
C1 [Tsujikawa, Akitaka] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Takahashi, Kanji] Kansai Med Univ, Dept Ophthalmol, Hirakata, Osaka 5731191, Japan.
   [Obata, Ryo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Yanagi, Yasuo] Yokohama City Univ, Dept Ophthalmol & Microtechnol, Yokohama, Kanagawa, Japan.
   [Koizumi, Hideki] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, Nishihara, Okinawa, Japan.
   [Yamashita, Hidetoshi] Yamagata Univ, Dept Ophthalmol & Visual Sci, Fac Med, Yamagata, Japan.
   [Shiraga, Fumio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Okayama, Japan.
   [Sakamoto, Taiji] Kagoshima Univ, Dept Ophthalmol, Kagoshima, Japan.
C3 Kyoto University; Kansai Medical University; University of Tokyo; Tokyo
   Women's Medical University; Yokohama City University; University of
   Ryukyus; Yamagata University; Okayama University; Kagoshima University
RP Takahashi, K (通讯作者)，Kansai Med Univ, Dept Ophthalmol, Hirakata, Osaka 5731191, Japan.
EM takahask@takii.kmu.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022
FU Health and Labor Sciences Research Grants for Research on Rare and
   Intractable Diseases
FX This survey was supported by Health and Labor Sciences Research Grants
   for Research on Rare and Intractable Diseases.
CR Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Bikbov MM, 2020, AM J OPHTHALMOL, V210, P146, DOI 10.1016/j.ajo.2019.10.004
   Campa C, 2020, CURR DRUG TARGETS, V21, P1194, DOI 10.2174/1389450121666200428101738
   Cheng QE, 2018, OPHTHALMOL RETINA, V2, P518, DOI 10.1016/j.oret.2017.08.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Guymer R, 2020, CLIN EXP OPHTHALMOL, V48, P983, DOI 10.1111/ceo.13837
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Koizumi H, 2020, JPN J OPHTHALMOL, V64, P338, DOI 10.1007/s10384-020-00745-0
   Komuku Y, 2020, JPN J OPHTHALMOL, V64, P265, DOI 10.1007/s10384-020-00734-3
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Obata R, 2018, BRIT J OPHTHALMOL, V102, P1047, DOI 10.1136/bjophthalmol-2016-309980
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rim TH, 2020, OPHTHALMOLOGY, V127, P1371, DOI 10.1016/j.ophtha.2020.04.019
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Shen LL, 2020, OPHTHALMOL RETINA, V4, P899, DOI 10.1016/j.oret.2020.03.020
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Takahashi Kanji, 2015, Nippon Ganka Gakkai Zasshi, V119, P671
   Wilde C, 2021, EYE, V35, P1697, DOI 10.1038/s41433-020-01169-3
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2020, JPN J OPHTHALMOL, V64, P555, DOI 10.1007/s10384-020-00773-w
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN
PY 2022
VL 66
IS 1
BP 8
EP 13
DI 10.1007/s10384-021-00892-y
EA DEC 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YF7XO
UT WOS:000734348500001
PM 34957534
DA 2022-11-30
ER

PT J
AU Zambarakji, HJ
   Lane, AM
   Ezra, E
   Gauthier, D
   Goitein, M
   Adams, JA
   Munzenrider, JE
   Miller, JW
   Gragoudas, ES
AF Zambarakji, Hadi J.
   Lane, Anne Marie
   Ezra, Eric
   Gauthier, Danny
   Goitein, Michael
   Adams, Judy A.
   Munzenrider, John E.
   Miller, Joan W.
   Gragoudas, Evangelos S.
TI Proton beam irradiation for neovascular age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   RADIATION-THERAPY; PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY;
   VISUAL-ACUITY; RADIOTHERAPY; TELETHERAPY; MEMBRANES; SECONDARY
AB Objective: To evaluate safety and visual outcomes after proton therapy for subfoveal neovascular age-related macular degeneration (AMD).
   Design: Randomized dose-ranging clinical trial.
   Participants: One hundred sixty-six patients with angiographic evidence of classic choroidal neovascularization resulting from AMD and best-corrected visual acuity of 20/320 or better.
   Methods: Patients were assigned randomly (1:1) to receive 16-cobalt gray equivalent (CGE) or 24-CGE proton radiation in 2 equal fractions. Visual acuity was measured using standardized protocol refraction. Complete ophthalmological examinations, color fundus photography, and fluorescein angiography were performed before and 3, 6, 12, 18, and 24 months after treatment.
   Main Outcome Measure: Proportion of eyes losing 3 or more lines of vision from baseline. Kaplan-Meier statistics were used to compare cumulative rates of vision loss between the 2 treatment groups. Results: At 12 months after treatment, 36 eyes (42%) and 27 eyes (35%) lost 3 or more lines of vision in the 16-CGE and 24-CGE groups, respectively. Rates increased to 62% in the 16-CGE group and 53% in the 24-CGE group by 24 months after treatment (P=0.40). Radiation complications developed in 15.7% of patients receiving 16 CGE and 14.8% of patients receiving 24 CGE.
   Conclusions: No significant differences in rates of visual loss were found between the 2 dose groups. Proton radiation may be useful as an adjuvant therapy or as an alternative for patients who decline or are not appropriate for approved therapies. (c) 2006 by the American Academy of Ophthalmology.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA 02114 USA.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Harvard University; Harvard Medical School; Massachusetts
   General Hospital
RP Gragoudas, ES (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM Evangelos_Gragoudas@meei.harvard.edu
RI Zambarakji, Hadi/AAM-6095-2020
OI Miller, Joan/0000-0003-2046-3996
CR Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P1241, DOI 10.3109/02713688909013903
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAGOUDAS ES, 1979, BRIT J OPHTHALMOL, V63, P135, DOI 10.1136/bjo.63.2.135
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Moyers MF, 1999, MED PHYS, V26, P777, DOI 10.1118/1.598587
   Palmer JD, 1997, INT OPHTHALMOL CLIN, V37, P159, DOI 10.1097/00004397-199703740-00014
   PLOWMAN PN, 1988, BRIT J OPHTHALMOL, V72, P286, DOI 10.1136/bjo.72.4.286
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Suit H, 2003, ACTA ONCOL, V42, P800, DOI 10.1080/02841860310017676
   Suit HD, 2003, CLIN ONCOL-UK, V15, pS29, DOI 10.1053/clon.2002.0171
   Tsina EK, 2005, OPHTHALMOLOGY, V112, P337, DOI 10.1016/j.ophtha.2004.09.013
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Valmaggia C, 1997, DOC OPHTHALMOL, V93, P317, DOI 10.1007/BF02569069
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
NR 34
TC 42
Z9 43
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2006
VL 113
IS 11
BP 2012
EP 2019
DI 10.1016/j.ophtha.2006.05.036
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 101CS
UT WOS:000241717100015
PM 16935343
DA 2022-11-30
ER

PT J
AU Malek, G
   Campisi, J
   Kitazawa, K
   Webster, C
   Lakkaraju, A
   Skowronska-Krawczyk, D
AF Malek, Goldis
   Campisi, Judith
   Kitazawa, Koji
   Webster, Corey
   Lakkaraju, Aparna
   Skowronska-Krawczyk, Dorota
TI Does senescence play a role in age-related macular degeneration?
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Age -related macular degeneration; Senescence; Aging; Retinal pigment
   epithelium
ID RETINAL-PIGMENT EPITHELIUM; RPE CELL SENESCENCE; OXIDATIVE STRESS;
   AMYLOID-BETA; COMPLEMENT ACTIVATION; ENDOTHELIAL-CELLS; DEPENDENT
   CHANGE; ARPE-19 CELLS; ACHILLES-HEEL; AGING CHANGES
AB Advanced age is the most established risk factor for developing age-related macular degeneration (AMD), one of the leading causes of visual impairment in the elderly, in Western and developed countries. Similarly, after middle age, there is an exponential increase in pathologic molecular and cellular events that can induce senescence, traditionally defined as an irreversible loss of the cells??? ability to divide and most recently reported to also occur in select post-mitotic and terminally differentiated cells, such as neurons. Together these facts raise the question as to whether or not cellular senescence, may play a role in the development of AMD. A number of studies have reported the effect of ocular-relevant inducers of senescence using primarily in vitro models of poorly polarized, actively dividing retinal pigment epithelial (RPE) cell lines. However, in interpretating the data, the fidelity of these culture models to the RPE in vivo, must be considered. Fewer studies have explored the presence and/or impact of senescent cells in in vivo models that present with phenotypic features of AMD, leaving this an open field for further investigation. The goal of this review is to discuss current thoughts on the potential role of senescence in AMD development and progression, with consideration of the model systems used and their relevance to human disease.
C1 [Malek, Goldis] Duke Univ, Sch Med, Dept Ophthalmol, Duke Eye Ctr, Durham, NC USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
   [Campisi, Judith; Kitazawa, Koji; Webster, Corey] Buck Inst Res Aging, Novato, CA USA.
   [Campisi, Judith] Lawrence Berkeley Natl Lab, Berkeley, CA USA.
   [Kitazawa, Koji] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.
   [Lakkaraju, Aparna] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA USA.
   [Lakkaraju, Aparna] Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA USA.
   [Skowronska-Krawczyk, Dorota] Univ Calif Irvine, Sch Med, Ctr Translat Vis Res, Dept Physiol & Biophys,Dept Ophthalmol, Irvine, CA 92717 USA.
C3 Duke University; Duke University; Buck Institute for Research on Aging;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory; Kyoto Prefectural University of Medicine; University of
   California System; University of California San Francisco; University of
   California System; University of California San Francisco; University of
   California System; University of California Irvine
RP Malek, G (通讯作者)，Albert Eye Res Inst, Room 4006, Durham, NC 27710 USA.
EM gmalek@duke.edu
CR Aguayo-Mazzucato C, 2019, CELL METAB, V30, P129, DOI 10.1016/j.cmet.2019.05.006
   Lopez-Dominguez JA, 2021, AGING-US, V13, P13380, DOI 10.18632/aging.203110
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Boccardi V, 2021, MECH AGEING DEV, V197, DOI 10.1016/j.mad.2021.111526
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Caceres PS, 2020, CURR OPIN CELL BIOL, V62, P37, DOI 10.1016/j.ceb.2019.08.001
   Campello L, 2021, ANNU REV VIS SCI, V7, P633, DOI 10.1146/annurev-vision-100419-114940
   Campisi J, 2019, NATURE, V571, P183, DOI 10.1038/s41586-019-1365-2
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Chae JB, 2021, GEROSCIENCE, V43, P2809, DOI [10.1007/s11357-021-00457-4, 10.1371/journal.pone.0101072, 10.3390/ijms21228840]
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659
   Chilosi M, 2013, TRANSL RES, V162, P156, DOI 10.1016/j.trsl.2013.06.004
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Cormenier J, 2018, MECH AGEING DEV, V170, P82, DOI 10.1016/j.mad.2017.08.003
   Crespo-Garcia S, 2021, CELL METAB, V33, P818, DOI 10.1016/j.cmet.2021.01.011
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davalos AR, 2013, J CELL BIOL, V201, P613, DOI 10.1083/jcb.201206006
   de Jong PTVM, 2016, OPHTHALMOL EYE DIS, V8, P5, DOI 10.4137/OED.S40523
   Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012
   Dentchev T, 2003, MOL VIS, V9, P184
   Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eastlake K, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100970
   Efrat S, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.614234
   El-Nimri NW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78802-4
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Eton EA, 2022, EUR J OPHTHALMOL, V32, P417, DOI 10.1177/1120672121997288
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng L, 2016, DISCOV MED, V21, P149
   Ferdous S, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.7.9
   Ferrington DA, 2021, ADV EXP MED BIOL, V1256, P237, DOI 10.1007/978-3-030-66014-7_10
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Giacalone JC, 2019, MICROVASC RES, V123, P50, DOI 10.1016/j.mvr.2018.12.002
   Gibbs D, 2003, ADV EXP MED BIOL, V533, P347
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gokhale KM, 2022, BRIT J OPHTHALMOL, DOI 10.1136/bjophthalmol-2021-319641
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005
   Grosse L, 2020, CELL METAB, V32, P87, DOI 10.1016/j.cmet.2020.05.002
   Hadziahmetovic M, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.612812
   Hall BM, 2016, AGING-US, V8, P1294, DOI 10.18632/aging.100991
   HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375
   HAYASAKA S, 1989, JPN J OPHTHALMOL, V33, P36
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Itahana Koji, 2007, Methods Mol Biol, V371, P21
   Jablonski MM, 2007, INVEST OPHTH VIS SCI, V48, P479, DOI 10.1167/iovs.06-0972
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Johmura Y, 2021, SCIENCE, V371, P265, DOI 10.1126/science.abb5916
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474-9726.2012.00870.x
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kovacs-Valasek A, 2021, CELLS TISSUES ORGANS, V210, P135, DOI 10.1159/000515447
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   La Cunza N, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142254
   Lahne M, 2020, ANNU REV VIS SCI, V6, P171, DOI 10.1146/annurev-vision-121219-081808
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lekwuwa M, 2022, MODERN PATHOL, V35, P165, DOI 10.1038/s41379-021-00887-7
   Liton PB, 2005, EXP GERONTOL, V40, P745, DOI 10.1016/j.exger.2005.06.005
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu HT, 2019, DIABETOLOGIA, V62, P2365, DOI 10.1007/s00125-019-04998-4
   Liu JY, 2019, P NATL ACAD SCI USA, V116, P2603, DOI 10.1073/pnas.1818313116
   Liu XC, 2012, INFLAMMATION, V35, P776, DOI 10.1007/s10753-011-9379-4
   Loeven MA, 2018, INVEST OPHTH VIS SCI, V59, P722, DOI 10.1167/iovs.IOVS-17-22893
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lu YC, 2020, NATURE, V588, P124, DOI 10.1038/s41586-020-2975-4
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Makin RD, 2018, INVEST OPHTH VIS SCI, V59, P5795, DOI 10.1167/iovs.18-25215
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mansour H, 2008, AGING CELL, V7, P526, DOI 10.1111/j.1474-9726.2008.00402.x
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Merz SE, 2019, J COMP PATHOL, V173, P41, DOI 10.1016/j.jcpa.2019.10.004
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Musi N, 2018, AGING CELL, V17, DOI 10.1111/acel.12840
   NABI IR, 1993, J CELL SCI, V104, P37
   Nateras OS, 2014, CURR EYE RES, V39, P1059, DOI 10.3109/02713683.2014.892997
   Nie C, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110459
   Nishimura A, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat5185
   Nivison-Smith L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67829-2
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Nuzzi R, 1996, J FR OPHTALMOL, V19, P89
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Pappas CM, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246-021-00359-8
   Paraoan L, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100859
   Peavey J, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11152386
   Peavey J, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.19
   Pedersen HR, 2018, BRIT J OPHTHALMOL, V102, P146, DOI 10.1136/bjophthalmol-2017-310719
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Rebustini IT, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23147745
   Rocha LR, 2020, AGING CELL, V19, DOI 10.1111/acel.13089
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Samuel MA, 2011, J NEUROSCI, V31, P16033, DOI 10.1523/JNEUROSCI.3580-11.2011
   Samuel W, 2017, MOL VIS, V23, P60
   Sapieha P, 2018, TRENDS CELL BIOL, V28, P595, DOI 10.1016/j.tcb.2018.03.003
   Schlecht A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413318
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Skowronska-Krawczyk D, 2015, MOL CELL, V59, P931, DOI 10.1016/j.molcel.2015.07.027
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Sone H, 2005, DIABETOLOGIA, V48, P58, DOI 10.1007/s00125-004-1605-2
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sreekumar PG, 2022, EXP EYE RES, V215, DOI 10.1016/j.exer.2021.108918
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Stewart EA, 2011, EXP EYE RES, V93, P761, DOI 10.1016/j.exer.2011.09.010
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   TATE DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P963, DOI 10.1001/archopht.1993.01090070083023
   Hoang T, 2020, SCIENCE, V370, P934, DOI 10.1126/science.abb8598
   Todd L, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109857
   Tonade D, 2017, DIABETOLOGIA, V60, P2111, DOI 10.1007/s00125-017-4381-5
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Tuttle CSL, 2021, AGEING RES REV, V68, DOI 10.1016/j.arr.2021.101334
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Vaghefi E, 2020, ASIA-PAC J OPHTHALMO, V9, P137, DOI 10.1097/APO.0000000000000278
   Vergroesen JE, 2022, JAMA OPHTHALMOL, V140, P674, DOI 10.1001/jamaophthalmol.2022.1435
   von Zglinicki T, 2021, ANTIOXID REDOX SIGN, V34, P308, DOI 10.1089/ars.2020.8048
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wiley CD, 2021, CELL METAB, V33, P1124, DOI 10.1016/j.cmet.2021.03.008
   Wiley CD, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130056
   Wiley CD, 2016, CELL METAB, V23, P1013, DOI 10.1016/j.cmet.2016.05.010
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593
   WYSZYNSKI RE, 1989, INVEST OPHTH VIS SCI, V30, P2341
   Yamada K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.1
   Yao P.L., 2022, P NATL ACAD SCI USA, V119
   Yaswen P, 2002, INT J BIOCHEM CELL B, V34, P1382, DOI 10.1016/S1357-2725(02)00047-X
   Yip VCH, 2019, J GLAUCOMA, V28, P80, DOI 10.1097/IJG.0000000000001125
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yousefzadeh MJ, 2021, NATURE, V594, P100, DOI 10.1038/s41586-021-03547-7
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zhang J, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103327
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhou M, 2021, BRIT J OPHTHALMOL, V105, P1427, DOI 10.1136/bjophthalmol-2020-316820
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 180
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2022
VL 225
AR 109254
DI 10.1016/j.exer.2022.109254
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5H1HU
UT WOS:000867437500003
PM 36150544
DA 2022-11-30
ER

PT J
AU Helotera, H
   Kaarniranta, K
AF Helotera, Hanna
   Kaarniranta, Kai
TI A Linkage between Angiogenesis and Inflammation in Neovascular
   Age-Related Macular Degeneration
SO CELLS
LA English
DT Review
DE aging; angiogenesis; aggregation; degeneration; inflammation; macula
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; VEGF-TRAP;
   CHOROIDAL NEOVASCULARIZATION; FACTOR EXPRESSION; OXIDATIVE STRESS; BASIC
   SCIENCE; MACROPHAGES; HYPOXIA; BINDING
AB Age-related macular degeneration (AMD) is the leading cause of visual impairment in the aging population with a limited understanding of its pathogenesis and the number of patients are all the time increasing. AMD is classified into two main forms: dry and neovascular AMD (nAMD). Dry AMD is the most prevalent form (80-90%) of AMD cases. Neovascular AMD (10-20% of AMD cases) is treated with monthly or more sparsely given intravitreal anti-vascular endothelial growth factor inhibitors, but unfortunately, not all patients respond to the current treatments. A clinical hallmark of nAMD is choroidal neovascularization. The progression of AMD is initially characterized by atrophic alterations in the retinal pigment epithelium, as well as the formation of lysosomal lipofuscin and extracellular drusen deposits. Cellular damage caused by chronic oxidative stress, protein aggregation and inflammatory processes may lead to advanced geographic atrophy and/or choroidal neovascularization and fibrosis. Currently, it is not fully known why different AMD phenotypes develop. In this review, we connect angiogenesis and inflammatory regulators in the development of nAMD and discuss therapy challenges and hopes.
C1 [Helotera, Hanna; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland
RP Helotera, H (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
EM hanna.helotera@roche.com
OI Kaarniranta, Kai/0000-0003-2600-8679
FU Academy of Finland [296840, 333302]; Kuopio University Hospital VTR
   grant [5503770]; Finnish Eye Foundation; Sigrid Juselius Foundation;
   Paivikki and Sakari Sohlberg Foundation
FX The Academy of Finland (296840, 333302); the Kuopio University Hospital
   VTR grant (5503770); the Finnish Eye Foundation, the Sigrid Juselius
   Foundation; the Paivikki and Sakari Sohlberg Foundation.
CR Aguilar-Cazares D, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01399
   Aiello A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02247
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baluk P, 2009, J CLIN INVEST, V119, P2954, DOI 10.1172/JCI37626
   Brown KA, 2019, DRUG TEST ANAL, V11, P1207, DOI 10.1002/dta.2609
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Caprara C, 2011, INVEST OPHTH VIS SCI, V52, P2109, DOI 10.1167/iovs.10-6222
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chanchal S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00073
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chernykh V, 2019, INT J OPHTHALMOL-CHI, V12, P25, DOI 10.18240/ijo.2019.01.04
   Claesson-Welsh L, 2021, TRENDS MOL MED, V27, P314, DOI 10.1016/j.molmed.2020.11.006
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Corazza P, 2021, BMC OPHTHALMOL, V21, DOI 10.1186/s12886-021-02055-6
   Cox JT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10050981
   DiPietro LA, 2016, J LEUKOCYTE BIOL, V100, P979, DOI 10.1189/jlb.4MR0316-102R
   Droho S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97522-x
   Du HL, 2012, INT J ONCOL, V40, P2049, DOI 10.3892/ijo.2012.1415
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eelen G, 2020, CIRC RES, V127, P310, DOI 10.1161/CIRCRESAHA.120.316851
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hudson N, 2020, NEURAL REGEN RES, V15, P1656, DOI 10.4103/1673-5374.276332
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Izzedine H, 2014, MEDICINE, V93, P333, DOI 10.1097/MD.0000000000000207
   Jeong JH, 2021, ARCH PHARM RES, V44, P1, DOI 10.1007/s12272-020-01287-2
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Kaarniranta K, 2022, AUTOPHAGY, DOI 10.1080/15548627.2022.2069437
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim SA, 2020, BIOCHEM BIOPH RES CO, V522, P240, DOI 10.1016/j.bbrc.2019.11.085
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Li H, 2021, EXPERT REV GASTROENT, V15, P217, DOI 10.1080/17474124.2021.1842732
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lipecz A, 2019, GEROSCIENCE, V41, P341, DOI 10.1007/s11357-019-00078-y
   Lis-Lopez L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9121747
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liukkonen MPK, 2022, ACTA OPHTHALMOL, V100, pE1153, DOI 10.1111/aos.15051
   Long Q, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6958752
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Murray H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179580
   Nahavandipour A, 2020, ACTA OPHTHALMOL, V98, P434, DOI 10.1111/aos.14402
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Leary F, 2021, FEBS J, DOI 10.1111/febs.16330
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ollero M, 2015, NEPHROL DIAL TRANSPL, V30, P1449, DOI 10.1093/ndt/gfu368
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Presta LG, 1997, CANCER RES, V57, P4593
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Ronning KE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41141-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roshanipour N, 2021, OPHTHALMIC GENET, V42, P641, DOI 10.1080/13816810.2021.1955274
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009
   Singh NK, 2015, EBIOMEDICINE, V2, P1767, DOI 10.1016/j.ebiom.2015.09.042
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Stacker SA, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8010001
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Subhi Y, 2019, JAMA OPHTHALMOL, V137, P515, DOI 10.1001/jamaophthalmol.2019.0010
   Suzuki S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105473
   Szabo Emese, 2018, J Pharmacol Exp Ther, V365, P422, DOI 10.1124/jpet.117.246249
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Tenbrock L, 2022, CELL TISSUE RES, V387, P361, DOI 10.1007/s00441-021-03514-8
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169
   Wang ZL, 2019, TRENDS IMMUNOL, V40, P825, DOI 10.1016/j.it.2019.07.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zhang LJ, 2019, HUM MOL GENET, V28, P3475, DOI 10.1093/hmg/ddz159
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 121
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2022
VL 11
IS 21
AR 3453
DI 10.3390/cells11213453
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 6A7YK
UT WOS:000880866100001
PM 36359849
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Behrendt, CE
AF Behrendt, CE
TI Visual acuity and its decrease in classic neovascular age-related
   macular degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; natural history; neovascularization;
   prognosis; visual acuity
ID CHOROIDAL NEOVASCULARIZATION; ASSOCIATION; PROGRESSION; SUBFOVEAL
AB PURPOSE To identify factors affecting visual acuity and its decrease in eyes with subfoveal choroldal neovascularization (CNV) associated with age-related macular degeneration (AMD).
   METHODS Distance visual acuity was recorded at screening and up to five follow-up visits during the first year of a randomized, double-blind, placebo-controlled trial of oral prinomastat. Subjects had AMD in both eyes and neovascular AMD in at least one eye. Analysis employed a generalized linear mixed model.
   RESULTS Of 158 eligible subjects (age 56-90), 125 (79.1%) received prinomastat. Visual acuity was independently affected by relative acuity of the fellow eye, whether the study eye had been the first or second to develop CNV, age, current smoking, leakage area, and prior photocoagulation. Decrease in visual acuity score, unaffected by prinomastat, was less steep in eyes that had been second to develop CNV Such eyes had a comparable time since CNV onset to other study eyes.
   CONCLUSION Fellow eye features independently affect visual acuity and its decrease in eyes with classic neovascular AMD.
C1 Pfizer Global Res & Dev, San Diego, CA 92121 USA.
C3 Pfizer
RP Behrendt, CE (通讯作者)，Pfizer Global Res & Dev, 11085 Torreyana Rd, San Diego, CA 92121 USA.
EM carolynbehrendt@yahoo.com
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   BLODI BA, 2000, INVEST OPHTH VIS SCI, V42, pS311
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Diggle P., 2002, J AM STAT ASSOC, V90, DOI DOI 10.2307/2983303
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   *REDS, 1999, CONTROL CLIN TRIALS, V20, P573
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x
   SINGERMAN LJ, 1985, RETINA-J RET VIT DIS, V5, P135, DOI 10.1097/00006982-198500530-00001
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
NR 22
TC 5
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD DEC
PY 2004
VL 11
IS 5
BP 359
EP 367
DI 10.1080/09286580490515125
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 887SF
UT WOS:000226325100004
PM 15590583
DA 2022-11-30
ER

PT J
AU Swanson, MW
   McGwin, G
AF Swanson, Mark W.
   McGwin, Gerald, Jr.
TI Anti-Inflammatory Drug Use and Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; medication; anti-inflammatory;
   prevention
ID MACULOPATHY; ASSOCIATION; EYE; STATINS; ASPIRIN; DRUSEN; RISK
AB Purpose. Basic research has shown that early processes in the development of age-related macular degeneration (ARMD) are related to inflammation. The purpose of this manuscript is to evaluate the associated of ARMD and the use of anti-inflammatory medications.
   Methods. A nested case control study was carried out among male patients at the Veteran's Medical Center in Birmingham, Alabama (BVAMC). Cases were 614 patients with incident ARMD diagnosed between 1997 and 2001 by International Classification of Disease, Ninth Revision code. Controls (4526) were individuals with no diagnosis of ARMD by International Classification of Disease, Ninth Revision coding and matched on age. Formulary records of all medications dispensed through the Veteran's Administration Medical Center were accessed. All oral or injectable drugs with anti-inflanimatory properties were considered anti-inflarninatory medications for study purposes. Topical ophthalmic and dermatologic preparations were not considered anti-inflammatory.
   Results. Among Veterans with a diagnosis of ARMD 24% (150/614) patients had filled a prescription for any of the anti-inflammatory medications compared with 60% (3051/4526) individuals in the control population. Individuals who had filled a prescription for anti-inflammatory drugs had an 85% reduced odds of having a diagnosis of ARMD (odds ratio 0.15, 95% confidence interval 0.12-0.18).
   Conclusions. The results Of this study Suggest that veterans who had filled a prescription for anti-inflammatory medications had a reduced risk of ARMD. further studies are needed to confirm this result. (Optom Vis Sci 2008;85:947-950)
C1 [Swanson, Mark W.] Univ Alabama Birmingham, Sch Optometry, Dept Optometry, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Swanson, MW (通讯作者)，Univ Alabama Birmingham, Sch Optometry, Dept Optometry, 1716 Univ Blvd, Birmingham, AL 35294 USA.
EM mswanson@uab.edu
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   *FACTS COMP, 2004, DRUG FACTS COMP
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein-Nulend Jenneke, 2003, Curr Osteoporos Rep, V1, P5
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ray KK, 2006, AM J CARDIOL, V98, p18P, DOI 10.1016/j.amjcard.2006.09.016
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
NR 19
TC 7
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD OCT
PY 2008
VL 85
IS 10
BP 947
EP 950
DI 10.1097/OPX.0b013e31818883e0
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 358TI
UT WOS:000259940000007
PM 18832975
DA 2022-11-30
ER

PT J
AU Dziedziak, J
   Kasarello, K
   Cudnoch-Jedrzejewska, A
AF Dziedziak, Jacek
   Kasarello, Kaja
   Cudnoch-Jedrzejewska, Agnieszka
TI Dietary Antioxidants in Age-Related Macular Degeneration and Glaucoma
SO ANTIOXIDANTS
LA English
DT Review
DE antioxidants; age-related macular degeneration; glaucoma; carotenoids;
   resveratrol
ID ALPHA-LIPOIC ACID; RETINAL-PIGMENT EPITHELIUM; GANGLION-CELL DEATH;
   OXIDATIVE STRESS; VITAMIN-E; EYE DISEASE; NEURODEGENERATIVE DISEASES;
   GLOBAL PREVALENCE; ZINC-DEFICIENCY; VISUAL FUNCTION
AB Age-related macular degeneration (AMD) and glaucoma are ophthalmic neurodegenerative diseases responsible for irreversible vision loss in the world population. Only a few therapies can be used to slow down the progression of these diseases and there are no available treatment strategies for reversing the degeneration of the neural retina. In AMD, the pathological process causes the malfunction and damage of the retinal pigmented epithelium and photoreceptors in the macula. In glaucoma, damage of the retinal ganglion cells and their axons is observed and treatment strategies are limited to intraocular pressure lowering. Therefore, other prophylactic and/or therapeutic methods are needed. Oxidative stress is involved in the neurodegenerative process accompanying both AMD and glaucoma; therefore, the use of antioxidant agents would clearly be beneficial, which is supported by the decreased prevalence and progression of AMD in patients adherent to a diet naturally rich in antioxidants. Dietary antioxidants are easily available and their use is based on the natural route of administration. Many preclinical studies both in vitro and using animal models of retinal degeneration showed the efficacy of dietary antioxidants, which was further proved in clinical trials. Resveratrol is beneficial both in AMD and glaucoma animal models, but confirmed only among AMD patients. For AMD, carotenoids and omega-3 fatty acids were also proved to be sufficient in preventing neurodegeneration. For glaucoma, coenzyme Q10 and alpha-lipoic acid showed efficacy for decreasing retinal ganglion cell loss and inhibiting the accompanying destructive processes. Interestingly, the benefits of vitamins, especially vitamin E was not confirmed, neither in preclinical nor in clinical studies.
C1 [Dziedziak, Jacek; Kasarello, Kaja; Cudnoch-Jedrzejewska, Agnieszka] Med Univ Warsaw, Ctr Preclin Res, Dept Expt & Clin Physiol, PL-02097 Warsaw, Poland.
C3 Medical University of Warsaw
RP Kasarello, K (通讯作者)，Med Univ Warsaw, Ctr Preclin Res, Dept Expt & Clin Physiol, PL-02097 Warsaw, Poland.
EM jacek.dziedziak@wum.edu.pl; kaja.kasarello@wum.edu.pl;
   agnieszka.cudnoch-jedrzejewska@wum.edu.pl
RI Dziedziak, Jacek/AAC-5199-2022; Kasarełło, Kaja/ABH-3532-2020
OI Kasarełło, Kaja/0000-0002-0851-0975; Dziedziak,
   Jacek/0000-0002-9255-710X
FU CePT infrastructure - European Regional Development Fund
FX This project was supported by the CePT infrastructure financed by the
   European Regional Development Fund with the Operational Programme
   "Innovative Economy" for 2007-2013.
CR Aaseth J, 2021, MECH AGEING DEV, V197, DOI 10.1016/j.mad.2021.111521
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Ahmad Anas, 2020, J Immunoassay Immunochem, V41, P257, DOI 10.1080/15321819.2020.1726774
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Alaimo A, 2020, ARCH TOXICOL, V94, P553, DOI 10.1007/s00204-019-02637-w
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Allison K, 2020, CUREUS, V12, DOI 10.7759/cureus.11686
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Aslan M, 2013, REDOX REP, V18, P76, DOI 10.1179/1351000212Y.0000000033
   Avallone R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174256
   Aydemir Orhan, 2004, International Ophthalmology, V25, P283, DOI 10.1007/s10792-005-2034-z
   Balasubramanian V, 2009, J PHYSIOL-LONDON, V587, P2753, DOI 10.1113/jphysiol.2009.170704
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Cenini G, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2105607
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chidlow G, 2002, NEUROPHARMACOLOGY, V43, P1015, DOI 10.1016/S0028-3908(02)00129-6
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2020, JAMA OPHTHALMOL, V138, P1280, DOI 10.1001/jamaophthalmol.2020.4409
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cornebise C, 2020, MOLECULES, V25, DOI 10.3390/molecules25235564
   Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063
   Davis BM, 2017, MITOCHONDRION, V36, P114, DOI 10.1016/j.mito.2017.05.010
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delmas D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031295
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Demmig-Adams B, 2020, MOLECULES, V25, DOI 10.3390/molecules25163607
   Di Carlo E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153297
   Diyana I., 2017, INT J OPHTHALMOL CLI, V4, P1, DOI [10.23937/2378-346X/1410082, DOI 10.23937/2378-346X/1410082]
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Edwards G, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100952
   Acar SE, 2020, EUR J OPHTHALMOL, V30, P714, DOI 10.1177/1120672119833271
   El Barky A. R., 2017, J PLANT CHEM ECOPHYS, V2, P1016
   ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Fatokun AA, 2008, FRONT BIOSCI-LANDMRK, V13, P3288, DOI 10.2741/2926
   Fitzgerald KC, 2013, ANN NEUROL, V73, P236, DOI 10.1002/ana.23820
   Fujimura S, 2016, CLIN OPHTHALMOL, V10, P2149, DOI 10.2147/OPTH.S119251
   Gauthier Angela C., 2016, Yale Journal of Biology and Medicine, V89, P73
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Heshmati J, 2019, PHARMACOL RES, V149, DOI 10.1016/j.phrs.2019.104462
   Himori N, 2021, CLIN OPHTHALMOL, V15, P2293, DOI 10.2147/OPTH.S314288
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Icer MA, 2021, ACTA NEUROBIOL EXP, V81, P21, DOI 10.21307/ane-2021-003
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Jardim FR, 2018, MOL NEUROBIOL, V55, P2085, DOI 10.1007/s12035-017-0448-z
   Jarosz M, 2017, INFLAMMOPHARMACOLOGY, V25, P11, DOI 10.1007/s10787-017-0309-4
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Garcia-Medina JJ, 2015, ACTA OPHTHALMOL, V93, P546, DOI 10.1111/aos.12629
   Ju WK, 2018, BIOCHEM BIOPH RES CO, V503, P2639, DOI 10.1016/j.bbrc.2018.08.016
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P29
   Kaur D, 2021, LIFE SCI, V284, DOI 10.1016/j.lfs.2021.119899
   Kesse-Guyot E, 2014, BRIT J NUTR, V111, P915, DOI 10.1017/S0007114513003188
   Khadangi F, 2019, IUBMB LIFE, V71, P411, DOI 10.1002/iub.1990
   Kim J, 2019, ANAT CELL BIOL, V52, P369, DOI 10.5115/acb.19.119
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Ko ML, 2010, CURR EYE RES, V35, P842, DOI 10.3109/02713683.2010.489728
   Koopman WJH, 2010, ANTIOXID REDOX SIGN, V12, P1431, DOI 10.1089/ars.2009.2743
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Koriyama Y, 2013, BRAIN RES, V1499, P145, DOI 10.1016/j.brainres.2012.12.041
   Korobelnik JF, 2017, JAMA OPHTHALMOL, V135, P1259, DOI 10.1001/jamaophthalmol.2017.3398
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lee D, 2014, APOPTOSIS, V19, P603, DOI 10.1007/s10495-013-0956-x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindsey JD, 2015, NEUROBIOL AGING, V36, P1969, DOI 10.1016/j.neurobiolaging.2014.12.021
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Luo HD, 2018, INVEST OPHTH VIS SCI, V59, P3879, DOI 10.1167/iovs.18-23806
   Ma Ho Hin, 2021, Acta Med Litu, V28, P36, DOI 10.15388/Amed.2021.28.1.7
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Maekawa S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06969-4
   Man MQ, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/2676307
   Manzar H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239299
   Leo EEM, 2019, J NUTR HEALTH AGING, V23, P694, DOI 10.1007/s12603-019-1240-8
   Masland RH, 2001, CURR OPIN NEUROBIOL, V11, P431, DOI 10.1016/S0959-4388(00)00230-0
   Miceli MV, 1999, INVEST OPHTH VIS SCI, V40, P1238
   Milani A, 2017, BRIT J PHARMACOL, V174, P1290, DOI 10.1111/bph.13625
   Min JY, 2014, DEMENT GERIATR COGN, V37, P246, DOI 10.1159/000356486
   Miyazawa T, 2019, IUBMB LIFE, V71, P430, DOI 10.1002/iub.2008
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moreira PI, 2005, ANN NY ACAD SCI, V1043, P545, DOI 10.1196/annals.1333.062
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Muangnoi C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094722
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Murthy RK, 2014, CUTAN OCUL TOXICOL, V33, P132, DOI 10.3109/15569527.2013.812108
   Mustacich DJ, 2007, VITAM HORM, V76, P1, DOI 10.1016/S0083-6729(07)76001-6
   Nakajima Y, 2008, BRAIN RES, V1226, P226, DOI 10.1016/j.brainres.2008.06.026
   Neal SE, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.32
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nieves JW, 2016, JAMA NEUROL, V73, P1425, DOI 10.1001/jamaneurol.2016.3401
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Organisciak DT, 2013, MOL VIS, V19, P1433
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Ozates S, 2019, EUR J OPHTHALMOL, V29, P196, DOI 10.1177/1120672118779486
   PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R
   Pant AB, 2017, J NEUROIMMUNOL, V303, P22, DOI 10.1016/j.jneuroim.2016.12.010
   Parisi V, 2014, J GLAUCOMA, V23, P391, DOI 10.1097/IJG.0b013e318279b836
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pasquale LR, 2009, J GLAUCOMA, V18, P423, DOI 10.1097/IJG.0b013e31818d3899
   Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071
   Pinazo-Duran MD, 2018, CURR NEUROPHARMACOL, V16, P903, DOI 10.2174/1570159X15666170705101910
   Pinazo-Duran MD, 2015, PROG BRAIN RES, V220, P127, DOI 10.1016/bs.pbr.2015.06.001
   Pintea A, 2011, J OCUL PHARMACOL TH, V27, P315, DOI 10.1089/jop.2010.0144
   Pirhan D, 2016, CURR EYE RES, V41, P59, DOI 10.3109/02713683.2015.1004719
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Pradhan N, 2021, N-S ARCH PHARMACOL, V394, P2197, DOI 10.1007/s00210-021-02161-8
   Prasad AS, 2008, EXP GERONTOL, V43, P370, DOI 10.1016/j.exger.2007.10.013
   Gomes BAQ, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8152373
   Quaranta L, 2019, ADV THER, V36, P2506, DOI 10.1007/s12325-019-01023-3
   Regner-Nelke L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810087
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Villadoniga SR, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8259371
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Salehi B, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080356
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sanz-Gonzalez S M, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P120, DOI 10.1016/j.oftal.2019.11.009
   Sawda C, 2017, ANN NY ACAD SCI, V1403, P142, DOI [10.1126/scitranslmed.aam6055, 10.1111/nyas.13431]
   Scoditti E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082336
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seong H, 2017, CURR EYE RES, V42, P1650, DOI 10.1080/02713683.2017.1344713
   Sley EG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240244
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stahl W, 1997, CARCINOGENESIS, V18, P89, DOI 10.1093/carcin/18.1.89
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suzumura A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100920
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P396, DOI 10.1167/iovs.06-0872
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Usategui-Martin R, 2021, NEURAL REGEN RES, V16, P117, DOI 10.4103/1673-5374.283498
   Vernazza S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157994
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Wang H, 2011, EYE BRAIN, V3, P19, DOI 10.2147/EB.S24951
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.23
   Weinreb RN, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.67
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Xia N, 2017, BRIT J PHARMACOL, V174, P1633, DOI 10.1111/bph.13492
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang X, 2018, LIFE SCI, V207, P234, DOI 10.1016/j.lfs.2018.06.010
   Zhao YG, 2011, TOXICOL LETT, V200, P100, DOI 10.1016/j.toxlet.2010.11.001
NR 165
TC 3
Z9 3
U1 5
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD NOV
PY 2021
VL 10
IS 11
AR 1743
DI 10.3390/antiox10111743
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA XH4LG
UT WOS:000725407400001
PM 34829613
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hwang, HS
   Lee, SB
   Jee, D
AF Hwang, Ho Sik
   Lee, Seung Bum
   Jee, Donghyun
TI Association between Blood Lead Levels and Age-Related Macular
   Degeneration
SO PLOS ONE
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; KOREAN NATIONAL-HEALTH; DEVELOPMENTAL
   IMMUNOTOXICITY; CARDIOVASCULAR-DISEASE; ALCOHOL-CONSUMPTION;
   GENDER-DIFFERENCES; RISK-FACTORS; EXPOSURE; CADMIUM; TOXICITY
AB Purpose
   To investigate the association between blood lead levels and prevalence of age-related macular degeneration (AMD).
   Methods
   A nationwide population-based cross-sectional study included 4,933 subjects aged over 40 years who participated in the 2008-2012 Korean National Health and Nutrition Examination Survey, and for whom fundus photographs were available. All participants underwent a standardized interview, evaluation of blood lead concentration, and a comprehensive ophthalmic examination. Digital fundus photographs (45 degrees) were taken of both eyes under physiological mydriasis. All fundus photographs were graded using an international classification and grading system.
   Results
   Mean blood lead levels were 3.15 mu g/dL in men and 2.27 mu g/dL in women (P < 0.001). After adjusting for potential confounders including age, gender, smoking status, total cholesterol levels, triglyceride levels, heart problems and strokes, the adjusted odds ratio (OR) in women for any AMD was 1.86 (95% Confidence Interval [CI], 1.03-3.36) and for early AMD was 1.92 (95% CI, 1.06-3.48), for those in the highest quintile of lead level compared with the lowest quintile. In men, however, blood lead level was not significantly associated with AMD.
   Conclusions
   Blood lead levels were higher in men, but were only associated with AMD in women. Increased levels of blood lead may be involved in the pathogenesis of AMD development in women.
C1 [Hwang, Ho Sik] Hallym Univ, Coll Med, Chuncheon Sacred Heart Hosp, Dept Ophthalmol, Chunchon, South Korea.
   [Lee, Seung Bum] Seoul St Marys Eye Hosp, Suwon, South Korea.
   [Jee, Donghyun] Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
C3 Hallym University; Catholic University of Korea
RP Jee, D (通讯作者)，Catholic Univ Korea, Coll Med, St Vincents Hosp, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
EM doj087@mail.harvard.edu
FU Ajou Pharm from Catholic Medical Center Research Foundation in the
   program [5-2013-D0383-00002]
FX This study was supported by the fund of Ajou Pharm (5-2013-D0383-00002)
   from Catholic Medical Center Research Foundation in the program year of
   2012.
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becker K, 2002, INT J HYG ENVIR HEAL, V205, P297, DOI 10.1078/1438-4639-00155
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjorkman L, 2000, ENVIRON HEALTH PERSP, V108, P719, DOI 10.2307/3434724
   Brown D V, 1974, Trans Am Ophthalmol Soc, V72, P404
   Bunn TL, 2000, J TOXICOL ENV HEAL A, V61, P677, DOI 10.1080/00984100050195152
   Bunn TL, 2001, J TOXICOL ENV HEAL A, V64, P223, DOI 10.1080/15287390152543708
   BUSHNELL PJ, 1977, SCIENCE, V196, P333, DOI 10.1126/science.403610
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   FOX DA, 1994, NEUROTOXICOLOGY, V15, P503
   GOYER RA, 1993, ENVIRON HEALTH PERSP, V100, P177, DOI 10.2307/3431524
   Gulson BL, 1997, J LAB CLIN MED, V130, P51, DOI 10.1016/S0022-2143(97)90058-5
   Hsu PC, 2002, TOXICOLOGY, V180, P33, DOI 10.1016/S0300-483X(02)00380-3
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jacob B, 2000, ENVIRON RES, V82, P150, DOI 10.1006/enrs.1999.4011
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim K, 2012, ENVIRON RES, V112, P225, DOI 10.1016/j.envres.2011.12.008
   Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96
   Kim Y, 2012, ENVIRON RES, V118, P124, DOI 10.1016/j.envres.2012.06.003
   La TY, 2014, CURR EYE RES, V39, P1232, DOI 10.3109/02713683.2014.907431
   Lee BK, 2012, ENVIRON RES, V115, P59, DOI 10.1016/j.envres.2012.03.010
   Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014
   Mecocci P, 2004, NEUROL RES, V26, P598, DOI 10.1179/016164104225017659
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mortada WI, 2004, MED SCI MONITOR, V10, pCR112
   Navas-Acien A, 2005, ENVIRON HEALTH PERSP, V113, P164, DOI 10.1289/ehp.7329
   Navas-Acien A, 2007, ENVIRON HEALTH PERSP, V115, P472, DOI 10.1289/ehp.9785
   Papanikolaou NC, 2005, MED SCI MONITOR, V11, pRA329
   Parish C, 2013, PRIORITY LIST HAZARD
   Park HA, 2013, KOREAN J FAM MED, V34, P79, DOI 10.4082/kjfm.2013.34.2.79
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   Park SJ, 2014, OPHTHALMOLOGY
   Park S, 2012, SCI TOTAL ENVIRON, V430, P161, DOI 10.1016/j.scitotenv.2012.05.009
   Pirkle JL, 1998, ENVIRON HEALTH PERSP, V106, P745, DOI 10.2307/3434264
   Popovic M, 2005, ENVIRON HEALTH PERSP, V113, P478, DOI 10.1289/ehp.7386
   Rhee S.Y., 2008, CARDIOVASC DIABETOL, V9, P12
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   Sim CS, 2014, ENVIRON RES, V130, P1, DOI 10.1016/j.envres.2014.01.004
   STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Vahter M, 2007, ENVIRON RES, V104, P85, DOI 10.1016/j.envres.2006.08.003
   Vig EK, 2000, J AM GERIATR SOC, V48, P1501, DOI 10.1111/jgs.2000.48.11.1501
   Vlaanderen J, 2014, AM J EPIDEMIOL, V179, P290, DOI 10.1093/aje/kwt273
   Webber CE, 1995, ENVIRON HEALTH PERSP, V103, P1150, DOI 10.2307/3432612
   Weikel KA, 2012, MOL ASPECTS MED
   Won YS, 2013, J CLIN PERIODONTOL, V40, P118, DOI 10.1111/jcpe.12033
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Yuki K, 2009, BIOL TRACE ELEM RES, V132, P1, DOI 10.1007/s12011-009-8376-z
NR 58
TC 14
Z9 14
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 7
PY 2015
VL 10
IS 8
AR e0134338
DI 10.1371/journal.pone.0134338
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO4HF
UT WOS:000359121100051
PM 26252225
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Hagbi-Levi, S
   Grunin, M
   Jaouni, T
   Tiosano, L
   Rinsky, B
   Elbaz-Hayoun, S
   Peled, A
   Chowers, I
AF Hagbi-Levi, Shira
   Grunin, Michelle
   Jaouni, Tareq
   Tiosano, Liran
   Rinsky, Batya
   Elbaz-Hayoun, Sarah
   Peled, Amnon
   Chowers, Itay
TI Proangiogenic characteristics of activated macrophages from patients
   with age-related macular degeneration
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Neuroinflammation; Macrophages; Monocytes; Angiogenesis
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PERIPHERAL-BLOOD MONOCYTES;
   ENDOTHELIAL GROWTH-FACTOR; TNF-ALPHA; POLARIZATION; INFLAMMATION;
   NEOVASCULARIZATION; INTERLEUKIN-6; EXPRESSION; PROMOTES
AB Macrophages were previously implicated in the pathogenesis of neovascular age-related macular degeneration (nvAMD). It is unclear if a specific macrophage phenotype is associated with nvAMD, and if macrophages from nvAMD patients are more pathogenic as compared with controls. To address these issues, we evaluated macrophages derived from peripheral blood monocytes of nvAMD patients and age-matched controls. Macrophages were assessed in terms of their expression profile and of their angiogenic potential in the choroid sprouting assay and the rat model of laser- induced choroidal neovascularization. Results showed a proangiogenic and inflammatory gene and protein expression profiles in classic (M[IFN gamma and LPS]) and alternative ( M[ IL-4 and IL-13]) polarized macrophages. Furthermore, activated macrophages, particularly of the M( IFNg and LPS) phenotype from nvAMD patients, were proangiogenic ex vivo and in vivo. These findings implicate activated human macrophages, particularly M( IFNg and LPS) macrophages from nvAMD patients, in nvAMD. Further research is required to determine whether activated macrophages can serve as therapeutic targets in nvAMD. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Hagbi-Levi, Shira; Grunin, Michelle; Jaouni, Tareq; Tiosano, Liran; Rinsky, Batya; Elbaz-Hayoun, Sarah; Chowers, Itay] Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
   [Hagbi-Levi, Shira; Grunin, Michelle; Jaouni, Tareq; Tiosano, Liran; Rinsky, Batya; Elbaz-Hayoun, Sarah; Chowers, Itay] Hebrew Univ Jerusalem, Hadassah Sch Med, Jerusalem, Israel.
   [Peled, Amnon] Hadassah Hebrew Univ Med Ctr, Goldyne Savad Inst Gene Therapy, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858; Hagbi-Levi,
   Shira/0000-0002-2891-0079
FU Israel Science Foundation [1006/13]; Israeli Ministry of Health (MOH)
   [9184]; Israel Ministry of Health's Helsinki Committee for Genetic
   Experiments on Human Subjects [22-03.08.07];  [MD-15-14240-4]; 
   [OPRR-A01-5011]
FX This work was supported in part by grants from the Israel Science
   Foundation (#1006/13) and the Israeli Ministry of Health (MOH, #9184).
   Ethical approval for all experimental protocols and study involving
   human subjects were approved by the Local Committee on Research
   Involving Human Subjects of the Hebrew UniversityHadassah Medical
   School, the Helsinki Committee of Hadassah Medical Organization, and the
   Israel Ministry of Health's Helsinki Committee for Genetic Experiments
   on Human Subjects (File #22-03.08.07). All patients and controls signed
   informed consent forms that adhered to the tenets of the Declaration of
   Helsinki before participating in the study. Ethical approval for all
   protocols involving animals was approved by the Authority for Biological
   and Biomedical Models (ABBM) and the University Ethics Committee for the
   Care and Use of Laboratory Animals in Hebrew University, which is
   certified by the Association for Assessment and Accreditation of
   Laboratory Animal Care (AAALAC) (ethical approval number: MD-15-14240-4,
   NIH approval number: OPRR-A01-5011). All researchers working with
   laboratory animals underwent approval by the ethics committee of the
   ABBM to allow them to ethically work with laboratory animals. All
   guidelines with regards to humane and ethical treatment of laboratory
   animals (from ARVO) were followed to the utmost and all methods used in
   this study were carried out in accordance with the approved guidelines
   for the study.
CR Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517
   Colombo MP, 2005, CANCER RES, V65, P9113, DOI 10.1158/0008-5472.CAN-05-2714
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P4914, DOI 10.1167/iovs.03-0371
   Ferguson TA, 2008, SEMIN IMMUNOPATHOL, V30, P111, DOI 10.1007/s00281-008-0113-8
   Gelinas L, 2011, J RENIN-ANGIO-ALDO S, V12, P295, DOI 10.1177/1470320310391332
   Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013
   Gopinathan G, 2015, CANCER RES, V75, P3098, DOI 10.1158/0008-5472.CAN-15-1227
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Lederman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087751
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep20639
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Liyanage SE, 2016, ARTERIOSCL THROM VAS, V36, P19, DOI 10.1161/ATVBAHA.115.306681
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Martinez F. O., 2014, F1000PRIME REPORTS, V6, P13
   Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Robertson MJ, 2002, INVEST OPHTH VIS SCI, V43, P2250
   ROSENBAUM JT, 1987, CURR EYE RES, V6, P793, DOI 10.3109/02713688709034846
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Shinriki S, 2009, CLIN CANCER RES, V15, P5426, DOI 10.1158/1078-0432.CCR-09-0287
   Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y
   Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754
   Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wang HB, 2016, MOL VIS, V22, P116
   Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226
   Wert KJ, 2012, JOVE-J VIS EXP, DOI 10.3791/4286
   Westenskow P., 2015, JOVE-J VIS EXP, P25
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Wu L, 2011, RETINA-J RET VIT DIS, V31, P298, DOI 10.1097/IAE.0b013e3181eac7a6
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Zhang RZ, 2011, J NEUROIMMUNOL, V230, P114, DOI 10.1016/j.jneuroim.2010.08.012
NR 76
TC 17
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2017
VL 51
BP 71
EP 82
DI 10.1016/j.neurobiolaging.2016.11.018
PG 12
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA EP1UA
UT WOS:000397168600008
PM 28039766
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Hong, T
   McCluskey, P
   Grigg, JR
   Schlub, TE
   Chang, AA
AF Broadhead, Geoffrey K.
   Hong, Thomas
   McCluskey, Peter
   Grigg, John R.
   Schlub, Timothy E.
   Chang, Andrew A.
TI Choroidal Thickness and Microperimetry Sensitivity in Age-Related
   Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choroid; Microperimetry
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; YOUNG; EYES
AB Purpose: To assess choroidal thickness (CT) and its relationship to retinal sensitivity in mild/moderate age-related macular degeneration (AMD). Methods: Seventy-two eyes of 51 participants with mild/moderate AMD and 36 eyes of 18 age-matched normal participants were prospectively recruited to undergo enhanced-depth imaging optical coherence tomography (EDI-OCT) imaging and microperimetry (MP) functional assessment. OCT-measured CT and retinal thickness (RT) were matched with MP sensitivity at 13 retinal loci, and correlations were analysed. Results: Patients with AMD had an average RT 56.5 mu m greater than those without AMD (p < 0.001). There was no significant difference in CT between normal and AMD participants (p = 0.36). In patients without atrophy or pigment epithelial detachment, there was no correlation between MP sensitivity and CT (p = 0.08); however, a correlation between RT and MP was detected (b = 0.006, p = 0.046). Among patients without AMD, MP sensitivity was positively correlated with RT (b = 0.007, p < 0.001) and negatively correlated with CT (b = 0.0046, p = 0.035). Conclusions: CT does not correlate with retinal sensitivity in AMD. Although choroidal damage and impaired choroidal perfusion appear to be important concepts in AMD pathogenesis, increasing choroidal thinning may not be associated with worsening retinal function in AMD. (C) 2017 S. Karger AG, Basel
C1 [Broadhead, Geoffrey K.; McCluskey, Peter; Grigg, John R.; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Chang, Andrew A.] Sydney Retina Clin & Day Surg, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia.
   [Broadhead, Geoffrey K.] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 University of Sydney; University of Sydney; Royal Victorian Eye & Ear
   Hospital
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
RI McCluskey, Peter J/H-7607-2013; Grigg, John/A-6851-2013
OI McCluskey, Peter J/0000-0002-8177-1637; Grigg, John/0000-0002-6763-8119;
   Schlub, Timothy/0000-0001-7746-9649
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Esmaeelpour M, 2012, INVEST OPHTH VIS SCI, V53, P6803, DOI 10.1167/iovs.12-10314
   Ishikawa S, 2014, BRIT J OPHTHALMOL, V98, P1508, DOI 10.1136/bjophthalmol-2014-305333
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim M, 2012, INVEST OPHTH VIS SCI, V53, P7710, DOI 10.1167/iovs.12-10464
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Parravano M, 2014, OPHTHALMIC RES, V52, P97, DOI 10.1159/000362880
   Riva CE, 2010, ACTA OPHTHALMOL, V88, P622, DOI 10.1111/j.1755-3768.2009.01621.x
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sogawa K, 2012, AM J OPHTHALMOL, V153, P1129, DOI 10.1016/j.ajo.2011.11.005
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zaben A, 2015, RETINA-J RET VIT DIS, V35, P398, DOI 10.1097/IAE.0000000000000367
NR 22
TC 8
Z9 8
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 58
IS 1
BP 27
EP 34
DI 10.1159/000464447
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OX
UT WOS:000403362700005
PM 28427081
DA 2022-11-30
ER

PT J
AU Kar, T
   Yildirim, Y
   Altundag, A
   Sonmez, M
   Kaya, A
   Colakoglu, K
   Tekeli, H
   Cayonu, M
   Hummel, T
AF Kar, Taner
   Yildirim, Yildiray
   Altundag, Aytug
   Sonmez, Murat
   Kaya, Abdullah
   Colakoglu, Kadir
   Tekeli, Hakan
   Cayonu, Melih
   Hummel, Thomas
TI The Relationship between Age-Related Macular Degeneration and Olfactory
   Function
SO NEURODEGENERATIVE DISEASES
LA English
DT Article
DE Age-related macular degeneration; Olfactory functions; Sniffin' Sticks
ID ALZHEIMERS-DISEASE; ODOR DISCRIMINATION; PARKINSONS-DISEASE;
   IDENTIFICATION; BULB; EYE; ACCUMULATION; PATHOGENESIS; INFLAMMATION;
   INVOLVEMENT
AB Background: Olfactory dysfunction is a common symptom of many neurodegenerative diseases, and age-related macular degeneration (AMD) is a late-onset neurodegenerative disease. Objective: Thus, the aim of this study was to investigate olfactory functions in patients with AMD. Methods: A total of 69 subjects with AMD and 69 age- and sex-matched healthy controls were enrolled. After a complete ophthalmic evaluation, the AMD patients were subclassified as early- and late-stage AMD. Psychophysical testing of olfactory function was performed using the validated Sniffin' Sticks test. Results: This study was carried out in 138 subjects, with a mean age of 74.3 +/- 8.9 years (range 51-89). The current investigation showed the following two major findings: (1) patients with AMD had decreased olfactory abilities, especially in odor discrimination and odor identification, even at early stages compared to controls, whereas patients had decreased olfactory abilities in all subtasks of olfactory testings in advanced stages of AMD disease, and (2) as the visual acuity of AMD patients decreased, the olfactory abilities of these patients worsened. Conclusion: This study demonstrated that AMD had significant negative effects on all orthonasal olfactory tasks, particularly in advanced stages. Similar to other neurodegenerative diseases, odor discrimination and identification seemed to be more affected than odor detection threshold tasks. (C) 2015 S. Karger AG, Basel
C1 [Kar, Taner; Yildirim, Yildiray; Sonmez, Murat; Kaya, Abdullah] GATA Haydarpasa Training Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Tekeli, Hakan] GATA Haydarpasa Training Hosp, Dept Neurol, Istanbul, Turkey.
   [Altundag, Aytug] Istanbul Surg Hosp, Taste & Smell Clin, TR-34365 Istanbul, Turkey.
   [Colakoglu, Kadir] Kasimpasa Mil Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Cayonu, Melih] Amasya Univ SS Training & Res Hosp, Dept Otorhinolaryngol, Amasya, Turkey.
   [Hummel, Thomas] Tech Univ Dresden, Taste & Smell Clin, D-01062 Dresden, Germany.
C3 Gulhane Military Medical Academy; Istanbul Haydarpasa Sultan Abdulhamid
   Training & Research Hospital; Gulhane Military Medical Academy; Istanbul
   Haydarpasa Sultan Abdulhamid Training & Research Hospital; Istanbul
   Cerrahi Hospital; Kasimpasa Military Hospital; Amasya University;
   Technische Universitat Dresden
RP Altundag, A (通讯作者)，Istanbul Surg Hosp, Taste & Smell Clin, Ferah Sok 22 Sisli, TR-34365 Istanbul, Turkey.
EM aaltundagkbb@gmail.com
RI Altundag, Aytug/AAP-5557-2020; TEKELİ, HAKAN/B-6117-2016
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attems J, 2005, J ALZHEIMERS DIS, V7, P149
   Attems J, 2006, CLIN NEUROPATHOL, V25, P265
   Attems J, 2014, ACTA NEUROPATHOL, V127, P459, DOI 10.1007/s00401-014-1261-7
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Calabrese V, 2000, NEUROCHEM RES, V25, P1315, DOI 10.1023/A:1007604414773
   Doty RL, 2012, NEUROBIOL DIS, V46, P527, DOI 10.1016/j.nbd.2011.10.026
   Frasnelli J, 2005, EUR ARCH OTO-RHINO-L, V262, P231, DOI 10.1007/s00405-004-0796-y
   Gopinath B, 2011, AM J GERIAT PSYCHIAT, V19, P830, DOI 10.1097/JGP.0b013e318211c205
   Hawkes CH, 1998, EXP NEUROL, V150, P248, DOI 10.1006/exnr.1997.6773
   Huisman E, 2004, MOVEMENT DISORD, V19, P687, DOI 10.1002/mds.10713
   Hummel T, 2007, EUR ARCH OTO-RHINO-L, V264, P237, DOI 10.1007/s00405-006-0173-0
   Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kobal G, 2000, EUR ARCH OTO-RHINO-L, V257, P205, DOI 10.1007/s004050050223
   Kovacs I, 1998, BRAIN RES, V789, P167, DOI 10.1016/S0006-8993(98)00097-3
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Perry G, 2003, ACTA NEUROPATHOL, V106, P552, DOI 10.1007/s00401-003-0761-7
   Rahayel S, 2012, BEHAV BRAIN RES, V231, P60, DOI 10.1016/j.bbr.2012.02.047
   Tekeli H, 2013, MED SCI MONITOR, V19, P1221, DOI 10.12659/MSM.889838
   Wolfensberger M, 2000, ACTA OTO-LARYNGOL, V120, P303, DOI 10.1080/000164800750001134
   Yang MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059673
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 27
TC 5
Z9 5
U1 1
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1660-2854
EI 1660-2862
J9 NEURODEGENER DIS
JI Neurodegener. Dis.
PY 2015
VL 15
IS 4
BP 219
EP 224
DI 10.1159/000381216
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CO2FQ
UT WOS:000358972000004
PM 25871947
OA Green Published
DA 2022-11-30
ER

PT J
AU Woo, SJ
   Ahn, J
   Morrison, MA
   Ahn, SY
   Lee, J
   Kim, KW
   DeAngelis, MM
   Park, KH
AF Woo, Se Joon
   Ahn, Jeeyun
   Morrison, Margaux A.
   Ahn, So Yeon
   Lee, Jaebong
   Kim, Ki Woong
   DeAngelis, Margaret M.
   Park, Kyu Hyung
TI Analysis of Genetic and Environmental Risk Factors and Their
   Interactions in Korean Patients with Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FACTOR-H GENE; CIGARETTE-SMOKING;
   LOC387715/HTRA1 POLYMORPHISMS; ASSOCIATION; SUSCEPTIBILITY; POPULATION;
   PREVALENCE; JAPANESE; CFH
AB Purpose
   To investigate the association of genetic and environmental factors, and their interactions in Korean patients with exudative age-related macular degeneration (AMD).
   Methods
   A total of 314 robustly characterized exudative AMD patients, including 111 PCV (polypoidal choroidal vasculopathy) and 154 typical choroidal neovascularization (CNV), and 395 control subjects without any evidence of AMD were enrolled. Full ophthalmologic examinations including fluorescein angiography (FA), indocyanine green angiography (ICG) and optical coherence tomography (OCT) were done, according to which patients were divided into either PCV or typical CNV. Standardized questionnaires were used to collect information regarding underlying systemic diseases, dietary habits, smoking history and body mass index (BMI). A total of 86 SNPs from 31 candidate genes were analyzed. Genotype association and logistic regression analyses were done and stepwise regression models to best predict disease for each AMD subtype were constructed.
   Results
   Age, spherical equivalent, myopia, and ever smoking were associated with exudative AMD. Age, hypertension, hyperlipidemia, spherical equivalent, and myopia were risk factors for typical CNV, while increased education and ever smoking were significantly associated with PCV (p<.05 for all). Four SNPs, ARMS2/HTRA1 rs10490924, rs11200638, and rs2736911, and CFH rs800292, showed association with exudative AMD. Two of these SNPs, ARMS2/HTRA1 rs10490924 and rs11200638, showed significant association with typical CNV and PCV specifically. There were no significant interactions between environmental and genetic factors. The most predictive disease model for exudative AMD included age, spherical equivalent, smoking, CFH rs800292, and ARMS2 rs10490924 while that for typical CNV included age, hyperlipidemia, spherical equivalent, and ARMS2 rs10490924. Smoking, spherical equivalent, and ARMS2 rs10490924 were the most predictive variables for PCV. When comparing PCV cases to CNV cases, age, BMI, and education were the most predictive risk factors of PCV.
   Conclusions
   Only one locus, the ARMS2/HTRA1 was a significant genetic risk factor for Korean exudative AMD, including its subtypes, PCV and typical CNV. Stepwise regression revealed that CFH was important to risk of exudative AMD in general but not to any specific subtype. While increased education was a unique risk factor to PCV when compared to CNV, this association was independent of refractive error in this homogenous population from South Korea. No significant interactions between environmental and genetic risk factors were observed.
C1 [Woo, Se Joon; Ahn, Jeeyun; Park, Kyu Hyung] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, Songnam, South Korea.
   [Ahn, Jeeyun] Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Morrison, Margaux A.; DeAngelis, Margaret M.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
   [Ahn, So Yeon; Lee, Jaebong] Seoul Natl Univ, Bundang Hosp, Med Res Collaborating Ctr, Songnam, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul, South Korea.
   [Kim, Ki Woong] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Songnam, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital; Utah
   System of Higher Education; University of Utah; Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU)
RP DeAngelis, MM (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
EM Margaret.DeAngelis@utah.edu; jiani4@snu.ac.kr
RI DeAngelis, e/J-7863-2015
OI Ahn, Jeeyun/0000-0001-9017-1652
FU Seoul National University Bundang Hospital Research Fund [03-2009-008];
   National Research Foundation of Korea (NRF) - Ministry of Education,
   Science, and Technology [2009-0072603, 2012R1A1A2008943]; Research to
   Prevent Blindness; ALSAM Foundation
FX This study was supported by the Seoul National University Bundang
   Hospital Research Fund (Grant No. 03-2009-008), National Research
   Foundation of Korea (NRF) grants funded by the Ministry of Education,
   Science, and Technology (2009-0072603, 2012R1A1A2008943), an
   unrestricted grant from Research to Prevent Blindness
   (http://www.rpbusa.org/rpb/) to the Department of Ophthalmology and
   Visual Sciences - Moran Eye Center, and the ALSAM Foundation. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen HY, 2012, MOL VIS, V18, P816
   Chen LJ, 2006, MOL VIS, V12, P1536
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jhoo JH, 2008, DEMENT GERIATR COGN, V26, P270, DOI 10.1159/000160960
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Keller MC, 2014, BIOL PSYCHIAT, V75, P18, DOI 10.1016/j.biopsych.2013.09.006
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kondo N, 2009, OPHTHALMOLOGY, V116, P304, DOI 10.1016/j.ophtha.2008.11.011
   KyuHyung Park，, 2010, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V51, P516
   Lee SJ, 2010, CLIN EXP OPHTHALMOL, V38, P698, DOI 10.1111/j.1442-9071.2010.02316.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nakanishi H, 2010, INVEST OPHTH VIS SCI, V51, P6183, DOI 10.1167/iovs.09-4948
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P5228, DOI 10.1167/iovs.14-14299
   Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Singerman Lawrence J, 2005, Retina, V25, pS1
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
NR 42
TC 32
Z9 34
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 14
PY 2015
VL 10
IS 7
AR e0132771
DI 10.1371/journal.pone.0132771
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN1QN
UT WOS:000358194900083
PM 26171855
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Shimada, H
   Fujita, K
   Matsumoto, Y
   Mori, R
   Yuzawa, M
AF Shimada, H
   Fujita, K
   Matsumoto, Y
   Mori, R
   Yuzawa, M
TI Surgical excision of type 2 choroidal neovascularization in age-related
   macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; surgical excision; type 2 subfoveal
   choroidal neovascularization
ID MEMBRANES
AB Purpose: To evaluate the visual acuity outcome and the influence of various factors on visual outcome in patients undergoing surgical removal of type 2 choroidal neovascular neovascularization (CNV) caused by age-related macular degeneration (AMD).
   Methods: We studied the records of 92 patients (92 eyes) who were followed for at least 1 year after surgical excision of CNV associated with AMD.
   Results: The final visual acuity was 0.4 or better in 21%, 0.1 to 0.3 in 66%, and worse than 0.1 in 13% of the patients. Final visual acuity was improved in 62%, stable in 29%, and worse in 9%. Stepwise regression identified CNV size as a significant factor influencing final visual acuity (R = 0.287, P = 0.0045).
   Conclusions: Surgical excision of CNV for AMD is indicated for patients with subfoveal active type 2 CNV with a visual acuity of 0.3 or worse. To achieve better postoperative visual acuity it is important to operate on AMD patients in the early stage of CNV.
C1 Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, Tokyo, Japan.
C3 Nihon University
RP Shimada, H (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 13 Surugadai, Tokyo, Japan.
EM sshimada@olive.ocn.ne.jp
CR Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   SHIMADA H, 2000, J JPN OPHTHALMOL SOC, V104, P489
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
NR 4
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL-AUG
PY 2005
VL 49
IS 4
BP 321
EP 323
DI 10.1007/s10384-004-0193-5
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 952MS
UT WOS:000231008600010
PM 16075335
DA 2022-11-30
ER

PT J
AU Xu, YT
   Wang, Y
   Chen, P
   Xu, HF
AF Xu, Yi-Ting
   Wang, Ye
   Chen, Peng
   Xu, Hai-Feng
TI Age-related maculopathy susceptibility 2 participates in the
   phagocytosis functions of the retinal pigment epithelium
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related maculopathy susceptibility 2; age-related macular
   degeneration; retinal pigment epithelium; phagocytosis
ID COMPLEMENT-FACTOR-H; ROD OUTER SEGMENTS; MACULAR DEGENERATION;
   CHROMOSOME 10Q26; POLYMORPHISM; LOC387715; GENE; ASSOCIATION; LINKAGE;
   CELLS
AB AIM: Age-related macular degeneration (AMD) is a multifactorial disease and a prevalent cause of visual impairment in developed countries. Many studies suggest that age-related maculopathy susceptibility 2 (ARMS2) is a second major susceptibility gene for AMD. At present, there is no functional information on this gene. Therefore, the purpose of the present study was to detect the expression of ARMS2 in retinal pigment epithelium (RPE) cells and to investigate the effect of ARMS2 on the phagocytosis function of RPE cells.
   METHODS: Immunofluorescence and reverse transcriptase PCR were used to demonstrate the presence and location of ARMS2 in ARPE-19 (human retinal pigment epithelial cell line, ATCC, catalog No.CRL-2302) cells. siRNA was used to knock down ARMS2 mRNA, and the effects of the knockdown on the phagocytosis function of the ARPE-19 cells were evaluated via Fluorescence Activated Cell Sorting (FACS).
   RESULTS: ARMS2 was present in ARPE-19 cells, localized in the cytosol of the perinuclear region. The expression of ARMS2 mRNA (messenger RNA) in ARPE-19 cells transfected with ARMS2-siRNA (small interfering RNA, 0.73+/- 0.08) was decreased compared with normal cells (1.00+/- 0.00) or with cells transfected with scrambled siRNA (0.95+/- 0.13) (P<0.05). After incubation of RPE cells with a latex beads medium for 12, 18, or 24 hours, the fluorescence intensities were 38.04 +/- 1.02, 68.92 +/- 0.92, and 78.00 +/- 0.12 in the ARMS2-siRNA-transfected groups, respectively, and 77.98 +/- 5.43, 94.87 +/- 0.60, and 98.30 +/- 0.11 in the scrambled siRNA-transfected groups, respectively. The fluorescent intensities of the same time points in the two groups were compared using Student's t-test, and the p values were all less than 0.001 at the three different time points.
   CONCLUSION: There is endogenous expression of ARMS2 in ARPE-19 cells. ARMS2 plays a role in the phagocytosis function of RPE cells, and this role may be one of the mechanisms that participates in the development of AMD.
C1 [Xu, Yi-Ting; Wang, Ye; Chen, Peng; Xu, Hai-Feng] Shandong Acad Med Sci, Shandong Eye Inst, Shandong Prov Key Lab Ophthalmol, State Key Lab Cultivat Base, Qingdao 266071, Shandong, Peoples R China.
   [Xu, Yi-Ting] Univ Jinan, Shandong Acad Med Sci, Sch Med & Life Sci, Jinan 250022, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; University of Jinan; Shandong First Medical University &
   Shandong Academy of Medical Sciences; University of Jinan
RP Xu, HF (通讯作者)，Shandong Acad Med Sci, Shandong Eye Inst, Shandong Prov Key Lab Ophthalmol, State Key Lab Cultivat Base, Qingdao 266071, Shandong, Peoples R China.
EM chxhf@126.com
FU National Natural Science Foundation of China [30901637]; Qingdao Sci-Tec
   Bureau, China [08-2-1-3-nsh]
FX Supported by National Natural Science Foundation of China (No.30901637);
   Qingdao Sci-Tec Bureau, China(No.08-2-1-3-nsh)
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627
   BESHARSE JC, 1998, RETINAL PIGMENT EPIT, P152
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464
   Chen LJ, 2006, MOL VIS, V12, P1536
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Miceli MV, 1997, INVEST OPHTH VIS SCI, V38, P1588
   PHILP NJ, 1981, EXP EYE RES, V33, P47, DOI 10.1016/S0014-4835(81)80080-2
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Ryeom SW, 1996, J CELL SCI, V109, P387
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   SPITZNAS M, 1970, ARCH OPHTHALMOL-CHIC, V84, P810, DOI 10.1001/archopht.1970.00990040812022
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tong Y, 2010, MOL VIS, V16, P1958
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Xu YL, 2008, MOL VIS, V14, P1373
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 44
TC 17
Z9 18
U1 0
U2 8
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2012
VL 5
IS 2
BP 125
EP 132
DI 10.3980/j.issn.2222-3959.2012.02.02
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 929PI
UT WOS:000303077500002
PM 22762035
DA 2022-11-30
ER

PT J
AU Wu, BH
   Wang, B
   Wu, HQ
   Chang, Q
   Lu, HQ
AF Wu, Bing-Hui
   Wang, Bing
   Wu, Hui-Qin
   Chang, Qin
   Lu, Hui-Qin
TI Intravitreal conbercept injection for neovascular age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; intravitreal injection; conbercept
ID AFLIBERCEPT; RANIBIZUMAB; BEVACIZUMAB; AMD
AB AIM: To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD).
   METHODS: Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 consecutive months, and then pro re nata treatment was performed. The changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before and after treatments. Minimum follow-up time was 12mo. SPSS 22.0 statistical software was used for statistical analysis.
   RESULTS: The mean BCVA and CMT of 66 eyes (63 patients) were 1.11 +/- 0.60, 533.20 +/- 219.95 mu m at baseline, and were 0.68 +/- 0.38, 310.28 +/- 125.60 mu m at 3mo. No subjects were lost during the first three months, the improvements were all significantly (P<0.05). During the whole follow-up time of 12mo, 15 subjects (18 eyes) were lost. The mean BCVA and CMT of the rest 48 eyes with the follow-up time at least 1y were 0.83 +/- 0.46 and 547.59 +/- 196.77 mu m at baseline, after 3mo and 12mo of conbercept injections became 0.55 +/- 0.41, 318.24 +/- 141.29 mu m and 0.55 +/- 0.51, 333.87 +/- 173.25 mu m. The differences were significant (P<0.05). No serious complications were observed.
   CONCLUSION: Intravitreal injection of conbercept appears to significantly improve visual acuity and anatomical outcomes in patients with neovascular AMD, no serious adverse reactions and complications are observed.
C1 [Wu, Bing-Hui; Wang, Bing; Wu, Hui-Qin; Chang, Qin; Lu, Hui-Qin] Xian 1 Hosp, Dept Ophthalmol, 30 Fenxiang St, Xian 710001, Shaanxi, Peoples R China.
RP Lu, HQ (通讯作者)，Xian 1 Hosp, Dept Ophthalmol, 30 Fenxiang St, Xian 710001, Shaanxi, Peoples R China.
EM luhuiqinxian@163.com
CR Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   Cai XA., 2016, INT EYE SCI, V16, P1501
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Papakostas TD, 2016, EYE, V30, P79, DOI 10.1038/eye.2015.175
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283
   Sun Z, 2016, RETINA, V37, P1723
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 20
TC 7
Z9 7
U1 0
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2019
VL 12
IS 2
BP 252
EP 257
DI 10.18240/ijo.2019.02.11
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HP3RX
UT WOS:000461596100011
PM 30809481
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kumar, M
   Moptom, SE
   Sen, P
   Khetan, V
   Bhende, M
   Sivaprasad, S
   Raman, R
AF Kumar, Meenakshi
   Moptom, Sangeetha E.
   Sen, Parveen
   Khetan, Vikas
   Bhende, Muna
   Sivaprasad, Sobha
   Raman, Rajiv
CA Sankara Nethralaya Vitreore
TI Prevalence of polypoidal choroidal vasculopathy in Indian population:
   Risk factors, clinical and imaging characteristics
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; CHINESE; FEATURES
AB Aim
   To assess prevalence, clinical presentation and multimodal imaging characteristics of polypoidal choroidal vasculopathy (PCV) in a hospital-based setting in South India.
   Methods
   Electronic medical records (EMR) of new patients presenting with suspected clinical signs of wet age-related macular degeneration (AMD) in a tertiary hospital from January to December 2016 were retrospectively analyzed using keywords and filtered for patient who underwent multimodal imaging. Clinical presentations were categorized into predominantly hemorrhagic, exudative or mixed pattern. The imaging features were compared in these clinical groups. The multimodal images were graded by two masked graders and discrepancies between them were settled by a senior arbitrator.
   Results
   Of the 147 clinically suspicious cases of PCV out of 785 patients with clinical presentation of AMD as recorded in the EMR, 73 (49.7%) patients had a multimodal imaging diagnosis of PCV. There was no difference in the demography, distribution of polyps, ICGA and OCT characteristics in eyes presenting with hemorrhagic, exudative or mixed clinical features.
   Conclusion
   Approximately half of South Asian patients presenting with clinical features of neovascular AMD harbor PCV irrespective of their clinical presentation and so we recommend that multimodal imaging is done in all cases of suspicious neovascular AMD in Indian population.
C1 [Kumar, Meenakshi; Sen, Parveen; Khetan, Vikas; Bhende, Muna; Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
   [Moptom, Sangeetha E.] Sankara Nethralaya, Diabet Retinopathy Project, Chennai, Tamil Nadu, India.
   [Sivaprasad, Sobha] NIHR Moorfields Biomed Res Ctr, London, England.
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Bhende, Muna/0000-0002-9251-170X;
   Khetan, Vikas/0000-0003-4396-9877
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Bhoomibunchoo C, 2017, CLIN OPHTHALMOL, V11, P317, DOI 10.2147/OPTH.S126226
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Li Y, 2014, OPHTHALMOLOGY, V121, P2290, DOI 10.1016/j.ophtha.2014.06.016
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Yadav S, 2017, BRIT J OPHTHALMOL, V101, P1377, DOI 10.1136/bjophthalmol-2016-310074
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1982, MAC SOC M MIAM 5 FEB
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P416
NR 25
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 28
PY 2020
VL 15
IS 4
AR e0231901
DI 10.1371/journal.pone.0231901
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LS8WP
UT WOS:000536661300018
PM 32343707
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kwok, AKH
   Lai, TYY
   Chan, CWN
   Neoh, EL
   Lam, DSC
AF Kwok, AKH
   Lai, TYY
   Chan, CWN
   Neoh, EL
   Lam, DSC
TI Polypoidal choroidal vasculopathy in Chinese patients
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENTS; CLINICAL SPECTRUM
AB Aims: To report the clinical features and outcomes of polypoidal choroidal vasculopathy (PCV) in Chinese patients with or without loser treatment.
   Methods: A consecutive series of 204 indocyanine green angiographies (ICGA) performed for patients with a provisional diagnosis of age related macular degeneration were reviewed retrospectively. Inclusion criteria were ICGA with angiographic features of PCV and patients of Chinese ethnic origin. Medical records were then reviewed and patients were recalled for further assessments.
   Results: 22 eyes of 19 patients (9.3%) were included. The mean follow up period was 27.4 months (range 4-60 months). The mean age of patients at presentation was 65.1 years (range 51-77 years). The commonest clinical feature at presentation was subretinal haemorrhage (63.6%), followed by retinal exudation (59.1%) and haemorrhagic pigment epithelial detachment (59.1%). There was a predominance of males (68.4%), unilaterality (84.2%), and macular location of polyps (63.6%). Nine eyes received laser photocoagulation. The median initial visual acuity for both the laser and non-loser groups was 6/18. Stable or improved vision was attained in 56% and 31% of laser and non-laser groups, respectively (Fisher's exact test, p = 0.38). Mean loss of Snellen lines was 3.1 and I. I for the two groups, respectively (two sample t test, p = 0.31). At the lost follow up, 15 (68.2%) eyes had poor visual acuity of 6/60 or worse, mostly attributed to disciform scar or exudative maculopathy.
   Conclusions: There is a predominance of Males, unilaterality, and macular location of polyps in Chinese patients with PCV. The overall visual prognosis is guarded regardless of treatment. There is a large amount of variation in the natural course of PCV among different ethnic groups.
C1 Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Kwok, AKH (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Univ Eye Ctr 3 F, Hong Kong Eye Hosp, 147K Argyle St, Kowloon, Hong Kong, Peoples R China.
RI Lam, Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1982, MAC SOC M 5 FEBR MIA
NR 16
TC 111
Z9 125
U1 0
U2 3
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2002
VL 86
IS 8
BP 892
EP 897
DI 10.1136/bjo.86.8.892
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 580RT
UT WOS:000177249200018
PM 12140211
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Tuuminen, R
   Uusitalo-Jarvinen, H
   Aaltonen, V
   Hautala, N
   Kaipiainen, S
   Laitamaki, N
   Ollila, M
   Rantanen, J
   Valimaki, S
   Sipila, R
   Laukkala, T
   Komulainen, J
   Tommila, P
   Immonen, I
   Tuulonen, A
   Kaarniranta, K
AF Tuuminen, Raimo
   Uusitalo-Jarvinen, Hannele
   Aaltonen, Vesa
   Hautala, Nina
   Kaipiainen, Sulevi
   Laitamaki, Nina
   Ollila, Marko
   Rantanen, Jari
   Valimaki, Satu
   Sipila, Raija
   Laukkala, Tanja
   Komulainen, Jorma
   Tommila, Petri
   Immonen, Ilkka
   Tuulonen, Anja
   Kaarniranta, Kai
TI The Finnish national guideline for diagnosis, treatment and follow-up of
   patients with wet age related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL
   AFLIBERCEPT INJECTION; EVALUATING FLUORESCEIN ANGIOGRAMS; VERTEPORFIN
   PHOTODYNAMIC THERAPY; CHOROIDAL NEOVASCULAR MEMBRANES; FACTOR-H
   POLYMORPHISM; 2.0 MG RANIBIZUMAB; RETINA SPECIALISTS; 5-YEAR INCIDENCE
AB Age-related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti-VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of society and of thehealthcare system poses challenges for the provision and development of care. In context of these current aspects, we aimed to set evidence-based medical guidelines for diagnosis, treatment and follow-up of patients with wAMD.
C1 [Tuuminen, Raimo] Kymenlaakso Cent Hosp, Dept Ophthalmol, Kotka, Finland.
   [Tuuminen, Raimo] Univ Helsinki, Helsinki Retina Res Grp, Helsinki, Finland.
   [Tuuminen, Raimo] Patient Insurance Ctr, Helsinki, Finland.
   [Uusitalo-Jarvinen, Hannele; Tuulonen, Anja] Tampere Univ Hosp, Tays Eye Ctr, Tampere, Finland.
   [Aaltonen, Vesa] Turku Univ Hosp, Dept Ophthalmol, Turku, Finland.
   [Hautala, Nina] Oulu Univ Hosp, Dept Ophthalmol, Oulu, Finland.
   [Hautala, Nina] Univ Oulu, Med Res Ctr, Oulu, Finland.
   [Kaipiainen, Sulevi] North Karelian Cent Hosp, Dept Ophthalmol, Joensuu, Finland.
   [Laitamaki, Nina] Kanta Hame Cent Hosp, Dept Ophthalmol, Hameenlinna, Finland.
   [Ollila, Marko] Lapland Cent Hosp, Dept Ophthalmol, Rovaniemi, Finland.
   [Rantanen, Jari] Satakunta Cent Hosp, Dept Ophthalmol, Pori, Finland.
   [Valimaki, Satu] Paijat Hame Cent Hosp, Dept Ophthalmol, Lahti, Finland.
   [Sipila, Raija; Laukkala, Tanja; Komulainen, Jorma] Finnish Med Soc Duodecim, Helsinki, Finland.
   [Tommila, Petri; Immonen, Ilkka] Helsinki Univ Hosp, Dept Ophthalmol, Helsinki, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, Kuopio, Finland.
C3 University of Helsinki; Tampere University; Tampere University Hospital;
   University of Turku; University of Oulu; University of Oulu; Satakunta
   Central Hospital; Paijat Hame Central Hospital; University of Helsinki;
   Helsinki University Central Hospital; Kuopio University Hospital;
   University of Eastern Finland; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
EM kai.kaarniranta@kuh.fi
FU Finnish Ophthalmological Society; Departments of Ophthalmology of the
   University and Central Hospitals in Finland
FX This review was supported by grants from the Finnish Ophthalmological
   Society and the Departments of Ophthalmology of the University and
   Central Hospitals in Finland.
CR Abell RG, 2012, BRIT J OPHTHALMOL, V96, P1474, DOI 10.1136/bjophthalmol-2012-302030
   [Anonymous], 2014, ANN REPORT FINNISH R
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Augustin AJ, 2005, RETINA-J RET VIT DIS, V25, P443, DOI 10.1097/00006982-200506000-00008
   Barikian A, 2015, AM J OPHTHALMOL, V159, P131, DOI 10.1016/j.ajo.2014.10.005
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Castillo MM, 2014, EYE, V28, P1399, DOI 10.1038/eye.2014.214
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Falavarjani KG, 2015, CAN J OPHTHALMOL, V50, P33, DOI 10.1016/j.jcjo.2014.09.005
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jiang S, 2014, J CLIN PHARM THER, V39, P234, DOI 10.1111/jcpt.12146
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2014, OPHTHALMOLOGY, V121, P1220, DOI 10.1016/j.ophtha.2014.01.003
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Landa G, 2007, EUR J OPHTHALMOL, V17, P615, DOI 10.1177/112067210701700421
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mowatt G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18690
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Muni RH, 2008, RETINA-J RET VIT DIS, V28, P1421, DOI 10.1097/IAE.0b013e3181814470
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Si JK, 2014, INT J OPHTHALMOL-CHI, V7, P541, DOI 10.3980/j.issn.2222-3959.2014.03.28
   Simcock P, 2014, EYE, V28, P1161, DOI 10.1038/eye.2014.153
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Sturzlinger Heidi, 2007, GMS Health Technol Assess, V3, pDoc02
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   YANNUZZI LA, 1982, OPHTHALMOLOGY, V89, P157
   Yong M, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0064-5
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zayit-Soudry S, 2007, RETINA-J RET VIT DIS, V27, P798, DOI 10.1097/IAE.0b013e31802c50a3
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
NR 83
TC 22
Z9 23
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUL
PY 2017
VL 95
SU A105
SI SI
DI 10.1111/aos.13501
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ9YR
UT WOS:000405086900001
PM 28686003
OA Bronze
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Braun, MD
   Thiele, S
   Ferrara, D
   Honigberg, L
   Gao, SS
   Chen, H
   Steffen, V
   Holz, FG
   Sassmannshausen, M
AF Schmitz-Valckenberg, Steffen
   Braun, Martina D.
   Thiele, Sarah
   Ferrara, Daniela
   Honigberg, Lee
   Gao, Simon S.
   Chen, Hao
   Steffen, Verena
   Holz, Frank G.
   Sassmannshausen, Marlene
TI Conversion from Intermediate Age-Related Macular Degeneration to
   Geographic Atrophy in a Proxima B Subcohort Using a Multimodal Approach
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Geographic atrophy; Multimodal
   imaging; Reticular pseudodrusen
ID RETICULAR PSEUDODRUSEN; NATURAL-HISTORY; PROGRESSION;
   NEOVASCULARIZATION; ASSOCIATION; SECONDARY; DISEASE; FORM
AB Introduction: This retrospective analysis assessed geographic atrophy (GA) progression in fellow eyes from the Proxima B trial intermediate age-related macular degeneration (iAMD) subcohort using high-resolution multimodal imaging anchored on optical coherence tomography (OCT). Methods: Thirty-two patients from the Proxima B iAMD subcohort were assessed; all had GA with no macular neovascularization (MNV) in the contralateral eye. Imaging data, including color fundus photography, fluorescein angiography, near-infrared reflectance, fundus autofluorescence (FAF), and spectral-domain OCT, were obtained. Features preceding progression/conversion to advanced AMD (drusen, reticular pseudodrusen [RPD], MNV, incomplete/complete retinal pigment epithelium and outer retinal atrophy [iRORA/cRORA]) were assessed. Results: Of 30 fellow eyes with available follow-up images, 12 converted to GA (FAF), 2 converted to MNV, and 16 were nonconverters during the review period (median: 17.8 months). iRORA/cRORA features (present in all converters at baseline) were identified on OCT in eyes that progressed to GA. Median time interval from iRORA to cRORA and from cRORA to GA was 7 months each. GA development/progression was either drusen- or RPD-associated (n = 6 each). Eyes with baseline RPD showed faster GA progression versus eyes with drusen (1.49 vs. 0.38 mm(2)/year). Conclusions: RPD presence was associated with rapid GA lesion enlargement and may provide an early indication of faster GA progression.
C1 [Schmitz-Valckenberg, Steffen; Braun, Martina D.; Thiele, Sarah; Holz, Frank G.; Sassmannshausen, Marlene] Univ Bonn, GRADE Reading Ctr, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen; Braun, Martina D.; Thiele, Sarah; Holz, Frank G.; Sassmannshausen, Marlene] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
   [Ferrara, Daniela; Honigberg, Lee; Gao, Simon S.; Chen, Hao; Steffen, Verena] Genentech Inc, San Francisco, CA 94080 USA.
C3 University of Bonn; University of Bonn; Utah System of Higher Education;
   University of Utah; Roche Holding; Genentech
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, GRADE Reading Ctr, Bonn, Germany.; Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Bonn, Germany.; Schmitz-Valckenberg, S (通讯作者)，Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84112 USA.
EM steffen.valckenberg@utah.edu
OI Gao, Simon/0000-0002-7020-037X
CR Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Chen L, 2020, OPHTHALMOLOGY, V127, P931, DOI 10.1016/j.ophtha.2020.01.040
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Greferath U, 2016, OPHTHALMOLOGY, V123, P1320, DOI 10.1016/j.ophtha.2016.02.009
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Heiferman MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217805
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Terheyden JH, 2019, OPHTHALMOLOGE, V116, P1186, DOI 10.1007/s00347-019-0907-1
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 32
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2021
VL 244
IS 6
BP 523
EP 534
DI 10.1159/000517881
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1U6VT
UT WOS:000805548500006
PM 34348335
OA hybrid
DA 2022-11-30
ER

PT J
AU Su, Y
   Yi, YX
   Li, L
   Chen, CZ
AF Su, Yu
   Yi, Yuexiong
   Li, Lu
   Chen, Changzheng
TI circRNA-miRNA-mRNA network in age-related macular degeneration: From
   construction to identification
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Noncoding RNA; Age-related macular degeneration; Bioinformatics;
   Neurodegeneration disease
ID PROTEIN-INTERACTION NETWORKS; RETINAL-PIGMENT EPITHELIUM; OXIDATIVE
   STRESS; CIRCULAR RNAS; GENE-EXPRESSION; R PACKAGE; MICRORNAS; CERNA;
   NEOVASCULARIZATION; TARGET
AB The aim of the present study was to investigate the pathogenesis of age-related macular degeneration (AMD) by constructing a regulatory circRNA-miRNA-mRNA network. By adjusting the P value to 0.05 and the absolute log value of fold change to 0.25, 2920 and 1057 differentially expressed mRNAs were identified from GSE50195 and GSE29801, respectively. Based on a literature review, Starbase database analysis, and RNA hybrid assays, we obtained 77 miRNA-mRNA and 331 circRNA-miRNA pairs. After combining these pairs, we constructed a circRNA-miRNA-mRNA network possessing 303 circRNA nodes, 4 miRNA nodes, 51 mRNA nodes, and 408 edges. By utilizing protein-protein network analysis, the MCODE algorithm, and the highest degree of circRNA node, we identified the regulatory axis of hsa_circRNA7329/hsa-miR-9/SCD. Hsa_circRNA7329 may regulate SCD through hsa-miR-9 to promote macrophage-mediated inflammation and pathologic angiogenesis, which lead to AMD development. However, the underlying details require further investigation.
C1 [Su, Yu; Li, Lu; Chen, Changzheng] Wuhan Univ, Renmin Hosp, Ctr Eye, Wuhan 430060, Hubei, Peoples R China.
   [Yi, Yuexiong] Wuhan Univ, Zhongnan Hosp, Dept Obstet & Gynecol, Wuhan 430071, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University
RP Chen, CZ (通讯作者)，Wuhan Univ, Renmin Hosp, Ctr Eye, Wuhan 430060, Hubei, Peoples R China.
EM whuchenchzh@163.com
OI Chen, Changzheng/0000-0002-7281-552X; Su, Yu/0000-0002-4159-1033
FU National Natural Science Foundation of China [81500744]
FX This project was supported by the National Natural Science Foundation of
   China (Grant No. 81500744).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Bai YH, 2015, NATURE, V524, P252, DOI 10.1038/nature14549
   Barangi S, 2019, PHARMACOL RES, V142, P22, DOI 10.1016/j.phrs.2019.02.010
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Cao DD, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060842
   Cao MJ, 2019, INT J MED SCI, V16, P1356, DOI 10.7150/ijms.35149
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen X, 2020, MOL THER, V28, P929, DOI 10.1016/j.ymthe.2020.01.010
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.382
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Conway JR, 2017, BIOINFORMATICS, V33, P2938, DOI 10.1093/bioinformatics/btx364
   Dieguez HH, 2019, FREE RADICAL BIO MED, V131, P72, DOI 10.1016/j.freeradbiomed.2018.11.035
   Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Feng LL, 2017, AM J PATHOL, V187, P2208, DOI 10.1016/j.ajpath.2017.06.015
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Guo N, 2019, INT J MED SCI, V16, P513, DOI 10.7150/ijms.29750
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang H, 2017, MOL BIOSYST, V13, P1182, DOI 10.1039/c7mb00094d
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Juzwik CA, 2019, PROG NEUROBIOL, V182, DOI 10.1016/j.pneurobio.2019.101664
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243
   Kulcheski FR, 2016, J BIOTECHNOL, V238, P42, DOI 10.1016/j.jbiotec.2016.09.011
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Liu WL, 2019, J CELL BIOCHEM, V120, P8032, DOI 10.1002/jcb.28081
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Muangnoi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133367
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Pelaez R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010140
   Pockar S, 2019, GENE, V696, P162, DOI 10.1016/j.gene.2019.02.004
   Radhakrishnan B, 2016, J EXP NEUROSCI, V10, P101, DOI 10.4137/JEN.S32843
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rossato FA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092057
   Rowan S, 2018, GUT MICROBES, V9, P452, DOI 10.1080/19490976.2018.1435247
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Sun HJ, 2020, PHARMACOLOGY, V105, P28, DOI 10.1159/000502614
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tong NT, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00137
   Venkatesan N, 2014, BIOINFORM BIOL INSIG, V8, P177, DOI [10.4137/BBi.s16958, 10.4137/BBI.S16958]
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang ML, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00153
   Wawrzyniak O, 2018, ACTA BIOCHIM POL, V65, P497, DOI 10.18388/abp.2018_2639
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wu XY, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/856521
   Yoon C, 2014, GRAEF ARCH CLIN EXP, V252, P1369, DOI 10.1007/s00417-014-2698-z
   Zhao JJ, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00342
NR 66
TC 7
Z9 8
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2021
VL 203
AR 108427
DI 10.1016/j.exer.2020.108427
EA JAN 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG8HZ
UT WOS:000617823700004
PM 33383027
DA 2022-11-30
ER

PT J
AU Schick, T
   Steinhauer, M
   Aslanidis, A
   Altay, L
   Karlstetter, M
   Langmann, T
   Kirschfink, M
   Fauser, S
AF Schick, T.
   Steinhauer, M.
   Aslanidis, A.
   Altay, L.
   Karlstetter, M.
   Langmann, T.
   Kirschfink, M.
   Fauser, S.
TI Local complement activation in aqueous humor in patients with
   age-related macular degeneration
SO EYE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RISK; VARIANT; DEFICIENCY; HYPOTHESIS;
   COMPONENTS; DRUSEN
AB Purpose To investigate complement activation in aqueous humor and in plasma of patients with neovascular age-related macular degeneration (nAMD).
   Patients and methods Aqueous humor and EDTA-plasma of 31 nAMD patients and 30 age-matched controls was collected. The levels of the complement factor 3 (C3), the regulators factor H (FH), and factor I (FI), and of the complement activation products Ba, C3a, and the terminal complement complex (sC5b-9) were measured. Associations between complement levels and phenotype were determined using Mann-Whitney U-test.
   Results In plasma, no significant differences were found between the nAMD group and the control group. In aqueous humor, significantly increased levels of Ba (P= 0.002), and C3a (P= 0.002) indicate local complement activation in nAMD patients and a trend for a concomitant upregulation of the complement regulators FH (P= 0.02) and FI (P= 0.04).
   Conclusions Our findings provide strong evidence for a local complement dysregulation in nAMD patients.
C1 [Schick, T.; Steinhauer, M.; Altay, L.; Fauser, S.] Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
   [Aslanidis, A.; Karlstetter, M.; Langmann, T.] Univ Hosp Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
   [Kirschfink, M.] Heidelberg Univ, Inst Immunol, Heidelberg, Germany.
C3 University of Cologne; University of Cologne; Ruprecht Karls University
   Heidelberg
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@gmail.com
RI Kirschfink, Michael/AAG-5410-2020
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grumach AS, 2006, CLIN EXP IMMUNOL, V143, P297, DOI 10.1111/j.1365-2249.2005.02988.x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kotnik V, 1997, IMMUNOPHARMACOLOGY, V38, P215, DOI 10.1016/S0162-3109(97)00074-X
   Licht C, 2005, AM J KIDNEY DIS, V45, P415, DOI 10.1053/j.ajkd.2004.10.018
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 19
TC 56
Z9 56
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2017
VL 31
IS 5
BP 810
EP 813
DI 10.1038/eye.2016.328
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EU4YF
UT WOS:000401036900023
PM 28128795
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Iyer, S
   Radwan, AE
   Hafezi-Moghadam, A
   Malyala, P
   Amiji, M
AF Iyer, Shwetha
   Radwan, Ahmed E.
   Hafezi-Moghadam, Ali
   Malyala, Padma
   Amiji, Mansoor
TI Long-acting intraocular Delivery strategies for biological therapy of
   age-related macular degeneration
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Anatomy of the eye; Age-related macular degeneration; Intraocular
   delivery strategies; Biological therapy; Sustained delivery; PLGA
   microspheres
ID CHOROIDAL NEOVASCULARIZATION; DRUG-DELIVERY; CONTROLLED-RELEASE; PLGA
   MICROSPHERES; BEVACIZUMAB; HYDROGEL; IMPLANTS; PHARMACOKINETICS;
   MANAGEMENT; RABBITS
AB As one of the leading causes of central vision loss in elderly population, worldwide cases of age-related macular degeneration (AMD) have seen a dramatic increase over the past several years. Treatment regimens for AMD, especially with biological agents, are complicated due to anatomical and physiological barriers, as well as administration of high doses and frequent regimens. Some clinical examples include monthly intravitreal administration of anti-VEGF antibody ranibizumab (Lucentis (R)) from Genentech and aflibercept (Eylea (R)) from Regeneron Pharmaceuticals. Long-acting sustained intraocular drug delivery provides promising solutions, such as Vitrasert (R) from Bausch & Lomb, an intravitreal biodegradable polymeric implant made from poly(D, L-lactic co glycolic acid) (PLGA), and can be used as a guiding reference to formulate sustained delivery systems. In this review, we discuss the anatomy and physiology of the eye, barriers to delivery, pathology of AMD, opportunities for biological therapeutics, and future prospects of intraocular delivery strategies that are in development for treatment of AMD.
C1 [Iyer, Shwetha; Amiji, Mansoor] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   [Radwan, Ahmed E.; Hafezi-Moghadam, Ali] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
   [Iyer, Shwetha; Malyala, Padma] Novartis Inst Biomed Sci, Cambridge, MA 02139 USA.
C3 Northeastern University; Harvard University; Brigham & Women's Hospital;
   Harvard Medical School; Novartis
RP Amiji, M (通讯作者)，Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM m.amiji@northeastern.edu
RI Radwan, Ahmed E./M-1034-2017; Amiji, Mansoor M/AAK-1531-2020
OI Radwan, Ahmed E./0000-0002-3011-5832; Amiji, Mansoor
   M/0000-0001-6170-881X
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Barakat D. P., 2015, AMD RETIN PHYS, V12, P26
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Booth BA, 2007, DRUG AGING, V24, P581, DOI 10.2165/00002512-200724070-00006
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   Cui CM, 2018, CLIN INTERV AGING, V13, P51, DOI 10.2147/CIA.S151225
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Falavarjani KG, 2017, CURR PHARM DESIGN, V23, P535, DOI 10.2174/1381612822666161216121105
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Ignatius AA, 1996, BIOMATERIALS, V17, P831, DOI 10.1016/0142-9612(96)81421-9
   Ishikawa M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/281214
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kelly SJ, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030092
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li H, 2006, EXP EYE RES, V83, P824, DOI 10.1016/j.exer.2006.04.014
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Manuscript A., 2015, OCULAR DELIVERY MACR, P172, DOI [10.1016/j.jconrel.2014.06.043.Ocular, DOI 10.1016/J.JCONREL.2014.06.043.OCULAR]
   Mitchell P., 2012, POSTERIOR SEGMENT AG, P34, DOI [10.17925/EOR.2012.06.01.34, DOI 10.17925/EOR.2012.06.01.34]
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OHAGAN DT, 1991, IMMUNOLOGY, V73, P239
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Phan VHG, 2016, SCI REP-UK, V6, DOI 10.1038/srep29978
   Pindrus M., 2015, SOLUBILITY CHALLENGE, DOI [10.1021/acs.molpharmaceut.5b00336, DOI 10.1021/ACS.MOLPHARMACEUT.5B00336]
   Quiroz-Mercado H., 2013, RETIN TODAY SEP, P30
   Rai UDJP, 2015, DRUG DISCOV TODAY, V20, P491, DOI 10.1016/j.drudis.2014.10.010
   Rhee YS, 2011, AAPS PHARMSCITECH, V12, P1293, DOI 10.1208/s12249-011-9693-z
   Rimm EB, 2012, NEW ENGLAND J N ENGL, V367, P1387, DOI [10.1056/NEJMoa1203039, DOI 10.1056/NEJMOA1203039]
   Ruel-Gariepy E, 2002, J CONTROL RELEASE, V82, P373, DOI 10.1016/S0168-3659(02)00146-3
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Suggs L. J., 2007, SYNTHETIC BIODEGRADA, DOI [10.1007/978-0-387-69002-5_55, DOI 10.1007/978-0-387-69002-5_55]
   Thackaberry EA, 2017, INVEST OPHTH VIS SCI, V58, P4274, DOI 10.1167/iovs.16-21334
   Turabee MH, 2018, BIOMATER SCI-UK, V6, P661, DOI 10.1039/c7bm00980a
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wang GF, 2012, INT J OPHTHALMOL-CHI, V5, P609, DOI 10.3980/j.issn.2222-3959.2012.05.13
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wazen RM, 2014, NIH PUBLIC ACCESS, V8, DOI [10.2217/nnm.12.167.gene, DOI 10.2217/NNM.12.167.GENE]
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Zandi S., 2015, CELL REP, V57, P742, DOI [10.1002/dev.21214.Developmental, DOI 10.1002/DEV.21214.DEVELOPMENTAL]
   Zhao M, 2017, J CONTROL RELEASE, V266, P187, DOI 10.1016/j.jconrel.2017.09.029
NR 52
TC 19
Z9 20
U1 1
U2 45
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 28
PY 2019
VL 296
BP 140
EP 149
DI 10.1016/j.jconrel.2019.01.007
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HL5JO
UT WOS:000458763000011
PM 30660630
DA 2022-11-30
ER

PT J
AU Kolosova, NG
   Kozhevnikova, OS
   Telegina, DV
   Fursova, AZ
   Stefanova, NA
   Muraleva, NA
   Venanzi, F
   Sherman, MY
   Kolesnikov, SI
   Sufianov, AA
   Gabai, VL
   Shneider, AM
AF Kolosova, Nataliya G.
   Kozhevnikova, Oyuna S.
   Telegina, Darya V.
   Fursova, Anzhela Zh
   Stefanova, Natalia A.
   Muraleva, Natalia A.
   Venanzi, Franco
   Sherman, Michael Y.
   Kolesnikov, Sergey I.
   Sufianov, Albert A.
   Gabai, Vladimir L.
   Shneider, Alexander M.
TI p62/SQSTM1 coding plasmid prevents age related macular degeneration in a
   rat model
SO AGING-US
LA English
DT Article
DE p62/SQSTM1; age-related macular degeneration; inflammation; gliosis;
   OXYS rats; aging; retina
ID AMD-LIKE RETINOPATHY; ACCELERATED OXYS RATS; RETINAL-PIGMENT EPITHELIUM;
   CELL-DEATH; P62; PATHWAY; MITOCHONDRIA; INFLAMMATION; MACROPHAGES;
   EXPRESSION
AB P62/SQSTM1, a multi-domain protein that regulates inflammation, apoptosis, and autophagy, has been linked to age-related pathologies. For example, previously we demonstrated that administration of p62/SQSTM1-encoding plasmid reduced chronic inflammation and alleviated osteoporosis and metabolic syndrome in animal models. Herein, we built upon these findings to investigate effect of the p62-encoding plasmid on an age-related macular degeneration (AMD), a progressive neurodegenerative ocular disease, using spontaneous retinopathy in senescence-accelerated OXYS rats, as a model. Overall, the p62DNA decreased the incidence and severity of retinopathy. In retinal pigment epithelium (RPE), p62DNA administration slowed down development of the destructive alterations of RPE cells, including loss of regular hexagonal shape, hypertrophy, and multinucleation. In neuroretina, p62DNA prevented gliosis, retinal thinning, and significantly inhibited microglia/macrophages migration to the outer retina, prohibiting their subretinal accumulation. Taken together, our results suggest that the p62DNA has a strong retinoprotective effect in AMD.
C1 [Kolosova, Nataliya G.; Kozhevnikova, Oyuna S.; Telegina, Darya V.; Fursova, Anzhela Zh; Stefanova, Natalia A.; Muraleva, Natalia A.] RAS, Inst Cytol & Genet, SB, Novosibirsk, Russia.
   [Fursova, Anzhela Zh] Novosibirsk State Reg Clin Hosp, Novosibirsk, Russia.
   [Gabai, Vladimir L.; Shneider, Alexander M.] CureLab Oncol Inc, Deadham, MA 02492 USA.
   [Venanzi, Franco] Univ Camerino, Sch Biosci, Camerino, Italy.
   [Sherman, Michael Y.; Shneider, Alexander M.] Ariel Univ, Dept Mol Biol, Ariel, Israel.
   [Sufianov, Albert A.; Shneider, Alexander M.] Sechenov First Moscow State Med Univ, Moscow, Russia.
   [Kolesnikov, Sergey I.] Russian Acad Sci, Moscow, Russia.
   [Kolesnikov, Sergey I.] Lomonosov Moscow State Univ, Moscow, Russia.
   [Kolesnikov, Sergey I.] Res Ctr Family Hlth & Reprod Problems, Irkutsk, Russia.
   [Gabai, Vladimir L.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.
   [Sufianov, Albert A.] Fed Ctr Neurosurg, Tyumen, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; University of Camerino; Ariel University; Sechenov First Moscow
   State Medical University; Russian Academy of Sciences; Lomonosov Moscow
   State University; Boston University
RP Kolosova, NG (通讯作者)，RAS, Inst Cytol & Genet, SB, Novosibirsk, Russia.; Shneider, AM (通讯作者)，CureLab Oncol Inc, Deadham, MA 02492 USA.; Shneider, AM (通讯作者)，Ariel Univ, Dept Mol Biol, Ariel, Israel.; Shneider, AM (通讯作者)，Sechenov First Moscow State Med Univ, Moscow, Russia.
EM kolosova@bionet.nsc.ru; ashneider@curelab.com
RI Muraleva, Natalia/S-2392-2018; Kolesnikov, Sergey Ivanovich/M-4020-2016;
   fursova, anzhella/AAE-1495-2022; Telegina, Darya/AAQ-6062-2020; Gabai,
   Vladimir L/I-1650-2013; Kozhevnikova, Oyuna S./H-3588-2016; Stefanova,
   Natalia/V-1530-2018; Sufianov, Albert A/C-4799-2017; Kolosova, Nataliya
   G/P-3178-2015; Kolosova, Nataliya G/AAR-7409-2020
OI Muraleva, Natalia/0000-0002-0665-1723; Kolesnikov, Sergey
   Ivanovich/0000-0003-2124-6328; fursova, anzhella/0000-0001-6311-5452;
   Telegina, Darya/0000-0001-8096-0519; Gabai, Vladimir
   L/0000-0003-4505-4718; Kozhevnikova, Oyuna S./0000-0001-6475-4061;
   Kolosova, Nataliya G/0000-0003-2398-8544; Kolosova, Nataliya
   G/0000-0003-2398-8544; Stefanova, natalia/0000-0001-5127-5993; Sufianov,
   Albert/0000-0001-7580-0385
FU Russian Scientific Foundation grant [18-75-00031]; CureLab Oncology,
   Inc.; Russian Science Foundation [18-75-00031] Funding Source: Russian
   Science Foundation
FX The funduscopy, western blotting and immunohistochemical examination
   were supported by a Russian Scientific Foundation grant (18-75-00031).
   The DNA plasmid construction and the publication costs for this article
   were funded by CureLab Oncology, Inc.
CR Caccamo A, 2017, MOL PSYCHIATR, V22, P865, DOI 10.1038/mp.2016.139
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Hoz R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2954721
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Fan LH, 2018, APOPTOSIS, V23, P187, DOI 10.1007/s10495-018-1445-z
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ganesh BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018305
   Halenova T, 2017, ONCOTARGET, V8, P56030, DOI 10.18632/oncotarget.19840
   Into T, 2010, J BIOL CHEM, V285, P35759, DOI 10.1074/jbc.M110.126904
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim JY, 2009, J IMMUNOL, V182, P2131, DOI 10.4049/jimmunol.0802755
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Markovets AM, 2011, AGING-US, V3, P44
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Pun NT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00456-6
   Rashid A, 2016, ADV EXP MED BIOL, V854, P757, DOI 10.1007/978-3-319-17121-0_101
   Sabbieti MG, 2015, ONCOTARGET, V6, P3590, DOI 10.18632/oncotarget.2884
   Sergin I, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad5614
   Stefanova NA, 2016, AGING-US, V8, P2713, DOI 10.18632/aging.101054
   Stefanova NA, 2014, CELL CYCLE, V13, P898, DOI 10.4161/cc.28255
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Venanzi F, 2013, ONCOTARGET, V4, P1829, DOI 10.18632/oncotarget.1397
   Wang L, 2016, ADV EXP MED BIOL, V854, P17, DOI 10.1007/978-3-319-17121-0_3
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
NR 31
TC 18
Z9 19
U1 2
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG
PY 2018
VL 10
IS 8
BP 2136
EP 2147
DI 10.18632/aging.101537
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA GS1RN
UT WOS:000443308900028
PM 30153656
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Zimmer, CN
AF Dugel, Pravin U.
   Zimmer, Cheryl N.
TI Imaging of Melanin Disruption in Age-Related Macular Degeneration Using
   Multispectral Imaging
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AUTOFLUORESCENCE; DISEASE; AMD
AB BACKGROUND AND OBJECTIVE: To investigate whether multispectral imaging (MSI) is able to obtain a noninvasive view of melanin disruption associated with age-related macular degeneration (AMD), which could support early diagnosis and potential treatment strategies.
   PATIENTS AND METHODS: A single retinal center, retrospective, observational, image analysis study of MSI images of 43 patients was done to determine the extent of melanin pigment exhibited in association with AMD, based on the Age-Related Eye Disease Study classification and grading scale. Corresponding fundus photos were also graded for 12 of the eyes.
   RESULTS: Fifty-one of 61 eyes (84%) of 43 patients with AMD were determined to have melanin disruption in their MSI images in at least the central and/or one of four inner ETDRS areas. There was a relationship between severity of disease and the degree of melanin disruption. The sensitivity of fundus photography for melanin pigment as compared to MSI was only 62.5%, with three false-negatives.
   CONCLUSION: A direct, noninvasive, unobstructed view of melanin disruption associated with AMD can be observed using MSI.
C1 [Dugel, Pravin U.] Keck Sch Med, Retinal Consultants Arizona, Phoenix, AZ USA.
   [Dugel, Pravin U.; Zimmer, Cheryl N.] Keck Sch Med, USC Eye Inst, Phoenix, AZ USA.
   [Zimmer, Cheryl N.] Annidis Corp, 100 Maple Grove, Ottawa, ON K2V 1B8, Canada.
RP Zimmer, CN (通讯作者)，Annidis Corp, 100 Maple Grove, Ottawa, ON K2V 1B8, Canada.
EM cherylz@annidis.com
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Bennett T.J., MONOCHROMATIC FUNDUS
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Curico CA, 2013, RETINA, V33, P265
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domalpally A, 2009, RETINA-J RET VIT DIS, V29, P775, DOI 10.1097/IAE.0b013e3181a0848b
   Ferrell WD, 2012, ARVO 2012 MAY 6 9 FO
   Freund K., 2014, RETINA TODAY, V9, P94
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   HITCHMOTH DL, 2013, ADV OCULAR CARE, V4, P76
   Howes KA, 2006, REV OPHTHALMOLOGY
   Joachim NDL, 2015, JAMA OPHTHALMOL, V133, P698, DOI 10.1001/jamaophthalmol.2015.0498
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Maldonado ME, 2013, REV OPHTHALMOLOGY
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   National Eye Institute, 2013, AREDS 2 RES
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Schmitz-Valckenberg S, 2007, RETIN PHYS      1101
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Vaz F., 2010, GEOGRAPHIC ATROPHY
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Zarbin MA, 2014, RETIN PHYS, V11, P30
   [No title captured]
NR 29
TC 12
Z9 15
U1 1
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2016
VL 47
IS 2
BP 134
EP 141
DI 10.3928/23258160-20160126-06
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UX
UT WOS:000378844100006
PM 26878446
DA 2022-11-30
ER

PT J
AU Choi, M
   Kim, SW
   Yun, C
   Oh, J
AF Choi, Mihyun
   Kim, Seong-Woo
   Yun, Cheolmin
   Oh, Jaeryung
TI OCT Angiography Features of Neovascularization as Predictive Factors for
   Frequent Recurrence in Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION; TYPE-1
   NEOVASCULARIZATION; GEOGRAPHIC ATROPHY; SPECTRAL-DOMAIN; EXUDATIVE AMD;
   RANIBIZUMAB; THERAPY; AFLIBERCEPT; PROGRESSION
AB PURPOSE: To investigate the features of neovascularization (NV) in eyes with neovascular age-related macular degeneration using optical coherence tomography angiography (OCTA) according to the treatment interval of intravitreal aflibercept injection (IVI).
   DESIGN: Retrospective, interventional, comparative case series.
   METHODS: Patients with type 1 NV treated with the "pro re nata" regimen after 3 loading IVI were classified into 2 groups based on the numbers of treatments during 12 months, specifically a stable group who required fewer than 2 injections and an unstable group who required more than 3 injections. Quantitative features of OCTA including NV area, NV length, NV density, endpoint density (open-ended vessels per unit length), junction density (vessel junction per unit length), lacunarity, and largest vessel caliber were compared between the 2 groups.
   RESULTS: Among 71 eyes, 38 and 33 eyes were classified into the stable and unstable groups, respectively. The unstable group had higher endpoint densities (stable vs unstable: 2.72 vs 3.18; P = .03) and higher levels of lacunarity (0.177 vs 0.211; P = .028). The area, density, length of NV, junction density, and largest vessel caliber were not different between the 2 groups (P = .057, P = .184, P = .062, P = .160, and P = .473, respectively). Endpoint density was correlated with the unstable group in both univariate and multivariate analyses (P = .004, P = .002, respectively). A predictive model with an endpoint index demonstrated a sensitivity of 93.75% and a negative predictive value of 89.47% for the unstable group.
   CONCLUSIONS: The characteristics of NV in eyes of exudative age-related macular degeneration with type 1 NV were different according to treatment requirements. Identifying the features of NV on OCTA might be helpful for predicting clinical outcomes and optimal treatment intervals. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Choi, Mihyun; Kim, Seong-Woo; Yun, Cheolmin; Oh, Jaeryung] Korea Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Kim, SW (通讯作者)，Korea Univ, Dept Ophthalmol, Guro Hosp, 148 Gurodong Ro, Seoul, South Korea.
EM ksw64723@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Kim, Seong-Woo/0000-0003-0073-5800;
   choi, mihyun/0000-0003-2420-0907
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Baer K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46235-3
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corvi F, 2019, RETINA-J RET VIT DIS, V39, P2378, DOI 10.1097/IAE.0000000000002335
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Gould DJ, 2011, MICROCIRCULATION, V18, P136, DOI 10.1111/j.1549-8719.2010.00075.x
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hara C, 2019, BRIT J OPHTHALMOL, V103, P623, DOI 10.1136/bjophthalmol-2018-312275
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Hirano T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27536-5
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kim CG, 2020, JPN J NURS SCI, V17, DOI 10.1111/jjns.12257
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kumar JB, 2019, BRIT J OPHTHALMOL, V103, P918, DOI 10.1136/bjophthalmol-2018-312625
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Malamos P, 2017, CURR EYE RES, V42, P1689, DOI 10.1080/02713683.2017.1356336
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Nakano Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216304
   Nesper PL, 2018, INVEST OPHTH VIS SCI, V59, P1944, DOI 10.1167/iovs.17-23361
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P67, DOI 10.1136/bjophthalmol-2017-311752
   Rajabi M, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020034
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Schierling W, 2009, J VASC RES, V46, P365, DOI 10.1159/000189797
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sugano Y, 2018, CLIN OPHTHALMOL, V12, P2267, DOI 10.2147/OPTH.S179634
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Takeuchi J, 2018, OPHTHALMOLOGICA, V240, P90, DOI 10.1159/000487611
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   Wu S, 2010, MOL CELL BIOCHEM, V343, P223, DOI 10.1007/s11010-010-0517-3
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 61
TC 13
Z9 14
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2020
VL 213
BP 109
EP 119
DI 10.1016/j.ajo.2020.01.012
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LK8GN
UT WOS:000531098400015
PM 31954711
DA 2022-11-30
ER

PT J
AU Varma, R
   Choudhury, F
   Chen, S
   Wu, S
   Hsu, CY
   Torres, M
   Klein, R
   Azen, SP
   McKean-Cowdin, R
AF Varma, Rohit
   Choudhury, Farzana
   Chen, Sardius
   Wu, Shuang
   Hsu, Chunyi
   Torres, Mina
   Klein, Ronald
   Azen, Stanley P.
   McKean-Cowdin, Roberta
CA Chinese Amer Eye Study Grp
TI Prevalence of Age-Related Macular Degeneration in Chinese American
   Adults The Chinese American Eye Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER DAM EYE; RACIAL-DIFFERENCES; 5-YEAR
   INCIDENCE; UNITED-STATES; MACULOPATHY; POPULATION
AB IMPORTANCE Population-based prevalence estimates of age-related macular degeneration (AMD) need to be determined to assess its burden among Chinese Americans, the fastest growing racial group in the United States.
   OBJECTIVE To determine the age-and sex-specific prevalence of AMD among Chinese Americans.
   DESIGN The Chinese American Eye Study (CHES) was conducted in a general urban community of 10 census tracts in Monterey Park, California. A total of 4582 Chinese American adults aged 50 years or older participated in this population-based, cross-sectional study from February 16, 2010, through October 9, 2013, and underwent an interview as well as comprehensive clinical and eye examinations, including detailed retinal photography of both eyes. Fundus photographs were graded for drusen and retinal pigment epithelium abnormalities and were evaluated for AMD.
   MAIN OUTCOMES AND MEASURES The prevalence of early and advanced AMD, drusen, geographic atrophy, and neovascular AMD were determined by using a modified Wisconsin Age-Related Maculopathy Grading Scale (a 6-level scale: 10, no AMD; 60, advanced AMD).
   RESULTS Of the 4582 participants completing both the home survey and clinical examination, 4172 individuals (91.1%) had at least 1 gradable photograph. A total of 1526 (36.6%) participants were men, and the mean (SD) age was 61.2 (8.8) years. When examined by 10-year age groups, the prevalence of early AMD ranged from 5.8% (n = 119) in participants aged 50 to 59 years to 17.6%(n = 37) in those 80 years or older, retinal pigment epithelium abnormalities from 4.1% (n = 85) to 7.2%(n = 16), large drusen (>= 125 mu m) from 9.8% to 32.4%, soft drusen from 27.6%(n = 567) to 58.6%(n = 123), and soft indistinct drusen from 3.7%(n = 76) to 15.2%(n = 32). The prevalence of advanced AMD ranged from 0.2%(n = 3) in participants aged 50 to 59 years to 1.0% (n = 2) in those 80 years or older. Of the 14 cases of advanced AMD, 85.7%(95% CI, 57.2%-98.2%; n = 12) were neovascular AMD and 14.3%(95% CI, 2.0%-42.8%; n = 2) were geographic atrophy. Acute macular degeneration was more common in men (10.9%[9.3%-12.5%]; n = 166) than women (5.8% [4.9%-6.7%]; n = 154) in this cohort.
   CONCLUSIONS AND RELEVANCE Data from CHES suggest that Chinese Americans have a lower prevalence of early and advanced AMD compared with non-Hispanic white individuals. The prevalence of early AMD, advanced AMD, and large drusen was higher among Chinese Americans in CHES than among the Chinese population living in urban/rural China but lower than that in urban-dwelling Taiwanese.
C1 [Varma, Rohit; Choudhury, Farzana; Wu, Shuang; Hsu, Chunyi; Torres, Mina] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Inst Eye, 1450 San Pablo St,Ste 4900, Los Angeles, CA 90033 USA.
   [Chen, Sardius] New York Med Coll, Sch Med, Valhalla, NY 10595 USA.
   [Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53706 USA.
   [Azen, Stanley P.; McKean-Cowdin, Roberta] Univ So Calif, Keck Sch Med, Dept Prevent Med, 1450 San Pablo St,Ste 4900, Los Angeles, CA 90033 USA.
C3 University of Southern California; New York Medical College; University
   of Wisconsin System; University of Wisconsin Madison; University of
   Southern California
RP Varma, R (通讯作者)，Univ So Calif, Keck Sch Med, Dept Ophthalmol, Inst Eye, 1450 San Pablo St,Ste 4900, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
FU National Eye Institute, National Institutes of Health [EY-017337];
   Research to Prevent Blindness
FX This work was supported by grant EY-017337 from the National Eye
   Institute, National Institutes of Health and an unrestricted
   departmental grant from Research to Prevent Blindness.
CR Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hoeffel EM, 2012, ASIAN POPULATION 201
   Humes K, 2011, OVERVIEW RACE HISPAN
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2013, OPHTHAL EPIDEMIOL, V20, P335, DOI 10.3109/09286586.2013.823505
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
NR 20
TC 8
Z9 9
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2016
VL 134
IS 5
BP 571
EP 577
DI 10.1001/jamaophthalmol.2016.0588
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL7CB
UT WOS:000375796100023
PM 27055183
OA Bronze
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Figueroa, MS
   Araiz, J
   Ruiz-Moreno, JM
   Gomez-Ulla, F
   Arias-Barquet, L
   Reiter, N
AF Garcia-Layana, Alfredo
   Figueroa, Marta S.
   Araiz, Javier
   Ruiz-Moreno, Jose M.
   Gomez-Ulla, Francisco
   Arias-Barquet, Luis
   Reiter, Nicholas
TI Treatment of Exudative Age-related Macular Degeneration: Focus on
   Aflibercept
SO DRUGS & AGING
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR; SHORT-TERM
   EFFICACY; RETINAL ANGIOMATOUS PROLIFERATION; VERTEPORFIN PHOTODYNAMIC
   THERAPY; TREATMENT-NAIVE PATIENTS; VEGF TRAP-EYE; INTRAVITREAL
   AFLIBERCEPT; CLINICAL-PRACTICE; RANIBIZUMAB TREATMENT
AB A formulation of aflibercept for intravitreal injection (Eylea) is approved for the treatment of patients with exudative age-related macular degeneration (AMD). Aflibercept has a significantly higher affinity for Vascular endothelial growth factor (VEGF)-A compared with other monoclonal anti-VEGF antibodies. In addition to binding all VEGF-A isoforms, aflibercept also blocks other proangiogenic factors such as VEGF-B and placental growth factor. The VIEW 1 and 2 trials showed this drug achieves improved results in patients with exudative AMD similar to those obtained with monthly ranibizumab, using a bimonthly treatment regimen after a loading dose of three intravitreal injections, which translates to less use of healthcare resources. There is a subgroup of patients that present with persistent fluid after the loading dose that could benefit from monthly injections or personalized proactive treatment after the first year. In the second year of treatment, the Treat and Extend patterns can permit even more lengthening of the time between injections. More data are needed to confirm the optimal monitoring and retreatment dosing, to maintain long-term efficacy. Other preliminary data suggest that patients that do not respond to other anti-angiogenics and patients with special pathologies such as polypoidal choroidopathy or retinal angiomatous proliferation can improve upon switching to aflibercept. To date, the safety profile of aflibercept is excellent and is comparable to other anti-angiogenic treatments.
C1 [Garcia-Layana, Alfredo; Reiter, Nicholas] Univ Navarra Clin, Dept Ophthalmol, Navarra 31080, Spain.
   [Garcia-Layana, Alfredo; Figueroa, Marta S.; Araiz, Javier; Ruiz-Moreno, Jose M.; Gomez-Ulla, Francisco; Arias-Barquet, Luis] Inst Salud Carlos III, Red Temat Invest Cooperat Oftared, SERV, Madrid, Spain.
   [Figueroa, Marta S.] Hosp Univ Ramon & Cajal, Dept Retina & Vitreous, Vissum Madrid, Madrid, Spain.
   [Araiz, Javier] Hosp San Eloy, Ophthalmol Serv, Baracaldo, Bizcaia, Spain.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Clin Baviera, Inst Europeo Retina, Albacete, Spain.
   [Gomez-Ulla, Francisco] Inst Oftalmol Gomez Ulla, Santiago De Compostela, A Coruna, Spain.
   [Arias-Barquet, Luis] Hosp Univ Bellvitge, Ophthalmol Serv, Hosp Llobregat, Barcelona, Spain.
C3 University of Navarra; Instituto de Salud Carlos III; Hospital
   Universitario Ramon y Cajal; Universidad de Castilla-La Mancha; Institut
   d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University
   Hospital
RP Garcia-Layana, A (通讯作者)，Univ Navarra Clin, Dept Ophthalmol, Pio 12 36, Navarra 31080, Spain.
EM aglayana@unav.es
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
FU Instituto de Salud Carlos III [RD12/0034]; thel ISCIII-Subdireccion
   General de Redes y Centros de Investigacion Cooperativa; European
   Program FEDER; Ministerio de Economia y Competitividad, Spain; PN I +
   D+i; Age-Related Ocular Diseases, Quality of Life, and Vision
   [RD07-0062]
FX A. G. L., M. S. F., J. A., J. M. R. M., F. G. U., and L. A. B. received
   grants from the RETICs: RD07-0062: "Age-Related Ocular Diseases, Quality
   of Life, and Vision'', and RETICS OFTARED (RD12/0034) "Prevention, Early
   Detection, and Treatment of the Prevalent Degenerative and Chronic
   Ocular Pathology'' from the Instituto de Salud Carlos III from the
   Ministerio de Economia y Competitividad, Spain. This work has been
   partly funded by the PN I + D+i 2008-2011; thel ISCIII-Subdireccion
   General de Redes y Centros de Investigacion Cooperativa; and the
   European Program FEDER.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casaroli-Marano R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/346360
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cho Han Joo, 2012, Korean J Ophthalmol, V26, P157, DOI 10.3341/kjo.2012.26.3.157
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Frampton JE, 2012, DRUG AGING, V29, P839, DOI 10.1007/s40266-012-0015-2
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Garcia-Layana A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/595132
   Garcia-Layana A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/287893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gianniou C, 2015, EYE, V29, P450, DOI 10.1038/eye.2014.321
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Ijiri S, 2015, GRAEF ARCH CLIN EXP, V253, P351, DOI 10.1007/s00417-014-2707-2
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Khanani AM, 2015, CLIN OPHTHALMOL, V9, P1315, DOI 10.2147/OPTH.S88624
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Marques IR, 2013, OPHTHALMOLOGICA, V229, P158, DOI 10.1159/000343709
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Miura M, 2013, CLIN OPHTHALMOL, V7, P1591, DOI 10.2147/OPTH.S50634
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Noble J, 2010, CAN MED ASSOC J, V182, P1759, DOI 10.1503/cmaj.090378
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sainz-Gomez C, 2010, EUR J OPHTHALMOL, V20, P442, DOI 10.1177/112067211002000228
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sheibani Nader, 2013, J Ophthalmic Vis Res, V8, P1
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Thai HT, 2011, BRIT J CLIN PHARMACO, V72, P402, DOI 10.1111/j.1365-2125.2011.04015.x
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsaousis KT, 2015, GRAEF ARCH CLIN EXP, V253, P663, DOI 10.1007/s00417-014-2835-8
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Xu D, 2013, IMMUNOTHERAPY-UK, V5, P121, DOI [10.2217/IMT.12.158, 10.2217/imt.12.158]
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yonekawa Y, 2013, CAN J OPHTHALMOL, V48, pE59, DOI 10.1016/j.jcjo.2012.12.015
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 88
TC 18
Z9 20
U1 0
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD OCT
PY 2015
VL 32
IS 10
BP 797
EP 807
DI 10.1007/s40266-015-0300-y
PG 11
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA CT8KO
UT WOS:000363065500003
PM 26442858
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Awh, CC
   Lane, AM
   Hawken, S
   Zanke, B
   Kim, IK
AF Awh, Carl C.
   Lane, Anne-Marie
   Hawken, Steven
   Zanke, Brent
   Kim, Ivana K.
TI CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and
   Zinc in Patients with Age-related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; OXIDATIVE STRESS; CAROTENOIDS; ASSOCIATION
AB Objective: The Age-Related Eye Disease Study (AREDS) demonstrated that antioxidant and zinc supplementation decreases progression to advanced age-related macular degeneration (AMD) in patients with moderate to severe disease. We evaluated the interaction of genetics and type of nutritional supplement on progression from moderate to advanced AMD.
   Design: Genetic analysis of a randomized, prospective clinical trial.
   Participants: White patients with AREDS category 3 AMD in 1 eye and AREDS categories 1 through 4 AMD in the fellow eye enrolled in the AREDS with available peripheral blood-derived DNA (995).
   Methods: Subjects were evaluated for known AMD genetic risk markers and treatment category. The progression rate to advanced AMD was analyzed by genotypes and AREDS treatment group using Cox regression.
   Main Outcome Measures: The effect of inherited gene polymorphisms on treatment groupespecific rate of progression to advanced AMD.
   Results: Over an average of 10.1 years, individuals with 1 or 2 complement factor H (CFH) risk alleles derived maximum benefit from antioxidants alone. In these patients, the addition of zinc negated the benefits of antioxidants. Treatment with zinc and antioxidants was associated with a risk ratio (RR) of 1.83 with 2 CFH risk alleles (P=1.03E-02), compared with outcomes for patients without CFH risk alleles. Patients with age-related maculopathy sensitivity 2 (ARMS2) risk alleles derived maximum benefit from zinc-containing regimens, with a deleterious response to antioxidants in the presence of ARMS2 risk alleles. Treatment with antioxidants was associated with an RR of 2.58 for those with 1 ARMS2 risk allele and 3.96 for those with 2 ARMS2 risk alleles (P 1.04E-6), compared with patients with no ARMS2 risk alleles. Individuals homozygous for CFH and ARMS2 risk alleles derived no benefit from any category of AREDS treatment.
   Conclusions: Individuals with moderate AMD could benefit from pharmacogenomic selection of nutritional supplements. In this analysis, patients with no CFH risk alleles and with 1 or 2 ARMS2 risk alleles derived maximum benefit from zinc-only supplementation. Patients with one or two CFH risk alleles and no ARMS2 risk alleles derived maximum benefit from antioxidant-only supplementation; treatment with zinc was associated with increased progression to advanced AMD. These recommendations could lead to improved outcomes through genotype-directed therapy. (C) 2013 by the American Academy of Ophthalmology.
C1 [Awh, Carl C.] Tennessee Retina PC, Nashville, TN USA.
   [Lane, Anne-Marie; Kim, Ivana K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA USA.
   [Hawken, Steven] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Zanke, Brent] Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
   [Zanke, Brent] Univ Ottawa, Dept Med, Div Hematol, Ottawa, ON, Canada.
   [Zanke, Brent] Arctic Grp Co, Toronto, ON, Canada.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; University of Ottawa; Ottawa Hospital Research Institute;
   University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa
RP Zanke, B (通讯作者)，Arctic Diagnost Inc, 101 Coll St,Suite 335, Toronto, ON M5G 1L7, Canada.
EM Brent.zanke@arcticdx.com
OI Kim, Ivana/0000-0003-0310-6129
FU ArcticDx, Inc., Toronto, Canada
FX Supported by funding from ArcticDx, Inc., Toronto, Canada.
CR Abdi H., 2007, ENCY MEASUREMENT STA, V3, P103, DOI DOI 10.4135/9781412952644
   Bao B, 2010, AM J CLIN NUTR, V91, P1634, DOI 10.3945/ajcn.2009.28836
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Calder PC, 2009, BRIT J NUTR, V101, pS1, DOI 10.1017/S0007114509377867
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zambon A, 2003, CURR OPIN LIPIDOL, V14, P179, DOI 10.1097/00041433-200304000-00010
   Zar JH, 1999, BIOSTAT ANAL, P132
NR 27
TC 82
Z9 83
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2013
VL 120
IS 11
BP 2317
EP 2323
DI 10.1016/j.ophtha.2013.07.039
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FT
UT WOS:000326681700030
PM 23972322
DA 2022-11-30
ER

PT J
AU Wang, Y
   Wang, VM
   Chan, CC
AF Wang, Y.
   Wang, V. M.
   Chan, C-C
TI The role of anti-inflammatory agents in age-related macular degeneration
   (AMD) treatment
SO EYE
LA English
DT Review
DE age-related macular degeneration; inflammation; corticosteroid;
   nonsteoridal anti-inflammatory drug; immunosuppressant; biologics
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; CHLAMYDIA-PNEUMONIAE INFECTION;
   PIGMENT EPITHELIAL DETACHMENT; RANDOMIZED CLINICAL-TRIAL; PHOTODYNAMIC
   THERAPY; CHOROIDAL NEOVASCULARIZATION; TRIPLE THERAPY; COMPLEMENT;
   BEVACIZUMAB; INJECTION
AB Although age-related macular degeneration (AMD) is not a classic inflammatory disease like uveitis, inflammation has been found to have an important role in disease pathogenesis and progression. Innate immunity and autoimmune components, such as complement factors, chemokines, cytokines, macrophages, and ocular microglia, are believed to be heavily involved in AMD development. Targeting these specific inflammatory molecules has recently been explored in an attempt to better understand and treat AMD. Although antivascular endothelial growth factor therapy is the first line of defence against neovascular AMD, anti-inflammatory agents such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive agents (eg, methotrexate and rapamycin), and biologics (eg, infliximab, daclizumab, and complement inhibitors) may provide an adjunct or alternative mechanism to suppress the inflammatory processes driving AMD progression. Further investigation is required to evaluate the long-term safety and efficacy of these drugs for both neovascular and non-neovascular AMD. Eye (2011) 25, 127-139; doi: 10.1038/eye.2010.196; published online 24 December 2010
C1 [Wang, Y.; Wang, V. M.; Chan, C-C] NEI, Immunol Lab, Immunopathol Sect, NIH, Bethesda, MD 20892 USA.
   [Wang, Y.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Sun Yat Sen University
RP Chan, CC (通讯作者)，NEI, Immunol Lab, Immunopathol Sect, NIH, 10 Ctr Dr,10-10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI wang, yujuan/C-8428-2016
FU NEI; NATIONAL EYE INSTITUTE [ZIAEY000222, ZIAEY000418] Funding Source:
   NIH RePORTER
FX The NEI Intramural Research Program provided the funding support. Mrs
   Pamela Sieving provided helpful editing assistance.
CR Adjunctive Diclofenac with Verteporfin (ADD-V) Study Group, 2007, Retina, V27, P693
   Agurto-Rivera Ricardo, 2005, BMC Ophthalmol, V5, P27
   Apte RS, 2010, ADV EXP MED BIOL, V664, P15, DOI 10.1007/978-1-4419-1399-9_2
   Attur MG, 2000, INFLAMM RES, V49, P20, DOI 10.1007/PL00000199
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Baranano DE, 2009, BRIT J OPHTHALMOL, V93, P1387, DOI 10.1136/bjo.2009.157297
   Botting RM, 2010, PHARMACOL REP, V62, P518, DOI 10.1016/S1734-1140(10)70308-X
   Chakraborti AK, 2010, CURR MED CHEM, V17, P1563, DOI 10.2174/092986710790979980
   Chan A, 2009, OPHTHAL SURG LAS IM, V40, P561, DOI 10.3928/15428877-20091030-05
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   *CLINICALTRIALS, 2010, COMB RAN BROMF NEOV
   *CLINICALTRIALS, 2008, INTR INFL DIAB MAC E
   *CLINICALTRIALS, 2010, SIR TREAT GEOGR ATR
   *CLINICALTRIALS, 2009, COMPL INH EC TREATM
   *CLINICALTRIALS, 2010, SAF INTR POT 4 THER
   *CLINICALTRIALS, 2010, INTR AD PAT CHOR NEO
   *CLINICALTRIALS GO, 2010, NCT00304954 CLINICAL
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cronstein BN, 2005, PHARMACOL REV, V57, P163, DOI 10.1124/pr.57.2.3
   CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Francis BA, 1996, OPHTHALMOLOGY, V103, P1884, DOI 10.1016/S0161-6420(96)30411-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gamache DA, 2000, INFLAMMATION, V24, P357, DOI 10.1023/A:1007049015148
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Giganti M, 2010, RETINA-J RET VIT DIS, V30, P71, DOI 10.1097/IAE.0b013e3181bcef3b
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Gilson MM, 2007, OPHTHALMOLOGY, V114, P1713, DOI 10.1016/j.ophtha.2007.03.071
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Goebel J, 2000, TRANSPL IMMUNOL, V8, P153, DOI 10.1016/S0966-3274(00)00021-6
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Jermak CM, 2007, SURV OPHTHALMOL, V52, P503, DOI 10.1016/j.survophthal.2007.06.004
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jonas JB, 2007, EYE, V21, P387, DOI 10.1038/sj.eye.6702222
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Kalayoglu MV, 2007, CLIN EXP OPHTHALMOL, V35, P3, DOI 10.1111/j.1442-9071.2007.01432.x
   Kim SJ, 2010, SURV OPHTHALMOL, V55, P108, DOI 10.1016/j.survophthal.2009.07.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Komarowska I, 2009, RETINA-J RET VIT DIS, V29, P98, DOI 10.1097/IAE.0b013e31817d8c09
   KU EC, 1986, AM J MED, V80, P18, DOI 10.1016/0002-9343(86)90074-4
   Kurup SK, 2010, ACTA OPHTHALMOL, V88, pe145, DOI 10.1111/j.1755-3768.2009.01560.x
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lee J, 2007, RETINA-J RET VIT DIS, V27, P1205, DOI 10.1097/IAE.0b013e31815ec367
   Libondi T, 2010, ACTA OPHTHALMOL, V88, pe32, DOI 10.1111/j.1755-3768.2008.01491.x
   Lie S, 2010, ACTA OPHTHALMOL, V88, P212, DOI 10.1111/j.1755-3768.2008.01405.x
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   McDyer JF, 2002, J IMMUNOL, V169, P2736, DOI 10.4049/jimmunol.169.5.2736
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Mikuls Ted R, 2003, Curr Rheumatol Rep, V5, P270, DOI 10.1007/s11926-003-0005-9
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Miller Joan W, 2008, Trans Am Ophthalmol Soc, V106, P357
   Montesinos MC, 2007, ARTHRITIS RHEUM-US, V56, P1440, DOI 10.1002/art.22643
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Mottershead M, 2007, EXPERT OPIN BIOL TH, V7, P1583, DOI 10.1517/14712598.7.10.1583
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Nussenblatt RB, 2005, OPHTHALMOLOGY, V112, P764, DOI 10.1016/j.ophtha.2004.12.034
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pe'er J, 2009, OCUL IMMUNOL INFLAMM, V17, P299, DOI 10.3109/09273940903370755
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Phillips DC, 2003, BRIT J PHARMACOL, V138, P501, DOI 10.1038/sj.bjp.0705054
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Sfikakis PP, 2010, CURR DIR AUTOIMMUN, V11, P180, DOI 10.1159/000289205
   Shanmuganathan VA, 2005, BRIT J OPHTHALMOL, V89, P666, DOI 10.1136/bjo.2004.048199
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Snir M, 2000, OPHTHALMOLOGY, V107, P1884, DOI 10.1016/S0161-6420(00)00350-X
   Soheilian M, 2010, RETINA-J RET VIT DIS, V30, P509, DOI 10.1097/IAE.0b013e3181bdfa43
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Vane JR, 1998, AM J MED, V104, p2S, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Weber U, 2010, KLIN MONATSBL AUGENH, V227, P897, DOI 10.1055/s-0029-1245370
   WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303
   World Health Organization, 2009, VIS IMP BLINDN
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Zohlnhofer D, 2004, MOL PHARMACOL, V65, P880, DOI 10.1124/mol.65.4.880
   Zweifel SA, 2009, RETINA-J RET VIT DIS, V29, P1527, DOI 10.1097/IAE.0b013e3181b32f4c
NR 107
TC 97
Z9 106
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2011
VL 25
IS 2
BP 127
EP 139
DI 10.1038/eye.2010.196
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 719FR
UT WOS:000287187300001
PM 21183941
OA Green Published, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Wu, EW
   Schaumberg, DA
   Park, SK
AF Wu, Erin W.
   Schaumberg, Debra A.
   Park, Sung Kyun
TI Environmental cadmium and lead exposures and age-related macular
   degeneration in US adults: The National Health and Nutrition Examination
   Survey 2005 to 2008
SO ENVIRONMENTAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Cadmium; Lead; NHANES
ID URINARY CADMIUM; IRON; PATHOGENESIS; BLOOD; TOXICITY; SMOKING;
   ASSOCIATION; PREVALENCE; DISEASE; MELANIN
AB Age-related macular degeneration (AMD) is a complex disease resulting from the interplay of genetic predisposition and environmental exposures, and has been linked to oxidative stress and inflammatory mechanisms. Lead and cadmium can accumulate in human retinal tissues and may damage the retina through oxidative stress, and may thereby play a role in the development of AMD. We examined associations between blood lead, blood cadmium, and urinary cadmium concentrations and the presence of AMD in 5390 participants aged 40 years and older with blood lead and blood cadmium measures and a subsample of 1548 with urinary cadmium measures in the 2005-2008 National Health and Nutrition Examination Surveys. AMD was identified by grading retinal photographs with a modification of the Wisconsin Age-Related Maculopathy Grading System. The weighted prevalence of AMD was 6.6% (n=426). Controlling for age, gender, race/ethnicity, education and body mass index, adults in the highest blood cadmium quartile had higher odds of AMD compared to the lowest quartile (odds ratio [OR], 1.56; 95% CI, 1.02-2.40), with a significant trend across quartiles (p-trend =0.02). After further adjustment for pack-years of cigarette smoking, estimates were somewhat attenuated (OR, 1.43; 95% CI, 0.91-227; p-trend=0.08). Similar associations were found with urinary cadmium. The association between urinary cadmium and AMD was stronger in non-Hispanic whites (NHW) than in non-Hispanic blacks (NHB) (OR, 3.31; 95% CL 1.37-8.01 for levels above versus below the median among NHW; OR,1.45; 95% CI, 0.40-532 for levels above versus below the median among NHB; p-inter-action=0.03). We found no association between blood lead levels and AMD. Higher cadmium body burden may increase risk of AMD, particularly among non-Hispanic white individuals; however, additional studies are needed before firm conclusions can be drawn. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Wu, Erin W.; Park, Sung Kyun] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Schaumberg, Debra A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Ctr Translat Med, Salt Lake City, UT USA.
   [Park, Sung Kyun] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; Harvard
   University; Brigham & Women's Hospital; Harvard Medical School; Harvard
   University; Harvard T.H. Chan School of Public Health; Utah System of
   Higher Education; University of Utah; University of Michigan System;
   University of Michigan
RP Park, SK (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Epidemiol, SPH 2-M5541,1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM sungkyun@umich.edu
OI Park, Sung Kyun/0000-0001-9981-6250
FU National Institute of Environmental Health Sciences (NIEHS)
   [K01-ES016587]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [P30DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ENVIRONMENTAL HEALTH SCIENCES [K01ES016587, P30ES017885] Funding
   Source: NIH RePORTER
FX This study was supported by the National Institute of Environmental
   Health Sciences (NIEHS) Grant K01-ES016587.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   ATSDR, 2008, CAS STUD ENV MED CAD
   ATSDR (Agency for Toxic Substances and Disease Registry), 2008, TOX PROF CADM
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattacharyya M., 2000, MOL BIOL TOXICOLOGY
   Choi YH, 2012, ENVIRON HEALTH PERSP, V120, P1544, DOI 10.1289/ehp.1104863
   Choudhury H, 2001, J TOXICOL ENV HEAL A, V63, P321, DOI 10.1080/15287390152103643
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Eichenbaum JW, 2000, J TOXICOL-CLIN TOXIC, V38, P377, DOI 10.1081/CLT-100100946
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Gallagher CM, 2011, ENVIRON RES, V111, P702, DOI 10.1016/j.envres.2011.03.007
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hsu PC, 2002, TOXICOLOGY, V180, P33, DOI 10.1016/S0300-483X(02)00380-3
   Hu H, 2007, ENVIRON HEALTH PERSP, V115, P455, DOI 10.1289/ehp.9783
   Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Knol MJ, 2012, INT J EPIDEMIOL, V41, P514, DOI 10.1093/ije/dyr218
   National Centers for Health Statistics, 2005, NHANES OPHTH PROC MA
   National Centers for Health Statistics, 2005, NHANES LAB PROC MAN
   National Centers for Health Statistics, 2006, NHANES AN REP GUID
   National Centers for Health Statistics, 2007, NHANES LAB PROC MAN
   Navas-Acien A, 2009, AM J EPIDEMIOL, V170, P1156, DOI 10.1093/aje/kwp248
   Olsson IM, 2002, ENVIRON HEALTH PERSP, V110, P1185, DOI 10.1289/ehp.021101185
   POTTS AM, 1976, EXP EYE RES, V22, P487, DOI 10.1016/0014-4835(76)90186-X
   RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979
   Satarug S, 2010, ENVIRON HEALTH PERSP, V118, P182, DOI 10.1289/ehp.0901234
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H
   Tellez-Plaza M, 2012, ENVIRON HEALTH PERSP, V120, P204, DOI 10.1289/ehp.1104020
   Tellez-Plaza M, 2010, AM J EPIDEMIOL, V172, P671, DOI 10.1093/aje/kwq172
   ULSHAFER RJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P113, DOI 10.1001/archopht.1990.01070030119041
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wright RO, 2003, J PEDIATR-US, V142, P9, DOI 10.1067/mpd.2003.mpd0344
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 41
TC 38
Z9 39
U1 0
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0013-9351
EI 1096-0953
J9 ENVIRON RES
JI Environ. Res.
PD AUG
PY 2014
VL 133
BP 178
EP 184
DI 10.1016/j.envres.2014.05.023
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA AM2UI
UT WOS:000339705900024
PM 24959985
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tsao, SW
   Fong, DS
AF Tsao, Sean W.
   Fong, Donald S.
TI Do Statins Have a Role in the Prevention of Age-Related Macular
   Degeneration?
SO DRUGS & AGING
LA English
DT Article
ID C-REACTIVE PROTEIN; CHOLESTEROL-LOWERING MEDICATIONS; REDUCTASE
   INHIBITORS STATINS; CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE;
   RISK-FACTORS; OXIDATIVE STRESS; BRUCHS MEMBRANE; MACULOPATHY;
   PROGRESSION
AB Age-related macular degeneration (AMD) is a leading cause of blindness worldwide for which preventative therapies are few. Evidence suggesting shared common risk factors and mirrored pathophysiology between cardiovascular disease and AMID led to the hypothesis that hydroxymethylglutaryl-CoA reductase inhibitors (statins) could be helpful in preventing AMID. For over a decade, observational studies have repeatedly investigated this hypothesis with conflicting conclusions. Although many reports conclude that statin use has no effect on the risk of AMID, no randomized controlled trial has yet been completed. Furthermore, relatively few studies factor characteristics of statin use into their analysis. A few studies have observed an incompletely explained protective effect against drusen, a funduscopic finding associated with AMD. Although there is insufficient evidence for a preventive effect of statins on dry AMD, there does seem to be stronger evidence against any effect on the development of exudative AMID. Overall, we find that there is insufficient evidence to conclude whether statin use is helpful in preventing AMD.
C1 [Tsao, Sean W.; Fong, Donald S.] So Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Pk, CA 91101 USA.
C3 Kaiser Permanente; Southern California Permanente Medical Group (SCPMG);
   Permanente Medical Groups
RP Tsao, SW (通讯作者)，4950 West Sunset Blvd,Room 633, Los Angeles, CA 90027 USA.
EM Sean.Wade.Tsao@kp.org
CR Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brautbar A, 2011, NAT REV CARDIOL, V8, P253, DOI 10.1038/nrcardio.2011.2
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chuo JY, 2007, OPHTHAL EPIDEMIOL, V14, P367, DOI 10.1080/09286580701421684
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong DS, 2010, AM J OPHTHALMOL, V149, P955, DOI 10.1016/j.ajo.2009.12.037
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gehlbach P, 2012, COCHRANE DB SYST REV, V3
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Guymer RH, 2008, CLIN INTERV AGING, V3, P581
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ito MK, 2006, PHARMACOTHERAPY, V26, p85S, DOI 10.1592/phco.26.7part2.85S
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones PH, 2003, AM J CARDIOL, V92, P152, DOI 10.1016/S0002-9149(03)00530-7
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Klein R, 2004, AM J OPHTHALMOL, V137, P747, DOI 10.1016/j.ajo.2004.01.037
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Ridker PM, 2005, NEW ENGL J MED, V352, P20, DOI 10.1056/NEJMoa042378
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
   Venero CV, 2009, ENDOCRIN METAB CLIN, V38, P121, DOI 10.1016/j.ecl.2008.11.002
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2007, AM J OPHTHALMOL, V144, P117, DOI 10.1016/j.ajo.2007.04.018
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
NR 55
TC 13
Z9 13
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2013
VL 30
IS 4
BP 205
EP 213
DI 10.1007/s40266-013-0061-4
PG 9
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 138TR
UT WOS:000318533400001
PM 23423861
DA 2022-11-30
ER

PT J
AU Starr, MR
   Kung, FF
   Mejia, CA
   Bui, YT
   Bakri, SJ
AF Starr, Matthew R.
   Kung, Felix F.
   Mejia, Camilo A.
   Bui, Yvonne T.
   Bakri, Sophie J.
TI TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR
   DEGENERATION TREATED WITH INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH
   FACTOR INJECTIONS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-vascular endothelial growth
   factor; long-term outcomes; 10-year follow-up
ID LONG-TERM OUTCOMES; GEOGRAPHIC ATROPHY; PHOTODYNAMIC THERAPY;
   RANIBIZUMAB; EXTEND; VERTEPORFIN; RISK; AMD
AB Purpose: To identify the visual acuity outcomes of patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections over a 10-year period. Methods: This was a retrospective, cohort study of eyes with exudative age-related macular degeneration that received >= 2 intravitreal anti-vascular endothelial growth factor injections and had at least 10 years of follow-up after the initiation of treatment. Snellen visual acuity was recorded at baseline and then annually until the last year of follow-up. Optical coherence tomography data were collected at the time of treatment initiation and at the last examination visit. A subanalysis was performed on patients who continued to receive anti-vascular endothelial growth factor therapy using a modified treat and extend protocol versus those who discontinued treatment for longer than 1 year. Results: One hundred thirty eyes of 115 patients met the inclusion criteria. The mean follow-up after treatment initiation was 11.1 +/- 0.7 years. Eyes received an average of 45.1 +/- 32.3 intravitreal injections in total and a mean of 5 to 7 injections per year. The baseline mean logMAR visual acuity was 0.61 +/- 0.5 (Snellen acuity 20/81), and the final mean logMAR visual acuity was 0.88 +/- 0.7 (20/152,Pvalue = <0.0001). There were 40 eyes that received at least one injection every year. These eyes did not have a significant change in visual acuity between the baseline and final examinations 0.47 +/- 0.4 (20/59 vs. 0.58 +/- 0.5 [20/76,P= 0.28]), whereas the eyes that did not receive at least one injection every year saw a significant decline in visual acuity 0.67 +/- 0.5 (20/94 vs. 1.01 +/- 0.7 [20/205,P< 0.0001]). Conclusion: Eyes with exudative age-related macular degeneration that received intravitreal injections every year had stable visual acuity over a 10-year period. Continuous intravitreal anti-vascular endothelial growth factor therapy may stabilize visual acuity for 10 years and potentially longer.
C1 [Starr, Matthew R.; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
   [Kung, Felix F.; Mejia, Camilo A.; Bui, Yvonne T.] Mayo Clin, Alix Sch Med, Rochester, MN 55905 USA.
   [Bakri, Sophie J.] Genentech Inc, San Francisco, CA 94080 USA.
   [Bakri, Sophie J.] Roche, Basel, Switzerland.
   [Bakri, Sophie J.] Allergan, Dublin, Ireland.
   [Bakri, Sophie J.] Novartis, Basel, Switzerland.
C3 Mayo Clinic; Mayo Clinic; Roche Holding; Genentech; Roche Holding;
   AbbVie; Allergan
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
OI Starr, Matthew/0000-0002-3021-5630; Kung, Felix/0000-0002-9965-6434;
   Mejia, Camilo/0000-0001-8207-0747
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Amstutz CA, 2015, KLIN MONATSBL AUGENH, V232, P533, DOI 10.1055/s-0035-1545673
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atchison EA, 2017, RETINA-J RET VIT DIS, V37, P1371, DOI 10.1097/IAE.0000000000001372
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   Engman SJ, 2011, SEMIN OPHTHALMOL, V26, P380, DOI 10.3109/08820538.2011.622337
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Thalgott V, 2016, OPHTHALMOLOGE, V113, P668, DOI 10.1007/s00347-016-0228-6
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 27
TC 9
Z9 11
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2020
VL 40
IS 9
BP 1665
EP 1672
DI 10.1097/IAE.0000000000002668
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NQ9JY
UT WOS:000571183800005
PM 31725524
DA 2022-11-30
ER

PT J
AU Hadziahmetovic, M
   Malek, G
AF Hadziahmetovic, Majda
   Malek, Goldis
TI Age-Related Macular Degeneration Revisited: From Pathology and Cellular
   Stress to Potential Therapies
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE age-related macular degeneration; oxidative stress; retinal pigment
   epithelial (RPE); choroidal endothelial cells; therapy
AB Age-related macular degeneration (AMD) is a neurodegenerative disease of the aging retina, in which patients experience severe vision loss. Therapies available to patients are limited and are only effective in a sub-population of patients. Future comprehensive clinical care depends on identifying new therapeutic targets and adopting a multi-therapeutic approach. With this goal in mind, this review examines the fundamental concepts underlying the development and progression of AMD and re-evaluates the pathogenic pathways associated with the disease, focusing on the impact of injury at the cellular level, with the understanding that critical assessment of the literature may help pave the way to identifying disease-relevant targets. During this process, we elaborate on responses of AMD vulnerable cells, including photoreceptors, retinal pigment epithelial cells, microglia, and choroidal endothelial cells, based on in vitro and in vivo studies, to select stressful agents, and discuss current therapeutic developments in the field, targeting different aspects of AMD pathobiology.
C1 [Hadziahmetovic, Majda; Malek, Goldis] Duke Univ, Sch Med, Dept Ophthalmol, Duke Eye Ctr, Durham, NC 27707 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
C3 Duke University; Duke University
RP Hadziahmetovic, M; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Duke Eye Ctr, Durham, NC 27707 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
EM majda.hadziahmetovic@duke.edu; gmalek@duke.edu
OI Malek, Goldis/0000-0003-0026-2388
FU National Eye Institute [R01 EY027802, EY028160, P30 EY005722]; Research
   to Prevent Blindness, Inc. (RPB) Core grant
FX We thank our funding agencies, the National Eye Institute grants R01
   EY027802 (to GM), EY028160 (to GM), P30 EY005722 (to Duke Eye Center),
   and Research to Prevent Blindness, Inc. (RPB) Core grant (to Duke Eye
   Center). Figure 2 was created with BioRender.com.
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Balaiya S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3187594
   Balaiya S, 2013, MOL VIS, V19, P2385
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Benedetto MM, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00139
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bian MJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0516-8
   Biswas L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123740
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Calugaru D, 2019, AM J OPHTHALMOL, V198, P262, DOI 10.1016/j.ajo.2018.09.027
   Cao Y, 2015, BIOMED PHARMACOTHER, V69, P345, DOI 10.1016/j.biopha.2014.12.030
   Cascella R, 2018, EYE, V32, P446, DOI 10.1038/eye.2017.192
   Chen C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9899
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chen WJ, 2017, EXP EYE RES, V154, P151, DOI 10.1016/j.exer.2016.12.001
   Chen XP, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0019-6
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Choudhary M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186777
   Choudhury F, 2016, JAMA OPHTHALMOL, V134, P683, DOI 10.1001/jamaophthalmol.2016.0794
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crespo-Garcia S, 2015, EXP EYE RES, V139, P13, DOI 10.1016/j.exer.2015.07.012
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Edwards AO, 2006, OPHTHALMOLOGY, V113, P509, DOI 10.1016/j.ophtha.2006.01.018
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrer-Martin RM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135238
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Garcia-Ayuso D, 2018, NEURAL REGEN RES, V13, P1885, DOI 10.4103/1673-5374.239436
   Garcia-Ayuso D, 2015, INVEST OPHTH VIS SCI, V56, P4592, DOI 10.1167/iovs.15-16808
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hsu YJ, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080712
   Hurst J, 2017, ATLA-ALTERN LAB ANIM, V45, P11, DOI 10.1177/026119291704500105
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Kortuem K, 2000, INVEST OPHTH VIS SCI, V41, P3176
   Kraja AT, 2019, AM J HUM GENET, V104, P112, DOI 10.1016/j.ajhg.2018.12.001
   Lajko M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180384
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Luo J, 2020, AGEING RES REV, V57, DOI 10.1016/j.arr.2019.100982
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Maliha AM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41113-4
   Mann SS, 2011, GRAEF ARCH CLIN EXP, V249, P209, DOI 10.1007/s00417-010-1483-x
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Moreira-Neto CA, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8125267
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nakatake S, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87781
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Pietrucha-Dutczak M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00834
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Rashid Khalid, 2019, Front Immunol, V10, P1975, DOI 10.3389/fimmu.2019.01975
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Rivera JC, 2013, ARTERIOSCL THROM VAS, V33, P1881, DOI 10.1161/ATVBAHA.113.301331
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Santiago AR, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/465694
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scholl HPN, 2005, OPHTHALMOLOGE, V102, P1029, DOI 10.1007/s00347-005-1270-y
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Sharma A, 2020, EYE, V34, P797, DOI 10.1038/s41433-019-0607-8
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Sparrow JR, 2012, ADV EXP MED BIOL, V723, P761, DOI 10.1007/978-1-4614-0631-0_97
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strauss O, 2016, EUR J PHARMACOL, V787, P84, DOI 10.1016/j.ejphar.2016.03.066
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsuruma K, 2012, J PHARMACOL SCI, V118, P351, DOI 10.1254/jphs.11110FP
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang HB, 2016, MOL VIS, V22, P116
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu TH, 2005, INVEST OPHTH VIS SCI, V46, P1117, DOI 10.1167/iovs.04-0517
   Yang Benjamin, 2004, Discov Med, V4, P79
   Yang L, 2009, ARCH OPHTHALMOL-CHIC, V127, P1475, DOI 10.1001/archophthalmol.2009.288
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yoon KD, 2011, MOL VIS, V17, P1839
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou YD, 2017, MOL MED REP, V15, P3949, DOI 10.3892/mmr.2017.6491
NR 149
TC 19
Z9 19
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JAN 25
PY 2021
VL 8
AR 612812
DI 10.3389/fcell.2020.612812
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA QD9GJ
UT WOS:000615818000001
PM 33569380
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Malek, G
   Lad, EM
AF Malek, Goldis
   Lad, Eleonora M.
TI Emerging roles for nuclear receptors in the pathogenesis of age-related
   macular degeneration
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Drusen; Geographic atrophy; Choroidal neovascularization; Transcription
   factors; Aryl hydrocarbon receptor; Liver X receptors; Peroxisome
   proliferator-activated receptors; Retinoid X receptors
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; SUBRETINAL DRUSENOID
   DEPOSITS; POLYUNSATURATED FATTY-ACIDS; ENDOTHELIAL GROWTH-FACTOR;
   GENOME-WIDE ASSOCIATION; BASAL LAMINAR DEPOSIT; C-REACTIVE PROTEIN;
   RETICULAR PSEUDODRUSEN; DIETARY-FAT
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly in the Western world. Over the last 30 years, our understanding of the pathogenesis of the disease has grown exponentially thanks to the results of countless epidemiology, genetic, histological, and biochemical studies. This information, in turn, has led to the identification of multiple biologic pathways potentially involved in development and progression of AMD, including but not limited to inflammation, lipid and extracellular matrix dysregulation, and angiogenesis. Nuclear receptors are a superfamily of transcription factors that have been shown to regulate many of the pathogenic pathways linked with AMD and as such they are emerging as promising targets for therapeutic intervention. In this review, we will present the fundamental phenotypic features of AMD and discuss our current understanding of the pathobiological disease mechanisms. We will introduce the nuclear receptor superfamily and discuss the current literature on their effects on AMD-related pathophysiology.
C1 [Malek, Goldis; Lad, Eleonora M.] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27710 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, 2351 Erwin Rd,AERI Room 4006, Durham, NC 27710 USA.
EM gmalek@duke.edu
OI Malek, Goldis/0000-0003-0026-2388
FU US National Eye Institute [EY02868, 5K12EY016333-08, P30 EY005722];
   Research to Prevent Blindness, Inc. (RPB) Sybil B. Harrington Scholars
   Award; Research to Prevent Blindness, Inc. (RPB); NATIONAL EYE INSTITUTE
   [K12EY016333, R01EY020868, P30EY005722] Funding Source: NIH RePORTER
FX Sincere thanks to the North Carolina Eye Bank, the Alabama Eye Bank, the
   eye donors and their families for their generosity to our group, and
   others, allowing us and other researchers to collectively understand the
   disease through their eyes. We would like to thank Mr. Steven Conlon for
   designing the artwork presented in Fig. 1. This work was supported by
   the US National Eye Institute grants EY02868 (GM), 5K12EY016333-08 (EL),
   and P30 EY005722 (Duke University), and the Research to Prevent
   Blindness, Inc. (RPB) Sybil B. Harrington Scholars Award (GM) and a RPB
   Core grant to the Duke Eye Center.
CR Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200
   ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson RE, 2004, LIPIDS, V39, P1121, DOI 10.1007/s11745-004-1338-8
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Ayalasomayajula SP, 2009, J OCUL PHARMACOL TH, V25, P97, DOI 10.1089/jop.2008.0090
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   BOULTON M, 1986, GRAEF ARCH CLIN EXP, V224, P106, DOI 10.1007/BF02141479
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Caicedo A, 2005, J COMP NEUROL, V483, P263, DOI 10.1002/cne.20413
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Calder PC, 2001, WORLD REV NUTR DIET, V88, P109
   Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197
   Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chang JY, 2008, PPAR RES, V2008, DOI 10.1155/2008/720163
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Cheng HC, 2008, MOL VIS, V14, P95
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697
   Crunkhorn S, 2012, NAT REV DRUG DISCOV, V11, P271, DOI 10.1038/nrd3706
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dentchev T, 2003, MOL VIS, V9, P184
   Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elliot S, 2008, EXP EYE RES, V86, P653, DOI 10.1016/j.exer.2008.01.010
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hatanaka H, 2012, INVEST OPHTH VIS SCI, V53, P6955, DOI 10.1167/iovs.12-10488
   HE SK, 1994, CURR EYE RES, V13, P257, DOI 10.3109/02713689408995786
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hughes DA, 1996, BIOCHEM SOC T, V24, pS389, DOI 10.1042/bst024389s
   Hughes DA, 1996, J NUTR, V126, P603, DOI 10.1093/jn/126.3.603
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang Q, 2008, NEURON, V58, P681, DOI 10.1016/j.neuron.2008.04.010
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Koldamova R, 2007, CURR ALZHEIMER RES, V4, P171, DOI 10.2174/156720507780362227
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kurakula K, 2013, MOL CELL ENDOCRINOL, V368, P71, DOI 10.1016/j.mce.2012.05.014
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288
   Lee TW, 2003, EUR J CANCER, V39, P1296, DOI 10.1016/S0959-8049(02)00733-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin FJ, 2011, ENDOCR REV, V32, P404, DOI 10.1210/er.2010-0021
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luostarinen R, 1996, PROSTAG LEUKOTR ESS, V55, P167, DOI 10.1016/S0952-3278(96)90093-9
   Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2010, ADV EXP MED BIOL, V664, P429, DOI 10.1007/978-1-4419-1399-9_49
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/en.143.7.2461
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mukundan L, 2009, NAT MED, V15, P1266, DOI 10.1038/nm.2048
   Mukutmoni-Norris M, 2000, CANCER LETT, V150, P101, DOI 10.1016/S0304-3835(99)00380-8
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rodrigues GA, 2011, INVEST OPHTH VIS SCI, V52, P890, DOI 10.1167/iovs.10-5715
   RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   SEDDON JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P176, DOI 10.1001/archopht.1994.01090140052021
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Sohrab MA, 2011, SEMIN OPHTHALMOL, V26, P156, DOI 10.3109/08820538.2011.570848
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, DNA CELL BIOL, V21, P453, DOI 10.1089/10445490260099746
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vandevyver S, 2013, ENDOCRINOLOGY, V154, P993, DOI 10.1210/en.2012-2045
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Willermain F, 2006, PROSTAG OTH LIPID M, V80, P136, DOI 10.1016/j.prostaglandins.2006.06.001
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zelcer N, 2007, P NATL ACAD SCI USA, V104, P10601, DOI 10.1073/pnas.0701096104
   Zhao B, 2006, BRIT J OPHTHALMOL, V90, P1052, DOI 10.1136/bjo.2006.091215
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 199
TC 35
Z9 35
U1 0
U2 16
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2014
VL 71
IS 23
BP 4617
EP 4636
DI 10.1007/s00018-014-1709-x
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AT6ZG
UT WOS:000345085000011
PM 25156067
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Meng, LH
   Chen, YX
AF Meng, Li-Hui
   Chen, You-Xin
TI Lipid accumulation and protein modifications of Bruch's membrane in
   age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Bruch's membrane; lipid accumulation; protein modifications; therapy
ID RETINAL-PIGMENT EPITHELIUM; HONEYCOMB POROUS FILMS; RISK-FACTORS;
   FIBRONECTIN; GLYCATION; STATIN; RPE; GLYCOLALDEHYDE; DEPOSITION;
   PARTICLES
AB Age-related macular degeneration (AMD) is a progressive retinal disease, which is the leading cause of blindness in western countries. There is an urgency to establish new therapeutic strategies that could prevent or delay the progression of AMD more efficiently. Until now, the pathogenesis of AMD has remained unclear, limiting the development of the novel therapy. Bruch's membrane (BM) goes through remarkable changes in AMD, playing a significant role during the disease course. The main aim of this review is to present the crucial processes that occur at the level of BM, with special consideration of the lipid accumulation and protein modifications. Besides, some therapies targeted at these molecules and the construction of BM in tissue engineering of retinal pigment epithelium (RPE) cells transplantation were listed. Hopefully, this review may provide a reference for researchers engaged in pathogenesis or management on AMD.
C1 [Meng, Li-Hui; Chen, You-Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Meng, Li-Hui; Chen, You-Xin] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Ocular Fundus Dis, Beijing 100730, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College
RP Chen, YX (通讯作者)，Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
RI meng, li/GVT-2063-2022
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bowden JA, 2017, J LIPID RES, V58, P2275, DOI 10.1194/jlr.M079012
   Calejo MT, 2017, ACTA BIOMATER, V54, P138, DOI 10.1016/j.actbio.2017.02.035
   Calejo MT, 2016, J BIOMED MATER RES A, V104, P1646, DOI 10.1002/jbm.a.35690
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deng HT, 2006, RAPID COMMUN MASS SP, V20, P3634, DOI 10.1002/rcm.2776
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Girgis RAM, 2004, AM J OPHTHALMOL, V138, P697, DOI 10.1016/j.ajo.2004.05.063
   Goffin AJJ, 2010, LANGMUIR, V26, P3514, DOI 10.1021/la9031317
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Gupta T, 2017, J HISTOCHEM CYTOCHEM, V65, P567, DOI 10.1369/0022155417726507
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Kaiserman N, 2009, CURR EYE RES, V34, P304, DOI 10.1080/02713680902741670
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kucukevcilioglu M, 2016, INT OPHTHALMOL, V36, P569, DOI 10.1007/s10792-015-0164-5
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Mao Y, 2005, J CELL SCI, V118, P4427, DOI 10.1242/jcs.02566
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Miller CG, 2017, EXP BIOL MED, V242, P1, DOI 10.1177/1535370216675245
   Miller CG, 2014, MOL BIOL CELL, V25, P2342, DOI 10.1091/mbc.E14-03-0800
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Murdaugh LS, 2009, EXP EYE RES, V89, P187, DOI 10.1016/j.exer.2009.03.021
   Naahidi S, 2017, BIOTECHNOL ADV, V35, P530, DOI 10.1016/j.biotechadv.2017.05.006
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Ooi KGJ, 2019, SURV OPHTHALMOL, V64, P401, DOI 10.1016/j.survophthal.2019.01.013
   Proulx S, 2003, MOL VIS, V9, P473
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Tan YSE, 2018, BRIT J OPHTHALMOL, V102, P1182, DOI 10.1136/bjophthalmol-2017-311390
   Thao MT, 2018, NITRIC OXIDE-BIOL CH, V79, P51, DOI 10.1016/j.niox.2018.07.006
   Thao MT, 2016, AMINO ACIDS, V48, P1631, DOI 10.1007/s00726-016-2222-3
   Thao MT, 2014, PHOTOCHEM PHOTOBIOL, V90, P329, DOI 10.1111/php.12200
   Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Velazquez-Villoria A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162296
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Wenick AS, 2018, RYANS RETINA, P1293
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu WC, 2014, KAOHSIUNG J MED SCI, V30, P1, DOI 10.1016/j.kjms.2013.06.002
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 70
TC 2
Z9 2
U1 1
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAY 18
PY 2021
VL 14
IS 5
BP 766
EP 773
DI 10.18240/ijo.2021.05.19
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RU3OH
UT WOS:000645058100019
PM 34012894
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Heier, JS
   Kherani, S
   Desai, S
   Dugel, P
   Kaushal, S
   Cheng, SH
   Delacono, C
   Purvis, A
   Richards, S
   Le-Halpere, A
   Connelly, J
   Wadsworth, SC
   Varona, R
   Buggage, R
   Scaria, A
   Campochiaro, PA
AF Heier, Jeffrey S.
   Kherani, Saleema
   Desai, Shilpa
   Dugel, Pravin
   Kaushal, Shalesh
   Cheng, Seng H.
   Delacono, Cheryl
   Purvis, Annie
   Richards, Susan
   Le-Halpere, Annaig
   Connelly, John
   Wadsworth, Samuel C.
   Varona, Rafael
   Buggage, Ronald
   Scaria, Abraham
   Campochiaro, Peter A.
TI Intravitreous injection of AAV2-sFLT01 in patients with advanced
   neovascular age-related macular degeneration: a phase 1, open-label
   trial
SO LANCET
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; EPITHELIUM-DERIVED FACTOR; GENE-THERAPY;
   CHOROIDAL NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; INHIBITION;
   VEGF; VECTORS; RANIBIZUMAB; SFLT-1
AB Background Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerability of a single intravitreous injection of an AAV2 vector expressing the VEGF-neutralising protein sFLT01 in patients with advanced neovascular age-related macular degeneration.
   Methods This was a phase 1, open-label, dose-escalating study done at four outpatient retina clinics in the USA. Patients were assigned to each cohort in order of enrolment, with the first three patients being assigned to and completing the first cohort before filling positions in the following treatment groups. Patients aged 50 years or older with neovascular age-related macular degeneration and a baseline best-corrected visual acuity score of 20/100 or less in the study eye were enrolled in four dose-ranging cohorts (cohort 1, 2 x 10(8) vector genomes (vg); cohort 2, 2 x 100. vg; cohort 3, 6 x 10(9). vg; and cohort 4, 2 x 10(10).vg, n=3 per cohort) and one maximum tolerated dose cohort (cohort 5, 2 x 10 1.vg, n=7) and followed up for 52 weeks. The primary objective of the study was to assess the safety and tolerability of a single intravitreous injection of AAV2-sFLT01, through the measurement of eye-related adverse events. This trial is registered with ClinicalTrials.gov, number NCT01024998.
   Findings 19 patients with advanced neovascular age-related macular degeneration were enrolled in the study between May 18, 2010, and July 14, 2014. All patients completed the 52-week trial period. Two patients in cohort 4 (2 x 10 1.vg) experienced adverse events that were possibly study-drug related: pyrexia and intraocular inflammation that resolved with a topical steroid. Five of ten patients who received 2 x 10 1.vg had aqueous humour concentrations of sFLT01 that peaked at 32.7-112.0 ng/mL (mean 73.7 ng/mL, SD 30.5) by week 26 with a slight decrease to a mean of 53.2 ng/mL at week 52 (SD 17.1). At baseline, four of these five patients were negative for anti-AAV2 serum antibodies and the fifth had a very low titre (1: 100) of anti-AAV2 antibodies, whereas four of the five non-expressers of sFLT01 had titres of 1: 400 or greater. In 11 of 19 patients with intraretinal or subretinal fluid at baseline judged to be reversible, six showed substantial fluid reduction and improvement in vision, whereas five showed no fluid reduction. One patient in cohort 5 showed a large decrease in vision between weeks 26 and 52 that was not thought to be vector-related.
   Interpretation Intravitreous injection of AAV2-sFLT01 seemed to be safe and well tolerated at all doses. Additional studies are needed to identify sources of variability in expression and anti-permeability activity, including the potential effect of baseline anti-AAV2 serum antibodies.
C1 [Heier, Jeffrey S.; Desai, Shilpa] Ophthalm Consultants Boston, Boston, MA USA.
   [Kherani, Saleema; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Kherani, Saleema; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Dugel, Pravin] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Kaushal, Shalesh] Univ Massachusetts, Med Ctr, Worcester, MA USA.
   [Cheng, Seng H.; Delacono, Cheryl; Purvis, Annie; Richards, Susan; Le-Halpere, Annaig; Connelly, John; Wadsworth, Samuel C.; Varona, Rafael; Buggage, Ronald; Scaria, Abraham] Sanofi Genzyme, Cambridge, MA USA.
C3 Ophthalmic Consultants of Boston; Johns Hopkins University; Johns
   Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine;
   University of Massachusetts System; University of Massachusetts
   Worcester; Sanofi-Aventis; Genzyme Corporation
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI Cheng, Seng H/AAC-6564-2022; Kherani, Saleema/AAD-8723-2019
FU Genzyme Corporation, Framingham, Massachusetts, USA
FX This study was fundede by Genzyme Corporation, Framingham,
   Massachusetts, USA
CR Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08
   Dinculescu A, 2005, HUM GENE THER, V16, P649, DOI 10.1089/hum.2005.16.649
   Early Treatment Diabetic Retinopathy Study research group, ARCH OPHTHALMOL
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Ivanova E, 2010, INVEST OPHTH VIS SCI, V51, P5288, DOI 10.1167/iovs.10-5389
   Kotterman MA, 2015, GENE THER, V22, P116, DOI 10.1038/gt.2014.115
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Li QH, 2008, MOL VIS, V14, P1760
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Maguire AM, 2008, N ENGL J MED
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Yin L, INVEST OPHTHALMOL VI
NR 29
TC 117
Z9 124
U1 3
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 1
PY 2017
VL 390
IS 10089
BP 50
EP 61
DI 10.1016/S0140-6736(17)30979-0
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EZ0LK
UT WOS:000404396300027
PM 28526489
DA 2022-11-30
ER

PT J
AU Hsu, J
   Patel, SN
   Wolfe, JD
   Shah, CP
   Chen, E
   Jenkins, TL
   Wibbelsman, TD
   Obeid, A
   Mikhail, M
   Garg, SJ
   Ho, AC
   Chiang, A
   Spirn, MJ
   Vander, JF
AF Hsu, Jason
   Patel, Samir N.
   Wolfe, Jeremy D.
   Shah, Chirag P.
   Chen, Eric
   Jenkins, Thomas L.
   Wibbelsman, Turner D.
   Obeid, Anthony
   Mikhail, Mikel
   Garg, Sunir J.
   Ho, Allen C.
   Chiang, Allen
   Spirn, Marc J.
   Vander, James F.
TI Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular
   Age-Related Macular Degeneration A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SYSTEMIC BETA-BLOCKERS; ADRENERGIC SYSTEM; MOUSE MODEL; RANIBIZUMAB;
   PHARMACOKINETICS; BEVACIZUMAB; RELEVANT; EFFICACY; THERAPY; EDEMA
AB Question How does topical dorzolamide-timolol affect eyes with neovascular age-related macular degeneration with persistent exudation following frequent fixed-interval intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections? Findings In this randomized clinical trial, among 50 patients with neovascular age-related macular degeneration receiving frequent anti-VEGF injections, those randomized to use topical dorzolamide-timolol had no better vision compared with placebo but had a greater reduction in central subfield thickness and maximum pigment epithelial detachment height from baseline to approximately 3 months. Meaning These findings suggest adjuvant dorzolamide-timolol reduces macular edema in patients with persistent exudation following frequent anti-VEGF injections, although no differences in visual acuity were identified in this short-term trial.
   This randomized clinical trial compares the short-term effect of topical dorzolamide-timolol vs placebo in eyes with neovascular age-related macular degeneration that have persistent exudation following intravitreal anti-vascular endothelial growth factor injections.
   Importance Some eyes with neovascular age-related macular degeneration (AMD) have persistent exudation despite frequent intravitreal anti-vascular endothelial growth factor (VEGF) injections. Adjuvant therapies that further reduce edema may improve vision outcomes. Objective To compare the short-term effect of topical dorzolamide-timolol vs placebo in eyes with neovascular AMD that have persistent exudation following intravitreal anti-VEGF injections. Design, Setting, and Participants Randomized placebo-controlled clinical trial with enrollment from March 1, 2017, through October 30, 2018. Multicenter trial at 4 clinical sites in the United States. Sixty-three patients with neovascular AMD who had persistent exudation despite intravitreal anti-VEGF injections at 4-week, 5-week, or 6-week intervals. Interventions Patients were randomized to use dorzolamide-timolol or artificial tears for the study duration. They continued to receive the same anti-VEGF drug at the same interval as the 2 visits before enrollment for 3 additional study visits. Main Outcomes and Measures The primary outcome measure was change in mean central subfield thickness on optical coherence tomography from baseline to visit 3 (approximately 3 months). Secondary measures included change in mean maximum subretinal fluid height, mean maximum pigment epithelial detachment height, and mean visual acuity (VA). Results This trial included 52 patients. All 27 patients (100%) assigned to dorzolamide-timolol and 23 of 25 (92%) assigned to placebo were analyzed for the primary outcome. Mean (SD) age was 78.4 (7) years, and 34 of 50 patients (68%) were women. Mean (SD) injections were 20.5 (14) (range, 4-58) before enrollment. Mean (SD) baseline logMAR VA was 0.361 (0.26) (approximate Snellen equivalent, 20/50). Comparing the dorzolamide-timolol with placebo group from baseline to visit 3, mean (SD) change in central subfield thickness (primary outcome) was -36.6 (54) mu m vs 1.7 (52.3) mu m (difference, 30.8; 95% CI, 0.3-61.3; P = .04); secondary outcomes: maximum PED height was -39.1 (65) mu m vs 1.1 (16) mu m (difference, 39.6; 95% CI, 9.6-69.6; P = .01) and change in VA from baseline to visit 3 was -2.3 (5) vs 0.3 (1) letters (difference, 2.6 letters; 95% CI, -1.9 to 7.1 letters; P = .78). Conclusions and Relevance These findings suggest use of dorzolamide-timolol in patients with neovascular AMD with persistent exudation resulted in anatomic but not visual acuity improvements compared with placebo at approximately 3 months. Additional clinical trials with longer follow-up and larger sample sizes presumably would be needed to determine the role, if any, of dorzolamide-timolol in neovascular AMD.
C1 [Hsu, Jason; Patel, Samir N.; Jenkins, Thomas L.; Wibbelsman, Turner D.; Obeid, Anthony; Garg, Sunir J.; Ho, Allen C.; Chiang, Allen; Spirn, Marc J.; Vander, James F.] Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
   [Wolfe, Jeremy D.; Mikhail, Mikel] William Beaumont Hosp, Associated Retinal Consultants, Royal Oak, MI 48072 USA.
   [Shah, Chirag P.] Ophthalm Consultants Boston, Boston, MA USA.
   [Chen, Eric] Retina Consultants Houston, Houston, TX USA.
C3 Jefferson University; Beaumont Health; Ophthalmic Consultants of Boston
RP Hsu, J (通讯作者)，Wills Eye Hosp & Res Inst, Mid Atlantic Retina, Retina Serv, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
EM jhsu@midatlanticretina.com
OI Wolfe, Jeremy/0000-0003-2781-7152; Ho, Allen/0000-0003-3921-608X
FU J. Arch McNamara Retina Research Fund of Willis Eye Hospital
FX This study received funding from the J. Arch McNamara Retina Research
   Fund of Willis Eye Hospital.
CR Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brubaker RF, 2000, OPHTHALMOLOGY, V107, P283, DOI 10.1016/S0161-6420(99)00044-5
   Byeon SH, 2009, GRAEF ARCH CLIN EXP, V247, P35, DOI 10.1007/s00417-008-0917-1
   Casini G, 2014, PROG RETIN EYE RES, V42, P103, DOI 10.1016/j.preteyeres.2014.06.001
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Genead MA, 2012, RETINA-J RET VIT DIS, V32, P826, DOI 10.1097/IAE.0b013e3182215ae9
   Genead MA, 2010, ARCH OPHTHALMOL-CHIC, V128, P190, DOI 10.1001/archophthalmol.2009.398
   Grover S, 2006, AM J OPHTHALMOL, V141, P850, DOI 10.1016/j.ajo.2005.12.030
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Harris A, 2003, BRIT J OPHTHALMOL, V87, P753, DOI 10.1136/bjo.87.6.753
   Harris A, 2001, AM J OPHTHALMOL, V132, P490, DOI 10.1016/S0002-9394(01)01158-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Lee JH, 2019, RETINA-J RET VIT DIS, V39, P1953, DOI 10.1097/IAE.0000000000002293
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martini D, 2011, J NEUROCHEM, V119, P1317, DOI 10.1111/j.1471-4159.2011.07530.x
   Montero JA, 2013, RETINA-J RET VIT DIS, V33, P508, DOI 10.1097/IAE.0b013e3182695ba0
   Noergaard MH, 2008, INVEST OPHTH VIS SCI, V49, P1136, DOI 10.1167/iovs.07-0508
   Pikkel J, 2002, OPHTHALMOLOGY, V109, P1723, DOI 10.1016/S0161-6420(02)01157-0
   Rahimy E, 2019, RETINA-J RET VIT DIS, V39, P636, DOI [10.1097/IAE.000000000002124, 10.1097/IAE.0000000000002124]
   Ristori C, 2011, INVEST OPHTH VIS SCI, V52, P155, DOI 10.1167/iovs.10-5536
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sridhar J, 2016, JAMA OPHTHALMOL, V134, P437, DOI 10.1001/jamaophthalmol.2016.0045
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Terashima H, 1996, JPN J OPHTHALMOL, V40, P142
   Traband A, 2017, RETINA-J RET VIT DIS, V37, P41, DOI 10.1097/IAE.0000000000001226
NR 33
TC 4
Z9 4
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2020
VL 138
IS 5
BP 560
EP 567
DI 10.1001/jamaophthalmol.2020.0724
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LS2QZ
UT WOS:000536235300021
PM 32239190
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Koh, AHC
   Chen, LJ
   Chen, SJ
   Chen, YX
   Giridhar, A
   Iida, T
   Kim, H
   Lai, TYY
   Lee, WK
   Li, XX
   Lim, TH
   Ruamviboonsuk, P
   Sharma, T
   Tang, SB
   Yuzawa, M
AF Koh, Adrian H. C.
   Chen, Lee-Jen
   Chen, Shih-Jen
   Chen, Youxin
   Giridhar, Anantharam
   Iida, Tomohiro
   Kim, Hakyoung
   Lai, Timothy Yuk Yau
   Lee, Won Ki
   Li, Xiaoxin
   Lim, Tock Han
   Ruamviboonsuk, Paisan
   Sharma, Tarun
   Tang, Shibo
   Yuzawa, Mitsuko
CA Expert PCV Panel
TI POLYPOIDAL CHOROIDAL VASCULOPATHY Evidence-Based Guidelines for Clinical
   Diagnosis and Treatment
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE indocyanine green angiography; pigment epithelium detachment; polypoidal
   choroidal vasculopathy; ranibizumab; verteporfin PDT
ID INDOCYANINE GREEN ANGIOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN
   PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB INJECTION; PIGMENT
   EPITHELIAL DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY; BRANCHING VASCULAR
   NETWORKS; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; LASER
   PHOTOCOAGULATION
AB Background: Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy affecting vision, with clinical features distinct from neovascular age-related macular degeneration. Currently, no evidence-based guidelines exist for its diagnosis and treatment.
   Methods: A panel of experts analyzed a systematic literature search on PCV together with results of the EVEREST trial, the only published randomized controlled clinical trial in PCV. At a subsequent Roundtable meeting, recommendations for the management of PCV were agreed based on this analysis and their own expert opinion.
   Results: Diagnosis of PCV should be based on early-phase nodular hyperfluorescence from choroidal vasculature visualized using indocyanine green angiography. Recommended initial treatment of juxtafoveal and subfoveal PCV is either indocyanine green angiography-guided verteporfin photodynamic therapy or verteporfin photodynamic therapy plus 3 x 0.5 mg ranibizumab intravitreal injections 1 month apart. If there is incomplete regression of polyps by indocyanine green angiography, eyes should be retreated with verteporfin photodynamic therapy monotherapy or verteporfin photodynamic therapy plus ranibizumab. If there is complete regression of polyps by indocyanine green angiography, but there is leakage on fluorescein angiography and other clinical or anatomical signs of disease activity, eyes should be retreated with ranibizumab.
   Conclusion: Practical guidance on the clinical management of PCV is proposed based on expert evaluation of current evidence. RETINA 33:686-716, 2013
C1 [Chen, Lee-Jen] Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Chen, Shih-Jen] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 112, Taiwan.
   [Chen, Youxin] Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Giridhar, Anantharam] Giridhar Eye Inst, Kochi, Kerala, India.
   [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
   [Iida, Tomohiro] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Kim, Hakyoung] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Seoul, South Korea.
   [Lee, Won Ki] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
   [Li, Xiaoxin] Catholic Univ Korea, Seoul St Marys Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lim, Tock Han] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Sharma, Tarun] Sankara Nethralaya, Madras, Tamil Nadu, India.
   [Tang, Shibo] Sun Yat Sen Univ, Zhong Shan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
   [Yuzawa, Mitsuko] Surugadai Nihon Univ, Dept Ophthalmol, Chiyoda Ku, Tokyo, Japan.
C3 Mackay Memorial Hospital; National Yang Ming Chiao Tung University;
   Taipei Veterans General Hospital; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Peking Union Medical College Hospital;
   Tokyo Women's Medical University; Fukushima Medical University; Hallym
   University; Chinese University of Hong Kong; Catholic University of
   Korea; Seoul St. Mary's Hospital; Peking University; Tan Tock Seng
   Hospital; Rajavithi Hospital; Sun Yat Sen University
RP Koh, AHC (通讯作者)，Camden Med Ctr, 1 Orchard Blvd, Singapore 248649, Singapore.
EM ahckoh@yahoo.com
RI Lai, Timothy Y Y/AAC-2120-2020; TANG, Shi/GXH-5719-2022
OI Lai, Timothy Y Y/0000-0002-7832-6428; 
FU College of Ophthalmologists, Singapore
FX The authors would like to acknowledge the contribution of Professor
   Giovanni Staurenghi (University of Brescia, Italy) who participated in
   earlier meetings of the international expert PCV panel and who has
   reviewed this manuscript. Acknowledgment is also made of the medical
   writing services provided by Susanna Ryan of Chameleon Communications
   International with funding from the College of Ophthalmologists,
   Singapore.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Akaza Eriko, 2006, Nippon Ganka Gakkai Zasshi, V110, P288
   Ampornpruet Atchara, 2005, Journal of the Medical Association of Thailand, V88, pS51
   Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Bessho H, 2011, MOL VIS, V17, P977
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Cackett P, 2010, EYE, V24, P789, DOI 10.1038/eye.2009.214
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chae Ju Byung, 2011, Korean J Ophthalmol, V25, P98, DOI 10.3341/kjo.2011.25.2.98
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chang AA, 2005, INVEST OPHTH VIS SCI, V46, P1463, DOI 10.1167/iovs.04-0825
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Cheng CK, 2011, RETINA-J RET VIT DIS, V31, P846, DOI 10.1097/IAE.0b013e3181f84fdf
   Cho HJ, 2012, EYE, V26, P426, DOI 10.1038/eye.2011.324
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   de Crecchio G, 2011, CURR DRUG TARGETS, V12, P206, DOI 10.2174/138945011794182782
   Desmettre T, 2000, SURV OPHTHALMOL, V45, P15, DOI 10.1016/S0039-6257(00)00123-5
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Helbig H, 2005, KLIN MONATSBL AUGENH, V222, P202, DOI 10.1055/s-2005-858011
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Hikichi T, 2009, RETINA-J RET VIT DIS, V29, P395, DOI 10.1097/IAE.0b013e318192f53a
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Honda S, 2009, OPHTHALMOLOGICA, V223, P333, DOI 10.1159/000221837
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Hussain Nazimul, 2005, Indian Journal of Ophthalmology, V53, P101
   Iida T, 2002, RETINA-J RET VIT DIS, V22, P455, DOI 10.1097/00006982-200208000-00010
   Imasawa M, 2011, JPN J OPHTHALMOL, V55, P241, DOI 10.1007/s10384-011-0006-6
   Imasawa M, 2009, JPN J OPHTHALMOL, V53, P588, DOI 10.1007/s10384-009-0732-1
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Jalali S, 2006, AM J OPHTHALMOL, V142, P608, DOI 10.1016/j.ajo.2006.05.055
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim Aya, 2006, Nippon Ganka Gakkai Zasshi, V110, P19
   Kim KS, 2011, JPN J OPHTHALMOL, V55, P370, DOI 10.1007/s10384-011-0045-z
   Kim M, 2011, OPHTHALMOLOGICA, V226, P205, DOI 10.1159/000330793
   Kim SJ, 2011, RETINA-J RET VIT DIS, V31, P1827, DOI 10.1097/IAE.0b013e318214d01e
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lai TYY, 2011, RETINA-J RET VIT DIS, V31, P1581, DOI 10.1097/IAE.0b013e31820d3f3f
   Lai TYY, 2010, J OCUL PHARMACOL TH, V26, P91, DOI 10.1089/jop.2009.0073
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee MW, 2009, EYE, V23, P1417, DOI 10.1038/eye.2008.265
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee Sun Young, 2008, Korean J Ophthalmol, V22, P92, DOI 10.3341/kjo.2008.22.2.92
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee YH, 2011, RETINA-J RET VIT DIS, V31, P1287, DOI 10.1097/IAE.0b013e3182003ccd
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lucentis&REG;, 2008, LUC RAN SUMM PROD CH
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Machida S, 2012, DOC OPHTHALMOL, V124, P91, DOI 10.1007/s10633-011-9307-9
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumiya W, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/742020
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mauget-Faysse M, 2006, RETINA-J RET VIT DIS, V26, P396, DOI 10.1097/00006982-200604000-00003
   Mitamura Y, 2009, EYE, V23, P67, DOI 10.1038/sj.eye.6702996
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Moon SW, 2011, OPHTHALMOLOGICA, V225, P169, DOI 10.1159/000323811
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Mori R, 2010, GRAEF ARCH CLIN EXP, V248, P1233, DOI 10.1007/s00417-010-1365-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Nishijima K, 2004, AM J OPHTHALMOL, V137, P770, DOI 10.1016/j.ajo.2003.09.059
   Ogino T, 2007, JPN J OPHTHALMOL, V51, P210, DOI 10.1007/s10384-007-0436-3
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Okubo A, 2008, GRAEF ARCH CLIN EXP, V246, P491, DOI 10.1007/s00417-007-0680-8
   Okubo A, 2010, ACTA OPHTHALMOL, V88, pe107, DOI 10.1111/j.1755-3768.2009.01850.x
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Ricci F, 2012, RETINA-J RET VIT DIS, V32, P1280, DOI 10.1097/IAE.0b013e318236e835
   Romano MR, 2010, CLIN OPHTHALMOL, V4, P1237, DOI 10.2147/OPTH.S12577
   Rosen RB, 2009, INVEST OPHTH VIS SCI, V50, P851, DOI 10.1167/iovs.08-1855
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Ruamviboonsuk P, 2010, BRIT J OPHTHALMOL, V94, P1045, DOI 10.1136/bjo.2009.173120
   Sa Ho-Seok, 2005, Korean J Ophthalmol, V19, P275
   Sagong M, 2012, AM J OPHTHALMOL, V153, P873, DOI 10.1016/j.ajo.2011.09.031
   Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Shah AM, 2011, AM J OPHTHALMOL, V152, P332, DOI 10.1016/j.ajo.2011.04.015
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   Song MH, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329466
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tomita K, 2012, AM J OPHTHALMOL, V153, P68, DOI 10.1016/j.ajo.2011.07.001
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsuchiya D, 2009, RETINA-J RET VIT DIS, V29, P960, DOI 10.1097/IAE.0b013e3181a3b7c5
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Visudyne&REG;, 2007, VIS VERT SUMM PROD C
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wakabayashi T, 2012, BRIT J OPHTHALMOL, V96, P394, DOI 10.1136/bjo.2011.204123
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Windisch R, 2008, CAN J OPHTHALMOL, V43, P678, DOI 10.3129/i08-153
   Yamaoka S, 2010, OPHTHALMOLOGICA, V224, P147, DOI 10.1159/000236040
   Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2
   Yamashita A, 2010, AM J OPHTHALMOL, V149, P465, DOI 10.1016/j.ajo.2009.09.020
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yannuzzi LA, 1982, MAC SOC M MIAM FL
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Yoon JS, 2007, YONSEI MED J, V48, P225, DOI 10.3349/ymj.2007.48.2.225
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 177
TC 184
Z9 213
U1 0
U2 38
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2013
VL 33
IS 4
BP 686
EP 716
DI 10.1097/IAE.0b013e3182852446
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115GZ
UT WOS:000316801900004
PM 23455233
DA 2022-11-30
ER

PT J
AU Meyer, CH
   Mennel, S
   Horle, S
   Schmidt, JC
AF Meyer, Carsten H.
   Mennel, Stefan
   Hoerle, Steffen
   Schmidt, Joerg C.
TI Visual hallucinations after intravitreal injection of bevacizumab in
   vascular age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHARLES-BONNET-SYNDROME
AB PURPOSE: To describe transient structured visual hallucinations in a patient with vascular age-related macular degeneration (AMD), following an intravitreal Avastin-injection.
   DESIGN: Interventional case reports.
   METHODS: A fully alert 83-year-old woman with disciform scar right eye (OD) and occult choroidal neovascularization (CNV) left eye (OS) experienced a progressive visual loss to 20/800 OD and 20/400 OS. A coherent 84-year-old woman with occult CNV both eyes (OU) experienced decreased vision of 20/800 OU. After both patients gave informed consent, an uneventful intravitreal injection of 1.25 mg Avastin was performed in the left eyes.
   RESULTS: One day and three days after an uneventful intravitreal injection both patients experienced structured hallucinations including trees, faces, and water for approximately 15 to 30 minutes.
   CONCLUSIONS: We report a typical symptoms of Charles, Bonnet syndrome (CBS) in patients with severe AMD after intravitreal Avastin-injections. The reduced retinal edema and realignment of the photoreceptors may promote the release phenomenon and trigger hallucinatory episodes.
C1 Univ Marburg, Dept Ophthalmol, D-35037 Marburg, Germany.
C3 Philipps University Marburg
RP Meyer, CH (通讯作者)，Univ Marburg, Dept Ophthalmol, Robert Koch Str 4, D-35037 Marburg, Germany.
EM meyer_eye@yahoo.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298
CR COGAN DG, 1973, A GRAEF ARCH KLIN EX, V188, P139, DOI 10.1007/BF00407835
   Cohen SY, 2000, AM J OPHTHALMOL, V129, P815, DOI 10.1016/S0002-9394(00)00374-3
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Eong KGA, 2001, AM J OPHTHALMOL, V131, P664
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
NR 5
TC 35
Z9 36
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2007
VL 143
IS 1
BP 169
EP 170
DI 10.1016/j.ajo.2006.08.003
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123QY
UT WOS:000243311700033
PM 17188061
DA 2022-11-30
ER

PT J
AU Shimada, H
   Fujita, K
   Matsumoto, Y
   Mori, R
   Yuzawa, M
AF Shimada, H
   Fujita, K
   Matsumoto, Y
   Mori, R
   Yuzawa, M
TI Surgical excision of type 1+2 choroidal neovascularization in
   age-related macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; surgical excision; type 1+2 subfoveal
   choroidal neovascularization
ID MEMBRANES
AB Purpose: To evaluate the visual acuity outcome and the various factors influencing visual outcome in patients undergoing surgical removal of type I + 2 choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).
   Methods: We studied the records of 54 patients (54 eyes) followed for at least I year after surgical excision of CNV associated with AMD.
   Results: The final visual acuity was 0.4 or better in 4%, 0.1 to 0.3 in 46%, and worse than 0.1 in 50% of the patients. Final visual acuity was improved in 39%, stable in 37%, and worse in 24%. Stepwise regression showed that the distance between the center of the foveal avascular zone and the CNV margin had the greatest effect on final visual acuity.
   Conclusions: Surgical excision of typel + 2 CNV due to AMD may be indicated for preserving preoperative visual acuity. The distance between the center of the foveal avascular zone and the CNV margin is the most important factor affecting final visual acuity.
C1 Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, Tokyo 1018309, Japan.
C3 Nihon University
RP Shimada, H (通讯作者)，Nihon Univ, Surugadai Hosp, Dept Ophthalmol, Chiyoda Ku, 1-8-13 Surugadai, Tokyo 1018309, Japan.
EM sshimada@olive.ocn.ne.jp
CR GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   HIROSE T, 2003, JPN J CLIN OPHTHAL, V57, P1001
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   SHIMADA H, 2000, J JPN OPHTHALMOL SOC, V104, P489
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
NR 6
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL-AUG
PY 2005
VL 49
IS 4
BP 324
EP 326
DI 10.1007/s10384-004-0192-6
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 952MS
UT WOS:000231008600011
PM 16075336
DA 2022-11-30
ER

PT J
AU Matias-Perez, D
   Garcia-Montalvo, IA
AF Matias-Perez, Diana
   Antonio Garcia-Montalvo, Ivan
TI Fatty Acids and Lipid Derivatives Protecting Photooxidative Attack in
   Age-related Macular Degeneration
SO JOURNAL OF OLEO SCIENCE
LA English
DT Review
DE AMD; photooxidative attack; ROS; fatty acids; lipid derivatives
ID RETINAL-PIGMENT EPITHELIUM; VITAMIN-E; DIETARY ANTIOXIDANTS; OXIDATIVE
   STRESS; BRUCHS MEMBRANE; DRUSEN; RISK; MACULOPATHY; DISEASE; SUPPLEMENTS
AB The objective is the systematic review of studies published in Scielo, Redalyc, Dialnet, Web of Science, Scopus and Pubmed, related to the inclusion of fatty acids and lipid derivatives in the daily diet to prevent or delay the appearance or progression of Age-Related Macular Degeneration (AMD). The analysis of the research results consulted shows that AMD is one of the most frequent causes of blindness in subjects over 55 years of age. AMD is characterized by decreased vision, metamorphopsia, macropsies, micropsies, and central scotoma. Disease that must be diagnosed early as it can lead to irreversible blindness. Among the components of the diet that in numerous epidemiological studies have shown an association in the treatment of AMD and that are reviewed in this work are fatty acids, vitamins and carotenoids. There is ample evidence that fatty acids and lipid derivatives can be included in the diet plans of subjects with AMD.
C1 [Matias-Perez, Diana; Antonio Garcia-Montalvo, Ivan] Technol Inst Oaxaca, Div Grad Studies & Res, Natl Technol Mexico, Ave Lng Victor Bravo Ahuja 125 Esquina Calzada Te, Oaxaca 68030, Oaxaca, Mexico.
RP Garcia-Montalvo, IA (通讯作者)，Technol Inst Oaxaca, Div Grad Studies & Res, Natl Technol Mexico, Ave Lng Victor Bravo Ahuja 125 Esquina Calzada Te, Oaxaca 68030, Oaxaca, Mexico.
EM ivan.garcia@itoaxaca.edu.mx
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bazan NG, 2018, MOL ASPECTS MED, V64, P18, DOI 10.1016/j.mam.2018.09.003
   Bazan-Salinas I., 2014, AVAN C SALUD MED, V2, P22
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benowitz NL, 2003, PROG CARDIOVASC DIS, V46, P91, DOI 10.1016/S0033-0620(03)00087-2
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Buring Julie E., 1995, P223
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   DeCaprio AP, 1999, CRIT REV TOXICOL, V29, P283, DOI 10.1080/10408449991349221
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424
   Friberg TR, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.02.048
   Gong Y, 2017, AM J CLIN NUTR, V106, P16, DOI 10.3945/ajcn.117.153825
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Green RW, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Kuzniarz M, 2002, OPHTHAL EPIDEMIOL, V9, P283, DOI 10.1076/opep.9.4.283.1511
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lister Tracy, 2019, Integr Med (Encinitas), V18, P30
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Mukhtar S, 2019, INT OPHTHALMOL, V39, P2975, DOI 10.1007/s10792-019-01140-6
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   National Eye Institute, 2014, AGE RELATED MACULAR
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Skowronska-Krawczyk D, 2019, ADV EXP MED BIOL, V1185, P39, DOI 10.1007/978-3-030-27378-1_7
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
NR 54
TC 0
Z9 0
U1 0
U2 0
PU JAPAN OIL CHEMISTS SOC
PI TOKYO
PA YUSHI KOGYO KAIKAN BLDG, 13-11, NIHONBASHI 3-CHOME, CHUO-KU, TOKYO,
   103-0027, JAPAN
SN 1345-8957
EI 1347-3352
J9 J OLEO SCI
JI J. Oleo Sci.
PY 2021
VL 70
IS 4
BP 453
EP 458
DI 10.5650/jos.ess20314
PG 6
WC Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Food Science & Technology
GA XE9LZ
UT WOS:000723704400001
PM 33692241
OA gold
DA 2022-11-30
ER

PT J
AU Lin, JB
   Moolani, HV
   Sene, A
   Sidhu, R
   Kell, P
   Lin, JB
   Dong, ZY
   Ban, N
   Ory, DS
   Apte, RS
AF Lin, Jonathan B.
   Moolani, Harsh V.
   Sene, Abdoulaye
   Sidhu, Rohini
   Kell, Pamela
   Lin, Joseph B.
   Dong, Zhenyu
   Ban, Norimitsu
   Ory, Daniel S.
   Apte, Rajendra S.
TI Macrophage microRNA-150 promotes pathological angiogenesis as seen in
   age-related macular degeneration
SO JCI INSIGHT
LA English
DT Article
ID CHOLESTEROL EFFLUX; ATHEROSCLEROSIS; ATHEROGENESIS; ACCUMULATION;
   POLARIZATION; ACTIVATION; REGRESSION; EXPRESSION; RESOURCE; MONOCYTE
AB Macrophage aging is pathogenic in diseases of the elderly, including age-related macular degeneration (AMD), a leading cause of blindness in older adults. However, the role of microRNAs, which modulate immune processes, in regulating macrophage dysfunction and thereby promoting age-associated diseases is underexplored. Here, we report that microRNA-150 (miR-150) coordinates transcriptomic changes in aged murine macrophages, especially those associated with aberrant lipid trafficking and metabolism in AMD pathogenesis. Molecular profiling confirmed that aged murine macrophages exhibit dysregulated ceramide and phospholipid profiles compared with young macrophages. Of translational relevance, upregulation of miR-150 in human peripheral blood mononuclear cells was also significantly associated with increased odds of AMD, even after controlling for age. Mechanistically, miR-150 directly targets stearoyl-CoA desaturase-2, which coordinates macrophage-mediated inflammation and pathologic angiogenesis, as seen in AMD, in a VEGF-independent manner. Together, our results implicate miR-150 as pathogenic in AMD and provide potentially novel molecular insights into diseases of aging.
C1 [Lin, Jonathan B.; Moolani, Harsh V.; Sene, Abdoulaye; Lin, Joseph B.; Dong, Zhenyu; Ban, Norimitsu; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Lin, Jonathan B.] Washington Univ, Sch Med, Neurosci Grad Program, Div Biol & Biomed Sci, St Louis, MO USA.
   [Sidhu, Rohini; Kell, Pamela; Ory, Daniel S.; Apte, Rajendra S.] Washington Univ, Sch Med, Diabet Cardiovasc Dis Ctr, St Louis, MO USA.
   [Sidhu, Rohini; Kell, Pamela; Ory, Daniel S.; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL); Washington University
   (WUSTL)
RP Apte, RS (通讯作者)，660 South Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@wustl.edu
RI Sidhu, Rohini/G-3547-2012
OI Sidhu, Rohini/0000-0003-1703-2167; Lin, Joseph/0000-0001-6667-9018;
   Moolani, Harsh/0000-0001-7061-0312
FU NIH [R01 EY019287, P30 EY02687, P30 DK020579, UL1 TR000448, P30
   CA91842]; Starr Foundation; Carl Marshall Reeves and Mildred Almen
   Reeves Foundation; Bill and Emily Kuzma Family Gift for retinal
   research; Physician-Scientist Award from Research to Prevent Blindness;
   Nelson Trust Award from Research to Prevent Blindness; Jeffrey Fort
   Innovation Fund; Glenn Foundation; Thome Foundation; Research to Prevent
   Blindness; Washington University in St. Louis Medical Scientist Training
   Program (NIH grant) [T32 GM07200]; Washington University in St. Louis
   Institute of Clinical and Translational Sciences (NIH grants) [UL1
   TR002345, TL1 TR002344]; VitreoRetinal Surgery Foundation; NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR002344, UL1TR000448,
   UL1TR002345] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY019287, P30EY002687] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [T32GM007200] Funding Source: NIH RePORTER
FX This work was supported by NIH grants R01 EY019287 (RSA), P30 EY02687
   (Vision Core Grant), P30 DK020579 (Diabetes Research Center Metabolomics
   Core), UL1 TR000448 (GTAC), and P30 CA91842 (GTAC); the Starr Foundation
   (RSA); the Carl Marshall Reeves and Mildred Almen Reeves Foundation
   (RSA); the Bill and Emily Kuzma Family Gift for retinal research (RSA);
   a Physician-Scientist Award and a Nelson Trust Award from Research to
   Prevent Blindness (RSA); the Jeffrey Fort Innovation Fund (RSA); the
   Glenn Foundation (RSA); and the Thome Foundation (RSA). Additional
   funding comes from an unrestricted grant to the Department of
   Ophthalmology and Visual Sciences of Washington University School of
   Medicine from Research to Prevent Blindness. JBL was supported by the
   Washington University in St. Louis Medical Scientist Training Program
   (NIH grant T32 GM07200), the Washington University in St. Louis
   Institute of Clinical and Translational Sciences (NIH grants UL1
   TR002345, TL1 TR002344), and the VitreoRetinal Surgery Foundation. The
   authors thank Andrea Santeford, Alexander Cammack, Howard Chen, Michael
   Casey, Rei Nakamura, and Nicole Zapata for technical assistance; Clay
   Semenkovich and Hide Tsukamoto for providing mutant mice; and Danyel
   Cavazos for help with scientific illustration.
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002
   Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dong ZY, 2013, MOL VIS, V19, P536
   Fadini GP, 2014, ATHEROSCLEROSIS, V237, P805, DOI 10.1016/j.atherosclerosis.2014.10.106
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   GERRITY RG, 1979, AM J PATHOL, V95, P775
   GERRITY RG, 1981, AM J PATHOL, V103, P181
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Heinz RE, 2016, DEVELOPMENT, V143, P4236, DOI 10.1242/dev.139642
   Ishikawa T, 2015, ATHEROSCLEROSIS, V242, P318, DOI 10.1016/j.atherosclerosis.2015.06.028
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Khalil H, 2016, EPIGENETICS-US, V11, P381, DOI 10.1080/15592294.2016.1144007
   KRAMSCH DM, 1971, J CLIN INVEST, V50, P1666, DOI 10.1172/JCI106656
   Lai KKY, 2017, GASTROENTEROLOGY, V152, P1477, DOI 10.1053/j.gastro.2017.01.021
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Lv YC, 2014, ATHEROSCLEROSIS, V236, P215, DOI 10.1016/j.atherosclerosis.2014.07.005
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Masuda M, 2015, J CLIN INVEST, V125, P4544, DOI 10.1172/JCI82871
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Meiler S, 2015, ARTERIOSCL THROM VAS, V35, P323, DOI 10.1161/ATVBAHA.114.304878
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Miyazaki M, 2005, P NATL ACAD SCI USA, V102, P12501, DOI 10.1073/pnas.0503132102
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Peled M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00579
   Rayner KJ, 2011, J CLIN INVEST, V121, P2921, DOI 10.1172/JCI57275
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Schilling JD, 2013, J BIOL CHEM, V288, P2923, DOI 10.1074/jbc.M112.419978
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Tarasov K, 2014, J CLIN ENDOCR METAB, V99, pE45, DOI 10.1210/jc.2013-2559
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215
   Wei XC, 2016, NATURE, V539, P294, DOI 10.1038/nature20117
   Wong CK, 2017, J IMMUNOL, V199, P1060, DOI 10.4049/jimmunol.1700397
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021
NR 54
TC 27
Z9 28
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD APR 5
PY 2018
VL 3
IS 7
AR e120157
DI 10.1172/jci.insight.120157
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GC5AA
UT WOS:000429796600015
PM 29618664
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lambert, V
   Lecomte, J
   Hansen, S
   Blacher, S
   Gonzalez, MLA
   Struman, I
   Sounni, NE
   Rozet, E
   de Tullio, P
   Foidart, JM
   Rakic, JM
   Noel, A
AF Lambert, Vincent
   Lecomte, Julie
   Hansen, Sylvain
   Blacher, Silvia
   Gonzalez, Maria-Luz Alvarez
   Struman, Ingrid
   Sounni, Nor Eddine
   Rozet, Eric
   de Tullio, Pascal
   Foidart, Jean Michel
   Rakic, Jean-Marie
   Noel, Agnes
TI Laser-induced choroidal neovascularization model to study age-related
   macular degeneration in mice
SO NATURE PROTOCOLS
LA English
DT Article
ID ACTIVATOR INHIBITOR TYPE-1; MURINE MODEL; GROWTH-FACTOR; ANIMAL-MODEL;
   VEGF; CELLS; METABOLOMICS; SEVERITY; THERAPY; CANCER
AB The mouse model of laser-induced choroidal neovascularization (CNCNV) has been used extensively in studies of the exudative form of age-related macular degeneration (AMD). This experimental in vivo model relies on laser injury to perforate Bruch's membrane, resulting in subretinal blood vessel recruitment from the choroid. By recapitulating the main features of the exudative form of human AMD, this assay has served as the backbone for testing antiangiogenic therapies. This standardized protocol can be applied to transgenic mice and can include treatments with drugs, recombinant proteins, antibodies, adenoviruses and pre-microRNAs to aid in the search for new molecular regulators and the identification of novel targets for innovative treatments. This robust assay requires 7-14 d to complete, depending on the treatment applied and whether immunostaining is performed. This protocol includes details of how to induce CNCNV, including laser induction, lesion excision, processing and different approaches to quantify neoformed vasculature.
C1 [Lambert, Vincent; Rakic, Jean-Marie] Univ Hosp CHU, Dept Ophthalmol, Liege, Belgium.
   [Lambert, Vincent; Lecomte, Julie; Hansen, Sylvain; Blacher, Silvia; Gonzalez, Maria-Luz Alvarez; Sounni, Nor Eddine; Foidart, Jean Michel; Noel, Agnes] Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, Liege, Belgium.
   [Struman, Ingrid] Univ Liege, GIGA Canc, Unit Mol Biol & Genet Engn, Liege, Belgium.
   [Rozet, Eric] Univ Liege, Analyt Chem Lab CIRM, Liege, Belgium.
   [de Tullio, Pascal] Univ Liege, Drug Res Ctr CIRM, Liege, Belgium.
C3 University of Liege; University of Liege; University of Liege;
   University of Liege; University of Liege
RP Noel, A (通讯作者)，Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, Liege, Belgium.
EM agnes.noel@ulg.ac.be
RI Sounni, Nor Eddine/AAY-8766-2021; De Tullio, Pascal/ABE-5585-2021
OI Sounni, Nor Eddine/0000-0001-9962-9236; Noel, Agnes/0000-0002-7670-6179;
   struman, ingrid/0000-0003-2550-3707
FU Fonds National de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium);
   Foundation against Cancer (foundation of public interest, Belgium);
   Fonds speciaux de la Recherche (University of Liege); Direction Generale
   Operationnelle de l'Economie, de l'Emploi et de la Recherche from the
   S.P.W. (Region Wallonne, Belgium); Interuniversity Attraction Poles
   Programme-Belgian Science Policy (Brussels, Belgium); Plan National
   Cancer (Service Public Federal); Actions de Recherche Concertees
   (University of Liege, Belgium)
FX This work was supported by grants from the Fonds National de la
   Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium), the Foundation
   against Cancer (foundation of public interest, Belgium), the Fonds
   speciaux de la Recherche (University of Liege), the Direction Generale
   Operationnelle de l'Economie, de l'Emploi et de la Recherche from the
   S.P.W. (Region Wallonne, Belgium), the Interuniversity Attraction Poles
   Programme-Belgian Science Policy (Brussels, Belgium), the Plan National
   Cancer (Service Public Federal), the Actions de Recherche Concertees
   (University of Liege, Belgium). We thank S. Ormenese and G. Moraes from
   the GIGA Cell Imaging and Flow Cytometry facility for their support with
   confocal microscopy acquisitions, as well as members of the GIGA animal
   facility platform for their help.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Campochiaro PA, 2010, JAMA-J AM MED ASSOC, V303, P657, DOI 10.1001/jama.2010.142
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Detry B, 2013, INVEST OPHTH VIS SCI, V54, P3082, DOI 10.1167/iovs.12-10856
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Halkein J, 2013, J CLIN INVEST, V123, P2143, DOI 10.1172/JCI64365
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Johnson CH, 2012, J CELL PHYSIOL, V227, P2975, DOI 10.1002/jcp.24002
   Jost M, 2007, AM J PATHOL, V171, P1369, DOI 10.2353/ajpath.2007.070074
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lecomte J, 2011, CELL MOL LIFE SCI, V68, P677, DOI 10.1007/s00018-010-0476-6
   Lien S., 2008, V181, P131
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Machalinska A, 2011, GRAEF ARCH CLIN EXP, V249, P1785, DOI 10.1007/s00417-011-1767-9
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Miki K, 2009, OPHTHALMOLOGY, V116, P1748, DOI 10.1016/j.ophtha.2009.05.020
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   O'Connell TM, 2012, BIOANALYSIS, V4, P431, DOI [10.4155/BIO.11.326, 10.4155/bio.11.326]
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Qi XP, 2012, INVEST OPHTH VIS SCI, V53, P574, DOI 10.1167/iovs.11-8728
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ridder WH, 2002, EXP EYE RES, V75, P365, DOI 10.1006/exer.2002.2007
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2010, INVEST OPHTH VIS SCI, V51, P2697, DOI 10.1167/iovs.09-4137
   Shi Y, 2011, INT J INF TECH DECIS, V10, P1, DOI 10.1142/S0219622011004294
   Slakter Jason S, 2006, Ophthalmol Clin North Am, V19, P373
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V320, P372, DOI 10.1016/j.bbrc.2004.05.177
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Wang JY, 2011, ARTERIOSCL THROM VAS, V31, pE11, DOI 10.1161/ATVBAHA.110.215517
   Zhang AH, 2013, CLIN CHIM ACTA, V424, P3, DOI 10.1016/j.cca.2013.05.003
   Zhang XL, 2013, BBA-MOL BASIS DIS, V1832, P1207, DOI 10.1016/j.bbadis.2013.03.009
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
   Zhou JH, 2005, MOL VIS, V11, P414
NR 58
TC 213
Z9 223
U1 0
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD NOV
PY 2013
VL 8
IS 11
BP 2197
EP 2211
DI 10.1038/nprot.2013.135
PG 15
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 241JX
UT WOS:000326164100009
PM 24136346
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ratnapriya, R
   Sosina, OA
   Starostik, MR
   Kwicklis, M
   Kapphahn, RJ
   Fritsche, LG
   Walton, A
   Arvanitis, M
   Gieser, L
   Pietraszkiewicz, A
   Montezuma, SR
   Chew, EY
   Battle, A
   Abecasis, GR
   Ferrington, DA
   Chatterjee, N
   Swaroop, A
AF Ratnapriya, Rinki
   Sosina, Olukayode A.
   Starostik, Margaret R.
   Kwicklis, Madeline
   Kapphahn, Rebecca J.
   Fritsche, Lars G.
   Walton, Ashley
   Arvanitis, Marios
   Gieser, Linn
   Pietraszkiewicz, Alexandra
   Montezuma, Sandra R.
   Chew, Emily Y.
   Battle, Alexis
   Abecasis, Goncalo R.
   Ferrington, Deborah A.
   Chatterjee, Nilanjan
   Swaroop, Anand
TI Retinal transcriptome and eQTL analyses identify genes associated with
   age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; UNWANTED VARIATION; GWAS; IDENTIFICATION;
   EXPRESSION; ENRICHMENT; GENETICS; PACKAGE; TISSUES; SCALE
AB Genome-wide association studies (GWAS) have identified genetic variants at 34 loci contributing to age-related macular degeneration (AMD)(1-3). We generated transcriptional profiles of postmortem retinas from 453 controls and cases at distinct stages of AMD and integrated retinal transcriptomes, covering 13,662 protein-coding and 1,462 noncoding genes, with genotypes at more than 9 million common SNPs for expression quantitative trait loci (eQTL) analysis of a tissue not included in Genotype-Tissue Expression (GTEx) and other large datasets(4,5). Cis-eQTL analysis identified 10,474 genes under genetic regulation, including 4,541 eQTLs detected only in the retina. Integrated analysis of AMD-GWAS with eQTLs ascertained likely target genes at six reported loci. Using transcriptome-wide association analysis (TWAS), we identified three additional genes, RLBP1, HIC1 and PARP12, after Bonferroni correction. Our studies expand the genetic landscape of AMD and establish the Eye Genotype Expression (EyeGEx) database as a resource for post-GWAS interpretation of multifactorial ocular traits.
C1 [Ratnapriya, Rinki; Sosina, Olukayode A.; Starostik, Margaret R.; Kwicklis, Madeline; Walton, Ashley; Gieser, Linn; Pietraszkiewicz, Alexandra; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Sosina, Olukayode A.; Chatterjee, Nilanjan] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Kapphahn, Rebecca J.; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Fritsche, Lars G.; Abecasis, Goncalo R.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Arvanitis, Marios] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA.
   [Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Battle, Alexis] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA.
   [Battle, Alexis] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; University of Minnesota System; University of Minnesota
   Twin Cities; University of Michigan System; University of Michigan;
   Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Johns Hopkins University; Johns Hopkins
   University
RP Swaroop, A (通讯作者)，NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.; Chatterjee, N (通讯作者)，Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.; Ferrington, DA (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu; nchatte2@jhu.edu; swaroopa@nei.nih.gov
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Starostik,
   Margaret/0000-0002-5274-2765; Ferrington, Deborah/0000-0003-2561-7464;
   Ratnapriya, Rinki/0000-0002-0469-4631
FU Intramural Research Program of the National Eye Institute [EY000450,
   EY000474, EY000475]; NIH [EY028554, EY026012]; Minnesota Lions Vision
   Foundation; Johns Hopkins Bloomberg Distinguished Professorship
   Endowment; Lindsay Family Foundation; NATIONAL EYE INSTITUTE
   [R01EY028554, R01EY026012] Funding Source: NIH RePORTER
FX The authors acknowledge B. Weber for providing liver eQTL data. We thank
   members of the laboratory of A. S., especially H. Yang, J. Bryan, A.
   Police Reddy, and F. Giuste for assistance, and the Lions Gift of Sight
   members for procuring human retina tissue. This work was supported by
   the Intramural Research Program of the National Eye Institute EY000450,
   EY000474, and EY000475 (to A.S.), NIH grants EY028554 and EY026012, The
   Lindsay Family Foundation, an anonymous benefactor, and the Minnesota
   Lions Vision Foundation (to D.A.F.), and the Johns Hopkins Bloomberg
   Distinguished Professorship Endowment (to N.C.). This study used the
   high-performance computational capabilities of the Biowulf Linux cluster
   (see URLs).
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Beasley TM, 2009, BEHAV GENET, V39, P580, DOI 10.1007/s10519-009-9281-0
   Beck T, 2014, EUR J HUM GENET, V22, P949, DOI 10.1038/ejhg.2013.274
   Brown CD, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003649
   Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108
   Chakravarti A, 2013, CELL, V155, P21, DOI 10.1016/j.cell.2013.09.001
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Delaneau O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15452
   Eisenberg E, 2013, TRENDS GENET, V29, P569, DOI 10.1016/j.tig.2013.05.010
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finucane HK, 2018, NAT GENET, V50, P621, DOI 10.1038/s41588-018-0081-4
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fromer M, 2016, NAT NEUROSCI, V19, P1442, DOI 10.1038/nn.4399
   Gagnon-Bartsch JA, 2012, BIOSTATISTICS, V13, P539, DOI 10.1093/biostatistics/kxr034
   Gallagher MD, 2018, AM J HUM GENET, V102, P717, DOI 10.1016/j.ajhg.2018.04.002
   Gamazon ER, 2018, NAT GENET, V50, P956, DOI 10.1038/s41588-018-0154-4
   Gandal MJ, 2018, SCIENCE, V359, P693, DOI 10.1126/science.aad6469
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hormozdiari F, 2018, NAT GENET, V50, P1041, DOI 10.1038/s41588-018-0148-2
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200
   Langemeyer L, 2015, DEV CELL, V33, P121, DOI 10.1016/j.devcel.2015.04.008
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Leek JT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku864
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355
   Mullin AP, 2015, J NEUROSCI, V35, P325, DOI 10.1523/JNEUROSCI.3542-14.2015
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Oberstein SAJL, 2006, AM J HUM GENET, V79, P562, DOI 10.1086/507567
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190
   Pinelli M, 2016, NUCLEIC ACIDS RES, V44, P5773, DOI 10.1093/nar/gkw486
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355
   Scherer A., 2009, BATCH EFFECTS NOISE
   Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Small KS, 2011, NAT GENET, V43, P561, DOI 10.1038/ng.833
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
NR 52
TC 102
Z9 101
U1 3
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD APR
PY 2019
VL 51
IS 4
BP 606
EP +
DI 10.1038/s41588-019-0351-9
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HQ9SJ
UT WOS:000462767500007
PM 30742112
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ashraf, M
   Banaee, T
   Silva, FQ
   Singh, RP
AF Ashraf, Mohammed
   Banaee, Touka
   Silva, Fabiana Q.
   Singh, Rishi P.
TI Switching Anti-Vascular Endothelial Growth Factors in Refractory
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; INTRAVITREAL AFLIBERCEPT; CHOROIDAL
   NEOVASCULARIZATION; ANATOMICAL OUTCOMES; RANIBIZUMAB; BEVACIZUMAB; EYES;
   PREDICTORS; RESPONDERS; INJECTION
AB BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is the treatment of choice for cases with neovascular age-related macular degeneration (AMD). Switching to an alternate anti-VEGF has been suggested as a possible option for resistant cases. The purpose of this review is to evaluate whether the timing of switching affects treatment outcomes.
   PATIENTS AND METHODS: A review of published literature was performed looking at all studies where patients with refractory neovascular AMD were switched to an alternative anti-VEGF. Studies were then stratified based on the timing of switching into early (< 12 previous injections) and late (> 12 previous injections).
   RESULTS: A total of 38 studies were identified: 18 where patients were switched early and 20 where they were switched late. Both subgroups showed anatomic improvement after switching, with limited visual gains.
   CONCLUSION: There are insufficient data to recommend early versus late switching. However, both groups showed a reduction of fluid on optical coherence tomography and visual gains in 25% to 30% of patients.
C1 [Ashraf, Mohammed] Alexandria Fac Med, Ophthalmol Dept, Alexandria, Egypt.
   [Banaee, Touka] Mashhad Univ Med Sci, Ophthalm Res Ctr, Mashhad, Iran.
   [Banaee, Touka] Mashhad Univ Med Sci, Fac Med, Mashhad, Iran.
   [Banaee, Touka; Silva, Fabiana Q.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Mashhad University
   Medical Science; Mashhad University Medical Science; Cleveland Clinic
   Foundation
RP Singh, RP (通讯作者)，9500 Euclid Ave,Desk I32, Cleveland, OH 44195 USA.
EM SINGHR@ccf.org
RI Elmasry, Mohamed Ashraf/Q-8843-2019; Silva, Fabiana/GWU-9143-2022
OI Elmasry, Mohamed Ashraf/0000-0003-4231-2566; 
FU Regeneron; Genentech; Novartis; Optos; Zeiss
FX Dr. Singh reports grants and personal fees from Regeneron, Genentech,
   and Novartis; and personal fees from Optos and Zeiss. The remaining
   authors report no relevant financial disclosures.
CR Aghdam KA, 2016, LASER SURG MED, V48, P668, DOI 10.1002/lsm.22531
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Barthelmes D, 2016, BRIT J OPHTHALMOL, V100, P1640, DOI 10.1136/bjophthalmol-2015-308090
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   De Massougnes S, 2016, RETINA-J RET VIT DIS, V36, P881, DOI 10.1097/IAE.0000000000000813
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gale R, 2016, OPHTHALMOLOGICA, V236, P193, DOI 10.1159/000451065
   Gharbiya M, 2015, EYE, V29, P1186, DOI 10.1038/eye.2015.113
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kucukerdonmez C, 2015, EUR J OPHTHALMOL, V25, P51, DOI 10.5301/ejo.5000480
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Major JC, 2015, CAN J OPHTHALMOL, V50, P373, DOI 10.1016/j.jcjo.2014.12.012
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massamba N, 2017, GRAEF ARCH CLIN EXP, V255, P61, DOI 10.1007/s00417-016-3423-x
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Moisseiev E, 2015, RETINA-J RET VIT DIS, V35, P1323, DOI 10.1097/IAE.0000000000000500
   Muftuoglu IK, 2016, AM J OPHTHALMOL, V167, P1, DOI 10.1016/j.ajo.2016.03.038
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Pinheiro-Costa J, 2014, OPHTHALMOLOGICA, V232, P149, DOI 10.1159/000363422
   Ricci F, 2016, EYE, V30, P1077, DOI 10.1038/eye.2016.95
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P1, DOI 10.1136/bjophthalmol-2014-305502
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Waizel M, 2016, EUR J OPHTHALMOL, V26, pE139, DOI 10.5301/ejo.5000842
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 37
TC 3
Z9 3
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2018
VL 49
IS 3
BP 166
EP +
DI 10.3928/23258160-20180221-03
PG 13
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GA4CX
UT WOS:000428278300004
PM 29554383
DA 2022-11-30
ER

PT J
AU Du, HJ
   Lim, SL
   Grob, S
   Zhang, K
AF Du, Hongjun
   Lim, Siok Lam
   Grob, Seanna
   Zhang, Kang
TI Induced Pluripotent Stem Cell Therapies for Geographic Atrophy of
   Age-Related Macular Degeneration
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE cell replacement; disease models; photoreceptors; retinal pigment
   epithelium
ID RETINAL-PIGMENT EPITHELIUM; PROGENITOR CELLS; VISUAL FUNCTION; RAT
   MODEL; SUBRETINAL TRANSPLANTATION; AUTOLOGOUS TRANSLOCATION;
   GENE-THERAPY; IN-VITRO; RCS RATS; GENERATION
AB There is currently no FDA-approved therapy for treating patients with geographic atrophy (GA), a late stage of age-related macular degeneration (AMD). Cell transplantation has the potential to restore vision in these patients. This review discusses how recent advancement in induced pluripotent stem (iPS) cells provides a promising therapy for GA treatment. Recent advances in stem cell biology have demonstrated that it is possible to derive iPS cells from human somatic cells by introducing reprogramming factors. Human retinal pigment epithelium (RPE) cells and photoreceptors can be derived from iPS cells by defined factors. Studies show that transplanting these cells can stabilize or recover vision in animal models. However, cell derivation protocols and transplantation procedures still need to be optimized. Much validation has to be done before clinical-grade, patient-derived iPS can be applied for human therapy. For now, RPE cells and photoreceptors derived from patient-specific iPS cells can serve as a valuable tool in elucidating the mechanism of pathogenesis and drug discovery for GA.
C1 [Du, Hongjun; Lim, Siok Lam; Grob, Seanna; Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Du, Hongjun; Lim, Siok Lam; Grob, Seanna; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Du, Hongjun] Fourth Mil Med Univ, Xijing Hosp, Eye Inst Chinese PLA, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Zhang, Kang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego; Air
   Force Military Medical University; Sichuan University
RP Zhang, K (通讯作者)，Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
EM kang.zhang@gmail.com
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU National Institutes of Health [R01EY14428, RO1EY18660]; Ronald McDonald
   House Charities; Macular Vision Research Foundation; West China Hospital
   of Sichuan University; NATIONAL EYE INSTITUTE [R01EY021374, R01EY018660,
   R01EY014428] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health [Grants
   R01EY14428, RO1EY18660]. We further wish to acknowledge support from
   Research to Prevent Blindness, the Ruth and Milton Steinbach Fund,
   Ronald McDonald House Charities, the Macular Vision Research Foundation,
   Burroughs Wellcome Fund Clinical Scientist Award in Translational
   Research, and West China Hospital of Sichuan University.
CR Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   Balasubramanian S, 2009, STEM CELLS, V27, P3053, DOI 10.1002/stem.242
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Boulton ME, 2004, OPHTHALMOLOGE, V101, P877
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cai H, 2006, ARCH OPHTHALMOL-CHIC, V124, P1276, DOI 10.1001/archopht.124.9.1276
   CARAMOY A, BR J OPHTHALMOL, V94, P1040
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Castanheira P, 2008, ARQ BRAS OFTALMOL, V71, P644, DOI 10.1590/S0004-27492008000500007
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Comyn O, 2010, CURR OPIN NEUROL, V23, P4, DOI 10.1097/WCO.0b013e3283352f96
   DEGENRING RF, 2009, ACTA OPHTHALMOL, V50, P2975
   Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799
   Eminli S, 2009, NAT GENET, V41, P968, DOI 10.1038/ng.428
   Francis PJ, 2009, INVEST OPHTH VIS SCI, V50, P3425, DOI 10.1167/iovs.08-2908
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Ghosh F, 2004, RETINA-J RET VIT DIS, V24, P98, DOI 10.1097/00006982-200402000-00014
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jia FJ, 2010, NAT METHODS, V7, P197, DOI [10.1038/NMETH.1426, 10.1038/nmeth.1426]
   Jiang CH, 2010, MOL VIS, V16, P983
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Joeres S, 2008, EYE, V22, P782, DOI 10.1038/sj.eye.6702761
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kanuga N, 2002, INVEST OPHTH VIS SCI, V43, P546
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Klassen H, 2007, STEM CELLS, V25, P1222, DOI 10.1634/stemcells.2006-0541
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li WL, 2010, METHODS MOL BIOL, V636, P293, DOI 10.1007/978-1-60761-691-7_18
   Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/NMETH.1393, 10.1038/nmeth.1393]
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   Markoulaki S, 2009, NAT BIOTECHNOL, V27, P169, DOI 10.1038/nbt.1520
   Mellough CB, 2007, RESTOR NEUROL NEUROS, V25, P177
   Merhi-Soussi F, 2006, STEM CELLS, V24, P2060, DOI 10.1634/stemcells.2005-0311
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554
   Morgan JIW, 2009, INVEST OPHTH VIS SCI, V50, P1350, DOI 10.1167/iovs.08-2618
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Osakada F, 2009, J PHARMACOL SCI, V109, P168, DOI 10.1254/jphs.08R19FM
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Schraermeyer U, 2000, GRAEF ARCH CLIN EXP, V238, P979, DOI 10.1007/s004170000194
   Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011
   Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013
   Sun N, 2010, CELL CYCLE, V9, P880, DOI 10.4161/cc.9.5.10827
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Thumann G, 2009, GRAEF ARCH CLIN EXP, V247, P363, DOI 10.1007/s00417-008-0998-x
   Tomita M, 2006, STEM CELLS, V24, P2270, DOI 10.1634/stemcells.2005-0507
   Van Hoffelen SJ, 2003, INVEST OPHTH VIS SCI, V44, P426, DOI 10.1167/iovs.02-0269
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wilson KD, 2009, STEM CELLS DEV, V18, P749, DOI 10.1089/scd.2008.0247
   Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zhao Y, 2008, CELL STEM CELL, V3, P475, DOI 10.1016/j.stem.2008.10.002
   Zhu S, CELL STEM CELL, V7, P651
NR 98
TC 25
Z9 27
U1 0
U2 20
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD MAY
PY 2011
VL 26
IS 3
BP 216
EP 224
DI 10.3109/08820538.2011.577498
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802IG
UT WOS:000293502200018
PM 21609235
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schuchard, RA
AF Schuchard, RA
TI Preferred retinal loci and macular scotoma characteristics in patients
   with age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; macular degeneration; ocular fixation; scotoma
ID SCANNING LASER OPHTHALMOSCOPE; SACCADIC EYE-MOVEMENTS; LOW-VISION;
   FIXATION STABILITY; READING RATE; DISEASE; PSYCHOPHYSICS; LOCATIONS;
   TARGETS; FOVEA
AB Many patients with macular scotomas due to age-related macular degeneration do not perceive black spots in the visual field where the scotomas are located. Rather, they describe objects as "vanishing," "jumping out of nowhere" or "having blurry parts," or a combination of features. In addition, when the macular scotoma affects the fovea, the visual system uses I or more preferred retinal loci (PRLs) as a "pseudofovea" to perform visual tasks. Visual function testing with the scanning laser ophthalmoscope has provided a wealth of information regarding how patients perceive the visual world and how the oculomotor system directs eye movements. This article describes 2 specific functions of the oculomotor system, fixation stability and refixation precision, with data collected from normally sighted people and patients with visual field loss. The implications of the characteristics of PRLs and macular scotomas for clinical testing are discussed.
C1 Dept Vet Affairs Rehabil Res & Dev, Ctr Excellence Aging Vis Loss, Atlanta, GA USA.
RP Schuchard, RA (通讯作者)，Atlanta VA Rehabil Res & Dev Ctr 151R, 1670 Clairmont Rd, Decatur, GA 30033 USA.
EM rschuch@emory.edu
CR Bishop P. O., 1987, ADLERS PHYSL EYE
   CULHAM LE, 1992, OPHTHAL PHYSL OPT, V12, P281, DOI 10.1111/j.1475-1313.1992.tb00398.x
   CULHAM LE, 1993, CLIN VISION SCI, V8, P551
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   DALGLEISH R, 1963, Br J Ophthalmol, V47, P11, DOI 10.1136/bjo.47.1.11
   Fletcher D. C., 1994, OPHTHALMOLOGY CLIN N, V7, P257
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   GOODRICH GL, 1986, AM J OPTOM PHYS OPT, V63, P119
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   KOSNIK W, 1986, INVEST OPHTH VIS SCI, V27, P1720
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   McDonnell J. M., 1989, RETINA
   MCMAHON TT, 1993, OPTOMETRY VISION SCI, V70, P506, DOI 10.1097/00006324-199306000-00010
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   RUBIN GS, 1992, VISION RES, V32, P895, DOI 10.1016/0042-6989(92)90032-E
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   SCHUCHARD RA, 1992, CLIN VISION SCI, V7, P511
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Schuchard RA, 1995, OSA TECH DIG SER, V1, P332
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   SKAVENSKI AA, 1979, VISION RES, V19, P675, DOI 10.1016/0042-6989(79)90243-8
   STEINMAN RM, 1968, VISION RES, V8, P277, DOI 10.1016/0042-6989(68)90015-1
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
NR 36
TC 87
Z9 95
U1 0
U2 5
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 303
EP 312
DI 10.1016/S0008-4182(05)80073-0
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400006
PM 15947800
DA 2022-11-30
ER

PT J
AU Min, JK
   Kim, J
   Woo, JM
AF Min, Jung Kee
   Kim, Jaehong
   Woo, Je Moon
TI Elevated Plasma Pentraxin3 Levels and Its Association with Neovascular
   Age-related Macular Degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; biomarker; C-reactive protein;
   inflammation; pentraxin3
ID C-REACTIVE PROTEIN; SYSTEMIC COMPLEMENT ACTIVATION; CARDIOVASCULAR
   RISK-FACTORS; RECOGNITION RECEPTOR PTX3; HUMORAL INNATE IMMUNITY;
   AMYLOID-P COMPONENT; BLUE-MOUNTAINS-EYE; FACTOR-H; ALTERNATIVE PATHWAY;
   DENDRITIC CELLS
AB Purpose: To evaluate pentraxin3 (PTX3) levels in patients with neovascular age-related macular degeneration (N-ARMD) and to investigate its role as a predictive biomarker.
   Methods: Thirty individuals with N-ARMD and 30 controls without N-ARMD were studied. Plasma concentrations of C-reactive protein (CRP) and PTX3 were measured in frozen samples using an enzyme-linked immunosorbent assay kit.
   Results: PTX3 concentration was 1341 +/- 625 pg/mL (mean +/- standard deviation) in N-ARMD patients, which was significantly higher than in control subjects (887 +/- 478, p = 0.003). The mean CRP level was also significantly higher in N-ARMD (2121 +/- 2300) than in control (748 +/- 618, p = 0.004). Pearson's correlation analysis showed a significant positive correlation between PTX3 and CRP (r = 0.407, p = 0.002).
   Conclusions: Our data support the role of chronic inflammation in the development of ARMD. They also show PTX3 may contribute to efforts to understand pathogenesis of N-ARMD.
C1 [Min, Jung Kee; Woo, Je Moon] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, Ulsan 682714, South Korea.
   [Kim, Jaehong] Gachon Univ, Sch Med, Dept Biochem, Inchon, South Korea.
C3 University of Ulsan; Ulsan University Hospital; Gachon University
RP Woo, JM (通讯作者)，Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, 290-3 Jeonha Dong, Ulsan 682714, South Korea.
EM limbus68@naver.com
RI Min, Jung Kee/V-5010-2019
OI Min, Jung Kee/0000-0002-8006-8560; Kim, Jaehong/0000-0001-5653-1159
CR Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Alberti L, 2009, ATHEROSCLEROSIS, V202, P455, DOI 10.1016/j.atherosclerosis.2008.05.015
   ALLES VV, 1994, BLOOD, V84, P3483
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baruah P, 2006, J LEUKOCYTE BIOL, V80, P87, DOI 10.1189/jlb.0805445
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817
   BREVIARIO F, 1992, J BIOL CHEM, V267, P22190
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Dias AAM, 2001, J LEUKOCYTE BIOL, V69, P928
   Diniz SN, 2004, J LEUKOCYTE BIOL, V75, P649, DOI 10.1189/jlb.0803371
   Doni A, 2003, EUR J IMMUNOL, V33, P2886, DOI 10.1002/eji.200324390
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Han B, 2005, J IMMUNOL, V175, P8303, DOI 10.4049/jimmunol.175.12.8303
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Inoue K, 2007, ARTERIOSCL THROM VAS, V27, P161, DOI 10.1161/01.ATV.0000252126.48375.d5
   Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jeannin P, 2005, IMMUNITY, V22, P551, DOI 10.1016/j.immuni.2005.03.008
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kume N, 2011, J CARDIOL, V58, P38, DOI 10.1016/j.jjcc.2011.03.006
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee Dong-Hyeon, 2010, Korean Circ J, V40, P370, DOI 10.4070/kcj.2010.40.8.370
   LEE GW, 1993, J IMMUNOL, V150, P1804
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Manfredi AA, 2008, CURR OPIN IMMUNOL, V20, P538, DOI 10.1016/j.coi.2008.05.004
   Mantovani A, 2013, ANN NY ACAD SCI, V1285, P1, DOI 10.1111/nyas.12043
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P465, DOI 10.1002/immu.200310022
   Norata GD, 2009, CIRCULATION, V120, P699, DOI 10.1161/CIRCULATIONAHA.108.806547
   Ohbayashi H, 2009, J ATHEROSCLER THROMB, V16, P490, DOI 10.5551/jat.No613
   PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perrier P, 2004, J IMMUNOL, V172, P7031, DOI 10.4049/jimmunol.172.11.7031
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481
   Rolph MS, 2002, ARTERIOSCL THROM VAS, V22, pE10, DOI 10.1161/01.ATV.0000015595.95497.2F
   Rovere P, 2000, BLOOD, V96, P4300
   Salio M, 2008, CIRCULATION, V117, P1055, DOI 10.1161/CIRCULATIONAHA.107.749234
   Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056
   Savchenko AS, 2008, J PATHOL, V215, P48, DOI 10.1002/path.2314
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sobrin L, 2011, AM J OPHTHALMOL, V151, P345, DOI 10.1016/j.ajo.2010.08.015
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Woo JM, 2013, MOL VIS, V19, P303
   Yilmaz MI, 2009, CLIN J AM SOC NEPHRO, V4, P535, DOI 10.2215/CJN.04330808
   Yuan DQ, 2013, MOL VIS, V19, P374
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 72
TC 8
Z9 8
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD JUN
PY 2015
VL 23
IS 3
BP 205
EP 211
DI 10.3109/09273948.2014.891755
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK9BZ
UT WOS:000356536700003
PM 24654791
DA 2022-11-30
ER

PT J
AU Bartlett, H
   Eperjesi, F
AF Bartlett, H
   Eperjesi, F
TI Age-related macular degeneration and nutritional supplementation: a
   review of randomised controlled trials
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE age-related macular degeneration; antioxidants; carotenoids; lutein;
   randomised controlled trials
ID PIGMENT OPTICAL-DENSITY; ALPHA-TOCOPHEROL; BETA-CAROTENE;
   GAMMA-TOCOPHEROL; GENETIC-LINKAGE; ZINC NUTRITURE; ASCORBIC-ACID;
   RISK-FACTORS; ORAL ZINC; VITAMIN-C
AB Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world. The lack of effective treatment modalities, coupled with evidence supporting an oxidative pathogenesis, has increased interest in the potential preventative role of nutritional supplementation. This article reviews seven randomised controlled trials (RCTs) that have investigated the role of nutritional supplementation in AMD. Three of these trials reported a positive effect of nutritional supplementation on AMD; the Age-related eye study (AREDS), the Lutein Antioxidant Supplementation Trial (LAST), and the oral zinc trial by Newsome et al. (1988). However, the oral zinc trial by Newsome et al. (1988) was unlikely to detect any difference between treatments smaller than 72%, and the AREDS results were based on a subgroup of their study population. Lutein was considered for the AREDS formulation, but was not commercially available at that time. The findings of the LAST support a possible therapeutic role of lutein in AMD.
C1 Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Bartlett, H (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Neurosci Res Inst, Aston Triangle, Birmingham B4 7ET, W Midlands, England.
EM bartlehe@aston.ac.uk
RI Eperjesi, Frank/A-9275-2013
OI Eperjesi, Frank/0000-0003-4358-0095; Bartlett Eperjesi, Hannah
   E/0000-0002-7531-6902
CR Abramson DH, 2002, ARCH OPHTHALMOL-CHIC, V120, P1602
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   ALVAREZ RA, 1987, AM J CLIN NUTR, V46, P481, DOI 10.1093/ajcn/46.3.481
   Armstrong RA, 2000, OPHTHAL PHYSL OPT, V20, P235, DOI 10.1046/j.1475-1313.2000.00502.x
   BEARDSLEY T, 1991, SCI AM, P16
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BERGER A, 2002, BMJ-BRIT MED J, V325, P1063
   Bernstein PS, 2002, PURE APPL CHEM, V74, P1419, DOI 10.1351/pac200274081419
   BIELSKI BHJ, 1982, AM CHEM SOC ADV CHEM, V200, P81
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BISCHOFF PM, 1983, AM J OPHTHALMOL, V96, P398, DOI 10.1016/S0002-9394(14)77839-0
   BODANNES RS, 1979, FEBS LETT, V105, P195, DOI 10.1016/0014-5793(79)80609-2
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   BURTON GW, 1985, PHILOS T R SOC B, V311, P565, DOI 10.1098/rstb.1985.0164
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156
   BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   CLARKE MP, 1990, BRIT J OPHTHALMOL, V74, P526, DOI 10.1136/bjo.74.9.526
   COSTAGLIOLA C, 1990, OPHTHALMOLOGICA, V201, P45, DOI 10.1159/000310124
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Department of Health, 1992, NUTR ELD PEOPL REP H, V43
   DILLEY RA, 1970, J MEMBRANE BIOL, V2, P317, DOI 10.1007/BF01869867
   DREVON CA, 1991, FREE RADICAL RES COM, V14, P229, DOI 10.3109/10715769109088952
   DUNLAP WM, 1974, ANN INTERN MED, V80, P470, DOI 10.7326/0003-4819-80-4-470
   ECKHERT CD, 1979, FED PROC, V38, P872
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   EVANS J, 2002, COCHRANE LIBR
   FARBER DB, 1985, INVEST OPHTH VIS SCI, V26, P1558
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FISCHER PWF, 1983, J NUTR, V113, P462, DOI 10.1093/jn/113.2.462
   FLANAGAN PR, 1983, J NUTR, V113, P962, DOI 10.1093/jn/113.5.962
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FUKUZAWA K, 1983, ARCH BIOCHEM BIOPHYS, V226, P242, DOI 10.1016/0003-9861(83)90290-4
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955
   GRAY JAM, 1997, EVIDENCE BASED HEALT
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Ham W.T., 1989, LASER APPL MED BIOL, P191
   HAM WT, 1983, J OCCUP ENVIRON MED, V25, P101
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1985, J NUTR, V115, P807, DOI 10.1093/jn/115.6.807
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hawkins BS, 1999, MOL VIS, V5
   HEMILA H, 1984, FEBS LETT, V178, P25, DOI 10.1016/0014-5793(84)81232-6
   HUBER AM, 1975, J NUTR, V105, P1486, DOI 10.1093/jn/105.11.1486
   Hulley SB, 2013, DESIGNING CLIN RES
   HUNT DF, 1984, CURR EYE RES, V3, P1281, DOI 10.3109/02713688409007414
   Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   JACQUES PF, 1992, J AM COLL NUTR, V11, P139
   JACQUES PF, 1992, ANN NY ACAD SCI, V669, P205
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KHACHIK F, 1989, J AGR FOOD CHEM, V37, P1465, DOI 10.1021/jf00090a003
   KHACHIK F, 1988, J AGR FOOD CHEM, V36, P929, DOI 10.1021/jf00083a010
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   KHACHIK F, 1987, J AGR FOOD CHEM, V35, P732, DOI 10.1021/jf00077a022
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Klevay LM, 2000, J NUTR, V130, p489S, DOI 10.1093/jn/130.2.489S
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LAZARIDES L, 1997, NUTR HLTH BIBLE
   Leo MA, 1997, J NATL CANCER I, V89, P1722, DOI 10.1093/jnci/89.22.1722
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Machlin L. J., 1980, VITAMIN E COMPREHENS
   MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807
   MANGELS AR, 1993, J AM DIET ASSOC, V93, P284, DOI 10.1016/0002-8223(93)91553-3
   MANSON JE, 1991, CIRCULATION S2, V84, P546
   Martin HD, 1999, PURE APPL CHEM, V71, P2253, DOI 10.1351/pac199971122253
   MATHEWSROTH MM, 1986, BIOCHIMIE, V68, P875, DOI 10.1016/S0300-9084(86)80104-3
   MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543
   MCCLAIN CJ, 1985, PROG FOOD NUTR SCI, V9, P185
   MELLERIO J, 2001, SPEC INT S XANTH CAR, P5
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X
   OLSON JA, 1984, J NATL CANCER I, V73, P1439
   ONG ASH, 1992, METHOD ENZYMOL, V213, P142
   OSILESI O, 1991, NUTR RES, V11, P405, DOI 10.1016/S0271-5317(05)80002-8
   OZAWA T, 1983, BIOCHEM INT, V6, P685
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pippenger CE, 1991, IDIOSYNCRATIC REACTI, P75
   Potts A M, 1966, Trans Am Acad Ophthalmol Otolaryngol, V70, P1058
   RICHER S, 2002, INVEST OPHTHALMOL VI, V43
   RIDGMAN WJ, 1975, EXPT BIOL
   Schalch W, 2001, CHIM OGGI, V19, P12
   SCHALCH W, 1992, FREE RADICALS AGING, P280
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM., 1999, VITAMIN NUTR INFORMA, V2, P1
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SIEGEL E, 1961, BRIT J CANCER, V15, P647, DOI 10.1038/bjc.1961.74
   SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2
   SIGEL H, 1983, ITS ROLE BIOL NUTR
   Silvestri G, 1997, MOL MED TODAY, V3, P84, DOI 10.1016/S1357-4310(96)10057-5
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SOLOMONS NW, 1979, AM J CLIN NUTR, V32, P856, DOI 10.1093/ajcn/32.4.856
   SOLOMONS NW, 1980, AM J CLIN NUTR, V33, P2031, DOI 10.1093/ajcn/33.9.2031
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   STONE EM, 1992, NAT GENET, V1, P246, DOI 10.1038/ng0792-246
   STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   SWANSON AA, 1971, BIOCHEM BIOPH RES CO, V45, P1488, DOI 10.1016/0006-291X(71)90188-4
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   TURNLAND J, 1981, AM J CLIN NUTR, V34, P2641, DOI 10.1093/ajcn/34.12.2641
   UJIIE M, 1979, ACTA SOC OPTHALMOL, V83, P2149
   URBACH C, 1951, EXP MED SURG, V10, P7
   van der Hagen A M, 1993, J Am Optom Assoc, V64, P871
   Verhoeff FH, 1937, ARCH OPHTHALMOL-CHIC, V18, P561
   Vinding T, 1995, ACTA OPHTHALMOL SCAN, V73, P3
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   VITALE S, 1993, EPIDEMIOLOGY, V4, P195, DOI 10.1097/00001648-199305000-00003
   WAGNER PA, 1985, GERIATRICS, V40, P111
   WAGNER PA, 1983, INT J VITAM NUTR RES, V53, P94
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WILLIAMS HT, 1971, SURG GYNECOL OBSTETR, V132, P662
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   ZHANG K, 1994, ARCH OPHTHALMOL-CHIC, V112, P759, DOI 10.1001/archopht.1994.01090180057035
NR 146
TC 56
Z9 60
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD SEP
PY 2003
VL 23
IS 5
BP 383
EP 399
DI 10.1046/j.1475-1313.2003.00130.x
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 725PC
UT WOS:000185550700001
PM 12950886
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tilleul, J
   Richard, F
   Puche, N
   Zerbib, J
   Leveziel, N
   Sahel, JA
   Cohen, SY
   Korobelnik, JF
   Feingold, J
   Munnich, A
   Kaplan, J
   Rozet, JM
   Souied, EH
AF Tilleul, Julien
   Richard, Florence
   Puche, Nathalie
   Zerbib, Jennyfer
   Leveziel, Nicolas
   Sahel, Jose Alain
   Cohen, Salomon Yves
   Korobelnik, Jean-Francois
   Feingold, Josue
   Munnich, Arnold
   Kaplan, Josseline
   Rozet, Jean-Michel
   Souied, Eric H.
TI Genetic association study of mitochondrial polymorphisms in neovascular
   age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT-FACTOR-H; CHOROIDAL NEOVASCULARIZATION; FRENCH POPULATION;
   RETINAL DEGENERATION; FINNISH POPULATION; CHINESE POPULATION; OXIDATIVE
   STRESS; DNA HAPLOGROUPS; DISEASE RISK; SUSCEPTIBILITY
AB Purpose: Age-related macular degeneration (AMD) is a multifactorial disease involving genetic and environmental factors. Most of the genetic factors identified so far involve the nuclear genome. Recently, two studies in North America and Australia reported an association between advanced AMD and the mitochondrial T2 haplogroup. Our purpose was to assess this association in a large French population.
   Methods: This case control study included 1,224 patients with neovascular AMD and 559 controls with normal fundus. Mitochondrial DNA polymorphisms at and around nucleotides 4917, 11,812, and 14,233 were determined using PCR amplification and direct sequencing of mitochondrial DNA.
   Results: No association was found between the mitochondrial T2 haplogroup and neovascular AMD in the French population: 94/1,152 patients with neovascular AMD had the T2 haplogroup (8.2%) versus 34/482 controls (7.1%; odds ratio=0.9 [0.5-1.5], p=0.66).
   Conclusions: An association between AMD and the T2 haplogroup, previously described in North American and Australian populations, was not confirmed in a large French population.
C1 [Tilleul, Julien; Puche, Nathalie; Zerbib, Jennyfer; Leveziel, Nicolas; Souied, Eric H.] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Tilleul, Julien; Feingold, Josue; Munnich, Arnold; Kaplan, Josseline; Rozet, Jean-Michel] Univ Paris 05, Hop Necker Enfants Malad, INSERM U781, Dept Genet, Paris, France.
   [Richard, Florence] Univ Lille Nord France, INSERM, UMR744, Inst Pasteur Lille, Lille, France.
   [Sahel, Jose Alain] Univ Paris 06, INSERM, Dept Ophthalmol, Inst Vis, Paris, France.
   [Cohen, Salomon Yves] Ophthalmol Ctr Imaging & Laser, Paris, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux 2, Hop Pellegrin, CHU Bordeaux, INSERM U897, F-33076 Bordeaux, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Necker-Enfants Malades - APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; Universite de
   Lille; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU
   Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux
RP Souied, EH (通讯作者)，Hop Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI ROZET, Jean-Michel/E-5737-2016; KOROBELNIK, Jean-Francois/A-5448-2016;
   Sahel, Jose-Alain/F-3172-2017; KAPLAN, Josseline/I-2622-2017
OI ROZET, Jean-Michel/0000-0001-7951-7886; Sahel,
   Jose-Alain/0000-0002-4831-1153; KAPLAN, Josseline/0000-0002-1849-8658;
   Nicolas, Leveziel/0000-0001-8533-9457
FU Fondation de France (Fondation Paulette Darty)
FX A poster of these results was presented at the ARVO meeting in May 2011,
   Fort Lauderdale, Florida, USA. The authors are especially grateful to J.
   Dumas and P. Ledudal for collecting blood and DNA. We thank also N.
   Delphin, I. Perrault, S. Gerber, S. Hanein, L. Fares-Taie for their
   advices during genotyping. The authors thank also Dr. A. Platel at APMW
   for his help with the manuscript. Funding/ support: this work has been
   performed thanks to a grant from the Fondation de France (Fondation
   Paulette Darty, scientific director: Prof. G. Coscas). Financial
   disclosures: none of the authors have a proprietary interest in this
   manuscript.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bilal E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002421
   Cai XY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006423
   Caicedo A, 2005, J COMP NEUROL, V483, P263, DOI 10.1002/cne.20413
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Keck Anna-Sigrid, 2004, Integr Cancer Ther, V3, P5, DOI 10.1177/1534735403261831
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Leveziel N, 2007, MOL VIS, V13, P2153
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maruszak A, 2009, NEUROBIOL AGING, V30, P1749, DOI 10.1016/j.neurobiolaging.2008.01.004
   Muller WE, 2010, MOL NEUROBIOL, V41, P159, DOI 10.1007/s12035-010-8141-5
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pello R, 2008, HUM MOL GENET, V17, P4001, DOI 10.1093/hmg/ddn303
   Reitsamer HA, 2012, PLOS ONE, V7
   Riso P, 2009, NUTR CANCER, V61, P232, DOI 10.1080/01635580802425688
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seitsonen S, 2006, MOL VIS, V12, P796
   Someya S, 2010, MECH AGEING DEV, V131, P480, DOI 10.1016/j.mad.2010.04.006
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   Velarde MC, 2012, AGING-US, V4, P3, DOI 10.18632/aging.100423
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zerbib J, 2010, MOL VIS, V16, P1324
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 48
TC 6
Z9 6
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 29
PY 2013
VL 19
BP 1132
EP 1139
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 158QW
UT WOS:000319988400004
PM 23734082
DA 2022-11-30
ER

PT J
AU Souied, EH
   Delcourt, C
   Querques, G
   Bassols, A
   Merle, B
   Zourdani, A
   Smith, T
   Benlian, P
AF Souied, Eric H.
   Delcourt, Cecile
   Querques, Giuseppe
   Bassols, Ana
   Merle, Benedicte
   Zourdani, Alain
   Smith, Theodore
   Benlian, Pascale
CA Nutr AMD Treatment 2 Study Grp
TI Oral Docosahexaenoic Acid in the Prevention of Exudative Age-Related
   Macular Degeneration The Nutritional AMD Treatment 2 Study
SO OPHTHALMOLOGY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; DIETARY-FAT; FISH INTAKE; LONG-CHAIN;
   CARDIOVASCULAR-DISEASE; RISK; OMEGA-3-FATTY-ACIDS; CONSUMPTION;
   SUPPLEMENTATION; ASSOCIATIONS
AB Objective: To evaluate the efficacy of docosahexaenoic acid (DHA)-enriched oral supplementation in preventing exudative age-related macular degeneration (AMD).
   Design: The Nutritional AMD Treatment 2 study was a randomized, placebo-controlled, double-blind, parallel, comparative study.
   Participants: Two hundred sixty-three patients 55 years of age or older and younger than 85 years with early lesions of age-related maculopathy and visual acuity better than 0.4 logarithm of minimum angle of resolution units in the study eye and neovascular AMD in the fellow eye.
   Methods: Patients were assigned randomly to receive either 840 mg/day DHA and 270 mg/day eicosapentaenoic acid (EPA) from fish oil capsules or the placebo (olive oil capsules) for 3 years.
   Main Outcome Measures: The primary outcome measure was time to occurrence of choroidal neovascularization (CNV) in the study eye. Secondary outcome measures in the study eye were: incidence of CNV developing in patients, changes in visual acuity, occurrence and progression of drusen, and changes in EPA plus DHA level in red blood cell membrane (RBCM).
   Results: Time to occurrence and incidence of CNV in the study eye were not significantly different between the DHA group (19.5 +/- 10.9 months and 28.4%, respectively) and the placebo group (18.7 +/- 10.6 months and 25.6%, respectively). In the DHA group, EPA plus DHA levels increased significantly in RBCM (+70%; P < 0.001), suggesting that DHA easily penetrated cells, but this occurred unexpectedly also in the placebo group (+9%; P = 0.007). In the DHA-allocated group, patients steadily achieving the highest tertile of EPA plus DHA levels in RBCM had significantly lower risk (-68%; P = 0.047; hazard ratio, 0.32; 95% confidence interval, 0.10-0.99) of CNV developing over 3 years. No marked changes from baseline in best-corrected visual acuity, drusen progression, or geographic atrophy in the study eye were observed throughout the study in either group.
   Conclusions: In patients with unilateral exudative AMD, 3 years of oral DHA-enriched supplementation had the same effect on CNV incidence in the second eye as did the placebo. However, RBCM fatty acid measurements revealed that CNV incidence was significantly reduced in DHA-supplemented patients showing a steadily high EPA plus DHA index over 3 years. (C) 2013 by the American Academy of Ophthalmology.
C1 [Souied, Eric H.; Querques, Giuseppe; Zourdani, Alain] Univ Paris Est Creteil, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Delcourt, Cecile; Merle, Benedicte] Univ Bordeaux, ISPED, Bordeaux, France.
   [Delcourt, Cecile; Merle, Benedicte] INSERM, Ctr INSERM, Bordeaux, France.
   [Bassols, Ana] Lab Bausch & Lomb Chauvin, Montpellier, France.
   [Smith, Theodore] NYU, Dept Ophthalmol, Sch Med, New York, NY 10016 USA.
   [Benlian, Pascale] Hop St Antoine, APHP, Endocrinol & Metab Dis Dept, F-75571 Paris, France.
   [Benlian, Pascale] Univ Lille 2, Sch Med, Dept Biochem & Mol Biol, Lille, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); New York
   University; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Antoine
   - APHP; UDICE-French Research Universities; Sorbonne Universite;
   Universite de Franche-Comte; Universite de Lille - ISITE; CHU Lille;
   Universite de Lille
RP Souied, EH (通讯作者)，Hop Intercommunal Creteil, Serv Ophtalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr; pascale.benlian@inserm.fr
RI Merle, Benedicte MJ/AAQ-5021-2021; Delcourt, Cecile/I-2627-2013; Merle,
   Benedicte MJ/F-1247-2015; Benlian, Pascale/I-7964-2016
OI Merle, Benedicte MJ/0000-0003-1332-0954; Delcourt,
   Cecile/0000-0002-2099-0481; Merle, Benedicte MJ/0000-0003-1332-0954;
   Nicolas, Leveziel/0000-0001-8533-9457; Querques,
   Giuseppe/0000-0002-3292-9581; Benlian, Pascale/0000-0002-3423-8979
FU Laboratoire Bausch Lomb Chauvin; Laboratoire Bausch Lomb; Laboratoires
   Thea; Laboratoire Bausch & Lomb Chauvin, Montpellier, France
FX Pascale Benlian: Financial support and lecturer-Laboratoire Bausch &
   Lomb Chauvin; Cecile Delcourt: Consultant and financial
   support-Laboratoire Bausch & Lomb; Chauvin; Consultant and financial
   support-Laboratoires Thea;; Sponsored by Laboratoire Bausch & Lomb
   Chauvin, Montpellier, France.
CR Afssa, 2010, AV REL ACT APP NUTR
   [Anonymous], 1997, FED REGISTER, P30751
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Balk EM, 2006, ATHEROSCLEROSIS, V189, P19, DOI 10.1016/j.atherosclerosis.2006.02.012
   Bazan NG, 2009, PROSTAG LEUKOTR ESS, V81, P205, DOI 10.1016/j.plefa.2009.05.024
   Benlian P, 2000, CLIN CHEM, V46, P493
   Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Coscas G, 1991, DEGENERESCENCES MACU, P160
   Daures J P, 2000, J Epidemiol Biostat, V5, P109
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Filion KB, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-24
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Hoffman DR, 2004, AM J OPHTHALMOL, V137, P704, DOI 10.1016/j.ajo.2003.10.045
   Hyun DH, 2006, AGEING RES REV, V5, P209, DOI 10.1016/j.arr.2006.03.005
   Le Tien V, 2006, J FR OPHTALMOL, V29, P796, DOI 10.1016/S0181-5512(06)73849-9
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Marik PE, 2009, CLIN CARDIOL, V32, P365, DOI 10.1002/clc.20604
   Massaro M, 2008, PROSTAG LEUKOTR ESS, V79, P109, DOI 10.1016/j.plefa.2008.09.009
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438
   Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   von Schacky C, 2011, PROSTAG OTH LIPID M, V96, P94, DOI 10.1016/j.prostaglandins.2011.06.008
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 48
TC 92
Z9 95
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1619
EP 1631
DI 10.1016/j.ophtha.2013.01.005
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000024
PM 23395546
DA 2022-11-30
ER

PT J
AU Arslan, J
   Baird, PN
AF Arslan, Janan
   Baird, Paul N.
TI Changing vision: a review of pharmacogenetic studies for treatment
   response in age-related macular degeneration patients
SO PHARMACOGENOMICS
LA English
DT Review
DE age-related macular degeration; pharmacogenetics; pharmacogenomics;
   personalized medicine; DNA; treatment response
ID COMPLEMENT FACTOR-H; INTRAVITREAL RANIBIZUMAB TREATMENT; GROWTH-FACTOR
   TREATMENT; VEGFR2 GENE POLYMORPHISMS; PHOTODYNAMIC THERAPY; CHOROIDAL
   NEOVASCULARIZATION; RISK-FACTORS; PERSONALIZED MEDICINE; LOC387715
   GENOTYPES; COST-EFFECTIVENESS
AB Nonresponsiveness to age-related macular degeneration (AMD) treatments has become a growing concern in ophthalmology. Disparity among publications that have assessed pharmacogenetic (PGx) connections between AMD disease genes and treatments has delayed the implementation of PGx testing in AMD. We assessed all AMD PGx publications to identify the degree of agreement for publications within similar ethnic cohorts and worldwide, and the causes for differences in study outcomes. There are no accepted genotype-phenotype correlations, either within similar ethnic cohorts or worldwide. The diversity of measured outcomes, treatment protocols and statistical methods used may be causing this discrepancy. A universally accepted treatment protocol and the creation of agreed response group classification may bridge the gap between AMD PGx publications.
C1 [Arslan, Janan; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Baird, PN (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Dept Surg Ophthalmol, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
RI Arslan, Janan/AAA-7160-2022
OI Arslan, Janan/0000-0003-2683-3775; Baird, Paul/0000-0002-1305-3502
FU National Health and Medical Research Council of Australia (NHMRC) Senior
   Research Fellowship [1138585]
FX The authors acknowledge funding from the National Health and Medical
   Research Council of Australia (NHMRC) Senior Research Fellowship 1138585
   (PN Baird). The Centre for Eye Research Australia (CERA) receives
   Operational Infrastructure Support from the Victorian Government. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abbasi J, 2016, JAMA-J AM MED ASSOC, V316, P1533, DOI 10.1001/jama.2016.12103
   Abedi F, 2012, INVEST OPHTH VIS SCI, V53, P2931
   Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Andreatta W, 2014, OPHTHALMOLOGICA, V231, P185, DOI 10.1159/000357528
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Australian Institute of Health Welfare, 2005, VIS PROBL OLD AUSTR
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bahadorani Sepehr, 2017, F1000Res, V6, P519, DOI 10.12688/f1000research.10998.1
   Bakbak B, 2016, CURR EYE RES, V41, P862, DOI 10.3109/02713683.2015.1067325
   Bardak H, 2016, GENET MOL RES, V15, P1
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Bielinski SJ, 2014, MAYO CLIN PROC, V89, P25, DOI 10.1016/j.mayocp.2013.10.021
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Broglio KR, 2014, J BIOPHARM STAT, V24, P685, DOI 10.1080/10543406.2014.888569
   Buck DA, 2015, CLIN EXP OPHTHALMOL, V43, P277, DOI 10.1111/ceo.12405
   Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053
   Campioni M, 2010, MOL CANCER RES, V8, P1248, DOI 10.1158/1541-7786.MCR-09-0473
   Chang W, 2013, MOL VIS, V19, P702
   Chaudhary V, 2016, OPHTHALMOLOGICA, V236, P88, DOI 10.1159/000446819
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Cohen N., 2008, METHODS PHARM TOXICO, V6
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cooper K, 2015, AGE AGEING, V44, P1026, DOI 10.1093/ageing/afv126
   Cruz-Gonzalez F, 2016, INT J OPHTHALMOL-CHI, V9, P1304, DOI 10.18240/ijo.2016.09.12
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Veloso CED, 2014, OPHTHALMIC RES, V51, P1, DOI 10.1159/000354328
   Veloso CED, 2012, REV BRAS OFTALMOL, V71, P194, DOI 10.1590/S0034-72802012000300011
   Economics A., 2010, CLEAR FOC EC IMP VIS
   Ehmann F, 2015, PHARMACOGENOMICS J, V15, P201, DOI 10.1038/tpj.2014.86
   Faber Jorge, 2014, Dental Press J. Orthod., V19, P27, DOI 10.1590/2176-9451.19.4.027-029.ebo
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Golik Pawel, 2012, Klin Oczna, V114, P79
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   Habibi I, 2016, KLIN MONATSBL AUGENH, V233, P465, DOI 10.1055/s-0041-111801
   Habibi I, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-15
   Hagstrom SA, 2003, OPHTHALMOLOGY, V121, P1141
   Hagstrom SA, 2015, OPHTHALMOLOGY, V122, P1563, DOI 10.1016/j.ophtha.2015.04.024
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hampton BM, 2015, CLIN OPHTHALMOL, V9, P873, DOI 10.2147/OPTH.S84155
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Harrell Jr FE, 2001, REGRESSION MODELING
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Hautamaki A, 2013, RETINA-J RET VIT DIS, V33, P1815, DOI 10.1097/IAE.0b013e318285cf92
   Hermann MM, 2014, OPHTHALMOLOGY, V121, P905, DOI 10.1016/j.ophtha.2013.10.047
   Hicks JK, 2016, AM J HEALTH-SYST PH, V73, P1967, DOI 10.2146/ajhp160030
   Hobbs Ronald P, 2014, J Ophthalmic Vis Res, V9, P487, DOI 10.4103/2008-322X.150829
   Holz F.G., 2013, AGE RELATED MACULAR
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Institute for Prospective Technological Studies, 2006, PHARM PHARM STAT OF
   Ji Y, 2016, J MOL DIAGN, V18, P438, DOI 10.1016/j.jmoldx.2016.01.003
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kang H, 2010, INVEST OPHTH VIS SCI, V51, P5906
   Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P523, DOI 10.1097/IAE.0000000000001554
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Kitchens JW, 2011, INVEST OPHTH VIS SCI, V52, P5259
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2012, INVEST OPHTH VIS SCI, V53, P5168
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471
   Kovach JL, 2011, INVEST OPHTH VIS SCI, V52, P5231
   Lazzeri S, 2016, PHARMACOGENOMICS, V17, P27, DOI 10.2217/pgs.15.153
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Ma CR, 2015, BIOMED REP, V3, P503, DOI 10.3892/br.2015.448
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MARMION VJ, 1971, P ROY SOC MED, V64, P628, DOI 10.1177/003591577106400614
   Matsumiya W, 2014, PHARMACOGENOMICS, V15, P833, DOI [10.2217/PGS.14.51, 10.2217/pgs.14.51]
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Medina FM, 2019, OPHTHALMIC RES, V61, P168, DOI 10.1159/000475995
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Messmer KJ, 2001, ANN PHARMACOTHER, V35, P1593
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Minami S, 2018, SCI REP, V8
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nakai S, 2017, MOL VIS, V23, P514
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Noffke AS, 2001, ARCH OPHTHALMOL-CHIC, V119, P143
   Noh DH, 2012, INVEST OPHTH VIS SCI, V53, P3328
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Ong FS, 2013, J PERS MED, V3, P40, DOI 10.3390/jpm3010040
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park UC, 2014, MOL VIS, V20, P1680
   Park UC, 2014, RETINA-J RET VIT DIS, V34, P288, DOI 10.1097/IAE.0b013e3182979e1e
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2015, INT J MOL SCI, V16, P19796, DOI 10.3390/ijms160819796
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Pearce E, 2011, EYE, V25, P149, DOI 10.1038/eye.2010.167
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pirmohamed M, 2001, BRIT J CLIN PHARMACO, V52, P345, DOI 10.1046/j.0306-5251.2001.01498.x
   Rakel D, 2012, INTEGRATIVE MED, P838
   Riaz M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37924
   Rubin GS., 2013, RETINA, P300
   Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Sengul EA, 2018, OCUL IMMUNOL INFLAMM, V26, P971, DOI 10.1080/09273948.2017.1311925
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stanek EJ, 2012, CLIN PHARMACOL THER, V91, P450, DOI 10.1038/clpt.2011.306
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein Joshua D, 2013, Trans Am Ophthalmol Soc, V111, P56
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Teper SJ, 2016, PHOTODIAGN PHOTODYN, V13, P108, DOI 10.1016/j.pdpdt.2016.01.006
   Teper SJ, 2010, MOL VIS, V16, P2598
   The Department of Health-Australian Government, SECT 2 EP IMP BLINDN
   Tiaden AN, 2013, AM J PATHOL, V182, P1482, DOI 10.1016/j.ajpath.2013.02.003
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   US FDA, TABL PHARM BIOM DRUG
   US Food and Drug Administration, 2013, CLIN PHARM PREM EV E
   US Food and Drug Administration, SAF REV UPD COD US C
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Wang VM, 2012, MOL VIS, V18, P2578
   Wang VM, 2011, INVEST OPHTHALMOL VI, V52
   WHO, BLINDN VIS 2020 GLOB
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamashiro K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09632-0
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yildiz BK, 2016, OPHTHALMIC RES, V56, P132, DOI 10.1159/000446186
   Yuan DQ, 2013, OPHTHALMOLOGICA, V230, P227, DOI 10.1159/000355068
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 194
TC 5
Z9 5
U1 0
U2 10
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD APR
PY 2018
VL 19
IS 5
BP 435
EP 461
DI 10.2217/pgs-2017-0183
PG 27
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GF3OB
UT WOS:000431864400007
PM 29577807
DA 2022-11-30
ER

PT J
AU Ghosh, S
   Padmanabhan, A
   Vaidya, T
   Watson, AM
   Bhutto, IA
   Hose, S
   Shang, P
   Stepicheva, N
   Yazdankhah, M
   Weiss, J
   Das, M
   Gopikrishna, S
   Aishwarya
   Yadav, N
   Berger, T
   Mak, TW
   Xia, SL
   Qian, J
   Lutty, GA
   Jayagopal, A
   Zigler, JS
   Sethu, S
   Handa, JT
   Watkins, SC
   Ghosh, A
   Sinha, D
AF Ghosh, Sayan
   Padmanabhan, Archana
   Vaidya, Tanuja
   Watson, Alan M.
   Bhutto, Imran A.
   Hose, Stacey
   Shang, Peng
   Stepicheva, Nadezda
   Yazdankhah, Meysam
   Weiss, Joseph
   Das, Manjula
   Gopikrishna, Santosh
   Aishwarya
   Yadav, Naresh
   Berger, Thorsten
   Mak, Tak W.
   Xia, Shuli
   Qian, Jiang
   Lutty, Gerard A.
   Jayagopal, Ashwath
   Zigler, J. Samuel, Jr.
   Sethu, Swaminathan
   Handa, James T.
   Watkins, Simon C.
   Ghosh, Arkasubhra
   Sinha, Debasish
TI Neutrophils homing into the retina trigger pathology in early
   age-related macular degeneration
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID PIGMENT EPITHELIUM; INCREASED LIPOCALIN-2; KAPPA-B; CELLS; MIGRATION;
   INTEGRIN; ACTIVATION; ADHESION; CANCER; INFLAMMATION
AB Age-related macular degeneration (AMD) is an expanding problem as longevity increases worldwide. While inflammation clearly contributes to vision loss in AMD, the mechanism remains controversial. Here we show that neutrophils are important in this inflammatory process. In the retinas of both early AMD patients and in a mouse model with an early AMD-like phenotype, we show neutrophil infiltration. Such infiltration was confirmed experimentally using ribbon-scanning confocal microscopy (RSCM) and IFN lambda- activated dye labeled normal neutrophils. With neutrophils lacking lipocalin-2 (LCN-2), infiltration was greatly reduced. Further, increased levels of IFNX in early AMD trigger neutrophil activation and LCN-2 upregulation. LCN-2 promotes inflammation by modulating integrin beta 1 levels to stimulate adhesion and transmigration of activated neutrophils into the retina. We show that in the mouse model, inhibiting AKT2 neutralizes IFN lambda inflammatory signals, reduces LCN-2-mediated neutrophil infiltration, and reverses early AMD-like phenotype changes. Thus, AKT2 inhibitors may have therapeutic potential in early, dry AMD.
C1 [Ghosh, Sayan; Bhutto, Imran A.; Hose, Stacey; Shang, Peng; Stepicheva, Nadezda; Yazdankhah, Meysam; Weiss, Joseph; Sinha, Debasish] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
   [Padmanabhan, Archana; Vaidya, Tanuja; Gopikrishna, Santosh; Aishwarya; Yadav, Naresh; Sethu, Swaminathan; Ghosh, Arkasubhra] Narayana Nethralaya Fdn, Bengaluru, India.
   [Watson, Alan M.; Watkins, Simon C.] Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA USA.
   [Watson, Alan M.; Watkins, Simon C.] Univ Pittsburgh, Sch Med, Dept Cellular Biol, Pittsburgh, PA USA.
   [Das, Manjula] Beyond Antibody, Bengaluru, India.
   [Berger, Thorsten; Mak, Tak W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada.
   [Berger, Thorsten; Mak, Tak W.] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada.
   [Xia, Shuli] Johns Hopkins Univ, Sch Med, Dept Neurol, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.
   [Qian, Jiang; Lutty, Gerard A.; Zigler, J. Samuel, Jr.; Handa, James T.; Sinha, Debasish] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Jayagopal, Ashwath] F Hoffmann La Roche Ltd, Pharma Res & Early Dev, Roche Innovat Ctr, Basel, Switzerland.
   [Jayagopal, Ashwath] Kodiak Sci, Palo Alto, CA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of
   Toronto; University Toronto Affiliates; University Health Network
   Toronto; University of Toronto; University Toronto Affiliates;
   University Health Network Toronto; Johns Hopkins University; Johns
   Hopkins University; Johns Hopkins Medicine; Roche Holding
RP Sinha, D (通讯作者)，Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA.; Sinha, D (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
EM Debasish@pitt.edu
RI Ghosh, Sayan/ABB-8587-2021; Sethu, Swaminathan/R-8577-2019; .,
   Aishwarya/AAR-3832-2020; Watkins, Simon/ABG-2590-2021
OI Watkins, Simon/0000-0003-4092-1552; Ghosh,
   Arkasubhra/0000-0002-6570-5891; /0000-0002-3780-5641; Sethu,
   Swaminathan/0000-0001-9210-2554
FU National Eye Institute [EY019037-S, EY027691, EY016151, EY 08098];
   RPB/IRRF Catalyst Award for Innovative Research Approaches for AMD; F.
   Hoffmann-La Roche, Ltd., Switzerland; Jennifer Salvitti Davis Chair in
   Ophthalmology; Robert Bond Welch Chair in Ophthalmology; G. Edward and
   G. Britton Durell Chair in Ophthalmology; Karl H Hagen Chair in
   Ophthalmology; Research to Prevent Blindness (Ophthalmology), NY;
   Research to Prevent Blindness (UPMC), NY; Research to Prevent Blindness
   (JHMI), NY
FX We thank Drs. Morton Goldberg (Wilmer Eye Institute, USA) and Shomi
   Bhattacharya (UCL Institute of Ophthalmology, UK) for critical reading
   and discussions regarding this manuscript. This study was funded by
   National Eye Institute: EY019037-S (DS), EY027691 (JTH), EY016151
   (G.A.L.), and EY 08098 (NIH core P30 to Ophthalmology, UPMC), RPB/IRRF
   Catalyst Award for Innovative Research Approaches for AMD (D.S.), F.
   Hoffmann-La Roche, Ltd., Switzerland (D.S.), Jennifer Salvitti Davis
   Chair in Ophthalmology (D.S.), Robert Bond Welch Chair in Ophthalmology
   (J.T.H.), G. Edward and G. Britton Durell Chair in Ophthalmology
   (G.A.L.), Karl H Hagen Chair in Ophthalmology (J.Q.), Research to
   Prevent Blindness (Ophthalmology, UPMC and JHMI), NY.
CR Abella V, 2015, BIOMARKERS, V20, P565, DOI 10.3109/1354750X.2015.1123354
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andrews RK, 2014, THROMB HAEMOSTASIS, V112, P659, DOI 10.1160/TH14-05-0455
   Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103
   Beyrau M, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120134
   Broggi A, 2017, NAT IMMUNOL, V18, P1084, DOI 10.1038/ni.3821
   Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001
   Cera MR, 2009, J CELL SCI, V122, P268, DOI 10.1242/jcs.037127
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036
   Du ZP, 2015, BBA-MOL CELL RES, V1853, P2240, DOI 10.1016/j.bbamcr.2015.07.007
   Fortunati E, 2009, CLIN EXP IMMUNOL, V155, P559, DOI 10.1111/j.1365-2249.2008.03791.x
   Gao Y, 2015, MOL CANCER RES, V13, P1602, DOI 10.1158/1541-7786.MCR-15-0213
   Gestermann N, 2018, J IMMUNOL, V200, P3364, DOI 10.4049/jimmunol.1700778
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Ghosh S, 2015, CELL SIGNAL, V27, P1398, DOI 10.1016/j.cellsig.2015.03.013
   Hanlon SD, 2014, EXP EYE RES, V120, P61, DOI 10.1016/j.exer.2014.01.004
   Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415
   Huang CL, 2004, J BIOL CHEM, V279, P42279, DOI 10.1074/jbc.M402540200
   Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516
   Kaifi JT, 2001, J IMMUNOL, V166, P6795, DOI 10.4049/jimmunol.166.11.6795
   Kim SB, 2017, LANCET ONCOL, V18, P1360, DOI 10.1016/S1470-2045(17)30450-3
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Kobayashi SD, 2009, WIRES SYST BIOL MED, V1, P309, DOI 10.1002/wsbm.32
   Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Langereis JD, 2013, CELL ADHES MIGR, V7, P476, DOI 10.4161/cam.27293
   Lerman YV, 2014, BLOOD, V124, P3515, DOI 10.1182/blood-2014-01-552943
   Ma CX, 2017, CLIN CANCER RES, V23, P6823, DOI 10.1158/1078-0432.CCR-17-1260
   Maher SG, 2008, CANCER BIOL THER, V7, P1109, DOI 10.4161/cbt.7.7.6192
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   McDonald B, 2017, BLOOD, V129, P1357, DOI 10.1182/blood-2016-09-741298
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Nielsen MK, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0100-9
   Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Price AA, 2016, P NATL ACAD SCI USA, V113, P10678, DOI 10.1073/pnas.1602319113
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rosales C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00113
   Rosales C, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/9748345
   Rosenbauer F, 2002, EMBO J, V21, P211, DOI 10.1093/emboj/21.3.211
   Roy S, 2017, J BIOL CHEM, V292, P435, DOI 10.1074/jbc.M116.748970
   Sarangi PP, 2012, SHOCK, V38, P281, DOI 10.1097/SHK.0b013e31826136f8
   Scholz M, 2004, J INVEST SURG, V17, P239, DOI 10.1080/08941930490502808
   Schroll A, 2012, EUR J IMMUNOL, V42, P3346, DOI 10.1002/eji.201142351
   Shang P, 2018, J VIS EXP, V133
   Shang P, 2017, AGING CELL, V16, P349, DOI 10.1111/acel.12561
   Shao S, 2016, J INVEST DERMATOL, V136, P1418, DOI 10.1016/j.jid.2016.03.002
   Sinha D, 2005, EXP EYE RES, V80, P323, DOI 10.1016/j.exer.2004.09.014
   Subramanian P, 2016, CURR OPIN HEMATOL, V23, P36, DOI 10.1097/MOH.0000000000000198
   Teckchandani A, 2009, J CELL BIOL, V186, P98, DOI 10.1083/jcb.200812160
   Tufekci KU, 2012, ADV PROTEIN CHEM STR, V88, P69, DOI 10.1016/B978-0-12-398314-5.00004-0
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   van der Windt DJ, 2018, HEPATOLOGY, V68, P1347, DOI 10.1002/hep.29914
   Wang Q, 2017, BRIT J CANCER, V117, P159, DOI 10.1038/bjc.2017.153
   Watson AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180486
   Waxman S, 2018, INVEST OPHTH VIS SCI, V59, P2371, DOI 10.1167/iovs.17-23075
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Wu MY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07250-6
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Yap TA, 2011, MOL CANCER THER, V10, P360, DOI 10.1158/1535-7163.MCT-10-0760
   Zenaro E, 2015, NAT MED, V21, P880, DOI 10.1038/nm.3913
   Zhao P, 2013, MOL METAB, V2, P161, DOI 10.1016/j.molmet.2013.04.003
   Zhao ZY, 2017, FASEB J, V31, P4903, DOI 10.1096/fj.201700533R
NR 76
TC 19
Z9 19
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD SEP 20
PY 2019
VL 2
AR 348
DI 10.1038/s42003-019-0588-y
PG 17
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA JB1GG
UT WOS:000488308200001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mathew, R
   Richardson, M
   Sivaprasad, S
AF Mathew, Raeba
   Richardson, Matthew
   Sivaprasad, Sobha
TI Predictive Value of Spectral-Domain Optical Coherence Tomography
   Features in Assessment of Visual Prognosis in Eyes With Neovascular
   Age-Related Macular Degeneration Treated With Ranibizumab
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FOVEAL PHOTORECEPTOR LAYER; ACUITY; INTEGRITY; EDEMA
AB PURPOSE: To determine whether pretreatment (baseline) optical coherence tomography (OCT) features can be used as predictors of visual acuity outcome at 12 months in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab and to assess whether baseline OCT features can predict a change in visual acuity from baseline to 12 months.
   DESIGN: Retrospective, observational study.
   METHODS: We retrospectively evaluated the serial cross-sectional images of the macula obtained using the Spectralis OCT (HRA + OCT; Heidelberg Engineering) in 100 eyes of 94 patients attending a single center and undergoing treatment with intravitreal ranibizumab for neovascular age-related macular degeneration. The baseline OCT characteristics and visual acuity were correlated to the final visual acuity (Early Treatment Diabetic Retinopathy Study letters) and change in visual acuity after, 12 months of monitoring and treatment. Univariate and multivariate analyses were carried out to correlate these morphologic features with the final visual acuity and the change in visual acuity.
   RESULTS: Intact ellipsoid zone (P = .0001) and external limiting membrane in the subfoveal area (P < .0001) at baseline were the only 2 independent good prognostic indicators of final visual acuity at 12 months. However, none of the morphologic features at baseline could predict the change in visual acuity by 12 months.
   CONCLUSIONS: The results suggest that integrity of the outer retinal layers at baseline is crucial for determining final visual acuity at 12 months in eyes undergoing treatment with ranibizumab for neovascular age-related macular degeneration. (Am J Ophthalmol 2013;155:720-726. (C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Mathew, Raeba; Richardson, Matthew; Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Mathew, R (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM r_mathew@hotmail.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Richardson,
   Matthew/0000-0002-7390-9480
FU Novartis; Pfizer; Allergan; Alimera Services; Bayer
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported.
   Sobha Sivaprasad has received research grants and travel grants from and
   has participated in advisory boards for Novartis, Pfizer, Allergan,
   Alimera Services, and Bayer. Raeba Mathew has received travel grants
   from Allergan and Novartis and speaker fees from Allergan. Involved in
   Design and conduct of study (R.M., M.R., S.S.); Collection of data
   (R.M., M.R.); Management, analysis, and interpretation of data (R.M.,
   S.S.); and Preparation, review, and approval of manuscript (R.M., S.S.).
CR Bottoni F, 2011, INVEST OPHTH VIS SCI, V52, P4439, DOI 10.1167/iovs.10-6732
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Flahault A, 2005, J CLIN EPIDEMIOL, V58, P859, DOI 10.1016/j.jclinepi.2004.12.009
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Ghazi NG, 2007, AM J OPHTHALMOL, V144, P747, DOI 10.1016/j.ajo.2007.07.012
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Maftouhi MQE, 2010, J FR OPHTALMOL, V33, P605, DOI 10.1016/j.jfo.2010.09.015
   Matsumoto H, 2008, AM J OPHTHALMOL, V145, P162, DOI 10.1016/j.ajo.2007.08.024
   Matsumoto H, 2011, AM J OPHTHALMOL, V151, P617, DOI 10.1016/j.ajo.2010.09.031
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Murakami T, 2011, AM J OPHTHALMOL, V151, P310, DOI 10.1016/j.ajo.2010.08.022
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Ota M, 2007, BRIT J OPHTHALMOL, V91, P1644, DOI 10.1136/bjo.2007.118497
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Spaide RF, 2012, OPHTHALMOLOGY, V119, P2203, DOI 10.1016/j.ophtha.2012.09.009
   Wilkins JR, 1996, OPHTHALMOLOGY, V103, P2142, DOI 10.1016/S0161-6420(96)30377-1
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Yamaike N, 2008, OPHTHALMOLOGY, V115, P355, DOI 10.1016/j.ophtha.2007.04.052
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 27
TC 33
Z9 36
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2013
VL 155
IS 4
BP 720
EP 726
DI 10.1016/j.ajo.2012.11.003
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 118JS
UT WOS:000317022400015
PM 23317653
DA 2022-11-30
ER

PT J
AU Wang, K
   Li, HR
   Sun, RP
   Liu, CX
   Luo, YF
   Fu, SH
   Ying, Y
AF Wang, Kai
   Li, Haoran
   Sun, Ruipu
   Liu, Chaxian
   Luo, Yunfei
   Fu, Shuhua
   Ying, Ying
TI Emerging roles of transforming growth factor signaling in wet
   age-related macular degeneration
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Review
DE TGF-beta superfamily; wet AMD; angiogenesis
ID BONE MORPHOGENETIC PROTEIN-2; EPITHELIAL-MESENCHYMAL TRANSITION;
   RETINAL-PIGMENT EPITHELIUM; TGF-BETA; SUBRETINAL FIBROSIS;
   ENDOTHELIAL-CELLS; KINASE (ALK)1; MESSENGER-RNA; AQUEOUS-HUMOR;
   EXPRESSION
AB Age-related macular degeneration (AMD) is one of the major causes of irreversible blindness among aging populations in developed countries and can be classified as dry or wet according to its progression. Wet AMD, which is characterized by angiogenesis on the choroidal membrane, is uncommonly seen but more severe. Controlling or completely inhibiting the factors that contribute to the progression of events that lead to angiogenesis may be an effective strategy for treating wet AMD. Emerging evidence has shown that transforming growth factor- (TGF-) signaling plays a significant role in the progression of wet AMD. In this review, we described the roles of and changes in TGF- signaling in the development of AMD and discussed the mechanisms of the TGF- superfamily in choroidal neovascularization (CNV) and wet AMD, including the modulation of angiogenesis-related factors, inflammation, vascular fibrosis, and immune responses, as well as cross-talk with other signaling pathways. These remarkable findings indicate that TGF- signaling is a potential target for wet AMD treatment.
C1 [Wang, Kai; Li, Haoran; Sun, Ruipu; Liu, Chaxian; Luo, Yunfei; Ying, Ying] Nanchang Univ, Med Coll, Sch Basic Med Sci, Jiangxi Prov Key Lab Tumor Pathogens & Mol Pathol, Nanchang 330006, Jiangxi, Peoples R China.
   [Wang, Kai; Li, Haoran; Sun, Ruipu; Liu, Chaxian; Luo, Yunfei; Ying, Ying] Nanchang Univ, Med Coll, Sch Pharmaceut Sci, Jiangxi Prov Key Lab Tumor Pathogens & Mol Pathol, Nanchang 330006, Jiangxi, Peoples R China.
   [Wang, Kai; Li, Haoran; Sun, Ruipu; Liu, Chaxian; Luo, Yunfei; Ying, Ying] Nanchang Univ, Med Coll, Sch Basic Med Sci, Dept Pathol, Nanchang 330006, Jiangxi, Peoples R China.
   [Wang, Kai; Li, Haoran; Sun, Ruipu; Liu, Chaxian; Luo, Yunfei; Ying, Ying] Nanchang Univ, Med Coll, Sch Pharmaceut Sci, Dept Pathol, Nanchang 330006, Jiangxi, Peoples R China.
   [Wang, Kai; Li, Haoran; Sun, Ruipu] Queen Mary Univ London, Nanchang Joint Program, London E1 4NS, England.
   [Liu, Chaxian] Nanchang Univ, Sch Med, Clin Dept 2, Nanchang 330006, Jiangxi, Peoples R China.
   [Luo, Yunfei; Ying, Ying] Nanchang Univ, Sch Med, Dept Pathophysiol, Nanchang 330006, Jiangxi, Peoples R China.
   [Fu, Shuhua] Nanchang Univ, Affiliated Hosp 2, Dept Ophthalmol, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University; University of London; Queen Mary University London; Nanchang
   University; Nanchang University; Nanchang University
RP Ying, Y (通讯作者)，Nanchang Univ, Med Coll, Sch Basic Med Sci, Jiangxi Prov Key Lab Tumor Pathogens & Mol Pathol, Nanchang 330006, Jiangxi, Peoples R China.; Ying, Y (通讯作者)，Nanchang Univ, Med Coll, Sch Pharmaceut Sci, Jiangxi Prov Key Lab Tumor Pathogens & Mol Pathol, Nanchang 330006, Jiangxi, Peoples R China.; Ying, Y (通讯作者)，Nanchang Univ, Med Coll, Sch Basic Med Sci, Dept Pathol, Nanchang 330006, Jiangxi, Peoples R China.; Ying, Y (通讯作者)，Nanchang Univ, Med Coll, Sch Pharmaceut Sci, Dept Pathol, Nanchang 330006, Jiangxi, Peoples R China.; Ying, Y (通讯作者)，Nanchang Univ, Sch Med, Dept Pathophysiol, Nanchang 330006, Jiangxi, Peoples R China.
EM yingying@ncu.edu.cn
RI Sun, Ruipu/GYR-3422-2022
OI luo, yunfei/0000-0002-6838-5950
FU National Natural Science Foundation of China [81660163, 81560299];
   Science and Technology Foundation of Jiangxi Province [20142BAB215053,
   2015BBG70171]; Foundation of the Second Affiliated Hospital of Nanchang
   University [2016YNZJ12001]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (Nos. 81660163 and 81560299), the Science and
   Technology Foundation of Jiangxi Province (Nos. 20142BAB215053 and
   2015BBG70171), the Foundation of the Second Affiliated Hospital of
   Nanchang University (No. 2016YNZJ12001).
CR Agarwal P, 2015, MOL VIS, V21, P612
   Akeel S, 2012, ARCH ORAL BIOL, V57, P445, DOI 10.1016/j.archoralbio.2011.10.002
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bai YJ, 2014, MOL VIS, V20, P1258
   Barben M, 2018, ADV EXP MED BIOL, V1074, P177, DOI 10.1007/978-3-319-75402-4_22
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Biswal MR, 2018, J MOL MED, V96, P1107, DOI 10.1007/s00109-018-1683-0
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Braunger BM, 2015, AM J PATHOL, V185, P1749, DOI 10.1016/j.ajpath.2015.02.007
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Cai J, 2012, FEBS LETT, V586, P1993, DOI 10.1016/j.febslet.2012.04.030
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Csiszar A, 2006, AM J PATHOL, V168, P629, DOI 10.2353/ajpath.2006.050284
   de Vinuesa AG, 2016, BIOCHEM SOC T, V44, P1142, DOI 10.1042/BST20160093
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dong YY, 2015, J EXP MED, V212, P235, DOI 10.1084/jem.20121878
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Garcia CM, 2004, DEV BRAIN RES, V152, P25, DOI 10.1016/j.devbrainres.2004.05.008
   Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1
   Grumbine FL, 2008, EVID BASED OPHTHALMO, V9, P189
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Hussein KA, 2014, EXP EYE RES, V125, P79, DOI 10.1016/j.exer.2014.05.012
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsson L, 2013, EXP CELL RES, V319, P1264, DOI 10.1016/j.yexcr.2013.02.015
   Jin Y, 2014, BIOCHEM SOC T, V42, P1576, DOI 10.1042/BST20140231
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kapur NK, 2013, VASC HEALTH RISK MAN, V9, P195, DOI 10.2147/VHRM.S29144
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Komai Toshihiko, 2016, Nihon Rinsho Meneki Gakkai Kaishi, V39, P51, DOI 10.2177/jsci.39.51
   Kurihara T, 2014, ADV EXP MED BIOL, V801, P275, DOI 10.1007/978-1-4614-3209-8_35
   Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069
   Lonn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Moon K, 2017, MOL VIS, V23, P1029
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nakerakanti SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021911
   Ntumba K, 2016, ONCOTARGET, V7, P55957, DOI 10.18632/oncotarget.11182
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Platania CBM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102076
   Pollman MJ, 1999, CIRCULATION, V99, P2019, DOI 10.1161/01.CIR.99.15.2019
   Rao PE, 2005, J IMMUNOL, V174, P1446, DOI 10.4049/jimmunol.174.3.1446
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565
   Santibanez JF, 2011, CLIN SCI, V121, P233, DOI 10.1042/CS20110086
   Schlecht A, 2017, AM J PATHOL, V187, P2570, DOI 10.1016/j.ajpath.2017.06.018
   Semkova I, 2014, EXP EYE RES, V118, P80, DOI 10.1016/j.exer.2013.11.006
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Takeyama K, 2016, BONE, V86, P68, DOI 10.1016/j.bone.2016.03.001
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Tian HY, 2018, FASEB J, V32, P2934, DOI 10.1096/fj.201700867RR
   Tosi GM, 2017, INVEST OPHTH VIS SCI, V58, P162, DOI 10.1167/iovs.16-20922
   Van Geest RJ, 2010, INVEST OPHTH VIS SCI, V51, P1857, DOI 10.1167/iovs.09-4181
   Wahl SM, 1999, MICROBES INFECT, V1, P1247, DOI 10.1016/S1286-4579(99)00261-0
   Wang L, 2016, GUOJI YANKE ZAZHI, V16, P1847
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wheeler SE, 2017, J CELL PHYSIOL, V232, P486, DOI 10.1002/jcp.25506
   Wynn TA, 2007, J CLIN INVEST, V117, P524, DOI 10.1172/JCI31487
   Xu HH, 2015, CLIN EXP PHARMACOL P, V42, P1207, DOI 10.1111/1440-1681.12470
   Yamashita H, 1997, EXP CELL RES, V235, P218, DOI 10.1006/excr.1997.3664
   Yan XH, 2012, J BIOL CHEM, V287, P13705, DOI 10.1074/jbc.M112.346221
   Ye L, 2016, CANCER LETT, V380, P586, DOI 10.1016/j.canlet.2015.10.036
   Ying Y, 2017, ONCOTARGET, V8, P32794, DOI 10.18632/oncotarget.15825
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang J, 2014, PROTEIN CELL, V5, P503, DOI 10.1007/s13238-014-0058-8
NR 75
TC 16
Z9 16
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672-9145
EI 1745-7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD JAN
PY 2019
VL 51
IS 1
BP 1
EP 8
DI 10.1093/abbs/gmy145
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HQ6QW
UT WOS:000462544100001
PM 30496406
DA 2022-11-30
ER

PT J
AU Veloso, CED
   de Almeida, LNF
   Recchia, FM
   Pelayes, D
   Nehemy, MB
AF dos Reis Veloso, Carlos Eduardo
   Frota de Almeida, Luciana Negrao
   Maria Recchia, Franco
   Pelayes, David
   Nehemy, Marcio Bittar
TI VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in
   Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Genetics; Polymorphism; Ranibizumab;
   Intravitreal injection
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; POLYPOIDAL CHOROIDAL
   VASCULOPATHY; PHOTODYNAMIC THERAPY; LOC387715 GENOTYPES; RISK-FACTORS;
   ASSOCIATION; BEVACIZUMAB; VARIANTS; CFH
AB Background/Aims: To investigate the association between VEGF gene polymorphism and response to ranibizumab in neovascular age-related macular degeneration (AMD). Methods: A total of 92 patients were genotyped for the VEGF rs1413711 single nucleotide polymorphism. Patients with neovascular AMD initially received 3 monthly ranibizumab intravitreal injections and were retreated as needed. Visual acuity (VA) and central retinal thickness (CRT) were measured before and 1, 3, 6 and 12 months after treatment. Results: For patients with TT and CT genotypes, paired comparisons of mean VA showed improvement when the data obtained at all visits were compared with baseline values, in contrast to patients with the CC genotype. CRT statistically improved at all visits for all genotypes. Conclusion: Patients with the CC genotype showed poorer long-term functional and anatomical response to anti-VEGF therapy. (C) 2013 S. Karger AG, Basel
C1 [dos Reis Veloso, Carlos Eduardo; Frota de Almeida, Luciana Negrao; Nehemy, Marcio Bittar] Univ Fed Minas Gerais, Dept Ophthalmol, Belo Horizonte, MG, Brazil.
   [Maria Recchia, Franco] Vanderbilt Eye Inst, Nashville, TN USA.
   [Pelayes, David] Univ Buenos Aires, Dept Ophthalmol, Buenos Aires, DF, Argentina.
C3 Universidade Federal de Minas Gerais; Vanderbilt University; University
   of Buenos Aires
RP Veloso, CED (通讯作者)，Rua Otoni 881,13 Andar, BR-30150270 Belo Horizonte, MG, Brazil.
EM cerveloso@hotmail.com
RI Nehemy, Marcio/ABD-5089-2021; Veloso, Carlos Eduardo dos
   Reis/E-1815-2016
OI Veloso, Carlos Eduardo dos Reis/0000-0002-8817-7200; Nehemy,
   Marcio/0000-0002-4104-0346
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown G, 2010, CURR OPIN OPHTHALMOL, V21, P169, DOI 10.1097/ICU.0b013e3283388605
   Chowers I, 2008, MOL VIS, V14, P2263
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Veloso CED, 2012, REV BRAS OFTALMOL, V71, P194, DOI 10.1590/S0034-72802012000300011
   Fang AM, 2009, MOL VIS, V15, P2710
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mitamura Y, 2010, INDIAN J OPHTHALMOL, V58, P291, DOI 10.4103/0301-4738.64130
   Nakata I, 2011, JPN J OPHTHALMOL, V55, P435, DOI 10.1007/s10384-011-0061-z
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Petrovic MG, 2008, MOL VIS, V14, P1382
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Renner W, 2000, J VASC RES, V37, P443, DOI 10.1159/000054076
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 43
TC 13
Z9 15
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 51
IS 1
BP 1
EP 8
DI 10.1159/000354328
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 265AS
UT WOS:000327922700001
PM 24157918
DA 2022-11-30
ER

PT J
AU Sakamoto, S
   Takahashi, H
   Tan, X
   Inoue, Y
   Nomura, Y
   Arai, Y
   Fujino, Y
   Kawashima, H
   Yanagi, Y
AF Sakamoto, Shinichi
   Takahashi, Hidenori
   Tan, Xue
   Inoue, Yuji
   Nomura, Yoko
   Arai, Yusuke
   Fujino, Yujiro
   Kawashima, Hidetoshi
   Yanagi, Yasuo
TI Changes in multiple cytokine concentrations in the aqueous humour of
   neovascular age-related macular degeneration after 2 months of
   ranibizumab therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE aqueous humour; macula; inflammation; retina
ID CHOROIDAL NEOVASCULARIZATION; INFLAMMATORY CYTOKINES; ENDOTHELIAL-CELLS;
   GENE-EXPRESSION; VEGF; AMD; ASSOCIATION; INHIBITION; BIOMARKERS; PROFILE
AB Purpose To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD).
   Methods This prospective study included 48 treatment-naive neovascular AMD eyes of 48 patients who received three consecutive monthly injections of ranibizumab at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between November 2010 and August 2012. We collected 0.2mL aqueous humour before the first and third (2 months later) injections. Controls were 80 eyes with cataracts without retinal disease. The cytokines C-X-C motif chemokine ligand 1 (CXCL1), interferon--induced protein 10 (IP-10), C-X-C motif chemokine ligand 12 (CXCL12), C-X-C motif chemokine ligand 13 (CXCL13), monocyte chemoattractant protein 1 (MCP-1), CCL11, C-C motif chemokine ligand 11 (CCL11), interleukin-6 (IL-6), interleukin-10 (IL-10) and matrix metalloproteinase 9 (MMP-9) were analysed using multiplex cytokine assays.
   Results Mean ages of the patients with AMD and controls were 73 and 75 years, respectively, and 31 (65%) and 37 (46%) subjects were men, respectively. Polypoidal choroidal vasculopathy was found in 27 eyes (56%). Mean concentrations of cytokines in aqueous humour in patients with neovascular AMD before the first and third ranibizumab injections were as follows (in pg/mL): CXCL1, 8.4 and 3.3; IP-10, 110 and 55; CXCL12, 480 and 240; CXCL13, 9.2 and 2.6; MCP-1, 620 and 220; CCL11, 7.1 and 2.8; IL-6, 5.9 and 1.6; IL-10, 0.15 and 0.015 (all p<0.0001), and MMP-9, 0.92 and 1.5 (p=0.0216), respectively. Concentrations of all cytokines decreased significantly after two consecutive ranibizumab injections, except for MMP-9, which increased significantly.
   Conclusions After twomonthly consecutive antivascular endothelial growth factor injections, inflammatory cytokine levels in the aqueous humour of the eyes with AMD were strongly suppressed, while MMP-9 levels increased.
C1 [Sakamoto, Shinichi; Takahashi, Hidenori; Inoue, Yuji; Arai, Yusuke; Kawashima, Hidetoshi] Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290431, Japan.
   [Takahashi, Hidenori; Tan, Xue; Inoue, Yuji; Nomura, Yoko] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo, Japan.
   [Takahashi, Hidenori; Fujino, Yujiro] Japan Community Hlth Care Org, Tokyo Shinjuku Med Ctr, Dept Ophthalmol, Tokyo, Japan.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Dept Med Retina, Singapore, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Dept Med Retina, Singapore, Singapore.
   [Yanagi, Yasuo] Natl Univ Singapore, Duke NUS Med Sch, Dept Ophthalmol & Visual Sci, Acad Clin Program, Singapore, Singapore.
C3 Jichi Medical University; University of Tokyo; Singapore National Eye
   Center; National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Takahashi, H (通讯作者)，Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290431, Japan.
EM takahah-tky@umin.ac.jp
RI Yanagi, Yasuo/AAF-2670-2020; Yanagi, Yasuo/AAA-5441-2022; Takahashi,
   Hidenori/H-2945-2019
OI Takahashi, Hidenori/0000-0001-5331-4730; Yanagi,
   Yasuo/0000-0002-0362-7285
FU KAKENHI grant from the Japan Society for the Promotion of Science
   [15K10899]; Grants-in-Aid for Scientific Research [15K10899] Funding
   Source: KAKEN
FX This work was supported by a KAKENHI grant from the Japan Society for
   the Promotion of Science, Grant Number 15K10899.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104
   Fujimura S, 2012, INVEST OPHTH VIS SCI, V53, P1999, DOI 10.1167/iovs.11-8232
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hanrahan EO, 2010, J CLIN ONCOL, V28, P193, DOI 10.1200/JCO.2009.22.4279
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Miao H, 2012, MOL VIS, V18, P574
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Nomura Y, 2016, RETINA-J RET VIT DIS, V36, P192, DOI 10.1097/IAE.0000000000000668
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Salnikov AV, 2006, INT J CANCER, V119, P2795, DOI 10.1002/ijc.22217
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Spinetti G, 2001, BIOCHEM BIOPH RES CO, V289, P19, DOI 10.1006/bbrc.2001.5924
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8
   Takahashi H, 2016, INVEST OPHTH VIS SCI, V57, P462, DOI 10.1167/iovs.15-18245
   Takahashi H, 2015, BRIT J OPHTHALMOL, V99, P1065, DOI 10.1136/bjophthalmol-2014-306051
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 25
TC 20
Z9 22
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2018
VL 102
IS 4
BP 448
EP 454
DI 10.1136/bjophthalmol-2017-310284
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC4DD
UT WOS:000429732500006
PM 28765149
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Iguchi, Y
   Ito, Y
   Kikuchi, M
   Ishikawa, K
   Oshima, H
   Yatsuya, H
   Terasaki, H
AF Iguchi, Y.
   Ito, Y.
   Kikuchi, M.
   Ishikawa, K.
   Oshima, H.
   Yatsuya, H.
   Terasaki, H.
TI Seasonal variations of acute massive submacular haemorrhage associated
   with age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; AMBIENT-TEMPERATURE;
   HEART-DISEASE; MORTALITY; STROKE; JAPAN
AB Aims: To determine whether there is a seasonal variation in the onset of acute, massive submacular haemorrhage associated with age-related macular degeneration.
   Methods: Sixty eyes of 59 patients diagnosed between April 1998 and March 2005, were studied retrospectively. For each patient, the month and season of onset of the submacular haemorrhage and the mean monthly ambient temperature in Nagoya were analysed. Any history of systemic hypertension was also recorded, and the seasonal variations were also investigated in hypertensive and non-hypertensive groups.
   Results: The number of cases peaked in winter with a trough in summer, and this seasonal variation was significant ( Roger's R = 12.03, p < 0.01). The monthly incidence was inversely correlated with the temperature ( Spearman's rank correlation coefficient r = 0.89, p < 0.01). The seasonal variations were significant in the hypertensive group but not in the non-hypertensive group.
   Conclusion: The considerable seasonal variations suggests that the mechanism for the haemorrhage is strongly correlated with the systemic blood pressure.
C1 Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagano 4668550, Japan.
   Nagoya Univ, Grad Sch Med, Dept Publ Hlth,Program Hlth & Community Med, Hlth Informat Dynam,Field Social Life Sci, Nagoya, Aichi, Japan.
C3 Nagoya University; Nagoya University
RP Ito, Y (通讯作者)，Nagoya Univ, Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagano 4668550, Japan.
EM yasu@med.nagoya-u.ac.jp
RI Ito, Yasuki/M-4876-2014; Yatsuya, Hiroshi/L-4213-2016; Terasaki,
   Hiroko/M-5054-2014
OI Ito, Yasuki/0000-0001-9219-9261; Yatsuya, Hiroshi/0000-0002-6220-9251; 
CR BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BLUMENTHAL M, 1970, AM J OPHTHALMOL, V69, P608, DOI 10.1016/0002-9394(70)91628-4
   BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang CL, 2004, J CLIN EPIDEMIOL, V57, P749, DOI 10.1016/j.jclinepi.2003.10.016
   EBRINGER R, 1985, BRIT J OPHTHALMOL, V69, P202, DOI 10.1136/bjo.69.3.202
   HABERMAN S, 1981, J NEUROL SCI, V52, P25, DOI 10.1016/0022-510X(81)90131-3
   HELLER RF, 1978, J EPIDEMIOL COMMUN H, V32, P235, DOI 10.1136/jech.32.4.235
   HILLMAN JS, 1977, BRIT J OPHTHALMOL, V61, P512, DOI 10.1136/bjo.61.8.512
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Inagawa T, 2003, J NEUROSURG, V98, P326, DOI 10.3171/jns.2003.98.2.0326
   Kinoshita N, 2005, CIRC J, V69, P1170, DOI 10.1253/circj.69.1170
   KristalBoneh E, 1997, HYPERTENSION, V30, P436, DOI 10.1161/01.HYP.30.3.436
   LIM JI, 1995, OPHTHALMOLOGY, V102, P1393, DOI 10.1016/S0161-6420(95)30858-5
   PAN WH, 1995, LANCET, V345, P353, DOI 10.1016/S0140-6736(95)90341-0
   ROGER JH, 1977, BIOMETRIKA, V64, P152, DOI 10.2307/2335789
   SHINKAWA A, 1990, STROKE, V21, P1262, DOI 10.1161/01.STR.21.9.1262
   STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9
   WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267
NR 19
TC 9
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2006
VL 90
IS 10
BP 1256
EP 1258
DI 10.1136/bjo.2006.099259
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 084HX
UT WOS:000240525100014
PM 16837537
OA Green Published
DA 2022-11-30
ER

PT J
AU Schneider, U
   Gelisken, F
   Inhoffen, W
   Bartz-Schmidt, KU
AF Schneider, U
   Gelisken, F
   Inhoffen, W
   Bartz-Schmidt, KU
TI Pigment epithelial detachments with retinal vascular anomalous complex
   in age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; fluorescein angiography; indocyanine
   green angiography; occult choroidal neovascularization; retinal vascular
   anomalous complex; retinal choroidal anastomosis
ID OCCULT CHOROIDAL NEOVASCULARIZATION; ANASTOMOSES
AB Purpose:To analyze and compare the angiographic features of retinal vascular anomalous complex (RVAC) in patients with a vascularized pigment epithelial detachment (PED) secondary to age-related macular degeneration. Methods: Retrospective evaluation of fluorescein and indocyanine green angiographies of 180 patients with occult choroidal neovascularization and PED. Results: On indocyanine green angiography (ICGA), RVAC demonstrated as a focal hyperfluorescence in connection with retinal choroidal anastomosis was identified in 12 of the 180 eyes (6.7%) with a vascularized PED. In comparison, fluorescein angiography revealed RVAC in 6 of the 12 eyes. Associated clinical and angiographic features were intraretinal hemorrhage in all 12 eyes, cystoid macular edema in 6 eyes and preretinal hemorrhage in 4 eyes. Conclusions: RVAC is better delineated on ICGA than on fluorescein angiography. In clinically suspected cases with a vascularized PED in connection with intraretinal hemorrhage and/or cystoid macular edema, ICGA should be performed to enhance management considerations. Copyright (C) 2005 S. Karger AG, Basel.
C1 Univ Tubingen, Eye Clin, DE-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen
RP Schneider, U (通讯作者)，Univ Tubingen, Eye Clin, Schleichstr 12, DE-72076 Tubingen, Germany.
EM ulrike.schneidef@med.uni-tuebingen.de
CR Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gelisken F, 1998, RETINA-J RET VIT DIS, V18, P37
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   HARNETT ME, 1992, GRAEFES ARCH CLIN EX, V230, P11
   HARNETT ME, 1996, OPHTHALMOLOGY, V103, P2042
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 13
TC 3
Z9 3
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2005
VL 219
IS 5
BP 303
EP 308
DI 10.1159/000086116
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 961ZH
UT WOS:000231700300010
PM 16123558
DA 2022-11-30
ER

PT J
AU Fong, DS
   Contreras, R
AF Fong, Donald S.
   Contreras, Richard
TI Recent Statin Use and 1-Year Incidence of Exudative Age-Related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; 5-YEAR INCIDENCE; RISK; PROGRESSION; MACULOPATHY;
   ASSOCIATION; EVENTS
AB PURPOSE: To determine whether the statin class of drug is protective against exudative age-related macular degeneration (AMD).
   DESIGN: Case-control study.
   METHODS: The study was conducted at Kaiser Permanente Southern California. Cases was defined as incident cases, identified using outpatient diagnosis data. Controls were patients who had seen an ophthalmologist during the same year without the diagnosis of AMD. Drug use information was obtained using computerized databases.
   RESULTS: In 2007, 86 635 patients older than 60 years underwent an eye examination. Cases comprised 719 patients newly diagnosed with exudative AMD. Controls (78 650) comprised everyone else who did not have any form of AMD. Use of statins was not associated with newly diagnosed exudative AMD.
   CONCLUSIONS: Recent statin use is not associated with newly diagnosed exudative AMD. The current study had 80% statistical power to detect a protective effect of 0.70, but it cannot exclude a smaller effect. (Am J Ophthalmol 2010;149:955-958. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Fong, Donald S.] So Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Pk, CA USA.
   [Fong, Donald S.; Contreras, Richard] SCPMG, Dept Res & Evaluat, Pasadena, CA 91101 USA.
C3 Kaiser Permanente; Southern California Permanente Medical Group (SCPMG);
   Permanente Medical Groups; Kaiser Permanente; Southern California
   Permanente Medical Group (SCPMG)
RP Fong, DS (通讯作者)，SCPMG, Dept Res & Evaluat, 100 S Los Robles, Pasadena, CA 91101 USA.
EM Donald.s.fong@kp.org
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Byington RP, 2001, CIRCULATION, V103, P387
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tonkin A, 1998, NEW ENGL J MED, V339, P1349
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   Wong TY, 2007, AM J OPHTHALMOL, V144, P117, DOI 10.1016/j.ajo.2007.04.018
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 23
TC 15
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2010
VL 149
IS 6
BP 955
EP 958
DI 10.1016/j.ajo.2009.12.037
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 610SI
UT WOS:000278755400014
PM 20346439
DA 2022-11-30
ER

PT J
AU Fu, B
   Liu, ZL
   Zhang, H
   Gu, F
AF Fu, Bo
   Liu, Zhe-Li
   Zhang, Han
   Gu, Feng
TI Interleukin-13 and age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE interleukin-13; age-related macular degeneration; retinal pigment
   epithelial cell
ID GROWTH-FACTOR-BETA; RETINAL-PIGMENT EPITHELIUM; SYSTEMIC-SCLEROSIS;
   TNF-ALPHA; CHOROIDAL NEOVASCULARIZATION; SUBRETINAL FIBROSIS; TIGHT
   JUNCTIONS; AQUEOUS-HUMOR; MOUSE MODEL; RPE CELLS
AB AIM: To identify the effects of interleukin (IL) -13 on retinal pigment epithelial (RPE) cells and the IL -13 level in aqueous humor of age-related macular degeneration (AMD) patients.
   METHODS: IL -13 levels in aqueous humor specimens from AMD patients were detected with enzyme-linked immunosorbent assay (ELISA). ARPE-19 cells were treated with 10 ng/mL IL -13 for 12, 24, and 48h. The cell proliferaton was evaluated by the MTS method. The mRNA and protein levels of alpha-SMA and ZO-1 were evaluated with quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot respectively. The expression of tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta)and vascular endothelial growth factor (VEGF) were assessed by ELISA.
   RESULTS: IL -13 levels in the aqueous humor of patients with AMD were significantly higher than those in the control (167.33 +/- 17.64 vs 27.12 +/- 5.65 pg/mL; P<0.01). In vitro, IL -13 of high concentrations (10, 15, and 20 ng/mL) inhibited ARPE-19 cell proliferation. a-SMA mRNA in ARPE-19 cell were increased (1.017 +/- 0.112 vs 1.476 +/- 0.168; P<0.001) and ZO-1 decreased (1.051 +/- 0.136 vs 0.702 +/- 0.069; P<0.001) after treated with 10 ng/mL IL -13 for 48h. The protein expression of a-SMA and ZO-1 also showed the same tendency (a-SMA: P=0.038; ZO-1: P=0.008). IL -13 significantly reduced the level of TNF-a (44.7 +/- 01.67 vs 31.79 +/- 3.53 pg/mL; P=0.005) at 48h, but the level of TGF-I32 was significantly increased from 34.44 +/- 2.92 to 57.61 +/- 6.31 pg/mL at 24h (P=0.004) and from 61.26 +/- 1.11 to 86.91 +/- 3.59 pg/mL at 48h (P<0.001). While expressions of VEGF didn't change after IL -13 treatment.
   CONCLUSION: IL -13 in vitro inhibit ARPE-19 cell proliferation and expression in the aqueous may be associated with AMD.
C1 [Fu, Bo; Liu, Zhe-Li] China Med Univ, Shenyang 110001, Liaoning Provin, Peoples R China.
   [Zhang, Han; Gu, Feng] China Med Univ, Hosp 1, Dept Ophthalmol, Shenyang 110001, Liaoning Provin, Peoples R China.
C3 China Medical University; China Medical University
RP Liu, ZL (通讯作者)，China Med Univ, Shenyang 110001, Liaoning Provin, Peoples R China.
EM zheli_liu12@163.com
OI Zhang, Han/0000-0002-9338-0051
CR Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Baraut J, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0708-0
   Boltz A, 2012, OPHTHALMOLOGY, V119, P1615, DOI 10.1016/j.ophtha.2012.02.001
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Do DV, 2012, CASE REP OPHTHALM, V3, P384, DOI 10.1159/000338969
   Doganay S, 2002, EYE, V16, P163, DOI 10.1038/sj/eye/6700095
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Friedrich U, 2015, HUM MOL GENET, V24, P6361, DOI 10.1093/hmg/ddv346
   Fuschiotti P, 2009, ARTHRITIS RHEUM-US, V60, P1119, DOI 10.1002/art.24432
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Guo J., 2015, PLOS ONE, V10
   Haas CS, 2007, ARTHRITIS RHEUM-US, V56, P2535, DOI 10.1002/art.22823
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   JAMPEL HD, 1990, CURR EYE RES, V9, P963, DOI 10.3109/02713689009069932
   Jobling AI, 2004, J BIOL CHEM, V279, P18121, DOI 10.1074/jbc.M400381200
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Lafyatis R, 2009, CURR OPIN RHEUMATOL, V21, P617, DOI 10.1097/BOR.0b013e32832fd69e
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Mitchel JA, 2016, AM J RESP CELL MOL, V54, P524, DOI 10.1165/rcmb.2015-0252OC
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nishimura Y, 2008, CIRC J, V72, P469, DOI 10.1253/circj.72.469
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Savetsky IL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126908
   Sinha S, 2015, ALLERGY RHINOL, V6, pE111, DOI 10.2500/ar.2015.6.0126
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Thichanpiang P, 2014, MOL VIS, V20, P781
   Van Bergen T, 2015, INVEST OPHTH VIS SCI, V56, P5280, DOI 10.1167/iovs.14-15513
   Wang HB, 2016, MOL VIS, V22, P116
   Yao Y, 2014, EXP PARASITOL, V142, P17, DOI 10.1016/j.exppara.2014.04.004
   Zech JC, 1998, INVEST OPHTH VIS SCI, V39, P1600
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhou Chao-Qun, 2013, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V31, P400
NR 36
TC 11
Z9 11
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2017
VL 10
IS 4
BP 535
EP 540
DI 10.18240/ijo.2017.04.06
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES6BK
UT WOS:000399631100006
PM 28503424
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Steinberg, JS
   Gobel, AP
   Fleckenstein, M
   Holz, FG
   Schmitz-Valckenberg, S
AF Steinberg, Julia S.
   Goebel, Arno P.
   Fleckenstein, Monika
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
TI Reticular drusen in eyes with high-risk characteristics for progression
   to late-stage age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; Macula; Imaging
ID SCANNING LASER OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY;
   GEOGRAPHIC-ATROPHY; LONGITUDINAL ANALYSIS; FELLOW-EYES; PSEUDODRUSEN;
   DEPOSITS; PREVALENCE
AB Background/aims To analyse appearance, development over 2 years and characteristic patterns of reticular drusen (RDR) in eyes with high-risk characteristics for progression to late-stage age-related macular degeneration (AMD) (age-related eye disease study stages 3 and 4).
   Methods 98 eyes of 98 patients (median age 73.4years, IQR [69-78]) participating in the Molecular Diagnostic of Age-related Macular Degeneration study were included. Simultaneous combined confocal scanning laser ophthalmoscopy (cSLO) and spectral-domain optical coherence tomography (SD-OCT) imaging as well as colour-fundus imaging was performed at baseline and at 24months. Two independent graders determined the presence of different RDR phenotypes (cSLO modalities: dot', target', ribbon'; SD-OCT: spike' and wave') at both visits.
   Results At baseline, RDR were detected in 44% ( 0.96). They were always visible in near-infrared reflectance images. Detection rate was 42% using fundus autofluorescence (FAF), 39% on SD-OCT (waves: 100%; spikes: 90%) and 26% on blue reflectance (BR). Dots' were more frequently detected in all imaging compared with targets'. The ribbon' pattern was most frequently observed in colour images, BR images and FAF images. In 8 of the 48 eyes with no signs of RDR in any imaging modality at baseline, the development of RDR lesions was observed at 24months (16.6%, 0.42).
   Conclusions Careful and meticulous analysis using three-dimensional in vivo imaging reveals distinct characteristic RDR patterns underlying detectable dynamic changes over a period of 2 years. RDR in eyes with early or intermediate AMD are a common observation but appear to be overall less common compared with eyes with geographic atrophy.
C1 [Steinberg, Julia S.; Goebel, Arno P.; Fleckenstein, Monika; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
FU Gertrud Kusen foundation, German Ministry of Education and Research
   (BMBF) [FKZ 13N10349]
FX Gertrud Kusen foundation, German Ministry of Education and Research
   (BMBF), FKZ 13N10349 conducted at the Department of Ophthalmology,
   University of Bonn, Germany.
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 25
TC 37
Z9 37
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2015
VL 99
IS 9
BP 1289
EP 1294
DI 10.1136/bjophthalmol-2014-306535
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ2VL
UT WOS:000360460000028
PM 25795913
DA 2022-11-30
ER

PT J
AU Burgess, S
   Smith, GD
AF Burgess, Stephen
   Smith, George Davey
TI Mendelian Randomization Implicates High-Density Lipoprotein Cholesterole
   Associated Mechanisms in Etiology of Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PLEIOTROPIC GENETIC-VARIANTS; CORONARY-HEART-DISEASE; RISK; INSTRUMENTS;
   METAANALYSIS; INFORMATION; REDUCTION; STATINS; ALLELE; LIPIDS
AB Purpose: Undertake a systematic investigation into associations between genetic predictors of lipid fractions and age-related macular degeneration (AMD) risk.
   Design: Two-sample Mendelian randomization investigation using published data.
   Participants: A total of 33 526 individuals (16 144 cases, 17 832 controls) predominantly of European ancestry from the International Age-related Macular Degeneration Genomics Consortium.
   Methods: We consider 185 variants previously demonstrated to be associated with at least 1 of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides at a genome-wide level of significance, and test their associations with AMD. We particularly focus on variants in gene regions that are proxies for specific pharmacologic agents for lipid therapy. We then conduct a 2-sample Mendelian randomization investigation to assess the causal roles of LDL-cholesterol, HDL-cholesterol, and triglycerides on AMD risk. We also conduct parallel investigations for coronary artery disease (CAD) (viewed as a positive control) and Alzheimer's disease (a negative control) for comparison.
   Main Outcome Measures: Diagnosis of AMD.
   Results: Wefind evidence that HDL-cholesterol is a causal risk factor for AMD, with an odds ratio (OR) estimate of 1.22 (95% confidence interval [CI], 1.03-1.44) per 1 standard deviation increase in HDL-cholesterol. No causal effect of LDL-cholesterol or triglycerides was found. Variants in the CETP gene region associated with increased circulating HDL-cholesterol also associate with increased AMD risk, although variants in the LIPC gene region that increase circulating HDL-cholesterol have the opposite direction of association with AMD risk. Parallel analyses suggest that lipids have a greater role for AMD compared with Alzheimer's disease, but a lesser role than for CAD.
   Conclusions: Some genetic evidence suggests that HDL-cholesterol is a causal risk factor for AMD risk and that increasing HDL-cholesterol (particularly via CETP inhibition) will increase AMD risk.
C1 [Burgess, Stephen] Univ Cambridge, MRC Biostat Unit, Cambridge, England.
   [Burgess, Stephen] Univ Cambridge, Cardiovasc Epidemiol Unit, 2 Worts Causeway, Cambridge CB18RN, England.
   [Smith, George Davey] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
C3 MRC Biostatistics Unit; University of Cambridge; University of
   Cambridge; University of Bristol
RP Burgess, S (通讯作者)，Univ Cambridge, Cardiovasc Epidemiol Unit, 2 Worts Causeway, Cambridge CB18RN, England.
EM sb452@medschl.cam.ac.uk
RI Davey Smith, George/A-7407-2013
OI Davey Smith, George/0000-0002-1407-8314; s, hema/0000-0002-3440-9475;
   Burgess, Stephen/0000-0001-5365-8760; Venkatasubramanian,
   Siddharth/0000-0002-5860-0768
FU Wellcome Trust [204623/Z/16/Z]; Royal Society [204623/Z/16/Z]; Medical
   Research Council Integrative Epidemiology Unit at the University of
   Bristol [MC_UU_12013/1]; British Heart Foundation [RG/08/014/24067]
   Funding Source: researchfish; Medical Research Council [MC_UU_00002/7,
   MR/L003120/1, MC_UU_12013/1] Funding Source: researchfish; National
   Institute for Health Research [NF-SI-0512-10165] Funding Source:
   researchfish; MRC [MC_UU_00002/7, MR/L003120/1, MC_UU_12013/1] Funding
   Source: UKRI
FX S. B.: Support - Sir Henry Dale Fellowship jointly funded by the
   Wellcome Trust and the Royal Society (grant no. 204623/Z/16/Z).; G. D.
   S.: Works within the Medical Research Council Integrative Epidemiology
   Unit at the University of Bristol (MC_UU_12013/1).
CR [Anonymous], 2013, NAT GENET, DOI [DOI 10.1038/NG.2797, 10.1038/ng.2797]
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess S., 2021, MENDELIAN RANDOMIZAT, DOI DOI 10.1201/B18084
   Burgess S, 2016, STAT MED, V35, P1880, DOI 10.1002/sim.6835
   Burgess S, 2015, EUR J EPIDEMIOL, V30, P543, DOI 10.1007/s10654-015-0011-z
   Burgess S, 2015, AM J EPIDEMIOL, V181, P290, DOI 10.1093/aje/kwv017
   Burgess S, 2015, AM J EPIDEMIOL, V181, P251, DOI 10.1093/aje/kwu283
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Cannon CP, 2015, NEW ENGL J MED, V372, P2387, DOI 10.1056/NEJMoa1410489
   Collett D, 2003, C&H TEXT STAT SCI, P45
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Del Greco MF, 2015, STAT MED, V34, P2926, DOI 10.1002/sim.6522
   Ference BA, 2015, J AM COLL CARDIOL, V65, P1552, DOI 10.1016/j.jacc.2015.02.020
   Ference BA, 2012, J AM COLL CARDIOL, V60, P2631, DOI 10.1016/j.jacc.2012.09.017
   Fitzgerald K, 2014, LANCET, V383, P60, DOI 10.1016/S0140-6736(13)61914-5
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Gotto AM, 2014, AM J CARDIOL, V113, P76, DOI 10.1016/j.amjcard.2013.08.041
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37
   Khetarpal SA, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0609-y
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Linsel-Nitschke P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002986
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Nyholt DR, 2009, EUR J HUM GENET, V17, P147, DOI 10.1038/ejhg.2008.198
   Ostergaard SD, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001841
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Raal FJ, 2014, J AM COLL CARDIOL, V63, P1278, DOI 10.1016/j.jacc.2014.01.006
   Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5
   VanderBeek BL, 2013, RETINA-J RET VIT DIS, V33, P414, DOI 10.1097/IAE.0b013e318276e0cf
   Viney NJ, 2016, LANCET, V388, P2239, DOI 10.1016/S0140-6736(16)31009-1
   Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
NR 45
TC 67
Z9 69
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2017
VL 124
IS 8
BP 1165
EP 1174
DI 10.1016/j.ophtha.2017.03.042
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA9SH
UT WOS:000405785700021
PM 28456421
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Tiosano, L
   Segal, O
   Mathalone, N
   Pollack, A
   Ehrlich, R
   Klemperer, I
   Barak, Y
   Moroz, I
   Chowers, I
   Goldstein, M
AF Tiosano, L.
   Segal, O.
   Mathalone, N.
   Pollack, A.
   Ehrlich, R.
   Klemperer, I.
   Barak, Y.
   Moroz, I.
   Chowers, I.
   Goldstein, M.
TI Aflibercept as a Second Line Therapy for Neovascular Age Related Macular
   Degeneration in Israel (ASLI) study
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT; ANATOMICAL
   OUTCOMES; VEGF TRAP; RANIBIZUMAB; BEVACIZUMAB; EYES; INJECTION;
   RESISTANT; RESPONDERS
AB Purpose The purpose of this study is to evaluate an early switch to aflibecept in eyes with neovascular age-related macular degeneration (nvAMD) showing partial or lack of response for initial therapy with bevacizumab.
   Methods The Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) was a prospective, multicenter, single-arm clinical trial. Eyes with nvAMD having incomplete response to 3-9 prior bevacizumab injections were recruited. Three monthly intravitreal aflibercept (2 mg) injections were administered, followed by two bi-monthly injections and a final examination at week 28. An optional injection was allowed at week 20.
   Results Forty-seven eyes of 46 patients (mean +/- SD age 76 +/- 8 years) were recruited. The mean number of prior bevacizumab injections was 5.5 +/- 2.9. The mean visual acuity improved from 60.3 +/- 10 ETDRS letters at baseline to 63.1 +/- 15 letters at week 28 (P= 0.02, paired t-test). The central subfield thickness (CST) reduced from 409 +/- 127 micron at baseline to 330 +/- 110 microns at week 4 (P= 0.0002; paired t-test), and 277 +/- 70 microns at week 28 (P= 0.00002; paired t-test). Twenty-two eyes had three to five prior bevacizumab injections (mean 5.1 +/- 0.7), and 25 eyes had six to nine prior injections (7.32 +/- 1.2). Both groups had reduced CST from baseline to week 28 (P= 0.0004 and P= 0.0007; paired t-test, respectively). Thirtyfive (75%) eyes required the optional additional aflibercept injection at week 20.
   Conclusions The ASLI study demonstrated improved BCVA and reduced CST following an early switch to aflibercept therapy in eyes with prior incomplete response to initial therapy with three to nine bevacizumab injections.
C1 [Tiosano, L.; Chowers, I.] Hebrew Univ Jerusalem, Dept Ophthalmol Hadassah, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel.
   [Segal, O.] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Kefar Sava, Israel.
   [Mathalone, N.] Carmel Hosp, Haifa, Israel.
   [Pollack, A.] Kaplan Med Ctr, Rehovot, Israel.
   [Ehrlich, R.] Tel Aviv Univ, Rabin Med Ctr, Sackler Fac Med, Tel Aviv, Israel.
   [Klemperer, I.] Soroka Univ, Med Ctr, Beer Sheva, Israel.
   [Barak, Y.] Rambam Med Ctr, Haifa, Israel.
   [Moroz, I.] Sheba Med Ctr, Tel Hashomer, Israel.
   [Goldstein, M.] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Fac Med, Tel Aviv, Israel.
C3 Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of
   Medicine; Clalit Health Services; Carmel Medical Center; Hebrew
   University of Jerusalem; Kaplan Medical Center; Rabin Medical Center;
   Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University;
   Soroka Medical Center; Rambam Health Care Campus; Technion Israel
   Institute of Technology; Chaim Sheba Medical Center; Tel Aviv
   University; Sackler Faculty of Medicine
RP Chowers, I (通讯作者)，Hebrew Univ Jerusalem, Dept Ophthalmol Hadassah, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
OI Segal, Ori/0000-0001-5701-9544
FU Bayer
FX The study was partially funded by Bayer. The study medication was
   provided by Bayer.
CR Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Griffin DR, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/497178
   Grover S, 2010, INVEST OPHTH VIS SCI, V51, P2644, DOI 10.1167/iovs.09-4774
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Mahmood S, 2015, OPHTHALMOLOGY, V122, P1348, DOI 10.1016/j.ophtha.2015.03.017
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 40
TC 3
Z9 3
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2017
VL 31
IS 6
BP 890
EP 898
DI 10.1038/eye.2017.7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX2ON
UT WOS:000403066000010
PM 28211882
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Fragiotta, S
   Fernandez-Avellaneda, P
   Breazzano, MP
   Curcio, CA
   Leong, BCS
   Kato, K
   Yannuzzi, LA
   Freund, KB
AF Fragiotta, Serena
   Fernandez-Avellaneda, Pedro
   Breazzano, Mark P.
   Curcio, Christine A.
   Leong, Belinda C. S.
   Kato, Kenneth
   Yannuzzi, Lawrence A.
   Freund, K. Bailey
TI The Fate and Prognostic Implications of Hyperreflective Crystalline
   Deposits in Nonneovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE cholesterol; crystals; age-related macular degeneration; hyperreflective
   crystalline deposits; spectral-domain optical coherence tomography;
   macular neovascularization; complete retinal pigment epithelium and
   outer retinal atrophy; drusen; refractile deposits
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC
   ATROPHY; REFRACTILE DRUSEN; BASAL DEPOSITS; VISUAL-ACUITY; CHOLESTEROL;
   EVOLUTION; PROGRESSION; DISEASE
AB PURPOSE. To explore patterns of disease progression in nonneovascular age-related macular degeneration (AMD) associated with hyperreflective crystalline deposits (HCDs) in the subretinal pigment epithelium-basal laminar space.
   METHODS. Retrospective review of medical records, multimodal imaging, and longitudinal eye-tracked near-infrared reflectance (NIR) and optical coherence tomography (OCT) spanning >= 2 years. NIR/OCT images were analyzed with ImageJ software to identify HCD morphology and location. Associated macular complications were reviewed from the time of HCD detection to the most recent follow-up, using NIR/OCT.
   RESULTS. Thirty-three eyes with HCDs from 33 patients (mean age: 72 +/- 7.5 years) had 46.7 months (95% confidence limits: 33.7, 59.6) of serial eye-tracked NIR/OCT follow-up. Baseline best-corrected visual acuity (BCVA) was 0.44 logMAR (Snellen equivalent 20/55). At a mean of 11.3 months (3.1, 19.6) after HCD detection, 31/33 (93.9%) eyes had developed macular complications including de novo areas of complete retinal pigment epithelium and outer retinal atrophy (cRORA) in 21/33 (64%) eyes, enlargement of preexisting cRORA in 4/33 (12%) eyes, and incident macular neovascularization in 3/33 (9%) eyes. Movement and clearance of HCDs in 9/33 (27%) eyes was associated with enlargement of preexisting cRORA (r = 0.44, P = 0.02). BCVA at the last follow-up visit had decreased to 0.72 logMAR (20/105).
   CONCLUSIONS. Eyes with nonneovascular AMD demonstrating HCDs are at risk for vision loss due to macular complications, particularly when movement and clearance of these structures appear on multimodal imaging. HCD reflectivity and dynamism may be amenable to automated recognition and analysis to assess cellular activity related to drusen end-stages.
C1 [Fragiotta, Serena; Fernandez-Avellaneda, Pedro; Breazzano, Mark P.; Leong, Belinda C. S.; Kato, Kenneth; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 950 Third Ave, New York, NY 10022 USA.
   [Fragiotta, Serena; Fernandez-Avellaneda, Pedro; Breazzano, Mark P.; Leong, Belinda C. S.; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Fragiotta, Serena] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, UOSD Ophthalmol, Rome, Italy.
   [Fernandez-Avellaneda, Pedro] Basurto Univ Hosp, Dept Ophthalmol, Bilbao, Spain.
   [Breazzano, Mark P.; Yannuzzi, Lawrence A.; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Breazzano, Mark P.; Yannuzzi, Lawrence A.; Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Harkness Eye Inst, New York, NY USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Sapienza University Rome; Basurto Hospital; New York
   University; Columbia University; University of Alabama System;
   University of Alabama Birmingham
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 950 Third Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Fragiotta, Serena/I-5227-2016; Freund, K. Bailey/V-7488-2018
OI Fragiotta, Serena/0000-0002-6214-6270; Freund, K.
   Bailey/0000-0002-7888-9773; Breazzano, Mark/0000-0002-7093-965X
FU Macula Foundation, Inc., New York, New York, United States; Honors
   Center of Italian Universities (H2CU); Heidelberg Engineering; Hoffman
   La Roche
FX Supported by The Macula Foundation, Inc., New York, New York, United
   States, the Honors Center of Italian Universities (H2CU) (SF),
   Heidelberg Engineering, and Hoffman La Roche (CAC). The Department of
   Ophthalmology and Visual Science of the University of Alabama at
   Birmingham receives institutional support from EyeSight Foundation of
   Alabama and Research to Prevent Blindness, Inc.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Baumer Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01186-z
   Bertazzo S, 2013, NAT MATER, V12, P576, DOI [10.1038/NMAT3627, 10.1038/nmat3627]
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christakopoulos C, 2013, ACTA OPHTHALMOL, V91, pE248, DOI 10.1111/aos.12000
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Ford ES, 2010, INT J CARDIOL, V140, P226, DOI 10.1016/j.ijcard.2008.11.033
   Gliem M, 2014, AM J OPHTHALMOL, V158, P198, DOI 10.1016/j.ajo.2014.04.005
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Haik B G, 1991, Trans Am Ophthalmol Soc, V89, P371
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Heiferman MJ, 2016, RETINA-J RET VIT DIS, V36, pS137, DOI 10.1097/IAE.0000000000001254
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hu YJ, 2014, DISCOV MED, V18, P7
   JENSEN OA, 1977, A GRAEF ARCH KLIN EX, V203, P311, DOI 10.1007/BF00409836
   Kellner-Weibel G, 1999, ARTERIOSCL THROM VAS, V19, P1891, DOI 10.1161/01.ATV.19.8.1891
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Li ML, 2019, RETINA-J RET VIT DIS, V39, P802, DOI 10.1097/IAE.0000000000002461
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Liu LB, 2011, NAT MED, V17, P1010, DOI 10.1038/nm.2409
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MANSCHOT WA, 1967, BRIT J OPHTHALMOL, V51, P145, DOI 10.1136/bjo.51.3.145
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Nishimura S, 2017, J CARDIOL, V69, P253, DOI 10.1016/j.jjcc.2016.04.003
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Ong SS, 2019, JAMA OPHTHALMOL, V137, P176, DOI 10.1001/jamaophthalmol.2018.5654
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Querques G, 2016, RETINA-J RET VIT DIS, V36, pS65, DOI 10.1097/IAE.0000000000001231
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P6196, DOI 10.1167/iovs.17-23339
   Tan ACS, 2017, INVEST OPHTH VIS SCI, V58, P2349, DOI 10.1167/iovs.16-21237
   Tearney GJ, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192697
   Tearney GJ, 2012, J AM COLL CARDIOL, V59, P1058, DOI 10.1016/j.jacc.2011.09.079
   Tian B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02407-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 60
TC 11
Z9 11
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2019
VL 60
IS 8
BP 3100
EP 3109
DI 10.1167/iovs.19-26589
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN6XZ
UT WOS:000478827000006
PM 31323680
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Brown, GC
   Brown, MM
   Rapuano, S
   Boyer, D
AF Brown, Gary C.
   Brown, Melissa M.
   Rapuano, Sara
   Boyer, David
TI Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; LONG-TERM OUTCOMES; TIME TRADE-OFF; CHOROIDAL
   NEOVASCULARIZATION; VISUAL-ACUITY; DIABETIC-RETINOPATHY;
   CATARACT-SURGERY; RANIBIZUMAB; BEVACIZUMAB; AFLIBERCEPT
AB PURPOSE: To perform 11- and 2-year health care sector (ophthalmic) and societal cost perspective reference case, cost-utility analyses comparing bevacizumab, ranibizumab, and aflibercept monotherapies for neovascular agerelated macular degeneration (NVAMD).
   DESIGN: Cost-utility analysis.
   METHODS: The authors performed 11-year and 2-year ophthalmic and societal cost perspective, cost-utility analyses comparing bevacizumab, ranibizumab, and aflibercept monotherapies for neovascular age-related macular degeneration (NVAMD). We employed patient utilities, bilateral outcomes, 2018 U.S. dollars, vision-related mortality, a Medicare fee schedule, and CATT (Comparison of Age-Related Macular Degeneration Treatments) study and VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) trial. Cochrane data were also used. SETTING: Center for Value-Based Medicine. PATIENT/STUDY POPULATION: patients with NVAMD. INTERVENTION: Cost-utility analyses using published data. Data-modeled 10-year vision outcomes were modeled forward to year 11. MAIN OUTCOME MEASUREMENT: These included cost-utility ratios (CURs), costs, and qualityadjusted life-years (QALYs) gained. $100,00/QALY was considered the US cost-effectiveness upper limit.
   RESULTS: Bevacizumab and ranibizumab each conferred an 11-year, 1.339 QALY gain versus observation. Aflibercept conferred a 1.380 QALY gain. Aflibercept conferred greater QALY gain for less cost than ranibizumab but was not cost-effective compared to bevacizumab ($1,151,451/QALY incremental CUR). The average ophthalmic cost perspective CUR for bevacizumab was $11,033/QALY, $79,600/QALY for ranibizumab, and $44,801/QALY for aflibercept. Eleven-year therapies saved a 1.0 year-of-life loss without treatment from the 11.0-year life expectancy. Early treatment was 138%, 149% more cost-effective than late treatment. Two-year therapy prevented a 1-month-of-life loss, and revealed bevacizumab, ranibizumab, and aflibercept conferred 0.141, 0.141, and 0.164 QALY gains, respectively, with corresponding average CURs of $40,371/QALY, $335 ,726/QALY, and $168,006/QALY, respectively.
   CONCLUSIONS: From an ophthalmic (medical) cost perspective, bevacizumab, ranibizumab, and aflibercept NVAMD monotherapies were all cost-effective over 11 years, with bevacizumab 6.21 X more cost-effective than ranibizumab and 3.06 x more cost-effective than aflibercept. Two-year modeling revealed bevacizumab was costeffective, whereas ranibizumab and aflibercept were not. Early treatment was critical for obtaining optimal vision and cost-effectiveness, as is long-term follow-up and adherence to treatment. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Brown, Gary C.; Brown, Melissa M.; Rapuano, Sara] Ctr Value Based Med, Box 3417, Hilton Head Isl, SC 29928 USA.
   [Brown, Gary C.; Brown, Melissa M.; Rapuano, Sara] Jefferson Med Univ, Wills Eye Hosp, Philadelphia, PA USA.
   [Brown, Gary C.; Brown, Melissa M.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Boyer, David] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
C3 Jefferson University; Emory University; Retina Vitreous Associates
   Medical Group
RP Brown, GC (通讯作者)，Ctr Value Based Med, Box 3417, Hilton Head Isl, SC 29928 USA.
EM gary0514@gmail.com
CR Arias E., 2017, NATL VITAL STAT REP, V66, P9
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bochicchio S, 2019, OPHTHALMOL RETINA, V3, P27, DOI 10.1016/j.oret.2018.08.003
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brault MW, 2010, P70131 US CENS BUR
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2019, AM J MED SCI, V358, P121, DOI 10.1016/j.amjms.2019.04.007
   Brown GC, 2019, J CATARACT REFR SURG, V45, P927, DOI 10.1016/j.jcrs.2019.02.006
   Brown GC, 2018, OPHTHALMOLOGY, V125, P965, DOI 10.1016/j.ophtha.2017.12.033
   Brown GC, 2013, OPHTHALMOLOGY, V120, P2367, DOI 10.1016/j.ophtha.2013.04.030
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Brown MM, 1999, AM J OPHTHALMOL, V128, P324, DOI 10.1016/S0002-9394(99)00146-4
   Brown MM, 2003, OPHTHALMOLOGY, V110, P1076, DOI 10.1016/S0161-6420(03)00254-9
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2002, BRIT J OPHTHALMOL, V86, P8, DOI 10.1136/bjo.86.1.8
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Centers for Medicare and Medicaid Services, LIC US CURR PROC TER
   Centers for Medicare and Medicaid Services, PAYM ALL LIM MED B
   Centers for Medicare and Medicaid Services, 2018, 2018 AN CONV FACT ZI
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chen GH, 2015, RETINA-J RET VIT DIS, V35, P187, DOI 10.1097/IAE.0000000000000301
   Christ SL, 2014, JAMA OPHTHALMOL, V132, P1400, DOI 10.1001/jamaophthalmol.2014.2847
   Cohen SY, 2008, GRAEF ARCH CLIN EXP, V246, P1527, DOI 10.1007/s00417-008-0890-8
   DiScala G, 2019, EUR J OPHTHALMOL
   Dugel PU, 2019, OPHTHALMOLOGY, V12, pS0161
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Ganiats, 2017, PANEL COST EFFECTIVE, P319
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollands H, 2001, CAN J OPHTHALMOL, V36, P202, DOI 10.1016/S0008-4182(01)80041-7
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00125
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rao P, 2018, OPHTHALMOLOGY, V125, P522, DOI 10.1016/j.ophtha.2017.10.010
   Rayess N, 2016, AM J OPHTHALMOL, V165, P88, DOI 10.1016/j.ajo.2016.02.028
   Real FJ, 2008, BRIT J OPHTHALMOL, V92, P770, DOI 10.1136/bjo.2007.127407
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Suner I, 2019, RET SOC 52 ANN SCI M
   US Bureau of Labor Statistics, LAB FORC STAT CURR P
   US Bureau of Labor Statistics, CPI ALL URB CONS CPI
   US Food and Drug Administration, HIGHL PRESCR INF
   Webb A, WHAT IS DISTRIBUTION
NR 73
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2020
VL 218
BP 225
EP 241
DI 10.1016/j.ajo.2020.05.029
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NW3OL
UT WOS:000574919700025
PM 32565050
DA 2022-11-30
ER

PT J
AU Ghoshal, R
   Sharanjeet-Kaur, S
   Fadzil, NM
   Ghosh, S
   Ngah, NF
   Abd Aziz, RA
AF Ghoshal, Rituparna
   Sharanjeet-Kaur, Sharanjeet
   Fadzil, Norliza Mohamad
   Ghosh, Somnath
   Ngah, Nor Fariza
   Abd Aziz, Roslin Azni
TI Patient-Perceived Benefit of Treatment in Polypoidal Choroidal
   Vasculopathy: A Pilot Study
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE polypoidal choroidal vasculopathy; patient-perceived treatment outcome;
   vision-targeted quality of life
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; VISION-RELATED FUNCTION;
   MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; NEI VFQ-25; EYE;
   RANIBIZUMAB; AFLIBERCEPT; POPULATION
AB Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration, requires repeated treatment. The objective of this pilot study was to evaluate and compare vision-targeted quality of life (QOL) at baseline and after 6 months of treatment in patients with PCV. Naive PCV patients were recruited. Visual functions assessed were distance visual acuity (DVA), near visual acuity (NVA), contrast sensitivity (CS), reading speed (RS), and QOL at baseline and after 6 months of treatment. Thirty patients (average age of 67.62 +/- 8.05 years) revealed mean DVA and NVA improvements of 0.24 logMAR and 0.30 logMAR, respectively. Mean CS and RS improved by 0.39 log contrast and 25.58 words per minute, respectively. The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25) composite score significantly increased from a baseline of 66.73 +/- 13.74 to 73.54 +/- 14.26. Twenty-eight of the patients showed overall improvement in QOL score by 5 units or more or remained stable. Subscales of NEI-VFQ-25 significantly improved, with general vision, mental health, and role difficulties improving by 10 or more units. The present pilot study reports a significant improvement of QOL in PCV patients after 6 months of treatment, with mental health, role difficulties, social functioning, and distance vision activities being the most improved subscales.
C1 [Ghoshal, Rituparna; Sharanjeet-Kaur, Sharanjeet; Fadzil, Norliza Mohamad] Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Kuala Lumpur 50300, Malaysia.
   [Ghoshal, Rituparna] Supreme Inst Management & Technol, Dept Optometry, Mankundu Hooghly 712123, W Bengal, India.
   [Ghosh, Somnath] Brainware Univ, Dept Allied Hlth Sci, Kalkata 700125, W Bengal, India.
   [Ngah, Nor Fariza; Abd Aziz, Roslin Azni] Hosp Shah Alam, Dept Ophthalmol, Seksyen 7, Shah Alam 40000, Selangor, Malaysia.
C3 Universiti Kebangsaan Malaysia
RP Sharanjeet-Kaur, S (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Optometry & Vis Sci Program, Kuala Lumpur 50300, Malaysia.
EM rituparna.ghoshal@skf.edu.in; sharanjeet@ukm.edu.my;
   norlizafadzil@ukm.edu.my; somnath4ab@yahoo.co.in;
   drfarizangah@gmail.com; roslinazni@gmail.com
RI SHARANJEET-KAUR, SHARANJEET/G-9539-2018
OI Kaur, Sharanjeet/0000-0003-0734-5151
CR Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Broman AT, 2001, INVEST OPHTH VIS SCI, V42, P606
   Buari NH, 2015, BANGLADESH J MED SCI, V14, P236, DOI 10.3329/bjms.v14i3.18964
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chhablani JK, 2011, GRAEF ARCH CLIN EXP, V249, P791, DOI 10.1007/s00417-010-1478-7
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Ghoshal R, 2018, SAINS MALAYS, V47, P2447, DOI 10.17576/jsm-2018-4710-21
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Mangione C.M., VFQ25 NEI
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Rahman M., 2015, THESIS
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Sharanjeet-Kaur S., 2018, MALAYS J PUBLIC HLTH, V1, P124
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   Weyer-Wendl H, 2016, HEALTH ECON REV, V6, DOI 10.1186/s13561-016-0116-4
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   [张雅琳 Zhang Yalin], 2016, [兵工学报, Acta Armamentarii], V37, P165
NR 35
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2020
VL 17
IS 17
AR 6378
DI 10.3390/ijerph17176378
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA NP4HO
UT WOS:000570138800001
PM 32887213
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Asahi, MG
   Avaylon, J
   Wallsh, J
   Gallemore, RP
AF Asahi, Masumi G.
   Avaylon, Jaycob
   Wallsh, Josh
   Gallemore, Ron P.
TI Emerging biological therapies for the treatment of age-related macular
   degeneration
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Review
DE Age-related macular degeneration; biologic; emerging; exudative;
   nonexudative; stem cell therapy; gene therapy
ID CILIARY NEUROTROPHIC FACTOR; PIGMENT EPITHELIAL-CELLS; MESENCHYMAL
   STEM-CELLS; GEOGRAPHIC ATROPHY; MOUSE MODEL; ANTI-VEGF; CHOROIDAL
   NEOVASCULARIZATION; ABICIPAR PEGOL; COMPLEMENT; RANIBIZUMAB
AB Introduction Age-related macular degeneration (AMD) is the leading cause of blindness in individuals over age 50 in developed countries. Current therapy for nonexudative AMD (neAMD) is aimed at modifying risk factors and vitamin supplementation to slow progression, while intravitreal anti-vascular endothelial factor (VEGF) injections are the mainstay for treatment of choroidal neovascularization in exudative AMD (eAMD). Areas covered Over the past decade, promising therapies have emerged that aim to improve the current standard of care for both diseases. Clinical trials for neAMD are investigating targets in the complement cascade, vitamin A metabolism, metformin, and tetracycline, whereas clinical trials for eAMD are aiming to decrease treatment burden through novel port delivery systems, increasing drug half-life, and targeting new sites of the VEGF cascade. Stem cell and gene therapy are also being evaluated for treatment of neAMD and eAMD. Expert opinion With an aging population, the need for effective, long term, low burden treatment options for AMD will be in increasingly high demand. Current investigations aim to address the shortcomings of current treatment options with breakthrough treatment approaches. Therapeutics in the pipeline hold promise for improving the treatment of AMD, and are on track for widespread use within the next decade.
C1 [Asahi, Masumi G.] George Washington Univ, Dept Ophthalmol, Washington, DC USA.
   [Avaylon, Jaycob] Calif Northstate Univ, Coll Med, Elk Grove, CA USA.
   [Wallsh, Josh] Albany Med Coll, Dept Ophthalmol, Albany, NY 12208 USA.
   [Gallemore, Ron P.] Retina Macula Inst, Torrance, CA USA.
   [Gallemore, Ron P.] Univ Calif Los Angeles, Jules Eye Inst, Los Angeles, CA USA.
C3 George Washington University; Albany Medical College; University of
   California System; University of California Los Angeles
RP Gallemore, RP (通讯作者)，Univ Calif Los Angeles, Sch Med, Jules Eye Inst, 4201 Torrance Blvd,Suite 220, Torrance, CA 90503 USA.
EM rongallemoremd@gmail.com
OI Asahi, Masumi/0000-0002-5624-1458; Avaylon, Jaycob/0000-0001-8360-9409
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alkeus Pharmaceuticals I, ALK 001 HALTS VISION
   [Anonymous], 2021, GRAYBUG VISION REPOR
   [Anonymous], ALKAHEST
   [Anonymous], GRAYBUG
   [Anonymous], 2021, COHERENT MARKET INSI
   Aoki H, 2006, EXP EYE RES, V82, P265, DOI 10.1016/j.exer.2005.06.021
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown EE, 2019, INVEST OPHTH VIS SCI, V60, P1470, DOI 10.1167/iovs.18-26422
   Ca J., 2001, IMMUNOBIOLOGY IMMUNE
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/1649156
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Darrow JJ, 2019, DRUG DISCOV TODAY, V24, P949, DOI 10.1016/j.drudis.2019.01.019
   Di Caprio R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329418
   Ding JD, 2014, ADV EXP MED BIOL, V801, P213, DOI 10.1007/978-1-4614-3209-8_28
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Dugel PU, 2020, OPHTHALMOL RETINA, V4, P250, DOI 10.1016/j.oret.2019.10.008
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Finger RP., 2020, JAMA OPHTHALMOL, V138, P1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fursova A Zh, 2005, Adv Gerontol, V16, P76
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hu CX, 2015, CRIT REV EUKAR GENE, V25, P323
   Hussain RM, 2020, EXPERT OPIN BIOL TH, V20, P999, DOI 10.1080/14712598.2020.1782379
   Hussain RM, 2018, EXPERT OPIN PHARMACO, V19, P471, DOI 10.1080/14656566.2018.1448060
   Iejima Daisuke, 2015, J Stem Cells, V10, P193
   J M., MARKET SCOPE
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanani AM, 2021, ACTA OPHTHALMOL, V99, pE823, DOI 10.1111/aos.14686
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   King NMP, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt474
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Kolev M, 2014, NAT REV IMMUNOL, V14, P811, DOI 10.1038/nri3761
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Kuppermann BD, 2021, RETINA-J RET VIT DIS, V41, P144, DOI 10.1097/IAE.0000000000002789
   Kusari J, 2011, INVEST OPHTH VIS SCI, V52, P5424, DOI 10.1167/iovs.10-6262
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592
   Lee AY, 2018, BRIT J OPHTHALMOL, V102, P465, DOI 10.1136/bjophthalmol-2017-310939
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luu KT, 2020, J PHARMACOL EXP THER, V373, P184, DOI 10.1124/jpet.119.263178
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16-0428
   Ng W., 2021, STATISTA
   Ogura Y, 2022, BRIT J OPHTHALMOL, V106, P994, DOI 10.1136/bjophthalmol-2021-319090
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   Patel AK, 2016, NUTRITION, V32, P384, DOI 10.1016/j.nut.2015.09.017
   Patel S.S., 2020, INVESTIG OPHTHALMOL, V61, P4286
   Patel S, 2018, OPHTHALMOL RETINA, V2, P785, DOI 10.1016/j.oret.2017.12.006
   Pera MF, 2000, J CELL SCI, V113, P5
   Qu LH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00241-5
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   RICHARDSON PM, 1994, PHARMACOL THERAPEUT, V63, P187, DOI 10.1016/0163-7258(94)90045-0
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Scholl HP, 2019, INVEST OPHTH VIS SCI, V60
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Schultz NM, 2021, OPHTHALMOL THER, V10, P151, DOI 10.1007/s40123-020-00325-y
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma A, 2020, EYE, V34, P802, DOI 10.1038/s41433-019-0670-1
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Sirivichayakul S, 2019, NEUROTOX RES, V35, P122, DOI 10.1007/s12640-018-9937-8
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Smith A, 2006, NATURE, V441, P1060, DOI 10.1038/nature04954
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Stewart JM, 2020, OPHTHALMOL RETINA, V4, P1118, DOI 10.1016/j.oret.2020.06.003
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   Wang HB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157748
   Wang KV, 2020, OPHTHALMIC GENET, V41, P465, DOI 10.1080/13816810.2020.1790616
   Wang Y, 2015, MOLECULES, V20, P22395, DOI 10.3390/molecules201219785
   WILLIAMSON B, 1982, NATURE, V298, P416, DOI 10.1038/298416a0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yang LY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8584136
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
NR 129
TC 2
Z9 2
U1 2
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8214
EI 1744-7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PD APR 3
PY 2021
VL 26
IS 2
BP 193
EP 207
DI 10.1080/14728214.2021.1931120
EA JUN 2021
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SO9JJ
UT WOS:000657241500001
PM 34030572
DA 2022-11-30
ER

PT J
AU Corradetti, G
   Corvi, F
   Nittala, MG
   Nassisi, M
   Alagorie, AR
   Scharf, J
   Lee, MY
   Sadda, SR
   Sarraf, D
AF Corradetti, Giulia
   Corvi, Federico
   Nittala, Muneeswar Gupta
   Nassisi, Marco
   Alagorie, Ahmed Roshdy
   Scharf, Jackson
   Lee, Mee Yon
   Sadda, Srinivas R.
   Sarraf, David
TI Natural history of incomplete retinal pigment epithelial and outer
   retinal atrophy in age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID GEOGRAPHIC ATROPHY; PROGRESSION; SECONDARY; RODS
AB Objective: To assess the time course and risk factors for conversion of incomplete retinal pigment epithelium and outer retina atrophy (iRORA) to complete retinal pigment epithelium and outer retina atrophy (cRORA) in eyes with non-neovascular intermediate age-related macular degeneration (iAMD), using optical coherence tomography (OCT) analysis.
   Design: Retrospective survival study.
   Participants: Tracked structural Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany) volume datasets from 2 retinal specialists at the University of California-Los Angeles were retrospectively screened to identify consecutive participants with non-neovascular iAMD without signs of atrophy or macular neovascularization in either eye at baseline.
   Methods: In the first stage of selection, 321 consecutive iAMD eyes were screened for onset of iRORA. Eyes that developed iRORA within the first 24 months were followed for an additional 24 months to assess the rate of conversion to cRORA. A Kaplan-Meier survival curve was formulated to illustrate the conversion from iRORA to cRORA.
   Results: Among 321 baseline participants with iAMD, 87 incident iRORA lesions (50 eyes, 42 participants) were included in the conversion analysis. Eighty-one iRORA lesions (93.1%) converted to cRORA within 24 months (median 14 months). Multivariate binary logistic regression analysis indicated that intraretinal hyperreflective foci and extrafoveal iRORA location at baseline were associated with a faster rate of progression to cRORA (model R-2 = 0.816, p < 0.05).
   Conclusions: The majority of incident iRORA lesions progress to cRORA within a 24-month period. These findings may be of value in the design of early intervention trials for risk stratification and prognostication but need to be validated with a prospective analysis.
C1 [Corradetti, Giulia; Corvi, Federico; Nittala, Muneeswar Gupta; Nassisi, Marco; Alagorie, Ahmed Roshdy; Sadda, Srinivas R.] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Corradetti, Giulia; Scharf, Jackson; Lee, Mee Yon; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retina Disorders & Ophthalm Genet, Los Angeles, CA 90095 USA.
   [Corvi, Federico] Univ Milan, Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Nassisi, Marco] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Nassisi, Marco] Fdn IRCCS Ca Granda, Ophthalmol Unit, Osped Maggiore Policlin, Milan, Italy.
   [Alagorie, Ahmed Roshdy] Tanta Univ, Fac Med, Dept Ophthalmol, Tanta, Egypt.
   [Sadda, Srinivas R.; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of Milan; Luigi Sacco Hospital;
   University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   Egyptian Knowledge Bank (EKB); Tanta University; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Greater Los Angeles Healthcare System
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@jsei.ucla.edu
RI Nassisi, Marco/P-9939-2019; Alagorie, Ahmed/AAW-5304-2020; Corradetti,
   Giulia/Q-5400-2019
OI Nassisi, Marco/0000-0002-9354-9005; Alagorie, Ahmed/0000-0001-5489-0617;
   Corradetti, Giulia/0000-0001-9213-5575; Corvi,
   Federico/0000-0002-2661-5500
CR Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Daniel E, 2020, JAMA OPHTHALMOL, V138, P510, DOI 10.1001/jamaophthalmol.2020.0437
   Eng VA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232353
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Gune S, 2020, OPHTHALMOLOGY, V127, P523, DOI 10.1016/j.ophtha.2019.09.030
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mondol MH, 2019, STAT MED, V38, P2544, DOI 10.1002/sim.8126
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Paul S, 2014, STAT MED, V33, P3869, DOI 10.1002/sim.6198
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P1360, DOI 10.1016/j.ophtha.2020.03.031
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tiosano L, 2020, GRAEF ARCH CLIN EXP, V258, P2353, DOI 10.1007/s00417-020-04837-y
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
NR 33
TC 6
Z9 6
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2021
VL 56
IS 5
BP 325
EP 334
DI 10.1016/j.jcjo.2021.01.005
EA SEP 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UT1JX
UT WOS:000697880700020
PM 33539821
DA 2022-11-30
ER

PT J
AU Binder, S
   Stolba, U
   Krebs, I
   Kellner, L
   Jahn, C
   Feichtinger, H
   Povelka, M
   Frohner, U
   Kruger, A
   Hilgers, RD
   Krugluger, W
AF Binder, S
   Stolba, U
   Krebs, I
   Kellner, L
   Jahn, C
   Feichtinger, H
   Povelka, M
   Frohner, U
   Kruger, A
   Hilgers, RD
   Krugluger, W
TI Transplantation of autologous retinal pigment epithelium in eyes with
   foveal neovascularization resulting from age-related macular
   degeneration: A pilot study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CELLS IN-VITRO; RPE TRANSPLANTS; RCS RAT; MEMBRANES; ALLOGRAFTS
AB PURPOSE: To describe the indications, surgical technique, and clinical results of 14 eyes in 13 patients with age-related macular degeneration and foveal choroidal neovascularization, in which subretinal surgery was combined with simultaneous transplantation of autologous retinal pigment epithelial cells.
   METHODS: Between March 1999 and February 2000, in a prospective study, 14 eyes (13 patients) with age related macular degeneration underwent subretinal surgery because of foveal choroidal neovascularization with simultaneous transplantation of retinal pigment epithelium harvested from the nasal subretinal area of the same eye. Preoperatively, 1 month postoperatively, 3 months postoperatively and at 3-month intervals thereafter, examinations were performed including best-corrected visual acuity, visual field, biomicroscopy of anterior and posterior segment, tonometry, fluorescein and indocyanine angiographies, autofluorescence, scotometry, and fixation tests.
   RESULTS: Postoperatively, after median observation of 17 months (range, 12 to 24 months) best,corrected visual acuity was improved 2 or more lines in eight eyes (57.1%), remained the same (+/- 1 line) in five eyes (35%), and decreased by more than 2 lines in one eye (7.1%). Pairwise t test showed significant improvement after 1 month (P = .0031, P = .0062) as well as 1 year (P = .0066, P = .0105). Satisfactory reading vision between Jaeger 1 and 4 was achieved in three eyes (21.2%). No significant intraoperative or postoperative complications occurred in any eye. No recurrence of choroidal neovascularization was observed during the observation period.
   CONCLUSIONS: In eyes with age-related macular de generation and foveal choroidal neovascularization, autotransplantation of retinal pigment epithelium was performed in addition to conventional removal of the choroidal neovascularization without significant intraoperative or postoperative complications. Visual acuity improvement of 2 or more lines in 57% of the eyes was achieved. No recurrent choroidal neovascularization. formation was observed during the observation period. The results of this pilot study suggest that autologous transplantation of retinal pigment epithelium combined with submacular surgery might be a reasonable treatment option for patients with foveal choroidal neovascularization secondary to age,related macular degeneration. (Am J Ophthalmol 2002;133:215-225. (C) 2002 by Elsevier Science Inc. All rights reserved.).
C1 Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   Rudolf Fdn Clin, Inst Pathol & Bacteriol, Vienna, Austria.
   Univ Clin, Inst Histol & Embryol, Dept Cellbiol & Ultrastruct Res, Vienna, Austria.
   Univ Vienna, Eye Clin, AKH, Vienna, Austria.
   Rhein Westfal TH Aachen, Inst Biometrie, D-5100 Aachen, Germany.
   Rudolf Fdn Clin, Inst Clin Chem, Vienna, Austria.
C3 Ludwig Boltzmann Institute; University of Vienna; RWTH Aachen University
RP Binder, S (通讯作者)，Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
RI Hilgers, Ralf-Dieter/C-7090-2013
OI Hilgers, Ralf-Dieter/0000-0002-5945-1119
CR ALESSANDRO A, 1998, RETINA, V18, P143
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   ASSADOULINA A, 2001, OPHTHALMOLOGE, V98, P1
   AWYLARD GW, 1999, 12 ANN M RET SOC REG
   BINDER S, 2000, SPEKTRUM AUGENHEILK, V14, P249
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CASTELLARIN AA, 1998, RETINA, V18, P139
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   DELCHERRO M, 1998, J NEURAL TRANSP PLAS, V1, P1
   Dintelmann TS, 1999, GRAEF ARCH CLIN EXP, V237, P830, DOI 10.1007/s004170050320
   Durlu YK, 1997, CELL TRANSPLANT, V6, P149, DOI 10.1016/S0963-6897(96)00142-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P326, DOI 10.1007/s004170050240
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HOLM S, 1979, SCAND J STAT, V6, P65
   Holz FG, 2001, OPHTHALMOLOGE, V98, P10, DOI 10.1007/s003470170194
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   KAPLAN HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1186
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   MASHHOUR P, 1997, INVEST OPHTH VIS SCI, V38, P657
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   OMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   RUCKMANN A, 1999, GRAEFES ARCH CLIN EX, V237, P1
   *SAS INC, 1990, SAS STAT US GUID VER
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   SEATON AD, 1992, INVEST OPHTH VIS SCI, V33, P83
   SEATON AD, 1994, INVEST OPHTH VIS SCI, V35, P162
   SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   STANGA PE, 2000, CLUB J GON SEPT 2 6
   Tamai M, 1999, RETINA CURRENT PRACT, P151
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   THOMAS M, 1996, OPHTHALMOLOGY, V101, P1384
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   TURNER JE, 1986, BRAIN RES, V391, P91
   WIEDEMANN P, 2000, SPEKTRUM AUGENHEILKU, V14, P254
NR 48
TC 155
Z9 172
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2002
VL 133
IS 2
BP 215
EP 225
DI 10.1016/S0002-9394(01)01373-3
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518LM
UT WOS:000173669900006
PM 11812425
DA 2022-11-30
ER

PT J
AU Leung, E
   Landa, G
AF Leung, Ella
   Landa, Gennady
TI Update on current and future novel therapies for dry age-related macular
   degeneration
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE amyloid-beta antibodies; AREDS; ciliaryneurotrophic factors; complement
   cascade; lasers; macular degeneration; rheopheresis; stem cells
ID CILIARY NEUROTROPHIC FACTOR; RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC
   ATROPHY; COMPLEMENT; MODEL; RPE; SUPPLEMENTATION; IMPROVEMENT;
   ACTIVATION; COMPOUND
AB Age-related macular degeneration (ARMD) is the leading cause of irreversible blindness in developed countries. There are currently no cures, but there are promising potential therapies that target the underlying disease mechanisms of dry ARMD. Stem cells, ciliary neurotrophic factor, rheopheresis, ozonated autohemotherapy and prostaglandins show promise in stabilizing or improving visual acuity. Age-Related Eye Disease Study vitamins may reduce progression to severe ARMD. Adjuvant therapy like low vision rehabilitation and implantable miniature telescopes may help patients adjust to the sequelae of their disease, and herbal supplementation with saffron, zinc monocysteine and phototrop may be helpful. Therapies that are currently in clinical trials include brimonidine, doxycycline, anti-amyloid antibodies (GSK933776 and RN6G), RPE65 inhibitor (ACU-4429), complement inhibitors (ARC1905, FCFD4514S), hydroxychloroquine, intravitreal fluocinolone acetate and vasodilators like sildenafil, moxaverine and MC-1101. Therapies that have not been shown to be effective include POT-4, eculizumab, tandospirone, anecortave acetate, the antioxidant OT-551, sirolimus and vitamin E.
C1 [Leung, Ella; Landa, Gennady] New York Eye & Ear Infirm, Dept Ophthalmol, New York, NY 10003 USA.
   [Landa, Gennady] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College
RP Landa, G (通讯作者)，New York Eye & Ear Infirm, Dept Ophthalmol, New York, NY 10003 USA.
EM doctor.landa@gmail.com
CR Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Azzouni F, 2011, J SEX MED, V8, P2894, DOI 10.1111/j.1743-6109.2011.02382.x
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Birch DG, 2002, AM J OPHTHALMOL, V133, P665, DOI 10.1016/S0002-9394(02)01338-7
   Borrelli E, 2012, INT J OPHTHALMOL-CHI, V5, P708, DOI 10.3980/j.issn.2222-3959.2012.06.11
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Eller AW, 2012, OPHTHALMOLOGY, V119, P1011, DOI 10.1016/j.ophtha.2011.10.032
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Evans J.R., 2000, COCHRANE DB SYST REV, V2
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Gill K, 2013, EYE, V27, P639, DOI 10.1038/eye.2013.14
   Homma K, 2013, STEM CELLS, V31, P1149, DOI 10.1002/stem.1372
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Ladewig MS, 2005, PROSTAG LEUKOTR ESS, V72, P251, DOI 10.1016/j.plefa.2004.11.006
   Landa G, 2011, J OCUL PHARMACOL TH, V27, P77, DOI 10.1089/jop.2010.0109
   Leung KW, 2008, INVEST OPHTH VIS SCI, V49, P1221, DOI 10.1167/iovs.07-0781
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Lockington D, 2010, CAN J OPHTHALMOL, V45, P649, DOI 10.3129/i10-060
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Mellwig KP, 2003, THER APHER DIAL, V7, P365, DOI 10.1046/j.1526-0968.2003.00051.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Parodi MB, 2009, COCHRANE DB SYST REV, V3
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Pikkel J, 2013, GRAEF ARCH CLIN EXP, V251, P1687, DOI 10.1007/s00417-012-2256-5
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257
   Ryan SJ, 2013, RETINA
   Salehi-Had Hani, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS89, DOI 10.3928/15428877-20101031-17
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stieger K, 2007, GENE THER, V14, P1668, DOI 10.1038/sj.gt.3303034
   Tate DJ, 2006, CURR EYE RES, V31, P675, DOI 10.1080/02713680600801024
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Wang LL, 2013, MOL NUTR FOOD RES, V57, P1557, DOI 10.1002/mnfr.201200718
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058821
NR 72
TC 39
Z9 45
U1 0
U2 34
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD SEP
PY 2013
VL 6
IS 5
BP 565
EP 579
DI 10.1586/17512433.2013.829645
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V37SL
UT WOS:000209295400015
PM 23971874
DA 2022-11-30
ER

PT J
AU Kim, BJ
   Ying, GS
   Huang, JY
   Levy, NE
   Maguire, MG
AF Kim, Benjamin J.
   Ying, Gui-Shuang
   Huang, Jiayan
   Levy, Nicole E.
   Maguire, Maureen G.
CA CATT Res Grp
TI Sporadic Visual Acuity Loss in the Comparison of Age-Related Macular
   Degeneration Treatments Trials (CATT)
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISION LOSS; RANIBIZUMAB; DEPRESSION; REPRODUCIBILITY; ASSOCIATION;
   IMPAIRMENT; PREDICTORS; OUTCOMES; OLDER
AB PURPOSE: To evaluate transient, large visual acuity (VA) decreases, termed sporadic vision loss, during anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD).
   DESIGN: Cohort within a randomized clinical trial.
   METHODS: (SETTING) under bar : Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). (STUDY POPULATION) under bar : Total of 1185 CATT patients. (MAIN OUTCOME MEASURES) under bar : Incidence of sporadic vision loss and odds ratio (OR) for association with patient and ocular factors. Sporadic vision loss was a decline of >= 15 letters from the previous visit, followed by a return at the next visit to no more than 5 letters worse than the visit before the VA loss.
   RESULTS: There were 143 sporadic vision loss events in 122 of 1185 patients (10.3%). Mean VA at 2 years for those with and without sporadic vision loss was 58.5 (similar to 20/63) and 68.4 (similar to 20/40) letters, respectively (P < .001). Among patients treated pro re nata, no injection was given for 27.6% (27/98) of sporadic vision loss events. Multivariate analysis demonstrated that baseline predictors for sporadic vision loss included worse baseline VA (OR 2.92, 95% confidence interval [CI]:1.65-5.17 for <= 20/200 compared with >= 20/40), scar (OR 2.21, 95% CI: 1.22-4.01), intraretinal foveal fluid on optical coherence tomography (OR 1.80, 95% CI:1.11-2.91), and medical history of anxiety (OR 1.90, 95% CI:1.12-3.24) and syncope (OR 2.75, 95% C1:1.4-55.22) Refraction decreased the likelihood of sporadic vision loss (OR 0.62, 95%CI: 0.42-0.91).
   CONCLUSIONS: Approximately 10% of CATT patients had sporadic vision loss. Baseline predictors included AMD-related factors and factors independent of AMD. These data are relevant for clinicians in practice and those involved in clinical trials. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Kim, Benjamin J.; Ying, Gui-Shuang; Huang, Jiayan; Levy, Nicole E.; Maguire, Maureen G.; CATT Res Grp] Univ Penn, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Kim, BJ (通讯作者)，Scheie Eye Inst, 51 N 39th St, Philadelphia, PA 19104 USA.
EM benjamin.kim@uphs.upenn.edu
RI Kim, Benjamin/AAG-3786-2019; Ciulla, Thomas/AAA-1299-2020
OI Kim, Benjamin/0000-0003-0230-3868; Ciulla, Thomas/0000-0001-5557-6777;
   Folk, James/0000-0002-6271-2906; Stinnett, Sandra/0000-0001-7192-0195;
   Vavvas, Demetrios/0000-0002-8622-6478; Losordo,
   Douglas/0000-0002-6857-7506
FU National Eye Institute [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; National Institutes of Health; Department of Health and Human
   Services, Bethesda, Maryland, USA; NATIONAL EYE INSTITUTE [U10EY017823,
   U10EY017825, U10EY017828, U10EY017826] Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. The authors indicate the following
   financial disclosures: B.J.K. has been on advisory boards for
   Thrombogenics, Eyetech, and Allergan. The other authors have no
   financial disclosures. Supported by cooperative agreements U10 EY017823,
   U10 EY017825, U10 EY017826, and U10 EY017828 from the National Eye
   Institute, National Institutes of Health, Department of Health and Human
   Services, Bethesda, Maryland, USA. Contributions of authors: design and
   conduct of the study (B.J.K., G.S.Y., M.G.M.); collection and management
   of data (G.S.Y., J.H., N.E.L.); analysis and interpretation of data
   (B.J.K., G.S.Y., J.H., N.E.L., M.G.M.); preparation, review, approval of
   manuscript (B.J.K., G.S.Y., MOM.).
CR Armstrong RA, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/908306
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carriere I, 2013, J AFFECT DISORDERS, V151, P164, DOI 10.1016/j.jad.2013.05.071
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Groll DL, 2005, J CLIN EPIDEMIOL, V58, P595, DOI 10.1016/j.jclinepi.2004.10.018
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jackson GR, 2003, NEUROL CLIN, V21, P709, DOI 10.1016/S0733-8619(02)00107-X
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenny RA, 2013, PROG CARDIOVASC DIS, V55, P357, DOI 10.1016/j.pcad.2012.11.006
   Khera S, 2013, J AM MED DIR ASSOC, V14, P326, DOI 10.1016/j.jamda.2012.12.001
   Kirby E, 2010, J ALZHEIMERS DIS, V21, P15, DOI 10.3233/JAD-2010-080785
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moschos MM, 2012, CURR ALZHEIMER RES, V9, P782
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2011, ARCH OPHTHALMOL-CHIC, V129, P885, DOI 10.1001/archophthalmol.2011.146
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Ying GS, JAMA OPHTHA IN PRESS
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
NR 27
TC 12
Z9 12
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2014
VL 158
IS 1
BP 128
EP 135
DI 10.1016/j.ajo.2014.04.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK0IY
UT WOS:000338097300018
PM 24727261
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ashraf, M
   Souka, A
   Adelman, RA
AF Ashraf, Mohammed
   Souka, Ahmed
   Adelman, Ron A.
TI ASSOCIATION BETWEEN THE VITREOMACULAR INTERFACE AND OPTICAL COHERENCE
   TOMOGRAPHY CHARACTERISTICS IN WET AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retina; macula; AMD; OCT; vitreomacular interface
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL NEOVASCULAR MEMBRANES; CHOROIDAL
   BLOOD-FLOW; AFLIBERCEPT THERAPY; TREATMENTS TRIALS; FELLOW EYE; SURGICAL
   EXCISION; THICKNESS; ADHESION; OUTCOMES
AB Purpose: To study the effect of the vitreomacular interface on various wet age-related macular degeneration (AMD) characteristics including the size and type of choroidal neovascularization (CNV), choroidal thickness, and activity of the CNV.
   Methods: This was a retrospective observational cross-sectional study. The study included 43 patients (51 eyes) with treatment-naive age-related macular degeneration. Twenty-six patients with wet AMD in one eye and dry AMD in the other eye were included in a paired-eye analysis. Patients underwent optical coherence tomography examination using Heidelberg Spectralis (spectral domain optical coherence tomography) at presentation to determine the type of CNV and the vitreomacular status. In addition, various parameters were measured including the choroidal thickness and horizontal width and vertical height measurements of the CNV.
   Results: There was no correlation between the height, width, activity or type of the CNV, and the presence or absence of vitreomacular adhesion. The mean choroidal thickness (using enhanced depth imaging) in cases with vitreomacular adhesion was 272.57 mm compared with 197.32 mm in cases with no vitreomacular adhesion, a statistically significant difference (P = 0.003). In the paired-eye study (21 patients), there was no significant difference between the eyes with wet AMD and dry AMD with regard to vitreomacular status or the choroidal thickness. In a subgroup analysis, patients with Type 1 CNV had a significantly higher percentage of vitreomacular adhesion compared with the other eye with dry AMD (P = 0.034).
   Conclusion: In conclusion, the vitreomacular interface does seem to be associated with an increased choroidal thickness in cases of wet AMD. Furthermore, the association between the vitreomacular interface and wet AMD is more significant for Type 1 CNV.
C1 [Ashraf, Mohammed; Souka, Ahmed] Alexandria Univ, Dept Ophthalmol, Fac Med, Infront 27 Maarouf Rasafi St, Alexandria, Egypt.
   [Adelman, Ron A.] Yale Med Sch, Dept Ophthalmol & Visual Studies, European Vitreoretinal Soc EVRS, New Haven, CT USA.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Yale University
RP Ashraf, M (通讯作者)，Alexandria Univ, Dept Ophthalmol, Fac Med, Infront 27 Maarouf Rasafi St, Alexandria, Egypt.
EM Moah384@gmail.com
RI Elmasry, Mohamed Ashraf/Q-8843-2019; Souka, Ahmed/AAD-8225-2022
OI Elmasry, Mohamed Ashraf/0000-0003-4231-2566; Souka,
   Ahmed/0000-0002-1664-704X
CR Ahn SJ, 2012, OPHTHAL SURG LAS IM, V43, P374, DOI 10.3928/15428877-20120628-01
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Houston SK, 2015, RETINA-J RET VIT DIS, V35, P1757, DOI 10.1097/IAE.0000000000000663
   Kim J. H., 2016, SCI TECHNOL NUCL INS, V2016, P7, DOI DOI 10.1155/2016/8634080
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maier M, 2012, KLIN MONATSBL AUGENH, V229, P1030, DOI 10.1055/s-0032-1315305
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   McKibbin MA, 2015, RETINA-J RET VIT DIS, V35, P1951, DOI 10.1097/IAE.0000000000000587
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   REESE AB, 1967, AM J OPHTHALMOL, V64, P544
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   STEFANSSON E, 1990, GRAEF ARCH CLIN EXP, V228, P120, DOI 10.1007/BF00935719
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P718, DOI 10.1111/j.1600-0420.2006.00778.x
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Ying GS, 2015, OPHTHALMOLOGY
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
NR 40
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2017
VL 37
IS 9
BP 1738
EP 1745
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE9PU
UT WOS:000408536400027
PM 28005632
DA 2022-11-30
ER

PT J
AU Lechner, J
   Chen, M
   Hogg, RE
   Toth, L
   Silvestri, G
   Chakravarthy, U
   Xu, HP
AF Lechner, Judith
   Chen, Mei
   Hogg, Ruth E.
   Toth, Levente
   Silvestri, Giuliana
   Chakravarthy, Usha
   Xu, Heping
TI Alterations in Circulating Immune Cells in Neovascular Age-Related
   Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MHC CLASS-II; CHOROIDAL NEOVASCULARIZATION; LUNG FIBROSIS; RISK-FACTORS;
   T-LYMPHOCYTES; NEUTROPHILS; EXPRESSION; ANGIOGENESIS; MONOCYTES; TISSUE
AB Neovascular age-related macular degeneration (nAMD) is the leading cause of irreversible blindness in developed countries. Recent advances have highlighted the essential role of inflammation in the development of the disease. In addition to local retinal chronic inflammatory response, systemic immune alterations have also been observed in AMD patients. In this study we investigated the association between the frequency of circulating leukocyte populations and the prevalence as well as clinical presentations of nAMD. Leukocyte subsets of 103 nAMD patients (most of them were receiving anti-VEGF therapy prior to enrolment) and 26 controls were analysed by flow cytometry by relative cell size, granularity and surface markers. Circulating CD11b(+) cells and CD16(hi)HLA-DR- neutrophils were significantly increased (P = 0.015 and 0.009 respectively) in nAMD when compared to controls. The percentage of circulating CD4(+) T-cells was reduced in nAMD patients without subretinal fibrosis (P = 0.026) compared to patients with subretinal fibrosis. There was no correlation between the percentage of circulating leukocytes and the responsiveness to anti-VEGF therapy in nAMD patients. Our results suggest that higher levels of circulating CD11b(+) cells and neutrophils are associated with nAMD and that reduced levels of CD4(+) T-cells are associated with the absence of subretinal fibrosis in nAMD.
C1 [Lechner, Judith; Chen, Mei; Hogg, Ruth E.; Toth, Levente; Silvestri, Giuliana; Chakravarthy, Usha; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; Xu, Heping/A-4430-2008; Lechner,
   Judith/GQH-8616-2022
OI Hogg, Ruth E./0000-0001-9413-2669; Xu, Heping/0000-0003-4000-931X;
   Chakravarthy, Usha/0000-0002-2606-3734
FU Dunhill Medical Trust [R188/0211]; Guide Dogs for the Blind Association
   UK [2008-5a]; The Dunhill Medical Trust [R188/0211] Funding Source:
   researchfish
FX We thank the patients who participated in this study. Special thanks to
   the research nurses Rebecca Denham and Georgina Sterrett for their help
   in patient recruitment. The study was funded by the Dunhill Medical
   Trust (R188/0211) and Guide Dogs for the Blind Association UK (2008-5a).
CR Abeles D, 2012, CYTOM PART A, V81A, P823, DOI 10.1002/cyto.a.22104
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Barbarin V, 2004, AM J RESP CELL MOL, V31, P78, DOI 10.1165/rcmb.2003-0299OC
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cascao R, 2010, AUTOIMMUN REV, V9, P531, DOI 10.1016/j.autrev.2009.12.013
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Christensen PJ, 1999, AM J PATHOL, V155, P1773, DOI 10.1016/S0002-9440(10)65493-4
   Christoffersson G, 2012, BLOOD, V120, P4653, DOI 10.1182/blood-2012-04-421040
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Deryugina EI, 2014, NEOPLASIA, V16, P771, DOI 10.1016/j.neo.2014.08.013
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Faucher JL, 2007, CYTOM PART A, V71A, P934, DOI 10.1002/cyto.a.20457
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gong Y, 2010, CELL TISSUE RES, V339, P437, DOI 10.1007/s00441-009-0908-5
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hansch GM, 2003, CHEM IMMUNOL, V83, P45
   Hatanaka E, 2006, CLIN EXP IMMUNOL, V146, P443, DOI 10.1111/j.1365-2249.2006.03229.x
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Ilhan N, 2014, OCULAR IMMUNOLOGY IN, P1, DOI 10.3109/09273948.2014.970283
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu LL, 2012, AM J NEPHROL, V36, P386, DOI 10.1159/000343283
   Lo Re S, 2013, J LEUKOCYTE BIOL, V93, P499, DOI 10.1189/jlb.0512261
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220
   Nassar K., 2014, GRAEFES ARCH CLIN EX
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Papiris SA, 2005, CHEST, V128, P2971, DOI 10.1016/S0012-3692(15)52722-0
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pliyev BK, 2015, EUR J CELL BIOL, V94, P67, DOI 10.1016/j.ejcb.2014.11.001
   Scapini P, 2003, J EXP MED, V197, P297, DOI 10.1084/jem.20021343
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Simon DI, 2012, CIRC RES, V110, P1036, DOI 10.1161/CIRCRESAHA.112.268367
   Singh A, 2013, OPHTHALMOLOGY, V120, P1029, DOI 10.1016/j.ophtha.2012.11.002
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Tazzyman S, 2009, INT J EXP PATHOL, V90, P222, DOI 10.1111/j.1365-2613.2009.00641.x
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067
   Zampell JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049940
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
NR 50
TC 30
Z9 31
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 17
PY 2015
VL 5
AR 16754
DI 10.1038/srep16754
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CW1ND
UT WOS:000364756000001
PM 26572732
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Altay, L
   Scholz, P
   Schick, T
   Felsch, M
   Hoyng, CB
   den Hollander, AI
   Langmann, T
   Fauser, S
AF Altay, Lebriz
   Scholz, Paula
   Schick, Tina
   Felsch, Moritz
   Hoyng, Carel B.
   den Hollander, Anneke I.
   Langmann, Thomas
   Fauser, Sascha
TI Association of Hyperreflective Foci Present in Early Forms of
   Age-Related Macular Degeneration With Known Age-Related Macular
   Degeneration Risk Polymorphisms
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE hyperreflective foci; age-related macular degeneration; ARMS2; HTRA1;
   CFH; APOE; VEGFA; microglia
ID OPTICAL COHERENCE TOMOGRAPHY; MICROGLIAL ACTIVATION;
   DIABETIC-RETINOPATHY; EXTRACELLULAR-MATRIX; RETINAL MICROGLIA;
   EPITHELIAL-CELLS; APOLIPOPROTEIN-E; BRUCHS MEMBRANE; RAT-MODEL;
   INFLAMMATION
AB PURPOSE. We evaluated the association of hyperreflective foci (HF) observed in early and intermediate age-related macular degeneration (AMD) with known AMD risk alleles.
   METHODS. In this pilot case-control study, HF were defined as lesions with reflectivity equal or higher than the retinal pigment epithelium band in spectral domain optical coherence tomography (SDOCT). Hyperreflective foci in the outer nuclear layer and photoreceptor complex were evaluated in 518 individuals with early and intermediate AMD. Definite presence of HF was defined as at least 10 HF in all SDOCT scans. Genotyping was performed for 22 single nucleotide polymorphisms (SNPs). Associations between AMD severity stages, HF, and SNPs were determined by logistic regression analyses.
   RESULTS. Hyperreflective foci (n >= 10) were significantly associated with AMD severity and the association was strongest with intermediate AMD (odds ratio [OR], 8.45; P = 1.092*10(-8)). Independently, HF showed associations with ARMS2 rs104909/HtRA1 rs11200638 (OR, 1.64; P = 0.017), CFH rs1061170 (OR, 1.70; P = 0.011), and APOE4/TOMM40 rs2075650 (OR, 2.26; P = 0.005) variants. Within the group of intermediate AMD, associations were similar (ARMS2 rs104909/HtRA1 rs11200638 OR, 1.79, P = 0.010; CFH rs1061170 OR, 1.77, P = 0.013; APOE4/TOMM40 rs2075650 OR, 1.98; P = 0.034) and showed additional trending associations with VEGFA rs943080 variant (OR, 0.59; P = 0.024). After Bonferroni-correction for 22 SNPs, none of the associations was statistically significant (P <= 0.0023).
   CONCLUSIONS. The presence of HF is related to AMD severity. Despite limited power of this pilot study, our results suggest an association of HF with polymorphisms in ARMS2/HTRA1, CFH, APOE4/TOMM40, and VEGFA genes which could be triggered by modification of the extracellular matrix, altered complement system or lipid metabolism.
C1 [Altay, Lebriz; Scholz, Paula; Schick, Tina; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
   [Altay, Lebriz; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Expt Immunol Eye, Cologne, Germany.
   [Felsch, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany.
   [Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
C3 University of Cologne; University of Cologne; University of Cologne;
   Radboud University Nijmegen; Radboud University Nijmegen
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
EM sascha.fauser@gmail.com
RI Hollander, Anneke den/N-4911-2014
FU Deutsche Forschungsgemeinschaft [DFG-FOR2240]
FX Supported by the Deutsche Forschungsgemeinschaft (DFG-FOR2240).
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Couturier A, 2014, MOL VIS, V20, P908
   Cudaback E, 2011, FASEB J, V25, P2082, DOI 10.1096/fj.10-176891
   Folgar FA, 2011, INVEST OPHTH VIS SCI, V53, P4626
   Framme C, 2012, INVEST OPHTH VIS SCI, V53, P5814, DOI 10.1167/iovs.12-9950
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kuroda M, 2014, CLIN OPHTHALMOL, V8, P435, DOI 10.2147/OPTH.S58164
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Polazzi E, 2015, J NEUROPATH EXP NEUR, V74, P818, DOI 10.1097/NEN.0000000000000222
   Rodriguez GA, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-111
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852
   Toops KA, 2016, APOLIPOPROTEIN E ISO, P3
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 42
TC 16
Z9 16
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2016
VL 57
IS 10
BP 4315
EP 4320
DI 10.1167/iovs.15-18855
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW9LR
UT WOS:000383981600045
PM 27552409
OA Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Biarnes, M
   Arias, L
   Alonso, J
   Garcia, M
   Hijano, M
   Rodriguez, A
   Serrano, A
   Badal, J
   Muhtaseb, H
   Verdaguer, P
   Mones, J
AF Biarnes, Marc
   Arias, Luis
   Alonso, Jordi
   Garcia, Miriam
   Hijano, Miriam
   Rodriguez, Anabel
   Serrano, Anna
   Badal, Josep
   Muhtaseb, Hussein
   Verdaguer, Paula
   Mones, Jordi
TI Increased Fundus Autofluorescence and Progression of Geographic Atrophy
   Secondary to Age-Related Macular Degeneration: The GAIN Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT ACTIVATION; LIPOFUSCIN; RPE; FLUORESCENCE; EPIDEMIOLOGY;
   DISEASE; A2E
AB PURPOSE: To define the role of increased fundus auto-fluorescence (FAF), a surrogate for lipofuscin content, as a risk factor for progression of geographic atrophy (GA).
   DESIGN: Prospective natural history cohort study, the GAIN (Characterization of geographic atrophy progression in patients with age-related macular degeneration).
   METHODS: SETTING: Single-center study conducted in Barcelona, Spain. PATIENTS: After screening of 211 patients, 109 eyes of 82 patients with GA secondary to age-related macular degeneration and a minimum follow-up of 6 months were included. OBSERVATION PROCEDURES: Lipofuscin content was classified independently by 2 masked observers according to FAF patterns described previously. Bivariate, stratified, and multivariable analyses were used to explore the associations between GA growth and independent variables. Mediation analysis was used to evaluate the contribution of FAF patterns to GA progression. MAIN OUTCOME: Progression of GA in mm(2)/year as measured with FAF.
   RESULTS: Median follow-up was 18 months (range, 6 42). Median GA growth was 1.61 mm(2)/year. FAF, baseline area of atrophy, and time of follow-up were independently associated with GA progression (P < .004). FAF patterns and baseline area of atrophy were strongly associated (P < .0001), suggesting potential confounding. Mediation analysis suggested that most of the effect of FAF patterns on GA growth was actually caused by baseline area of atrophy.
   CONCLUSIONS: FAF patterns, baseline area of atrophy, and time of follow-up were associated with GA progression. However, FAF patterns seem to be a consequence (not a cause) of enlarging atrophy and their effect on GA progression seems mostly driven by baseline area of atrophy. ((C) 2015 by Elsevier Inc. All rights reserved.)
C1 [Biarnes, Marc; Garcia, Miriam; Hijano, Miriam; Rodriguez, Anabel; Serrano, Anna; Badal, Josep; Muhtaseb, Hussein; Verdaguer, Paula; Mones, Jordi] Ctr Med Teknon, Inst Macula & Retina, Barcelona, Spain.
   [Biarnes, Marc; Alonso, Jordi] Univ Pompeu Fabra, Barcelona, Spain.
   [Arias, Luis] Hosp Univ Bellvitge, Barcelona, Spain.
   [Alonso, Jordi] IMIM Inst Hosp del Mar Invest Med, Hlth Serv Res Unit, Barcelona, Spain.
   [Badal, Josep] Hosp Moises Broggi, Barcelona, Spain.
   [Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [Alonso, Jordi] C1BER Epidemiol & Salud Publ, Barcelona, Spain.
C3 Pompeu Fabra University; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona;
   Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del
   Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP
RP Biarnes, M (通讯作者)，Ctr Med Teknon, Inst Macula & Retina, C Vilana 12,Off 90, Barcelona, Spain.
EM biarnes@oo.upc.edu
RI Alonso, Jordi/A-5514-2010; mones, jordi/CAJ-2963-2022
OI Alonso, Jordi/0000-0001-8627-9636; mones, jordi/0000-0003-3685-2160;
   Biarnes, Marc/0000-0003-2584-4894
FU Barcelona Macula Foundation, Barcelona, Spain
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST. Financial disclosures: Marc Biarnes:
   travel/accommodations/meeting expenses, Novartis (Basel, Switzerland),
   Heidelberg (Heidelberg, Germany); Luis Arias: board membership, Alcon
   (Ontario, Canada), Allergan (Irvine, California), Bayer (Leverkusen,
   Germany), Novartis (Basel, Switzerland); Miriam Garcia:
   accommodations/meeting expenses, Salvat (Barcelona, Spain); Josep Badal:
   accommodations/meeting expenses, Alcon (Ontario, Canada), Allergan
   (Irvine, California), Bausch & Lomb (Rochester, New York), Novartis
   (Basel, Switzerland), Pfizer (New York, New York); Hussein Muhtaseb:
   accommodations/meeting expenses, Allergan (Irvine, California), Angelini
   (Rome, Italy), Bloss (Barcelona, Spain), Novartis (Basel, Switzerland),
   Thea (Barcelona, Spain); Jordi Mones: board membership, Alcon (Ontario,
   Canada), Allergan (Irvine, California), Bayer (Leverkusen, Germany),
   Novartis (Basel, Switzerland); payment for lectures including service on
   speakers bureaus Alcon (Ontario, Canada), Allergan (Irvine, California),
   Bayer (Leverkusen, Germany), Novartis (Basel, Switzerland); stock
   options, Notal Vision (Tel Aviv, Israel), Ophthotech (Princeton, New
   Jersey). Funding support was provided by Barcelona Macula Foundation,
   Barcelona, Spain. All authors attest that they meet the current ICMJE
   requirements to qualify as authors.
CR Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Dreyhaupt J, 2007, METHOD INFORM MED, V46, P432, DOI 10.1160/ME0328
   Fujinami K, 2013, INVEST OPHTH VIS SCI, V54, P8181, DOI 10.1167/iovs.13-12104
   Guo JL, 2014, NAT MED, V20, P130, DOI 10.1038/nm.3457
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hopkins J, 2006, INVEST OPHTH VIS SCI, V47, P2269, DOI 10.1167/iovs.05-1482
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Richiardi L, 2013, INT J EPIDEMIOL, V42, P1511, DOI 10.1093/ije/dyt127
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Rothman KJ, 2013, INT J EPIDEMIOL, V42, P1012, DOI 10.1093/ije/dys223
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Vittinghoff E, 2005, STAT BIOL HEALTH, P1, DOI 10.1007/b138825
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 36
TC 42
Z9 43
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2015
VL 160
IS 2
BP 345
EP 353
DI 10.1016/j.ajo.2015.05.009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN6NY
UT WOS:000358552700017
PM 25982972
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zeydanli, EO
   Gurelik, G
AF Zeydanli, Ece Ozdemir
   Gurelik, Gokhan
TI Optical coherence tomography angiography markers associated with
   treatment response in neovascular age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; age-related macular degeneration; medical therapies; techniques
   of retinal examination
ID CHOROIDAL NEOVASCULARIZATION; QUANTITATIVE-ANALYSIS; SUBGROUP ANALYSIS;
   OCT ANGIOGRAPHY; RANIBIZUMAB; THERAPY; BIOMARKERS; OUTCOMES; ANCHOR;
   MARINA
AB Purpose: To investigate whether qualitative and quantitative features of choroidal neovascular membranes are associated with anti-vascular endothelial growth factor treatment response in patients with neovascular age-related macular degeneration.
   Methods: A total of 41 eyes were included in this cross-sectional observational study and divided into "good responders" and "poor responders" based on the long-term functional changes, frequency of recurrent choroidal neovascular activity, and injection need. Enface optical coherence tomography angiography images were obtained and qualitative features of choroidal neovascular membranes were described based on vessel network density. Then, quantitative measurements including vessel area, vessel length, junction density, and lacunarity were calculated using validated software (ImageJ and AngioTool). Chi-square tests, t-test, or Mann-Whitney U tests were used for group comparisons, and intraclass correlation coefficients were calculated for reliability assessment of quantitative analyses.
   Results: Twenty-two eyes treated by a median of 9 (3-24) anti-vascular endothelial growth factor injections at a median follow-up of 41 (12-89) months were categorized as good responders, 19 treated by a median of 26 (11-46) injections at a median follow-up of 44.5 (12-84) months as poor responders. Good responder group mostly had loose network (45.5%), and poor responders mostly had dense network (47.7%). The difference was not statistically significant (p=0.25). The size of the lesion was 2.7 times greater at baseline (p=0.04) and 1.7 times greater at final examination in the poor responder group (p=0.04). Lacunarity index, showing lesion heterogeneity, was higher in good responders (p=0.018) than poor responders. Other quantitative vascular features did not significantly differ between the groups (p>0.05).
   Conclusion: Long-term remodeling of chronically treated choroidal neovascular may be non-invasively and reproducibly investigated using optical coherence tomography angiography. Quantitative analysis and lacunarity index, in particular, may be used as a measure of vessel maturation and guide treatment strategies in neovascular age-related macular degeneration.
C1 [Zeydanli, Ece Ozdemir; Gurelik, Gokhan] Gazi Univ, Sch Med, TR-06500 Ankara, Turkey.
C3 Gazi University
RP Zeydanli, EO (通讯作者)，Gazi Univ, Sch Med, TR-06500 Ankara, Turkey.
EM eceozdemirzeydanli@gmail.com
RI Özdemir Zeydanlı, Ece/GPK-6060-2022
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bellou S, 2013, CANCER LETT, V338, P219, DOI 10.1016/j.canlet.2013.05.015
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Ho AC, 2018, OPHTHALMOL RETINA, V2, P676, DOI 10.1016/j.oret.2017.10.017
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Nesper PL, 2018, INVEST OPHTH VIS SCI, V59, P1944, DOI 10.1167/iovs.17-23361
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Yasukawa T, 2015, EXPERT REV OPHTHALMO, V10, P105, DOI 10.1586/17469899.2015.1019473
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 34
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2021
VL 31
IS 3
BP 1192
EP 1200
AR 1120672120925790
DI 10.1177/1120672120925790
EA MAY 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2CF
UT WOS:000536223800001
PM 32450717
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Francis, PJ
   George, S
   Schultz, DW
   Rosner, B
   Klein, ML
AF Seddon, Johanna M.
   Francis, Peter J.
   George, Sarah
   Schultz, Dennis W.
   Rosner, Bernard
   Klein, Michael L.
TI Association of CFH Y402H and LOC387715 A69S with progression of
   age-related macular degeneration
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID BODY-MASS INDEX; FACTOR-H POLYMORPHISM; CIGARETTE-SMOKING; ENVIRONMENTAL
   ASSOCIATIONS; US TWIN; VARIANT; SUSCEPTIBILITY; GENE; RISK; CFH
AB Context Studies have reported that single-nucleotide polymorphisms in the genes CFH and LOC387715 are associated with age-related macular degeneration (AMD).
   Objective To assess whether these genetic variants have prognostic importance for progression to advanced AMD and related visual loss.
   Design, Setting, and Participants Prospective analysis of 1466 white participants in the Age-Related Eye Disease Study (AREDS), a US multicenter clinical trial conducted from 1990 to 2001 with a mean follow-up time of 6.3 years. Age-related macular degeneration status was determined by grading of fundus photographs. Progression (n = 281) was defined as newly diagnosed advanced AMD (geographic atrophy, exudative disease, or AMD causing visual loss) in one or both eyes during the course of the study. Genotypic analysis was conducted in 2006.
   Main Outcome Measure Incidence rates of dry and neovascular advanced AMD.
   Results The CFH Y402H and LOC387115 A69S polymorphisms were each independently related to progression from early or intermediate stages to advanced stages of AMD, controlling for demographic factors, smoking, body mass index, and AREDS vitamin-mineral treatment assignment, with odds ratios (ORs) of 2.6 (95% confidence interval [CI], 1.7-3.9) for CFH and 4.1 (95% CI, 2.7- 6.3) for LOC387715 for the homozygous risk geno-types (P < .001 for trend for each additional risk allele for both genes). The effect of LOC387715 was stronger for progression to neovascular disease (OR, 6.1; 95% CI, 3.3-11.2) compared with geographic atrophy (OR, 3.0; 95% CI, 1.4-6.5) relative to no progression for the homozygous risk state. The presence of all adverse factors (both risk genotypes, smoking, and bodymass index >= 25) increased risk 19-fold. Smoking and high body mass index increased odds of progression within each risk genotype. Genetic plus nongenetic risk scores provided an area under the receiver operating characteristic curve of up to 0.78.
   Conclusions Common polymorphisms in the genes CFH and LOC387715 are independently related to AMD progression after adjustment for other known AMD risk factors. Presence of these polymorphisms plus AREDS vitamin-mineral treatment, smoking, and body mass index of 25 or higher identify patients who are highly susceptible to developing advanced stages of this visually disabling disease.
C1 Tufts Univ New England Med Ctr, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, Portland, OR 97239 USA.
   Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Grad Sch Educ, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Grad Sch Educ, Dept Biostat, Boston, MA 02115 USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Macular Degenerat Ctr, Portland, OR 97201 USA.
C3 Tufts Medical Center; Harvard University; Harvard Medical School;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Oregon Health &
   Science University
RP Seddon, JM (通讯作者)，Tufts Univ New England Med Ctr, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol, 750 Washington St 450, Portland, OR 97239 USA.
EM jseddon@earthlink.net; kleinm@ohsu.edu
FU NCRR NIH HHS [U54 RR020278] Funding Source: Medline; NEI NIH HHS [R01
   EY011309, R01-EY11309, EY12203] Funding Source: Medline; NATIONAL CENTER
   FOR RESEARCH RESOURCES [U54RR020278] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY012203, R01EY011309] Funding Source: NIH
   RePORTER
CR D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 26
TC 244
Z9 257
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD APR 25
PY 2007
VL 297
IS 16
BP 1793
EP 1800
DI 10.1001/jama.297.16.1793
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 160DW
UT WOS:000245922100025
PM 17456821
OA Bronze
DA 2022-11-30
ER

PT J
AU den Hollander, AI
AF den Hollander, Anneke I.
TI Omics in Ophthalmology: Advances in Genomics and Precision Medicine for
   Leber Congenital Amaurosis and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; genetic diseases; retinal dystrophy;
   gene therapy; retinal degeneration
ID GENE-THERAPY; RETINITIS-PIGMENTOSA; WIDE ASSOCIATION; HIGH-RISK;
   PROTEOMIC ANALYSIS; AQUEOUS-HUMOR; MOLECULAR DIAGNOSIS; RECESSIVE
   MUTATIONS; NMNAT1 MUTATIONS; COMMON VARIANTS
AB The genomic revolution has had a huge impact on our understanding of the genetic defects and disease mechanisms underlying ophthalmic diseases. Two examples are discussed here. The first is Leber congenital amaurosis (LCA), a severe inherited retinal dystrophy leading to severe vision loss in children, and the second is age-related macular degeneration (AMD), the most common cause of vision loss in the elderly. Twenty years ago, the genetic causes of these diseases were unknown. Currently, more than 20 LCA genes have been identified, and genetic testing can now successfully identify the genetic defects in at least 75% of all LCA cases. Gene-specific treatments have entered the clinical trial phase for three LCA genes, and for seven LCA genes gene-specific therapies have been tested in model systems. Age-related macular degeneration is a multifactorial disease caused by a combination of genetic and environmental factors. Currently, more than 40 loci have been identified for AMD, accounting for 15%-65% of the total genetic contribution to AMD. Despite the progress that has been made so far, genetic testing is not yet recommended for AMD, but this may change if we move to clinical trials or treatments that are dependent on an individual's genotype. The identification of serum or plasma biomarkers using other "-omics'' technologies may further improve predictive tests and our understanding of the disease mechanisms of AMD. Ultimately, it is anticipated that predictive tests will help to stratify patients for the most suitable therapy, which will enable the development of precision medicine, tailored to individual needs.
C1 [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol 409, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM Anneke.denhollander@radboudumc.nl
RI Hollander, Anneke den/N-4911-2014
FU Foundation Fighting Blindness USA [C-GE-0811-0548-RAD04]; Netherlands
   Organisation for Scientific Research [016.096.309]; European Research
   Council under European Union/ERC [310644]; Cogan award
FX I am honored to receive the Cogan award, and express my sincere
   gratitude to Martine Jager, Rod McInnes, Eric Pierce, and Dean Bok for
   supporting my nomination. I am also thankful to two people who have been
   an inspiration to me and have helped shape my career. Frans Cremers has
   been my mentor since the early days when I embarked on my PhD studies in
   his group on the genetics of retinal dystrophies. I admire his honesty
   and genuineness, and value his efforts in advancing the careers of young
   researchers. I am also thankful to Carel Hoyng, who has been my clinical
   partner for the past seven years. His determination and devotion to
   research are an inspiration. He invested heavily in establishing the
   EUGENDA database, which is a valuable resource for our current research
   on AMD. Much of the work I presented here was performed by talented
   young researchers in our group, whom I have the honor to work with
   during the past years and gratefully acknowledge for their dedication
   and hard work. I also acknowledge my valued collaborators from all over
   the world. Many of them I meet every year at ARVO, and have become dear
   friends. I look forward to continuing our collaborations and friendships
   during the years to come. I thank my husband, Tim, and our children,
   Joost and Liza, for supporting my career, and for being there to share
   the big and small things in life.; Supported in part by the Foundation
   Fighting Blindness USA (Center Grant C-GE-0811-0548-RAD04), the
   Netherlands Organisation for Scientific Research (Vidi Innovational
   Research Award 016.096.309), and the European Research Council under the
   European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant
   Agreement n. 310644 (MACULA).
CR Annas GJ, 2014, NEW ENGL J MED, V370, P2248, DOI 10.1056/NEJMc1404692
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Asai-Coakwell M, 2013, HUM MOL GENET, V22, P1432, DOI 10.1093/hmg/dds560
   Awh CC, 2015, OPHTHALMOLOGY, V122, P162, DOI 10.1016/j.ophtha.2014.07.049
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Batten ML, 2005, PLOS MED, V2, P1177, DOI 10.1371/journal.pmed.0020333
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boye SE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011306
   Buitendijk GHS, 2014, INVEST OPHTH VIS SCI, V55, P6167, DOI 10.1167/iovs.14-15142
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Burnight ER, 2014, GENE THER, V21, P662, DOI 10.1038/gt.2014.39
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chiang PW, 2012, NAT GENET, V44, P972, DOI 10.1038/ng.2370
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Collin RWJ, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.3
   Coppieters F, 2012, GENET MED, V14, P576, DOI 10.1038/gim.2011.51
   Coppieters F, 2010, HUM MUTAT, V31, pE1709, DOI 10.1002/humu.21336
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Daiger SP, 2010, ADV EXP MED BIOL, V664, P325, DOI 10.1007/978-1-4419-1399-9_37
   den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848
   den Hollander AI, 1999, GENOMICS, V58, P240, DOI 10.1006/geno.1999.5823
   den Hollander AI, 2001, AM J HUM GENET, V69, P198
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   den Hollander AI, 2007, NAT GENET, V39, P889, DOI 10.1038/ng2066
   den Hollander AI, 2006, AM J HUM GENET, V79, P556, DOI 10.1086/507318
   den Hollander AI, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017202
   den Hollander AI, 2010, J CLIN INVEST, V120, P3042, DOI 10.1172/JCI42258
   Dryja TP, 2001, AM J HUM GENET, V68, P1295, DOI 10.1086/320113
   Estrada-Cuzcano A, 2011, INVEST OPHTH VIS SCI, V52, P834, DOI 10.1167/iovs.10-5221
   Evans K, 1996, BRIT J OPHTHALMOL, V80, P763, DOI 10.1136/bjo.80.8.763
   Falk MJ, 2012, NAT GENET, V44, P1040, DOI 10.1038/ng.2361
   Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311
   Friedman JS, 2006, AM J HUM GENET, V79, P1059, DOI 10.1086/510021
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gaub BM, 2014, P NATL ACAD SCI USA, V111, pE5574, DOI 10.1073/pnas.1414162111
   Gerard X, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.21
   Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Hagstrom SA, 1998, NAT GENET, V18, P174, DOI 10.1038/ng0298-174
   Hampton BM, 2015, CLIN OPHTHALMOL, V9, P873, DOI 10.2147/OPTH.S84155
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Huang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7687
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Janecke AR, 2004, NAT GENET, V36, P850, DOI 10.1038/ng1394
   Kalf RRJ, 2014, GENET MED, V16, P85, DOI 10.1038/gim.2013.80
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kim HJ, 2014, INVEST OPHTH VIS SCI, V55, P7166, DOI 10.1167/iovs.14-15168
   Kim TW, 2012, J PROTEOME RES, V11, P4034, DOI 10.1021/pr300080s
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koenekoop RK, 2007, CLIN EXP OPHTHALMOL, V35, P473, DOI 10.1111/j.1442-9071.2007.01534.x
   Koenekoop RK, 2014, LANCET, V384, P1513, DOI 10.1016/S0140-6736(14)60153-7
   Koenekoop RK, 2012, NAT GENET, V44, P1035, DOI 10.1038/ng.2356
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269
   Lotery AJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P415, DOI 10.1001/archopht.119.3.415
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959
   Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Molday LL, 2013, HUM MOL GENET, V22, P3894, DOI 10.1093/hmg/ddt244
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neveling K, 2012, HUM MUTAT, V33, P963, DOI 10.1002/humu.22045
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pawlyk BS, 2005, INVEST OPHTH VIS SCI, V46, P3039, DOI 10.1167/iovs.05-0371
   Pellissier LP, 2015, HUM MOL GENET, V24, P3104, DOI 10.1093/hmg/ddv062
   Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461
   Perrault Isabelle, 2007, Hum Mutat, V28, P416, DOI 10.1002/humu.9485
   Perrault I, 2012, NAT GENET, V44, P975, DOI 10.1038/ng.2357
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sergouniotis PI, 2011, AM J HUM GENET, V89, P183, DOI 10.1016/j.ajhg.2011.06.002
   Servick K, 2015, SCIENCE, V349, P1472, DOI 10.1126/science.349.6255.1472
   Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389
   Sohocki MM, 2000, NAT GENET, V24, P79, DOI 10.1038/71732
   Stone EM, 2007, AM J OPHTHALMOL, V144, P791, DOI 10.1016/j.ajo.2007.08.022
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Tan MH, 2009, HUM MOL GENET, V18, P2099, DOI 10.1093/hmg/ddp133
   Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7355, DOI 10.1167/iovs.14-15317
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wang H, 2009, AM J HUM GENET, V84, P380, DOI 10.1016/j.ajhg.2009.02.005
   Wang X, 2013, J MED GENET, V50, P674, DOI 10.1136/jmedgenet-2013-101558
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wetterstrand K. A, 2015, DNA SEQUENCING COSTS
   Wiley LA, 2015, PROG RETIN EYE RES, V44, P15, DOI 10.1016/j.preteyeres.2014.10.002
   Xu MC, 2015, HUM GENET, V134, P1069, DOI 10.1007/s00439-015-1586-x
   Xu XR, 2014, INT J OPHTHALMOL-CHI, V7, P256, DOI 10.3980/j.issn.2222-3959.2014.02.12
   Xu Y, 2016, CLIN GENET, V89, P442, DOI 10.1111/cge.12617
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zernant J, 2005, INVEST OPHTH VIS SCI, V46, P3052, DOI 10.1167/iovs.05-0111
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 114
TC 19
Z9 19
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2016
VL 57
IS 3
BP 1378
EP 1387
DI 10.1167/iovs.15-18167
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK4BE
UT WOS:000374860600082
PM 27010695
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Kawaguchi, A
   Sharafeldin, N
   Sundaram, A
   Campbell, S
   Tennant, M
   Rudnisky, C
   Weis, E
   Damji, KF
AF Kawaguchi, Atsushi
   Sharafeldin, Noha
   Sundaram, Aishwarya
   Campbell, Sandy
   Tennant, Matthew
   Rudnisky, Christopher
   Weis, Ezekiel
   Damji, Karim F.
TI Tele-Ophthalmology for Age-Related Macular Degeneration and Diabetic
   Retinopathy Screening: A Systematic Review and Meta-Analysis
SO TELEMEDICINE AND E-HEALTH
LA English
DT Review
DE tele-ophthalmology; clinical; systematic review; meta-analysis
ID RANDOMIZED CLINICAL-TRIAL; EYE HOME; TELEMEDICINE; CARE;
   TELEOPHTHALMOLOGY; SERVICES; NUMBER
AB Background:To synthesize high-quality evidence to compare traditional in-person screening and tele-ophthalmology screening.Methods:Only randomized controlled trials (RCTs) were included in this systematic review and meta-analysis. The intervention of interest was any type of tele-ophthalmology, including screening of diseases using remote devices. Studies involved patients receiving care from any trained provider via tele-ophthalmology, compared with those receiving equivalent face-to-face care. A search was executed on the following databases: Medline, EMBASE, EBM Reviews, Global Health, EBSCO-CINAHL, SCOPUS, ProQuest Dissertations and Theses Global, OCLC Papers First, and Web of Science Core Collection. Six outcomes of care for age-related macular degeneration (AMD), diabetic retinopathy (DR), or glaucoma were measured and analyzed.Results:Two hundred thirty-seven records were assessed at the full-text level; six RCTs fulfilled inclusion criteria and were included in this review. Four studies involved participants with diabetes mellitus, and two studies examined choroidal neovascularization in AMD. Only data of detection of disease and participation in the screening program were used for the meta-analysis. Tele-ophthalmology had a 14% higher odds to detect disease than traditional examination; however, the result was not statistically significant (n=2,012, odds ratio: 1.14, 95% confidence interval (CI): 0.52-2.53, p=0.74). Meta-analysis results show that odds of having DR screening in the tele-ophthalmology group was 13.15 (95% CI: 8.01-21.61; p < 0.001) compared to the traditional screening program.Conclusions:The current evidence suggests that tele-ophthalmology for DR and age-related macular degeneration is as effective as in-person examination and potentially increases patient participation in screening.
C1 [Kawaguchi, Atsushi; Sharafeldin, Noha] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.
   [Kawaguchi, Atsushi] Univ Alberta, Dept Pediat, Pediat Crit Care Med, Edmonton, AB, Canada.
   [Sharafeldin, Noha] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Sundaram, Aishwarya] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS, Canada.
   [Campbell, Sandy] Univ Alberta, Hlth Sci Lib, JW Scott Lib, Edmonton, AB, Canada.
   [Tennant, Matthew; Rudnisky, Christopher; Weis, Ezekiel; Damji, Karim F.] Univ Alberta, Dept Ophthalmol & Visual Sci, Edmonton, AB, Canada.
   [Weis, Ezekiel] Univ Calgary, Dept Surg, Div Ophthalmol, Calgary, AB, Canada.
C3 University of Alberta; University of Alberta; University of Alabama
   System; University of Alabama Birmingham; Dalhousie University;
   University of Alberta; University of Alberta; University of Calgary
RP Damji, KF (通讯作者)，Univ Alberta, Fac Med, Dept Ophthalmol & Visual Sci, 2319,10240 Kingsway Ave NW, Edmonton, AB T5H 3V9, Canada.
EM kdamji@ualberta.ca
RI Campbell, Sandy/C-3152-2013; kawaguchi, atsushi/H-6861-2019
OI Campbell, Sandy/0000-0002-9347-3880; Weis, Ezekiel/0000-0002-6862-0850
FU NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [P30DK079626] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000032]
   Funding Source: Medline; NIDDK NIH HHS [P30 DK079626] Funding Source:
   Medline
CR Bellan L, 2007, CAN J OPHTHALMOL, V42, P34, DOI 10.3129/canjophthalmol.06-115
   Bellan L, 2013, CAN J OPHTHALMOL, V48, P160, DOI 10.1016/j.jcjo.2013.01.017
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Das T, 2015, MIDDLE EAST AFR J OP, V22, P174, DOI 10.4103/0974-9233.154391
   Davis RM, 2003, IOVSARVO E ABSTRACT, P166
   Ekeland AG, 2010, INT J MED INFORM, V79, P736, DOI 10.1016/j.ijmedinf.2010.08.006
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Lamminen H, 2003, ACTA OPHTHALMOL SCAN, V81, P105, DOI 10.1034/j.1600-0420.2003.00045.x
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Li HK, 1999, SURV OPHTHALMOL, V44, P61, DOI 10.1016/S0039-6257(99)00059-4
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   Linkous JD, 2004, TELEMED J E-HEALTH, V10, P469, DOI 10.1089/tmj.2004.10.469
   Maa AY, 2014, TELEMED E-HEALTH, V20, P318, DOI 10.1089/tmj.2013.0185
   Mansberger SL, 2010, J INVEST MED, V58, P116
   Mansberger SL, 2015, JAMA OPHTHALMOL, V133, P518, DOI 10.1001/jamaophthalmol.2015.1
   Mansberger SL, 2013, TELEMED E-HEALTH, V19, P942, DOI 10.1089/tmj.2012.0313
   Murthy KR, 2012, DIABETES RES CLIN PR, V97, P343, DOI 10.1016/j.diabres.2012.04.025
   National Eye Institute, 2015, PREV AD VIS IMP AG R
   Resnikoff S, 2012, BRIT J OPHTHALMOL, V96, P783, DOI 10.1136/bjophthalmol-2011-301378
   Shanit D, 1998, J TELEMED TELECARE, V4, P1, DOI 10.1258/1357633981931317
   Sreelatha OK, 2016, CLIN OPHTHALMOL, V10, P285, DOI 10.2147/OPTH.S80487
   Tan IJ, 2017, J TELEMED TELECARE, V23, P629, DOI 10.1177/1357633X16660640
NR 23
TC 26
Z9 26
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD APR
PY 2018
VL 24
IS 4
BP 301
EP 308
DI 10.1089/tmj.2017.0100
PG 8
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA GC0DR
UT WOS:000429447600008
PM 28783458
OA Green Published
DA 2022-11-30
ER

PT J
AU Arias, L
   Ruiz-Moreno, JM
   Gomez-Ulla, F
   Fernandez, M
   Montero, J
AF Arias, Luis
   Ruiz-Moreno, Jose M.
   Gomez-Ulla, Francisco
   Fernandez, Maribel
   Montero, Javier
TI A 1-YEAR RETROSPECTIVE REVIEW OF RANIBIZUMAB FOR NAIVE NONSUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intravitreal ranibizumab; nonsubfoveal choroidal neovascularization;
   age-related macular degeneration
ID PHOTODYNAMIC THERAPY
AB Purpose: To assess efficacy and safety in the treatment of nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration with intravitreal ranibizumab.
   Methods: Retrospective, multicentric, noncomparative, interventional case series. We included patients with naive extrafoveal and juxtafoveal choroidal neovascularization treated with intravitreal ranibizumab and a follow-up of 1 year. Patients were evaluated using visual acuity testing with Snellen charts, fluorescein angiography, and optical coherence tomography scans.
   Results: There were 15 patients with a mean age of 72.4 years (SD, 7.2). There were 11 juxtafoveal lesions (73.3%) and 4 extrafoveal lesions (26.6%). Eight lesions were predominantly classic (53.3%), 6 lesions were occult (40%), and 1 lesion was minimally classic (6.6%). The mean visual acuity improved from 20/60 (mean logarithm of the minimum angle of resolution 0.47) at baseline to 20/40 (mean logarithm of the minimum angle of resolution = 0.34) at the 1-year follow-up visit (P = 0.03). The mean foveal thickness improved from 312 mu m to 262 mu m (P = 0.01), and the mean lesion size (disk areas) improved from 1.9 to 1.1 (P = 0.01). No cases progressed to a subfoveal location. The mean number of injections was 3.8. As complications, we had an endophthalmitis and a macular hole.
   Conclusion: In our study, intravitreal ranibizumab showed efficacy for the treatment of nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration mainly in terms of preventing subfoveal progression. RETINA 29:1444-1449, 2009
C1 [Arias, Luis] Bellvitge Univ Hosp, Dept Ophthalmol, Barcelona 08907, Spain.
   [Arias, Luis] Ctr Med Teknon, Inst Macula & Retina, Barcelona, Spain.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Dept Ophthalmol, Albacete, Spain.
   [Ruiz-Moreno, Jose M.; Montero, Javier] VISSUM, Alicante Inst Ophthalmol, Alicante, Spain.
   [Gomez-Ulla, Francisco; Fernandez, Maribel] Univ Santiago de Compostela, ITO, Santiago De Compostela, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge
   University Hospital; University of Barcelona; Universidad de Castilla-La
   Mancha; Universidade de Santiago de Compostela
RP Arias, L (通讯作者)，Bellvitge Univ Hosp, Dept Ophthalmol, Barcelona 08907, Spain.
EM luisarias@telefonica.net
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788; ARIAS, LUIS/0000-0001-7041-5576
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Beaumont PE, 2006, ARCH OPHTHALMOL-CHIC, V124, P807, DOI 10.1001/archopht.124.6.807
   Blair MP, 2004, RETINA-J RET VIT DIS, V24, P501, DOI 10.1097/00006982-200408000-00001
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Mones JM, 2007, OPHTHAL SURG LAS IM, V38, P226, DOI 10.3928/15428877-20070501-07
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
NR 14
TC 8
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2009
VL 29
IS 10
BP 1444
EP 1449
DI 10.1097/IAE.0b013e3181ae712d
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 519SH
UT WOS:000271787600009
PM 19730163
DA 2022-11-30
ER

PT J
AU Lains, I
   Duarte, D
   Barros, AS
   Martins, AS
   Carneiro, TJ
   Gil, JQ
   Miller, JB
   Marques, M
   Mesquita, TS
   Barreto, P
   Kim, IK
   Cachulo, MD
   Vavvas, DG
   Carreira, IM
   Murta, JN
   Silva, R
   Miller, JW
   Husain, D
   Gil, AM
AF Lains, Ines
   Duarte, Daniela
   Barros, Antonio S.
   Martins, Ana Sofia
   Carneiro, Tatiana J.
   Gil, Joao Q.
   Miller, John B.
   Marques, Marco
   Mesquita, Tania S.
   Barreto, Patricia
   Kim, Ivana K.
   Cachulo, Maria da Luz
   Vavvas, Demetrios G.
   Carreira, Isabel M.
   Murta, Joaquim Neto
   Silva, Rufino
   Miller, Joan W.
   Husain, Deeba
   Gil, Ana M.
TI Urine Nuclear Magnetic Resonance (NMR) Metabolomics in Age-Related
   Macular Degeneration
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE age-related macular degeneration; urine; metabolomics; nuclear magnetic
   resonance spectroscopy
ID SIGNATURES; SPECTROSCOPY; DISEASE; PLASMA; METABONOMICS; PREVALENCE;
   VALIDATION; DIAGNOSIS; REVEALS; CANCER
AB Biofluid biomarkers of age-related macular degeneration (AMD) are still lacking, and their identification is challenging. Metabolomics is well-suited to address this need, and urine is a valuable accessible biofluid. This study aimed to characterize the urinary metabolomic signatures of patients with different stages of AMD and a control group (>50 years). It was a prospective, cross-sectional study, where subjects from two cohorts were included: 305 from Coimbra, Portugal (AMD patients n = 252; controls n = 53) and 194 from Boston, United States (AMD patients n = 147; controls n = 47). For all participants, we obtained color fundus photographs (for AMD staging) and fasting urine samples, which were analyzed using 1H nuclear magnetic resonance (NMR) spectroscopy. Our results revealed that in both cohorts, urinary metabolomic profiles differed mostly between controls and late AMD patients, but important differences were also found between controls and subjects with early AMD. Analysis of the metabolites responsible for these separations revealed that, even though distinct features were observed for each cohort, AMD was in general associated with depletion of excreted citrate and selected amino acids at some stage of the disease, suggesting enhanced energy requirements. In conclusion, NMR metabolomics enabled the identification of urinary signals of AMD and its severity stages, which might represent potential metabolomic biomarkers of the disease.
C1 [Lains, Ines; Miller, John B.; Kim, Ivana K.; Vavvas, Demetrios G.; Miller, Joan W.; Husain, Deeba] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02115 USA.
   [Lains, Ines; Gil, Joao Q.; Marques, Marco; Cachulo, Maria da Luz; Carreira, Isabel M.; Murta, Joaquim Neto; Silva, Rufino] Univ Coimbra FMUC, Fac Med, P-3000354 Coimbra, Portugal.
   [Lains, Ines; Gil, Joao Q.; Marques, Marco; Mesquita, Tania S.; Barreto, Patricia; Cachulo, Maria da Luz; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, P-3000548 Coimbra, Portugal.
   [Lains, Ines; Gil, Joao Q.; Marques, Marco; Cachulo, Maria da Luz; Murta, Joaquim Neto; Silva, Rufino] CHUC, Dept Ophthalmol, P-3075 Coimbra, Portugal.
   [Duarte, Daniela; Barros, Antonio S.; Martins, Ana Sofia; Carneiro, Tatiana J.; Gil, Ana M.] Univ Aveiro, Dept Chem, CICECO Aveiro Inst Mat CICECO UA, P-3810193 Aveiro, Portugal.
   [Barros, Antonio S.] Fac Med, Dept Cardiothorac Surg & Physiol, P-4200319 Porto, Portugal.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Universidade de Coimbra; Universidade de Coimbra;
   Universidade de Coimbra; Universidade de Aveiro; Universidade do Porto
RP Gil, AM (通讯作者)，Univ Aveiro, Dept Chem, CICECO Aveiro Inst Mat CICECO UA, P-3810193 Aveiro, Portugal.
EM agil@ua.pt
RI Duarte, Daniela/AAD-3491-2020; Barros, António S./B-5847-2009; Miller,
   John J/GZG-5663-2022; Silva, Rufino M/J-2817-2012; Carreira, Isabel
   M/C-7711-2018; Murta, Joaquim/V-5494-2017
OI Duarte, Daniela/0000-0001-9460-1162; Barros, António
   S./0000-0002-9103-5852; Silva, Rufino M/0000-0001-8676-0833; Carreira,
   Isabel M/0000-0001-6842-1707; Martins, Ana Sofia/0000-0001-6865-5853;
   Murta, Joaquim/0000-0001-8926-5176; Husain, Deeba/0000-0002-8494-0950;
   Quadrado Gil, Joao/0000-0001-9032-1008; Kim, Ivana/0000-0003-0310-6129
FU "Fundacao para a Ciencia e a Tecnologia" (FCT) [HMSP-ICJ/0006/2013];
   Miller Retina Research Fund (MEE); Miller Champalimaud Award (MEE);
   project CICECO-Aveiro Institute of Materials, FCT [UID/CTM/50011/2019,
   POCI-01-0145-FEDER-007679]; national funds through the FCT/MCTES; FCT
   [SFRH/BD/119509/2016]; NATIONAL EYE INSTITUTE [R01EY030088] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [K01HL146980] Funding Source: NIH RePORTER
FX This project was funded by the "Fundacao para a Ciencia e a Tecnologia"
   (FCT) (HMSP-ICJ/0006/2013), the Miller Retina Research Fund (MEE) and
   the Miller Champalimaud Award (MEE). This work was developed within the
   scope of the project CICECO-Aveiro Institute of Materials, FCT ref.
   UID/CTM/50011/2019 and POCI-01-0145-FEDER-007679, financed by national
   funds through the FCT/MCTES. AMG and DD acknowledge the Portuguese
   National NMR Network (RNRMN), supported by FCT funds, and grant
   SFRH/BD/119509/2016.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   An MX, 2015, GENOM PROTEOM BIOINF, V13, P345, DOI 10.1016/j.gpb.2015.08.005
   [Anonymous], 2010, R LANG ENV STAT COMP
   Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376
   Berben L, 2012, INT J NURS STUD, V49, P1039, DOI 10.1016/j.ijnurstu.2012.01.015
   Bouatra S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073076
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Carrola J, 2011, J PROTEOME RES, V10, P221, DOI 10.1021/pr100899x
   Chen ZH, 2016, BMC UROL, V16, DOI 10.1186/s12894-016-0129-7
   Cloarec O, 2005, ANAL CHEM, V77, P1282, DOI 10.1021/ac048630x
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Deng L, 2017, INT J COLORECTAL DIS, V32, P741, DOI 10.1007/s00384-016-2729-9
   Diaz SO, 2016, J PROTEOME RES, V15, P311, DOI 10.1021/acs.jproteome.5b00977
   Diaz SO, 2013, J PROTEOME RES, V12, P2946, DOI 10.1021/pr4002355
   Duarte IF, 2012, PROG NUCL MAG RES SP, V62, P51, DOI 10.1016/j.pnmrs.2011.11.002
   Duarte IF, 2010, VIRCHOWS ARCH, V457, P715, DOI 10.1007/s00428-010-0993-6
   Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335
   Emwas AH, 2016, J PROTEOME RES, V15, P360, DOI 10.1021/acs.jproteome.5b00885
   Fernandez-Peralbo M. A., 2016, SCI REP, P6
   Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833
   Finco G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150476
   HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X
   Junot C, 2014, MASS SPECTROM REV, V33, P471, DOI 10.1002/mas.21401
   Kohler I, 2016, BIOANALYSIS, V8, P1509, DOI 10.4155/bio-2016-0090
   Lains I, 2018, RETINA-J RET VIT DIS, V38, P1145, DOI 10.1097/IAE.0000000000001659
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Li ZF, 2015, MOL BIOSYST, V11, P3387, DOI 10.1039/c5mb00489f
   Liang Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep19763
   Maitre L, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0706-3
   Mal M, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa-2015-0014
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Monteiro MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep37275
   Nicholson JK, 2012, NATURE, V491, P384, DOI 10.1038/nature11708
   Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047
   Obuchowski NA, 2004, CLIN CHEM, V50, P1118, DOI 10.1373/clinchem.2004.031823
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957
   Rocha CM, 2011, J PROTEOME RES, V10, P4314, DOI 10.1021/pr200550p
   Senn T, 2012, PROG CARDIOVASC DIS, V55, P70, DOI 10.1016/j.pcad.2012.06.004
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Szymanska E, 2012, METABOLOMICS, V8, pS3, DOI 10.1007/s11306-011-0330-3
   Tan SZ, 2016, EYE, V30, P773, DOI 10.1038/eye.2016.37
   Triba MN, 2015, MOL BIOSYST, V11, P13, DOI 10.1039/c4mb00414k
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   Tsiropoulou S, 2017, METHODS MOL BIOL, V1527, P61, DOI 10.1007/978-1-4939-6625-7_5
   Veselkov KA, 2009, ANAL CHEM, V81, P56, DOI 10.1021/ac8011544
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep35010
   Yan B, 2016, BIOMED CHROMATOGR, V30, P1877, DOI 10.1002/bmc.3734
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 53
TC 11
Z9 11
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR
PY 2019
VL 18
IS 3
BP 1278
EP 1288
DI 10.1021/acs.jproteome.8b00877
PG 11
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HN9BA
UT WOS:000460491800042
PM 30672297
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Johnson, D
   Sharma, S
AF Johnson, Davin
   Sharma, Sanjay
TI Ocular and systemic safety of bevacizumab and ranibizumab in patients
   with neovascular age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE bevacizumab; ranibizumab; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; OCCULT CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; RANDOMIZED CLINICAL-TRIAL; ARTERIAL
   THROMBOEMBOLIC EVENTS; ACUTE INTRAOCULAR INFLAMMATION; 12-MONTH
   FOLLOW-UP; INTRAVITREAL BEVACIZUMAB; VISUAL-ACUITY; SHORT-TERM
AB Purpose of review
   This study reviews differences in both ocular and systemic safety between intravitreal bevacizumab and ranibizumab in the setting of neovascular age-related macular degeneration.
   Recent findings
   Serious adverse events associated with either bevacizumab or ranibizumab injections are generally rare. However, acute intraocular inflammation (AII) tends to occur more frequently following bevacizumab injection. Systemic absorption of bevacizumab is greater than with ranibizumab, and many studies have shown an increased risk of systemic adverse events in patients receiving bevacizumab compared with those receiving ranibizumab.
   Summary
   Although rare, adverse events with off-label use of bevacizumab are more common than with ranibizumab. Continued study into long-term safety of the two agents is warranted.
C1 [Johnson, Davin; Sharma, Sanjay] Queens Univ Kingston, Dept Ophthalmol, Kingston, ON, Canada.
C3 Queens University - Canada
RP Sharma, S (通讯作者)，Hop Hotel Dieu, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM sanjay_sharma60@hotmail.com
FU Alcon; Allergan; Novartis; Genentech; Bausch and Lomb; Bayer; Health
   Canada; CIHR
FX S.S. has served as an advisor or received research funds from the
   following organizations: Alcon, Allergan, Novartis, Genentech, Bausch
   and Lomb, Bayer, Health Canada, and the CIHR.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Arias L, 2009, RETINA-J RET VIT DIS, V29, P1444, DOI 10.1097/IAE.0b013e3181ae712d
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Bayar SA, 2010, OCUL IMMUNOL INFLAMM, V18, P268, DOI 10.3109/09273948.2010.490630
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brooks SA, 2004, MOL BIOTECHNOL, V28, P241, DOI 10.1385/MB:28:3:241
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cackett P, 2008, BRIT J OPHTHALMOL, V92, P1564, DOI 10.1136/bjo.2008.143875
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Carneiro AM, 2010, RETINA-J RET VIT DIS, V30, P85, DOI 10.1097/IAE.0b013e3181c700a9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P78, DOI 10.1159/000338730
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dunavoelgyi R, 2012, RETINA-J RET VIT DIS, V32, P1471, DOI 10.1097/IAE.0b013e318236e805
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Fielden M, 2009, CAN J OPHTHALMOL, V45, P239
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Flaxel C, 2012, RETINA-J RET VIT DIS, V32, P417, DOI 10.1097/IAE.0b013e318229b0af
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Furino C, 2009, ACTA OPHTHALMOL, V87, P404, DOI 10.1111/j.1755-3768.2008.01262.x
   Gamulescu Maria-Andreea, 2010, International Ophthalmology, V30, P261, DOI 10.1007/s10792-009-9318-7
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Hall R, 2009, TOR CAN OPHTH SOC AN
   Hermeling S, 2004, PHARM RES-DORDR, V21, P897, DOI 10.1023/B:PHAM.0000029275.41323.a6
   Hoffman-La Roche Limited, IMP SAF INF AV BEV
   Holland S, 2009, TOR CAN OPHTH SOC AN
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   IVAN Study Investigators, 2012, ALT TREATM INH VEGF
   Johnson D, 2010, CAN J OPHTHALMOL, V45, P239, DOI 10.3129/i10-013
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P1218, DOI 10.1097/IAE.0b013e3181b32c45
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Levy Jaime, 2009, International Ophthalmology, V29, P349, DOI 10.1007/s10792-008-9243-1
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Li XX, 2012, OPHTHALMOLOGY, V119, P2087, DOI 10.1016/j.ophtha.2012.05.016
   Lien S., 2008, V181, P131
   Luu ST, 2010, CLIN EXP OPHTHALMOL, V38, P659, DOI 10.1111/j.1442-9071.2010.02309.x
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Mamalis N, 2006, J CATARACT REFR SURG, V32, P324, DOI 10.1016/j.jcrs.2006.01.065
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   McKibbin M, 2010, EYE, V24, P994, DOI 10.1038/eye.2009.271
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x
   Mezad-Koursh D, 2010, RETINA-J RET VIT DIS, V30, P1051, DOI 10.1097/IAE.0b013e3181cd47ed
   Modarres M, 2009, RETINA-J RET VIT DIS, V29, P319, DOI 10.1097/IAE.0b013e318198148e
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Ness T, 2010, RETINA-J RET VIT DIS, V30, P332, DOI 10.1097/IAE.0b013e3181baf691
   Olea JL, 2012, EUR J OPHTHALMOL, V22, P404, DOI 10.5301/ejo.5000023
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Ramulu PY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1335, DOI 10.1001/archophthalmol.2010.224
   Ranpura V, 2010, ACTA ONCOL, V49, P287, DOI 10.3109/02841860903524396
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086
   Rudnisky CJ, 2010, RETINA-J RET VIT DIS, V30, P548, DOI 10.1097/IAE.0b013e3181bcf1b8
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   Sato T, 2010, OPHTHALMOLOGY, V117
   Sato T, 2010, OPHTHALMOLOGY, V117, P512, DOI 10.1016/j.ophtha.2009.07.041
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmid-Kubista KE, 2011, CURR EYE RES, V36, P958, DOI 10.3109/02713683.2011.597536
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sonmez K, 2011, RETINA-J RET VIT DIS, V31, P645, DOI 10.1097/IAE.0b013e3182012d18
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Suzuki M, 2010, JPN J OPHTHALMOL, V54, P124, DOI 10.1007/s10384-009-0775-3
   Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428
   Tano Y, 2011, ACTA OPHTHALMOL, V89, P208, DOI 10.1111/j.1755-3768.2010.02065.x
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wan YQ, 2007, J NEUROSCI RES, V85, P73, DOI 10.1002/jnr.21091
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yamashiro K, 2010, RETINA-J RET VIT DIS, V30, P485, DOI 10.1097/IAE.0b013e3181bd2d51
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
   Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9
NR 121
TC 14
Z9 19
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2013
VL 24
IS 3
BP 205
EP 212
DI 10.1097/ICU.0b013e32835f8ec0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ML
UT WOS:000317394000005
PM 23518613
DA 2022-11-30
ER

PT J
AU Nassar, K
   Grisanti, S
   Elfar, E
   Luke, J
   Luke, M
   Grisanti, S
AF Nassar, Khaled
   Grisanti, Salvatore
   Elfar, Elshaymaa
   Lueke, Julia
   Lueke, Matthias
   Grisanti, Swaantje
TI Serum cytokines as biomarkers for age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Biomarker; Choroidal neovascular
   membrane; Cytokines; Macular oedema; Inflammation
ID TACHYPHYLAXIS; RANIBIZUMAB; BEVACIZUMAB; MARKERS
AB This study evaluates the potential of serum pro-inflammatory cytokines as AMD biomarkers.
   Serum samples from 30 age-related macular degeneration (AMD) patients and 15 age-matched controls were examined for 16 inflammatory cytokines using multiplex ELISA. Patients were divided into three subgroups (improvement/no change/deterioration during anti-VEGF treatment) by OCT and funduscopy, and correlated to the cytokine levels.
   Serum concentrations of IL-1 alpha, IL-1 beta, IL-4, IL-5, IL-10, IL-13, and IL-17 were significantly higher in AMD patients than in controls. None of the co-variables expressed a significant effect on the tested cytokines. Only IL-1a and IL-17 showed a statistically significant difference between groups (improved, unchanged, deteriorated) as determined by one-way ANOVA. Patients with increased macular thickness during treatment showed significantly lower levels of IL-17 compared to improved cases and to unchanged cases (p = 0.004, 0.03 respectively, Dunnett's T3 post hoc multiple test). TNF-alpha was significantly higher in improved cases compared to deteriorated cases (p =0.03, Dunnett's T3 post hoc multiple test). IL-17 was a significant predictor for macular oedema using linear regression (beta = -0.888, p < 0.05).
   Elevation of IL-1 alpha, IL-1 beta, IL-4, IL-5, IL-10, IL-13, and IL-17 in the serum of AMD patients supports the hypothesis of AMD as an inflammatory disease. Patients with high IL-17 and TNF-alpha serum levels were more likely to have a favourable course under VEGF therapy. These cytokines may be used as easy-to-obtain biomarkers.
C1 [Nassar, Khaled; Grisanti, Salvatore; Elfar, Elshaymaa; Lueke, Julia; Lueke, Matthias; Grisanti, Swaantje] Med Univ Lubeck, Dept Ophthalmol, D-23538 Lubeck, Germany.
   [Nassar, Khaled] Fayoum Univ, Dept Ophthalmol, EG-63514 Al Fayyum, Egypt.
   [Elfar, Elshaymaa] Cairo Univ, Dept Rheumatol & Rehabil, EG-11956 Cairo, Egypt.
C3 University of Lubeck; Egyptian Knowledge Bank (EKB); Fayoum University;
   Egyptian Knowledge Bank (EKB); Cairo University
RP Nassar, K (通讯作者)，Med Univ Lubeck, Dept Ophthalmol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM khaledmohnassar@yahoo.com
FU Novartis Pharma GmbH, Nurnberg, Germany
FX We thank Mrs. Christine Oeruen for her technical assistance. We thank
   Dr. Reinhard Vonthein, Luebeck University, Institute for Medical
   Biometry and Statistics (IMBS), Centre for Clinical Trials for his
   valuable advice during statistical evaluation. The work was supported by
   Novartis Pharma GmbH, Nurnberg, Germany.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Jovanovic DV, 1998, J IMMUNOL, V160, P3513
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Siakavellas SI, 2012, DISCOV MED, V14, P253
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Toussirot Eric, 2012, Inflammation & Allergy Drug Targets, V11, P159
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yehoshua Zohar, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS6, DOI 10.3928/15428877-20101031-19
   Zimmermann J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057307
NR 20
TC 59
Z9 61
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2015
VL 253
IS 5
BP 699
EP 704
DI 10.1007/s00417-014-2738-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CH1RZ
UT WOS:000353800400004
PM 25056526
DA 2022-11-30
ER

PT J
AU Papadopoulos, Z
AF Papadopoulos, Zois
TI Recent Developments in the Treatment of Wet Age-related Macular
   Degeneration
SO CURRENT MEDICAL SCIENCE
LA English
DT Article
DE neovascular age-related macular degeneration; exudative AMD; medical
   retina; retinal diseases; neovascularization; angiogenesis; vascular
   endothelial growth factor
ID STEREOTACTIC RADIOTHERAPY; FUNDUS AUTOFLUORESCENCE; INTRAVITREAL
   INJECTION; ADVERSE EVENTS; VEGF DRUGS; AFLIBERCEPT; EXTEND
AB Age-related macular degeneration (AMD) is the most common cause of irreversible blindness and visual impairment in individuals over the age of 50 years in western societies. More than 25 million people currently suffer from this illness in the world, with an additional 500 000 every year, approximately. It is a multifactorial ocular disease that affects the maculae due to a late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). There are many subtypes of AMD but basically two broad forms: the nonneovascular (dry, nonexudative) and neovascular (wet, exudative). Exudative AMD is the less common form (about 15 %) but tends to progress more rapidly. At the moment, wet AMD is treated primarily on the basis of anti-vascular endothelial growth factor (VEGF) agents, which have led to massive improvement in the prognosis of the disease since they were first introduced. This article focuses on the latest treatment approaches to neovascular AMD. An extensive literature review was performed in order to illustrate the effectiveness of current and future anti-VEGF agents as well as the landmark clinical studies that have been carried out to establish these drugs as a gold standard in the therapy of wet AMD.
C1 [Papadopoulos, Zois] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Papadopoulos, Z (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
EM zoispapadopoulos@gmail.com
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Boxler D., BROLUCIZUMABD BLL AP
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Denniston A, 2014, OXFORD HDB OPHTHALMO, P515
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Frampton JE, 2012, DRUG AGING, V29, P839, DOI 10.1007/s40266-012-0015-2
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Hassan M, 2016, EXPERT OPIN BIOL TH, V16, P699, DOI 10.1517/14712598.2016.1167182
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Kanski J.J., 2011, CLIN OPHTHALMOLOGY S, V7, P594
   Kanski JJ, 2016, CLIN OPHTHALMOLOGY S, P580
   Kanski JJ, 2013, SYNOPSIS CLIN OPHTHA, P268
   Lang Gerhard K., 2007, OPHTHALMOLOGY POCKET, P305
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Papadopoulos Z, 2019, EUR J OPHTHALMOL, V29, P368, DOI 10.1177/1120672119832432
   Peng Q, 2013, GENET MOL RES, V12, P6140, DOI 10.4238/2013.December.2.11
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Sharma V, 2019, INT J AD HOC UBIQ CO, V30, P1
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yanoff M, 2014, AGE RELATED MACULAR, P580
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 40
TC 8
Z9 8
U1 1
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2096-5230
EI 2523-899X
J9 CURR MED SCI
JI Curr. Med. Sci.
PD OCT
PY 2020
VL 40
IS 5
BP 851
EP 857
DI 10.1007/s11596-020-2253-6
EA SEP 2020
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA OH9KB
UT WOS:000573199000003
PM 32980899
DA 2022-11-30
ER

PT J
AU Roh, MI
   Kim, JH
   Byeon, SH
   Koh, HJ
   Lee, SC
   Kwon, OW
AF Roh, Mi In
   Kim, Ji Hyun
   Byeon, Suk Ho
   Koh, Hyoung Jim
   Lee, Sung Chu
   Kwon, Oh Woong
TI Estimated Prevalence and Risk Factor for Age-related Maculopathy
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Age-related maculopathy; hepatitis B; triglyceride; high-density
   lipoprotein
ID NUTRITION EXAMINATION SURVEY; ELDERLY CHINESE POPULATION; BLUE MOUNTAINS
   EYE; BODY-MASS INDEX; BEAVER DAM EYE; MACULAR DEGENERATION;
   NATIONAL-HEALTH; VISUAL IMPAIRMENT; CARDIOVASCULAR-DISEASE; AUTOIMMUNE
   UVEITIS
AB Purpose: To assess the estimate prevalence and risk factors for age-related maculopathy (ARM) in Seoul, Korea. Patients and Methods: We examined 9,530 subjects with, 40 years of age or older between January 2006 and December 2006 in Seoul, Korea. Subjects underwent fundus photography, clinical examinations (including blood analyses), and completed detailed questionnaires. Fundus images were graded according to definitions from the Wisconsin Age-Related Maculopathy Grading System. Results: ARM was present in 235 subjects, corresponding to an estimate prevalence of 2.46%. Hepatitis B infection (positive status for HBsAg and HBcAb), serum triglyceride levels and high density lipoprotein levels remained as significant risk factors after age-adjustment. Multivariate analyses showed that the prevalence of ARM was significantly higher in older subjects [odds ratio (OR) 1.134; 95% CI 1.1141.154] and those who were seropositive for hepatitis B surface antigen (OR 2.566; 95% CI 1.519-4.335). Conclusion: The estimated prevalence of ARM was 2.46%. Age and hepatitis B infection may increase the risk of ARM.
C1 [Roh, Mi In; Kim, Ji Hyun; Byeon, Suk Ho; Koh, Hyoung Jim; Lee, Sung Chu; Kwon, Oh Woong] Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Kwon, OW (通讯作者)，Yonsei Univ, Dept Ophthalmol, Coll Med, Inst Vis Res, 250 Seongsanno, Seoul 120752, South Korea.
EM owkwon0301@yuhs.ac
OI Roh, Miin/0000-0003-3346-754X; Koh, Hyoung Jun/0000-0002-5932-8516; ,
   Sung Chul/0000-0001-9438-2385; Byeon, suk ho/0000-0001-8101-0830
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   FRIBERG TR, 1983, AM J OPHTHALMOL, V95, P712, DOI 10.1016/0002-9394(83)90400-2
   Gangadharan B, 2007, CLIN CHEM, V53, P1792, DOI 10.1373/clinchem.2007.089144
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jang Myoung Kuk, 2001, Korean Journal of Internal Medicine, V16, P153
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lee DH, 2002, J KOREAN MED SCI, V17, P457, DOI 10.3346/jkms.2002.17.4.457
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Liu SM, 2000, INT J EPIDEMIOL, V29, P29, DOI 10.1093/ije/29.1.29
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nicolas CM, 2003, CLIN EXP OPHTHALMOL, V31, P465, DOI 10.1046/j.1442-9071.2003.00711.x
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SHINOHARA T, 1990, EXP EYE RES, V50, P751, DOI 10.1016/0014-4835(90)90125-E
   SINGH VK, 1990, J IMMUNOL, V144, P1282
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   SLEPOVA OS, 1994, VESTN OFTALMOL, V110, P27
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsai CY, 2005, JPN J OPHTHALMOL, V49, P166, DOI 10.1007/s10384-004-0164-x
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 59
TC 19
Z9 20
U1 0
U2 1
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD DEC 31
PY 2008
VL 49
IS 6
BP 931
EP 941
DI 10.3349/ymj.2008.49.6.931
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 390LI
UT WOS:000262165400010
PM 19108016
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Daniel, E
   Toth, CA
   Grunwald, JE
   Jaffe, GJ
   Martin, DF
   Fine, SL
   Huang, JY
   Ying, GS
   Hagstrom, SA
   Winter, K
   Maguire, MG
AF Daniel, Ebenezer
   Toth, Cynthia A.
   Grunwald, Juan E.
   Jaffe, Glenn J.
   Martin, Daniel F.
   Fine, Stuart L.
   Huang, Jiayan
   Ying, Gui-shuang
   Hagstrom, Stephanie A.
   Winter, Katrina
   Maguire, Maureen G.
CA Comparison of Age-related Macular
TI Risk of Scar in the Comparison of Age-related Macular Degeneration
   Treatments Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL ANGIOMATOUS PROLIFERATION; GLAUCOMA
   FILTRATION SURGERY; NATURAL-HISTORY; CHOROIDAL NEOVASCULARIZATION;
   SUBRETINAL HEMORRHAGE; PHOTODYNAMIC THERAPY; VISUAL FUNCTION;
   RANIBIZUMAB; BEVACIZUMAB
AB Objective: To describe risk factors for scar in eyes treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD).
   Design: Prospective cohort study within a randomized clinical trial.
   Participants: Patients with no scar on color fundus photography (CFP) or fluorescein angiography (FA) at enrollment in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
   Methods: Eyes were assigned to ranibizumab or bevacizumab treatment and to 1 of 3 dosing regimens for 2 years. Masked readers assessed CFP and FA. Baseline demographic characteristics, visual acuity, morphologic features on photography and optical coherence tomography (OCT), and genotypes associated with AMD risk were evaluated as risk factors using adjusted hazard ratios (aHRs) and associated 95% confidence intervals (CIs). Scars were classified as fibrotic with well-demarcated elevated mounds of yellowish white tissue or nonfibrotic with discrete flat areas of hyperpigmentation with varying amounts of central depigmentation.
   Main Outcome Measures: Scar formation.
   Results: Scar developed in 480 of 1059 eyes (45.3%) by 2 years. Baseline characteristics associated with greater risk of scarring were predominantly classic choroidal neovascularization (CNV) (aHR, 3.1; CI, 2.4-3.9) versus occult CNV, blocked fluorescence (aHR, 1.4; CI, 1.1-1.8), foveal retinal thickness >212 mu m (aHR, 2.4; CI, 1.7-3.6) versus <120 mu m, foveal subretinal tissue complex thickness >275 mu m (aHR, 2.4; CI, 1.7-3.6) versus <= 75 mu m, foveal subretinal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subretinal fluid, and subretinal hyperreflective material (SHRM) (aHR, 1.7; CI, 1.3-2.3) versus no SHRM. Eyes with elevation of the retinal pigment epithelium had lower risk (aHR, 0.6; CI, 0.5-0.8) versus no elevation. Drug, dosing regimen, and genotype had no statistically significant association with scarring. Fibrotic scars developed in 24.7% of eyes, and nonfibrotic scars developed in 20.6% of eyes. Baseline risk factors for the scar types were similar except that eyes with larger lesion size or visual acuity <20/40 were more likely to develop fibrotic scars.
   Conclusions: Approximately half of eyes enrolled in CATT developed scar by 2 years. Eyes with classic neovascularization, a thicker retina, and more fluid or material under the foveal center of the retina are more likely to develop scar. (C) 2014 by the American Academy of Ophthalmology.
C1 [Daniel, Ebenezer; Grunwald, Juan E.; Huang, Jiayan; Ying, Gui-shuang; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Toth, Cynthia A.; Jaffe, Glenn J.; Winter, Katrina] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Martin, Daniel F.; Hagstrom, Stephanie A.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Fine, Stuart L.] Univ Colorado Denver, Dept Ophthalmol, Aurora, CO USA.
C3 University of Pennsylvania; Duke University; Cleveland Clinic
   Foundation; Children's Hospital Colorado; University of Colorado System;
   University of Colorado Anschutz Medical Campus
RP Daniel, E (通讯作者)，Univ Penn, Dept Ophthalmol, Fundus Photograph Reading Ctr, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM ebdaniel@mail.med.upenn.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [U10 EY017823, U10 EY017825, U10 EY017826, U10
   EY017828]; Duke University from Genentech; NATIONAL EYE INSTITUTE
   [U10EY017826] Funding Source: NIH RePORTER
FX The author(s) have made the following disclosure(s): C. A. T. receives
   research support through Duke University from Genentech and royalties
   through Duke University from Alcon Laboratories. G.J.J. has a
   consultancy relationship with Heidelberg Engineering, has active or
   pending grants from Regeneron, is a scientific advisory board member for
   Bayer and Pfizer, and is a consultant for Neurotech. Other members of
   the writing committee have no proprietary or commercial interest in any
   materials discussed in this article.; Supported by cooperative
   agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828
   from the National Eye Institute, National Institutes of Health,
   Department of Health and Human Services. ClinicalTrials.gov number,
   NCT00593450.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Beaumont PE, 2006, ARCH OPHTHALMOL-CHIC, V124, P807, DOI 10.1001/archopht.124.6.807
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kuiper EJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1457, DOI 10.1001/archopht.124.10.1457
   Li ZQ, 2009, INVEST OPHTH VIS SCI, V50, P5217, DOI 10.1167/iovs.08-2662
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Memarzadeh F, 2009, INVEST OPHTH VIS SCI, V50, P3233, DOI 10.1167/iovs.08-2441
   Nakashima M, 2010, NAT GENET, V42, P768, DOI 10.1038/ng.645
   O'Neill EC, 2010, INVEST OPHTH VIS SCI, V51, P6524, DOI 10.1167/iovs.10-5669
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Trikha R, 2011, RETINA-J RET VIT DIS, V31, P1303, DOI 10.1097/IAE.0b013e318203ee46
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wilgus TA, 2000, LAB INVEST, V8, P579
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   ZAUBERMAN H, 1970, AM J OPHTHALMOL, V70, P498, DOI 10.1016/0002-9394(70)90882-2
NR 40
TC 182
Z9 191
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2014
VL 121
IS 3
BP 656
EP 666
DI 10.1016/j.ophtha.2013.10.019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC3FT
UT WOS:000332401800015
PM 24314839
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Xu, XY
   Wu, J
   Yu, XN
   Tang, YL
   Tang, XJ
   Shentu, XC
AF Xu, Xiayan
   Wu, Jing
   Yu, Xiaoning
   Tang, Yelei
   Tang, Xiajing
   Shentu, Xingchao
TI Regional differences in the global burden of age-related macular
   degeneration
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Macular degeneration; Disability-adjusted life years; Global burden of
   disease
ID EYE CARE; VISUAL IMPAIRMENT; ADULT-POPULATION; RISK-FACTORS; PREVALENCE;
   RANIBIZUMAB; BEVACIZUMAB; MACULOPATHY; STATES; CHINA
AB Background Age-related Macular Degeneration (AMD) is the leading cause of blindness. This study aims to analyze regional differences on the global burden of AMD and help direct related policy making. Methods Disability-adjusted life years (DALY) data were collected from the Global Burden of Disease Study (GBD) 2017 to estimate the AMD burden. Mean education years, human development index (HDI) and Public Health Expenditure were extracted from the Human Development Report 2018, and latitude data were obtained from the Google Earth. These four factors were analyzed to see their importance in regional differences of AMD burden, using Kruskal-Wallis test, Dunn's multiple comparisons test as well as regression analysis. Results Global age-standardized DALY rates have decreased since 2011. Based on the WHO region system, age-standardized DALY rates in African and Eastern Mediterranean region were significantly lower than those of other four regions. Linear regression analysis indicated that age-standardized DALY rates were inversely related to HDI and mean education years. Conclusions The age-standardized AMD burden had a decreasing tendency recently. Lower socioeconomic status and fewer education years were associated with higher AMD burden. The finding of this study may highlight the importance of national development and education on relieving AMD burden.
C1 [Xu, Xiayan; Wu, Jing; Yu, Xiaoning; Tang, Yelei; Tang, Xiajing; Shentu, Xingchao] Zhejiang Univ, Coll Med, Dept Ophthalmol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Shentu, XC (通讯作者)，Zhejiang Univ, Coll Med, Dept Ophthalmol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China.
EM stxc@zju.edu.cn
FU National Natural Science Foundation of China [81800869]; Natural Science
   Foundation of Zhejiang Province [LY17H090004]
FX This work was supported by the National Natural Science Foundation of
   China (Grant no. 81670834); the Natural Science Foundation of Zhejiang
   Province (no. LY17H090004); the National Natural Science Foundation of
   China (Grant no. 81800807); and the National Natural Science Foundation
   of China (Grant no. 81800869).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bailey R. N., 2006, Morbidity and Mortality Weekly Report, V55, P1321
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chan Y, 1997, PHYS THER, V77, P1755, DOI 10.1093/ptj/77.12.1755
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Global Health Data Exchange, GBD RES TOOL
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kyu HH, 2018, LANCET, V392, P1859, DOI [10.1016/S0140-6736(18)32335-3, 10.1016/s0140-6736(18)32335-3]
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6
   Nachar N, 2008, TUTORIALS QUANT METH, V4
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Orr P, 1999, OPHTHALMOLOGY, V106, P904, DOI 10.1016/S0161-6420(99)00508-4
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Prevent Blindness, COST VIS PROBL
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Rothen Michelle, 2005, Ophthalmol Clin North Am, V18, P561
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   United Nations Development Programme Database, HUM DEV REP 2018 WOR
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 35
TC 14
Z9 14
U1 2
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD MAR 30
PY 2020
VL 20
IS 1
AR 410
DI 10.1186/s12889-020-8445-y
PG 9
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA LA8RF
UT WOS:000524208400010
PM 32228540
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yang, L
   Men, H
   Luo, D
   Deng, TT
   Miao, L
   Zou, B
   Ge, XF
   Hu, X
   Liu, Y
   Li, XF
   Deng, XL
   Guo, SX
   Liang, JR
   Chen, TT
   Wen, XF
   Li, JJ
   Wei, L
   Jin, M
AF Yang, Liu
   Men, Huan
   Luo, Dan
   Deng, Tingting
   Miao, Li
   Zou, Bin
   Ge, Xiaofei
   Hu, Xiao
   Liu, Yu
   Li, Xifang
   Deng, Xiuli
   Guo, Shixin
   Liang, Juanran
   Chen, Tingting
   Wen, Xiaofeng
   Li, Jing Jing
   Wei, Lai
   Jin, Ming
TI Inhibition of Experimental Age-Related Macular Degeneration by ZQMT in
   Mice
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Age-related macular degeneration; traditional Chinese medicine; CX3CR1;
   ZQMT; CCL2; VEGF
ID MICROGLIA; FUTURE
AB Background: Age-related macular degeneration (AMD) is a progressive and irreversible eye disease. The anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD. However, the expense for such treatment is quite high.
   Methods: We used a traditional Chinese medicine ZQMT as an alternative therapeutic regimen for AMD. We employed two in vivo animal models mimicking dry and wet AMD respectively to assess the therapeutic efficacy of ZQMT on treating AMD-related retinopathy. AMD-related retinopathy in Crb1(rd8) mice was evaluated from week 1 to 8 by fundus photography. Laser-induced choroidal neovascularization (CNV) was evaluated by fluorescein angiography and histopathology.
   Results: ZQMT increased CX3CR1 expression in murine CD4(+) T cells either cultured in vitro or directly isolated from animals treated with ZQMT. We also performed both in vitro and in vivo studies to confirm that ZQMT has no apparent toxic effects. ZQMT alleviated AMD-related retinopathy in both Crb1(r)(d8) and CNV models. Depletion of CCL2 and CX3CR1 in Crb1(r)(d8) mice abolished the efficacy of ZQMT, suggesting that CCL2 and/or CX3CR1 may underlie the mechanisms of ZQMT in treating AMD-related retinopathy in mice.
   Conclusion: In summary, our study supports the protective roles of a traditional Chinese medicine ZQMT in AMD.
C1 [Yang, Liu; Miao, Li; Zou, Bin; Ge, Xiaofei; Hu, Xiao; Liu, Yu; Li, Xifang; Deng, Xiuli; Guo, Shixin; Liang, Juanran; Chen, Tingting; Wen, Xiaofeng; Li, Jing Jing; Wei, Lai] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Men, Huan; Luo, Dan; Deng, Tingting; Jin, Ming] China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
C3 Sun Yat Sen University; China-Japan Friendship Hospital
RP Wei, L (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.; Jin, M (通讯作者)，China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
EM weil9@mail.sysu.edu.cn; jinming57@163.com
OI ge, xiaofei/0000-0002-0886-2567; Zou, Bin/0000-0001-9243-9923; Hu,
   Xiao/0000-0001-7589-2769
FU National Natural Science Foundation of China [81570828]; National Basic
   Research Program of China [2015CB964601]; Li Foundation Heritage Prize
FX This work was supported by the National Natural Science Foundation of
   China 81373693 to MJ; the National Basic Research Program of China
   2015CB964601, the Li Foundation Heritage Prize, and the National Natural
   Science Foundation of China 81570828 to LW.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bowes Rickman C., 2013, INVEST OPHTH VIS SCI, V54
   Chen MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061901
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duan L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00702
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Hussain RM, 2017, OSLI RETINA, V48, P780, DOI 10.3928/23258160-20170928-01
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Jin M, 2018, CURR MOL MED, V18, P622, DOI 10.2174/1566524019666190107155311
   Jin M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-118
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Liu Y, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/184503
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MELO PA, 1994, TOXICON, V32, P595, DOI 10.1016/0041-0101(94)90207-0
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Shaw AC, 2013, NAT REV IMMUNOL, V13, P875, DOI 10.1038/nri3547
   Song L., 2014, CHIN J CLIN RAT DRUG, V7, P138
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Wang SS, 2013, EXPERT OPIN THER PAT, V23, P269, DOI 10.1517/13543776.2013.751972
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang J, 2013, SYNAPSE, V67, P515, DOI 10.1002/syn.21674
   Zhang Wenxin, 2013, Eye Sci, V28, P140
NR 32
TC 1
Z9 1
U1 2
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2019
VL 19
IS 6
BP 434
EP 442
DI 10.2174/1566524019666190425195706
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IE6VT
UT WOS:000472514500005
PM 31288713
DA 2022-11-30
ER

PT J
AU Mathai, G
   Rosen, D
   Melkote, S
   Olsen, T
AF Mathai, George
   Rosen, David
   Melkote, Shreyes
   Olsen, Timothy
TI Tissue Translocation Device for Surgical Correction of Age-Related
   Macular Degeneration
SO JOURNAL OF MEDICAL DEVICES-TRANSACTIONS OF THE ASME
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CHOROID TRANSLOCATION
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the western world in those over age 60. While this disorder is complex, the origin of injury appears to be at the level of the retinal pigment epithelium (RPE), Bruchs membrane, and inner choroid. A potential method to replace damaged tissue in AMD is to harvest healthy donor tissue (RPE-Bruchs-Choroid) from an eye and translocate it to the injured subretinal region. Such an autograft avoids immune mediated rejection and can theoretically restore function to the neurosensory retina (light sensitive part of the retina) by restoring the damaged tissue. Such a procedure requires the design of a device that mechanically supports the integrity of the graft while inside the eye, without injuring or disrupting the tissue. This paper presents the systematic design and manufacture of a thin shape memory foil-based tissue translocation device. The selected embodiment of the design uses thermal adhesion of the tissue to the foil surfaces for tissue support. The shape memory effect enables insertion of the device into the eye via a small incision. The device is manufactured using micromachining techniques and has been tested both ex vivo and in vivo with acceptable anatomic results.
C1 [Mathai, George; Rosen, David; Melkote, Shreyes] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
   [Olsen, Timothy] Emory Eye Ctr, Atlanta, GA 30322 USA.
C3 University System of Georgia; Georgia Institute of Technology
RP Mathai, G (通讯作者)，Georgia Inst Technol, George W Woodruff Sch Mech Engn, 813 Ferst Dr NW, Atlanta, GA 30332 USA.
FU Georgia Research Alliance; Emtech Biotechnology Development Inc.;
   Research to Prevent Blindness; Dobbs Foundation
FX This work was supported in part from a grant from the Georgia Research
   Alliance, Emtech Biotechnology Development Inc., an unrestricted grant
   from Research to Prevent Blindness and The Dobbs Foundation.
CR Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Brown, 2005, T AM OPHTHAL SOC, P184
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   CAMPOS M, 1993, INVEST OPHTH VIS SCI, V34, P2493
   CPOB, 2009, COMP AG REL MAC DEG
   Eandi C. M., 2008, GRAEFES ARCH CLIN EX, V4, P1
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   NEI, 2010, FACTS AG REL MAC DEG
   Olsen T. W., 2012, ANN MAC SOC M JER IS
   Olsen T. W., 2007, U.S. Patent No, Patent No. [20,070,179,512, 20070179512]
   Olsen TW, 2011, AM J OPHTHALMOL, V151, P287, DOI 10.1016/j.ajo.2010.08.026
   Pahl G, 2007, ENG DESIGN SYSTEMATI, P125
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 1932-6181
EI 1932-619X
J9 J MED DEVICES
JI J. Med. Devices
PD DEC
PY 2013
VL 7
IS 4
AR 041006
DI 10.1115/1.4025184
PG 8
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 274PT
UT WOS:000328619200008
DA 2022-11-30
ER

PT J
AU Saptarshi, N
   Green, D
   Cree, A
   Lotery, A
   Paraoan, L
   Porter, LF
AF Saptarshi, Neil
   Green, Daniel
   Cree, Angela
   Lotery, Andrew
   Paraoan, Luminita
   Porter, Louise F.
TI Epigenetic Age Acceleration Is Not Associated with Age-Related Macular
   Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; epigenetic clock; DNA methylation;
   ageing; retinal pigment epithelium; whole blood
ID DNA METHYLATION; IL17RC PROMOTER; SMOKING; BLOOD; GENE; HYPOMETHYLATION;
   EXPRESSION; DISCOVERY; RISK
AB DNA methylation age (DNAm age) estimation is a powerful biomarker of human ageing. To date, epigenetic clocks have not been evaluated in age-related macular degeneration (AMD). Here, we perform genome-wide DNA methylation analyses in blood of AMD patients with a documented smoking history (14 AMD, 16 Normal), identifying loci of differential methylation (DML) with a relaxed p-value criterion (p <= 10(-4)). We conduct DNAm age analyses using the Horvath-multi tissue, Hannum and Skin & Blood epigenetic clocks in both blood and retinal pigment epithelium (RPE). We perform Ingenuity Pathway Analysis Causal Network Analysis (IPA CNA) on the topmost significantly differentially methylated CpG probes in blood and RPE. Results show poor performance of epigenetic clocks in RPE. Epigenetic age acceleration (EAA) was not observed in AMD. However, we observe positive EAA in blood of smokers, and in smokers with AMD. DML analysis revealed hypomethylation at cg04953735 within RPTOR (p = 6.51 x 10(-5); Delta beta = -11.95%). IPA CNA in the RPE also identified RPTOR as the putative master regulator, predicted to be inhibited in AMD. In conclusion, this is the first study evaluating an association of epigenetic ageing in AMD. We posit a role for RPTOR as a common master regulator of methylation changes in the RPE in AMD.
C1 [Saptarshi, Neil; Paraoan, Luminita; Porter, Louise F.] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.
   [Green, Daniel] Univ Liverpool, Inst Life Course & Med Sci, Dept Musculoskeletal Biol, Liverpool L7 8TX, Merseyside, England.
   [Cree, Angela; Lotery, Andrew] Univ Southampton, Fac Med, Southampton SO16 6YD, Hants, England.
   [Porter, Louise F.] Univ Strasbourg, INSERM, U1112, Lab Genet Med,Inst Genet Med Alsace IGMA, F-67000 Strasbourg, France.
   [Porter, Louise F.] Inst Genet Med Alsace IGMA, Ctr Reference Affect Rares Genet Ophtalmol CARGO, Serv Genet Med, F-67000 Strasbourg, France.
C3 University of Liverpool; University of Liverpool; University of
   Southampton; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg
RP Paraoan, L; Porter, LF (通讯作者)，Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool L7 8TX, Merseyside, England.; Porter, LF (通讯作者)，Univ Strasbourg, INSERM, U1112, Lab Genet Med,Inst Genet Med Alsace IGMA, F-67000 Strasbourg, France.; Porter, LF (通讯作者)，Inst Genet Med Alsace IGMA, Ctr Reference Affect Rares Genet Ophtalmol CARGO, Serv Genet Med, F-67000 Strasbourg, France.
EM daniel.green@liverpool.ac.uk
RI Porter, Louise/GQP-6108-2022; Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116; Porter,
   Louise/0000-0002-7406-0319; Cree, Angela/0000-0002-1987-8900; Lotery,
   Andrew/0000-0001-5541-4305
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambatipudi S, 2016, EPIGENOMICS-UK, V8, P599, DOI 10.2217/epi-2016-0001
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Benjamini Y, 1995, J R STAT SOC B, V57, P289
   Bergsma T, 2020, NEUROSCI INSIGHTS, V15, DOI 10.1177/2633105520942221
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Breton CV, 2017, ENVIRON HEALTH PERSP, V125, P511, DOI [10.1289/EHP595, 10.1289/ehp595]
   Castle JR, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00834-4
   Chen D, 2020, AGING CELL, V19, DOI 10.1111/acel.13100
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Ecker S, 2019, AGING-US, V11, P833, DOI 10.18632/aging.101712
   El Khoury LY, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1810-4
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Foster KG, 2010, J BIOL CHEM, V285, P80, DOI 10.1074/jbc.M109.029637
   Geeleher P, 2013, BIOINFORMATICS, V29, P1851, DOI 10.1093/bioinformatics/btt311
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Hewitt AW, 2017, SCI REP-UK, V7, DOI 10.1038/srep46330
   Horvath S, 2018, AGING-US, V10, P1758, DOI 10.18632/aging.101508
   Horvath S, 2018, NAT REV GENET, V19, P371, DOI 10.1038/s41576-018-0004-3
   Horvath S, 2015, AGING-US, V7, P1130, DOI 10.18632/aging.100859
   Horvath S, 2015, AGING-US, V7, P294, DOI 10.18632/aging.100742
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Jung M, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0118-4
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Koestler DC, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0943-7
   Koks G, 2015, AM J PATHOL, V185, P2898, DOI 10.1016/j.ajpath.2015.07.006
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Krishnamoorthy J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0326-2
   Levine ME, 2018, AGING-US, V10, P573, DOI 10.18632/aging.101414
   Levine ME, 2015, AGING-US, V7, P1198, DOI 10.18632/aging.100864
   Lu YC, 2020, NATURE, V588, P124, DOI 10.1038/s41586-020-2975-4
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Papadopoli David, 2019, F1000Res, V8, DOI 10.12688/f1000research.17196.1
   Peters TJ, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/1756-8935-8-6
   Pidsley R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1066-1
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Ren JT, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4884-6
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Voisin S, 2020, J CACHEXIA SARCOPENI, V11, P887, DOI 10.1002/jcsm.12556
   Wang T, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-019-0801-3
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu XH, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0777-z
   Xiao CH, 2021, CANCER-AM CANCER SOC, V127, P3361, DOI 10.1002/cncr.33641
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zheng CL, 2019, CANCER EPIDEM BIOMAR, V28, P1720, DOI 10.1158/1055-9965.EPI-19-0208
NR 56
TC 1
Z9 1
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2021
VL 22
IS 24
AR 13457
DI 10.3390/ijms222413457
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YA1JF
UT WOS:000738097600001
PM 34948253
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Feskanich, D
   Cho, E
   Schaumberg, DA
   Colditz, GA
   Hankinson, SE
AF Feskanich, Diane
   Cho, Eunyoung
   Schaumberg, Debra A.
   Colditz, Graham A.
   Hankinson, Susan E.
TI Menopausal and reproductive factors and risk of age-related macular
   degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; PIGMENT EPITHELIAL-CELLS; BEAVER DAM EYE;
   POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTOR; GENE-EXPRESSION; BRUCHS
   MEMBRANE; MACULOPATHY; POPULATION; DISEASE
AB Objective: To investigate whether estrogen exposures are associated with lower risks of age-related macular degeneration (AMD).
   Methods: Postmenopausal hormone (PMH) use, past use of oral contraceptives (OCs), ages at menarche and menopause, and parity were assessed among 74 996 postmenopausal women. Over 22 years, cases of early (n = 554) and neovascular (n=334) AMD with a visual acuity of 20/30 or worse were identified. Cox models were used to calculate the relative risk for each exposure, adjusted for smoking and other factors.
   Results: Current PMH users had a notable 48% lower risk of neovascular AMD compared with those who had never used PMH, although risk did not decline linearly with longer durations of use. Risk was lowest for PMH users who had used OCs in the past (P value for interaction, .03). In contrast, risk of early AMD was a notable 34% higher among current PMH users and OC use was unassociated with risk. The only remarkable finding for the endogenous estrogenic factors was a 26% lower risk of early AMD for parous women.
   Conclusions: Although PMH and OC use were associated with a lower risk of neovascular AMD, no benefit was observed for early AMD. Factors influencing lifetime exposure to estrogens were not consistently associated with the disease.
C1 [Feskanich, Diane; Cho, Eunyoung; Colditz, Graham A.; Hankinson, Susan E.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Harvard Med Sch, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA USA.
   [Colditz, Graham A.; Hankinson, Susan E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard Medical School;
   Schepens Eye Research Institute; Harvard University; Harvard T.H. Chan
   School of Public Health
RP Feskanich, D (通讯作者)，Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.
RI Cho, Eunyoung/AAV-4469-2020; Colditz, Graham/A-3963-2009
OI Cho, Eunyoung/0000-0001-6594-2582; Colditz, Graham/0000-0002-7307-0291
FU NATIONAL EYE INSTITUTE [R01EY013834, R01EY009611, R01EY017362] Funding
   Source: NIH RePORTER; NCI NIH HHS [CA87979] Funding Source: Medline; NEI
   NIH HHS [R01 EY013834-03, EY09611, R01 EY017362, R01 EY017362-01A2, R01
   EY013834] Funding Source: Medline
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bhavnani BR, 2001, MENOPAUSE, V8, P408, DOI 10.1097/00042192-200111000-00005
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leung H, 2004, MICROVASC RES, V67, P48, DOI 10.1016/j.mvr.2003.10.002
   Leung H, 2003, INVEST OPHTH VIS SCI, V44, P2900, DOI 10.1167/iovs.02-1114
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Nirmalan PK, 2004, INVEST OPHTH VIS SCI, V45, P4273, DOI 10.1167/iovs.04-0285
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1740, DOI 10.1167/iovs.02-0775
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
NR 38
TC 50
Z9 51
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2008
VL 126
IS 4
BP 519
EP 524
DI 10.1001/archopht.126.4.519
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 285SQ
UT WOS:000254796900011
PM 18413522
OA Bronze
DA 2022-11-30
ER

PT J
AU Trikha, R
   Morse, LS
   Zawadzki, RJ
   Werner, JS
   Park, SS
AF Trikha, Rupan
   Morse, Lawrence S.
   Zawadzki, Robert J.
   Werner, John S.
   Park, Susanna S.
TI TEN-YEAR FOLLOW-UP OF EYES TREATED WITH STEREOTACTIC FRACTIONATED
   EXTERNAL BEAM RADIATION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; exudative age-related macular
   degeneration; geographic atrophy; neovascular age-related macular
   degeneration; radiation; radiation retinopathy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY;
   RANDOMIZED CLINICAL-TRIAL; GEOGRAPHIC ATROPHY; THERAPY; RADIOTHERAPY;
   IRRADIATION; RETINOPATHY; MEMBRANES; RANIBIZUMAB
AB Purpose: To determine the long-term effects of stereotactic fractionated external beam radiation on eyes treated for neovascular age-related macular degeneration.
   Methods: A retrospective review of all eyes treated with stereotactic fractionated external beam radiation (20-40 Gy, 2-Gy fractions) between 1997 and 2000 was performed to identify eyes with >= 2-year follow-up for analysis. A subset was imaged prospectively using a high-resolution Fourier-domain optical coherence tomography.
   Results: Among 94 eyes treated, 33 eyes (32 subjects) had >= 2-year follow-up information (mean follow-up, 6.2 years; range, 2-10 years). Final visual acuity ranged from 20/50 to no light perception. Final macular findings included central geographic atrophy (49%), disciform scar (30%), and active choroidal neovascular membrane (9%). Fourier-domain optical coherence tomography images of three eyes with geographic atrophy revealed photoreceptor layer loss within areas of geographic atrophy with intact retinal morphology in areas of radiation exposure outside geographic atrophy. Radiation retinopathy was suspected in 18% and confirmed by fluorescein angiography in 15%, ranging from mild to neovascular glaucoma/phthisis bulbi (2 eyes). Mean time from stereotactic fractionated external beam radiation to development of radiation retinopathy was 5.4 years (range, 1-10 years).
   Conclusion: A moderate rate of delayed radiation retinopathy was noted in eyes with neovascular age-related macular degeneration treated with stereotactic fractionated external beam radiation. Geographic atrophy was a common finding. RETINA 31: 1303-1315, 2011
C1 [Trikha, Rupan; Morse, Lawrence S.; Zawadzki, Robert J.; Werner, John S.; Park, Susanna S.] Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis
RP Park, SS (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM susanna.park@ucdmc.ucdavis.edu
RI Zawadzki, Robert J./S-3236-2019; Zawadzki, Robert/E-7534-2011
OI Zawadzki, Robert J./0000-0002-9574-156X; Zawadzki,
   Robert/0000-0002-9574-156X; Morse, Lawrence/0000-0002-1758-2348
FU National Eye Institute, Bethesda, MD [014743]; Research to Prevent
   Blindness, New York; NATIONAL EYE INSTITUTE [R01EY014743] Funding
   Source: NIH RePORTER
FX Supported in part by the National Eye Institute, Bethesda, MD (Grant
   Number 014743 to J.S.W.), and the Research to Prevent Blindness, New
   York, unrestricted departmental grant.
CR Amoaku WMK, 1995, EYE, V9, P738, DOI 10.1038/eye.1995.187
   Archambeau JO, 1998, INT J RADIAT ONCOL, V40, P1125, DOI 10.1016/S0360-3016(97)00919-X
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Berson AM, 1999, SEMIN RADIAT ONCOL, V9, P155, DOI 10.1016/S1053-4296(99)80005-8
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BROWN GC, 1982, OPHTHALMOLOGY, V89, P1494
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   EGBERT PR, 1980, BRIT J OPHTHALMOL, V64, P660, DOI 10.1136/bjo.64.9.660
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel Christina J, 2002, Ophthalmol Clin North Am, V15, P437, DOI 10.1016/S0896-1549(02)00038-X
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P1278
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   LETT JT, 1993, BIOL EFFECTS PHYS A, P177
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Monroe AT, 2005, INT J RADIAT ONCOL, V61, P856, DOI 10.1016/j.ijrobp.2004.07.664
   PARSONS JT, 1994, INT J RADIAT ONCOL, V30, P765, DOI 10.1016/0360-3016(94)90347-6
   Prettenhofer U, 2004, STRAHLENTHER ONKOL, V180, P91, DOI 10.1007/s00066-004-1177-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V18
   Smith AJ, 2008, OPHTHALMOLOGY, V115, P1923, DOI 10.1016/j.ophtha.2008.05.025
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Takahashi K, 1998, AM J OPHTHALMOL, V125, P367, DOI 10.1016/S0002-9394(99)80148-2
   Takeda A, 1999, INT J RADIAT ONCOL, V44, P599, DOI 10.1016/S0360-3016(99)00057-7
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   WILLIAMS GR, 1996, ADV SPACE RES-SERIES, V18, P55, DOI 10.1016/0273-1177(95)00790-L
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 42
TC 13
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2011
VL 31
IS 7
BP 1303
EP 1315
DI 10.1097/IAE.0b013e318203ee46
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 794CA
UT WOS:000292871700010
PM 21499195
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Stradiotto, E
   Allegrini, D
   Fossati, G
   Raimondi, R
   Sorrentino, T
   Tripepi, D
   Barone, G
   Inforzato, A
   Romano, MR
AF Stradiotto, Elisa
   Allegrini, Davide
   Fossati, Giovanni
   Raimondi, Raffaele
   Sorrentino, Tania
   Tripepi, Domenico
   Barone, Gianmaria
   Inforzato, Antonio
   Romano, Mario R.
TI Genetic Aspects of Age-Related Macular Degeneration and Their
   Therapeutic Potential
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE AMD; polymorphism; genetic test; biomarkers; personalized treatments;
   complement therapy; gene therapy
ID COMPLEMENT FACTOR-H; MANGANESE SUPEROXIDE-DISMUTASE; ENDOTHELIAL
   GROWTH-FACTOR; MEMBRANE ATTACK COMPLEX; FACTOR B POLYMORPHISM; ANTI-VEGF
   TREATMENT; GEOGRAPHIC ATROPHY; HIGH-RISK; OXIDATIVE STRESS;
   APOLIPOPROTEIN-E
AB Age-related macular degeneration (AMD) is a complex and multifactorial disease, resulting from the interaction of environmental and genetic factors. The continuous discovery of associations between genetic polymorphisms and AMD gives reason for the pivotal role attributed to the genetic component to its development. In that light, genetic tests and polygenic scores have been created to predict the risk of development and response to therapy. Still, none of them have yet been validated. Furthermore, there is no evidence from a clinical trial that the determination of the individual genetic structure can improve treatment outcomes. In this comprehensive review, we summarize the polymorphisms of the main pathogenetic ways involved in AMD development to identify which of them constitutes a potential therapeutic target. As complement overactivation plays a major role, the modulation of targeted complement proteins seems to be a promising therapeutic approach. Herein, we summarize the complement-modulating molecules now undergoing clinical trials, enlightening those in an advanced phase of trial. Gene therapy is a potential innovative one-time treatment, and its relevance is quickly evolving in the field of retinal diseases. We describe the state of the art of gene therapies now undergoing clinical trials both in the field of complement-suppressors and that of anti-VEGF.
C1 [Stradiotto, Elisa; Fossati, Giovanni; Raimondi, Raffaele; Sorrentino, Tania; Tripepi, Domenico; Barone, Gianmaria; Inforzato, Antonio; Romano, Mario R.] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy.
   [Stradiotto, Elisa; Allegrini, Davide; Fossati, Giovanni; Raimondi, Raffaele; Sorrentino, Tania; Tripepi, Domenico; Barone, Gianmaria; Romano, Mario R.] Dept Ophthalmol, Eye Unit Humanitas Gavazzeni Castelli, Via Mazzini 11, I-24128 Bergamo, Italy.
   [Inforzato, Antonio] IRCCS Humanitas Res Hosp, Via Manzoni 56, I-20089 Rozzano Milan, Italy.
C3 Humanitas University
RP Stradiotto, E (通讯作者)，Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy.; Stradiotto, E (通讯作者)，Dept Ophthalmol, Eye Unit Humanitas Gavazzeni Castelli, Via Mazzini 11, I-24128 Bergamo, Italy.
EM elisa.stradiotto@humanitas.it
OI Fossati, Giovanni/0000-0002-3374-8539; Tripepi,
   Domenico/0000-0003-4984-5496
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   [Anonymous], REGENXBIO ANNOUNCES
   Arslan J, 2018, PHARMACOGENOMICS, V19, P435, DOI 10.2217/pgs-2017-0183
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bakbak B, 2016, CURR EYE RES, V41, P862, DOI 10.3109/02713683.2015.1067325
   Balikova I, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000273
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Biggs RM, 2022, CURR EYE RES, V47, P1087, DOI 10.1080/02713683.2022.2053725
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Busbee B, 2021, INVEST OPHTH VIS SCI, V62
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Chatterjee N, 2016, NAT REV GENET, V17, P392, DOI 10.1038/nrg.2016.27
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Chew EY, 2021, OPHTHALMOLOGY, V128, P1618, DOI 10.1016/j.ophtha.2021.07.002
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Cserhalmi M, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101341
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Breuk A, 2021, JAMA OPHTHALMOL, V139, P1218, DOI 10.1001/jamaophthalmol.2021.4102
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P381, DOI 10.1097/IAE.0000000000000466
   den Hollander AI, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017202
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dong Y, 2015, INT J OPHTHALMOL-CHI, V8, P385, DOI 10.3980/j.issn.2222-3959.2015.02.31
   Duvvari MR, 2015, MOL VIS, V21, P285
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Endres M, 2004, J CLIN INVEST, V113, P1711, DOI 10.1172/JCI200420926
   Fauser S, 2015, SURV OPHTHALMOL, V60, P138, DOI 10.1016/j.survophthal.2014.11.002
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gorgun E, 2010, INVEST OPHTH VIS SCI, V51, P4732, DOI 10.1167/iovs.09-4842
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halawa OA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122580
   Harris CL, 2018, MOL IMMUNOL, V102, P89, DOI 10.1016/j.molimm.2018.06.008
   Harris CL, 2012, TRENDS IMMUNOL, V33, P513, DOI 10.1016/j.it.2012.06.001
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Joachim N, 2018, OPHTHALMOL RETINA, V2, P684, DOI 10.1016/j.oret.2017.10.019
   Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kaur I, 2010, P NATL ACAD SCI USA, V107, pE112, DOI 10.1073/pnas.1007476107
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Khanani AM, 2022, EYE, V36, P303, DOI 10.1038/s41433-021-01842-1
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Kozhevnikova OS, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10071658
   Kucukevcilioglu M, 2016, INT OPHTHALMOL, V36, P569, DOI 10.1007/s10792-015-0164-5
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Ling SK, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00656-y
   Liu Y, 2020, BMC MED GENET, V21, DOI 10.1186/s12881-020-01047-5
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Lu FT, 2018, GENET TEST MOL BIOMA, V22, P526, DOI 10.1089/gtmb.2018.0110
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Maloney SC, 2010, OPHTHALMIC RES, V44, P237, DOI 10.1159/000313989
   Mantel I, 2014, OPHTHALMIC GENET, V35, P12, DOI 10.3109/13816810.2013.766217
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Mullins RF, 2019, OPHTHALMOLOGY, V126, P591, DOI 10.1016/j.ophtha.2018.10.037
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Oca AI, 2021, J PERS MED, V11, DOI 10.3390/jpm11121329
   Oltra M, 2020, J CELL MOL MED, V24, P1428, DOI 10.1111/jcmm.14822
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Paun CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26568
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pecen PE, 2015, CURR OPIN OPHTHALMOL, V26, P188, DOI 10.1097/ICU.0000000000000147
   Qassim A, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.6.14
   Raimondi R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020682
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reid CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29726-7
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Restrepo NA, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14246
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Silva AS, 2012, MOL VIS, V18, P2288
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Steinle NC, 2021, AM J OPHTHALMOL, V227, P116, DOI [10.1016/i.aio.2021.02.031, 10.1016/j.ajo.2021.02.031]
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stravalaci M, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.811344
   Stravalaci M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.591908
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Thakkinstian A, 2012, AM J EPIDEMIOL, V176, P361, DOI 10.1093/aje/kws031
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tong Y, 2010, MOL VIS, V16, P1958
   Tsai DC, 2006, OPHTHALMOLOGICA, V220, P246, DOI 10.1159/000093079
   Uehara H, 2015, AM J OPHTHALMOL, V159, P92, DOI 10.1016/j.ajo.2014.09.036
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang J, 2021, OPHTHALMIC RES, V64, P656, DOI 10.1159/000515053
   Wang Q, 2016, INT J OPHTHALMOL-CHI, V9, P298, DOI 10.18240/ijo.2016.02.23
   Wang X, 2014, GENE, V538, P306, DOI 10.1016/j.gene.2014.01.032
   Wang X, 2013, INT J OPHTHALMOL-CHI, V6, P861, DOI 10.3980/j.issn.2222-3959.2013.06.21
   Wang YF, 2016, GRAEF ARCH CLIN EXP, V254, P323, DOI 10.1007/s00417-015-3211-z
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Yan X, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251931
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yu QQ, 2015, GENE, V561, P249, DOI 10.1016/j.gene.2015.02.039
   Yu QQ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200406
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhang J, 2021, OPHTHALMIC RES, V64, P192, DOI 10.1159/000508738
   Zhao L, 2013, CURR MOL MED, V13, P929, DOI 10.2174/15665240113139990048
NR 172
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2022
VL 23
IS 21
AR 13280
DI 10.3390/ijms232113280
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 6B5YN
UT WOS:000881408500001
PM 36362067
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Levy, O
   Lavalette, S
   Hu, SLJ
   Housset, M
   Raoul, W
   Eandi, C
   Sahel, JA
   Sullivan, PM
   Guillonneau, X
   Sennlaub, F
AF Levy, Olivier
   Lavalette, Sophie
   Hu, Shulong J.
   Housset, Michael
   Raoul, William
   Eandi, Chiara
   Sahel, Jose-Alain
   Sullivan, Patrick M.
   Guillonneau, Xavier
   Sennlaub, Florian
TI APOE Isoforms Control Pathogenic Subretinal Inflammation in Age-Related
   Macular Degeneration
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE apolipoprotein E; mononuclear phagocyte; neurodegeneration;
   neuroinflammation
ID HUMAN RETINITIS-PIGMENTOSA; APOLIPOPROTEIN-E; RETINAL DEGENERATION;
   MICROGLIAL ACTIVATION; CHOROIDAL NEOVASCULARIZATION; DEFICIENT MICE;
   MOUSE; CHOLESTEROL; PROTEIN; CX3CR1
AB Contrary to Alzheimer's disease (AD), the APOE2 allele increases and the APOE4 allele reduces the risk to develop age-related macular degeneration (AMD) compared with the most common APOE3 allele. The underlying mechanism for this association with AMD and the reason for the puzzling difference with AD are unknown. We previously demonstrated that pathogenic subretinal mononuclear phagocytes (MPs) accumulate in Cx3cr1-deficient mice due to the overexpression of APOE, interleukin-6, and CC chemokine ligand 2 (CCL2). We here show using targeted replacement mice expressing the human APOE isoforms (TRE2, TRE3, and TRE4) that MPs of TRE2 mice express increased levels of APOE, interleukin-6, and CCL2 and develop subretinal MP accumulation, photoreceptor degeneration, and exaggerated choroidal neovascularization similar toAMD. Pharmacological inhibition of the cytokine induction inhibited the pathogenic subretinal inflammation. In the context of APOE-dependent subretinal inflammation in Cx3cr1(GFP/GFP) mice, the APOE4 allele led to diminished APOE and CCL2 levels and protected Cx3cr1(GFP/GFP) mice against harmful subretinal MP accumulation observed in Cx3cr1(GFP/GFP)TRE3 mice. Our study shows that pathogenic subretinal inflammation is APOE isoform-dependent and provides the rationale for the previously unexplained implication of the APOE2 isoform as a risk factor and the APOE4 isoform as a protective factor in AMD pathogenesis.
C1 [Levy, Olivier; Lavalette, Sophie; Hu, Shulong J.; Housset, Michael; Raoul, William; Sahel, Jose-Alain; Guillonneau, Xavier; Sennlaub, Florian] INSERM, U968, F-75012 Paris, France.
   [Levy, Olivier; Lavalette, Sophie; Hu, Shulong J.; Housset, Michael; Raoul, William; Sahel, Jose-Alain; Guillonneau, Xavier; Sennlaub, Florian] Univ Paris 06, Sorbonne Univ, Unite Mixte Rech S 968, Inst Vis, F-75012 Paris, France.
   [Levy, Olivier; Lavalette, Sophie; Hu, Shulong J.; Housset, Michael; Raoul, William; Sahel, Jose-Alain; Guillonneau, Xavier; Sennlaub, Florian] CNRS, Unite Mixte Rech 7210, F-75012 Paris, France.
   [Sahel, Jose-Alain] INSERM, DHOS, CIC 503, Ctr Hosp Natl Ophtalmol Quinze Vingts, F-75012 Paris, France.
   [Eandi, Chiara] Univ Turin, Dept Surg Sci, Eye Clin, Turin, Italy.
   [Sullivan, Patrick M.] Duke Univ, Dept Med, Durham Vet Affairs Med Ctr, Ctr Aging & Clin Ctr, Durham, NC 27710 USA.
   [Sullivan, Patrick M.] Duke Univ, Dept Med, Durham Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin Ctr, Durham, NC 27710 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); UDICE-French Research Universities;
   Universite Paris Cite; CHNO des Quinze-Vingts; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; University of Turin; Duke University;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Durham VA Medical Center; Duke University; Geriatric Research Education
   & Clinical Center; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Durham VA Medical Center
RP Sennlaub, F (通讯作者)，Inst Vis, INSERM, Unite Mixte Rech S 968, F-75012 Paris, France.
EM florian.sennlaub@inserm.fr
RI Guillonneau, xavier/E-3995-2017; Sennlaub, Florian/F-2756-2017;
   guillonneau, xavier/AAF-9495-2021; Raoul, William/H-2118-2018; Sahel,
   Jose-Alain/F-3172-2017
OI Guillonneau, xavier/0000-0001-7379-3935; Sennlaub,
   Florian/0000-0003-4412-1341; guillonneau, xavier/0000-0001-7379-3935;
   Raoul, William/0000-0002-5040-3372; Sahel,
   Jose-Alain/0000-0002-4831-1153
FU Institut National de la Sante et de la Recherche Medicale; ANR Maladies
   Neurologiques et Psychiatriques [ANR-08-MNPS-003, ANR Geno 2009
   R09099DS]; Labex Lifesenses; Carnot; ERC starting Grant [210345];
   Association de Prevoyance Sante de ALLIANZ
FX This work was supported by Institut National de la Sante et de la
   Recherche Medicale, ANR Maladies Neurologiques et Psychiatriques Grant
   ANR-08-MNPS-003, Grant ANR Geno 2009 R09099DS, Labex Lifesenses, Carnot,
   ERC starting Grant ERC-2007 St.G. 210345, and Association de Prevoyance
   Sante de ALLIANZ.
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Bales KR, 2009, J NEUROSCI, V29, P6771, DOI 10.1523/JNEUROSCI.0887-09.2009
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Chen M, 2013, INVEST OPHTH VIS SCI, V54, P682, DOI 10.1167/iovs.12-10888
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053
   Fryer JD, 2005, J BIOL CHEM, V280, P25754, DOI 10.1074/jbc.M502143200
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Heeren J, 2004, J BIOL CHEM, V279, P55483, DOI 10.1074/jbc.M409324200
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kezic JM, 2013, INVEST OPHTH VIS SCI, V54, P854, DOI 10.1167/iovs.12-10876
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Peri F, 2008, CELL, V133, P916, DOI 10.1016/j.cell.2008.04.037
   Riddell DR, 2008, J NEUROSCI, V28, P11445, DOI 10.1523/JNEUROSCI.1972-08.2008
   ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006
   Sullivan PM, 2011, NEUROBIOL AGING, V32, P791, DOI 10.1016/j.neurobiolaging.2009.05.011
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Yu CE, 2013, HUM MOL GENET, V22, P5036, DOI 10.1093/hmg/ddt354
NR 43
TC 52
Z9 55
U1 0
U2 13
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 7
PY 2015
VL 35
IS 40
BP 13568
EP 13576
DI 10.1523/JNEUROSCI.2468-15.2015
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CX9UJ
UT WOS:000366050900004
PM 26446211
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Katta, S
   Kaur, I
   Chakrabarti, S
AF Katta, Saritha
   Kaur, Inderjeet
   Chakrabarti, Subhabrata
TI The molecular genetic basis of age-related macular degeneration: an
   overview
SO JOURNAL OF GENETICS
LA English
DT Review
DE AMD; epidemiology; genes; polymorphism; risk
ID COMPLEMENT-FACTOR-H; STARGARDT-DISEASE GENE; APOLIPOPROTEIN-E GENE;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; SINGLE NUCLEOTIDE POLYMORPHISMS;
   HTRA1 PROMOTER POLYMORPHISM; FACTOR HY402H POLYMORPHISM; GENOME-WIDE
   ASSOCIATION; C-REACTIVE PROTEIN; GROWTH-FACTOR GENE
AB Age-related macular degeneration (AMD) is a complex disorder of the eye and the third leading cause of blindness worldwide. With a multifactorial etiology, AMD results in progressive loss of central vision affecting the macular region of the eye in elderly. While the prevalence is relatively higher in the Caucasian populations, it has gradually become a major public health issue among the non-Caucasian populations (including Indians) as well due to senescence, rapidly changing demographics and life-style factors. Recent genome-wide association studies (GWAS) on large case-control cohorts have helped in mapping genes in the complement cascade that are involved in the regulation of innate immunity with AMD susceptibility. Genes involved with mitochondrial oxidative stress and extracellular matrix regulation also play a role in AMD pathogenesis. Majority of the associations observed in complement (CFH, CFB, C2 and C3) and other (ARMS2 and HTRA1) genes have been replicated in diverse populations worldwide. Gene-gene (CFH with ARMS2 and HTRA1) interactions and correlations with environmental traits (smoking and body mass index) have been established as significant covariates in AMD pathology. In this review, we have provided an overview on the underlying molecular genetic mechanisms in AMD worldwide and highlight the AMD-associated-candidate genes and their potential role in disease pathogenesis.
C1 [Katta, Saritha; Kaur, Inderjeet; Chakrabarti, Subhabrata] LV Prasad Eye Inst, Hyderabad Eye Res Fdn, Champalimaud Translat Ctr, Brien Holden Eye Res Ctr, Hyderabad 500034, Andhra Pradesh, India.
C3 L. V. Prasad Eye Institute
RP Chakrabarti, S (通讯作者)，LV Prasad Eye Inst, Hyderabad Eye Res Fdn, Champalimaud Translat Ctr, Brien Holden Eye Res Ctr, Hyderabad 500034, Andhra Pradesh, India.
EM subho@lvpei.org
RI Chakrabarti, Subhabrata/F-2468-2015; Kaur, Inderjeet/ABD-1833-2021
OI Chakrabarti, Subhabrata/0000-0003-3717-4963; 
FU Department of Biotechnology [BT/PR/9561/ICD/16/759/2006]; Department of
   Science and Technology, Government of India [SR/FT/L-66/2006]; Council
   of Scientific and Industrial Research (CSIR), Government of India
FX The authors thank all the AMD patients and normal volunteers for their
   participation in the LVPEI study on the genetics of AMD. We appreciate
   the help of our clinician colleagues from the Kannuri Santhamma Retina
   Vitreous Centre in the diagnosis of the subjects and Mr Avid Hussain for
   some technical support. This study was supported in part by grants from
   the Department of Biotechnology (BT/PR/9561/ICD/16/759/2006) and the
   Department of Science and Technology (SR/FT/L-66/2006), Government of
   India, to Drs Chakrabarti and Kaur, respectively. Ms Saritha Katta
   acknowledges the receipt of a senior research fellowship from the
   Council of Scientific and Industrial Research (CSIR), Government of
   India.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   Asensio-Sánchez V.M., 2006, Arch Soc Esp Oftalmol, V81, P09
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Bojanowski Christine M, 2005, Trans Am Ophthalmol Soc, V103, P37
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen LJ, 2006, MOL VIS, V12, P1536
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2008, MOL VIS, V14, P1395
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hawkins BS, 1999, MOL VIS, V5
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KAUR I, 2009, INVEST OPHT IN PRESS
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim IK, 2008, MOL VIS, V14, P1487
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Kuehn MH, 2001, INVEST OPHTH VIS SCI, V42, P3123
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Leveziel N, 2007, MOL VIS, V13, P2153
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   LOKKI ML, 1991, IMMUNOGENETICS, V34, P242, DOI 10.1007/BF00215259
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   MARIOLI DI, 2009, GRAEFES ARCH CLIN EX
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   McKay GJ, 2004, MOL VIS, V10, P682
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Neuner B, 2008, OPHTHAL EPIDEMIOL, V15, P148, DOI 10.1080/09286580802105830
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okamoto H, 2006, MOL VIS, V12, P156
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   PATEL S, 2009, RETINA, V29, P45
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   RONALD AB, 1996, HISTOLOGY SAUNDERS T
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sauer CG, 2001, BRIT J OPHTHALMOL, V85, P969, DOI 10.1136/bjo.85.8.969
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   SCOTT LJ, 2005, HUM MOL GENET, V14, P2257
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Seitsonen S, 2006, MOL VIS, V12, P796
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Seng KC, 2008, EUR J HUM GENET, V16, P554, DOI 10.1038/ejhg.2008.12
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   SWAROOP A, 2009, ANN REV GENOMICS HUM
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   TANG NP, 2009, ANN EPIDEMIOL
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   THEODORE SR, 2007, RETINAL DEGENERATION
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weger M, 2007, MOL VIS, V13, P1274
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 235
TC 75
Z9 81
U1 1
U2 11
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0022-1333
EI 0973-7731
J9 J GENET
JI J. Genet.
PD DEC
PY 2009
VL 88
IS 4
SI SI
BP 425
EP 449
DI 10.1007/s12041-009-0064-4
PG 25
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 553AH
UT WOS:000274336300006
PM 20090206
DA 2022-11-30
ER

PT J
AU Barikian, A
   Salti, H
   Safar, A
   Mahfoud, ZR
   Bashshur, ZF
AF Barikian, Anita
   Salti, Haytham
   Safar, Ammar
   Mahfoud, Ziyad R.
   Bashshur, Ziad F.
TI INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR
   BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION A Prospective Pilot Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; choroidal
   neovascularization; corticosteroids; dexamethasone implant
ID VERTEPORFIN PLUS RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; BARRIER
   BREAKDOWN; THERAPY; TRIAMCINOLONE; TACHYPHYLAXIS; AFLIBERCEPT; EDEMA;
   MONOTHERAPY; UVEITIS
AB Purpose: To study the benefit of intravitreal dexamethasone implant in the management of neovascular age-related macular degeneration resistant to bevacizumab and ranibizumab.
   Methods: Patients with persistent macular fluid on optical coherence tomography despite monthly treatment with at least three consecutive bevacizumab injections followed by at least three ranibizumab injections were prospectively enrolled. A single dexamethasone implant was administered followed by intravitreal ranibizumab 1 week later. Ranibizumab was continued afterward on an as-needed basis. Main outcomes were improvement in central retinal thickness and best-corrected visual acuity.
   Results: Nineteen patients (19 eyes) were enrolled. There was no significant change in best-corrected visual acuity over 6 months. Greatest reduction in mean central retinal thickness, from 295.2 mu m to 236.2 mu m, occurred 1 month after dexamethasone implant (P < 0.0001). By Month 6, mean central retinal thickness was 287.3 mu m (P = 0.16). Eyes with only intraretinal fluid (13 eyes) achieved a fluid-free macula. Eyes with predominantly subretinal fluid (6 eyes) did not improve central retinal thickness and continued monthly ranibizumab. Mean baseline intraocular pressure was 13.2 mmHg, which peaked at 15.6 mmHg by Month 2 (P = 0.004).
   Conclusion: Intravitreal dexamethasone implant improved only macular intraretinal fluid in eyes with neovascular age-related macular degeneration resistant to bevacizumab and ranibizumab. However, this treatment had a limited duration.
C1 [Barikian, Anita; Salti, Haytham; Bashshur, Ziad F.] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Safar, Ammar] Amer Hosp Dubai, Dept Ophthalmol, Dubai, U Arab Emirates.
   [Mahfoud, Ziyad R.] Weill Cornell Med, Dept Hlth Policy & Res, Doha, Qatar.
C3 American University of Beirut; Weill Cornell Medical College Qatar
RP Bashshur, ZF (通讯作者)，Amer Univ Beirut, Med Ctr, POB 11-0236-B11, Beirut 11072020, Lebanon.
EM zb00@aub.edu.lb
OI Mahfoud, Ziyad/0000-0003-4098-6401
FU University Research Board at the American University of Beirut
FX Supported by the University Research Board at the American University of
   Beirut.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Dang YL, 2014, DRUG DES DEV THER, V8, P1441, DOI 10.2147/DDDT.S66611
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Loewenstein A. K. B. D., 2010, INVEST OPHTHALMOL VI, V51
   Lowder C, 2011, ARCH OPHTHALMOL-CHIC, V129, P545, DOI 10.1001/archophthalmol.2010.339
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ozkok A, 2015, RETINA-J RET VIT DIS, V35, P1393, DOI 10.1097/IAE.0000000000000475
   Ranchod TM, 2013, RETINA-J RET VIT DIS, V33, P1600, DOI 10.1097/IAE.0b013e318285cb71
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shen WY, 2014, GLIA, V62, P1110, DOI 10.1002/glia.22666
   Thompson JT, 2006, AM J OPHTHALMOL, V141, P629, DOI 10.1016/j.ajo.2005.11.050
   Tomkins-Netzer O, 2014, OPHTHALMOLOGY, V121, P1649, DOI 10.1016/j.ophtha.2014.02.003
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
NR 30
TC 8
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2017
VL 37
IS 7
BP 1337
EP 1344
DI 10.1097/IAE.0000000000001366
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6ZG
UT WOS:000404133400019
PM 27768640
DA 2022-11-30
ER

PT J
AU Uney, GO
   Unlu, N
   Acar, MA
   Hazirolan, D
   Altiparmak, UE
   Yalniz-Akkaya, Z
   Ornek, F
AF Uney, Guner O.
   Unlu, Nurten
   Acar, Mehmet A.
   Hazirolan, Dicle
   Altiparmak, Ugur E.
   Yalniz-Akkaya, Zuleyha
   Ornek, Firdevs
TI ROLE OF POSTERIOR VITREOUS DETACHMENT ON OUTCOME OF ANTI-VASCULAR
   ENDOTHELIAL GROWTH FACTOR TREATMENT IN AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age related macular degeneration; anti-vascular endothelial growth
   factor; vitreomacular surface; posterior vitreous detachment
ID OPTICAL COHERENCE TOMOGRAPHY; VITREOMACULAR ADHESION; EYE; INFLAMMATION;
   DISEASE; RISK; PATHOGENESIS; THERAPY; BARRIER
AB Purpose: The aim of this study was to determine the effect of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor injection.
   Methods: Sixty-one eyes with age-related macular degeneration that had received intravitreal bevacizumab or ranibizumab injections were retrospectively reviewed. The vitreomacular interface was evaluated, and eyes were grouped according to the presence of posterior vitreous detachment (Group 1, n = 25) or vitreomacular adhesion (Group 2, n = 36). All patients received three loading doses of intravitreal anti-vascular endothelial growth factor injections at monthly intervals, and subsequently, pro re nata regimen was performed. Best-corrected visual acuity and central foveal thickness measurement at follow-up were evaluated. The development of posterior vitreous detachment during the follow-up was also reported.
   Results: The best-corrected visual acuity changes at each visit compared with baseline were significantly better in Group 1 (P = 0.01, 0.02, 0.02, 0.009, 0.009, respectively at third, sixth, ninth, 12th month, and last visit). When best-corrected visual acuity was classified according to the change in visual acuity of 10 letters or more, the rate of improved or stable best-corrected visual acuity was greater in Group 1 (P = 0.02). During the follow-up, 5 eyes (14.3%) developed posterior vitreous detachment.
   Conclusion: Vitreomacular adhesion seems to have an adverse effect on the visual prognosis of anti-vascular endothelial growth factor treatment for age-related macular degeneration.
C1 [Uney, Guner O.; Unlu, Nurten; Acar, Mehmet A.; Hazirolan, Dicle; Altiparmak, Ugur E.; Yalniz-Akkaya, Zuleyha; Ornek, Firdevs] Ankara Numune Training & Res Hosp, Ophthalmol Clin, Minist Hlth, Ankara, Turkey.
C3 Ankara Numune Training & Research Hospital; Ministry of Health - Turkey
RP Uney, GO (通讯作者)，Ankara Egitim & Arastirma Hastanesi, Goz Hastaliklari Klinigi, TR-06520 Ankara, Turkey.
EM guner_ozkan@yahoo.com
RI Hazırolan, Dicle/GSE-1019-2022; altiparmak, ugur/W-7944-2018
OI altiparmak, ugur/0000-0002-3262-5959
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   FOOS R Y, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P480
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schubert H D, 1989, Prog Clin Biol Res, V312, P277
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Tan LE, 2011, INVEST OPHTH VIS SCI, V52, P1111, DOI 10.1167/iovs.10-5813
   Weber-Krause Brigitte, 1997, Der Ophthalmologe, V94, P619
   Worst JGF, 1995, FUNCTIONAL ANATOMY V, P33
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 37
TC 26
Z9 26
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 32
EP 37
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700007
PM 23751943
DA 2022-11-30
ER

PT J
AU Rovner, BW
   Casten, RJ
   Tasman, WS
AF Rovner, BW
   Casten, RJ
   Tasman, WS
TI Effect of depression on vision function in age-related macular
   degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CHRONIC DISEASE SCORE; DISABILITY; QUESTIONNAIRE; SYMPTOMS; DISTRESS;
   HEALTH; LIFE; AREA
AB Objectives: To report the prevalence rate of depression in older patients with recent vision loss due to age-related macular degeneration (AMD) and to describe the effect of depression on self-reported vision function during 6 months.
   Methods: Prospective cohort study of 51 older patients with recent-onset bilateral AMD attending the Retina Clinic of Wills Eye Hospital, Philadelphia, Pa. Main outcome measures included the Center for Epidemiological Studies Depression Scale, visual acuity, Functional Vision Screening Questionnaire, Chronic Disease Score, and Community Disability Scale.
   Results: Seventeen patients (33%) were depressed at baseline and had worse visual acuity (P=.04) and greater levels of vision-specific (P=.03) and general (P=.002) physical disability than nondepressed patients. The correlations of Center for Epidemiological Studies Depression Scale score with visual acuity and visual-specific disability, however, were not significant after controlling for general physical disability. An increase in depressive symptoms over time predicted decline in self-reported vision function independent of changes in visual acuity or medical status (P<.05).
   Conclusions: The prevalence and disabling effects of depression in older patients with AMD are substantial. Recognizing that depression is a treatable disorder that exacerbates the effects of AMD will lead to improved outcomes. Innovative interventions to prevent or treat depression in specialty eye clinics are possible.
C1 Thomas Jefferson Univ, Wills Eye Hosp, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Dept Ophthalmol, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University; Jefferson University
RP Rovner, BW (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, 900 Walnut St,8th Floor, Philadelphia, PA 19107 USA.
EM Barry.Rovner@mail.tju.edu
FU NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061331] Funding Source: NIH
   RePORTER; NIMH NIH HHS [MH61331] Funding Source: Medline
CR BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Bruce ML, 2001, AM J GERIAT PSYCHIAT, V9, P102, DOI 10.1176/appi.ajgp.9.2.102
   Casten RJ, 2000, INT J GERIATR PSYCH, V15, P813, DOI 10.1002/1099-1166(200009)15:9<813::AID-GPS192>3.3.CO;2-G
   CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   FECHNERBATES S, 1994, J CONSULT CLIN PSYCH, V62, P550, DOI 10.1037/0022-006X.62.3.550
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOLSTEIN MF, 1985, PSYCHOL MED, V15, P809, DOI 10.1017/S0033291700005031
   HOROWITZ A, 1991, J GERONTOL SOC WORK, V17, P37, DOI 10.1300/J083v17n03_04
   KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326
   Kennedy G J, 1990, J Community Health, V15, P93, DOI 10.1007/BF01321314
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   NORRIS FH, 1985, J GERONTOL, V40, P627, DOI 10.1093/geronj/40.5.627
   Penninx BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720, DOI 10.1001/jama.279.21.1720
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Rovner BW, 2001, J AM GERIATR SOC, V49, P1097, DOI 10.1046/j.1532-5415.2001.49215.x
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   SHMUELYDULITZKI Y, 1995, AM J GERIAT PSYCHIAT, V3, P325, DOI 10.1097/00019442-199503040-00007
   VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G
NR 24
TC 177
Z9 181
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2002
VL 120
IS 8
BP 1041
EP 1044
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 582JF
UT WOS:000177346500003
PM 12149057
DA 2022-11-30
ER

PT J
AU Esfandiary, H
   Chakravarthy, U
   Patterson, C
   Young, I
   Hughes, AE
AF Esfandiary, H
   Chakravarthy, U
   Patterson, C
   Young, I
   Hughes, AE
TI Association study of detoxification genes in age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LUNG-CANCER; SUSCEPTIBILITY; POLYMORPHISMS
AB Background/aims: Age related macular degeneration (AMD) is a complex disorder leading to loss of central vision, and identification of risk factors associated with susceptibility to AMD has been a key objective for ophthalmic genetics research for almost a decade. This association study has examined genetic polymorphisms in 12 candidate genes as possible risk factors for predisposition to the development of the exudative variant of AMD in a Northern Irish population. The choice of genes was based on their function in the breakdown of industrial pollutants, cigarette smoke, defence against oxidative stress, or involvement in the general ageing process.
   Methods: Up to five single nucleotide polymorphisms (SNPs) were typed for CYP1A1, CYP1A2, CYP2E1, CYP2D6, EPHX1, MnSOD, AhR, NAT2, CAT, GPX1, PON1, and ADPRT1 by multiplex snapshot single base primer extension method. Genes showing high linkage disequilibrium (LD) between SNPs were analysed by haplotype analysis. Genes showing low LD were assessed using individual SNPs based on genotypes.
   Results: After correction for number of genes/SNPs tested, no significant association with AMD was found although several genes merit further investigation. This study suggests that a coding SNP in EPHX1 (Y113H) may be important in AMD and supports a previous observation of an association with exudative AMD. In addition, haplotype analysis highlighted ADPRT1, CYP2D6, and AhR as worthy of further study.
   Conclusion: This study has identified a number of genes requiring further investigation including EPHX1, ADPRT1, CYP2D6, and AhR.
C1 Queens Univ Belfast, Ctr Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
   Queens Univ Belfast, Ctr Epidemiol & Populat Studies, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Hughes, AE (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Inst Clin Sci, Ctr Vis Sci, Belfast BT12 6BA, Antrim, North Ireland.
EM a.hughes@qub.ac.uk
RI Hughes, Anne/A-1307-2012
OI Young, Ian/0000-0003-3890-3152; Chakravarthy, Usha/0000-0002-2606-3734
CR DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003
   GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759
   HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Kao YL, 1998, J CLIN ENDOCR METAB, V83, P2589, DOI 10.1210/jc.83.7.2589
   Kawajiri K, 1996, CANCER RES, V56, P72
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 2003, DEV OPHTHALMOL, V37, P155
   NAKACHI K, 1991, CANCER RES, V51, P5177
   National Statistics Office, NAT POP PROJ
   Schneider S., 2000, ARLEQUIN SOFTWARE PO, V2, P2496
   Xu XP, 1996, CANCER EPIDEM BIOMAR, V5, P687
   Zhao JH, 2002, HUM HERED, V53, P36, DOI 10.1159/000048602
NR 13
TC 48
Z9 50
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2005
VL 89
IS 4
BP 470
EP 474
DI 10.1136/bjo.2004.047340
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907JU
UT WOS:000227713800018
PM 15774926
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Yoon, JS
   Lee, J
   Lee, SC
   Koh, HJ
   Kim, SS
   Kwon, OW
AF Yoon, Jin Sook
   Lee, Jonghyun
   Lee, Sung Chul
   Koh, Hyoung Jun
   Kim, Sung Soo
   Kwon, Oh Woong
TI Polypoidal choroidal vasculopathy in Korean patients with large
   submacular hemorrhage
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE submacular hemorrhage; hemorrhagic polypoidal choroidal vasculopathy;
   hemorrhagic choroidal neovascularization; photodynamic therapy
ID TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; PNEUMATIC DISPLACEMENT; SUBRETINAL
   HEMORRHAGE; NATURAL-HISTORY; VERTEPORFIN; INJECTION; NEOVASCULARIZATION
AB Purpose: To determine and compare the clinical characteristics, visual prognosis and treatment of hemorrhagic polypoidal choroidal vasculopathy (HPCV) with those of hemorrhagic choroidal neovascularization (HCNV) due to age-related macular degeneration (ARMD).
   Materials and Methods: Retrospective analysis of 44 consecutive eyes with a submacular hemorrhage comprising more than 50% of the neovascular lesion. Patients were diagnosed as having HPCV or HCNV on the basis of indocyanine green angiography.
   Results: Of the 44 eyes with submacular hemorrhage, 26 were classified as HPCV and 18 as HCNV. The baseline patient characteristics were similar for both groups. At the final follow-up the HPCV group had 17 eyes showing visual improvement, four showing maintained vision, and five showing visual deterioration. In contrast, the HCNV group had four eyes showing visual improvement, one showing maintained vision, and 13 showing visual deterioration. Visual acuity of < 0.1 at follow-up was found in 7 (27%) of HPCV eyes and 10 (56%) of HCNV eyes. PDT was performed in 15 HPCV eyes, of which 13 (87%) showed improvement or no change in visual acuity, while only 2 (22%) of the 9 HCNV eyes responded similarly after PDT. Eyes treated with PDT did not have better outcomes compared to eyes that underwent other types of treatment (Fisher's exact test, p > 0.05).
   Conclusion: PCV accounts for the largest proportion of submacular hemorrhage in Koreans. PCV showed a better visual prognosis than CNV.
C1 Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
   Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Ophthalmol, Goyang, Gyeonggi, South Korea.
C3 Yonsei University; Yonsei University Health System; Inje University
RP Lee, SC (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, 134 Sinchon Dong, Seoul 120752, South Korea.
EM sunglee@yumc.yonsei.ac.kr
OI Yoon, Jin Sook/0000-0002-8751-9467
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Gelisken F, 2005, GRAEF ARCH CLIN EXP, V243, P198, DOI 10.1007/s00417-004-0959-y
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
NR 23
TC 21
Z9 22
U1 0
U2 0
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD APR 30
PY 2007
VL 48
IS 2
BP 225
EP 232
DI 10.3349/ymj.2007.48.2.225
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 163WJ
UT WOS:000246193600011
PM 17461520
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Friberg, TR
   Brennen, PM
   Freeman, WR
   Musch, DC
AF Friberg, Thomas R.
   Brennen, Peter M.
   Freeman, William R.
   Musch, David C.
CA PTAMD Study Grp
TI Prophylactic Treatment of Age-Related Macular Degeneration Report Number
   2: 810-Nanometer Laser to Eyes With Drusen: Bilaterally Eligible
   Patients
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; HIGH-DOSE SUPPLEMENTATION; MICROPULSE
   DIODE-LASER; CHOROIDAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY;
   BETA-CAROTENE; GROWTH-FACTOR; SOFT DRUSEN; VISION LOSS; VITAMIN-C
AB BACKGROUND AND OBJECTIVE: To determine the prophylactic and therapeutic value of a single subthreshold 810-nanometer laser treatment in patients with high risk drusen as a manifestation of dry age-related macular degeneration in both eyes.
   PATIENTS AND METHODS: The Prophylactic Treatment of Age-related Macular Degeneration study enrolled 1,278 eyes of 639 participants who were 50 years or older with at least 5 drusen 63 pm or more in diameter in each eye. Treatment consisted of the placement of an annular grid of 48 extrafoveal, subthreshold 810-nm diode laser applications centered at but sparing the foveola in one eye of each participant, with the fellow eye serving as a control. Development of choroidal neovascularization and change in best-corrected visual acuity were compared between treated and untreated eyes.
   RESULTS: Subthreshold laser treatment did not decrease the incidence of choroidal neovascularization in treated versus untreated eyes. A modest visual a acuity benefit in treated eyes was found at 24 months (1.5 letter difference; P = .04) and in the treated eyes of participants with a baseline visual acuity between 20/32 and 20/63 (4.0 letter difference; P = .0034). However, this treatment effect was not sustained at 3 years.
   CONCLUSION: A single subthreshold 810-nanometer laser treatment to eyes of participants with bilateral high risk drusen is not an effective prophylactic strategy against choroidal neovascularization.
C1 [Friberg, Thomas R.; Brennen, Peter M.] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15213 USA.
   [Freeman, William R.] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Musch, David C.] Univ Michigan, WK Kellogg Eye Ctr, Ann Arbor, MI 48109 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of California System; University of California
   San Diego; University of Michigan System; University of Michigan
RP Friberg, TR (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, 203 Lothrop St,Suite 824, Pittsburgh, PA 15213 USA.
RI Da Mota, Sergio Hernandez/AAZ-6253-2021
OI Da Mota, Sergio Hernandez/0000-0001-5882-3462; Musch,
   David/0000-0002-4164-3841; Morse, Lawrence/0000-0002-1758-2348
FU Iridex Corporation, Mountain View, California; Eye and Ear Foundation of
   Pittsburgh, Pittsburgh, Pennsylvania; Research to Prevent Blindness,
   Inc., New York
FX Supported by Iridex Corporation, Mountain View, California, and the
   sources listed under the individual center descriptions found at the end
   of the article; the Eye and Ear Foundation of Pittsburgh, Pittsburgh,
   Pennsylvania; Research to Prevent Blindness, Inc., New York, New York
   and unrestricted funds from several participating centers.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Dorin Giorgio, 2004, Semin Ophthalmol, V19, P62, DOI 10.1080/08820530490884173
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Friberg TR, 1997, OPHTHALMOLOGY, V104, P2030, DOI 10.1016/S0161-6420(97)30061-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JD, 2001, T AM ACAD OPHTHALMOL, V75, P580
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guymer RH, 1997, ARCH OPHTHALMOL-CHIC, V115, P595, DOI 10.1001/archopht.1997.01100150597004
   Hogan AC, 2006, EYE, V20, P649, DOI 10.1038/sj.eye.6702028
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lanchoney DM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1045, DOI 10.1001/archopht.116.8.1045
   Lanzetta P, 2001, Semin Ophthalmol, V16, P8, DOI 10.1076/soph.16.1.8.4216
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Marshall J, 1981, Dev Ophthalmol, V2, P308
   Moorman CM, 1999, EYE, V13, P145, DOI 10.1038/eye.1999.41
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Sivaprasad S, 2007, CLIN EXP OPHTHALMOL, V35, P640, DOI 10.1111/j.1442-9071.2007.01566.x
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Sternberg P, 1998, OPHTHALMOLOGY, V105, P11
   Yamamoto C, 1996, GRAEF ARCH CLIN EXP, V234, P695, DOI 10.1007/BF00292356
NR 34
TC 24
Z9 24
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2009
VL 40
IS 6
BP 530
EP 538
DI 10.3928/15428877-20091030-01
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 529IY
UT WOS:000272510500001
PM 19928717
DA 2022-11-30
ER

PT J
AU Wang, K
   Mitra, RN
   Zheng, M
   Han, ZC
AF Wang, Kai
   Mitra, Rajendra Narayan
   Zheng, Min
   Han, Zongchao
TI Nanoceria-loaded injectable hydrogels for potential age-related macular
   degeneration treatment
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE alginate injectable hydrogel; cerium oxide nanoparticle; AMD; cellular
   models
ID CERIUM OXIDE NANOPARTICLES; BIOMEDICAL APPLICATIONS; VISUAL IMPAIRMENT;
   OXIDATIVE STRESS; DRY AMD; ANTIOXIDANT; CELLS; TRANSPLANTATION;
   BEVACIZUMAB; DELIVERY
AB The major purpose of this article is to evaluate oligochitosan coated cerium oxide nanoparticles (OCCNPs) alginate laden injectable hydrogels and their potential treatment for age-related macular degeneration (AMD). The water soluble OCCNPs were loaded within injectable hydrogels as antioxidative agents. The release of OCCNPs from hydrogel, radical scavenging properties, and biocompatibility were evaluated and calculated in vitro. The effects of OCCNP laden hydrogel downregulating expression of angiogenic proteins and proinflammatory cytokines were quantified in human retinal pigment epithlium-19 (ARPE-19) and umbilical endothelium cell lines. The hydrogels behaved with moderate swelling and controllable degradation. The laden OCCNPs were released in a controlled manner in vitro during two months of testing. The OCCNP loaded hydrogels exhibited robust antioxidative properties in oxygen radical absorbance capacity tests and reduced apoptosis in H2O2-induced ARPE-19 cells. Furthermore, OCCNP loaded injectable hydrogels are biocompatible and suppressed the ipopolysaccharides-induced inflammation response in ARPE-19 cells, and inhibited expression of vascular endothelium growth factor in human ARPE-19 and umbilical endothelium cell lines. The alginate-gelatin injectable hydrogel loaded OCCNPs are biocompatible and have high potential in protecting cells from apoptosis, angiogenesis, and production of proinflammatory cytokines in AMD cellular models. (c) 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 2795-2804, 2018.
C1 [Wang, Kai; Mitra, Rajendra Narayan; Zheng, Min; Han, Zongchao] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Carolina Inst NanoMed, Chapel Hill, NC 27599 USA.
   [Han, Zongchao] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill
RP Han, ZC (通讯作者)，Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC 27599 USA.; Han, ZC (通讯作者)，Univ N Carolina, Carolina Inst NanoMed, Chapel Hill, NC 27599 USA.; Han, ZC (通讯作者)，Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
EM zongchao@med.unc.edu
RI Wang, Kai/AAE-4566-2021; Wang, Kai/GQI-1260-2022
OI Wang, Kai/0000-0002-4419-9598; Wang, Kai/0000-0002-4419-9598; Mitra,
   Rajendra Narayan/0000-0003-0654-9654
FU National Eye Institute [R21EY024059, R01EY026564]; Carolina Center of
   Nanotechnology Excellence; UNC Junior Faculty Development Award; NC
   TraCS Translational Research Grant [550KR151611]; NATIONAL EYE INSTITUTE
   [R01EY026564, R21EY024059] Funding Source: NIH RePORTER
FX Contract grant sponsor: National Eye Institute; contract grant number:
   R21EY024059 and R01EY026564; Contract grant sponsor: Carolina Center of
   Nanotechnology Excellence; Contract grant sponsor: UNC Junior Faculty
   Development Award; Contract grant sponsor: NC TraCS Translational
   Research Grant; contract grant number: 550KR151611
CR Alili L, 2011, BIOMATERIALS, V32, P2918, DOI 10.1016/j.biomaterials.2010.12.056
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Cai X, 2016, ADV EXP MED BIOL, V854, P111, DOI 10.1007/978-3-319-17121-0_16
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Falkeborg M, 2014, FOOD CHEM, V164, P185, DOI 10.1016/j.foodchem.2014.05.053
   Fay J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2102
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Karakoti AS, 2008, JOM-US, V60, P33, DOI 10.1007/s11837-008-0029-8
   Karakoti A, 2010, CHEM SOC REV, V39, P4422, DOI 10.1039/b919677n
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelishomi ZH, 2016, FOOD CHEM, V196, P897, DOI 10.1016/j.foodchem.2015.09.091
   Kong L, 2011, NEUROBIOL DIS, V42, P514, DOI 10.1016/j.nbd.2011.03.004
   Kumar A, 2014, ENVIRON SCI-NANO, V1, P516, DOI 10.1039/c4en00052h
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Lee SS, 2013, ACS NANO, V7, P9693, DOI 10.1021/nn4026806
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mawad D, 2012, CURR PHARM DESIGN, V18, P2558, DOI 10.2174/138161212800492895
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Overstreet DJ, 2012, J POLYM SCI POL PHYS, V50, P881, DOI 10.1002/polb.23081
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pulido-Reyes G, 2015, SCI REP-UK, V5, DOI 10.1038/srep15613
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Ulijn RV, 2007, MATER TODAY, V10, P40, DOI 10.1016/S1369-7021(07)70049-4
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang K, 2016, ACTA BIOMATER, V36, P143, DOI 10.1016/j.actbio.2016.03.016
   Wei L, 2011, POLYMER, V52, P5139, DOI 10.1016/j.polymer.2011.09.006
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 43
TC 21
Z9 21
U1 8
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1549-3296
EI 1552-4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV
PY 2018
VL 106
IS 11
BP 2795
EP 2804
DI 10.1002/jbm.a.36450
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA HA5JD
UT WOS:000450305800001
PM 29752862
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lane, J
   Rohan, EMF
   Sabeti, F
   Essex, RW
   Maddess, T
   Barnes, N
   He, XM
   Robbins, RA
   Gradden, T
   McKone, E
AF Lane, Jo
   Rohan, Emilie M. F.
   Sabeti, Faran
   Essex, Rohan W.
   Maddess, Ted
   Barnes, Nick
   He, Xuming
   Robbins, Rachel A.
   Gradden, Tamara
   McKone, Elinor
TI Improving face identity perception in age-related macular degeneration
   via caricaturing
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IMAGE-ENHANCEMENT; RECOGNITION; VISION; SPACE; DISTINCTIVENESS;
   IDENTIFICATION; REPRESENTATION; PROSOPAGNOSIA; PERFORMANCE
AB Patients with age-related macular degeneration (AMD) have difficulty recognising people's faces. We tested whether this could be improved using caricaturing: an image enhancement procedure derived from cortical coding in a perceptual lace-space'. Caricaturing exaggerates the distinctive ways in which an individual's face shape differs from the average. We tested 19 AMD-affected eyes (from 12 patients; ages 66-93 years) monocularly, selected to cover the full range of vision loss. Patients rated how different in identity people's faces appeared when compared in pairs (e.g., two young men, both Caucasian), at four caricature strengths (0, 20, 40, 60% exaggeration). This task gives data reliable enough to analyse statistically at the individual-eye level. All 9 eyes with mild vision loss (acuity >= 6/18) showed significant improvement in identity discrimination (higher dissimilarity ratings) with caricaturing. The size of improvement matched that in normal-vision young adults. The caricature benefit became less stable as visual acuity further decreased, but caricaturing was still effective in half the eyes with moderate and severe vision loss (significant improvement in 5 of 10 eyes; at acuities from 6/24 to poorer than <6/360). We conclude caricaturing has the potential to help many AMD patients recognise faces.
C1 [Lane, Jo; McKone, Elinor] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Lane, Jo; McKone, Elinor] Australian Natl Univ, ARC Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
   [Rohan, Emilie M. F.; Sabeti, Faran; Maddess, Ted] Australian Natl Univ, JCSMR, Canberra, ACT, Australia.
   [Essex, Rohan W.] Australian Natl Univ, Acad Unit Ophthalmol, Canberra, ACT, Australia.
   [Barnes, Nick] Australian Natl Univ, Res Sch Engn, Canberra, ACT, Australia.
   [Barnes, Nick] CSIRO, Data61, Canberra, ACT, Australia.
   [He, Xuming] ShanghaiTech Univ, Sch Informat Sci & Technol, Shanghai, Peoples R China.
   [Robbins, Rachel A.; Gradden, Tamara] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.
   [Sabeti, Faran] Univ Canberra, Discipline Optometry & Vis Sci, Bruce, ACT, Australia.
C3 Australian National University; Australian National University;
   Australian National University; Australian National University;
   Australian National University; Commonwealth Scientific & Industrial
   Research Organisation (CSIRO); ShanghaiTech University; Australian
   National University; University of Canberra
RP McKone, E (通讯作者)，Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia.; McKone, E (通讯作者)，Australian Natl Univ, ARC Ctr Excellence Cognit & Its Disorders, Canberra, ACT, Australia.
EM elinor.mckone@anu.edu.au
RI Sabeti, Faran/AAR-1767-2021; Barnes, Nick/Y-2744-2018; Robbins, Rachel
   A/A-5542-2008; Maddess, Teddy L/A-3200-2008
OI Barnes, Nick/0000-0002-9343-9535; Maddess, Teddy L/0000-0003-4591-3658;
   McKone, Elinor/0000-0003-1655-4297; Lane, Jo/0000-0002-2518-1050; Essex,
   Rohan/0000-0001-5323-0334; SABETI, Faran/0000-0001-9187-7569
FU Australian Research Council [CE110001021, DP150100684]; NHMRC Project
   [1063458]; NuCoria Pty Ltd; Rebecca Cooper Medical Foundation Grant
FX This research was supported by: grants CE110001021 and DP150100684
   (Australian Research Council) to EM; NHMRC Project Grant 1063458 to TM,
   ER and FS, NuCoria Pty Ltd, Rebecca Cooper Medical Foundation Grant to
   FS. Dr. David Tridgell provided vision data for one patient.
CR BENSON P J, 1991, European Journal of Cognitive Psychology, V3, P105, DOI 10.1080/09541449108406222
   BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
   BRUCE V, 1994, Q J EXP PSYCHOL-A, V47, P119, DOI 10.1080/14640749408401146
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Bunting R, 2012, AUST PRESCR, V35, P90, DOI 10.18773/austprescr.2012.038
   Burton AM, 1999, PSYCHOL SCI, V10, P243, DOI 10.1111/1467-9280.00144
   Calder AJ, 1996, BRIT J PSYCHOL, V87, P141, DOI 10.1111/j.2044-8295.1996.tb02581.x
   Davis J. M., 2011, INDIVIDUAL DIFFERENC, DOI [10.1371/journal.pone.0028800, DOI 10.1371/JOURNAL.PONE.0028800]
   Dawel A., J EXP PSYCHOL APPL
   Duchaine B, 2015, ANNU REV VIS SCI, V1, P393, DOI 10.1146/annurev-vision-082114-035518
   Ehrlich JR, 2017, AM J OPHTHALMOL, V176, P26, DOI 10.1016/j.ajo.2016.12.021
   FERRIS FL, 1993, AM J OPHTHALMOL, V116, P735
   Irons J, 2014, J VISION, V14, DOI 10.1167/14.2.12
   Irons JL, 2017, VISION RES, V137, P61, DOI 10.1016/j.visres.2017.06.002
   Itz ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149796
   Johnston RA, 1997, VIS COGN, V4, P59, DOI 10.1080/713756748
   Kanwisher N, 2014, NEW VISUAL NEUROSCIENCES, P733
   Kaufmann JM, 2008, BRAIN RES, V1228, P177, DOI 10.1016/j.brainres.2008.06.092
   Kayaert G, 2005, EUR J NEUROSCI, V22, P212, DOI 10.1111/j.1460-9568.2005.04202.x
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x
   Lee K, 2000, PSYCHOL SCI, V11, P379, DOI 10.1111/1467-9280.00274
   Lee KJ, 1997, PERCEPTION, V26, P733, DOI 10.1068/p260733
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McKone E., PLOS ONE
   McKone E, 2014, VISION RES, V98, P1, DOI 10.1016/j.visres.2014.01.007
   Owen VMF, 2008, INVEST OPHTH VIS SCI, V49, P2449, DOI 10.1167/iovs.07-0877
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Palermo R, 2011, NEUROPSYCHOLOGIA, V49, P3801, DOI 10.1016/j.neuropsychologia.2011.09.039
   Pasupathy A, 2001, J NEUROPHYSIOL, V86, P2505, DOI 10.1152/jn.2001.86.5.2505
   PELI E, 1994, J OPT SOC AM A, V11, P1929, DOI 10.1364/JOSAA.11.001929
   PELI E, 1991, INVEST OPHTH VIS SCI, V32, P2337
   Peli E., 1989, NONINVASIVE ASSESSME, P64
   Rhodes G, 1996, PSYCHOL SCI, V7, P105, DOI 10.1111/j.1467-9280.1996.tb00338.x
   RHODES G, 1987, COGNITIVE PSYCHOL, V19, P473, DOI 10.1016/0010-0285(87)90016-8
   Rhodes G., 2005, FITTING MIND WORLD A, P213, DOI DOI 10.1093/ACPROF:OSO/9780198529699.003.0009
   Rhodes G, 2006, VISION RES, V46, P2977, DOI 10.1016/j.visres.2006.03.002
   Rhodes G, 2013, J EXP PSYCHOL HUMAN, V39, P313, DOI 10.1037/a0031568
   Susilo T, 2010, J VISION, V10, DOI 10.1167/10.13.1
   Taylor DJ, 2018, GRAEF ARCH CLIN EXP, V256, P815, DOI 10.1007/s00417-017-3879-3
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   VALENTINE T, 1986, PERCEPTION, V15, P525, DOI 10.1068/p150525
   VALENTINE T, 1991, Q J EXP PSYCHOL-A, V43, P161, DOI 10.1080/14640749108400966
   Valentine T, 2016, Q J EXP PSYCHOL, V69, P1996, DOI 10.1080/17470218.2014.990392
   van Rheede JJ, 2015, INVEST OPHTH VIS SCI, V56, P4802, DOI 10.1167/iovs.14-16311
   Wan L, 2017, J EXP PSYCHOL GEN, V146, P102, DOI 10.1037/xge0000249
   Wang SW, 2008, CLIN REHABIL, V22, P816, DOI 10.1177/0269215508091435
   Wei Liu, 2016, Computer Vision - ECCV 2016. 14th European Conference. Proceedings: LNCS 9905, P21, DOI 10.1007/978-3-319-46448-0_2
   Yang H, 2015, IEEE T IMAGE PROCESS, V24, P2393, DOI 10.1109/TIP.2015.2421438
   Yardley L, 2008, J PSYCHOSOM RES, V65, P445, DOI 10.1016/j.jpsychores.2008.03.013
NR 51
TC 9
Z9 9
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 12
PY 2018
VL 8
AR 15205
DI 10.1038/s41598-018-33543-3
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA GW7DK
UT WOS:000447125400027
PM 30315188
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Curtin, K
   Theilen, LH
   Fraser, A
   Smith, KR
   Varner, MW
   Hageman, GS
AF Curtin, Karen
   Theilen, Lauren H.
   Fraser, Alison
   Smith, Ken R.
   Varner, Michael W.
   Hageman, Gregory S.
TI Hypertensive disorders of pregnancy increase the risk of developing
   neovascular age-related macular degeneration in later life
SO HYPERTENSION IN PREGNANCY
LA English
DT Article
DE Gestational hypertension; preeclampsia; age-related macular
   degeneration; choroidal neovascularization; population health
ID HIP FRACTURE; PREECLAMPSIA; SECONDARY; SEQUELAE; OUTCOMES; DISEASE;
   WOMEN; TERM
AB Background: Hypertensive disorders of pregnancy (HDP) and short-term adverse outcomes have long been recognized; however, survivors remain at risk of long-term complications. We investigated whether HDP is associated with the development of choroidal neovascular age-related macular degeneration (CNV AMD). Methods: We identified 31,454 women who experienced HDP based on Utah birth certificates and 62,908 unexposed women matched 2:1 to the exposed. Risk of CNV AMD was estimated using Cox models. Findings: Women with HDP exhibited an 80% higher risk for early CNV AMD (age < 70 y; 95%CI 1.23-2.58). Conclusion: Our findings may have implications forearlier CNV AMD screening and detection.
C1 [Curtin, Karen] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84112 USA.
   [Curtin, Karen; Fraser, Alison; Smith, Ken R.] Univ Utah, Huntsman Canc Inst, Pedigree & Populat Resource, Salt Lake City, UT 84112 USA.
   [Curtin, Karen; Hageman, Gregory S.] Univ Utah, Dept Ophthalmol & Visual Sci, John A Moran Eye Ctr, Steele Ctr Translat Med, Salt Lake City, UT 84112 USA.
   [Theilen, Lauren H.; Varner, Michael W.] Univ Utah, Dept Obstet Gynecol, Sch Med, Salt Lake City, UT 84112 USA.
   [Smith, Ken R.] Univ Utah, Family Studies & Populat Sci, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute; Utah System of Higher Education; University of Utah; Utah
   System of Higher Education; University of Utah; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Curtin, K (通讯作者)，Univ Utah, Pedigree & Populat Resource, Huntsman Canc Inst, Sch Med, 2000 Circle Hope, Salt Lake City, UT 84112 USA.
EM Karen.curtin@hsc.utah.edu
OI Theilen, Lauren/0000-0002-5662-6040
FU National Institute on Aging [R01 AG022095]; Research to Prevent
   Blindness; National Cancer Institute [P30-CA2014]; National Center for
   Advancing Translational Sciences [1UL1TR001067]; John A. Moran Eye
   Center; Steele Center for Translational Medicine; NATIONAL CANCER
   INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL CENTER
   FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001067, UL1TR002538] Funding
   Source: NIH RePORTER
FX This work was supported by the National Institute on Aging [R01
   AG022095]; Research to Prevent Blindness [N/A]; John A. Moran Eye Center
   and the Steele Center for Translational Medicine [N/A]; National Cancer
   Institute [P30-CA2014]; National Center for Advancing Translational
   Sciences [1UL1TR001067].
CR Abalos E, 2014, BJOG-INT J OBSTET GY, V121, P14, DOI 10.1111/1471-0528.12629
   Ackerman CM, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2019.02.010
   Ahmed R, 2014, J AM COLL CARDIOL, V63, P1815, DOI 10.1016/j.jacc.2014.02.529
   Auger N, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.11.1043
   Auger N, 2017, OBSTET GYNECOL, V129, P42, DOI 10.1097/AOG.0000000000001758
   Beharier O, 2016, AM J PERINAT, V33, P703, DOI 10.1055/s-0036-1571321
   Bellamy L, 2007, BMJ-BRIT MED J, V335, P974, DOI 10.1136/bmj.39335.385301.BE
   Bibbins-Domingo K, 2017, JAMA-J AM MED ASSOC, V317, P1661, DOI 10.1001/jama.2017.3439
   Bruckmann A, 2015, HYPERTENSION, V66, P900, DOI 10.1161/HYPERTENSIONAHA.115.05734
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   DORNAN KJ, 1982, OBSTET GYNECOL, V60, P657
   English FA, 2015, INTEGR BLOOD PRESS C, V8, P7, DOI 10.2147/IBPC.S50641
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gordin D, 2013, ACTA DIABETOL, V50, P781, DOI 10.1007/s00592-012-0415-0
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   LARATORRE E, 1940, PUBMED, V100, P940
   Latkany Paul, 2010, J Ocul Biol Dis Infor, V3, P30, DOI 10.1007/s12177-010-9052-4
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   LUNN M, 1995, BIOMETRICS, V51, P524, DOI 10.2307/2532940
   McDonald SD, 2008, AM HEART J, V156, P918, DOI 10.1016/j.ahj.2008.06.042
   Muir KW, 2013, JAMA OPHTHALMOL, V131, P119, DOI 10.1001/jamaophthalmol.2013.577
   Murphy MA, 2005, J NEURO-OPHTHALMOL, V25, P122, DOI 10.1097/01.WNO.0000165102.93612.57
   Pauli JM, 2015, OBSTET GYN CLIN N AM, V42, P299, DOI 10.1016/j.ogc.2015.01.007
   Prahalad S, 2004, ARTHRITIS RHEUM, V50, P4022, DOI 10.1002/art.20677
   Rigourd V, 2009, J REPROD IMMUNOL, V82, P174, DOI 10.1016/j.jri.2009.05.001
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   SCHREYER P, 1991, INT J GYNECOL OBSTET, V34, P127, DOI 10.1016/0020-7292(91)90226-U
   Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5
   SOLOMON SD, 2014, PUBMED
   Theilen LH, 2016, OBSTET GYNECOL, V128, P238, DOI 10.1097/AOG.0000000000001534
   Theodossiadis PG, 2002, AM J OPHTHALMOL, V133, P707, DOI 10.1016/S0002-9394(01)01430-1
   van Dijk M, 2010, HUM MOL GENET, V19, P2658, DOI 10.1093/hmg/ddq152
   Wagener HP, 1933, J AMER MED ASSOC, V101, P1380, DOI 10.1001/jama.1933.02740430026009
   Wang ZF, 2017, ENDOCRINE, V55, P809, DOI 10.1007/s12020-016-1075-6
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 40
TC 3
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1064-1955
EI 1525-6065
J9 HYPERTENS PREGNANCY
JI Hypertens. Pregnancy
PD JUL 3
PY 2019
VL 38
IS 3
BP 141
EP 148
DI 10.1080/10641955.2019.1597107
EA APR 2019
PG 8
WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology
GA IQ1QE
UT WOS:000466657100001
PM 30977693
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Romond, K
   Alam, M
   Kravets, S
   de Sisternes, L
   Leng, T
   Lim, JI
   Rubin, D
   Hallak, JA
AF Romond, Kathleen
   Alam, Minhaj
   Kravets, Sasha
   de Sisternes, Luis
   Leng, Theodore
   Lim, Jennifer, I
   Rubin, Daniel
   Hallak, Joelle A.
TI Imaging and artificial intelligence for progression of age-related
   macular degeneration
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Artificial intelligence; machine learning; deep learning; age-related
   macular degeneration; disease progression; imaging modalities
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; PREDICTION; RISK; OCT;
   PREVALENCE
AB Age-related macular degeneration (AMD) is a leading cause of severe vision loss. With our aging population, it may affect 288 million people globally by the year 2040. AMD progresses from an early and intermediate dry form to an advanced one, which manifests as choroidal neovascularization and geographic atrophy. Conversion to AMD-related exudation is known as progression to neovascular AMD, and presence of geographic atrophy is known as progression to advanced dry AMD. AMD progression predictions could enable timely monitoring, earlier detection and treatment, improving vision outcomes. Machine learning approaches, a subset of artificial intelligence applications, applied on imaging data are showing promising results in predicting progression. Extracted biomarkers, specifically from optical coherence tomography scans, are informative in predicting progression events. The purpose of this mini review is to provide an overview about current machine learning applications in artificial intelligence for predicting AMD progression, and describe the various methods, data-input types, and imaging modalities used to identify high-risk patients. With advances in computational capabilities, artificial intelligence applications are likely to transform patient care and management in AMD. External validation studies that improve generalizability to populations and devices, as well as evaluating systems in real-world clinical settings are needed to improve the clinical translations of artificial intelligence AMD applications.
C1 [Romond, Kathleen; Kravets, Sasha; Lim, Jennifer, I; Hallak, Joelle A.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Alam, Minhaj; Rubin, Daniel] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94304 USA.
   [Kravets, Sasha] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA.
   [de Sisternes, Luis] Carl Zeiss Meditec Inc, Dublin, CA 94568 USA.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94303 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Stanford University; University
   of Illinois System; University of Illinois Chicago; University of
   Illinois Chicago Hospital; Carl Zeiss AG; Stanford University
RP Hallak, JA (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
EM joelle@uic.edu
FU BrightFocus Foundation [M2019155]; Unrestricted Grant for Research to
   Prevent Blindness, Department of Ophthalmology and Visual Sciences,
   University of Illinois at Chicago, Chicago, IL; Core grant for Vision
   Research, Department of Ophthalmology and Visual Sciences, University of
   Illinois at Chicago, Chicago, IL [2P30EY001792 41]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by a BrightFocus Foundation grant M2019155 (JAH), an
   Unrestricted Grant for Research to Prevent Blindness, Department of
   Ophthalmology and Visual Sciences, University of Illinois at Chicago,
   Chicago, IL (RK, SK, JIL, JAH), and the Core grant for Vision Research
   (2P30EY001792 41), Department of Ophthalmology and Visual Sciences,
   University of Illinois at Chicago, Chicago, IL, (RK, SK, JIL, JAH).
CR Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Bhuiyan A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.25
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   de Sisternes Luis, 2017, Transl Vis Sci Technol, V6, P12, DOI 10.1167/tvst.6.1.12
   de Sisternes L, 2015, INVEST OPHTH VIS SCI, V56, P4631, DOI 10.1167/iovs.14-16344
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gass, 1998, STEREOSCOPIC ATLAS M
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Graham, 1979, ARTIF INTELL, V1076
   Hallak JA, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.16
   Hallak JA, 2019, JAMA OPHTHALMOL, V137, P738, DOI 10.1001/jamaophthalmol.2019.0868
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kim DW, 2019, KOREAN J RADIOL, V20, DOI 10.3348/kjr.2019.0025
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Lu W, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5278196
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nattagh Khashayar, 2020, Transl Vis Sci Technol, V9, P6, DOI 10.1167/tvst.9.7.6
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rieke N, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00323-1
   Rivail A, 2019, LECT NOTES COMPUT SC, V11843, P44, DOI 10.1007/978-3-030-32281-6_5
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Sheller MJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69250-1
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2021, OPHTHALMOL RETINA, V5, P118, DOI 10.1016/j.oret.2020.06.026
   Wu ZC, 2021, BRIT J OPHTHALMOL, V105, P711, DOI 10.1136/bjophthalmol-2020-315935
   Yan Q, 2020, NAT MACH INTELL, V2, P141, DOI 10.1038/s42256-020-0154-9
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yao XC, 2020, EXP BIOL MED, V245, P301, DOI 10.1177/1535370219899893
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
NR 50
TC 4
Z9 4
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD OCT
PY 2021
VL 246
IS 20
SI SI
BP 2159
EP 2169
AR 15353702211031547
DI 10.1177/15353702211031547
EA AUG 2021
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA WN1CM
UT WOS:000686092000001
PM 34404252
OA Green Published
DA 2022-11-30
ER

PT J
AU Weinberger, D
   Lichter, H
   Goldenberg-Cohen, N
   Priel, E
   Bahar, I
   Yassur, Y
   Axer-Siegel, R
AF Weinberger, D
   Lichter, H
   Goldenberg-Cohen, N
   Priel, E
   Bahar, I
   Yassur, Y
   Axer-Siegel, R
TI Retinal microangiopathies overlying pigment epithelial detachment in
   age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; pigment epithelial detachment
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULAR MEMBRANES
AB Purpose: To evaluate alterations in the retinal vasculature overlying pigment epithelial detachments (PED) in exudative age-related macular degeneration (ARMD) using indocyanine green and fluorescein angiography.
   Methods: Forty-one patients (41 eyes) with a clinical diagnosis of exudative ARMD with PED underwent simultaneous fluorescein and indocyanine green angiography, also under high (10degrees) magnification. Vascular abnormalities in the retina were compared between patients with vascularized (n = 34, group 1) and nonvascularized (n = 7, group 2) PED on indocyanine green angiography and correlated with the size of the PED and the presence of serous retinal detachment.
   Results: In all, 67 vascular abnormalities were found by indocyanine green angiography and only 22 by fluorescein angiography; this finding was statistically significant (P < 0.0001). The finding of retinal vasculopathy (32 patients in group 1 and two patients in group 2) was directly correlated with the presence of choroidal neovascularizations (P = 0.002). There was also a direct correlation between the presence of choroidal neovascularization and size of the PED (P = 0.03). The number of retinal vascular findings was not significantly correlated with serous elevation of the retina.
   Conclusions: Retinal vasculopathies may be observed in eyes with FED and are detectable by indocyanine green and fluorescein angiography.
C1 Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   Mor Diagnost Inst, Bnei Braq, Israel.
C3 Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine
RP Weinberger, D (通讯作者)，Rabin Med Ctr, Dept Ophthalmol, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.
RI Goldenberg-Cohen, Nitza/F-2936-2018; Goldenberg-Cohen, Nitza/O-1638-2019
OI Goldenberg-Cohen, Nitza/0000-0002-5648-1873; Goldenberg-Cohen,
   Nitza/0000-0002-5648-1873
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Berg TJ, 1998, DIABETES CARE, V21, P1997, DOI 10.2337/diacare.21.11.1997
   BOLDT HC, 1990, RETINA-J RET VIT DIS, V10, P244, DOI 10.1097/00006982-199010000-00003
   DILHOFERBLIESEN.R, 1996, EUR J CLIN CHEM, V34, P355
   FREDERICK AR, 1993, RETINA-J RET VIT DIS, V13, P3, DOI 10.1097/00006982-199313010-00002
   GASS DM, 1997, STEREOSCOPIC ATLAS M, P39
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Murphy R P, 1985, Trans Am Ophthalmol Soc, V83, P63
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   VALASSARA H, 1996, DIABETES, V45, P65
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANUZZI LA, 2001, RETINA, V21, P416
   YAZAWA M, 1995, OPHTHALMOLOGY, V102, P622
NR 17
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2002
VL 22
IS 4
BP 406
EP 411
DI 10.1097/00006982-200208000-00002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583XT
UT WOS:000177437200002
PM 12172105
DA 2022-11-30
ER

PT J
AU Bracha, P
   Moore, NA
   Ciulla, TA
AF Bracha, Peter
   Moore, Nicholas A.
   Ciulla, Thomas A.
TI Induced pluripotent stem cell-based therapy for age-related macular
   degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE Induced pluripotent stem cell; stem cell; non-neovascular age-related
   macular degeneration; neovascular age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; NEURAL PROGENITOR CELLS; CHOROIDAL
   NEOVASCULARIZATION SECONDARY; MEMBRANE ATTACK COMPLEX; DAILY
   CLINICAL-PRACTICE; BRUCHS MEMBRANE; VISUAL-ACUITY; GROWTH-FACTOR;
   PRECURSOR CELLS; IN-VITRO
AB Introduction: In age-related macular degeneration (AMD), stem cells could possibly replace or regenerate disrupted pathologic retinal pigment epithelium (RPE), and produce supportive growth factors and cytokines such as brain-derived neurotrophic factor. Induced pluripotent stem cells (iPSCs)-derived RPE was first subretinally transplanted in a neovascular AMD patient in 2014.Areas covered: Induced PSCs are derived from the introduction of transcription factors to adult cells under specific cell culture conditions, followed by differentiation into RPE cells. Induced PSC-derived RPE cells exhibit ion transport, membrane potential, polarized VEGF secretion and gene expression that is similar to native RPE. Despite having similar in vitro function, morphology, immunostaining and microscopic analysis, it remains to be seen if iPSC-derived RPE can replicate the myriad of in vivo functions, including immunomodulatory effects, of native RPE cells. Historically, adjuvant RPE transplantation during CNV resections were technically difficult and complicated by immune rejection. Autologous iPSCs are hypothesized to reduce the risk of immune rejection, but their production is time-consuming and expensive. Alternatively, allogenic transplantation using human leukocyte antigen (HLA)-matched iPSCs, similar to HLA-matched organ transplantation, is currently being investigated.Expert opinion: Challenges to successful transplantation with iPSCs include surgical technique, a pathologic subretinal microenvironment, possible immune rejection, and complications of immunosuppression.
C1 [Bracha, Peter; Moore, Nicholas A.; Ciulla, Thomas A.] Indiana Univ Sch Med, Dept Ophthalmol, Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Ciulla, Thomas A.] Midwest Eye Inst, Retina Serv, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington
RP Ciulla, TA (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, Glick Eye Inst, Indianapolis, IN 46202 USA.; Ciulla, TA (通讯作者)，Midwest Eye Inst, Retina Serv, Indianapolis, IN USA.
EM thomasciulla@gmail.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Baehr W, 2003, VISION RES, V43, P2957, DOI 10.1016/j.visres.2003.10.001
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   Cai S, 2012, J BIOMAT SCI-POLYM E, V23, P1451, DOI 10.1163/092050611X584388
   Calejo MT, 2016, J BIOMED MATER RES A, V104, P1646, DOI 10.1002/jbm.a.35690
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   Chakradhar S, 2016, NAT MED, V22, P116, DOI 10.1038/nm0216-116
   Chao JR, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.4
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Cho MS, 2012, STEM CELL RES, V9, P101, DOI 10.1016/j.scr.2012.05.002
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Choudhary P, 2016, STEM CELL TRANSL MED, V6, P490
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Drukker M, 2004, SPRINGER SEMIN IMMUN, V26, P201, DOI 10.1007/s00281-004-0163-5
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Foss AJ, 2016, BR J OPHTHALMOL
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Gong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143272
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Guha P, 2013, CELL STEM CELL, V12, P407, DOI 10.1016/j.stem.2013.01.006
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Guo Y, 2003, INVEST OPHTH VIS SCI, V44, P3194, DOI 10.1167/iovs.02-0875
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ishida K, 2003, OCUL IMMUNOL INFLAMM, V11, P91, DOI 10.1076/ocii.11.2.91.15914
   Jia FJ, 2010, NAT METHODS, V7, P197, DOI [10.1038/NMETH.1426, 10.1038/nmeth.1426]
   JIANG LQ, 1991, TRANSPLANTATION, V52, P513, DOI 10.1097/00007890-199109000-00025
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535
   Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005
   Kim JY, 2016, RETIN CASES BRIEF RE, V11, P227
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Lawley E, 2015, J BIOMATER APPL, V29, P894, DOI 10.1177/0885328214547751
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Leung EH, 2016, OSLI RETINA, V47, P600, DOI 10.3928/23258160-20160601-16
   Li TQ, 2013, CELL RES, V23, P788, DOI 10.1038/cr.2013.48
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lu B, 2014, DEV OPHTHALMOL, V53, P155, DOI 10.1159/000357375
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lu Y, 2017, ACTA OPHTHALMOL, V95, pE443, DOI 10.1111/aos.13054
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mali P, 2008, STEM CELLS, V26, P1998, DOI 10.1634/stemcells.2008-0346
   Malik Nasir, 2013, Methods Mol Biol, V997, P23, DOI 10.1007/978-1-62703-348-0_3
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Meyer JS, 2004, BRAIN RES, V1014, P131, DOI 10.1016/j.brainres.2004.04.019
   Mimeault M, 2007, CLIN PHARMACOL THER, V82, P252, DOI 10.1038/sj.clpt.6100301
   Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001
   Mizumoto H, 2003, VISION RES, V43, P1699, DOI 10.1016/S0042-6989(03)00235-9
   Moisseiev E, 2016, INVEST OPHTH VIS SCI, V57, P4125, DOI 10.1167/iovs.16-19252
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Park SS, 2017, PROG RETIN EYE RES, V56, P148, DOI 10.1016/j.preteyeres.2016.10.002
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Pressmar S, 2001, INVEST OPHTH VIS SCI, V42, P3311
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Schraermeyer U, 2001, CELL TRANSPLANT, V10, P673, DOI 10.3727/000000001783986215
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Songstad AE, 2015, INVEST OPHTH VIS SCI, V56, P8258, DOI 10.1167/iovs.15-17073
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P9598, DOI 10.1167/iovs.11-8400
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012
   West EL, 2012, STEM CELLS, V30, P1424, DOI 10.1002/stem.1123
   Wojciechowski AB, 2002, EXP EYE RES, V75, P23, DOI 10.1006/exer.2001.1172
   Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanai A, 2016, METHODS MOL BIOL, V1307, P357, DOI 10.1007/7651_2013_57
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
   Yoshihara M, 2017, STEM CELL REV REP, V13, P7, DOI 10.1007/s12015-016-9680-6
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhang YS, 2012, J ASSIST REPROD GEN, V29, P735, DOI 10.1007/s10815-012-9802-2
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006-291X(02)02126-5
   Zhao Xing, 2006, V330, P401
NR 198
TC 22
Z9 24
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PY 2017
VL 17
IS 9
BP 1113
EP 1126
DI 10.1080/14712598.2017.1346079
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FC9FN
UT WOS:000407146600007
PM 28664762
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Montero, JA
   Sanchez-Tocino, H
   Maldonado, MJM
   Nino, CA
   Bartolom, RMP
   Coomonte, AV
AF Montero, Javier A.
   Sanchez-Tocino, Hortensia
   Marti Maldonado, Maria Josefa
   Nino, Concepcion Arnaiz
   Perez Bartolom, Rosa Maria
   Coomonte, Antonio Valera
TI Epidemiological factors associated with exudative age-related macular
   degeneration in Spain
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE exudative age-related macular degene-ration; iris color; smoking; blood
   pressure; hyperlipemia; smoking habit
ID RISK-FACTORS; MACULOPATHY; EYE
AB AIM: To report the demographic characteristics of a sample of population affected by exudative age-related macular degeneration (AMD) in the region of Castilla-Leon (North-Central Spain), and to compare them with a group of population of the same age and from the same geographic area.
   METHODS: In this observational, prospective study, AMD patients attending a regional reference clinic for photodynamic therapy were interviewed. The patients reported their medical history for high blood pressure, hyperlipemia and smoking habit. Iris color was examined and classified as light (green, blue and grey) or dark (hazel, brown, black).
   RESULTS: A total of 343 patients were interviewed. Mean age at onset was 74.9 years (range 55 to 93), among whom 64.5% were female and 35.5% male. Iris color was rated as light in 45.1% of the patients. Arterial hypertension (AH) was present in 50% of the cases and 15.3% were on treatment for hypercholesterolemia, and 30.2% of the patients were smokers or had quit smoking (80.9% of males).
   CONCLUSION: The frequency of light colored iris is higher among patients with exudative AMD. In our series, other risk factors for exudative AMD were smoking habit in males, not being on treatment for hypercholes-terolemia and being female.
C1 [Montero, Javier A.; Sanchez-Tocino, Hortensia; Marti Maldonado, Maria Josefa; Nino, Concepcion Arnaiz; Perez Bartolom, Rosa Maria; Coomonte, Antonio Valera] Pio del Rio Hortega Univ Hosp, Ophthalmol Unit, Valladolid 47010, Spain.
   [Montero, Javier A.] Alicante Inst Ophthalmol, VISSUM, Retina Unit, Alicante, Spain.
   [Montero, Javier A.] Univ Castilla La Mancha, Albacete Med Sch, E-13071 Ciudad Real, Spain.
C3 Universidad de Castilla-La Mancha
RP Montero, JA (通讯作者)，Pio del Rio Hortega Univ Hosp, Ophthalmol Unit, Avda Cardenal Torquemada S-N, Valladolid 47010, Spain.
EM javmonmor@hotmail.com
RI Tocino, Hortensia Sanchez/AAI-1096-2019
OI Tocino, Hortensia Sanchez/0000-0003-2695-7794
CR Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   LEON JDY, RIESGO ENFERMEDAD CA
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Roca-Santiago H.M., 2006, Arch Soc Esp Oftalmol, V81, P73
   Santos Laura Patrícia Ferreira, 2005, Arq. Bras. Oftalmol., V68, P229, DOI 10.1590/S0004-27492005000200014
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 12
TC 1
Z9 1
U1 1
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAR 18
PY 2009
VL 2
IS 1
BP 74
EP 76
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BK
UT WOS:000282933700018
DA 2022-11-30
ER

PT J
AU Faber, C
   Jehs, T
   Juel, HB
   Singh, A
   Falk, MK
   Sorensen, TL
   Nissen, MH
AF Faber, Carsten
   Jehs, Tina
   Juel, Helene Baek
   Singh, Amardeep
   Falk, Mads Krueger
   Sorensen, Torben Lykke
   Nissen, Mogens Holst
TI Early and exudative age-related macular degeneration is associated with
   increased plasma levels of soluble TNF receptor II
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cytokine; inflammation; plasma;
   sTNFRII
ID NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; SYSTEMIC COMPLEMENT
   ACTIVATION; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; INTERFERON-GAMMA;
   ARPE-19 CELLS; IFN-GAMMA; T-CELLS; INFLAMMATION
AB PurposeWe have recently identified homeostatic alterations in the circulating T cells of patients with age-related macular degeneration (AMD). In cultures of retinal pigment epithelial cells, we have demonstrated that T-cell-derived cytokines induced the upregulation of complement, chemokines and other proteins implicated in AMD pathogenesis. The purpose of this study was to test whether increased plasma levels of cytokines were present in patients with AMD.
   MethodsWe conducted a case-control study. Age-related macular degeneration status was assessed using standardized multimodal imaging techniques. Plasma was isolated from freshly drawn peripheral venous blood samples and analysed for interleukin (IL)15, IL18, interferon (IFN), soluble tumour necrosis factor (TNF) receptor II (sTNFRII) and complement factor H (CFH) Y402H genotype.
   ResultsWe included 136 individuals with early or late forms of AMD and 74 controls. Significantly increased levels of sTNFRII were observed in patients with early or exudative AMD (p<0.01). After adjusting for CFH Y402H genotype, age, sex and smoking history, the level of sTNFRII remained a significant predictor for prevalence of AMD with odds ratios at 3.0 in the middle and 3.6 in the highest tertiles. Levels of IL15, IL18 and IFN were low and not associated with AMD.
   ConclusionsIncreased plasma level of sTNFRII is found to be associated with AMD. The data supports the observations of low-grade, systemic inflammatory alterations in patients with AMD. However, it remains to be determined whether increased levels of TNF can be found, which directly reflects an increased activity of macrophages and T cells.
C1 [Faber, Carsten; Jehs, Tina; Juel, Helene Baek; Nissen, Mogens Holst] Univ Copenhagen, Fac Hlth & Med Sci, Dept Int Hlth Immunol & Microbiol, DK-2200 Copenhagen N, Denmark.
   [Faber, Carsten; Falk, Mads Krueger] Glostrup Cty Hosp, Dept Ophthalmol, Glostrup, Denmark.
   [Singh, Amardeep; Falk, Mads Krueger; Sorensen, Torben Lykke] Univ Copenhagen, Hosp Roskilde, Dept Ophthalmol, Roskilde, Denmark.
   [Singh, Amardeep; Falk, Mads Krueger; Sorensen, Torben Lykke] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; University of
   Copenhagen; University of Copenhagen
RP Faber, C (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Int Hlth Immunol & Microbiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.
EM carstenfaber@gmail.com
RI Faber, Carsten/I-4150-2013; Faber, Carsten/N-3210-2019; Juel,
   Helene/AAD-2843-2020; Nissen, Mogens/B-4825-2008; Singh,
   Amardeep/ABI-4544-2020
OI Faber, Carsten/0000-0002-2517-7270; Faber, Carsten/0000-0002-2517-7270;
   Nissen, Mogens/0000-0001-7729-8667; Juel, Helene B/0000-0002-5763-8545
FU Lundbeckfonden; Danish Eye Research Foundation; Fabrikant Einar
   Willumsens Mindelegat; Grosserer Chr. Andersens Legat; Marie og Borge
   Krogs Fond; Dagmar Marshalls Fond; Fight for Sight Denmark; Augustinus
   Fonden
FX This work was supported by Lundbeckfonden, The Danish Eye Research
   Foundation, Fabrikant Einar Willumsens Mindelegat, Grosserer Chr.
   Andersens Legat, Marie og Borge Krogs Fond, Dagmar Marshalls Fond, Fight
   for Sight Denmark and Augustinus Fonden. The funders had no role in the
   design or conduct of this research. No conflicting relationship exits
   for any author.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   AUKRUST P, 1994, BLOOD, V84, P2136
   Barbara JAJ, 1996, IMMUNOL CELL BIOL, V74, P434, DOI 10.1038/icb.1996.73
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Correia MP, 2011, IMMUNOBIOLOGY, V216, P604, DOI 10.1016/j.imbio.2010.09.012
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Erke MG, 2014, ACTA OPHTHALMOL
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   GIRARDIN E, 1992, IMMUNOLOGY, V76, P20
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kotter I, 2005, CLIN EXP RHEUMATOL, V23, pS20
   Kubicka-Trzaska A, 2014, ACTA OPHTHALMOL
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Liu BY, 2010, MOL VIS, V16, P184
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Luo C, 2011, MOL VIS, V17, P1588
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Mahmoud RAK, 2005, CLIN BIOCHEM, V38, P134, DOI 10.1016/j.clinbiochem.2004.11.002
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Owczarek D, 2012, POL ARCH MED WEWN, V122, P616, DOI 10.20452/pamw.1537
   Papadakis KA, 2004, J IMMUNOL, V172, P7002, DOI 10.4049/jimmunol.172.11.7002
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   RUTENFRANZ I, 1988, J INTERFERON RES, V8, P573, DOI 10.1089/jir.1988.8.573
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   van de Wetering D, 2009, INT IMMUNOL, V21, P145, DOI 10.1093/intimm/dxn132
   van Hagen PM, 2014, ACTA OPHTHALMOL
   Van Hauwermeiren F, 2011, CYTOKINE GROWTH F R, V22, P311, DOI 10.1016/j.cytogfr.2011.09.004
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845
NR 51
TC 18
Z9 19
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2015
VL 93
IS 3
BP 242
EP 247
DI 10.1111/aos.12581
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG1SA
UT WOS:000353053000023
PM 25363549
OA Bronze
DA 2022-11-30
ER

PT J
AU Adams, MKM
   Simpson, JA
   Richardson, AJ
   English, DR
   Aung, KZ
   Makeyeva, GA
   Guymer, RH
   Giles, GG
   Hopper, J
   Robman, LD
   Baird, PN
AF Adams, Madeleine K. M.
   Simpson, Julie A.
   Richardson, Andrea J.
   English, Dallas R.
   Aung, Khin Zaw
   Makeyeva, Galina A.
   Guymer, Robyn H.
   Giles, Graham G.
   Hopper, John
   Robman, Liubov D.
   Baird, Paul N.
TI Apolipoprotein E Gene Associations in Age-related Macular Degeneration
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aging; apolipoprotein E; genetics; macular degeneration
ID E POLYMORPHISMS; APOE GENE; MORTALITY; RISK; LONGEVITY; DEMENTIA; EYE;
   ATHEROSCLEROSIS; METAANALYSIS; MACULOPATHY
AB The apolipoprotein E gene (APOE) has been found to be associated with age-related macular degeneration (AMD). Reported associations have been questioned, as they are opposite those for Alzheimer's disease and cardiovascular disease. The authors examined associations between APOE genotype and AMD using a case-control study (2,287 cases and 2,287 controls individually matched on age, sex, and country of origin) nested within Melbourne Collaborative Cohort Study participants aged 48-86 years at AMD detection. The odds ratio for early AMD among participants with epsilon 2-containing genotypes (epsilon 2 epsilon 2/epsilon 2 epsilon 3/epsilon 2 epsilon 4) was 1.32 (95% confidence interval (CI): 1.11, 1.58; P = 0.002) versus persons with genotype epsilon 3 epsilon 3. Associations with early AMD varied by smoking status; epsilon 2-containing genotypes were positively associated with early AMD for never and previous smokers (never smokers: odds ratio (OR) = 1.40, 95% CI: 1.12, 1.76 (P = 0.003); previous smokers: OR = 1.39, 95% CI: 1.00, 1.93 (P = 0.05)) but not for current smokers (OR = 0.66, 95% CI: 0.34, 1.30 (P = 0.2; interaction P = 0.05). The epsilon 4-containing genotype group (epsilon 3 epsilon 4/epsilon 4 epsilon 4) had an inverse association with early AMD among current smokers only (OR = 0.41, 95% CI: 0.22, 0.77 (P = 0.005)). These results highlight the importance of stratifying by smoking status in elderly populations. Smokers who survive to old age may be more likely to possess unknown genotypes which modify exposure-disease associations.
C1 [Adams, Madeleine K. M.; Richardson, Andrea J.; Aung, Khin Zaw; Makeyeva, Galina A.; Guymer, Robyn H.; Robman, Liubov D.; Baird, Paul N.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Simpson, Julie A.; English, Dallas R.; Giles, Graham G.; Hopper, John] Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
   [Simpson, Julie A.; English, Dallas R.; Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne; Cancer Council
   Victoria
RP Adams, MKM (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM madam@student.unimelb.edu.au
RI English, Dallas/AAH-5005-2019; Adams, Madeleine K M/B-7915-2016;
   Simpson, Julie A/P-7299-2014
OI English, Dallas/0000-0001-7828-8188; Adams, Madeleine K
   M/0000-0002-5277-5487; Giles, Graham/0000-0003-4946-9099; Guymer,
   Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502; Simpson,
   Julie/0000-0002-2660-2013
FU VicHealth; Cancer Council Victoria; National Health and Medical Research
   Council of Australia (NHMRC) [209057, 251533, 396414]; Ophthalmic
   Research Institute of Australia; American Health Assistance Foundation;
   John Reid Charitable Trust; Perpetual Trustees; Royal Victorian Eye and
   Ear Hospital; Wagstaff Fellowship; Hugh Noel Puckle Scholarship
FX This work was supported by VicHealth; the Cancer Council Victoria
   (initial cohort recruitment); and the National Health and Medical
   Research Council of Australia (NHMRC) (program grant 209057,
   capacity-building grant 251533, and enabling grant 396414). The
   ophthalmic component of the study was funded by the Ophthalmic Research
   Institute of Australia, the American Health Assistance Foundation, the
   John Reid Charitable Trust, the Perpetual Trustees, and the Royal
   Victorian Eye and Ear Hospital. Support was also provided through the
   awarding of an NHMRC Practitioner Fellowship to R. H. G., a Wagstaff
   Fellowship to L. D. R., and an NHMRC PhD Scholarship and Hugh Noel
   Puckle Scholarship to M. K. M. A. The Centre for Eye Research Australia
   receives operational infrastructure support from the Victorian
   government.
CR Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Atmon G, 2005, MECH AGEING DEV, V126, P341, DOI 10.1016/j.mad.2004.08.026
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1
   Ewbank DC, 2004, J GERONTOL A-BIOL, V59, P16
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gerdes LU, 2003, CLIN CHEM LAB MED, V41, P628, DOI 10.1515/CCLM.2003.094
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Lewis SJ, 2004, INT J EPIDEMIOL, V33, P962, DOI 10.1093/ije/dyh214
   Little DM, 2009, J AM GERIATR SOC, V57, P231, DOI 10.1111/j.1532-5415.2008.02113.x
   Lucotte G, 1997, HUM BIOL, V69, P253
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Marshall Stephen W, 2007, Epidemiol Perspect Innov, V4, P4, DOI 10.1186/1742-5573-4-4
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   Rosvall L, 2009, NEUROBIOL AGING, V30, P1545, DOI 10.1016/j.neurobiolaging.2007.12.003
   Rozing MP, 2009, AGING-US, V1, P714, DOI 10.18632/aging.100071
   Sambrooke J., 1989, MOL CLONING LAB MANU, pE3
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Seipp Michael T, 2009, J Biomol Tech, V20, P160
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Singh PP, 2006, ANN HUM BIOL, V33, P279, DOI 10.1080/03014460600594513
   Skoog I, 1998, J NEUROL NEUROSUR PS, V64, P37, DOI 10.1136/jnnp.64.1.37
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 41
TC 26
Z9 27
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD MAR 15
PY 2012
VL 175
IS 6
BP 511
EP 518
DI 10.1093/aje/kwr329
PG 8
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA 910XJ
UT WOS:000301681600005
PM 22328704
OA Bronze
DA 2022-11-30
ER

PT J
AU Frampton, JE
AF Frampton, James E.
TI Aflibercept for Intravitreal Injection In Neovascular Age-Related
   Macular Degeneration
SO DRUGS & AGING
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR TRAP-EYE; VEGF-TRAP; BIOLOGY; SYSTEM;
   WET
AB Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B and placental growth factor, thereby preventing these ligands from binding to, and activating, their cognate receptors. The efficacy of intravitreal aflibercept in the treatment of wet (neovascular) age-related macular degeneration has been compared with that of intravitreal ranibizumab, the current gold standard for this indication, in two pivotal phase III studies of virtually identical design (VIEW 1 and 2). In both trials, the recommended regimen of aflibercept [2 mg every second month (after three initial monthly doses)] was shown to be noninferior to the recommended regimen of ranibizumab (0.5 mg every month) in terms of the primary endpoint of the proportion of patients who maintained their vision after 1 year of treatment; similar results were seen when monthly dosing with aflibercept (0.5 or 2 mg) was compared with ranibizumab. Over a period of 96 weeks in the VIEW studies, patients receiving the recommended regimen of aflibercept during the first year followed by modified quarterly treatment during the second year had a similar visual acuity gain to those receiving the recommended regimen of ranibizumab during first year followed by modified quarterly treatment during the second year, but on average required five fewer injections. Aflibercept was generally well tolerated in the VIEW studies; the ocular and non-ocular adverse event profile of the drug was similar to that of ranibizumab.
C1 Adis, Auckland 0754, New Zealand.
C3 Adis International
RP Frampton, JE (通讯作者)，Adis, 41 Centorian Dr,Private Bag 65901, Auckland 0754, New Zealand.
EM DRA@adis.com
CR [Anonymous], BAYER VASC END GROWT
   [Anonymous], REG VASC END GROWTH
   [Anonymous], 2012, EYLEA AFL INJ US PRE
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blick SKA, 2007, RANIBIZUMAB DRUGS, V67, P1199
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   European Medicines Agency Committee for Medicinal Products for Human Use, SUMM OP IN AUTH EYL
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frampton JE, 2012, DRUGS, V72, P509, DOI 10.2165/11208410-000000000-00000
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen QD, 2011, 2011 ANN M ASS RES V
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regeneron Pharmaceuticals Inc, 2010, BAYER REG REP POS TO
   Regeneron Pharmaceuticals Inc, 2 YEARS RES PHAS 3 S
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schmidt-Erfurth U, 2011, 2011 ANN M ASS RES V
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Stewart MW, 2012, BR J OPHTHALMOL
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Vinores SA, 2006, INT J NANOMED, V1, P263
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wiegand SJ, 2005, INVEST OPHTHALMOL VI, V46
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
NR 35
TC 11
Z9 12
U1 0
U2 4
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2012
VL 29
IS 10
BP 839
EP 846
DI 10.1007/s40266-012-0015-2
PG 8
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 038KR
UT WOS:000311174100006
PM 23038609
DA 2022-11-30
ER

PT J
AU Casaroli-Marano, R
   Gallego-Pinazo, R
   Fernandez-Blanco, CT
   Figueroa, MS
   Marin, BP
   Vaca, GFB
   Pinero-Bustamante, A
   Lopez, JD
   Garcia-Arumi, J
   Marti, JF
AF Casaroli-Marano, Ricardo
   Gallego-Pinazo, Roberto
   Torron Fernandez-Blanco, Clemencia
   Figueroa, Marta S.
   Pina Marin, Begona
   Fernandez-Baca Vaca, Gustavo
   Pinero-Bustamante, Antonio
   Donate Lopez, Juan
   Garcia-Arumi, Jose
   Farres Marti, Jordi
TI Age-Related Macular Degeneration: Clinical Findings following Treatment
   with Antiangiogenic Drugs
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL-ACUITY; INTRAVITREAL RANIBIZUMAB; THERAPY
AB Purpose. To survey the management of patients with neovascular age-related macular degeneration (nvAMD) in Spain. Methods. An observational retrospective multicenter study was conducted. The variables analyzed were sociodemographic characteristics, foveal and macular thickness, visual acuity (VA), type of treatment, number of injections, and the initial administration of a loading dose of an antiangiogenic drug. Results. 208 patients were followed up during 23.4 months in average. During the first and second years, patients received a mean of 4.5 +/- 1.8 and 1.6 +/- 2.1 injections of antiangiogenic drugs, and 5.4 +/- 2.8 and 3.6 +/- 2.2 follow-up visits were performed, respectively. The highest improvement in VA was observed at 3 months of follow-up, followed by a decrease in the response that stabilized above baseline values until the end of the study. Patients who received an initial loading dose presented greater VA gains than those without. Conclusions. Our results suggest the need for a more standardized approach in the management and diagnosis of nvAMD receiving VEGF inhibitors. To achieve the visual outcomes reported in pivotal trials, an early diagnosis, proactive approach (more treating than follow-up visits), and a close monitoring might be the key to successfully manage nvAMD.
C1 [Casaroli-Marano, Ricardo] Univ Barcelona, Hosp Clin Barcelona, Inst Clin Oftalmol, E-08028 Barcelona, Spain.
   [Gallego-Pinazo, Roberto] Hosp Univ & Politecn La Fe, Valencia 46026, Spain.
   [Gallego-Pinazo, Roberto; Torron Fernandez-Blanco, Clemencia] Inst Salud Carlos III, RETICS Oftared, Madrid 28029, Spain.
   [Torron Fernandez-Blanco, Clemencia] Hosp Univ Miguel Servet, Zaragoza 50009, Spain.
   [Figueroa, Marta S.] Hosp Univ Ramon y Cajal, Madrid 28034, Spain.
   [Pina Marin, Begona] Hosp Dos de Maig Barcelona, Barcelona 08025, Spain.
   [Fernandez-Baca Vaca, Gustavo] Hosp Reg Univ Carlos Haya, Malaga 29010, Spain.
   [Pinero-Bustamante, Antonio] Hosp Univ Valme, Seville 41014, Spain.
   [Donate Lopez, Juan] Hosp Clin Univ San Carlos, Madrid 28040, Spain.
   [Garcia-Arumi, Jose] Hosp Univ Vall dHebron, Barcelona 119129, Spain.
   [Farres Marti, Jordi] Bayer HealthCare, Barcelona 08970, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; Hospital
   Universitari i Politecnic La Fe; Instituto de Salud Carlos III; Miguel
   Servet University Hospital; Hospital Universitario Ramon y Cajal;
   Hospital Carlos Haya; Hospital Valme; Hospital Universitari Vall
   d'Hebron; Bayer AG; Bayer Healthcare Pharmaceuticals
RP Casaroli-Marano, R (通讯作者)，Univ Barcelona, Hosp Clin Barcelona, Inst Clin Oftalmol, Carrer Sabino Arana 1, E-08028 Barcelona, Spain.
EM rcasaroli@ub.edu
RI Donate-Lopez, Juan/AAB-5144-2019; Casaroli-Marano, Ricardo
   Pedro/D-4535-2014
OI Donate-Lopez, Juan/0000-0002-9944-6736; Casaroli-Marano, Ricardo
   Pedro/0000-0003-1812-9323; Garcia-Arumi, Jose/0000-0001-8827-1160
FU Bayer; Carl Zeiss Meditec; Novartis; Bayer HealthCare
FX Roberto Gallego-Pinazo is a consultant for Novartis and has received
   investigational grants and travel expenses from Bayer, Carl Zeiss
   Meditec, and Novartis; Marta S. Figueroa is a consultant for Bayer,
   Alcon, Allergan, and Novartis; IMS Health received funding from Bayer
   HealthCare for the conduct, analysis, and reporting of the study; Jordi
   Farres Marti is a salaried employee of Bayer HealthCare.
CR Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pauleikhoff D, 2011, Ophthalmologe, V108, P85, DOI 10.1007/s00347-010-2326-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno J.M., 2009, Arch Soc Esp Oftalmol, V84, P333
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
NR 23
TC 9
Z9 9
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 346360
DI 10.1155/2014/346360
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC1IS
UT WOS:000332249300001
PM 24693418
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Terluk, MR
   Kapphahn, RJ
   Soukup, LM
   Gong, H
   Gallardo, C
   Montezuma, SR
   Ferrington, DA
AF Terluk, Marcia R.
   Kapphahn, Rebecca J.
   Soukup, Lauren M.
   Gong, Hwee
   Gallardo, Christopher
   Montezuma, Sandra R.
   Ferrington, Deborah A.
TI Investigating Mitochondria as a Target for Treating Age-Related Macular
   Degeneration
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE age-related macular degeneration; mitochondria; mitochondrial DNA;
   oxidative damage; retina; retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; DNA-DAMAGE; ANTIOXIDANT ENZYMES; PROGRESSIVE
   STAGES; OXIDATIVE STRESS; REPAIR; PROTEOMICS; NUCLEAR; EYES
AB Age-related macular degeneration (AMD) is the leading cause of blindness among older adults in the developed world. Although the pathological mechanisms have not been definitively elucidated, evidence suggests a key role for mitochondrial (mt) dysfunction. The current study used our unique collection of human retinal samples graded for the donor's stage of AMD to address fundamental questions about mtDNA damage in the retina. To evaluate the distribution of mtDNA damage in the diseased retina, damage in the retinal pigment epithelium (RPE) and neural retina from individual donors were compared. To directly test a long-held belief that the macula is selectively damaged with AMD, RPE mtDNA damage was measured in the macula and peripheral sections from individual donors. Small segments of the entire mt genome were examined to determine whether specific regions are preferentially damaged. Our results show that mtDNA damage is limited to the RPE, equivalent mtDNA damage is found in the macular and peripheral RPE, and sites of damage are localized to regions of the mt genome that may impact mt function. These results provide a scientific basis for targeting the RPE mitochondria with therapies that protect and enhance mt function as a strategy for combating AMD.
C1 [Terluk, Marcia R.; Kapphahn, Rebecca J.; Gong, Hwee; Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Gallardo, Christopher] Univ Minnesota, Grad Program Pharmacol, Minneapolis, MN 55455 USA.
   [Soukup, Lauren M.] Univ St Thomas, St Paul, MN 55105 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of St Thomas Minnesota
RP Ferrington, DA (通讯作者)，Univ Minnesota, 380 Lions Res Bldg,2001 6th St SE, Minneapolis, MN 55455 USA.
EM ferri013@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU Arnold and Mabel Beckman Initiative for Macular Research; Foundation
   Fighting Blindness; University of Minnesota Academic Health Center Grant
   for Faculty Development; Minnesota Lions Vision Foundation; National
   Institutes of Health [T32-AG029796]; University of Minnesota Diversity
   of Views and Experiences; Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [P30EY011374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   ON AGING [T32AG029796] Funding Source: NIH RePORTER
FX This work was supported by funding from the Arnold and Mabel Beckman
   Initiative for Macular Research, Foundation Fighting Blindness, a
   University of Minnesota Academic Health Center Grant for Faculty
   Development, an anonymous benefactor for AMD Research, Minnesota Lions
   Vision Foundation, National Institutes of Health (MRT, T32-AG029796),
   University of Minnesota Diversity of Views and Experiences Fellowship
   (C.G.), and an unrestricted grant to the Department of Ophthalmology and
   Visual Neurosciences from the Research to Prevent Blindness. We thank
   the Minnesota Lions Eye Bank personnel for their assistance in procuring
   eyes, Kathy Goode and Sung Lee for photographing and processing eye
   tissue, and Dr Timothy Olsen for grading donor eyes before 2011.
CR Alliance for Eye and Vision Research, 2013, 20 ANN SPEC REP
   Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6
   Colby S.L., 2015, PROJECTIONS SIZE COM
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.bi.63.070194.004411
   Droge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474-9726.2007.00294.x
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gendron SP, 2013, MUTAGENESIS, V28, P197, DOI 10.1093/mutage/ges071
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kovalenko OA, 2009, CURR PROTOC HUM GENE, V62
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159
   Santos JH, 2004, AGING CELL, V3, P399, DOI 10.1111/j.1474-9728.2004.00124.x
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Yen K, 2013, J MOL ENDOCRINOL, V50, pR11, DOI 10.1530/JME-12-0203
NR 33
TC 143
Z9 149
U1 5
U2 26
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 6
PY 2015
VL 35
IS 18
BP 7304
EP 7311
DI 10.1523/JNEUROSCI.0190-15.2015
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CL0YG
UT WOS:000356668400028
PM 25948278
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Montero, JA
   Ruiz-Moreno, JM
   Sanchis-Merino, E
   Perez-Martin, S
AF Montero, Javier A.
   Ruiz-Moreno, Jose M.
   Sanchis-Merino, Eugenia
   Perez-Martin, Santiago
TI SYSTEMIC BETA-BLOCKERS MAY REDUCE THE NEED FOR REPEATED INTRAVITREAL
   INJECTIONS IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED
   BY BEVACIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; beta-adrenergic blocking agents;
   bevacizumab; choroidal neovascularization; concomitant medication
ID OXYGEN-INDUCED RETINOPATHY; PERIOCULAR INFANTILE HEMANGIOMAS;
   PHOTODYNAMIC THERAPY; MOUSE MODEL; PROPRANOLOL; RANIBIZUMAB; SAFETY;
   EYE; DEXAMETHASONE; MACULOPATHY
AB Purpose: To evaluate the effect of concomitant systemic therapy in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) treated by intravitreal bevacizumab and to propose a mechanism for different interindividual response.
   Methods: Retrospective, nonrandomized, single-center, consecutive interventional case series study. Forty-six eyes from 46 patients with choroidal neovascularization secondary to age-related macular degeneration were treated by monthly intravitreal 1.25 mg bevacizumab injections on a pro re nata regime. Patients' files were revised and changes in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity, central foveal thickness as determined by spectral domain optical coherence tomography, number of injections performed, occurrence of severe adverse effects, and systemic concomitant medication were recorded. The effect of systemic medication on final best-corrected visual acuity, central foveal thickness, and number of injections performed was evaluated.
   Results: The most frequent systemic medications recorded were angiotensin-converting-enzyme inhibitors in 19 patients, beta-adrenergic blocking agents (n = 18), nonsteroidal antiinflammatory drugs (n = 17), diuretics (n = 16), calcium channel blockers (n = 14), benzodiazepines (n = 11), proton-pump inhibitors (n = 9), and statins (n = 8). Thirty-two patients had arterial hypertension. Average follow-up was 25.1 months (standard deviation [SD] = 8.9). Average gain in best-corrected visual acuity was 0.9 (SD = 13.6) and -2.1 letters (SD = 15.9) at 12 months and 24 months, respectively. The average reduction in central foveal thickness was 111 mu m (SD = 54) and 105 mu mm (SD = 71) at 12 months and 24 months, respectively. The average number of intravitreal injections required was 6.7 (SD = 3.2). Patients on treatment with systemic beta-adrenergic blocking agents required less intravitreal injections (5.2, SD = 2.4 vs. 7.9, SD = 3.4) and this difference was statistically significant (P = 0.0068, multiple linear regression).
   Conclusion: Concomitant systemic beta-adrenergic blocking agents treatment may reduce the need for repeated intravitreal injections of bevacizumab in patients with choroidal neovascularization associated with age-related macular degeneration. RETINA 33: 508-512, 2013
C1 [Montero, Javier A.; Perez-Martin, Santiago] Pio Del Rio Hortega Univ Hosp, Ophthalmol Unit, Valladolid 47012, Spain.
   [Ruiz-Moreno, Jose M.] Alicante Inst Ophthalmol, VISSUM, Alicante, Spain.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Ophthalmol Unit, Albacete Med Sch, Albacete, Spain.
   [Sanchis-Merino, Eugenia] Pio Del Rio Hortega Univ Hosp, Allergy Unit, Valladolid 47012, Spain.
C3 Universidad de Castilla-La Mancha
RP Montero, JA (通讯作者)，Pio Del Rio Hortega Univ Hosp, Calle Dulzaina S-N, Valladolid 47012, Spain.
EM javmonmor@hotmail.com
RI Ruiz-Moreno, José M/E-4644-2016
OI Ruiz-Moreno, Jose M/0000-0001-9636-0788
FU Spanish Ministry of Health, Instituto de Salud Carlos III, Red Tematica
   de Investigacion Cooperativa en Salud "Patologia ocular del
   envejecimiento, calidad visual y calidad de vida" [RD07/0062/0019]
FX Supported in part by a grant of the Spanish Ministry of Health,
   Instituto de Salud Carlos III, Red Tematica de Investigacion Cooperativa
   en Salud "Patologia ocular del envejecimiento, calidad visual y calidad
   de vida" (RD07/0062/0019).
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Al Dhaybi R, 2011, OPHTHALMOLOGY, V118, P1184, DOI 10.1016/j.ophtha.2010.10.031
   Amrite A, 2010, EXPERT OPIN DRUG DEL, V7, P631, DOI 10.1517/17425241003663236
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Dayani PN, 2007, AM J OPHTHALMOL, V144, P451, DOI 10.1016/j.ajo.2007.05.006
   Fabian ID, 2011, AM J OPHTHALMOL, V151, P53, DOI 10.1016/j.ajo.2010.07.022
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Filippi L, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-83
   Forte R, 2011, OPHTHALMIC RES, V45, P129, DOI 10.1159/000318877
   Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802
   Haider KM, 2010, J AAPOS, V14, P251, DOI 10.1016/j.jaapos.2010.05.002
   Hajighasemi Fatemeh, 2009, Iranian Biomedical Journal, V13, P223
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jadhav VM, 2010, INDIAN J DERMATOL VE, V76, P691, DOI 10.4103/0378-6323.72472
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li YC, 2010, CLIN EXP OPHTHALMOL, V38, P554, DOI 10.1111/j.1442-9071.2010.02327.x
   Liew SH, 2010, PLAST RECONSTR SURG, V126, P671, DOI [10.1097/PRS.0b013e3181dela32, 10.1097/PRS.0b013e3181de1a32]
   Loffler H, 2009, HAUTARZT, V60, P1013, DOI 10.1007/s00105-009-1856-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martini D, 2011, J NEUROCHEM, V119, P1317, DOI 10.1111/j.1471-4159.2011.07530.x
   Maturo S, 2010, INT J PEDIATR OTORHI, V74, P323, DOI 10.1016/j.ijporl.2009.12.008
   Nguyen J, 2009, SEMIN OPHTHALMOL, V24, P178, DOI 10.1080/08820530902805602
   Ricci B, 2000, OPHTHALMOLOGICA, V214, P136, DOI 10.1159/000027483
   Ristori C, 2011, INVEST OPHTH VIS SCI, V52, P155, DOI 10.1167/iovs.10-5536
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sidbury R, 2010, CURR OPIN PEDIATR, V22, P432, DOI 10.1097/MOP.0b013e32833bb764
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Smith C, 1999, CARDIOVASC DRUG THER, V13, P123, DOI 10.1023/A:1007784109255
   Weil Joachim, 2003, Angiogenesis, V6, P303, DOI 10.1023/B:AGEN.0000029411.76494.33
   Wester Sara Tullis, 2011, Ophthalmic Surg Lasers Imaging, V42 Online, pe18, DOI 10.3928/15428877-20110203-04
NR 34
TC 28
Z9 29
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2013
VL 33
IS 3
BP 508
EP 512
DI 10.1097/IAE.0b013e3182695ba0
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 097DW
UT WOS:000315455200007
PM 23099497
DA 2022-11-30
ER

PT J
AU Colijn, JM
   Meester-Smoor, M
   Verzijden, T
   de Breuk, A
   Silva, R
   Merle, BMJ
   Cougnard-Gregoire, A
   Hoyng, CB
   Fauser, S
   Coolen, A
   Creuzot-Garcher, C
   Hense, HW
   Ueffing, M
   Delcourt, C
   den Hollander, AI
   Klaver, CCW
AF Colijn, Johanna M.
   Meester-Smoor, Magda
   Verzijden, Timo
   de Breuk, Anita
   Silva, Rufino
   Merle, Benedicte M. J.
   Cougnard-Gregoire, Audrey
   Hoyng, Carel B.
   Fauser, Sascha
   Coolen, Anthonius
   Creuzot-Garcher, Catherine
   Hense, Hans-Werner
   Ueffing, Marius
   Delcourt, Cecile
   den Hollander, Anneke, I
   Klaver, Caroline C. W.
CA EYE-RISK Consortium
TI Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe
   The EYE-RISK Consortium
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Europe; Genetics; Pathways; Population
ID CIGARETTE-SMOKING; COMPLEMENT-SYSTEM; ASSOCIATION; OMEGA-3-FATTY-ACIDS;
   PREVALENCE; RARE
AB Purpose: Age-related macular degeneration (AMD) is a common multifactorial disease in the elderly with a prominent genetic basis. Many risk variants have been identified, but the interpretation remains challenging. We investigated the genetic distribution of AMD-associated risk variants in a large European consortium, calculated attributable and pathway-specific genetic risks, and assessed the influence of lifestyle on genetic outcomes.
   Design: Pooled analysis of cross-sectional data from the European Eye Epidemiology Consortium.
   Participants: Seventeen thousand one hundred seventy-four individuals 45 years of age or older participating in 6 population-based cohort studies, 2 clinic-based studies, and 1 case-control study.
   Methods: Age-related macular degeneration was diagnosed and graded based on fundus photographs. Data on genetics, lifestyle, and diet were harmonized. Minor allele frequencies and population-attributable fraction (PAF) were calculated. A total genetic risk score (GRS) and pathway-specific risk scores (complement, lipid, extra-cellular matrix, other) were constructed based on the dosage of SNPs and conditional beta values; a lifestyle score was constructed based on smoking and diet.
   Main Outcome Measures: Intermediate and late AMD.
   Results: The risk variants with the largest difference between late AMD patients and control participants and the highest PAFs were located in ARMS2 (rs3750846) and CHF (rs570618 and rs10922109). Combining all genetic variants, the total genetic risk score ranged from -3.50 to 4.63 and increased with AMD severity. Of the late AMD patients, 1581 of 1777 (89%) showed a positive total GRS. The complement pathway and ARMS2 were by far the most prominent genetic pathways contributing to late AMD (positive GRS, 90% of patients with late disease), but risk in 3 pathways was most frequent (35% of patients with late disease). Lifestyle was a strong determinant of the outcome in each genetic risk category; unfavorable lifestyle increased the risk of late AMD at least 2-fold.
   Conclusions: Genetic risk variants contribute to late AMD in most patients. However, lifestyle factors have a strong influence on the outcome of genetic risk and should be a strong focus in patient management. Genetic risks in ARMS2 and the complement pathway are present in most late AMD patients but are mostly combined with risks in other pathways. (C) 2020 by the American Academy of Ophthalmology.
C1 [Colijn, Johanna M.; Meester-Smoor, Magda; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Colijn, Johanna M.; Meester-Smoor, Magda; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [de Breuk, Anita; Hoyng, Carel B.; den Hollander, Anneke, I; Klaver, Caroline C. W.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Silva, Rufino] Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res, Coimbra, Portugal.
   [Silva, Rufino] Coimbra Hosp & Univ Ctr, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Merle, Benedicte M. J.; Cougnard-Gregoire, Audrey; Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team LEHA, Bordeaux, France.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Fauser, Sascha] Hoffmann La Roche AG, Basel, Switzerland.
   [Coolen, Anthonius] Kings Coll London, Randall Div Cellular & Mol Biophys, London, England.
   [Coolen, Anthonius] Kings Coll London, Dept Math, London, England.
   [Creuzot-Garcher, Catherine] Univ Hosp, INRAe, Eye & Nutr Res Grp, Dept Ophthalmol, Dijon, France.
   [Hense, Hans-Werner] Univ Munster, Inst Epidemiol & Social Med, Munster, Germany.
   [Ueffing, Marius] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Tubingen, Germany.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Radboud University Nijmegen; Universidade de Coimbra;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Institut National de la Sante et de la
   Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux; University of Cologne; Roche Holding; University
   of London; King's College London; University of London; King's College
   London; CHU Dijon Bourgogne; INRAE; Institut Agro; AgroSup Dijon;
   Universite de Bourgogne; University of Munster; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital
RP Klaver, CCW (通讯作者)，Erasmus MC, Dept Ophthalmol, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM c.c.w.klaver@erasmusmc.nl
RI Merle, Benedicte MJ/AAQ-5021-2021; Delcourt, Cecile/I-2627-2013
OI Merle, Benedicte MJ/0000-0003-1332-0954; Delcourt,
   Cecile/0000-0002-2099-0481; Silva, Rufino/0000-0001-8676-0833
FU European Union [634479]; Erasmus Medical Center; Rotterdam Eye Hospital
   through the CORR (Combined Ophthalmic Research Rotterdam) Foundation;
   Uitzicht [2015-36]; Oogfonds; MaculaFonds; LSBS; Novartis Fonds;
   Laboratoires Thea (Clermont-Ferrand, France); Fondation Voir et Entendre
   (Paris, France); Caisse Nationale de Solidarite pour l'Autonomie (Paris,
   France); Inter-regional grant (Programme Hospitalier de Recherche
   Clinique [PHRC]); Regional Council of Burgundy; INRA; CNRS; Universite
   de Bourgogne; Regional Council of Burgundy France; FEDER (European
   Funding for Regional Economic Development); French Government; French
   National Research Agency (ANR) [ANR-11-LABX-0021-01-LipSTIC]; AIBILI;
   Novartis Pharma AG; Deutsche Forschungsgemeinschaft [HE 2293/5-1, HE
   2293/5-2, HE 2293/5-3]; University of Muenster; Pro Retina Foundation;
   Jackstaedt Foundation; Landelijke Stiching voor Blinden en
   Slechtzienden; Stichting Blindenhulp; Stichting A.F. Deutman
   Oogheelkunde Researchfonds; Netherlands Organization for Scientific
   Research [016.096.309]; European Research Council under the European
   Union [310644]; Dutch Organization for Scientific Research
   [016.Vici.170.024]; Netherlands Organisation of Scientific Research NWO
   [175.010.2005.011, 911-03-012]; Genetic Laboratory of the Department of
   Internal Medicine, Erasmus MC; Research Institute for Diseases in the
   Elderly [014-93-015 [RIDE2]]; Netherlands Genomics
   Initiative/Netherlands Organisation for Scientific Research; Netherlands
   Consortium for Healthy Aging [050-060-810]; Erasmus University,
   Rotterdam, The Netherlands; Netherlands Organization for the Health
   Research and Development; Research Institute for Diseases in the Elderly
   (RIDE); Ministry of Education, Culture and Science; Ministry of Health,
   Welfare and Sports; European Commission (DG XII); Municipality of
   Rotterdam
FX Supported by the European Union (Horizon 2020 grant no.: 634479
   [EYE-RISK]). The Rotterdam Study is funded by Erasmus Medical Center and
   Erasmus University, Rotterdam, The Netherlands; The biobank CORRBI of
   both Department of Ophthalmology and the Rotterdam Eye Hospital is
   financed through the CORR (Combined Ophthalmic Research Rotterdam)
   Foundation; The ophthalmic research within the Rotterdam Study was
   supported by Uitzicht grant number: 2015-36, Oogfonds, MaculaFonds,
   LSBS, Novartis Fonds. The sponsors and funding organization had no role
   in the design or conduct of this research; the Netherlands Organization
   for the Health Research and Development; the Research Institute for
   Diseases in the Elderly (RIDE); the Ministry of Education, Culture and
   Science; the Ministry of Health, Welfare and Sports; the European
   Commission (DG XII); and the Municipality of Rotterdam. The Alienor-3C
   study received financial support from Laboratoires Thea
   (Clermont-Ferrand, France), Fondation Voir et Entendre (Paris, France),
   and Caisse Nationale de Solidarite pour l'Autonomie (Paris, France).
   Laboratoires Thea participated in the design of the study, but no
   sponsor participated in the collection, management, statistical analysis
   and interpretation of the data, nor in the preparation, review or
   approval of the present manuscript. The genomewide association study
   genotype data for the Alienor-3C study are managed by the RID-AGE (Risk
   factors and molecular determinants of aging-related diseases) group of
   University of Lille, Institut Pasteur de Lille, and INSERM U1167 (Lille,
   France). MONRACHET funding was provided by an Inter-regional grant
   (Programme Hospitalier de Recherche Clinique [PHRC]) and the Regional
   Council of Burgundy. This study was also funded by INRA, CNRS,
   Universite de Bourgogne, Regional Council of Burgundy France (PARI
   Agrale 1), FEDER (European Funding for Regional Economic Development)
   and French Government grant managed by the French National Research
   Agency (ANR) as part of the "Investissements d'Avenir" program
   (reference ANR-11-LABX-0021-01-LipSTIC Labex). The funding organizations
   had no role in the design or conduct of this research. The Coimbra Eye
   Study is an Investigator-Initiated Study sponsored by AIBILI that was
   financially supported by Novartis Pharma AG. The funding organization
   played no role in the design or conduct of this research. Supported in
   part by grants from Deutsche Forschungsgemeinschaft HE 2293/5-1, 5-2,
   5-3; the Intramural IMF fund of the University of Muenster; the Pro
   Retina Foundation; and the Jackstaedt Foundation. EUGENDA was funded by
   grants from the Oogfonds, MaculaFonds, Landelijke Stiching voor Blinden
   en Slechtzienden, Stichting Blindenhulp, Stichting A.F. Deutman
   Oogheelkunde Researchfonds, the Netherlands Organization for Scientific
   Research (Vidi Innovational Research Award 016.096.309), and the
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013) (ERC Grant Agreement no. 310644 MACULA). This
   research was supported by the Dutch Organization for Scientific Research
   (016.Vici.170.024 to AIdH). The ophthalmic research within the Rotterdam
   Study was supported by Uitzicht grant number: 2015-36, Oogfonds,
   MaculaFonds, LSBS, Novartis Fonds. The sponsors and funding organization
   had no role in the design or conduct of this research.; The generation
   and management of GWAS genotype data for the Rotterdam Study (I, II, and
   III) was executed by the Human Genotyping Facility of the Genetic
   Laboratory of the Department of Internal Medicine, Erasmus MC,
   Rotterdam, The Netherlands. The GWAS datasets are supported by the
   Netherlands Organisation of Scientific Research NWO Investments (nos.:
   175.010.2005.011 and 911-03-012); the Genetic Laboratory of the
   Department of Internal Medicine, Erasmus MC; the Research Institute for
   Diseases in the Elderly (grant no.: 014-93-015 [RIDE2]); the Netherlands
   Genomics Initiative/Netherlands Organisation for Scientific Research and
   Netherlands Consortium for Healthy Aging (grant no.: 050-060-810).
CR [Anonymous], 2019, DATABASE SINGLE NUCL
   Bonyadi MHJ, 2019, INT OPHTHALMOL, V39, P949, DOI 10.1007/s10792-018-0853-y
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Delcourt C, 2016, EUR J EPIDEMIOL, V31, P197, DOI 10.1007/s10654-015-0098-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Keenan TD, 2019, OPHTHALMOL RETINA, V4, P3
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Merle B, 2011, INVEST OPHTH VIS SCI, V52, P6004, DOI 10.1167/iovs.11-7254
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Rajendran A, 2018, BRIT J OPHTHALMOL, V102, P1213, DOI 10.1136/bjophthalmol-2017-311384
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 31
TC 21
Z9 21
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2021
VL 128
IS 7
BP 1039
EP 1049
DI 10.1016/j.ophtha.2020.11.024
EA JUN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TB1BR
UT WOS:000667677700017
PM 33253757
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Figurska, M
   Bogdan-Bandurska, A
   Rekas, M
AF Figurska, Malgorzata
   Bogdan-Bandurska, Agnieszka
   Rekas, Marek
TI Effect of Phacoemulsification on Visual Acuity and Macular Morphology in
   Patients with Wet Age-Related Macular Degeneration
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Injections, Intraocular; Phacoemulsification; Vascular Endothelial
   Growth Factors; Wet Macular Degeneration
ID FILTERING INTRAOCULAR LENSES; ENDOTHELIAL GROWTH-FACTOR;
   CATARACT-SURGERY; CHOROIDAL NEOVASCULARIZATION; OXIDATIVE STRESS;
   VISIBLE-LIGHT; FOLLOW-UP; RISK; EYE; MACULOPATHY
AB Background: This article discusses the effectiveness of phacoemulsification cataract surgery with intraocular lens implantation in patients with wet age-related macular degeneration in the inactive phase of the disease.
   Material/Methods: Forty-nine patients (50 eyes) aged 78.94 +/- 5.54 years, previously treated with intravitreal injections of anti-vascular endothelial growth factor agents, were qualified for a prospective, randomized 12-month study. The participants were divided into 2 groups. Group I consisted of 25 patients (25 eyes) who were subjected to phacoemulsification cataract surgery. Group II consisted of 24 patients (25 eyes) who were not subjected to phacoemulsification cataract surgery despite having a lens opacity of grade II or higher according to the Lens Opacities Classification System.
   Results: After 12 months of follow-up, patients in group I gained on average 8.04 letters (p<0.001). Furthermore, 20% of the eyes had a significant improvement in best corrected visual acuity of >= 15 Early Treatment of Diabetic Retinopathy Study Chart letters. Patients in group II lost on average 1.96 letters (p>0.05). No significant differences between central retinal thickness values in either group (p>0.05) were noted. The mean number of intravitreal injections of anti-vascular endothelial growth factor agents during the study was 2.64 +/- 1.98 in group I and 2.92 +/- 2.40 in group II (p>0.05).
   Conclusions: Phacoemulsification performed in eyes with wet age-related macular degeneration during the inactive phase of the disease significantly improves visual acuity. In addition, it does not significantly influence the frequency of intravitreal injections of anti-vascular endothelial growth factor agents or disease activity.
C1 [Figurska, Malgorzata; Bogdan-Bandurska, Agnieszka; Rekas, Marek] Minist Natl Def, Cent Clin Hosp, Mil Inst Med, Dept Ophthalmol, Warsaw, Poland.
C3 Military Institute of Aviation Medicine
RP Figurska, M (通讯作者)，Minist Natl Def, Cent Clin Hosp, Mil Inst Med, Dept Ophthalmol, Warsaw, Poland.
EM mfigurska@wim.mil.pl
OI Rekas, Marek/0000-0003-0429-6649
CR Age-Related Eye Disease Study 2 Research Group, 2014, Ophthalmology, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Casparis H, 2012, COCHRANE DB SYST REV, V6
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Grixti A, 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/417603.
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Kara N, 2011, J CATARACT REFR SURG, V37, P2115, DOI 10.1016/j.jcrs.2011.06.024
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kruk J, 2016, MINI-REV MED CHEM, V16, P241, DOI 10.2174/1389557516666151120114605
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lak Dariusz, 2007, Roczniki Pomorskiej Akademii Medycznej w Szczecinie, V53, P43
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lee RMH, 2012, ACTA OPHTHALMOL, V90, pe151, DOI 10.1111/j.1755-3768.2011.02166.x
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Mentes J, 2003, OPHTHALMOLOGICA, V217, P408, DOI 10.1159/000073070
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Rappoport Daniel, 2017, Harefuah, V156, P79
   Rim TH, 2017, SEMIN OPHTHALMOL, V32, P466, DOI 10.3109/08820538.2015.1119861
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Symes RJ, 2012, EYE, V26, P1397, DOI 10.1038/eye.2012.178
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Ursell PG, 1999, J CATARACT REFR SURG, V25, P1492, DOI 10.1016/S0886-3350(99)00196-0
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang H, 2014, CURR OPIN OPHTHALMOL, V25, P40, DOI 10.1097/ICU.0000000000000020
   Yilmaz T, 2016, MED SCI MONITOR, V22, P1566
   Zhu XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033013
NR 47
TC 2
Z9 3
U1 0
U2 2
PU INT SCIENTIFIC LITERATURE, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD SEP 17
PY 2018
VL 24
BP 6517
EP 6524
DI 10.12659/MSM.909652
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GT9DW
UT WOS:000444841000001
PM 30220702
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Toyama, T
   Ohtomo, K
   Noda, Y
   Ueta, T
AF Toyama, T.
   Ohtomo, K.
   Noda, Y.
   Ueta, T.
TI Polypoidal choroidal vasculopathy and history of central serous
   chorioretinopathy
SO EYE
LA English
DT Article
ID TERM FOLLOW-UP; MACULAR DEGENERATION; CLINICAL CHARACTERISTICS; JAPANESE
   PATIENTS; VISUAL-ACUITY; THICKNESS; EYES
AB Purpose To evaluate the possible causative role of central serous chorioretinopathy (CSC) in the development of exudative age-related macular degeneration (AMD).
   Methods In a cross-sectional study at an institutional setting, 150 control subjects who had senile cataract or nasolacrimal duct stenosis and who were older than 50 years were enrolled. The background data for 89 patients with typical AMD (tAMD) and 138 patients with polypoidal choroidal vasculopathy (PCV) were used for comparison. Their medical records were taken for history of CSC, hypertension, systemic steroid use, and smoking. The fundus was also evaluated for signs of atrophic retinal pigment epithelial (RPE) tract and for focal photocoagulation scars in the macula.
   Results After adjusting for age, gender, and history of hypertension, systemic steroid use, and smoking, history of CSC was significantly more frequent (P < 0.0001) in patients with PCV (15 patients, 10.9%) compared with patients with tAMD (2 patients, 2.2%) or control subjects (0 patients). On fundoscopy, an atrophic RPE tract (seven patients) or a focal photocoagulation scar (one patient) was observed only in patients with PCV (eight patients, 5.8%), and the frequency was statistically significant compared with that with tAMD (P = 0.0143) or control subjects (P = 0.0143). The laterality of CSC and AMD involved the same eye in 9 of 10 patients among those who had unilateral AMD and a reported unilateral CSC history.
   Conclusion A history of CSC may be a predisposing factor for the development of PCV in the Japanese population.
C1 [Toyama, T.; Ohtomo, K.; Noda, Y.; Ueta, T.] Univ Tokyo, Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Ueta, T (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM ueta-tky@umin.ac.jp
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bujarborua D, 2001, ACTA OPHTHALMOL SCAN, V79, P417, DOI 10.1034/j.1600-0420.2001.079004417.x
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Klais CM, 2006, RETINA, V2, P1135, DOI DOI 10.1016/B978-0-323-02598-0.50069-02-S2.0-84917282576
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Park Han Sang, 2012, Korean J Ophthalmol, V26, P15, DOI 10.3341/kjo.2012.26.1.15
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
   Yap EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P689, DOI 10.1001/archopht.1996.01100130681007
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 29
TC 28
Z9 29
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2014
VL 28
IS 8
BP 992
EP 997
DI 10.1038/eye.2014.132
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO3GE
UT WOS:000341216400010
PM 24924443
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Trumbo, PR
   Ellwood, KC
AF Trumbo, Paula R.
   Ellwood, Kathleen C.
TI Lutein and zeaxanthin intakes and risk of age-related macular
   degeneration and cataracts: an evaluation using the Food and Drug
   Administration's evidence-based review system for health claims
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE lutein; zeaxanthin; age-related macular degeneration; cataracts; health
   claims
ID 3RD NATIONAL-HEALTH; SERUM CONCENTRATIONS; PIGMENT DENSITY; CAROTENOID
   CONCENTRATIONS; TISSUE CONCENTRATIONS; ANTIOXIDANT INTAKE;
   ALPHA-TOCOPHEROL; VISUAL FUNCTION; ADIPOSE-TISSUE; VITAMIN-A
AB The labeling of health claims that meet the significant scientific agreement standard and of qualified health claims on conventional foods and dietary supplements requires premarket approval by the Food and Drug Administration (FDA). The FDA conducts an evidence-based review to ascertain whether sufficient evidence exists to support a significant scientific agreement standard or a qualified health claim. The FDA recently reviewed intervention and observational studies that evaluated the role of lutein and zeaxanthin in reducing the risk of age-related macular degeneration and cataracts. On the basis of this evidence-based review, the FDA concluded that no credible evidence exists for a health claim about the intake of lutein or zeaxanthin (or both) and the risk of age-related macular degeneration or cataracts.
C1 US FDA, Div Nutr Programs & Labeling, College Pk, MD USA.
C3 US Food & Drug Administration (FDA)
RP Trumbo, PR (通讯作者)，HFS-830,5100 Paint Branch Pkwy, College Pk, MD 20740 USA.
EM paula.trumbo@fda.gov
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Cardinault N, 2003, EXP GERONTOL, V38, P573, DOI 10.1016/S0531-5565(03)00039-1
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dagnelie G, 2000, Optometry, V71, P147
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   El-Sohemy A, 2002, AM J CLIN NUTR, V76, P172, DOI 10.1093/ajcn/76.1.172
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Flegal KM, 1999, AM J CLIN NUTR, V69, p1339S
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Lyle BJ, 1999, AM J CLIN NUTR, V69, P272
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MICOZZI MS, 1990, JNCI-J NATL CANCER I, V82, P282, DOI 10.1093/jnci/82.4.282
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Olmedilla B, 2002, CLIN SCI, V102, P447, DOI 10.1042/CS20010159
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sempos CT, 1999, AM J CLIN NUTR, V69, p1330S
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1366
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1228
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1499
   SPILKER B, 1991, GUIDE CLIN STUDIES
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   *US COURTS FED JUD, 2000, REF MAN SCI EV
   *US FDA, CONS HLTH INF BETT N
   *US FDA, SIGN SCI AGR REV HLT
   *US FDA, QUAL HLTH CLIM LETT
   Valero MP, 2002, J NUTR, V132, P1299, DOI 10.1093/jn/132.6.1299
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VARMA SD, 1991, AM J CLIN NUTR, V53, pS335, DOI 10.1093/ajcn/53.1.335S
NR 55
TC 70
Z9 77
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV
PY 2006
VL 84
IS 5
BP 971
EP 974
DI 10.1093/ajcn/84.5.971
PG 4
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 104DZ
UT WOS:000241937700004
PM 17093145
OA Bronze
DA 2022-11-30
ER

PT J
AU Jefferys, JL
   Alexander, J
   Hiner, CJ
   Javornik, NB
   Smith, RE
   Bressler, NM
   Hawkins, BS
   Maguire, MG
AF Jefferys, Joan L.
   Alexander, Judith
   Hiner, Cheryl J.
   Javornik, Noreen B.
   Smith, Rochelle E.
   Bressler, Neil M.
   Hawkins, Barbara S.
   Maguire, Maureen G.
CA Macular Photocoagulat Stdy Grp
TI Reproducibility of gradings of retinal photographs in eyes with
   subfoveal choroidal neovascularization and age-related macular
   degeneration in the macular photocoagulation study
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; fundus
   photographs; randomized clinical trials; reproducibility of results
AB Purpose: To assess the reproducibility of the evaluation of color photographs and fluorescein angiograms of the macula of each eye for patients enrolled in the Macular Photocoagulation Study (MPS) trials of laser photocoagulation of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration. Methods: A total of 65 pre-enrollment and 26 posttreatment sets of photographs were regraded. The two gradings were compared on selected items judged to be of primary importance with respect to the role of the MPS Reading Center. Results: Agreement on eligibility of the neovascular lesion for an MPS trial was 88% (kappa statistic = 0.59); agreement on the size of the lesion was 86% (kappa statistic = 0.80); agreement on whether the lesion was covered by heavy treatment was 69% (kappa statistic = 0.35); and agreement on whether the treatment was in compliance with the study protocol was 73% (kappa statistic = 0.06). Conclusions: Interpretation of photographs of eyes with CNV secondary to age-related macular degeneration for eligibility and size of the lesion was reproducible in the MPS. However, adequacy of laser photocoagulation treatment could not be determined reliably from photographs.
C1 [Jefferys, Joan L.; Smith, Rochelle E.; Bressler, Neil M.; Hawkins, Barbara S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Alexander, Judith; Hiner, Cheryl J.; Javornik, Noreen B.; Maguire, Maureen G.; Macular Photocoagulat Stdy Grp] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of
   Pennsylvania; Pennsylvania Medicine
RP Jefferys, JL (通讯作者)，Wilmer Clin Trials Baltimore, 550 N Broadway,9th Floor, Baltimore, MD USA.
EM jjeffrey@jhmi.edu
FU NATIONAL EYE INSTITUTE [U10EY003281, U01EY006237, U10EY002548,
   U01EY002563, U01EY003288, U01EY002564, U01EY002553, U10EY006238,
   P30EY001765, U01EY006488, U10EY002549, U10EY005958, U01EY003284,
   U10EY006488, U01EY002548, U01EY002556, U10EY006239, U01EY002549,
   U01EY006238, U10EY002563, U10EY003284, U10EY002554, U10EY003288,
   U01EY003281, U10EY002556, U01EY002554, U01EY005995, U10EY006237,
   U01EY005958, U10EY002553, U01EY006239, U10EY005995] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY6237, EY6238, EY5995, EY5958, EY3288, EY3284,
   EY1765, EY3281, EY2548, EY2564, EY2549, EY2553, EY2563, EY2556, EY2554,
   EY6239, EY6488] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Altman D., 1991, PRACTICAL STAT MED R
   ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937
   *AM AC OPHTH, 2003, PREF PRACT PATT AG R
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P807
   [Anonymous], 1991, Ophthalmology, V98, P786
   AZEN SP, 1989, OPHTHALMOLOGY, V96, P352, DOI 10.1016/S0161-6420(89)32895-8
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   DUNN G, 1989, DESIGN ANAL RELIABIL, P34
   Fisher R, 1970, STATISTICAL METHODS, P96
   Fleiss JL, 1981, STATISTICAL METHODS, P217
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hollander M., 1973, NONPARAMETRIC STAT M, P115
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lachin John M, 2004, Clin Trials, V1, P553, DOI 10.1191/1740774504cn057oa
   LANDIS JR, 1977, BIOMETRICS, V33, P174
   LESKE MC, 1988, ARCH OPHTHALMOL-CHIC, V106, P327
   *MAC PHOT STUD GRO, 1991, PB91207903 NTIS
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   *SUBM SURG TRIALS, 2005, RETINA, V25, P253
   *US DEP HHS, OC PHOT THER VERT MA
   VARMA R, 1992, OPHTHALMOLOGY, V99, P215
   WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73
   1993, ARCH OPHTHALMOL, V111, P900
NR 33
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2008
VL 15
IS 3
BP 191
EP 201
DI 10.1080/09286580701772003
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318CN
UT WOS:000257069300009
PM 18569815
DA 2022-11-30
ER

PT J
AU Nan, R
   Tetchner, S
   Rodriguez, E
   Pao, PJ
   Gor, J
   Lengyel, I
   Perkins, SJ
AF Nan, Ruodan
   Tetchner, Stuart
   Rodriguez, Elizabeth
   Pao, Po-Jung
   Gor, Jayesh
   Lengyel, Imre
   Perkins, Stephen J.
TI Zinc-induced Self-association of Complement C3b and Factor H
   IMPLICATIONS FOR INFLAMMATION AND AGE-RELATED MACULAR DEGENERATION
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID X-RAY; SEDIMENTATION-VELOCITY; SCATTERING DATA; FACTOR-B; FACTOR-I;
   BINDING; POLYMORPHISM; VARIANT; PROTEIN; LIGAND
AB The sub-retinal pigment epithelial deposits that are a hallmark of age-related macular degeneration contain both C3b and millimolar levels of zinc. C3 is the central protein of complement, whereas C3u is formed by the spontaneous hydrolysis of the thioester bridge in C3. During activation, C3 is cleaved to form active C3b, then C3b is inactivated by Factor I and Factor H to form the C3c and C3d fragments. The interaction of zinc with C3 was quantified using analytical ultracentrifugation and x-ray scattering. C3, C3u, and C3b associated strongly in >100 mu M zinc, whereas C3c and C3d showed weak association. With zinc, C3 forms soluble oligomers, whereas C3u and C3b precipitate. We conclude that the C3, C3u, and C3b association with zinc depended on the relative positions of C3d and C3c in each protein. Computational predictions showed that putative weak zinc binding sites with different capacities exist in all five proteins, in agreement with experiments. Factor H forms large oligomers in >10 mu M zinc. In contrast to C3b or Factor H alone, the solubility of the central C3b-Factor H complex was much reduced at 60 mu M zinc and even more so at >100 mu M zinc. The removal of the C3b-Factor H complex by zinc explains the reduced C3u/C3b inactivation rates by zinc. Zinc-induced precipitation may contribute to the initial development of sub-retinal pigment epithelial deposits in the retina as well as reducing the progression to advanced age-related macular degeneration in higher risk patients.
C1 [Perkins, Stephen J.] UCL, Dept Struct & Mol Biol, London WC1E 6BT, England.
   [Lengyel, Imre] UCL Inst Ophthalmol, Dept Ocular Biol & Therapeut, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London
RP Perkins, SJ (通讯作者)，UCL, Dept Struct & Mol Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@ucl.ac.uk
RI Lengyel, Imre/B-5217-2009
OI Lengyel, Imre/0000-0001-7467-2174
FU Medical Research Council; Wellcome Trust; Fight For Sight; Mercer Fund
   from Fight for Sight; Bill Brown Charitable Trust; BBSRC [BB/E013104/1]
   Funding Source: UKRI; MRC [G0801724] Funding Source: UKRI; Biotechnology
   and Biological Sciences Research Council [BB/E013104/1] Funding Source:
   researchfish; Medical Research Council [G0801724] Funding Source:
   researchfish
FX This work was supported by the Medical Research Council (to R. N.), the
   Wellcome Trust (to S. T.), and Fight For Sight (to P.-J. P.).; Supported
   by the Mercer Fund from Fight for Sight, the Special Trustees of
   Moorfields Eye Hospital, and the Bill Brown Charitable Trust.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Cole JL, 2008, METHOD CELL BIOL, V84, P143, DOI 10.1016/S0091-679X(07)84006-4
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Craddock TJA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033552
   CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173
   DODDS AW, 1993, METHOD ENZYMOL, V223, P46
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Gilbert HE, 2005, J MOL BIOL, V346, P859, DOI 10.1016/j.jmb.2004.12.006
   Glatter O., 1982, SMALL ANGLE XRAY SCA, P17
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231
   Guinier A., 1955, SMALL ANGLE SCATTERI, P126
   Guthridge JM, 2001, BIOCHEMISTRY-US, V40, P5931, DOI 10.1021/bi0101749
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Haase H, 2010, CELLULAR AND MOLECULAR BIOLOGY OF METALS, P181, DOI 10.1201/9781420059984-c8
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan S, 2012, BIOCHEM J, V444, P417, DOI 10.1042/BJ20120183
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krezel A, 2006, J BIOL INORG CHEM, V11, P1049, DOI 10.1007/s00775-006-0150-5
   Law SKA, 1995, COMPLEMENT
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lengyel I, 2008, EXPERT REV OPHTHALMO, V3, P1, DOI 10.1586/17469899.3.1.1
   Li KY, 2008, J MOL BIOL, V384, P137, DOI 10.1016/j.jmb.2008.08.084
   Li KY, 2010, BIOCHEM J, V431, P63, DOI 10.1042/BJ20100759
   Luo C, 2011, MOL VIS, V17, P1588
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maret W, 2009, CHEM REV, V109, P4682, DOI 10.1021/cr800556u
   Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018
   Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277
   Nan R, 2011, J MOL BIOL, V408, P714, DOI 10.1016/j.jmb.2011.03.006
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8
   NEWSOME DA, 1992, CURR EYE RES, V11, P213, DOI 10.3109/02713689209001772
   Nolan EM, 2009, ACCOUNTS CHEM RES, V42, P193, DOI 10.1021/ar8001409
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Okemefuna AI, 2009, J MOL BIOL, V391, P98, DOI 10.1016/j.jmb.2009.06.010
   PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Perkins SJ, 2008, METHOD CELL BIOL, V84, P375, DOI 10.1016/S0091-679X(07)84013-1
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Perkins SJ, 2011, METHODS, V54, P181, DOI 10.1016/j.ymeth.2011.01.004
   Schmidt C, 2008, REV ECON POLIT, V118, P3
   Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X
   Sodhi JS, 2004, J MOL BIOL, V342, P307, DOI 10.1016/j.jmb.2004.07.019
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118
   Tsiftsoglou SA, 2004, J IMMUNOL, V173, P367, DOI 10.4049/jimmunol.173.1.367
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 74
TC 33
Z9 33
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 28
PY 2013
VL 288
IS 26
BP 19197
EP 19210
DI 10.1074/jbc.M113.476143
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 176WB
UT WOS:000321335800053
PM 23661701
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Nam, KT
   Chung, HW
   Jang, S
   Hwang, SY
   Kim, SW
   Oh, J
   Yun, C
AF Nam, Ki Tae
   Chung, Hyun Woo
   Jang, Sungmin
   Hwang, Soon-Young
   Kim, Seong-Woo
   Oh, Jaeryung
   Yun, Cheolmin
TI GANGLION CELL-INNER PLEXIFORM LAYER THICKNESS IN EYES WITH NONEXUDATIVE
   AGE-RELATED MACULAR DEGENERATION OF DIFFERENT DRUSEN SUBTYPES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; drusen; ganglion cell-inner plexiform
   layer thickness; pachydrusen; subretinal drusenoid deposit
ID GEOGRAPHIC ATROPHY; CHOROIDAL THICKNESS; CHORIOCAPILLARIS; DEPOSITS;
   MACULOPATHY; MORPHOLOGY
AB Purpose: We sought to investigate the ganglion cell-inner plexiform layer (GCIPL) thickness in eyes with nonexudative age-related macular degeneration. Methods: We classified eyes into four categories-pachydrusen, soft drusen, subretinal drusenoid deposit (SDD), and soft drusen with SDD-and compared the baseline mean macular GCIPL thickness according to the Early Treatment Diabetic Retinopathy Study grid and its change between groups. Results: We classified 53, 29, 36, and 34 eyes into the four categories, respectively. The mean GCIPL thickness values in the 3-mm area were 82.61 +/- 9.54 mu m for the pachydrusen group, 79.11 +/- 10.26 mu m for the soft drusen group, 77.72 +/- 6.04 mu m for the SDD group, and 71.63 +/- 8.69 mu m for the soft drusen with SDD group (P < 0.001). The soft drusen with the SDD group showed a greater change in GCIPL thickness (-2.50 +/- 0.29 mu m/year) in the 3-mm area as compared with the pachydrusen group (-0.18 +/- 0.35 mu m/year), soft drusen group (-0.55 +/- 0.36 mu m/year), and SDD group (-0.55 +/- 0.37) (all P < 0.001). Conclusion: The GCIPL thickness varied according to the type of nonexudative age-related macular degeneration. The thinner baseline GCIPL and its greater change in eyes with soft drusen with SDD may suggest that these eyes are experiencing more prominent neuroretinal degeneration in the central 3-mm area than those in the other groups.
C1 [Nam, Ki Tae; Chung, Hyun Woo; Kim, Seong-Woo; Oh, Jaeryung; Yun, Cheolmin] Korea Univ, Dept Ophthalmol, Coll Med, Seoul, South Korea.
   [Jang, Sungmin] Saevit Eye Hosp, Dept Ophthalmol, Goyang, South Korea.
   [Hwang, Soon-Young] Korea Univ, Dept Biostat, Coll Med, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Yun, C (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 123 Jeokgeum Ro, Ansan 15355, Gyeonggi Do, South Korea.
EM yuncheolmin@korea.ac.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562; Hwang, Soon Young/0000-0001-7474-1803
FU Korea University [K2011041]
FX Supported by a grant from Korea University (K2011041).
CR Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nam KT, 2020, RETINA-J RET VIT DIS, V40, P2270, DOI 10.1097/IAE.0000000000002758
   Pazos M, 2017, OPHTHALMOLOGY, V124, P1218, DOI 10.1016/j.ophtha.2017.03.044
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sayegh RG, 2017, AM J OPHTHALMOL, V179, P118, DOI 10.1016/j.ajo.2017.03.031
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xu XY, 2017, AM J OPHTHALMOL, V175, P87, DOI 10.1016/j.ajo.2016.11.021
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
NR 30
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2021
VL 41
IS 8
BP 1686
EP 1696
DI 10.1097/IAE.0000000000003100
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5JN
UT WOS:000711803800014
PM 33411476
DA 2022-11-30
ER

PT J
AU Wu, AK
   Perkins, SW
   Singh, S
   Singh, RP
AF Wu, Anna K.
   Perkins, Scott W.
   Singh, Sachin
   Singh, Rishi P.
TI The Impact of Early Residual Fluid After Anti- Vascular Endothelial
   Growth Factor Initiation in Patients With Neovascular Age-Related
   Macular Degeneration: A Meta-Analysis Review
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Review
ID SUBRETINAL FLUID; ANATOMIC OUTCOMES; VISUAL-ACUITY; RANIBIZUMAB; VEGF;
   QUANTIFICATION; PREDICTORS; EYES
AB Fluid in neovascular age-related macular degeneration is often used to assess patient response to anti-vascular endothelial growth factor therapy. Various studies theorize that early residual fluid (ERF), noted as persistence of intraretinal fluid and subretinal fluid after the anti-vascular endothelial growth factor loading phase (LP), may be predictive of visual outcomes. This meta-analysis examined the existing literature on the relationship between ERF and long-term visual acuity (VA) and found that those who were fluid-free after the LP tended to have the highest VA gains overall. Early intraretinal fluid appeared to be associated with reduced VA gains, whereas the impact of early sub-retinal fluid was more debated. For those with ERF, monthly or more frequent dosing regimens following the LP appeared most optimal for VA. As most studies in this review were post hoc analyses, this highlights the need for real-world studies investigating ERF and its effect on visual outcomes in neovascular age-related macular degeneration.
C1 [Wu, Anna K.] Case Western Univ, Sch Med, Cleveland, OH 44106 USA.
   [Wu, Anna K.; Singh, Sachin; Singh, Rishi P.] Cole Eye Inst, Ctr Ophthalm Bioinformat, Cleveland Clin, Cleveland, OH 44106 USA.
   [Perkins, Scott W.] Cleveland Clin Lerner Coll Med, Cleveland Hts, OH 44106 USA.
   [Singh, Rishi P.] Cole Eye Inst, Cleve land Clin, 9500 Euclid Ave, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Case
   Western Reserve University; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation
RP Singh, RP (通讯作者)，Cole Eye Inst, Cleve land Clin, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM singhr@ccf.org
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Core JQ, 2021, OPHTHALMOL RETINA, V5, P962, DOI 10.1016/j.oret.2021.06.003
   Dugel PU, 2022, RETINA-J RET VIT DIS, V42, P511, DOI 10.1097/IAE.0000000000003349
   Ehlers JP, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.3.29
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Iyer A, 2021, INVEST OPHTH VIS SCI, V62
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jhaveri C, 2022, AM J OPHTHALMOL, V236, P12, DOI 10.1016/j.ajo.2021.10.017
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kodjikian L, 2022, OPHTHALMOL RETINA, V6, P109, DOI 10.1016/j.oret.2021.04.015
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moshfeghi DM, 2016, OSLI RETINA, V47, P238, DOI 10.3928/23258160-20160229-06
   Ohji M, 2021, GRAEF ARCH CLIN EXP, V259, P3637, DOI 10.1007/s00417-021-05293-y
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Riedl S, 2022, OPHTHALMOL RETINA, V6, P291, DOI 10.1016/j.oret.2021.12.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saenz-de-Viteri M, 2021, ACTA OPHTHALMOL, V99, P861, DOI 10.1111/aos.14786
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Sharma A, 2020, RETINA-J RET VIT DIS, V40, P1451, DOI 10.1097/IAE.0000000000002870
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Staurenghi G, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0256461
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2022
VL 53
IS 9
BP 506
EP +
DI 10.3928/23258160-20220726-01
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 4Z5YM
UT WOS:000862283800005
PM 36107627
DA 2022-11-30
ER

PT J
AU Fujimura, S
   Ueta, T
   Takahashi, H
   Obata, R
   Smith, RT
   Yanagi, Y
AF Fujimura, Shigeto
   Ueta, Takashi
   Takahashi, Hidenori
   Obata, Ryo
   Smith, R. Theodore
   Yanagi, Yasuo
TI Characteristics of fundus autofluorescence and drusen in the fellow eyes
   of Japanese patients with exudative age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Fundus autofluorescence; Age-related macular degeneration; Typical
   age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Soft drusen; RPE abnormality
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; HIGH-RISK; 2ND EYE; LIPOFUSCIN;
   DISEASE; OPHTHALMOSCOPE; THERAPY
AB The main purpose of this study is to investigate the characteristics of fundus autofluorescence (FAF) and area of soft drusen among the fellow eyes of unilateral typical age-related macular degeneration (typical AMD) and polypoidal choroidal vasculopathy (PCV) in Japanese patients.
   FAF images were obtained from the fellow eyes of unilateral typical AMD (n = 64), unilateral PCV (n = 95), unilateral retinal angiomatous proliferation (RAP) (n = 4) and 56 control subjects, then classified into normal, minimal-change, and abnormal patterns by two graders. Interobserver variability between two graders and intraobserver variability were assessed for FAF classifications, and cases with inconsistent decisions were finally classified by the third grader. Soft drusen were segmented and their total areas were compared between the fellow eyes of typical AMD and PCV. Area(s) with increased autofluorescence were segmented to assess the relationship with soft drusen area(s).
   Assessment for interobserver variability between two graders and intraobserver variability in one grader showed substantial agreement (kappa = 0.70) and almost perfect agreement (kappa = 0.85), respectively. In the final decision mediated by third grader, the proportions of eyes with either minimal-change FAF pattern or abnormal FAF pattern in the fellow eyes of both typical AMD (37 cases, 58 %) and PCV (47 cases, 49 %) were significantly higher than that of the control cases (15 cases, 27 %; p < 0.01). The proportion of abnormal FAF pattern in the fellow eyes of typical AMD (20 cases, 31 %) was higher than that of PCV (15 cases, 16 %; p < 0.05). Total soft drusen areas in the fellow eyes of typical AMD (0.369 +/- 0.718 mm(2)) were larger than those of PCV (0.173 +/- 0.408 mm(2); p < 0.05), and those in the eyes with abnormal FAF pattern were larger than those with minimal-change FAF pattern or normal FAF pattern (p < 0.01). Image analysis revealed a relationship between increased autofluorescence and soft drusen, especially in the cases with large total soft drusen areas.
   FAF characteristics were different between the fellow eyes of unilateral typical AMD and PCV in Japan, which might be due to the difference of total soft drusen areas between them.
C1 [Fujimura, Shigeto; Ueta, Takashi; Takahashi, Hidenori; Obata, Ryo; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Smith, R. Theodore] NYU, Dept Ophthalmol, New York, NY 10016 USA.
C3 University of Tokyo; New York University
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Takahashi, Hidenori/H-2945-2019; Yanagi,
   Yasuo/AAF-2670-2020
OI Takahashi, Hidenori/0000-0001-5331-4730; Obata, Ryo/0000-0002-1762-0797;
   smith, theodore/0000-0002-1693-943X; Yanagi, Yasuo/0000-0002-0362-7285
FU Ministry of Education, Science, Sports, and Culture of Japan; Japan
   Society for the Promotion of Science
FX This work was supported in part by a grant-in-aid from the Ministry of
   Education, Science, Sports, and Culture of Japan, and Japan Society for
   the Promotion of Science.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Chen JA, 2010, IEEE T BIO-MED ENG, V57, P1707, DOI 10.1109/TBME.2010.2042169
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Heimes B, 2008, GRAEF ARCH CLIN EXP, V246, P1229, DOI 10.1007/s00417-008-0854-z
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   McBain VA, 2007, BRIT J OPHTHALMOL, V91, P491, DOI 10.1136/bjo.2006.095109
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 29
TC 6
Z9 8
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2013
VL 251
IS 12
BP 1
EP 9
DI 10.1007/s00417-013-2363-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 270US
UT WOS:000328345000001
PM 23677486
DA 2022-11-30
ER

PT J
AU Garcia-Layana, A
   Cabrera-Lopez, F
   Garcia-Arumi, J
   Arias-Barquet, L
   Ruiz-Moreno, JM
AF Garcia-Layana, Alfredo
   Cabrera-Lopez, Francisco
   Garcia-Arumi, Jose
   Arias-Barquet, Lluis
   Ruiz-Moreno, Jose M.
TI Early and intermediate age-related macular degeneration: update and
   clinical review
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE age-related macular degeneration; early AMD; intermediate AMD; risk
   factors; classification; prevention; nutritional supplementation
ID DIETARY FATTY-ACIDS; CIGARETTE-SMOKING; CADMIUM ACCUMULATION; OXIDATIVE
   STRESS; FISH CONSUMPTION; GENETIC RISK; ZINC; OMEGA-3-FATTY-ACIDS;
   SUSCEPTIBILITY; POLYMORPHISMS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in developed countries. With the aging of population, AMD will become globally an increasingly important and prevalent disease worldwide. It is a complex disease whose etiology is associated with both genetic and environmental risk factors. An extensive decline in the quality of life and progressive need of daily living assistance resulting from AMD among those most severely affected highlights the essential role of preventive strategies, particularly advising patients to quit smoking. In addition, maintaining a healthy diet, controlling other risk factors (such as hypertension, obesity, and atherosclerosis), and the use of nutritional supplements (antioxidants) are recommendable. Genetic testing may be especially important in patients with a family history of AMD. Recently, unifying criteria for the clinical classification of AMD, defining no apparent aging changes; normal aging changes; and early, intermediate, and late AMD stages, are of value in predicting AMD risk of progression and in establishing recommendations for the diagnosis, therapeutic approach, and follow-up of patients. The present review is focused on early and intermediate AMD and presents a description of the clinical characteristics and ophthalmological findings for these stages, together with algorithms for the diagnosis and management of patients, which are easily applicable in daily clinical practice.
C1 [Garcia-Layana, Alfredo] Clin Univ Navarra, Dept Ophthalmol, Ave Pio XII 36, E-31008 Pamplona, Spain.
   [Garcia-Layana, Alfredo] SERV, Madrid, Spain.
   [Garcia-Layana, Alfredo; Ruiz-Moreno, Jose M.] Inst Salud Carlos III, Red Telemat Invest Cooperat Oftared, Madrid, Spain.
   [Cabrera-Lopez, Francisco] Complejo Hosp Univ Insular Maternoinfantil Gran C, Serv Ophthalmol, Las Palmas Gran Canaria, Spain.
   [Cabrera-Lopez, Francisco] Las Palmas Gran Canaria Univ, Las Palmas Gran Canaria, Spain.
   [Garcia-Arumi, Jose] IMO, Dept Retina & Vitreous, Barcelona, Spain.
   [Garcia-Arumi, Jose] Univ Autonoma Barcelona, Dept Ophthalmol, Barcelona, Spain.
   [Garcia-Arumi, Jose] Hosp Univ Valle Hebron, Barcelona, Spain.
   [Arias-Barquet, Lluis] Hosp Univ Bellvitge, Serv Ophthalmol, Sect Med Surg Retina, Barcelona, Spain.
   [Arias-Barquet, Lluis] Univ Barcelona, Barcelona, Spain.
   [Ruiz-Moreno, Jose M.] Univ Castilla La Mancha, Albacete, Spain.
   [Ruiz-Moreno, Jose M.] Vissum Corp Oftalmol, Madrid, Spain.
C3 University of Navarra; Instituto de Salud Carlos III; Universidad de Las
   Palmas de Gran Canaria; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); Bellvitge University Hospital; University of
   Barcelona; University of Barcelona; Universidad de Castilla-La Mancha
RP Garcia-Layana, A (通讯作者)，Clin Univ Navarra, Dept Ophthalmol, Ave Pio XII 36, E-31008 Pamplona, Spain.
EM aglayana@unav.es
RI CABRERA LOPEZ, FRANCISCO/ABE-2892-2021
OI CABRERA LOPEZ, FRANCISCO/0000-0002-5074-5102; Garcia-Arumi,
   Jose/0000-0001-8827-1160; Ruiz-Moreno, Jose M/0000-0001-9636-0788
CR American Academy of Ophthalmology, AG REL MAC DEG PPP U
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Crooke A, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12430
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Dhubhghaill SSN, 2010, ADV EXP MED BIOL, V664, P437, DOI 10.1007/978-1-4419-1399-9_50
   Díaz-Llopis M., 2008, Arch Soc Esp Oftalmol, V83, P575
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frisen L, 2009, BRIT J OPHTHALMOL, V93, P714, DOI 10.1136/bjo.2008.149088
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Marshall Leisa L, 2013, Consult Pharm, V28, P723, DOI 10.4140/TCP.n.2013.723
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Nowomiejska K, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-13
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perlee LT, 2013, OPHTHALMOLOGY, V120, P1880, DOI 10.1016/j.ophtha.2013.02.007
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   Rim TH, 2017, BR J OPHTHALMOL
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Saxena N, 2015, INDIAN J OPHTHALMOL, V63, P516, DOI 10.4103/0301-4738.158533
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Simunovic MP, 2015, RETINA-J RET VIT DIS, V35, P1285, DOI 10.1097/IAE.0000000000000581
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   The Royal College of Ophthalmologists, AG REL MAC DEG GUID
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang Q, 2016, INT J OPHTHALMOL-CHI, V9, P298, DOI 10.18240/ijo.2016.02.23
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MX, 2016, OPHTHALMIC RES, V55, P135, DOI 10.1159/000442257
   Yeoh J, 2006, EXPERT OPIN PHARMACO, V7, P2355, DOI 10.1517/14656566.7.17.2355
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
NR 64
TC 70
Z9 72
U1 2
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2017
VL 12
BP 1579
EP 1587
DI 10.2147/CIA.S142685
PG 9
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA FJ0LM
UT WOS:000412400400003
PM 29042759
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Qiu, CX
   Cotch, MF
   Sigurdsson, S
   Eiriksdottir, G
   Jonasson, F
   Klein, R
   Klein, BEK
   Harris, TB
   van Buchem, MA
   Gudnason, V
   Launer, LJ
AF Qiu, Chengxuan
   Cotch, Mary Frances
   Sigurdsson, Sigurdur
   Eiriksdottir, Gudny
   Jonasson, Fridbert
   Klein, Ronald
   Klein, Barbara E. K.
   Harris, Tamara B.
   van Buchem, Mark A.
   Gudnason, Vilmundur
   Launer, Lenore J.
TI Cerebral microbleeds and age-related macular degeneration: the
   AGES-Reykjavik Study
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Age-related macular degeneration; Cerebral microbleeds; Amyloid-beta;
   The AGES-Reykjavik Study
AB We test the hypothesis that cerebral microbleeds (CMB) and age-related macular degeneration (AMD), both linked to amyloid-beta deposition, are correlated. This study includes 4205 participants (mean age 76.2; 57.8% women) in the Age, Gene/Environment Susceptibility (AGES)Reykjavik Study (2002-2006). CMB were assessed from magnetic resonance images, and AMD was assessed using digital retinal images. Data were analyzed with multinomial logistic models controlling for major confounders. Evidence of CMB was detected in 476 persons (272 with strict lobar CMB and 204 with nonlobar CMB). AMD was detected in 1098 persons (869 with early AMD, 140 with exudative AMD, and 89 with pure geographic atrophy). Early and exudative AMD were not associated with CMB. The adjusted odds ratio of pure geographic atrophy was 1.62 (95% confidence interval 0.93-2.82, p = 0.089) for having any CMB, 1.43 (0.66-3.06, p = 0.363) for strict lobar CMB, and 1.85 (0.89-3.87, p = 0.100) for nonlobar CMB. This study provides no evidence that amyloid deposits in the brain and AMD are correlated. However, the suggestive association of geographic atrophy with CMB warrants further investigation. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Qiu, Chengxuan] Stockholm Univ, Karolinska Inst, Aging Res Ctr, SE-11330 Stockholm, Sweden.
   [Qiu, Chengxuan; Harris, Tamara B.; Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, NIH, Bethesda, MD 20892 USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Sigurdsson, Sigurdur; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
   [Jonasson, Fridbert; Gudnason, Vilmundur] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Jonasson, Fridbert] Natl Univ Hosp Reykjavik, Dept Ophthalmol, Reykjavik, Iceland.
   [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [van Buchem, Mark A.] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands.
C3 Karolinska Institutet; Stockholm University; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Icelandic Heart Association; University of Iceland; Landspitali National
   University Hospital; University of Wisconsin System; University of
   Wisconsin Madison; Leiden University; Leiden University Medical Center
   (LUMC); Leiden University - Excl LUMC
RP Qiu, CX (通讯作者)，Stockholm Univ, Karolinska Inst, Aging Res Ctr, Gavlegatan 16, SE-11330 Stockholm, Sweden.
EM chengxuan.qiu@ki.se; launerl@nia.nih.gov
RI Gudnason, Vilmundur/AAE-7126-2019; Gudnason, Vilmundur/K-6885-2015; van
   Buchem, Mark/AAC-9843-2022; Jonasson, Fridbert/ABA-9889-2021
OI Gudnason, Vilmundur/0000-0001-5696-0084; Gudnason,
   Vilmundur/0000-0001-5696-0084; van Buchem, Mark/0000-0003-1881-1998;
   Cotch, Mary Frances/0000-0002-2046-4350; Qiu,
   Chengxuan/0000-0003-1922-4912; Klein, Ronald/0000-0002-4428-6237
FU NIH [N01-AG-12100]; National Institute on Aging; National Eye Institute,
   USA [ZIAEY000401]; Icelandic Heart Association; Icelandic Parliament,
   Iceland; Swedish Council for Working Life and Social Research; Swedish
   Research Council for Medical Research; Karolinska Institutet, Sweden;
   NATIONAL EYE INSTITUTE [ZIAEY000401] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON AGING [ZIAAG007420, N01AG012100, ZIAAG007270]
   Funding Source: NIH RePORTER
FX The AGES-Reykjavik Study was funded by NIH contract N01-AG-12100, the
   Intramural Research Program of the National Institute on Aging, and the
   National Eye Institute (ZIAEY000401), USA, and by the Icelandic Heart
   Association and the Icelandic Parliament, Iceland. We thank all the
   participants of the AGES-Reykjavik Study and the clinic staff at the
   Icelandic Heart Association for their invaluable contribution. C. Q. is
   supported by grants from the Swedish Council for Working Life and Social
   Research, the Swedish Research Council for Medical Research, and
   Karolinska Institutet, Sweden.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Harris TB, 2007, AM J EPIDEMIOL, V165, P1076, DOI 10.1093/aje/kwk115
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
NR 3
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD DEC
PY 2012
VL 33
IS 12
BP 2935
EP 2937
DI 10.1016/j.neurobiolaging.2012.01.012
PG 3
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 025OJ
UT WOS:000310200000019
PM 22382405
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shima, N
   Markowitz, SN
   Reyes, SV
AF Shima, Noboru
   Markowitz, Samuel N.
   Reyes, Sophia V.
TI Residual colour detection abilities in age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID VISUAL-ACUITY; LOW-VISION; RECOGNITION
AB Objective: To quantify residual abilities to identify a target's colour in cases with age-related macular degeneration (AMD).
   Methods: Subjects with AMD with best corrected visual acuity (BCVA) of 20/50 to 20/400 in the better eye (test eye) and age older than 55 years were recruited. A separate matching control group was recruited with subjects with BCVA of 20/40 or better. Each subject was presented sequentially with square-shaped colour targets corresponding in size to optotype sizes used in standard Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing protocols, all against a white background. Four major colour hues were selected for testing: blue, yellow, green, and red. The same subjects were tested with standard ETDRS targets (black on white), and results served as control group references. The primary outcome measure selected for analysis was the minimum angle of resolution (MAR) required to correctly identify the hue presented.
   Results: Forty study subjects (14 males and 26 females) aged 55 to 95 years (mean 79.45 years, SD 8.82) were recruited. Thirty similar subjects were recruited for a control group. Red on white estimates were better than for other colours and related best to standard black on white ETDRS estimates (20/121 vs 20/132, respectively). Also, red on white estimates seem not to be affected by age. Estimates for colour detection for the control group were not different among colours tested and were not affected by age.
   Conclusions: Ranking abilities according to the MAR required to identify a hue can serve as a quantifying measure for residual colour vision. Our findings reflect functional abilities rather than psychophysical measurements.
C1 [Shima, Noboru; Markowitz, Samuel N.; Reyes, Sophia V.] Univ Toronto, Univ Hlth Network Hosp, Dept Ophthalmol & Vis Sci, Low Vis Serv, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
FU Eye Foundation of Canada
FX This work was supported by an unrestricted research grant from the Eye
   Foundation of Canada.
CR Cavanagh P, 1996, NATURE, V379, P26, DOI 10.1038/379026a0
   CHAPARRO A, 1993, NATURE, V361, P348, DOI 10.1038/361348a0
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Eperjesi F, 2002, OPHTHAL PHYSL OPT, V22, P68, DOI 10.1046/j.1475-1313.2002.00004.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Oliva A, 2000, COGNITIVE PSYCHOL, V41, P176, DOI 10.1006/cogp.1999.0728
   WURM LH, 1993, J EXP PSYCHOL HUMAN, V19, P899, DOI 10.1037/0096-1523.19.4.899
NR 8
TC 0
Z9 0
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2013
VL 48
IS 4
BP 274
EP 278
DI 10.1016/j.jcjo.2013.03.006
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OI
UT WOS:000331148900028
PM 23931466
DA 2022-11-30
ER

PT J
AU Rahimy, E
   Rayess, N
   Ho, AC
   Regillo, CD
AF Rahimy, Ehsan
   Rayess, Nadim
   Ho, Allen C.
   Regillo, Carl D.
TI TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
   PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND
   REGIMEN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE macular degeneration; choroidal neovascularization; ranibizumab;
   bevacizumab; treat-and-extend; visual acuity
ID LINE VISUAL-ACUITY; GROWTH-FACTOR THERAPY; INTRAVITREAL BEVACIZUMAB;
   RANIBIZUMAB TREATMENT; DOSING REGIMEN; TRIAL; EYE
AB Purpose: To determine treatment outcomes in eyes with neovascular age-related macular degeneration having visual acuity better than 20/40 after 1 years to 2 years of ranibizumab or bevacizumab therapy using a treat-and-extend regimen.
   Methods: Retrospective observational case series. Clinical records were reviewed from patients with treatment-naive neovascular age-related macular degeneration and baseline best-corrected Snellen visual acuity >20/40 treated with intravitreal ranibizumab or bevacizumab for a minimum of 1 year using a treat-and-extend regimen. The primary outcome measures were change from initial visual acuity, proportion of eyes losing,3 best-corrected visual acuity lines, proportion of eyes maintaining visual acuity >= 20/40, change from baseline central retinal thickness, and mean number of injections after 1 years and 2 years of follow-up.
   Results: A total of 42 eyes from 40 patients were included. The mean follow-up period was 1.44 years. The mean initial logMAR visual acuity was 0.226, and remained stable at 0.257 and 0.267 after 1 years and 2 years of follow-up, respectively. At baseline, mean central retinal thickness was 305.8 mu m, improved to 272.6 mu m after 1 year of treatment (P < 0.001), and remained stable at 266.2 mu m (P = 0.015) after 2 years. At 1-year follow-up period, 94.4% of eyes had lost less than 3 Snellen lines, and 94.1% of eyes lost less than 3 Snellen lines after 2 years. The percentage of eyes maintaining visual acuity >= 20/40 was 81% and 75% after each year. Eyes received on average 7.8 injections during the first year of treatment and 6.1 injections over the second year.
   Conclusion: Eyes with neovascular age-related macular degeneration presenting with initial visual acuity better than 20/40 on average maintained vision, lost less than 3 lines of acuity, and achieved anatomical improvements using a treat-and-extend regimen over a 2-year period.
C1 [Rahimy, Ehsan; Rayess, Nadim; Ho, Allen C.; Regillo, Carl D.] Thomas Jefferson Univ, Retina Serv Wills Eye Hosp, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
C3 Jefferson University
RP Regillo, CD (通讯作者)，Thomas Jefferson Univ, Retina Serv Wills Eye Hosp, Mid Atlantic Retina, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM CRegillo@midatlanticretina.com
OI Ho, Allen/0000-0003-3921-608X; Rahimy, Ehsan/0000-0001-8446-7078
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Axer-Siegel R, 2012, RETINA-J RET VIT DIS, V32, P1811, DOI 10.1097/IAE.0b013e31825db771
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   El-Mollayess GM, 2013, RETINA-J RET VIT DIS, V33, P1828, DOI 10.1097/IAE.0b013e3182877a0d
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Raja MSA, 2010, BRIT J OPHTHALMOL, V94, P1543, DOI 10.1136/bjo.2009.174763
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stone TW, 2014, 2014 PREFERENCES TRE
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 31
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2016
VL 36
IS 5
BP 875
EP 880
DI 10.1097/IAE.0000000000000814
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL2RG
UT WOS:000375482100011
PM 26630316
DA 2022-11-30
ER

PT J
AU Askou, AL
   Alsing, S
   Holmgaard, A
   Bek, T
   Corydon, TJ
AF Askou, Anne Louise
   Alsing, Sidsel
   Holmgaard, Andreas
   Bek, Toke
   Corydon, Thomas J.
TI Dissecting microRNA dysregulation in age-related macular degeneration:
   new targets for eye gene therapy
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; gene regulation; gene therapy;
   inflammation; microRNA; neovascularization; oxidative stress;
   therapeutic targets
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULARIZATION; RETINAL NEOVASCULARIZATION; MACROPHAGE POLARIZATION;
   DIABETIC-RETINOPATHY; EXPRESSION PROFILES; VITREOUS-HUMOR; SEED REGION;
   ANGIOGENESIS
AB MicroRNAs (miRNAs) are key regulators of gene expression in humans. Overexpression or depletion of individual miRNAs is associated with human disease. Current knowledge suggests that the retina is influenced by miRNAs and that dysregulation of miRNAs as well as alterations in components of the miRNA biogenesis machinery are involved in retinal diseases, including age-related macular degeneration (AMD). Furthermore, recent studies have indicated that the vitreous has a specific panel of circulating miRNAs and that this panel varies according to the specific pathological stress experienced by the retinal cells. MicroRNA (miRNA) profiling indicates subtype-specific miRNA profiles for late-stage AMD highlighting the importance of proper miRNA regulation in AMD. This review will describe the function of important miRNAs involved in inflammation, oxidative stress and pathological neovascularization, the key molecular mechanisms leading to AMD, and focus on dysregulated miRNAs as potential therapeutic targets in AMD.
C1 [Askou, Anne Louise; Alsing, Sidsel; Holmgaard, Andreas; Corydon, Thomas J.] Aarhus Univ, Dept Biomed, Bartholins Alle 6, DK-8000 Aarhus C, Denmark.
   [Bek, Toke] Aarhus Univ Hosp, Dept Ophthalmol, Aarhus C, Denmark.
C3 Aarhus University; Aarhus University
RP Corydon, TJ (通讯作者)，Aarhus Univ, Dept Biomed, Bartholins Alle 6, DK-8000 Aarhus C, Denmark.
EM corydon@biomed.au.dk
RI Askou, Anne/AGW-2995-2022
OI Askou, Anne Louise/0000-0002-5512-1796; Corydon, Thomas
   Juhl/0000-0003-3588-6350; Bek, Toke/0000-0002-0409-2534
FU Gene Therapy Initiative Aarhus (GTI-Aarhus) - Lundbech Foundation
   [R126-2012-12456]; Danish Eye Foundations; Lundbeck Foundation
   [R165-2013-15631]
FX This work was supported by the Gene Therapy Initiative Aarhus
   (GTI-Aarhus) funded by the Lundbech Foundation (TJC. Grant No.
   R126-2012-12456), the Danish Eye Foundations (TJC) and the Lundbeck
   Foundation (ALA. Grant No. R165-2013-15631).
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803
   Arora A, 2007, INVEST OPHTH VIS SCI, V48, P3962, DOI 10.1167/iovs.06-1221
   Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Askou AL, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2014.64
   Askou AL, 2014, ACTA OPHTHALMOL, V92, P1, DOI 10.1111/aos.12452
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bak RO, 2014, WIRES RNA, V5, P317, DOI 10.1002/wrna.1213
   Bak RO, 2013, MOL THER, V21, P1478, DOI 10.1038/mt.2013.113
   Bak RO, 2013, RNA, V19, P280, DOI 10.1261/rna.034850.112
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   Bykhovskaya Y, 2015, OPHTHALMIC GENET, V36, P244, DOI 10.3109/13816810.2013.848908
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Caruso P, 2010, ARTERIOSCL THROM VAS, V30, P716, DOI 10.1161/ATVBAHA.109.202028
   Cassetta L, 2011, THESCIENTIFICWORLDJO, V11, P2391, DOI 10.1100/2011/213962
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344
   Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200
   Cheng YH, 2009, J MOL CELL CARDIOL, V47, P5, DOI 10.1016/j.yjmcc.2009.01.008
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Conte I, 2015, P NATL ACAD SCI USA, V112, pE3236, DOI 10.1073/pnas.1401464112
   Corydon TJ, 2015, HUM GENE THER, V26, P525, DOI 10.1089/hum.2015.064
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dong A, 2014, ANGIOGENESIS, V17, P553, DOI 10.1007/s10456-013-9402-5
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ehlert EM, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-20
   Ellis-Behnke Rutledge G, 2013, J Glaucoma, V22 Suppl 5, pS32, DOI 10.1097/IJG.0b013e3182934aca
   Ertekin S, 2014, MOL VIS, V20, P1057
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Federici C, 2009, INT J CANCER, V124, P2804, DOI 10.1002/ijc.24255
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Foulkes WD, 2014, NAT REV CANCER, V14, P662, DOI 10.1038/nrc3802
   FRITSCHE LG, 2013, NAT GENET 45 433 439, V439, P1
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Garcia M, 2015, ACTA OPHTHALMOL, V93, pE658, DOI 10.1111/aos.12790
   Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980
   Gordiyenko NV, 2010, INVEST OPHTH VIS SCI, V51, P1143, DOI 10.1167/iovs.09-4117
   Gorospe M, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00007
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Guduric-Fuchs J, 2012, J CELL BIOCHEM, V113, P2098, DOI 10.1002/jcb.24084
   Guedes J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/186872
   Hackler L, 2010, INVEST OPHTH VIS SCI, V51, P1823, DOI 10.1167/iovs.09-4657
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haque R, 2015, MOL VIS, V21, P224
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105
   Hauberg ME, 2016, EUR NEUROPSYCHOPHARM, V26, P1522, DOI 10.1016/j.euroneuro.2016.06.014
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hautamaki A, 2015, ACTA OPHTHALMOL, V93, P726, DOI 10.1111/aos.12799
   Hirota K, 2015, GRAEF ARCH CLIN EXP, V253, P335, DOI 10.1007/s00417-014-2692-5
   Ho JJD, 2012, J BIOL CHEM, V287, P29003, DOI 10.1074/jbc.M112.373365
   Hollensen AK, 2013, RNA BIOL, V10, P406, DOI 10.4161/rna.23543
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Hou Q, 2013, INVEST OPHTH VIS SCI, V54, P6481, DOI 10.1167/iovs.13-11873
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Hughes AE, 2011, AM J HUM GENET, V89, P628, DOI 10.1016/j.ajhg.2011.09.014
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Iannaccone A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145323
   Iliff BW, 2012, INVEST OPHTH VIS SCI, V53, P348, DOI 10.1167/iovs.11-8783
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakob P, 2012, CIRCULATION, V126, P2962, DOI 10.1161/CIRCULATIONAHA.112.093906
   Kandalam MM, 2012, MOL VIS, V18, P2279
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Karali M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-715
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly TJ, 2011, MOL CELL BIOL, V31, P2696, DOI 10.1128/MCB.01242-10
   Kim JH, 2014, ANTIOXID REDOX SIGN, V21, P2469, DOI 10.1089/ars.2014.5856
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Kovacs B, 2011, INVEST OPHTH VIS SCI, V52, P4402, DOI 10.1167/iovs.10-6879
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Kutty RK, 2013, MOL VIS, V19, P737
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Kutty RK, 2010, MOL VIS, V16, P1475
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Li P, 2011, MOL BIOL REP, V38, P355, DOI 10.1007/s11033-010-0115-1
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lin ST, 2009, DIS MODEL MECH, V2, P178, DOI 10.1242/dmm.001065
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Liu GD, 2013, INT J OPHTHALMOL-CHI, V6, P280, DOI 10.3980/j.issn.2222-3959.2013.03.05
   Londin E, 2015, P NATL ACAD SCI USA, V112, pE1106, DOI 10.1073/pnas.1420955112
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lukiw WJ, 2007, J INORG BIOCHEM, V101, P1265, DOI 10.1016/j.jinorgbio.2007.06.004
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Marion S, 2011, TRAFFIC, V12, P421, DOI 10.1111/j.1600-0854.2011.01158.x
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martin JN, 2011, GENE THER, V18, P666, DOI 10.1038/gt.2011.10
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mocharla P, 2013, BLOOD, V121, P226, DOI 10.1182/blood-2012-01-407106
   Moffett HF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-221
   Mu GY, 2010, HUM PATHOL, V41, P493, DOI 10.1016/j.humpath.2009.08.022
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Munch IC, 2016, ACTA OPHTHALMOL, V94, P657, DOI 10.1111/aos.13198
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Murray AR, 2013, INVEST OPHTH VIS SCI, V54, P1689, DOI 10.1167/iovs.12-10921
   Nomura T, 2008, HUM MOL GENET, V17, P1192, DOI 10.1093/hmg/ddn011
   Nunes DN, 2015, P NATL ACAD SCI USA, V112, P3770, DOI 10.1073/pnas.1500008112
   Otani A, 1999, INVEST OPHTH VIS SCI, V40, P1912
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Pandi SPS, 2013, INVEST OPHTH VIS SCI, V54, P8140, DOI 10.1167/iovs.13-12631
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pihlmann M, 2012, J GENE MED, V14, P328, DOI 10.1002/jgm.2623
   Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266
   Ragusa M, 2013, MOL VIS, V19, P430
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253
   Ryan D, 2006, MOL VIS, V12, P1175
   Sabatel C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016979
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shalom-Feuerstein R, 2012, STEM CELLS, V30, P898, DOI 10.1002/stem.1068
   Shao Y, 2015, J MOL NEUROSCI, V56, P461, DOI 10.1007/s12031-015-0522-9
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Takahashi Y, 2015, FEBS LETT, V589, P1143, DOI 10.1016/j.febslet.2015.03.010
   Tan C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119210
   Tang YH, 2009, INT HEART J, V50, P377, DOI 10.1536/ihj.50.377
   Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tian B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160887
   Tugal D, 2013, ARTERIOSCL THROM VAS, V33, P1135, DOI 10.1161/ATVBAHA.113.301453
   Wang L, 2016, J PHYSIOL BIOCHEM, V72, P583, DOI 10.1007/s13105-016-0496-2
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang P, 2013, MOL CELL BIOL, V33, P3689, DOI 10.1128/MCB.00343-13
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26909
   Westenskow PD, 2013, J CLIN INVEST, V123, P4900, DOI 10.1172/JCI70230
   Wu C, 2011, MOL CELL BIOL, V31, P4760, DOI 10.1128/MCB.05776-11
   Yan LL, 2015, J BIOL CHEM, V290, P23264, DOI 10.1074/jbc.M115.646950
   Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang L, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-211
   Zhao JJ, 2008, CHILD NERV SYST, V24, P485, DOI 10.1007/s00381-007-0520-5
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhou QY, 2012, INVEST OPHTH VIS SCI, V53, P5665, DOI 10.1167/iovs.12-9832
   Zhuang Z, 2015, MOL VIS, V21, P1173
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 166
TC 25
Z9 26
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2018
VL 96
IS 1
BP 9
EP 23
DI 10.1111/aos.13407
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FT3SB
UT WOS:000423066600024
PM 28271607
OA Bronze
DA 2022-11-30
ER

PT J
AU Moisseiev, E
   Katz, G
   Moisseiev, J
   Loewenstein, A
   Goldstein, M
   Lomnicky, Y
   Abend, Y
   Treister, G
   Goldenberg, D
   Levkovitch-Verbin, H
AF Moisseiev, Elad
   Katz, Gabriel
   Moisseiev, Joseph
   Loewenstein, Anat
   Goldstein, Michaella
   Lomnicky, Yosef
   Abend, Yitzhak
   Treister, Giora
   Goldenberg, Dafna
   Levkovitch-Verbin, Hana
TI SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
   FROM BEVACIZUMAB TO RANIBIZUMAB Who is Likely to Benefit From the
   Switch?
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; ranibizumab; age-related macular degeneration; switch
ID INTRAVITREAL BEVACIZUMAB; AFLIBERCEPT; TACHYPHYLAXIS; OUTCOMES; THERAPY
AB Purpose:To evaluate the safety and efficacy of switching from bevacizumab to ranibizumab in patients with neovascular age-related macular degeneration.Methods:Retrospective study of patients with neovascular age-related macular degeneration initially treated with bevacizumab and switched to ranibizumab. Visual acuity and central retinal thickness (CRT) were retrieved at four time points: before the last three bevacizumab injections, at the switch, after the first three ranibizumab injections, and at the end of follow-up.Results:One hundred and fourteen eyes of 110 patients were included. Switching from bevacizumab to ranibizumab did not achieve a significant change in visual acuity, and a significant reduction in CRT was achieved after the first three injections but was not maintained by the end of follow-up. Eyes that lost 0.1 logMAR before the switch were more likely to improve in visual acuity (P = 0.013), and eyes with 10% increase in CRT before the switch were more likely to improve anatomically (P = 0.0003). In 47.3% of the eyes, the CRT was reduced by 10% after the first 3 ranibizumab injections, and the reduction was maintained with additional injections.Conclusion:Switching to ranibizumab should be considered in patients with visual acuity decrease or CRT increase, despite monthly bevacizumab injections. The response should be evaluated after the first three injections to guide future treatment.
C1 [Moisseiev, Elad; Loewenstein, Anat; Goldstein, Michaella; Goldenberg, Dafna] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
   [Moisseiev, Elad; Katz, Gabriel; Moisseiev, Joseph; Loewenstein, Anat; Goldstein, Michaella; Goldenberg, Dafna; Levkovitch-Verbin, Hana] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
   [Katz, Gabriel; Moisseiev, Joseph; Levkovitch-Verbin, Hana] Chaim Sheba Med Ctr, Dept Ophthalmol, Ramat Gan, Israel.
   [Katz, Gabriel; Treister, Giora; Goldenberg, Dafna] Assuta Med Ctr, Tel Aviv, Israel.
   [Lomnicky, Yosef; Abend, Yitzhak; Levkovitch-Verbin, Hana] Maccabi Healthcare Serv, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim
   Sheba Medical Center
RP Moisseiev, E (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Weitzman 6 St, IL-64239 Tel Aviv, Israel.
EM elad_moi@netvision.net.il
RI Yiu, Glenn/AAF-2858-2020
CR Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   de Geus SJR, 2013, ACTA OPHTHALMOL, V91, pE411, DOI 10.1111/aos.12090
   Ehlers JP, 2012, OPHTHAL SURG LAS IM, V41, P182
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Karagiannis DA, 2009, CLIN INTERV AGING, V4, P457
   Karagiannis DA, 2009, OPHTHALMOLOGICA, V223, P279, DOI 10.1159/000213644
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Krzystolik MG, 2007, OPHTHALMOLOGY, V114, P1520, DOI 10.1016/j.ophtha.2006.10.055
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 26
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1323
EP 1330
DI 10.1097/IAE.0000000000000500
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600005
PM 26102434
DA 2022-11-30
ER

PT J
AU Hahn, P
   Qian, Y
   Dentchev, T
   Chen, L
   Beard, J
   Harris, ZL
   Dunaief, JL
AF Hahn, P
   Qian, Y
   Dentchev, T
   Chen, L
   Beard, J
   Harris, ZL
   Dunaief, JL
TI Disruption of ceruloplasmin and hephaestin in mice causes retinal iron
   overload and retinal degeneration with features of age-related macular
   degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; PIGMENT EPITHELIUM; EXPRESSION; DEFICIENCY;
   INJURY; EFFLUX; RATS; GENE; FERRITIN; MODEL
AB Mechanisms of brain and retinal iron homeostasis have become subjects of increased interest after the discovery of elevated iron levels in brains of patients with Alzheimer's disease and retinas of patients with age-related macular degeneration. To determine whether the ferroxidase ceruloplasmin (Cp) and its homolog hephaestin (Heph) are important for retinal iron homeostasis, we studied retinas from mice deficient in Cp and/or Heph. In normal mice, Cp and Heph localize to Muller glia and retinal pigment epithelium, a blood-brain barrier. Mice deficient in both Cp and Heph, but not each individually, had a striking, age-dependent increase in retinal pigment epithelium and retinal iron. The iron storage protein ferritin was also increased in Cp-/-Heph-/Y retinas. After retinal iron levels had increased, Cp-/-Heph-/Y mice had age-dependent retinal pigment epithelium hypertrophy, hyperplasia and death, photoreceptor degeneration, and subretinal neovascularization, providing a model of some features of the human retinal diseases aceruloplasminemia and age-related macular degeneration. This pathology indicates that Cp and Heph are critical for CNS iron homeostasis and that loss of Cp and Heph in the mouse leads to age-dependent retinal neurodegeneration, providing a model that can be used to test the therapeutic efficacy of iron chelators and antiangiogenic agents.
C1 Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophtalmol, Philadelphia, PA 19104 USA.
   Penn State Univ, Coll Hlth & Human Dev, Dept Nutr, University Pk, PA 16802 USA.
   Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Div Pediat Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Pennsylvania State University - University Park; Johns
   Hopkins University
RP Dunaief, JL (通讯作者)，Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophtalmol, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768; Hahn, Paul/0000-0002-6574-388X;
   Harris, Zena Leah/0000-0003-0110-8438
FU NEI NIH HHS [EY015240, K08 EY000417, EY00417, R01 EY015240] Funding
   Source: Medline; NIDDK NIH HHS [R01 DK058086, DK02464] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R01EY015240] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [K08DK002464] Funding Source: NIH RePORTER
CR Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   CHEN H, 2004, IN PRESS BLOOD
   Chen L, 2003, MOL VIS, V9, P151
   DOLY M, 1986, OPHTHALMIC RES, V18, P21, DOI 10.1159/000265409
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Erikson KM, 1997, J NUTR, V127, P2030, DOI 10.1093/jn/127.10.2030
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Han J, 2002, J NUTR, V132, P2769, DOI 10.1093/jn/132.9.2769
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200
   Kaur D, 2003, NEURON, V37, P899, DOI 10.1016/S0896-6273(03)00126-0
   Klomp LWJ, 1996, HUM MOL GENET, V5, P1989, DOI 10.1093/hmg/5.12.1989
   Klomp LWJ, 1996, J CLIN INVEST, V98, P207, DOI 10.1172/JCI118768
   Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157
   MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761
   MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515
   Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185
   Patel BN, 2002, J NEUROSCI, V22, P6578
   Perry G, 2002, CNS DRUGS, V16, P339, DOI 10.2165/00023210-200216050-00006
   RAWSON AJ, 1993, ECOTOX ENVIRON SAFE, V25, P41, DOI 10.1006/eesa.1993.1005
   Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5
   Sarkar J, 2003, J BIOL CHEM, V278, P44018, DOI 10.1074/jbc.M304926200
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   TAWARA A, 1986, INVEST OPHTH VIS SCI, V27, P226
   VERGARA O, 1989, EXP EYE RES, V49, P1115, DOI 10.1016/S0014-4835(89)80030-2
   Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
NR 31
TC 217
Z9 223
U1 1
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 21
PY 2004
VL 101
IS 38
BP 13850
EP 13855
DI 10.1073/pnas.0405146101
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 856UF
UT WOS:000224069800029
PM 15365174
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Smith, RT
   Sohrab, MA
   Pumariega, N
   Chen, Y
   Chen, JA
   Lee, N
   Laine, A
AF Smith, R. Theodore
   Sohrab, Mahsa A.
   Pumariega, Nicole
   Chen, Yue
   Chen, Jian
   Lee, Noah
   Laine, Andrew
TI Dynamic soft drusen remodelling in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AUTOFLUORESCENCE CHARACTERISTICS; LASER PHOTOCOAGULATION; GRADING
   SYSTEM; MACULOPATHY; IMAGES; RECONSTRUCTION; ABNORMALITIES;
   REGISTRATION; PROGNOSIS; TRIAL
AB Aims To demonstrate and quantify the dynamic remodelling process of soft drusen resorption and new drusen formation in age-related macular degeneration (AMD) with novel interactive methods.
   Methods Twenty patients with large soft drusen bilaterally and without advanced AMD were imaged at baseline and again at a mean interval of 2 years (40 eyes, 80 images). Each of the 40 serial pairs of images was precisely registered by an automated technique. The drusen were segmented by a user-interactive method based on a background levelling algorithm and classified into three groups: new drusen (only in the final image), resorbed drusen (present initially but not in the final image) and stable drusen (present in both images). We measured each of these classes as well as the absolute change in drusen broken vertical bar D1 - D0 broken vertical bar and the dynamic drusen activity (creation and resorption) D(new) + D(resorbed).
   Results Mean dynamic activity for the right eye (OD) was 7.33 +/- 5.50%, significantly greater than mean absolute change (2.71 +/- 2.89%, p=0.0002, t test), with similar results for the left eye (OS). However, dynamic activity OD compared with OS (mean 7.33 +/- 5.50 vs 7.91 +/- 4.16%, NS) and absolute net change OD versus OS (2.71 +/- 2.89 vs 3.46 +/- 3.97%, NS) tended to be symmetrical between fellow eyes.
   Conclusions Dynamic remodelling processes of drusen resorption and new drusen formation are distinct disease activities that can occur simultaneously and are not captured by change in total drusen load. Dynamic changes occur at rates more than twice that of net changes, and may be a useful marker of disease activity.
C1 [Smith, R. Theodore; Sohrab, Mahsa A.; Pumariega, Nicole; Chen, Yue] Columbia Univ, Harkness Eye Inst, Dept Ophthalmol, New York, NY 10032 USA.
   [Pumariega, Nicole; Chen, Jian; Lee, Noah; Laine, Andrew] Columbia Univ, Dept Biomed Engn, Fu Fdn SEAS, New York, NY 10032 USA.
   [Chen, Jian] Chinese Acad Sci, Inst Automat, Beijing, Peoples R China.
C3 Columbia University; Columbia University; Chinese Academy of Sciences;
   Institute of Automation, CAS
RP Smith, RT (通讯作者)，Columbia Univ, Harkness Eye Inst, Dept Ophthalmol, 160 Ft Washington Ave,Room 509C, New York, NY 10032 USA.
EM rts1@columbia.edu
RI Lee, Noah/AAG-9697-2022; Lee, Noah/AEX-3553-2022
OI smith, theodore/0000-0002-1693-943X
FU New York Community Trust (New York, USA); National Eye Institute
   (Bethesda, Maryland, USA) [R01 EY015520]; National Institutes of Health;
   Research to Prevent Blindness (New York, USA); NATIONAL EYE INSTITUTE
   [R01EY015520] Funding Source: NIH RePORTER
FX Supported by grants from The New York Community Trust (New York, USA),
   National Eye Institute Grant R01 EY015520 (Bethesda, Maryland, USA) and
   the National Institutes of Health, and unrestricted funds from Research
   to Prevent Blindness (New York, USA). The funding organisations had no
   role in the design or conduct of this research.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chen J, 2008, IEEE ENG MED BIO, P2242, DOI 10.1109/IEMBS.2008.4649642
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   *GROUP A REDSR, 2001, AM J OPHTHALMOL, V132, P668
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   Pluim JPW, 2003, IEEE T MED IMAGING, V22, P986, DOI 10.1109/TMI.2003.815867
   PUMARIEGA NM, 2009, INVEST OPHTH VIS SCI, V50, pE306
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2009, INVEST OPHTH VIS SCI, V50, P3907, DOI 10.1167/iovs.08-2448
   Smith RT, 2005, INVEST OPHTH VIS SCI, V46, P2940, DOI 10.1167/iovs.04-0778
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Smith RT, 2004, J BIOMED OPT, V9, P162, DOI 10.1117/1.1630604
   UY K, 2006, INVEST OPHTH VIS SCI, V47, pE5715
NR 24
TC 17
Z9 19
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2010
VL 94
IS 12
BP 1618
EP 1623
DI 10.1136/bjo.2009.166843
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 683IJ
UT WOS:000284469000014
PM 20530179
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Birch, DG
   Toler, SM
   Swanson, WH
   Fish, GE
   Laties, AM
AF Birch, DG
   Toler, SM
   Swanson, WH
   Fish, GE
   Laties, AM
TI A double-blind placebo-controlled evaluation of the acute effects of
   sildenafil citrate (VIAGRA) on visual function in subjects with
   early-stage age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAOCULAR-PRESSURE; SAFETY
AB PURPOSE: To assess the effects of a single 100-mg dose of sildenafil citrate on visual function in men with early-stage age,related macular degeneration.
   DESIGN: Randomized double,blind placebo,controlled clinical trial.
   METHODS: Nine men (mean age 71 years, range 59-85 years) with early-stage (minimal visual impairment and large drusen in the macula) age,related macular degeneration and 20/40 or better-corrected visual acuity in at least one eye were prospectively randomized to receive either placebo or sildenafil citrate (Viagra; Pfizer Inc, New York, New York) 100 mg as a single oral dose. After 7-14 days, they received the alternate treatment. Subjects underwent visual acuity, Amsler grid, color discrimination (D15), traffic light, Humphrey perimetry, and photo,stress testing in each eye before and at specific intervals within 8 hours after dosing.
   RESULTS: Compared with placebo, no pattern of errors were evident in any visual function test following sildenafil administration. No statistically or clinically relevant changes from baseline were observed in visual acuity, Humphrey perimetry (corrected pattern standard deviation), D 15 color discrimination, or photo-stress tests. No clinically relevant changes were observed in the Amsler grid or traffic light tests. Sildenafil treatment was associated with transient mild or moderate headache, flushing, and rhinitis. There were no visual adverse events spontaneously reported to the investigator.
   CONCLUSION: A single 100,mg dose of sildenafil was well tolerated and produced no acute visual effects or exacerbation of preexisting visual impairment in nine men with early,stage age related macular degeneration.
C1 Retina Fdn SW, Dallas, TX 75231 USA.
   Pfizer Ltd, Groton, CT USA.
   SUNY Coll Optometry, Dept Clin Serv, New York, NY 10010 USA.
   Univ Penn, Sch Med, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 Retina Foundation of the Southwest; Pfizer; State University of New York
   (SUNY) System; SUNY Optometry; University of Pennsylvania
RP Birch, DG (通讯作者)，Retina Fdn SW, 9900 N Cent Expressway,Suite 400, Dallas, TX 75231 USA.
EM dbirch@retinafoundation.org
OI Swanson, William/0000-0003-1331-3658; Birch, David/0000-0002-6594-2897
CR Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3
   *COMM INT ECL, 1988, PUB N CIE, P79
   Cunningham AV, 2001, J NEURO-OPHTHALMOL, V21, P22, DOI 10.1097/00041327-200103000-00006
   Egan R, 2000, ARCH OPHTHALMOL-CHIC, V118, P291
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fraunfelder FT, 2001, DRUG INDUCED OCULAR, P367
   GLASER JS, 1977, AM J OPHTHALMOL, V83, P255, DOI 10.1016/0002-9394(77)90624-9
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   Grunwald JE, 2001, AM J OPHTHALMOL, V132, P872, DOI 10.1016/S0002-9394(01)01268-5
   Kretschmann U, 1999, INVEST OPHTH VIS SCI, V40, pS766
   Laties A EP, 1998, OPHTHALMIC RES, V30, P177
   Luu JK, 2001, AM J OPHTHALMOL, V132, P388, DOI 10.1016/S0002-9394(01)01052-2
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   Morales A, 1998, INT J IMPOT RES, V10, P69, DOI 10.1038/sj.ijir.3900354
   Moreland RB, 1998, LIFE SCI, V62, pPL309, DOI 10.1016/S0024-3205(98)00158-1
   Sadovsky R, 2001, INT J CLIN PRACT, V55, P115
   SIEGEL RL, 2000, OCULAR SURG NEWS, V18, P5
   Sponsel WE, 2000, NEW ENGL J MED, V342, P1680, DOI 10.1056/NEJM200006013422218
   VINGRYS AJ, 1988, INVEST OPHTH VIS SCI, V29, P50
   Vobig MA, 1999, LANCET, V353, P375, DOI 10.1016/S0140-6736(98)05473-7
   Yajima T, 2000, AM J OPHTHALMOL, V129, P675, DOI 10.1016/S0002-9394(00)00375-5
   Zrenner E, 2000, INVEST OPHTH VIS SCI, V41, pS592
NR 22
TC 24
Z9 25
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2002
VL 133
IS 5
BP 665
EP 672
AR PII S0002-9394(02)01338-7
DI 10.1016/S0002-9394(02)01338-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 550QL
UT WOS:000175513700010
PM 11992864
DA 2022-11-30
ER

PT J
AU Patterson, DM
   Rustin, GJS
   Serradell, N
   Rosa, E
   Bolos, J
AF Patterson, Daniel M.
   Rustin, Gordon J. S.
   Serradell, N.
   Rosa, E.
   Bolos, J.
TI Combretastatin A-4 phosphate - Vascular disrupting agent, oncolytic,
   treatment of age-related macular degeneration
SO DRUGS OF THE FUTURE
LA English
DT Article
DE CA4DP; CA4P; Zybrestat (TM)
ID PHASE-I TRIAL; 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID DMXAA; A4 PHOSPHATE;
   ANTIVASCULAR AGENT; TARGETING AGENT; SOLID TUMORS; TISSUE METABOLISM;
   ADVANCED CANCER; COLCHICINE; TUBULIN
AB Combretastatin A-4 phosphate (CA4P, Zybrestat (TM)) is a vascular disrupting agent (VDA) that binds to tubulin and selectively damages established tumor vasculature. Preclinical studies have shown that CA4P causes rapid vascular shutdown, leading to central tumor necrosis, although it leaves a rim of viable cells at the periphery, which requires additional antineoplastic treatment to enhance efficacy. Phase I monotherapy trials have shown the agent to be well tolerated, with tumor pain and mild transient cardiovascular effects being the most common side effects. Clinical trials of various CA4P combinations have been conducted or are ongoing with initially promising results. Preclinical work has shown CA4P to also be effective in disrupting ocular neovascularization, and human proof of concept was established for i.v. drug in patients with myopic macular degeneration; a topical formulation is in development as a potential treatment for age-related macular degeneration (AMD).
C1 [Patterson, Daniel M.; Rustin, Gordon J. S.] Mt Vernon Hosp, Dept Med Oncol, Northwood HA6 2RN, Middx, England.
   [Serradell, N.; Rosa, E.; Bolos, J.] Prous Sci, Barcelona 08080, Spain.
RP Patterson, DM (通讯作者)，Mt Vernon Hosp, Dept Med Oncol, Northwood HA6 2RN, Middx, England.
EM danpatterson@doctors.org.uk
RI Rustin, Gordon J. S./J-9763-2019
CR Anderson HL, 2003, J CLIN ONCOL, V21, P2823, DOI 10.1200/JCO.2003.05.186
   Beauregard DA, 1998, BRIT J CANCER, V77, P1761, DOI 10.1038/bjc.1998.294
   Beerepoot LV, 2006, J CLIN ONCOL, V24, P1491, DOI 10.1200/JCO.2005.02.7458
   Bilenker JH, 2005, CLIN CANCER RES, V11, P1527, DOI 10.1158/1078-0432.CCR-04-1434
   Boyland E, 1940, BIOCHEM J, V34, P280, DOI 10.1042/bj0340280
   Boyland E, 1937, BIOCHEM J, V31, P454, DOI 10.1042/bj0310454
   Chaplin DJ, 1999, ANTICANCER RES, V19, P189
   Cooney MM, 2004, CLIN CANCER RES, V10, P96, DOI 10.1158/1078-0432.CCR-0364-3
   Dark GG, 1997, CANCER RES, V57, P1829
   DENEKAMP J, 1983, EUR J CANCER CLIN ON, V19, P271, DOI 10.1016/0277-5379(83)90426-1
   DENEKAMP J, 1982, BRIT J CANCER, V46, P711, DOI 10.1038/bjc.1982.263
   Dowlati A, 2002, CANCER RES, V62, P3408
   ELZAYAT AAE, 1993, ANTI-CANCER DRUG, V4, P19, DOI 10.1097/00001813-199302000-00002
   Fox E, 2006, CLIN CANCER RES, V12, P4882, DOI 10.1158/1078-0432.CCR-06-0534
   GABRA H, 2006, J CLIN ONCOL S, V24
   Galbraith SM, 2001, ANTICANCER RES, V21, P93
   Galbraith SM, 2003, J CLIN ONCOL, V21, P2831, DOI 10.1200/JCO.2003.05.187
   Gill GS, 2006, ORG PREP PROCED INT, V38, P604, DOI 10.1080/00304940609356450
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   Griggs J, 2001, BRIT J CANCER, V84, P832, DOI 10.1054/bjoc.2000.1653
   Grosios K, 1999, BRIT J CANCER, V81, P1318, DOI 10.1038/sj.bjc.6692174
   Horsman MR, 2000, ADV EXP MED BIOL, V476, P311
   Iyer S, 1998, CANCER RES, V58, P4510
   Jameson MB, 2003, BRIT J CANCER, V88, P1844, DOI 10.1038/sj.bjc.6600992
   LEITER J, 1950, J NATL CANCER I, V10, P1273
   LIN CM, 1988, MOL PHARMACOL, V34, P200
   LIN CM, 1989, BIOCHEMISTRY-US, V28, P6984, DOI 10.1021/bi00443a031
   LUDFORD RJ, 1945, J NATL CANCER I, V6, P89
   LUDFORD RJ, 1948, BRIT J CANCER, V2, P75, DOI 10.1038/bjc.1948.10
   Maxwell RJ, 2002, NMR BIOMED, V15, P89, DOI 10.1002/nbm.754
   MCKEAGE M, 2006, J CLIN ONCOL S, V24
   Murata R, 2001, RADIOTHER ONCOL, V60, P155, DOI 10.1016/S0167-8140(01)00384-X
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Nelkin BD, 2001, ONCOL REP, V8, P157
   Patel S, 2006, CANCER-AM CANCER SOC, V107, P2881, DOI 10.1002/cncr.22334
   Patterson DA, 2007, CLIN ONCOL-UK, V19, P443, DOI 10.1016/j.clon.2007.03.014
   PATTERSON DM, 2007, J CLIN ONCOL S, V25
   PETTIT GR, 1982, CAN J CHEM, V60, P1374, DOI 10.1139/v82-202
   Pettit GR, 1998, ANTI-CANCER DRUG DES, V13, P183
   PETTIT GR, 1995, ANTI-CANCER DRUG DES, V10, P299
   RICART AD, 2006, J CLIN ONCOL S, V24
   Rustin GJS, 2003, J CLIN ONCOL, V21, P2815, DOI 10.1200/JCO.2003.05.185
   Rustin GJS, 2003, BRIT J CANCER, V88, P1160, DOI 10.1038/sj.bjc.6600885
   RUSTIN GJS, 2005, 41 ANN M AM SOC CLIN
   RUSTIN GJS, 2005, 1N AACR NCI EORTC IN
   Schoffski P, 2004, ANN ONCOL, V15, P671, DOI 10.1093/annonc/mdh141
   Seed L, 1940, SURGERY, V7, P696
   Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592
   Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901
   SPEAR MA, 2007, J CLIN ONCOL S
   Stevenson JP, 2003, J CLIN ONCOL, V21, P4428, DOI 10.1200/JCO.2003.12.986
   Tamura K, 2007, CANCER CHEMOTH PHARM, V60, P285, DOI 10.1007/s00280-006-0382-7
   TOLCHER AW, 2003, P AM SOC CLIN ONCOL, V22
   Tozer GM, 1999, CANCER RES, V59, P1626
   Tozer GM, 2001, CANCER RES, V61, P6413
   WALSHE WH, 1844, ANATOMY PHYSL PATHOL
   Woglom WH, 1923, J CANC RES, V7, P283
   2007, SAFETY STUDY INCREAS
   2007, STUDY COMBRETASTATIN
NR 59
TC 22
Z9 24
U1 0
U2 10
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 0377-8282
J9 DRUG FUTURE
JI Drug Future
PD DEC
PY 2007
VL 32
IS 12
BP 1025
EP 1032
DI 10.1358/dof.2007.032.12.1158960
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 254ZQ
UT WOS:000252626900001
DA 2022-11-30
ER

PT J
AU Baird, PN
   Chu, D
   Guida, E
   Vu, HTV
   Guymer, R
AF Baird, PN
   Chu, D
   Guida, E
   Vu, HTV
   Guymer, R
TI Association of the M55L and Q192R paraoxonase gene polymorphisms with
   age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK
AB PURPOSE: To investigate the reported association of the two single,nucleotide polymorphisms (SNPs) of the paraoxonase gene (PON1), Met-Leu 55 (M55L) and Gln-Arg 192 (Q192R), in individuals of Anglo-Celtic descent who have age-related macular degeneration (AMD). DESIGN: Case-control association study. METHODS: Sixty-two individuals with late (end-stage) AMD and 115 control subjects (without AMD) were included in this study. The M55L and Q192R SNPs were amplified by polymerase chain reaction and genotyped, and statistical analysis was undertaken. RESULTS: No association of either SNP was detected in persons of Anglo-Celtic descent who had AMD, although there was a significant difference in SNP allele frequency between Anglo-Celtic and Japanese individuals. CONCLUSION: The M55L and Q192R SNPs of the PON1 gene do not appear to be associated with late AMD in individuals of Anglo-Celtic descent. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.
   Univ Melbourne, Dept Pharmacol, Mol Pharmacol Lab, Parkville, Vic 3052, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Walter &
   Eliza Hall Institute; University of Melbourne
RP Baird, PN (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
OI Baird, Paul/0000-0002-1305-3502; Guymer, Robyn/0000-0002-9441-4356
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Gorin MB, 1999, MOL VIS, V5, pU31
   Hasselwander O, 1999, KIDNEY INT, V56, P289, DOI 10.1046/j.1523-1755.1999.00521.x
   HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
NR 5
TC 29
Z9 31
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2004
VL 138
IS 4
BP 665
EP 666
DI 10.1016/j.ajo.2004.04.053
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 864UO
UT WOS:000224658600031
PM 15488805
DA 2022-11-30
ER

PT J
AU Wang, YX
   Xu, L
   Bin Li, Y
   Jonas, JB
AF Wang, Ya Xing
   Xu, Liang
   Bin Li, Yi
   Jonas, Jost B.
TI Association of beta zone of parapapillary atrophy with age-related
   macular degeneration in adult Chinese. The Beijing Eye Study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE parapapillary atrophy; peripapillary atrophy; age-related macular
   degeneration; alpha zone; beta zone of parapapillary atrophy; glaucoma
ID CHORIORETINAL ATROPHY; HIGH MYOPIA; OPTIC DISK; MACULOPATHY; PREVALENCE
AB Background Since parapapillary atrophy and age-related macular degeneration (AMD) share features of their ophthalmoscopic and histological appearance, such as irregular pigmentation, proliferation and loss of the retinal pigment epithelium, it was the purpose of the study to assess whether parapapillary atrophy, particularly beta zone of parapapillary atrophy, is associated with AMD in a population-based investigation.
   Methods The Beijing Eye Study included 4439 subjects out of 5324 subjects invited to participate (response rate 83.4%) with an age of 40 + years. The present investigation consisted of 3874 (82.3%) subjects for whom readable fundus photographs of at least one eye were available with normal intraocular pressure, a refractive error of >- 8 diopters, and no signs of glaucomatous optic neuropathy.
   Results In a multivariate analysis, beta zone of parapapillary atrophy was significantly associated with age (P < 0.001), optic disc size (P < 0.001) and myopic refractive error (P < 0.001). It was not significantly associated with presence of retinal pigment depigmentation (P = 0.20) or hyperpigmentation (P = 0.99), drusen size (P = 0.27), and presence of early AMD (P = 0.72) or late AMD (P = 0.99).
   Conclusions Although beta zone of parapapillary atrophy and age-related macular degeneration have a similar histology with irregularities of the retinal pigment epithelium and eventual closure of the choriocapillaris and loss of retinal pigment epithelium cells, the entities are clinically not significantly associated with each other.
C1 [Jonas, Jost B.] Univ Heidelberg, Dept Ophthalmol, Fac Clin Med Mannheim, D-6800 Mannheim, Germany.
   [Wang, Ya Xing; Xu, Liang; Bin Li, Yi; Jonas, Jost B.] Capital Univ Med Sci, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Capital Medical University
RP Jonas, JB (通讯作者)，Univ Heidelberg, Dept Ophthalmol, Fac Clin Med Mannheim, D-6800 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
FU Beijing Natural Science Foundation, Beijing, China [7071003]
FX Supported by Beijing Natural Science Foundation No 7071003, Beijing,
   China.
CR JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   JONAS JB, 1988, INVEST OPHTH VIS SCI, V29, P1151
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   JONAS JB, 1988, GRAEF ARCH CLIN EXP, V226, P587, DOI 10.1007/BF02169209
   JONAS JB, 1992, ARCH CLIN EXP OPHTHA, V230, P134, DOI DOI 10.1007/BF00164651
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KUBOTA T, 1993, BRIT J OPHTHALMOL, V77, P103, DOI 10.1136/bjo.77.2.103
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Wang YX, 2006, AM J OPHTHALMOL, V141, P1078, DOI 10.1016/j.ajo.2006.01.023
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
NR 10
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2008
VL 246
IS 10
BP 1391
EP 1394
DI 10.1007/s00417-008-0882-8
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 344WX
UT WOS:000258959100005
PM 18642022
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Abdelfattah, NS
   Uji, A
   Nittala, MG
   Boyer, DS
   Sadda, SR
AF Borrelli, Enrico
   Abdelfattah, Nizar Saleh
   Uji, Akihito
   Nittala, Muneeswar Gupta
   Boyer, David S.
   Sadda, Srinivas R.
TI Postreceptor Neuronal Loss in Intermediate Age-related Macular
   Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INNER PLEXIFORM LAYER; GANGLION-CELL;
   THICKNESS MEASUREMENTS; MORPHOMETRIC ANALYSIS; GEOGRAPHIC ATROPHY;
   RETINAL LAYERS; VISUAL-ACUITY; SD-OCT; EYES
AB PURPOSE: To investigate the relationship between ganglion cell complex (GCC) thickness and photoreceptor alterations in eyes with intermediate age-related macular degeneration (AMD).
   DESIGN: Retrospective case-control study.
   METHODS: We collected data from 68 eyes with intermediate AMD from 68 patients with spectral-domain optical coherence tomography (SDOCT) imaging. A control group of 50 eyes from 50 healthy subjects was included for comparison. Our main outcome measures for comparison between groups were (1) the average and minimum GCC thickness and (2) the "normalized" reflectivity of the ellipsoid zone (EZ) en face image.
   RESULTS: The average and minimum GCC thicknesses were thinner in AMD patients (69.54 +/- 9.30 mu m and 63.22 +/- 14.11 mu m, respectively) than in healthy controls (78.57 +/- 6.28 mu m and 76.28 +/- 6.85 mu m, P < .0001 and P < .0001, respectively). Agreement was found to be excellent in the "normalized" EZ reflectivity assessment (intraclass correlation coefficient = 0.986, coefficient of variation = 1.11). The EZ "normalized" reflectivity was 0.67 +/- 0.11 in controls and 0.61 +/- 0.09 in the AMD group (P = .006). In univariate analysis, EZ "normalized" reflectivity was found to have a significant direct relationship with average (P < .0001) and minimum (P < .0001) GCC thickness in AMD patients, but not in controls (P = .852 and P = .892, respectively).
   CONCLUSIONS: Eyes with intermediate AMD exhibit GCC thinning, as well as a reduced EZ "normalized" reflectivity, and these parameters are correlated. This study supports the concept of postreceptor retinal neuronal loss as a contributor to retinal thinning in intermediate AMD. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Borrelli, Enrico; Abdelfattah, Nizar Saleh; Uji, Akihito; Nittala, Muneeswar Gupta; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Borrelli, Enrico; Abdelfattah, Nizar Saleh; Uji, Akihito; Nittala, Muneeswar Gupta; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Borrelli, Enrico] Univ G dAnnunzio, Dept Med & Sci Ageing, Ophthalmol Clin, Chieti, Italy.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; G d'Annunzio University
   of Chieti-Pescara; Retina Vitreous Associates Medical Group
RP Sadda, SR (通讯作者)，1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI Borrelli, Enrico/AAR-3693-2020; Abdelfattah, Nizar Saleh/H-6908-2019;
   Nittala, Muneeswar/AAT-7533-2020
OI Borrelli, Enrico/0000-0003-2815-5031; Abdelfattah, Nizar
   Saleh/0000-0002-9396-3054; 
FU Alcon; Allergan; Genentech; Novartis; Regeneron Pharmaceuticals, Inc;
   Carl Zeiss Meditec; Optos; Optovue; Regeneron
FX DAVID S. BOYER: AERPIO (CONSULTANT), Alcon (Consultant, Recipient),
   Allergan (Consultant, Recipient), Bayer (Consultant), Genentech
   (Consultant, Recipient), GS (Consultant), KalVista (Consultant),
   Neurotech (Consultant), Nicox (Consultant), Novartis (Consultant,
   Recipient), Ohr (Consultant), Santaris (Consultant), Santen
   (Consultant), ThromboGenics (Consultant), Regeneron Pharmaceuticals, Inc
   (Consultant, Recipient); SriniVas R. Sadda: Allergan (Consultant,
   Financial Support), Carl Zeiss Meditec (Financial Support), Genentech
   (Consultant, Financial Support), Iconic (Consultant), Novartis
   (Consultant), Optos (Consultant, Financial Support), Optovue
   (Consultant, Financial Support), Regeneron (Financial Support),
   Thrombogenics (Consultant). The following authors have no financial
   disclosures: Enrico Borrelli, Nizar Saleh Abdelfattah, Akihito Uji, and
   Muneeswar Gupta Nittala. All authors attest that they meet the current
   ICMJE criteria for authorship.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Bloch E, 2017, JAMA OPHTHALMOL, V135, P31, DOI 10.1001/jamaophthalmol.2016.4486
   Carpineto P, 2016, EYE, V30, P673, DOI 10.1038/eye.2016.13
   Carpineto P, 2014, OPHTHALMOLOGICA, V232, P163, DOI 10.1159/000362177
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hendrickson A, 2015, BRAIN STRUCT FUNCT, V220, P351, DOI 10.1007/s00429-013-0659-7
   Hirasawa H, 2013, INVEST OPHTH VIS SCI, V54, P2562, DOI 10.1167/iovs.12-10552
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Hu ZH, 2013, OSLI RETINA, V44, pS5, DOI 10.3928/23258160-20131101-02
   Hwang YH, 2016, OPHTHALMOLOGY, V123, P950, DOI 10.1016/j.ophtha.2015.12.032
   Hwang YH, 2014, INVEST OPHTH VIS SCI, V55, P3995, DOI 10.1167/iovs.14-14438
   Kim KE, 2015, OPHTHALMOLOGY, V122, P502, DOI 10.1016/j.ophtha.2014.09.031
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Nouri-Mahdavi K, 2013, AM J OPHTHALMOL, V156, P1297, DOI 10.1016/j.ajo.2013.08.001
   Oh J, 2010, INVEST OPHTH VIS SCI, V51, P1651, DOI 10.1167/iovs.09-4420
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Sallo FB, 2012, INVEST OPHTH VIS SCI, V53, P6145, DOI 10.1167/iovs.12-10580
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Villate N, 2005, AM J OPHTHALMOL, V139, P280, DOI 10.1016/j.ajo.2004.09.029
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 39
TC 41
Z9 41
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2017
VL 181
BP 1
EP 11
DI 10.1016/j.ajo.2017.06.005
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH1CV
UT WOS:000410878200002
PM 28624323
DA 2022-11-30
ER

PT J
AU Dougherty, BE
   Cooley, SSL
   Davidorf, FH
AF Dougherty, Bradley E.
   Cooley, San-San L.
   Davidorf, Frederick H.
TI Measurement of Perceived Stress in Age-Related Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE perceived stress; age-related macular degeneration; low vision; Rasch
   analysis; patient-reported outcome measures
ID QUALITY-OF-LIFE; VISUAL-ACUITY; PSYCHOLOGICAL STRESS; PSYCHOMETRIC
   PROPERTIES; RASCH ANALYSIS; NEI VFQ-25; DEPRESSION; VALIDITY;
   RELIABILITY; VALIDATION
AB Purpose To validate the Perceived Stress Scale (PSS) in patients with age-related macular degeneration (AMD) using Rasch analysis.
   Methods Study participants with AMD were recruited from the retina service of the Department of Ophthalmology at the Ohio State University during clinical visits for treatment or observation. Visual acuity with habitual distance correction was assessed. A 10-item version of the PSS was administered in large print or by reading the items to the patient. Rasch analysis was used to investigate the measurement properties of the PSS, including fit to the model, ability to separate between people with different levels of perceived stress, category response structure performance, and unidimensionality.
   Results A total of 137 patients with a diagnosis of AMD were enrolled. The mean (SD) age of participants was 82 +/- 9 years. Fifty-four percent were female. Median Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity of the better eye was 65 letters (Snellen 20/50), with a range of approximately 20/800 to 20/15. Forty-seven percent of participants were receiving an anti-VEGF injection on the day of the study visit. The response category structure was appropriate. One item, How often have you felt confident in your ability to handle your personal problems? was removed due to poor fit statistics. The remaining nine items showed good fit to the model, acceptable measurement precision as assessed by the Rasch person separation statistic, and unidimensionality. There was some evidence of differential item functioning by age and visual acuity.
   Conclusions The Perceived Stress Scale demonstrated acceptable measurement properties and may be useful for the measurement of perceived stress in patients with AMD.
C1 [Dougherty, Bradley E.; Cooley, San-San L.] Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA.
   [Davidorf, Frederick H.] Ohio State Univ, Dept Ophthalmol, Columbus, OH USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University
RP Dougherty, BE (通讯作者)，Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA.
EM dougherty.85@osu.edu
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services [K23EY022940]; NATIONAL EYE INSTITUTE
   [K23EY022940] Funding Source: NIH RePORTER
FX Supported by National Eye Institute/National Institutes of Health,
   Department of Health and Human Services grant K23EY022940.
CR Andreou E, 2011, INT J ENV RES PUB HE, V8, P3287, DOI 10.3390/ijerph8083287
   ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Bond T.G., 2015, APPLYING RASCH MODEL, V3rd ed., DOI DOI 10.4324/9781315814698
   Bond T. G., 2021, APPL RASCH MODEL FUN, V4th
   Boone WJ., 2014, RASCH ANAL HUMAN SCI, DOI 10.1007/978-94-007-6857-4
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Cohen S, 1999, PSYCHOSOM MED, V61, P175, DOI 10.1097/00006842-199903000-00009
   COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   COHEN S, 1988, CLAR SYMP, P31
   Cohen S, 2007, JAMA-J AM MED ASSOC, V298, P1685, DOI 10.1001/jama.298.14.1685
   Cohen S, 2012, J APPL SOC PSYCHOL, V42, P1320, DOI 10.1111/j.1559-1816.2012.00900.x
   Denny F, 2007, INVEST OPHTH VIS SCI, V48, P1976, DOI 10.1167/iovs.06-0135
   Dougherty BE, 2010, OPTOMETRY VISION SCI, V87, P543, DOI 10.1097/OPX.0b013e3181e61bd8
   Duncan LG, 2012, J PAIN SYMPTOM MANAG, V43, P161, DOI 10.1016/j.jpainsymman.2011.04.007
   Ebrecht M, 2004, PSYCHONEUROENDOCRINO, V29, P798, DOI 10.1016/S0306-4530(03)00144-6
   Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101
   Eskildsen A, 2015, SCAND J WORK ENV HEA, V41, P486, DOI 10.5271/sjweh.3510
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Golden-Kreutz DM, 2004, ASSESSMENT, V11, P216, DOI 10.1177/1073191104267398
   Gothwal VK, 2009, OPTOMETRY VISION SCI, V86, P1160, DOI 10.1097/OPX.0b013e3181bab10c
   Hemingway H, 1999, BMJ-BRIT MED J, V318, P1460, DOI 10.1136/bmj.318.7196.1460
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5
   KUIPER NA, 1986, J HUM STRESS, V12, P149, DOI 10.1080/0097840X.1986.9936781
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Leung DYP, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-513
   Linacre J. M., 2005, WINSTEPS RASCH MEASU
   Linacre J. M., 2009, USERS GUIDE WINSTEPS
   Linacre J.M., 1998, RASCH MEAS T, V12, P636
   Mallinson T, 2007, OPTOMETRY VISION SCI, V84, P675, DOI 10.1097/OPX.0b013e3181339f44
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Massof RW, 2002, OPTOMETRY VISION SCI, V79, P516, DOI 10.1097/00006324-200208000-00015
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, pE6890
   McDade TW, 2006, PSYCHOSOM MED, V68, P376, DOI 10.1097/01.psy.0000221371.43607.64
   McNair DM, 1992, POMS PROFILE MOOD ST
   Mitchell AM, 2008, RES NURS HEALTH, V31, P576, DOI 10.1002/nur.20284
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Nielsen MG, 2016, J PSYCHOSOM RES, V84, P22, DOI 10.1016/j.jpsychores.2016.03.009
   Parswani Manish J, 2013, Int J Yoga, V6, P111, DOI 10.4103/0973-6131.113405
   Pbert L, 2012, THORAX, V67, P769, DOI 10.1136/thoraxjnl-2011-200253
   Pesudovs K, 2007, OPTOMETRY VISION SCI, V84, P663, DOI 10.1097/OPX.0b013e318141fe75
   Raasch TW, 1998, OPTOMETRY VISION SCI, V75, P342, DOI 10.1097/00006324-199805000-00024
   Rasch G., 1993, PROBABILISTIC MODELS
   Rod NH, 2009, J INTERN MED, V266, P467, DOI 10.1111/j.1365-2796.2009.02124.x
   Ryan C. L., 2016, CURRENT POPULATION R
   Sallat S, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/606470
   Sgalla G, 2015, BMJ OPEN RESPIR RES, V2, DOI 10.1136/bmjresp-2014-000065
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   VandenBosch ME, 1997, EYE, V11, P411, DOI 10.1038/eye.1997.87
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wright B., 1994, RASCH MEAS T, V8, P370
   Wright B.D., 1999, MEASUREMENT ESSENTIA
NR 57
TC 7
Z9 7
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2017
VL 94
IS 3
BP 290
EP 296
DI 10.1097/OPX.0000000000001055
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EM9KU
UT WOS:000395631200003
PM 28225371
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Park, SJ
   Lee, JH
   Woo, SJ
   Kang, SW
   Park, KH
AF Park, Sang Jun
   Lee, Ju Hyun
   Woo, Se Joon
   Kang, Se Woong
   Park, Kyu Hyung
CA Korean Ophthalmologic Soc
TI Five Heavy Metallic Elements and Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; RETINAL-PIGMENT EPITHELIUM; EXAMINATION
   SURVEY KNHANES; KOREAN NATIONAL-HEALTH; CADMIUM ACCUMULATION; BLOOD
   LEAD; ZINC; MERCURY; MANGANESE; TOXICITY
AB Objective: To investigate the association between age-related macular degeneration (AMD) and 5 heavy metallic elements (lead, mercury, cadmium, manganese, and zinc).
   Design: A cross-sectional study using a complex, stratified, multistage, probability cluster survey.
   Participants: Participants of the Korean National Health and Nutrition Examination Survey from 2008 to 2011.
   Methods: Using a standardized protocol, AMD was determined by fundus photograph grading. Blood concentrations of lead, mercury, cadmium, manganese, and zinc were measured. Associations between AMD and these 5 elements were estimated using logistic regression analyses (LRAs). The distributions of the 5 metallic elements in blood were analyzed, and the same set of LRAs estimating the association between AMD and logarithmic-transformed blood concentrations of the 5 elements were also conducted.
   Main Outcome Measures: Association between AMD and 5 heavy metals.
   Results: Lead was positively associated with both early AMD and late AMD in all LRAs. Mercury and cadmium also had a positive association with late AMD in all LRAs, but not with early AMD. In contrast, manganese and zinc had an inverse association with late AMD in all LRAs. Manganese and zinc were not associated with early AMD. Using logarithmic-transformed blood concentrations for each metallic element, the LRAs showed similar results compared with those of the LRAs using nontransformed blood concentrations, despite the skewed distribution of these metallic elements in the blood.
   Conclusions: This study suggests that the toxic heavy metals (lead, mercury, and cadmium) may negatively influence late AMD, whereas essential heavy metals (manganese and zinc) may favorably influence late AMD. Lead may widely affect the pathogenesis of both early and late AMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [Park, Sang Jun; Woo, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam 463707, Gyeonggi Do, South Korea.
   [Lee, Ju Hyun] Seoul Natl Univ, Bundang Hosp, Med Res Collaborating Ctr, Songnam 463707, Gyeonggi Do, South Korea.
   [Kang, Se Woong] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU);
   Sungkyunkwan University (SKKU); Samsung Medical Center
RP Park, KH (通讯作者)，Seoul Natl Univ, Bundang Hosp, Dept Ophthalmol, 300 Gumi Dong, Songnam 463707, Gyeonggi Do, South Korea.
EM jiani4@snu.ac.kr
RI Park, Sang Jun/C-3234-2015; Woo, Se Joon/I-7357-2013
OI Park, Sang Jun/0000-0003-0542-2758; Woo, Se Joon/0000-0003-3692-7169
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science, and Technology [NRF-2013R1A2A2A04015829]
FX Supported by a National Research Foundation of Korea (NRF) grant funded
   by the Ministry of Education, Science, and Technology
   (NRF-2013R1A2A2A04015829). The sponsor or funding organization had no
   role in the design or conduct of this research.
CR [Anonymous], 2007, VIS 2010 RIGHT SIGHT, P32
   Bertin G, 2006, BIOCHIMIE, V88, P1549, DOI 10.1016/j.biochi.2006.10.001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bridges CC, 2007, TOXICOL APPL PHARM, V221, P251, DOI 10.1016/j.taap.2007.03.004
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   da Costa GM, 2008, ENVIRON RES, V107, P98, DOI 10.1016/j.envres.2007.10.007
   DAVIS LE, 1994, ANN NEUROL, V35, P680, DOI 10.1002/ana.410350608
   Erie JC, 2007, AM J OPHTHALMOL, V144, P414, DOI 10.1016/j.ajo.2007.05.020
   Erie JC, 2009, AM J OPHTHALMOL, V148, P890, DOI 10.1016/j.ajo.2009.07.001
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Farina M, 2013, NEUROCHEM INT, V62, P575, DOI 10.1016/j.neuint.2012.12.006
   Harrell FE, 2001, REGRESSION MODELING, P35
   He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kalariya NM, 2009, EXP EYE RES, V89, P494, DOI 10.1016/j.exer.2009.05.011
   Karagas MR, 2012, ENVIRON HEALTH PERSP, V120, P799, DOI 10.1289/ehp.1104494
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   Kobayashi K, 2007, J PHARMACOL EXP THER, V320, P721, DOI 10.1124/jpet.106.112912
   Korbas M, 2013, ACS CHEM BIOL, V8, P2256, DOI 10.1021/cb4004805
   Kuzniarz M, 2002, OPHTHAL EPIDEMIOL, V9, P283, DOI 10.1076/opep.9.4.283.1511
   Lee BK, 2013, AM J IND MED, V56, P682, DOI 10.1002/ajim.22107
   Lee MS, 2011, ENVIRON RES, V111, P171, DOI 10.1016/j.envres.2010.10.006
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Mecocci P, 2004, NEUROL RES, V26, P598, DOI 10.1179/016164104225017659
   Mela M, 2012, NEUROTOXICOLOGY, V33, P407, DOI 10.1016/j.neuro.2012.04.009
   Mela M, 2010, NEUROTOXICOLOGY, V31, P448, DOI 10.1016/j.neuro.2010.04.009
   Ministry of Food and Drug Safety (Korea), 2000, LIB TOX SUBST
   Moon SS, 2013, DIABETIC MED, V30, pe143, DOI 10.1111/dme.12103
   Moulis JM, 2010, BIOMETALS, V23, P877, DOI 10.1007/s10534-010-9336-y
   Nash D, 2003, JAMA-J AM MED ASSOC, V289, P1523, DOI 10.1001/jama.289.12.1523
   Navas-Acien A, 2005, ENVIRON HEALTH PERSP, V113, P164, DOI 10.1289/ehp.7329
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nordberg GF, 2007, HDB TOXICOLOGY METAL, P925
   Nordberg GF, 2007, HANDBOOK ON THE TOXICOLOGY OF METALS, 3RD EDITION, P445, DOI 10.1016/B978-012369413-3/50078-1
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Prasad AS, 2012, J TRACE ELEM MED BIO, V26, P66, DOI 10.1016/j.jtemb.2012.04.004
   Rhee SY, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-9
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Vig EK, 2000, J AM GERIATR SOC, V48, P1501, DOI 10.1111/jgs.2000.48.11.1501
   Warfvinge K, 2000, ENVIRON RES, V83, P102, DOI 10.1006/enrs.1999.4029
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Won YS, 2013, J CLIN PERIODONTOL, V40, P118, DOI 10.1111/jcpe.12033
   Yablonskaya D. A., 2010, Meditsina Truda i Promyshlennaya Ekologiya, P40
   Yoon Kyung-Chul, 2011, Korean J Ophthalmol, V25, P421, DOI 10.3341/kjo.2011.25.6.421
   Yuki K, 2009, BIOL TRACE ELEM RES, V132, P1, DOI 10.1007/s12011-009-8376-z
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
NR 54
TC 27
Z9 28
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2015
VL 122
IS 1
BP 129
EP 137
DI 10.1016/j.ophtha.2014.07.039
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX1XK
UT WOS:000346737000029
PM 25225109
DA 2022-11-30
ER

PT J
AU Luu, CD
   Dimitrov, PN
   Wu, ZC
   Ayton, LN
   Makeyeva, G
   Aung, KZ
   Varsamidis, M
   Robman, L
   Vingrys, AJ
   Guymer, RH
AF Luu, Chi D.
   Dimitrov, Peter N.
   Wu, Zhichao
   Ayton, Lauren N.
   Makeyeva, Galina
   Aung, Khin-Zaw
   Varsamidis, Mary
   Robman, Luba
   Vingrys, Algis J.
   Guymer, Robyn H.
TI Static and Flicker Perimetry in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; static perimetry; flicker perimetry;
   visual function
ID SENSITIVITY; PROGRESSION; MACULOPATHY; RISK; EYES; MICROPERIMETRY;
   ECCENTRICITY; ADAPTATION; ROD
AB PURPOSE. The relationship between clinical severity of age-related macular degeneration (AMD) and macular function has not been well established. In this study, we investigated the correlation between clinical severity and functional deficits as detected by static and flicker perimetry.
   METHODS. This cross-sectional study consisted of 279 AMD subjects and 24 control participants. AMD subjects were allocated into 1 of 10 AMD severity groups depending on the status of the designated study eye and the fellow eye, as assessed by color fundus photographs. Visual acuity, and static and flicker perimetry were tested on one eye during the same session. The geometric means, SDs, and percentage of abnormal eyes of static and flicker sensitivity of each AMD severity group were determined and compared.
   RESULTS. The pattern of change in sensitivity and percentage of abnormal eyes for static perimetry across all AMD severity groups were similar to flicker perimetry. Eyes with drusen > 125 mu m (P[static] = 0.018, P[flicker] = 0.024), drusenoid epithelial detachment (P[static and flicker] < 0.001) and noncentral geographic atrophy (GA; P[static and flicker] < 0.001) had significant reductions in static and flicker sensitivities compared to normal eyes. Static (beta-coefficient -1.59, 95% confidence interval [CI] -4.78-1.60) and flicker (beta-coefficient -1.29, 95% CI -4.66-2.08) sensitivities declined at a similar rate in eyes that showed clinical signs of progression.
   CONCLUSIONS. Static and flicker perimetry were affected similarly across the spectrum of AMD severity, and methods appeared to be valid techniques for assessing retinal sensitivity in AMD once drusen > 125 mu m are present, but before the development of late AMD.
C1 [Luu, Chi D.; Dimitrov, Peter N.; Wu, Zhichao; Ayton, Lauren N.; Makeyeva, Galina; Aung, Khin-Zaw; Varsamidis, Mary; Robman, Luba; Guymer, Robyn H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Vingrys, Algis J.] Univ Melbourne, Dept Optometry & Vis Sci, Carlton, Vic 3053, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097; Vingrys, Algis/0000-0001-5920-4604
FU National Health and Medical Research Council [350224]; Australian
   Research Council Linkage Project [ARC-LP0211474]; Macular Degeneration
   Foundation Research Grant; NH and MRC practitioner fellowship [529905];
   Victorian Government; NHMRC Centre for Clinical Research Excellence
   Award [529923]
FX Supported by the National Health and Medical Research Council (NH and
   MRC) Project Grant 350224, Australian Research Council Linkage Project
   (ARC-LP0211474), Macular Degeneration Foundation Research Grant, NH and
   MRC practitioner fellowship (RHG, #529905). CERA receives Operational
   Infrastructure Support from the Victorian Government and is supported by
   a NHMRC Centre for Clinical Research Excellence Award (#529923).
CR Acton JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039944
   Anderson AJ, 2000, CLIN EXP OPHTHALMOL, V28, P223, DOI 10.1046/j.1442-9071.2000.00299.x
   Anderson AJ, 2002, VISION RES, V42, P1149, DOI 10.1016/S0042-6989(02)00033-0
   Anderson AJ, 2001, VISION RES, V41, P2449, DOI 10.1016/S0042-6989(01)00139-0
   Anderson AJ, 2000, VISION RES, V40, P2579, DOI 10.1016/S0042-6989(00)00121-8
   Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   KIRYU J, 1995, INVEST OPHTH VIS SCI, V36, P1240
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Landers J, 2003, BRIT J OPHTHALMOL, V87, P690, DOI 10.1136/bjo.87.6.690
   Luu CD, 2012, ARCH OPHTHALMOL-CHIC, V130, P690, DOI 10.1001/archophthalmol.2012.277
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vingrys AJ, 1995, PERIMETRY UPDATE 199
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Zele AJ, 2008, OPTOMETRY VISION SCI, V85, P309, DOI 10.1097/OPX.0b013e31816be9e3
NR 31
TC 17
Z9 17
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2013
VL 54
IS 5
BP 3560
EP 3568
DI 10.1167/iovs.12-10465
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173YC
UT WOS:000321118300055
PM 23620428
DA 2022-11-30
ER

PT J
AU Edwards, AO
   Chen, D
   Fridley, BL
   James, KM
   Wu, YH
   Abecasis, G
   Swaroop, A
   Othman, M
   Branham, K
   Iyengar, SK
   Sivakumaran, TA
   Klein, R
   Klein, BEK
   Tosakulwong, N
AF Edwards, Albert O.
   Chen, Dequan
   Fridley, Brooke L.
   James, Katherine M.
   Wu, Yanhong
   Abecasis, Goncalo
   Swaroop, Anand
   Othman, Mohammad
   Branham, Kari
   Iyengar, Sudha K.
   Sivakumaran, Theru A.
   Klein, Ronald
   Klein, Barbara E. K.
   Tosakulwong, Nirubol
TI Toll-like receptor polymorphisms and age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; PIGMENT EPITHELIAL-CELLS; DOUBLE-STRANDED-RNA;
   BRUCHS MEMBRANE; INNATE IMMUNITY; FUNCTIONAL ANALYSES; ADAPTIVE
   IMMUNITY; EXTENDED FAMILIES; ANIMAL-MODEL; DRUSEN
AB PURPOSE. Evidence from genetic-association studies in conjunction with the demonstration of complement deposition in the retina and choroid implicates noncellular pathways of innate immunity in the pathogenesis of age-related macular degeneration (AMD). The purpose of this study was to determine whether common variation in the 10 human toll-like receptors (TLRs) alters the risk of AMD.
   METHODS. Sixty-eight SNPs were iteratively genotyped across the TLR genes in a cohort of 577 subjects, with and without AMD. Two additional cohorts were used for replication studies. Standard genetic-association methods were used to analyze the results for association with disease and interaction with other loci.
   RESULTS. Coding SNPs in TLR3 (rs3775291) and TLR7 (rs179008) showed association with AMD in one group ( P = 0.01 and P = 0.02, respectively) before correction for multiple testing. For both SNPs, the association with AMD arose due to an excess of heterozygotes compared with homozygotes for the major allele. The two coding SNPs were not associated with AMD in another case - control cohort or an extended-family cohort. Although an intronic SNP in TLR4 was associated marginally with AMD ( P = 0.03), it was not possible to replicate a previous association with the rare coding SNP D299G in this gene ( P = 0.6).
   CONCLUSIONS. Although borderline support for association between polymorphisms in TLR genes and AMD was reported for some cohorts, these initial observations of coding SNPs in TLR3, TLR4, and TLR7 were not replicated. TLR variants are unlikely to have a major impact on overall AMD risk, and the common variants studied were not associated with AMD.
C1 [Edwards, Albert O.; Chen, Dequan; James, Katherine M.; Tosakulwong, Nirubol] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Fridley, Brooke L.] Mayo Clin, Div Biostat, Rochester, MN 55905 USA.
   [Wu, Yanhong] Mayo Clin, Adv Genom Technol Ctr, Rochester, MN 55905 USA.
   [Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Swaroop, Anand; Othman, Mohammad; Branham, Kari] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Swaroop, Anand; Othman, Mohammad; Branham, Kari] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   [Iyengar, Sudha K.; Sivakumaran, Theru A.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA.
   [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan; Case
   Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; University of Wisconsin System; University
   of Wisconsin Madison
RP Edwards, AO (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM edwardslab@mayo.edu
RI /S-1190-2019; Branham, Kari/AAA-8336-2022; Abecasis, Goncalo
   R/B-7840-2010; Fridley, Brooke L/D-8315-2015
OI /0000-0001-7488-250X; Fridley, Brooke L/0000-0001-7739-7956; Swaroop,
   Anand/0000-0002-1975-1141; Abecasis, Goncalo/0000-0003-1509-1825;
   Branham, Kari/0000-0002-2492-254X; Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY10605, EY015810, EY016862, EY014467] Funding Source:
   Medline; NATIONAL EYE INSTITUTE [R01EY010605, ZIAEY000475, R01EY016862,
   Z01EY000449, R01EY015810, R01EY014467] Funding Source: NIH RePORTER
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102
   Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Duncan R.D., 2006, CASE CONTROL HAPLOTY
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Epstein MP, 2003, AM J HUM GENET, V73, P1316, DOI 10.1086/380204
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Forrester JV, 2005, BRIT J OPHTHALMOL, V89, P369, DOI 10.1136/bjo.2004.054197
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hoffman RW, 2004, ARTHRITIS RHEUM-US, V50, P2891, DOI 10.1002/art.20428
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Kelly KM, 2006, ARTHRITIS RHEUM-US, V54, P1557, DOI 10.1002/art.21819
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lang KS, 2006, J CLIN INVEST, V116, P2456, DOI 10.1172/JCI28349
   Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630
   Lee MT, 2007, CLIN EXP IMMUNOL, V147, P71, DOI 10.1111/j.1365-2249.2006.03253.x
   Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Parker LC, 2007, CLIN EXP IMMUNOL, V147, P199, DOI 10.1111/j.1365-2249.2006.03203.x
   Pawar RD, 2006, J AM SOC NEPHROL, V17, P3365, DOI 10.1681/ASN.2006030263
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Prehaud C, 2005, J VIROL, V79, P12893, DOI 10.1128/JVI.79.20.12893-12904.2005
   Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200
   RIVERA A, 2005, HUM MOL GENET, V3227, DOI UNSP UNSP:C387715
   Ronnefarth VM, 2006, J IMMUNOL, V177, P7740, DOI 10.4049/jimmunol.177.11.7740
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200
   Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 66
TC 68
Z9 70
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2008
VL 49
IS 4
BP 1652
EP 1659
DI 10.1167/iovs.07-1378
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282ON
UT WOS:000254577200049
PM 18385087
DA 2022-11-30
ER

PT J
AU Fan, Q
   Maranville, JC
   Fritsche, L
   Sim, XL
   Cheung, CMG
   Chen, LJ
   Gorski, M
   Yamashiro, K
   Ahn, J
   Laude, A
   Dorajoo, R
   Lim, TH
   Teo, YY
   Blaustein, RO
   Yoshimura, N
   Park, KH
   Pang, CP
   Tai, ES
   Khor, CC
   Wong, TY
   Runz, H
   Cheng, CY
AF Fan, Qiao
   Maranville, Joseph C.
   Fritsche, Lars
   Sim, Xueling
   Cheung, Chui Ming Gemmy
   Chen, Li Jia
   Gorski, Mathias
   Yamashiro, Kenji
   Ahn, Jeeyun
   Laude, Augustinus
   Dorajoo, Rajkumar
   Lim, Tock Han
   Teo, Yik-Ying
   Blaustein, Robert O.
   Yoshimura, Nagahisa
   Park, Kyu-Hyung
   Pang, Chi Pui
   Tai, E. Shyong
   Khor, Chiea Chuen
   Wong, Tien Yin
   Runz, Heiko
   Cheng, Ching-Yu
CA IAMDGC
   AGEN Consortium
   GAMA Consortium
TI HDL-cholesterol levels and risk of age-related macular degeneration: a
   multiethnic genetic study using Mendelian randomization
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE HDL-cholesterol; AMD; lipids; Mendelian randomization; genetic
   association
ID HIGH-DENSITY-LIPOPROTEIN; GENOME-WIDE ASSOCIATION; SERUM-LIPOPROTEIN;
   VARIANTS; DISEASE; MACULOPATHY; LOCI; BIAS; SUSCEPTIBILITY; EPIDEMIOLOGY
AB Dyslipidemia, particularly high-density lipoprotein cholesterol (HDL-C), has recently been implicated in the pathogenesis of age-related macular degeneration (AMD), the leading cause of vision loss. However, epidemiological studies have yielded conflicting results.
   We investigated the causal role of plasma lipid levels in AMD in multiethnic populations comprising 16 144 advanced AMD cases and 17 832 controls of European descent, together with 2219 cases and 5275 controls of Asian descent, using Mendelian randomization in three models. Model 1 is a conventional meta-analysis which does not account for pleiotropy of instrumental variable (IV) effects. Model 2 is a univariate, inverse variance weighted regression analysis that accounts for potential unbalanced pleiotropy using MR-Egger method. Finally, Model 3 is a multivariate regression analysis that addresses pleiotropy by MR-Egger method and by adjusting for effects on other lipid traits.
   A 1 standard deviation (SD) higher HDL-cholesterol level was associated with an odds ratio (OR) for AMD of 1.17 (95% confidence interval: 1.07-1.29) in Europeans (P = 6.88 x 10(-4)) and of 1.58 (1.24-2.00) in Asians (P = 2.92 x 10(-4)) in Model 3. The corresponding OR estimates were 1.30 (1.09-1.55) in Europeans (P = 3.18 x 10(-3)) and 1.42 (1.11-1.80) in Asians (P = 4.42 x 10(-3)) in Model 1, and 1.21 (1.11-1.31) in Europeans (P = 3.12 x 10(-5)) and 1.51 (1.20-1.91) in Asians (P = 7.61 x 10(-4)) in Model 2. Conversely, neither LDL-C (Europeans: OR = 0.96, P = 0.272; Asians: OR = 1.02, P = 0.874; Model 3) nor triglyceride levels (Europeans: OR = 0.91, P = 0.102; Asians: OR = 1.06, P = 0.613) were associated with AMD. We also assessed the association between lipid levels and polypoidal choroidal vasculopathy (PCV) in Asians, a subtype of AMD, and found a similar trend for association of PCV with HDL-C levels.
   Our study shows that high levels of plasma HDL-C are causally associated with an increased risk for advanced AMD in European and Asian populations, implying that strategies reducing HDL-C levels may be useful to prevent and treat AMD.
C1 [Fan, Qiao] Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore.
   [Maranville, Joseph C.; Blaustein, Robert O.; Runz, Heiko] Merck Res Labs, Kenilworth, NJ USA.
   [Fritsche, Lars] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Sim, Xueling; Teo, Yik-Ying; Tai, E. Shyong; Wong, Tien Yin] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Sim, Xueling; Teo, Yik-Ying; Tai, E. Shyong; Wong, Tien Yin] Natl Univ Hlth Syst, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy; Khor, Chiea Chuen; Wong, Tien Yin; Cheng, Ching-Yu] Singapore Natl Eye Ctr, Singapore Eye Res Inst, 20 Coll Rd, Singapore 169856, Singapore.
   [Chen, Li Jia; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Gorski, Mathias] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Kyoto, Japan.
   [Ahn, Jeeyun; Park, Kyu-Hyung] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Gyeonggi, South Korea.
   [Laude, Augustinus; Lim, Tock Han] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Dorajoo, Rajkumar; Khor, Chiea Chuen] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore.
   [Teo, Yik-Ying] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore, Singapore.
   [Tai, E. Shyong] Natl Univ Hlth Syst, Dept Med, Singapore, Singapore.
   [Tai, E. Shyong] Natl Univ Singapore, Singapore, Singapore.
   [Wong, Tien Yin; Cheng, Ching-Yu] Duke NUS Med Sch, Clin Sci, Singapore, Singapore.
C3 National University of Singapore; Merck & Company; University of
   Michigan System; University of Michigan; National University of
   Singapore; National University of Singapore; National University of
   Singapore; Singapore National Eye Center; Chinese University of Hong
   Kong; University of Regensburg; Kyoto University; Seoul National
   University (SNU); Tan Tock Seng Hospital; Agency for Science Technology
   & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS);
   National University of Singapore; National University of Singapore;
   National University of Singapore; National University of Singapore
RP Cheng, CY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 20 Coll Rd, Singapore 169856, Singapore.
EM chingyu.cheng@duke-nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020; Chen, Li Jia/I-5078-2014; Sim,
   Xueling/AAZ-6652-2020; Fritsche, Lars G/AAF-9387-2019; Cheng,
   Ching-Yu/Y-2229-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Chen, Li Jia/0000-0003-3500-5840;
   Sim, Xueling/0000-0002-1233-7642; Fritsche, Lars G/0000-0002-2110-1690;
   Cheng, Ching-Yu/0000-0003-0655-885X; Yamashiro,
   Kenji/0000-0001-9354-8558; Dorajoo, Rajkumar/0000-0001-6608-2051;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Ahn,
   Jeeyun/0000-0001-9017-1652; Tai, E Shyong/0000-0003-2929-8966;
   Maranville, Joseph/0000-0002-1688-1573
FU Singapore National Medical Research Council [CG/SERI/2010, CSA/033/2012,
   SHF/PRISM003/2015]
FX This work was supported by the Singapore National Medical Research
   Council (CG/SERI/2010, CSA/033/2012 and SHF/PRISM003/2015). The detailed
   funding support for each study is in the Supplementary Note, available
   as Supplementary Data at IJE online.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Bautista LE, 2006, ANN EPIDEMIOL, V16, P675, DOI 10.1016/j.annepidem.2006.02.001
   Bowden J, 2016, INT J EPIDEMIOL, V45, P1961, DOI 10.1093/ije/dyw220
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Brion MJA, 2013, INT J EPIDEMIOL, V42, P1497, DOI 10.1093/ije/dyt179
   Brunham LR, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0623-0
   Burgess S, 2017, STAT METHODS MED RES, V26, P2333, DOI 10.1177/0962280215597579
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2015, AM J EPIDEMIOL, V181, P251, DOI 10.1093/aje/kwu283
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Do R, 2013, NAT GENET, V45, P1345, DOI 10.1038/ng.2795
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garg A, 2017, AM J MED, V130, P173, DOI 10.1016/j.amjmed.2016.07.038
   Gehlbach P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub5
   Gotto AM, 2014, AM J CARDIOL, V113, P76, DOI 10.1016/j.amjcard.2013.08.041
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Landray MJ, 2014, NEW ENGL J MED, V371, P203, DOI 10.1056/NEJMoa1300955
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McTaggart F, 2008, CARDIOVASC DRUG THER, V22, P321, DOI 10.1007/s10557-008-6113-z
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nelson CP, 2015, NEW ENGL J MED, V372, P1608, DOI 10.1056/NEJMoa1404881
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Perez VL, 2013, J AUTOIMMUN, V45, P7, DOI 10.1016/j.jaut.2013.06.011
   PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712
   Pierce BL, 2013, AM J EPIDEMIOL, V178, P1177, DOI 10.1093/aje/kwt084
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Sene A, 2014, TRENDS ENDOCRIN MET, V25, P107, DOI 10.1016/j.tem.2013.10.007
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sheridan C, 2016, NAT BIOTECHNOL, V34, P5, DOI 10.1038/nbt0116-5
   Singh IM, 2007, JAMA-J AM MED ASSOC, V298, P786, DOI 10.1001/jama.298.7.786
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tyrrell J, 2016, JAMA-J AM MED ASSOC, V315, P1129, DOI 10.1001/jama.2016.1975
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   White J, 2016, JAMA CARDIOL, V1, P692, DOI 10.1001/jamacardio.2016.1884
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
NR 67
TC 43
Z9 43
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD DEC
PY 2017
VL 46
IS 6
BP 1891
EP 1902
DI 10.1093/ije/dyx189
PG 12
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA FP6OJ
UT WOS:000417745100033
PM 29025108
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Nitsch, D
   Evans, J
   Roderick, PJ
   Smeeth, L
   Fletcher, AE
AF Nitsch, Dorothea
   Evans, Jennifer
   Roderick, Paul J.
   Smeeth, Liam
   Fletcher, Astrid E.
TI Associations Between Chronic Kidney Disease and Age-Related Macular
   Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; chronic kidney disease; glomerular
   filtration rate; proteinuria; renal disease
ID COMPLEMENT FACTOR-H; RENAL-DISEASE; OLDER-PEOPLE; VISUAL IMPAIRMENT;
   RISK-FACTORS; MRC TRIAL; ADD-ON; MANAGEMENT; COMMUNITY; ACTIVATION
AB Purpose: Age-related macular degeneration (AMD) and renal impairment are both associated with cardiovascular risk factors and with alterations in the complement pathways. There are few data on the association of AMD with chronic kidney disease. Methods: People who were visually impaired (binocular acuity 6/18) due to AMD (ascertained from review of medical notes; n = 516) were compared to people with normal vision (6/6 or better; n = 2755). Cases with AMD and controls derive from a population-based cross-sectional study of people aged 75 years and over registered with 49 family practices in Britain. Glomerular filtration rate (eGFR) was estimated with the Modification of Diet in Renal Disease formula and proteinuria assessed by dipsticks. Results: After adjusting for a wide range of confounding factors, the presence of proteinuria was positively associated with AMD among men (odds ratio (OR) 2.06, 95% confidence interval (CI) 1.05, 4.04) but not in women (OR 0.62 95%CI 0.36,1.08). Among men, eGFR 45 ml/min/1.73 m2 was associated with AMD but not after adjusting for proteinuria. This was not observed for women. Both proteinuria and eGFR showed different associations with AMD by sex (p-values for interaction 0.05). Conclusions: Proteinuria appears to be a risk factor for AMD among men but not among women, possibly due to measurement errors in detecting proteinuria in women.
C1 [Nitsch, Dorothea; Smeeth, Liam; Fletcher, Astrid E.] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Evans, Jennifer] Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England.
   [Roderick, Paul J.] Univ Southampton, Publ Hlth Sci & Med Stat, Southampton, Hants, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University of Southampton
RP Nitsch, D (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM Dorothea.Nitsch@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012; Smeeth, Liam/X-5862-2018
OI Evans, Jennifer/0000-0002-6137-2030; Smeeth, Liam/0000-0002-9168-6022;
   Nitsch, Dorothea/0000-0001-5767-248X
FU Thomas Pocklington, London; Wellcome Trust
FX The sponsor or funding organization had no role in the design or conduct
   of this research. L. S. is supported by a Wellcome Trust Senior Research
   Fellowship in Clinical Science.
CR Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Fletcher AE, 2004, LANCET, V364, P1667, DOI 10.1016/S0140-6736(04)17353-4
   Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21
   Froissart M, 2005, J AM SOC NEPHROL, V16, P763, DOI 10.1681/ASN.2004070549
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallan SI, 2006, BMJ-BRIT MED J, V333, P1047, DOI 10.1136/bmj.39001.657755.BE
   Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Konta Tsuneo, 2007, Clin Exp Nephrol, V11, P51, DOI 10.1007/s10157-006-0458-z
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Murthy K, 2005, KIDNEY INT, V68, P1884, DOI 10.1111/j.1523-1755.2005.00608.x
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Roderick PJ, 2008, AGE AGEING, V37, P179, DOI 10.1093/ageing/afm180
   ROSE G, 1977, BRIT J PREV SOC MED, V31, P42
   Seelen MA, 2006, AUTOIMMUNITY, V39, P411, DOI 10.1080/08916930600739688
   Thompson CL, 2007, HUM MOL GENET, V16, P2135, DOI 10.1093/hmg/ddm164
   Timmerman JJ, 1996, KIDNEY INT, V49, P730, DOI 10.1038/ki.1996.102
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Trouw LA, 2003, MOL IMMUNOL, V40, P125, DOI 10.1016/S0161-5890(03)00105-6
   van Kooten C, 1999, KIDNEY BLOOD PRESS R, V22, P53, DOI 10.1159/000025909
   Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013
   Verhave JC, 2003, J AM SOC NEPHROL, V14, P1330, DOI 10.1097/01.ASN.0000060573.77611.73
NR 29
TC 19
Z9 20
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2009
VL 16
IS 3
BP 181
EP 186
AR PII 911123967
DI 10.1080/09286580902863064
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 445CC
UT WOS:000266026200007
PM 19437313
DA 2022-11-30
ER

PT J
AU Heier, JS
   Boyer, DS
   Ciulla, TA
   Ferrone, PJ
   Jumper, JM
   Gentile, RC
   Kotlovker, D
   Chung, CY
   Kim, RY
AF Heier, Jeffrey S.
   Boyer, David S.
   Ciulla, Thomas A.
   Ferrone, Philip J.
   Jumper, J. Michael
   Gentile, Ronald C.
   Kotlovker, Debbi
   Chung, Carol Y.
   Kim, Robert Y.
TI Ranibizumab combined with verteporfin photodynamic therapy in
   neovascular age-related macular degeneration - Year 1 results of the
   FOCUS study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; FLUOROURACIL; BEVACIZURNAB; LEUCOVORIN; PREVALENCE;
   ANTIBODY
AB Objective: : To investigate the safety and efficacy of intravitreal ranibizumab treatment combined with verteporfin photodynamic therapy ( PDT) in patients with predominantly classic choroidal neovascularization secondary to age-related macular degeneration.
   Methods: In this 2-year, phase I/II, multicenter, randomized, single-masked, controlled study, patients received monthly ranibizumab ( 0.5 mg) ( n=106) or sham ( n=56) injections. The PDT was performed 7 days before initial ranibizumab or sham treatment and then quarterly as needed.
   Main Outcomes Measures: Proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months ( primary efficacy outcome) and the incidence and severity of adverse events.
   Results: At 12 months, 90.5% of the ranibizumab-treated patients and 67.9% of the control patients had lost fewer than 15 letters ( P < .001). The most frequent ranibizumab-associated serious ocular adverse events were intraocular inflammation ( 11.4%) and endophthalmitis ( 1.9%; 4.8% if including presumed cases). On average, patients with serious inflammation had better visual acuity outcomes at 12 months than did controls. Key serious nonocular adverse events included myocardial infarctions in the PDT-alone group ( 3.6%) and cerebrovascular accidents in the ranibizumab-treated group ( 3.8%).
   Conclusion/Application to Clinical Practice: Ranibizumab + PDT was more efficacious than PDT alone for treating neovascular age-related macular degeneration. Although ranibizumab treatment increased the risk of serious intraocular inflammation, affected patients, on average, still experienced visual acuity benefit.
C1 Ophthalm Consultants Boston, Boston, MA 02114 USA.
   Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   Long Isl Viteoretinal Consultants, Great Neck, NY USA.
   Midw Eye Inst, Indianapolis, IN USA.
   W Coast Retina Med Grp Inc, San Francisco, CA USA.
   New York Eye & Ear Infirm, New York Med Coll, Valhalla, NY USA.
   Genentech Inc, San Francisco, CA USA.
C3 Ophthalmic Consultants of Boston; Retina Vitreous Associates Medical
   Group; New York Eye & Ear Infirmary of Mount Sinai; New York Medical
   College; Roche Holding; Genentech
RP Heier, JS (通讯作者)，Ophthalm Consultants Boston, 50 Staniford St,Suite 600, Boston, MA 02114 USA.
EM jsheier@eyeboston.com
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   *GEN INC, 2004, AV PACK INS
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HOGAN MJ, 1959, AM J OPHTHALMOL, V47, P155, DOI 10.1016/S0002-9394(14)78239-X
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   *NOV AG, 2002, VIS US PACK INS
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.OPHTHA.2006.01.027
   Skillings JR, 2005, J CLIN ONCOL, V23, p196S
NR 27
TC 223
Z9 243
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2006
VL 124
IS 11
BP 1532
EP 1542
DI 10.1001/archopht.124.11.1532
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 104VG
UT WOS:000241987700001
PM 17101999
DA 2022-11-30
ER

PT J
AU Hart, PM
   Chakravarthy, U
   Mackenzie, G
   Chisholm, IH
   Bird, AC
   Stevenson, MR
   Owens, SL
   Hall, V
   Houston, RF
   McCulloch, DW
   Plowman, N
AF Hart, PM
   Chakravarthy, U
   Mackenzie, G
   Chisholm, IH
   Bird, AC
   Stevenson, MR
   Owens, SL
   Hall, V
   Houston, RF
   McCulloch, DW
   Plowman, N
TI Visual outcomes in the subfoveal radiotherapy study - A randomized
   controlled trial of teletherapy for age-related macular degeneration
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; RADIATION-THERAPY; BEAM RADIOTHERAPY;
   IRRADIATION; MEMBRANES; CATARACT
AB Objective: To determine Whether teletherapy with 6-mV photons can reduce visual loss in patients with subfoveal choroidal neovascularization in age-related macular degeneration.
   Design: A multicenter, single-masked, randomized controlled trial of 12 Gy of external beam radiation therapy delivered to the macula of an affected eye ws observation only.
   Setting: Three United Kingdom-based hospital units:
   Participants: Patients with age-related macular degeneration, aged 60 years and older; who had subfoveal choroidal neovascularization and a visual. acuity of 20/200 (logMAR 1.0) or better:
   Methods: Two hundred three patients were randomly assigned to radiotherapy- or-observation. Treatment was undertaken at designated radiotherapy centers, and patients assigned to the treatment group received a total dosage of 12 Gy of 6-mV photons in 6 fractions: Follow-up was scheduled at 3, 6, 12, and 24 months. After excluding protocol violators, the data from 199 patients were analyzed.
   Main Outcome Measures: The primary outcome measure was mean loss of distance visual acuity in the study eye at 12 and 24 months. Other outcome variables analyzed were near visual acuity and contrast sensitivity. The proportions of patients losing 3 or more or 6 or more lines of distance and near acuity and 0.3 or more or 0.6 or more log units:of contrast sensitivity at. each follow-up were also analyzed.
   Results: At all time.points, mean distance visual acuity was better, in the radiotherapy-treated group than in the control group; but the differences did not reach statistical significance. At 24 months, analysis of the proportions,of patients with loss of 3 or more (moderate) (P = .08) or 6 or: more (severe) (P= . 29) lines of distance vision showed that fewer treated patients had severe losses, but there was no statistically significant difference between groups: For near, visual acuity, although there was no evidence of treatment benefit at 12 and 24 months, a significant difference in favor of treatment was present at 6 months (P = .048).. When analyzed by the proportions of patients losing 3 lines of contrast sensitivity, there was a significant difference in favor of treatment at 24 months (P = .02). No adverse retinal effects were observed during the study; but transient disturbance of the precorneal tear film:was noted in treated patients.
   Conclusion:The results of the present trial do not support the routine clinical use of external beam radiation therapy in subjects with subfoveal choroidal neovascularization in age-related macular degeneration.
C1 Queens Univ Belfast, Royal Victoria Hosp, Dept Ophthalmol & Visual Sci, Belfast BT12 6BA, Antrim, North Ireland.
   Queens Univ Belfast, Royal Victoria Hosp, Dept Epidemiol, Belfast BT12 6BA, Antrim, North Ireland.
   Belvoir Pk Hosp, No Ireland Radiotherapy Ctr, Belfast, Antrim, North Ireland.
   Univ Keele, Ctr Med Stat, Keele ST5 5BG, Staffs, England.
   Southampton Univ Hosp, Southampton, Hants, England.
   Royal S Hants Hosp, Wessex Radiotherapy Ctr, Southampton SO9 4PE, Hants, England.
   UCL, Inst Ophthalmol, London, England.
   Moorfields Eye Hosp, London WC1V 7AN, England.
   St Bartholomews Hosp, Dept Radiotherapy & Oncol, London, England.
C3 Queens University Belfast; Queens University Belfast; Keele University;
   University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; Queen Mary University London
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Dept Ophthalmol & Visual Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM g.mcgoldrick@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Briggs MC, 2001, INVEST OPHTH VIS SCI, V42, pS127
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   ELLIOTT DB, 1990, EYE, V4, P712, DOI 10.1038/eye.1990.100
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1358
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   Haas A, 2000, OPHTHALMOLOGY, V107, P1358, DOI 10.1016/S0161-6420(00)00154-8
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Immonen IJ, 2001, INVEST OPHTH VIS SCI, V42, pS127
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605
   *MAC PHOT STUD GRO, 1991, MPS MAN PROC
   *MAC PHOT STUD GRO, 1908, ARCH OPHTHALMOL-CHIC, V104, P694
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   *MOL PHOT STUD GRO, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   Reeves J, 1998, J ROY STAT SOC D-STA, V47, P607, DOI 10.1111/1467-9884.00158
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
NR 36
TC 58
Z9 62
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD AUG
PY 2002
VL 120
IS 8
BP 1029
EP 1038
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 582JF
UT WOS:000177346500002
PM 12149056
DA 2022-11-30
ER

PT J
AU Kuang, TM
   Xirasagar, S
   Kao, YW
   Ho, JD
   Lin, HC
AF Kuang, Tung-Mei
   Xirasagar, Sudha
   Kao, Yi-Wei
   Ho, Jau-Der
   Lin, Herng-Ching
TI Association of neovascular age-related macular degeneration with
   migraine
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL DYSFUNCTION; MACULOPATHY; PREVALENCE; DISEASE; RISK;
   HYPERALGESIA; MECHANISMS; AMD
AB Patients with early onset vascular pathology have been reported to manifest neovascular age-related macular degeneration (AMD). While the blood vessels involved in pathogenesis of migraine remains controversial, it is generally accepted that a major contributor is blood vessel pathology. This study aimed to examine the association between migraine and AMD using a nationwide population-based dataset. Retrospective claims data were collected from the Taiwan National Health Insurance Research Database. We identified 20,333 patients diagnosed with neovascular AMD (cases), and we selected 81,332 propensity score-matched controls from the remaining beneficiaries in Taiwan's National Health Insurance system. We used Chi-square tests to explore differences in the prevalence of migraine prior to the index date between cases and controls. We performed multiple logistic regressions to estimate the odds of prior migraine among neovascular AMD patients vs. controls after adjusting for age, sex, monthly income, geographic location, residential urbanization level, hyperlipidemia, diabetes, coronary heart disease, hypertension, and previous cataract surgery. A total of 5184 of sample patients (5.1%) had a migraine claim before the index date; 1215 (6.1%) among cases and 3969 (4.9%) among controls (p < 0.001), with an unadjusted OR of 1.239 (95% CI 1.160 similar to 1.324, p < 0.001) for prior migraine among cases relative to controls. Furthermore, the adjusted OR was 1.201 (95% CI 1.123 similar to 1.284; p < 0.001) for AMD cases relative to controls. The study offers population-based evidence that persons with migraine have 20% higher risk of subsequently being diagnosed with neovascular AMD.
C1 [Kuang, Tung-Mei] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Kuang, Tung-Mei] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Kuang, Tung-Mei] Taipei Med Univ, Coll Med, Res Ctr Sleep Med, Taipei, Taiwan.
   [Xirasagar, Sudha] Univ South Carolina, Arnold Sch Publ Hlth, Dept Hlth Serv Policy & Management, Columbia, SC 29208 USA.
   [Kao, Yi-Wei] Taipei Med Univ, Big Data Res Ctr, Taipei, Taiwan.
   [Kao, Yi-Wei] Fu Jen Catholic Univ, Coll Management, Grad Inst Business Adm, New Taipei, Taiwan.
   [Ho, Jau-Der] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ, Coll Management, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.
C3 Taipei Veterans General Hospital; National Yang Ming Chiao Tung
   University; Taipei Medical University; University of South Carolina
   System; University of South Carolina Columbia; Taipei Medical
   University; Fu Jen Catholic University; Taipei Medical University;
   Taipei Medical University Hospital; Taipei Medical University; Taipei
   Medical University Hospital; Taipei Medical University
RP Lin, HC (通讯作者)，Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.; Lin, HC (通讯作者)，Taipei Med Univ, Coll Management, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.
EM henry11111@tmu.edu.tw
CR Ashina K, 2015, BIOCHEM BIOPH RES CO, V464, P590, DOI 10.1016/j.bbrc.2015.07.014
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840
   Chang CC, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.020071
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Jacobs B, 2016, NEUROSCIENCE, V338, P130, DOI 10.1016/j.neuroscience.2016.06.012
   Joseph EK, 2015, NEUROSCIENCE, V284, P678, DOI 10.1016/j.neuroscience.2014.10.056
   Joseph EK, 2011, NEUROSCIENCE, V178, P189, DOI 10.1016/j.neuroscience.2011.01.043
   Joseph EK, 2014, J PAIN, V15, P771, DOI 10.1016/j.jpain.2014.04.005
   Kallela M, 1998, CEPHALALGIA, V18, P329, DOI 10.1046/j.1468-2982.1998.1806329.x
   Kiel C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102257
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Loo L, 2012, J NEUROSCI, V32, P11942, DOI 10.1523/JNEUROSCI.1330-12.2012
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Papadopoulos Zois, 2020, Curr Aging Sci, V13, P102, DOI 10.2174/1874609813666200129161833
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Suzuki T, 2014, J DERMATOL SCI, V74, P116, DOI 10.1016/j.jdermsci.2013.12.013
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
NR 32
TC 2
Z9 2
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 2
PY 2022
VL 12
IS 1
AR 1792
DI 10.1038/s41598-022-05638-5
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YS9HB
UT WOS:000750981100088
PM 35110596
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sorbera, LA
   Leeson, PA
   Bayes, M
AF Sorbera, LA
   Leeson, PA
   Bayes, M
TI Ranibizumab - Treatment of age-related macular degeneration humanized
   monoclonal anti-VEGF antibodiy angiogenesis inhibitor
SO DRUGS OF THE FUTURE
LA English
DT Article
DE rhu-Fab VEG; rhuFab V2; Lucentis
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; APOLIPOPROTEIN-E; VERTEPORFIN; MEMBRANES
AB Wet type or exudative age-related macular degeneration (AMD) is a complex and multifactorial disease which affects older individuals and is characterized by subretinal or choroidal neovascularization (CNV) evident under the retina and macula. These new, abnormal blood vessels may bleed or leak fluid, causing the macula to bulge and lift up which results in rapid and severe distortion or destruction of central vision. Overexpression of vascular endothelial growth factors (VEGFs) and their receptors has been found to be associated with increased microvascular permeability in the eye. Thus, antiangiogenic therapy using VEGF as a target may be a selective and effective treatment option for the wet form of AMD. Ranibizumab is the antigen-binding fragment of a recombinant humanized monoclonal antibody directed toward VEGF that can penetrate the internal limiting membrane to access the subretinal space. Ranibizumab was chosen for further development as a treatment for the wet form of AMD.
C1 Prous Sci, Barcelona 08080, Spain.
RP Sorbera, LA (通讯作者)，Prous Sci, POB 540, Barcelona 08080, Spain.
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   BLUMENKRANZ M, 2001, ANN M ASS RES VIS OP
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008
   GAUDREAULT J, 2003, ANN M ASS RES VIS OP
   GAUDREAULT J, 2002, ANN M ASS RES VIS OP
   GAUDREAULT J, 2001, ANN M ASS RES VIS OP
   GAUDREAULT J, 1999, ANN M AM ASS PHARM S
   GAUTHIER D, 2003, ANN M ASS RES VIS OP
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   HEIER JS, 2002, ANN M ASS RES VIS OP
   HEIER JS, 2002, 35 ANN M RET SOC SEP
   HEIER JS, 2003, ANN M ASS RES VIS OP
   HSEI V, 1999, ANN M AM ASS PHARM S
   HUSAIN D, 2002, 35 ANN M RET SOC SEP
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LOWE J, 2003, ANN M ASS RES VIS OP
   MCCLUSKEY ER, 2002, 4 INT OC PHARM PHARM
   ONEILL CA, 2003, ANN M ASS RES VIS OP
   PULIAFITO CA, 2002, 35 ANN M RET SOC SEP
   ROSENFELD PJ, 2003, ANN M AS RES VIS OPH
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   2003, MACULAR DEGENERATION
   2003, 299O 1 QUARTER REPOR
   2003, CLIN TRIALS GOV 0602
NR 35
TC 5
Z9 7
U1 1
U2 9
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD JUN
PY 2003
VL 28
IS 6
BP 541
EP 545
DI 10.1358/dof.2003.028.06.738510
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 723QL
UT WOS:000185443000003
DA 2022-11-30
ER

PT J
AU Brody, BL
   Field, LC
   Roch-Levecq, AC
   Depp, C
   Edland, SD
   Minasyan, L
   Brown, SI
AF Brody, Barbara L.
   Field, Linda C.
   Roch-Levecq, Anne-Catherine
   Depp, Colin
   Edland, Steven D.
   Minasyan, Lilit
   Brown, Stuart I.
TI Computer Use among Patients with Age-Related Macular Degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Computer; Macular degeneration; Quality of life; Universal access; Low
   vision
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; SELF-MANAGEMENT;
   OLDER-ADULTS; DEPRESSIVE SYMPTOMS; VISUAL FUNCTION; IMPACT; TECHNOLOGY
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of incurable vision loss in older adults in industrialized countries and is on a trajectory to disable a growing number of persons as societies age. To assess the potential of using telemedicine for expansion of an in-person AMD self-management program, we examined the extent of computer use in a sample of older adults with AMD.
   Methods: 160 older adult volunteers (mean age = 76 years; female = 51%) with AMD (mean visual acuity in better eye: 20/40; worse eye: 20/90) were randomly selected from members of the San Diego County AMD Registry. Computer use was assessed with a Health and Impact Questionnaire. Dependent measures were Snellen visual acuity, National Eye Institute-Visual Function Questionnaire, the AMD Self-Efficacy Questionnaire, and the Geriatric Depression Scale.
   Results: Overall 70.6% reported computer use at least once per month. By age and gender stratum, 76.5% of men aged 60-74 years, 73.3% of men aged 75 years and over, 74.3% of women aged 60-74 years, and 60.9% of women aged 75 years and over used computers. In logistic regression analyses controlling for age and gender, computer use was associated with better visual acuity (P = 0.029), higher education (P = 0.002), and self-efficacy for communication (P = 0.027).
   Conclusion: The majority of older adults with AMD in our sample used computers, with use highest among more educated and visually intact patients. Computer use to access the Internet is feasible in AMD patients and should be encouraged. The inclusion of computer use in measures of AMD-related functioning appears warranted.
C1 [Brody, Barbara L.; Field, Linda C.; Roch-Levecq, Anne-Catherine; Minasyan, Lilit; Brown, Stuart I.] Univ Calif San Diego, Dept Ophthalmol, Sch Med, La Jolla, CA 92093 USA.
   [Brody, Barbara L.; Edland, Steven D.] Univ Calif San Diego, Div Biostat, Sch Med, Dept Family & Prevent Med,SDE, La Jolla, CA 92093 USA.
   [Depp, Colin] Univ Calif San Diego, Dept Psychiat, Sch Med, La Jolla, CA 92093 USA.
   [Edland, Steven D.] Univ Calif San Diego, Dept Neurosci, Sch Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Brody, BL (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Sch Med, 9415 Campus Point Dr, La Jolla, CA 92093 USA.
EM bbrody@ucsd.edu
RI depp, colin a/D-1264-2009
OI Depp, Colin/0000-0002-1841-6229
FU Shiley Awards in Health, Education and the Arts
FX The study was funded by Shiley Awards in Health, Education and the Arts.
   The funding source did not play any part in the study design; the
   collection, analysis, or interpretation of data; or the writing of this
   report.
CR Blaschke CM, 2009, BRIT J SOC WORK, V39, P641, DOI 10.1093/bjsw/bcp025
   Brody BL, 2006, J AM GERIATR SOC, V54, P1557, DOI 10.1111/j.1532-5415.2006.00881.x
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Cohen Robin A, 2011, NCHS Data Brief, P1
   Dickinson A, 2006, INT J HUM-COMPUT ST, V64, P744, DOI 10.1016/j.ijhcs.2006.03.001
   Dobransky K., 2006, Information Communication & Society, V9, P313, DOI 10.1080/13691180600751298
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Jacko J. A., 2000, P 4 INT ACM C ASS TE, P1
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   Klein R, 2005, MACULAR DEGENERATION, P79
   Leonard R., 2002, STAT VISION IMPAIRME, V5th ed.
   Madden M, 2010, OLDER ADULTS SOCIAL, P1
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   R Development Core Team, 2020, R VERS 4 0 3 LANG EN
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Scott IU, 2002, AM J OPHTHALMOL, V133, P350, DOI 10.1016/S0002-9394(01)01406-4
   Selwyn N, 2003, AGEING SOC, V23, P561, DOI 10.1017/S0144686X03001302
   Shapira N, 2007, AGING MENT HEALTH, V11, P477, DOI 10.1080/13607860601086546
   SHEIKH J I, 1986, Clinical Gerontologist, V5, P165
   Vinkers DJ, 2004, INT J GERIATR PSYCH, V19, P80, DOI 10.1002/gps.1043
   Wagner N, 2010, COMPUT HUM BEHAV, V26, P870, DOI 10.1016/j.chb.2010.03.029
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 25
TC 6
Z9 6
U1 1
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD AUG
PY 2012
VL 19
IS 4
BP 190
EP 195
DI 10.3109/09286586.2012.672618
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 971GH
UT WOS:000306191300003
PM 22775273
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Dhillon, B
   Wright, AF
   Tufail, A
   Pappworth, I
   Hayward, C
   Moore, I
   Strain, L
   Kavanagh, D
   Barlow, PN
   Herbert, AP
   Schmidt, CQ
   Armbrecht, AM
   Laude, A
   Deary, IJ
   Staniforth, SJ
   Holmes, LV
   Goodship, THJ
   Marchbank, KJ
AF Dhillon, Baljean
   Wright, Alan F.
   Tufail, Adnan
   Pappworth, Isabel
   Hayward, Caroline
   Moore, Iain
   Strain, Lisa
   Kavanagh, David
   Barlow, Paul N.
   Herbert, Andrew P.
   Schmidt, Christoph Q.
   Armbrecht, Ana-Maria
   Laude, Augustinus
   Deary, Ian J.
   Staniforth, Scott J.
   Holmes, Lucy V.
   Goodship, Timothy H. J.
   Marchbank, Kevin J.
TI Complement Factor H Autoantibodies and Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; C-REACTIVE PROTEIN; MEDICAL PROGRESS; RISK;
   POLYMORPHISM; BINDING; VARIANT; GENES; CFH; DISEASE
AB PURPOSE. In this case-control study, the hypothesis that factor H autoantibodies are associated with age-related macular degeneration (AMD) was examined.
   METHODS. One hundred AMD patients (median age, 78 years), 98 age-matched control subjects (median age, 78 years) known not to have AMD, and 100 healthy blood donors (median age, 43 years) were enrolled. An enzyme-linked immunosorbent assay (ELISA) was used to screen for complement factor H autoantibodies and either quantitative polymerase chain reaction (qPCR) or multiplex ligation-dependent probe amplification (MLPA) were performed to measure the copy number of the gene encoding complement factor H-related protein 3 (CFHR3).
   RESULTS. There was a significant difference in the median complement factor H autoantibody titer between the three groups (AMD patients, 196 reference units [RU]]; age-match control subjects, 316 RU; and blood donor control subjects, 121 RU; Kruskal-Wallis test, P < 0.001). Pair-wise comparison (Mann-Whitney test) showed that all three groups were significantly different from each other. Two different thresholds were used in the healthy blood donors to identify individuals with complement factor H autoantibodies. Both suggested that the prevalence of factor H autoantibodies was decreased in AMD patients. The CFHR3 copy number was measured as a surrogate for the deletion of the genes encoding complement factor H-related proteins 3 and 1 (CFHR3/1). The allele frequency of the deletion was significantly higher in the age-matched control subjects than in the AMD patients (22.2% vs. 8.2%).
   CONCLUSIONS. The level of factor H autoantibodies is lower in AMD patients than in age-matched control subjects. (Invest Ophthalmol Vis Sci. 2010;51:5858-5863) DOI:10.1167/iovs.09-5124
C1 [Moore, Iain; Kavanagh, David; Holmes, Lucy V.; Goodship, Timothy H. J.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Dhillon, Baljean; Armbrecht, Ana-Maria; Laude, Augustinus] Univ Edinburgh, Dept Clin & Surg Sci, Edinburgh, Midlothian, Scotland.
   [Barlow, Paul N.; Herbert, Andrew P.; Schmidt, Christoph Q.] Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland.
   [Deary, Ian J.] Univ Edinburgh, Dept Psychol, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland.
   [Wright, Alan F.; Hayward, Caroline] Western Gen Hosp, MRC Med Res Council Human Genet Unit, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Tufail, Adnan] Moorfields Eye Hosp, NHS Natl Hlth Serv Fdn Trust, London, England.
   [Pappworth, Isabel; Staniforth, Scott J.; Marchbank, Kevin J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Strain, Lisa] Newcastle Upon Tyne Hosp, No Mol Genet Serv, NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; University of Edinburgh; University of
   Edinburgh; University of Edinburgh; University of Edinburgh; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; Newcastle University - UK; Newcastle University - UK;
   Newcastle Upon Tyne Hospitals NHS Foundation Trust
RP Goodship, THJ (通讯作者)，Newcastle Univ, Inst Human Genet, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM t.h.j.goodship@ncl.ac.uk
RI Herbert, Andrew P/C-4755-2008; Barlow, Paul N/G-2853-2011; Deary, Ian
   J/C-6297-2009; Kavanagh, David/E-8498-2011; Rosby, Lucy
   Victoria/N-3458-2018; Hayward, Caroline/M-8818-2016; Herbert, Andy
   P/F-6693-2010
OI Herbert, Andrew P/0000-0002-4549-6965; Deary, Ian J/0000-0002-1733-263X;
   Kavanagh, David/0000-0003-4718-0072; Hayward,
   Caroline/0000-0002-9405-9550; Herbert, Andy P/0000-0002-4549-6965;
   marchbank, kevin james/0000-0003-1312-5411; Tufail,
   Adnan/0000-0001-6131-7640
FU U.K. National Institute of Health Research (NIHR) Biomedical Research
   Centre for Ageing; MRC [G0701325]; Chief Scientist Office (Scotland)
   [CZB/4/79]; Macula Vision Research Foundation; Age-Related Disease
   Award; MRC [MC_U127584475, G0700704, G0001089] Funding Source: UKRI;
   Medical Research Council [G0700704, G0001089, G0701325, MC_U127584475]
   Funding Source: researchfish; Chief Scientist Office [CZB/4/505] Funding
   Source: researchfish
FX Supported by the U.K. National Institute of Health Research (NIHR)
   Biomedical Research Centre for Ageing and an Age-Related Disease Award
   to the Newcastle-upon-Tyne Hospitals NHS Foundation Trust; a grant from
   the MRC (AFW); MRC Grant G0701325 (THJG); Chief Scientist Office
   (Scotland) Grant CZB/4/79 (BD); and the Macula Vision Research
   Foundation (AFW).
CR Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Deary IJ, 2004, J PERS SOC PSYCHOL, V86, P130, DOI 10.1037/0022-3514.86.1.130
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Prelog M, 2006, AUTOIMMUN REV, V5, P136, DOI 10.1016/j.autrev.2005.09.008
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   ROWLEY MJ, 1968, LANCET, V2, P24
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   SOLBERG HE, 1987, CLIN CHIM ACTA, V170, pS13, DOI 10.1016/0009-8981(87)90151-3
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yung RL, 2008, AUTOIMMUNITY, V41, P329, DOI 10.1080/08916930802024889
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 40
TC 21
Z9 21
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5858
EP 5863
DI 10.1167/iovs.09-5124
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400059
PM 20592223
DA 2022-11-30
ER

PT J
AU Blasiak, J
   Hyttinen, JMT
   Szczepanska, J
   Pawlowska, E
   Kaarniranta, K
AF Blasiak, Janusz
   Hyttinen, Juha M. T.
   Szczepanska, Joanna
   Pawlowska, Elzbieta
   Kaarniranta, Kai
TI Potential of Long Non-Coding RNAs in Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE age-related macular degeneration; AMD; long non-coding RNA; epigenetic
   regulation; oxidative stress-induced dedifferentiation; micro RNA
ID RETINAL-PIGMENT EPITHELIUM; MOUSE MODEL; EXPRESSION; CELLS; PREVALENCE;
   DIFFERENTIATION; CLASSIFICATION; TRANSCRIPTION; INACTIVATION;
   EPIGENETICS
AB Age-related macular degeneration (AMD) is the leading cause of visual impairment in the aging population with poorly known pathogenesis and lack of effective treatment. Age and family history are the strongest AMD risk factors, and several loci were identified to contribute to AMD. Recently, also the epigenetic profile was associated with AMD, and some long non-coding RNAs (lncRNAs) were shown to involve in AMD pathogenesis. The Vax2os1/2 (ventral anterior homeobox 2 opposite strand isoform 1) lncRNAs may modulate the balance between pro- and anti-angiogenic factors in the eye contributing to wet AMD. The stress-induced dedifferentiation of retinal pigment epithelium cells can be inhibited by the ZNF503-AS1 (zinc finger protein 503 antisense RNA 2) and LINC00167 lncRNAs. Overexpression of the PWRN2 (Prader-Willi region non-protein-coding RNA 2) lncRNA aggravated RPE cells apoptosis and mitochondrial impairment induced by oxidative stress. Several other lncRNAs were reported to exert protective or detrimental effects in AMD. However, many studies are limited to an association between lncRNA and AMD in patients or model systems with bioinformatics. Therefore, further works on lncRNAs in AMD are rational, and they should be enriched with mechanistic and clinical studies to validate conclusions obtained in high-throughput in vitro research.
C1 [Blasiak, Janusz] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.
   [Szczepanska, Joanna] Med Univ Lodz, Dept Pediat Dent, PL-92216 Lodz, Poland.
   [Pawlowska, Elzbieta] Med Univ Lodz, Dept Orthodont, PL-92217 Lodz, Poland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
C3 University of Lodz; University of Eastern Finland; Medical University
   Lodz; Medical University Lodz; Kuopio University Hospital; University of
   Eastern Finland
RP Blasiak, J (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Mol Genet, Pomorska 141-143, PL-90236 Lodz, Poland.; Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
EM janusz.blasiak@biol.uni.lodz.pl; Juha.Hyttinen@uef.fi;
   joanna.szczepanska@umed.lodz.pl; elzbieta.pawlowska@umed.lodz.pl;
   kai.kaarniranta@uef.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Hyttinen,
   Juha/0000-0002-3414-4032; Blasiak, Janusz/0000-0001-9539-9584
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Alfano G, 2005, HUM MOL GENET, V14, P913, DOI 10.1093/hmg/ddi084
   Andergassen D, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008268
   Anderson DM, 2015, CELL, V160, P595, DOI 10.1016/j.cell.2015.01.009
   Anderson KM, 2016, NATURE, V539, P433, DOI 10.1038/nature20128
   Aznaourova M, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.527484
   Baek JH, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0941-9
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041684
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Bunch H, 2018, MOL GENET GENOMICS, V293, P1, DOI 10.1007/s00438-017-1370-9
   Chen X, 2020, MOL THER-NUCL ACIDS, V19, P1015, DOI 10.1016/j.omtn.2019.12.040
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.382
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruickshanks KJ, 2017, JAMA OPHTHALMOL, V135, P1417, DOI 10.1001/jamaophthalmol.2017.5001
   da Rocha ST, 2017, NAT STRUCT MOL BIOL, V24, P197, DOI 10.1038/nsmb.3370
   Dahariya S, 2019, MOL IMMUNOL, V112, P82, DOI 10.1016/j.molimm.2019.04.011
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Desmettre TJ, 2018, J FR OPHTALMOL, V41, pE407, DOI 10.1016/j.jfo.2018.09.001
   Dewell TE, 2021, STEM CELL RES, V53, DOI 10.1016/j.scr.2021.102368
   Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025
   Dong PX, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00471
   Dong Y, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109959
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu SJ, 2020, CANCER MANAG RES, V12, P10181, DOI 10.2147/CMAR.S276022
   Fujimura N, 2015, DEV GENES EVOL, V225, P121, DOI 10.1007/s00427-015-0493-4
   Furlan G, 2016, WIRES RNA, V7, P702, DOI 10.1002/wrna.1359
   Gregory-Evans Kevin, 2021, Handb Clin Neurol, V178, P1, DOI 10.1016/B978-0-12-821377-3.00001-5
   Groff AF, 2016, CELL REP, V16, P2178, DOI 10.1016/j.celrep.2016.07.050
   Guo WX, 2016, CLIN CANCER RES, V22, P2041, DOI 10.1158/1078-0432.CCR-14-3106
   He S, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02210-0
   He Y, 2020, AM J PHYSIOL-ENDOC M, V320, pE598, DOI 10.1152/ajpendo.00089.2020
   Hjelmeland LM, 2011, INVEST OPHTH VIS SCI, V52, P1622, DOI 10.1167/iovs.10-6765
   Huang L, 2015, EYE, V29, P691, DOI 10.1038/eye.2015.32
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hyttinen JMT, 2021, AGEING RES REV, V67, DOI 10.1016/j.arr.2021.101260
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Jiang Q, 2016, ONCOTARGET, V7, P49688, DOI 10.18632/oncotarget.10434
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341
   Karali M, 2019, HUM GENET, V138, P957, DOI 10.1007/s00439-018-1931-y
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kiel C, 2018, ADV EXP MED BIOL, V1074, P247, DOI 10.1007/978-3-319-75402-4_30
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Klein R, 2008, OPHTHALMOLOGY, V115, P1460, DOI 10.1016/j.ophtha.2008.01.026
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Kutty RK, 2018, CYTOKINE, V104, P147, DOI 10.1016/j.cyto.2017.10.009
   Lee H, 2019, TRENDS GENET, V35, P892, DOI 10.1016/j.tig.2019.09.006
   Liu P, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181469
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lumsden Amanda L, 2018, BMC Res Notes, V11, P285, DOI 10.1186/s13104-018-3384-8
   Luu J, 2020, HUM MOL GENET, V29, P2611, DOI 10.1093/hmg/ddaa158
   Maiorano NA, 2012, INT J MOL SCI, V13, P558, DOI 10.3390/ijms13010558
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Matsumoto A, 2017, NATURE, V541, P228, DOI 10.1038/nature21034
   Meng H, 2018, J BIOL CHEM, V293, P13786, DOI 10.1074/jbc.R117.813485
   Meola N, 2012, RNA, V18, P111, DOI 10.1261/rna.029454.111
   Mullins RF, 2006, MOL VIS, V12, P224
   Muramatsu F, 2013, ONCOGENE, V32, P414, DOI 10.1038/onc.2012.68
   Nair L, 2020, NAT REV MOL CELL BIO, V21, P123, DOI 10.1038/s41580-019-0209-0
   Oskooei VK, 2018, CANCER MANAG RES, V10, P3451, DOI 10.2147/CMAR.S174244
   Pan J, 2021, BIOENGINEERED, V12, P2228, DOI 10.1080/21655979.2021.1933821
   Pawlowska E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112317
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Qiu GZ, 2016, BIOCHEM BIOPH RES CO, V471, P135, DOI 10.1016/j.bbrc.2016.01.164
   Rapicavoli NA, 2011, NEURAL DEV, V6, DOI 10.1186/1749-8104-6-32
   Rapicavoli NA, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-49
   Ratnayaka JA, 2020, NEURAL REGEN RES, V15, P863, DOI 10.4103/1673-5374.268972
   Rinn JL, 2020, ANNU REV BIOCHEM, V89, P283, DOI 10.1146/annurev-biochem-062917-012708
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun C, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0427-3
   Sun HJ, 2021, BIOCHEM GENET, V59, P1617, DOI 10.1007/s10528-021-10072-9
   Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Tiffon C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113425
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang WL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.645647
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   White RJ, 2011, NAT REV GENET, V12, P459, DOI 10.1038/nrg3001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xing YH, 2017, CELL, V169, P664, DOI 10.1016/j.cell.2017.04.011
   Xu XD, 2014, MOL BIOL REP, V41, P4493, DOI 10.1007/s11033-014-3320-5
   Yang T, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0166177, 10.1371/journal.pone.0152687]
   Yao J, 2016, EMBO MOL MED, V8, P346, DOI 10.15252/emmm.201505725
   Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8
   Ye Z, 2017, MOL MED REP, V16, P8399, DOI 10.3892/mmr.2017.7606
   Yin GZ, 2019, AM J TRANSL RES, V11, P3426
   Yin L, 2019, MED SCI MONITOR, V25, P2845, DOI 10.12659/MSM.913359
   Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027
   Yu XY, 2021, BIOCHEM BIOPH RES CO, V535, P39, DOI 10.1016/j.bbrc.2020.10.104
   Zeng BZ, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119811
   Zhang LW, 2020, INT J MED SCI, V17, P292, DOI 10.7150/ijms.37804
   Zhang LS, 2019, INT J MED SCI, V16, P537, DOI 10.7150/ijms.31274
   Zhang PF, 2020, CURR EYE RES, V45, P1403, DOI 10.1080/02713683.2020.1748659
   Zhang XP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225573
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao Y, 2019, EUR REV MED PHARMACO, V23, P9163, DOI 10.26355/eurrev_201911_19406
   Zhu W, 2017, INT J NANOMED, V12, P7589, DOI 10.2147/IJN.S140275
   Zhu YX, 2018, BIOCHEM BIOPH RES CO, V496, P1236, DOI 10.1016/j.bbrc.2018.01.177
   Zylicz JJ, 2019, CELL, V176, P182, DOI 10.1016/j.cell.2018.11.041
NR 108
TC 2
Z9 2
U1 4
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2021
VL 22
IS 17
AR 9178
DI 10.3390/ijms22179178
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UO0KQ
UT WOS:000694393800001
PM 34502084
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Patel, PN
   Patel, PA
   Land, MR
   Bakerkhatib-Taha, I
   Ahmed, H
   Sheth, V
AF Patel, Prem N.
   Patel, Parth A.
   Land, Matthew R.
   Bakerkhatib-Taha, Ibrahim
   Ahmed, Harris
   Sheth, Veeral
TI Targeting the Complement Cascade for Treatment of Dry Age-Related
   Macular Degeneration
SO BIOMEDICINES
LA English
DT Review
DE age-related macular degeneration; geographic atrophy; complement
   cascade; therapeutics; clinical trials
ID GEOGRAPHIC ATROPHY; AVACINCAPTAD PEGOL; C5 INHIBITOR; PROGRESSION;
   CLASSIFICATION; PREVALENCE; DELIVERY; VARIANT; MODELS; DRUSEN
AB Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly population. AMD is characterized in its late form by neovascularization (wet type) or geographic atrophy of the retinal pigment epithelium cell layer (dry type). Regarding the latter type, there is growing evidence supporting an association between the pathophysiology of dry AMD and key proteins in the complement cascade. The complement cascade works as a central part of the innate immune system by defending against foreign pathogens and modified self-tissues. Through three distinct pathways, a series of plasma and membrane-associated serum proteins are activated upon identification of a foreign entity. Several of these proteins have been implicated in the development and progression of dry AMD. Potential therapeutic targets include C1q, C3, C5, complement factors (B, D, H, I), membrane attack complex, and properdin. In this review, we provide an understanding of the role of the complement system in dry AMD and discuss the emerging therapies in early phase clinical trials. The tentative hope is that these drugs may offer the potential to intervene at earlier stages in dry AMD pathogenesis, thereby preventing progression to late disease.
C1 [Patel, Prem N.] Univ Texas Southwestern Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA.
   [Patel, Parth A.; Land, Matthew R.] Augusta Univ, Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA.
   [Bakerkhatib-Taha, Ibrahim; Sheth, Veeral] Univ Retina & Macula Associates, Oak Forest, IL 60452 USA.
   [Ahmed, Harris] Loma Linda Univ, Dept Ophthalmol, Med Ctr, Loma Linda, CA 92350 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University System of Georgia; Augusta University; Loma
   Linda University
RP Sheth, V (通讯作者)，Univ Retina & Macula Associates, Oak Forest, IL 60452 USA.
EM vsheth@uretina.com
OI Patel, Parth/0000-0001-6001-8462; Patel, Prem/0000-0003-4942-3277
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Agron E, 2022, OPHTHALMOL RETINA, V6, P762, DOI 10.1016/j.oret.2022.03.022
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], GEMINI THERAPEUTICS
   [Anonymous], APELLIS COMPLETES EN
   Arrigo A, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5516981
   Belgio B, 2021, BIOENGINEERING-BASEL, V8, DOI 10.3390/bioengineering8020018
   Bhattarai N, 2022, IMMUNOL RES, V70, P678, DOI 10.1007/s12026-022-09300-0
   Bird AC, 2018, EYE, V32, P858, DOI 10.1038/eye.2017.247
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brown GC, 2020, AM J OPHTHALMOL, V218, P225, DOI 10.1016/j.ajo.2020.05.029
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chang YY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084056
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cooper RC, 2019, J CONTROL RELEASE, V306, P29, DOI 10.1016/j.jconrel.2019.05.034
   Costa JR, 2015, EUR J CLIN MICROBIOL, V34, P1255, DOI 10.1007/s10096-015-2344-7
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Desai D, 2022, EYE, V36, P294, DOI 10.1038/s41433-021-01765-x
   Dorschmann P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239272
   Dreismann AK, 2021, GENE THER, V28, P265, DOI 10.1038/s41434-021-00239-9
   Dugel PU., 2020, RETIN PHYS, V17, P16
   Eells JT, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020031
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fong D., 2021, P 2 DRY AMD THERAPEU
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia-Garcia Julian, 2022, Ophthalmic Res, DOI 10.1159/000524942
   Glazer LC, 2016, INVEST OPHTH VIS SCI, V57
   Goldberg R., 2022, P 2022 ARVO ANN M
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P673, DOI 10.1016/j.oret.2020.01.019
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Horner F, 2021, CLIN OPHTHALMOL, V15, P1703, DOI 10.2147/OPTH.S305141
   Hsu MY, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10071125
   Hu ML, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070635
   Hughes S, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108391
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2020, INVEST OPHTH VIS SCI, V61
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Johnson L, 2016, INVEST OPHTH VIS SCI, V57
   Kalu K., 2022, CURR DEV NUTR, V6, P295, DOI [10.1093/cdn/nzac053.036, DOI 10.1093/CDN/NZAC053.036]
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kaushal S., 2009, INVESTIG OPHTHALMOL, V50, P5010
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Khanani Arshad M, 2022, Ophthalmol Sci, V2, P100154, DOI 10.1016/j.xops.2022.100154
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kim B.J., 2020, P RETINA SOC
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Kuan V, 2021, JAMA OPHTHALMOL, V139, P1299, DOI 10.1001/jamaophthalmol.2021.4601
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lazzarini R, 2022, MOL CELL BIOCHEM, V477, P67, DOI 10.1007/s11010-021-04258-3
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Lin Jonathan B, 2022, Ophthalmol Sci, V2, DOI 10.1016/j.xops.2022.100118
   Liutkeviciene R, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1357
   Lorthiois E, 2017, J MED CHEM, V60, P5717, DOI 10.1021/acs.jmedchem.7b00425
   Lynch CR, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00228
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Matsubara JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00574
   Maugeri A, 2019, ACTA OPHTHALMOL, V97, pE8, DOI 10.1111/aos.13849
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Nagata K, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101958
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Nielsen J.S., 2022, P ARVO 2022 ANN M
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nittala MG, 2022, JAMA OPHTHALMOL, V140, P243, DOI 10.1001/jamaophthalmol.2021.6067
   Pandi SPS, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108404
   Qin SQ, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9945725
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   Ratnapriya R, 2020, HUM MOL GENET, V29, P2022, DOI 10.1093/hmg/ddaa057
   Robin AL, 2019, EXPERT REV OPHTHALMO, V14, P199, DOI 10.1080/17469899.2019.1635456
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Seddon JM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.32
   Sheth V, 2021, INVEST OPHTH VIS SCI, V62
   Sobolewska B, 2021, CLIN OPHTHALMOL, V15, P4317, DOI 10.2147/OPTH.S325763
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Sterling JK, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110942
   Tang MH, 2021, J RECEPT SIG TRANSD, V41, P188, DOI 10.1080/10799893.2020.1805625
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Udsen M, 2022, EXP EYE RES, V218, DOI 10.1016/j.exer.2022.108982
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang JC, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e08973
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wykoff CC, 2022, AM J OPHTHALMOL, V235, P131, DOI 10.1016/j.ajo.2021.08.018
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yip JLY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132565
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zhou HJ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1004-y
NR 108
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD AUG
PY 2022
VL 10
IS 8
AR 1884
DI 10.3390/biomedicines10081884
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 4D5DE
UT WOS:000847159900001
PM 36009430
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fragiotta, S
   Scuderi, L
   Iodice, CM
   Rullo, D
   Di Pippo, M
   Maugliani, E
   Abdolrahimzadeh, S
AF Fragiotta, Serena
   Scuderi, Luca
   Iodice, Clemente Maria
   Rullo, Daria
   Di Pippo, Mariachiara
   Maugliani, Elisa
   Abdolrahimzadeh, Solmaz
TI Choroidal Vasculature Changes in Age-Related Macular Degeneration: From
   a Molecular to a Clinical Perspective
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE choroid; retina; age-related macular degeneration; choroidal vascularity
   index; aging
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; COMPLEMENT
   FACTOR-H; SUBRETINAL DRUSENOID DEPOSITS; SWEPT-SOURCE; RETICULAR
   PSEUDODRUSEN; BRUCHS MEMBRANE; GEOGRAPHIC ATROPHY; VASCULARITY INDEX;
   HUMAN CHORIOCAPILLARIS
AB The contribution of choroidal vasculature to the pathogenesis of age-related macular degeneration (AMD) has been long debated. The present narrative review aims to discuss the primary molecular and choroidal structural changes occurring with aging and AMD with a brief overview of the principal multimodal imaging modalities and techniques that enable the optimal in vivo visualization of choroidal modifications. The molecular aspects that target the choroid in AMD mainly involve human leukocyte antigen (HLA) expression, complement dysregulation, leukocyte interaction at Bruch's membrane, and mast cell infiltration of the choroid. A mechanistic link between high-risk genetic loci for AMD and mast cell recruitment has also been recently demonstrated. Recent advances in multimodal imaging allow more detailed visualization of choroidal structure, identifying alterations that may expand our comprehension of aging and AMD development.
C1 [Fragiotta, Serena; Iodice, Clemente Maria; Rullo, Daria; Di Pippo, Mariachiara; Maugliani, Elisa] Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sense Organs NESMOS, Ophthalmol Unit, St Andrea Hosp, I-00189 Rome, Italy.
   [Scuderi, Luca; Abdolrahimzadeh, Solmaz] Univ Sapienza Rome, Dept Sense Organs, I-00161 Rome, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza
   University Rome
RP Fragiotta, S (通讯作者)，Univ Roma La Sapienza, Dept Neurosci Mental Hlth & Sense Organs NESMOS, Ophthalmol Unit, St Andrea Hosp, I-00189 Rome, Italy.
EM s.fragiotta@hotmail.it
RI Iodice, Clemente M./GLU-4013-2022; Fragiotta, Serena/I-5227-2016
OI Iodice, Clemente M./0000-0003-1688-6646; Fragiotta,
   Serena/0000-0002-6214-6270; Di Pippo, Mariachiara/0000-0002-1089-2060
FU Sapienza University of Rome [AR22117A81528669]
FX The APC was partially funded by Sapienza University of Rome through the
   support of "Research Initiation Projects-Type 2", 2021. Protocol n.
   AR22117A81528669. The funder had no role in study design; data
   collection and analysis; the decision to publish; or the preparation of
   the manuscript.
CR Abdolrahimzadeh S, 2022, EYE, DOI 10.1038/s41433-022-02134-y
   Abdolrahimzadeh S, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app112110487
   Abdolrahimzadeh S, 2019, EYE, V33, P1290, DOI 10.1038/s41433-019-0405-3
   Abdolrahimzadeh S, 2017, OPHTHALMIC GENET, V38, P567, DOI 10.1080/13816810.2017.1313995
   Abdolrahimzadeh S, 2017, SURV OPHTHALMOL, V62, P250, DOI 10.1016/j.survophthal.2016.11.005
   Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Bafiq R, 2015, AM J OPHTHALMOL, V160, P1034, DOI 10.1016/j.ajo.2015.07.027
   Banister K, 2022, HEALTH TECHNOL ASSES, V26, DOI 10.3310/VLFL1739
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Breher K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.8
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Clemens CR, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97771-w
   Corvi F, 2021, RETINA-J RET VIT DIS, V41, P686, DOI 10.1097/IAE.0000000000002990
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Csaky Karl, 2022, Exp Eye Res, V221, P109134, DOI 10.1016/j.exer.2022.109134
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dansingani K.K., 2019, CENTRAL SEROUS CHORI, P11, DOI [10.1016/B978-0-12-816800-4.00002-4, DOI 10.1016/B978-0-12-816800-4.00002-4]
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V191, P23, DOI 10.1016/j.ajo.2018.03.038
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   Fragiotta Serena, 2022, Invest Ophthalmol Vis Sci, V63, P16, DOI 10.1167/iovs.63.3.16
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Grenga PL, 2016, EUR J OPHTHALMOL, V26, P145, DOI 10.5301/ejo.5000687
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gupta N., 2022, ANATOMY HEAD NECK EY
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kinoshita T, 2017, BRIT J OPHTHALMOL, V101, P360, DOI 10.1136/bjophthalmol-2016-308594
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Ledesma-Gil G, 2020, RETINA-J RET VIT DIS, V40, P1865, DOI 10.1097/IAE.0000000000002866
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Lee MW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229134
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lejoyeux R, 2022, PROG RETIN EYE RES, V87, DOI 10.1016/j.preteyeres.2021.100997
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   MANCINI MA, 1986, INVEST OPHTH VIS SCI, V27, P336
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mcharg S, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2118510119
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Munk M, 2021, KLIN MONATSBL AUGENH, V238, P951, DOI 10.1055/a-1562-8731
   Nassisi M, 2021, AM J OPHTHALMOL, V222, P302, DOI 10.1016/j.ajo.2020.04.018
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Ozcaliskan S, 2020, EUR J OPHTHALMOL, V30, P1512, DOI 10.1177/1120672120919341
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rahman W, 2011, INVEST OPHTH VIS SCI, V52, P2267, DOI 10.1167/iovs.10-6024
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Sacconi R, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.12.26
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P98, DOI 10.1136/bjo.57.2.98
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Shi YY, 2021, AM J OPHTHALMOL, V224, P321, DOI 10.1016/j.ajo.2020.12.015
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tan CS, 2016, BRIT J OPHTHALMOL, V100, P995, DOI 10.1136/bjophthalmol-2015-307541
   Tan CSH, 2015, BRIT J OPHTHALMOL, V99, P354, DOI 10.1136/bjophthalmol-2014-305331
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Viggiano P, 2022, EUR J OPHTHALMOL, V32, P460, DOI 10.1177/1120672121992009
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Wei X, 2018, INVEST OPHTH VIS SCI, V59, P1206, DOI 10.1167/iovs.17-22720
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Wu ZC, 2022, PROG RETIN EYE RES, V88, DOI 10.1016/j.preteyeres.2021.101017
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
NR 126
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2022
VL 23
IS 19
AR 12010
DI 10.3390/ijms231912010
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 5H5UP
UT WOS:000867744500001
PM 36233311
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mallik, S
   Grodstein, F
   Bennett, DA
   Vavvas, DG
   Lemos, B
AF Mallik, Saurav
   Grodstein, Fran
   Bennett, David A.
   Vavvas, Demetrios G.
   Lemos, Bernardo
TI Novel Epigenetic Clock Biomarkers of Age-Related Macular Degeneration
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE age related macular degeneration (AMD); age acceleration; age clocks;
   biomarkers; GDF11; retina; clocks; FBN2
ID GEOGRAPHIC ATROPHY; SKELETAL-MUSCLE; IL17RC PROMOTER; DNA METHYLATION;
   GDF11; RISK; HYPOMETHYLATION; PROGRESSION; PREVALENCE; EXPRESSION
AB Age-Related Macular Degeneration (AMD) is a bilateral ocular condition resulting in irreversible vision impairment caused by the progressive loss of photoreceptors in the macula, a region at the center of the retina. The progressive loss of photoreceptor is a key feature of dry AMD but not always wet AMD, though both forms of AMD can lead to loss of vision. Regression-based biological age clocks are one of the most promising biomarkers of aging but have not yet been used in AMD. Here we conducted analyses to identify regression-based biological age clocks for the retina and explored their use in AMD using transcriptomic data consisting of a total of 453 retina samples including 105 Minnesota Grading System (MGS) level 1 samples, 175 MGS level 2, 112 MGS level 3 and 61 MGS level 4 samples, as well as 167 fibroblast samples. The clocks yielded good separation among AMD samples with increasing severity score viz., MGS1-4, regardless of whether clocks were trained in retina tissue, dermal fibroblasts, or in combined datasets. Clock application to cultured fibroblasts, embryonic stem cells, and induced Pluripotent Stem Cells (iPSCs) were consistent with age reprograming in iPSCs. Moreover, clock application to in vitro neuronal differentiation suggests broader applications. Interesting, many of the age clock genes identified include known targets mechanistically linked to AMD and aging, such as GDF11, C16ORF72, and FBN2. This study provides new observations for retina age clocks and suggests new applications for monitoring in vitro neuronal differentiation. These clocks could provide useful markers for AMD monitoring and possible intervention, as well as potential targets for in vitro screens.
C1 [Mallik, Saurav; Lemos, Bernardo] Harvard T H Chan Sch Publ Hlth, Dept Environm Hlth, Program Mol & Integrat Physiol Sci, Boston, MA 02115 USA.
   [Grodstein, Fran; Bennett, David A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL USA.
   [Vavvas, Demetrios G.] Harvard Med Sch, Dept Ophthalmol Mass Eye & Ear, Retina Serv, Ines & Frederick Yeatts Retina Res Lab, Boston, MA USA.
   [Lemos, Bernardo] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Rush
   University; Harvard University; Harvard Medical School; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad Institute
RP Lemos, B (通讯作者)，Harvard T H Chan Sch Publ Hlth, Dept Environm Hlth, Program Mol & Integrat Physiol Sci, Boston, MA 02115 USA.; Lemos, B (通讯作者)，Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
EM blemos@hsph.harvard.edu
OI Mallik, Saurav/0000-0003-4107-6784
FU NIH [R01ES027981, R01AG069904, P30AG72975]; Lemann Foundation Award
FX We thank members of the Lemos Lab for their valuable comments and
   discussions during development of this project. Research in the Lemos
   lab was partially supported by NIH grants R01ES027981, R01AG069904, and
   a Lemann Foundation Award. This research was also partially supported by
   NIH grant P30AG72975.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Bandyopadhyay S, 2014, IEEE ACM T COMPUT BI, V11, P95, DOI 10.1109/TCBB.2013.147
   Benslimane Y, 2021, AGING CELL, V20, DOI 10.1111/acel.13331
   Bontzos G, 2020, OPHTHALMOL RETINA, V4, P1138, DOI 10.1016/j.oret.2019.11.004
   Brooks MJ, 2019, STEM CELL REP, V13, P891, DOI 10.1016/j.stemcr.2019.09.009
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Di Lena P, 2021, NUCLEIC ACIDS RES, V49, pW199, DOI 10.1093/nar/gkab426
   Dudik JM, 2015, COMPUT BIOL MED, V59, P10, DOI 10.1016/j.compbiomed.2015.01.007
   Egerman MA, 2019, CRIT REV BIOCHEM MOL, V54, P174, DOI 10.1080/10409238.2019.1610722
   Egerman MA, 2015, CELL METAB, V22, P164, DOI 10.1016/j.cmet.2015.05.010
   Engebretsen S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0730-1
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fransquet PD, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0656-7
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Galkin F, 2020, AGEING RES REV, V60, DOI 10.1016/j.arr.2020.101050
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hahsler M, 2019, J STAT SOFTW, V91, P1, DOI 10.18637/jss.v091.i01
   Hammers DW, 2017, EMBO MOL MED, V9, P531, DOI 10.15252/emmm.201607231
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Harper SC, 2018, CIRC RES, V123, P1220, DOI 10.1161/CIRCRESAHA.118.312955
   Hartmann A, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.686320
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Horvath S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r115
   Hoyle D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189053
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2015, J CLIN MED, V4, P425, DOI 10.3390/jcm4030425
   Lai RW, 2019, BMB REP, V52, P86, DOI 10.5483/BMBRep.2019.52.1.296
   Lee AY, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.62
   Lin JB, 2022, EYE, V36, P312, DOI 10.1038/s41433-021-01780-y
   Ma YT, 2021, AGING-US, V13, P12258, DOI 10.18632/aging.202881
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miller JW, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051124
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nguyen T, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.604220
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Oliver VF, 2013, CELL REP, V5, P1527, DOI 10.1016/j.celrep.2013.11.042
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Ratnapriya R, 2019, NAT GENET, V51, P1067, DOI 10.1038/s41588-019-0430-y
   Ratnapriya R, 2014, HUM MOL GENET, V23, P5827, DOI 10.1093/hmg/ddu276
   Reich NG, 2016, AM STAT, V70, P285, DOI 10.1080/00031305.2016.1148631
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schick T, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.17
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8
   Sinha M, 2014, SCIENCE, V344, P649, DOI 10.1126/science.1251152
   Vallee A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030820
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE5640, DOI 10.1073/pnas.1804781115
   Vavvas DG, 2018, P NATL ACAD SCI USA, V115, pE696, DOI 10.1073/pnas.1718059115
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vickers AJ, 2018, P NATL ACAD SCI USA, V115, pE5639, DOI 10.1073/pnas.1803536115
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang M, 2019, GENOME RES, V29, P325, DOI 10.1101/gr.241745.118
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
NR 70
TC 2
Z9 2
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 16
PY 2022
VL 9
AR 856853
DI 10.3389/fmed.2022.856853
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2O9JF
UT WOS:000819365800001
PM 35783640
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schlecht, A
   Boneva, S
   Gruber, M
   Zhang, PP
   Horres, R
   Bucher, F
   Auw-Haedrich, C
   Hansen, L
   Stahl, A
   Hilgendorf, I
   Agostini, H
   Wieghofer, P
   Schlunck, G
   Wolf, J
   Lange, CAK
AF Schlecht, Anja
   Boneva, Stefaniya
   Gruber, Markus
   Zhang, Peipei
   Horres, Ralf
   Bucher, Felicitas
   Auw-Haedrich, Claudia
   Hansen, Lutz
   Stahl, Andreas
   Hilgendorf, Ingo
   Agostini, Hansjurgen
   Wieghofer, Peter
   Schlunck, Gunther
   Wolf, Julian
   Lange, Clemens A. K.
TI Transcriptomic Characterization of Human Choroidal Neovascular Membranes
   Identifies Calprotectin as a Novel Biomarker for Patients with
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GENE-EXPRESSION; CELLS; DISEASE; RNA;
   COMPLEX; SURGERY; TARGET; S100A9
AB Recent studies deciphering the transcriptional profile of choroidal neovascularization (CNV) in body donor eyes with neovascular age-related macular degeneration are limited by the time span from death to preservation and the associated 5'-RNA degradation. This study therefore used CNV and control specimens that were formalin-fixed and paraffin-embedded immediately after surgical extraction and analyzed them by a 3'-RNA sequencing approach. Transcriptome profiles were analyzed to estimate content of immune and stromal cells and to define disease-associated gene signatures by using statistical and bioinformatics methods. This study identified 158 differentially expressed genes (DEGs) that were significantly increased in CNV compared with control tissue. Cell type enrichment analysis revealed a diverse cellular landscape with an enrichment of endothelial cells, macrophages, T cells, and natural killer T cells in the CNV. Gene ontology enrichment analysis found that DEGs contributed to blood vessel development, extracellular structure organization, response to wounding, and several immune-related terms. The S100 calciumbinding proteins A8 (S100A8) and A9 (S100A9) emerged among the top DEGs, as confirmed by immunohistochemistry on CNV tissue and protein analysis of vitreous samples. This study provides a high-resolution RNA-sequencing-based transcriptional signature of human CNV, characterizes its compositional pattern of immune and stromal cells, and reveals S100A8/A9 to be a novel biomarker and promising target for therapeutics and diagnostics directed at age-related macular degeneration.
C1 [Schlecht, Anja; Boneva, Stefaniya; Gruber, Markus; Zhang, Peipei; Bucher, Felicitas; Auw-Haedrich, Claudia; Hansen, Lutz; Stahl, Andreas; Agostini, Hansjurgen; Schlunck, Gunther; Wolf, Julian; Lange, Clemens A. K.] Univ Freiburg, Eye Ctr, Freiburg, Germany.
   [Hilgendorf, Ingo] Univ Freiburg, Med Ctr, Fac Med, Freiburg, Germany.
   [Hilgendorf, Ingo] Univ Freiburg, Heart Ctr Freiburg, Freiburg, Germany.
   [Horres, Ralf] GenXPro GmbH, Frankfurt Innovat Ctr Biotechnol, Frankfurt, Germany.
   [Stahl, Andreas] Univ Med Ctr Greifswald, Dept Ophthalmol, Greifswald, Germany.
   [Wieghofer, Peter] Univ Leipzig, Inst Anat, Leipzig, Germany.
C3 University of Freiburg; University of Freiburg; Universitats Herzzentrum
   Freiburg; University of Freiburg; Greifswald Medical School; Leipzig
   University
RP Lange, CAK (通讯作者)，Univ Freiburg, Med Ctr, Eye Ctr, Killianstr 5, D-79106 Freiburg, Germany.
EM clemens.lange@uniklinik-freiburg.de
RI Wieghofer, Peter/AAV-9572-2020; Wolf, Julian/AAV-9571-2020; Hilgendorf,
   Ingo/AFM-6379-2022
OI Wolf, Julian/0000-0002-3470-9697; Hilgendorf, Ingo/0000-0002-0024-1643;
   Boneva, Stefaniya/0000-0002-9811-2160; Bucher,
   Felicitas/0000-0003-0081-1420
FU DFG [SFB/TRR167]; Helmut Ecker Foundation [02/19]
FX Supported by DFG SFB/TRR167 (C.A.K.L.) and Helmut Ecker Foundation grant
   02/19 (C.A.K.L.).
CR Abdueva D, 2010, J MOL DIAGN, V12, P409, DOI 10.2353/jmoldx.2010.090155
   Afgan E, 2018, NUCLEIC ACIDS RES, V46, pW537, DOI 10.1093/nar/gky379
   Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Bjork P, 2009, PLOS BIOL, V7, P800, DOI 10.1371/journal.pbio.1000097
   Blair JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151615
   Boeck M, 2020, GLIA, V68, P1859, DOI 10.1002/glia.23810
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cesaro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045478
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Esteve P, 2019, NAT NEUROSCI, V22, P1258, DOI 10.1038/s41593-019-0432-1
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Finotello F, 2018, CANCER IMMUNOL IMMUN, V67, P1031, DOI 10.1007/s00262-018-2150-z
   Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Hijioka K, 2008, BIOCHEM BIOPH RES CO, V374, P38, DOI 10.1016/j.bbrc.2008.06.080
   Hunter A, 2012, INVEST OPHTH VIS SCI, V53, P2089, DOI 10.1167/iovs.11-8449
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Lange CAK, 2018, EYE, V32, P1772, DOI 10.1038/s41433-018-0172-6
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu F, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-153
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Maguire MG, 2016, JAMA OPHTHALMOL, V134, P674, DOI 10.1001/jamaophthalmol.2016.0669
   Malik KF, 2003, INVEST OPHTH VIS SCI, V44, P2730, DOI 10.1167/iovs.02-1120
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363
   Sung HJ, 2012, MOL VIS, V18, P234
   Swindell WR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01215
   Tran TL, 2016, OPHTHALMIC RES, V55, P180, DOI 10.1159/000443207
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wada T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122723
   Wagner GP, 2012, THEOR BIOSCI, V131, P281, DOI 10.1007/s12064-012-0162-3
   Wang C, 2014, ACTA NEUROPATHOL, V127, P507, DOI 10.1007/s00401-013-1208-4
   Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu D, 2019, FASEB J, V33, P2498, DOI 10.1096/fj.201801227R
   Yendrek Craig R, 2012, BMC Res Notes, V5, P506, DOI 10.1186/1756-0500-5-506
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
NR 57
TC 22
Z9 21
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD AUG
PY 2020
VL 190
IS 8
BP 1632
EP 1642
DI 10.1016/j.ajpath.2020.04.004
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA MQ1RI
UT WOS:000552675100006
PM 32339498
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Acton, JH
   Gibson, JM
   Cubbidge, RP
AF Acton, Jennifer H.
   Gibson, Jonathan M.
   Cubbidge, Robert P.
TI Quantification of Visual Field Loss in Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID WAVELENGTH AUTOMATED PERIMETRY; BLUE-ON-YELLOW; MULTIFOCAL
   ELECTRORETINOGRAM; MACULOPATHY; SENSITIVITY; VULNERABILITY; DISEASE;
   DRUSEN; ACUITY; CLASSIFICATION
AB Background: An evaluation of standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP) for the central 10-2 visual field test procedure in patients with age-related macular degeneration (AMD) is presented in order to determine methods of quantifying the central sensitivity loss in patients at various stages of AMD.
   Methods: 10-2 SAP and SWAP Humphrey visual fields and stereoscopic fundus photographs were collected in 27 eyes of 27 patients with AMD and 22 eyes of 22 normal subjects.
   Results: Mean Deviation and Pattern Standard Deviation (PSD) varied significantly with stage of disease in SAP (both p < 0.001) and SWAP (both p < 0.001), but post hoc analysis revealed overlap of functional values among stages. In SWAP, indices of focal loss were more sensitive to detecting differences in AMD from normal. SWAP defects were greater in depth and area than those in SAP. Central sensitivity (within 1 degrees) changed by -3.9 and -4.9 dB per stage in SAP and SWAP, respectively. Based on defect maps, an AMD Severity Index was derived.
   Conclusions: Global indices of focal loss were more sensitive to detecting early stage AMD from normal. The SWAP sensitivity decline with advancing stage of AMD was greater than in SAP. A new AMD Severity Index quantifies visual field defects on a continuous scale. Although not all patients are suitable for SWAP examinations, it is of value as a tool in research studies of visual loss in AMD.
C1 [Acton, Jennifer H.] NYU, Dept Ophthalmol, New York, NY 10016 USA.
   [Acton, Jennifer H.; Gibson, Jonathan M.; Cubbidge, Robert P.] Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
   [Gibson, Jonathan M.] Birmingham & Midland Eye Ctr, Birmingham, W Midlands, England.
C3 New York University; Aston University
RP Acton, JH (通讯作者)，NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.
EM jenniferhacton@gmail.com
RI Acton, Jennifer/AAU-3307-2021
OI Acton, Jennifer/0000-0002-0347-7651; Gibson, Jonathan
   M/0000-0002-9281-5244; Cubbidge, Robert P/0000-0002-7851-1375
FU College of Optometrists
FX Presented in part at the 2009 annual meeting of the Association for
   Research in Vision and Ophthalmology, Florida, for which the College of
   Optometrists provided a travel grant to J Acton.
CR Agardh E, 2006, DIABETOLOGIA, V49, P200, DOI 10.1007/s00125-005-0072-8
   Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   ATCHISON DA, 1990, OPTOMETRY VISION SCI, V67, P179, DOI 10.1097/00006324-199003000-00006
   Bengtsson B, 2005, DIABETOLOGIA, V48, P2494, DOI 10.1007/s00125-005-0001-x
   Bengtsson B, 2008, ACTA OPHTHALMOL, V86, P170, DOI 10.1111/j.1600-0420.2007.01019.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Conway M, 2008, EPILEPSIA, V49, P108, DOI 10.1111/j.1528-1167.2007.01249.x
   CRABB DP, 1995, BRIT J OPHTHALMOL, V79, P213, DOI 10.1136/bjo.79.3.213
   Cubbidge RP, 2002, GRAEF ARCH CLIN EXP, V240, P650, DOI 10.1007/s00417-002-0509-4
   Durad AC, 1910, J AMER MED ASSOC, V55, P369, DOI 10.1001/jama.1910.04330050007004
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   HART WM, 1983, OPHTHALMOLOGY, V90, P1028
   HOOD DC, 1984, INVEST OPHTH VIS SCI, V25, P864
   Hudson C, 1998, DIABETOLOGIA, V41, P918, DOI 10.1007/s001250051008
   Johnson C A, 1994, J Glaucoma, V3 Suppl 1, pS32
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P645, DOI 10.1001/archopht.1993.01090050079034
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P651, DOI 10.1001/archopht.1993.01090050085035
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Remky A, 2000, INVEST OPHTH VIS SCI, V41, P274
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SAMPLE PA, 1994, AM J OPHTHALMOL, V118, P632, DOI 10.1016/S0002-9394(14)76578-X
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wild JM, 1998, INVEST OPHTH VIS SCI, V39, P54
   WILD JM, 1995, OPHTHALMOLOGY, V102, P911, DOI 10.1016/S0161-6420(95)30935-9
NR 45
TC 14
Z9 15
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2012
VL 7
IS 6
AR e39944
DI 10.1371/journal.pone.0039944
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 967FO
UT WOS:000305892100148
PM 22768178
OA gold, Green Submitted, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Patel, N
   Adewoyin, T
   Chong, NV
AF Patel, N.
   Adewoyin, T.
   Chong, N. V.
TI Age-related macular degeneration: a perspective on genetic studies
SO EYE
LA English
DT Article
DE genetics; age-related macular degeneration; systemic review; complement
   factor H
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E POLYMORPHISMS; STARGARDT DISEASE
   GENE; ALLELIC VARIATION; CANDIDATE GENE; BEST-DISEASE; ABCR GENE; VMD2
   GENE; JAPANESE PATIENTS; EPSILON-4 ALLELE
AB Aim Age-related macular degeneration (AMD) is a common macular disease in the developed world and recent studies have shown that specific genes may be associated with it and may contribute to a higher risk of developing AMD.
   Objective Our objective was to review systematically recent publications related to the genetics of AMD and provide relevant information that would help both scientists and clinicians in advising patients.
   Method A systematic search was performed on PubMed, Medline, and National Library of Medicine as well as ARVO abstracts using key words relevant to the genetic associations of AMD.
   Results The most important genetic associations in AMD involved the complement factor H (CFH) gene, which showed that possession of the variant Y402H polymorphism significantly increases the risk for AMD. Protective genes have also been identified such as those on either factor B (BF or complement factor B (CFB)) or complement component 2 (C2) genes. The genes involved in inherited macular dystrophies such as ATP-binding cassette, subfamily A (ABC1), member 4 (ABCA4), vitelliform macular dystrophy (VMD2), tissue inhibitor of matrix metalloproteinase-3 (TIMP3), and EFEMP1 have yielded some important information but further confirmatory work has yet to establish a clear association with AMD.
   Conclusion Patients with AMD possess specific genetic variants of the CFH gene, which put them at a higher risk of developing the disease. Other unaffected individuals may possess certain protective genetic variants, which could prevent them from developing AMD. Further research will no doubt shed light on other such mechanisms and these will be useful in identifying possible direct targets for drugs or indirectly through modulation of the genes responsible for disease presentation.
C1 [Patel, N.; Adewoyin, T.; Chong, N. V.] Kings Coll Hosp London, Laser & Retinal Res Unit, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Chong, NV (通讯作者)，Kings Coll Hosp London, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018; Chong, Ngaihang V/A-5141-2009
OI Chong, Victor/0000-0002-7693-522X; 
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Akimoto A, 2001, GRAEF ARCH CLIN EXP, V239, P66, DOI 10.1007/PL00007900
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2004, AM J OPHTHALMOL, V138, P665, DOI 10.1016/j.ajo.2004.04.053
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Bernstein PS, 2002, INVEST OPHTH VIS SCI, V43, P466
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2000, JPN J OPHTHALMOL, V44, P245, DOI 10.1016/S0021-5155(00)00150-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Guymer RH, 2002, CLIN EXP OPHTHALMOL, V30, P419, DOI 10.1046/j.1442-9071.2002.00572.x
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayashi M, 2004, Ophthalmic Genet, V25, P111
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson LV, 2004, NEW ENGL J MED, V351, P320, DOI 10.1056/NEJMp048131
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein Michael L, 2003, Ophthalmol Clin North Am, V16, P567, DOI 10.1016/S0896-1549(03)00063-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447
   Kuehn MH, 2001, INVEST OPHTH VIS SCI, V42, P3123
   Kuroiwa S, 1999, BRIT J OPHTHALMOL, V83, P613, DOI 10.1136/bjo.83.5.613
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Lu H, 2005, CANCER RES, V65, P5015, DOI 10.1158/0008-5472.CAN-04-2786
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   Marx J, 2006, SCIENCE, V314, P405
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Morohashi K, 2003, CHEST, V123, P1520, DOI 10.1378/chest.123.5.1520
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak Mariusz, 2004, Klin Oczna, V106, P427
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Suganthalakshmi B, 2006, MOL VIS, V12, P336
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Wong TY, 2006, OPHTHALMOLOGY, V113, P255, DOI 10.1016/j.ophtha.2005.10.048
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 92
TC 48
Z9 53
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 768
EP 776
DI 10.1038/sj.eye.6702844
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800005
PM 17491602
OA Bronze
DA 2022-11-30
ER

PT J
AU Miotto, S
   Zemella, N
   Gusson, E
   Panozzo, G
   Saviano, S
   Scarpa, G
   Boschi, G
   Piermarocchi, S
AF Miotto, Stefania
   Zemella, Nicola
   Gusson, Elena
   Panozzo, Giacomo
   Saviano, Sandro
   Scarpa, Giuseppe
   Boschi, Giorgio
   Piermarocchi, Stefano
CA Italian GAT Grp Angiografico
TI Morphologic Criteria of Lesion Activity in Neovascular Age-Related
   Macular Degeneration: A Consensus Article
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
DE neovascular age-related macular degeneration; choroidal
   neovascularization; lesion activity; morphologic criteria; antivascular
   endothelial growth factor
ID OPTICAL-COHERENCE-TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL
   ANGIOMATOUS PROLIFERATION; PIGMENT EPITHELIAL DETACHMENT; FUNDUS
   FLUORESCEIN ANGIOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; ENDOTHELIAL
   GROWTH-FACTOR; PHOTODYNAMIC THERAPY; VISUAL-ACUITY; CLINICOPATHOLOGICAL
   CORRELATION
AB Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD). Individualized treatment regimens aim at obtaining the same visual benefits of monthly injections with a reduced number of injections and follow-up visits, and, consequently, of treatment burden. The target of these strategies is to timely recognize lesion recurrence, even before visual deterioration. Early detection of lesion activity is critical to ensure that clinical outcomes are not compromised by inappropriate delays in treatment, but questions remain on how to effectively monitor the choroidal neovascularization (CNV) activity. To assess the persistence/recurrence of lesion activity in patients undergoing treatment for nAMD, an expert panel developed a decision algorithm based on the morphological features of CNV. After evaluating all current retinal imaging techniques, the panel identified optical coherent tomography as the most reliable tool to ascertain lesion activity when funduscopy is not obvious.
C1 [Miotto, Stefania] ULSS 6 Euganea, Camposampiero Hosp, Dept Ophthalmol, Via Gattamelata 134, I-35128 Padua, Italy.
   [Zemella, Nicola] ULSS 3 Serenissima, Mestre Hosp, Dept Ophthalmol, Venice, Italy.
   [Gusson, Elena] Univ Verona, Dept Ophthalmol, Verona, Italy.
   [Panozzo, Giacomo] ULSS 9 Scaligera, Bussolengo Hosp, Dept Ophthalmol, Verona, Italy.
   [Saviano, Sandro] Univ Trieste, Dept Ophthalmol, Trieste, Italy.
   [Scarpa, Giuseppe; Boschi, Giorgio] ULSS 2 Marca Trevigiana, Ca Foncello Hosp, Dept Ophthalmol, Treviso, Italy.
   [Piermarocchi, Stefano] Univ Padua, Dept Ophthalmol, Padua, Italy.
C3 ULSS 6 Euganea; Ospedale di Camposampiero; ULSS 3 Serenissima; Ospedale
   SS Giovanni Paolo Venezia; University of Verona; ULSS 9 Scaligera;
   Ospedale Orlandi di Bussolengo; University of Trieste; ULSS 2 Marca TV;
   Ospedale Ca' Foncello Treviso; University of Padua
RP Miotto, S (通讯作者)，ULSS 6 Euganea, Camposampiero Hosp, Dept Ophthalmol, Via Gattamelata 134, I-35128 Padua, Italy.
EM stefania.miotto@libero.it
FU Novartis Farma SpA, Italy
FX Writing assistance was provided by Dr. Colin Gerard Egan and Dr. Clara
   Ricci (Primula Multimedia S.r.l.) and funded by Novartis Farma SpA,
   Italy.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Avci R, 2008, EYE, V22, P1099, DOI 10.1038/sj.eye.6702877
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   BIRD AC, 1991, EYE, V5, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2009, OPHTHALMOLOGY, V116
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gillies M. C., 2015, OPHTHALMOLOGY, V122
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Henschel A, 2009, EUR J OPHTHALMOL, V19, P831, DOI 10.1177/112067210901900523
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kuehlewein L, 2015, EYE, V29, P932, DOI 10.1038/eye.2015.80
   Kuehlewein L, 2016, OSLI RETINA, V47, P224, DOI 10.3928/23258160-20160229-04
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Muether PS, 2014, BRIT J OPHTHALMOL, V98, P179, DOI 10.1136/bjophthalmol-2013-303954
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Punjabi OS, 2013, BRIT J OPHTHALMOL, V97, P1024, DOI 10.1136/bjophthalmol-2013-303155
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   Reche-Frutos J, 2011, EUR J OPHTHALMOL, V21, P783, DOI 10.5301/EJO.2011.6526
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Schachat AP, 2015, OPHTHALMOLOGY, V122, P222, DOI 10.1016/j.ophtha.2014.09.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah N, 2016, BRIT J OPHTHALMOL, V100, P1346, DOI 10.1136/bjophthalmol-2015-307375
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Takayama K, 2017, EYE, V31, P45, DOI 10.1038/eye.2016.232
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 101
TC 6
Z9 6
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR
PY 2018
VL 34
IS 3
BP 298
EP 308
DI 10.1089/jop.2017.0022
EA NOV 2017
PG 11
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA GB8MN
UT WOS:000417127000001
PM 29148864
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Blaha, M
   Rencova, E
   Langrova, H
   Studnicka, J
   Blaha, V
   Rozsival, P
   Lanska, M
   Sobotka, L
AF Blaha, M.
   Rencova, E.
   Langrova, H.
   Studnicka, J.
   Blaha, V.
   Rozsival, P.
   Lanska, M.
   Sobotka, L.
TI Rheohaemapheresis in the treatment of nonvascular age-related macular
   degeneration
SO ATHEROSCLEROSIS SUPPLEMENTS
LA English
DT Article
DE Rheohaemapheresis; Blood viscosity; Rheological parameters;
   Electroretinography
ID RHEOLOGICAL PARAMETERS; DRY FORM; RHEOPHERESIS; APHERESIS; THERAPY;
   DRUSEN
AB Purpose: To evaluate the experience with rheohaemapheresis (RH) in the treatment of age-related macular degeneration (AMD).
   Methods: Thirty-eight patients were each treated with 8 procedures of RH (14 males, 24 females). The control group consisted of 34 random patients (30 females, 4 males) with the dry form of AMD but not treated by RH. Our modification of the cascade method (named rheohaemapheresis) was used for plasma separation. After plasma separation (blood cell separator, Cobe Spectra, Denver, CO, USA), the separated plasma was pumped through a rheofilter (Evaflux 4A, Kuraray, Osaka, Japan) to remove lipoproteins and other high-molecular-weight rheologic factors.
   Results: In treated patients, best-corrected visual acuity (BCVA) increased significantly from 0.61 (0.06-1.00) to 0.68 (0.35-1.00) after 2.5 years (p = 0.035). We found no significant changes or differences in scotopic activity, whereas cone response and paramacular activity in the more peripheral region between 14 degrees and 22 degrees of eccentricity were significantly higher in treated patients after 2.5 years.
   Conclusion: RH therapy favourably influenced BCVA. During 2.5 years after the therapy, no progression of dry to wet AMD was observed in our patients. RH reduced the area of drusenoid retinal pigment epithelium detachment (which increased during the natural course of dry form AMD). RH influenced rheological markers and probably improved metabolism in the affected retinal areas which lead to the aforementioned positive results. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Blaha, M.] Charles Univ Prague, Fac Med, Separator Ctr, Dept Internal Med 2, Hradec Kralove 50009, Czech Republic.
   [Blaha, M.; Rencova, E.; Langrova, H.; Studnicka, J.; Blaha, V.; Rozsival, P.; Lanska, M.; Sobotka, L.] Teaching Hosp, Hradec Kralove 50009, Czech Republic.
   [Rencova, E.; Langrova, H.; Studnicka, J.; Rozsival, P.; Lanska, M.] Charles Univ Prague, Sch Med, Dept Ophthalmol, Hradec Kralove 50009, Czech Republic.
   [Blaha, V.; Sobotka, L.] Charles Univ Prague, Sch Med, Dept Gerontol & Metab, Hradec Kralove 50009, Czech Republic.
C3 Charles University Prague; University Hospital Hradec Kralove; Charles
   University Prague; Charles University Prague
RP Blaha, M (通讯作者)，Charles Univ Prague, Fac Med, Separator Ctr, Dept Internal Med 2, Hradec Kralove 50009, Czech Republic.
EM blaham@email.cz
RI Sobotka, Lubos/V-2620-2017; Studnička, Jan/AAC-4127-2022; Studnicka,
   Jan/K-2875-2017; Blaha, Vladimir/C-1151-2016; Rozsival,
   Pavel/N-9978-2017; Blaha, Milan/H-8955-2016
OI Sobotka, Lubos/0000-0002-0372-5790; Studnicka, Jan/0000-0002-9911-4379;
   Blaha, Vladimir/0000-0001-8088-9919; Rozsival,
   Pavel/0000-0001-6628-7954; Blaha, Milan/0000-0003-2330-5838; Langrova,
   Hana/0000-0001-8488-7208
FU research task of Charles University: PRVOUK [P37/12]
FX The work was supported by the research task of Charles University:
   PRVOUK P37/12.
CR Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Blaha M, 2009, CLIN HEMORHEOL MICRO, V42, P37, DOI 10.3233/CH-2009-1184
   Blaha M, 2006, VNITR LEK, V52, P1102
   Blaha M, 2007, THER APHER DIAL, V11, P9, DOI 10.1111/j.1744-9987.2007.00450.x
   Blaha Milan, 2003, Acta Medica (Hradec Kralove), V46, P3
   Blaha M, 2012, CLIN HEMORHEOL MICRO, V50, P245, DOI 10.3233/CH-2011-1431
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Borberg H, 2009, TRANSFUS APHER SCI, V41, P49, DOI 10.1016/j.transci.2009.05.013
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Marmor MF, 2004, DOC OPHTHALMOL, V108, P107, DOI 10.1023/B:DOOP.0000036793.44912.45
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Prochazkova R, 2009, MULTICOMPONENT APHER
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Rencova E, 2011, TRENDS CURRENT OPHTH, P17
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
NR 25
TC 16
Z9 16
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1567-5688
J9 ATHEROSCLEROSIS SUPP
JI Atheroscler. Suppl.
PD JAN
PY 2013
VL 14
IS 1
BP 179
EP 184
DI 10.1016/j.atherosclerosissup.2012.10.023
PG 6
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 089BX
UT WOS:000314885000030
PM 23357162
DA 2022-11-30
ER

PT J
AU Kawczyk-Krupka, A
   Bugaj, AM
   Potempa, M
   Wasilewska, K
   Latos, W
   Sieron, A
AF Kawczyk-Krupka, A.
   Bugaj, A. M.
   Potempa, M.
   Wasilewska, K.
   Latos, W.
   Sieron, A.
TI Vascular-targeted photodynamic therapy in the treatment of neovascular
   age-related macular degeneration: Clinical perspectives
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Age-related macular degeneration; Vascular-targeted photodynamic
   therapy; Verteporfin; Clinical trials
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN PLUS RANIBIZUMAB;
   INTRAVITREAL TRIAMCINOLONE; TRIPLE THERAPY; COST-EFFECTIVENESS;
   ANECORTAVE ACETATE; VISUAL-ACUITY; VEGF TRAP; BEVACIZUMAB; SECONDARY
AB Vascular targeted photodynamic therapy (VTP), with use of verteporfin as a photosensitizer is one of the few therapies, which has been shown to effectively slow the progression of the "wet" form of age-related macular degeneration (AMD), and even to stabilize visual acuity over many years. Although, due to considerable advance of AMD treatment, it is currently not recommended in monotherapy of AMD, however, its combination with steroids and anti-angiogenic biologic drugs may reveal high therapeutic potential in the treatment of neovascular AMD. The future of VTP as a method of AMD treatment is development of new selective and targeted photosensitizer and combination of this method with other therapeutic strategies targeting cellular structures or pathways involved in AMD progression. (c) 2015 Elsevier B.V. All rights reserved.
C1 [Kawczyk-Krupka, A.; Bugaj, A. M.; Latos, W.; Sieron, A.] Ctr Laser Diagnost & Therapy, Clin Dept Internal Dis Angiol & Phys Med, Bytom, Poland.
   [Kawczyk-Krupka, A.; Bugaj, A. M.; Potempa, M.; Latos, W.; Sieron, A.] Silesian Med Univ, Katowice, Poland.
   [Kawczyk-Krupka, A.; Bugaj, A. M.; Potempa, M.; Latos, W.; Sieron, A.] Dept Med, Zabrze, Poland.
   [Kawczyk-Krupka, A.; Bugaj, A. M.; Potempa, M.; Latos, W.; Sieron, A.] Div Med & Dent, Zabrze, Poland.
   [Wasilewska, K.] Univ Cambridge, Newnham Coll, Cambridge, England.
   [Bugaj, A. M.] Coll Hlth Beauty Care & Educ, Poznan, Poland.
C3 Medical University Silesia; University of Cambridge
RP Kawczyk-Krupka, A (通讯作者)，Med Univ Silesia, Ctr Laser Diagnost & Therapy, Batory 15 St, Bytom, Poland.
EM akawczyk@gmail.com
RI Bugaj, Andrzej M/D-4877-2013; Potempa-Jeziorowska, Magdalena/R-4222-2019
OI Bugaj, Andrzej M/0000-0001-7213-6765; Kawczyk-Krupka,
   Aleksandra/0000-0003-1284-3809
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   ALLISON BA, 1991, PHOTOCHEM PHOTOBIOL, V54, P709, DOI 10.1111/j.1751-1097.1991.tb02079.x
   [Anonymous], PHARM MED DIR
   [Anonymous], 2013, VIS DRUG INF
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2009, RET C
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   Axer-Siegel R, 2004, ARCH OPHTHALMOL-CHIC, V122, P453, DOI 10.1001/archopht.122.4.453
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bonnett R, 2000, CHEM ASPECTS PHOTODY, P286
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown S, 2008, NAT PHOTONICS, V2, P394, DOI 10.1038/nphoton.2008.112
   Bugaj AM, 2011, PHOTOCH PHOTOBIO SCI, V10, P1097, DOI 10.1039/c0pp00147c
   Busquets MA, 2009, RET C
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chiang A, 2011, CURR OPIN OPHTHALMOL, V22, P199, DOI 10.1097/ICU.0b013e32834597d9
   Collins HA, 2008, NAT PHOTONICS, V2, P420, DOI 10.1038/nphoton.2008.100
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Deng H, 2013, DYES PIGMENTS, V99, P930, DOI 10.1016/j.dyepig.2013.06.037
   Drobizhev M, 2005, J PHYS CHEM B, V109, P7223, DOI 10.1021/jp044261x
   European Medicines Agency (EMA), 2007, VIS SCI DISC PROC
   European Medicines Agency (EMA), 2014, VIS PROC STEPS TAK S
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frennesson CI, 2004, ACTA OPHTHALMOL SCAN, V82, P645, DOI 10.1111/j.1600-0420.2004.00368.x
   Gallemore RP, 2006, REV OPHTHALMOL, V2
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hu Z, 2014, J ANAL BIOANAL TECH, V1, pe001, DOI [10.4172/2155-9872.S1-e001, DOI 10.4172/2155-9872.S1-E001]
   Huang Z, 2005, TECHNOL CANCER RES T, V4, P283, DOI 10.1177/153303460500400308
   Hudson H, 2009, RET C
   Hughes MS, 2009, RET C
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Jurklies B, 2007, RETINAL VASCULAR DIS, P239
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Lim Jennifer I, 2002, Ophthalmol Clin North Am, V15, P473, DOI 10.1016/S0896-1549(02)00044-5
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Manku KK, 2007, CLIN EXP OPHTHALMOL, V35, P330, DOI 10.1111/j.1442-9071.2007.01482.x
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Nakata I, 2013, GRAEF ARCH CLIN EXP, V251, P1073, DOI 10.1007/s00417-012-2137-y
   Nelson MH, 2009, ANN M ASS RES VIS OP
   Nowak-liwinska P, 2013, J ANAL BIOANAL TECH
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ogawa K, 2008, ANTI-CANCER AGENT ME, V8, P269, DOI 10.2174/187152008783961860
   Olivo M, 2010, PHARMACEUTICALS-BASE, V3, P1507, DOI 10.3390/ph3051507
   Ozawa Y, 2013, ADV NEUROIMMUNE BIOL, V4, P161, DOI 10.3233/NIB-130062
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Postelmans L, 2004, AM J OPHTHALMOL, V138, P803, DOI 10.1016/j.ajo.2004.06.033
   Potter MJ, 2008, EYE, V22, P194, DOI 10.1038/sj.eye.6702547
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Probodh I, 2012, AGE RELATED MACULAR, P212
   QLT, 2009, QLT ANN 12 MONTH RES
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   RICHTER AM, 1990, J PHOTOCH PHOTOBIO B, V5, P231, DOI 10.1016/1011-1344(90)80008-L
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1987, J NATL CANCER I, V79, P1327
   Rosenfeld PJ, 2007, AM J OPHTHALMOL, V144, P970, DOI 10.1016/j.ajo.2007.08.017
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SchmidtErfurth U, 1997, BRIT J CANCER, V75, P54, DOI 10.1038/bjc.1997.9
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   Sharma R, 2012, INVEST OPHTHALMOL VI, V53
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Sheidow T, 2009, ANN M ASS RES VIS OP
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Sin M, 2014, BIOMED PAP, V158, P138, DOI 10.5507/bp.2012.066
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Small KW, 2009, ANN M ASS RES VIS OP
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Veritti D, 2009, ANN M ASS RES VIS OP
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
   Wolf S, 2014, OPHTHALMOLOGY, V121, p682e2
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617
NR 114
TC 25
Z9 26
U1 0
U2 30
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2015
VL 12
IS 2
BP 161
EP 175
DI 10.1016/j.pdpdt.2015.03.007
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CK9IQ
UT WOS:000356554200002
PM 25843911
DA 2022-11-30
ER

PT J
AU Diaz-Villamarin, X
   Blanquez-Martinez, D
   Pozo-Agundo, A
   Perez-Gutierrez, AM
   Munoz-Avila, JI
   Antunez-Rodriguez, A
   Fernandez-Gomez, AE
   Garcia-Navas, P
   Martinez-Gonzalez, LJ
   Davila-Fajardo, CL
AF Diaz-Villamarin, Xando
   Blanquez-Martinez, David
   Pozo-Agundo, Ana
   Perez-Gutierrez, Ana Maria
   Munoz-Avila, Jose Ignacio
   Antunez-Rodriguez, Alba
   Fernandez-Gomez, Ana Estefania
   Garcia-Navas, Paloma
   Martinez-Gonzalez, Luis Javier
   Davila-Fajardo, Cristina Lucia
TI Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal
   Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis
SO GENES
LA English
DT Review
DE pharmacogenetics; personalized medicine; SNP; anti-VEGF; polypoidal
   choroidal vasculopathy
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   INTRAVITREAL INJECTION; RANIBIZUMAB TREATMENT; RISK ALLELES;
   POLYMORPHISM; BEVACIZUMAB; ASSOCIATION; MONOTHERAPY
AB Polypoidal choroidal vasculopathy (PCV) is usually regarded as a subtype of choroidal neovascularization (CNV) that is secondary to age-related macular degeneration (AMD) characterized by choroidal vessel branching, ending in polypoidal lesions. Despite their close association, PCV and neovascular AMD have shown differences, especially regarding patients' treatment response. Currently, antivascular endothelial growth factor (anti-VEGF) drugs, such as ranibizumab, bevacizumab and aflibercept, have demonstrated their efficacy in CNV patients. However, in PCV, anti-VEGF treatments have shown inconclusive results. Many genetic polymorphisms have been associated with a variable response in exudative/wet AMD patients. Thus, the aim of this study is to explore the genetic variants affecting anti-VEGF drug response in PCV patients. In this regard, we performed a systematic review and meta-analysis. We found four variants (CFH I62V, CFH Y402H, ARMS2 A69S, and HTRA1-62A/G) that have been significantly related to response. Among them, the ARMS2 A69S variant is assessed in our meta-analysis. In conclusion, in order to implement anti-VEGF pharmacogenetics in clinical routines, further studies should be performed, distinguishing physio-pathogenic circumstances between PCV and exudative AMD and the combined effect on treatment response of different genetic variants.
C1 [Diaz-Villamarin, Xando; Fernandez-Gomez, Ana Estefania; Garcia-Navas, Paloma; Davila-Fajardo, Cristina Lucia] Hosp Univ Clin San Cecilio, Inst Invest Biosanitaria Ibs Granada, Pharm Dept, Granada 18016, Spain.
   [Diaz-Villamarin, Xando; Pozo-Agundo, Ana; Antunez-Rodriguez, Alba; Martinez-Gonzalez, Luis Javier] Univ Granada, Pfizer, Junta Andalucia, Ctr Genom & Oncol Res GENYO, Granada 18016, Spain.
   [Blanquez-Martinez, David] Hosp Univ Ceuta, Pharm Dept, Ceuta 51003, Spain.
   [Perez-Gutierrez, Ana Maria] Univ Granada, Sch Pharm, Dept Biochem & Mol Biol 2, Granada 18011, Spain.
   [Munoz-Avila, Jose Ignacio] Hosp Univ Clin San Cecilio, Ophthalmol Dept, Granada 18016, Spain.
C3 Pfizer; University of Granada; University of Granada
RP Diaz-Villamarin, X (通讯作者)，Hosp Univ Clin San Cecilio, Inst Invest Biosanitaria Ibs Granada, Pharm Dept, Granada 18016, Spain.; Diaz-Villamarin, X (通讯作者)，Univ Granada, Pfizer, Junta Andalucia, Ctr Genom & Oncol Res GENYO, Granada 18016, Spain.
EM xandodv@gmail.com; david.blanquez.sspa@juntadeandalucia.es;
   ana.pozo@genyo.es; ampergut@correo.ugr.es;
   josei.munoz.sspa@juntadeandalucia.es; alba.antunez@genyo.es;
   efernandez@fibaosalud.com; palomichi_96@hotmail.com;
   luisjavier.martinez@genyo.es; cristinal.davila.sspa@juntadeandalucia.es
RI Antunez-Rodriguez, Alba/AAC-5130-2020; Martinez-Gonzalez, Luis
   Javier/L-6136-2014; diaz-villamarin, xando/AAA-7223-2020
OI Antunez-Rodriguez, Alba/0000-0002-3963-6546; Martinez-Gonzalez, Luis
   Javier/0000-0003-2202-0662; diaz-villamarin, xando/0000-0003-0849-9902;
   Perez Gutierrez, Ana Maria/0000-0002-9785-8921; Pozo-Agundo,
   Ana/0000-0003-2188-6296; DAVILA-FAJARDO, CRISTINA
   LUCIA/0000-0003-3339-239X
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P524, DOI 10.1016/j.ajo.2013.04.029
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1
   Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P189, DOI 10.1007/s00417-014-2675-6
   Hautamaki A, 2014, OPHTHALMOLOGY, V121, P973, DOI 10.1016/j.ophtha.2013.11.035
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hikichi T, 2013, BRIT J OPHTHALMOL, V97, P617, DOI 10.1136/bjophthalmol-2012-302652
   Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lazzeri S, 2013, PHARMACOGENOMICS, V14, P623, DOI [10.2217/PGS.13.43, 10.2217/pgs.13.43]
   Lores-Motta L, 2016, PHARMACOGENET GENOM, V26, P20, DOI 10.1097/FPC.0000000000000180
   Matsumiya W, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-10
   Medina FM, 2015, OPHTHALMIC RES, V54, P169, DOI 10.1159/000439172
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Nakai S, 2019, JPN J OPHTHALMOL, V63, P389, DOI 10.1007/s10384-019-00683-6
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Park DH, 2012, RETINA-J RET VIT DIS, V32, P299, DOI 10.1097/IAE.0b013e318225290f
   Park UC, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0631-z
   Rondanelli M, 1997, AGING-CLIN EXP RES, V9, P221, DOI 10.1007/BF03340153
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018
   Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/PGS.12.53, 10.2217/pgs.12.53]
   Tsujikawa A, 2010, JPN J OPHTHALMOL, V54, P310, DOI 10.1007/s10384-010-0813-1
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Valverde-Megias A, 2017, GRAEF ARCH CLIN EXP, V255, P2091, DOI 10.1007/s00417-017-3748-0
   Wells GA., 2011, NEWCASTLE OTTAWA SCA
   Whirl-Carrillo M, 2012, CLIN PHARMACOL THER, V92, P414, DOI 10.1038/clpt.2012.96
   Yamashiro K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072034
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P1
   Yoneyama S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64301-z
   Zhou YL, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0487-2
NR 49
TC 3
Z9 3
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD NOV
PY 2020
VL 11
IS 11
AR 1335
DI 10.3390/genes11111335
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA OY1OV
UT WOS:000594023200001
PM 33198211
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mazaraki, K
   Fassnacht-Riederle, H
   Blum, R
   Becker, M
   Michels, S
AF Mazaraki, Kyriaki
   Fassnacht-Riederle, Heidi
   Blum, Robert
   Becker, Matthias
   Michels, Stephan
TI Change in choroidal thickness after intravitreal aflibercept in
   pretreated and treatment-naive eyes for neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; THERAPY; VASCULOPATHY; BEVACIZUMAB; INJECTION; EFFICACY
AB Aim Evaluation of effects of intravitreal aflibercept therapy on choroidal thickness (CT) in neovascular age-related macular degeneration.
   Methods Retrospective cohort study evaluating the change in CT following a loading dose of three intravitreal aflibercept injections at 4 weeks interval. Pretreated and treatment-naive eyes as well as untreated fellow eyes were evaluated at five retinal locations (subfoveal, 300 and 2500 mm nasal and temporal to the fovea) using spectral domain optical coherence tomography prior to and 4 weeks after a loading dose of three intravitreal aflibercept injections.
   Results A total of 84 treated eyes (61 pretreated, 23 treatment naive) and 48 fellow eyes were enrolled into the study. Treatment-naive and pretreated eyes showed a significant reduction in CT at all retinal locations. The effect was more pronounced in treatment-naive eyes. In the pretreated group, the mean reduction in CT was greatest at 2500 mm temporal to the fovea at 10.7 mm compared with 22.4 at 300 mm nasal to the fovea in the treatment-naive group. Only the fellow eyes in the treatment-naive group showed a significant CT reduction 12 weeks after initiation of therapy to the partner eye.
   Conclusions Aflibercept induces a reduction in CT in treatment-naive and pretreated eyes with neovascular age-related macular degeneration. There is some evidence of a systemic effect of aflibercept reflected by CT reduction in untreated fellow eyes.
C1 [Mazaraki, Kyriaki; Fassnacht-Riederle, Heidi; Blum, Robert; Becker, Matthias; Michels, Stephan] City Hosp Triemli, Dept Ophthalmol, CH-8063 Zurich, Switzerland.
   [Becker, Matthias] Heidelberg Univ, Heidelberg, Germany.
   [Michels, Stephan] Univ Zurich, Zurich, Switzerland.
C3 Triemli Hospital; Ruprecht Karls University Heidelberg; University of
   Zurich
RP Michels, S (通讯作者)，City Hosp Triemli, Dept Ophthalmol, Birmensdorferstr 497, CH-8063 Zurich, Switzerland.
EM stephan.michels@zuerich.ch
RI Becker, Matthias/A-8733-2014
FU Stiftung wissenschaftliche Forschung, Fonds Ophthalmologie, City
   Hospital Triemli; Werner H. Spross Foundation
FX The study was supported by the "Stiftung wissenschaftliche Forschung,
   Fonds Ophthalmologie, City Hospital Triemli" and the Werner H. Spross
   Foundation. Both funding organisations had no role in the design or
   conduct of this research.
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cheung CMG, 2014, EYE, V28, P1148, DOI 10.1038/eye.2014.105
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pitcher JD, 2015, BRIT J OPHTHALMOL, V99, P848, DOI 10.1136/bjophthalmol-2014-306018
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
NR 16
TC 28
Z9 28
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2015
VL 99
IS 10
BP 1341
EP 1344
DI 10.1136/bjophthalmol-2015-306636
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5BJ
UT WOS:000362821400007
PM 25877895
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Luu, J
   Palczewski, K
AF Luu, Jennings
   Palczewski, Krzysztof
TI Human aging and disease: Lessons from age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE age-related macular degeneration; retina; eye; photoreceptors; GPCR
ID PROTEIN-COUPLED RECEPTORS; RETINAL DEGENERATION; STARGARDT DISEASE;
   MICE; HORMONE; THERAPIES; SCIENCE; COMPLEX; STRESS; BRAIN
AB Aging is the most significant risk factor associated with chronic disease in humans. The accumulation of genetic damage throughout life leads to a variety of biological aberrations, including disrupted protein homeostasis, metabolic dysfunction, and altered cellular signaling. Such changes ultimately result in cellular senescence, death, or transformation to uncontrolled proliferation, thereby compromising human health. Events contributing to age-dependent physiological decline also occur in the context of hormonal and metabolic changes, affecting interconnected cellular networks. This complexity often confounds the development of effective treatments for aging and age-related diseases. In contrast to monotherapy and polypharmacology, an innovative systems pharmacology approach can identify synergistic combinations of drugs that modulate distinct mechanistic nodes within a network, minimizing off-target side effects and enabling better therapeutic outcomes. G protein-coupled receptors (GPCRs) are particularly good targets for the application of systems pharmacology, because they activate different signal transduction pathways that can culminate in a common response. Here, we describe a systems pharmacology strategy for the treatment of age-related macular degeneration (AMD), a multifactorial chronic disease of the eye. By considering the retina as part of a large, interconnected network, systems pharmacology will enable the identification of combination therapies targeting GPCRs to help restore genomic, proteomic, and endocrine homeostasis. Such an approach can be advantageous in providing drug regimens for the treatment of AMD, while also having broader ramifications for ameliorating adverse effects of chronic, age-related disease in humans.
C1 [Luu, Jennings; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.
   [Luu, Jennings; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University
RP Palczewski, K (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.; Palczewski, K (通讯作者)，Case Western Reserve Univ, Sch Med, Cleveland Ctr Membrane & Struct Biol, Cleveland, OH 44106 USA.
EM kxp65@case.edu
OI Luu, Jennings C./0000-0001-7283-0335
FU NIH [EY009339, EY027283, EY024864]; NATIONAL EYE INSTITUTE [R24EY024864,
   R24EY027283, R01EY009339] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH
   RePORTER
FX We thank Leslie T. Webster Jr. for valuable comments on this manuscript.
   This research was supported, in part, by NIH Grants EY009339, EY027283,
   and EY024864. K.P. is the John H. Hord Professor of Pharmacology.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bartke A, 2008, CLIN INTERV AGING, V3, P659, DOI 10.2147/CIA.S3697
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blagosklonny MV, 2008, CELL CYCLE, V7, P3344, DOI 10.4161/cc.7.21.6965
   Chen Y, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag0245
   Chen Y, 2016, ANNU REV PHARMACOL, V56, P273, DOI 10.1146/annurev-pharmtox-010715-103033
   Chen Y, 2013, J CLIN INVEST, V123, P5119, DOI 10.1172/JCI69076
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Cohen LJ, 2017, NATURE, V549, P48, DOI 10.1038/nature23874
   Friedman D., 2008, VISION PROBLEMS US P
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724
   Hebert LE, 2013, NEUROLOGY, V80, P1778, DOI 10.1212/WNL.0b013e31828726f5
   Hones GS, 2017, P NATL ACAD SCI USA, V114, pE11323, DOI 10.1073/pnas.1706801115
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298
   Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578
   Iyengar R, 2013, EMBO REP, V14, P1039, DOI 10.1038/embor.2013.177
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4
   Karasek M, 2004, EXP GERONTOL, V39, P1723, DOI 10.1016/j.exger.2004.04.012
   Kelly MP, 2018, CELL SIGNAL, V42, P281, DOI 10.1016/j.cellsig.2017.11.004
   Khattak RM, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0111-3
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Lagerstrom MC, 2008, NAT REV DRUG DISCOV, V7, P339, DOI 10.1038/nrd2518
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li J, 2017, SCIENCE, V355, P1312, DOI 10.1126/science.aad8242
   Lodato MA, 2018, SCIENCE, V359, P555, DOI 10.1126/science.aao4426
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mustafi D, 2012, J CLIN INVEST, V122, P2989, DOI 10.1172/JCI64427
   Ng L, 2017, ENDOCRINOLOGY, V158, P1999, DOI 10.1210/en.2017-00055
   Ortega-Molina A, 2012, CELL METAB, V15, P382, DOI 10.1016/j.cmet.2012.02.001
   Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X
   Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reiser J, 2014, NAT REV NEPHROL, V10, P104, DOI 10.1038/nrneph.2013.274
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701
   Roshan S, 1999, EUR J CLIN INVEST, V29, P210
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sapra KT, 2008, LANGMUIR, V24, P1330, DOI 10.1021/la702299z
   Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028
   US Department of Health and Human Services, 2017, NAT DIAB STAT REP 20
   Woo DK, 2011, CELL, V144, P11, DOI 10.1016/j.cell.2010.12.023
   Wood SH, 2013, AGE, V35, P763, DOI 10.1007/s11357-012-9410-1
NR 51
TC 34
Z9 35
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 20
PY 2018
VL 115
IS 12
BP 2866
EP 2872
DI 10.1073/pnas.1721033115
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FZ8BF
UT WOS:000427829500038
PM 29483257
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ho, JD
   Xirasagar, S
   Kao, LT
   Lin, HC
AF Ho, Jau-Der
   Xirasagar, Sudha
   Kao, Li-Ting
   Lin, Herng-Ching
TI Neovascular age-related macular degeneration is associated with cataract
   surgery
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; cataract surgery; epidemiology
ID BEAVER DAM EYE; RISK; MACULOPATHY; INFLAMMATION; PROGRESSION;
   PREVALENCE; EXTRACTION; ROTTERDAM; THERAPY; LENSES
AB PurposeThis retrospective cohort study examines the association between cataract surgery and neovascular age-related macular degeneration (AMD) during 5-year follow-up using population-based claims data.
   MethodsWe analysed data sourced from the Taiwan Longitudinal Health Insurance Database 2005. The study included 3465 patients who had undergone cataract operations and did not have a diagnosis of AMD before or on the surgery date (study group), and 10395 age- and sex-matched comparison patients selected randomly from the remaining patients without an AMD diagnosis before the index date. We tracked the claims of each patient for a 5-year period to identify patients with a subsequent diagnosis of neovascular AMD.
   ResultsThe incidence rate of neovascular AMD was 0.88 (95% confidence interval (CI): 0.66-1.14) per 1000 person-years among all sampled patients, 1.60 (95% CI: 1.04-2.36) among the cataract surgery patients and 0.64 (95% CI: 0.43-0.91) among comparison patients (p<0.001). Stratified Cox proportional analysis showed that relative to the comparison cohort, the adjusted hazard ratio for neovascular AMD during 5-year follow-up was 2.68 (95% CI: 1.55-4.66) for patients who had undergone cataract operation. We censored those who died during follow-up period and adjusted for patients' monthly income, geographical location, urbanization level, diabetes, hypertension, cardiovascular disease and hyperlipidaemia.
   ConclusionThis study demonstrated epidemiological evidence of a link between cataract surgery and neovascular AMD during a 5-year follow-up period.
C1 [Ho, Jau-Der] Taipei Med Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Xirasagar, Sudha] Univ South Carolina, Dept Hlth Serv Policy & Management, Arnold Sch Publ Hlth, Columbia, SC USA.
   [Kao, Li-Ting] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan.
   [Lin, Herng-Ching] Taipei Med Univ Hosp, Sleep Res Ctr, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University Hospital;
   University of South Carolina System; University of South Carolina
   Columbia; National Defense Medical Center; Taipei Medical University;
   Taipei Medical University; Taipei Medical University Hospital
RP Lin, HC (通讯作者)，Taipei Med Univ, Sch Hlth Care Adm, Coll Med, 250 Wu Hsing St, Taipei 110, Taiwan.
EM henry11111@tmu.edu.tw
RI Xirasagar, Sudha/AAA-2350-2022; Kao, Li-Ting/W-9287-2018
OI Kao, Li-Ting/0000-0003-0692-7408
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Coleman AL, 2010, AM J OPHTHALMOL, V149, P160, DOI 10.1016/j.ajo.2009.07.025
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Hu CC, 2017, ACTA OPHTHA IN PRESS
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lundqvist B, 2006, J CATARACT REFR SURG, V32, P1944, DOI 10.1016/j.jcrs.2006.06.023
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Modi SS, 2014, J CATARACT REFR SURG, V40, P203, DOI 10.1016/j.jcrs.2013.07.042
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Park SJ, 2016, J KOREAN MED SCI, V31, P963, DOI 10.3346/jkms.2016.31.6.963
   Qian CX, 2014, SEMIN OPHTHALMOL, V29, P301, DOI 10.3109/08820538.2014.962166
   Rim TH, 2016, SEMIN OPHTH IN PRESS
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2016, OPHTHALMOLOGY, V123, P1829, DOI 10.1016/j.ophtha.2016.02.003
   Wang JJ, 2012, OPHTHALMOLOGY, V119, P2298, DOI 10.1016/j.ophtha.2012.07.003
   Wilson ME, 2016, EYE, V30, P1187, DOI 10.1038/eye.2016.132
NR 34
TC 7
Z9 8
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2018
VL 96
IS 2
BP e213
EP e217
DI 10.1111/aos.13511
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FW5PL
UT WOS:000425369200017
PM 28671319
OA Bronze
DA 2022-11-30
ER

PT J
AU Elshelmani, H
   Wride, MA
   Saad, T
   Rani, S
   Kelly, DJ
   Keegan, D
AF Elshelmani, Hanan
   Wride, Michael A.
   Saad, Tahira
   Rani, Sweta
   Kelly, David J.
   Keegan, David
TI Identification of Novel Serum MicroRNAs in Age-Related Macular
   Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; microRNAs; serum; biomarkers
ID POTENTIAL BIOMARKERS; CIRCULATING MIRNAS; EXPRESSION; CANCER;
   NEOVASCULARIZATION; ANGIOGENESIS; MARKERS; MIR-126; PROFILE; MEMBERS
AB Purpose: To identify circulating microRNAs (miRNA) associated with age-related macular degeneration (AMD). Thus differentially expressed serum miRNA could be used as AMD biomarkers.
   Methods: This study involved total RNA isolation from sera from patients with atrophic AMD (n = 10), neovascular AMD (n = 10), and age- and sex-matched controls (n = 10). A total of 377 miRNAs were coanalyzed using array technologies, and differentially regulatedmiRNAswere determined. Extensive validation studies (n= 90) of serum from AMD patients and controls confirmed initial results. Total RNA isolation was carried out from sera from patients with atrophic AMD (n = 30), neovascular AMD (n = 30), and controls (n = 30). Fourteen miRNAs from the discovery dataset were coanalyzed using quantitative real-time polymerase chain reaction (qRT-PCR) to validate their presence.
   Results: Unsupervised hierarchical clustering indicated that AMD serum specimens have a different miRNA profile to healthy controls. We successfully identified and validated the differentially regulated miRNAs in serum from AMD patients versus controls. The biomarker potential of threemiRNAs (miR-126, miR-19a, and miR-410) was confirmed by qRT-PCR, with significantly increased quantities in serum of AMD patients compared with healthy controls.
   Conclusions: Increased quantities of miR-126, miR-410, and miR-19a in serum from AMD patients indicate that these miRNAs could potentially serve as diagnostic AMD biomarkers. All three miRNAs significantly correlated with AMD pathogenesis.
   Translational Relevance: The discovery of new AMD miRNA may act as biomarkers in evaluating AMD diagnosis and prognosis.
C1 [Elshelmani, Hanan; Wride, Michael A.] Univ Dublin, Trinity Coll Dublin, Sch Nat Sci, Ocular Dev & Neurobiol Res Grp,Zool Dept, Dublin, Ireland.
   [Saad, Tahira; Keegan, David] Mater Misericordiae Univ Hosp, Eccles St, Dublin 7, Ireland.
   [Rani, Sweta] Waterford Inst Technol, Dept Sci, Waterford, Ireland.
   [Kelly, David J.] Univ Dublin, Trinity Coll Dublin, Sch Nat Sci, Zool Dept, Dublin, Ireland.
C3 Trinity College Dublin; Mater Misericordiae University Hospital;
   University College Dublin; South East Technological University (SETU);
   Trinity College Dublin
RP Keegan, D (通讯作者)，Mater Misericordiae Univ Hosp, Eccles St, Dublin 7, Ireland.
EM dkeegan@mater.ie
OI Rani, Sweta/0000-0003-0937-0094; Kelly, David/0000-0002-5880-4162
FU Irish Research Council for Science, Engineering, and Technology/EMBARK
   Initiative; Mater Vision Institute; Libyan Ministry of Higher Education
   and Scientific Research; Fighting Blindness Ireland [FB14 SAA]
FX Supported by the Irish Research Council for Science, Engineering, and
   Technology/EMBARK Initiative, the Mater Vision Institute, the Libyan
   Ministry of Higher Education and Scientific Research, and Fighting
   Blindness Ireland (FB14 SAA).
CR Agudo J, 2014, NAT IMMUNOL, V15, P54, DOI 10.1038/ni.2767
   Askou AL, 2018, ACTA OPHTHALMOL, V96, P9, DOI 10.1111/aos.13407
   Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Blondal T, 2013, METHODS, V59, pS1, DOI 10.1016/j.ymeth.2012.09.015
   Chen NTM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086474
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Ertekin S, 2014, MOL VIS, V20, P1057
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Grillari J, 2010, BIOGERONTOLOGY, V11, P501, DOI 10.1007/s10522-010-9272-9
   Hackler L, 2010, INVEST OPHTH VIS SCI, V51, P1823, DOI 10.1167/iovs.09-4657
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Horwich MD, 2008, NAT PROTOC, V3, P1537, DOI 10.1038/nprot.2008.145
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Liang Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-166
   Mar-Aguilar F, 2013, DIS MARKERS, V34, P163, DOI [10.1155/2013/259454, 10.3233/DMA-120957]
   Marcuzzo S, 2014, EXP NEUROL, V253, P91, DOI 10.1016/j.expneurol.2013.12.007
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Moqadam FA, 2014, LEUKEMIA, V28, P1008, DOI 10.1038/leu.2013.308
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Nikolic Iva, 2010, J Angiogenes Res, V2, P9, DOI 10.1186/2040-2384-2-9
   Raghunath A, 2015, OPHTHALMIC RES, V53, P169, DOI 10.1159/000371853
   Ragusa M, 2013, MOL VIS, V19, P430
   Ratert N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039309
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Todoerti K, 2010, HAEMATOL-HEMATOL J, V95, P260, DOI 10.3324/haematol.2009.012088
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Wang XC, 2011, LUNG CANCER, V72, P92, DOI 10.1016/j.lungcan.2010.07.014
   Wong Linda, 2010, APPL BIOSYSTEMS
   Xu XL, 2014, ANN THORAC SURG, V97, P1037, DOI 10.1016/j.athoracsur.2013.10.042
   Yang CL, 2014, INT J MOL SCI, V15, P423, DOI 10.3390/ijms15010423
   Yelamanchili SV, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.56
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 48
TC 7
Z9 7
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2020
VL 9
IS 4
AR 28
DI 10.1167/tvst.9.4.28
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB9VX
UT WOS:000524980600028
PM 32818115
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, CY
   Chen, OM
   Liu, TC
AF Chen, Chin-Shyan
   Chen, Conmin
   Liu, Tsai-Ching
TI Dust Storms Increase the Risk of Age-Related Macular Degeneration
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE AMD; dust storm; air pollution; particulate matter; outpatient;
   inpatient
ID PREVALENCE; POPULATION; DISEASE; EYE
AB The main purpose of this study was to examine the association between dust storms (DSs) and age-related macular degeneration (AMD) using a 5 year representative national dataset with one million participants, according to information on DS, meteorology, and air pollution in Taiwan. There were 18,855 AMD outpatient cases and 1080 AMD inpatient cases during 2008-2012. A Poisson time-series model was used for the analysis. The results show that AMD cases are significantly associated with exposure to dust storm events. Average daily numbers of wet and dry AMD outpatient cases increased from 6.03 and 4.26 on no-event days to 8.25 and 6.67, 2 days after DSs. Average daily numbers of wet and dry AMD inpatient cases increased from 0.26 and 0.33 on no-event days to 0.58 and 0.75, 1 day after DSs. Both genders and different age groups are all affected by the occurrence of DSs, especially 1 and 2 days after DS events. Women are at a higher risk of outpatient visits and hospitalizations for relatively severe wet AMD. Although AMD highly correlated with age, this study also found that dry AMD outpatient visits in people under the age of 50 were also found to be significantly associated with DS events. In order to protect the health of eyes and avoid AMD, one should reduce or avoid outdoor activities when DS events occur.
C1 [Chen, Chin-Shyan] Natl Taipei Univ, Dept Econ, New Taipei 23741, Taiwan.
   [Chen, Conmin] Tzu Chi Univ, Sch Med, Hualien 97004, Taiwan.
   [Liu, Tsai-Ching] Natl Taipei Univ, Dept Publ Finance, New Taipei 23741, Taiwan.
C3 National Taipei University; Tzu Chi University; National Taipei
   University
RP Liu, TC (通讯作者)，Natl Taipei Univ, Dept Publ Finance, New Taipei 23741, Taiwan.
EM stan@mail.ntpu.edu.tw; 107311116@gms.tcu.edu.tw; tching@mail.ntpu.edu.tw
FU Ministry of Science and Technology (MOST), Taiwan
   [MOST110-2410-H-305-040]
FX This work was supported by the Ministry of Science and Technology
   (MOST), Taiwan, grant number: MOST110-2410-H-305-040.
CR Brannas K., 2001, ECONOMET REV, V20, P425, DOI [10.1081/ETC-100106998, DOI 10.1081/ETC-100106998]
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Brunnus K., 1995, UMEA EC STUD, P381
   Cai QL, 2020, SCI TOTAL ENVIRON, V709, DOI 10.1016/j.scitotenv.2019.136146
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Chen CS, 2022, INT J ENVIRON HEAL R, V32, P1337, DOI 10.1080/09603123.2021.1879740
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Chien LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109175
   Chua SYL, 2022, BRIT J OPHTHALMOL, V106, P705, DOI 10.1136/bjophthalmol-2020-316218
   Chung SD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120003
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Faraji M, 2019, J ENVIRON HEALTH SCI, V17, P493, DOI 10.1007/s40201-018-00327-w
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Huang EJC, 2014, EYE, V28, P705, DOI 10.1038/eye.2014.55
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Ju MJ, 2022, ENVIRON RES, V204, DOI 10.1016/j.envres.2021.111953
   Kang JH, 2012, ANN EPIDEMIOL, V22, P257, DOI 10.1016/j.annepidem.2012.02.008
   Karimi SM, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139053
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Liu ST, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040428
   Liu TC, 2022, J ENVIRON HEALTH SCI, V20, P305, DOI 10.1007/s40201-021-00777-9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mu HS, 2011, J ENVIRON HEALTH, V73, P18
   Rezaei S, 2018, J ENVIRON HEALTH SCI, V16, P147, DOI 10.1007/s40201-018-0303-9
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Serener A, 2019, 2019 MEDICAL TECHNOLOGIES CONGRESS (TIPTEKNO), P74
   Shin J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249231
   Teng JCY, 2016, PUBLIC HEALTH NURS, V33, P118, DOI 10.1111/phn.12209
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Wang CH, 2014, GLOB PUBLIC HEALTH, V9, P1040, DOI 10.1080/17441692.2014.951871
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yeh CC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050790
NR 34
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2022
VL 19
IS 12
AR 7403
DI 10.3390/ijerph19127403
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 2M2YO
UT WOS:000817571700001
PM 35742653
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kang, SW
   Chung, SE
   Shin, WJ
   Lee, JH
AF Kang, S. W.
   Chung, S. E.
   Shin, W. J.
   Lee, J-H
TI Polypoidal choroidal vasculopathy and late geographic hyperfluorescence
   on indocyanine green angiography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; FLUORESCEIN ANGIOGRAPHY;
   JAPANESE PATIENTS; FEATURES
AB Background/aims: To report the clinical significance of late geographic hyperfluorescence (LGH) on indocyanine green angiography (ICGA) in cases of polypoidal choroidal vasculopathy (PCV).
   Methods: The medical records of 43 eyes with PCV, all of which had undergone at least 12 months of follow-up, 40 eyes with exudative age-related macular degeneration (AMD) and 20 eyes of age-matched normal subjects were retrospectively analysed. The incidence of LGH, defined as a well-demarcated geographic hyperfluorescent lesion on late phase ICGA, was compared in each respective group. The natural course of the LGH and its changes after photodynamic therapy (PDT) were analysed.
   Results: LGH was noted in all of the eyes with PCV, whereas LGH was noted in three eyes (7.5%) of the eyes with exudative AMD and was not noted in any of the normal subjects (p<0.01). Of the 27 eyes (62.8%) with PCV, LGH was matched to the total area of the branching vascular network and polyps. The extent of LGH was enlarged over time in approximately one-half of the cases. As compared with the eyes demonstrating persistent LGH after PDT, the eyes with fading or disappearing LGH evidenced a lower recurrence of active PCV (p<0.05).
   Conclusion: LGH is a highly sensitive and specific ICGA finding for the diagnosis of PCV. Increased surveillance should be implemented in eyes in which LGH persists after PDT.
C1 [Kang, S. W.] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Sch Med, 50 Ilwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Obata R, 2006, JPN J OPHTHALMOL, V50, P354, DOI 10.1007/s10384-005-0337-2
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 24
TC 31
Z9 34
U1 1
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2009
VL 93
IS 6
BP 759
EP 764
DI 10.1136/bjo.2008.145862
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450LI
UT WOS:000266401600014
PM 19304584
DA 2022-11-30
ER

PT J
AU Wang, ZY
   Zhao, KK
   Song, ZM
   Shen, LJ
   Qu, J
AF Wang, Zhao-Yang
   Zhao, Ke-Ke
   Song, Zong-Ming
   Shen, Li-Jun
   Qu, Jia
TI Erythropoietin as a novel therapeutic agent for atrophic age-related
   macular degeneration
SO MEDICAL HYPOTHESES
LA English
DT Article
ID INFLAMMATORY RESPONSE; PATHOGENESIS; MACULOPATHY; PROTECTS; SMOKING;
   PIGMENT; CELLS
AB The purpose of this article is to propose a novel therapeutic approach to the treatment of age-related macular degeneration (ARMD), the leading cause of blindness in the elderly population (over 60 years of age) in developed countries. Although recent advances have been made in the treatment of the neovascular form of ARMD, there is still no effective treatment for the most prevalent atrophic form of ARMD. Although the exact etiology and molecular pathogenesis of the atrophic ARMD are not fully understood, it is believed that oxidative stress and local inflammation play a major role in the pathologic processes and that the disease is triggered by dysfunction in the retinal pigment epithelia, leading to the degeneration of macular photoreceptor cells, followed by irreversible loss of vision. Considering that erythropoietin (EPO) has antioxidant, anti-inflammatory, and neuroprotective properties, we hypothesize that it can be developed as a novel therapeutic agent for the treatment of the atrophic form of ARMD. Future studies are needed to confirm or rule out this hypothesis. If successful, such studies may also help shield the lights on molecular mechanisms of atrophic ARMD. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Wang, Zhao-Yang; Zhao, Ke-Ke; Song, Zong-Ming; Shen, Li-Jun; Qu, Jia] Wenzhou Med Coll, Sch Ophthalmol & Optometry, Hosp Eye, Wenzhou 325027, Zhejiang, Peoples R China.
   [Wang, Zhao-Yang] Zhejiang Univ, Sch Med, Dept Ophthalmol, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Zhejiang University
RP Qu, J (通讯作者)，Wenzhou Med Coll, Sch Ophthalmol & Optometry, Hosp Eye, 270 Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.
EM zhaokekewzy@hotmail.com
FU Zhejiang Foundation of Natural Sciences, Zhejiang, China [Y207411,
   Y206706]
FX The Project was supported in part by two grants from Zhejiang Foundation
   of Natural Sciences, Zhejiang, China (Grant number Y207411 and Y206706).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bartesaghi S, 2005, NEUROTOXICOLOGY, V26, P923, DOI 10.1016/j.neuro.2005.01.016
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Becerra SP, 2002, NEW ENGL J MED, V347, P1968, DOI 10.1056/NEJMcibr022629
   Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Feng QP, 2006, CARDIOVASC RES, V71, P615, DOI 10.1016/j.cardiores.2006.07.001
   Fisher JW, 2003, EXP BIOL MED, V228, P1
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Fu QL, 2008, CELL MOL NEUROBIOL, V28, P317, DOI 10.1007/s10571-007-9155-z
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Hardee ME, 2006, CLIN CANCER RES, V12, P332, DOI 10.1158/1078-0432.CCR-05-1771
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jonas JB, 2007, CLIN EXP OPHTHALMOL, V35, P186, DOI 10.1111/j.1442-9071.2006.01437.x
   Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399
   Katavetin P, 2007, KIDNEY INT, V72, pS10, DOI 10.1038/sj.ki.5002482
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Kvanta A, 2008, ACTA OPHTHALMOL, V86, P468, DOI 10.1111/j.1755-3768.2008.01283.x
   Liu XM, 2006, LIFE SCI, V78, P2255, DOI 10.1016/j.lfs.2005.09.053
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Rui T, 2005, CARDIOVASC RES, V65, P719, DOI 10.1016/j.cardiores.2004.11.019
   SACU S, 2008, EYE             0829
   Tsai JC, 2007, J GLAUCOMA, V16, P567, DOI 10.1097/IJG.0b013e318156a556
   YANG Z, 2008, NEW ENGL J MED  0827
   Yeoh J, 2006, EXPERT OPIN PHARMACO, V7, P2355, DOI 10.1517/14656566.7.17.2355
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang JF, 2008, INVEST OPHTH VIS SCI, V49, P732, DOI 10.1167/iovs.07-0721
NR 36
TC 9
Z9 10
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD APR
PY 2009
VL 72
IS 4
BP 448
EP 450
DI 10.1016/j.mehy.2008.09.055
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 425EM
UT WOS:000264619800021
PM 19128888
DA 2022-11-30
ER

PT J
AU Heiferman, MJ
   Fawzi, AA
AF Heiferman, Michael J.
   Fawzi, Amani A.
TI Progression of subclinical choroidal neovascularization in age-related
   macular degeneration
SO PLOS ONE
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; VISUAL-ACUITY; EYES; CHORIOCAPILLARIS;
   PREVALENCE; ATROPHY; DRUSEN
AB Purpose
   To use optical coherence tomography angiography (OCTA) to study longitudinal subclinical choroidal neovascularization (CNV) changes and their correlation with progression to exudation in age-related macular degeneration (AMD).
   Methods
   This study included a total of 34 patients with unilateral neovascular AMD who were evaluated prospectively using OCTA to detect subclinical CNV in their fellow eye. Eyes with baseline subclinical CNV were followed with serial OCTA for a minimum of one year (15.2 +/- 3.27 months) to monitor the development of exudation.
   Results
   Of the 34 fellow eyes studied, five were found to have baseline subclinical CNV. One of the five cases of baseline subclinical CNV converted to exudative AMD during the follow up period. The average surface area of baseline subclinical CNV on OCTA was 0.131 +/- 0.096 mm(2) which progressed to 0.136 +/- 0.104 mm(2) at the final follow up (P = 0.539). Geographic atrophy grew at a rate of 0.82 +/- 1.20mm(2)/year in four eyes without subclinical CNV and 0.02mm(2)/year in one eye with subclinical CNV.
   Conclusion and importance
   The rate of conversion to exudative AMD in eyes with subclinical CNV of 20% in our study is similar to previous reports and suggests the importance of vigilance in these eyes. The lower growth rate of geographic atrophy may suggest a protective effect of subclinical CNV that deserves further study.
C1 [Heiferman, Michael J.; Fawzi, Amani A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Fawzi, AA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
EM afawzimd@gmail.com
RI fawzi, amani/AAA-9199-2021
OI fawzi, amani/0000-0002-9568-3558
FU National Institutes of Health [AAF - 1DP3DK108248]
FX This work was supported by AAF - 1DP3DK108248, National Institutes of
   Health (www.nih.gov).The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Fayed A. E., 2018, PREVALENCE SUBCLINIC
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Palejwala NV, 2015, RETINA-J RET VIT DIS, V35, P2204, DOI 10.1097/IAE.0000000000000867
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Yanagi Y, 2018, JAMA OPHTHALMOL, V136, P905, DOI 10.1001/jamaophthalmol.2018.2154
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
NR 24
TC 24
Z9 24
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2019
VL 14
IS 6
AR e0217805
DI 10.1371/journal.pone.0217805
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IB2FX
UT WOS:000470086200037
PM 31163067
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Rumelt, S
   Kaiserman, I
   Rehany, U
   Ophir, A
   Pikkel, J
   Loewenstein, A
AF Rumelt, S
   Kaiserman, I
   Rehany, U
   Ophir, A
   Pikkel, J
   Loewenstein, A
TI Detachment of subfoveal choroidal neovascularization in age-related
   macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC
   THERAPY; TEARS; PATHOGENESIS; VERTEPORFIN; PHASE-1
AB PURPOSE: To report the entity of partial detachment and folding of subfoveal choroidal neovascularization (CNV) in age,related macular degeneration (ARMD).
   DESIGN: Interventional case reports.
   METHODS: Review of the features of CNV detachment in two patients with CNV due to ARMD by contact lens slit-lamp biomicroscopy, fluorescein angiography, optical coherence tomography, and three-dimensional confocal scanning laser indocyanine green (ICG) angiography.
   RESULTS: One patient out of approximately 300 (0.5%) ARMD patients treated by photodynamic therapy (PDT) developed partial CNV detachment and folding 6 weeks after the second PDT treatment. Another patient out of approximately 100 (1.0%) ARMD patients treated by transpupillary thermotherapy (TTT) developed partial CNV detachment and folding 6 weeks after the second TTT treatment. The CNVs were large (2,500 mum to 4,500 mum) and located between the retina and the retinal pigment epithelium. In each, these findings were clearly visualized by slit,lamp biomicroscopy. Fluorescein angiography demonstrated an associated retinal pigment epithelium tear in one patient. Optical coherence tomography showed distinctive features and confocal scanning laser ICG further delineated the detached folded CNV. The best-corrected visual acuity improved in one patient from 20/80 to 20/40 and in the other from counting fingers at 6 feet to 20/200 after the CNV detachment.
   CONCLUSIONS: Partial CNV detachment and folding represent a unique, not previously reported, and possibly favorable outcome of PDT and TTT. The low energy and selectivity of these treatments may explain this phenomenon.
C1 Western Galilee Nahariya Med Ctr, Dept Ophthalmol, IL-22100 Nahariyya, Israel.
   Hadassah Univ Hosp, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
   Leumit Hlth Care Syst, Dept Ophthalmol, Jerusalem, Israel.
   Hillel Yaffe Med Ctr, Dept Ophthalmol, Hadera, Israel.
   Elias Sorasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
C3 Western Galilee Hospital; Hebrew University of Jerusalem
RP Rumelt, S (通讯作者)，Western Galilee Nahariya Med Ctr, Dept Ophthalmol, POB 21, IL-22100 Nahariyya, Israel.
OI Kaiserman, Igor/0000-0003-0130-8819
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Coscas G, 1982, Bull Soc Ophtalmol Fr, V82, P815
   DECKER WL, 1983, OPHTHALMOLOGY, V101, P509
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   GREEN SL, 1983, RETINA, V90, P16
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   KRISHAN NR, 1985, AM J OPHTHALMOL, V100, P698, DOI 10.1016/0002-9394(85)90626-9
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V109, P1219
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   NOLTHENIUS PAT, 1985, INT OPHTHALMOL, V8, P19, DOI 10.1007/BF00136457
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   TOTH CA, 1995, OPHTHALMOLOGY, V102, P272
   WORMALD R, 2002, COCHRANE LIB, DOI UNSP AB002030
   YEO JH, 1988, OPHTHALMOLOGY, V95, P13
NR 24
TC 3
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2002
VL 134
IS 6
BP 822
EP 827
AR PII S0002-9394(02)01817-2
DI 10.1016/S0002-9394(02)01817-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624BA
UT WOS:000179738600004
PM 12470749
DA 2022-11-30
ER

PT J
AU Chang, LK
   Flaxel, CJ
   Lauer, AK
   Sarraf, D
AF Chang, Louis K.
   Flaxel, Christina J.
   Lauer, Andreas K.
   Sarraf, David
TI RPE tears affer pegaptanib treatment in age-related macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   pegaptanib; pigment epithelial detachment; retinal pigment epithelium
   tear; vascular endothelial growth factor
ID PIGMENT EPITHELIAL TEAR; CHOROIDAL NEOVASCULARIZATION SECONDARY; OPTICAL
   COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PATHOGENESIS; DETACHMENTS;
   INJECTION
AB Purpose: To describe retinal pigment epithelial (RPE) tears in patients with age-related macular degeneration (AMD) status post pegaptanib (Macugen) injection.
   Methods: Six eyes from six patients who developed FIFE tears while undergoing treatment with pegaptanib for AMD-related fibrovascular pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were identified retrospectively. Diagnosis of pre-pegaptanib fibrovascular PED and post-pegaptanilb RPE tears were made by clinical examination, fluorescein angiography (FA), and optical coherence tomography (OCT) imaging of the macula.
   Results: Four patients developed an RPE tear within 8 weeks after the first pegaptanib injection, while RPE tears were found in two patients following a second injection. Only one of the patients reported acute vision loss, although three of six eyes had a decrease.in objective visual acuity in the affected eye to the count fingers level. All six cases displayed the classic clinical and angiographic appearance of RPE tears. In addition, OCT imaging showed an irregular, hyperreflective RPE layer with a focal defect.
   Conclusions: FIFE tears are known to occur in the setting of PED spontaneously or after laser treatment, but have only recently been described in association with intravitreal pegaptanib. OCT imaging of eyes status post pegaptanib therapy may be helpful in identifying this complication. Patients with AMD, especially those with occult CNV and fibrovascular PED, receiving pegaptanib therapy should be monitored for RPE tears, which may warrant deferral of further injections.
C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   Oregon Hlth & Sci Univ, Dept Ophthalmol, Casey Eye Inst, Portland, OR 97201 USA.
   Kaiser Permanente, Dept Ophthalmol, Woodland Hills, CA USA.
   King Drew Med Ctr, Dept Ophthalmol, Los Angeles, CA USA.
   Greater LA VA Healthcare Ctr, Dept Ophthalmol, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   Oregon Health & Science University; Kaiser Permanente
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   GOLDSTEIN BG, 1987, BRIT J OPHTHALMOL, V71, P676, DOI 10.1136/bjo.71.9.676
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Ishida Y, 2004, RETINA-J RET VIT DIS, V24, P633, DOI 10.1097/00006982-200408000-00028
   JAEGER RD, 2004, RETINA, V24, P676
   Jogiya A, 2004, EYE, V18, P960, DOI 10.1038/sj.eye.6701376
   LIM JI, 1990, ARCH OPHTHALMOL-CHIC, V108, P1672, DOI 10.1001/archopht.1990.01070140026013
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 25
TC 43
Z9 43
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 857
EP 863
DI 10.1097/IAE.0b013e3180342c42
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600009
PM 17891009
DA 2022-11-30
ER

PT J
AU van Landingham, SW
   Massof, RW
   Chan, E
   Friedman, DS
   Ramulu, PY
AF van Landingham, Suzanne W.
   Massof, Robert W.
   Chan, Emilie
   Friedman, David S.
   Ramulu, Pradeep Y.
TI Fear of falling in age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Fear of falling; Falls; Age-related macular degeneration; Disability;
   Older adults; Visual acuity; vision loss; Physical function; Safety
ID BEAVER DAM EYE; OLDER-ADULTS; VISUAL IMPAIRMENT; INJURIOUS FALLS;
   UNITED-STATES; RISK-FACTORS; PREVALENCE; GLAUCOMA; POPULATION; COMMUNITY
AB Background: Prior studies have shown age-related macular degeneration (AMD) to be associated with falls. The purpose of this study is to determine if (AMD) and AMD-related vision loss are associated with fear of falling, an important and distinct outcome.
   Methods: Sixty-five persons with AMD with evidence of vision loss in one or both eyes and 60 glaucoma suspects with normal vision completed the University of Illinois at Chicago Fear of Falling questionnaire. Responses were Rasch analyzed. Scores were expressed in logit units, with lower scores demonstrating lesser ability and greater fear of falling.
   Results: Compared to glaucoma suspect controls, AMD subjects had worse visual acuity (VA) (median better-eye VA = 20/48 vs. 20/24, p < 0.001) and worse contrast sensitivity (CS) (binocular CS = 1.9 vs. 1.5 log units, p < 0.001). AMD subjects were also older, more likely to be Caucasian, and less likely to be employed (p < 0.05 for all), but were similar with regards to other demographic and health measures. In multivariable models controlling for age, gender, body habitus, strength, and comorbid illnesses, AMD subjects reported greater fear of falling as compared to controls (beta = -0.77 logits, 95% CI = -1.5 to -0.002, p = 0.045). In separate multivariable models, fear of falling increased with worse VA (beta = -0.15 logits/1 line decrement, 95% CI = -0.28 to -0.03, p = 0.02) and CS (beta = -0.20 logits/0.1 log unit decrement, 95% CI = -0.31 to -0.09, p = 0.001). Greater fear of falling was also associated with higher BMI, weaker grip, and more comorbid illnesses (p < 0.05 for all).
   Conclusions: AMD and AMD-related vision loss are associated with greater fear of falling in the elderly. Development, validation, and implementation of methods to address falls and fear of falling for individuals with vision loss from AMD are important goals for future work.
C1 [van Landingham, Suzanne W.; Massof, Robert W.; Chan, Emilie; Friedman, David S.; Ramulu, Pradeep Y.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Ramulu, PY (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 600 North Wolfe St Maumenee B-110, Baltimore, MD 21287 USA.
EM pramulu@jhmi.edu
OI Friedman, David/0000-0002-2055-5797
FU Dennis W. Jahnigen Memorial Award, NIH [EY018595]; Research to Prevent
   Blindness Robert and Helen Schaub Special Scholar Award; Intramural
   Research Program of the NIH (National Institute on Aging); Doris Duke
   Charitable Research Foundation Clinical Research Fellowship; NATIONAL
   EYE INSTITUTE [K23EY018595] Funding Source: NIH RePORTER
FX This research was supported in part by the Dennis W. Jahnigen Memorial
   Award, NIH Grant EY018595, the Research to Prevent Blindness Robert and
   Helen Schaub Special Scholar Award, the Intramural Research Program of
   the NIH (National Institute on Aging), and the Doris Duke Charitable
   Research Foundation Clinical Research Fellowship. All funding
   organizations had no role in the design or conduct of this research. The
   corresponding author had full access to all the data in the study and
   takes responsibility for the integrity of the data and the accuracy of
   the data analysis.
CR ARFKEN CL, 1994, AM J PUBLIC HEALTH, V84, P565, DOI 10.2105/AJPH.84.4.565
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cumming RG, 2000, J GERONTOL A-BIOL, V55, pM299, DOI 10.1093/gerona/55.5.M299
   de Boer MR, 2004, J BONE MINER RES, V19, P1539, DOI 10.1359/JBMR.040504
   Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x
   GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43
   Lawrence RH, 1998, J AGING HEALTH, V10, P267, DOI 10.1177/089826439801000301
   Legters K, 2002, PHYS THER, V82, P264, DOI 10.1093/ptj/82.3.264
   Massof RW, 2011, OPHTHAL EPIDEMIOL, V18, P1, DOI 10.3109/09286586.2010.545501
   Montorio I, 1996, Int Psychogeriatr, V8, P103, DOI 10.1017/S1041610296002505
   Murphy SL, 2003, J GERONTOL A-BIOL, V58, P943
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Radvay X, 2007, J VESTIBUL RES-EQUIL, V17, P183
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.037
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, P1159, DOI 10.1016/j.ophtha.2012.01.013
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   van Landingham SW, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-4
   Velozo CA, 2001, AM J PHYS MED REHAB, V80, P662, DOI 10.1097/00002060-200109000-00006
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Yardley L, 2002, GERONTOLOGIST, V42, P17, DOI 10.1093/geront/42.1.17
NR 38
TC 27
Z9 28
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 28
PY 2014
VL 14
AR 10
DI 10.1186/1471-2415-14-10
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AF1DC
UT WOS:000334453600001
PM 24472499
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Serrano-Aguilar, P
   Abreu, R
   Anton-Canalis, L
   Guerra-Artal, C
   Ramallo-Farina, Y
   Gomez-Ulla, F
   Nadal, J
AF Serrano-Aguilar, P.
   Abreu, R.
   Anton-Canalis, L.
   Guerra-Artal, C.
   Ramallo-Farina, Y.
   Gomez-Ulla, F.
   Nadal, J.
TI Development and validation of a computer-aided diagnostic tool to screen
   for age-related macular degeneration by optical coherence tomography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AUTOMATED DETECTION; MACULOPATHY
AB Background To develop and assess the technical validity of new computer-aided diagnostic software (CAD) for automated analyses of optical coherence tomography (OCT) images for the purpose of screening for neovascular age-related macular degeneration.
   Methods Artificial visual techniques were used to develop the CAD in two steps: normalisation and feature vector extraction from OCT images; and training and classification by means of decision trees. Technical validation was performed by a retrospective study design based on OCT images randomly extracted from clinical charts. Images were classified as normal or abnormal to serve for screening purposes. Sensitivity, specificity, positive predictive values and negative predictive values were obtained.
   Results The CAD was able to quantify image information by working in the perceptually uniform hue-saturation-value colour space. Particle swarm optimisation with Haar-like features is suitable to reveal structural features in normal and abnormal OCT images. Decision trees were useful to characterise normal and abnormal images using feature vectors obtained from descriptive statistics of detected structures. The sensitivity of the CAD was 96% and the specificity 92%.
   Conclusions This new CAD for automated analysis of OCT images offers adequate sensitivity and specificity to distinguish normal OCT images from those showing potential neovascular age-related macular degeneration. These results will enable its clinical validation and a subsequent cost-effectiveness assessment to be made before recommendations are made for population-screening purposes.
C1 [Serrano-Aguilar, P.] Canary Isl Hlth Serv, Evaluat & Planning Unit, Canary Isl, Spain.
   [Serrano-Aguilar, P.; Ramallo-Farina, Y.] CIBERESP, Barcelona, Spain.
   [Abreu, R.] Univ Hosp La Candelaria, Dept Ophthalmol, Canary Isl, Spain.
   [Anton-Canalis, L.; Guerra-Artal, C.] Univ Las Palmas Gran Canaria, Artificial Intelligence & Syst Grp GIAS, Canary Isl, Spain.
   [Ramallo-Farina, Y.] Canary Isl Fdn Hlth & Res FUNCIS, Canary Isl, Spain.
   [Gomez-Ulla, F.] Univ Santiago de Compostela, ITO, Santiago De Compostela, Spain.
   [Nadal, J.] Barraquer Ophthalmol Ctr, Barcelona, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universidad
   de Las Palmas de Gran Canaria; Universidade de Santiago de Compostela
RP Serrano-Aguilar, P (通讯作者)，C Perez de Rozas 5,4A Planta,CP 38004, Santa Cruz De Tenerife, Islas Canarias, Spain.
EM pserrano@gobiernodecanarias.org
RI Ramallo-Fariña, Yolanda/AAE-9355-2021
OI Ramallo-Fariña, Yolanda/0000-0002-1541-3989; Abreu-Gonzalez,
   Rodrigo/0000-0002-0354-4252
FU Health Institute Carlos III [PS09/01308]
FX This research study was financed by the Health Institute Carlos III
   (Fondo de Investigaciones Sanitarias File No PS09/01308).
CR Bagci AM, 2008, AM J OPHTHALMOL, V146, P679, DOI 10.1016/j.ajo.2008.06.010
   Baroni M, 2007, IFMBE PROC, V16, P847
   Bouhaimed M, 2008, DIABETES TECHNOL THE, V10, P142, DOI 10.1089/dia.2007.0239
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Doi K, 2007, COMPUT MED IMAG GRAP, V31, P198, DOI 10.1016/j.compmedimag.2007.02.002
   Eriksson U, 2009, BRIT J OPHTHALMOL, V93, P1448, DOI 10.1136/bjo.2007.131094
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Fuller AR, 2007, IEEE T VIS COMPUT GR, V13, P1719, DOI 10.1109/TVCG.2007.70590
   Hall M., 2009, SIGKDD EXPLORATIONS, V11, P10, DOI [10.1145/1656274.1656278, DOI 10.1145/1656274.1656278]
   Karnon J, 2008, Health Technol Assess, V12, piii
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P274, DOI 10.1136/bjo.2008.148163
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Larsen M, 2007, CURR EYE RES, V32, P331, DOI 10.1080/02713680701215587
   National Screening Committee, NSC CRIT APPR VIAB E
   Omran MG, 2005, INFORM-J COMPUT INFO, V29, P261
   PICARD RR, 1984, J AM STAT ASSOC, V79, P575, DOI 10.2307/2288403
   Quinlan JR, 2014, C4 5 PROGRAMS MACHIN
   Rossant F, 2009, I S BIOMED IMAGING, P1370, DOI 10.1109/ISBI.2009.5193320
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P1187, DOI 10.1016/j.ophtha.2005.12.020
   Schmitt NJ, 2003, AM J OPHTHALMOL, V136, P314, DOI 10.1016/S0002-9394(03)00208-3
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Viola P, 2001, PROC CVPR IEEE, P511, DOI 10.1109/cvpr.2001.990517
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
NR 25
TC 6
Z9 6
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2012
VL 96
IS 4
BP 503
EP 507
DI 10.1136/bjophthalmol-2011-300660
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 914GW
UT WOS:000301938700010
PM 21873314
DA 2022-11-30
ER

PT J
AU Weeks, DE
   Conley, YP
   Tsai, HJ
   Mah, TS
   Schmidt, S
   Postel, EA
   Agarwal, A
   Haines, JL
   Pericak-Vance, MA
   Rosenfeld, PJ
   Paul, TO
   Eller, AW
   Morse, LS
   Dailey, JP
   Ferrell, RE
   Gorin, MB
AF Weeks, DE
   Conley, YP
   Tsai, HJ
   Mah, TS
   Schmidt, S
   Postel, EA
   Agarwal, A
   Haines, JL
   Pericak-Vance, MA
   Rosenfeld, PJ
   Paul, TO
   Eller, AW
   Morse, LS
   Dailey, JP
   Ferrell, RE
   Gorin, MB
TI Age-related maculopathy: A genomewide scan with continued evidence of
   susceptibility loci within the 1q31, 10q26, and 17q25 regions
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID APOLIPOPROTEIN-E GENE; MACULAR DEGENERATION; LINKAGE ANALYSIS; EPSILON-4
   ALLELE; SMOKING; ASSOCIATION; MUTATION; PROGRAM; DISEASE; MODELS
AB Age-related maculopathy (ARM), or age-related macular degeneration, is one of the most common causes of visual impairment in the elderly population of developed nations. In a combined analysis of two previous genomewide scans that included 391 families, containing up to 452 affected sib pairs, we found linkage evidence in four regions: 1q31, 9p13, 10q26, and 17q25. We now have added a third set of families and have performed an integrated analysis incorporating 530 families and up to 736 affected sib pairs. Under three diagnostic models, we have conducted linkage analyses using parametric (heterogeneity LOD [HLOD] scores under an autosomal dominant model) and nonparametric (S-all statistic) methods. There is ongoing evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions. If we treat the third set of families as a replication set, then two regions ( 10q26 and 17q25) are replicated, with LOD scores >1.0. If we pool all our data together, then four regions (1q31, 2q14.3, 10q26, and 17q25) show HLOD or S-all scores greater than or equal to2.0. Within the 1q31 region, we observed an HLOD of 2.72 (genomewide P = .061) under our least stringent diagnostic model, whereas the 17q25 region contained a maximal HLOD of 3.53 (genomewide P = .007) under our intermediate diagnostic model. We have evaluated our results with respect to the findings from several new independent genomewide linkage studies and also have completed ordered subset analyses (OSAs) with apolipoprotein E alleles, smoking history, and age at onset as stratifying covariates. The OSAs generate the interesting hypothesis that the effect of smoking on the risk of ARM is accentuated by a gene in the 10q26 region - a region implicated by four other studies.
C1 Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA USA.
   Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA.
   Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
   Duke Univ, Med Ctr, Dept Ophthalmol, Duke Eye Ctr, Durham, NC USA.
   Duke Univ, Med Ctr, Ctr Human Genet, Dept Med, Durham, NC USA.
   Vanderbilt Univ, Med Ctr, Ctr Human Genet Res, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Dept Ophthalmol, Nashville, TN USA.
   Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33152 USA.
   Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA.
   Univ Calif Davis, Dept Ophthalmol, Davis, CA 95616 USA.
   Case Western Reserve Univ, Cleveland, OH 44106 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Duke University; Duke University; Vanderbilt University;
   Vanderbilt University; Bascom Palmer Eye Institute; University of Miami;
   The Smith-Kettlewell Eye Research Institute; University of California
   System; University of California Davis; Case Western Reserve University
RP Gorin, MB (通讯作者)，Univ Pittsburgh, Sch Med, Dept Ophthalmol, Eye & Ear Inst Bldg,203 Lothrop St, Pittsburgh, PA 15213 USA.
EM gorinmb@upmc.edu
RI Haines, Jonathan/C-3374-2012; Tsai, Hui-Ju/E-3937-2010; Weeks, Daniel
   E/B-2995-2012
OI Haines, Jonathan/0000-0002-4351-4728; Weeks, Daniel
   E/0000-0001-9410-7228; Morse, Lawrence/0000-0002-1758-2348
FU NATIONAL EYE INSTITUTE [R01EY009859] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [N01HG065403] Funding Source:
   NIH RePORTER; NEI NIH HHS [R01 EY009859, R01-EY09859] Funding Source:
   Medline; NHGRI NIH HHS [N01HG65403, N01-HG-48141] Funding Source:
   Medline; NHLBI NIH HHS [N01HV48141] Funding Source: Medline
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Breitner JCS, 1998, ALZ DIS ASSOC DIS, V12, P40, DOI 10.1097/00002093-199803000-00006
   Broman KW, 2001, GENET EPIDEMIOL, V20, P307, DOI 10.1002/gepi.2.abs
   Cordell HJ, 2001, ANN HUM GENET, V65, P491, DOI 10.1017/S0003480001008831
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Ghosh S, 2000, AM J HUM GENET, V67, P1174, DOI 10.1016/S0002-9297(07)62948-6
   Ghosh S, 1999, P NATL ACAD SCI USA, V96, P2198, DOI 10.1073/pnas.96.5.2198
   Gorin MB, 1998, OX MG MED G, P407
   Goring HHH, 2000, AM J HUM GENET, V66, P1298, DOI 10.1086/302846
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   Hauser ER, 1998, BIOMETRICS, V54, P1238, DOI 10.2307/2533653
   Hauser ER, 2001, AM J HUM GENET, V69, P529
   HAUSER ER, 2004, IN PRESS GENET EPIDE, V27
   HODGE SE, 1983, AM J HUM GENET, V35, P1139
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mandal N, 2002, BRIT J OPHTHALMOL, V86, P118, DOI 10.1136/bjo.86.1.118
   McPeek MS, 2000, AM J HUM GENET, V66, P1076, DOI 10.1086/302800
   Meyer MR, 1998, NAT GENET, V19, P321, DOI 10.1038/1206
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   OTT J, 1992, AM J HUM GENET, V51, P283
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   SCHULTZ DW, 2003, ASS RES VIS OPHTH M
   SCHWARTZ B, 1994, SURV OPHTHALMOL, V39, P1, DOI 10.1016/S0039-6257(05)80040-2
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Tamakoshi A, 1998, BRIT J OPHTHALMOL, V82, P207
   Tamakoshi A, 1997, BRIT J OPHTHALMOL, V81, P901, DOI 10.1136/bjo.81.10.901
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Watanabe RM, 1999, GENET EPIDEMIOL, V17, pS385
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
NR 51
TC 132
Z9 140
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD AUG
PY 2004
VL 75
IS 2
BP 174
EP 189
DI 10.1086/422476
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 838GR
UT WOS:000222702000003
PM 15168325
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Chang, AA
   Tan, WC
   Beaumont, PE
   Zeldovich, A
AF Chang, AA
   Tan, WC
   Beaumont, PE
   Zeldovich, A
TI Limited macular translocation for subfoveal choroidal neovascularization
   in age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; limited macular translocation;
   subfoveal choroidal neovascularization
ID RETINOTOMY; SECONDARY
AB Purpose: To examine the safety and efficacy of limited macular translocation followed by laser photocoagulation in the management of subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   Methods: A prospective study was conducted on eight consecutive patients undergoing limited macular translocation followed by laser photocoagulation for the treatment of subfoveal classic CNV form of AMD. Patients were followed up for a minimum of 12 months. The magnitude of foveal translocation, visual outcomes and complications were assessed.
   Results: In all cases the fovea was successfully translocated inferiorly, with a median displacement of 1.1 mm. Thermal laser photocoagulation was subsequently performed in all cases. Visual acuity improved in five eyes, remained unchanged in two eyes and worsened in one eye. The mean improvement in visual acuity was by 0.19 logMAR. At 12 months, six of the eight patients (75%) achieved Snellen visual acuity of at least 6/15, with four patients (50%) achieving Snellen visual acuity of 6/9.
   Conclusion: In this small case series, limited macular translocation was found to be an effective and reproducible means of treating small well-defined subfoveal CNV.
C1 Sydney Retina, Sydney, NSW 2000, Australia.
   Sydney Eye Hosp, Vitreoretinal Unit, Sydney, NSW, Australia.
RP Chang, AA (通讯作者)，Sydney Retina, Level 13,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Lewis H, 2001, AM J OPHTHALMOL, V132, P156, DOI 10.1016/S0002-9394(01)01088-1
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Soubrane G, 1987, Bull Soc Ophtalmol Fr, V87, P249
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   Wong D, 2001, AM J OPHTHALMOL, V132, P139, DOI 10.1016/S0002-9394(01)00892-3
NR 20
TC 5
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2003
VL 31
IS 2
BP 103
EP 109
DI 10.1046/j.1442-9071.2003.00614.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 658TE
UT WOS:000181735900004
PM 12648041
DA 2022-11-30
ER

PT J
AU Alexander, P
   Gibson, J
   Cree, AJ
   Ennis, S
   Lotery, AJ
AF Alexander, Philip
   Gibson, Jane
   Cree, Angela J.
   Ennis, Sarah
   Lotery, Andrew J.
TI Complement factor I and age-related macular degeneration
SO MOLECULAR VISION
LA English
DT Article
ID GENE; SUSCEPTIBILITY; ASSOCIATION; VARIANTS; RISK
AB Purpose: The complement system has been implicated in the pathogenesis of age-related macular degeneration (AMD). Complement factor I (CFI) is a serum protease that inhibits all complement pathways. A previous multicenter study identified a single missense CFI mutation (p.Gly119Arg) in 20/3,567 (0.56%) of AMD cases versus 1/3,937 (0.025%) of controls, thus suggesting that this mutation confers a high risk of AMD. A second CFI mutation, p. Gly188Ala, was identified in one patient with AMD.
   Methods: We screened 521 unrelated AMD cases and 627 controls for the p. Gly119Arg and p. Gly188Ala variants. All participants were Caucasian and >55 years, and recruited through Southampton Eye Unit or research clinics in Guernsey. All participants underwent dilated fundal examination by an experienced retinal specialist. SNP assays were performed using KASP T biochemistry.
   Results: The p. Gly119Arg mutation was identified in 7/521 AMD cases compared to 1/627 age-matched controls (odds ratio [OR] = 8.47, confidence interval [CI] = 1.04-69.00, p = 0.027). There was a varied phenotype among the seven cases with the mutation, which was present in 4/254 (1.6%) cases with active or end-stage wet AMD and 3/267 dry AMD cases (1.1%). The p.Gly188Ala substitution was identified in 1/521 cases and 1/627 controls.
   Conclusions: Our results identified a much higher frequency of heterozygosity for p. Gly119Arg in both cases and controls than in previous studies. Of note is that our sub-cohort from Guernsey had a particularly high frequency of p.Gly119Arg heterozygosity in affected individuals (4%) compared to our sub-cohort from the mainland (0.71%). Although these data support the conclusions of van de Ven et al. that the p.Gly119Arg substitution confers a high risk of AMD, our data suggest that this missense mutation is not as rare or as highly penetrant as previously reported. There was no difference in frequency for a second CFI variant, p.Gly188Ala, between the cases and the controls.
C1 [Alexander, Philip; Cree, Angela J.; Ennis, Sarah; Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
   [Gibson, Jane] Univ Southampton, Fac Nat & Environm Studies, Ctr Biol Sci, Southampton, Hants, England.
C3 University of Southampton; University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
EM a.j.lotery@soton.ac.uk
RI Gibson, Jane/I-1630-2012
OI Gibson, Jane/0000-0002-0973-8285; Cree, Angela/0000-0002-1987-8900
FU Brian Mercer Charitable Trust; Macular Society; TFC Frost Charitable
   Trust
FX Andrew Lotery (a.j.lotery@soton.ac.uk) and Sarah Ennis
   (s.ennis@soton.ac.uk) contributed equally to the work presented here. We
   are grateful to the Brian Mercer Charitable Trust, Macular Society, TFC
   Frost Charitable Trust, and the Gift of Sight Appeal for providing
   funding for this study. We are grateful to Helen Griffiths for her
   technical expertise and Marie Nelson and the Wellcome Trust Clinical
   Research Facility in Southampton for patient recruitment, and the
   patients themselves for their participation in the study.
CR Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cipriani V, 2012, EUR J HUM GENET, V20, P1, DOI 10.1038/ejhg.2011.118
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Ennis S, 2010, EUR J HUM GENET, V18, P15, DOI 10.1038/ejhg.2009.113
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Qian D, 2014, EUROPEAN J HUMAN GEN, V37
   Regillo CD, 2013, AM AC OPHTH AAO ANN
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 15
TC 18
Z9 18
U1 0
U2 18
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 13
PY 2014
VL 20
BP 1253
EP 1257
PG 5
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AP3LD
UT WOS:000341976600001
PM 25352734
DA 2022-11-30
ER

PT J
AU Qin, S
AF Qin, Suofu
TI Oxidative damage of retinal pigment epithelial cells and age-related
   macular degeneration
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Review
DE age-related macular degeneration; inflammation; oxidative stress;
   reactive oxygen species; retinal pigment epithelial cells
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; MITOCHONDRIAL-DNA DAMAGE;
   BLUE-LIGHT; DOCOSAHEXAENOIC ACID; INDUCED APOPTOSIS; GENE-EXPRESSION;
   15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CHOROIDAL NEOVASCULARIZATION;
   SUPEROXIDE-DISMUTASE; CYTOKINE EXPRESSION
AB Damage to the retinal pigment epithelial (RPE) cells is an early and crucial event in the molecular pathways leading to clinically relevant age-related macular degeneration (AMD) changes. Oxidative stress, the major environmental risk factor for atrophic AMD, causes RPE injury that results in a chronic inflammatory response, drusen formation, and RPE atrophy. RPE degeneration ultimately leads to a progressive irreversible degeneration of photoreceptors. In vitro studies show that oxidant-treated RPE cells undergo apoptosis, a possible mechanism by which RPE cells are lost during the early phase of atrophic AMD. The main target of oxidative injury appears to be mitochondria, an organelle known to accumulate genomic damage during aging. Addition of GSH, the most abundant intracellular thiol antioxidant, protects RPE cells from oxidant-induced apoptosis. Similar protection occurs with dietary enzyme inducers that increase GSH synthesis. In addition, enhancing survival signaling preserves RPE cells under oxidative stress. These results indicate that therapeutic or nutritional intervention to enhance the antioxidant capacity and survival signaling of RPE may provide an effective way to prevent or treat AMD. This review describes major molecular and cellular events leading to RPE death, and presents currently used and new experimental, forthcoming therapeutic strategies.
C1 [Qin, Suofu] Allergan Pharmaceut Inc, Dept Biol Sci, Retinal Dis Res, Irvine, CA 92612 USA.
C3 AbbVie; Allergan
RP Qin, S (通讯作者)，Allergan Pharmaceut Inc, Dept Biol Sci, Retinal Dis Res, RD3-2D,2525 Dupont Dr, Irvine, CA 92612 USA.
EM qin_suofu@allergan.com
OI Qin, Suofu/0000-0002-3323-8846
CR AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516
   ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Anderson CM, 2002, FAM PROCESS, V41, P1, DOI 10.1111/j.1545-5300.2002.40102000001.x
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Aoun P, 2003, INVEST OPHTH VIS SCI, V44, P2999, DOI 10.1167/iovs.02-1060
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ban Y, 2000, DEV BRAIN RES, V121, P89
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Benson AB, 2000, CLIN CANCER RES, V6, P3870
   Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306
   Bian ZM, 2001, INVEST OPHTH VIS SCI, V42, P1660
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chan D, 1998, OPTOMETRY VISION SCI, V75, P476, DOI 10.1097/00006324-199807000-00015
   Chen YF, 2002, ADV COMP THE PRACT, V10, P79
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   COMPORTI M, 1987, CHEM PHYS LIPIDS, V45, P143, DOI 10.1016/0009-3084(87)90064-8
   Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049
   Coudray C, 1997, BIOL TRACE ELEM RES, V57, P183, DOI 10.1007/BF02778201
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DOREY CK, 1990, CURR EYE RES, V9, P549, DOI 10.3109/02713689008999595
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   EMBER JA, 1994, AM J PATHOL, V144, P393
   Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097-4547(19991015)58:2<254::AID-JNR5>3.0.CO;2-U
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fernandez-Robredo P, 2005, INVEST OPHTH VIS SCI, V46, P1140, DOI 10.1167/iovs.04-0516
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fukuoka Y, 2001, CURR EYE RES, V23, P320, DOI 10.1076/ceyr.23.5.320.5437
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Gupta E, 1995, CLIN CANCER RES, V1, P1133
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamann S, 2000, PFLUG ARCH EUR J PHY, V440, P84, DOI 10.1007/s004249900236
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hinton DR, 1998, EXP CELL RES, V239, P11, DOI 10.1006/excr.1997.3873
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KONDA BR, 1994, INVEST OPHTH VIS SCI, V35, P40
   Koppal T, 2000, BRAIN RES, V867, P115, DOI 10.1016/S0006-8993(00)02270-8
   Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Liang Y, 2000, CURR EYE RES, V20, P25, DOI 10.1076/0271-3683(200001)2011-HFT025
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7
   McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mochizuki M, 2005, AM J RESP CRIT CARE, V171, P1260, DOI 10.1164/rccm.200406-755OC
   MOORE GA, 1983, FEBS LETT, V153, P289, DOI 10.1016/0014-5793(83)80626-7
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   Moriarty-Craige SE, 2007, AM J OPHTHALMOL, V143, P206, DOI 10.1016/j.ajo.2006.09.056
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Musiek ES, 2005, J BIOL CHEM, V280, P35562, DOI 10.1074/jbc.M504785200
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   Nataf S, 1999, J IMMUNOL, V162, P4018
   Nelson KC, 1999, INVEST OPHTH VIS SCI, V40, P1927
   Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004
   NEWSOME DA, 1994, PROG RETIN EYE RES, V13, P101, DOI 10.1016/1350-9462(94)90006-X
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Nosjean O, 2002, CELL SIGNAL, V14, P573, DOI 10.1016/S0898-6568(01)00281-9
   ODwyer PJ, 1996, J CLIN INVEST, V98, P1210, DOI 10.1172/JCI118904
   OLIVER PD, 1992, INVEST OPHTH VIS SCI, V33, P1909
   ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730
   Osborne NN, 1997, INVEST OPHTH VIS SCI, V38, P1390
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Rao NA, 2000, PROG RETIN EYE RES, V19, P41, DOI 10.1016/S1350-9462(99)00003-8
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rose RC, 1998, P SOC EXP BIOL MED, V217, P397, DOI 10.3181/00379727-217-44250
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Schmidt-Erfurth U, 2005, DEV OPHTHALMOL, V38, P120, DOI 10.1159/000082772
   SCHNEEWEIS DM, 1995, SCIENCE, V268, P1053, DOI 10.1126/science.7754386
   SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Tanner V, 1998, EYE, V12, P679, DOI 10.1038/eye.1998.168
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tate DJ, 1999, FREE RADICAL BIO MED, V26, P704, DOI 10.1016/S0891-5849(98)00253-6
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev
   Ueda T, 1996, OPHTHALMIC RES, V28, P184, DOI 10.1159/000267901
   van der Hagen A M, 1993, J Am Optom Assoc, V64, P871
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200
   Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098
   Wang JS, 1999, JNCI-J NATL CANCER I, V91, P347, DOI 10.1093/jnci/91.4.347
   Wassell J, 1998, INVEST OPHTH VIS SCI, V39, P1487
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Winkler B S, 1999, Mol Vis, V5, P32
   Wolfensberger T., 1998, RETINAL PIGMENT EPIT, P103
   Wu GS, 2005, INVEST OPHTH VIS SCI, V46, P2271, DOI 10.1167/iovs.04-1525
   Wu ZH, 2006, J CELL PHYSIOL, V209, P996, DOI 10.1002/jcp.20819
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yoshida A, 2001, BRIT J OPHTHALMOL, V85, P872, DOI 10.1136/bjo.85.7.872
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   ZHENG J, 2000, EXP EYE RES S, V71, pS113
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
NR 156
TC 18
Z9 18
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD AUG
PY 2007
VL 68
IS 5
BP 213
EP 225
DI 10.1002/ddr.20185
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 240CH
UT WOS:000251564100002
DA 2022-11-30
ER

PT J
AU O'Connell, E
   Neelam, K
   Nolan, J
   Eong, KGA
   Beatty, S
AF O'Connell, Eamonn
   Neelam, Kumari
   Nolan, John
   Eong, Kah-Guan Au
   Beatty, Stephan
TI Macular carotenoids and age-related maculopathy
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Review
DE lutein; macular degeneration; oxidative stress; zeaxanthin
ID PIGMENT OPTICAL-DENSITY; ALPHA-TOCOPHEROL; DIETARY CAROTENOIDS; TISSUE
   DISTRIBUTION; LIPID-PEROXIDATION; PROTECTIVE ROLE; LUNG-CANCER; LUTEIN;
   ZEAXANTHIN; SERUM
AB Lutein (L) and zeaxanthin (Z) are concentrated at the macula, where they are collectively known as macular pigment (MP), and where they are believed to play a major role in protecting retinal tissues against oxidative stress. Whilst the exact pathogenesis of age-related maculopathy (ARM) remains unknown, the disruption of cellular processes by oxidative stress may play an important role. Manipulation of dietary intake of L and Z has been shown to augment MP, thereby raising hopes that dietary supplementation with these carotenoids might prevent, delay, or modify the course of ARM. This article discusses the scientific rationale supporting the hypothesis that L and Z are protective against ARM, and presents the recent evidence germane to this theory.
C1 Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
   Waterford Inst Technol, Waterford, Ireland.
   Alexandria Hosp, Natl Healthcare Grp, Inst Eye, Singapore, Singapore.
   Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117548, Singapore.
   Singapore Eye Res Inst, Singapore, Singapore.
   Tan Tock Seng Hosp, Inst Eye, Singapore, Singapore.
   Med Coll Georgia, Augusta, GA 30912 USA.
C3 South East Technological University (SETU); National University of
   Singapore; National University of Singapore; Singapore National Eye
   Center; Tan Tock Seng Hospital; University System of Georgia; Augusta
   University
RP O'Connell, E (通讯作者)，Waterford Reg Hosp, Dept Ophthalmol, Dunmore Rd, Waterford, Ireland.
EM dreamonnoconnell@iolfree.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2
   deMejia EG, 1997, MUTAT RES-GEN TOX EN, V389, P219, DOI 10.1016/S1383-5718(96)00151-9
   deMejia EG, 1997, ENVIRON MOL MUTAGEN, V30, P346, DOI 10.1002/(SICI)1098-2280(1997)30:3&lt;346::AID-EM14&gt;3.0.CO;2-D
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Eperjesi F, 2005, NUTR EYE PRACTICAL A, P91
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GORALCZCYK R, 2002, ASS RES VISION OPHTH, V43, P2546
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   HAM WT, 1979, PHOTOCHEM PHOTOBIOL, V29, P735, DOI 10.1111/j.1751-1097.1979.tb07759.x
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Holden Joanne M., 1999, Journal of Food Composition and Analysis, V12, P169, DOI 10.1006/jfca.1999.0827
   Holick CN, 2002, AM J EPIDEMIOL, V156, P536, DOI 10.1093/aje/kwf072
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Jenkins MY, 2000, NUTR CANCER, V37, P207, DOI 10.1207/S15327914NC372_14
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson Elizabeth J, 2002, Nutr Clin Care, V5, P56, DOI 10.1046/j.1523-5408.2002.00004.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LEMARCHAND L, 1995, INT J CANCER, V63, P18, DOI 10.1002/ijc.2910630105
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   MASSACESI KR, 2001, ASS RES VISION OPHTH, V42, pS234
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   Michaud DS, 2000, AM J CLIN NUTR, V72, P990
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Olmedilla B, 1997, CANCER LETT, V114, P179, DOI 10.1016/S0304-3835(97)04656-9
   Olmedilla B, 2002, CLIN SCI, V102, P447, DOI 10.1042/CS20010159
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   RUFFOLO JJ, 1984, INVEST OPHTH VIS SCI, V25, P893
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEIS H, 1991, AM J MED, V91, P31
   Semba RD, 2003, MED HYPOTHESES, V61, P465, DOI 10.1016/S0306-9877(03)00198-1
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Winkler BS, 1999, MOL VIS, V5
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 80
TC 18
Z9 18
U1 0
U2 3
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD NOV
PY 2006
VL 35
IS 11
BP 821
EP 830
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 121KJ
UT WOS:000243156200014
PM 17160199
DA 2022-11-30
ER

PT J
AU Chen, M
   Yang, N
   Lechner, J
   Toth, L
   Hogg, R
   Silvestri, G
   Chakravarthy, U
   Xu, HP
AF Chen, Mei
   Yang, Nan
   Lechner, Judith
   Toth, Levente
   Hogg, Ruth
   Silvestri, Giuliana
   Chakravarthy, Usha
   Xu, Heping
TI Plasma level of lipocalin 2 is increased in neovascular age-related
   macular degeneration patients, particularly those with macular fibrosis
SO IMMUNITY & AGEING
LA English
DT Article
DE Age-related macular degeneration; Inflammation; Neutrophils; Lipocalin
   2; Matrix metalloproteinase; Macular fibrosis; Plasma
ID GELATINASE-ASSOCIATED LIPOCALIN; AQUEOUS-HUMOR; MICE; ACTIVATION;
   DISEASE; NGAL; INFLAMMATION; CYTOKINES; CANCER; MMP-9
AB Background Previously, we and others have reported higher populations of circulating neutrophils in patients with neovascular age-related macular degeneration (nAMD). Neutrophil gelatinase-associated lipocalin (NGAL, also known as lipocalin-2, LCN2), an important innate immune mediator, is known to be critically involved in sterile inflammation-mediated organ failure, fibrosis, cancer progression and retinal degeneration. This study investigated the plasma levels of LCN2, matrix metalloproteinase 9 (MMP9) and LCN2/MMP9 complex in different types of nAMD and examined whether the levels were related to patients' responsiveness to anti-VEGF therapy. Results One hundred and seventy-four nAMD patients, including 108 with choroidal neovascularisation (CNV), 32 with retinal angiomatous proliferation (RAP), 23 with polypoidal choroidal vasculopathy (PCV) and 11 unclassified patients, and 43 healthy controls were recruited to this case-control study. Fifty-eight nAMD patients had macular fibrosis and 110 patients did not. Out of the 174 nAMD patients, 80 patients responded completely, 90 responded partially, and 4 did not respond to the anti-VEGF therapy. The plasma levels of LCN2 in nAMD patients (181.46 +/- 73.62 ng/ml) was significantly higher than that in healthy controls (152.24 +/- 49.55 ng/ml, P = 0.047). However, the difference disappeared after adjusting for age. A positive correlation between plasma level of LCN2 and age was observed in nAMD patients (r = 0.29, P = 0.0002) but not in healthy controls. The plasma level of LCN2 was also positively correlated with circulating neutrophils in nAMD patients (r = 0.34, p = 0.0007) but not in healthy controls (r = 0.057, p = 0.77). No correlation was observed between age and circulating neutrophils. Further analysis of nAMD subtypes uncovered a significantly higher level of LCN2 in patients with macular fibrosis even after adjusting for age. No relationship was observed between plasma levels of LCN2 and patients' responsiveness to anti-VEGF therapy. The plasma levels of MMP9 and LCN2/MMP9 complex were comparable between nAMD and controls. Conclusions Our results suggest that higher plasma levels of LCN2 in nAMD are related to ageing and increased population of circulating neutrophils. Our results also suggest that higher levels of LCN2 may increase the risk of macular fibrosis in nAMD.
C1 [Chen, Mei; Yang, Nan; Lechner, Judith; Toth, Levente; Xu, Heping] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Ctr Med Expt, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Hogg, Ruth; Chakravarthy, Usha] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Silvestri, Giuliana] Belfast Hlth & Social Care Trust, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Ctr Med Expt, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Lechner, Judith/GQH-8616-2022; Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X; Silvestri, Giuliana/0000-0001-5662-5374;
   Hogg, Ruth/0000-0001-9413-2669
FU Dunhill Medical Trust [R188/0211]; Guide Dogs for the Blindness
   Association UK [2008-5a]
FX The study was funded by the Dunhill Medical Trust (R188/0211) and Guide
   Dogs for the Blindness Association UK (2008-5a). The funding bodies have
   no role in the design of the study, collection, analysis and
   interpretation of data, and in writing the manuscript.
CR Al Nimer F, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000191
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Aoyama T, 2017, LAB INVEST, V97, P890, DOI 10.1038/labinvest.2017.44
   Bi FF, 2013, P NATL ACAD SCI USA, V110, P4069, DOI 10.1073/pnas.1218497110
   CHAKRAVARTHY U, 2010, BMJ-BRIT MED J, V340, DOI DOI 10.1136/BMJ.C981
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Entin-Meer M, 2012, AM J NEPHROL, V36, P190, DOI 10.1159/000341651
   Flower DR, 1996, BIOCHEM J, V318, P1
   Forster CS, 2020, PEDIATR NEPHROL, V35, P2121, DOI 10.1007/s00467-020-04654-9
   Ghosh S, 2020, CELL MOL LIFE SCI, V77, P835, DOI 10.1007/s00018-019-03423-8
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Goldstein SL, 2015, PEDIATR NEPHROL, V30, P1047, DOI 10.1007/s00467-015-3046-1
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guiteras R, 2017, CELL PHYSIOL BIOCHEM, V42, P1945, DOI 10.1159/000479835
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Ilhan N, 2014, LECT NOTES SOC NETW, P1, DOI 10.1007/978-3-7091-1797-2__1
   Kashiwagi E, 2014, EXP TOXICOL PATHOL, V66, P301, DOI 10.1016/j.etp.2014.04.007
   Krogh Nielsen M, 2017, IMMUN AGEING, V14, P18, DOI DOI 10.1186/s12979-017-0100-9
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Miao H, 2012, MOL VIS, V18, P574
   Nahavandipour A, 2020, ACTA OPHTHALMOL
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Obasanmi G, 2020, CURR EYE RES, V45, P1144, DOI 10.1080/02713683.2020.1718165
   Ozgonul C, 2014, OCUL IMMUNOL INFLAMM, P1
   Parmar T, 2018, J IMMUNOL, V200, P3128, DOI 10.4049/jimmunol.1701573
   Parmar T, 2016, INVEST OPHTH VIS SCI, V57, P3257, DOI 10.1167/iovs.15-18993
   Rodvold JJ, 2012, CANCER LETT, V316, P132, DOI 10.1016/j.canlet.2011.11.002
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Stanski N, 2019, J CRIT CARE, V53, P1, DOI 10.1016/j.jcrc.2019.05.017
   Subhi Y, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0160-0
   Subhi Y, 2019, JAMA OPHTHALMOL, V137, P515, DOI 10.1001/jamaophthalmol.2019.0010
   Tang WY, 2018, INVEST OPHTH VIS SCI, V59, P6014, DOI 10.1167/iovs.18-25213
   Tang WY, 2018, CELL PHYSIOL BIOCHEM, V46, P375, DOI 10.1159/000488472
   Tarjus A, 2015, HYPERTENSION, V66, P158, DOI 10.1161/HYPERTENSIONAHA.115.05431
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004
   Wang YP, 2013, HEPATOLOGY, V58, P1349, DOI 10.1002/hep.26467
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200
   Yang J, 2009, CELL CYCLE, V8, P2347, DOI 10.4161/cc.8.15.9224
   Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 54
TC 5
Z9 5
U1 1
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4933
J9 IMMUN AGEING
JI Immun. Ageing
PD NOV 14
PY 2020
VL 17
IS 1
AR 35
DI 10.1186/s12979-020-00205-w
PG 9
WC Geriatrics & Gerontology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Immunology
GA OY3QO
UT WOS:000594164500002
PM 33292361
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Fox, AR
   Chew, EY
   Meyerle, C
   Vitale, S
   Ferris, FL
   Nussenblatt, RB
   Sen, HN
AF Fox, Austin R.
   Chew, Emily Y.
   Meyerle, Catherine
   Vitale, Susan
   Ferris, Frederick L.
   Nussenblatt, Robert B.
   Sen, H. Nida
TI Age-related macular degeneration in patients with uveitis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Inflammation; Immunology; Macula; Degeneration
ID ANTI-RETINAL ANTIBODIES; FACTOR-H POLYMORPHISM; ASPIRIN USE; DRUSEN;
   CLASSIFICATION; MACULOPATHY; MICROGLIA; EYE
AB Purpose To evaluate the prevalence of large drusen in a uveitis clinic population.
   Design Retrospective, cohort study.
   Methods Patients with primary, non-infectious uveitis 55years or older who were seen at the National Eye Institute of the National Institutes of Health from 2004 through August 2013 were reviewed using electronic medical records and photographic databases. Patients were classified as having age-related macular degeneration (AMD) if either eye had large drusen, geographic atrophy or neovascular AMD according to definitions used by the Eye Diseases Prevalence Research Group (EDPRG). The expected number of cases and standardised mortality ratio (SMR) for large drusen were estimated based on EDPRG estimates.
   Results We identified 177 patients aged 55years as having primary non-infectious uveitis; 170 (96.0%) had gradable fundus photos. Average age was 65.07.5years (range 55-87), and 87 were non-Hispanic white, 66 non-Hispanic black, 6 Hispanic white and 11 of other race/ethnicity. Large drusen were identified in four patients (2.4%; 95% CI 0.6 to 6.0). No patients were identified to have late AMD. In the uveitis cohort, the SMR for cases of large drusen, which was adjusted for age, was calculated to be 0.32 (95% CI 0.12 to 0.70) for the whole cohort, 0.28 (95% CI 0.09 to 0.79) for non-Hispanic whites and 0.46 (95% CI 0.14 to 1.29) for non-Hispanic blacks.
   Conclusions Large drusen prevalence among patients with uveitis 55years of age appears less than the prevalence in the general US population after accounting for differences in age distribution, especially for non-Hispanic whites. Although the racial and gender distribution in this study population is not directly representative of the general US population, results of this study suggest possible sparing of patients with uveitis from AMD. A larger systematic study with greater power would be needed to confirm these findings.
C1 [Fox, Austin R.; Chew, Emily Y.; Vitale, Susan; Ferris, Frederick L.; Nussenblatt, Robert B.; Sen, H. Nida] NEI, NIH, 10 Ctr Dr 10D45, Bethesda, MD 20892 USA.
   [Meyerle, Catherine] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University; Johns Hopkins Medicine
RP Sen, HN (通讯作者)，NEI, NIH, 10 Ctr Dr 10D45, Bethesda, MD 20892 USA.
EM senh@nei.nih.gov
OI Ferris, Frederick/0000-0002-4933-0639; vitale, susan/0000-0002-5972-6848
FU NEI Intramural Research Program; NIH Medical Research Scholars Program;
   NIH; Pfizer; Doris Duke Charitable Foundation; Newport Foundation;
   American Association for Dental Research; Howard Hughes Medical
   Institute; Colgate-Palmolive Company; NATIONAL EYE INSTITUTE
   [ZIEEY000482, ZIAEY000557] Funding Source: NIH RePORTER
FX This work is supported by the NEI Intramural Research Program and the
   NIH Medical Research Scholars Program. The NIH Medical Research Scholars
   Program is a public-private partnership supported jointly by the NIH and
   generous contributions to the Foundation for the NIH from Pfizer, the
   Doris Duke Charitable Foundation, the Newport Foundation, the American
   Association for Dental Research, the Howard Hughes Medical Institute and
   the Colgate-Palmolive Company, as well as other private donors. For a
   complete list, please visit the Foundation website at
   http://fnih.org/work/education-training-0/medical-research-scholars-prog
   ram.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Christen WG, 2009, OPHTHALMOLOGY, V116, P2386, DOI 10.1016/j.ophtha.2009.05.031
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   de Jong PTVM, 2012, OPHTHALMOLOGY, V119, P112, DOI 10.1016/j.ophtha.2011.06.025
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein BEK, 2012, JAMA-J AM MED ASSOC, V308, P2469, DOI 10.1001/jama.2012.65406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liew G, 2013, JAMA INTERN MED, V173, P258, DOI 10.1001/jamainternmed.2013.1583
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   McGeer PL, 2005, NEUROBIOL AGING, V26, P1199, DOI 10.1016/j.neurobiolaging.2005.02.003
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Nussenblatt RB, 2010, UVEITIS FUNDAMENTALS, V4th
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   US Census Bureau, 2000, CENS 2000 PHC T 9 PO
NR 28
TC 2
Z9 2
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2017
VL 101
IS 3
BP 342
EP 347
DI 10.1136/bjophthalmol-2016-308587
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM8BQ
UT WOS:000395536600019
PM 27154918
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tsai, YY
   Lin, JM
   Wan, L
   Lin, HJ
   Tsai, YS
   Lee, CC
   Tsai, CH
   Tsai, FJ
   Tseng, SH
AF Tsai, Yi-Yu
   Lin, Jane-Ming
   Wan, Lei
   Lin, Hui-Ju
   Tsai, Yushin
   Lee, Cheng-Chun
   Tsai, Chang-Hai
   Tsai, Fuu-Jen
   Tseng, Sung-Huei
TI Interleukin gene polymorphisms in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; SYNCYTIAL VIRUS BRONCHIOLITIS;
   NECROSIS-FACTOR-ALPHA; JAPANESE POPULATION; GASTRIC-CARCINOMA; VISUAL
   IMPAIRMENT; UNITED-STATES; ASSOCIATION; MACULOPATHY
AB PURPOSE. To investigate polymorphisms in a candidate gene of interleukin (IL) in unrelated Taiwan Chinese patients with late age-related macular degeneration (AMD) and control subjects without AMD.
   METHODS. In this retrospective, case-control study, 312 unrelated Taiwan Chinese patients with late AMD and 180 age- and sex-matched control subjects were enrolled. Late AMD was classified as either atrophic (dry) or neovascular (wet) according to the International ARM Epidemiologic Study. Genomic DNA was prepared from peripheral blood obtained from all patients with AMD and control subjects. Polymerase chain reactions were used to analyze 14 single-nucleotide polymorphisms (SNPs) in candidate genes of 5 ILs: IL-1 beta(2q14): -511 T/C; IL-6 (7p21): -572 C/G and -596 G/A; IL-8 (4q13-q21): -251 A/T, +781 C/T, +1633 T/C, and +2767 A/T; IL-10 (1q31-q32): -592 A/C, -819 C/T, and -1082 G/A; and IL-18 (11q22.2-q22.3): +105 A/C, -137 C/G, -607 A/C, and -656 T/G.
   RESULTS. In the 312 patients with late AMD, dry AMD was diagnosed in 136 and wet AMD in 176. Among the 14 SNPs in the 5 IL genes studied, only the IL-8 +781 C/T SNP was significantly associated with wet AMD (T allele: 46% in wet AMD versus 28% in the control subjects, P = 1.03 x 10(-6), OR = 2.16, 95% CI = 1.58-2.94). The association analysis based on genotypes at both IL-8 +781 C/T and the CFH Y402H demonstrated that the IL-8 +781 C/T to AMD was not significant when analyzed conditional on the presence of the CFH Y402H C risk allele and vice versa. The IL-8 +781 C/T was in low linkage disequilibrium with CFH Y402H (D' = 0.02).
   CONCLUSIONS. The data suggest that Taiwan Chinese carriers of the IL-8 +781 T allele, independent of the CFH Y402H polymorphism, are at increased risk of developing wet AMD.
C1 [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung 404, Taiwan.
   [Tseng, Sung-Huei] Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan 70428, Taiwan.
   [Tsai, Yushin; Tsai, Fuu-Jen] China Med Univ, Grad Inst Chinese Med Sci, Taichung, Taiwan.
   [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan.
   [Wan, Lei; Lee, Cheng-Chun; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan.
   [Tsai, Yi-Yu; Lin, Jane-Ming; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung 404, Taiwan.
   [Wan, Lei; Tsai, Chang-Hai; Tsai, Fuu-Jen] China Med Univ Hosp, Grad Inst Chinese Med Sci, Taichung 404, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; National Cheng Kung University; National Cheng Kung University
   Hospital; China Medical University Taiwan; Asia University Taiwan; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan
RP Tsai, FJ (通讯作者)，China Med Univ Hosp, Dept Med Genet, 2 Yuh Der Rd, Taichung 404, Taiwan.
EM d0704@www.cmuh.org.tw
RI Tsai, Fuu-Jen/J-4140-2015; Wan, Lei/F-4719-2010
OI Wan, Lei/0000-0002-9525-3232
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen LJ, 2006, MOL VIS, V12, P1536
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Heinzmann A, 2004, J ALLERGY CLIN IMMUN, V114, P671, DOI 10.1016/j.jaci.2004.06.038
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942
   MUKAIDA N, 1989, J IMMUNOL, V143, P1366
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Ohyauchi M, 2005, GUT, V54, P330, DOI 10.1136/gut.2003.033050
   Okamoto H, 2006, MOL VIS, V12, P156
   Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Warle MC, 2003, LIVER TRANSPLANT, V9, P170, DOI 10.1053/jlts.2002.50014
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wu MS, 2002, J INFECT DIS, V185, P106, DOI 10.1086/324771
NR 42
TC 54
Z9 59
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2008
VL 49
IS 2
BP 693
EP 698
DI 10.1167/iovs.07-0125
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256RK
UT WOS:000252747100029
PM 18235016
DA 2022-11-30
ER

PT J
AU Roller, AB
   Mahajan, VB
   Boldt, HC
   Abramoff, MD
   Russell, SR
   Folk, JC
AF Roller, A. Brock
   Mahajan, Vinit B.
   Boldt, H. Culver
   Abramoff, Michael D.
   Russell, Stephen R.
   Folk, James C.
TI Effects of Vitrectomy on Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID POSTERIOR VITREOMACULAR ADHESION; BLOOD-AQUEOUS BARRIER; LONG-TERM
   INCIDENCE; C-REACTIVE PROTEIN; BRUCHS MEMBRANE; BLUE-LIGHT; ASSOCIATION;
   PROGRESSION; INFLAMMATION; MACULOPATHY
AB Purpose: To determine whether vitrectomy alters the long-term progression of age-related macular degeneration (AMD).
   Design: Retrospective case-control study.
   Participants: Forty-four eyes of 22 patients with AMD who underwent vitrectomy in 1 eye were included in the study. The progression of AMD at follow-up in the 22 eyes that underwent vitrectomy was compared with the 22 fellow, nonvitrectomized eyes.
   Methods: The charts and photographs of subjects with Age-Related Eye Disease Study category 3 AMD in both eyes who previously underwent vitrectomy surgery for an epiretinal membrane or macular hole were reviewed. Subjects were excluded if they had had a vitrectomy in both eyes, had < 2 years of follow-up, had previous choroidal neovascularization (CNV), retinal detachment, diabetic retinopathy, angioid streaks, high myopia, vascular occlusions, or extensive macular scarring in either eye, or insufficient hospital records or photographs to determine the extent of AMD. Clinical notes throughout the follow-up interval were reviewed. Two vitreoretinal specialists independently graded pre-and postvitrectomy fundus photographs of all eyes in a masked fashion.
   Main Outcome Measures: The development or progression of geographic atrophy of the retinal pigment epithelium and the development of CNV.
   Results: Twenty-two patients were included. The average follow up interval was 5.5 years (range, 2-15). Choroidal neovascularization developed in 5 control eyes and in 2 vitrectomized eyes, and atrophy developed in 7 control and 4 vitrectomized eyes. The difference between vitrectomized eyes and fellow eyes for the combined end points of RPE geographic atrophy or CNV was significant (P = 0.02).
   Conclusions: In this pilot study, we did not detect that vitrectomy increased the progression of AMD. In fact, it was associated with a reduced progression to geographic atrophy or CNV. Additional studies are needed to confirm or refute this association.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2010; 117: 1381-1386 (C) 2010 by the American Academy of Ophthalmology.
C1 [Roller, A. Brock; Mahajan, Vinit B.; Boldt, H. Culver; Abramoff, Michael D.; Russell, Stephen R.; Folk, James C.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Vitreoretinal Serv, Iowa City, IA 52242 USA.
   [Mahajan, Vinit B.] Om Lab, Iowa City, IA USA.
   [Abramoff, Michael D.] Vet Adm Med Ctr, Iowa City, IA USA.
C3 University of Iowa; US Department of Veterans Affairs; Veterans Health
   Administration (VHA)
RP Roller, AB (通讯作者)，Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Vitreoretinal Serv, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM aaron-roller@uiowa.edu
RI Abramoff, Michael D/A-5836-2009
OI Abramoff, Michael D/0000-0002-3490-0037; Folk,
   James/0000-0002-6271-2906; Mahajan, Vinit/0000-0003-1886-1741; Russell,
   Stephen/0000-0003-3776-1367; Boldt, H. Culver/0000-0002-7292-2093
FU Research to Prevent Blindness, Inc., New York, NY
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness, Inc., New York, NY. The funding organization had no role in
   the design or conduct of this research.
CR Barbazetto IA, 2004, EXP EYE RES, V78, P917, DOI 10.1016/j.exer.2004.01.003
   BARONDES M, 1990, BRIT J OPHTHALMOL, V74, P180, DOI 10.1136/bjo.74.3.180
   Becker M, 2005, AM J OPHTHALMOL, V140, P1096, DOI 10.1016/j.ajo.2005.07.017
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Damian J, 2007, JAMA-J AM MED ASSOC, V298, P1637, DOI 10.1001/jama.298.14.1637-a
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   FERGUSON VMG, 1992, BRIT J OPHTHALMOL, V76, P453, DOI 10.1136/bjo.76.8.453
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garner WH, 2001, CURR EYE RES, V23, P372, DOI 10.1076/ceyr.23.5.372.5439
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayreh S S, 1983, Indian J Ophthalmol, V31, P158
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P302, DOI 10.1016/j.ajo.2004.09.046
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Inoue Y, 2009, RETINA-J RET VIT DIS, V29, P477, DOI 10.1097/IAE.0b013e31819a6004
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MEYERS SM, 1982, AM J OPHTHALMOL, V94, P26, DOI 10.1016/0002-9394(82)90186-6
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Querques G, 2009, AM J OPHTHALMOL, V147, P375, DOI 10.1016/j.ajo.2008.10.008
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Schauersberger J, 2000, EYE, V14, P61, DOI 10.1038/eye.2000.13
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shaban H, 2002, BIOL CHEM, V383, P537, DOI 10.1515/BC.2002.054
   Smith Bradley T, 2005, Curr Opin Ophthalmol, V16, P166, DOI 10.1097/01.icu.0000163030.33401.3d
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
NR 53
TC 27
Z9 29
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2010
VL 117
IS 7
BP 1381
EP 1386
DI 10.1016/j.ophtha.2009.11.007
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 619NF
UT WOS:000279436200015
PM 20176401
DA 2022-11-30
ER

PT J
AU Roth, DB
   Kulkarni, KM
   Walsman, S
   Modi, A
AF Roth, Daniel B.
   Kulkarni, Kaushal M.
   Walsman, Scott
   Modi, Amy
TI Intravitreal Triamcinolone Acetonide Preceding Photodynamic Therapy for
   Exudative Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN; INJECTION; OCCULT
AB BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal triamcinolone acetonide 1 week before photodynamic therapy (PDT) with verteporfin in the treatment of exudative age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Retrospective chart review of 70 eyes of 66 consecutive patients who were treated with intravitreal triamcinolone acetonide followed by standard PDT 1 week later. Group 1 consisted of 42 eyes that received one or more previous treatments with PDT alone and responded poorly. Group 2 consisted of 28 eyes that had never received PDT.
   RESULTS: No statistically significant change in mean visual acuity was seen during the follow-up period for either group. At 12 months, 90% of group 1 eyes and 80% of group 2 eyes lost less than 2 lines of Snellen visual acuity. A mean of 1.24 additional PDT sessions were required In group 1 eyes and 1.04 additional sessions in group 2 eyes during the follow-up period. 0
   CONCLUSION: In eyes with exudative AMD, intravitreal triamcinolone acetonide preceding PDT with verteporfin results in stabilization of visual acuity and a decreased need for re-treatments with PDT This regimen may be superior to PDT monotherapy.
C1 [Roth, Daniel B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Ophthalmol, Retina Vitreous Ctr, New Brunswick, NJ 08901 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Roth, DB (通讯作者)，Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Ophthalmol, Retina Vitreous Ctr, Clin Acad Bldg,4th Floor,125 Paterson St, New Brunswick, NJ 08901 USA.
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BUNSE A, 2005, ANN M ASS RES VIS OP
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   KAISER PK, 2005, ANN M ASS RES VIS OP
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Ruiz-Moreno JM, 2006, RETINA-J RET VIT DIS, V26, P602, DOI 10.1097/00006982-200607000-00003
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD SEP-OCT
PY 2009
VL 40
IS 5
BP 467
EP 471
DI 10.3928/15428877-20090901-05
PG 5
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 496ZQ
UT WOS:000270020400005
PM 19772270
DA 2022-11-30
ER

PT J
AU Khandhadia, S
   Foster, S
   Cree, A
   Griffiths, H
   Osmond, C
   Goverdhan, S
   Lotery, A
AF Khandhadia, Sam
   Foster, Sebastian
   Cree, Angela
   Griffiths, Helen
   Osmond, Clive
   Goverdhan, Srinivas
   Lotery, Andrew
TI Chlamydia infection status, genotype, and age-related macular
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID BLUE MOUNTAINS EYE; CORONARY HEART-DISEASE; FACTOR-H POLYMORPHISM;
   PNEUMONIAE INFECTION; NEOVASCULAR MEMBRANES; GENE POLYMORPHISMS; VISUAL
   IMPAIRMENT; COMPLEMENT; PREVALENCE; ASSOCIATION
AB Purpose: To evaluate whether Chlamydia (C.) infections are associated with age-related macular degeneration (AMD) and to assess if this association is influenced by the complement factor H (CFH) Y402H or the high temperature requirement A serine peptidase 1 (HTRA1) rs11200638 risk genotypes.
   Methods: One hundred ninety-nine AMD patients with early and late forms of the disease and 100 unaffected controls, at least 50 years old were included in the study. Patients in the AMD and control groups were selected based on known CFH Y402H variant genotype status (one third homozygous CC, one third heterozygous CT, and one third wild-type TT). Plasma from all patients and controls was tested for C. pneumoniae, C. trachomatis, and C. psittaci IgG seropositivity using a micro-immunofluorescent assay to establish previous infection status. Assays were conducted blind to risk genotypes and the results analyzed using univariate and multivariate (logistic regression) analysis.
   Results: IgG seropositivity to C. pneumoniae was most prevalent (69.2%, n=207), followed by C. trachomatis (7.4%, n=22) and C. psittaci (3.3%, n=10). No association was found between each of the three Chlamydia species IgG seropositivity and AMD status or severity (early/late). There was also no significant association between Chlamydia species IgG seropositivity and AMD status or severity, in patients carrying at least one CFH Y402H risk allele (C) or HTRA1 rs11200638 risk allele (A), with univariate or logistic regression analysis.
   Conclusions: Chlamydia infection status does not appear to be associated with AMD status or severity. The presence of CFH Y402H and HTRA1 rs11200638 risk genotypes does not alter this negative association.
C1 [Khandhadia, Sam; Cree, Angela; Griffiths, Helen; Goverdhan, Srinivas; Lotery, Andrew] Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.
   [Osmond, Clive] Univ Southampton, MRC Epidemiol Resource Ctr, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.
   [Goverdhan, Srinivas; Lotery, Andrew] Southampton Gen Hosp, Southampton Eye Unit, Southampton SO9 4XY, Hants, England.
   [Foster, Sebastian] Queen Alexandra Hosp, Cosham, England.
C3 University of Southampton; University of Southampton; University of
   Southampton; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital
RP Lotery, A (通讯作者)，Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, S Lab & Pathol Block,MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM A.J.Lotery@southampton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305; Cree, Angela/0000-0002-1987-8900;
   Osmond, Clive/0000-0002-9054-4655
FU American Health Assistance Foundation (AHAF); T.F.C. Frost Charitable
   Trust; Gift of Sight Appeal; Medical Research Council [MC_UP_A620_1017]
   Funding Source: researchfish; National Institute for Health Research
   [NF-SI-0507-10094] Funding Source: researchfish; MRC [MC_UP_A620_1017]
   Funding Source: UKRI
FX This work was funded by the American Health Assistance Foundation
   (AHAF), T.F.C. Frost Charitable Trust and the Gift of Sight Appeal.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Brooks G.F, 2007, MED MICROBIOLOGY
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cortes C, 2011, INFECT IMMUN, V79, P724, DOI 10.1128/IAI.00980-10
   Dowell SF, 2001, CLIN INFECT DIS, V33, P492, DOI 10.1086/322632
   Dreses-Werringloer U, 2009, INT J MED MICROBIOL, V299, P187, DOI 10.1016/j.ijmm.2008.07.002
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Enzmann V, 2010, ARVO ANN M MAY 2 6 F
   Fainardi E, 2008, CURR NEUROVASC RES, V5, P60, DOI 10.2174/156720208783565609
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Haas P, 2008, ARVO ANN M APR 27 MA
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALL RT, 1993, INFECT IMMUN, V61, P1829, DOI 10.1128/IAI.61.5.1829-1834.1993
   Harkinezhad T, 2009, J MED MICROBIOL, V58, P1207, DOI 10.1099/jmm.0.011379-0
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kessler W, 2006, ACTA OPHTHALMOL SCAN, V84, P333, DOI 10.1111/j.1600-0420.2005.00591.x
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501
   LIN JSL, 1992, INFECT IMMUN, V60, P2547, DOI 10.1128/IAI.60.6.2547-2550.1992
   LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morre SA, 1999, J CLIN MICROBIOL, V37, P3092
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Persson K, 2000, CLIN DIAGN LAB IMMUN, V7, P739, DOI 10.1128/CDLI.7.5.739-744.2000
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   SHOR A, 1992, S AFR MED J, V82, P158
   Skowasch D, 2003, J HEART VALVE DIS, V12, P68
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68
   Tong Y, 2010, MOL VIS, V16, P1958
   Villegas E, 2010, J MED MICROBIOL, V59, P1267, DOI 10.1099/jmm.0.020362-0
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wilson JS, 2002, HUM REPROD UPDATE, V8, P385, DOI 10.1093/humupd/8.4.385
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 55
TC 6
Z9 6
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 10
PY 2012
VL 18
IS 4-6
BP 29
EP 37
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 904YS
UT WOS:000301236600002
PM 22259222
DA 2022-11-30
ER

PT J
AU Narayanan, R
   Butani, V
   Boyer, DS
   Atilano, SR
   Resende, GP
   Kim, DS
   Chakrabarti, S
   Kuppermann, BD
   Khatibi, N
   Chwa, M
   Nesburn, AB
   Kenney, MC
AF Narayanan, Raja
   Butani, Virit
   Boyer, David S.
   Atilano, Shari R.
   Resende, Gilberto P.
   Kim, David S.
   Chakrabarti, Subhabrata
   Kuppermann, Baruch D.
   Khatibi, Nikan
   Chwa, Marilyn
   Nesburn, Anthony B.
   Kenney, M. Cristina
TI Complement factor H polymorphism in age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ALTERNATIVE PATHWAY; GENETIC ASSOCIATION; APOLIPOPROTEIN-E; MACULOPATHY;
   DISEASE; VARIANT; RISK; SUSCEPTIBILITY; HAPLOTYPE; INCREASES
AB Purpose: To determine the association between complement factor H (CFH) polymorphism T1277C (tyrosine-402 -> histidine-402) and phenotypic variations of age-related macular degeneration (AMD).
   Design: Cross-sectional observational study.
   Participants: Subjects with dry or wet AMD and a control population consisting of age-matched non-AMD subjects from 2 clinical facilities examined during the period January 1, 1999 through December 31, 2002.
   Methods: Total DNA isolated from the leukocytes of 66 AMD subjects and 58 age-matched control subjects was studied. The CFH gene was amplified by polymerase chain reaction and analyzed by Nla III restriction fragment length analysis.
   Main Outcome Measures: Incidence of CHIF polymorphism with the occurrence of AMD.
   Results: Among the AMD patients, 15 had dry and 51 had wet AMD. For the CFH gene, the T1277C variant showed the genotype distribution as CC, TC, and TT. There was a strong association between homozygous C and AMD compared with the control population (odds ratio [OR] = 3.4; 95% confidence interval [CI], 1.32-8.74; P = 0.0053). Furthermore, dry AMD had a stronger association (OR, 8.32; 95% CI, 2.30-30.11; P = 0.001) than wet AMD (OR, 2.49; 95% CI, 0.90-6.84; P = 0.039) compared with the control population. Homozygous T was more prevalent in the control subjects compared with AMD patients (OR, 5; 95% CI, 2.18-11.43; P = 0.00005).
   Conclusions: Complement factor H polymorph ism T1277C (tyrosine-402 -> histidine-402) is strongly associated with both dry and wet AMD and points to a possible role for inflammation in the pathogenesis of AMD.
C1 Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Orange, CA 92868 USA.
   LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
   Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   Univ Kansas, Sch Med, Kansas City, KS 66103 USA.
   Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
C3 University of California System; University of California Irvine; L. V.
   Prasad Eye Institute; Retina Vitreous Associates Medical Group;
   University of Kansas; University of Kansas Medical Center; Cedars Sinai
   Medical Center
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Med Ctr, Dept Ophthalmol, 101 City Dr, Orange, CA 92868 USA.
EM mkenney@usi.edu
RI Narayanan, Raja/AAT-3098-2021; Chakrabarti, Subhabrata/F-2468-2015
OI Narayanan, Raja/0000-0001-9688-5859; Chakrabarti,
   Subhabrata/0000-0003-3717-4963; Atilano, Shari/0000-0002-7729-7864
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Fiotti N, 2005, GENET MED, V7, P272, DOI 10.1097/01.GIM.0000159903.69597.73
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 26
TC 36
Z9 36
U1 3
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2007
VL 114
IS 7
BP 1327
EP 1331
DI 10.1016/j.ophtha.2006.10.035
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 184GS
UT WOS:000247629700014
PM 17306880
DA 2022-11-30
ER

PT J
AU Todisco, L
   Capuano, V
   Costanzo, E
   Recupero, SM
   Souied, EH
   Querques, G
AF Todisco, Lorenzo
   Capuano, Vittorio
   Costanzo, Eliana
   Recupero, Santi Maria
   Souied, Eric H.
   Querques, Giuseppe
TI Hyperreflective Choroidal Vessels in Geographic Atrophy Secondary to
   Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; STARGARDT
   DISEASE; EYE DISEASE; PROGRESSION; THICKNESS; SCLEROSIS; SEVERITY
AB BACKGROUND AND OBJECTIVE: To describe choroidal vessels in areas of geographic atrophy (GA) secondary to age-related macular degeneration that appear as hyperreflective choroidal vessels (HRCVs) on multicolor (MC) imaging.
   PATIENTS AND METHODS: Retrospective case series of patients with GA. Multimodal imaging evaluation was performed.
   RESULTS: HRCVs, which seem to be sclerotic on MC imaging, appeared as hyperautofluorescent on fundus autofluorescence, clearly distinguishable over the background of hypo-autofluorescence, and correlated with late-phase hypocyanescence areas on indocyanine green angiography. Average size of GA areas was significantly larger in eyes with (4.19 mm +/- 0.83 mm) compared to eyes without (3.22 mm +/- 1.05 mm) HRVCs (P = .0002). Similarly, mean choroidal thickness (CT) was significantly thinner in eyes with (78.5 mu m +/- 33.8 mu m) compared to eyes without (155.4 mu m +/- 69.8 mu m) HRVCs (P < .0001).
   CONCLUSIONS: HRCVs are more clearly distinguishable than other choroidal vessels on MC imaging in GA. HRCV identification is more frequent in eyes with larger areas of atrophy and reduced CT, and thus possibly represent a maker of more advanced GA.
C1 [Todisco, Lorenzo; Capuano, Vittorio; Costanzo, Eliana; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Todisco, Lorenzo; Recupero, Santi Maria] Univ Rome Sapienza, NESMOS Dept, St Andrea Hosp, Ophthalmol Unit, Rome, Italy.
   [Querques, Giuseppe] Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Sapienza
   University Rome; Azienda Ospedaliera Sant'Andrea; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI Costanzo, Eliana/AAA-7690-2020
OI Querques, Giuseppe/0000-0002-3292-9581
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Coscas F, 2016, AM J OPHTHALMOL, V161, P160, DOI 10.1016/j.ajo.2015.10.008
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Green W R, 1999, Mol Vis, V5, P27
   Hart WM, 1992, ADLERS PHYSL EYE OCU, P198
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Hwang JC, 2010, RETINA-J RET VIT DIS, V30, P1095, DOI 10.1097/IAE.0b013e3181cd48f9
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nunes RP, 2015, OSLI RETINA, V46, P814, DOI 10.3928/23258160-20150909-05
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P1735, DOI 10.1097/IAE.0000000000000553
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P98, DOI 10.1136/bjo.57.2.98
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Shinojima A, 2016, OPHTHALMOLOGICA, V235, P208, DOI 10.1159/000444885
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   2008, OPHTHALMOLOGY, V115, P1474
NR 25
TC 0
Z9 0
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD DEC
PY 2016
VL 47
IS 12
BP 1106
EP 1114
DI 10.3928/23258160-20161130-04
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3ID
UT WOS:000393104900004
PM 27977833
DA 2022-11-30
ER

PT J
AU Ho, VY
   Yeh, S
   Olsen, TW
   Bergstrom, CS
   Yan, J
   Cribbs, BE
   Hubbard, GB
AF Ho, Vincent Y.
   Yeh, Steven
   Olsen, Timothy W.
   Bergstrom, Chris S.
   Yan, Jiong
   Cribbs, Blaine E.
   Hubbard, G. Baker, III
TI Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular
   Degeneration in Eyes Previously Treated With Other Vascular Endothelial
   Growth Factor Inhibitors
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; VEGF-TRAP; INTRAVITREAL
   BEVACIZUMAB; RANIBIZUMAB; MACROPHAGE; TACHYPHYLAXIS
AB PURPOSE: To report results of aflibercept therapy in eyes with neovascular age-related macular degeneration previously treated with bevacizumab, ranibizumab, or both.
   DESIGN: Retrospective, interventional, noncomparative, consecutive case series.
   METHODS: Ninety-six eyes from 85 patients with neovascular age-related macular degeneration who previously had received bevacizumab, ranibizumab, or both were treated with aflibercept monthly for 3 months followed by a fourth injection within 2 months. Outcomes were determined 4 +/- 1 months after the first aflibercept dose and included: proportion of patients gaining or losing 2 lines or more of best-corrected visual acuity, proportion remaining within a gain or loss of 1 line, mean change in logarithm of the minimal angle of resolution visual acuity, mean change in central foveal thickness, mean change in macular cube volume, and qualitative anatomic response as assessed by spectral-domain optical coherence tomography.
   RESULTS: At baseline, 82 (85%) eyes had signs of active exudation despite a mean of 17 previous anti-vascular endothelial growth factor injections. At final visit, 82 (85%) remained stable within a gain or loss of 1 line, 7 (7%) gained 2 lines or more, and 7 (7%) lost 2 lines or more of best-corrected visual acuity. Mean logarithm of the minimal angle of resolution visual acuity showed minimal change 0.02 (range, -0.46 to 0.70; P = .14). Mean central foveal thickness decreased -18 mu m (range, -242 to 198 mu m; P = .06). Mean macular volume decreased -0.27 mm(3) (95% confidence interval, -0.4 to -0.1 mm(3); P = .004). On qualitative analysis, 4 (5%) eyes had complete resolution of exudative fluid, 40 (49%) showed partial resolution, 26 (32%) remained unchanged, and 12 (14%) showed worsened exudative fluid.
   CONCLUSIONS: Aflibercept seems to be an effective alternative for neovascular age-related macular degeneration patients previously treated with bevacizumab, ranibizumab, or both at 4 months of follow-up. Most treated eyes demonstrated stable visual acuity and anatomic improvements by spectral-domain optical coherence tomography. Published by Elsevier Inc.
C1 [Ho, Vincent Y.; Yeh, Steven; Olsen, Timothy W.; Bergstrom, Chris S.; Yan, Jiong; Cribbs, Blaine E.; Hubbard, G. Baker, III] Emory Univ, Sch Med, Dept Ophthalmol, Emory Eye Ctr,Sect Vitreoretinal Dis & Surg, Atlanta, GA 30322 USA.
C3 Emory University
RP Hubbard, GB (通讯作者)，Emory Univ, Sch Med, Dept Ophthalmol, Emory Eye Ctr, 1365B Clifton Rd NE, Atlanta, GA 30322 USA.
EM ghubba2@emory.edu
FU Research to Prevent Blindness, Inc, New York, New York; National
   Institutes of Health, Bethesda, Maryland [EYO 6360]; Children's Hospital
   of Philadelphia Research Institute; NATIONAL EYE INSTITUTE [P30EY006360]
   Funding Source: NIH RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported. Dr
   Hubbard receives a consulting fee from the Children's Hospital of
   Philadelphia Research Institute as a consultant/expert reader for the
   Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of
   Prematurity Study (eROP Study). He also has financial activity outside
   the submitted work involving expert witness testimony. There were no
   other financial disclosures from the remaining authors. Supported in
   part by an Unrestricted Grant from Research to Prevent Blindness, Inc,
   New York, New York; and by Core Grant EYO 6360 from the National
   Institutes of Health, Bethesda, Maryland Involved in design and conduct
   of study (V.Y.H., S.Y., G.B.H.); collection (V.Y.H., S.Y., G.B.H.,
   C.S.B., J.Y., B.E.C., T.W.O.), management (S.Y., G.B.H., T.W.O., C.S.B.,
   J.Y., B.E.C.), analysis (V.Y.H., S.Y., G.B.H., T.W.O.), and
   interpretation (V.Y.H., G.B.H., S.Y., T.W.O.) of data; and preparation,
   review, or approval of the manuscript (V.Y.H., G.B.H., S.Y., T.W.O.,
   C.S.B., J.Y., B.E.C.).
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
NR 21
TC 108
Z9 113
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2013
VL 156
IS 1
BP 23
EP 28
DI 10.1016/j.ajo.2013.02.009
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 179OT
UT WOS:000321531900005
PM 23664153
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mimura, T
   Funatsu, H
   Noma, H
   Shimura, M
   Kamei, Y
   Yoshida, M
   Kondo, A
   Watanabe, E
   Mizota, A
AF Mimura, Tatsuya
   Funatsu, Hideharu
   Noma, Hidetaka
   Shimura, Masahiko
   Kamei, Yuko
   Yoshida, Maiko
   Kondo, Aki
   Watanabe, Emiko
   Mizota, Atsushi
TI Aqueous Humor Levels of Cytokines in Patients with Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Aqueous humor; Cytokine; Polypoidal
   choroidal vasculopathy; Typical age-related macular degeneration;
   Vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   EPITHELIUM-DERIVED FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL
   VEIN OCCLUSION; INTRAVITREAL BEVACIZUMAB; NEOVASCULARIZATION;
   RANIBIZUMAB; EXPRESSION; INFLAMMATION
AB Purpose: To compare aqueous humor levels of various cytokines between patients with age-related macular degeneration (AMD) and cataract patients. Methods: Thirteen eyes with wet-type AMD (AMD group) and 14 eyes with cataract (cataract group) were studied. Aqueous humor levels of 11 factors (vascular endothelial growth factor receptors, growth factors, and inflammatory factors) were measured by the suspension array method. Results: Aqueous humor levels of vascular endothelial growth factor, soluble vascular endothelial growth factor receptor (sVEGFR)-1, sVEGFR-2, and inflammatory factors (monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, and IL-8) were significantly higher in the AMD group than in the cataract group (all p < 0.05). In contrast, aqueous humor levels of placental growth factor (PGF), tumor necrosis factor-a, soluble intercellular adhesion molecule (sICAM)-1, IL-12 (p70), and IL-13 showed no significant difference between the two groups. There were significant correlations between sVEGFR-1 or sVEGFR-2 levels and some of the inflammatory molecules (PGF, sICAM-1, MCP-1, IL-6, and IL-8). Conclusions: These findings suggest that various cytokines/growth factors involved in inflammation and angiogenesis may be associated with the pathogenesis of AMD. (C) 2018 S. Karger AG, Basel
C1 [Mimura, Tatsuya; Watanabe, Emiko; Mizota, Atsushi] Teikyo Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Mimura, Tatsuya; Kamei, Yuko; Yoshida, Maiko; Kondo, Aki] Tokyo Womens Med Univ, Med Ctr East, Dept Ophthalmol, Tokyo, Japan.
   [Funatsu, Hideharu] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Ophthalmol, Yachiyo, Japan.
   [Noma, Hidetaka; Shimura, Masahiko] Tokyo Med Univ, Hachioji Med Ctr, Dept Ophthalmol, Tokyo, Japan.
C3 Teikyo University; Tokyo Women's Medical University; Tokyo Women's
   Medical University; Tokyo Medical University
RP Mimura, T (通讯作者)，Teikyo Univ, Sch Med, Dept Ophthalmol, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.
EM mimurat-tky@umin.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This work was partly supported by a Grant-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology
   of Japan.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P1308, DOI 10.1097/IAE.0b013e31818358b2
   Crane IJ, 2000, IMMUNOLOGY, V101, P426, DOI 10.1046/j.0019-2805.2000.01105.x
   Dell'Omo R, 2012, AM J OPHTHALMOL, V153, P155, DOI 10.1016/j.ajo.2011.06.001
   Desai TR, 2002, J SURG RES, V104, P118, DOI 10.1006/jsre.2002.6415
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Heidenkummer H.-P., 1995, Ophthalmologe, V92, P631
   HOEKZEMA R, 1992, INVEST OPHTH VIS SCI, V33, P532
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jaipersad AS, 2014, J AM COLL CARDIOL, V63, P1, DOI 10.1016/j.jacc.2013.09.019
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kawai M, 2012, INVEST OPHTH VIS SCI, V53, P7951, DOI 10.1167/iovs.12-10231
   Kim JH, 2009, J CEREBR BLOOD F MET, V29, P1559, DOI 10.1038/jcbfm.2009.78
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Motohashi R, 2017, OPHTHALMIC RES, V58, P209, DOI 10.1159/000478705
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Noma H, 2015, INVEST OPHTH VIS SCI, V56, P1122, DOI 10.1167/iovs.14-15789
   Noma H, 2014, INVEST OPHTH VIS SCI, V55, P3878, DOI 10.1167/iovs.14-13961
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Ojima T, 2006, AM J PATHOL, V168, P331, DOI 10.2353/ajpath.2006.050435
   Okuma H, 2016, INT OPHTHALMOL, V36, P159, DOI 10.1007/s10792-015-0089-z
   Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JCI33361, 10.1172/JC133361]
   Spoerri PE, 2006, MOL VIS, V12, P32
   Thylefors B, 2002, OPHTHALMIC EPIDEMIOL, V9, P83, DOI 10.1076/opep.9.2.83.1523
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
NR 46
TC 14
Z9 15
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 2
BP 81
EP 89
DI 10.1159/000490153
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM5LS
UT WOS:000459517800003
PM 30048978
DA 2022-11-30
ER

PT J
AU Chang, KH
   Hsu, PY
   Lin, CJ
   Lin, CL
   Juo, SHH
   Liang, CL
AF Chang, Kuang-Hsi
   Hsu, Po-Yuan
   Lin, Chun-Ju
   Lin, Cheng-Li
   Juo, Suh-Hang Hank
   Liang, Chung-Ling
TI Traffic-related air pollutants increase the risk for age-related macular
   degeneration
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Article
ID POLLUTION EXPOSURE; STROKE; PREVALENCE
AB The aim of this study was to investigate whether ambient nitrogen dioxide (NO2) and carbon monoxide (CO) increase the risk for age-related macular degeneration (AMD). This is a longitudinal population-based study using the data on Taiwan National Health Insurance Program between year 2000 and 2010. From the nationwide dataset, we enrolled subjects aged 50 or older and the annually total NO2 and CO exposure was calculated from 1998 to 2010 for each subject. The Cox proportional hazard regression was used to estimate the HRs with adjustment for other variables. A total of 39,819 AMD-free residents were enrolled, and 1442 participants developed AMD during the 11 -year follow-up. Compared with the lowest exposure quartile, the highest quartile of each air pollutant was associated with an increased risk for AMD. The adjusted HR was 1.91 (95% CI 1.64 to 2.23, p<0.001) for the highest NO2 quartile, and was 1.84 (95% CI 1.5 to 2.15, p<0.001) for the highest CO quartile. In this study, chronic exposure to the highest quartile of ambient NO2 or CO significantly increases the risk for AMD.
C1 [Chang, Kuang-Hsi] Tungs Taichung Metroharbor Hosp, Dept Med Res, Taichung, Taiwan.
   [Chang, Kuang-Hsi] Jen Teh Jr Coll Med Nursing & Management, Gen Educ Ctr, Miaoli, Taiwan.
   [Chang, Kuang-Hsi; Juo, Suh-Hang Hank] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.
   [Hsu, Po-Yuan; Juo, Suh-Hang Hank] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   [Lin, Chun-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Lin, Chun-Ju] China Med Univ, Coll Med, Sch Med, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Juo, Suh-Hang Hank] China Med Univ, Inst New Drug Dev, Taichung, Taiwan.
   [Juo, Suh-Hang Hank] China Med Univ, Drug Dev Ctr, Taichung, Taiwan.
   [Juo, Suh-Hang Hank; Liang, Chung-Ling] China Med Univ Hosp, Ctr Myopia & Eye Dis, Taichung, Taiwan.
   [Liang, Chung-Ling] Asia Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Liang, Chung-Ling] Asia Univ, Coll Med & Hlth Sci, Dept Optometry, Taichung, Taiwan.
   [Liang, Chung-Ling] Bright Eyes Clin, Kaohsiung, Taiwan.
C3 Tungs' Taichung MetroHarbor Hospital; China Medical University Taiwan;
   China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   Asia University Taiwan
RP Juo, SHH (通讯作者)，China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.; Juo, SHH (通讯作者)，China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.; Juo, SHH (通讯作者)，China Med Univ, Inst New Drug Dev, Taichung, Taiwan.; Juo, SHH (通讯作者)，China Med Univ, Drug Dev Ctr, Taichung, Taiwan.; Juo, SHH; Liang, CL (通讯作者)，China Med Univ Hosp, Ctr Myopia & Eye Dis, Taichung, Taiwan.; Liang, CL (通讯作者)，Asia Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.; Liang, CL (通讯作者)，Asia Univ, Coll Med & Hlth Sci, Dept Optometry, Taichung, Taiwan.; Liang, CL (通讯作者)，Bright Eyes Clin, Kaohsiung, Taiwan.
EM hjuo@mail.cmu.edu.tw; ling0228@gmail.com
FU Asia University-CMU Hospital intramural grant [ASIA-106-CMUH-18]; Tungs'
   Taichung Metroharbor Hospital [TTMHH-108R0029]; Taiwan Ministry of
   Health and Welfare Clinical Trial Center [MOHW108-TDU-B-212-133004];
   Taiwan Ministry of Science and Technology [MOST 107-2321-B-039-004, MOST
   106-3114-8-039-002]; "Drug Development Center, China Medical University"
   from The Featured Areas Research Center Program within the framework of
   the Higher Education Sprout Project by the Ministry of Education in
   Taiwan
FX This study was supported by the grants from the Asia University-CMU
   Hospital intramural grant (ASIA-106-CMUH-18), Tungs' Taichung
   Metroharbor Hospital (TTMHH-108R0029), Taiwan Ministry of Health and
   Welfare Clinical Trial Center (MOHW108-TDU-B-212-133004), Taiwan
   Ministry of Science and Technology (MOST 107-2321-B-039-004 and MOST
   106-3114-8-039-002), the "Drug Development Center, China Medical
   University" from The Featured Areas Research Center Program within the
   framework of the Higher Education Sprout Project by the Ministry of
   Education in Taiwan.
CR Andersen ZJ, 2012, STROKE, V43, P320, DOI 10.1161/STROKEAHA.111.629246
   Block ML, 2009, TRENDS NEUROSCI, V32, P506, DOI 10.1016/j.tins.2009.05.009
   Bressler SB, 2016, JAMA OPHTHALMOL, V134, P278, DOI 10.1001/jamaophthalmol.2015.5346
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chang KH, 2016, ENVIRON INT, V94, P495, DOI 10.1016/j.envint.2016.06.008
   Chang KH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103078
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chiang CY, 2016, POPUL HEALTH METR, V14, DOI 10.1186/s12963-016-0109-x
   Krause L, 2013, CURR MED RES OPIN, V29, P1391, DOI 10.1185/03007995.2013.832184
   Kunzli N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009096
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee BJ, 2014, TOXICOL RES-GER, V30, P71, DOI [10.5487/TR.2014.30.2.71, 10.5487/TR.2014.30.2.071]
   Lisabeth LD, 2008, ANN NEUROL, V64, P53, DOI 10.1002/ana.21403
   Oftedal B, 2008, EPIDEMIOLOGY, V19, P129, DOI 10.1097/EDE.0b013e31815c0827
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pujol J, 2016, NEUROIMAGE, V129, P175, DOI 10.1016/j.neuroimage.2016.01.036
   Ritz B, 2016, ENVIRON HEALTH PERSP, V124, P351, DOI 10.1289/ehp.1409313
   Rozanova E, 2009, ARH HIG RADA TOKSIKO, V60, P205, DOI 10.2478/10004-1254-60-2009-1869
   Sunyer J, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001792
   Tsai SS, 2003, STROKE, V34, P2612, DOI 10.1161/01.STR.0000095564.33543.64
   Turin TC, 2012, CEREBROVASC DIS, V34, P130, DOI 10.1159/000339680
   Wang J., 2016, J NANOMATER, V2016, P1, DOI DOI 10.1109/JPR0C.2015.2487976
   Yuan H, 2016, J SOUND 6, V2016, P1
NR 24
TC 23
Z9 23
U1 6
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD OCT
PY 2019
VL 67
IS 7
BP 1076
EP 1081
DI 10.1136/jim-2019-001007
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA NI9RQ
UT WOS:000565683400008
PM 31427389
DA 2022-11-30
ER

PT J
AU Mehrzadi, S
   Hemati, K
   Reiter, RJ
   Hosseinzadeh, A
AF Mehrzadi, Saeed
   Hemati, Karim
   Reiter, Russel J.
   Hosseinzadeh, Azam
TI Mitochondrial dysfunction in age-related macular degeneration: melatonin
   as a potential treatment
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE Age-related macular degeneration; melatonin; mitochondria; oxidative
   stress; autophagy; apoptosis
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; NITRIC-OXIDE SYNTHASE;
   INDUCED OXIDATIVE STRESS; EARLY BRAIN-INJURY; INDUCED APOPTOSIS; DNA
   DAMAGE; CELL-DEATH; INFLAMMATORY CYTOKINES; SEROTONIN-TRANSFERASE
AB Introduction: Age-related Macular Degeneration (AMD), a retinal neurodegenerative disease is the most common cause of blindness among the elderly in developed countries. The impairment of mitochondrial biogenesis has been reported in human retinal pigment epithelium (RPE) cells affected by AMD. Oxidative/nitrosative stress plays an important role in AMD development. The mitochondrial respiratory system is considered a major site of reactive oxygen species (ROS) generation. During aging, insufficient free radical scavenger systems, impairment of DNA repair mechanisms and reduction of mitochondrial degradation and turnover contribute to the massive accumulation of ROS disrupting mitochondrial function. Impaired mitochondrial function leads to the decline in the autophagic capacity and induction of inflammation and apoptosis in human RPE cells affected by AMD. Areas covered: This article evaluates the ameliorative effect of melatonin on AMD and examines AMD pathogenesis with an emphasis on mitochondrial dysfunction. It also considers the potential effects of melatonin on mitochondrial function. Expert opinion: The effect of melatonin on mitochondrial function results in the reduction of oxidative stress, inflammation and apoptosis in the retina; these findings demonstrate that melatonin has the potential to prevent and treat AMD.
C1 [Mehrzadi, Saeed; Hosseinzadeh, Azam] Iran Univ Med Sci, Razi Drug Res Ctr, POB 1449614535, Tehran, Iran.
   [Hemati, Karim] Ilam Univ Med Sci, Dept Anesthesiol, Ilam, Iran.
   [Reiter, Russel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
C3 Iran University of Medical Sciences; University of Texas System;
   University of Texas Health San Antonio
RP Hosseinzadeh, A (通讯作者)，Iran Univ Med Sci, Razi Drug Res Ctr, POB 1449614535, Tehran, Iran.
EM azam.hosseinzade@yahoo.com
RI Hosseinzadeh, Azam/AAN-6886-2021; Mehrzadi, Saeed/AAY-8389-2020
OI Hosseinzadeh, Azam/0000-0001-6379-5769; Mehrzadi,
   Saeed/0000-0001-6619-2330
CR Castroviejo DA, 2011, CURR TOP MED CHEM, V11, P221
   Acuna-Castroviejo D, 2007, FRONT BIOSCI-LANDMRK, V12, P947, DOI 10.2741/2116
   Aguirre E, 2012, MITOCHONDRION, V12, P126, DOI 10.1016/j.mito.2011.05.010
   Alarma-Estrany P, 2007, PHARMACOL THERAPEUT, V113, P507, DOI 10.1016/j.pharmthera.2006.11.003
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Amara CE, 2007, P NATL ACAD SCI USA, V104, P1057, DOI 10.1073/pnas.0610131104
   Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje
   Argun M, 2014, EYE, V28, P752, DOI 10.1038/eye.2014.50
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bardak H, 2018, CUTAN OCUL TOXICOL, V37, P112, DOI 10.1080/15569527.2017.1354218
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736
   Boga JA, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12534
   Bonnefont-Rousselot D, 2010, TOXICOLOGY, V278, P55, DOI 10.1016/j.tox.2010.04.008
   CAHILL GM, 1993, NEURON, V10, P573, DOI 10.1016/0896-6273(93)90160-S
   Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Cao SL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02679-z
   Cardinali DP, 2013, HORM BEHAV, V63, P322, DOI 10.1016/j.yhbeh.2012.02.020
   Carretero M, 2009, J PINEAL RES, V47, P192, DOI 10.1111/j.1600-079X.2009.00700.x
   Carrillo-Vico A, 2003, CELL MOL LIFE SCI, V60, P2272, DOI 10.1007/s00018-003-3207-4
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   CHEN Y, 2013, J BIOL CHEM
   Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Coto-Montes A, 2012, MOL CELL ENDOCRINOL, V361, P12, DOI 10.1016/j.mce.2012.04.009
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Das A, 2010, J PINEAL RES, V48, P157, DOI 10.1111/j.1600-079X.2009.00739.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Escames G, 2003, FASEB J, V17, P932, DOI 10.1096/fj.02-0692fje
   Fang J, 2018, AGING-US, V10, P2954, DOI 10.18632/aging.101602
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fernandez B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174474
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frudd K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02352-z
   Fu Y, 2012, FRONT BIOSCI-LANDMRK, V17, P1461, DOI 10.2741/3997
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Garcia JA, 2015, FASEB J, V29, P3863, DOI 10.1096/fj.15-273656
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005
   Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Godley BF, 2002, EXP EYE RES, V74, P663, DOI 10.1006/exer.2001.1146
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Hardeland R, 2009, J PINEAL RES, V47, P109, DOI 10.1111/j.1600-079X.2009.00701.x
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He XP, 2012, INT J CANCER, V130, P1029, DOI 10.1002/ijc.26044
   Higgins GC, 2014, BRIT J PHARMACOL, V171, P1917, DOI 10.1111/bph.12503
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hosseinzadeh A, 2019, CURR DRUG TARGETS, V20, P1112, DOI 10.2174/1389450120666190319162147
   Hosseinzadeh A, 2018, EXPERT OPIN THER TAR, V22, P1049, DOI 10.1080/14728222.2018.1541318
   Hosseinzadeh A, 2018, LIFE SCI, V201, P17, DOI 10.1016/j.lfs.2018.03.032
   Hosseinzadeh A, 2016, J PINEAL RES, V61, P411, DOI 10.1111/jpi.12362
   Hu ZP, 2013, J PINEAL RES, V55, P388, DOI 10.1111/jpi.12085
   Huo XK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12390
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318
   Jeong JK, 2012, J PINEAL RES, V53, P138, DOI 10.1111/j.1600-079X.2012.00980.x
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Jiang TT, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3528274
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Jou MJ, 2007, J PINEAL RES, V43, P389, DOI 10.1111/j.1600-079X.2007.00490.x
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kang J C, 2001, J Vet Sci, V2, P85
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197
   Kaufman BA, 2003, J CELL BIOL, V163, P457, DOI 10.1083/jcb.200306132
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   KERENYI NA, 1975, HISTOCHEMISTRY, V46, P77, DOI 10.1007/BF02463562
   KERENYI NA, 1979, CELL MOL BIOL, V25, P259
   KERRISON JB, 1995, OPHTHALMOLOGY, V102, P1509
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Koh PO, 2012, J PINEAL RES, V53, P358, DOI 10.1111/j.1600-079X.2012.01005.x
   Kriegenburg F, 2012, FEBS J, V279, P532, DOI 10.1111/j.1742-4658.2011.08456.x
   Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7
   Lartigue L, 2009, MOL BIOL CELL, V20, P4871, DOI 10.1091/mbc.E09-07-0649
   Laurent V, 2017, EXP EYE RES, V165, P90, DOI 10.1016/j.exer.2017.09.007
   Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liang FQ, 2001, NEUROREPORT, V12, P1011, DOI 10.1097/00001756-200104170-00029
   LIM SC, 2018, SCI REP UK, V8
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lismont C, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00035
   Liu C, 2012, INT IMMUNOPHARMACOL, V12, P394, DOI 10.1016/j.intimp.2011.12.012
   Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1
   Liu L, 2014, CELL RES, V24, P787, DOI 10.1038/cr.2014.75
   Liu R, 2015, AUTOPHAGY, V11, P847, DOI 10.1080/15548627.2015.1037549
   Lopez A, 2009, J PINEAL RES, V46, P188, DOI 10.1111/j.1600-079X.2008.00647.x
   Lundmark PO, 2006, VISUAL NEUROSCI, V23, P853, DOI 10.1017/S0952523806230189
   Lv XD, 2016, EUR REV MED PHARMACO, V20, P4196
   Maejima Y, 2013, NAT MED, V19, P1478, DOI 10.1038/nm.3322
   Maldonado MD, 2016, J CELL BIOCHEM, V117, P1926, DOI 10.1002/jcb.25491
   Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267
   Martin M, 2000, FASEB J, V14, P1677
   Martin M, 2000, J PINEAL RES, V28, P242, DOI 10.1034/j.1600-079X.2000.280407.x
   MARTIN S, 2008, INVEST OPHTH VIS SCI, V49, P206
   Mayo JC, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12373
   Mazat JP, 2013, IUBMB LIFE, V65, P171, DOI 10.1002/iub.1138
   Meyer P, 2002, BRIT J OPHTHALMOL, V86, P1053, DOI 10.1136/bjo.86.9.1053
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mokranjac D, 2009, BBA-MOL CELL RES, V1793, P33, DOI 10.1016/j.bbamcr.2008.06.021
   Montero J, 2018, CELL DEATH DIFFER, V25, P56, DOI 10.1038/cdd.2017.183
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Ng TK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28639
   Ng TK, 2012, ASIA-PAC J OPHTHALMO, V1, P51, DOI 10.1097/APO.0b013e31823e57fe
   Norberg E, 2010, BIOCHEM BIOPH RES CO, V396, P95, DOI 10.1016/j.bbrc.2010.02.163
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Okano K, 2012, J NEUROCHEM, V121, P146, DOI 10.1111/j.1471-4159.2012.07647.x
   Ortiz F, 2015, J PINEAL RES, V58, P34, DOI 10.1111/jpi.12191
   Osborne NN, 1998, INVEST OPHTH VIS SCI, V39, P2374
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Pujol-Lereis LM, 2016, ADV EXP MED BIOL, V854, P87, DOI 10.1007/978-3-319-17121-0_13
   Radogna F, 2008, J PINEAL RES, V44, P316, DOI 10.1111/j.1600-079X.2007.00532.x
   Radogna F, 2007, J PINEAL RES, V43, P154, DOI 10.1111/j.1600-079X.2007.00455.x
   Rambold AS, 2011, CELL CYCLE, V10, P4032, DOI 10.4161/cc.10.23.18384
   Reiter RJ, 2007, ADV MED SCI-POLAND, V52, P11
   Reiter RJ, 2000, ANN NY ACAD SCI, V917, P376
   Reiter RJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082439
   Reiter RJ, 2017, CELL MOL LIFE SCI, V74, P3863, DOI 10.1007/s00018-017-2609-7
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Reiter RJ, 2014, BRAIN STRUCT FUNCT, V219, P1873, DOI 10.1007/s00429-014-0719-7
   Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4
   Reynafarje Baltazar D, 2008, Int J Med Sci, V5, P143
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosen R, 2009, MOL VIS, V15, P1673
   Rosen RB, 2012, MOL VIS, V18, P1640
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sagrillo-Fagundes L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0202458
   Saito T, 2015, CIRC RES, V116, P1477, DOI 10.1161/CIRCRESAHA.116.303790
   Sakamoto K, 2004, J NEUROCHEM, V90, P1019, DOI 10.1111/j.1471-4159.2004.02571.x
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Sanphui P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.148
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seitsonen S, 2006, MOL VIS, V12, P796
   Semak I, 2005, BIOCHEMISTRY-US, V44, P9300, DOI 10.1021/bi050202d
   Semak I, 2008, J PINEAL RES, V45, P515, DOI 10.1111/j.1600-079X.2008.00630.x
   Shi LG, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00093
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Siu AW, 2004, BRIT J OPHTHALMOL, V88, P1078, DOI 10.1136/bjo.2003.037879
   Souied EH, 2005, MOL VIS, V11, P1135
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sripathi Srinivas R, 2017, Int J Sci Eng Res, V8, P502
   Steuer H, 2005, INVEST OPHTH VIS SCI, V46, P1047, DOI 10.1167/iovs.04-0925
   Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979
   Suofu Y, 2017, P NATL ACAD SCI USA, V114, pE7997, DOI 10.1073/pnas.1705768114
   Suwanjang W, 2016, NEUROCHEM INT, V97, P34, DOI 10.1016/j.neuint.2016.05.003
   Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124
   Tan DX, 2016, J PINEAL RES, V61, P27, DOI 10.1111/jpi.12336
   Tan DX, 2015, MOLECULES, V20, P18886, DOI 10.3390/molecules201018886
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Torrens-Mas M, 2017, CANCERS, V9, DOI 10.3390/cancers9070090
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002
   Verghese J, 2012, MICROBIOL MOL BIOL R, V76, P115, DOI 10.1128/MMBR.05018-11
   Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westphal D, 2014, CELL DEATH DIFFER, V21, P196, DOI 10.1038/cdd.2013.139
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xie MY, 2014, MOL VIS, V20, P921
   Xu SC, 2011, J PINEAL RES, V51, P426, DOI 10.1111/j.1600-079X.2011.00906.x
   Xu Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12473
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yang GG, 2018, J TOXICOL SCI, V43, P659, DOI 10.2131/jts.43.659
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Yu T, 2017, INT J OPHTHALMOL-CHI, V10, P524, DOI [10.18240/ijo.2017.04.04, 10.18240/1jo.2017.04.04]
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang N, 2007, INVEST OPHTH VIS SCI, V48, P3846, DOI 10.1167/iovs.06-1145
   Zhang Y, 2016, J PINEAL RES, V60, P405, DOI 10.1111/jpi.12322
   ZHAO D, 2019, FRONT ENDOCRINOL, V10
   Zhu B, 2013, INT J MOL SCI, V14, P24476, DOI 10.3390/ijms141224476
   Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367
NR 231
TC 29
Z9 31
U1 5
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD APR 2
PY 2020
VL 24
IS 4
BP 359
EP 378
DI 10.1080/14728222.2020.1737015
EA MAR 2020
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KX5YE
UT WOS:000518296800001
PM 32116056
DA 2022-11-30
ER

PT J
AU Zheng, F
   Motulsky, EH
   Dias, JRD
   de Lopez, EP
   Gregori, G
   Rosenfeld, PJ
AF Zheng, Fang
   Motulsky, Elie H.
   Dias, Joao Rafael de Oliveira
   Perez de Lopez, Edith
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI OCT Angiography Helps Distinguish Between Proliferative Macular
   Telangiectasia Type 2 and Neovascular Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; JUXTAFOVEOLAR RETINAL TELANGIECTASIS;
   CLASSIFICATION
AB BACKGROUND AND OBJECTIVE: To demonstrate the advantage of optical coherence tomography angiography (OCTA) for the diagnosis and management of proliferative macular telangiectasia type 2 (MacTel2) masquerading as neovascular age-related macular degeneration (AMD).
   PATIENTS AND METHODS: This is an observational cases series. Three patients referred with the diagnosis of neovascular AMD were identified in this retrospective study. In addition to color fundus, fluorescein angiography, and spectral-domain OCT (SD-OCT) imaging, SD-OCTA (AngioPlex; Carl Zeiss Me ditec, Dublin, CA) was performed.
   RESULTS: SD-OCTA revealed bilateral parafoveal retinal microvascular changes in three patients and unambiguously confirmed the diagnosis of MacTel2,
   CONCLUSION: OCTA is an important tool for the correct diagnosis of MacTel2 in older patients with the concomitant or masquerading diagnosis of AMD.
C1 [Zheng, Fang; Motulsky, Elie H.; Dias, Joao Rafael de Oliveira; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Zheng, Fang] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Perez de Lopez, Edith] Punta Pacifica Hosp, Dept Ophthalmol, Panama City, Panama.
C3 Bascom Palmer Eye Institute; University of Miami; Tianjin Medical
   University
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
FU Carl Zeiss Meditec; National Eye Institute [R01EY024158]; Research to
   Prevent Blindness, New York; National Eye Institute Center Core Grant
   [P30EY014801]; Apellis; Genentech; Astellas Institute for Regenerative
   Medicine; Tyrogenex
FX This research was supported by grants from Carl Zeiss Meditec; the
   National Eye Institute (R01EY024158); an unrestricted grant from the
   Research to Prevent Blindness, New York; and the National Eye Institute
   Center Core Grant (P30EY014801) to the Department of Ophthalmology,
   University of Miami Miller School of Medicine. Drs. Gregori and
   Rosenfeld received research support from Carl Zeiss Meditec. Dr. Gregori
   and the University of Miami co-own a patent that is licensed to Carl
   Zeiss Meditec. Dr. Rosenfeld also received additional research support
   from Apellis, Genentech, Astellas Institute for Regenerative Medicine,
   and Tyrogenex; is a consultant to Achillion Pharmaceuticals, Acucela,
   Boehringer-Ingelheim, Carl Zeiss Meditec, Cell Cure Neurosciences,
   Chengdu Kanghong Biotech, Genentech, Healios K.K, Hemera Biosciences, F.
   Hoffmann-La Roche Ltd., Isarna Pharmaceuticals, MacRegen, Ocudyne,
   Ocunexus Therapeutics, Tyrogenex, and Unity Biotechnology; and has
   equity interests in Apellis, Digisight, and Ocudyne. The remaining
   authors report no relevant financial disclosures.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Atmani K, 2013, OPHTHALMOLOGICA, V230, P126, DOI 10.1159/000354111
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JD, 1982, ARCH OPHTHALMOL-CHIC, V100, P769
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Lekha T, 2015, GMS Ophthalmol Cases, V5, pDoc09, DOI 10.3205/oc000031
   Querques G, 2010, EUR J OPHTHALMOL, V20, P466, DOI 10.1177/112067211002000234
   Roisman L, 2016, DEV OPHTHALMOL, V56, P146, DOI 10.1159/000442807
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   Spaide RF, 2015, OPHTHALMOLOGY, V122, P2261, DOI 10.1016/j.ophtha.2015.07.025
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P66, DOI 10.1001/jamaophthalmol.2014.3950
   Thorell MR, 2014, OSLI RETINA, V45, P369, DOI 10.3928/23258160-20140909-06
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
NR 16
TC 2
Z9 2
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2018
VL 49
IS 5
BP 303
EP 312
DI 10.3928/23258160-20180501-03
PG 10
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA GG9DF
UT WOS:000433000200003
PM 29772040
OA Green Published
DA 2022-11-30
ER

PT J
AU Rabina, G
   Pillar, S
   Nemet, A
   Mimouni, M
   Levinger, N
   Chowers, I
   Ehrlich, R
   Gal-Or, O
   Barequet, D
   Rosenblatt, A
   Moisseiev, E
   Greifner, H
   Magal, I
   Segal, O
AF Rabina, Gilad
   Pillar, Shani
   Nemet, Achia
   Mimouni, Michael
   Levinger, Nadav
   Chowers, Itay
   Ehrlich, Rita
   Gal-Or, Orly
   Barequet, Dana
   Rosenblatt, Amir
   Moisseiev, Elad
   Greifner, Hillel
   Magal, Itay
   Segal, Ori
TI FULL-THICKNESS MACULAR HOLE IN AGE-RELATED MACULAR DEGENERATION PATIENTS
   WITH TWO DISTINCT ENTITIES A Multicenter Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE full-thickness macular hole; traction; degenerative; AMD; OCT
ID INJECTION; OUTCOMES; ATROPHY; EYES
AB Purpose: To describe optical coherence tomography characteristics of full-thickness macular holes (FTMHs) in age-related macular degeneration patients. Methods: A multicenter, retrospective, observational case series of patients diagnosed with age-related macular degeneration and FTMHs seen between January 1, 2009, and January 3, 2020. Clinical charts and spectral-domain optical coherence tomography images were reviewed. Optical coherence tomography findings included FTMH-inverted trapezoid or hourglass appearance, central macular thickness (CMT), complete retinal pigment epithelium and complete retinal outer retinal atrophy, and presence of pigment epithelium detachment and epiretinal membrane. The mean outcome was the morphologic and functional characterization of different subtypes of FTMHs. Results: A total of 86 eyes of 85 consecutive patients, with mean age of 80.31 +/- 8.06 and mean best-corrected visual acuity of 1.17 +/- 0.58 logarithm of the minimal angle of resolution. Two different subtypes of FTMHs were identified: tractional and degenerative. Fifty (58%) degenerative FTMHs characterized with inverted trapezoid appearance and 36 (42%) tractional FTMHs characterized with hourglass appearance. Degenerative FTMHs presented with 66% of CMT < 240 mu m, 14% of CMT > 320, and 70% of complete retinal outer retinal atrophy, in comparison with 41% of CMT < 240 mu m, 42.9% of CMT > 320%, and 20% of complete retinal outer retinal atrophy in the tractional FTMH group (P = 0.002, 0.003, <0.001, respectively). The presence of epiretinal membrane and pigment epithelium detachment where significantly higher in tractional FTMHs (P = 0.02, 0.03, respectively). Conclusion: Degenerative and tractional FTMHs may be two distinct clinical entities. Discerning degenerative from tractional FTMHs is possible by using optical coherence tomography features including shape of the FTMHs, CMT, internal-external ratio of FTMHs, and presence of complete retinal outer retinal atrophy, pigment epithelium detachment, and epiretinal membrane.
C1 [Rabina, Gilad; Barequet, Dana; Rosenblatt, Amir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Pillar, Shani; Nemet, Achia; Moisseiev, Elad; Segal, Ori] Meir Med Ctr, Dept Ophthalmol, Kefar Sava, Israel.
   [Pillar, Shani; Nemet, Achia; Ehrlich, Rita; Gal-Or, Orly; Moisseiev, Elad; Segal, Ori] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Mimouni, Michael] Technion Israel Inst Technol, Dept Ophthalmol, Rambam Hlth Care Campus, Haifa, Israel.
   [Levinger, Nadav; Chowers, Itay] Hebrew Univ Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Ehrlich, Rita; Gal-Or, Orly] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Greifner, Hillel] Hillel Yaffe Med Ctr, Dept Ophthalmol Ogy, Hadera, Israel.
   [Greifner, Hillel] Technion Israel Inst Technol, Haifa, Israel.
   [Magal, Itay] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel
   Aviv University; Sackler Faculty of Medicine; Rambam Health Care Campus;
   Technion Israel Institute of Technology; Rabin Medical Center; Technion
   Israel Institute of Technology; Hebrew University of Jerusalem; Shaare
   Zedek Medical Center
RP Rabina, G (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, 6 Weizmann St, IL-64239 Tel Aviv, Israel.
EM giladrabina@hotmail.com
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Berinstein DM, 2000, OPHTHALMOLOGY, V107, P2233, DOI 10.1016/S0161-6420(00)00417-6
   Ch'ng SW, 2018, AM J OPHTHALMOL, V195, P36, DOI 10.1016/j.ajo.2018.07.027
   Clemens CR, 2010, J OCUL PHARMACOL TH, V26, P297, DOI 10.1089/jop.2009.0140
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Duker JS, 2013, OPHTHALMOLOGY, V120, P2611, DOI 10.1016/j.ophtha.2013.07.042
   Ezra E, 2001, BRIT J OPHTHALMOL, V85, P102, DOI 10.1136/bjo.85.1.102
   Felfeli T, 2019, RETINA-J RET VIT DIS, V39, P743, DOI 10.1097/IAE.0000000000002013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Haouchine B, 2004, AM J OPHTHALMOL, V138, P732, DOI 10.1016/j.ajo.2004.06.088
   Ho AC, 1998, SURV OPHTHALMOL, V42, P393, DOI 10.1016/S0039-6257(97)00132-X
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kabanarou SA, 2017, CLIN INTERV AGING, V12, P911, DOI 10.2147/CIA.S135364
   Klein R, 1994, Trans Am Ophthalmol Soc, V92, P403
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Michalewska Z, 2021, EUR J OPHTHALMOL, V31, P1320, DOI 10.1177/1120672120921376
   Michalewska Z, 2015, RETINA-J RET VIT DIS, V35, P1844, DOI 10.1097/IAE.0000000000000555
   Moisseiev E, 2010, CASE REP OPHTHALM, V1, P36, DOI 10.1159/000319827
   Nowosielska A, 2019, CASE REP OPHTHALM, V10, P369, DOI 10.1159/000503415
   Okamoto T, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-114
   Parravano M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009080.pub2
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Querques G, 2009, ACTA OPHTHALMOL, V87, P235, DOI 10.1111/j.1755-3768.2008.01226.x
   Rao P, 2017, OPHTHALMOL RETINA, V1, P158, DOI 10.1016/j.oret.2016.09.014
   Rishi P, 2011, CLIN OPHTHALMOL, V5, P167, DOI 10.2147/OPTH.S16947
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Tabandeh H, 2004, RETINA-J RET VIT DIS, V24, P714, DOI 10.1097/00006982-200410000-00005
   Takezawa M, 2011, CLIN OPHTHALMOL, V5, P101, DOI 10.2147/OPTH.S16549
   Yun C, 2012, RETINA-J RET VIT DIS, V32, P2077, DOI 10.1097/IAE.0b013e31825620ba
   Zhao PP, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/7389412
NR 30
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2021
VL 41
IS 10
BP 2066
EP 2072
DI 10.1097/IAE.0000000000003141
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5GS
UT WOS:000711796500009
PM 34310095
DA 2022-11-30
ER

PT J
AU la Cour, M
   Kiilgaard, JF
   Nissen, MH
AF la Cour, M
   Kiilgaard, JF
   Nissen, MH
TI Age-related macular degeneration - Epidemiology and optimal treatment
SO DRUGS & AGING
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TISSUE-PLASMINOGEN ACTIVATOR;
   PIGMENT EPITHELIAL-CELLS; SINGLE INTRAVITREAL INJECTION; VERTEPORFIN
   PHOTODYNAMIC THERAPY; RETROBULBAR ANECORTAVE ACETATE; GUIDED LASER
   PHOTOCOAGULATION; INDOCYANINE GREEN ANGIOGRAPHY; LONG-TERM
   SUPPLEMENTATION; RANDOMIZED CLINICAL-TRIAL
AB Age-related macular degeneration (AMD) is a common macular disease affecting elderly people in the Western world. It is characterised by the appearance of drusen in the macula, accompanied by choroidal neovascularisation (CNV) or geographic atrophy. The disease is more common in Caucasian individuals than in pigmented races. In predominantly Caucasian populations, the age-standardised prevalence of AMD in at least one eye is 7760 cases per million. The age-standardised cumulated 1-year incidence of AMD in at least one eye is 1051 cases per million individuals. AMD is the most important single cause of blindness among Caucasian individuals in developed countries. Blindness resulting from AMD rarely occurs before age 70, and most cases occur after age 80. The age-standardised 1-year incidence of legal blindness resulting from AMD is 212 cases per million. Two-thirds of AMD cases have CNV (exudative cases); the remainder has only geographic atrophy. In cross-sectional population-based studies about 45% of eyes with AMD have visual acuity reduced to 20/200 or worse. This is true both for exudative AMD and pure geographic atrophy. Age and genetic predisposition are known risk factors for AMD. Smoking is probably also a risk factor.
   Preventive strategies using macular laser photocoagulation are under investigation, but their efficacy in preventing visual loss is as yet unproven. There is no treatment with proven efficacy for geographic atrophy. Optimal treatment for exudative AMD requires a fluorescein angiographic study and a physician capable of interpreting it. For CNV not involving the foveal centre, the only evidence-based treatment is laser photocoagulation. For AMD cases with subfoveal CNV, good visual acuity, and predominantly classic fluorescence pattern on fluorescein angiography, photodynamic therapy with verteporfin is the treatment of choice. Photodynamic therapy is also effective in eyes with pure occult CNV and evidence of recent disease progression. For new subfoveal CNV with poor vision and recurrent CNV, laser photocoagulation can be considered.
C1 Natl Univ Hosp, Rigshosp, Eye Dept, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Eye Pathol Inst, Copenhagen, Denmark.
   Univ Copenhagen, Dept Med Anat, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   University of Copenhagen
RP la Cour, M (通讯作者)，Natl Univ Hosp, Rigshosp, Eye Dept 261, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM m.la.cour@dadlnet.dk
RI la Cour, Morten/L-1600-2013; Nissen, Mogens/B-4825-2008; Kiilgaard, Jens
   Folke/H-3943-2019
OI Nissen, Mogens/0000-0001-7729-8667; Kiilgaard, Jens
   Folke/0000-0003-1054-1460; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Allikmets R, 1997, NAT GENET, V17, P122, DOI 10.1038/ng0997-122b
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1994, Arch Ophthalmol, V112, P489
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 1998, Ophthalmology, V105, P11
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   Baudo TA, 2001, INVEST OPHTH VIS SCI, V42, pS438
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   BERGINK GJ, 1994, GRAEF ARCH CLIN EXP, V232, P591, DOI 10.1007/BF00193119
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Berson AM, 1996, INT J RADIAT ONCOL, V36, P861, DOI 10.1016/S0360-3016(96)00338-0
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blumenkranz MS, 2000, INVEST OPHTH VIS SCI, V41, pS531
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Blumenkranz MS, 2000, AM J OPHTHALMOL, V129, P353, DOI 10.1016/S0002-9394(99)00462-6
   Bok D, 1999, NEURON, V23, P412, DOI 10.1016/S0896-6273(00)80791-6
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   BRANCO A, 2000, INVEST OPHTH VIS SCI, V42, pS512
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P747, DOI 10.1001/archopht.1996.01100130739020
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Buring Julie E., 1994, Annals of Epidemiology, V4, P111
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Christen WG, 2000, ANN EPIDEMIOL, V10, P125, DOI 10.1016/S1047-2797(99)00042-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   *CIBA VIS, 2000, PROD MON CIBA VIS AG
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   D'Amico DJ, 2001, INVEST OPHTH VIS SCI, V42, pS232
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   *DANM STAT, 2001, STATB DENM
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651
   *EUROSTAT, 1999, DEM STAT 1960 99
   EVANS JR, 2000, COCHRANE DB SYST REV
   Evans JR, 2000, COCHRANE DB SYST REV
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fine SL, 2001, INVEST OPHTH VIS SCI, V42, pS127
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Freire J, 1996, INT J RADIAT ONCOL, V36, P857, DOI 10.1016/S0360-3016(96)00428-2
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Gass J D, 1971, Trans Am Acad Ophthalmol Otolaryngol, V75, P580
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   Gillies MC, 2001, INVEST OPHTH VIS SCI, V42, pS522
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Green WR, 1999, AGE RELATED MACULAR, P81
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Guyer DR, 1997, ARCH OPHTHALMOL-CHIC, V115, P865
   Guyer DR, 1996, ARCH OPHTHALMOL-CHIC, V114, P693, DOI 10.1001/archopht.1996.01100130685008
   Guyer DR, 2001, INVEST OPHTH VIS SCI, V42, pS522
   Hart PM, 1996, BRIT J OPHTHALMOL, V80, P1046, DOI 10.1136/bjo.80.12.1046
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   HO AC, 1999, AGE RELATED MACULAR, P263
   HOLEKAMP NM, 2000, MACULAR SURG, P212
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Horle S, 2000, OPHTHALMOLOGICA, V214, P122, DOI 10.1159/000027480
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 1997, OPHTHALMOLOGY, V104, P1242, DOI 10.1016/S0161-6420(97)30151-1
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Hyman L, 1992, AGE RELATED MACULAR, P1
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KORTE GE, 1989, INT REV CYTOL, V114, P221
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   KWUN RC, 1999, AGE RELATED MACULAR, P237
   la Cour M, 2001, Ugeskr Laeger, V163, P6396
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Liang Y, 2000, CURR EYE RES, V20, P25, DOI 10.1076/0271-3683(200001)2011-HFT025
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Luo W, 2001, INVEST OPHTH VIS SCI, V42, pS232
   *MAC PHOT STUD GRO, 2001, ARCH OPHTHALMOL-CHIC, V109, P1232
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Maguire MG, 2001, INVEST OPHTH VIS SCI, V42, pS233
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7
   MARCUS DM, 1999, AGE RELATED MACULAR, P309
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   MILLER JM, 2000, MACULAR SURG, P240
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Moyers MF, 1999, MED PHYS, V26, P777, DOI 10.1118/1.598587
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   *NAT EYE I, 2000, CLIN STUD SUPP NAT E
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Niffenegger J, 1998, OPHTHALMOLOGY, V105, P1364
   *NOV OPHTH, 2001, VIS INT S ONL PROGR
   O'Neill CA, 2001, INVEST OPHTH VIS SCI, V42, pS225
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Ohno-Matsui K, 2001, INVEST OPHTH VIS SCI, V42, pS227
   Olk RJ, 2000, INVEST OPHTH VIS SCI, V41, pS319
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Ono M, 1999, CANCER CHEMOTH PHARM, V43, pS69, DOI 10.1007/s002800051101
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   ORMEROD LD, 1994, OPHTHALMOLOGY, V101, P1201
   Ostenfeld-Akerblom A, 1999, ACTA OPHTHALMOL SCAN, V77, P76, DOI 10.1034/j.1600-0420.1999.770117.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENN JS, 2002, INVEST OPHTH VIS SCI, V42, P283
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   PIERAMICI DJ, 1999, AGE RELATED MACULAR, P219
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   RICHER S, 1996, J AM OPTOMETRIC ASS, V0067
   Richer S, 1996, J Am Optom Assoc, V67, P30
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Rosa RH, 1996, AM J OPHTHALMOL, V122, P853, DOI 10.1016/S0002-9394(14)70382-4
   Rosenberg T, 1987, Arctic Med Res, V46, P13
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Rosenberg T, 1987, Arctic Med Res, V46, P64
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schwartz SD, 2001, INVEST OPHTH VIS SCI, V42, pS522
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P7, DOI 10.1016/S0008-4182(01)80060-0
   Shiragami C, 1998, BRIT J OPHTHALMOL, V82, P1056, DOI 10.1136/bjo.82.9.1056
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Singerman LJ, 2001, INVEST OPHTH VIS SCI, V42, pS231
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SMIDDY WE, 1984, ARCH OPHTHALMOL-CHIC, V102, P1086, DOI 10.1001/archopht.1984.01040030880039
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Spaide RF, 1998, OPHTHALMOLOGY, V105, P24, DOI 10.1016/S0161-6420(98)90980-0
   Spaide RF, 1999, OPHTHALMOLOGY, V106, P2254, DOI 10.1016/S0161-6420(99)90524-9
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Stalmans P, 1997, RETINA-J RET VIT DIS, V17, P481
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Stur M, 2001, INVEST OPHTH VIS SCI, V42, pS442
   Subasi M, 1999, Radiat Med, V17, P169
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SUNNESS JS, 1999, AGE RELATED MACULAR, P155
   SYKES SO, 1994, ARCH OPHTHALMOL-CHIC, V112, P1561, DOI 10.1001/archopht.1994.01090240067027
   Talks KL, 2000, BRIT J HAEMATOL, V109, P477, DOI 10.1046/j.1365-2141.2000.01864.x
   Teikari JM, 1997, ACTA OPHTHALMOL SCAN, V75, P634
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thomas EL, 2000, INVEST OPHTH VIS SCI, V41, pS531
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   Vinding T, 1995, Acta Ophthalmol Scand Suppl, P1
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P53
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   WEISZ JM, 2000, MACULAR SURG, P201
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Winkler BS, 1999, MOL VIS, V5
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Yonemoto LT, 1996, INT J RADIAT ONCOL, V36, P867, DOI 10.1016/S0360-3016(96)00339-2
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 348
TC 87
Z9 95
U1 0
U2 8
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PY 2002
VL 19
IS 2
BP 101
EP 133
DI 10.2165/00002512-200219020-00003
PG 33
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 549DP
UT WOS:000175429500003
PM 11950377
DA 2022-11-30
ER

PT J
AU Das, UN
AF Das, Undurti N.
TI Diabetic macular edema, retinopathy and age-related macular degeneration
   as inflammatory conditions
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE vascular endothelial growth factor; inflammation; diabetic retinopathy;
   polyunsaturated fatty acids; lipoxins
ID ENDOTHELIAL GROWTH-FACTOR; POLYUNSATURATED FATTY-ACIDS;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; NITRIC-OXIDE FORMATION; LIPOXIN A(4);
   DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS; TNF-ALPHA; ARACHIDONIC-ACID;
   AQUEOUS-HUMOR
AB Diabetic macular edema (DME) and diabetic retinopathy (DR) are complications affecting about 25% of all patients with long-standing type 1 and type 2 diabetes mellitus and are a major cause of significant decrease in vision and quality of life. Age-related macular degeneration (AMD) is not uncommon, and diabetes mellitus affects the incidence and progression of AMD through altering hemodynamics, increasing oxidative stress, accumulating advanced glycation end products, etc. Recent studies suggest that DME, DR and AMD are inflammatory conditions characterized by a breakdown of the blood-retinal barrier, inflammatory processes and an increase in vascular permeability. Key factors that seem to have a dominant role in DME, DR and AMD are angiotensin II, prostaglandins and the vascular endothelial growth factor and a deficiency of anti-inflammatory bioactive lipids. The imbalance between pro- and anti-inflammatory eicosanoids and enhanced production of pro-angiogenic factors may initiate the onset and progression of DME, DR and AMD. This implies that bioactive lipids that possess anti-inflammatory actions and suppress the production of angiogenic factors could be employed in the prevention and management of DME, DR and AMD.
C1 [Das, Undurti N.] UND Life Sci, 2020 S 360th St,K-202, Federal Way, WA 98003 USA.
RP Das, UN (通讯作者)，UND Life Sci, 2020 S 360th St,K-202, Federal Way, WA 98003 USA.
EM Undurti@hotmail.com
CR Adamis AP, 2002, BRIT J OPHTHALMOL, V86, P363, DOI 10.1136/bjo.86.4.363
   ADAMSON GM, 1994, J BIOCHEM TOXICOL, V9, P181, DOI 10.1002/jbt.2570090403
   Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Akirav EM, 2011, DIABETES, V60, P876, DOI 10.2337/db10-0793
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ansquer JC, 2011, CURR PHARM BIOTECHNO, V12, P396, DOI 10.2174/138920111794480570
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Bai YY, 2009, J PATHOL, V219, P446, DOI 10.1002/path.2611
   Bansal S, 2013, CLIN BIOCHEM, V46, P109, DOI 10.1016/j.clinbiochem.2012.10.019
   Barajas-Espinosa A, 2012, FASEB J, V26, P1100, DOI 10.1096/fj.11-195792
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   Bento AF, 2011, J IMMUNOL, V187, P1957, DOI 10.4049/jimmunol.1101305
   Birnbaum Y, 2006, CIRCULATION, V114, P929, DOI 10.1161/CIRCULATIONAHA.106.629907
   Biteman B, 2007, FASEB J, V21, P2257, DOI 10.1096/fj.06-7918com
   Boccellino M, 2002, LIPIDS, V37, P1047, DOI 10.1007/s11745-002-0999-7
   Borgeson E, 2011, INFECT IMMUN, V79, P1489, DOI 10.1128/IAI.00777-10
   BRATT J, 1995, ARTHRITIS RHEUM, V38, P768, DOI 10.1002/art.1780380609
   Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200
   Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216
   Chen XH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0064227, 10.1371/journal.pone.0067120]
   Chen Y, 2010, MOL CANCER THER, V9, P2164, DOI 10.1158/1535-7163.MCT-10-0173
   Chen ZQ, 2013, INFLAMMATION, V36, P468, DOI 10.1007/s10753-012-9567-x
   CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786
   Cicero A. F. G., 2014, NUTRAfoods, V13, P5
   COLLIER A, 1986, DIABETOLOGIA, V29, P471, DOI 10.1007/BF00453495
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Cummings M, 2008, CLIN OPHTHALMOL, V2, P369
   Das U N, 2006, J Assoc Physicians India, V54, P133
   Das U N, 1998, J Assoc Physicians India, V46, P630
   DAS UN, 1994, PROSTAG LEUKOTR ESS, V51, P207, DOI 10.1016/0952-3278(94)90136-8
   Das UN, 2011, MOLECULAR BASIS OF HEALTH AND DISEASE, P1, DOI 10.1007/978-94-007-0495-4
   DAS UN, 1995, PROSTAG LEUKOTR ESS, V52, P387, DOI 10.1016/0952-3278(95)90066-7
   Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4
   DAS UN, 1995, MED SCI RES, V23, P723
   Das UN, 2001, PROSTAG LEUKOTR ESS, V65, P37, DOI 10.1054/plef.2001.0285
   DAS UN, 2010, METABOLIC SYNDROME P
   Das UN, 2013, MED HYPOTHESES, V81, P1135, DOI 10.1016/j.mehy.2013.10.020
   Das UN, 2013, NUTRITION, V29, P1175, DOI 10.1016/j.nut.2013.01.012
   Das UN, 2013, PROSTAG LEUKOTR ESS, V88, P201, DOI 10.1016/j.plefa.2012.11.009
   Das UN, 2013, NUTRITION, V29, P1, DOI 10.1016/j.nut.2012.02.003
   Das UN, 2012, MED SCI MONITOR, V18, pLE1, DOI 10.12659/MSM.882187
   Das UN, 2012, PROSTAG LEUKOTR ESS, V86, P3, DOI 10.1016/j.plefa.2011.09.008
   Das UN, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-76
   Das UN, 2010, J INFLAMM RES, V3, P143, DOI 10.2147/JIR.S9425
   Das UN, 2010, MED SCI MONITOR, V16, pLE13
   Das UN, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-37
   Das UN, 2013, CLIN LIPIDOL, V8, P437, DOI 10.2217/CLP.13.31
   Das UN, 2013, CLIN LIPIDOL, V8, P465, DOI 10.2217/CLP.13.32
   De La Cruz JP, 2003, FUND CLIN PHARMACOL, V17, P363, DOI 10.1046/j.1472-8206.2003.00137.x
   Devi MMS, 2006, PROSTAG LEUKOTR ESS, V74, P39, DOI 10.1016/j.plefa.2005.09.003
   Divangahi M, 2013, ADV EXP MED BIOL, V783, P103, DOI 10.1007/978-1-4614-6111-1_6
   Douros Stella, 2001, Documenta Ophthalmologica, V103, P27, DOI 10.1023/A:1017557600233
   Du YP, 2004, AM J PHYSIOL-REG I, V287, pR735, DOI 10.1152/ajpregu.00080.2003
   Fiorucci S, 2003, BRIT J PHARMACOL, V139, P1351, DOI 10.1038/sj.bjp.0705356
   FRANCO VW, 1986, DIABETES CARE, V9, P104, DOI 10.2337/diacare.9.1.104a
   Fu ZJ, 2015, AM J CLIN NUTR, V101, P879, DOI 10.3945/ajcn.114.099291
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Funatsu H, 2003, AM J OPHTHALMOL, V135, P321, DOI 10.1016/S0002-9394(02)01971-2
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P537, DOI 10.1016/S0002-9394(02)01323-5
   Gani OABSM, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-6
   Gilroy DW, 2005, MEM I OSWALDO CRUZ, V100, P49, DOI 10.1590/S0074-02762005000900009
   Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359
   Gustavsson C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012699
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258
   Hardy P, 2005, PROSTAG LEUKOTR ESS, V72, P301, DOI 10.1016/j.plefa.2005.02.004
   Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139
   Harizi H, 2002, J IMMUNOL, V168, P2255, DOI 10.4049/jimmunol.168.5.2255
   Hedi H, 2004, CELL IMMUNOL, V228, P99, DOI 10.1016/j.cellimm.2004.04.003
   Hein TW, 2012, INVEST OPHTH VIS SCI, V53, P7943, DOI 10.1167/iovs.12-11005
   Hennekens CH, 2010, J CARDIOVASC PHARM T, V15, P344, DOI 10.1177/1074248410375091
   Hetzel S, 2013, J CARDIOVASC PHARM T, V18, P217, DOI 10.1177/1074248413482753
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   Huang T, 2012, ASIA PAC J CLIN NUTR, V21, P394
   Jin SW, 2007, ANESTH ANALG, V104, P369, DOI 10.1213/01.ane.0000252414.00363.c4
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Jung SH, 2014, INVEST OPHTH VIS SCI, V55, P2290, DOI 10.1167/iovs.13-13587
   KATOH T, 1994, KIDNEY INT, V46, P341, DOI 10.1038/ki.1994.280
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kern TS, 2001, DIABETES, V50, P1636, DOI 10.2337/diabetes.50.7.1636
   Kernt M, 2013, DIABETES RES CLIN PR, V100, pE11, DOI 10.1016/j.diabres.2013.01.006
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Koczy-Baron E, 2014, POSTEP HIG MED DOSW, V68, P57, DOI 10.5604/17322693.1086360
   KOMORI T, 1985, JPN J MED, V24, P231
   KUMAR GS, 1992, NUTR RES, V12, P815, DOI 10.1016/S0271-5317(05)80639-6
   KUMAR KV, 1993, FREE RADICAL RES COM, V19, P59, DOI 10.3109/10715769309056499
   Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105
   Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lin Tony, 2013, Cytokine, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Liu HQ, 2013, NUTR RES, V33, P849, DOI 10.1016/j.nutres.2013.07.004
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462
   Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1
   Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549
   Lutty GA, 1997, AM J PATHOL, V151, P707
   Ma Q, 2014, CRIT REV FOOD SCI, V54, P1, DOI 10.1080/10408398.2011.565523
   Mandal LK, 2013, CAN J DIABETES, V37, P401, DOI 10.1016/j.jcjd.2013.05.004
   Menezes-de-Lima O, 2006, PROSTAG OTH LIPID M, V80, P123, DOI 10.1016/j.prostaglandins.2006.05.016
   Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190
   Mohan IK, 1997, PROSTAG LEUKOTR ESS, V56, P193, DOI 10.1016/S0952-3278(97)90533-0
   Mohan IK, 2001, NUTRITION, V17, P126, DOI 10.1016/S0899-9007(00)00468-8
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Mullner E, 2014, J HUM NUTR DIET, V27, P468, DOI 10.1111/jhn.12168
   Nascimento-Silva V, 2005, AM J PHYSIOL-CELL PH, V289, pC557, DOI 10.1152/ajpcell.00045.2005
   Nascimento-Silva V, 2007, THROMB HAEMOSTASIS, V97, P88, DOI 10.1160/TH06-06-0315
   NAVEH N, 1990, OPHTHALMIC RES, V22, P3, DOI 10.1159/000266995
   Neschen S, 2006, DIABETES, V55, P924, DOI 10.2337/diabetes.55.04.06.db05-0985
   Nishida S, 2002, J PINEAL RES, V32, P26, DOI 10.1034/j.1600-079x.2002.10797.x
   Noda K, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/279037
   O'Kane P, 2009, CARDIOVASC RES, V83, P123, DOI 10.1093/cvr/cvp120
   Othman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057254
   Paul-Clark MJ, 2004, J EXP MED, V200, P69, DOI 10.1084/jem.20040566
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Planaguma A, 2010, MUCOSAL IMMUNOL, V3, P270, DOI 10.1038/mi.2009.141
   POWELL EDU, 1964, LANCET, V2, P17
   Prescott D, 2011, AM J PHYSIOL-GASTR L, V301, pG487, DOI 10.1152/ajpgi.00042.2011
   Ramos EJB, 2003, SURGERY, V134, P329, DOI 10.1067/msy.2003.267
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Rhodes LE, 2009, FASEB J, V23, P3947, DOI 10.1096/fj.09-136077
   Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Roy MS, 2013, INVEST OPHTH VIS SCI, V54, P5471, DOI 10.1167/iovs.13-12212
   Rysz J, 2007, J NEPHROL, V20, P444
   Saishin Y, 2003, J CELL PHYSIOL, V195, P210, DOI 10.1002/jcp.10238
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Schoenberger SD, 2012, INVEST OPHTH VIS SCI, V53, P5906, DOI 10.1167/iovs.12-10410
   Scholl S, 2011, EUR J OPHTHALMOL, V21, pS10, DOI 10.5301/EJO.2010.6050
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Selim KM, 2010, INDIAN J OPHTHALMOL, V58, P375, DOI 10.4103/0301-4738.67042
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Shen JH, 2013, ARCH MED RES, V44, P514, DOI 10.1016/j.arcmed.2013.09.010
   Shen JH, 2014, ARCH MED SCI, V10, P1167, DOI 10.5114/aoms.2014.47826
   Shen JH, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-90
   Sim R, 2012, REV RECENT CLIN TRIA, V7, P71, DOI 10.2174/157488712799363299
   Stem MS, 2013, CURR MED CHEM, V20, P3241, DOI 10.2174/09298673113209990027
   Stepien M, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-29
   Suresh Y, 2003, NUTRITION, V19, P213, DOI 10.1016/S0899-9007(02)00855-9
   Suresh Y, 2003, NUTRITION, V19, P93, DOI 10.1016/S0899-9007(02)00856-0
   Suresh Y, 2001, PROSTAG LEUKOTR ESS, V64, P37, DOI 10.1054/plef.2000.0236
   SURYAPRABHA P, 1991, PROSTAG LEUKOTR ESS, V43, P251, DOI 10.1016/0952-3278(91)90038-7
   Tamaoki J, 1995, EUR J PHARMACOL, V287, P233, DOI 10.1016/0014-2999(95)00490-4
   Tang Y, 2009, INT J CANCER, V124, P1545, DOI 10.1002/ijc.24118
   THOMAS MA, 1985, BRIT J OPHTHALMOL, V69, P275, DOI 10.1136/bjo.69.4.275
   Tikhonenko M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055177
   Tranos PG, 2004, SURV OPHTHALMOL, V49, P470, DOI 10.1016/j.survophthal.2004.06.002
   Tsai CH, 2013, BBA-GEN SUBJECTS, V1830, P2649, DOI 10.1016/j.bbagen.2012.12.017
   Tsuzuki T, 2007, J NUTR, V137, P641, DOI 10.1093/jn/137.3.641
   Tuuminen R, 2014, ACTA OPHTHALMOL, V92, P675, DOI 10.1111/aos.12363
   Ulu A, 2013, J CARDIOVASC PHARM, V62, P285, DOI 10.1097/FJC.0b013e318298e460
   Vainio M, 2004, ACTA OBSTET GYN SCAN, V83, P1119, DOI 10.1111/j.0001-6349.2004.00396.x
   Vetrivel U, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-109
   Vidinova CN, 2012, KLIN MONATSBL AUGENH, V229, P1204, DOI 10.1055/s-0032-1315307
   Vinores SA, 1997, HISTOL HISTOPATHOL, V12, P99
   Waisbourd M, 2011, ACTA OPHTHALMOL, V89, P203, DOI 10.1111/j.1755-3768.2010.02010.x
   Wang B, 2011, PULM PHARMACOL THER, V24, P434, DOI 10.1016/j.pupt.2011.04.001
   Waszczykowska A, 2013, ARCH MED SCI, V9, P1107, DOI 10.5114/aoms.2013.39217
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wolf AM, 2004, BIOCHEM BIOPH RES CO, V323, P630, DOI 10.1016/j.bbrc.2004.08.145
   Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013
   Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457
   Wu SH, 2005, KIDNEY INT, V68, P35, DOI 10.1111/j.1523-1755.2005.00379.x
   Wu Y, 2012, NEUROCHEM RES, V37, P1690, DOI 10.1007/s11064-012-0776-3
   Yamaguchi N, 2005, FEBS LETT, V579, P6821, DOI 10.1016/j.febslet.2005.11.019
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200
   Zhang GD, 2013, P NATL ACAD SCI USA, V110, P6530, DOI 10.1073/pnas.1304321110
   Zhao QF, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/231351
   Zhuang W, 2013, J CARDIOVASC TRANSL, V6, P287, DOI 10.1007/s12265-012-9409-0
NR 177
TC 26
Z9 33
U1 0
U2 11
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND
SN 1734-1922
EI 1896-9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PD OCT
PY 2016
VL 12
IS 5
BP 1142
EP 1157
DI 10.5114/aoms.2016.61918
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DU7QW
UT WOS:000382410700027
PM 27695506
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Liu, L
   Li, C
   Yu, HH
   Yang, XH
AF Liu, Lei
   Li, Cong
   Yu, Honghua
   Yang, Xiaohong
TI A critical review on air pollutant exposure and age-related macular
   degeneration
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Review
DE Air pollutant exposure; Age-related macular degeneration; Epidemiology;
   Mechanism; Prevention
ID RETINAL-PIGMENT EPITHELIUM; LONG-TERM INCIDENCE; RISK-FACTORS;
   CIGARETTE-SMOKING; EYE DISEASE; CARDIOVASCULAR-DISEASE; COMPLEMENT
   ACTIVATION; CHOROIDAL THICKNESS; VISUAL IMPAIRMENT; ATTRIBUTABLE RISK
AB Age-related macular degeneration (AMD) is the leading cause of visual impairments and blindness worldwide in the elderly and its incidence strongly increases with ages. The etiology of AMD is complex and attributed to the genetic modifiers, environmental factors and gene-environment interactions. Recently, the impacts of air pollution on the development of eye diseases have become the new area of focus, and disordered air exposure combined with inadequate health management has caused problems for the eye health, such as dry eye, glaucoma, and retinopathy, while its specific role in the occurrence of AMD is still not well understood. In order to summarize the progress of this research field, we performed a critical review to summarize the epidemiological and mechanism evidence on the association between air pollutants exposure and AMD. This review documented that exposure to air pollutants will accelerate or worsen the morbidity and prevalence of AMD. Air pollutants exposure may change the homeostasis, interfere with the inflamma-tory response, and take direct action on the lipid metabolism and oxidative stress in the macula. More attention should be given to understanding the impact of ambient air pollution on AMD worldwide.
C1 [Liu, Lei; Li, Cong; Yu, Honghua; Yang, Xiaohong] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Eye Inst, Dept Ophthalmol, Guangzhou 510080, Peoples R China.
   [Li, Cong] South China Univ Technol, Sch Med, Guangzhou 510006, Peoples R China.
   [Yang, Xiaohong] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Eye Inst, Dept Ophthalmol, Guangzhou, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   South China University of Technology; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital
RP Yang, XH (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Eye Inst, Dept Ophthalmol, Guangzhou, Peoples R China.
EM syyangxh@scut.edu.cn
FU Science and Technology Program of Guangzhou, China [202002020049];
   Project of Special Research on Cardiovascular Diseases [2020XXG007];
   National Natural Science Foundation of China [81870663, 82171075];
   Outstanding Young Talent Trainee Program of Guangdong Provincial
   People's Hospital [KJ012019087]; Guangdong Provincial People's Hospital
   Scientific Research Funds for Leading Medical Talents and Distinguished
   Young Scholars in Guangdong Province [KJ012019457]; Talent Introduction
   Fund of Guangdong Provincial People's Hospital [Y012018145]
FX This work was supported by the Science and Technology Program of
   Guangzhou, China (202002020049) (Xiaohong Yang) ; Project of Special
   Research on Cardiovascular Diseases (2020XXG007) (Xiaohong Yang) ;
   Na-tional Natural Science Foundation of China (81870663, 82171075)
   (Honghua Yu) , Outstanding Young Talent Trainee Program of Guangdong
   Provincial People's Hospital (KJ012019087) (Honghua Yu) , Guangdong
   Provincial People's Hospital Scientific Research Funds for Leading
   Medical Talents and Distinguished Young Scholars in Guangdong Province
   (KJ012019457) (Honghua Yu) , Talent Introduction Fund of Guangdong
   Provincial People's Hospital (Y012018145) (Honghua Yu) . The funders had
   no role in study design, data collection and analysis, decision to
   pub-lish, or preparation of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ananth S, 2014, BBA-MOL BASIS DIS, V1842, P603, DOI 10.1016/j.bbadis.2014.01.010
   Bao N, 2021, ENVIRON RES, V195, DOI 10.1016/j.envres.2021.110807
   Bauer AK, 2022, TOXICS, V10, DOI 10.3390/toxics10010028
   Bhattarai N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061405
   Brogan AP, 2005, P NATL ACAD SCI USA, V102, P10433, DOI 10.1073/pnas.0504721102
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Campbell SC, 2008, ATHEROSCLEROSIS, V201, P225, DOI 10.1016/j.atherosclerosis.2008.04.046
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chan KH, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003716
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Chua SYL, 2022, BRIT J OPHTHALMOL, V106, P705, DOI 10.1136/bjophthalmol-2020-316218
   Chua SYL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.32
   Chun LF, 2017, AM J PHYSIOL-LUNG C, V313, pL193, DOI 10.1152/ajplung.00071.2017
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Deng YH, 2022, GENES DIS, V9, P62, DOI 10.1016/j.gendis.2021.02.009
   DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401
   Durga M, 2015, ENVIRON TOXICOL PHAR, V40, P615, DOI 10.1016/j.etap.2015.06.024
   Engle ML, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212866
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng LW, 2022, EXP BIOL MED, V247, P77, DOI 10.1177/15353702211052245
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Grant A, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.10.7
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Haque A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01728
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Hu ML, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070635
   Hullmann M, 2017, PART FIBRE TOXICOL, DOI 10.1186/s12989-017-0213-5
   Husain Deeba, 2002, Ophthalmol Clin North Am, V15, P87, DOI 10.1016/S0896-1549(01)00009-8
   Hwang JH, 2016, J MOL MED, V94, P667, DOI 10.1007/s00109-016-1378-3
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Jang S, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11030373
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Ju MJ, 2022, ENVIRON RES, V204, DOI 10.1016/j.envres.2021.111953
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kang YJ, 2021, ADV SCI, V8, DOI 10.1002/advs.202101251
   Karakocak BB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38803-4
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Korhonen E, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108687
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Li S, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/7654143
   Liang CL, 2022, ENVIRON SCI POLLUT R, V29, P51942, DOI 10.1007/s11356-022-19278-9
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Lin C.-C., 2022, INT J ENV RES PUB HE, V19
   Lin HL, 2017, STROKE, V48, P1191, DOI [10.1161/STROKEAHA.116.015739, 10.1161/strokeaha.116.015739]
   Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074
   Ludtke L, 2019, MED SCI MONITOR, V25, P6383, DOI 10.12659/MSM.915493
   Lynn SA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020413
   Makri OE, 2020, TOXICS, V8, DOI 10.3390/toxics8040085
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Miersch T, 2019, SCI TOTAL ENVIRON, V686, P382, DOI 10.1016/j.scitotenv.2019.05.412
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Moon BG, 2012, J KOREAN MED SCI, V27, P537, DOI 10.3346/jkms.2012.27.5.537
   Motozawa N, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-05006-3
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Naseer S, 2022, ENVIRON SCI POLLUT R, V29, P40520, DOI 10.1007/s11356-022-19961-x
   Nebbioso M, 2022, DRUG AGING, V39, P107, DOI 10.1007/s40266-021-00914-x
   Orona NS, 2020, ECOTOX ENVIRON SAFE, V190, DOI 10.1016/j.ecoenv.2019.110120
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Ren JB, 2022, J INFLAMM RES, V15, P865, DOI 10.2147/JIR.S347231
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riggs DW, 2020, ENVIRON RES, V180, DOI 10.1016/j.envres.2019.108890
   Rowan S, 2020, FREE RADICAL BIO MED, V150, P75, DOI 10.1016/j.freeradbiomed.2020.02.010
   Schaefer A, 2022, J SEX MARITAL THER, DOI [10.1007/s10900-022-01085-5, 10.1080/0092623X.2022.2126808]
   Schmidt S, 2005, MOL VIS, V11, P941
   Schmidt S, 2000, MOL VIS, V6, P287
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sendra VG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.618597
   Shadrach KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067983
   Sigala I, 2021, J PERS MED, V11, DOI 10.3390/jpm11090867
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Sreekumar PG, 2022, EXP EYE RES, V215, DOI 10.1016/j.exer.2021.108918
   Srirangarajan S, 2021, INT J PERIODONT REST, V41, pE213, DOI 10.11607/prd.4573
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Tsai H.-Y., 2022, BIOMEDICINES, P10
   Ulas F, 2014, CURR EYE RES, V39, P504, DOI 10.3109/02713683.2013.850099
   Varinthra P, 2021, MAR DRUGS, V19, DOI 10.3390/md19010001
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang F, 2021, J MOL MED, V99, P1459, DOI 10.1007/s00109-021-02108-9
   Wang WQ, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.16
   Wang YY, 2021, GERONTOLOGY, DOI 10.1159/000518822
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yako T., 2022, INT J MOL SCI, V23, P1790, DOI [10.3390/ijms23031790, DOI 10.3390/IJMS23031790]
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Yang XR, 2021, AGING-US, V13, P19614, DOI 10.18632/aging.203374
   Zeng YX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.607341
   Zhang LM, 2019, TOXICOL LETT, V311, P105, DOI 10.1016/j.toxlet.2019.05.001
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 121
TC 0
Z9 0
U1 13
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD SEP 20
PY 2022
VL 840
AR 156717
DI 10.1016/j.scitotenv.2022.156717
PG 11
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA 2L4OP
UT WOS:000816997600014
PM 35709989
OA hybrid
DA 2022-11-30
ER

PT J
AU Lutty, GA
   McLeod, DS
   Bhutto, IA
   Edwards, MM
   Seddon, JM
AF Lutty, Gerard A.
   McLeod, D. Scott
   Bhutto, Imran A.
   Edwards, Malia M.
   Seddon, Johanna M.
TI Choriocapillaris dropout in early age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Choriocapillaris; Basal laminar
   deposit; Choroidal neovascularization; Hypertension
ID CHOROIDAL BLOOD-FLOW; BRUCHS MEMBRANE; MORPHOMETRIC-ANALYSIS; PIGMENT
   EPITHELIUM; HUMAN EYES; NEOVASCULARIZATION; ASSOCIATION; PROGRESSION;
   DRUSEN; REGION
AB Loss of choriocapillaris (CC) in advanced age-related macular degeneration (AMD) is well documented but changes in early AMD have not been quantified. Postmortem eyes from donors with clinically documented early AMD were examined in choroidal whole mounts to determine the area, pattern, and severity of CC loss. Choroids from postmortem human eyes without AMD (n = 7; mean age = 86.1) and from eyes with a Grade 2 clinical classification of early AMD (n = 7; mean age = 87) were immunolabeled with Ulex europaeus agglutinin (UEA) lectin-FITC to stain blood vessels. Whole mounts were imaged using confocal microscopy and image analysis was performed to determine the area of vascular changes and density of vasculature (percent vascular area, %VA). All areas evaluated had a complete RPE monolayer upon gross examination. In age-matched control eyes, the CC had broad lumens and a homogenous pattern of freely interconnecting capillaries. The mean %VA +/- standard deviation in submacula of control subjects was 78.1 +/- 3.25%. In eyes with early AMD, there was a significant decrease in mean %VA to 60.1 +/- 10.4% (p < 0.0001). The paramacular %VA was not significantly different in eyes with or without AMD. The area of submacular choroid affected by CC dropout was 0.04 +/- 0.09 mm(2) in control eyes. In eyes with early AMD, the mean area affected by CC dropout was significantly increased (10.4 +/- 6.1 mm(2); p < 0.001). In some cases, incipient neovascular buds were observed at the border of regions with CC dropout in early AMD choroids. In conclusion, UEA lectin-labeled choroidal whole mounts from donors with clinically documented early AMD has provided a unique opportunity to examine regional changes in vascular pathology associated with choriocapillaris. The study demonstrated attenuation of submacular CC in early AMD subjects but no vascular pathology was observed outside the submacular region. While the affected area in some eyes was quite extensive histologically, these changes may not be detectable clinically using standard in vivo imaging.
C1 [Lutty, Gerard A.; McLeod, D. Scott; Bhutto, Imran A.; Edwards, Malia M.] Johns Hopkins Univ Hosp, Wilmer Ophthahnol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
   [Seddon, Johanna M.] Univ Massachusetts, Dept Ophthalmol & Visual Sci, Med Sch, Worcester, MA 01655 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of
   Massachusetts System; University of Massachusetts Worcester
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthahnol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.; Seddon, JM (通讯作者)，Univ Massachusetts, Degenerat Ctr Excellence, Med Sch, 55 Lake Ave North,S3-119, Worcester, MA 01655 USA.
EM glutty@jhmi.edu; Johanna.seddon@umassmed.edu
FU NIH [EY016151, EY01765]; Arnold and Mabel Beckman Foundation;
   Altsheler-Durell Foundation; Foundation Fighting Blindness; RPB
   Unrestricted Grant; Macular Degeneration Center of Excellence Fund,
   University of Massachusetts Medical School; RPB Senior Scientific
   Investigator Award in 2008; RPB Wasserman Award in 1995
FX qq NIH grants EY016151 (GL), EY01765 (Wilmer); Arnold and Mabel Beckman
   Foundation (GL, JMS), the Altsheler-Durell Foundation (GL), Foundation
   Fighting Blindness, an RPB Unrestricted Grant (Wilmer), and the Macular
   Degeneration Center of Excellence Fund, University of Massachusetts
   Medical School (JMS). Gerard Lutty received an RPB Senior Scientific
   Investigator Award in 2008 and Johanna Seddon received the RPB Wasserman
   Award in 1995.
CR Arentson-Lantz EJ, 2016, J APPL PHYSIOL, V120, P965, DOI 10.1152/japplphysiol.00799.2015
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hogg EE., 2008, OPHTHALMOLOGY, V115
   Hotta K, 2018, J PHYSIOL-LONDON, V596, P1903, DOI 10.1113/JP275459
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Lane M, 2016, OSLI RETINA, V47, P778, DOI 10.3928/23258160-20160808-13
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sohn EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086538
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 48
TC 31
Z9 31
U1 4
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2020
VL 192
AR 107939
DI 10.1016/j.exer.2020.107939
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KS7QN
UT WOS:000518501300013
PM 31987759
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, Peter K.
TI Emerging Therapies for Neovascular Age-Related Macular Degeneration
   Drugs in the Pipeline
SO OPHTHALMOLOGY
LA English
DT Article
ID RADIATION-THERAPY; TARGETED THERAPY; VEGF; ANGIOGENESIS; RADIOTHERAPY;
   BEVACIZUMAB; IRRADIATION; SECONDARY; SAFETY
AB Topic: Discuss the emerging therapies that could improve the treatment of neovascular age-related macular degeneration (AMD).
   Clinical Relevance: Current antiangiogenic therapies require frequent injections, and not all patients respond to these therapies. Thus, there is a need to identify additional therapies that could improve the treatment of neovascular AMD.
   Methods: Review of medical literature and ongoing clinical trials as well as their results in the area of neovascular AMD treatment.
   Results: There are numerous areas of investigation into new treatment for AMD, including the newly approved aflibercept eye; sustained-release compounds that may allow for fewer injections, combination therapy with anti-vascular endothelial growth factor (VEGF) therapy and ionizing radiation, and investigational drugs that address different targets along the angiogenic signaling cascade, or other pathways related to the pathophysiology of neovascular AMD altogether.
   Conclusions: Despite the outstanding advances made in the treatment of neovascular AMD with anti-VEGF therapies, patients still require numerous injections and office visits. Future therapies, however, have the potential not only to reduce patient visits and injections, but also to improve outcomes by targeting additional pathways, increasing target affinity, and lengthening treatment durability.
C1 [Kaiser, Peter K.] Cleveland Clin, Lerner Coll Med, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Main Campus,Mail Code i32,9500 Euc, Cleveland, OH 44195 USA.
EM pkaiser@gmail.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Regeneron Pharmaceuticals, Inc, Tarrytown, NY
FX Supported by an educational grant from Regeneron Pharmaceuticals, Inc,
   Tarrytown, NY.
CR Adams J A, 1999, Med Dosim, V24, P233, DOI 10.1016/S0958-3947(99)00024-2
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Boyer DS, 2009, INVEST OPHTHALMOL VI, V50
   Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249
   Carmeliet P., 2000, ANN NY ACAD SCI, V902, P62
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Clinicaltrials.gov, COMPL INH EC TREATM
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Finger PT, 2003, BRIT J OPHTHALMOL, V87, P1497, DOI 10.1136/bjo.87.12.1497
   Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   KRISHNAN L, 1988, INT J RADIAT ONCOL, V15, P147, DOI 10.1016/0360-3016(88)90359-8
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   Myers AL, 2010, J PEDIATR SURG, V45, P1080, DOI 10.1016/j.jpedsurg.2010.02.068
   Nieder C, 2006, CANCER TREAT REV, V32, P348, DOI 10.1016/j.ctrv.2006.03.006
   Rasmussen H, 2001, Hum Gene Ther, V12, P2029
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   US Food and Drug Administration, VEGF TRAP EYE AFL OP
   Willett CG, 2007, ONCOLOGY-NY, V21, P1055
   Willett CG, 2006, SEMIN ONCOL, V33, pS35, DOI 10.1053/j.seminoncol.2006.08.007
   Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 33
TC 49
Z9 52
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2013
VL 120
IS 5
SU S
BP S11
EP S15
DI 10.1016/j.ophtha.2013.01.061
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140UW
UT WOS:000318682500004
PM 23642781
DA 2022-11-30
ER

PT J
AU Huang, YM
   Hsieh, MH
   Li, AF
   Chen, SJ
AF Huang, Yi-Ming
   Hsieh, Ming-Hung
   Li, An-Fei
   Chen, Shih-Jen
TI Sensitivity, Specificity, and Limitations of Optical Coherence
   Tomography Angiography in Diagnosis of Polypoidal Choroidal Vasculopathy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Purpose. To evaluate the sensitivity and specificity of optical coherence tomography angiography (OCTA) in differentiating polypoidal choroidal vasculopathy (PCV) from age-related macular degeneration (AMD). Methods. Fundus color photographs, spectral-domain optical coherence tomography, and fluorescein angiography (step 1) and OCTA (step 2) of 50 eyes that had PCV or AMD were presented to two ophthalmologists. The final diagnoses of PCV were masked. Sensitivity and specificity were calculated and compared to the 2-step approach (before and after OCTA) in detecting PCV. The limitations were also evaluated. Results. Of the 50 eyes, 31 were PCV and 19 were non-PCV. The sensitivity increased from 69.5% to 90% after OCTA; however, there was no significant improvement in specificity after OCTA. 70.9% of the eyes with PCV had clear or obvious branching vascular nets (BVNs) in OCTA with high sensitivity (97.5%) after OCTA. Contrarily, 29.1% had insignificant BVNs with a low sensitivity (72.5%) after OCTA. 27% of the occult choroidal neovascularization (CNV) cases were overdiagnosed as PCV when OCTA was applied. Conclusions. OCTA based on clear BVNs at the choroidal level increased sensitivity of diagnosis of PCV by 20%. However, the false-positive rate also increased in occult CNV. Several limitations for a correct diagnosis of PCV were noted.
C1 [Huang, Yi-Ming; Hsieh, Ming-Hung; Li, An-Fei; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 Taipei Veterans General Hospital
RP Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
EM sjchen96@gmail.com
OI Chen, Shih-Jen/0000-0001-9798-1578
CR Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Wakabayashi T, 2008, BRIT J OPHTHALMOL, V92, P936, DOI 10.1136/bjo.2007.132357
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
NR 16
TC 5
Z9 6
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2017
VL 2017
AR 3479695
DI 10.1155/2017/3479695
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FR2MZ
UT WOS:000418902600001
PM 29379653
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Das, RA
   Romano, A
   Chiosi, F
   Menzione, M
   Rinaldi, M
AF Das, R. A.
   Romano, A.
   Chiosi, F.
   Menzione, M.
   Rinaldi, M.
TI Combined Treatment Modalities for Age Related Macular Degeneration
SO CURRENT DRUG TARGETS
LA English
DT Review
DE Choroidal neovascularisation (CNV); age related macular degeneration
   (AMD); retinal degeneration; vascular endothelial growth factor (VEGF);
   verteporfin photodynamic therapy (V-PDT); anti-angiogenic therapies;
   combined therapies
ID ENDOTHELIAL GROWTH-FACTOR; VISION-RELATED FUNCTION; CHOROIDAL
   NEOVASCULARIZATION SECONDARY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   BEVACIZUMAB AVASTIN THERAPY; TRIPLE THERAPY; INTRAVITREAL TRIAMCINOLONE;
   RANIBIZUMAB TREATMENT; PEGAPTANIB SODIUM; SUBGROUP ANALYSIS
AB Background: Age-related macular degeneration (AMD) is a condition that accounts for 75% of cases of legal blindness in individuals over the age of 50. Objectives: The objective of this review has been to evaluate the clinical effectiveness of available combined treatments modalities in the treatment of neovascular AMD. Data Sources: Central and Medline were searched for original research studies (Phase I, II, III), abstracts, and review articles concerning combination therapies for the control of neovascular AMD. We included randomized controlled trials (RCTs). Results: The results of therapeutic trials focused on the actual options in the management of neovascular AMD are discussed. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF) results in a significant increase in visual acuity in patients with neovascular AMD. The combination with occlusive therapies like verteporfin photodynamic therapy (V-PDT) potentially offers a reduction of re-treatment frequency rate and long-term maintenance of the benefit reached. Despite the promise from combining anti-VEGF therapies with V-PDT, other combinations to improve outcomes with V-PDT deserve attention. Corticosteroids demonstrated an antiangiogenic effect and targeted the extravascular components of CNV, such as inflammatory cells and fibrocytes. Nevertheless, the study on the clinical application of corticosteroids will require a better understanding of the potential complications. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available. In AMD the goal of a combination regimen is to address the therapy toward neovascular, inflammatory, and proliferative components of the disease. Conclusions: Combined treatments strategies are an obvious step providing disease control when it is not achieved with a single therapeutic approach. One risk of using a single therapy to control AMD is a rebound induced by compensatory stimulation of other pathogenetic pathways. Combination therapy is a logical approach to address mechanisms of disease progression that appear to be self-sustaining once initiated.
C1 [Romano, A.; Chiosi, F.; Menzione, M.; Rinaldi, M.] Univ Naples 2, Eye Clin, I-80131 Naples, Italy.
   [Das, R. A.] Hosp Selayang Batu Caves, Selayang Eye Dept, Selangor, Malaysia.
C3 Universita della Campania Vanvitelli
RP Rinaldi, M (通讯作者)，Univ Naples 2, Eye Clin, Via S Pansini 5, I-80131 Naples, Italy.
EM michrinaldi@libero.it
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Amoaku WMK, 2008, EYE, V22, P864, DOI 10.1038/eye.2008.1
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin A, 2009, RETINA-J RET VIT DIS, V29, pS5
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   BARRON H, FDA MEDWATCH
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   BOLZ M, 2008, EURETINA C VIENN AUS
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan A, 2009, OPHTHAL SURG LAS IM, V40, P561, DOI 10.3928/15428877-20091030-05
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Deissler H, 2008, BRIT J OPHTHALMOL, V92, P839, DOI 10.1136/bjo.2007.135640
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HOLZ FG, 2008, AAO SOE JOINT ANN M
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2009, RETINA-J RET VIT DIS, V29, pS12
   KAISER PK, 2008, AAO SOE JOINT ANN M
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Markabi S, 2009, RETINA-J RET VIT DIS, V29, pS9
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   National Advisory Eye Council (U.S.), 1993, NIH PUBL
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   OESTER A, 2008, FOCAL POINTS, V26, P1
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   *POS RET SOC, 2007, KLIN MONATSBL AUGENH, V224, P559
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   She HC, 2008, INVEST OPHTH VIS SCI, V49, P5008, DOI 10.1167/iovs.07-1154
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, V4
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P193, DOI 10.1001/archophthalmol.2007.40
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Vinores SA, 2003, CURR OPIN MOL THER, V5, P673
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   2005, 00TINA, V25, P119
   2000, RETINA, V22, P6
   LUCENTIS ONE YEAR
NR 80
TC 8
Z9 8
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD FEB
PY 2011
VL 12
IS 2
BP 182
EP 189
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 720RX
UT WOS:000287299000005
PM 20887244
DA 2022-11-30
ER

PT J
AU Veritti, D
   Sarao, V
   Samassa, F
   Danese, C
   Lowenstein, A
   Schmidt-Erfurth, U
   Lanzetta, P
AF Veritti, Daniele
   Sarao, Valentina
   Samassa, Francesco
   Danese, Carla
   Lowenstein, Anat
   Schmidt-Erfurth, Ursula
   Lanzetta, Paolo
TI State-of-the art pharmacotherapy for non-neovascular age-related macular
   degeneration
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE Age-related macular degeneration; AMD; AREDS; Non-exudative;
   Pharmacotherapy
ID PIGMENT-EPITHELIUM DETACHMENT; CILIARY NEUROTROPHIC FACTOR; OCULAR
   BLOOD-FLOW; GEOGRAPHIC ATROPHY; COMPLEMENT ACTIVATION; INFLAMMATORY
   MARKERS; GLATIRAMER ACETATE; POTENTIAL THERAPY; OXIDATIVE STRESS; FISH
   CONSUMPTION
AB Introduction: Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly in the industrialized world. While effective treatment is available for neovascular AMD, no therapy is successful for the non-neovascular form. Herein, the authors report the current knowledge on non-neovascular AMD pathogenesis and the promising research on treatments. Areas covered: In the present review, the authors summarize the most recent advances in the treatment of non-neovascular AMD and provide an update on current treatment strategies. Evidence available from preclinical and clinical studies and from a selective literature search is reported. Expert opinion: When investigating AMD, numerous pathological cascades and alterations of physiological processes have been investigated. It is well-known that AMD is a multifactorial disease, with environmental causes and genetics playing a role. Perturbations in multiple pathogenic pathways have been identified and this led to the development of several molecules directed at specific therapeutic targets. However, despite the huge research effort, the only proven approach so far is oral antioxidant supplementation. We believe that, in addition to successful advancement of promising drugs, further research should be directed at tailoring therapy to specific patient groups, eventually employing a combinational therapy strategy.
C1 [Veritti, Daniele; Sarao, Valentina; Samassa, Francesco; Danese, Carla; Lanzetta, Paolo] Univ Udine, Dept Med Ophthalmol, Ple Santa Maria Della Misericordia 15, I-33100 Udine, Italy.
   [Sarao, Valentina; Lanzetta, Paolo] IEMO, Udine, Italy.
   [Lowenstein, Anat] Tel Aviv Med Ctr & Sch Med, Div Ophthalmol, Tel Aviv, Israel.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 University of Udine; Tel Aviv University; Sackler Faculty of Medicine;
   Medical University of Vienna
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Med Ophthalmol, Ple Santa Maria Della Misericordia 15, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
RI Danese, Carla/AHE-2872-2022
OI Danese, Carla/0000-0001-7603-7502
CR Aharoni R, 2014, J AUTOIMMUN, V54, P81, DOI 10.1016/j.jaut.2014.05.005
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2013, RETINA, P1213
   Brilliant MH, 2016, AM J MED, V129, P292, DOI 10.1016/j.amjmed.2015.10.015
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   CASTORINA C, 1992, NEUROCHEM RES, V17, P599, DOI 10.1007/BF00968789
   Chen M, 2017, MOL MED REP, V15, P2179, DOI 10.3892/mmr.2017.6271
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Falk TH, 2012, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2012-192
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Francis PJ, 2008, MOL VIS, V14, P1395
   Freeman WR, 2016, AM AC OPHTH AAO 2016
   Gabai A, 2015, INDIAN J OPHTHALMOL, V63, P406, DOI 10.4103/0301-4738.159868
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Georgiou Tassos, 2015, J Stem Cells, V10, P205
   Georgiou Tassos, 2014, PharmaNutrition, V2, P8, DOI 10.1016/j.phanu.2013.10.001
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Jaffe GJ, 2019, AM AC OPHTH AAO 2019
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kolar P, 2013, CLASSIFICATION CLIN
   Landa G, 2008, CURR EYE RES, V33, P1011, DOI 10.1080/02713680802484637
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Mittur A, 2017, CLIN PHARMACOKINET, V56, P999, DOI 10.1007/s40262-017-0511-y
   Nebbioso M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071693
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   Nizari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.397
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Parsons CG, 2015, NEUROPHARMACOLOGY, V92, P158, DOI 10.1016/j.neuropharm.2014.12.038
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pemp B, 2012, ACTA OPHTHALMOL, V90, P139, DOI 10.1111/j.1755-3768.2010.01878.x
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Querques G, 2014, SURV OPHTHALMOL, V59, P532, DOI 10.1016/j.survophthal.2014.01.001
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Resch H, 2009, ACTA OPHTHALMOL, V87, P731, DOI 10.1111/j.1755-3768.2008.01338.x
   RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1
   Rosenfeld PJ, 2018, OPHTHALMOL RETINA, V2, P1028, DOI 10.1016/j.oret.2018.03.001
   Saad L, 2016, ADV EXP MED BIOL, V854, P355, DOI 10.1007/978-3-319-17121-0_47
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Sarao V, 2016, RETINA-J RET VIT DIS, V36, P770, DOI 10.1097/IAE.0000000000000751
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shiragami C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006422
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VANDEWOUDE MFJ, 1987, J AM COLL NUTR, V6, P307, DOI 10.1080/07315724.1987.10720192
   Veritti D, 2019, RETINA-J RET VIT DIS, V39, P2077, DOI 10.1097/IAE.0000000000002299
   Veritti D, 2017, EUR J OPHTHALMOL, V27, P74, DOI 10.5301/ejo.5000880
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 2009, AM J EPIDEMIOL, V169, P633, DOI 10.1093/aje/kwn358
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zarling JA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00325
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 95
TC 8
Z9 8
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PY 2020
VL 21
IS 7
BP 773
EP 784
DI 10.1080/14656566.2020.1736557
EA MAR 2020
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MD5VN
UT WOS:000520334000001
PM 32153203
DA 2022-11-30
ER

PT J
AU Mitchell, P
   Korobelnik, JF
   Lanzetta, P
   Holz, FG
   Pruente, C
   Schmidt-Erfurth, U
   Tano, Y
   Wolf, S
AF Mitchell, P.
   Korobelnik, J-F
   Lanzetta, P.
   Holz, F. G.
   Pruente, C.
   Schmidt-Erfurth, U.
   Tano, Y.
   Wolf, S.
TI Ranibizumab (Lucentis) in neovascular age-related macular degeneration:
   evidence from clinical trials
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; COHERENCE
   TOMOGRAPHY FINDINGS; VISION-RELATED FUNCTION; PHOTODYNAMIC THERAPY;
   VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; SUBGROUP ANALYSIS;
   NATURAL-HISTORY; VERTEPORFIN
AB Background: Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes.
   Methods: An international retina expert panel assessed evidence available from prospective, multicentre studies evaluating different ranibizumab treatment schedules (ANCHOR, MARINA, PIER, SAILOR, SUSTAIN and EXCITE) and a literature search to generate evidence-based and consensus recommendations for treatment indication and assessment, retreatment and monitoring.
   Results: Ranibizumab is indicated for choroidal neovascular lesions with active disease, the clinical parameters of which are outlined. Treatment initiation with three consecutive monthly injections, followed by continued monthly injections, has provided the best visual-acuity outcomes in pivotal clinical trials. If continued monthly injections are not feasible after initiation, a flexible strategy appears viable, with monthly monitoring of lesion activity recommended. Initiation regimens of fewer than three injections have not been assessed. Continuous careful monitoring with flexible retreatment may help avoid vision loss recurring. Standardised biomarkers need to be determined.
   Conclusion: Evidence-based guidelines will help to optimise treatment outcomes with ranibizumab in neovascular AMD.
C1 [Mitchell, P.] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Korobelnik, J-F] CHU Bordeaux, Dept Ophthalmol, Bordeaux, France.
   [Lanzetta, P.] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Holz, F. G.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Pruente, C.; Schmidt-Erfurth, U.] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Tano, Y.] Osaka Univ, Sch Med, Dept Ophthalmol, Osaka, Japan.
   [Wolf, S.] Univ Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Sydney; CHU Bordeaux; University of Udine; University of
   Bonn; Medical University of Vienna; Osaka University; University of
   Bern; University Hospital of Bern
RP Mitchell, P (通讯作者)，Westmead Hosp, Eye Clin B4A, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Wolf, Sebastian/B-8782-2008; KOROBELNIK,
   Jean-Francois/A-5448-2016
OI Wolf, Sebastian/0000-0002-7467-7028; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Novartis Pharma AG, Basel, Switzerland
FX Medical writing assistance was provided under the direction of the
   authors and was funded unconditionally by Novartis Pharma AG, Basel,
   Switzerland.
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   AMOAKU W, EYE IN PRESS
   Amoaku WMK, 2008, EYE, V22, P864, DOI 10.1038/eye.2008.1
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   BOLZ M, 2008, 8 EURETINA C 22 25 M
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   BOYER DS, 2008, AAO SOE JOINT ANN M
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BROWN DM, 2008, AAO SOE JOINT ANN M
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Ceklic L, 2008, OPHTHALMIC RES, V40, P235, DOI 10.1159/000127830
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   DADGOSTAR H, 2008, AAO SOE JOINT ANN M
   DAVANGER M, 1991, ACTA OPHTHALMOL, V69, P561
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Deissler H, 2008, BRIT J OPHTHALMOL, V92, P839, DOI 10.1136/bjo.2007.135640
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   *EYEW ORG, LUC ON YEAR
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HOLZ FG, 2008, AAO SOE JOINT ANN M
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KAISER PK, 2008, AAO SOE JOINT ANN M
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   OESTER A, 2008, FOCAL POINTS, V26, P1
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P1084, DOI 10.1167/iovs.07-1203
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   *POS RET SOC, 2007, KLIN MONATSBL AUGENH, V224, P559
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   REGILLO CD, 2007, AAO
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   *US FDA, 2006, LAB INSTR RAN BLA 12
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   WOLFSCHNURRBUSC.UE, INVEST OPHT IN PRESS
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 75
TC 232
Z9 255
U1 1
U2 35
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2010
VL 94
IS 1
BP 2
EP 13
DI 10.1136/bjo.2009.159160
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 544IW
UT WOS:000273650300002
PM 19443462
DA 2022-11-30
ER

PT J
AU Owsley, C
   McGwin, G
   Scilley, K
   Dreer, LE
   Bray, CR
   Mason, JO
AF Owsley, C
   McGwin, G
   Scilley, K
   Dreer, LE
   Bray, CR
   Mason, JO
TI Focus groups with persons who have age-related macular degeneration:
   Emotional issues
SO REHABILITATION PSYCHOLOGY
LA English
DT Article
DE vision impairment; emotion; age-related macular degeneration; focus
   group
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; SELF-MANAGEMENT;
   PSYCHOMETRIC PROPERTIES; MACULOPATHY; DEPRESSION; IMPACT; PREVALENCE;
   IMPAIRMENT; THERAPY
AB Objective: To identify content areas characterizing emotional issues faced by persons with age-related macular degeneration (AMD). Design and Participants: Six focus groups (N = 53) were conducted with persons having AMD, with discussion addressing feelings about vision. Discussion was audiotaped, transcribed, and subjected to content analysis. Results: Twice as many comments conveyed negative as compared with positive affect. Negative comments communicated feelings of frustration, fear, sadness, and inadequacy. Positive comments addressed gratitude and hope. Positive and negative comments were just as likely regardless of disease severity. The tendency to make positive versus negative comments was related to participants' mental health score on the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) but unrelated to other psychosocially oriented subscales of the NEI VFQ-25 and the presence of probable depression as defined by the 10-item Center for Epidemiological Studies-Depression Scale. Conclusions: When persons with AMD are given the opportunity to frame the emotional accompaniments of vision impairment from their own perspectives, predominantly negative issues were expressed, yet positive emotions were also mentioned. This information can be used for psychoeducational interventions for this population and the selection of emotional outcome measures when evaluating interventions.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Owsley, C (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM owsley@uab.edu
OI Dreer, Laura/0000-0002-4728-5467
CR ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6
   [Anonymous], 2000, FOCUS GROUPS PRACTIC
   Berry S, 2003, OPHTHALMOLOGY, V110, P2285, DOI 10.1016/j.ophtha.2003.08.021
   Brennan M., 2001, J GERONTOL SOC WORK, V35, P107, DOI DOI 10.1300/J083V35N01_
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Brink TL, 1982, CLIN GERONTOLOGIST, V1, P37, DOI DOI 10.1300/J018V01N01_06
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   CHEAVENS JS, IN PRESS SOCIAL INDI
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dreer LE, 2005, REHABIL PSYCHOL, V50, P232, DOI 10.1037/0090-5550.50.3.232
   DZurilla T. J., 2009, HDB COGNITIVE BEHAV
   Elliot TR, 2004, HDB GROUP COUNSELING, P338
   ELLIOTT T, 2000, COGNITIVE BEHAV INTE, P00309
   Elliott T.R., 2002, HDB POSITIVE PSYCHOL, P687
   Elliott TR, 2002, J CLIN PSYCHOL MED S, V9, P65, DOI 10.1023/A:1014931924809
   ELLIOTT TR, 1991, J PERS SOC PSYCHOL, V61, P608, DOI 10.1037/0022-3514.61.4.608
   Emmons RA, 2003, J PERS SOC PSYCHOL, V84, P377, DOI 10.1037/0022-3514.84.2.377
   First M. B., 1995, STRUCTURAL CLIN INTE
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hays RD, 2003, OPHTHALMOLOGY, V110, P2292, DOI 10.1016/j.ophtha.2002.07.001
   Holsti O.R., 1969, CONTENT ANAL SOCIAL
   HOROWITZ AH, 1992, ASSESSING ADAPTATION
   Irwin M, 1999, ARCH INTERN MED, V159, P1701, DOI 10.1001/archinte.159.15.1701
   Jackson WT, 1998, J CLIN PSYCHOL MED S, V5, P173, DOI 10.1023/A:1026259115029
   KAPLAN RM, 1996, QUALITY LIFE PHARMAC, P309
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klausner EJ, 2000, PL S SOC CL, P295
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McNair D.M., 1992, POMS MANUAL PROFILE
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nezu A.M., 1989, PROBLEM SOLVING THER
   Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9
   Owsley C, 2004, AM J PREV MED, V26, P222, DOI 10.1016/j.amepre.2003.12.005
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   RADLOFF L S, 1986, Clinical Gerontologist, V5, P119
   Reinhardt JP, 1996, J GERONTOL B-PSYCHOL, V51, pP268, DOI 10.1093/geronb/51B.5.P268
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Scilley K, 2004, OPHTHAL EPIDEMIOL, V11, P131, DOI 10.1076/opep.11.2.131.28159
   Scilley K, 2002, QUAL LIFE RES, V11, P449, DOI 10.1023/A:1015677501386
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2001, AM J OPHTHALMOL, V131, P584, DOI 10.1016/S0002-9394(01)00832-7
   Shewchuk R, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P553, DOI 10.1037/10361-026
   SNYDER CR, 1991, J PERS SOC PSYCHOL, V60, P570, DOI 10.1037/0022-3514.60.4.570
   Tasman W, 2004, ARCH OPHTHALMOL-CHIC, V122, P648, DOI 10.1001/archopht.122.4.648
   TENNANT C, 1977, MED J AUSTRALIA, V2, P392, DOI 10.5694/j.1326-5377.1977.tb114568.x
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 57
TC 30
Z9 30
U1 0
U2 6
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0090-5550
EI 1939-1544
J9 REHABIL PSYCHOL
JI Rehabil. Psychol.
PD FEB
PY 2006
VL 51
IS 1
BP 23
EP 29
DI 10.1037/0090-5550.51.1.23
PG 7
WC Psychology, Clinical; Rehabilitation
WE Social Science Citation Index (SSCI)
SC Psychology; Rehabilitation
GA 022FH
UT WOS:000236040000004
DA 2022-11-30
ER

PT J
AU Lu, F
   Hu, JB
   Zhao, PQ
   Lin, Y
   Yang, Y
   Liu, XQ
   Fan, YC
   Chen, B
   Liao, SH
   Du, Q
   Lei, CT
   Cameron, DJ
   Kang, Z
   Yang, ZL
AF Lu, Fang
   Hu, Jianbin
   Zhao, Peiquan
   Lin, Ying
   Yang, Yang
   Liu, Xiaoqi
   Fan, Yingchuan
   Chen, Bin
   Liao, Shihuang
   Du, Qiong
   Lei, Chuntao
   Cameron, D. Joshua
   Zhang, Kang
   Yang, Zhenglin
TI HTRA1 variant increases risk to neovascular age-related macular
   degeneration in Chinese population
SO VISION RESEARCH
LA English
DT Article
DE AMD; HTRA1; chinese
ID FACTOR-H; DRUSEN; COMMON; GENE; SUSCEPTIBILITY; ASSOCIATION; LOC387715;
   DISEASE
AB Age-related macular degeneration (AMD) is a leading cause of irreversible visual impairment in the world. Advanced AMD can be divided into wet AMD (choroidal neovascularization) and dry AMD (geographic atrophy, GA). Drusen is characterized by deposits in the macula without visual loss and is an early AMD sign in the Caucasian population. rs11200638 in the promoter of HTRA1 has recently been shown to increases the risk for wet AMD in both Caucasian and Hong Kong Chinese populations. In order to replicate these results in a different cohort, we genotyped rs11200638 for 164 Chinese patients (90 wet AMD and 74 drusen) and 106 normal controls in a Han Mainland Chinese cohort. The genotypes were compared using chi square analysis for an additive allelic model. rs11200638 was significantly associated with wet AMD (p = 5.00 x 10(-12)). Unlike in the Caucasian population, the risk allele of rs11200638 was not associated with drusen in our Chinese population. These findings confirm the association of HTRA1 with wet AMD. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Shanghai Jiao Tong Univ, Xinghua Hosp, Dept Ophthalmol, Shanghai 200092, Peoples R China.
   Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Shanghai Jiao Tong University; Utah System of Higher Education;
   University of Utah
EM kzhang@hmbg.utah.edu; zliny@yahoo.com
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
CR Anderson RE, 2002, MOL VIS, V8, P351
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Muller M, 2001, SCHMERZ, V15, P3, DOI 10.1007/s004820170042
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 17
TC 29
Z9 31
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD NOV
PY 2007
VL 47
IS 24
BP 3120
EP 3123
DI 10.1016/j.visres.2007.08.010
PG 4
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 236VM
UT WOS:000251331500010
PM 17904186
OA Bronze
DA 2022-11-30
ER

PT J
AU Stur, M
   Manor, Y
AF Stur, Michael
   Manor, Yair
TI Long-Term Monitoring of Age-Related Macular Degeneration With
   Preferential Hyperacuity Perimetry
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID SUBGROUP ANALYSIS; CLINICAL-TRIAL; RANIBIZUMAB; FLUCTUATION; FREQUENCY;
   MEMBRANES; GLAUCOMA; PHP
AB BACKGROUND AND OBJECTIVE: To estimate the efficacy and usability of preferential hyperacuity perimetry (PHP) for monitoring patients with high-risk intermediate age-related macular degeneration (AMD).
   PATIENTS AND METHODS: A long-term, observational, prospective case series of patients with intermediate AMD who underwent fluorescein angiography at recruitment. Eyes were examined every 3 months with PHP, visual acuity, and biomicroscopy. Optical coherence tomography (OCT) imaging was performed when PHP was outside normal limits. In case of suspected findings in OCT, fluorescein angiography was also performed. Patients diagnosed as having choroidal neovascularization (CNV) were offered anti-vascular endothelial growth factor therapy.
   RESULTS: Twenty-six eyes (25 patients) were monitored for a mean follow-up period of 600 days. Of the 172 PHP tests done by these 26 eyes with intermediate AMD, 158 were within normal limits yielding a false-positive rate of 8.1%. Three of 4 eyes that converted to CNV had PHP test results outside normal limits before or on the day of diagnosis.
   CONCLUSION: PHP is useful for detecting CNV in regularly monitored eyes with intermediate AMD while maintaining a low false-positive rate.
C1 [Stur, Michael] Netzhautklin, A-1180 Vienna, Austria.
   [Manor, Yair] Notal Vis Ltd, Tel Aviv, Israel.
RP Stur, M (通讯作者)，Netzhautklin, Anton Frankgasse 5, A-1180 Vienna, Austria.
EM michael.stur@reflex.at
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chauhan DS, 1999, INVEST OPHTH VIS SCI, V40, P2332
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   FLAMMER J, 1984, ARCH OPHTHALMOL-CHIC, V102, P704, DOI 10.1001/archopht.1984.01040030560017
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Gonzalez-Hernandez M, 2007, OPHTHALMIC RES, V39, P338, DOI 10.1159/000109997
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kampmeier J, 2006, KLIN MONATSBL AUGENH, V223, P752, DOI 10.1055/s-2006-926880
   Klatt C, 2006, OPHTHALMOLOGE, V103, P945, DOI 10.1007/s00347-006-1381-0
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Watanabe A, 2009, OPHTHALMOLOGY, V116, P1788, DOI 10.1016/j.ophtha.2009.04.046
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
   Zhang N, 2007, AM J OPHTHALMOL, V144, P37, DOI 10.1016/j.ajo.2007.03.056
NR 27
TC 5
Z9 5
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
EI 1938-2375
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD NOV-DEC
PY 2010
VL 41
IS 6
BP 598
EP 606
DI 10.3928/15428877-20100830-05
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA V23XU
UT WOS:000208376300003
PM 20839666
DA 2022-11-30
ER

PT J
AU Kauppinen, A
   Kaarniranta, K
   Salminen, A
AF Kauppinen, Anu
   Kaarniranta, Kai
   Salminen, Antero
TI Potential Role of Myeloid-Derived Suppressor Cells (MDSCs) in
   Age-Related Macular Degeneration (AMD)
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE myeloid-derived suppressor cell; age-related macular degeneration;
   inflammation; innate immunity; adaptive immunity
ID RETINAL-PIGMENT EPITHELIUM; DELTA-T-CELLS; RPE CELLS; CIRCULATING
   MONOCYTES; INFLAMMASOME ACTIVATION; SUBRETINAL MICROGLIA; ANAPHYLATOXIN
   C5A; OXIDATIVE STRESS; CANCER-CELLS; COMPLEMENT
AB Myeloid cells, such as granulocytes/neutrophils and macrophages, have responsibilities that include pathogen destruction, waste material degradation, or antigen presentation upon inflammation. During persistent stress, myeloid cells can remain partially differentiated and adopt immunosuppressive functions. Myeloid-derived suppressor cells (MDSCs) are primarily beneficial upon restoring homeostasis after inflammation. Because of their ability to suppress adaptive immunity, MDSCs can also ameliorate autoimmune diseases and semi-allogenic responses, e.g., in pregnancy or transplantation. However, immunosuppression is not always desirable. In certain conditions, such as cancer or chronically inflamed tissue, MDSCs prevent restorative immune responses and thereby aggravate disease progression. Age-related macular degeneration (AMD) is the most common disease in Western countries that severely threatens the central vision of aged people. The pathogenesis of this multifactorial disease is not fully elucidated, but inflammation is known to participate in both dry and wet AMD. In this paper, we provide an overview about the potential role of MDSCs in the pathogenesis of AMD.
C1 [Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland; University of
   Eastern Finland
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland.
EM anu.kauppinen@uef.fi
FU Academy of Finland [AK297267, AK307341, KK296840, AK328443]; Kuopio
   University Hospital VTR grant [KK5503743]; Emil Aaltonen Foundation;
   Sigrid Juselius Foundation; Paivikki and Sakari Sohlberg Foundation;
   Finnish Cultural Foundation; Finnish Eye Foundation
FX PThis study was financially supported by the grants from the Academy of
   Finland (AK297267, AK307341, KK296840, and AK328443), the Kuopio
   University Hospital VTR grant (KK5503743), the Emil Aaltonen Foundation,
   the Sigrid Juselius Foundation, the Paivikki and Sakari Sohlberg
   Foundation, the Finnish Cultural Foundation, and the Finnish Eye
   Foundation.
CR Adamus G, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-154
   Ajona D, 2007, J IMMUNOL, V178, P5991, DOI 10.4049/jimmunol.178.9.5991
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150
   Bunt SK, 2009, J LEUKOCYTE BIOL, V85, P996, DOI 10.1189/jlb.0708446
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Carbone C, 2011, CLIN CANCER RES, V17, P5822, DOI 10.1158/1078-0432.CCR-11-1185
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Chou HS, 2011, HEPATOLOGY, V53, P1007, DOI 10.1002/hep.24162
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304
   Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002
   Consonni FM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00949
   Corrales L, 2012, J IMMUNOL, V189, P4674, DOI 10.4049/jimmunol.1201654
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Darling VR, 2015, EXPERT REV CLIN IMMU, V11, P255, DOI 10.1586/1744666X.2015.983081
   De Wilde V, 2009, AM J TRANSPLANT, V9, P2034, DOI 10.1111/j.1600-6143.2009.02757.x
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Downs-Canner S, 2016, ANN SURG ONCOL, V23, P655, DOI 10.1245/s10434-015-4778-7
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dvashi Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122229
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Ekkens MJ, 2007, INFECT IMMUN, V75, P2291, DOI 10.1128/IAI.01328-06
   Faber C, 2015, ACTA OPHTHALMOL, V93, P242, DOI 10.1111/aos.12581
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fan QP, 2014, CANCER RES, V74, P471, DOI 10.1158/0008-5472.CAN-13-2134-T
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055
   Futagami Y, 2007, J IMMUNOL, V178, P6994, DOI 10.4049/jimmunol.178.11.6994
   Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Ghosh S, 2017, J PATHOL, V241, P583, DOI 10.1002/path.4870
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Gregerson DS, 2007, INVEST OPHTH VIS SCI, V48, P4654, DOI 10.1167/iovs.07-0286
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hsieh CC, 2013, BLOOD, V121, P1760, DOI 10.1182/blood-2012-06-440214
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299
   Iacobaeus E, 2018, IMMUNOL CELL BIOL, V96, P820, DOI 10.1111/imcb.12042
   Ioannou M, 2012, J IMMUNOL, V188, P1136, DOI 10.4049/jimmunol.1101816
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Jeong HJ, 2018, J IMMUNOL, V200, P1306, DOI 10.4049/jimmunol.1700617
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawanaka N, 2011, J NEUROIMMUNOL, V232, P17, DOI 10.1016/j.jneuroim.2010.09.025
   Ke Y, 2010, J LEUKOCYTE BIOL, V88, P1241, DOI 10.1189/jlb.0610332
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1647, DOI 10.1016/j.ophtha.2019.06.023
   Kerr EC, 2008, J AUTOIMMUN, V31, P354, DOI 10.1016/j.jaut.2008.08.006
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim JA, 2010, BLOOD, V116, P1623, DOI 10.1182/blood-2009-08-237040
   Kondo M, 2010, IMMUNOL REV, V238, P37, DOI 10.1111/j.1600-065X.2010.00963.x
   Kwak Y, 2015, ARCH IMMUNOL THER EX, V63, P269, DOI 10.1007/s00005-015-0342-1
   Lee D, 2017, CELL MOL LIFE SCI, V74, P1793, DOI 10.1007/s00018-016-2432-6
   Lee HJ, 2015, J IMMUNOL, V194, P3634, DOI 10.4049/jimmunol.1402139
   Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240
   Li Y, 2014, J IMMUNOL, V193, P2127, DOI 10.4049/jimmunol.1400857
   Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Ma WX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08702-7
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655
   McHugh KJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216215
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nitta H, 2014, ONCOL REP, V32, P1715, DOI 10.3892/or.2014.3341
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825
   Ostrand-Rosenberg S, 2020, CANCER IMMUNOL IMMUN, V69, P215, DOI 10.1007/s00262-019-02388-8
   Pan PY, 2010, CANCER RES, V70, P99, DOI 10.1158/0008-5472.CAN-09-1882
   Parsons N, 2019, MOL IMMUNOL, V108, P8, DOI 10.1016/j.molimm.2019.02.001
   Pawelec G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01099
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Saban DR, 2018, CELL IMMUNOL, V330, P79, DOI 10.1016/j.cellimm.2018.04.008
   Saika S, 2006, LAB INVEST, V86, P106, DOI 10.1038/labinvest.3700375
   Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sendo S, 2018, INFLAMM REGEN, V38, DOI 10.1186/s41232-018-0076-7
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621
   Shi Q, 2015, INVEST OPHTH VIS SCI, V56, P7728, DOI 10.1167/iovs.15-17677
   Silverman MD, 2003, INVEST OPHTH VIS SCI, V44, P1608, DOI 10.1167/iovs.02-0233
   Sin M, 2014, BIOMED PAP, V158, P138, DOI 10.5507/bp.2012.066
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977
   Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Sugita S, 2010, INVEST OPHTH VIS SCI, V51, P5783, DOI 10.1167/iovs.09-5098
   Sugita S, 2008, J IMMUNOL, V181, P7525, DOI 10.4049/jimmunol.181.11.7525
   Sunthamala N, 2014, BIOCHEM BIOPH RES CO, V446, P977, DOI 10.1016/j.bbrc.2014.03.042
   Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883
   Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tu ZD, 2012, INVEST OPHTH VIS SCI, V53, P959, DOI 10.1167/iovs.11-8377
   Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x
   Was H, 2010, CURR DRUG TARGETS, V11, P1551, DOI 10.2174/1389450111009011551
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Yoneda M, 2019, ONCOL LETT, V17, P913, DOI 10.3892/ol.2018.9715
   Yu Y, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0251-z
   Zhao JW, 2014, INVEST OPHTH VIS SCI, V55, P7572, DOI 10.1167/iovs.14-15495
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zhao Y, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1004983
   Zhao ZY, 2017, FASEB J, V31, P4903, DOI 10.1096/fj.201700533R
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
   Zhu B, 2011, J IMMUNOL, V187, P2418, DOI 10.4049/jimmunol.1100403
NR 150
TC 3
Z9 3
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 20
PY 2020
VL 11
AR 384
DI 10.3389/fimmu.2020.00384
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA KZ7DB
UT WOS:000523417100001
PM 32265903
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Swaroop, A
   Branham, KEH
   Chen, W
   Abecasis, G
AF Swaroop, Anand
   Branham, Karl E. H.
   Chen, Wei
   Abecasis, Goncalo
TI Genetic susceptibility to age-related macular degeneration: a paradigm
   for dissecting complex disease traits
SO HUMAN MOLECULAR GENETICS
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; FACTOR-H POLYMORPHISM; APOLIPOPROTEIN-E
   POLYMORPHISMS; BEAVER DAM EYE; C-REACTIVE PROTEIN; BODY-MASS INDEX;
   STARGARDT-DISEASE; EXTENDED FAMILIES; ALLELIC VARIATION; CHROMOSOME
   10Q26
AB Age-related macular degeneration (AMD) is a progressive neurodegenerative disease, which affects quality of life for millions of elderly individuals worldwide. AMD is associated with a diverse spectrum of clinical phenotypes, all of which include the death of photoreceptors in the central part of the human retina (called the macula). Tremendous progress has been made in identifying genetic susceptibility variants for AMD. Variants at chromosome 1q32 (in the region of CFH) and 10q26 (LOC387715/ARMS2) account for a large part of the genetic risk to AMD and have been validated in numerous studies. In addition, susceptibility variants at other loci, several as yet unidentified, make substantial cumulative contribution to genetic risk for AMD; among these, multiple studies support the role of variants in APOE and C2/BF genes. Genome-wide association and re-sequencing projects, together with gene-environment interaction studies, are expected to further define the causal relationships that connect genetic variants to AMD pathogenesis and should assist in better design of prevention and intervention.
C1 Univ Michigan, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Biostat, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Swaroop, A (通讯作者)，Univ Michigan, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
EM swaroop@umich.edu; Goncalo@umich.edu
RI Chen, Wei/AAX-5994-2020; Branham, Kari/AAA-8336-2022; Abecasis, Goncalo
   R/B-7840-2010
OI Chen, Wei/0000-0001-7196-8703; Swaroop, Anand/0000-0002-1975-1141;
   Branham, Kari/0000-0002-2492-254X; Abecasis, Goncalo/0000-0003-1509-1825
FU NEI NIH HHS [EY 016862] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [Z01EY000449, R01EY016862] Funding Source: NIH RePORTER
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 1999, HUM GENET, V104, P449, DOI 10.1007/s004390050986
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2007, CLIN EXP OPHTHALMOL, V35, P194, DOI 10.1111/j.1442-9071.2007.01477.x
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bentley DR, 2006, CURR OPIN GENET DEV, V16, P545, DOI 10.1016/j.gde.2006.10.009
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090
   BRESSLER S, 1999, RETINA VITREOUS MACU, V1, P79
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2004, AM J OPHTHALMOL, V138, P567, DOI 10.1016/j.ajo.2004.05.025
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KANDA A, 2007, IN PRESS PNAS
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lernmark A, 1998, NAT GENET, V19, P213, DOI 10.1038/881
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058
   Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morton NE, 1998, P NATL ACAD SCI USA, V95, P11389, DOI 10.1073/pnas.95.19.11389
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Romeo S, 2007, NAT GENET, V39, P513, DOI 10.1038/ng1984
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Schmidt S, 2000, MOL VIS, V6, P287
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 129
TC 151
Z9 152
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2007
VL 16
SI 2
BP R174
EP R182
DI 10.1093/hmg/ddm212
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 234LL
UT WOS:000251165500008
PM 17911160
OA hybrid
DA 2022-11-30
ER

PT J
AU He, Y
   Guo, Y
   Wang, JC
   Lv, WX
   Li, X
   Chen, K
AF He, Yuan
   Guo, Yue
   Wang, Jingchao
   Lv, Wenxin
   Li, Xuan
   Chen, Kinon
TI The posterior eye with age-related macular degeneration has isotropic
   and nonlinear viscoelastic properties
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Mechanical properties; Material constants; Retina; Choroid; Sclera
ID MECHANICAL CHARACTERISTICS; PERIPAPILLARY SCLERA; VISUAL IMPAIRMENT;
   BEHAVIOR; ATHEROSCLEROSIS; DISEASE; PREVALENCE; RETINA
AB Here we characterize and compare the anisotropic and nonlinear viscoelastic properties of the posterior eye of advanced dry age-related macular degeneration (AMD) patients and age-matched normal subjects. Ten normal horizontal, ten normal vertical, ten AMD horizontal, and ten AMD vertical strips of the macular retina and the underlying choroid and sclera were preloaded, preconditioned, and subjected to incremental stress-relaxation tests in body-temperature saline. The stress-relaxation response was characterized by a fully nonlinear viscoelastic formulation in which the relaxation modulus was approximated by a Pmny series and a second-order polynomial using the comprehensive viscoelastic characterization method. Normal retina, choroid, and sclera were found to be anisotmpic, whereas AMD tissues were isotropic. AMD retina and choroid showed greater stress-relaxation response than normal tissues (p < 0.05), whereas AMD sclera had smaller stress-relaxation response than normal tissue (p < 0.05). The nonlinear viscoelastic stress-strain relationship of the posterior eye is hence describable for the first time.
C1 [He, Yuan; Guo, Yue; Wang, Jingchao; Lv, Wenxin; Li, Xuan; Chen, Kinon] Beihang Univ BUAA, Sch Biol Sci & Med Engn, Yifu Sci Hall,37 Xueyuan Rd, Beijing 100191, Peoples R China.
   [He, Yuan; Guo, Yue; Wang, Jingchao; Lv, Wenxin; Li, Xuan; Chen, Kinon] BUAA, Beijing Adv Innovat Ctr Biomed Engn, Beijing 100191, Peoples R China.
C3 Beihang University
RP Chen, K (通讯作者)，Beihang Univ BUAA, Sch Biol Sci & Med Engn, Yifu Sci Hall,37 Xueyuan Rd, Beijing 100191, Peoples R China.
EM chen0606@umn.edu
OI Li, Xuan/0000-0002-5189-5591
FU Beijing Natural Science Foundation [7154215]; National Natural Science
   Foundation of China [81771347]
FX This work is supported by the Beijing Natural Science Foundation
   (project no. 7154215) and the National Natural Science Foundation of
   China (project no. 81771347).
CR ARCINIEGAS A, 1986, OPHTHALMOLOGICA, V193, P45, DOI 10.1159/000309678
   Chen KN, 2014, J BIOMED MATER RES A, V102, P2001, DOI 10.1002/jbm.a.34858
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   Chen KN, 2013, J MECH BEHAV BIOMED, V26, P54, DOI 10.1016/j.jmbbm.2013.05.015
   Chen K, 2012, RETINA-J RET VIT DIS, V32, P844, DOI 10.1097/IAE.0b013e318225d0c9
   Chen KN, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004289
   Chen K, 2010, J BIOMECH, V43, P1417, DOI 10.1016/j.jbiomech.2009.09.056
   Chen K, 2010, J BIOMED MATER RES A, V93A, P634, DOI 10.1002/jbm.a.32571
   Curtin B J, 1969, Trans Am Ophthalmol Soc, V67, P417
   DEGUILLEBON H, 1972, ARCH OPHTHALMOL-CHIC, V87, P545, DOI 10.1001/archopht.1972.01000020547012
   Downs JC, 2003, J BIOMECH ENG-T ASME, V125, P124, DOI 10.1115/1.1536930
   Downs JC, 2005, INVEST OPHTH VIS SCI, V46, P540, DOI 10.1167/iovs.04-0114
   Elsheikh A, 2010, EXP EYE RES, V90, P624, DOI 10.1016/j.exer.2010.02.010
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Forgacs G, 1998, BIOPHYS J, V74, P2227, DOI 10.1016/S0006-3495(98)77932-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung YC, 1981, BIOMECHANICS MECH PR
   GLOSTER J, 1957, Br J Ophthalmol, V41, P103, DOI 10.1136/bjo.41.2.103
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Klein R, 2013, OPHTHALMOLOGY, V120, P1012, DOI 10.1016/j.ophtha.2012.11.003
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nayar VT, 2012, TISSUE ENG PART C-ME, V18, P968, DOI [10.1089/ten.tec.2012.0034, 10.1089/ten.TEC.2012.0034]
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Palko JR, 2011, EXP EYE RES, V93, P825, DOI 10.1016/j.exer.2011.09.018
   Ramo NL, 2018, ACTA BIOMATER, V68, P78, DOI 10.1016/j.actbio.2017.12.024
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   SCHLEGEL WA, 1972, INVEST OPHTH VISUAL, V11, P593
   Shetye SS, 2014, ACTA BIOMATER, V10, P792, DOI 10.1016/j.actbio.2013.10.038
   STHELEN R, 1961, AM J OPHTHALMOL, V52, P539
   Troyer KL, 2012, J BIOMECH ENG-T ASME, V134, DOI 10.1115/1.4007630
   Troyer KL, 2012, J BIOMECH, V45, P684, DOI 10.1016/j.jbiomech.2011.12.009
   Troyer KL, 2012, ACTA BIOMATER, V8, P234, DOI 10.1016/j.actbio.2011.07.035
   Troyer KL, 2011, ACTA BIOMATER, V7, P700, DOI 10.1016/j.actbio.2010.09.003
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   WU W, 1987, J BIOMECH ENG-T ASME, V109, P65, DOI 10.1115/1.3138644
   Zhang ZH, 2018, J BIOMED MATER RES A, V106, P2151, DOI 10.1002/jbm.a.36417
NR 39
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1751-6161
EI 1878-0180
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD FEB
PY 2021
VL 114
AR 104207
DI 10.1016/j.jmbbm.2020.104207
PG 4
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA PS8MQ
UT WOS:000608178400008
PM 33307420
DA 2022-11-30
ER

PT J
AU Zuo, XT
   Zhuang, J
   Chen, NK
   Cousins, S
   Cunha, P
   Lad, EM
   Madden, DJ
   Potter, G
   Whitson, HE
AF Zuo, Xintong
   Zhuang, Jie
   Chen, Nan-kuei
   Cousins, Scott
   Cunha, Priscila
   Lad, Eleonora M.
   Madden, David J.
   Potter, Guy
   Whitson, Heather E.
TI Relationship between neural functional connectivity and memory
   performance in age-related macular degeneration
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE AMD; DMN; Episodic memory; Older adults; LPHC; Visual impairment
ID DEFAULT-MODE NETWORK; WHITE-MATTER INTEGRITY; COGNITIVE IMPAIRMENT;
   ALZHEIMERS-DISEASE; EPISODIC MEMORY; VISION IMPAIRMENT; BRAIN; DECLINE;
   DISCONNECTION; HIPPOCAMPAL
AB Age-related macular degeneration (AMD) has been linked to memory deficits, with no established neural mechanisms. We collected resting-state brain functional magnetic resonance imaging and standardized verbal recall tests from 42 older adults with AMD and 41 age-matched controls. We used seed-based whole brain analysis to quantify the strength of functional connectivity between hubs of the default mode network and a network of medial temporal regions relevant for memory. Our results indicated neither memory performance nor network connectivity differed by AMD status. However, the AMD participants exhibited stronger relationships than the controls between memory performance and connectivity from the memory network hub (left parahippocampal) to 2 other regions: the left temporal pole and the right superior/middle frontal gyri. Also, the connectivity between the medial prefrontal cortex and posterior cingulate cortex of default mode network correlated more strongly with memory performance in AMD compared to control. We concluded that stronger brain-behavior correlation in AMD may suggest a role for region-specific connectivity in supporting memory in the context of AMD. Published by Elsevier Inc.
C1 [Zuo, Xintong] Univ Hawaii, Dept Internal Med, Honolulu, HI 96822 USA.
   [Zuo, Xintong; Cunha, Priscila; Whitson, Heather E.] Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA.
   [Zhuang, Jie; Chen, Nan-kuei; Madden, David J.] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC USA.
   [Cousins, Scott; Lad, Eleonora M.; Whitson, Heather E.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Cunha, Priscila] Duke Univ, Sch Med, Durham, NC USA.
   [Madden, David J.; Potter, Guy] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Whitson, Heather E.] Duke Univ, Med Ctr, Dept Med Geriatr, Durham, NC USA.
   [Whitson, Heather E.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA.
C3 University of Hawaii System; Duke University; Duke University; Duke
   University; Duke University; Duke University; Duke University; Geriatric
   Research Education & Clinical Center; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Durham VA Medical Center
RP Whitson, HE (通讯作者)，Duke Univ, Dept Med, DUMC 3003, Durham, NC 27710 USA.
EM heather.whitson@duke.edu
RI ; Chen, Nan-kuei/E-7791-2016
OI Whitson, Heather/0000-0002-8417-4846; Chen,
   Nan-kuei/0000-0001-6564-4219; Madden, David/0000-0003-2815-6552
FU National Institute of Health [R01AG043438, K23EY026988, R01 AG039684,
   R56 AG052576];  [P30AG028716];  [U13AG054139];  [UL1TR002553]
FX The authors gratefully acknowledge the contributions of study staff
   members including Alice Ventura, Abigail Maciejewski, Xuan Duong
   Fernandez, and Kala Allen. This work was supported by the National
   Institute of Health R01AG043438 (HEW), K23EY026988 (EL), R01 AG039684
   (DJM PI), and R56 AG052576 (DJM PI). The following grants further
   contributed to the efforts and ideas presented here: P30AG028716,
   U13AG054139, UL1TR002553.
CR Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038
   Andrews-Hanna JR, 2014, ANN NY ACAD SCI, V1316, P29, DOI 10.1111/nyas.12360
   Anthony M, 2018, ARCH CLIN NEUROPSYCH, V33, P937, DOI 10.1093/arclin/acx125
   Anticevic A, 2012, TRENDS COGN SCI, V16, P584, DOI 10.1016/j.tics.2012.10.008
   Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Barredo J, 2015, CEREB CORTEX, V25, P1004, DOI 10.1093/cercor/bht291
   Barrick TR, 2010, NEUROIMAGE, V51, P565, DOI 10.1016/j.neuroimage.2010.02.033
   Bennett IJ, 2014, NEUROSCIENCE, V276, P187, DOI 10.1016/j.neuroscience.2013.11.026
   Besteher B, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00467
   Brier MR, 2012, J NEUROSCI, V32, P8890, DOI 10.1523/JNEUROSCI.5698-11.2012
   Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011
   Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585
   CDC, 2017, COMM EYE DIS
   Chen SP, 2017, JAMA OPHTHALMOL, V135, P963, DOI 10.1001/jamaophthalmol.2017.2838
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Corporation T.R., 1997, WAIS 3 WMS 3 TECHNIC
   De Simoni S, 2016, BRAIN, V139, P3137, DOI 10.1093/brain/aww241
   Evans J, 2017, JAMA OPHTHALMOL, V135, P971, DOI 10.1001/jamaophthalmol.2017.2843
   Fair DA, 2007, NEUROIMAGE, V35, P396, DOI 10.1016/j.neuroimage.2006.11.051
   Fjell AM, 2017, CEREB CORTEX, V27, P2303, DOI 10.1093/cercor/bhw082
   Fjell AM, 2010, REV NEUROSCIENCE, V21, P187, DOI 10.1515/revneuro.2010.21.3.187
   Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102
   Gili T, 2011, J NEUROL NEUROSUR PS, V82, P58, DOI 10.1136/jnnp.2009.199935
   Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008
   Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101
   Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100
   Griffanti L, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00449
   Hafkemeijer A, 2012, BBA-MOL BASIS DIS, V1822, P431, DOI 10.1016/j.bbadis.2011.07.008
   Huijbers W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017463
   HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172
   Jeong W, 2015, FRONT HUM NEUROSCI, V9, DOI [10.3339/fnhum.2015.00454, 10.3389/fnhum.2015.00454]
   Kennedy KM, 2005, J COGNITIVE NEUROSCI, P140
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Kramer JH, 2005, NEUROPSYCHOLOGY, V19, P799, DOI 10.1037/0894-4105.19.6.799
   Lech RK, 2013, BEHAV BRAIN RES, V254, P45, DOI 10.1016/j.bbr.2013.06.009
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   Lindekleiv H, 2013, EYE, V27, P1281, DOI 10.1038/eye.2013.181
   Madden D.J., 2017, COGNITIVE NEUROSCIEN, P71
   Madden DJ, 2017, NEUROBIOL AGING, V54, P199, DOI 10.1016/j.neurobiolaging.2017.01.027
   Madden DJ, 2012, BBA-MOL BASIS DIS, V1822, P386, DOI 10.1016/j.bbadis.2011.08.003
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Mitchell TW, 2002, ANN NEUROL, V51, P182, DOI 10.1002/ana.10086
   Monge ZA, 2016, NEUROSCI BIOBEHAV R, V69, P166, DOI 10.1016/j.neubiorev.2016.07.031
   Morrison JH, 2012, NAT REV NEUROSCI, V13, P240, DOI 10.1038/nrn3200
   NIH, 2011, FACTS AG REL MAC DEG
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Prins D, 2016, ACTA OPHTHALMOL, V94, P113, DOI 10.1111/aos.12825
   Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819
   Raichle ME, 2005, J COMP NEUROL, V493, P167, DOI 10.1002/cne.20752
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Shankar SK, 2010, INDIAN J PATHOL MICR, V53, P595, DOI 10.4103/0377-4929.71995
   Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175
   Smagula SF, 2018, AM J GERIAT PSYCHIAT, V26, P690, DOI 10.1016/j.jagp.2018.03.003
   Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008
   Szlyk JP, 2009, INVEST OPHTH VIS SCI, V50, P4487, DOI 10.1167/iovs.08-2258
   Tay T, 2006, GERONTOLOGY, V52, P386, DOI 10.1159/000095129
   Tromp D, 2015, AGEING RES REV, V24, P232, DOI 10.1016/j.arr.2015.08.006
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Tun PA, 2006, AGE AGEING, V35, P629, DOI 10.1093/ageing/afl095
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009
   Varin M, 2020, OPHTHALMOLOGY, V127, P660, DOI 10.1016/j.ophtha.2019.10.004
   Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006
   Ward AM, 2015, NEUROBIOL AGING, V36, P265, DOI 10.1016/j.neurobiolaging.2014.06.028
   Ward AM, 2014, HUM BRAIN MAPP, V35, P1061, DOI 10.1002/hbm.22234
   Whitson HE, 2007, J AM GERIATR SOC, V55, P885, DOI 10.1111/j.1532-5415.2007.01093.x
   Whitson HE, 2012, J AM GERIATR SOC, V60, P2087, DOI 10.1111/j.1532-5415.2012.04194.x
   Whitson HE, 2010, ARCH GERONTOL GERIAT, V50, P209, DOI 10.1016/j.archger.2009.03.010
   Wong TY, 2002, AM J OPHTHALMOL, V134, P828
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
   Zhuang J, 2018, NEUROBIOL AGING, V63, P65, DOI 10.1016/j.neurobiolaging.2017.11.003
NR 76
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD NOV
PY 2020
VL 95
BP 176
EP 185
DI 10.1016/j.neurobiolaging.2020.07.020
PG 10
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA OI5IV
UT WOS:000583312900018
PM 32829250
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yuksel, K
   Altinkaynak, H
   Kina, A
   Kara, N
   Yazici, AT
   Demirok, A
AF Yuksel, Kemal
   Altinkaynak, Hasan
   Kina, Adnan
   Kara, Necip
   Yazici, Ahmet Taylan
   Demirok, Ahmet
TI Can Intravitreal Ranibizumab Alter Retrobulbar Circulation in Eyes with
   Age-Related Macular Degeneration?
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; BLOOD-FLOW; BEVACIZUMAB AVASTIN(R);
   PATHOGENESIS; MACULOPATHY; PREVALENCE; RESOLUTION; GLAUCOMA; THERAPY;
   ORBIT
AB Purpose: To determine the effect of a single intravitreal ranibizumab injection on retrobulbar circulation in cases with neovascular age-related macular degeneration (AMD). Methods: In this prospective and interventional study, 32 patients with neovascular AMD were enrolled. A single intravitreal ranibizumab dose was in only 1 eye per patient. Peak systolic velocity, end-diastolic velocity, resistive index and pulsatility index values in the common carotid artery, ophthalmic artery, central retinal artery, nasal posterior ciliary artery, and temporal posterior ciliary artery in both injected and uninjected healthy fellow eyes were measured using color Doppler ultrasonography at baseline and 1 week and 1 month after the injection of ranibizumab. Results: All measurements revealed no statistically significant difference among baseline, first week, and first month after injection measurements for all parameters measured in all arteries in both the injected and uninjected healthy fellow eyes. Conclusion: A single intravitreal injection of ranibizumab does not significantly affect on retrobulbar circulation of either the injected or the uninjected healthy fellow eyes with neovascular AMD.
C1 [Yuksel, Kemal; Altinkaynak, Hasan; Yazici, Ahmet Taylan; Demirok, Ahmet] Beyoglu Eye Res & Educ Hosp, Dept Ophthalmol, TR-34001 Istanbul, Turkey.
   [Kina, Adnan] Taksim Educ & Res Hosp, Dept Radiol, Istanbul, Turkey.
   [Kara, Necip] Kanuni Sultan Suleyman Educ & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Istanbul Gaziosmanpasa Taksim Training & Research Hospital;
   Istanbul Kanuni Sultan Suleyman Training & Research Hospital
RP Altinkaynak, H (通讯作者)，Beyoglu Eye Res & Educ Hosp, Dept Ophthalmol, Silivri Kapi Mah,Yenicesme Sokak Besler Apt 43-3, TR-34001 Istanbul, Turkey.
EM altinkaynak167@yahoo.com
RI Demirok, Ahmet/AAE-1713-2020; Altinkaynak, Hasan/V-6058-2017
OI Demirok, Ahmet/0000-0001-8197-2458; 
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Distler Oliver, 2002, Int Rev Immunol, V21, P33, DOI 10.1080/08830180210415
   ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Galassi F, 2003, ARCH OPHTHALMOL-CHIC, V121, P1711, DOI 10.1001/archopht.121.12.1711
   Gherghel D, 2000, AM J OPHTHALMOL, V130, P597, DOI 10.1016/S0002-9394(00)00766-2
   Harris A, 1995, J Glaucoma, V4, P281
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P1055, DOI 10.1136/bjo.80.12.1055
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   LIEB WE, 1991, OPHTHALMOLOGY, V98, P548
   LIEB WE, 1992, ACTA OPHTHALMOL, V70, P50
   Mete A, 2012, OPHTHALMIC RES, V47, P141, DOI 10.1159/000330509
   Mete A, 2010, J CLIN ULTRASOUND, V38, P66, DOI 10.1002/jcu.20650
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Stalmans I, 2011, ACTA OPHTHALMOL, V89, pe609, DOI 10.1111/j.1755-3768.2011.02178.x
   Stalmans I, 2009, GRAEF ARCH CLIN EXP, V247, P1531, DOI 10.1007/s00417-009-1178-3
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wang YM, 2009, OPT EXPRESS, V17, P4061, DOI 10.1364/OE.17.004061
   Wang YM, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2998480
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
NR 33
TC 3
Z9 3
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT 1
PY 2013
VL 29
IS 8
BP 723
EP 727
DI 10.1089/jop.2013.0051
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 224UR
UT WOS:000324915900005
PM 23829173
DA 2022-11-30
ER

PT J
AU Wang, L
   Lee, AYW
   Wigg, JP
   Peshavariya, H
   Liu, P
   Zhang, H
AF Wang, Lei
   Lee, Amy Yi Wei
   Wigg, Jonathan P.
   Peshavariya, Hitesh
   Liu, Ping
   Zhang, Hong
TI miRNA involvement in angiogenesis in age-related macular degeneration
SO JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE miR-93; Age-related macular degeneration; Choroidal neovascularization;
   VEGF-A; HMEC
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION;
   DOWN-REGULATION; MICRORNAS; CELLS; IDENTIFICATION; EXPRESSION; MEMBERS;
   TARGET; MODEL
AB Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. Late-stage AMD is characterized by choroidal neovascularization (CNV). miR-93 appears to play a role in regulating vascular endothelial growth factor-A (VEGF-A), a known factor involved in neovascularization. Understanding its biological significance might enable development of therapeutic interventions for diseases like AMD. We aimed to determine the role of miR-93 in AMD using a laser-induced CNV mouse model. CNV was induced by laser photocoagulation in C57BL/6 mice. The CNV mice were transfected with scrambled miR or miR-93 mimic. The treatment effect was assessed by fundus photography and fluorescein angiography and confirmed by choroidal flatmount. The expression of miR-93 and VEGF-A in ocular tissues was analysed by quantitative polymerase chain reaction (qPCR) and Western blot. The overexpression effects of miR-93 were also proved on human microvascular endothelial cells (HMECs). Significantly decreased expression of miR-93 was observed by qPCR analysis in CNV mice compared to untreated mice (p < 0.05). VEGF-A messenger RNA (mRNA) and protein expression were upregulated with CNV; these changes were ameliorated by restoration of miR-93 (p < 0.05). CNV was reduced after miR-93 transfection. Transfection of miR-93 reduced the proliferation of HMECs (p < 0.01), but no significant changes were observed in 2D capillary-like tube formation (p > 0.05) and migration (p > 0.05) compared with that in the untreated cells. miR-93 has been shown to be a negative modulator of angiogenesis in the eye. All together, these results highlight the therapeutic potential of miR-93 and suggest that it may contribute as a putative therapeutic target for AMD in humans.
C1 [Wang, Lei; Liu, Ping; Zhang, Hong] Harbin Med Univ, Hosp Eye, 23 Youzheng St, Harbin, Heilongjiang Pr, Peoples R China.
   [Lee, Amy Yi Wei] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia.
   [Lee, Amy Yi Wei] Ctr Eye Res Australia, Drug Delivery Unit, Melbourne, Vic, Australia.
   [Wigg, Jonathan P.; Peshavariya, Hitesh; Zhang, Hong] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
C3 Harbin Medical University; University of Melbourne; Centre for Eye
   Research Australia; Centre for Eye Research Australia; Royal Victorian
   Eye & Ear Hospital; University of Melbourne
RP Liu, P (通讯作者)，Harbin Med Univ, Hosp Eye, 23 Youzheng St, Harbin, Heilongjiang Pr, Peoples R China.; Zhang, H (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM pingliu53@126.com; hong.zhang@unimelb.edu.au
RI Zhang, Hong/AAX-9632-2020
CR Behrens-Baumann W, 2002, ANTISEPTIC PROPHYLAX
   Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Caporali A, 2011, VASC PHARMACOL, V55, P79, DOI 10.1016/j.vph.2011.06.006
   Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Doebele C, 2010, BLOOD, V115, P4944, DOI 10.1182/blood-2010-01-264812
   Du L, 2014, ONCOGENE, V33, P4307, DOI 10.1038/onc.2013.381
   Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465
   Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670
   Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Kamal K, 1998, J CELL BIOCHEM, V71, P491, DOI 10.1002/(SICI)1097-4644(19981215)71:4<491::AID-JCB4>3.0.CO;2-P
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kuehbacher A, 2008, TRENDS PHARMACOL SCI, V29, P12, DOI 10.1016/j.tips.2007.10.014
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Leeper NJ, 2011, CIRCULATION, V123, P236, DOI 10.1161/CIRCULATIONAHA.110.003855
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Liu LD, 2011, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2011-2
   Long JY, 2010, J BIOL CHEM, V285, P23455, DOI 10.1074/jbc.M110.136168
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   Mulik S, 2012, AM J PATHOL, V181, P525, DOI 10.1016/j.ajpath.2012.04.014
   Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003
   Roberts TC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.40
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Schlenker MB, 2015, AM J OPHTHALMOL, V160, P569, DOI 10.1016/j.ajo.2015.06.011
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635
   van Romunde SHM, 2015, OPHTHALMOLOGY, V122, P1366, DOI 10.1016/j.ophtha.2015.03.012
   Wang W, 2014, ONCOL REP, V32, P2127, DOI 10.3892/or.2014.3439
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiao ZG, 2013, EUR J GASTROEN HEPAT, V25, P296, DOI 10.1097/MEG.0b013e32835c077a
   Yamakuchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020291
   Yang F, 2015, TUMOR BIOL, V36, P3763, DOI 10.1007/s13277-014-3017-3
   Yu XF, 2011, WORLD J GASTROENTERO, V17, P4711, DOI 10.3748/wjg.v17.i42.4711
   Zampetaki A, 2010, CIRC RES, V107, P810, DOI 10.1161/CIRCRESAHA.110.226357
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 41
TC 17
Z9 18
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1138-7548
EI 1877-8755
J9 J PHYSIOL BIOCHEM
JI J. Physiol. Biochem.
PD DEC
PY 2016
VL 72
IS 4
BP 583
EP 592
DI 10.1007/s13105-016-0496-2
PG 10
WC Biochemistry & Molecular Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Physiology
GA EC4LN
UT WOS:000388101700001
PM 27349759
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, YZ
   Wilson, E
   Locke, KG
   Edwards, AO
AF Wang, YZ
   Wilson, E
   Locke, KG
   Edwards, AO
TI Shape discrimination in age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-ACUITY; GEOGRAPHIC ATROPHY; MACULOPATHY; PSYCHOPHYSICS;
   THRESHOLDS
AB PURPOSE. Recent studies suggest that a global shape-discrimination task is sensitive to neural undersampling and/or irregular sampling, but is not affected by normal aging. In this study, the ability of patients with age-related macular degeneration (AMD) to perform the shape-discrimination task was examined.
   METHODS. Twenty patients with AMD (age range, 66-81 years) were selected on the basis of Snellen visual acuity of 20/50 or better in at least one eye and prior clinical documentation. A control group consisted of 10 older subjects (age range, 61 - 93 years) with normal findings in a fundus examination. Radial frequency (RF) patterns were used as stimuli. A spatial paradigm and a temporal two-alternative, forced-choice (2AFC) staircase paradigm were used. In each trial, two RF patterns (one deformed and one undeformed) were presented, and patients were asked to identify the deformed pattern. The peak spatial frequency of RF patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360degrees; mean radii were 0.5degrees, 1degrees, 2.0degrees, or 2.5degrees; and stimulus contrast was 80%. Thresholds for detecting the deformation were estimated by a maximum-likelihood fitting procedure.
   RESULTS. Thirty-five of 40 eyes with AMD had 20/50 or better acuity. Among them, 29 eyes had early AMD (drusen, hyper-pigmentation, hypopigmentation), 5 had extrafoveal geographic atrophy, and 1 had exudative AMD. With the spatial 2AFC, 91% (32/35) of eyes with AMD showed significant elevation of the threshold for detecting radial deformation of RF patterns when compared with normal control eyes. With the temporal 2AFC, 97% (31/32) of eyes with AMD showed significant threshold elevations, and the degree of the deficit in the shape discrimination did not correlate significantly with visual acuity loss (r = 0.3, P = 0.094). Comparison of the severity of AMD with shape-discrimination performance revealed that the average detection threshold of the eyes with extrafoveal geographic atrophy was significantly higher than that of the eyes with drusen only (P < 0.01), even though average acuity showed no significant difference.
   CONCLUSIONS. Patients with AMD had significant deficits in performing the global shape-discrimination task. The dissociation of shape discrimination with visual acuity suggests that the shape-discrimination task may provide distinguishable information about the integrity of the photoreceptor mosaic in AMD.
C1 Retina Fdn SW, Dallas, TX 75231 USA.
   Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX USA.
   Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas Dallas;
   University of Texas Southwestern Medical Center Dallas
RP Wang, YZ (通讯作者)，Retina Fdn SW, 9900 N Cent Expressway,Suite 400, Dallas, TX 75231 USA.
CR Age-Related Eye Disease Study Research Group, 2000, J NUTR, V130, p1516S
   Birch EE, 2000, INVEST OPHTH VIS SCI, V41, P3410
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   GELLER AM, 1992, J OPT SOC AM A, V9, P472, DOI 10.1364/JOSAA.9.000472
   Hess RF, 1999, VISION RES, V39, P901, DOI 10.1016/S0042-6989(98)00157-6
   Hess RF, 1999, VISION RES, V39, P4354, DOI 10.1016/S0042-6989(99)00153-4
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   NACHMIAS J, 1981, VISION RES, V21, P215, DOI 10.1016/0042-6989(81)90115-2
   OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   PITTS DG, 1982, J AM OPTOM ASSOC, V53, P117
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SHANNON CE, 1949, P IRE, V37, P10, DOI 10.1109/JRPROC.1949.232969
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   SWANSON WH, 1984, VISION RES, V24, P63, DOI 10.1016/0042-6989(84)90145-7
   SWANSON WH, 1992, PERCEPT PSYCHOPHYS, V51, P409, DOI 10.3758/BF03211637
   Wang YZ, 2001, OPTOMETRY VISION SCI, V78, P447, DOI 10.1097/00006324-200106000-00019
   WANG YZ, 2001, TRENDS OPTICS PHOTON, V35, P77
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
   WILLIAMS DR, 1985, VISION RES, V25, P195, DOI 10.1016/0042-6989(85)90113-0
   WILSON HR, 1999, CEREB CORTEX, V13, P445
   [No title captured]
NR 32
TC 57
Z9 57
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2002
VL 43
IS 6
BP 2055
EP 2062
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 557VA
UT WOS:000175927800053
PM 12037018
DA 2022-11-30
ER

PT J
AU Mataix, J
   Palacios, E
   Carmen, DM
   Garcia-Pous, M
   Navea, A
AF Mataix, Jorge
   Palacios, Elena
   Carmen, Desco M.
   Garcia-Pous, Maria
   Navea, Amparo
TI COMBINED RANIBIZUMAB AND PHOTODYNAMIC THERAPY TO TREAT EXUDATIVE
   AGE-RELATED MACULAR DEGENERATION An Option For Improving Treatment
   Efficiency
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE combined therapy; photodynamic therapy; ranibizumab; choroidal
   neovascularization; age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; VERTEPORFIN; TACHYPHYLAXIS; COMBINATION; INJECTION;
   LUCENTIS
AB Purpose: The purposes of this study were to determine whether the association of photodynamic therapy (PDT) and intravitreal ranibizumab could improve vision in a group of patients with choroidal neovascularization secondary to age-related macular degeneration and whether it could reduce the number and frequency of intravitreal injections, thus minimizing adverse effects.
   Methods: A nonrandomized, prospective, interventional study was conducted of a case series of 53 patients with sub-and juxtafoveal choroidal neovascularization secondary to age-related macular degeneration treated with a single initial dose of PDT and intravitreal ranibizumab. Retreatments were performed as required with monthly ranibizumab and PDT every 3 months if there were relapses. The retreatment criteria were based on visual acuity, optical coherence tomography, and fluorescein angiography. Follow-up lasted 12 months in all cases.
   Results: The mean initial visual acuity was 40.6 letters versus 47.8 letters at the end of follow-up with a gain of 7.2 letters (P < 0.001). Moreover, 78.8% maintained or improved their initial vision, and 92.3% avoided moderate vision loss (> 15 letters). A total of 65 PDT treatments (mean, 1.22 per patient) was performed and 126 doses of ranibizumab were injected (mean, 2.37 per patient). Only a single initial dose (PDT + ranibizumab) was required in 21 cases (39.6%). The central retinal thickness and choroidal neovascularization size decreased to 118 mu m and 0.26 disk areas, respectively, from baseline to 12 months.
   Conclusion: Combined customized PDT + ranibizumab treatment can achieve visual results similar to those obtained with intravitreal monotherapy with the advantage of fewer intravitreous injections and reduced potential for adverse effects. RETINA 30: 1190-1196, 2010
C1 [Mataix, Jorge; Palacios, Elena; Carmen, Desco M.; Garcia-Pous, Maria; Navea, Amparo] FOM, Vitreoretinal Dept, Valencia 46015, Spain.
RP Mataix, J (通讯作者)，FOM, Vitreoretinal Dept, Bifurcac Pio Baroja Gen Aviles S-N, Valencia 46015, Spain.
EM jormabo@ono.com
RI ESTEBAN, MARIA CARMEN DESCO/J-2281-2016; Navea, Amparo/D-4577-2009
OI ESTEBAN, MARIA CARMEN DESCO/0000-0002-9239-7847; Navea,
   Amparo/0000-0002-9856-5370; Mataix Boronat, Jorge/0000-0002-7018-3506
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   BENJAMIN LE, 1999, J CLIN INVEST, V271, P7788
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Falavarjani KG, 2009, OPHTHALMOLOGY, V116, P1016, DOI 10.1016/j.ophtha.2009.01.029
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Kloos P, 2008, KLIN MONATSBL AUGENH, V225, P385, DOI 10.1055/s-2008-1027252
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Mataix J, 2009, OPHTHAL SURG LAS IM, V40, P277, DOI 10.3928/15428877-20090430-09
   MITCHELL P, 2009, BR J OPHTHALMOL 0520
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Ruiz-Moreno JM, 2007, RETINA-J RET VIT DIS, V27, P458, DOI 10.1097/IAE.0b013e318030c77c
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wykrota Halina, 2007, Klin Oczna, V109, P402
NR 34
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2010
VL 30
IS 8
BP 1190
EP 1196
DI 10.1097/IAE.0b013e3181d2f172
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 647JF
UT WOS:000281614100007
PM 20539256
DA 2022-11-30
ER

PT J
AU Mendonca, LSM
   Levine, ES
   Waheed, NK
AF Mendonca, Luisa S. M.
   Levine, Emily S.
   Waheed, Nadia K.
TI Can the Onset of Neovascular Age-Related Macular Degeneration Be an
   Acceptable Endpoint for Prophylactic Clinical Trials?
SO OPHTHALMOLOGICA
LA English
DT Review
DE Prophylactic clinical trials; Clinical trial endpoints; Age-related
   macular degeneration (AMD); Intermediate AMD; Neovascular AMD
ID DRUSEN VOLUME; FELLOW EYES; PROGRESSION; CHORIOCAPILLARIS; PREDICTION;
   RISK; AMD; PREVALENCE; MODEL
AB Many studies over the past 20 years have pursued the goal of preventing or deferring progression from early and intermediate age-related macular degeneration (AMD) to advanced AMD. The onset of neovascular AMD has been used as a primary endpoint in some prophylactic clinical trials because it is easy to assess and relatively well-defined. Nevertheless, the use of this endpoint for assessing progression of AMD lacks validation. The aims of this paper are to review the current practice of clinical trials investigating the prevention of progression of early or intermediate AMD to neovascular AMD, so-called prophylactic trials, as well as identify ongoing efforts to standardize endpoints and select the ideal population for such studies.
C1 [Mendonca, Luisa S. M.; Levine, Emily S.; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
   [Mendonca, Luisa S. M.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Levine, Emily S.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
C3 Tufts Medical Center; Universidade Federal de Sao Paulo (UNIFESP); Tufts
   University
RP Waheed, NK (通讯作者)，New England Eye Ctr, 260 Tremont St, Boston, MA 02116 USA.
EM nadiakwaheed@gmail.com
FU Massachusetts Lions Club; CAPES, Ministry of Education, Brazil
   [88887.369769/201900]; Research to Prevent Blindness
FX The authors report grants from Massachusetts Lions Club and Research to
   Prevent Blindness. L.S.M.M. reports a research scholarship granted by
   CAPES, Ministry of Education, Brazil (in the scope of Capes-PrInt
   program, process No. 88887.369769/201900).
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chu ZD, 2018, QUANT IMAG MED SURG, V8, P1102, DOI 10.21037/qims.2018.12.09
   Clemons Traci E, 2005, Ophthalmology, V112, P533
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   H JS, 2019, AM SOC RET SPEC ANN
   Hu XF, 2020, RETINA-J RET VIT DIS, V40, P1070, DOI 10.1097/IAE.0000000000002531
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Lamin A, 2019, EYE, V33, P910, DOI 10.1038/s41433-019-0338-x
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Roberts PK, 2017, BRIT J OPHTHALMOL, V101, P1361, DOI 10.1136/bjophthalmol-2016-310004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Wu ZC, 2021, BRIT J OPHTHALMOL, V105, P711, DOI 10.1136/bjophthalmol-2020-315935
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 36
TC 2
Z9 1
U1 2
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD NOV
PY 2021
VL 244
IS 5
BP 379
EP 386
DI 10.1159/000513083
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XK8CK
UT WOS:000727686300005
PM 33197919
OA Bronze
DA 2022-11-30
ER

PT J
AU Troutbeck, R
   Al-Qureshi, S
   Guymer, RH
AF Troutbeck, Robyn
   Al-Qureshi, Salmaan
   Guymer, Robyn H.
TI Therapeutic targeting of the complement system in age-related macular
   degeneration: a review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE AMD; complement system; complement factor H
ID FACTOR-H POLYMORPHISM; CHOROIDAL NEOVASCULARIZATION; SERPING1 GENE;
   FACTOR-B; CHLAMYDIA-PNEUMONIAE; DISEASES; PATHWAY; VARIANT; DRUSEN; RISK
AB The last decade has produced pivotal change in our understanding of the molecular mechanisms underlying age-related macular degeneration (AMD), a leading cause of global blindness. In this time, the complement system has featured as a unifying theme for several elements of new evidence: initially, the discovery of complement proteins within drusen and subsequently, the association between AMD and mutations in various complement pathway genes, most notably complement factor H. Increasingly, a wealth of data are pointing towards a role for chronic local inflammation and complement activation in the patho-aetiology of AMD. These findings have paved the way for the exploration of a new paradigm of therapy in AMD management; targeting of specific molecular constituents in the complement pathway thus producing dampening or inhibition of the inflammatory response. Such an approach has the potential to intervene earlier in the disease process and ideally before vision is compromised. In this review we discuss the role of the complement system in AMD, novel therapies in preclinical evaluation and clinical trial, and whether these have a part to play in reducing the burden of disease.
C1 [Troutbeck, Robyn; Al-Qureshi, Salmaan; Guymer, Robyn H.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Troutbeck, R (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
EM rtroutbeck@gmail.com
OI Guymer, Robyn/0000-0002-9441-4356
FU Novartis Australia; National Health and Medical Research Council
   (NHMRC); Victorian Government; NHMRC Centre for Clinical Research
   Excellence [529923]
FX RT is supported by a retinal fellowship from Novartis Australia, and RHG
   is supported by a National Health and Medical Research Council (NHMRC)
   practitioner fellowship (RHG). CERA receives Operational Infrastructure
   Support from the Victorian Government and is also supported by an NHMRC
   Centre for Clinical Research Excellence #529923 award.
CR Allegretti M, 2005, CURR MED CHEM, V12, P217, DOI 10.2174/0929867053363379
   Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Amara U, 2008, ADV EXP MED BIOL, V632, P71, DOI 10.1007/978-0-387-78952-1_6
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431
   Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaushal S., 2009, INVESTIG OPHTHALMOL, V50, P5010
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549
   Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2009, EXP EYE RES, V89, P767, DOI 10.1016/j.exer.2009.07.001
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Park KH, 2009, MOL VIS, V15, P200
   Qin S, 2008, J INFLAMM RES, V1, P49
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schnatbaum K, 2006, BIOORG MED CHEM LETT, V16, P5088, DOI 10.1016/j.bmcl.2006.07.036
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Taube C, 2006, P NATL ACAD SCI USA, V103, P8084, DOI 10.1073/pnas.0602357103
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 49
TC 53
Z9 53
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD FEB
PY 2012
VL 40
IS 1
BP 18
EP 26
DI 10.1111/j.1442-9071.2011.02581.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 888JW
UT WOS:000300000800025
PM 22304025
OA Bronze
DA 2022-11-30
ER

PT J
AU Christen, WG
   Glynn, RJ
   Chew, EY
   Buring, JE
AF Christen, William G.
   Glynn, Robert J.
   Chew, Emily Y.
   Buring, Julie E.
TI Vitamin E and Age-Related Macular Degeneration in a Randomized Trial of
   Women
SO OPHTHALMOLOGY
LA English
DT Article
ID BETA-CAROTENE SUPPLEMENTATION; LOW-DOSE ASPIRIN; PRIMARY PREVENTION;
   CARDIOVASCULAR-DISEASE; DIETARY ANTIOXIDANTS; CIGARETTE-SMOKING;
   MACULOPATHY; CATARACT; CANCER; HEALTH
AB Objective: To test whether alternate day vitamin E affects the incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women.
   Design: Randomized, double-masked, placebo-controlled trial.
   Participants: Thirty-nine thousand eight hundred seventy-six apparently healthy female health professionals aged 45 years or older.
   Intervention: Participants were assigned randomly to receive either 600 IU of natural-source vitamin E on alternate days or placebo.
   Main Outcome Measures: Incident AMD responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.
   Results: After 10 years of treatment and follow-up, there were 117 cases of AMD in the vitamin E group and 128 cases in the placebo group (relative risk, 0.93; 95% confidence interval, 0.72-1.19).
   Conclusions: In a large-scale randomized trial of female health professionals, long-term alternate-day use of 600 IU of natural-source vitamin E had no large beneficial or harmful effect on risk of AMD.
C1 [Christen, William G.; Glynn, Robert J.; Buring, Julie E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
   [Glynn, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA.
   [Chew, Emily Y.] NEI, Bethesda, MD 20892 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   Medical School; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI)
RP Christen, WG (通讯作者)，900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
FU Astra Zeneca; National Institutes of Health, Bethesda, Maryland [CA
   47988, HL 43851, EY 06633]; NATIONAL CANCER INSTITUTE [R01CA047988]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006633]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL043851] Funding Source: NIH RePORTER
FX Dr. Glynn received a grant from Astra Zeneca.; Supported by the National
   Institutes of Health, Bethesda, Maryland (grant nos.: CA 47988, HL
   43851, and EY 06633). Pills and packaging were provided by Bayer
   Healthcare and the Natural Source Vitamin E Association. Bayer
   Healthcare and the Natural Source Vitamin E Association had no role in
   the design and conduct of the study; in the collection, analysis, and
   interpretation of the data; or in the preparation, review, or approval
   of the manuscript.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Christen WG, 2004, OPHTHAL EPIDEMIOL, V11, P401, DOI 10.1080/09286580490515152
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   COX DR, 1972, J R STAT SOC B, V187, P220
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glynn RJ, 2007, CIRCULATION, V116, P1497, DOI 10.1161/CIRCULATIONAHA.107.716407
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P1203, DOI 10.1016/j.ophtha.2007.09.011
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teikari JM, 1998, ACTA OPHTHALMOL SCAN, V76, P224, DOI 10.1034/j.1600-0420.1998.760220.x
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Winkler BS, 1999, MOL VIS, V5
NR 38
TC 26
Z9 26
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2010
VL 117
IS 6
BP 1163
EP 1168
DI 10.1016/j.ophtha.2009.10.043
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603QZ
UT WOS:000278224400011
PM 20153900
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kumar, H
   Goh, KL
   Guymer, RH
   Wu, ZC
AF Kumar, Himeesh
   Goh, Kai Lyn
   Guymer, Robyn H.
   Wu, Zhichao
TI A clinical perspective on the expanding role of artificial intelligence
   in age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE Age related macular degeneration; artificial intelligence; imaging
ID DIABETIC-RETINOPATHY; SEVERITY SCALE; HEALTH-CARE; RANIBIZUMAB; DISEASE;
   PREVALENCE; VALIDATION; OUTCOMES; MACHINE; SYSTEM
AB In recent years, there has been intense development of artificial intelligence (AI) techniques, which have the potential to improve the clinical management of age-related macular degeneration (AMD) and facilitate the prevention of irreversible vision loss from this condition. Such AI techniques could be used as clinical decision support tools to: (i) improve the detection of AMD by community eye health practitioners, (ii) enhance risk stratification to enable personalised monitoring strategies for those with the early stages of AMD, and (iii) enable early detection of signs indicative of possible choroidal neovascularisation allowing triaging of patients requiring urgent review. This review discusses the latest developments in AI techniques that show promise for these tasks, as well as how they may help in the management of patients being treated for choroidal neovascularisation and in accelerating the discovery of new treatments in AMD.
C1 [Kumar, Himeesh; Goh, Kai Lyn; Guymer, Robyn H.; Wu, Zhichao] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital
RP Wu, ZC (通讯作者)，Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
EM wu.z@unimelb.edu.au
RI Goh, Kai Lyn/AAG-1174-2022; Goh, Kai Lyn/AFK-2848-2022
OI Goh, Kai Lyn/0000-0003-2828-8723; Goh, Kai Lyn/0000-0003-2828-8723;
   Guymer, Robyn/0000-0002-9441-4356; Kumar, Himeesh/0000-0001-9169-5335
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Almansour NA, 2019, COMPUT BIOL MED, V109, P101, DOI 10.1016/j.compbiomed.2019.04.017
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Anwar SM, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1088-1
   Augustin AJ, 2005, RETINA-J RET VIT DIS, V25, P443, DOI 10.1097/00006982-200506000-00008
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choudhury A, 2020, JMIR MED INF, V8, DOI 10.2196/18599
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Ding Y, 2019, RADIOLOGY, V290, P456, DOI 10.1148/radiol.2018180958
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Faes Livia, 2020, Transl Vis Sci Technol, V9, P7, DOI 10.1167/tvst.9.2.7
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gonzalez G, 2018, AM J RESP CRIT CARE, V197, P193, DOI 10.1164/rccm.201705-0860OC
   Govindaiah Arun, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P702, DOI 10.1109/EMBC.2018.8512379
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Gunasekeran DV, 2020, ASIA-PAC J OPHTHALMO, V9, P61, DOI 10.1097/01.APO.0000656984.56467.2c
   High-Level Expert Group on Artificial Intelligence, 2020, ASS LIST TRUSTW ART
   Ho R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206690
   Hogarty DT, 2019, CLIN EXP OPHTHALMOL, V47, P128, DOI 10.1111/ceo.13381
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Jiang P, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.39
   Kapoor R, 2019, SURV OPHTHALMOL, V64, P233, DOI 10.1016/j.survophthal.2018.09.002
   Keane PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164095
   Keel S, 2019, CLIN EXP OPHTHALMOL, V47, P1009, DOI 10.1111/ceo.13575
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Keenan TDL, 2021, OPHTHALMOLOGY, V128, P100, DOI [10.1016/j.opatha.2020.06.038, 10.1016/j.ophtha.2020.06.038]
   Keenan TDL, 2020, OPHTHALMOLOGY, V127, P1674, DOI 10.1016/j.ophtha.2020.05.036
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Lazaridis G, 2021, OPHTHALMOL GLAUCOMA, V4, P295, DOI 10.1016/j.ogla.2020.10.008
   Lee A, 2017, OPHTHALMOLOGY, V124, P1726, DOI 10.1016/j.ophtha.2017.08.046
   Lee CS, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.9
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Loo J, 2020, OPHTHALMOLOGY, V127, P793, DOI 10.1016/j.ophtha.2019.12.015
   Ly A, 2018, CLIN EXP OPTOM, V101, P243, DOI 10.1111/cxo.12607
   Meyers KJ, 2015, OPHTHALMOLOGY, V122, P2286, DOI 10.1016/j.ophtha.2015.07.029
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Nahen K, 2020, KLIN MONATSBL AUGENH, V237, P1410, DOI 10.1055/a-1271-6834
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Optometry Australia, 2019, 2019 CLIN PRACT GUID
   Peng YF, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00317-z
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Rajpurkar P, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002686
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal Australian and New Zealand College of Ophthalmologists, 2016, RANZCO REF PATHW AMD
   Rusk N, 2016, NAT METHODS, V13, P35, DOI 10.1038/nmeth.3707
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Scheetz J, 2021, MED J AUSTRALIA, V214, P155, DOI 10.5694/mja2.50932
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schonberger D, 2019, INT J LAW INFORM TEC, V27, P171, DOI 10.1093/ijlit/eaz004
   Song G, 2021, PROG BIOMED ENG, V3, DOI 10.1088/2516-1091/abfeb7
   Sonobe T, 2019, INT OPHTHALMOL, V39, P1871, DOI 10.1007/s10792-018-1016-x
   Tamura H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133628
   Ting DSW, 2019, OPHTHALMOLOGY, V126, P1475, DOI 10.1016/j.ophtha.2019.09.014
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Tom E, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.36
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   van der Heijden AA, 2018, ACTA OPHTHALMOL, V96, P63, DOI 10.1111/aos.13613
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Wightman AJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.3
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Yanagihara RT, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.11
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zhao J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36745-x
NR 76
TC 1
Z9 1
U1 3
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD OCT 3
PY 2022
VL 105
IS 7
BP 674
EP 679
DI 10.1080/08164622.2021.2022961
EA JAN 2022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4E7WK
UT WOS:000746467500001
PM 35073498
DA 2022-11-30
ER

PT J
AU Akagi-Kurashige, Y
   Tsujikawa, A
   Yuzawa, M
   Ishibashi, T
   Nakanishi, H
   Nakatani, E
   Teramukai, S
   Fukushima, M
   Yoshimura, N
AF Akagi-Kurashige, Yumiko
   Tsujikawa, Akitaka
   Yuzawa, Mitsuko
   Ishibashi, Tatsuro
   Nakanishi, Hideo
   Nakatani, Eiji
   Teramukai, Satoshi
   Fukushima, Masanori
   Yoshimura, Nagahisa
CA AMD2000 Study Grp
TI A 5-year multicenter prospective cohort study on the long-term visual
   prognosis and predictive factors for visual outcome in Japanese patients
   with age-related macular degeneration: the AMD2000 study
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Photodynamic therapy; Polypoidal
   choroidal vasculopathy; Prospective study; Visual prognosis
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   OPTICAL COHERENCE TOMOGRAPHY; NEOVASCULARIZATION SECONDARY; RANIBIZUMAB;
   EFFICACY; TRIAL; ASSOCIATION; AFLIBERCEPT; HORIZON
AB In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD).
   This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment.
   Of the 409 study eyes followed up for at least 1 year, 243 eyes (59.4%) were treated with photodynamic therapy (PDT) using verteporfin, and 58 eyes (14.2%) were treated with intravitreal injections of antivascular endothelial growth factor agents as the initial treatment. The mean best-corrected visual acuities (BCVA) for typical AMD (tAMD; 0.688 +/- 0.498) and polypoidal choroidal vasculopathy (PCV; 0.451 +/- 0.395) were significantly less at 2 years (tAMD, 0.779 +/- 0.632, P < 0.05; PCV, 0.534 +/- 0.618, P < 0.05) and at 5 years (AMD, 0.873 +/- 0.718, P < 0.05; PCV, 0.635 +/- 0.668, P < 0.05) than at baseline. In eyes with tAMD, absence of blocked fluorescence was associated with 5-year maintenance of the baseline BCVA. Regarding PCV, the presence of polypoidal lesions and cystoid macular edema as well as the lesion size was associated with 5-year maintenance of the baseline BCVA. In some patients, the diagnosis changed: of the 192 eyes initially diagnosed with typical AMD, 19 were newly diagnosed with PCV during follow-up.
   Maintaining the baseline BCVA over the long term is difficult in Japanese eyes with wet AMD.
C1 [Akagi-Kurashige, Yumiko; Tsujikawa, Akitaka; Nakanishi, Hideo; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Yuzawa, Mitsuko] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan.
   [Ishibashi, Tatsuro] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Nakatani, Eiji; Teramukai, Satoshi; Fukushima, Masanori] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan.
   [Teramukai, Satoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biostat, Kyoto, Japan.
   [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University; Nihon University; Kyushu University; Institute for
   Biomedical Research & Innovation (IBRI); Kyoto Prefectural University of
   Medicine; Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.; Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Sakyo Ku, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011; Teramukai, Satoshi/I-2249-2019; Nakazawa,
   Mitsuru/ABI-7897-2020; Oishi, Akio/AAE-9996-2020; Nakatani,
   Eiji/O-2782-2013
OI TAMURA, Hiroshi/0000-0002-7740-2732; Teramukai,
   Satoshi/0000-0003-2184-0597; Nakazawa, Mitsuru/0000-0001-6095-5712;
   Oishi, Akio/0000-0002-0977-9458; Nakatani, Eiji/0000-0002-4876-446X;
   Gomi, Fumi/0000-0003-0807-8817; Yanagi, Yasuo/0000-0002-0362-7285;
   Tsujikawa, Akitaka/0000-0003-0779-7799
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Iijima H, 1999, AM J OPHTHALMOL, V127, P301, DOI 10.1016/S0002-9394(98)00411-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Semoun O, 2016, BRIT J OPHTHALMOL, V100, P1028, DOI 10.1136/bjophthalmol-2015-307494
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tano Yasuo, 2008, Nippon Ganka Gakkai Zasshi, V112, P590
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Tsujikawa A, 2011, AM J OPHTHALMOL, V151, P961, DOI 10.1016/j.ajo.2011.01.002
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhang J, 2015, OPTOMETRY VISION SCI, V92, pE21, DOI 10.1097/OPX.0000000000000440
NR 32
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD MAR
PY 2018
VL 62
IS 2
BP 137
EP 143
DI 10.1007/s10384-017-0554-5
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY6AZ
UT WOS:000426923200004
PM 29224056
DA 2022-11-30
ER

PT J
AU Tan, JSL
   Wang, JJ
   Liew, G
   Rochtchina, E
   Mitchell, P
AF Tan, J. S. L.
   Wang, J. J.
   Liew, G.
   Rochtchina, E.
   Mitchell, P.
TI Age-related macular degeneration and mortality from cardiovascular
   disease or stroke
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; MACULOPATHY
AB Background/aims: Age-related macular degeneration ( AMD) and vascular disease share similar risk factors. Recent data suggest AMD may independently predict stroke or coronary heart disease. We prospectively assessed the relationship between AMD and risk of stroke- or cardiovascular-related death in an Australian population.
   Methods: Of 3654 baseline participants ( 1992-4) aged 49+ years, 2335 were re-examined after 5 years and 1952 after 10 years. Retinal photographs were graded using the Wisconsin System. History and physical examination provided data on possible risk factors. Deaths and cause of death were confirmed by data linkage with the Australian National Death Index. Risk ratios ( RR) were estimated in Cox models.
   Results: Among persons aged,75 years at baseline, early AMD predicted a doubling of cardiovascular mortality ( RR, 2.32; 95% confidence interval ( CI), 1.03 to 5.19), over the next decade, after controlling for traditional cardiovascular risk factors. Late AMD predicted fivefold higher cardiovascular mortality ( RR, 5.57; 95% CI, 1.35 to 22.99) and 10-fold higher stroke mortality ( RR, 10.21; 95% CI, 2.39 to 43.60) after adjusting for age and sex only. These associations were not present when persons older than 75 were included.
   Conclusion: AMD predicted stroke and cardiovascular events over the long term in persons aged 49 - 75 years. This may have potential implications for new intravitreal anti-VEGF AMD therapies.
C1 [Tan, J. S. L.; Wang, J. J.; Liew, G.; Rochtchina, E.; Mitchell, P.] Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Mitchell, P (通讯作者)，Univ Sydney, Ctr Vis Res, Dept Ophthalmol, Westmead Hosp, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Liew,
   Gerald/AAB-6870-2022; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Di Napoli M, 2001, STROKE, V32, P1444, DOI 10.1161/01.STR.32.6.1443-a
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   *GEN, LUC RAN INJ SAF INF
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Magliano D, 2003, AUST NZ J PUBL HEAL, V27, P649, DOI 10.1111/j.1467-842X.2003.tb00615.x
   Margolis KL, 2005, ARCH INTERN MED, V165, P500, DOI 10.1001/archinte.165.5.500
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   WALKER AH, 1984, HEALTH SERV RES, V19, P291
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 22
TC 87
Z9 88
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2008
VL 92
IS 4
BP 509
EP 512
DI 10.1136/bjo.2007.131706
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 279XH
UT WOS:000254388200018
PM 18310310
DA 2022-11-30
ER

PT J
AU Guduru, A
   Fleischman, D
   Shin, S
   Zeng, DL
   Baldwin, JB
   Houghton, OM
   Say, EA
AF Guduru, Abhilash
   Fleischman, David
   Shin, Sunyoung
   Zeng, Donglin
   Baldwin, James B.
   Houghton, Odette M.
   Say, Emil A.
TI Ultra-widefield fundus autofluorescence in age-related macular
   degeneration
SO PLOS ONE
LA English
DT Article
ID PERIPHERAL AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY; LIPOFUSCIN;
   CLASSIFICATION; FLUOROPHORE; PREVALENCE; AGREEMENT; PATTERNS; A2E
AB Background
   Establish accuracy and reproducibility of subjective grading in ultra-widefield fundus auto-fluorescence (FAF) imaging in patients with age-related macular degeneration (AMD), and determine if an association exists between peripheral FAF abnormalities and AMD.
   Methods
   This was a prospective, single-blinded case-control study. Patients were consecutively recruited for the study. Patients were excluded if there was a history of prior or active ocular pathology other than AMD or image quality was insufficient for analysis as determined by two independent graders. Control patients were those without any evidence of AMD or other ophthalmic disease apart from cataract. Using the Optos 200Tx (Optos, Marlborough, MA, USA), a ResMax central macula and an ultra-widefield peripheral retina image was taken for each eye in both normal color and short wavelength FAF. Ultra-widefield photographs were modified to mask the macula. Each ResMax and ultra-widefield image was independently graded by two blinded investigators.
   Results
   There were 28 AMD patients and 11 controls. There was a significant difference in the average age between AMD patients and control groups (80 versus 64, respectively P<0.001). There was moderate, statistically significant agreement between observers regarding image interpretation (78.4%, K = 0.524, P<0.001), and 69.0% (K = 0.49, P<0.001) agreement between graders for FAF abnormality patterns. Patients with AMD were at greater risk for peripheral FAF abnormalities (OR: 3.43, P = 0.019) and patients with FAF abnormalities on central macular ResMax images were at greater risk of peripheral FAF findings (OR: 5.19, P = 0.017).
   Conclusion
   Subjective interpretation of FAF images has moderate reproducibility and validity in assessment of peripheral FAF abnormalities. Peripheral FAF abnormalities are seen in both AMD and control patients. Those with AMD, poor visual acuity, and macular FAF abnormalities are at greater risk.
C1 [Guduru, Abhilash] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
   [Fleischman, David; Zeng, Donglin; Baldwin, James B.; Houghton, Odette M.] Univ N Carolina, Dept Ophthalmol, Kittner Eye Ctr, Chapel Hill, NC 27599 USA.
   [Shin, Sunyoung] Univ Wisconsin, Dept Stat, Madison, WI 53706 USA.
   [Shin, Sunyoung] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
   [Say, Emil A.] Med Univ South Carolina, Storm Eye Inst, Dept Ophthalmol, Charleston, SC 29425 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of
   Wisconsin System; University of Wisconsin Madison; University of
   Wisconsin System; University of Wisconsin Madison; Medical University of
   South Carolina
RP Fleischman, D (通讯作者)，Univ N Carolina, Dept Ophthalmol, Kittner Eye Ctr, Chapel Hill, NC 27599 USA.
EM david8fleischman@gmail.com
OI Guduru, Abhilash/0000-0003-2138-3576
FU Research to Prevent Blindness, Inc (New York, NY)
FX University of North Carolina is a recipient of an unrestricted grant
   from Research to Prevent Blindness, Inc (New York, NY). The funders had
   no role in the design and conduct of the study, in the collection,
   analysis and interpretation of the data, and in the preparation, review
   or approval of the manuscript.
CR Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Domalpally A, 2014, INVEST OPHTH VIS SCI, V55
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Friberg TR, 2014, INVEST OPHTH VIS SCI, V55
   Friberg TR, 2015, INVEST OPHTH VIS SCI, V56
   Hardin JW., 2003, GEN ESTIMATING EQUAT
   Heussen FM, 2012, INVEST OPHTH VIS SCI, V53, P6526, DOI 10.1167/iovs.12-9909
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hosmer Jr D. W., 2013, APPL LOGISTIC REGRES
   Kernt Marcus, 2013, Oman J Ophthalmol, V6, pS32, DOI 10.4103/0974-620X.122292
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Nomura Y, 2015, CLIN OPHTHALMOL, V9, P297, DOI 10.2147/OPTH.S78210
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Reznicek L, 2012, INVEST OPHTH VIS SCI, V53, P2193, DOI 10.1167/iovs.11-8483
   Sadatsafavi M, 2008, J CLIN EPIDEMIOL, V61, P722, DOI 10.1016/j.jclinepi.2007.10.023
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Tan CS, 2013, OPHTHALMOLOGY, V120, P1271, DOI 10.1016/j.ophtha.2012.12.002
   Witmer MT, 2012, ACTA OPHTHALMOL, V90, pe428, DOI 10.1111/j.1755-3768.2012.02434.x
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
NR 25
TC 7
Z9 8
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 1
PY 2017
VL 12
IS 6
AR e0177207
DI 10.1371/journal.pone.0177207
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EW6HZ
UT WOS:000402611800007
PM 28570556
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Jaisankar, D
   Swaminathan, G
   Roy, R
   Kulothungan, V
   Sharma, T
   Raman, R
AF Jaisankar, Durgasri
   Swaminathan, Gayathri
   Roy, Rupak
   Kulothungan, Vaitheeswaran
   Sharma, Tarun
   Raman, Rajiv
TI Association of obesity and age-related macular degeneration in Indian
   population
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; age-related macular degeneration and
   obesity; age-related macular degeneration in South Indian population;
   obesity; obesity in South Indian population
ID BODY-MASS INDEX; RISK-FACTORS; ABDOMINAL OBESITY;
   CARDIOVASCULAR-DISEASE; JAPANESE POPULATION; CIGARETTE-SMOKING;
   MACULOPATHY; PREVALENCE; EYE; MEN
AB Purpose: The aim of this study was to establish the prevalence and association of age-related macular degeneration (AMD) and obesity which was not studied extensively in Indian population over 60 years of age. Methods: This was a cross-sectional, population-based study. A total of 4791 patients with gradable fundus photography were included. All patients underwent detailed ophthalmic examination and AMD was graded with retinal photographs. Grading of AMD was done according to the International ARM Epidemiological Study Group and staged based on grading in worse eye. The association of AMD severity and obesity (based on body mass index, waist-hip ratio, waist circumference, isolated abdominal obesity, isolated generalized obesity, and combined obesity) was assessed. The main outcome variable was an association between the presence and severity of AMD with different grades of obesity. Results: No direct significant association was noted between the presence and severity of AMD and any obesity indices. Subgroup analyses based on lifestyle patterns and common systemic pathologies in AMD population were done. Late AMD was significantly associated with tobacco consumption in population with combined obesity (P = 0.033 and odds ratio = 2.998). Conclusion: No direct association was noted between the presence or severity of AMD and obesity in South Indian population. However, indirect associations between the severity of AMD and combined obesity were found.
C1 [Jaisankar, Durgasri; Swaminathan, Gayathri; Roy, Rupak; Sharma, Tarun; Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
   [Kulothungan, Vaitheeswaran] Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, Tamil Nadu, India.
C3 Manonmaniam Sundaranar University
RP Raman, R (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM rajivpgraman@gmail.com
RI Raman, Rajiv/A-7234-2009
OI Raman, Rajiv/0000-0001-5842-0233; Jaisankar,
   Durgasri/0000-0002-7698-1963
FU Jamshetji Tata trust, Mumbai
FX This work was funded by Jamshetji Tata trust, Mumbai.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Despres JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Howard KP, 2014, INVEST OPHTH VIS SCI, V55, P2592, DOI 10.1167/iovs.13-13763
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moeini HA, 2005, BRIT J OPHTHALMOL, V89, P964, DOI 10.1136/bjo.2005.066241
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Paunksnis A, 2005, EUR J OPHTHALMOL, V15, P255, DOI 10.1177/112067210501500213
   Peeters A, 2008, ARCH OPHTHALMOL-CHIC, V126, P1554, DOI 10.1001/archopht.126.11.1554
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   World Health Organization, 2000, REG OFF W PAC AS PAC
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 27
TC 5
Z9 5
U1 0
U2 4
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2018
VL 66
IS 7
BP 976
EP 983
DI 10.4103/ijo.IJO_1265_17
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GL5IG
UT WOS:000437197400019
PM 29941743
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tarita-Nistor, L
   Lam, D
   Brent, MH
   Steinbach, MJ
   Gonzalez, EG
AF Tarita-Nistor, Luminita
   Lam, Dianne
   Brent, Michael H.
   Steinbach, Martin J.
   Gonzalez, Esther G.
TI Courier: a better font for reading with age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID LOW-VISION; PSYCHOPHYSICS; SPEED
AB Objective: This study examines the reading performance of patients with age-related macular degeneration (AMD) using 4 readily available fonts.
   Design: Experimental study.
   Participants: Twenty-four patients with bilateral AMD participated.
   Methods: Reading performance (reading acuity, critical print size, and maximum reading speed) was measured for all patients, using 4 versions of the MNRead charts. These charts were printed in the following fonts: Times New Roman (serif, proportionally spaced), Anal (sans serif, proportionally spaced), Courier (serif, mono spaced), and Andale Mono (sans serif, mono spaced).
   Results: Reading acuity was significantly better on the Courier chart (0.58 +/- 0.21 logMAR) and significantly worse on the Anal chart (0.69 +/- 0.20 log MAR) than on any of the other charts (P < 0.05). A larger proportion of patients were able to read >= 1 sentences on the Courier chart than on any of the other charts. Reading speed dropped below the limit for fluent reading first with the Anal chart. There was no difference in maximum reading speed with the 4 fonts, and differences in critical print size failed to reach significance (P = 0.052).
   Conclusions: Font has an effect on the reading performance of patients with AMD at print sizes close to their reading acuity. Courier was the most advantageous and Anal the worst font for reading smaller print. This is contrary to the advice given by agencies for the blind.
C1 [Tarita-Nistor, Luminita; Brent, Michael H.; Steinbach, Martin J.; Gonzalez, Esther G.] Toronto Western Hosp, Vis Sci Res Program, Toronto, ON M5T 2S8, Canada.
   [Tarita-Nistor, Luminita; Steinbach, Martin J.; Gonzalez, Esther G.] York Univ, Ctr Vis Res, Toronto, ON M3J 2R7, Canada.
   [Lam, Dianne] Ryerson Univ, Dept Psychol, Toronto, ON, Canada.
   [Brent, Michael H.; Steinbach, Martin J.; Gonzalez, Esther G.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; York University - Canada; Toronto Metropolitan
   University; University of Toronto
RP Gonzalez, EG (通讯作者)，Toronto Western Res Inst, Vis Sci Res Program, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
EM esther.gonzalez@utoronto.ca
FU Milton Harris Fund for Adult Macular Degeneration; Natural Sciences and
   Engineering Research Council of Canada Grant [A7664]; Vision Science
   Research Program, Toronto Western Hospital, Toronto, Ont.; Sandra and
   David Smith postdoctoral fellowship
FX This work was supported by the Milton Harris Fund for Adult Macular
   Degeneration (M.H.B.); Natural Sciences and Engineering Research Council
   of Canada Grant A7664 (MTS.); Vision Science Research Program, Toronto
   Western Hospital, Toronto, Ont.; Sandra and David Smith postdoctoral
   fellowship; and an anonymous donor.
CR Arditi A, 2005, VISION RES, V45, P2926, DOI 10.1016/j.visres.2005.06.013
   ARDITI A, 1990, J OPT SOC AM A, V7, P2011, DOI 10.1364/JOSAA.7.002011
   Canadian National Institute for the Blind, CLEAR PRINT ACC GUID
   Chung STL, 2002, INVEST OPHTH VIS SCI, V43, P1270
   Chung STL, 1998, VISION RES, V38, P2949, DOI 10.1016/S0042-6989(98)00072-8
   Kitchel JE, 2004, LARGE PRINT GUIDELIN
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Legge GE, 2011, J VISION, V11, DOI 10.1167/11.5.8
   Mansfield J.S., 1993, OPT SOC AM TECHNOL D, V3, P232
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   Morris R, 2002, SID S, P13
   Perera A., 2004, LPFONT INVESTIGATION
   Rubin GS, 2006, OPHTHAL PHYSL OPT, V26, P545, DOI 10.1111/j.1475-1313.2006.00409.x
   Russell-Minda E., 2006, CLEAR PRINT EVIDENCE
   Russell-Minda E, 2007, J VISUAL IMPAIR BLIN, V101, P402, DOI 10.1177/0145482X0710100703
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Yager D, 1998, VISION RES, V38, P2527, DOI 10.1016/S0042-6989(98)00116-3
NR 17
TC 17
Z9 17
U1 0
U2 8
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2013
VL 48
IS 1
BP 57
EP 63
DI 10.1016/j.jcjo.2012.09.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5NR
UT WOS:000331147200019
PM 23419299
DA 2022-11-30
ER

PT J
AU Salminen, A
   Kauppinen, A
   Hyttinen, JMT
   Toropainen, E
   Kaarniranta, K
AF Salminen, Antero
   Kauppinen, Anu
   Hyttinen, Juha M. T.
   Toropainen, Elisa
   Kaarniranta, Kai
TI Endoplasmic Reticulum Stress in Age-Related Macular Degeneration:
   Trigger for Neovascularization
SO MOLECULAR MEDICINE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; UNFOLDED-PROTEIN-RESPONSE; C-REACTIVE
   PROTEIN; OXIDATIVE STRESS; ER STRESS; TRANSCRIPTIONAL REGULATION;
   CIGARETTE-SMOKE; CHOROIDAL NEOVASCULARIZATION; OXIDIZED PHOSPHOLIPIDS;
   MOLECULAR REGULATION
AB Age-related macular degeneration (AMD) can be classified into two main categories: the atrophic, dry form and the exudative, wet form. The crucial difference between dry and wet AMD is the development of choroidal neovascularization in wet AMD. One fundamental cause of the neovascularization is the increased expression of VEGF (vascular endothelial growth factor) in retinal pigment epithelial cells. Progression of AMD is linked to augmentation of cellular stress, for example, oxidative stress, proteotoxic stress, inflammation and hypoxia. All these conditions can trigger stress in endoplasmic reticulum (ER), which maintains protein quality control in cells. ER stress induces the unfolded protein response (UPR) via IRE1 (inositol-requiring protein-1), PERK (protein kinase RNA-like ER kinase) and ATF6 (activating transcription factor-6) transducers. UPR signaling is a double-edged sword, that is, it can restore cellular homeostasis as far as possible, but ultimately may lead to chronic, overwhelming stress that can cause apoptotic cell death. Interestingly, ER stress is a well-known inducer of angiogenesis in cancer. Moreover, stress conditions associated with the progress of AMD can induce the expression of VEGF. We discuss the role of ER stress in the regulation of neovascularization and the conversion of dry AMD to its wet, detrimental counterpart, (C) 2010 The Feinstein Institute for Medical Research, www.feinsteininstitute.org
C1 [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FIN-70211 Kuopio, Finland.
   [Kauppinen, Anu; Hyttinen, Juha M. T.; Toropainen, Elisa; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Salminen, A (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Neurol, POB 1627, FIN-70211 Kuopio, Finland.
EM antero.salminen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Kaarniranta, Kai/0000-0003-2600-8679
FU Academy of Finland; University of Eastern Finland, Kuopio, Finland
FX This study was financially supported by grants from the Academy of
   Finland and the University of Eastern Finland, Kuopio, Finland. The
   authors thank E MacDonald for checking the language of the manuscript.
CR Afonyushkin T, 2010, ARTERIOSCL THROM VAS, V30, P1007, DOI 10.1161/ATVBAHA.110.204354
   Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bian ZM, 2009, INVEST OPHTH VIS SCI, V50, P6006, DOI 10.1167/iovs.09-3628
   Bian ZM, 2008, INVEST OPHTH VIS SCI, V49, P5593, DOI 10.1167/iovs.08-2116
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Breusing N, 2008, BIOL CHEM, V389, P203, DOI 10.1515/BC.2008.029
   Calabrese EJ, 2008, BRIT J CLIN PHARMACO, V66, P594, DOI 10.1111/j.1365-2125.2008.03243.x
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Doh SH, 2010, BRAIN RES, V1308, P158, DOI 10.1016/j.brainres.2009.10.025
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950
   Doroudgar S, 2009, J BIOL CHEM, V284, P29735, DOI 10.1074/jbc.M109.018036
   Drogat B, 2007, CANCER RES, V67, P6700, DOI 10.1158/0008-5472.CAN-06-3235
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Filleur S, 2009, J CELL BIOCHEM, V106, P769, DOI 10.1002/jcb.22072
   Fribley A, 2006, CANCER BIOL THER, V5, P745, DOI 10.4161/cbt.5.7.2971
   Gargalovic P, 2006, ARTERIOSCL THROM VAS, V26, pE50
   Ghosh R, 2010, PLOS ONE, V5, pA104, DOI 10.1371/journal.pone.0009575
   Giorgi C, 2009, INT J BIOCHEM CELL B, V41, P1817, DOI 10.1016/j.biocel.2009.04.010
   Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Hata N, 2008, CLIN OPHTHALMOL, V2, P743
   Hayakawa K, 2009, J IMMUNOL, V182, P1182, DOI 10.4049/jimmunol.182.2.1182
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   Hengstermann A, 2008, FREE RADICAL BIO MED, V44, P1097, DOI 10.1016/j.freeradbiomed.2007.12.009
   Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449
   Inokuchi Y, 2009, INVEST OPHTH VIS SCI, V50, P334, DOI 10.1167/iovs.08-2123
   Iriyama A, 2009, J CELL PHYSIOL, V220, P469, DOI 10.1002/jcp.21792
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Ji C, 2008, J GASTROEN HEPATOL, V23, pS16, DOI 10.1111/j.1440-1746.2007.05276.x
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Lin JH, 2008, ANNU REV PATHOL-MECH, V3, P399, DOI 10.1146/annurev.pathmechdis.3.121806.151434
   Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   Magnussen AL, 2010, INVEST OPHTH VIS SCI, V51, P4273, DOI 10.1167/iovs.09-4296
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Mandl J, 2009, TRENDS ENDOCRIN MET, V20, P194, DOI 10.1016/j.tem.2009.01.003
   Mattson MP, 2008, HUM EXP TOXICOL, V27, P155, DOI 10.1177/0960327107083417
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okubo A, 2000, INVEST OPHTH VIS SCI, V41, P4305
   Oskolkova OV, 2008, BLOOD, V112, P330, DOI 10.1182/blood-2007-09-112870
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Powers ET, 2009, ANNU REV BIOCHEM, V78, P959, DOI 10.1146/annurev.biochem.052308.114844
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Roybal CN, 2005, INVEST OPHTH VIS SCI, V46
   Roybal CN, 2005, J BIOL CHEM, V280, P20331, DOI 10.1074/jbc.M411275200
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41
   Sanson M, 2009, CIRC RES, V104, P328, DOI 10.1161/CIRCRESAHA.108.183749
   Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI 10.1089/ARS.2009.2625
   Sauer T, 2008, EXPERT REV OPHTHALMO, V3, P29, DOI 10.1586/17469899.3.1.29
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sekine Y, 2006, CURR MOL MED, V6, P87, DOI 10.2174/156652406775574541
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Terman A, 2002, ANN NY ACAD SCI, V973, P309, DOI 10.1111/j.1749-6632.2002.tb04657.x
   Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359
   Truettner JS, 2009, BRAIN RES, V1249, P9, DOI 10.1016/j.brainres.2008.10.032
   Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wei H, 2008, HUM MOL GENET, V17, P469, DOI 10.1093/hmg/ddm324
   Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007
   Werno C, 2008, J CELL PHYSIOL, V215, P708, DOI 10.1002/jcp.21351
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
NR 105
TC 99
Z9 101
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD NOV-DEC
PY 2010
VL 16
IS 11-12
BP 535
EP 542
DI 10.2119/molmed.2010.00070
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 679TL
UT WOS:000284183600010
PM 20683548
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Selid, PD
   Jundt, MC
   Fortney, AC
   Beal, JR
AF Selid, Paul D.
   Jundt, Michael C.
   Fortney, Aaron C.
   Beal, James R.
TI Intravitreal Bevacizumab and Aflibercept for the Treatment of Exudative
   Age-Related Macular Degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VISUAL-ACUITY; VEGF TRAP; RANIBIZUMAB; AVASTIN
AB BACKGROUND AND OBJECTIVE: To compare treatment of exudative age-related macular degeneration (AMD) with bevacizumab versus aflibercept in terms of central retinal thickness (CRT) and best corrected visual acuity (BCVA).
   PATIENTS AND METHODS: A retrospective cohort study examining changes in CRT and BCVA over 12 months of follow-up in 111 patients treated with bevacizumab and 91 treated with aflibercept for exudative AMD.
   RESULTS: Treatment with bevacizumab and aflibercept reduced CRT from baseline to 12 months. Aflibercept significantly reduced the mean change from baseline CRT at 12 months compared to bevacizumab. However, mean CRT at 12 months was not significantly different after aflibercept versus bevacizumab (271.6 +/- 74.0 mu m vs 257.9 +/- 48.5 mu m). BCVA was significantly better at 6 months in the aflibercept group. At baseline, 18.5% of bevacizumab and 26.4% of aflibercept patients had BCVA better than 20/40. At 12 months, 34.8% of bevacizumab and 38.9% of aflibercept patients had BCVA better than 20/40.
   CONCLUSION: CRT decreased and BCVA improved after treatment with bevacizumab and aflibercept for exudative AMD.
C1 [Selid, Paul D.; Jundt, Michael C.; Beal, James R.] Univ N Dakota, Sch Med & Hlth Sci, Grand Forks, ND 58202 USA.
   [Fortney, Aaron C.] Dakota Eye Inst, Bismarck, ND USA.
C3 University of North Dakota Grand Forks
RP Beal, JR (通讯作者)，Univ N Dakota, Sch Med & Hlth Sci, Dept Family & Community Med, Room 2514,501 N Columbia Rd,Stop 9037, Grand Forks, ND 58202 USA.
EM james.beal@med.und.edu
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Frampton JE, DRUGS AGING, V29, P839
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 20
TC 6
Z9 6
U1 0
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JUL-AUG
PY 2014
VL 45
IS 4
BP 275
EP 281
DI 10.3928/23258160-20140709-03
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA AY0OP
UT WOS:000347296300002
PM 25037009
DA 2022-11-30
ER

PT J
AU Buch, H
   Vinding, T
   la Cour, M
   Jensen, GB
   Prause, JU
   Nielsen, NV
AF Buch, H
   Vinding, T
   la Cour, M
   Jensen, GB
   Prause, JU
   Nielsen, NV
TI Age-related maculopathy: A risk indicator for poorer survival in women -
   The Copenhagen city eye study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; VISUAL IMPAIRMENT; MACULAR
   DEGENERATION; FOLLOW-UP; POSTMENOPAUSAL WOMEN; SENSORY IMPAIRMENT;
   5-YEAR INCIDENCE; LENS OPACITIES; OLDER-ADULTS
AB Purpose: To examine patient survival in age-related maculopathy in a 14-year follow-up study.
   Design: Population-based 14-year cohort study.
   Participants: Nine hundred forty-six residents, aged 60 to 80 years, living in the Osterbro district of Copenhagen, Denmark, participated in the first examination conducted from 1986 to 1988. These participants were followed until death or until May 1, 2002, whichever came first.
   Methods: Participants underwent an extensive ophthalmologic examination at Rigshospitalet, the National University Hospital of Copenhagen. Standardized protocols for physical examination, blood samples, and data from the National Central Person Register, the National Death Register, and the National Patient Register were used.
   Main Outcome Measures: Mortality and age-related maculopathy.
   Results: By May 1, 2002, 60.9% (577 of 946) of the participants of the baseline study cohort had died. The adjusted 14-year cumulative mortality hazard ratio for subjects with early and late age-related maculopathy at baseline was 1.26 (95% confidence interval [Cl], 1.06-1.51). We identified a strong correlation between mortality and age-related maculopathy among women (relative risk, 1.59; 95% Cl, 1.23-2.07) but not among men.
   Conclusions: When adjusting for survival-related factors, age-related maculopathy is a significant risk indicator for poorer survival in women and may be a marker of underlying serious systemic factors or aging processes specific to women.
C1 Natl Univ Hosp, Rigshosp, Dept Ophthalmol, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Herlev Hosp, Dept Ophthalmol, DK-2730 Herlev, Denmark.
   Bispebjerg Univ Hosp, Epidemiol Res Unit, Copenhagen City Heart Study, Copenhagen, Denmark.
   Hvidovre Univ Hosp, Dept Cardiol, DK-2650 Hvidovre, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg
   Hospital; University of Copenhagen
RP Buch, H (通讯作者)，Natl Univ Hosp, Rigshosp, Dept Ophthalmol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM hbh@dadlnet.dk
RI Hesgaard, Helena Buch/E-8226-2011; la Cour, Morten/L-1600-2013
OI Hesgaard, Helena Buch/0000-0002-2097-0202; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
CR BENGTSSON B, 1984, ACTA OPHTHALMOL, V62, P725
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   BUCH H, IN PRESS OPHTHALMOLO
   CALAF I, 1997, INT J FERTIL WOME S2, V42, P329
   CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x
   Clayton D., 1993, STAT MODELS EPIDEMIO
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   COLLET D, 1994, MODELLING SURVIVAL D, P254
   *COP CIT HEART STU, 1989, SCAND J SOC MED S, V17, P7
   DargentMolina P, 1996, INT J EPIDEMIOL, V25, P621, DOI 10.1093/ije/25.3.621
   FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128
   Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501
   Hennis A, 2001, OPHTHALMOLOGY, V108, P498, DOI 10.1016/S0161-6420(00)00542-X
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Korn EL, 1997, AM J EPIDEMIOL, V145, P72
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P48, DOI 10.1159/000027393
   Laforge R.G., 1992, J AGING HEALTH, V4, P126, DOI [10.1177/089826439200400108, DOI 10.1177/089826439200400108]
   Lee P, 1999, AM J OPHTHALMOL, V127, P447, DOI 10.1016/S0002-9394(98)00418-8
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   ROGOT E, 1966, J CHRON DIS, V19, P179, DOI 10.1016/0021-9681(66)90048-8
   *SAS I INC, 1999, SAS SYST WIND COMP P
   Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1
   Schnohr P, 1977, Ugeskr Laeger, V139, P1921
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   *STAT CORP, 1999, SATA COMP PROGR REL
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   THOMPSON JR, 1993, ARCH OPHTHALMOL-CHIC, V111, P675, DOI 10.1001/archopht.1993.01090050109039
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINDING Y, 1995, ACTA OPHTHALMOL SC S, V217, P1
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Whooley MA, 1998, ARCH INTERN MED, V158, P2129, DOI 10.1001/archinte.158.19.2129
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 52
TC 45
Z9 47
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2005
VL 112
IS 2
BP 305
EP 312
DI 10.1016/j.ophtha.2004.08.025
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 893RX
UT WOS:000226738000022
PM 15691568
DA 2022-11-30
ER

PT J
AU Hall, ER
   Klein, BEK
   Knudtson, MD
   Meuer, SM
   Klein, R
AF Hall, ER
   Klein, BEK
   Knudtson, MD
   Meuer, SM
   Klein, R
TI Age-related macular degeneration and optic disk cupping: The beaver dam
   eye study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LONGITUDINAL DATA-ANALYSIS; GLAUCOMA; ONSET
AB PURPOSE: To examine the association between presence, severity, and extent of lesions of age,related macular degeneration (AMD) and optic disk and cup diameters in a general population.
   DESIGN: Cross-sectional study.
   METHODS: SETTING: Population-based. STUDY POPULATION: Adults aged 43 to 86 years participating in the Beaver Dam Eye Study. OBSERVATION PROCEDURES: Fundus photographs were graded for lesions of AMD using standard protocols. The photographs were obtained during the baseline examination of the Beaver Dam Eye Study. MAIN OUTCOME MEASURE: Optic disk cupping as related to presence, severity, and extent of lesions of AMD.
   RESULTS: There were no significant differences in the vertical optic disk and cup measurements or in the vertical cup to disk ratios by severity of lesions of AMD (P values all greater than.10). In those eyes with late lesions of AMD, there was no association of the size of the lesions or their distribution in the fundus and the extent of cupping.
   CONCLUSIONS: From a population perspective, there is no relationship of the presence or severity of AMD and optic disk cupping.
C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Hall, ER (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM hall@epi.ophth.wisc.edu
FU NEI NIH HHS [EY 06594] Funding Source: Medline
CR Armaly M F, 1969, Trans Am Acad Ophthalmol Otolaryngol, V73, P898
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Hall ER, 2006, AM J OPHTHALMOL, V141, P494, DOI 10.1016/j.ajo.2005.10.049
   KIRSCH RE, 1973, T AM ACAD OPHTHALMOL, V77, P143
   KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1654
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   MAGLI YL, 1989, PROTOCOL OPTIC DISK
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   QUIGLEY HA, 1990, ARCH OPHTHALMOL-CHIC, V108, P51, DOI 10.1001/archopht.1990.01070030057028
   QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P135, DOI 10.1001/archopht.1982.01030030137016
   Read RM, 1974, T AM ACAD OPHTHALMOL, V78, P255
   Ryan S. J., 1989, RETINA, V2, P170
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHWARTZ B, 1973, ARCH OPHTHALMOL-CHIC, V89, P272
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P77, DOI 10.1001/archopht.1991.01080010079037
   Uchida H, 1996, INVEST OPHTH VIS SCI, V37, P2393
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
   ZEYEN TG, 1993, ARCH OPHTHALMOL-CHIC, V111, P62, DOI 10.1001/archopht.1993.01090010066028
NR 22
TC 13
Z9 13
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2006
VL 141
IS 3
BP 494
EP 497
DI 10.1016/j.ajo.2005.10.049
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 022LS
UT WOS:000236057900009
PM 16490495
DA 2022-11-30
ER

PT J
AU Navneet, S
   Rohrer, B
AF Navneet, Soumya
   Rohrer, Barbel
TI Elastin turnover in ocular diseases: A special focus on age-related
   macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Age -related macular degeneration; Extracellular matrix; Elastin;
   Elastase; Elastolytic enzymes; Elastin-derived peptides; Inflammation;
   Immune cell activity; Complement activation
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; HTRA1 PROMOTER
   POLYMORPHISM; FLOPPY EYELID SYNDROME; HUMAN BRUCHS MEMBRANE;
   SMOOTH-MUSCLE-CELLS; LYSYL-OXIDASE; LAMINA-CRIBROSA; CHOROIDAL
   NEOVASCULARIZATION; MATRIX METALLOPROTEINASES
AB The extracellular matrix (ECM) and its turnover play a crucial role in the pathogenesis of several inflammatory diseases, including age-related macular degeneration (AMD). Elastin, a critical protein component of the ECM, not only provides structural and mechanical support to tissues, but also mediates several intracellular and extracellular molecular signaling pathways. Abnormal turnover of elastin has pathological implications. In the eye elastin is a major structural component of Bruch's membrane (BrM), a critical ECM structure separating the retinal pigment epithelium (RPE) from the choriocapillaris. Reduced integrity of macular BrM elastin, increased serum levels of elastin-derived peptides (EDPs), and elevated elastin antibodies have been reported in AMD. Existing reports suggest that elastases, the elastin-degrading enzymes secreted by RPE, infiltrating macrophages or neutrophils could be involved in BrM elastin degradation, thus contributing to AMD pathogenesis. EDPs derived from elastin degradation can increase inflammatory and angiogenic responses in tissues, and the elastin antibodies are shown to play roles in immune cell activity and complement activation. This review summarizes our current understanding on the elastases/elastin fragments-mediated mechanisms of AMD pathogenesis.
C1 [Navneet, Soumya; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, Charleston, SC USA.
   [Rohrer, Barbel] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA.
   [Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC USA.
   [Navneet, Soumya; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Ralph H Johnson VA Medical Center; Medical
   University of South Carolina
RP Navneet, S; Rohrer, B (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM navneet@musc.edu; rohrer@musc.edu
FU National In- stitutes of Health (NIH) [R01EY030072]; Department of
   Veterans Affairs [IK6 BX004858, RX000444, BX003050]; South Carolina
   SmartState Endowment
FX Funding his project was provided in part by the National In- stitutes of
   Health (NIH) R01EY030072, the Department of Veterans Affairs IK6
   BX004858, RX000444 and BX003050 and the South Carolina SmartState
   Endowment. We would like to acknowledge the help from Navneet Ammal
   Kaidery PhD, Department of Pediatrics for creating the figures for this
   manuscript and Kyrie Wilson, Department of Ophthal- mology for editorial
   comments.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Ahmad S, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00688
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand-Apte B, 2019, J NEUROSCI RES, V97, P88, DOI 10.1002/jnr.24317
   Annamalai B, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.45
   Antonicelli F, 2007, CURR TOP DEV BIOL, V79, P99, DOI 10.1016/S0070-2153(06)79005-6
   BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Basalyga DM, 2004, CIRCULATION, V110, P3480, DOI 10.1161/01.CIR.0000148367.08413.E9
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bieth JG, 1986, REGULATION MATRIX AC, P217
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BOUDIER C, 1991, AM J RESP CELL MOL, V4, P497, DOI 10.1165/ajrcmb/4.6.497
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Brooke BS, 2003, TRENDS CARDIOVAS MED, V13, P176, DOI 10.1016/S1050-1738(03)00065-3
   BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149
   Butcher SK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00933
   Bykhovskaya Y, 2012, INVEST OPHTH VIS SCI, V53, P4152, DOI 10.1167/iovs.11-9268
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen K, 2014, ANN BIOMED ENG, V42, P678, DOI 10.1007/s10439-013-0936-x
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Cocciolone AJ, 2018, AM J PHYSIOL-HEART C, V315, pH189, DOI 10.1152/ajpheart.00087.2018
   Coral K, 2008, INVEST OPHTH VIS SCI, V49, P4746, DOI 10.1167/iovs.07-1550
   CROUTE F, 1991, BRIT J DERMATOL, V124, P538, DOI 10.1111/j.1365-2133.1991.tb04946.x
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davis EC, 1998, MATRIX BIOL, V17, P245, DOI 10.1016/S0945-053X(98)90078-6
   Dejneka NS, 2004, MOL VIS, V10, P964
   DeVera C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107988
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Di Marino M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.5
   Dietz HC, 1993, MARFAN SYNDROME
   Dudakova L, 2013, J NEURAL TRANSM, V120, P977, DOI 10.1007/s00702-013-0993-1
   Dudakova L, 2012, EXP EYE RES, V104, P74, DOI 10.1016/j.exer.2012.09.005
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   Elner Susan G, 2002, Trans Am Ophthalmol Soc, V100, P273
   Ewald CY, 2020, GERONTOLOGY, V66, P266, DOI 10.1159/000504295
   Feneck EM, 2018, EXP EYE RES, V177, P35, DOI 10.1016/j.exer.2018.07.024
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gelman S, 2010, EXP EYE RES, V90, P210, DOI 10.1016/j.exer.2009.10.007
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Gerth C, 2009, EYE, V23, P480, DOI 10.1038/eye.2008.251
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Gliem M, 2016, INVEST OPHTH VIS SCI, V57, P3323, DOI 10.1167/iovs.16-19388
   Godwin ARF, 2019, MATRIX BIOL, V84, P17, DOI 10.1016/j.matbio.2019.06.006
   Gourier HCY, 2015, J CLIN MED, V4, P874, DOI 10.3390/jcm4050874
   Greene WA, 2017, J OCUL PHARMACOL TH, V33, P132, DOI 10.1089/jop.2016.0070
   Grob S, 2012, EYE, V26, P1106, DOI 10.1038/eye.2012.107
   Groutas WC, 2011, EXPERT OPIN THER PAT, V21, P339, DOI 10.1517/13543776.2011.551115
   Gunda Venugopal, 2013, Invest Ophthalmol Vis Sci, V54, P7828, DOI 10.1167/iovs.12-10870
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hasanian-Langroudi F, 2015, OPHTHALMIC GENET, V36, P309, DOI 10.3109/13816810.2014.881507
   Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002
   He F., 2021, EYE LONDON ENGLAND
   Heinz A, 2011, BIOCHIMIE, V93, P187, DOI 10.1016/j.biochi.2010.09.011
   Hernandez MR, 2000, GLIA, V32, P122, DOI 10.1002/1098-1136(200011)32:2<122::AID-GLIA20>3.0.CO;2-J
   HERNANDEZ MR, 1992, INVEST OPHTH VIS SCI, V33, P2891
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   Horiguchi M, 2009, P NATL ACAD SCI USA, V106, P19029, DOI 10.1073/pnas.0908268106
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   JENSEN OA, 1977, A GRAEF ARCH KLIN EX, V203, P311, DOI 10.1007/BF00409836
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kaynak S, 2018, TURK OFTALMOL DERG, V48, P81, DOI 10.4274/tjo.27448
   Kim YM, 2011, AM J PATHOL, V179, P1560, DOI 10.1016/j.ajpath.2011.05.051
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2008, INVEST OPHTH VIS SCI, V49, P1101, DOI 10.1167/iovs.07-1145
   Kothapalli CR, 2010, ACTA BIOMATER, V6, P170, DOI 10.1016/j.actbio.2009.06.006
   Kumar S, 2017, AM J PATHOL, V187, P2841, DOI 10.1016/j.ajpath.2017.08.025
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lamande SR, 2020, ANAT REC, V303, P1527, DOI 10.1002/ar.24086
   Larche Mark, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS292, DOI 10.1513/AnnalsATS.201402-090AW
   Leonardi Andrea, 2010, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V9, P304
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Liu HT, 2019, DIABETOLOGIA, V62, P2365, DOI 10.1007/s00125-019-04998-4
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Lu ZG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216808
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Martinez-Velasco A, 2020, OPHTHALMIC GENET, V41, P539, DOI 10.1080/13816810.2020.1804945
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Miekus N, 2019, BIOCHIMIE, V165, P32, DOI 10.1016/j.biochi.2019.07.001
   Mithieux SM, 2005, ADV PROTEIN CHEM, V70, P437, DOI 10.1016/S0065-3233(05)70013-9
   Mohamad NA, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0197-3
   Mori H, 2019, GRAEF ARCH CLIN EXP, V257, P289, DOI 10.1007/s00417-018-4184-5
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277
   Mustafi D, 2013, FASEB J, V27, P4585, DOI 10.1096/fj.13-237537
   Nahum Y, 2008, ISR MED ASSOC J, V10, P179
   NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Natoli R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01666
   NETLAND PA, 1994, OPHTHALMOLOGY, V101, P174
   NEWSOME DA, 1988, EXP EYE RES, V46, P305, DOI 10.1016/S0014-4835(88)80022-8
   Nicoloff G, 2000, GEN PHARMACOL-VASC S, V35, P83, DOI 10.1016/S0306-3623(01)00095-7
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Noda K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1404
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Ortiz G, 2018, EXP EYE RES, V174, P29, DOI 10.1016/j.exer.2018.05.013
   Ortiz G, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-58
   Pena JDO, 1998, EXP EYE RES, V67, P517, DOI 10.1006/exer.1998.0539
   Pena JDO, 2001, INVEST OPHTH VIS SCI, V42, P2303
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Petersen E, 2002, EUR J VASC ENDOVASC, V24, P440, DOI 10.1053/ejvs.2002.1750
   Potilinski MC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072351
   QUIGLEY H, 1994, GRAEF ARCH CLIN EXP, V232, P257, DOI 10.1007/BF00194473
   Rabkin SW, 2017, PROG MOL BIOL TRANSL, V147, P239, DOI 10.1016/bs.pmbts.2017.02.002
   Risseeuw S, 2020, AM J OPHTHALMOL, V220, P82, DOI 10.1016/j.ajo.2020.07.022
   Risseeuw S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.34
   Risseeuw S, 2019, RETINA-J RET VIT DIS, V39, P1580, DOI 10.1097/IAE.0000000000002173
   Roach E Steve, 2015, Handb Clin Neurol, V132, P215, DOI 10.1016/B978-0-444-62702-5.00015-9
   Robinet A, 2005, J CELL SCI, V118, P343, DOI 10.1242/jcs.01613
   Rohrer B, 2019, MOL VIS, V25, P79
   Rohrer B, 2021, EXP EYE RES, V212, DOI 10.1016/j.exer.2021.108755
   Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043
   Sabatos-Peyton CA, 2010, CURR OPIN IMMUNOL, V22, P609, DOI 10.1016/j.coi.2010.08.006
   Saeed AFUH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00495
   SAGATIES MJ, 1989, CURR EYE RES, V8, P55, DOI 10.3109/02713688909013894
   SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Schlotzer-Schrehardt U, 2012, OPHTHALMOLOGY, V119, P1832, DOI 10.1016/j.ophtha.2012.03.015
   Schlotzer-Schrehardt U, 2005, OPHTHALMOLOGY, V112, P694, DOI 10.1016/j.ophtha.2004.11.031
   Schultz NM, 2021, CLIN THER, V43, P1792, DOI 10.1016/j.clinthera.2021.08.011
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Segawa Katsuzo, 1995, Nippon Ganka Gakkai Zasshi, V99, P1291
   Sekiyama E, 2012, FASEB J, V26, P567, DOI 10.1096/fj.11-184127
   Shadforth AMA, 2015, J FUNCT BIOMATER, V6, P946, DOI 10.3390/jfb6030946
   Shakya AK, 2018, TRENDS BIOTECHNOL, V36, P686, DOI 10.1016/j.tibtech.2018.02.008
   Sharma Rajesh K, 2005, BMC Ophthalmol, V5, P25, DOI 10.1186/1471-2415-5-25
   Shetty R, 2015, MOL VIS, V21, P12
   Sivaprasad S, 2005, INVEST OPHTH VIS SCI, V46, P3046, DOI 10.1167/iovs.04-1277
   Skeie JM, 2012, MATRIX BIOL, V31, P113, DOI 10.1016/j.matbio.2011.11.003
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Smith EL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00392
   Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200
   Sreekumar PG, 2018, J CONTROL RELEASE, V283, P94, DOI 10.1016/j.jconrel.2018.05.014
   Srivastava GK, 2011, J BIOMED MATER RES A, V97A, P243, DOI 10.1002/jbm.a.33050
   Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0
   Stockley RA, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.04.25
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181
   Sundaresan P, 2012, INVEST OPHTH VIS SCI, V53, P7492, DOI 10.1167/iovs.12-10073
   Taggart CC, 2005, AM J RESP CRIT CARE, V171, P1070, DOI 10.1164/rccm.200407-881PP
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Talukdar S, 2012, NAT MED, V18, P1407, DOI 10.1038/nm.2885
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tang NP, 2009, ANN EPIDEMIOL, V19, P740, DOI 10.1016/j.annepidem.2009.03.002
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Terai N, 2011, OPHTHALMOLOGE, V108, P467, DOI 10.1007/s00347-010-2312-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tong B, 2014, CLIN EXP IMMUNOL, V177, P586, DOI 10.1111/cei.12357
   Tong Y, 2010, MOL VIS, V16, P1958
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   UMIHIRA J, 1994, INVEST OPHTH VIS SCI, V35, P486
   Umihira Junichi, 1993, Nippon Ganka Gakkai Zasshi, V97, P1143
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Voigt AP, 2020, MICROVASC RES, V131, DOI 10.1016/j.mvr.2020.104031
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wachi H, 2005, CLIN BIOCHEM, V38, P643, DOI 10.1016/j.clinbiochem.2005.04.006
   Wang TT, 2015, IMMUNITY, V42, P213, DOI 10.1016/j.immuni.2015.01.022
   WERB Z, 1982, J INVEST DERMATOL, V79, pS154, DOI 10.1111/1523-1747.ep12546056
   White TL, 2017, INVEST OPHTH VIS SCI, V58, P2106, DOI 10.1167/iovs.16-21358
   White TL, 2017, EXP EYE RES, V159, P40, DOI 10.1016/j.exer.2017.03.002
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yanagisawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120643
   Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200
   Yeo GC, 2012, P NATL ACAD SCI USA, V109, P2878, DOI 10.1073/pnas.1111615108
   Younger J.R., 2006, INVEST OPHTH VIS SCI, V47, P732
   Yu HG, 2008, INVEST OPHTH VIS SCI, V49, P2599, DOI 10.1167/iovs.07-1508
   Yu Q, 2000, GENE DEV, V14, P163
   Zadeh N, 2011, AM J MED GENET A, V155A, P2661, DOI 10.1002/ajmg.a.34245
   ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855
   Zhang YW, 2010, EXP EYE RES, V90, P374, DOI 10.1016/j.exer.2009.09.018
   Zhang ZY, 2012, MOL VIS, V18, P2961
NR 200
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2022
VL 222
AR 109164
DI 10.1016/j.exer.2022.109164
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Y9NW
UT WOS:000861849000003
PM 35798060
DA 2022-11-30
ER

PT J
AU Baird, PN
   Richardson, AJ
   Robman, LD
   Dimitrov, PN
   Tikellis, G
   McCarty, CA
   Guymer, RH
AF Baird, PN
   Richardson, AJ
   Robman, LD
   Dimitrov, PN
   Tikellis, G
   McCarty, CA
   Guymer, RH
TI Apolipoprotein (APOE) gene is associated with progression of age-related
   macular degeneration (AMD)
SO HUMAN MUTATION
LA English
DT Article
DE age-related macular degeneration; apolipoprotein E; allele; association;
   progression; gender
ID AMINO-ACID-SEQUENCE; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; EPSILON-4
   ALLELE; MACULOPATHY; RISK; ESTROGEN; HETEROGENEITY; POPULATION;
   PREVALENCE
AB Progression of age,related macular degeneration (AMD), the leading cause of blindness in the elderly, was followed in a cohort of 238 individuals from a single center. Individuals with an epsilon (F)2 genotype (c.526C > T of reference sequence NM_000041.2) of the apolipoprotein (APOE) gene were found to be strongly associated with disease with a significant 4.8-fold increased relative risk compared to individuals with all 0 genotype (c.388T > C of reference sequence NM_000041.2) (odds ratio [OR], 4.8; 95% confidence interval [Cl], 1.19-19.09) and a nearly significant three-fold increased relative risk compared to individuals with an 0 genotype (reference sequence NM_000041.2) (OR, 2.8; 95% Cl, 0.96-19.09). This finding was present only in females who progressed with AMD, which suggests that there may be a gender-specific role in progression of AMD in individuals with an epsilon 2 allele. A gender related factor is therefore implicated either directly or indirectly in the AMD disease process.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA.
C3 Centre for Eye Research Australia; University of Melbourne; Marshfield
   Clinic
RP Baird, PN (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM pnb@unimelb.edu.au
OI Guymer, Robyn/0000-0002-9441-4356; McCarty,
   Catherine/0000-0003-1089-0142; Baird, Paul/0000-0002-1305-3502
CR Abramov Y, 2004, MENOPAUSE, V11, P62, DOI 10.1097/01.GME.0000074701.19603.11
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   DEKNIJFF P, 1994, HUM MUTAT, V4, P178, DOI 10.1002/humu.1380040303
   Duara R, 1996, NEUROLOGY, V46, P1575, DOI 10.1212/WNL.46.6.1575
   Edwards R, 2005, ADV BOT RES, V42, P1, DOI 10.1016/S0065-2296(05)42001-7
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hoyt BD, 2005, ARCH NEUROL-CHICAGO, V62, P454, DOI 10.1001/archneur.62.3.454
   Hyman BT, 1996, ANN NEUROL, V40, P55, DOI 10.1002/ana.410400111
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lambert JC, 2004, J MED GENET, V41, P104, DOI 10.1136/jmg.2003.005033
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pang CP, 2000, OPHTHALMOLOGICA, V214, P289, DOI 10.1159/000027506
   RALL SC, 1982, J BIOL CHEM, V257, P4171
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Sambrooke J., 1989, MOL CLONING LAB MANU, pE3
   SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   SCHULTZ DW, 2003, EPIDEMIOLOGY, V121, P679
   Scuteri A, 2001, AM J MED, V110, P28, DOI 10.1016/S0002-9343(00)00639-2
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Srivastava RAK, 1997, J BIOL CHEM, V272, P33360, DOI 10.1074/jbc.272.52.33360
   STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725
   Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9
   TIKELLIS G, IN PRESS EYE
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077
   Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 38
TC 79
Z9 85
U1 0
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD APR
PY 2006
VL 27
IS 4
BP 337
EP 342
DI 10.1002/humu.20288
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 028ZE
UT WOS:000236526500005
PM 16453339
DA 2022-11-30
ER

PT J
AU Aspinall, PA
   Borooah, S
   Al Alouch, C
   Roe, J
   Laude, A
   Gupta, R
   Gupta, M
   Montarzino, A
   Dhillon, B
AF Aspinall, P. A.
   Borooah, S.
   Al Alouch, C.
   Roe, J.
   Laude, A.
   Gupta, R.
   Gupta, M.
   Montarzino, A.
   Dhillon, B.
TI Gaze and pupil changes during navigation in age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EYE-MOVEMENTS; BEHAVIOR; STRATEGIES; LIFE; LOAD
AB Background The central visual field is particularly affected in age-related macular degeneration (AMD), and this can impinge on a variety of functional tasks, including navigation, which can affect activities of daily living. It has been difficult to assess navigational function under standardised conditions. The aim of this study is to examine gaze function and pupil diameter during navigation in patients with AMD.
   Methods This study was designed as an observational case-control investigation. 34 patients with AMD and 23 controls were recruited. We simulated a walking journey using video projection and monitored patients using automated eye tracking. Visual acuity, fixation count, fixation duration and pupil diameter were recorded while subjective measurements included recorded voice comments.
   Results The pupil diameters were significantly greater in the AMD group compared with the control group in both easy and difficult segments of navigation (p=0.002). Fixation counts were significantly higher in the AMD group during difficult segments of navigation (p=0.001). The differences in both pupil diameter and fixation count correlated with subject visual acuity.
   Conclusions Fixation count is a marker of difficult navigational environments in patients with AMD. The combination of video projection and eye tracking to assess visual navigation function is a useful clinical tool and an adjunct to current investigation tools in AMD intervention studies providing objective clinical measures under standardised settings.
C1 [Aspinall, P. A.; Roe, J.; Gupta, R.; Montarzino, A.] Heriot Watt Univ, Sch Built Environm, Edinburgh, Midlothian, Scotland.
   [Borooah, S.; Laude, A.; Dhillon, B.] Univ Edinburgh, Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Al Alouch, C.] Sultan Qaboos Univ, Coll Engn, Dept Civil & Architecture Engn, Muscat, Oman.
   [Laude, A.] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Gupta, M.] Stobhill Gen Hosp, NHS Greater Glasgow & Clyde, Glasgow G21 3UW, Lanark, Scotland.
C3 Heriot Watt University; University of Edinburgh; Sultan Qaboos
   University; Tan Tock Seng Hospital
RP Borooah, S (通讯作者)，Princess Alexandra Eye Pavil, Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM shyamanga@aol.com
RI Borooah, Shyamanga/AAM-6581-2021; Alalouch, Chaham/N-1670-2019
OI Alalouch, Chaham/0000-0002-2234-0351
FU Macular Society
FX This study received funding from the Macular Society.
CR Ahuja AK, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.4.1
   BEATTY J, 1982, PSYCHOL BULL, V91, P276, DOI 10.1037/0033-2909.91.2.276
   Bright Keith, 2010, COLOUR LIGHT CONTRAS
   Campbell S, 2005, DETERIORATING VISION
   Congdon N, ARCH OPHTHALMOL
   Geruschat DR, 2006, OPTOMETRY VISION SCI, V83, P550, DOI 10.1097/01.opx.0000232219.23362.a6
   Goldberg JH, 1999, INT J IND ERGONOM, V24, P631, DOI 10.1016/S0169-8141(98)00068-7
   Hamid SN, 2010, J VISION, V10, DOI 10.1167/10.12.28
   Hanson J, 2002, HOUSING SUPPORT NEED
   Hass EH, 1964, SCIENCE, V143, P1190
   Iorizzo DB, 2011, VISION RES, V51, P1173, DOI 10.1016/j.visres.2011.03.006
   Jacob RJK, 2003, MIND'S EYE: COGNITIVE AND APPLIED ASPECTS OF EYE MOVEMENT RESEARCH, P573, DOI 10.1016/B978-044451020-4/50031-1
   JUST MA, 1976, COGNITIVE PSYCHOL, V8, P441, DOI 10.1016/0010-0285(76)90015-3
   Kabanarou SA, 2006, OPHTHALMOLOGY, V113, P2251, DOI 10.1016/j.ophtha.2006.06.028
   KAHNEMAN D, 1966, SCIENCE, V154, P1583, DOI 10.1126/science.154.3756.1583
   Land MF, 2006, PROG RETIN EYE RES, V25, P296, DOI 10.1016/j.preteyeres.2006.01.002
   Magidson J., 2010, AM STAT ASS PROC
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Preuschoff K, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00115
   Schneider RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056556
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Turano KA, 2003, VISION RES, V43, P333, DOI 10.1016/S0042-6989(02)00498-4
   Uppal G, 2011, INVEST OPHTH VIS SCI, V52, P6486, DOI 10.1167/iovs.10-5879
   Vivekananda-Schmidt P, 2004, OPTOMETRY VISION SCI, V81, P844, DOI 10.1097/01.OPX.0000145021.86327.B0
   Watson AB, 2012, J VISION, V12, DOI 10.1167/12.10.12
NR 25
TC 14
Z9 14
U1 4
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2014
VL 98
IS 10
BP 1393
EP 1397
DI 10.1136/bjophthalmol-2014-305032
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ3HF
UT WOS:000342681400019
PM 24831715
DA 2022-11-30
ER

PT J
AU Somasundaran, S
   Constable, IJ
   Mellough, CB
   Carvalho, LS
AF Somasundaran, Shreya
   Constable, Ian J.
   Mellough, Carla B.
   Carvalho, Livia S.
TI Retinal pigment epithelium and age-related macular degeneration: A
   review of major disease mechanisms
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; apoptosis; eye; necrosis; retinal
   pigment epithelium
ID ALPHA-B-CRYSTALLIN; MITOCHONDRIAL-DNA DAMAGE; GEOGRAPHIC ATROPHY
   SECONDARY; MEMBRANE-CHOROID COMPLEX; OXIDATIVE STRESS; POTENTIAL ROLE;
   CELL-DEATH; APOPTOSIS; AUTOPHAGY; RPE
AB Age-related macular degeneration (AMD) is a progressive degenerative disease that is the leading cause of vision loss in the elderly population. Degeneration/dysregulation of the retinal pigment epithelium (RPE), a supportive monolayer of cells underlying the photoreceptors, is commonly seen in patients with AMD. While treatment exists for the neovascular/wet form of AMD, there is currently no cure for the non-exudative/dry form of AMD, making it imperative to understand the pathogenesis of this disease. Although our understanding of the aetiology of AMD has increased over the years, the underlying disease mechanism has not yet been identified, mainly due to the multifactorial nature of this disease. Herein, we review some of the commonly proposed degeneration pathways of RPE cells and their role in the pathogenesis of AMD; including activation of the complement cascade, oxidative stress-induced cell death mechanisms, dysfunctional mitochondria and the role of crystallins in AMD disease progression.
C1 [Somasundaran, Shreya; Constable, Ian J.; Mellough, Carla B.; Carvalho, Livia S.] Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, 2 Verdun St, Nedlands, WA 6009, Australia.
C3 Lions Eye Institute; University of Western Australia
RP Carvalho, LS (通讯作者)，Univ Western Australia, Lions Eye Inst, Ctr Ophthalmol & Visual Sci, 2 Verdun St, Nedlands, WA 6009, Australia.
EM liviacarvalho@lei.org.au
OI Mellough, Carla/0000-0003-3685-6516; Carvalho,
   Livia/0000-0002-3909-5778; Somasundaran, Shreya/0000-0002-3379-9360
FU Lions Eye Institute (LEI); LEI/Lions Save Sight Foundation (LSSF)
FX This work was funded by the Lions Eye Institute (LEI Livia S Carvalho)
   and a LEI/Lions Save Sight Foundation (LSSF)-funded Brian King
   Fellowship (Carla B. Mellough).
CR Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2015, BIORESEARCH OPEN ACC, V4, P334, DOI 10.1089/biores.2015.0022
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brandl C, 2015, J CLIN MED, V4, P282, DOI 10.3390/jcm4020282
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Candas D, 2014, ANTIOXID REDOX SIGN, V20, P1599, DOI 10.1089/ars.2013.5305
   Chapman NA, 2019, CLIN EXP OPHTHALMOL, V47, P106, DOI 10.1111/ceo.13343
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Correia-Melo C, 2015, BBA-BIOENERGETICS, V1847, P1373, DOI 10.1016/j.bbabio.2015.05.017
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841
   Dubois H, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007709
   Dunn JD, 2015, REDOX BIOL, V6, P472, DOI 10.1016/j.redox.2015.09.005
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Faatz H, 2017, KLIN MONATSBL AUGENH, V234, P1125, DOI 10.1055/s-0043-118346
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher Cody R., 2018, INVEST OPHTH VIS SCI, V59, P41, DOI DOI 10.1167/I0VS.18-24289
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gangalum RK, 2004, J BIOL CHEM, V279, P43374, DOI 10.1074/jbc.C400371200
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hageman G.S., 1995, ORIANIZATION RETINA
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Ho DT, 2006, J BIOL CHEM, V281, P13169, DOI 10.1074/jbc.M601010200
   Jarrett SG, 2010, OPHTHALMIC RES, V44, P179, DOI 10.1159/000316480
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Kim C, 2015, BMB REP, V48, P256, DOI 10.5483/BMBRep.2015.48.5.100
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P531, DOI 10.1111/aos.13772
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Lascaratos G, 2007, VISION RES, V47, P1191, DOI 10.1016/j.visres.2006.12.014
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   Li GY, 2010, BIOMED ENVIRON SCI, V23, P371, DOI 10.1016/S0895-3988(10)60078-5
   Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Lin MK, 2018, AGING CELL, V17, DOI 10.1111/acel.12710
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Maugeri A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7532507
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Newsholme P, 2007, J PHYSIOL-LONDON, V583, P9, DOI 10.1113/jphysiol.2007.135871
   Nissanka N, 2018, FEBS LETT, V592, P728, DOI 10.1002/1873-3468.12956
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ruan Q, 2011, MOL CANCER RES, V9, P1632, DOI 10.1158/1541-7786.MCR-11-0327
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Sharma Rajesh K, 2005, BMC Ophthalmol, V5, P25, DOI 10.1186/1471-2415-5-25
   Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100
   Sinha T, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101004
   Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Toms M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40507-8
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Watanabe G, 2009, CANCER SCI, V100, P2368, DOI 10.1111/j.1349-7006.2009.01316.x
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Zhang JH, 2000, CELL RES, V10, P205, DOI 10.1038/sj.cr.7290049
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
NR 116
TC 29
Z9 29
U1 3
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2020
VL 48
IS 8
SI SI
BP 1043
EP 1056
DI 10.1111/ceo.13834
EA AUG 2020
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OU0GL
UT WOS:000560642900001
PM 32710488
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Yang, SQ
   Zhao, JK
   Sun, XD
AF Yang, Shiqi
   Zhao, Jingke
   Sun, Xiaodong
TI Resistance to anti-VEGF therapy in neovascular age-related macular
   degeneration: a comprehensive review
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Review
DE age-related macular degeneration; vascular endothelial growth factor;
   choroidal neovascularization; resistance
ID ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL
   ANGIOMATOUS PROLIFERATION; OPTICAL-COHERENCE-TOMOGRAPHY; INTRAVITREAL
   RANIBIZUMAB; PHOTODYNAMIC THERAPY; 2.0 MG; ANATOMICAL OUTCOMES;
   SWITCHING TREATMENT; AFLIBERCEPT
AB As a progressive chronic disease, age-related macular degeneration (AMD) is the leading cause of irreversible vision impairment worldwide. Experimental and clinical evidence has demonstrated that vascular endothelial growth factor (VEGF) plays a vital role in the formation of choroidal neovascularization. Intravitreal injections of anti-VEGF agents have been recommended as a first-line treatment for neovascular AMD. However, persistent fluid or recurrent exudation still occurs despite standardized anti-VEGF therapy. Patients suffering from refractory or recurrent neovascular AMD may develop mechanisms of resistance to anti-VEGF therapy, which results in a diminished therapeutic effect. Until now, there has been no consensus on the definitions of refractory neovascular AMD and recurrent neovascular AMD. This article aims at clarifying these concepts to evaluate the efficacy of switching drugs, which contributes to making clinical decision more scientifically. Furthermore, insight into the causes of resistance to anti-VEGF therapy would be helpful for developing possible therapeutic approaches, such as combination therapy and multi-target treatment that can overcome this resistance.
C1 [Yang, Shiqi; Zhao, Jingke; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Eye Res Inst, Shanghai 200080, Peoples R China.
   [Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM xdsun@sjtu.edu.cn
RI Yang, Shiqi/CAI-7690-2022
OI Yang, Shiqi/0000-0003-1314-951X; Sun, Xiaodong/0000-0001-5015-0945
FU National Science Foundation for Distinguished Young Scholars [81425006]
FX This study was supported by grants from the National Science Foundation
   for Distinguished Young Scholars (81425006).
CR Abdullah SE, 2012, CANCER-AM CANCER SOC, V118, P3455, DOI 10.1002/cncr.26540
   Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549
   Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Arjamaa O, 2012, BRIT J OPHTHALMOL, V96, P1153, DOI 10.1136/bjophthalmol-2012-301823
   Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Avgikos KN, 2009, OPHTHALMOLOGY, V116, P1831, DOI 10.1016/j.ophtha.2009.03.040
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bressler NM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1741, DOI 10.1001/archopht.123.12.1741
   Broadhead GK, 2014, ACTA OPHTHALMOL, V92, P713, DOI 10.1111/aos.12463
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Bunnel CA, 2009, INTENSIVE REV INTERN
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Campa C, 2010, MEDIAT INFLAMM, V2010, P14
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chang YC, 2009, OPHTHAL SURG LAS IM, V40, P576, DOI 10.3928/15428877-20091030-07
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Cheung CMG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101057
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Criswell MH, 2008, ARCH OPHTHALMOL-CHIC, V126, P946, DOI 10.1001/archopht.126.7.946
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Ferrone PJ, 2014, BRIT J OPHTHALMOL, V98, P17, DOI 10.1136/bjophthalmol-2013-304474
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gharbiya M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273754
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grewal DS, 2014, EYE, V28, P895, DOI 10.1038/eye.2014.101
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hemeida TS, 2010, BRIT J OPHTHALMOL, V94, P701, DOI 10.1136/bjo.2009.167627
   Heussen FM, 2014, GRAEF ARCH CLIN EXP, V252, P909, DOI 10.1007/s00417-013-2553-7
   Hirano Y, 2015, OSLI RETINA, V46, P384, DOI 10.3928/23258160-20150323-16
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hu ZZ, 2015, BRIT J OPHTHALMOL, V99, P593, DOI 10.1136/bjophthalmol-2014-305488
   Huang JZ, 2004, MOL CANCER RES, V2, P36
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Joondeph Brian C, 2014, Retin Cases Brief Rep, V8, P342, DOI 10.1097/ICB.0000000000000065
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kaiser RS, 2012, OPHTHAL SURG LAS IM, V43, P13, DOI 10.3928/15428877-20111006-01
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kent JS, 2012, CAN J OPHTHALMOL, V47, P159, DOI 10.1016/j.jcjo.2012.01.003
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Messenger WB, 2014, BRIT J OPHTHALMOL, V98, P1205, DOI 10.1136/bjophthalmol-2013-304829
   Moon Da Ru Chi, 2015, Korean J Ophthalmol, V29, P226, DOI 10.3341/kjo.2015.29.4.226
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Morjaria R, 2014, EXPERT OPIN DRUG MET, V10, P1185, DOI 10.1517/17425255.2014.922543
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Pinheiro-Costa J, 2014, OPHTHALMOLOGICA, V232, P149, DOI 10.1159/000363422
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Puliafito CA, 2013, OPHTHAL SURG LAS IM, V44, P109, DOI 10.3928/23258160-20130313-01
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   ROGERS FB, 1963, B MED LIBR ASSOC, V51, P114
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Rusnati M, 2007, CURR PHARM DESIGN, V13, P2025
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shin Joo Young, 2013, Korean J Ophthalmol, V27, P425, DOI 10.3341/kjo.2013.27.6.425
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Sloan FA, 2014, JAMA OPHTHALMOL, V132, P456, DOI 10.1001/jamaophthalmol.2013.7647
   Souied EH, 2005, MOL VIS, V11, P1135
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   van Asten F, 2014, OPHTHAL EPIDEMIOL, V21, P347, DOI 10.3109/09286586.2014.949010
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Westfall TC., 2011, GOODMAN GILMANS PHAR, V12th ed
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   World Health Organization, 2012, PREV BLINDN VIS IMP
   Wu EX, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003794
   Wu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057642
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Yazdi MH, 2015, EXPERT OPIN BIOL TH, V15, P1349, DOI 10.1517/14712598.2015.1057565
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 129
TC 166
Z9 173
U1 6
U2 25
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2016
VL 10
BP 1857
EP 1867
DI 10.2147/DDDT.S97653
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DN3SH
UT WOS:000376983200001
PM 27330279
OA gold, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Nwosu, SNN
AF Nwosu, S. N. N.
TI Age-related macular degeneration in Onitsha, Nigeria
SO NIGERIAN JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
DE Age-related macular degeneration; age-related maculopathy; geographic
   atrophy; low vision; Nigeria
ID BLUE MOUNTAINS EYE; CARDIOVASCULAR-DISEASE; VISUAL-ACUITY; MACULOPATHY;
   RANIBIZUMAB; POPULATION; AUSTRALIA; 5-YEAR; AREDS
AB Objectives: To determine the incidence, pattern and ocular morbidity associated with age-related macular degeneration (AMD) at the Guinness Eye Center Onitsha Nigeria.
   Materials and Methods: The case files of all new patients aged 50 years and above seen between January 1997 and December 2004 were reviewed. The files of patients with AMD were further studied. Information on age, gender, occupation, duration of symptoms, type of maculopathy, visual acuity, ocular and systemic co-morbidities were abstracted into a standard proforma and analyzed using the chi-square test, student t-test and confidence interval estimation.
   Results: Two hundred and fifty-six of 7966 (3.2%) new patients had AMD; M: F = 2: 3; 60-79 year age group constitute 70% of the cases. Non-neovascular AMD occurred in 210 (82%) patients with 182 (71.1%) having early AMD and 28 (10.9%) geographic atrophy. Neovascular AMD occurred in 46 (18%) patients. AMD was bilateral in 221 (86.3%) patients. Most patients presented late. Systemic co-morbidities were hypertension and diabetes; the main ocular co-morbidities were cataract and glaucoma. Thirty-four (13.3%) patients were bilaterally blind and 130 (50.8%) had bilateral visual impairment. Of the blind patients 13(38.3%) had neovascular AMD and 6 (17.7%) had geographic atrophy. This makes AMD the cause of blindness in 7.4% of the patients. An affected eye was more likely to have low vision than an unaffected eye (95% CI: 0.07, 0.21; P<0.05); persons aged 70 years and above were more likely to be blind (chi(2)-7.26, df-1; P<0.05); females were also more likely to be blind than males (t-2.857, df-8; P<0.05) and neovascular AMD significantly causes more blindness than the non-neovascular type (95% CI: 0.11, 0.37; P<0.05).
   Conclusions: AMD was the main cause of blindness in 7.4% of the patients. Treatment facilities including low vision aids for AMD patients should be provided in eye hospitals in Nigeria. Health education of the public highlighting the risk factors for AMD should be mounted as part of Vision 2020 programme in Nigeria. A community based study is required to fully define the epidemiologic characteristics of AMD in Nigerians.
C1 Guinness Eye Ctr, Onitsha, Nigeria.
RP Nwosu, SNN (通讯作者)，Guinness Eye Ctr, Onitsha, Nigeria.
EM nwoseb@hotmail.com
CR Abiose A., 1978, NIGERIAN MED J, V6, P180
   Age-related Eye Disease Study Research Group, 2005, OPHTHALMOLOGY, V112, P533
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Ayanru JO, 1982, ENV CULTURE EYE DIS, P42
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   COOPER RL, 1990, AUST NZ J OPHTHALMOL, V18, P421, DOI 10.1111/j.1442-9071.1990.tb01828.x
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   Nwosu SN, 2002, NIGER J CLIN PRACT, V5, P123
   NWOSU SNN, 1994, TROP GEOGR MED, V46, P346
   Nwosu SNN, 2000, NIG J OPHTHALMOL, V8, P7
   Nwosu SNN, 1995, W AFR J MED, V14, P33
   Nwosu SNN, 1999, TROP J MED RES, V3, P75
   Omoti AE, 2004, CMS UNIBEN JMBR, V3, P7
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Tielsch JA, 1995, VISION PROBLEMS US R, P1
   2001, ARCH OPHTHALMOL, V119, P1417
NR 26
TC 6
Z9 6
U1 0
U2 2
PU MEDICAL & DENTAL CONSULTANTS ASSOC NIGERIA
PI NNEWI
PA UNIV TEACHING HOSP, DEPT SURGERY, NNAMDI AZIKIWE. PMB 5025, NNEWI,
   00000, NIGERIA
SN 1119-3077
J9 NIGER J CLIN PRACT
JI Niger. J. Clin. Pract.
PD JUL-SEP
PY 2011
VL 14
IS 3
BP 327
EP 331
DI 10.4103/1119-3077.86778
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 850AY
UT WOS:000297168000016
PM 22037079
DA 2022-11-30
ER

PT J
AU Cano, MD
   Gehlbach, PL
AF Cano, Marisol del V.
   Gehlbach, Peter L.
TI PPAR-alpha Ligands as Potential Therapeutic Agents for Wet Age-Related
   Macular Degeneration
SO PPAR RESEARCH
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATOR-ACTIVATED RECEPTORS; TISSUE
   DISTRIBUTION; PHARMACOLOGICAL TARGET; BEVACIZUMAB AVASTIN; GAMMA
   ACTIVATORS; EXPRESSION; CELLS; MACULOPATHY; FENOFIBRATE
AB The peroxisome proliferator-activated receptors (PPAR's) are members of the steroid/thyroid nuclear receptor, superfamily of transcription factors. There are currently three known PPAR subtypes, alpha, beta, and gamma. The PPARs are now recognized participants in a number of biological pathways some of which are implicated in the pathogenesis of age-related macular degeneration (AMD). These include immune modulation, lipid regulation, and oxidant/antioxidant pathways important to the onset and progression of "dry" AMD, and vascular endothelial growth factor (VEGF) mediated pathways that stimulate choroidal neovascularization (CNV), characteristic of "wet" AMD. PPAR-alpha is found in retina and also on vascular cells important to formation of CNV. At this time, however, relatively little is known about potential contributions of PPAR-alpha to the pathogenesis of dry and wet AMD. This review examines current literature for potential roles of PPAR-alpha in the pathogenesis and potential treatment of AMD with emphasis on prevention and treatment of wet AMD. Copyright (C) 2008 M. del V Cano and P. L. Gehlbach.
C1 [Cano, Marisol del V.; Gehlbach, Peter L.] Johns Hopkins Univ Hosp, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Gehlbach, PL (通讯作者)，Johns Hopkins Univ Hosp, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
EM pgelbach@jhmi.edu
FU JG Foundation; Research to Prevent Blindness (Wilmer Eye Institute);
   Research to Prevent Blindness Career Development Award; William Weis
   Award; Jack and Gail Baylin Philanthropic Fund; JHU
FX This work is financially supported by the JG Foundation (PLG); an
   unrestricted grant from Research to Prevent Blindness (Wilmer Eye
   Institute) and a Research to Prevent Blindness Career Development Award
   (PLG); William Weis Award (PLG); Jack and Gail Baylin Philanthropic
   Fund; the JHU Fund for Medical Discovery (PLG) and a gift from Kenneth
   and Brenda Richardson (PLG).
CR ACRA M, 2007, FREE RADICAL BIO MED, V42, P698
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319
   Auwerx J, 1996, J MOL MED, V74, P347, DOI 10.1007/s001090050036
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bonne C, 2005, J FR OPHTALMOL, V28, P326, DOI 10.1016/S0181-5512(05)81062-9
   Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341
   Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354
   Chang F, 2007, ANN PHARMACOTHER, V41, P973, DOI 10.1345/aph.1K013
   CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798
   Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216
   Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Ferrara N, 2005, EXP SUPPL, V94, P209
   Giaginis C, 2007, EXPERT OPIN INV DRUG, V16, P1561, DOI 10.1517/13543784.16.10.1561
   Han SH, 2005, HYPERTENSION, V46, P1086, DOI 10.1161/01.HYP.0000187900.36455.4c
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Iglarz M, 2003, ARTERIOSCL THROM VAS, V23, P45, DOI 10.1161/01.ATV.0000047447.67827.CD
   Inoue I, 1998, BIOCHEM BIOPH RES CO, V246, P370, DOI 10.1006/bbrc.1998.8622
   Israelian-Konaraki Z, 2005, CARDIOLOGY, V103, P1, DOI 10.1159/000081845
   Itoh H, 1999, CLIN EXP PHARMACOL P, V26, P558, DOI 10.1046/j.1440-1681.1999.03082.x
   Kinose F, 2005, MOL VIS, V11, P366
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Komers R, 1998, PHYSIOL RES, V47, P215
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lemberger T, 1996, ANN NY ACAD SCI, V804, P231, DOI 10.1111/j.1749-6632.1996.tb18619.x
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marx N, 1998, CIRC RES, V83, P1097, DOI 10.1161/01.RES.83.11.1097
   Meissner M, 2004, CIRC RES, V94, P324, DOI 10.1161/01.RES.0000113781.08139.81
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Michels S, 2005, KLIN MONATSBL AUGENH, V222, P480, DOI 10.1055/s-2005-858315
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Plutzky J, 2001, CURR OPIN LIPIDOL, V12, P511, DOI 10.1097/00041433-200110000-00006
   Pola R, 2004, J MOL CELL CARDIOL, V36, P363, DOI 10.1016/j.yjmcc.2003.10.016
   SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393
   Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701
   Varet J, 2003, CELL MOL LIFE SCI, V60, P810, DOI 10.1007/s00018-003-2322-6
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Yokoyama Y, 2007, MOL CANCER THER, V6, P1379, DOI 10.1158/1535-7163.MCT-06-0722
   Fokko ZA, 2007, BBA-MOL CELL BIOL L, V1771, P972, DOI 10.1016/j.bbalip.2007.04.021
NR 51
TC 6
Z9 6
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-4757
EI 1687-4765
J9 PPAR RES
JI PPAR Res.
PY 2008
VL 2008
AR 821592
DI 10.1155/2008/821592
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V14AE
UT WOS:000207706500001
PM 18401454
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Bora, NS
   Matta, B
   Lyzogubov, VV
   Bora, PS
AF Bora, Nalini S.
   Matta, Bharati
   Lyzogubov, Valeriy V.
   Bora, Puran S.
TI Relationship between the complement system, risk factors and prediction
   models in age-related macular degeneration
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE Complement system; Age-related macular degeneration; Retina; Choroid;
   Risk factors; Prediction models
ID MEMBRANE-ATTACK-COMPLEX; INDUCED CHOROIDAL NEOVASCULARIZATION;
   ENDOTHELIAL GROWTH-FACTOR; FACTOR-H POLYMORPHISM; MOUSE MODEL; OXIDATIVE
   STRESS; ANIMAL-MODELS; REGULATORY PROTEINS; ALTERNATIVE PATHWAY; DRUSEN
   FORMATION
AB Studies performed over the past decade in humans and experimental animals have been a major source of information and improved our understanding of how dysregulation of the complement system contributes to age-related macular degeneration (AMD) pathology. Drusen, the hall-mark of dry-type AMD are reported to be the by-product of complement mediated inflammatory processes. In wet AMD, unregulated complement activation results in increased production of angiogenic growth factors leading to choroidal neovascularization both in humans and in animal models. In this review article we have linked the complement system with modifiable and non-modifiable AMD risk factors as well as with prediction models of AMD. Understanding the association between the complement system, risk factors and prediction models will help improve our understanding of AMD pathology and management of this disease. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Bora, Nalini S.; Matta, Bharati; Lyzogubov, Valeriy V.; Bora, Puran S.] Univ Arkansas Med Sci, Pat & Willard Walker Eye Res Ctr, Jones Eye Inst, Dept Ophthalmol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Bora, NS (通讯作者)，Univ Arkansas Med Sci, Jones Eye Inst, Dept Ophthalmol, 4301 West Markham,Mail Slot 523, Little Rock, AR 72205 USA.
EM nbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU Lions of Arkansas Foundation, Inc.; Research to Prevent Blindness; Pat
   and Willard Walker Eye Research Center, Jones Eye Institute, University
   of Arkansas for Medical Sciences, Little Rock, AR, USA
FX The related work from our laboratory was supported in part by Lions of
   Arkansas Foundation, Inc., Research to Prevent Blindness and Pat and
   Willard Walker Eye Research Center, Jones Eye Institute, University of
   Arkansas for Medical Sciences, Little Rock, AR, USA.
CR Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   ATKINSON JP, 1987, IMMUNOL TODAY, V8, P212, DOI 10.1016/0167-5699(87)90167-8
   ATKINSON JP, 1980, CLIN IMMUNOLOGY, P219
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bonnel S, 2003, EXP GERONTOL, V38, P825, DOI 10.1016/S0531-5565(03)00093-7
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora Nalini S., 2011, Current Immunology Reviews, V7, P360
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Davis SJ, 2012, RETINA-J RET VIT DIS, V32, P1171, DOI 10.1097/IAE.0b013e31823496b8
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dzik JM, 2010, ACTA BIOCHIM POL, V57, P443
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Faber C, 2012, INVEST OPHTH VIS SCI, V53, P6324, DOI 10.1167/iovs.12-10385
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Fletcher EL, 2011, PROG MOL BIOL TRANSL, V100, P211, DOI 10.1016/B978-0-12-384878-9.00006-6
   Fraser DA, 2003, J BIOL CHEM, V278, P48921, DOI 10.1074/jbc.M302598200
   Gibson J, 2012, IMMUNOBIOLOGY, V217, P251, DOI 10.1016/j.imbio.2011.07.015
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman G.S., 2008, WEBVISION ORG RETINA
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hart ML, 2004, MOL IMMUNOL, V41, P165, DOI 10.1016/j.molimm.2004.03.013
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holst B, 2012, ANAESTHESIA, V67, P60, DOI 10.1111/j.1365-2044.2011.07011.x
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaliappan S, 2008, FEBS LETT, V582, P3451, DOI 10.1016/j.febslet.2008.09.009
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kohl J, 2006, ADV EXP MED BIOL, V586, P71
   Kondos SC, 2010, TISSUE ANTIGENS, V76, P341, DOI 10.1111/j.1399-0039.2010.01566.x
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liszewski MK, 2011, HEMATOL-AM SOC HEMAT, P9, DOI 10.1182/asheducation-2011.1.9
   LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Liu L, 2013, CLIN OPTOM, V5, P1, DOI 10.2147/OPTO.S29932
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Molina H, 2002, CELL MOL LIFE SCI, V59, P220, DOI 10.1007/s00018-002-8418-6
   Montezuma SR, 2009, SEMIN OPHTHALMOL, V24, P52, DOI 10.1080/08820530902800017
   MORGAN BP, 1999, COMPLEMENT REGULATOR, P1
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Ross G. D, 1986, IMMUNOBIOLOGY COMPLE
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rutkowski MJ, 2010, INFLAMM RES, V59, P897, DOI 10.1007/s00011-010-0220-6
   Sacks SH, 2012, NAT REV IMMUNOL, V12, P431, DOI 10.1038/nri3225
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P4195
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Wolf-Schnurrbusch UEK, 2009, RETINA-J RET VIT DIS, V29, P966, DOI 10.1097/IAE.0b013e3181a2f40f
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 109
TC 31
Z9 34
U1 0
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD FEB
PY 2015
VL 63
IS 2
SI SI
BP 176
EP 183
DI 10.1016/j.molimm.2014.07.012
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA AW8WT
UT WOS:000346540900008
PM 25074023
DA 2022-11-30
ER

PT J
AU Lee, GKY
   Lai, TYY
   Chan, WM
   Lam, DSC
AF Lee, Gary K. Y.
   Lai, Timothy Y. Y.
   Chan, Wai-Man
   Lam, Dennis S. C.
TI Retinal pigment epithelial tear following intravitreal ranibizumab
   injections for neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; choroidal
   neovascularisation; ranibizumab; retinal pigment epithelial tear
ID CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB AVASTIN
AB Background To report the development of retinal pigment epithelial (RPE) tear after intravitreal injection of ranibizumab (Lucentis, Novartis, Basel, Switzerland).
   Methods Case report with presentation of the fundus photography, fluorescein angiography (FA) and optical coherence tomography (OCT) findings.
   Results A 70-year-old man received intravitreal injections of ranibizumab for the treatment of occult choroidal neovascularisation (CNV) with fibrovascular pigment epithelial detachment due to age-related macular degeneration. One day after the third intravitreal ranibizumab injection, fundus examination showed a RPE defect at the foveal region. FA and OCT confirmed the presence of RPE tear sparing the fovea. No further progression of the RPE tear was observed after withholding subsequent ranibizumab injection and his right eye visual acuity remained at 20/100 at 3 months from the last injection.
   Conclusions As with other anti-vascular endothelial growth factor treatment for CNV, RPE tear might occur after intravitreal ranibizumab injection even after previous uneventful intravitreal injections.
C1 Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong
RP Lai, TYY (通讯作者)，Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, 147K Argyle St, Hong Kong, Hong Kong, Peoples R China.
EM tyylai@cuhk.edu.hk
RI Lam, Dennis/AAL-1211-2020; Lai, Timothy Y Y/AAC-2120-2020
OI Lai, Timothy Y Y/0000-0002-7832-6428
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
NR 10
TC 27
Z9 27
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2007
VL 245
IS 8
BP 1225
EP 1227
DI 10.1007/s00417-007-0536-2
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186MY
UT WOS:000247784000018
PM 17287977
DA 2022-11-30
ER

PT J
AU Vojnikovic, B
   Njiric, S
   Coklo, M
   Spanjol, J
AF Vojnikovic, Bozidar
   Njiric, Sanja
   Coklo, Miran
   Spanjol, Josip
TI Ultraviolet sun radiation and incidence of age-related macular
   degeneration on Croatian island Rab
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE AMD; exfoliation syndrome; exposure to sunlight
ID SPECTRUM; RETINA
AB This epidemiological study is completed on island Rob, located in North Adriatic Sea. For this study it is important that Adriatic Sea has one of the highest solar radiations in geographical area of Europe. The aim of this epidemiological study is to estimate correlation between incidence of Age-Related Macular Degeneration (AMD) and exposure of sunlight in two different populations on island Rab. In the first group of population of island Rob, agriculturists and fishermen (n = 1300), incidence of AMD was in 18%, but in urban population only 2.5%. It is very interesting that correlation exists between incidence of AMD and exfoliation syndrome. In the group of chronic exposure to sunlight (agriculturists and fishermen) exfoliation syndrome exists in 28%, but in urban population it has never been seen. The age in both populations was 45-65 years. We can conclude that there is a very significant correlation between chronic exposure to sunlight and appearance of AMD.
C1 Eye Polyclin Dr B Vojnikovic, Rijeka 51000, Croatia.
   Eye Polyclin Dr L Pavicevic, Rijeka, Croatia.
   Rijeka Univ, Sch Med, Dept Forens Med, Rijeka, Croatia.
   Rijeka Univ Hosp, Dept Urol, Rijeka, Croatia.
C3 University of Rijeka; University of Rijeka; University of Rijeka
RP Vojnikovic, B (通讯作者)，Eye Polyclin Dr B Vojnikovic, Antuna Barca 3B, Rijeka 51000, Croatia.
EM decv@decv.com
RI Španjol, Josip/A-1004-2010; Španjol, Josip/O-3756-2018
OI Španjol, Josip/0000-0002-5551-8128; Spanjol, Josip/0000-0001-9686-3393
CR BRUMEN V, 2003, SIGURNOST, V45, P107
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   HAM WT, 1982, AM J OPHTHALMOL, V93, P299, DOI 10.1016/0002-9394(82)90529-3
   Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028
   KANC RP, 1998, INT J CLIMAT, V18, P457
   Lerman S., 1980, RADIANT ENERGY EYE, P73
   LISAC I, 1998, GOSPODARSTVO OKOLIS, V33, P381
   LUCKE A, 1984, KLIN MONATSBL AUGENH, V184, P77, DOI 10.1055/s-2008-1054415
   MOM T, 1983, OPHTHALMOLOGY, V90, P952
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   MYRON Y, 1989, OCULAR PATHOLOGY
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Penzar B., 2001, VRIJEME KLIMA HRVATS
   RODNEY B, 2002, CONCEPTS BIOCH
   SYKES SM, 1981, INVEST OPHTH VIS SCI, V20, P425
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10579
   VOJNIKOVIC B, 2005, EINSTEINOV ZAKON ELE
NR 18
TC 29
Z9 31
U1 0
U2 12
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PD JAN
PY 2007
VL 31
SU 1
BP 43
EP 44
PG 2
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 143XD
UT WOS:000244758800010
PM 17469748
DA 2022-11-30
ER

PT J
AU Sarkar, A
   Junnuthula, V
   Dyawanapelly, S
AF Sarkar, Aira
   Junnuthula, Vijayabhaskarreddy
   Dyawanapelly, Sathish
TI Ocular Therapeutics and Molecular Delivery Strategies for Neovascular
   Age-Related Macular Degeneration (nAMD)
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE ocular therapeutics; age-related macular degeneration; gene therapy;
   cell therapy; bispecific antibodies; port delivery system
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; INTRAVITREAL
   TRIAMCINOLONE ACETONIDE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VEGF
   COMBINATION TREATMENT; RANDOMIZED CLINICAL-TRIAL; ANTI-VEGF;
   GENE-THERAPY; PHOTODYNAMIC THERAPY; DRUG-DELIVERY
AB Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies.
C1 [Sarkar, Aira] Johns Hopkins Univ, Chem & Biomol Engn, Baltimore, MD 21218 USA.
   [Junnuthula, Vijayabhaskarreddy] Univ Helsinki, Fac Pharm, Drug Res Program, Viikinkaari 5, Helsinki 00790, Finland.
   [Dyawanapelly, Sathish] Inst Chem Technol, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Mumbai 400019, Maharashtra, India.
C3 Johns Hopkins University; University of Helsinki; Institute of Chemical
   Technology - Mumbai
RP Junnuthula, V (通讯作者)，Univ Helsinki, Fac Pharm, Drug Res Program, Viikinkaari 5, Helsinki 00790, Finland.; Dyawanapelly, S (通讯作者)，Inst Chem Technol, Dept Pharmaceut Sci & Technol, Nathalal Parekh Marg, Mumbai 400019, Maharashtra, India.
EM asarka11@jhu.edu; junnuthula.vijayabhaskarreddy@helsinki.fi;
   sa.dyawanapelly@ictmumbai.edu.in
RI Dyawanapelly, Sathish/AAK-1843-2020; DYAWANAPELLY,
   SATHISH/AHC-3560-2022; Junnuthula, Vijayabhaskar Reddy/AAL-3716-2021;
   Junnuthula, Vijayabhaskarreddy/T-7064-2019
OI Dyawanapelly, Sathish/0000-0002-2310-1651; DYAWANAPELLY,
   SATHISH/0000-0002-2310-1651; Junnuthula,
   Vijayabhaskarreddy/0000-0003-2968-2036
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   [Anonymous], Adverum Down after Clinical Development Shift for Gene Therapy Program
   [Anonymous], Recommendations|Age-Related Macular Degeneration|Guidance
   [Anonymous], Adverum Halt Raises More Gene Therapy Questions
   [Anonymous], AMD Treatment Guidelines
   [Anonymous], GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months
   [Anonymous], Sunitinib-Loaded Injectable Polymer Depot Formulation for Potential Once per Year Treatment of Neovascular Age-Related Macular Degeneration (Wet AMD)
   [Anonymous]
   [Anonymous], SERIOUS ADVERSE REAC
   Anselmo AC, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10246
   Anselmo AC, 2016, BIOENG TRANSL MED, V1, P10, DOI 10.1002/btm2.10003
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Asahi MG, 2021, EXPERT OPIN EMERG DR, V26, P193, DOI 10.1080/14728214.2021.1931120
   Atale SS, 2019, INT J BIOL MACROMOL, V123, P97, DOI 10.1016/j.ijbiomac.2018.11.039
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Badiee P, 2018, J BIOMED MATER RES A, V106, P2261, DOI 10.1002/jbm.a.36424
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   Bande MF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18412-9
   Bantseev V, 2020, RETINA-J RET VIT DIS, V40, P1520, DOI 10.1097/IAE.0000000000002614
   Baradaran-Rafii A, 2020, CELL TISSUE BANK, V21, P339, DOI 10.1007/s10561-020-09826-3
   Basile AS, 2012, J CLIN PHARMACOL, V52, P1186, DOI 10.1177/0091270011412961
   Battaglia L, 2018, LIPID NANOCARRIERS FOR DRUG TARGETING, P269, DOI 10.1016/B978-0-12-813687-4.00007-4
   Baudin F, 2018, JAMA OPHTHALMOL, V136, P1352, DOI 10.1001/jamaophthalmol.2018.3939
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Becerra S.P, 1997, RESULTS PROBL CELL D, V425, P223, DOI [10.1007/978-1-4615-5391-5_21, DOI 10.1007/978-1-4615-5391-5_21]
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Booth C, 2016, TRENDS MOL MED, V22, P317, DOI 10.1016/j.molmed.2016.02.002
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Chakrabarty K, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1036-5
   Chaudhary V, 2016, CAN J OPHTHALMOL, V51, P302, DOI 10.1016/j.jcjo.2016.04.020
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Cheng LY, 2005, RETINA-J RET VIT DIS, V25, P193, DOI 10.1097/00006982-200502000-00013
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Collins M, 2021, DRUG DISCOV TODAY, V26, P44, DOI 10.1016/j.drudis.2020.10.025
   Constable IJ, 2017, AM J OPHTHALMOL, V177, P150, DOI 10.1016/j.ajo.2017.02.018
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cook G. P., 2006, INVEST OPHTH VIS SCI, V47, P5123
   D'Mello SAN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071144
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Daya S, 2008, CLIN MICROBIOL REV, V21, P583, DOI 10.1128/CMR.00008-08
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Dib E, 2012, CURR EYE RES, V37, P567, DOI 10.3109/02713683.2011.635916
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Du JD, 2016, DRUG DELIV TRANSL RE, V6, P781, DOI 10.1007/s13346-016-0299-6
   Dunn EN, 2017, OSLI RETINA, V48, P100, DOI 10.3928/23258160-20170130-02
   Edison LS, 2015, EMERG INFECT DIS, V21, P171, DOI 10.3201/eid2101.141040
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Everson EM, 2016, CURR OPIN VIROL, V21, P41, DOI 10.1016/j.coviro.2016.07.010
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Falk T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/278932
   Farjo KM, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-21
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Figueroa AG, 2021, AM J MED, V134, P122, DOI 10.1016/j.amjmed.2020.05.038
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Formica ML, 2021, PHARMACOL RES PERSPE, V9, DOI 10.1002/prp2.723
   Fu DJ, 2021, JAMA OPHTHALMOL, V139, P57, DOI 10.1001/jamaophthalmol.2020.5044
   Gandhi JK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227641
   Gandhi JK, 2018, ACTA BIOMATER, V67, P134, DOI 10.1016/j.actbio.2017.11.058
   Gao GP, 1996, J VIROL, V70, P8934, DOI 10.1128/JVI.70.12.8934-8943.1996
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gross N, 2013, MOL VIS, V19, P54
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hareendran S, 2013, REV MED VIROL, V23, P399, DOI 10.1002/rmv.1762
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Holekamp NM, 2019, AM J MANAG CARE, V25, pS172
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   Hussain N.M, 2020, NZ MED STUD J, V31, P23
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Iglicki M, 2021, EYE, V35, P1111, DOI 10.1038/s41433-020-01309-9
   Iovino C, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080703
   Iyer S, 2019, J CONTROL RELEASE, V296, P140, DOI 10.1016/j.jconrel.2019.01.007
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jermak CM, 2007, SURV OPHTHALMOL, V52, P503, DOI 10.1016/j.survophthal.2007.06.004
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Junnuthula V, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040445
   Kahook MY, 2010, J GLAUCOMA, V19, P437, DOI 10.1097/IJG.0b013e3181ca74de
   Kari OK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12080763
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kay MA, 2003, NATURE, V424, P251, DOI 10.1038/424251b
   Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280-000000000-00000
   Khanani AM, 2021, EXPERT OPIN DRUG DEL, V18, P1571, DOI 10.1080/17425247.2021.1968826
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Kumar M, 2001, HUM GENE THER, V12, P1893, DOI 10.1089/104303401753153947
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai LJ, 2007, J BIOMED SCI, V14, P313, DOI 10.1007/s11373-007-9153-7
   Lai YKY, 2003, ADV EXP MED BIOL, V533, P447
   Lajunen T, 2018, J CONTROL RELEASE, V284, P213, DOI 10.1016/j.jconrel.2018.06.029
   Lajunen T, 2016, MOL PHARMACEUT, V13, P2095, DOI 10.1021/acs.molpharmaceut.6b00207
   Lajunen T, 2015, J CONTROL RELEASE, V203, P85, DOI 10.1016/j.jconrel.2015.02.028
   Lazzara F, 2019, BIOCHEM PHARMACOL, V168, P341, DOI 10.1016/j.bcp.2019.07.021
   Li TH, 2015, PHOTOCH PHOTOBIO SCI, V14, P972, DOI 10.1039/c4pp00412d
   Ling SK, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00656-y
   Lisowski L, 2015, CURR OPIN PHARMACOL, V24, P59, DOI 10.1016/j.coph.2015.07.006
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Llabot JM, 2019, J DRUG DELIV SCI TEC, V52, P379, DOI 10.1016/j.jddst.2019.04.042
   Lopez VM, 2008, PLOS BIOL, V6, P1861, DOI 10.1371/journal.pbio.0060236
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Luaces-Rodriguez A, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118767
   de Redin IL, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107697
   Maeda T, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081785
   Mahaling B, 2018, NANOSCALE, V10, DOI 10.1039/c8nr00058a
   Malakouti-Nejad M, 2020, INT J PHARMACEUT, V590, DOI 10.1016/j.ijpharm.2020.119895
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Morral N, 1997, HUM GENE THER, V8, P1275, DOI 10.1089/hum.1997.8.10-1275
   Munoz-Ramon P V, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P75, DOI 10.1016/j.oftal.2019.09.011
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nishie H, 2016, ONCOTARGET, V7, P74259, DOI 10.18632/oncotarget.12366
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Patel S.S., 2020, INVESTIG OPHTHALMOL, V61, P4286
   Patel S, 2009, RETINA-J RET VIT DIS, V29, pS45, DOI 10.1097/IAE.0b013e3181ad22d5
   Patil A, 2021, J PHARM INNOV, V16, P747, DOI 10.1007/s12247-020-09484-8
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Petrukhin K, 2020, DRUG DELIV CHALL NOV, V35, P125, DOI [10.1007/7355_2020_105, DOI 10.1007/7355_2020_105]
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Powers J.H., 2019, J VITR DIS, V4, P327, DOI [10.1177/2474126419895692, DOI 10.1177/2474126419895692]
   Presta LG, 1997, CANCER RES, V57, P4593
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Ren XY, 2016, EXP EYE RES, V145, P352, DOI 10.1016/j.exer.2016.02.004
   Ribatti D, 2005, BRIT J HAEMATOL, V128, P303, DOI 10.1111/j.1365-2141.2004.05291.x
   Ricca AM, 2015, J OCUL PHARMACOL TH, V31, P2, DOI 10.1089/jop.2014.0062
   Ridolfo R, 2021, BIOMACROMOLECULES, V22, P126, DOI 10.1021/acs.biomac.0c00726
   Rimpela AK, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubio R.G., 2014, RETINA TODAY, P78
   Sadiq MA, 2016, DEV OPHTHALMOL, V55, P310, DOI 10.1159/000438953
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Sampat KM, 2013, OPHTHAL SURG LAS IM, V44, P385, DOI 10.3928/23258160-20130601-02
   Sarkar A, 2021, J CONTROL RELEASE, V329, P1262, DOI 10.1016/j.jconrel.2020.10.054
   Schargus M, 2020, CLIN OPHTHALMOL, V14, P897, DOI 10.2147/OPTH.S207978
   Schlottmann PG, 2017, ASIA-PAC J OPHTHALMO, V6, P514, DOI 10.22608/APO.2017258
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Scott IU, 2009, AM J OPHTHALMOL, V148, P725, DOI 10.1016/j.ajo.2009.06.004
   Sengillo JD, 2016, AM J MED GENET C, V172, P349, DOI 10.1002/ajmg.c.31534
   Sharma P, 2021, EXPERT OPIN DRUG DEL, V18, P1131, DOI 10.1080/17425247.2021.1888925
   Shaw A, 2014, BIOMEDICINES, V2, P14, DOI 10.3390/biomedicines2010014
   Sheridan C, 2021, NAT BIOTECHNOL, V39, P251, DOI 10.1038/s41587-021-00850-6
   Sheyman AT, 2013, JAMA OPHTHALMOL, V131, P864, DOI 10.1001/jamaophthalmol.2013.88
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Skelly Adrian, 2019, Vision (Basel), V3, DOI 10.3390/vision3030041
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stieger K, 2011, METHODS MOL BIOL, V807, P179, DOI 10.1007/978-1-61779-370-7_8
   Storey PP, 2019, AM J OPHTHALMOL, V199, P200, DOI 10.1016/j.ajo.2018.11.023
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Subrizi A, 2019, DRUG DISCOV TODAY, V24, P1446, DOI 10.1016/j.drudis.2019.02.001
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sung Y, 2021, BRIT J OPHTHALMOL, V105, P829, DOI 10.1136/bjophthalmol-2020-316225
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Surace EM, 2008, VISION RES, V48, P353, DOI 10.1016/j.visres.2007.07.027
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Tamaki Y, 2009, NANOMEDICINE-UK, V4, P341, DOI 10.2217/NNM.09.10
   Tanetsugu Y, 2017, BIOL PHARM BULL, V40, P145, DOI 10.1248/bpb.b16-00437
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tong Y, 2016, INT J OPHTHALMOL-CHI, V9, P1028, DOI 10.18240/ijo.2016.07.16
   Tsujinaka H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14340-x
   Uyama H, 2021, DEV GROWTH DIFFER, V63, P59, DOI 10.1111/dgd.12704
   Vakalis N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08627
   Vollrath M, 2017, EUR J PHARM BIOPHARM, V117, P244, DOI 10.1016/j.ejpb.2017.04.017
   Wan CR, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020288
   Wang JL, 2013, INVEST OPHTH VIS SCI, V54, P7983, DOI 10.1167/iovs.13-13068
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Wang YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02955-3
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Wels M, 2021, J CONTROL RELEASE, V333, P560, DOI 10.1016/j.jconrel.2021.04.008
   Wolfesberger B, 2007, J COMP PATHOL, V137, P30, DOI 10.1016/j.jcpa.2007.03.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodward B.W., 2008, COMP EFFICACY PROTON
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yao PL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082889
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
   Yu-Wai-Man P, 2016, BRIT J OPHTHALMOL, V100, P1322, DOI 10.1136/bjophthalmol-2015-308329
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhang XP, 2018, BIOMED PHARMACOTHER, V107, P1056, DOI 10.1016/j.biopha.2018.08.092
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
   Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998
NR 236
TC 10
Z9 10
U1 3
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2021
VL 22
IS 19
AR 10594
DI 10.3390/ijms221910594
PG 30
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WK5SN
UT WOS:000709786000001
PM 34638935
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lv, XD
   Liu, S
   Cao, Z
   Gong, LL
   Feng, XP
   Gao, QF
   Wang, J
   Hu, L
   Cheng, XC
   Yu, CH
   Xing, YQ
AF Lv, X. -D.
   Liu, S.
   Cao, Z.
   Gong, L. -L.
   Feng, X. -P.
   Gao, Q. -F.
   Wang, J.
   Hu, L.
   Cheng, X. -C.
   Yu, C. -H.
   Xing, Y. -Q.
TI Correlation between serum melatonin and aMT6S level for age-related
   macular degeneration patient
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Age-related macular degeneration (AMD); Melatonin; aMT6S; Smoking; Best
   corrected visual acuity; Correlation
ID PIGMENT EPITHELIAL-CELLS
AB OBJECTIVE: To analyze the levels of serum melatonin (MLT) and assay of 6-sulfatoxymelatonin (aMT6S) of age-related macular degeneration (AMD) patients and study their correlation with AMD risk factors.
   PATIENTS AND METHODS: 58 AMD cases were selected and 58 healthy cases of the same time period were selected according to 1:1 closest matching method. ELISA method was used to test serum MLT and aMT6S level.
   RESULTS: Levels of MLT and aMT6S in AMD group were lower than those in the control group, and differences were statistically significant (p < 0.05). Based on analysis of AMD subgroup, differences on gender had no statistical significance compared with AMD type. For cases with smoking, cardiovascular disease and corrected visual acuity lower than 0.1, MLT and aMT6S levels were reduced at 0.05). Through the regression analysis, we concluded that smoking history, cardiovascular disease history, best corrected visual acuity, MLT and aMT6S level were independent risk factors, among which MLT [OR = 3.624 (odds ratio: OR)] and aMT6S (OR = 3.201).
   CONCLUSIONS: MLT and aMT6S may be related to the incidence of AMD.
C1 [Lv, X. -D.; Xing, Y. -Q.] Wuhan Univ, Ctr Eye, Renmin Hosp, Wuhan, Hubei Province, Peoples R China.
   [Lv, X. -D.; Gong, L. -L.; Feng, X. -P.; Gao, Q. -F.; Cheng, X. -C.; Yu, C. -H.] Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Dept Ophthalmol, Xianning, Peoples R China.
   [Liu, S.] Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Dept Pediat, Xianning, Peoples R China.
   [Cao, Z.] Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Dept Radiol, Xianning, Peoples R China.
   [Wang, J.] Peoples Hosp, Dept Ophthalmol, Foshan, Guangdong, Peoples R China.
   [Hu, L.] Hubei Univ Sci & Technol, Affiliated Hosp 1, Xianning Cent Hosp, Dept Sci Educ, Xianning, Peoples R China.
C3 Wuhan University; Hubei University of Science & Technology; Hubei
   University of Science & Technology; Hubei University of Science &
   Technology; Hubei University of Science & Technology
RP Xing, YQ (通讯作者)，Wuhan Univ, Ctr Eye, Renmin Hosp, Wuhan, Hubei Province, Peoples R China.
EM xingyiqiao530530@sina.com
FU Youth Talent Project of Science and Technology Research Program of Hubei
   Provincial Department of Health of China [QJX2012-50]
FX Grant support was provided by the Youth Talent Project of Science and
   Technology Research Program of Hubei Provincial Department of Health of
   China. Grant Number: QJX2012-50.
CR ARANDA ML, 2016, J PINEAL RES, V16, P14
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Dag E, 2014, EUR REV MED PHARMACO, V18, P3025
   Demirtas CY, 2015, EUR REV MED PHARMACO, V19, P1915
   Emamgholipour S, 2016, BIOCHEM RES INT, V2016, DOI 10.1155/2016/5857940
   Kim JH, 2016, CLIN EXP OPTOM, V99, P56, DOI 10.1111/cxo.12315
   Kim Sukjin, 2015, Korean J Ophthalmol, V29, P424, DOI 10.3341/kjo.2015.29.6.424
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liu LF, 2014, EUR REV MED PHARMACO, V18, P3681
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Lundmark PO, 2006, VISUAL NEUROSCI, V23, P853, DOI 10.1017/S0952523806230189
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Ong BB, 2016, BRIT J HOSP MED, V77, pC18, DOI 10.12968/hmed.2016.77.2.C18
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Rosen R, 2009, MOL VIS, V15, P1673
   Rosen RB, 2012, MOL VIS, V18, P1640
   Schmid-Kubista KE, 2009, ACTA OPHTHALMOL, V87, P89, DOI 10.1111/j.1755-3768.2008.01173.x
   Stefanova N A, 2013, Adv Gerontol, V26, P122
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Ye ZM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20914
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yoo P, 2016, CAN J OPHTHALMOL, V51, pE1, DOI 10.1016/j.jcjo.2015.09.010
   ZETNER D, 2016, DRUG RES STUTTG, V20, P56
NR 25
TC 8
Z9 8
U1 0
U2 9
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD OCT
PY 2016
VL 20
IS 20
BP 4196
EP 4201
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EC6IA
UT WOS:000388238500005
PM 27831657
DA 2022-11-30
ER

PT J
AU Rosenthal, R
   Wohlleben, H
   Malek, G
   Schlichting, L
   Thieme, H
   Rickman, CB
   Strauss, O
AF Rosenthal, R
   Wohlleben, H
   Malek, G
   Schlichting, L
   Thieme, H
   Rickman, CB
   Strauss, O
TI Insulin-like growth factor-1 contributes to neovascularization in
   age-related macular degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE AMD; CNV; RPE; IGF-1; VEGF secretion
ID EPITHELIUM-DERIVED FACTOR; CHOROIDAL NEOVASCULARIZATION; TISSUE
   INHIBITOR; INCREASED EXPRESSION; EYE DISEASE; CELLS; ANGIOGENESIS;
   MEMBRANES; METALLOPROTEINASES-3; VITRONECTIN
AB Choroidal neovascularization (CNV) is a debilitating complication of age-related macular degeneration and a leading cause of vision loss. Along with other angiogenic factors like vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF)-1 and its receptor, IGF-1R, have been implicated in CNV. IGF-1 is produced in neurons and retinal pigment epithelium (RPE) but its targets and impact in CNV are not understood. IGF-1 immunoreactivity was abundant throughout surgically isolated human CNV tissues and RPE cells were immunopositive for IGF-1R. Cultured RPE cells obtained from CNV tissues expressed IGF-1R. IGF-1 stimulation of cultured cells from CNV tissues induced monophasic sustained rises in intracellular free Ca2+. VEGF concentration in the medium of unstimulated RPE cell cultures from CNV tissues increased with time to a steady-state (8 h) which was increased twofold by IGF-1 stimulation. Thus, in RPE cells IGF-1 stimulates the second messenger Ca2+ and increases VEGF secretion which, in turn, induces neovascularization. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Med Berlin, Charite, Augenklin, Berlin, Germany.
   Univ Med Berlin, Charite, Augenpoliklin, Berlin, Germany.
   Univ Med Berlin, Charite, Inst Klin Physiol, Berlin, Germany.
   Duke Univ, Med Ctr, Durham, NC USA.
   Univ Hamburg, Klinikum Eppendorf, Klin & Poliklin Augenheilkunde, Hamburg, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; Free University of Berlin; Humboldt University
   of Berlin; Charite Universitatsmedizin Berlin; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Duke University; University of Hamburg
RP Rosenthal, R (通讯作者)，Univ Med Berlin, Charite, Augenklin, Campus Benjamin Franklin, Berlin, Germany.
EM rita.rosenthal@charite.de
RI Strauss, Olaf/AAA-6485-2019; Rosenthal, Rita/M-5652-2014
OI Malek, Goldis/0000-0003-0026-2388; Strauss, Olaf/0000-0002-6272-8596;
   Bowes Rickman, Catherine/0000-0002-8555-9596
FU NATIONAL EYE INSTITUTE [R01EY011286] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY 11286, R01 EY011286] Funding Source: Medline
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FELDMAN EL, 1994, J CELL PHYSIOL, V158, P198, DOI 10.1002/jcp.1041580124
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Guan J, 2003, PROG NEUROBIOL, V70, P443, DOI 10.1016/j.pneurobio.2003.08.002
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Inokuchi N, 2001, CURR EYE RES, V23, P368, DOI 10.1076/ceyr.23.5.368.5441
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307
   KURIYAMA S, 1991, INVEST OPHTH VIS SCI, V32, P2882
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Li F, 1999, EXP EYE RES, V68, P19, DOI 10.1006/exer.1998.0572
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARTIN G, 2004, GRAEFES ARCH CLIN EX
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Murata T, 2000, OPHTHALMOLOGY, V107, P1364, DOI 10.1016/S0161-6420(00)00147-0
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Schlunck G, 2002, EXP EYE RES, V74, P571, DOI 10.1006/exer.2001.1148
   SOLMIANY MG, 2004, AM J PHYSL CELL PHYS
   SOLMIANY MG, 2004, INVEST OPHTH VIS SCI, V45, P2838
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Spraul CW, 2004, OPHTHAL RES, V36, P166, DOI 10.1159/000077330
   Thieme H, 1999, INVEST OPHTH VIS SCI, V40, P3254
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 41
TC 49
Z9 55
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 29
PY 2004
VL 323
IS 4
BP 1203
EP 1208
DI 10.1016/j.bbrc.2004.08.219
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 860JA
UT WOS:000224337300012
PM 15451424
DA 2022-11-30
ER

PT J
AU Ugurlu, N
   Asik, MD
   Yulek, F
   Neselioglu, S
   Cagil, N
AF Ugurlu, Nagihan
   Asik, Mehmet Dogan
   Yulek, Fatma
   Neselioglu, Salim
   Cagil, Nurullah
TI Oxidative Stress and Anti-oxidative Defence in Patients with Age-related
   Macular Degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; anti-oxidative defence; oxidative
   stress; ROS; TTS
ID LOW-DENSITY-LIPOPROTEIN; SERUM PARAOXONASE; LIPID-PEROXIDATION;
   HOMOCYSTEINE; PROTECTION; DISEASE; PLASMA; THIOLS; ATHEROSCLEROSIS;
   PATHOGENESIS
AB Purpose: To evaluate the oxidative stress status and anti-oxidative defence in patients with age-related macular degeneration (AMD).
   Methods: A total of 22 patients diagnosed with AMD and 23 age-matched healthy controls were included in the present study. Serum levels of total oxidant status (TOS), total antioxidant status (TAS), total thiol status (TTS) and paraoxonase 1 (PON1) activity were investigated from samples.
   Results: Significant increase in TOS levels were observed in sera of AMD patients (25.3 +/- 12.8) compared to controls (15.0 +/- 4.4). TTS (404.3 +/- 55.3) and serum PON1 enzyme activities (163.0 +/- 65.5) were significantly lower in AMD patients (594.0 +/- 64.2) relative to control groups (252.8 +/- 132.7).
   Conclusion: The results of the present study show that there is a significant increase in oxidative stress in AMD patients and significant decrease in antioxidant defence, in the total thiol level and in PON1 activity in AMD patients compared with controls. The increased oxidative stress and decreased antioxidant levels may have a synergistic role in AMD development.
C1 [Ugurlu, Nagihan; Yulek, Fatma; Cagil, Nurullah] Yildirim Beyazit Univ, Ankara Ataturk Training & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Asik, Mehmet Dogan] Hacettepe Univ, Inst Sci, Nanotechnol & Nanomed Dept, Ankara, Turkey.
   [Neselioglu, Salim] Yildirim Beyazit Univ, Ankara Ataturk Training & Res Hosp, Dept Biochem, Ankara, Turkey.
C3 Ankara Ataturk Training & Research Hospital; Yildirim Beyazit
   University; Hacettepe University; Ankara Ataturk Training & Research
   Hospital; Yildirim Beyazit University
RP Ugurlu, N (通讯作者)，48 Cadde 1474 Sokak 3-10,Pembekosk Apt, Ankara, Turkey.
EM drnagihanu@gmail.com
RI aşık, Mehmet/J-1587-2013; Cagil, Nurullah/AAG-1401-2019
OI aşık, Mehmet/0000-0001-9154-2697; Cagil, Nurullah/0000-0002-3845-066X
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andersson A, 1999, CLIN CHEM, V45, P1084
   [Anonymous], 2006, FREE RADICALS BIOL M
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Aviram M, 2005, CURR OPIN LIPIDOL, V16, P393, DOI 10.1097/01.mol.0000174398.84185.0f
   Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X
   Aviram M, 2011, CURR OPIN LIPIDOL, V22, P243, DOI 10.1097/MOL.0b013e3283474beb
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boemi M, 2001, ATHEROSCLEROSIS, V155, P229, DOI 10.1016/S0021-9150(00)00556-6
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Costa Carolina M. da, 2006, J. Bras. Patol. Med. Lab., V42, P345, DOI 10.1590/S1676-24442006000500006
   Dantoine TF, 1998, J AM SOC NEPHROL, V9, P2082
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   ECKERSON HW, 1983, AM J HUM GENET, V35, P1126
   Erel O, 2004, CLIN BIOCHEM, V37, P112, DOI 10.1016/j.clinbiochem.2003.10.014
   Erel O, 2004, CLIN BIOCHEM, V37, P277, DOI 10.1016/j.clinbiochem.2003.11.015
   Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008
   Ferretti G, 2008, CLIN BIOCHEM, V41, P381, DOI 10.1016/j.clinbiochem.2007.12.011
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HU ML, 1993, J LAB CLIN MED, V121, P257
   Jaouad L, 2006, ATHEROSCLEROSIS, V185, P191, DOI 10.1016/j.atherosclerosis.2005.06.012
   Javadzadeh A, 2012, RETINA-J RET VIT DIS, V32, P658, DOI 10.1097/IAE.0b013e31822529b1
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   MacDonald IM, 2005, CAN J OPHTHALMOL, V40, P288, DOI 10.1016/S0008-4182(05)80071-7
   Maxwell SRJ, 2000, BASIC RES CARDIOL, V95, P65, DOI 10.1007/s003950070012
   Ng CJ, 2005, FREE RADICAL BIO MED, V38, P153, DOI 10.1016/j.freeradbiomed.2004.09.035
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Pauer GJT, 2010, AM J OPHTHALMOL, V149, P513, DOI 10.1016/j.ajo.2009.09.024
   Quemeneur T, 2007, SEMIN ARTHRITIS RHEU, V37, P149, DOI 10.1016/j.semarthrit.2007.03.002
   Sen CK, 2000, CURR TOP CELL REGUL, V36, P1
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Suzuki M, 2007, MOL VIS, V13, P772
   Thiersch M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-73
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Winkler B S, 1999, Mol Vis, V5, P32
   Wlodek L, 2002, POL J PHARMACOL, V54, P215
   [World Health Organization Vision 2020], VIS 2020 GLOB IN EL
   Young IS, 2001, J CLIN PATHOL, V54, P176, DOI 10.1136/jcp.54.3.176
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 48
TC 16
Z9 17
U1 0
U2 19
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2013
VL 38
IS 4
BP 497
EP 502
DI 10.3109/02713683.2013.774023
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 105LO
UT WOS:000316071800010
PM 23432778
DA 2022-11-30
ER

PT J
AU Saini, JS
   Corneo, B
   Miller, JD
   Kiehl, TR
   Wang, QJ
   Boles, NC
   Blenkinsop, TA
   Stern, JH
   Temple, S
AF Saini, Janmeet S.
   Corneo, Barbara
   Miller, Justine D.
   Kiehl, Thomas R.
   Wang, Qingjie
   Boles, Nathan C.
   Blenkinsop, Timothy A.
   Stern, Jeffrey H.
   Temple, Sally
TI Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of
   Age-Related Macular Degeneration
SO CELL STEM CELL
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ADULT HUMAN RPE; STEM-CELL; GENE-EXPRESSION;
   CULTURE MODEL; COMPLEMENT; PROTEIN; ACTIVATION; LONGEVITY; PATHWAY
AB Age-related macular degeneration (AMD) affects the retinal pigment epithelium (RPE), a cell monolayer essential for photoreceptor survival, and is the leading cause of vision loss in the elderly. There are no disease-altering therapies for dry AMD, which is characterized by accumulation of subretinal drusen deposits and complement-driven inflammation. We report the derivation of human-induced pluripotent stem cells (hiPSCs) from patients with diagnosed AMD, including two donors with the rare ARMS2/HTRA1 homozygous genotype. The hiPSC-derived RPE cells produce several AMD/drusen-related proteins, and those from the AMD donors show significantly increased complement and inflammatory factors, which are most exaggerated in the ARMS2/HTRA1 lines. Using a panel of AMD biomarkers and candidate drug screening, combined with transcriptome analysis, we discover that nicotinamide (NAM) ameliorated disease-related phenotypes by inhibiting drusen proteins and inflammatory and complement factors while upregulating nucleosome, ribosome, and chromatin-modifying genes. Thus, targeting NAM-regulated pathways is a promising avenue for developing therapeutics to combat AMD.
C1 [Saini, Janmeet S.; Miller, Justine D.; Kiehl, Thomas R.; Wang, Qingjie; Boles, Nathan C.; Stern, Jeffrey H.; Temple, Sally] Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
   [Saini, Janmeet S.] SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA.
   [Corneo, Barbara] Columbia Univ, Med Ctr, Stem Cell Core Facil, New York, NY 10032 USA.
   [Blenkinsop, Timothy A.] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Albany; Columbia University; Icahn School of Medicine at Mount
   Sinai
RP Temple, S (通讯作者)，Neural Stem Cell Inst, Rensselaer, NY 12144 USA.
EM sallytemple@neuralsci.org
OI Corneo, Barbara/0000-0001-5189-6749
FU NIH/NIA [RF1AG042932]; NIH/NEI [R01EY022079, F32EY025931]; Regenerative
   Research Foundation; Empire State Stem Cell Fund through New York State
   Department of Health [C028504]; NATIONAL EYE INSTITUTE [F32EY025931,
   R01EY022079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [RF1AG042932] Funding Source: NIH RePORTER
FX We thank Melissa Campbell, Patty Lederman, Carol Charniga, and Susan
   Borden for technical assistance. We are grateful to the eye bank donors
   and their families. This work was supported by an NIH/NIA grant
   (RF1AG042932), NIH/NEI grant (R01EY022079), the Regenerative Research
   Foundation, and the Empire State Stem Cell Fund through New York State
   Department of Health (contract no. C028504). J.D.M. was supported by an
   NIH/NEI grant (F32EY025931). Opinions expressed here are solely those of
   the authors and do not necessarily reflect those of the Empire State
   Stem Cell Board, the New York State Department of Health, or the State
   of New York.
CR ALCAZAR O, 2009, PROTEOMICS, V8, P2201, DOI DOI 10.1074/MCP.M900203-MCP200
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Blenkinsop TA, 2015, INVEST OPHTH VIS SCI, V56, P7085, DOI 10.1167/iovs.14-16246
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Ewald CY, 2015, NATURE, V519, P97, DOI 10.1038/nature14021
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Green KN, 2008, J NEUROSCI, V28, P11500, DOI 10.1523/JNEUROSCI.3203-08.2008
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   He Shikun, 2006, Yan Ke Xue Bao, V22, P265
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang SY, 2012, J BIOL CHEM, V287, P19304, DOI 10.1074/jbc.M112.363747
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Khoo KH, 2014, NAT REV DRUG DISCOV, V13, DOI 10.1038/nrd4288
   Liu Tie Fu, 2013, Genes Cancer, V4, P135, DOI 10.1177/1947601913476948
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Luo C, 2011, MOL VIS, V17, P1588
   Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446
   Miller JD, 2013, CELL STEM CELL, V13, P691, DOI 10.1016/j.stem.2013.11.006
   Mills KF, 2016, CELL METAB, V24, P795, DOI 10.1016/j.cmet.2016.09.013
   Miyagishima K. J., 2016, STEM CELLS IN PRESS
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pal S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600584
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Phoenix TN, 2010, GENE DEV, V24, P45, DOI 10.1101/gad.1839510
   Rabin DM, 2013, AGING-US, V5, P51
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Saini JS, 2016, ADV EXP MED BIOL, V854, P557, DOI 10.1007/978-3-319-17121-0_74
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Scholl HPN, 2007, MOL VIS, V13, P196
   Shaw WM, 2007, CURR BIOL, V17, P1635, DOI 10.1016/j.cub.2007.08.058
   Stephan AH, 2013, J NEUROSCI, V33, P13460, DOI 10.1523/JNEUROSCI.1333-13.2013
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672
NR 51
TC 91
Z9 92
U1 1
U2 23
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD MAY 4
PY 2017
VL 20
IS 5
BP 635
EP +
DI 10.1016/j.stem.2016.12.015
PG 20
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA ET8QP
UT WOS:000400565700013
PM 28132833
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Zinkernagel, MS
   Zysset-Burri, DC
   Keller, I
   Berger, LE
   Leichtle, AB
   Largiader, CR
   Fiedler, GM
   Wolf, S
AF Zinkernagel, Martin S.
   Zysset-Burri, Denise C.
   Keller, Irene
   Berger, Lieselotte E.
   Leichtle, Alexander B.
   Largiader, Carlo R.
   Fiedler, Georg M.
   Wolf, Sebastian
TI Association of the Intestinal Microbiome with the Development of
   Neovascular Age-Related Macular Degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GUT MICROBIOME; DISEASE; PREVALENCE; ALIGNMENT; OBESITY; CORE; DIET
AB Age-related macular degeneration (AMD) is the most frequent cause of blindness in the elderly. There is evidence that nutrition, inflammation and genetic risk factors play an important role in the development of AMD. Recent studies suggest that the composition of the intestinal microbiome is associated with metabolic diseases through modulation of inflammation and host metabolism. To investigate whether compositional and functional alterations of the intestinal microbiome are associated with AMD, we sequenced the gut metagenomes of patients with AMD and controls. The genera Anaerotruncus and Oscillibacter as well as Ruminococcus torques and Eubacterium ventriosum were relatively enriched in patients with AMD, whereas Bacteroides eggerthii was enriched in controls. Patient's intestinal microbiomes were enriched in genes of the L-alanine fermentation, glutamate degradation and arginine biosynthesis pathways and decreased in genes of the fatty acid elongation pathway. These findings suggest that modifications in the intestinal microbiome are associated with AMD, inferring that this common sight threatening disease may be targeted by microbiome-altering interventions.
C1 [Zinkernagel, Martin S.; Zysset-Burri, Denise C.; Berger, Lieselotte E.; Wolf, Sebastian] Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Zinkernagel, Martin S.; Zysset-Burri, Denise C.; Keller, Irene; Wolf, Sebastian] Univ Bern, Dept Clin Res, Bern, Switzerland.
   [Keller, Irene] Swiss Inst Bioinformat, Bern, Switzerland.
   [Leichtle, Alexander B.; Largiader, Carlo R.; Fiedler, Georg M.] Univ Bern, Univ Hosp Bern, Univ Inst Clin Chem, Inselspital, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern;
   Swiss Institute of Bioinformatics; University of Bern; University
   Hospital of Bern
RP Zinkernagel, MS (通讯作者)，Univ Bern, Univ Hosp Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.; Zinkernagel, MS (通讯作者)，Univ Bern, Dept Clin Res, Bern, Switzerland.
EM martin.zinkernagel@insel.ch
RI Zinkernagel, Martin/C-3799-2017; Leichtle, Alexander/C-7262-2011;
   Largiader, Carlo R/B-8798-2008; Fiedler, Georg Martin/C-8341-2011; Wolf,
   Sebastian/B-8782-2008
OI Zinkernagel, Martin/0000-0002-5622-114X; Largiader, Carlo
   R/0000-0002-0889-8922; Fiedler, Georg Martin/0000-0001-5689-4574; Wolf,
   Sebastian/0000-0002-7467-7028; Zinkernagel, Martin
   S./0000-0003-3447-2359
CR Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358
   Andriessen E. M., 2016, EMBO MOL MED, DOI 10.15252/emmm.201606531
   Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944
   Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816
   Biagi E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010667
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176
   Bui BV, 2009, J NEUROCHEM, V111, P589, DOI 10.1111/j.1471-4159.2009.06354.x
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Conley MN, 2016, PEERJ, V4, DOI 10.7717/peerj.1854
   De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107
   Dray S., 2007, J STAT SOFTWARE, V22
   Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591
   Ersoy L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/413150
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gielda LM, 2012, MBIO, V3, DOI 10.1128/mBio.00171-12
   Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259
   Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014
   Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266
   Kirschner R, 2015, CURR DRUG METAB, V16, P272, DOI 10.2174/1389200216666150812124625
   Lam YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034233
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209
   Ochoa-Reparaz J, 2010, MUCOSAL IMMUNOL, V3, P487, DOI 10.1038/mi.2010.29
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, AM J CLIN NUTR, V85, p304S, DOI 10.1093/ajcn/85.1.304S
   Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]
   Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60
   SIMELL O, 1973, LANCET, V1, P1031
   Tap J, 2009, ENVIRON MICROBIOL, V11, P2574, DOI 10.1111/j.1462-2920.2009.01982.x
   Team R. D. C., 2008, R LANG ENV STAT COMP
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu CH, 2006, NUCLEIC ACIDS RES, V34, pD187, DOI 10.1093/nar/gkj161
   Ye YZ, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000465
NR 44
TC 93
Z9 99
U1 4
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 17
PY 2017
VL 7
AR 40826
DI 10.1038/srep40826
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EH8WD
UT WOS:000392052500001
PM 28094305
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Alizada, A
   Dogan, M
   Sabaner, MC
   Gulyesil, FF
   Gobeka, HH
AF Alizada, Anar
   Dogan, Mustafa
   Sabaner, Mehmet Cem
   Gulyesil, Furkan Fatih
   Gobeka, Hamidu Hamisi
TI An insight on the anatomical and functional consequences of aflibercept
   therapy in age-related macular degeneration
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Neovascular age-related macular degeneration; Aflibercept therapy;
   Microperimetry; Multifocal electroretinography
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL SENSITIVITY; MULTIFOCAL
   ELECTRORETINOGRAPHY; BEVACIZUMAB AVASTIN; VISUAL-ACUITY; MICROPERIMETRY;
   RANIBIZUMAB; MACULOPATHY; PREVALENCE; OUTCOMES
AB Background: Evaluation of anatomical and functional recovery of the retina after aflibercept therapy in neovascular age-related macular degeneration. Materials and methods: This prospective study enrolled 33 eyes of 33 naive age-related macular degeneration patients with an average age of 69 (55-82) years. Following a thorough ophthalmological examination, baseline color fundus photography, optical coherence tomography and fluorescein angiography were used to assess the angiographic characteristics and classification of the lesions. Multifocal electroretinography and microperimetry were recorded. In the first three months, all patients received three consecutive intravitreal aflibercept injections on a monthly basis. After the initial three doses, non-responders received additional afibercept injections. The baseline, 3rd and 6th month data were recorded for analysis. Results: The baseline average best-corrected visual acuity (1.05 log MAR) improved dramatically to 0.9 log MAR in the 3rd and 6th months, respectively. The baseline average central macular thickness of 358.5 +/- 232.1 mu m decreased significantly to 273.0 +/- 109.9 mu m and 245.5 +/- 109.3 mu m in the 3rd and 6th months, respectively. The average thickness of the central 1 mm macular region decreased significantly from 349.5 +/- 96.4 mu m to the 3rd and 6th month values of 320.6 +/- 101.9 and 290.5 +/- 86.4 mu m, respectively. While the mean retinal sensitivity increased significantly from 4.7 +/- 3.0 dB to 6.9 +/- 3.4 Db, local deficit decreased from -11.6 +/- 4.6 dB to -9.4 +/- 4.6 dB. Significant improvements were also observed in all rings of N1 and P1 waves. Conclusion: Intravitreal aflibercept therapy resulted in significant morphological improvements that were easily identifiable during the 3rd month. Electrophysiological improvements were delayed only to become statistically significant in the 6th month. However, it has been shown that visual acuity and optical coherence tomography parameters alone may be insufficient for both the morphological and functional assessment of the retina.
C1 [Alizada, Anar] Ermenek State Hosp, Ophthalmol Clin, Karaman, Turkey.
   [Dogan, Mustafa; Sabaner, Mehmet Cem; Gulyesil, Furkan Fatih] Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Ophthalmol, Zafer Kampusu, TR-03030 Afyon, Turkey.
   [Gobeka, Hamidu Hamisi] Ibrahim Cecen Univ Agri, Fac Med, Dept Ophthalmol, Agri, Turkey.
C3 Afyonkarahisar Health Sciences University; Afyon Kocatepe University;
   Agri Ibrahim Cecen University
RP Dogan, M (通讯作者)，Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Ophthalmol, Zafer Kampusu, TR-03030 Afyon, Turkey.
EM mustafadogan@yahoo.com
RI Sabaner, Mehmet Cem/AAI-1777-2020; GOBEKA, HAMIDU HAMISI/ABF-4732-2020;
   DOGAN, Mustafa/C-2642-2014
OI Sabaner, Mehmet Cem/0000-0002-0958-9961; GOBEKA, HAMIDU
   HAMISI/0000-0002-7656-3155; GULYESIL, FURKAN FATIH/0000-0003-1015-409X;
   DOGAN, Mustafa/0000-0001-7237-9847
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2011, INVEST OPHTH VIS SCI, V52, P3446, DOI 10.1167/iovs.10-6588
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dias JRDO, 2017, RETINA-J RET VIT DIS, V37, P1499, DOI 10.1097/IAE.0000000000001385
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Graham SL, 1998, AUST NZ J OPHTHALMOL, V26, P71, DOI 10.1111/j.1442-9071.1998.tb01446.x
   Greenstein VC, 2012, RETINA-J RET VIT DIS, V32, P349, DOI 10.1097/IAE.0b013e31821dfc17
   Hood DC, 2003, J NEURO-OPHTHALMOL, V23, P225, DOI 10.1097/00041327-200309000-00008
   Jaggi D, 2022, BRIT J OPHTHALMOL, V106, P246, DOI 10.1136/bjophthalmol-2020-316514
   Karanjia R, 2008, BRIT J OPHTHALMOL, V92, P1248, DOI 10.1136/bjo.2008.138800
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Molina-Martin A., 2017, SEMIN OPHTHALMOL, V9, P1
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Ozdemir H, 2008, EYE, V22, P204, DOI 10.1038/sj.eye.6702563
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Patama B., 2011, CLIN OPHTHALMOL, V5, P567
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Reinsberg M, 2017, CLIN OPHTHALMOL, V11, P621, DOI 10.2147/OPTH.S123513
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakai T, 2018, CLIN OPHTHALMOL, V12, P719, DOI 10.2147/OPTH.S156162
   Barboni MTS, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.25
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schulz-Forberg H., 2014, REINVENTING W CIVILI, P1
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Unsal E, 2018, J CURR OPHTHALMOL, V30, P337, DOI 10.1016/j.joco.2018.07.002
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
NR 41
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2021
VL 34
AR 102307
DI 10.1016/j.pdpdt.2021.102307
EA MAY 2021
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TE9FR
UT WOS:000670312500003
PM 33945883
DA 2022-11-30
ER

PT J
AU Grassmann, F
   Fritsche, LG
   Keilhauer, CN
   Heid, IM
   Weber, BHF
AF Grassmann, Felix
   Fritsche, Lars G.
   Keilhauer, Claudia N.
   Heid, Iris M.
   Weber, Bernhard H. F.
TI Modelling the Genetic Risk in Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; PREVALENCE; VARIANTS; SUSCEPTIBILITY; ASSOCIATION;
   MACULOPATHY; CLASSIFICATION; METAANALYSIS; RANIBIZUMAB; EXPRESSION
AB Late-stage age-related macular degeneration (AMD) is a common sight-threatening disease of the central retina affecting approximately 1 in 30 Caucasians. Besides age and smoking, genetic variants from several gene loci have reproducibly been associated with this condition and likely explain a large proportion of disease. Here, we developed a genetic risk score (GRS) for AMD based on 13 risk variants from eight gene loci. The model exhibited good discriminative accuracy, area-under-curve (AUC) of the receiver-operating characteristic of 0.820, which was confirmed in a cross-validation approach. Noteworthy, younger AMD patients aged below 75 had a significantly higher mean GRS (1.87, 95% CI: 1.69-2.05) than patients aged 75 and above (1.45, 95% CI: 1.36-1.54). Based on five equally sized GRS intervals, we present a risk classification with a relative AMD risk of 64.0 (95% CI: 14.11-1131.96) for individuals in the highest category (GRS 3.44-5.18, 0.5% of the general population) compared to subjects with the most common genetic background (GRS -0.05-1.70, 40.2% of general population). The highest GRS category identifies AMD patients with a sensitivity of 7.9% and a specificity of 99.9% when compared to the four lower categories. Modeling a general population around 85 years of age, 87.4% of individuals in the highest GRS category would be expected to develop AMD by that age. In contrast, only 2.2% of individuals in the two lowest GRS categories which represent almost 50% of the general population are expected to manifest AMD. Our findings underscore the large proportion of AMD cases explained by genetics particularly for younger AMD patients. The five-category risk classification could be useful for therapeutic stratification or for diagnostic testing purposes once preventive treatment is available.
C1 [Grassmann, Felix; Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Keilhauer, Claudia N.] Univ Eye Hosp Wurzburg, Wurzburg, Germany.
   [Heid, Iris M.] Univ Hosp Regensburg, Inst Epidemiol & Prevent Med, Regensburg, Germany.
   [Heid, Iris M.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.
C3 University of Regensburg; University of Wurzburg; University of
   Regensburg; Helmholtz Association; Helmholtz-Center Munich - German
   Research Center for Environmental Health
RP Grassmann, F (通讯作者)，Univ Regensburg, Inst Human Genet, Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Fritsche, Lars G/AAF-9387-2019
OI Fritsche, Lars G/0000-0002-2110-1690; Weber, Bernhard
   H.F./0000-0002-8808-7723; Grassmann, Felix/0000-0003-1390-7528
FU Deutsche Forschungsgemeinschaft [WE 1259/19-2]
FX This work was supported in part by a grant from the Deutsche
   Forschungsgemeinschaft WE 1259/19-2. No additional external funding was
   received for this study. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2010, R LANG ENV STAT COMP
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chongsuvivatwong V., 2010, EPICALC EPIDEMIOLOGI
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gibson J, 2010, BRIT J OPHTHALMOL, V94, P1382, DOI 10.1136/bjo.2010.182568
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hu B, 2006, STAT SINICA, V16, P847
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4
   Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu QZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008250
   Lumley T, 2009, RMETA METAANALYSIS R
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McFadden D, 1973, CONDITIONAL LOGIT AN, DOI DOI 10.1108/EB028592
   Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Mistry K, 2003, J AM BOARD FAM PRACT, V16, P95, DOI 10.3122/jabfm.16.2.95
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   [No title captured]
NR 50
TC 67
Z9 67
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 30
PY 2012
VL 7
IS 5
AR e37979
DI 10.1371/journal.pone.0037979
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959YF
UT WOS:000305353400065
PM 22666427
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Colak, E
   Majkic-Singh, N
   Zoric, L
   Radosavljevic, A
   Kosanovic-Jakovic, N
AF Colak, Emina
   Majkic-Singh, Nada
   Zoric, Lepsa
   Radosavljevic, Aleksandra
   Kosanovic-Jakovic, Natalija
TI The role of CRP and inflammation in the pathogenesis of age-related
   macular degeneration
SO BIOCHEMIA MEDICA
LA English
DT Review
DE age-related macular degeneration; C-reactive protein; inflammation
ID C-REACTIVE PROTEIN; COMPLEMENT FACTOR-H; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; ENDOTHELIAL-CELLS; MEDIATED DILATION; OXIDATIVE
   STRESS; POOLED FINDINGS; KAPPA-B; ASSOCIATION
AB Age-related macular degeneration (AMD) is a complex, degenerative and progressive disease involving the multiple genetic and environmental factors that can result in severe visual loss. The etiology of AMD is not well understood. Many theories exist and feature mechanisms of oxidative stress, atherosclerotic-like changes, genetic predisposition and inflammation. The most recent clinical studies appointed to a great role of inflammation and C-reactive protein (CRP) in the pathogenesis of AMD. There is a large body of evidence indicating the association of CRP with endothelial dysfunction, oxidative stress and production of reactive oxygen species (ROS), as well as with lipid status disorder in AMD patients. According to recent studies, CRP is definitely not only the inflammatory marker but also a mediator of development of the vascular disorders in the retinal circulation. The results obtained from the present studies may help our understanding the pathogenesis of the retinal vascular disease associated with high levels of CRP.
C1 [Colak, Emina; Majkic-Singh, Nada] Univ Belgrade, Inst Med Biochem, Clin Ctr Serbia, Belgrade, Serbia.
   [Colak, Emina; Majkic-Singh, Nada] Univ Belgrade, Farmaceut Fac, Belgrade, Serbia.
   [Zoric, Lepsa; Radosavljevic, Aleksandra; Kosanovic-Jakovic, Natalija] Univ Belgrade, Inst Ophthalmol, Med Retina Dept, Clin Ctr Serbia, Belgrade, Serbia.
   [Zoric, Lepsa; Radosavljevic, Aleksandra; Kosanovic-Jakovic, Natalija] Univ Belgrade, Fac Med, Belgrade, Serbia.
C3 Clinical Centre of Serbia; University of Belgrade; University of
   Belgrade; Clinical Centre of Serbia; University of Belgrade; University
   of Belgrade
RP Colak, E (通讯作者)，Univ Belgrade, Inst Med Biochem, Clin Ctr Serbia, Belgrade, Serbia.
EM eminacolak@sbb.rs
RI Radosavljevic, Aleksandra/K-3730-2014; Radosavljevic,
   Aleksandra/AAK-2407-2020; Čolak, Emina/AAQ-1969-2021
OI Radosavljevic, Aleksandra/0000-0002-8859-5103; Radosavljevic,
   Aleksandra/0000-0002-8859-5103; Čolak, Emina/0000-0003-1901-3146
FU Ministry of Science of Serbia [175036]
FX This work was supported by the Ministry of Science of Serbia through
   contract No175036.
CR Ali AA, 2011, J MED BIOCHEM, V30, P38, DOI 10.2478/v10011-010-0040-9
   Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], RETINAL PIGMENTED EP
   [Anonymous], MACULA RETINA
   [Anonymous], SCLERA
   [Anonymous], FOVEA CENTRALIS
   [Anonymous], CHOROID
   [Anonymous], EYE
   [Anonymous], RETINA
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Boey PY, 2010, INVEST OPHTH VIS SCI, V51, P1880, DOI 10.1167/iovs.09-4063
   Bourla DH, 2006, J AM GERIATR SOC, V54, P1130, DOI 10.1111/j.1532-5415.2006.00771.x
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Cederholm A, 2005, IMMUNOBIOLOGY, V210, P761, DOI 10.1016/j.imbio.2005.10.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang MK, 2002, P NATL ACAD SCI USA, V99, P13043, DOI 10.1073/pnas.192399699
   Chase HP, 2004, DIABETES, V53, P2569, DOI 10.2337/diabetes.53.10.2569
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Chen J, 2007, J CLIN INVEST, V117, P2758, DOI 10.1172/JCI33513
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   de Jong PT, 2005, INVEST OPHTHALMOL VI, V46
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Degn SE, 2011, AM J HUM GENET, V88, P689, DOI 10.1016/j.ajhg.2011.05.011
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fichtlscherer S, 2004, EUR HEART J, V25, P1412, DOI 10.1016/j.ehj.2004.06.026
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Jovicic S, 2010, J MED BIOCHEM, V29, P447
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kikuchi M, 2007, OPHTHALMOLOGY, V114, P1722, DOI 10.1016/j.ophtha.2006.12.021
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mueck AO, 2001, EXP CLIN ENDOCR DIAB, V109, P181, DOI 10.1055/s-2001-14843
   Nagaoka T, 2008, INVEST OPHTH VIS SCI, V49, P2053, DOI 10.1167/iovs.07-1387
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Shea JG, 1998, POSTGRAD MED J, V74, P203, DOI 10.1136/pgmj.74.870.203
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Olofsson SO, 2005, J INTERN MED, V258, P395, DOI 10.1111/j.1365-2796.2005.01556.x
   Pasceri V, 2001, CIRCULATION, V103, P2531
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Qamirani E, 2005, ARTERIOSCL THROM VAS, V25, P995, DOI 10.1161/01.ATV.0000159890.10526.1e
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sesso HD, 2003, JAMA-J AM MED ASSOC, V290, P2945, DOI 10.1001/jama.290.22.2945
   Simundic AM, 2011, BIOCHEM MEDICA, V21, P243
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Srewart CR, 2010, NAT IMMUNOL, V11, P155
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thiruvagounder M, 2010, BIOCHEM MEDICA, V20, P249
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van der Meer IM, 2002, ARTERIOSCL THROM VAS, V22, P838, DOI 10.1161/01.ATV.0000016249.96529.B8
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Verma S, 2003, J THORAC CARDIOV SUR, V126, P1886, DOI 10.1016/j.jtcvs.2003.07.026
   Verma S, 2003, AM J PHYSIOL-REG I, V285, pR1253, DOI 10.1152/ajpregu.00170.2003
   Wassmann S, 2004, AM J CARDIOL, V93, P84, DOI 10.1016/j.amjcard.2003.09.018
   Winkler B S, 1999, Mol Vis, V5, P32
   Yasukawa T, 2009, EXPERT REV OPHTHALMO, V4, P107, DOI 10.1586/EOP.09.1
   Yates YR, 2007, NEW ENGL J MED, V357, P19
   Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zoric L, 2008, VOJNOSANIT PREGL, V65, P313, DOI 10.2298/VSP0804313Z
NR 90
TC 29
Z9 31
U1 0
U2 15
PU CROATIAN SOC MEDICAL BIOCHEMISTRY & LABORATORY MEDICINE
PI ZAGREB
PA BOSKOVICEVA 18, ZAGREB, 10000, CROATIA
SN 1330-0962
EI 1846-7482
J9 BIOCHEM MEDICA
JI Biochem. Medica.
PY 2012
VL 22
IS 1
BP 39
EP 48
PG 10
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 896UP
UT WOS:000300597200005
PM 22384518
DA 2022-11-30
ER

PT J
AU Fauser, S
   Viebahn, U
   Muether, PS
AF Fauser, Sascha
   Viebahn, Ulrike
   Muether, Philipp S.
TI Intraocular and systemic inflammation-related cytokines during one year
   of ranibizumab treatment for neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; inflammation; plasma; ranibizumab;
   vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   EPITHELIUM-DERIVED FACTOR; AQUEOUS-HUMOR; CHOROIDAL NEOVASCULARIZATION;
   SUPPRESSION; EDEMA
AB Purpose: To determine inflammation-related intraocular and systemic cytokine concentrations in neovascular age-related macular degeneration (nAMD) compared with controls and to assess the influence of long-term intravitreal ranibizumab treatment over 1 year.
   Methods: Aqueous humour and blood plasma of 21 controls and 17 treatment-naive nAMD patients were collected prior to cataract surgery or ranibizumab treatment. Follow-up specimens in nAMD patients were acquired immediately prior to subsequent ranibizumab injections as needed. Multiplex bead assays were conducted for ten inflammation-related cytokines and vascular endothelial growth factor (VEGF). p-values were Holm-Bonferroni-corrected for multiple comparisons.
   Results: Prior to ranibizumab treatment, initiation aqueous humour levels of monocyte chemo-attractant protein (MCP)-1/CCL2 (p = 0.005) and vascular cell adhesin molecule (VCAM) (p = 0.002) were elevated in nAMD compared with controls. Other intraocular cytokines did not differ, including VEGF. In plasma, no differences between nAMD patients and controls were found at baseline. Pro re nata ranibizumab treatment over 12 months with 8 +/- 2 injections reduced aqueous VEGF (p < 0.0001) with a trend to reduced VEGF plasma concentrations (p = 0.046), with all specimens taken at least 28 days after the previous injection. All other local and systemic cytokines remained unchanged.
   Conclusion: Neovascular age-related macular degeneration is associated with local ocular MCP-1/CCL2 and VCAM elevations, suggesting a local inflammatory involvement in the pathophysiology of nAMD. We did not detect systemic differences. Ranibizumab treatment does not result in local or systemic changes of these cytokines, in contrast to VEGF suppression. MCP-1/CCL2 and VCAM may be potential additional treatment targets for nAMD.
C1 [Fauser, Sascha; Viebahn, Ulrike; Muether, Philipp S.] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
C3 University of Cologne
RP Muether, PS (通讯作者)，Univ Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM philmuether@mac.com
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Balasubramanian SA, 2014, TRANSL RES, V164, P179, DOI 10.1016/j.trsl.2014.04.005
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Hermann MM, 2012, BRIT J OPHTHALMOL, V96, P1008, DOI 10.1136/bjophthalmol-2011-300983
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Miao H, 2012, MOL VIS, V18, P574
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   van Kooij B, 2006, AM J OPHTHALMOL, V142, P192, DOI 10.1016/j.ajo.2006.02.052
   Yamada M, 2003, ARTERIOSCL THROM VAS, V23, P1996, DOI 10.1161/01.ATV.0000096208.80992.63
NR 18
TC 26
Z9 27
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2015
VL 93
IS 8
BP 734
EP 738
DI 10.1111/aos.12770
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2VI
UT WOS:000367654500028
PM 26016605
OA Bronze
DA 2022-11-30
ER

PT J
AU Shokoohmand, A
   Jeon, JE
   Theodoropoulos, C
   Baldwin, JG
   Hutmacher, DW
   Feigl, B
AF Shokoohmand, Ali
   Jeon, June E.
   Theodoropoulos, Christina
   Baldwin, Jeremy G.
   Hutmacher, Dietmar W.
   Feigl, Beatrix
TI A Novel 3D Cultured Model for Studying Early Changes in Age-Related
   Macular Degeneration
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE age-related macular degeneration; Bruch's membrane; choroid; coculture;
   retinal pigment epithelium
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO MODEL; BRUCHS MEMBRANE; RPE CELLS;
   DRUSEN; EXPRESSION; MACULOPATHY; PREVALENCE; ACTIVATION; SCAFFOLDS
AB Various in vitro culture systems have been used to investigate the pathogenesis of age-related macular degeneration (AMD). However, many still rely on oversimplified monolayer culture models. AMD is a complex disease, associated with the pathological changes to multiple structural components such as the Bruch's membrane, retinal pigment epithelium (RPE), and choroidal endothelial cells. This study aims to construct a novel 3D coculture model using the polycaprolactone (PCL)-gelatin electrospun scaffold, with human RPE cells (hRPE) and primate choroidal cells (RF-6A). Results from this study show that PCL-gelatin scaffolds have a highly porous ultrastructure that supports the attachment, proliferation, differentiation, and migration of the hRPEs and choroidal endothelial cells. It is also demonstrated that the PCL-gelatin 3D coculture model may be useful in exploring the molecular interplay between the hPRE and the choroidal endothelial cells, and their effects on growth factor modulation, which may be important in the pathogenesis of AMD.
C1 [Shokoohmand, Ali; Jeon, June E.; Theodoropoulos, Christina; Baldwin, Jeremy G.; Hutmacher, Dietmar W.; Feigl, Beatrix] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Shokoohmand, Ali; Hutmacher, Dietmar W.] QUT, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4102, Australia.
   [Hutmacher, Dietmar W.] Tech Univ Munich, Inst Adv Study, D-80333 Munich, Germany.
   [Hutmacher, Dietmar W.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30313 USA.
   [Feigl, Beatrix] Queensland Eye Inst, Brisbane, Qld 4101, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Technical University of Munich; University System of
   Georgia; Georgia Institute of Technology; Queensland Eye Institute
RP Hutmacher, DW; Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
EM dietmar.hutmacher@qut.edu.au; b.feigl@qut.edu.au
RI Baldwin, Jeremy/ABA-3910-2021
OI Baldwin, Jeremy/0000-0002-0367-8939; Theodoropoulos,
   Christina/0000-0002-1140-7813; Hutmacher, Dietmar
   Werner/0000-0001-5678-2134; Feigl, Beatrix/0000-0001-7198-7373
FU National Health and Medical Research Council (NHMRC); Australian
   Research Council Industrial Transformation Training Centre in Additive
   Biomanufacturing [IC160100026]
FX This study was funded by the National Health and Medical Research
   Council (NHMRC) and the Australian Research Council Industrial
   Transformation Training Centre in Additive Biomanufacturing
   (IC160100026).
CR Ainscough SL, 2009, EXP EYE RES, V89, P629, DOI 10.1016/j.exer.2009.06.005
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carr AJ, 2009, MOL VIS, V15, P283
   Chen HL, 2011, INT J BIOL MACROMOL, V48, P13, DOI 10.1016/j.ijbiomac.2010.09.019
   Christiansen A. T., 2012, STEM CELLS INT, V10, P1155
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Fan W, 2002, IN VITRO CELL DEV-AN, V38, P228
   Feigl B, 2013, ADV HEALTHC MATER, V2, P1056, DOI 10.1002/adhm.201200445
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hu J, 2001, MOL VIS, V7, P14
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Karl MO, 2007, GRAEF ARCH CLIN EXP, V245, P981, DOI 10.1007/s00417-006-0451-y
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Muerza-Cascante ML, 2017, ACTA BIOMATER, V52, P145, DOI 10.1016/j.actbio.2016.12.040
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shadforth AM, 2015, J TISSUE ENG REGEN M, V11, P1915, DOI 10.1002/term.2089
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Uetama T, 2003, J CELL PHYSIOL, V197, P77, DOI 10.1002/jcp.10342
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 42
TC 17
Z9 18
U1 2
U2 14
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-5187
EI 1616-5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD DEC
PY 2017
VL 17
IS 12
AR 1700221
DI 10.1002/mabi.201700221
PG 8
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA FO9NI
UT WOS:000417213800003
PM 29076662
DA 2022-11-30
ER

PT J
AU Chapman, NA
   Jacobs, RJ
   Braakhuis, AJ
AF Chapman, Naoko A.
   Jacobs, Robert J.
   Braakhuis, Andrea J.
TI Role of diet and food intake in age-related macular degeneration: a
   systematic review
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; carotenoids; diet; fatty acids;
   nutrients
ID BETA-CAROTENE; CANCER-RISK; MEDITERRANEAN DIET; DAIRY-PRODUCTS;
   DOCOSAHEXAENOIC ACID; ALPHA-TOCOPHEROL; PROCESSED MEAT; GLYCEMIC INDEX;
   FISH INTAKE; VITAMIN-C
AB A systematic literature review was conducted to evaluate the role of diet and food intake in age-related macular degeneration (AMD). Eighteen high-quality studies were identified. Adherence to a Mediterranean diet had decreased risk of AMD progression. An Oriental diet pattern had decreased association with AMD prevalence, whereas a Western diet pattern had increased association with AMD prevalence. High consumption of vegetables rich in carotenoids and fatty fish containing omega-3 fatty acids was beneficial for those at risk of AMD. Vegetable oils and animal fats containing omega-6 fatty acids, and red/processed meat should be consumed minimally to reduce the risk of AMD progression. High glycaemic index diets and alcohol consumption of greater than two drinks a day had increased association with AMD. As the quality of diet and food intake had a vital role in AMD, the provision of appropriate nutritional advice to those at risk of AMD is recommended.
C1 [Chapman, Naoko A.; Jacobs, Robert J.] Univ Auckland, Fac Med & Hlth Sci, Sch Optometry & Vis Sci, M & HS Bldg 503,Level 3,85 Pk Rd,Private Bag 9201, Auckland 1142, New Zealand.
   [Braakhuis, Andrea J.] Univ Auckland, Fac Med & Hlth Sci, Sch Med Sci, Dept Nutr, Auckland, New Zealand.
C3 University of Auckland; University of Auckland
RP Chapman, NA (通讯作者)，Univ Auckland, Fac Med & Hlth Sci, Sch Optometry & Vis Sci, M & HS Bldg 503,Level 3,85 Pk Rd,Private Bag 9201, Auckland 1142, New Zealand.
EM naka001@aucklanduni.ac.nz
RI Chapman, Naoko Akakura/AAJ-6223-2021
OI Chapman, Naoko Akakura/0000-0002-7898-392X
CR Adams KM, 2010, ACAD MED, V85, P1537, DOI 10.1097/ACM.0b013e3181eab71b
   Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Aune D, 2015, AM J CLIN NUTR, V101, P87, DOI 10.3945/ajcn.113.067157
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Barbaresko J, 2013, NUTR REV, V71, P511, DOI 10.1111/nure.12035
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bodai BI, 2018, PERM J, V22, P49
   Bordoni A, 2017, CRIT REV FOOD SCI, V57, P2497, DOI 10.1080/10408398.2014.967385
   Bouvard V, 2015, LANCET ONCOL, V16, P1599, DOI 10.1016/S1470-2045(15)00444-1
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Chan DSM, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020456, 10.1371/journal.pone.0027218]
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chirmade T. P., 2016, Omega-3 fatty acids: keys to nutritional health, P203
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Choi Y, 2013, WORLD J GASTROENTERO, V19, P1020, DOI 10.3748/wjg.v19.i7.1020
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2009, AM J EPIDEMIOL, V169, P867, DOI 10.1093/aje/kwn393
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Cougnard-Gregoire A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160240
   Cross AJ, 2004, ENVIRON MOL MUTAGEN, V44, P44, DOI 10.1002/em.20030
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2014, OPHTHAL PHYSL OPT, V34, P390, DOI 10.1111/opo.12142
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Islam FMA, 2014, OPHTHALMOLOGY, V121, P1428, DOI 10.1016/j.ophtha.2014.01.002
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kalariya N, 2013, OXIDAT STRESS DIS, V33, P77
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Kroenke CH, 2013, JNCI-J NATL CANCER I, V105, P616, DOI 10.1093/jnci/djt027
   Larsson SC, 2006, J NATL CANCER I, V98, P1078, DOI 10.1093/jnci/djj301
   Lu W, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0210-9
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Meester FD, 2013, OMEGA 6 3 FATTY ACID
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mir S. M., 2016, Omega-3 fatty acids: keys to nutritional health, P141
   Mossoba M. M., 2009, OFFICIAL METHODS DET
   Mowe M, 2008, CLIN NUTR, V27, P196, DOI 10.1016/j.clnu.2007.10.014
   NZ Ministry of Health, ALC INT GUID
   NZ Nutrition Foundation, NUTR FACTS NUTR CARB
   OCEBM Levels of Evidence Working Group, OXF 2011 LEV EV 2 OX
   Ocke MC, 2013, P NUTR SOC, V72, P191, DOI 10.1017/S0029665113000013
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Satia JA, 2009, AM J EPIDEMIOL, V169, P815, DOI 10.1093/aje/kwn409
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Stevens R, 2015, CLIN NUTR ESPEN, V10, pE112, DOI 10.1016/j.clnesp.2015.03.080
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tornwall ME, 2004, EUR HEART J, V25, P1171, DOI 10.1016/j.ehj.2004.05.007
   United States Department of Agriculture Agricultural Research Service, USDA FOOD COMP DAT
   Wrolstad R. E., 2012, FOOD CARBOHYDRATE CH
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
NR 64
TC 44
Z9 45
U1 3
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN
PY 2019
VL 47
IS 1
BP 106
EP 127
DI 10.1111/ceo.13343
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HL3KR
UT WOS:000458614400014
PM 29927057
DA 2022-11-30
ER

PT J
AU Hammer, M
   Jakob-Girbig, J
   Schwanengel, L
   Curcio, CA
   Hasan, S
   Meller, D
   Schultz, R
AF Hammer, Martin
   Jakob-Girbig, Juliane
   Schwanengel, Linda
   Curcio, Christine A.
   Hasan, Somar
   Meller, Daniel
   Schultz, Rowena
TI Progressive Dysmorphia of Retinal Pigment Epithelium in Age-Related
   Macular Degeneration Investigated by Fluorescence Lifetime Imaging
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration (AMD); retinal pigment epithelium
   (RPE); fundus autofluorescence (FAF); fluorescence lifetime;
   fluorescence spectra; atrophy; migration
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE PATTERNS;
   GEOGRAPHIC ATROPHY; HYPERREFLECTIVE FOCI; EYES; CELLS; LIPOFUSCIN;
   DRUSEN; CLASSIFICATION; MACULOPATHY
AB PURPOSE. The purpose of this study was to observe changes of the retinal pigment epithelium (RPE) on the transition from dysmorphia to atrophy in age-related macular degeneration (AMD) by fluorescence lifetime imaging ophthalmoscopy (FLIO).
   METHODS. Multimodal imaging including color fundus photography (CFP), optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging, and FLIO was performed in 40 eyes of 37 patients with intermediate AMD and no evidence for geographic atrophy or macular neovascularization (mean age = 74.2 +/- 7.0 years). Twenty-three eyes were followed for 28.3 +/- 18.3 months. Seven eyes had a second follow-up after 46.6 +/- 9.0 months. Thickened RPE on OCT, hyperpigmentation on CFP, hyper-reflective foci (HRF) on OCT, attributed to single or clustered intraretinal RPE, were identified. Fluorescence lifetimes in two spectral channels (short-wavelength spectral channel [SSC] = 500-560 nm, long-wavelength spectral channel [LSC] = 560-720 nm) as well as emission spectrum intensity ratio (ESIR) of the lesions were measured by FLIO.
   RESULTS. As hyperpigmented areas form and RPE migrates into the retina, FAF lifetimes lengthen and ESRI of RPE cells increase. Thickened RPE showed lifetimes of 256 +/- 49 ps (SSC) and 336 +/- 35 ps (LSC) and an ESIR of 0.552 +/- 0.079. For hyperpigmentation, these values were 317 +/- 68 ps (p < 0.001), 377 +/- 56 ps (P < 0.001), and 0.609 +/- 0.081 (P = 0.001), respectively, and for HRF 337 +/- 79 ps (P < 0.001), 414 +/- 50 ps (P < 0.001), and 0.654 +/- 0.075 (P < 0.001).
   CONCLUSIONS. In the process of RPE degeneration, comprising different steps of dysmorphia, hyperpigmentation, and migration, lengthening of FAF lifetimes and a hypsochromic shift of emission spectra can be observed by FLIO. Thus, FLIO might provide early biomarkers for AMD progression and contribute to our understanding of RPE pathology.
C1 [Hammer, Martin; Jakob-Girbig, Juliane; Schwanengel, Linda; Hasan, Somar; Meller, Daniel; Schultz, Rowena] Univ Hosp Jena, Dept Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Hammer, Martin] Univ Jena, Ctr Med Opt & Photon, Jena, Germany.
C3 Friedrich Schiller University of Jena; University of Alabama System;
   University of Alabama Birmingham; Friedrich Schiller University of Jena
RP Hammer, M (通讯作者)，Univ Hosp Jena, Dept Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
EM martin.hammer@med.uni-jena.de
OI Simon, Rowena/0000-0002-1588-6268
FU National Institutes of Health (NIH) [1R01EY027948]
FX Supported by National Institutes of Health (NIH) Grant 1R01EY027948.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Ben Ami T, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.5
   Bermond K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.35
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Cao D, 2021, INVEST OPHTHALMOL VI, DOI [10.1101/2021.04.26.21256056v2, DOI 10.1101/2021.04.26.21256056V2]
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Echols BS, 2020, OPHTHALMOL RETINA, V4, P1059, DOI 10.1016/j.oret.2020.05.001
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Giannakaki-Zimmermann H, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0452-0
   Hammer M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.20
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jakobiec FA, 2021, AM J OPHTHALMOL, V222, P388, DOI 10.1016/j.ajo.2020.09.020
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klemm M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131640
   Lad EM, 2016, GRAEF ARCH CLIN EXP, V254, P1239, DOI 10.1007/s00417-015-3249-y
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sauer L, 2021, EYE, V35, P93, DOI 10.1038/s41433-020-01287-y
   Sauer L, 2019, INVEST OPHTH VIS SCI, V60, P3054, DOI 10.1167/iovs.19-26835
   Sauer L, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.9.091415
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, pAMD65, DOI 10.1167/iovs.17-23764
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schultz R, 2022, ACTA OPHTHALMOL, V100, pE841, DOI 10.1111/aos.14963
   Schultz R, 2021, ACTA OPHTHALMOL, V99, pE970, DOI 10.1111/aos.14694
   Schultz R, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.9
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P406, DOI 10.1001/archopht.122.3.406
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 72
TC 3
Z9 3
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2021
VL 62
IS 12
AR 2
DI 10.1167/iovs.62.12.2
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WE2OW
UT WOS:000705465600012
PM 34491262
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, QY
   Tie, LJ
   Wu, SS
   Lv, PL
   Huang, HW
   Wang, WQ
   Wang, H
   Ma, L
AF Zhang, Qian-Yu
   Tie, Li-Jun
   Wu, Shan-Shan
   Lv, Pei-Lin
   Huang, Hong-Wei
   Wang, Wei-Qing
   Wang, Hui
   Ma, Le
TI Overweight, Obesity, and Risk of Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; body mass index; overweight; obesity
ID BODY-MASS INDEX; PROGRESSION; LUTEIN; PATHOGENESIS; METAANALYSIS;
   PREVALENCE; ZEAXANTHIN; ASSOCIATIONS; MACULOPATHY; ADIPOCYTES
AB PURPOSE. The aim of this study was to quantify the relationship between categories of body mass index (BMI) and age-related macular degeneration (AMD) risk in different stages.
   METHODS. MEDLINE, EMBASE, and ISI Web of Science were searched for all eligible studies on the relationship between BMI and incident early or late AMD. The analyses were based on data extracted from study reports. The pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated to evaluate the strength of this association, and dose-response relationship was assessed by restricted cubic spline.
   RESULTS. Seven prospective cohort studies with 1613 cases identified among 31,151 subjects were included. For overweight, the relationship remained insignificant for its association with both early AMD (RR = 0.92, 95% CI: 0.68-1.15; P = 0.54) and late AMD (RR = 1.09, 95% CI: 0.93-1.25; P = 0.18). A marked 32% increase in the risk of developing late AMD was noted among obese individuals (RR = 1.32, 95% CI: 1.11-1.53, P < 0.01), while obesity showed no significant association with early AMD (RR = 0.91, 95% CI: 0.74-1.08; P = 0.67). Furthermore, elevated BMI showed a linear dose-response relation with AMD risk (P-nonlinearity = 0.17), and the AMD risk increased by 2% (RR = 1.02, 95% CI: 1.01-1.04) for each 1 kg/m(2) increase in BMI within the overweight and obese BMI ranges.
   CONCLUSIONS. Excess body weight was weakly associated with increase in the risk of AMD in a dose-dependent fashion, especially for its late stage, indicating that keeping normal body weight and avoiding further weight gain may confer potential protection against this disease.
C1 [Zhang, Qian-Yu; Tie, Li-Jun] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China.
   [Zhang, Qian-Yu; Huang, Hong-Wei; Wang, Wei-Qing; Ma, Le] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
   [Wu, Shan-Shan] Capital Med Univ, Beijing Friendship Hosp, Natl Clin Res Ctr Digest Dis, Beijing, Peoples R China.
   [Lv, Pei-Lin] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Xian 710061, Shaanxi, Peoples R China.
   [Wang, Hui] Xian Int Univ, Xian, Peoples R China.
   [Ma, Le] Xi An Jiao Tong Univ, Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Capital Medical
   University; Xi'an Jiaotong University; Ministry of Education, China;
   Xi'an Jiaotong University
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM male@mail.xjtu.edu.cn
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-81202198,
   NSFC-81473059]; Natural Science Foundation of Shaanxi Province of China
   [2013JQ4008]; China Postdoctoral Science Special Foundation
   [2015T81036]; China Postdoctoral Science Foundation [2014M560790]
FX Supported in part by grants from the National Natural Science Foundation
   of China (NSFC-81202198, NSFC-81473059); the Natural Science Foundation
   of Shaanxi Province of China (2013JQ4008); the China Postdoctoral
   Science Special Foundation (2015T81036); and the China Postdoctoral
   Science Foundation Funded Project (2014M560790). The authors alone are
   responsible for the content and writing of the paper.
CR ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439
   [Anonymous], 2007, VIS 2020 RIGHT SIGHT, P1
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Bovier ER, 2013, NUTRIENTS, V5, P750, DOI 10.3390/nu5030750
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Cai ZJ, 1999, WHO TECH REP SER, V887, P1
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Despres JP, 2012, CIRCULATION, V126, P1301, DOI 10.1161/CIRCULATIONAHA.111.067264
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39
   GORDON T, 1975, AM HEART J, V90, P322, DOI 10.1016/0002-8703(75)90320-8
   GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237
   Haas P, 2015, ACTA OPHTHALMOL, V93, P533, DOI 10.1111/aos.12670
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Johnson EJ, 2005, NUTR REV, V63, P9, DOI 10.1301/nr.2004.janr.9-15
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kurokawa J, 2010, CELL METAB, V11, P479, DOI 10.1016/j.cmet.2010.04.013
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu Q, 2009, COMPUT STAT DATA AN, V53, P4157, DOI 10.1016/j.csda.2009.05.001
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Maury E, 2009, J CLIN ENDOCR METAB, V94, P1393, DOI 10.1210/jc.2008-2196
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265
   Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Wells GA., NEWCASTLE OTTAWA SCA
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 44
TC 50
Z9 51
U1 1
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2016
VL 57
IS 3
BP 1276
EP 1283
DI 10.1167/iovs.15-18637
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK4BE
UT WOS:000374860600069
PM 26990164
OA gold
DA 2022-11-30
ER

PT J
AU Shin, KU
   Song, SJ
   Bae, JH
   Lee, MY
AF Shin, Ko Un
   Song, Su Jeong
   Bae, Jeong Hun
   Lee, Mi Yeon
TI Risk Prediction Model for Progression of Age-Related Macular
   Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Risk; Prediction
ID PREVALENCE; SUBTYPES; SMOKING; DISEASE; ADULTS
AB Aims: The aim of this paper was to develop a risk prediction model for the progression of age-related macular degeneration (AMD) in Koreans using systemic and environmental factors. Methods: The study sample included 10,890 individuals 50 years of age or older; 318 (2.92%) presented with early AMD findings in baseline examinations. Re-examinations were performed in 157 (49.37%) who were followed up for 4.4 years. The multivariate analysis of covariates included demographic and environmental factors. After using these data to develop a risk prediction model, the individual algorithm was made, and receiver operating characteristic curves were calculated to assess the predictive ability of the risk model for AMD progression. Results: The individual algorithm to predict the AMD progression risk based on systemic and ocular factors was as follows: Y = -9.565 + 1.709 (drusen location(center)) + 0.795 (drusen location(paracentral)) + 1.074 (both eyes) + 0.094 (drusen size(intermediate)) + 0.034 (drusen size(large)) + 0.614 (drusen number(10-20)) + 2.278 (drusen number(>20)) + 0.577 (hyperpigmentation) + 0.725 (hypopigmentation) + 0.079 (male) - 0.025 (age) 0.921 (SMKex) + 1.574 (SMKcurrent) + 0.363 (total protein) + 1.626 (globulin), where SMK means smoking status. The C statistics for the model was 0.84 (0.75-0.92) indicating a good predictive power. Conclusion: A comprehensive risk prediction model for AMD progression was made to calculate the individual AMD progression risk using personal systemic and environmental factors. (C) 2016 S. Karger AG, Basel
C1 [Shin, Ko Un; Song, Su Jeong; Bae, Jeong Hun] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, 29 Saemunan Ro, Seoul 110746, South Korea.
   [Lee, Mi Yeon] Kangbuk Samsung Hosp, Dept Biostat, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center
RP Song, SJ (通讯作者)，Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Ophthalmol, 29 Saemunan Ro, Seoul 110746, South Korea.
EM eye-su@hanmail.net
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chiu CJ, 2014, OPHTHALMOLOGY, V121, P1421, DOI 10.1016/j.ophtha.2014.01.016
   Choi Y, 2015, HEART, V101, P686, DOI 10.1136/heartjnl-2014-306663
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Ryoo JH, 2015, DIABETES RES CLIN PR, V107, P407, DOI 10.1016/j.diabres.2014.12.005
   Ryu S, 2015, J HEPATOL, V62, P1164, DOI 10.1016/j.jhep.2014.11.041
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Sharma NK, 2013, DNA CELL BIOL, V32, P549, DOI 10.1089/dna.2013.2072
   Shim SH, 2016, OPHTHAL EPIDEMIOL, V7, P1
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
NR 18
TC 4
Z9 4
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 57
IS 1
BP 32
EP 36
DI 10.1159/000449168
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EF1KK
UT WOS:000390083500002
PM 27732974
DA 2022-11-30
ER

PT J
AU Ucer, B
   Kayikcioglu, O
   Seymenoglu, G
   Var, A
   Cam, S
AF Ucer, Basak
   Kayikcioglu, Ozcan
   Seymenoglu, Goktug
   Var, Ahmet
   Cam, Sirri
TI The Relationship Between Angiotensin Converting Enzyme
   Insertion/deletion Polymorphism and Age-related Macular Degeneration
SO OPHTHALMIC GENETICS
LA English
DT Article
DE age-related macular degeneration; angiotensin converting enzyme; genetic
   polymorphism; renin angiotensin aldosterone
ID DELETION POLYMORPHISM; GENE-EXPRESSION; MACULOPATHY; SYSTEM; RISK; EYE;
   ASSOCIATION; INHIBITORS; DISEASE
AB Background: To assess the role of serum angiotensin converting enzyme (ACE) levels and ACE insertion / deletion (I/D) genetic polymorphism in Turkish age-related macular degeneration (AMD) patients and control subjects.
   Methods: This prospective study consisted of 78 patients with AMD and 68 control subjects. The I/D polymorphism of the ACE was carried out by polymerase chain reaction. Serum ACE levels were determined by using the ELISA method.
   Results: There was no significant difference in the mean serum values of ACE between the control and patient groups (p = 0.107). The genotypic frequencies of ACE polymorphism in the control and patient groups were not significantly different either (p = 0.218).
   Conclusion: We could not show a significant role of serum ACE levels and ACE I/D genetic polymorphism in the etiopathogenesis of AMD in the Turkish population, and our findings did not support the idea that serum ACE levels and ACE DD genotype were risk factors for AMD.
C1 [Ucer, Basak; Kayikcioglu, Ozcan; Seymenoglu, Goktug] Celal Bayar Univ, Fac Med, Dept Ophthalmol, Manisa, Turkey.
   [Var, Ahmet] Celal Bayar Univ, Fac Med, Dept Biochem, Manisa, Turkey.
   [Cam, Sirri] Celal Bayar Univ, Fac Med, Dept Med Genet, Manisa, Turkey.
C3 Celal Bayar University; Celal Bayar University; Celal Bayar University
RP Ucer, B (通讯作者)，125-6 Sok,Deniz Sitesi B Blok Daire 5,Evka 3, TR-35040 Izmir, Turkey.
EM ucerbasak@yahoo.com
RI Cam, Sirri/D-2766-2011
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Dzau VJ, 2001, HYPERTENSION, V37, P1047, DOI 10.1161/01.HYP.37.4.1047
   Feghhi M., 2008, DIABETES RES CLIN PR, V81, P1
   FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141
   Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KUMAR A, 1988, J NEUROSCI RES, V19, P287, DOI 10.1002/jnr.490190302
   LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McConnell V, 2005, Ulster Med J, V74, P82
   O'Malley JP, 1999, CURR OPIN LIPIDOL, V10, P407, DOI 10.1097/00041433-199910000-00005
   PAUL M, 1993, J CLIN INVEST, V91, P2058, DOI 10.1172/JCI116428
   RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a
   RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Shehab DK, 2008, J BIOMED SCI, V15, P61, DOI 10.1007/s11373-007-9203-1
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wagner J, 1996, BRIT J OPHTHALMOL, V80, P159, DOI 10.1136/bjo.80.2.159
   Wu KHC, 2004, ACTA OPHTHALMOL SCAN, V82, P298, DOI 10.1111/j.1600-0420.2004.00265.x
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 21
TC 2
Z9 2
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1381-6810
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD SEP
PY 2011
VL 32
IS 3
BP 158
EP 161
DI 10.3109/13816810.2011.560060
PG 4
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA 806GJ
UT WOS:000293794000007
PM 21417676
DA 2022-11-30
ER

EF